Selegiline	O
-	O
induced	O
postural	B
hypotension	I
in	O
Parkinson	B
'	I
s	I
disease	I
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B
'	I
s	I
Disease	I
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	O
and	O
L	O
-	O
dopa	O
was	O
associated	O
with	O
selective	O
systolic	B
orthostatic	I
hypotension	I
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	O
.	O

This	O
unwanted	O
effect	O
on	O
postural	O
blood	O
pressure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonomic	O
failure	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	O
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	B
hypotension	I
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	B
patients	O
receiving	O
selegiline	O
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	B
orthostatic	I
hypotension	I
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B
patients	O
on	O
selegiline	O
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	O
lesser	O
degree	O
of	O
orthostatic	B
hypotension	I
occurred	O
with	O
standing	O
.	O

Orthostatic	B
hypotension	I
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	O
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Stopping	O
selegiline	O
also	O
significantly	O
reduced	B
the	I
supine	I
systolic	I
and	I
diastolic	I
blood	I
pressures	I
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	O
in	O
combination	O
with	O
L	O
-	O
dopa	O
is	O
associated	O
with	O
selective	O
orthostatic	B
hypotension	I
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	O
and	O
metamphetamine	O
are	O
discussed	O
.	O

Further	O
studies	O
on	O
effects	O
of	O
irrigation	O
solutions	O
on	O
rat	O
bladders	O
.	O

Further	O
studies	O
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	O
-	O
choloroaniline	O
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	O
-	O
digluconate	O
associated	O
erosive	O
cystitis	B
.	O

A	O
high	O
percentage	O
of	O
kanamycin	O
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	B
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	O
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	B
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Effects	O
of	O
tetrandrine	O
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	B
in	O
mice	O
and	O
human	O
platelet	B
aggregation	I
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	B
induced	O
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	B
aggregation	I
and	O
blood	B
coagulation	I
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	B
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O

In	O
the	O
vitro	O
human	O
platelet	B
aggregations	I
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	O
and	O
FAN	O
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	O
nor	O
FAN	O
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

Angioedema	B
due	O
to	O
ACE	O
inhibitors	O
:	O
common	O
and	O
inadequately	O
diagnosed	O
.	O

The	O
estimated	O
incidence	O
of	O
angioedema	B
during	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O

This	O
potentially	O
serious	O
adverse	O
effect	O
is	O
often	O
preceded	O
by	O
minor	O
manifestations	O
that	O
may	O
serve	O
as	O
a	O
warning	O
.	O

Cocaine	O
-	O
induced	O
mood	B
disorder	I
:	O
prevalence	O
rates	O
and	O
psychiatric	B
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance	O
-	O
induced	O
and	O
other	O
mood	B
disorders	I
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	O
mood	B
disorder	I
(	O
CIMD	B
)	O
,	O
other	O
mood	B
disorders	I
,	O
or	O
no	O
mood	B
disorder	I
were	O
compared	O
on	O
measures	O
of	O
psychiatric	B
symptoms	O
.	O

The	O
prevalence	O
rate	O
for	O
CIMD	B
was	O
12	O
%	O
at	O
baseline	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	B
disorders	I
.	O

Patients	O
with	O
CIMD	B
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	B
disorder	I
.	O

These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O

Effect	O
of	O
fucoidan	O
treatment	O
on	O
collagenase	O
-	O
induced	O
intracerebral	B
hemorrhage	I
in	O
rats	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	B
damage	I
following	O
ischemic	B
stroke	I
.	O

Intracerebral	B
hemorrhage	I
is	O
associated	O
with	O
more	O
inflammation	B
than	O
ischemic	B
stroke	I
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	B
damage	I
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	B
hemorrhage	I
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	O
(	O
30	O
micrograms	O
h	O
-	O
1	O
)	O
or	O
vehicle	O
.	O

The	O
hematoma	B
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O

Motor	O
behavior	O
,	O
passive	O
avoidance	O
,	O
and	O
skilled	O
forelimb	O
function	O
were	O
tested	O
repeatedly	O
for	O
six	O
weeks	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	B
blood	I
clotting	I
and	O
hemodilution	B
,	O
had	O
larger	O
hematomas	B
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	B
in	O
the	O
vicinity	O
of	O
the	O
hematoma	B
after	O
three	O
days	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	B
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Acute	O
white	B
matter	I
edema	I
and	O
eventual	O
neuronal	B
loss	I
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	B
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Investigation	O
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	B
hemorrhage	I
.	O

Recurarization	O
in	O
the	O
recovery	O
room	O
.	O

A	O
case	O
of	O
recurarization	O
in	O
the	O
recovery	O
room	O
is	O
reported	O
.	O

Accumulation	O
of	O
atracurium	O
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

A	O
respiratory	B
arrest	I
with	O
severe	O
desaturation	B
and	O
bradycardia	B
occurred	O
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	B
blockade	I
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

The	O
haemodynamic	O
effects	O
of	O
propofol	O
in	O
combination	O
with	O
ephedrine	O
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	O
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	O
to	O
propofol	O
in	O
order	O
to	O
obtund	O
the	O
hypotensive	B
response	O
.	O

The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	O
to	O
200	O
mg	O
of	O
propofol	O
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	B
response	O
to	O
propofol	O
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

However	O
,	O
marked	O
tachycardia	B
associated	O
with	O
the	O
use	O
of	O
ephedrine	O
in	O
combination	O
with	O
propofol	O
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	B
inducing	O
myocardial	B
ischemia	I
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Gemcitabine	O
plus	O
vinorelbine	O
in	O
nonsmall	B
cell	I
lung	I
carcinoma	I
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	O
.	O

Oncopaz	O
Cooperative	O
Group	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	B
cell	I
lung	I
carcinoma	I
(	O
NSCLC	B
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	B
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	O
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	B
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	B
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
.	O

All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	B
.	O

Treatment	O
was	O
comprised	O
of	O
VNB	O
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	O
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O

Patients	O
received	O
a	O
minimum	O
of	O
three	O
courses	O
unless	O
progressive	O
disease	O
was	O
detected	O
.	O

RESULTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
courses	O
were	O
administered	O
,	O
with	O
a	O
median	O
of	O
3	O
.	O

6	O
courses	O
per	O
patient	O
.	O

The	O
overall	O
response	O
rate	O
was	O
26	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O

Two	O
patients	O
attained	O
a	O
complete	O
response	O
(	O
4	O
%	O
)	O
and	O
11	O
patients	O
(	O
22	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
improved	O
in	O
35	O
%	O
of	O
those	O
patients	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
relief	O
of	O
at	O
least	O
1	O
symptom	O
without	O
worsening	O
of	O
other	O
symptoms	O
was	O
noted	O
in	O
27	O
patients	O
(	O
55	O
%	O
)	O
.	O

The	O
median	O
time	O
to	O
progression	O
was	O
16	O
weeks	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
33	O
%	O
.	O

Toxicity	B
was	O
mild	O
.	O

Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	B
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	B
.	O

Three	O
patients	O
with	O
severe	O
neutropenia	B
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B
.	O

The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3	O
-	O
4	O
neutropenia	B
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs	O
.	O
72	O
years	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
GEM	O
and	O
VNB	O
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O

This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	B
.	O

Therefore	O
the	O
prophylactic	O
use	O
of	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
should	O
be	O
considered	O
with	O
this	O
treatment	O
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B
.	O

A	O
selective	O
dopamine	O
D4	O
receptor	O
antagonist	O
,	O
NRA0160	O
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O

NRA0160	O
,	O
5	O
-	O
[	O
2	O
-	O
(	O
4	O
-	O
(	O
3	O
-	O
fluorobenzylidene	O
)	O
piperidin	O
-	O
1	O
-	O
yl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
(	O
4	O
-	O
fluorophenyl	O
)	O
thiazole	O
-	O
2	O
-	O
carboxamide	O
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamine	O
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	O
D2L	O
receptor	O
.	O

NRA0160	O
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
and	O
clozapine	O
antagonized	O
locomotor	O
hyperactivity	B
induced	O
by	O
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	O
and	O
clozapine	O
antagonized	O
MAP	O
-	O
induced	O
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
induced	O
catalepsy	B
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
shortened	O
the	O
phencyclidine	O
(	O
PCP	O
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

These	O
findings	O
suggest	O
that	O
NRA0160	O
may	O
have	O
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O

Warfarin	O
-	O
induced	O
artery	B
calcification	I
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	O
D	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B
calcification	I
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B
calcification	I
in	O
Warfarin	O
-	O
treated	O
rats	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	O
caused	O
massive	O
focal	O
calcification	B
of	I
the	I
artery	I
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

In	O
contrast	O
,	O
no	O
artery	B
calcification	I
could	O
be	O
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	O
treatment	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	O
-	O
induced	O
artery	B
calcification	I
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	O
produced	O
massive	O
focal	O
calcification	B
of	I
the	I
artery	I
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	B
calcification	I
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B
calcification	I
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	B
calcification	I
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	O
artery	B
calcification	I
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	O
-	O
induced	O
artery	B
calcification	I
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	O
levels	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	O
D	O
and	O
Warfarin	O
in	O
artery	B
calcification	I
.	O

High	O
doses	O
of	O
vitamin	O
D	O
are	O
known	O
to	O
cause	O
calcification	B
of	I
the	I
artery	I
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	O
the	O
vitamin	O
K	O
antagonist	O
Warfarin	O
are	O
also	O
known	O
to	O
cause	O
calcification	B
of	I
the	I
artery	I
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	O
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	B
in	O
the	O
media	O
of	O
vitamin	O
D	O
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	B
calcification	I
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	B
calcification	I
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	B
inhibitor	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	B
calcification	I
in	O
rats	O
treated	O
with	O
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	O
-	O
carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	B
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	B
sites	O
.	O

Test	O
conditions	O
influence	O
the	O
response	O
to	O
a	O
drug	O
challenge	O
in	O
rodents	O
.	O

These	O
studies	O
were	O
conducted	O
to	O
examine	O
the	O
differential	O
response	O
to	O
a	O
drug	O
challenge	O
under	O
varied	O
experimental	O
test	O
conditions	O
routinely	O
employed	O
to	O
study	O
drug	O
-	O
induced	O
behavioral	O
and	O
neurophysiological	O
responses	O
in	O
rodents	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	B
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	O
-	O
induced	O
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine	O
-	O
induced	O
hyperactivity	B
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	O
such	O
as	O
drug	O
-	O
induced	O
hypothermia	B
.	O

In	O
mice	O
,	O
apomorphine	O
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O

Drug	O
-	O
induced	O
gross	O
activity	O
counts	O
were	O
increased	O
in	O
the	O
novel	O
exploratory	O
box	O
only	O
,	O
while	O
measures	O
of	O
stereotypic	O
behavior	O
were	O
similar	O
in	O
both	O
.	O

By	O
contrast	O
,	O
apomorphine	O
-	O
induced	O
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

However	O
,	O
apomorphine	O
-	O
induced	O
reductions	O
in	O
striatal	O
dopamine	O
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

The	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmacological	O
challenge	O
tests	O
in	O
rodents	O
.	O

Hemolysis	B
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	O
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	B
cancer	I
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B
anemia	I
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	O
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	O
-	O
induced	O
hemolytic	B
anemia	I
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

TAM	O
induces	O
hemolysis	B
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O

The	O
extension	O
of	O
hemolysis	B
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	O
induces	O
total	O
hemolysis	B
of	O
all	O
tested	O
suspensions	O
.	O

Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	O
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O

The	O
hemolytic	B
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	B
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	O
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induced	O
hemolysis	B
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Hemolysis	B
caused	O
by	O
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	B
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

However	O
,	O
TAM	O
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O

Either	O
alpha	O
-	O
T	O
or	O
alpha	O
-	O
TAc	O
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	O
partition	O
into	O
model	O
membranes	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	B
by	O
tocopherols	O
is	O
related	O
to	O
a	O
decreased	O
TAM	O
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	O
-	O
induced	O
hemolysis	B
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	O
,	O
resulting	O
in	O
hemolytic	B
anemia	I
.	O

Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	O
may	O
contribute	O
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	B
.	O

In	O
the	O
cardiovascular	O
system	O
,	O
NO	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions	O
.	O

Inhibition	O
of	O
NO	O
synthesis	O
induces	O
sustained	O
hypertension	B
.	O

In	O
several	O
models	O
of	O
hypertension	B
,	O
elevation	O
of	O
intracellular	O
sodium	O
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	B
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

After	O
4	O
-	O
week	O
administration	O
of	O
L	O
-	O
NAME	O
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36	O
%	O
.	O

Two	O
weeks	O
after	O
terminating	O
the	O
treatment	O
,	O
the	O
SBP	O
recovered	O
to	O
control	O
value	O
.	O

When	O
activating	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

After	O
recovery	O
from	O
hypertension	B
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

The	O
K	O
(	O
Na	O
)	O
value	O
for	O
Na	O
+	O
returned	O
to	O
control	O
value	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	B
accompanied	O
by	O
depressed	B
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	O
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
activity	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	O
on	O
bromocriptine	O
-	O
induced	O
tachycardia	B
in	O
conscious	O
rats	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	B
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	O
could	O
abolish	O
bromocriptine	O
-	O
induced	O
tachycardia	B
in	O
conscious	O
rats	O
.	O

Isoproterenol	O
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	B
hypertrophy	I
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	O
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	B
and	O
tachycardia	B
.	O

Bromocriptine	O
-	O
induced	O
hypotension	B
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	B
was	O
reversed	O
to	O
significant	O
bradycardia	B
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	O
pretreatment	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	O
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	O
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	O
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	O
-	O
induced	O
tachycardia	B
to	O
bradycardia	B
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	B
of	O
bromocriptine	O
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	O
.	O

A	O
developmental	O
analysis	O
of	O
clonidine	O
'	O
s	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O

Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	O
of	O
the	O
alpha	O
(	O
2	O
)	O
adrenoceptor	O
agonist	O
,	O
clonidine	O
.	O

Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	O
response	O
to	O
clonidine	O
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	O
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	B
,	O
we	O
hypothesized	O
that	O
clonidine	O
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	O
of	O
clonidine	O
administration	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rats	O
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	O
-	O
induced	O
bradycardia	B
.	O

This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	O
'	O
s	O
detrimental	O
effects	O
on	O
cardiovascular	O
function	O
.	O

Recurrent	O
use	O
of	O
newer	O
oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
(	O
VTE	B
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	B
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O

Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	O
of	O
VTE	B
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

Totals	O
of	O
128	O
cases	O
and	O
650	O
controls	O
were	O
analysed	O
for	O
repeat	O
use	O
and	O
135	O
cases	O
and	O
622	O
controls	O
for	O
switching	O
patterns	O
.	O

The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	B
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	O
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	B
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O

These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	O
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O

Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	O
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	B
induced	O
by	O
intradermal	O
capsaicin	O
in	O
humans	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	B
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	B
induced	O
by	O
capsaicin	O
.	O

In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
,	O
we	O
studied	O
12	O
volunteers	O
in	O
three	O
experiments	O
.	O

Capsaicin	O
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	O
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	O
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	O
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	B
,	O
pain	B
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B
.	O

Ketamine	O
reduced	O
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	B
.	O

Lidocaine	O
reduced	O
the	O
area	O
of	O
punctate	O
-	O
evoked	O
hyperalgesia	B
significantly	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	B
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	B
.	O

The	O
differential	O
effects	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
static	O
and	O
dynamic	O
hyperalgesia	B
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	B
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Development	O
of	O
apomorphine	O
-	O
induced	O
aggressive	B
behavior	I
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

The	O
development	O
of	O
apomorphine	O
-	O
induced	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daily	O
)	O
aggressive	B
behavior	I
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	O
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	B
behavior	I
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	B
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	B
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	O
-	O
induced	O
aggressive	B
behavior	I
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

Intracranial	B
aneurysms	I
and	O
cocaine	B
abuse	I
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O

OBJECTIVE	O
:	O
The	O
outcome	O
of	O
subarachnoid	B
hemorrhage	I
associated	O
with	O
cocaine	B
abuse	I
is	O
reportedly	O
poor	O
.	O

However	O
,	O
no	O
study	O
in	O
the	O
literature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistical	O
model	O
to	O
analyze	O
the	O
variables	O
that	O
influence	O
outcome	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	O
-	O
related	O
aneurysms	B
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B
aneurysms	I
and	O
no	O
history	O
of	O
cocaine	B
abuse	I
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	B
hemorrhage	I
,	O
size	O
of	O
the	O
aneurysm	B
,	O
location	O
of	O
the	O
aneurysm	B
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

RESULTS	O
:	O
The	O
patients	O
in	O
the	O
study	O
group	O
were	O
significantly	O
younger	O
than	O
the	O
patients	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	B
were	O
located	O
in	O
the	O
anterior	O
circulation	O
.	O

The	O
majority	O
of	O
these	O
aneurysms	B
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
differences	O
in	O
mortality	O
and	O
morbidity	O
between	O
the	O
two	O
groups	O
were	O
not	O
significant	O
.	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	O
-	O
related	O
aneurysms	B
.	O

CONCLUSION	O
:	O
Cocaine	O
use	O
predisposed	O
aneurysmal	B
rupture	I
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	B
.	O

Contrary	O
to	O
the	O
published	O
literature	O
,	O
this	O
group	O
did	O
reasonably	O
well	O
with	O
aggressive	O
management	O
.	O

Effect	O
of	O
intravenous	O
nimodipine	O
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	B
stroke	I
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	B
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	B
in	I
blood	I
pressure	I
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	B
stroke	I
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	B
reduction	I
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	B
stroke	I
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
94	O
)	O
.	O

The	O
correlation	O
between	O
average	O
BP	O
change	O
during	O
the	O
first	O
2	O
days	O
and	O
the	O
outcome	O
at	O
day	O
21	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patients	O
were	O
included	O
in	O
this	O
analysis	O
(	O
n	O
=	O
92	O
,	O
93	O
,	O
and	O
80	O
for	O
placebo	O
,	O
low	O
dose	O
,	O
and	O
high	O
dose	O
,	O
respectively	O
)	O
.	O

Nimodipine	O
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	B
in	I
systolic	I
BP	I
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	B
reduction	I
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Patients	O
with	O
a	O
DBP	B
reduction	I
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	B
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correlation	O
between	O
SBP	O
change	O
and	O
outcome	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
nimodipine	O
after	O
acute	B
stroke	I
.	O

For	O
low	O
-	O
dose	O
nimodipine	O
,	O
the	O
results	O
were	O
not	O
conclusive	O
.	O

These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	O
.	O

Neonatal	O
pyridoxine	O
responsive	O
convulsions	B
due	O
to	O
isoniazid	O
therapy	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	O
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	B
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	B
fits	I
.	O

No	O
underlying	O
infective	O
or	O
biochemical	O
cause	O
could	O
be	O
found	O
.	O

The	O
fits	B
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

Ketamine	O
sedation	O
for	O
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	B
in	O
the	O
emergency	O
department	O
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	O
,	O
a	O
unique	O
anesthetic	O
,	O
for	O
emergency	O
-	O
department	O
procedures	O
requiring	O
sedation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	O
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children	O
'	O
s	O
fractures	B
in	O
the	O
emergency	O
department	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	B
or	O
dislocation	B
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	B
center	O
were	O
prospectively	O
evaluated	O
.	O

Ketamine	O
hydrochloride	O
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

A	O
board	O
-	O
certified	O
emergency	O
physician	O
skilled	O
in	O
airway	O
management	O
supervised	O
administration	O
of	O
the	O
anesthetic	O
,	O
and	O
the	O
patients	O
were	O
monitored	O
by	O
a	O
registered	O
nurse	O
.	O

Any	O
pain	B
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B
Scale	O
(	O
CHEOPS	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	O
to	O
manipulation	O
of	O
the	O
fracture	B
or	O
dislocation	B
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	B
during	O
fracture	B
reduction	O
.	O

Adequate	O
fracture	B
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O

Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
parents	O
present	O
during	O
the	O
reduction	O
were	O
pleased	O
with	O
the	O
sedation	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O

Patency	O
of	O
the	O
airway	O
and	O
independent	O
respiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
patients	O
.	O

Blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
stable	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	B
(	O
thirteen	O
patients	O
)	O
,	O
emesis	B
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B
)	O
,	O
clumsiness	B
(	O
evident	O
as	O
ataxic	B
movements	I
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B
reaction	I
(	O
one	O
patient	O
)	O
.	O

No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	O
patients	O
had	O
hallucinations	B
or	O
nightmares	O
.	O

CONCLUSIONS	O
:	O
Ketamine	O
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	B
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

Ketamine	O
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O

Cyclosporine	O
and	O
tacrolimus	O
-	O
associated	O
thrombotic	B
microangiopathy	I
.	O

The	O
development	O
of	O
thrombotic	B
microangiopathy	I
(	O
TMA	B
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	O
has	O
been	O
well	O
documented	O
.	O

Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	O
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

However	O
,	O
for	O
recipients	O
of	O
organ	O
transplantation	O
,	O
removing	O
the	O
inciting	O
agent	O
is	O
not	O
without	O
the	O
attendant	O
risk	O
of	O
precipitating	O
acute	O
rejection	O
and	O
graft	O
loss	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	O
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	O
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	O
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	O
-	O
induced	O
TMA	B
.	O

With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	O
in	O
organ	O
transplantation	O
,	O
tacrolimus	O
-	O
associated	O
TMA	B
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	B
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	O
and	O
tacrolimus	O
is	O
limited	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	O
-	O
induced	O
TMA	B
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	O
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

Introduction	O
of	O
tacrolimus	O
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	B
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	O
to	O
tacrolimus	O
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	B
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	O
in	O
cancer	B
patients	O
on	O
morphine	O
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B
not	O
responsive	O
to	O
morphine	O
is	O
often	O
problematic	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	B
syndromes	O
,	O
such	O
as	O
neuropathic	B
pain	I
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B
patients	O
whose	O
pain	B
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B
and	O
vomiting	B
,	O
drowsiness	O
,	O
confusion	B
,	O
and	O
dry	B
mouth	I
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Ketamine	O
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	O
the	O
pain	B
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O

This	O
effect	O
was	O
more	O
relevant	O
in	O
patients	O
treated	O
with	O
higher	O
doses	O
.	O

Hallucinations	B
occurred	O
in	O
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
"	O
empty	O
head	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O

These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	O
1	O
mg	O
intravenously	O
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	O
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	O
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	O
.	O

Ketamine	O
can	O
improve	O
morphine	O
analgesia	O
in	O
difficult	O
pain	B
syndromes	O
,	O
such	O
as	O
neuropathic	B
pain	I
.	O

However	O
,	O
the	O
occurrence	O
of	O
central	O
adverse	O
effects	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higher	O
doses	O
.	O

This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	O
administration	O
.	O

Paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	B
cell	I
lung	I
carcinoma	I
.	O

BACKGROUND	O
:	O
Cisplatin	O
-	O
based	O
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	B
cell	I
lung	I
carcinoma	I
(	O
NSCLC	B
)	O
.	O

The	O
emergence	O
of	O
new	O
active	O
drugs	O
might	O
translate	O
into	O
more	O
effective	O
regimens	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B
of	O
a	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
to	O
treat	O
metastatic	O
NSCLC	B
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	B
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	O
disease	O
progression	O
,	O
the	O
response	O
and	O
toxicity	B
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	B
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O

An	O
objective	O
response	O
was	O
observed	O
in	O
73	O
.	O
5	O
%	O
of	O
the	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
55	O
.	O
6	O
-	O
87	O
.	O
1	O
%	O
)	O
,	O
including	O
4	O
complete	O
responses	O
(	O
11	O
.	O
7	O
%	O
)	O
.	O

According	O
to	O
intention	O
-	O
to	O
-	O
treat	O
,	O
the	O
overall	O
response	O
rate	O
was	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85	O
.	O
4	O
%	O
)	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	O
(	O
86	O
.	O
2	O
%	O
)	O
.	O

World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B
and	O
thrombocytopenia	B
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
one	O
treatment	O
-	O
related	O
death	B
.	O

Nonhematologic	O
toxicities	B
were	O
mild	O
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
,	O
the	O
median	O
progression	O
free	O
survival	O
rate	O
was	O
7	O
months	O
,	O
and	O
the	O
median	O
survival	O
time	O
was	O
16	O
months	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	B
.	O

This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	O
-	O
based	O
regimens	O
.	O

Serotonergic	O
antidepressants	O
and	O
urinary	B
incontinence	I
.	O

Many	O
new	O
serotonergic	O
antidepressants	O
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urinary	B
incontinence	I
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	B
while	O
taking	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	O
carbonate	O
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B
.	O

Animal	O
studies	O
suggest	O
that	O
incontinence	B
secondary	O
to	O
serotonergic	O
antidepressants	O
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O

Further	O
research	O
is	O
needed	O
to	O
delineate	O
the	O
frequency	O
of	O
this	O
troubling	O
side	O
effect	O
and	O
how	O
best	O
to	O
treat	O
it	O
.	O

Acute	O
cocaine	O
-	O
induced	O
seizures	B
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	B
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	O
.	O

Cocaine	O
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O

Seizure	B
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	B
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	B
.	O

A	O
range	O
of	O
strain	O
specific	O
sensitivities	O
was	O
documented	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mice	O
being	O
most	O
sensitive	O
and	O
C57BL	O
/	O
6J	O
most	O
resistant	O
.	O

DBA	O
/	O
2J	O
,	O
BALB	O
/	O
cByJ	O
and	O
NZW	O
/	O
LacJ	O
strains	O
exhibited	O
intermediate	O
sensitivity	O
.	O

EEG	O
recordings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C57BL	O
/	O
6J	O
mice	O
revealing	O
a	O
close	O
correspondence	O
between	O
electrical	O
activity	O
and	O
behavior	O
.	O

Additionally	O
,	O
levels	O
of	O
cocaine	O
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	O
-	O
induced	O
seizures	B
.	O

Hypotension	B
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	B
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	B
related	O
to	O
disorders	B
of	I
the	I
central	I
nervous	I
system	I
.	O

In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	B
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

Adults	O
chronically	O
treated	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	B
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	B
who	O
developed	O
hypotension	B
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	B
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	O
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	B
or	O
spasticity	B
in	O
such	O
patients	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	O
-	O
carboline	O
-	O
induced	O
seizures	B
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	B
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	O
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Propylthiouracil	O
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	B
in	O
conjunction	O
with	O
pericarditis	B
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	O
-	O
induced	O
vasculitis	B
manifesting	O
with	O
pericarditis	B
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	B
,	O
fever	B
,	O
and	O
glomerulonephritis	B
developed	O
.	O

Serologic	O
testing	O
and	O
immunologic	O
studies	O
were	O
done	O
,	O
and	O
a	O
pericardial	O
biopsy	O
was	O
performed	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	B
'	I
disease	I
had	O
a	O
febrile	B
illness	I
and	O
evidence	O
of	O
pericarditis	B
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

Serologic	O
evaluation	O
revealed	O
the	O
presence	O
of	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
pANCA	O
)	O
against	O
myeloperoxidase	O
(	O
MPO	O
)	O
.	O

Propylthiouracil	O
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1	O
-	O
month	O
course	O
of	O
prednisone	O
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	B
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	B
associated	O
with	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

CONCLUSION	O
:	O
Pericarditis	B
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	B
attributable	O
to	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

Repeated	O
transient	O
anuria	B
following	O
losartan	O
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	B
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	B
renal	I
insufficiency	I
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	B
after	O
losartan	O
administration	O
.	O

He	O
was	O
hospitalized	O
for	O
a	O
myocardial	B
infarction	I
with	O
pulmonary	B
edema	I
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O

Due	O
to	O
severe	O
systolic	B
dysfunction	I
losartan	O
was	O
prescribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	O
resulted	O
in	O
a	O
sudden	O
anuria	B
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	O
and	O
amine	O
infusion	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	O
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	B
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	B
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80	O
%	O
renal	B
artery	I
stenosis	I
.	O

In	O
this	O
patient	O
,	O
renal	B
artery	I
stenosis	I
combined	O
with	O
heart	B
failure	I
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	O
II	O
receptor	O
blockade	O
by	O
losartan	O
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
losartan	O
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	B
disease	I
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	O
pain	B
syndrome	O
(	O
CIPS	B
)	O
:	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation	O
.	O

Bone	O
pain	B
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases	O
.	O

Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	B
.	O

Nine	O
patients	O
with	O
severe	O
pain	B
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O

Bone	O
scans	O
showed	O
an	O
increased	O
tracer	O
uptake	O
of	O
the	O
foot	O
bones	O
.	O

Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	B
marrow	I
oedema	I
in	O
the	O
painful	O
bones	O
.	O

Pain	B
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	B
,	O
like	O
reflex	B
sympathetic	I
dystrophy	I
,	O
polyneuropathy	B
,	O
Morton	B
'	I
s	I
neuralgia	I
,	O
gout	B
,	O
osteoporosis	B
,	O
avascular	B
necrosis	I
,	O
intermittent	B
claudication	I
,	O
orthopaedic	O
foot	B
deformities	I
,	O
stress	B
fractures	I
,	O
and	O
hyperparathyroidism	B
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	O
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	B
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	B
Syndrome	O
(	O
CIPS	B
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	B
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B
.	O

Anthracyclines	O
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	B
.	O

The	O
cardiotoxicity	B
of	O
conventional	O
anthracycline	O
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	B
dysfunction	I
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B
in	O
patients	O
with	O
acute	B
leukemia	I
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

Thirteen	O
patients	O
with	O
acute	B
leukemia	I
were	O
treated	O
with	O
a	O
DNR	O
-	O
containing	O
regimen	O
.	O

Cardiac	O
functions	O
were	O
evaluated	O
with	O
radionuclide	O
angiography	O
before	O
chemotherapies	O
.	O

The	O
plasma	O
levels	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
measured	O
at	O
the	O
time	O
of	O
radionuclide	O
angiography	O
.	O

Three	O
patients	O
developed	O
congestive	B
heart	I
failure	I
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B
failure	I
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B
failure	I
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	B
failure	I
by	O
radionuclide	O
angiography	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	B
failure	I
given	O
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B
failure	I
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B
.	O

Nephrotoxicity	B
of	O
combined	O
cephalothin	O
-	O
gentamicin	O
regimen	O
.	O

Two	O
patients	O
developed	O
acute	B
tubular	I
necrosis	I
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	B
renal	I
failure	I
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	O
.	O

Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	B
.	O

High	O
doses	O
of	O
this	O
antibiotic	O
combination	O
should	O
be	O
avoided	O
especially	O
in	O
elderly	O
patients	O
.	O

Patients	O
with	O
renal	B
insufficiency	I
should	O
not	O
be	O
given	O
this	O
regimen	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	B
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	B
,	O
amiodarone	O
-	O
induced	O
lung	B
toxicity	I
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

Grape	O
seed	O
extract	O
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	B
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	B
toxicity	I
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	B
in	O
mice	O
.	O

Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	O
alone	O
,	O
drug	O
alone	O
and	O
GSPE	O
+	O
drug	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Parameters	O
of	O
study	O
included	O
analysis	O
of	O
serum	O
chemistry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmentation	O
of	O
genomic	O
DNA	O
(	O
both	O
endonuclease	O
-	O
dependent	O
and	O
independent	O
)	O
in	O
addition	O
to	O
microscopic	O
evaluation	O
of	O
damage	O
and	O
/	O
or	O
protection	O
in	O
corresponding	O
PAS	O
stained	O
tissues	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	O
prior	O
to	O
AAP	O
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	B
damage	I
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	O
preexposure	O
than	O
in	O
its	O
presence	O
.	O

GSPE	O
+	O
drug	O
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O

Additionally	O
,	O
histopathological	O
alterations	O
mirrored	O
both	O
serum	O
chemistry	O
changes	O
and	O
the	O
pattern	O
of	O
DNA	O
fragmentation	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	B
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
repair	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevention	O
process	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	O
-	O
induced	O
apoptotic	O
death	O
in	O
the	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	O
'	O
s	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O

Antidepressant	O
-	O
induced	O
mania	B
in	O
bipolar	B
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	B
associated	O
with	O
antidepressants	O
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B
depression	I
.	O

METHOD	O
:	O
The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
bipolar	B
disorder	I
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	B
or	O
hypomanic	B
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	B
-	I
IV	I
bipolar	I
I	I
vs	O
.	O
bipolar	B
II	I
)	O
,	O
number	O
of	O
previous	O
manic	B
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O

a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	B
or	O
mania	B
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	B
episodes	O
.	O

Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B
I	I
vs	O
.	O
bipolar	B
II	I
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

The	O
incidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patients	O
receiving	O
an	O
anticonvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabilizer	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	O
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	O
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

The	O
number	O
of	O
previous	O
manic	B
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	O
therapy	O
may	O
be	O
reduced	O
by	O
lithium	O
treatment	O
.	O

Particular	O
attention	O
should	O
be	O
paid	O
to	O
patients	O
with	O
a	O
hyperthymic	O
temperament	O
,	O
who	O
have	O
a	O
greater	O
risk	O
of	O
mood	O
switches	O
.	O

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	B
disease	I
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B
glomerulopathy	I
(	O
TG	B
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

Although	O
such	O
an	O
association	O
is	O
of	O
practical	O
and	O
theoretical	O
importance	O
,	O
only	O
one	O
prospective	O
study	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

METHODS	O
:	O
We	O
examined	O
278	O
consecutive	O
renal	O
specimens	O
(	O
from	O
135	O
transplants	O
and	O
143	O
native	O
kidneys	O
)	O
for	O
ultrastructural	O
evidence	O
of	O
PTCR	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	B
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	B
,	O
chronic	B
allograft	I
nephropathy	I
and	O
stable	O
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	B
as	O
well	O
as	O
cases	O
of	O
thrombotic	B
microangiopathy	I
,	O
malignant	B
hypertension	I
,	O
acute	O
interstitial	B
nephritis	I
,	O
and	O
acute	B
tubular	I
necrosis	I
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	B
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	B
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	B
hypertension	I
,	O
thrombotic	B
microangiopathy	I
,	O
lupus	B
nephritis	I
,	O
Henoch	B
-	I
Schonlein	I
nephritis	I
,	O
crescentic	O
glomerulonephritis	B
,	O
and	O
cocaine	O
-	O
related	O
acute	B
renal	I
failure	I
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	B
did	O
not	O
predict	O
renal	B
failure	I
or	O
significant	O
proteinuria	B
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	B
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	B
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B
diseases	I
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	B
.	O

We	O
suggest	O
that	O
repeated	O
endothelial	B
injury	I
,	O
including	O
immunologic	B
injury	I
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

Caffeine	O
-	O
induced	O
cardiac	B
arrhythmia	I
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	B
valve	I
prolapse	I
who	O
developed	O
intractable	O
ventricular	B
fibrillation	I
after	O
consuming	O
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	O
.	O

This	O
case	O
highlights	O
the	O
need	O
for	O
adequate	O
labelling	O
and	O
regulation	O
of	O
such	O
products	O
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	O
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	O
effects	O
in	O
mice	O
.	O

Cocaine	O
'	O
s	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O

-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Competition	O
binding	O
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
affinities	O
for	O
sigma1	O
receptors	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	O
,	O
opioid	O
,	O
GABA	O
(	O
A	O
)	O
and	O
NMDA	O
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	O
attenuated	O
cocaine	O
-	O
induced	O
convulsions	B
and	O
lethality	O
.	O

Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	O
prevented	O
cocaine	O
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B
of	O
cocaine	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	O
,	O
BD1063	O
and	O
LR132	O
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	B
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	O
-	O
induced	O
behaviors	O
.	O

Ranitidine	O
-	O
induced	O
acute	O
interstitial	B
nephritis	I
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O

Ranitidine	O
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation	O
.	O

This	O
drug	O
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	B
nephritis	I
in	O
native	O
kidneys	O
.	O

There	O
are	O
no	O
similar	O
reports	O
with	O
renal	O
transplantation	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine	O
-	O
induced	O
acute	O
interstitial	B
nephritis	I
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O

The	O
biopsy	O
specimen	O
showed	O
pathognomonic	O
features	O
,	O
including	O
eosinophilic	O
infiltration	O
of	O
the	O
interstitial	O
compartment	O
.	O

Allograft	O
function	O
improved	O
rapidly	O
and	O
returned	O
to	O
baseline	O
after	O
stopping	O
the	O
drug	O
.	O

Liver	B
disease	I
caused	O
by	O
propylthiouracil	O
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B
active	I
(	I
aggressive	I
)	I
hepatitis	I
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	O
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	B
disease	I
.	O

Withdrawal	B
-	I
emergent	I
rabbit	I
syndrome	I
during	O
dose	O
reduction	O
of	O
risperidone	O
.	O

Rabbit	B
syndrome	I
(	O
RS	B
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal	B
-	I
emergent	I
RS	I
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
patient	O
developed	O
RS	B
during	O
dose	O
reduction	O
of	O
risperidone	O
.	O

The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	O
anticholinergic	O
therapy	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	B
-	I
emergent	I
RS	I
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	B
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	O
,	O
cisapride	O
,	O
terfenadine	O
and	O
terodiline	O
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

1	O
.	O

Torsades	B
de	I
pointes	I
(	O
TDP	B
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	B
tachycardia	I
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

TDP	B
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	O
and	O
terodiline	O
)	O
.	O

2	O
.	O

The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	B
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	B
were	O
investigated	O
:	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
and	O
E4031	O
.	O

On	O
the	O
basis	O
that	O
only	O
free	O
drug	O
in	O
the	O
systemic	O
circulation	O
will	O
elicit	O
a	O
pharmacological	O
response	O
target	O
,	O
free	O
concentrations	O
in	O
plasma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
drug	O
exposures	O
in	O
man	O
.	O

Infusion	O
regimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
target	O
-	O
free	O
concentrations	O
of	O
these	O
drugs	O
in	O
plasma	O
and	O
data	O
on	O
the	O
relationship	O
between	O
free	O
concentration	O
and	O
changes	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compounds	O
.	O

3	O
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	O
(	O
76	O
nM	O
)	O
,	O
cisapride	O
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	B
in	O
the	O
clinic	O
(	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	B
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O

Bladder	O
retention	B
of	I
urine	I
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	O
:	O
2	O
case	O
reports	O
.	O

Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	O
and	O
pain	B
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O

Fentanyl	O
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	O
chest	B
wall	I
rigidity	I
,	O
hypotension	B
,	O
respiratory	B
depression	I
,	O
and	O
bradycardia	B
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	B
bladder	I
retention	I
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	O
are	O
reported	O
.	O

Fatal	O
myeloencephalopathy	B
due	O
to	O
accidental	O
intrathecal	O
vincristin	O
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	O
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	B
lymphoblastic	I
leucemia	I
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	B
lymphoma	I
.	O

The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	O
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	B
,	I
sensory	I
and	I
motor	I
dysfunction	I
and	O
ascending	O
paralysis	B
.	O

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	B
of	I
myelin	I
and	I
axons	I
as	O
well	O
as	O
pseudocystic	B
transformation	I
in	O
areas	O
exposed	O
to	O
vincristine	O
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

The	O
clinical	O
course	O
and	O
histopathological	O
results	O
of	O
the	O
two	O
cases	O
are	O
presented	O
.	O

A	O
review	O
of	O
all	O
reported	O
cases	O
in	O
the	O
literature	O
is	O
given	O
.	O

A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	O
and	O
intrathecal	O
chemotherapy	O
is	O
recommended	O
.	O

Palpebral	B
twitching	I
in	O
a	O
depressed	B
adolescent	O
on	O
citalopram	O
.	O

Current	O
estimates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B
depression	I
.	O

We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	O
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	B
depression	I
who	O
exhibited	O
palpebral	B
twitching	I
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	O
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O

The	O
3	O
-	O
week	O
sulphasalazine	O
syndrome	O
strikes	O
again	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	B
,	O
fever	B
,	O
lymphadenopathy	B
and	O
hepatitis	B
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	B
arthritis	I
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	B
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B
drug	I
reaction	I
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B
-	I
induced	I
hepatitis	I
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	B
)	O
,	O
and	O
accompanied	O
by	O
multi	B
-	I
organ	I
failure	I
and	O
sepsis	B
,	O
supervened	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	B
hepatocellular	I
necrosis	I
,	O
acute	O
hypersensitivity	O
myocarditis	B
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	B
and	O
extensive	O
bone	B
marrow	I
necrosis	I
,	O
with	O
no	O
evidence	O
of	O
malignancy	B
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphasalazine	O
syndrome	O
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
.	O

Intravenous	O
administration	O
of	O
prochlorperazine	O
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	B
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	B
after	O
administration	O
of	O
intravenous	O
prochlorperazine	O
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
in	O
the	O
emergency	O
department	O
of	O
a	O
central	O
-	O
city	O
teaching	O
hospital	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	O
for	O
headache	B
,	O
nausea	B
,	O
or	O
vomiting	B
were	O
eligible	O
for	O
inclusion	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	O
administered	O
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	B
within	O
60	O
minutes	O
of	O
administration	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	B
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	B
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	B
rating	O
scale	O
.	O

The	O
intensity	O
of	O
headache	B
and	O
nausea	B
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

RESULTS	O
:	O
One	O
hundred	O
patients	O
were	O
enrolled	O
.	O

One	O
study	O
participant	O
was	O
excluded	O
after	O
protocol	O
violation	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	B
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nausea	B
.	O

In	O
the	O
bolus	O
group	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akathisia	B
compared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B
intensity	O
within	O
30	O
minutes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	B
when	O
prochlorperazine	O
was	O
administered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	O
in	O
the	O
treatment	O
of	O
headache	B
and	O
nausea	B
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B
and	O
elevates	O
plasma	O
lactate	O
in	O
transgenic	O
AIDS	B
mice	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	B
(	O
CM	B
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	B
through	O
mechanisms	O
of	O
mitochondrial	B
dysfunction	I
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	B
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	O
,	O
lamivudine	O
,	O
and	O
indinavir	O
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	B
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	O
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	O
.	O

Myocardial	O
histologic	O
features	O
were	O
analyzed	O
semiquantitatively	O
and	O
results	O
were	O
confirmed	O
by	O
transmission	O
electron	O
microscopy	O
.	O

After	O
35	O
days	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
,	O
left	O
ventricular	O
mass	O
increased	O
160	O
%	O
by	O
echocardiography	O
.	O

Molecularly	O
,	O
ANF	O
mRNA	O
increased	O
250	O
%	O
and	O
SERCA2	O
mRNA	O
decreased	O
57	O
%	O
.	O

Biochemically	O
,	O
LA	O
was	O
elevated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Pathologically	O
,	O
granular	O
cytoplasmic	O
changes	O
were	O
found	O
in	O
cardiac	O
myocytes	O
,	O
indicating	O
enlarged	O
,	O
damaged	O
mitochondria	O
.	O

Findings	O
were	O
confirmed	O
ultrastructurally	O
.	O

No	O
changes	O
were	O
found	O
in	O
other	O
cohorts	O
.	O

After	O
10	O
days	O
,	O
only	O
ANF	O
was	O
elevated	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
.	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	B
with	O
elevated	O
LA	O
in	O
AIDS	B
transgenic	O
mice	O
.	O

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	O
plus	O
WR	O
-	O
2721	O
(	O
amifostine	O
)	O
for	O
metastatic	O
breast	B
carcinoma	I
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B
carcinoma	I
.	O

Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	O
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	B
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B
,	O
ototoxicity	B
,	O
and	O
neurotoxicity	B
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B
carcinoma	I
.	O

WR	O
-	O
2721	O
or	O
amifostine	O
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

Amifostine	O
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	O
agents	O
and	O
cisplatin	O
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	B
,	O
ototoxicity	B
,	O
and	O
neuropathy	B
were	O
reduced	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	O
plus	O
amifostine	O
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	B
carcinoma	I
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Patients	O
received	O
amifostine	O
,	O
910	O
mg	O
/	O
m2	O
intravenously	O
over	O
15	O
minutes	O
.	O

After	O
completion	O
of	O
the	O
amifostine	O
infusion	O
,	O
cisplatin	O
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O

Intravenous	O
hydration	O
and	O
mannitol	O
was	O
administered	O
before	O
and	O
after	O
cisplatin	O
.	O

Treatment	O
was	O
administered	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
.	O

RESULTS	O
:	O
Forty	O
-	O
four	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineligible	O
.	O

A	O
median	O
of	O
2	O
cycles	O
of	O
therapy	O
was	O
administered	O
to	O
the	O
37	O
eligible	O
patients	O
.	O

Six	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

Most	O
patients	O
(	O
57	O
%	O
)	O
stopped	O
treatment	O
because	O
of	O
disease	O
progression	O
.	O

Neurologic	B
toxicity	I
was	O
reported	O
in	O
52	O
%	O
of	O
patients	O
.	O

Seven	O
different	O
life	O
-	O
threatening	O
toxicities	B
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
cisplatin	O
and	O
amifostine	O
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tumor	B
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	B
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	O
to	O
cisplatin	O
in	O
this	O
trial	O
.	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
myocardial	B
infarction	I
.	O

BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
myocardial	B
infarction	I
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B
infarction	I
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O

women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B
infarction	I
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Subjects	O
supplied	O
information	O
on	O
oral	O
-	O
contraceptive	O
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	B
infarction	I
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	O
contraceptive	O
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	O
contraceptives	O
.	O

Among	O
women	O
who	O
used	O
oral	O
contraceptives	O
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B
infarction	I
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	O
contraceptives	O
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

The	O
risk	O
of	O
myocardial	B
infarction	I
was	O
similar	O
among	O
women	O
who	O
used	O
oral	O
contraceptives	O
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

End	B
-	I
stage	I
renal	I
disease	I
(	O
ESRD	B
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

BACKGROUND	O
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	O
and	O
tacrolimus	O
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B
.	O

Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B
-	I
stage	I
renal	I
disease	I
(	O
ESRD	B
)	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B
and	O
chronic	B
renal	I
failure	I
(	O
CRF	B
)	O
in	O
OLTX	O
patients	O
.	O

METHODS	O
:	O
Patients	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B
or	O
ESRD	B
,	O
n	O
=	O
748	O
;	O
CRF	B
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B
,	O
n	O
=	O
45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B
dysfunction	I
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B
8	O
.	O
6	O
%	O
and	O
ESRD	B
9	O
.	O
5	O
%	O
)	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	B
and	O
ESRD	B
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B
syndrome	I
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	O
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B
or	O
ESRD	B
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B
was	O
only	O
28	O
.	O
2	O
%	O
compared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
control	O
group	O
.	O

Patients	O
developing	O
ESRD	B
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B
and	O
ESRD	B
at	O
a	O
high	O
rate	O
.	O

The	O
development	O
of	O
ESRD	B
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Patients	O
who	O
develop	O
ESRD	B
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	O
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B
syndrome	I
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	O
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B
or	O
ESRD	B
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O

Epileptic	B
seizures	I
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	O
acid	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
Fibrin	O
sealants	O
(	O
FS	O
)	O
derived	O
from	O
human	O
plasma	O
are	O
frequently	O
used	O
in	O
neurosurgery	O
.	O

In	O
order	O
to	O
increase	O
clot	O
stability	O
,	O
FS	O
typically	O
contain	O
aprotinin	O
,	O
a	O
natural	O
fibrinolysis	O
inhibitor	O
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	O
acid	O
(	O
tAMCA	O
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O

However	O
,	O
tAMCA	O
has	O
been	O
shown	O
to	O
cause	O
epileptic	B
seizures	I
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	O
retains	O
its	O
convulsive	B
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O

The	O
response	O
of	O
the	O
animals	O
was	O
evaluated	O
using	O
electroencephalography	O
and	O
by	O
monitoring	O
the	O
clinical	O
behaviour	O
during	O
and	O
after	O
recovery	O
from	O
anaesthesia	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	O
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B
behaviours	O
.	O

The	O
degree	O
of	O
these	O
seizures	B
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	O
evoked	O
generalized	B
seizures	I
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	B
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

In	O
contrast	O
,	O
FS	O
containing	O
aprotinin	O
did	O
not	O
evoke	O
any	O
paroxysmal	O
activity	O
.	O

INTERPRETATION	O
:	O
Tranexamic	O
acid	O
retains	O
its	O
convulsive	B
action	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	O
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

Sequential	O
observations	O
of	O
exencephaly	B
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	B
to	O
anencephaly	B
.	O

Anencephaly	B
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	B
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

We	O
examined	O
this	O
theory	O
using	O
the	O
exo	O
utero	O
development	O
system	O
that	O
allows	O
direct	O
and	O
sequential	O
observations	O
of	O
mid	O
-	O
to	O
late	O
-	O
gestation	O
mouse	O
embryos	O
.	O

We	O
observed	O
the	O
exencephaly	B
induced	O
by	O
5	O
-	O
azacytidine	O
at	O
embryonic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	B
to	O
anencephaly	B
.	O

However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	B
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	B
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	B
tissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	B
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	B
at	O
E18	O
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	B
tissue	O
at	O
E13	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	B
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	B
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	B
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B
tissue	O
at	O
E18	O
.	O
5	O
.	O

From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	B
head	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	B
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	B
failure	I
and	O
/	O
or	O
hemorrhaging	B
in	O
various	O
parts	O
of	O
the	O
exencephalic	B
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	B
to	O
anencephaly	B
.	O

99mTc	O
-	O
glucarate	O
for	O
detection	O
of	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

Infarct	B
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B
infarction	I
.	O

The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	B
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	O
.	O

A	O
new	O
infarct	B
-	O
avid	O
radiopharmaceutical	O
based	O
on	O
glucaric	O
acid	O
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc	O
-	O
glucarate	O
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	O
-	O
induced	O
acute	O
myocardial	B
infarction	I
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	B
18	O
h	O
after	O
isoproterenol	O
administration	O
.	O

The	O
rat	O
biodistribution	O
studies	O
showed	O
a	O
rapid	O
blood	O
clearance	O
via	O
the	O
kidneys	O
.	O

Thirty	O
minutes	O
after	O
99mTc	O
-	O
glucarate	O
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O

ROIs	O
drawn	O
over	O
the	O
gamma	O
camera	O
images	O
showed	O
a	O
ratio	O
of	O
4	O
.	O
4	O
.	O

The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect	O
,	O
in	O
patients	O
,	O
early	O
cardiac	B
infarction	I
.	O

Bupropion	O
(	O
Zyban	O
)	O
toxicity	B
.	O

Bupropion	O
is	O
a	O
monocyclic	O
antidepressant	O
structurally	O
related	O
to	O
amphetamine	O
.	O

Zyban	O
,	O
a	O
sustained	O
-	O
release	O
formulation	O
of	O
bupropion	O
hydrochloride	O
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
months	O
since	O
it	O
'	O
s	O
introduction	O
,	O
12	O
overdose	B
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O

8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	B
.	O

Common	O
features	O
included	O
tachycardia	B
,	O
drowsiness	O
,	O
hallucinations	B
and	O
convulsions	B
.	O

Two	O
patients	O
developed	O
severe	O
cardiac	B
arrhythmias	I
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B
arrest	I
.	O

All	O
patients	O
recovered	O
without	O
sequelae	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13	O
.	O
5g	O
bupropion	O
.	O

Recurrent	O
seizures	B
were	O
treated	O
with	O
diazepam	O
and	O
broad	O
complex	O
tachycardia	B
was	O
successfully	O
treated	O
with	O
adenosine	O
.	O

Zyban	O
caused	O
significant	O
neurological	B
and	I
cardiovascular	I
toxicity	I
in	O
overdose	B
.	O

The	O
potential	O
toxic	O
effects	O
should	O
be	O
considered	O
when	O
prescribing	O
it	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

GLEPP1	O
receptor	O
tyrosine	O
phosphatase	O
(	O
Ptpro	O
)	O
in	O
rat	O
PAN	O
nephrosis	B
.	O

A	O
marker	O
of	O
acute	O
podocyte	O
injury	O
.	O

Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	O
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O

This	O
receptor	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
structure	O
and	O
function	O
of	O
podocyte	O
foot	O
process	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B
injury	I
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

Puromycin	O
aminonucleoside	O
nephrosis	B
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	B
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	B
associated	O
with	O
glomerulosclerosis	B
(	O
days	O
45	O
-	O
126	O
)	O
.	O

At	O
day	O
5	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
reduced	O
from	O
the	O
normal	O
range	O
(	O
265	O
.	O
2	O
+	O
/	O
-	O
79	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
moles	O
/	O
glomerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
normal	O
(	O
41	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
8	O
x	O
10	O
(	O
6	O
)	O
moles	O
/	O
glomerulus	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

This	O
occurred	O
in	O
association	O
with	O
an	O
increase	O
in	O
urinary	O
protein	O
content	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
1	O
to	O
99	O
.	O
0	O
+	O
/	O
-	O
61	O
mg	O
/	O
day	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
contrast	O
,	O
podocalyxin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
time	O
.	O

By	O
day	O
11	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
baseline	O
.	O

By	O
day	O
45	O
-	O
126	O
,	O
at	O
a	O
time	O
when	O
glomerular	O
scarring	O
was	O
present	O
,	O
GLEPP1	O
was	O
absent	O
from	O
glomerulosclerotic	O
areas	O
although	O
the	O
total	O
glomerular	O
content	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
normal	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	O
.	O

GLEPP1	O
expression	O
may	O
be	O
a	O
useful	O
marker	O
of	O
podocyte	O
injury	O
.	O

Antithymocyte	O
globulin	O
in	O
the	O
treatment	O
of	O
D	O
-	O
penicillamine	O
-	O
induced	O
aplastic	B
anemia	I
.	O

A	O
patient	O
who	O
received	O
antithymocyte	O
globulin	O
therapy	O
for	O
aplastic	B
anemia	I
due	O
to	O
D	O
-	O
penicillamine	O
therapy	O
is	O
described	O
.	O

Bone	O
marrow	O
recovery	O
and	O
peripheral	O
blood	O
recovery	O
were	O
complete	O
1	O
month	O
and	O
3	O
months	O
,	O
respectively	O
,	O
after	O
treatment	O
,	O
and	O
blood	O
transfusion	O
or	O
other	O
therapies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
period	O
of	O
more	O
than	O
2	O
years	O
.	O

Use	O
of	O
antithymocyte	O
globulin	O
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	O
-	O
penicillamine	O
-	O
induced	O
aplastic	B
anemia	I
.	O

Metamizol	O
potentiates	O
morphine	O
antinociception	O
but	O
not	O
constipation	B
after	O
chronic	O
treatment	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	B
effects	O
of	O
the	O
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	O
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	B
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	O
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

Simultaneous	O
administration	O
of	O
morphine	O
with	O
metamizol	O
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	O
administration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Antinociceptive	O
effect	O
of	O
morphine	O
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxone	O
s	O
.	O
c	O
.	O

(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
suggesting	O
the	O
partial	O
involvement	O
of	O
the	O
opioidergic	O
system	O
in	O
the	O
synergism	O
observed	O
.	O

In	O
independent	O
groups	O
,	O
morphine	O
inhibited	O
the	O
intestinal	O
transit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	B
effects	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	O
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	O
-	O
induced	O
constipation	B
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	O
and	O
metamizol	O
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	B
pain	I
.	O

Ifosfamide	O
encephalopathy	B
presenting	O
with	O
asterixis	B
.	O

CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	O
(	O
IFX	O
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	B
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	O
for	O
plasmacytoma	B
.	O

He	O
was	O
awake	O
,	O
revealed	O
no	O
changes	O
of	O
mental	O
status	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
motor	O
symptoms	O
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	B
lesions	I
of	I
the	I
brain	I
and	O
metabolic	B
abnormalities	I
.	O

An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	B
.	O

The	O
administration	O
of	O
ifosfamide	O
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	B
resolved	O
completely	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	B
during	O
infusion	O
of	O
ifosfamide	O
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	B
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	O
-	O
induced	O
anemia	B
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Azidothymidine	O
(	O
AZT	O
)	O
-	O
induced	O
anemia	B
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Although	O
interleukin	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	O
-	O
treated	O
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
antagonistic	O
effect	O
of	O
IL	O
-	O
3	O
and	O
EPO	O
on	O
erythroid	O
cells	O
may	O
be	O
mediated	O
by	O
endothelial	O
cells	O
.	O

Bovine	O
liver	O
erythroid	O
cells	O
were	O
cultured	O
on	O
monolayers	O
of	O
human	O
bone	O
marrow	O
endothelial	O
cells	O
previously	O
treated	O
with	O
EPO	O
and	O
IGF	O
-	O
IL	O
-	O
3	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	O
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
reduced	O
thymidine	O
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
endothelial	O
cells	O
treated	O
simultaneously	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
negative	O
effect	O
on	O
erythroid	O
cell	O
production	O
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	B
-	O
prone	O
and	O
withdrawal	O
seizure	B
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O

BACKGROUND	O
:	O
The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	O
withdrawal	O
severity	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	O
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	O
withdrawal	O
severity	O
.	O

METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	O
-	O
na	O
ve	O
Withdrawal	O
Seizure	B
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O

Animals	O
were	O
administered	O
nicotine	O
,	O
carbachol	O
,	O
or	O
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	B
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	O
-	O
stimulated	O
acetylcholine	O
(	O
ACh	O
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

Potassium	O
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	O
also	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	B
endpoints	O
induced	O
by	O
nicotine	O
,	O
carbachol	O
,	O
and	O
neostigmine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	O
,	O
and	O
50	O
mM	O
KCl	O
increased	O
ACh	O
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	O
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	O
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

When	O
hippocampal	O
ACh	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B
,	O
extracellular	O
ACh	O
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	B
may	O
be	O
associated	O
with	O
ethanol	O
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	O
withdrawal	O
.	O

Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	B
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O

Capsaicin	O
-	O
induced	O
muscle	B
pain	I
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

The	O
pathophysiology	O
of	O
painful	O
temporomandibular	B
disorders	I
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	B
pain	I
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
nociceptive	B
muscle	I
afferent	O
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch	O
.	O

Capsaicin	O
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	B
in	O
11	O
healthy	O
volunteers	O
.	O

Short	O
-	O
latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	B
.	O

The	O
normalized	O
reflex	O
amplitude	O
increased	O
with	O
an	O
increase	O
in	O
velocity	O
at	O
a	O
given	O
displacement	O
,	O
but	O
remained	O
constant	O
with	O
different	O
displacements	O
at	O
a	O
given	O
velocity	O
.	O

The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	B
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	B
muscle	I
.	O

Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	B
pain	I
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O

Effects	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	O
-	O
induced	O
locomotor	B
hyperactivity	I
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B
hyperactivity	I
induced	O
by	O
cocaine	O
in	O
rats	O
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	O
55562	O
(	O
an	O
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	O
93129	O
(	O
an	O
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Systemic	O
cocaine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O

GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	O
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	B
hyperactivity	I
.	O

Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	O
55562	O
into	O
the	O
accumbens	O
core	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	O
,	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	O
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	O
with	O
GR	O
55562	O
(	O
1	O
microg	O
/	O
side	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	O
induced	O
hyperlocomotion	B
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

In	O
other	O
words	O
,	O
the	O
present	O
results	O
suggest	O
that	O
the	O
accumbal	O
shell	O
5	O
-	O
HT1B	O
receptors	O
play	O
a	O
permissive	O
role	O
in	O
the	O
behavioural	O
response	O
to	O
the	O
psychostimulant	O
.	O

Cocaine	O
related	O
chest	B
pain	I
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O

The	O
recreational	O
use	O
of	O
cocaine	O
is	O
on	O
the	O
increase	O
.	O

The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	O
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	O
to	O
produce	O
chest	B
pain	I
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	B
pain	I
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

The	O
mechanism	O
of	O
chest	B
pain	I
related	O
to	O
cocaine	O
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	O
users	O
will	O
be	O
addressed	O
.	O

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	O
10	O
mg	O
versus	O
ergotamine	O
/	O
caffeine	O
in	O
migraine	B
.	O

Rizatriptan	O
is	O
a	O
selective	O
5	O
-	O
HT	O
(	O
1B	O
/	O
1D	O
)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	B
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	O
1	O
mg	O
/	O
caffeine	O
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	B
attack	O
with	O
each	O
therapy	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	O
to	O
ergotamine	O
/	O
caffeine	O
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Faster	O
relief	O
of	O
headache	B
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	O
and	O
54	O
.	O
2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine	O
/	O
caffeine	O
.	O

The	O
co	O
-	O
primary	O
endpoint	O
of	O
being	O
pain	B
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	B
free	O
2	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Headache	B
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
30	O
min	O
of	O
dosing	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	O
were	O
pain	B
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	B
,	O
vomiting	B
,	O
phonophobia	B
or	O
photophobia	B
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	O
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Recurrence	O
rates	O
were	O
31	O
.	O
4	O
%	O
with	O
rizatriptan	O
and	O
15	O
.	O
3	O
%	O
with	O
ergotamine	O
/	O
caffeine	O
.	O

Both	O
active	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	O
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	B
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	B
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	B
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Severe	O
ocular	B
and	I
orbital	I
toxicity	I
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	O
glioblastomas	B
.	O

BACKGROUND	O
:	O
Glioblastoma	B
is	O
a	O
malignant	B
tumor	I
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

With	O
current	O
treatment	O
regimens	O
including	O
combined	O
surgery	O
,	O
radiation	O
and	O
chemotherapy	O
,	O
the	O
average	O
life	O
expectancy	O
of	O
the	O
patients	O
is	O
limited	O
to	O
approximately	O
1	O
year	O
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	B
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Generally	O
,	O
carboplatin	O
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	O
,	O
whose	O
ocular	B
and	I
orbital	I
toxicity	I
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	B
and	I
orbital	I
toxicity	I
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	O
glioblastomas	B
in	O
his	O
left	O
temporal	O
lobe	O
.	O

He	O
complained	O
of	O
pain	B
and	I
visual	I
disturbance	I
in	I
the	I
ipsilateral	I
eye	I
30	O
h	O
after	O
the	O
injection	O
.	O

Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	O
toxicity	B
were	O
seen	O
.	O

RESULTS	O
:	O
He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	O
and	O
glycerin	O
for	O
6	O
days	O
after	O
the	O
injection	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	B
decreased	O
and	O
ocular	B
pain	I
diminished	O
,	O
inexorable	O
papilledema	B
and	O
exudative	O
retinal	B
detachment	I
continued	O
for	O
3	O
weeks	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	B
atrophy	I
with	O
optic	B
atrophy	I
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	B
toxicity	I
.	O

It	O
is	O
recommended	O
that	O
further	O
studies	O
and	O
investigations	O
are	O
undertaken	O
in	O
the	O
effort	O
to	O
minimize	O
such	O
severe	O
side	O
effects	O
.	O

Visual	B
hallucinations	I
associated	O
with	O
zonisamide	O
.	O

Zonisamide	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	B
.	O

Although	O
visual	B
hallucinations	I
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	B
hallucinations	I
and	O
altered	O
mental	O
status	O
after	O
zonisamide	O
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	B
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O

During	O
monitoring	O
,	O
visual	B
hallucinations	I
did	O
not	O
correlate	O
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O

None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B
hallucinations	I
before	O
this	O
event	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	O
.	O

With	O
either	O
discontinuation	O
or	O
decreased	O
dosage	O
of	O
the	O
drug	O
the	O
symptoms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O

Further	O
observations	O
and	O
reports	O
will	O
help	O
clarify	O
this	O
adverse	O
effect	O
.	O

Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	O
.	O

Anti	O
-	O
epileptic	B
drugs	O
-	O
induced	O
de	O
novo	O
absence	B
seizures	I
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B
epilepsy	I
after	O
administration	O
of	O
carbamazepine	O
and	O
vigabatrin	O
.	O

Despite	O
the	O
underlying	O
diseases	O
,	O
the	O
prognosis	O
for	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B
seizure	I
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O

The	O
gamma	O
-	O
aminobutyric	O
acid	O
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	B
epilepsy	I
.	O

Because	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B
seizure	I
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O

The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	B
seizure	I
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	B
frequency	O
and	O
/	O
or	O
new	O
seizure	B
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	B
epilepsy	I
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	B
and	O
prevent	O
drug	O
-	O
induced	O
absence	B
seizures	I
.	O

Prenatal	O
dexamethasone	O
programs	O
hypertension	B
and	O
renal	B
injury	I
in	O
the	O
rat	O
.	O

Dexamethasone	O
is	O
frequently	O
administered	O
to	O
the	O
developing	O
fetus	O
to	O
accelerate	O
pulmonary	O
development	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	O
programmed	O
a	O
progressive	O
increase	B
in	I
blood	I
pressure	I
and	O
renal	B
injury	I
in	O
rats	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offspring	O
of	O
rats	O
administered	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	B
in	I
glomerular	I
number	I
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six	O
-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	O
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	B
blood	I
pressures	I
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	B
in	I
glomerular	I
number	I
.	O

Adult	O
rats	O
given	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	B
than	O
control	O
rats	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	O
in	O
rats	O
results	O
in	O
a	O
reduction	B
in	I
glomerular	I
number	I
,	O
glomerulosclerosis	B
,	O
and	O
hypertension	B
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

Hypertension	B
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	B
in	I
glomerular	I
number	I
,	O
suggesting	O
that	O
a	O
reduction	B
in	I
glomerular	I
number	I
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	B
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	O
with	O
cyclosporine	O
A	O
,	O
tacrolimus	O
and	O
sirolimus	O
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
Sirolimus	O
(	O
SRL	O
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

These	O
are	O
nephrotoxic	B
,	O
but	O
SRL	O
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	B
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	O
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	B
effect	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	O
A	O
(	O
CsA	O
)	O
,	O
tacrolimus	O
(	O
FK506	O
)	O
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	O
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

In	O
the	O
'	O
conscious	O
catheterized	O
rat	O
'	O
model	O
,	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
was	O
measured	O
as	O
the	O
clearance	O
of	O
Cr	O
(	O
EDTA	O
)	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	B
,	O
subcapsular	O
fibrosis	B
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

RESULTS	O
:	O
CsA	O
,	O
FK506	O
and	O
SRL	O
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

The	O
morphological	O
changes	O
presented	O
a	O
similar	O
pattern	O
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	O
plus	O
SRL	O
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
FK506	O
plus	O
SRL	O
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	B
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	B
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	B
damage	I
in	O
doxorubicin	O
-	O
induced	O
cardiomyopathy	B
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	B
cell	I
injury	I
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B
damage	I
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	B
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	B
disorders	I
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wistar	O
rats	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	O
,	O
i	O
.	O
v	O
.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

Ten	O
rats	O
received	O
saline	O
as	O
a	O
control	O
group	O
.	O

cTnI	O
was	O
measured	O
with	O
Access	O
(	O
R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
research	O
immunoassay	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
compared	O
with	O
cTnT	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
.	O

By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	O
or	O
saline	O
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O

Histology	O
was	O
performed	O
in	O
DOX	O
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	O
dose	O
and	O
in	O
all	O
controls	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	O
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	B
during	O
the	O
9	O
-	O
week	O
period	O
.	O

End	O
-	O
diastolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systolic	O
(	O
ES	O
)	O
LV	O
diameters	O
/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

These	O
parameters	O
remained	O
unchanged	O
in	O
controls	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	O
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	B
.	O

In	O
7	O
of	O
the	O
18	O
rats	O
,	O
degeneration	O
and	O
myocyte	O
vacuolisation	O
were	O
found	O
.	O

Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	B
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	O
rats	O
after	O
cumulative	O
doses	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	O
.	O

Maximal	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	O
rats	O
compared	O
with	O
controls	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	O
rats	O
compared	O
with	O
controls	O
.	O

All	O
markers	O
remained	O
stable	O
in	O
controls	O
.	O

Analysis	O
of	O
data	O
revealed	O
a	O
significant	O
correlation	O
between	O
maximal	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diameters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

A	O
significant	O
relationship	O
was	O
observed	O
between	O
maximal	O
cTnT	O
and	O
the	O
extent	O
of	O
myocardial	O
morphological	O
changes	O
,	O
and	O
between	O
LV	O
diameters	O
/	O
BW	O
and	O
histological	O
findings	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	B
injury	I
after	O
DOX	O
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	B
damage	I
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	O
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	B
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Octreotide	O
-	O
induced	O
hypoxemia	B
and	O
pulmonary	B
hypertension	I
in	O
premature	O
neonates	O
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	B
complicating	O
necrotizing	B
enterocolitis	I
.	O

Pulmonary	B
hypertension	I
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	O
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	B
.	O

The	O
authors	O
discuss	O
the	O
mechanism	O
of	O
the	O
occurrence	O
of	O
this	O
complication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
risk	O
premature	O
neonates	O
.	O

The	O
risk	O
of	O
venous	B
thromboembolism	I
in	O
women	O
prescribed	O
cyproterone	O
acetate	O
in	O
combination	O
with	O
ethinyl	O
estradiol	O
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	B
and	O
hirsutism	B
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	B
ovary	I
syndrome	I
(	O
PCOS	B
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	B
thromboembolism	I
(	O
VTE	B
)	O
associated	O
with	O
CPA	O
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

We	O
believe	O
the	O
results	O
of	O
those	O
studies	O
may	O
have	O
been	O
affected	O
by	O
residual	O
confounding	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	B
,	O
hirsutism	B
or	O
PCOS	B
to	O
estimate	O
the	O
risk	O
of	O
VTE	B
associated	O
with	O
CPA	O
/	O
EE	O
.	O

RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	O
/	O
EE	O
versus	O
conventional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	O
/	O
EE	O
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	B
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	B
,	O
hirsutism	B
or	O
PCOS	B
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

The	O
effect	O
of	O
treatment	O
with	O
gum	O
Arabic	O
on	O
gentamicin	O
nephrotoxicity	B
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	B
renal	I
failure	I
induced	O
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	B
.	O

Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	O
Arabic	O
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	O
Arabic	O
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	O
Arabic	O
concomitantly	O
with	O
GM	O
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Nephrotoxicity	B
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	B
necrosis	I
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	O
Arabic	O
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	O
nephrotoxicity	B
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B
renal	I
failure	I
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

Increased	O
frequency	O
of	O
venous	B
thromboembolism	I
with	O
the	O
combination	O
of	O
docetaxel	O
and	O
thalidomide	O
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B
cancer	I
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B
thromboembolism	I
(	O
VTE	B
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B
cancer	I
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

DESIGN	O
:	O
Retrospective	O
analysis	O
of	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O

SETTING	O
:	O
National	O
Institutes	O
of	O
Health	O
clinical	O
research	O
center	O
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B
cancer	I
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	O
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	O
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	O
regimen	O
.	O

This	O
4	O
-	O
week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	B
or	O
disease	O
progression	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	O
alone	O
developed	O
VTE	B
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	O
VTE	B
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	O
to	O
docetaxel	O
in	O
the	O
treatment	O
of	O
prostate	B
cancer	I
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	B
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	O
to	O
chemotherapeutic	O
regimens	O
.	O

Ticlopidine	O
-	O
induced	O
cholestatic	B
hepatitis	I
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	O
-	O
induced	O
cholestatic	B
hepatitis	I
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	B
hepatitis	I
after	O
receiving	O
ticlopidine	O
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	O
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	O
:	O
Cholestatic	B
hepatitis	I
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	O
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Our	O
patients	O
developed	O
jaundice	B
following	O
treatment	O
with	O
ticlopidine	O
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B
hepatitis	I
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Hepatitis	B
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	O
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases	O
.	O

An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	O
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine	O
-	O
induced	O
cholestasis	B
are	O
unclear	O
.	O

Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug	O
'	O
s	O
hepatotoxicity	B
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O

CONCLUSIONS	O
:	O
Cholestatic	B
hepatitis	I
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	O
that	O
may	O
be	O
immune	O
mediated	O
.	O

Patients	O
receiving	O
the	O
drug	O
should	O
be	O
monitored	O
with	O
liver	O
function	O
tests	O
along	O
with	O
complete	O
blood	O
cell	O
counts	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	O
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	O
.	O

Epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	B
syndrome	I
.	O

In	O
experimental	O
nephrotic	B
syndrome	I
,	O
urinary	O
sodium	O
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
leading	O
to	O
salt	O
retention	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	O
transport	O
is	O
the	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
-	O
induced	O
nephrotic	B
syndrome	I
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	O
aldosterone	O
concentration	O
and	O
proteinuria	B
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	O
in	O
kidneys	O
from	O
these	O
rats	O
by	O
real	O
-	O
time	O
quantitative	O
TaqMan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
proteins	O
by	O
Western	O
blot	O
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	O
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Sodium	O
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	O
injection	O
.	O

A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	O
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	O
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	O
excretion	O
to	O
control	O
values	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	O
-	O
induced	O
sodium	O
retention	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	O
-	O
induced	O
nephrotic	B
syndrome	I
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	O
after	O
day	O
3	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	O
)	O
inhibits	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

RATIONALE	O
:	O
gamma	O
-	O
Vinyl	O
GABA	O
(	O
GVG	O
)	O
irreversibly	O
inhibits	O
GABA	O
-	O
transaminase	O
.	O

This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	O
catabolism	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	B
abuse	I
and	O
the	O
increased	O
risk	O
of	O
visual	B
field	I
defects	I
(	O
VFD	B
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

METHODS	O
:	O
Using	O
in	O
vivo	O
microdialysis	O
,	O
we	O
compared	O
acute	O
exposure	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
identical	O
sub	O
-	O
chronic	O
exposure	O
(	O
150	O
mg	O
/	O
kg	O
per	O
day	O
for	O
3	O
days	O
)	O
,	O
followed	O
by	O
1	O
-	O
or	O
3	O
-	O
day	O
washout	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
low	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
)	O
using	O
a	O
similar	O
washout	O
period	O
.	O

RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	O
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	O
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	O
-	O
induced	O
increases	O
in	O
dopamine	O
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	O
-	O
induced	O
neurotoxicity	B
in	O
organ	O
transplant	O
patients	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	O
therapy	O
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	O
who	O
developed	O
neurologic	B
complications	I
.	O

In	O
each	O
patient	O
who	O
had	O
abnormalities	O
on	O
the	O
initial	O
MR	O
study	O
,	O
a	O
follow	O
-	O
up	O
MR	O
study	O
was	O
performed	O
1	O
month	O
later	O
.	O

Apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
values	O
on	O
the	O
initial	O
MR	O
study	O
were	O
correlated	O
with	O
reversibility	O
of	O
the	O
lesions	O
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
white	B
matter	I
abnormalities	I
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putaminal	B
hemorrhage	I
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Among	O
the	O
5	O
patients	O
with	O
white	B
matter	I
abnormalities	I
,	O
4	O
patients	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O

The	O
remaining	O
1	O
patient	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B
laminar	I
necrosis	I
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	O
-	O
induced	O
neurotoxicity	B
.	O

L	O
-	O
arginine	O
transport	O
in	O
humans	O
with	O
cortisol	O
-	O
induced	O
hypertension	B
.	O

A	O
deficient	O
L	O
-	O
arginine	O
-	O
nitric	O
oxide	O
system	O
is	O
implicated	O
in	O
cortisol	O
-	O
induced	O
hypertension	B
.	O

We	O
investigate	O
whether	O
abnormalities	O
in	O
L	O
-	O
arginine	O
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O

Eight	O
healthy	O
men	O
were	O
recruited	O
.	O

Hydrocortisone	O
acetate	O
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

Crossover	O
studies	O
were	O
performed	O
2	O
weeks	O
apart	O
.	O

Thirty	O
milliliters	O
of	O
blood	O
was	O
obtained	O
for	O
isolation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
after	O
each	O
treatment	O
period	O
.	O

L	O
-	O
arginine	O
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

Forearm	O
[	O
3H	O
]	O
-	O
L	O
-	O
arginine	O
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[	O
3H	O
]	O
-	O
L	O
-	O
arginine	O
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L	O
-	O
arginine	O
extraction	O
.	O

Plasma	O
cortisol	O
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Systolic	O
blood	O
pressure	O
was	O
elevated	O
by	O
an	O
average	O
of	O
7	O
mm	O
Hg	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O

cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

We	O
conclude	O
that	O
cortisol	O
-	O
induced	O
increases	B
in	I
blood	I
pressure	I
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	O
-	O
arginine	O
transport	O
system	O
.	O

Amount	O
of	O
bleeding	B
and	O
hematoma	B
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	B
hemorrhage	I
rat	O
model	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	B
hemorrhage	I
(	O
ICH	B
)	O
with	O
drugs	O
used	O
for	O
stroke	B
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	B
model	O
for	O
detection	O
of	O
ICH	B
deterioration	O
.	O

In	O
ICH	B
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	B
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	B
volume	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	B
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	B
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	B
deterioration	O
.	O

In	O
ICH	B
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	B
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	B
animals	O
and	O
the	O
bleeding	B
7	O
.	O
6	O
-	O
fold	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	B
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	B
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	B
.	O

Estradiol	O
reduces	O
seizure	B
-	O
induced	O
hippocampal	B
injury	I
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	B
injury	I
induced	O
by	O
kainic	O
acid	O
-	O
induced	O
status	B
epilepticus	I
(	O
SE	B
)	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
SE	B
.	O

Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta	O
-	O
estradiol	O
(	O
2	O
microg	O
/	O
rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O

SE	B
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silver	O
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	B
.	O

17beta	O
-	O
Estradiol	O
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O

17beta	O
-	O
Estradiol	O
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O

In	O
males	O
,	O
estradiol	O
increased	O
the	O
total	O
damage	O
score	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	O
on	O
seizure	B
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

Pseudoacromegaly	B
induced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
.	O

Acromegaly	B
is	O
an	O
endocrine	B
disorder	I
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	B
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B
verticis	I
gyrata	I
.	O

Pseudoacromegaly	B
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O

We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	B
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
at	O
an	O
unusually	O
high	O
dose	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	B
as	O
a	O
side	O
effect	O
of	O
minoxidil	O
use	O
.	O

Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	B
in	O
prostate	B
cancer	I
patients	O
without	O
bone	O
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-	O
induced	O
anemia	B
in	O
prostate	B
cancer	I
patients	O
without	O
bone	O
involvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
patients	O
with	O
biopsy	O
-	O
proven	O
prostatic	B
adenocarcinoma	I
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O

All	O
patients	O
received	O
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	B
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosterone	O
measurements	O
were	O
recorded	O
.	O

Patients	O
with	O
stage	O
D2	O
-	O
3	O
disease	O
,	O
abnormal	O
hemoglobin	O
level	O
or	O
renal	O
and	O
liver	O
function	O
tests	O
that	O
were	O
higher	O
than	O
the	O
upper	O
limits	O
were	O
excluded	O
from	O
the	O
study	O
.	O

The	O
duration	O
of	O
the	O
study	O
was	O
six	O
months	O
.	O

RESULTS	O
:	O
The	O
mean	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
were	O
significantly	O
declined	O
in	O
all	O
patients	O
from	O
baseline	O
of	O
14	O
.	O
2	O
g	O
/	O
dl	O
to	O
14	O
.	O
0	O
g	O
/	O
dl	O
,	O
13	O
.	O
5	O
g	O
/	O
dl	O
,	O
13	O
.	O
2	O
g	O
/	O
dl	O
and	O
12	O
.	O
7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
,	O
respectively	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	O
-	O
induced	O
anemia	B
was	O
normochromic	O
and	O
normocytic	O
.	O

At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	O
anemia	B
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	B
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
development	O
of	O
severe	O
anemia	B
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
development	O
of	O
severe	O
CAB	O
-	O
induced	O
anemia	B
in	O
prostate	B
cancer	I
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	O
anemia	B
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prostate	B
cancer	I
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O

Delirium	B
during	O
clozapine	O
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	B
during	O
clozapine	O
treatment	O
require	O
further	O
clarification	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	B
inpatients	O
treated	O
with	O
clozapine	O
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	B
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
,	O
hospitalized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
days	O
,	O
and	O
given	O
clozapine	O
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
days	O
.	O

Delirium	B
was	O
diagnosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidence	O
,	O
or	O
1	O
.	O
48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O

Associated	O
factors	O
were	O
co	O
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17	O
.	O
5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	O
-	O
morbidity	O
,	O
and	O
daily	O
clozapine	O
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

CONCLUSIONS	O
:	O
Delirium	B
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	O
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O

Delirium	B
was	O
inconsistently	O
recognized	O
clinically	O
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	B
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	B
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	O
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	O
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O

Methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	O
of	O
dopamine	O
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	O
-	O
methyl	O
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	O
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
induced	O
hyperthermia	B
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

MPEP	O
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	O
extracellular	O
dopamine	O
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	O
-	O
induced	O
toxicity	B
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	O
-	O
induced	O
dopamine	O
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	B
.	O

Protective	O
efficacy	O
of	O
neuroactive	O
steroids	O
against	O
cocaine	O
kindled	O
-	O
seizures	B
in	O
mice	O
.	O

Neuroactive	O
steroids	O
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B
and	I
psychiatric	I
disorders	I
.	O

They	O
offer	O
protection	O
against	O
seizures	B
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	B
dependence	I
in	O
preclinical	O
assessments	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	B
kindling	O
)	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O

-	O
kindled	O
seizures	B
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Kindled	O
seizures	B
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg	O
/	O
kg	O
cocaine	O
for	O
5	O
days	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	B
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

Allopregnanolone	O
and	O
pregnanolone	O
,	O
but	O
not	O
ganaxolone	O
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	O
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	O
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	O
-	O
induced	O
increase	B
in	I
locomotor	I
activity	I
of	O
mice	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	O
-	O
induced	O
increase	B
in	I
locomotor	I
activity	I
of	O
mice	O
was	O
studied	O
.	O

The	O
subcutaneous	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	O
-	O
HC1	O
produced	O
a	O
marked	O
increase	B
in	I
locomotor	I
activity	I
in	O
mice	O
.	O

The	O
morphine	O
-	O
induced	O
hyperactivity	B
was	O
potentiated	O
by	O
scopolamine	O
and	O
attenuated	O
by	O
physostigmine	O
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	B
produced	O
by	O
morphine	O
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha	O
-	O
methyltyrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	O
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	O
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	B
.	O

The	O
study	O
suggests	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
are	O
mediated	O
by	O
the	O
release	O
of	O
catecholamines	O
from	O
adrenergic	O
neurons	O
in	O
the	O
brain	O
.	O

And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	O
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	O
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
in	O
rats	O
.	O

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	O
-	O
induced	O
chronic	B
renal	I
failure	I
in	O
rats	O
.	O

Rats	O
with	O
lithium	O
-	O
induced	O
nephropathy	B
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	B
failure	I
.	O

Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	O
-	O
containing	O
diet	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
weeks	O
.	O

Corresponding	O
non	O
-	O
lithium	O
pretreated	O
groups	O
were	O
generated	O
.	O

When	O
comparing	O
all	O
lithium	O
treated	O
versus	O
non	O
-	O
lithium	O
-	O
treated	O
groups	O
,	O
lithium	O
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	O
clearance	O
.	O

Consequently	O
,	O
lithium	O
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	O
excretion	O
.	O

Lithium	O
also	O
caused	O
proteinuria	B
and	O
systolic	O
hypertension	B
in	O
absence	O
of	O
glomerulosclerosis	B
.	O

HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	B
failure	I
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	O
levels	O
in	O
lithium	O
pretreated	O
rats	O
.	O

NX	O
caused	O
an	O
additive	O
deterioration	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
ameliorated	O
by	O
HP	O
.	O

NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li	O
-	O
pretreated	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
Li	O
-	O
induced	O
nephropathy	B
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	B
and	O
arterial	O
systolic	O
hypertension	B
.	O

In	O
this	O
model	O
of	O
chronic	B
renal	I
failure	I
the	O
decline	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effective	O
renal	O
plasma	O
flow	O
,	O
which	O
may	O
be	O
the	O
functional	O
expression	O
of	O
the	O
formation	O
of	O
nonfiltrating	O
atubular	O
glomeruli	O
.	O

The	O
fractional	O
reabsorption	O
of	O
tubular	O
fluid	O
by	O
the	O
proximal	O
tubules	O
is	O
reduced	O
,	O
leaving	O
the	O
distal	O
delivery	O
unchanged	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Treatment	O
of	O
Crohn	B
'	I
s	I
disease	I
with	O
fusidic	O
acid	O
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	O
.	O

Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	O
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B
'	I
s	I
disease	I
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	O
acid	O
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

Eight	O
Crohn	B
'	I
s	I
disease	I
patients	O
were	O
included	O
.	O

Fusidic	O
acid	O
was	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
treatment	O
was	O
planned	O
to	O
last	O
8	O
weeks	O
.	O

The	O
disease	O
activity	O
was	O
primarily	O
measured	O
by	O
a	O
modified	O
individual	O
grading	O
score	O
.	O

Five	O
of	O
8	O
patients	O
(	O
63	O
%	O
)	O
improved	O
during	O
fusidic	O
acid	O
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O

There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	B
.	O

Biochemically	O
,	O
an	O
increase	O
in	O
alkaline	O
phosphatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
cases	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
increases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elevated	O
levels	O
prior	O
to	O
treatment	O
.	O

All	O
reversed	O
to	O
pre	O
-	O
treatment	O
levels	O
after	O
cessation	O
of	O
treatment	O
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	O
acid	O
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn	B
'	I
s	I
disease	I
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	O
acid	O
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	B
bowel	I
disease	I
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O

Changes	O
in	O
depressive	B
status	O
associated	O
with	O
topical	O
beta	O
-	O
blockers	O
.	O

Depression	B
and	O
sexual	B
dysfunction	I
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	O
beta	O
-	O
blockers	O
.	O

We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
beta	O
-	O
blocker	O
(	O
timolol	O
)	O
and	O
a	O
selective	O
beta	O
-	O
blocker	O
(	O
betaxolol	O
)	O
regarding	O
CNS	O
side	O
effects	O
.	O

Eight	O
glaucomatous	B
patients	O
chronically	O
treated	O
with	O
timolol	O
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
suffering	O
from	O
depression	B
diagnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
criteria	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

During	O
the	O
six	O
-	O
month	O
follow	O
up	O
,	O
depression	B
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung	O
-	O
Conde	O
scales	O
every	O
two	O
months	O
.	O

In	O
a	O
double	O
blind	O
cross	O
-	O
over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	O
under	O
timolol	O
treatment	O
presented	O
higher	O
depression	B
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
control	O
)	O
.	O

These	O
results	O
suggest	O
that	O
betaxolol	O
could	O
be	O
less	O
of	O
a	O
depression	B
-	O
inducer	O
than	O
timolol	O
in	O
predisposed	O
patients	O
.	O

Protection	O
against	O
amphetamine	O
-	O
induced	O
neurotoxicity	B
toward	O
striatal	O
dopamine	O
neurons	O
in	O
rodents	O
by	O
LY274614	O
,	O
an	O
excitatory	O
amino	O
acid	O
antagonist	O
.	O

LY274614	O
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	O
-	O
6	O
-	O
[	O
phosphonomethyl	O
]	O
decahydr	O
oisoquinoline	O
-	O
3	O
-	O
carboxylic	O
acid	O
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
subtype	O
of	O
glutamate	O
receptor	O
.	O

Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
by	O
amphetamine	O
in	O
iprindole	O
-	O
treated	O
rats	O
is	O
reported	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetamine	O
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	O
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
1	O
week	O
later	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	O
(	O
MK	O
-	O
801	O
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
.	O

The	O
protective	O
effect	O
of	O
LY274614	O
was	O
dose	O
-	O
dependent	O
,	O
being	O
maximum	O
at	O
10	O
-	O
40	O
mgkg	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	O
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	O
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	O
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	O
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	O
.	O

The	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	O
,	O
was	O
also	O
antagonized	O
dose	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	O
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	B
effect	O
of	O
amphetamine	O
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	O
neurons	O
involves	O
NMDA	O
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Ketoconazole	O
-	O
induced	O
neurologic	B
sequelae	I
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	B
of	I
extremities	I
,	O
legs	B
paralysis	I
,	O
dysarthria	B
and	O
tremor	B
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	O
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

All	O
complaints	O
faded	O
away	O
within	O
24	O
h	O
.	O

Few	O
days	O
later	O
,	O
the	O
patient	O
used	O
another	O
200	O
mg	O
ketoconazole	O
tablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours	O
.	O

Laboratory	O
evaluations	O
,	O
including	O
head	O
CT	O
scan	O
,	O
were	O
normal	O
.	O

This	O
case	O
illustrates	O
the	O
need	O
for	O
close	O
vigilance	O
in	O
adverse	B
drug	I
reactions	I
,	O
particularly	O
in	O
the	O
elderly	O
.	O

Development	O
of	O
levodopa	O
-	O
induced	O
dyskinesias	B
in	O
parkinsonian	B
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and	O
/	O
or	O
duration	O
of	O
symptoms	O
.	O

Levodopa	O
-	O
induced	O
dyskinesias	B
(	O
LIDs	B
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	O
of	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
patients	O
.	O

Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	O
the	O
development	O
of	O
LIDs	B
.	O

Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	O
-	O
induced	O
parkinsonism	B
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	O
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	B
.	O

Monkeys	O
with	O
acute	O
(	O
short	O
-	O
term	O
)	O
MPTP	O
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
developed	O
dyskinesia	B
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	O
administration	O
.	O

In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	O
exposure	O
,	O
slow	O
symptom	O
progression	O
and	O
/	O
or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	B
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	B
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	O
administration	O
)	O
.	O

All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	O
of	O
levodopa	O
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug	O
.	O

These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	B
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	O
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	B
.	O

A	O
diet	O
promoting	O
sugar	B
dependency	I
causes	O
behavioral	B
cross	I
-	I
sensitization	I
to	O
a	O
low	O
dose	O
of	O
amphetamine	O
.	O

Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	O
a	O
state	O
with	O
neurochemical	O
and	O
behavioral	O
similarities	O
to	O
drug	B
dependency	I
.	O

The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	O
behavioral	B
cross	I
-	I
sensitization	I
to	O
a	O
low	O
dose	O
of	O
amphetamine	O
.	O

After	O
a	O
30	O
-	O
min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(	O
day	O
0	O
)	O
,	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12	O
-	O
h	O
deprivation	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucrose	O
solution	O
and	O
chow	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period	O
)	O
for	O
21	O
days	O
.	O

Locomotor	O
activity	O
was	O
measured	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
days	O
1	O
and	O
21	O
of	O
sugar	O
access	O
.	O

Beginning	O
on	O
day	O
22	O
,	O
all	O
rats	O
were	O
maintained	O
on	O
ad	O
libitum	O
chow	O
.	O

Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	O
to	O
a	O
single	O
low	O
dose	O
of	O
amphetamine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	O
and	O
chow	O
were	O
hyperactive	B
in	O
response	O
to	O
amphetamine	O
compared	O
with	O
four	O
control	O
groups	O
(	O
ad	O
libitum	O
10	O
%	O
sucrose	O
and	O
chow	O
followed	O
by	O
amphetamine	O
injection	O
,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	O
injection	O
,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	O
,	O
or	O
cyclic	O
10	O
%	O
sucrose	O
and	O
chow	O
with	O
a	O
saline	O
injection	O
)	O
.	O

These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	O
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	O
system	O
.	O

Reversible	O
dilated	B
cardiomyopathy	I
related	O
to	O
amphotericin	O
B	O
therapy	O
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	B
cardiomyopathy	I
and	O
clinical	O
congestive	O
heart	B
failure	I
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	O
B	O
(	O
AmB	O
)	O
for	O
disseminated	O
coccidioidomycosis	B
.	O

His	O
echocardiographic	O
abnormalities	O
and	O
heart	B
failure	I
resolved	O
after	O
posaconazole	O
was	O
substituted	O
for	O
AmB	O
.	O

It	O
is	O
important	O
to	O
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	O
toxicity	B
of	O
AmB	O
.	O

NO	O
-	O
induced	O
migraine	B
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	O
release	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
platelet	O
serotonin	O
(	O
5	O
-	O
hydroxytriptamine	O
,	O
5	O
-	O
HT	O
)	O
content	O
during	O
the	O
immediate	O
headache	B
and	O
the	O
delayed	O
genuine	O
migraine	B
attack	O
provoked	O
by	O
nitroglycerin	O
.	O

Fifteen	O
female	O
migraineurs	B
(	I
without	I
aura	I
)	I
and	O
eight	O
controls	O
participated	O
in	O
the	O
study	O
.	O

Sublingual	O
nitroglycerin	O
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
administered	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	O
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	B
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O

In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	B
attack	O
(	O
11	O
subjects	O
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O

Plasma	O
CGRP	O
concentration	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migraine	B
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	B
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	B
headache	B
intensity	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
plasma	O
CGRP	O
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	B
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	B
attack	O
.	O

Basal	O
CGRP	O
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5	O
-	O
HT	O
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	B
attack	O
.	O

Platelet	O
serotonin	O
content	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerin	O
in	O
subjects	O
with	O
no	O
migraine	B
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	B
attack	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	O
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	B
headache	B
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	O
and	O
migraine	B
.	O

In	O
contrast	O
,	O
serotonin	O
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	B
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	B
and	O
the	O
concomitant	O
CGRP	O
release	O
in	O
this	O
model	O
.	O

Hyperbaric	O
oxygen	O
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide	O
-	O
induced	O
hemorrhagic	B
cystitis	I
.	O

We	O
report	O
a	O
case	O
of	O
intractable	O
hemorrhagic	B
cystitis	I
due	O
to	O
cyclophosphamide	O
therapy	O
for	O
Wegener	B
'	I
s	I
granulomatosis	I
.	O

Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	O
F2	O
alpha	O
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	B
.	O

We	O
then	O
used	O
hyperbaric	O
oxygen	O
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O

The	O
bleeding	B
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	B
thereafter	O
.	O

No	O
side	O
effect	O
was	O
noted	O
during	O
the	O
course	O
of	O
therapy	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide	O
-	O
induced	O
hemorrhagic	B
cystitis	I
.	O

Acute	B
psychosis	I
due	O
to	O
treatment	O
with	O
phenytoin	O
in	O
a	O
nonepileptic	O
patient	O
.	O

The	O
development	O
of	O
psychosis	B
related	O
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	B
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs	O
.	O

The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	O
psychosis	B
following	O
phenytoin	O
treatment	O
for	O
trigeminal	B
neuralgia	I
is	O
described	O
.	O

This	O
case	O
suggests	O
that	O
the	O
psychotic	B
symptoms	I
that	O
occur	O
following	O
phenytoin	O
treatment	O
in	O
some	O
epileptic	B
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	B
.	O

Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	O
.	O

Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	B
leg	I
cramps	I
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	O
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	O
may	O
produce	O
neurological	B
complications	I
,	O
including	O
confusion	B
,	O
altered	O
mental	O
status	O
,	O
seizures	B
,	O
and	O
coma	B
,	O
particularly	O
in	O
older	O
women	O
.	O

Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	O
-	O
containing	O
beverages	O
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O

Transient	O
platypnea	B
-	I
orthodeoxia	I
-	I
like	I
syndrome	I
induced	O
by	O
propafenone	O
overdose	B
in	O
a	O
young	O
woman	O
with	O
Ebstein	B
'	I
s	I
anomaly	I
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	B
'	I
s	I
anomaly	I
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea	B
-	I
orthodeoxia	I
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	B
and	O
cyanosis	B
.	O

This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	B
foramen	I
ovale	I
occurred	O
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	O
overdose	B
.	O

This	O
drug	O
caused	O
biventricular	B
dysfunction	I
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	O
,	O
and	O
hypotension	B
,	O
due	O
to	O
its	O
peripheral	O
vasodilatory	O
effect	O
.	O

These	O
effects	O
gave	O
rise	O
to	O
an	O
increase	O
in	O
the	O
right	O
atrial	O
pressure	O
and	O
a	O
decrease	O
in	O
the	O
left	O
one	O
with	O
a	O
consequent	O
stretching	O
of	O
the	O
foramen	O
ovale	O
and	O
the	O
creation	O
of	O
massive	O
right	O
-	O
to	O
-	O
left	O
shunting	O
.	O

In	O
our	O
case	O
this	O
interatrial	O
shunt	O
was	O
very	O
accurately	O
detected	O
at	O
bubble	O
contrast	O
echocardiography	O
.	O

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
-	O
-	O
an	O
experimental	O
model	O
for	O
vascular	B
dysfunctions	I
in	O
cluster	B
headache	I
.	O

Cluster	B
headache	I
is	O
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	O
including	O
facial	O
and	O
intracranial	B
vascular	I
disturbances	I
.	O

Both	O
the	O
trigeminal	O
and	O
the	O
cranial	O
parasympathetic	O
systems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfunctions	O
.	O

An	O
experimental	O
model	O
was	O
developed	O
in	O
the	O
rat	O
to	O
measure	O
changes	O
in	O
lacrimation	O
and	O
intracranial	O
blood	O
flow	O
following	O
noxious	O
chemical	O
stimulation	O
of	O
facial	O
mucosa	O
.	O

Blood	O
flow	O
was	O
monitored	O
in	O
arteries	O
of	O
the	O
exposed	O
cranial	O
dura	O
mater	O
and	O
the	O
parietal	O
cortex	O
using	O
laser	O
Doppler	O
flowmetry	O
.	O

Capsaicin	O
(	O
0	O
.	O
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	B
in	I
dural	I
and	I
cortical	I
blood	I
flow	I
and	O
provoked	O
lacrimation	O
.	O

These	O
responses	O
were	O
blocked	O
by	O
systemic	O
pre	O
-	O
administration	O
of	O
hexamethonium	O
chloride	O
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O

The	O
evoked	O
increases	B
in	I
dural	I
blood	I
flow	I
were	O
also	O
abolished	O
by	O
topical	O
pre	O
-	O
administration	O
of	O
atropine	O
(	O
1	O
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2	O
,	O
5	O
,	O
Arg3	O
,	O
4	O
,	O
Tyr6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O

We	O
conclude	O
that	O
noxious	O
stimulation	O
of	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
and	O
lacrimation	O
via	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
.	O

The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
release	O
of	O
acetylcholine	O
and	O
VIP	O
within	O
the	O
meninges	O
.	O

Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cluster	B
headache	I
.	O

Organophosphate	O
-	O
induced	O
convulsions	B
and	O
prevention	O
of	O
neuropathological	B
damages	I
.	O

Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	O
as	O
diisopropylfluorophosphate	O
(	O
DFP	O
)	O
,	O
sarin	O
and	O
soman	O
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

The	O
acute	O
toxicity	B
of	O
OPs	O
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	O
(	O
ACh	O
)	O
levels	O
.	O

The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
weeks	O
-	O
old	O
Han	O
-	O
Wistar	O
male	O
rats	O
.	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O

kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O
.	O

The	O
control	O
rats	O
received	O
atropine	O
sulfate	O
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	O
,	O
respectively	O
.	O

All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	O
injection	O
.	O

The	O
rats	O
treated	O
with	O
DFP	O
-	O
atropine	O
showed	O
severe	O
typical	O
OP	O
-	O
induced	O
toxicity	B
signs	O
.	O

When	O
CPA	O
,	O
diazepam	O
or	O
2PAM	O
was	O
given	O
immediately	O
after	O
DFP	O
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B
.	O

Atropine	O
-	O
MK801	O
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	O
toxicity	B
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	O
and	O
2PAM	O
in	O
combination	O
with	O
atropine	O
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B
and	O
thus	O
reduced	O
the	O
toxicity	B
of	O
DFP	O
in	O
rat	O
.	O

A	O
pyridoxine	O
-	O
dependent	O
behavioral	B
disorder	I
unmasked	O
by	O
isoniazid	O
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	O
had	O
behavioral	B
deterioration	I
,	O
with	O
hyperkinesis	B
,	O
irritability	B
,	O
and	O
sleeping	B
difficulties	I
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	O
.	O

The	O
administration	O
of	O
pharmacologic	O
doses	O
of	O
pyridoxine	O
hydrochloride	O
led	O
to	O
a	O
disappearance	O
of	O
symptoms	O
.	O

After	O
discontinuing	O
isoniazid	O
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	O
.	O

A	O
placebo	O
had	O
no	O
effect	O
,	O
but	O
niacinamide	O
was	O
as	O
effective	O
as	O
pyridoxine	O
.	O

Periodic	O
withdrawal	O
of	O
pyridoxine	O
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkinesis	B
.	O

The	O
level	O
of	O
pyridoxal	O
in	O
the	O
blood	O
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse	O
.	O

Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	O
pathway	O
of	O
tryptophan	O
metabolism	O
.	O

The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	O
to	O
control	O
her	O
behavior	O
.	O

Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	O
of	O
a	O
murine	O
model	O
of	O
temporal	B
lobe	I
epilepsy	I
.	O

Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	O
injection	O
causes	O
status	B
epilepticus	I
(	O
SE	B
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	B
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O

Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine	O
-	O
treated	O
and	O
untreated	O
mice	O
.	O

In	O
Mg	O
(	O
2	O
+	O
)	O
-	O
free	O
bathing	O
medium	O
containing	O
bicuculline	O
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	O
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	B
.	O

In	O
SE	B
survivors	O
,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	O
receptor	O
antagonists	O
.	O

Focal	O
glutamate	O
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	O
in	O
slices	O
from	O
SE	B
survivors	O
but	O
not	O
other	O
groups	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	B
-	O
induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	B
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	B
lobe	I
epilepsy	I
.	O

Urinary	B
bladder	I
cancer	I
in	O
Wegener	B
'	I
s	I
granulomatosis	I
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B
cancer	I
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	O
,	O
in	O
patients	O
with	O
Wegener	B
'	I
s	I
granulomatosis	I
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B
'	I
s	I
granulomatosis	I
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B
cancer	I
were	O
identified	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	O
and	O
bladder	B
cancer	I
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B
cancer	I
after	O
Wegener	B
'	I
s	I
granulomatosis	I
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B
cancer	I
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B
'	I
s	I
granulomatosis	I
,	O
were	O
also	O
estimated	O
.	O

RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	O
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
bladder	B
cancer	I
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	O
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
absolute	O
risk	O
for	O
bladder	B
cancer	I
in	O
the	O
cohort	O
reached	O
10	O
%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B
'	I
s	I
granulomatosis	I
,	O
and	O
a	O
history	O
of	O
bladder	B
cancer	I
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B
'	I
s	I
granulomatosis	I
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	O
and	O
the	O
risk	O
of	O
bladder	B
cancer	I
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B
'	I
s	I
granulomatosis	I
.	O

Differential	O
modulation	O
by	O
estrogen	O
of	O
alpha2	O
-	O
adrenergic	O
and	O
I1	O
-	O
imidazoline	O
receptor	O
-	O
mediated	O
hypotension	B
in	O
female	O
rats	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogen	O
negatively	O
modulates	O
the	O
hypotensive	B
effect	O
of	O
clonidine	O
(	O
mixed	O
alpha2	O
-	O
/	O
I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	O
involves	O
interaction	O
with	O
alpha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
receptors	O
.	O

Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	O
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	O
-	O
methyldopa	O
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alpha2	O
-	O
receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	O
replacement	O
.	O

Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed	O
:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat	O
-	O
to	O
-	O
beat	O
intervals	O
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R	O
-	O
wave	O
-	O
to	O
-	O
R	O
-	O
wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability	O
.	O

In	O
sham	O
-	O
operated	O
rats	O
,	O
rilmenidine	O
or	O
alpha	O
-	O
methyldopa	O
elicited	O
similar	O
hypotension	B
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O

SDRR	O
was	O
reduced	O
only	O
by	O
alpha	O
-	O
methyldopa	O
.	O

Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	B
response	O
to	O
alpha	O
-	O
methyldopa	O
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	O
hypotension	B
.	O

The	O
enhanced	O
alpha	O
-	O
methyldopa	O
hypotension	B
in	O
Ovx	O
rats	O
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B
reduced	I
locomotor	I
activity	I
.	O

Estrogen	O
replacement	O
(	O
17beta	O
-	O
estradiol	O
subcutaneous	O
pellet	O
,	O
14	O
.	O
2	O
microg	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	O
-	O
methyldopa	O
to	O
sham	O
-	O
operated	O
levels	O
.	O

These	O
findings	O
suggest	O
that	O
estrogen	O
downregulates	O
alpha2	O
-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	B
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	O
-	O
methyldopa	O
-	O
estrogen	O
interaction	O
.	O

Severe	O
reversible	O
left	B
ventricular	I
systolic	I
and	I
diastolic	I
dysfunction	I
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	O
overdose	B
.	O

Catecholamine	O
-	O
induced	O
cardiomyopathy	B
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	O
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O

In	O
contrast	O
,	O
reports	O
of	O
myocardial	B
dysfunction	I
due	O
to	O
acute	O
iatrogenic	O
overdose	B
are	O
rare	O
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	O
developed	O
myocardial	B
stunning	I
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	B
ventricular	I
systolic	I
and	I
diastolic	I
dysfunction	I
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	B
necrosis	I
.	O

Our	O
case	O
illustrates	O
the	O
serious	O
consequences	O
of	O
medical	O
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O

Cardioprotective	O
effect	O
of	O
tincture	O
of	O
Crataegus	O
on	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

Tincture	O
of	O
Crataegus	O
(	O
TCR	O
)	O
,	O
an	O
alcoholic	O
extract	O
of	O
the	O
berries	O
of	O
hawthorn	O
(	O
Crataegus	O
oxycantha	O
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	O
on	O
experimentally	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

Pretreatment	O
of	O
TCR	O
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	O
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

TCR	O
prevented	O
the	O
isoproterenol	O
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	O
-	O
stimulated	O
oxygen	O
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	O
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	O
in	O
rat	O
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	O
in	O
rat	O
heart	O
.	O

Treatment	O
of	O
tinnitus	B
by	O
intratympanic	O
instillation	O
of	O
lignocaine	O
(	O
lidocaine	O
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes	O
.	O

Idiopathic	B
subjective	I
tinnitus	I
(	O
IST	B
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O

This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	B
by	O
intratympanic	O
instillation	O
of	O
lignocaine	O
(	O
lidocaine	O
)	O
2	O
per	O
cent	O
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O

Fifty	O
-	O
two	O
patients	O
suffering	O
from	O
intractable	O
tinnitus	B
entered	O
this	O
therapeutic	O
trial	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	O
.	O

In	O
one	O
patient	O
,	O
the	O
tinnitus	B
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	B
changed	O
to	O
a	O
compensated	O
one	O
.	O

We	O
suggest	O
this	O
mode	O
of	O
treatment	O
for	O
patients	O
that	O
were	O
previously	O
treated	O
by	O
drugs	O
,	O
acupuncture	O
and	O
biofeedback	O
,	O
with	O
disappointing	O
results	O
.	O

Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	B
and	O
vomiting	B
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	O
,	O
and	O
that	O
the	O
tinnitus	B
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	O
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine	O
-	O
induced	O
seizures	B
and	O
hypolocomotion	B
in	O
mice	O
.	O

Binding	O
of	O
nicotine	O
to	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	B
,	O
to	O
seizures	B
and	O
death	B
.	O

nAChRs	O
are	O
pentameric	O
ion	O
channels	O
usually	O
composed	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

A	O
gene	O
cluster	O
comprises	O
the	O
alpha3	O
,	O
alpha5	O
and	O
beta4	O
subunits	O
,	O
which	O
coassemble	O
to	O
form	O
functional	O
receptors	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine	O
-	O
induced	O
seizures	B
and	O
hypolocomotion	B
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-	O
/	O
-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/	O
-	O
)	O
mice	O
.	O

beta4	O
-	O
/	O
-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	O
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	O
-	O
induced	O
seizures	B
.	O

Using	O
in	O
situ	O
hybridization	O
probes	O
for	O
the	O
alpha3	O
and	O
alpha5	O
subunits	O
,	O
we	O
showed	O
that	O
alpha5	O
mRNA	O
levels	O
are	O
unchanged	O
,	O
whereas	O
alpha3	O
mRNA	O
levels	O
are	O
selectively	O
decreased	O
in	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
olfactory	O
bulb	O
,	O
and	O
the	O
inferior	O
and	O
the	O
superior	O
colliculus	O
of	O
beta4	O
-	O
/	O
-	O
brains	O
.	O

alpha3	O
+	O
/	O
-	O
mice	O
were	O
partially	O
resistant	O
to	O
nicotine	O
-	O
induced	O
seizures	B
when	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

mRNA	O
levels	O
for	O
the	O
alpha5	O
and	O
the	O
beta4	O
subunits	O
were	O
unchanged	O
in	O
alpha3	O
+	O
/	O
-	O
brains	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine	O
-	O
induced	O
seizures	B
and	O
hypolocomotion	B
.	O

The	O
effects	O
of	O
sevoflurane	O
on	O
lidocaine	O
-	O
induced	O
convulsions	B
.	O

The	O
influence	O
of	O
sevoflurane	O
on	O
lidocaine	O
-	O
induced	O
convulsions	B
was	O
studied	O
in	O
cats	O
.	O

The	O
convulsive	B
threshold	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
with	O
lidocaine	O
infusion	O
(	O
6	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	O
was	O
0	O
.	O
8	O
%	O
.	O

However	O
,	O
the	O
threshold	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevoflurane	O
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sevoflurane	O
,	O
indicating	O
a	O
celling	O
effect	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	B
threshold	O
between	O
sevoflurane	O
and	O
enflurane	O
.	O

The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	O
or	O
enflurane	O
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B
decreased	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevoflurane	O
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enflurane	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	O
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O

Apamin	O
,	O
a	O
selective	O
blocker	O
of	O
calcium	O
-	O
dependent	O
potassium	O
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0	O
.	O
8	O
%	O
sevoflurane	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O

Apamin	O
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	B
threshold	O
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

It	O
is	O
suggested	O
that	O
sevoflurane	O
reduces	O
the	O
convulsive	B
effect	O
of	O
lidocaine	O
toxicity	B
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	B
.	O

Cardiac	B
toxicity	I
observed	O
in	O
association	O
with	O
high	O
-	O
dose	O
cyclophosphamide	O
-	O
based	O
chemotherapy	O
for	O
metastatic	O
breast	B
cancer	I
.	O

INTRODUCTION	O
:	O
Cyclophosphamide	O
is	O
an	O
alkylating	O
agent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens	O
.	O

In	O
high	O
doses	O
,	O
its	O
nonhematological	O
dose	O
-	O
limiting	O
toxicity	B
is	O
cardiomyopathy	B
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	O
paclitaxel	O
,	O
melphalan	O
and	O
high	O
-	O
dose	O
cyclophosphamide	O
,	O
thiotepa	O
,	O
and	O
carboplatin	O
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	B
cancer	I
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	B
cancer	I
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	O
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	B
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	B
mellitus	I
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

RESULTS	O
:	O
Six	O
of	O
61	O
women	O
(	O
10	O
%	O
)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	B
following	O
infusional	O
cyclophosphamide	O
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31	O
%	O
.	O

Incidence	O
of	O
transient	O
cyclophosphamide	O
-	O
related	O
cardiac	B
toxicity	I
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature	O
.	O

Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	B
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	B
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

No	O
association	O
was	O
found	O
with	O
other	O
pretreatment	O
characteristics	O
.	O

CONCLUSIONS	O
:	O
As	O
a	O
result	O
of	O
these	O
findings	O
,	O
oncologists	O
should	O
carefully	O
monitor	O
fluid	O
balance	O
in	O
older	O
patients	O
.	O

Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	O
did	O
not	O
predict	O
CHF	B
development	O
.	O

Tremor	B
side	O
effects	O
of	O
salbutamol	O
,	O
quantified	O
by	O
a	O
laser	O
pointer	O
technique	O
.	O

OBJECTIVE	O
:	O
To	O
study	O
tremor	B
side	O
effects	O
of	O
salbutamol	O
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
method	O
is	O
needed	O
.	O

A	O
new	O
method	O
using	O
a	O
commercially	O
available	O
,	O
pen	O
-	O
shaped	O
laser	O
pointer	O
was	O
developed	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
sensitivity	O
,	O
reproducibility	O
,	O
reference	O
values	O
and	O
the	O
agreement	O
with	O
a	O
questionnaire	O
.	O

METHODS	O
:	O
Tremor	B
was	O
measured	O
using	O
a	O
laser	O
pointer	O
technique	O
.	O

To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	B
in	O
44	O
patients	O
with	O
obstructive	B
lung	I
disease	I
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	O
.	O

Subjects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
centre	O
of	O
a	O
target	O
,	O
subdivided	O
in	O
concentric	O
circles	O
,	O
from	O
5	O
m	O
distance	O
.	O

The	O
circle	O
in	O
which	O
the	O
participant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millimetres	O
radius	O
.	O

In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	B
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

Postural	O
tremor	B
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	B
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	O
tremor	B
was	O
measured	O
after	O
holding	O
a	O
2	O
-	O
kg	O
weight	O
until	O
exhaustion	O
.	O

Inter	O
-	O
observer	O
variability	O
was	O
measured	O
in	O
a	O
series	O
of	O
10	O
healthy	O
subjects	O
.	O

Tremor	B
was	O
measured	O
simultaneously	O
by	O
two	O
independent	O
observers	O
.	O

RESULTS	O
:	O
Salbutamol	O
significantly	O
increased	O
tremor	B
severity	O
in	O
patients	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O

Within	O
healthy	O
adults	O
no	O
age	O
-	O
dependency	O
could	O
be	O
found	O
(	O
b	O
=	O
0	O
.	O
262	O
mm	O
/	O
year	O
;	O
P	O
=	O
0	O
.	O
72	O
)	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
tremor	B
severity	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O

Postural	O
tremor	B
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
session	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Support	O
of	O
the	O
arm	O
decreased	O
tremor	B
severity	O
,	O
exhaustion	O
increased	O
tremor	B
severity	O
significantly	O
.	O

A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independent	O
observers	O
(	O
interclass	O
correlation	O
coefficient	O
0	O
.	O
72	O
)	O
.	O

DISCUSSION	O
:	O
Quantifying	O
tremor	B
by	O
using	O
an	O
inexpensive	O
laser	O
pointer	O
is	O
,	O
with	O
the	O
exception	O
of	O
children	O
(	O
<	O
12	O
years	O
)	O
a	O
sensitive	O
and	O
reproducible	O
method	O
.	O

Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	O
:	O
multiple	O
outcomes	O
of	O
raloxifene	O
evaluation	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	O
on	O
major	O
adverse	O
events	O
that	O
occur	O
with	O
postmenopausal	O
estrogen	O
therapy	O
or	O
tamoxifen	O
.	O

METHODS	O
:	O
The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	O
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
enrolled	O
7	O
,	O
705	O
postmenopausal	O
women	O
with	O
osteoporosis	B
.	O

Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	O
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placebo	O
.	O

Outcomes	O
included	O
venous	B
thromboembolism	I
,	O
cataracts	B
,	O
gallbladder	B
disease	I
,	O
and	O
endometrial	B
hyperplasia	I
or	I
cancer	I
.	O

RESULTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
years	O
,	O
raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B
thromboembolism	I
(	O
relative	O
risk	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O

The	O
excess	O
event	O
rate	O
was	O
1	O
.	O
8	O
per	O
1	O
,	O
000	O
woman	O
-	O
years	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
4	O
.	O
1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
treat	O
to	O
cause	O
1	O
event	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3	O
.	O
3	O
years	O
.	O

Risk	O
in	O
the	O
raloxifene	O
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years	O
,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter	O
.	O

Raloxifene	O
did	O
not	O
increase	O
risk	O
for	O
cataracts	B
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallbladder	B
disease	I
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
endometrial	B
hyperplasia	I
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
endometrial	B
cancer	I
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B
thromboembolism	I
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	B
,	O
gallbladder	B
disease	I
,	O
endometrial	B
hyperplasia	I
,	O
or	O
endometrial	B
cancer	I
.	O

LEVEL	O
OF	O
EVIDENCE	O
:	O
I	O

Optimization	O
of	O
levodopa	O
therapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	O
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	O
-	O
levodopa	O
to	O
the	O
point	O
of	O
"	O
normality	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxicity	B
.	O

The	O
physician	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjunctive	O
medications	O
;	O
such	O
combined	O
therapy	O
has	O
become	O
the	O
standard	O
approach	O
to	O
treatment	O
.	O

Following	O
the	O
initial	O
period	O
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches	O
,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	O
of	O
a	O
dopamine	O
agonist	O
.	O

Other	O
possible	O
adverse	O
effects	O
-	O
-	O
such	O
as	O
gastrointestinal	B
disorders	I
,	O
orthostatic	B
hypotension	I
,	O
levodopa	O
-	O
induced	O
psychosis	B
,	O
sleep	B
disturbances	I
or	O
parasomnias	B
,	O
or	O
drug	O
interactions	O
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Nonpharmacologic	O
concerns	O
can	O
help	O
the	O
Parkinson	B
'	I
s	I
disease	I
patient	O
achieve	O
and	O
maintain	O
optimal	O
functioning	O
,	O
including	O
daily	O
exercise	O
,	O
physical	O
therapy	O
,	O
and	O
involvement	O
with	O
support	O
groups	O
.	O

Long	O
term	O
audiological	O
evaluation	O
of	O
beta	B
-	I
thalassemic	I
patients	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearing	B
loss	I
in	O
children	O
and	O
young	O
adults	O
with	O
beta	B
-	I
thalassemia	I
major	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patients	O
aged	O
6	O
-	O
35	O
years	O
(	O
mean	O
17	O
,	O
2	O
years	O
)	O
participated	O
in	O
the	O
study	O
.	O

All	O
patients	O
were	O
on	O
a	O
regular	O
transfusion	O
-	O
chelation	O
program	O
maintaining	O
a	O
mean	O
hemoglobin	O
level	O
of	O
9	O
.	O
5	O
gr	O
/	O
dl	O
.	O

Subjects	O
were	O
receiving	O
desferrioxamine	O
(	O
DFO	O
)	O
chelation	O
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
years	O
.	O

Patients	O
were	O
followed	O
for	O
8	O
-	O
14	O
years	O
.	O

RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patients	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
frequency	O
sensorineural	B
hearing	I
loss	I
(	O
SNHL	B
)	O
,	O
either	O
unilateral	O
or	O
bilateral	O
.	O

No	O
ototoxic	B
factor	O
,	O
other	O
than	O
DFO	O
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O

Patients	O
with	O
SNHL	B
presented	O
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	O
,	O
however	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
.	O

Subjects	O
with	O
SNHL	B
were	O
submitted	O
to	O
DFO	O
reduction	O
or	O
temporary	O
withdrawal	O
.	O

Following	O
intervention	O
,	O
7	O
out	O
of	O
21	O
affected	O
patients	O
recovered	O
,	O
10	O
remained	O
stable	O
and	O
4	O
demonstrated	O
aggravation	O
.	O

CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	O
'	O
s	O
contributing	O
role	O
in	O
the	O
development	O
of	O
hearing	B
impairment	I
.	O

Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	B
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	B
impairment	I
.	O

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin	O
-	O
induced	O
renal	B
damage	I
.	O

BACKGROUND	O
:	O
In	O
man	O
,	O
differences	O
in	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
levels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	O
prognosis	O
.	O

This	O
raises	O
the	O
hypothesis	O
that	O
individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
are	O
involved	O
in	O
renal	O
susceptibility	O
to	O
inflicted	O
damage	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	B
damage	I
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	O
in	O
rats	O
.	O

METHODS	O
:	O
Renal	O
ACE	O
activity	O
(	O
Hip	O
-	O
His	O
-	O
Leu	O
cleavage	O
by	O
cortical	O
homogenates	O
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O

After	O
1	O
week	O
of	O
recovery	O
,	O
proteinuria	B
was	O
induced	O
by	O
adriamycin	O
[	O
1	O
.	O
5	O
mg	O
/	O
kg	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
controls	O
,	O
saline	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

Proteinuria	B
was	O
measured	O
every	O
2	O
weeks	O
.	O

After	O
12	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
and	O
their	O
kidneys	O
harvested	O
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	O
elicited	O
nephrotic	B
range	O
proteinuria	B
,	O
renal	B
interstitial	I
damage	I
and	O
mild	O
focal	B
glomerulosclerosis	I
.	O

Baseline	O
renal	O
ACE	O
positively	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuria	B
after	O
adriamycin	O
(	O
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
renal	O
interstitial	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerular	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O

)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Baseline	O
renal	O
ACE	O
did	O
not	O
correlate	O
with	O
focal	B
glomerulosclerosis	I
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O

In	O
controls	O
,	O
no	O
predictive	O
values	O
for	O
renal	O
parameters	O
were	O
observed	O
.	O

CONCLUSION	O
:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin	O
-	O
induced	O
renal	B
damage	I
in	O
this	O
outbred	O
rat	O
strain	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	O
ACE	O
activity	O
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	B
damage	I
.	O

Recurrent	O
acute	O
interstitial	B
nephritis	I
induced	O
by	O
azithromycin	O
.	O

A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	O
-	O
induced	O
,	O
acute	O
interstitial	B
nephritis	I
.	O

The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	O
therapy	O
,	O
renal	O
function	O
remained	O
impaired	O
.	O

Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	B
nephritis	I
are	O
benign	O
and	O
self	O
-	O
limited	O
,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	B
injury	I
.	O

Spironolactone	O
-	O
induced	O
renal	B
insufficiency	I
and	O
hyperkalemia	B
in	O
patients	O
with	O
heart	B
failure	I
.	O

BACKGROUND	O
:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	O
in	O
heart	B
failure	I
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	B
(	O
2	O
%	O
)	O
and	O
renal	B
insufficiency	I
(	O
0	O
%	O
)	O
.	O

Because	O
treatments	O
for	O
heart	B
failure	I
have	O
changed	O
since	O
the	O
benefits	O
of	O
spironolactone	O
were	O
reported	O
,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	B
and	O
renal	B
insufficiency	I
in	O
heart	B
failure	I
patients	O
treated	O
with	O
spironolactone	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	B
failure	I
patients	O
treated	O
with	O
spironolactone	O
in	O
our	O
clinical	O
practice	O
.	O

Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	B
(	O
K	O
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
renal	B
insufficiency	I
(	O
Cr	O
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O
.	O

Clinical	O
characteristics	O
,	O
medications	O
,	O
and	O
serum	O
chemistries	O
at	O
baseline	O
and	O
follow	O
-	O
up	O
time	O
periods	O
were	O
compared	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patients	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
discontinuation	O
of	O
spironolactone	O
due	O
to	O
hyperkalemia	B
(	O
n	O
=	O
33	O
)	O
or	O
renal	B
failure	I
(	O
n	O
=	O
34	O
)	O
.	O

Patients	O
who	O
developed	O
hyperkalemia	B
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	B
,	O
had	O
higher	O
baseline	O
serum	O
potassium	O
levels	O
and	O
lower	O
baseline	O
potassium	O
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	O
who	O
developed	O
renal	B
insufficiency	I
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	O
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	O
diuretics	O
than	O
controls	O
.	O

CONCLUSIONS	O
:	O
Spironolactone	O
-	O
induced	O
hyperkalemia	B
and	O
renal	B
insufficiency	I
are	O
more	O
common	O
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O

This	O
difference	O
is	O
explained	O
by	O
patient	O
comorbidities	O
and	O
more	O
frequent	O
use	O
of	O
beta	O
-	O
blockers	O
.	O

Acute	O
reserpine	O
and	O
subchronic	O
haloperidol	O
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	O
uptake	O
and	O
elicit	O
orofacial	B
dyskinesia	I
in	O
rats	O
.	O

Reserpine	O
-	O
and	O
haloperidol	O
-	O
induced	O
orofacial	B
dyskinesia	I
are	O
putative	O
animal	O
models	O
of	O
tardive	B
dyskinesia	I
(	O
TD	B
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
induced	O
orofacial	B
dyskinesia	I
by	O
acute	O
reserpine	O
and	O
subchronic	O
haloperidol	O
administration	O
to	O
rats	O
.	O

Reserpine	O
injection	O
(	O
one	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
,	O
compared	O
to	O
the	O
control	O
.	O

Haloperidol	O
administration	O
(	O
one	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
observed	O
in	O
four	O
weekly	O
evaluations	O
.	O

After	O
the	O
treatments	O
and	O
behavioral	O
observation	O
,	O
glutamate	O
uptake	O
by	O
segments	O
of	O
the	O
brain	O
was	O
analyzed	O
.	O

A	O
decreased	O
glutamate	O
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	O
and	O
haloperidol	O
,	O
compared	O
to	O
the	O
control	O
.	O

Importantly	O
,	O
a	O
decrease	O
in	O
glutamate	O
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	B
diskinesia	I
.	O

These	O
results	O
indicate	O
that	O
early	O
changes	O
in	O
glutamate	O
transport	O
may	O
be	O
related	O
to	O
the	O
development	O
of	O
vacuous	O
chewing	O
movements	O
in	O
rats	O
.	O

Ceftriaxone	O
-	O
associated	O
biliary	B
pseudolithiasis	I
in	O
paediatric	O
surgical	O
patients	O
.	O

It	O
is	O
well	O
known	O
that	O
ceftriaxone	O
leads	O
to	O
pseudolithiasis	B
in	O
some	O
patients	O
.	O

Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	B
dysfunction	I
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	B
.	O

In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	B
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	O
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post	O
-	O
operative	O
period	O
.	O

Fifty	O
children	O
who	O
were	O
given	O
ceftriaxone	O
were	O
evaluated	O
by	O
serial	O
abdominal	O
sonograms	O
.	O

Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
biliary	O
pathology	O
.	O

Comparison	O
of	O
the	O
patients	O
with	O
or	O
without	O
pseudolithiasis	B
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	O
variables	O
.	O

After	O
cessation	O
of	O
the	O
treatment	O
,	O
pseudolithiasis	B
resolved	O
spontaneously	O
within	O
a	O
short	O
period	O
.	O

The	O
incidence	O
of	O
pseudolithiasis	B
is	O
not	O
affected	O
by	O
fasting	O
.	O

Coronary	B
aneurysm	I
after	O
implantation	O
of	O
a	O
paclitaxel	O
-	O
eluting	O
stent	O
.	O

Formation	O
of	O
coronary	B
aneurysm	I
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	B
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	B
or	O
vessel	B
rupture	I
.	O

We	O
present	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
a	O
coronary	B
aneurysm	I
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel	O
-	O
eluting	O
stent	O
.	O

The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O

Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15	O
-	O
mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	B
diameter	O
of	O
6	O
.	O
0	O
mm	O
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
a	O
graft	O
stent	O
.	O

Causes	O
of	O
acute	O
thrombotic	B
microangiopathy	I
in	O
patients	O
receiving	O
kidney	O
transplantation	O
.	O

OBJECTIVES	O
:	O
Thrombotic	B
microangiopathy	I
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O

In	O
postrenal	O
transplantation	O
,	O
thrombotic	B
microangiopathy	I
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B
uremic	I
syndrome	I
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B
microangiopathy	I
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	B
microangiopathy	I
during	O
a	O
1	O
-	O
year	O
period	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
interval	O
.	O

Pre	O
-	O
and	O
posttransplant	O
crossmatching	O
was	O
done	O
when	O
possible	O
.	O

RESULTS	O
:	O
Five	O
cases	O
of	O
thrombotic	B
microangiopathy	I
were	O
found	O
.	O

Three	O
of	O
these	O
cases	O
were	O
from	O
the	O
25	O
transplantations	O
performed	O
at	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
,	O
while	O
the	O
other	O
2	O
transplantations	O
had	O
been	O
performed	O
abroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O

Three	O
cases	O
were	O
related	O
to	O
cyclosporine	O
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	O
and	O
tacrolimus	O
.	O

The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B
microangiopathy	I
related	O
to	O
an	O
antiphospholipid	B
syndrome	I
in	O
a	O
patient	O
with	O
systemic	B
lupus	I
erythematosus	I
.	O

CONCLUSIONS	O
:	O
In	O
the	O
literature	O
,	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
hemolytic	B
uremic	I
syndrome	I
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	O
of	O
the	O
hemolytic	B
uremic	I
syndrome	I
.	O

Other	O
causes	O
include	O
drug	O
-	O
related	O
(	O
cyclosporine	O
,	O
tacrolimus	O
)	O
toxicity	B
,	O
procoagulant	O
status	O
,	O
and	O
antibody	O
-	O
mediated	O
rejection	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
thrombotic	B
microangiopathy	I
was	O
drug	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporine	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
frequency	O
of	O
thrombotic	B
microangiopathy	I
was	O
similar	O
to	O
the	O
percentage	O
reported	O
in	O
the	O
literature	O
(	O
20	O
%	O
)	O
.	O

Comparison	O
of	O
developmental	O
toxicity	B
of	O
selective	O
and	O
non	O
-	O
selective	O
cyclooxygenase	O
-	O
2	O
inhibitors	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WUBR	O
Wistar	O
rats	O
-	O
-	O
DFU	O
and	O
piroxicam	O
study	O
.	O

BACKGROUND	O
:	O
Cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingested	O
drugs	O
during	O
pregnancy	O
.	O

Unlike	O
general	O
toxicity	B
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	B
of	O
the	O
non	O
-	O
selective	O
(	O
piroxicam	O
)	O
and	O
selective	O
(	O
DFU	O
;	O
5	O
,	O
5	O
-	O
dimethyl	O
-	O
3	O
-	O
(	O
3	O
-	O
fluorophenyl	O
)	O
-	O
4	O
-	O
(	O
4	O
-	O
methylsulphonyl	O
)	O
phenyl	O
-	O
2	O
(	O
5H	O
)	O
-	O
furanon	O
)	O
COX	O
-	O
2	O
inhibitors	O
.	O

METHODS	O
:	O
Drugs	O
were	O
separately	O
,	O
orally	O
once	O
daily	O
dosed	O
to	O
pregnant	O
rats	O
from	O
day	O
8	O
to	O
21	O
(	O
GD1	O
=	O
plug	O
day	O
)	O
.	O

Doses	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
piroxicam	O
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	O
.	O

Fetuses	O
were	O
delivered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O

Comprehensive	O
clinical	O
and	O
developmental	O
measurements	O
were	O
done	O
.	O

The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	B
septal	I
(	I
VSD	I
)	I
and	I
midline	I
(	I
MD	I
)	I
defects	I
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	O
,	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data	O
.	O

RESULTS	O
:	O
Maternal	O
toxicity	B
,	O
intrauterine	B
growth	I
retardation	I
,	O
and	O
increase	B
of	I
external	I
and	I
skeletal	I
variations	I
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	O
.	O

Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	O
developmental	O
toxicity	B
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose	O
.	O

Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	O
and	O
DFU	O
-	O
exposed	O
groups	O
.	O

Prenatal	O
exposure	O
to	O
non	O
-	O
selective	O
COX	O
inhibitors	O
increases	O
the	O
risk	O
of	O
VSD	O
and	O
MD	O
when	O
compared	O
to	O
historic	O
control	O
but	O
not	O
with	O
selective	O
COX	O
-	O
2	O
inhibitors	O
.	O

CONCLUSION	O
:	O
Both	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inhibitors	O
were	O
toxic	O
for	O
rats	O
fetuses	O
when	O
administered	O
in	O
the	O
highest	O
dose	O
.	O

Unlike	O
DFU	O
,	O
piroxicam	O
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams	O
.	O

Prenatal	O
exposure	O
to	O
selective	O
COX	O
-	O
2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	B
septal	I
and	I
midline	I
defects	I
in	O
rat	O
when	O
compared	O
to	O
non	O
-	O
selective	O
drugs	O
and	O
historic	O
control	O
.	O

Lone	O
atrial	B
fibrillation	I
associated	O
with	O
creatine	O
monohydrate	O
supplementation	O
.	O

Atrial	B
fibrillation	I
in	O
young	O
patients	O
without	O
structural	O
heart	B
disease	I
is	O
rare	O
.	O

Therefore	O
,	O
when	O
the	O
arrhythmia	B
is	O
present	O
in	O
this	O
population	O
,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved	O
.	O

Thyroid	B
disorders	I
,	O
illicit	O
drug	O
or	O
stimulant	O
use	O
,	O
and	O
acute	B
alcohol	I
intoxication	I
are	O
among	O
these	O
causes	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
in	O
atrial	B
fibrillation	I
with	O
rapid	O
ventricular	O
response	O
.	O

His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	B
of	O
the	O
fingers	O
and	O
foot	O
.	O

Thyroid	O
-	O
stimulating	O
hormone	O
,	O
magnesium	O
,	O
and	O
potassium	O
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	O
drug	O
screen	O
was	O
negative	O
,	O
and	O
alcohol	O
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	O
monohydrate	O
was	O
revealed	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	O
,	O
and	O
given	O
intravenous	O
diltiazem	O
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	O
for	O
rate	O
and	O
rhythm	O
control	O
.	O

When	O
discharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprolol	O
and	O
aspirin	O
,	O
with	O
follow	O
-	O
up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion	O
.	O

Exogenous	O
creatine	O
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O

Vegetarians	O
may	O
also	O
take	O
creatine	O
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	O
products	O
.	O

Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	O
to	O
the	O
development	O
of	O
arrhythmia	B
.	O

Clinicians	O
must	O
be	O
diligent	O
when	O
interviewing	O
patients	O
about	O
their	O
drug	O
therapy	O
histories	O
and	O
include	O
questions	O
about	O
their	O
use	O
of	O
herbal	O
products	O
and	O
dietary	O
supplements	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
report	O
adverse	O
effects	O
associated	O
with	O
frequently	O
consumed	O
supplements	O
and	O
herbal	O
products	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
in	O
the	O
literature	O
.	O

Seizures	B
induced	O
by	O
the	O
cocaine	O
metabolite	O
benzoylecgonine	O
in	O
rats	O
.	O

The	O
half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
of	O
cocaine	O
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizures	B
and	O
strokes	B
,	O
can	O
occur	O
hours	O
after	O
exposure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	O
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae	O
.	O

We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	O
,	O
benzoylecgonine	O
(	O
BE	O
)	O
,	O
to	O
cause	O
seizures	B
.	O

Two	O
separate	O
equimolar	O
doses	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
mumol	O
)	O
of	O
either	O
cocaine	O
or	O
BE	O
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	O
.	O

Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence	O
,	O
latency	O
,	O
and	O
seizure	B
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	B
.	O

BE	O
-	O
Induced	O
seizures	B
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	O
.	O

Whereas	O
cocaine	O
-	O
induced	O
seizures	B
were	O
best	O
characterized	O
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	B
,	O
those	O
induced	O
by	O
BE	O
were	O
prolonged	O
,	O
often	O
multiple	O
and	O
mixed	O
in	O
type	O
,	O
and	O
rarely	O
resulted	O
in	O
death	B
.	O

Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	B
expression	O
.	O

BE	O
-	O
Injected	O
rats	O
that	O
did	O
not	O
have	O
seizures	B
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine	O
-	O
injected	O
animals	O
without	O
seizures	B
.	O

The	O
finding	O
that	O
cocaine	O
-	O
and	O
BE	O
-	O
induced	O
seizures	B
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine	O
-	O
induced	O
seizures	B
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	O
metabolite	O
,	O
BE	O
.	O

The	O
selective	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
Ro4368554	O
restores	O
memory	O
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	B
deficiency	I
in	O
the	O
rat	O
.	O

Antagonists	O
at	O
serotonin	O
type	O
6	O
(	O
5	O
-	O
HT	O
(	O
6	O
)	O
)	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O

Although	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	O
(	O
ACh	O
)	O
levels	O
.	O

The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	O
-	O
HT	O
(	O
6	O
)	O
antagonist	O
Ro4368554	O
(	O
3	O
-	O
benzenesulfonyl	O
-	O
7	O
-	O
(	O
4	O
-	O
methyl	O
-	O
piperazin	O
-	O
1	O
-	O
yl	O
)	O
1H	O
-	O
indole	O
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	O
pretreatment	O
)	O
and	O
a	O
serotonergic	O
-	O
(	O
tryptophan	O
(	O
TRP	O
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O

inhibitor	O
metrifonate	O
.	O

Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24	O
-	O
h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	O
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro4368554	O
was	O
inactive	O
.	O

Both	O
,	O
Ro4368554	O
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifonate	O
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
reversed	O
memory	B
deficits	I
induced	O
by	O
scopolamine	O
and	O
TRP	O
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
Ro4368554	O
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	B
deficit	I
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	O
and	O
,	O
possibly	O
,	O
other	O
5	O
-	O
HT	O
(	O
6	O
)	O
receptor	O
antagonists	O
.	O

Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	O
as	O
an	O
immunotherapy	O
for	O
cocaine	B
overdose	I
.	O

The	O
illicit	O
use	O
of	O
cocaine	O
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	B
overdose	I
remains	O
elusive	O
.	O

Current	O
protein	O
-	O
based	O
technology	O
offers	O
a	O
new	O
therapeutic	O
venue	O
by	O
which	O
antibodies	O
bind	O
the	O
drug	O
in	O
the	O
blood	O
stream	O
,	O
inactivating	O
its	O
toxic	O
effects	O
.	O

The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	O
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B
overdose	I
.	O

Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocaine	O
and	O
GNC92H2	O
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC92H2	O
was	O
delivered	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	O
treatment	O
.	O

Significant	O
blockade	O
of	O
cocaine	O
toxicity	B
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	O
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40	O
%	O
,	O
seizures	B
up	O
to	O
77	O
%	O
and	O
death	B
by	O
72	O
%	O
.	O

Importantly	O
,	O
GNC92H2	O
prevented	O
death	B
even	O
post	O
-	O
cocaine	O
injection	O
.	O

The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	O
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B
overdose	I
.	O

Electrocardiographic	O
evidence	O
of	O
myocardial	B
injury	I
in	O
psychiatrically	O
hospitalized	O
cocaine	O
abusers	O
.	O

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	O
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B
controls	O
.	O

Eleven	O
of	O
the	O
cocaine	O
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	B
injury	I
defined	O
as	O
myocardial	B
infarction	I
,	O
ischemia	B
,	O
and	O
bundle	B
branch	I
block	I
.	O

Behavioral	O
effects	O
of	O
urotensin	O
-	O
II	O
centrally	O
administered	O
in	O
mice	O
.	O

Urotensin	O
-	O
II	O
(	O
U	O
-	O
II	O
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Intracerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
injection	O
of	O
U	O
-	O
II	O
causes	O
hypertension	B
and	O
bradycardia	B
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O

However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	O
-	O
II	O
have	O
received	O
little	O
attention	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
injections	O
of	O
U	O
-	O
II	O
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O

Administration	O
of	O
graded	O
doses	O
of	O
U	O
-	O
II	O
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O

Intracerebroventricular	O
injection	O
of	O
U	O
-	O
II	O
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
mouse	O
,	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
.	O

Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U	O
-	O
II	O
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine	O
-	O
induced	O
penile	B
erection	I
and	O
climbing	O
behavior	O
,	O
and	O
stress	O
-	O
induced	O
plasma	O
corticosterone	O
level	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	O
-	O
II	O
at	O
doses	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
induces	O
anxiogenic	O
-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	O
.	O

These	O
data	O
suggest	O
that	O
U	O
-	O
II	O
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B
disorders	I
.	O

Learning	O
of	O
rats	O
under	O
amnesia	B
caused	O
by	O
pentobarbital	O
.	O

Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	B
produced	O
by	O
pentobarbital	O
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O

Rats	O
were	O
trained	O
to	O
approach	O
a	O
shelf	O
where	O
they	O
received	O
food	O
reinforcement	O
.	O

In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	O
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O

In	O
Group	O
2	O
the	O
rats	O
were	O
trained	O
to	O
approach	O
different	O
shelves	O
in	O
different	O
drug	O
states	O
.	O

It	O
was	O
shown	O
that	O
memory	B
dissociation	I
occurred	O
in	O
both	O
groups	O
.	O

Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	O
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed	O
.	O

These	O
findings	O
show	O
that	O
the	O
brain	O
-	O
dissociated	O
state	O
induced	O
by	O
pentobarbital	O
is	O
formed	O
with	O
the	O
participation	O
of	O
the	O
mechanisms	O
of	O
information	O
perception	O
.	O

The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	O
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O

BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	O
-	O
activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)	O
,	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
,	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	O
administration	O
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	O
with	O
osteopenia	B
or	O
osteoporosis	B
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O

Twenty	O
-	O
five	O
women	O
were	O
given	O
raloxifene	O
hydrochloride	O
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	O
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	O
.	O

Plasma	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O

Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
'	O
s	O
test	O
.	O

Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O

RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	O
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	B
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B
thromboembolism	I
due	O
to	O
raloxifene	O
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O

Valproate	O
-	O
induced	O
encephalopathy	B
.	O

Valproate	O
-	O
induced	O
encephalopathy	B
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B
individuals	O
.	O

It	O
may	O
even	O
present	O
in	O
patients	O
who	O
have	O
tolerated	O
this	O
medicine	O
well	O
in	O
the	O
past	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	B
.	O

The	O
EEG	O
shows	O
characteristic	O
triphasic	O
waves	O
in	O
most	O
patients	O
with	O
this	O
complication	O
.	O

A	O
case	O
of	O
valproate	O
-	O
induced	O
encephalopathy	B
is	O
presented	O
.	O

The	O
problems	O
in	O
diagnosing	O
this	O
condition	O
are	O
subsequently	O
discussed	O
.	O

Recurrent	O
dysphonia	B
and	O
acitretin	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	B
while	O
she	O
was	O
treated	O
by	O
acitretin	O
.	O

Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	O
withdrawal	O
and	O
reappeared	O
when	O
acitretin	O
was	O
reintroduced	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin	O
-	O
induced	O
dysphonia	B
.	O

This	O
effect	O
may	O
be	O
related	O
to	O
the	O
pharmacological	O
effect	O
of	O
this	O
drug	O
on	O
mucous	O
membranes	O
.	O

Nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
:	O
a	O
potential	O
protector	O
against	O
gentamicin	O
ototoxicity	B
.	O

The	O
nitric	O
oxide	O
(	O
NO	O
)	O
inhibitor	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high	B
-	I
frequency	I
hearing	I
loss	I
caused	O
by	O
gentamicin	O
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglycoside	O
antibiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost	O
.	O

Their	O
ototoxicity	B
is	O
a	O
serious	O
health	O
problem	O
and	O
,	O
as	O
their	O
ototoxic	B
mechanism	O
involves	O
the	O
production	O
of	O
NO	O
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	O
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside	O
-	O
induced	O
sensorineural	B
hearing	I
loss	I
.	O

In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
27	O
of	O
which	O
had	O
gentamicin	O
instilled	O
into	O
the	O
middle	O
ear	O
.	O

The	O
otoprotectant	O
L	O
-	O
NAME	O
was	O
administered	O
topically	O
to	O
12	O
/	O
27	O
animals	O
.	O

Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	B
loss	I
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold	O
.	O

L	O
-	O
NAME	O
reduced	O
gentamicin	O
-	O
induced	O
hearing	B
loss	I
in	O
the	O
high	O
-	O
frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O

Safety	O
profile	O
of	O
a	O
nicotine	O
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	O
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions	O
:	O
a	O
12	O
-	O
week	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
.	O

BACKGROUND	O
:	O
Nicotine	O
polacrilex	O
lozenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nicotine	O
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	O
polacrilex	O
gum	O
.	O

The	O
increased	O
nicotine	O
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4	O
-	O
mg	O
nicotine	O
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	O
gum	O
in	O
smokers	O
with	O
selected	O
label	O
-	O
restricted	O
diseases	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	B
disease	I
,	O
hypertension	B
not	O
controlled	O
by	O
medication	O
,	O
and	O
/	O
or	O
diabetes	B
mellitus	I
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nicotine	O
lozenge	O
or	O
4	O
-	O
mg	O
nicotine	O
gum	O
.	O

Safety	O
assessments	O
were	O
made	O
at	O
baseline	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	O
after	O
the	O
start	O
of	O
product	O
use	O
.	O

RESULTS	O
:	O
Nine	O
hundred	O
one	O
patients	O
were	O
randomized	O
to	O
treatment	O
,	O
447	O
who	O
received	O
the	O
lozenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(	O
safety	O
population	O
)	O
.	O

The	O
majority	O
were	O
women	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O

Patients	O
'	O
mean	O
age	O
was	O
53	O
.	O
9	O
years	O
,	O
their	O
mean	O
weight	O
was	O
193	O
.	O
9	O
pounds	O
,	O
and	O
they	O
smoked	O
a	O
mean	O
of	O
25	O
.	O
2	O
cigarettes	O
per	O
day	O
at	O
baseline	O
.	O

Five	O
hundred	O
fifty	O
-	O
three	O
patients	O
,	O
264	O
taking	O
the	O
lozenge	O
and	O
289	O
taking	O
the	O
gum	O
,	O
used	O
the	O
study	O
product	O
for	O
>	O
or	O
=	O
4	O
days	O
per	O
week	O
during	O
the	O
first	O
2	O
weeks	O
(	O
evaluable	O
population	O
)	O
.	O

The	O
nicotine	O
lozenge	O
and	O
nicotine	O
gum	O
were	O
equally	O
well	O
tolerated	O
,	O
despite	O
increased	O
nicotine	O
exposure	O
from	O
the	O
lozenge	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
in	O
the	O
2	O
groups	O
was	O
similar	O
during	O
the	O
first	O
2	O
weeks	O
of	O
product	O
use	O
(	O
evaluation	O
population	O
:	O
55	O
.	O
3	O
%	O
lozenge	O
,	O
54	O
.	O
7	O
%	O
gum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
study	O
(	O
safety	O
population	O
:	O
63	O
.	O
8	O
%	O
and	O
58	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

Stratification	O
of	O
patients	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
concurrent	O
smoking	O
,	O
extent	O
of	O
product	O
use	O
,	O
and	O
severity	O
of	O
adverse	O
events	O
revealed	O
no	O
clinically	O
significant	O
differences	O
between	O
the	O
lozenge	O
and	O
gum	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	B
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hiccups	B
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
headache	B
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O

Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
and	O
13	O
patients	O
in	O
the	O
respective	O
groups	O
.	O

Fewer	O
than	O
6	O
%	O
of	O
patients	O
in	O
either	O
group	O
were	O
considered	O
by	O
the	O
investigator	O
to	O
have	O
a	O
worsening	O
of	O
their	O
overall	O
disease	O
condition	O
during	O
the	O
study	O
.	O

The	O
majority	O
of	O
patients	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
disease	O
status	O
from	O
baseline	O
.	O

CONCLUSION	O
:	O
The	O
4	O
-	O
mg	O
nicotine	O
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	O
gum	O
had	O
comparable	O
safety	O
profiles	O
in	O
these	O
patients	O
with	O
label	O
-	O
restricted	O
medical	O
conditions	O
.	O

Pharmacological	O
modulation	O
of	O
pain	B
-	O
related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O

Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	B
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	B
injury	I
(	O
secondary	B
hyperalgesia	I
)	O
.	O

Secondary	B
hyperalgesia	I
shares	O
clinical	O
characteristics	O
with	O
neurogenic	B
hyperalgesia	I
in	O
patients	O
with	O
neuropathic	B
pain	I
.	O

Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	B
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	O
,	O
a	O
drug	O
effective	O
in	O
neuropathic	B
pain	I
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O

Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin	O
-	O
induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	O
-	O
induced	O
secondary	B
hyperalgesia	I
.	O

The	O
dose	O
of	O
gabapentin	O
was	O
1	O
,	O
800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	O
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex	O
,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization	O
;	O
(	O
ii	O
)	O
gabapentin	O
reduced	O
the	O
activation	O
in	O
the	O
brainstem	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
(	O
iii	O
)	O
gabapentin	O
suppressed	O
stimulus	O
-	O
induced	O
deactivations	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation	O
.	O

The	O
observed	O
drug	O
-	O
induced	O
effects	O
were	O
not	O
due	O
to	O
changes	O
in	O
the	O
baseline	O
fMRI	O
signal	O
.	O

These	O
findings	O
indicate	O
that	O
gabapentin	O
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	O
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	O
sensitization	O
is	O
present	O
.	O

Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	B
induced	O
by	O
pilocarpine	O
.	O

Mitochondrial	B
abnormalities	I
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	O
,	O
control	O
of	O
cell	O
death	B
,	O
neurotransmitter	O
synthesis	O
,	O
and	O
free	O
radical	O
(	O
FR	O
)	O
production	O
.	O

Increased	O
production	O
of	O
FRs	O
may	O
cause	O
mtDNA	O
damage	O
leading	O
to	O
decreased	O
activities	O
of	O
oxidative	O
phosphorylation	O
complexes	O
containing	O
mtDNA	O
-	O
encoded	O
subunits	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	B
epilepticus	I
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
CCO	O
)	O
,	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain	O
,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	O
model	O
of	O
temporal	B
lobe	I
epilepsy	I
.	O

DNA	O
analysis	O
revealed	O
low	O
amounts	O
of	O
a	O
4	O
.	O
8	O
kb	O
mtDNA	O
deletion	O
but	O
with	O
no	O
differences	O
in	O
frequency	O
or	O
quantity	O
in	O
the	O
control	O
and	O
experimental	O
groups	O
.	O

We	O
did	O
not	O
find	O
abnormalities	O
in	O
the	O
expression	O
and	O
distribution	O
of	O
an	O
mtDNA	O
-	O
encoded	O
subunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decrease	O
in	O
CCO	O
-	O
I	O
when	O
compared	O
with	O
nuclear	O
-	O
encoded	O
subunits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O

No	O
abnormality	O
in	O
CCO	O
activity	O
was	O
observed	O
through	O
histochemistry	O
.	O

Although	O
evidences	O
of	O
mitochondrial	B
abnormalities	I
were	O
found	O
in	O
previously	O
published	O
studies	O
,	O
our	O
results	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acute	O
phase	O
,	O
determined	O
important	O
abnormalities	O
in	O
mtDNA	O
,	O
in	O
expression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
activity	O
.	O

Adverse	O
effect	O
of	O
the	O
calcium	O
channel	O
blocker	O
nitrendipine	O
on	O
nephrosclerosis	B
in	O
rats	O
with	O
renovascular	B
hypertension	I
.	O

The	O
effect	O
of	O
a	O
6	O
-	O
week	O
treatment	O
with	O
the	O
calcium	O
channel	O
blocker	O
nitrendipine	O
or	O
the	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
enalapril	O
on	O
blood	O
pressure	O
,	O
albuminuria	B
,	O
renal	O
hemodynamics	O
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two	O
-	O
kidney	O
,	O
one	O
clip	O
renovascular	B
hypertension	I
.	O

Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery	O
,	O
hypertensive	B
rats	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
untreated	O
hypertensive	B
controls	O
(	O
n	O
=	O
8	O
)	O
,	O
enalapril	O
-	O
treated	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipine	O
-	O
treated	O
(	O
n	O
=	O
10	O
)	O
.	O

Sham	O
-	O
operated	O
rats	O
served	O
as	O
normotensive	O
controls	O
(	O
128	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O

After	O
6	O
weeks	O
of	O
treatment	O
,	O
renal	O
hemodynamics	O
(	O
glomerular	O
filtration	O
rate	O
and	O
renal	O
plasma	O
flow	O
)	O
were	O
measured	O
in	O
the	O
anesthetized	O
rats	O
.	O

Renal	O
tissue	O
was	O
obtained	O
for	O
determination	O
of	O
glomerular	O
size	O
and	O
sclerosis	O
.	O

Enalapril	O
but	O
not	O
nitrendipine	O
reduced	O
blood	O
pressure	O
significantly	O
.	O

After	O
6	O
weeks	O
of	O
therapy	O
,	O
glomerular	O
filtration	O
rate	O
was	O
not	O
different	O
among	O
the	O
studied	O
groups	O
.	O

Renal	O
plasma	O
flow	O
increased	O
,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	B
did	O
not	O
change	O
after	O
enalapril	O
treatment	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendipine	O
-	O
treated	O
group	O
albuminuria	B
increased	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
compared	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
hypertensive	B
controls	O
.	O

Furthermore	O
,	O
glomerulosclerosis	B
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine	O
-	O
treated	O
group	O
compared	O
with	O
the	O
hypertensive	B
controls	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	O
-	O
treated	O
group	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril	O
-	O
treated	O
group	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B
controls	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Ketoconazole	O
induced	O
torsades	B
de	I
pointes	I
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drug	O
.	O

Ketoconazole	O
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drugs	O
.	O

We	O
report	O
a	O
woman	O
with	O
coronary	B
artery	I
disease	I
who	O
developed	O
a	O
markedly	O
prolonged	B
QT	I
interval	I
and	O
torsades	B
de	I
pointes	I
(	O
TdP	B
)	O
after	O
taking	O
ketoconazole	O
for	O
treatment	O
of	O
fungal	B
infection	I
.	O

Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	O
.	O

Genetic	O
study	O
did	O
not	O
find	O
any	O
mutation	O
in	O
her	O
genes	O
that	O
encode	O
cardiac	O
IKr	O
channel	O
proteins	O
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	O
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP	B
.	O

This	O
calls	O
for	O
attention	O
when	O
ketoconazole	O
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	B
QT	I
syndrome	I
.	O

Cerebral	B
vasculitis	I
following	O
oral	O
methylphenidate	O
intake	O
in	O
an	O
adult	O
:	O
a	O
case	O
report	O
.	O

Methylphenidate	O
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	O
.	O

Cerebral	B
vasculitis	I
associated	O
with	O
amphetamine	B
abuse	I
is	O
well	O
documented	O
,	O
and	O
in	O
rare	O
cases	O
ischaemic	B
stroke	I
has	O
been	O
reported	O
after	O
methylphenidate	O
intake	O
in	O
children	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
63	O
-	O
year	O
-	O
old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	O
due	O
to	O
hyperactivity	B
and	O
suffered	O
from	O
multiple	O
ischaemic	B
strokes	I
.	O

We	O
consider	O
drug	O
-	O
induced	O
cerebral	B
vasculitis	I
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	B
strokes	I
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methylphenidate	O
mediated	O
vasculitis	B
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	O
therapy	O
.	O

This	O
potential	O
side	O
-	O
effect	O
,	O
though	O
very	O
rare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	O
.	O

MDMA	O
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B
social	I
and	I
emotional	I
judgement	I
processes	I
.	O

In	O
recent	O
years	O
working	O
memory	B
deficits	I
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	O
(	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
,	O
ecstasy	O
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	O
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefrontal	O
"	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

Fifteen	O
polydrug	O
ecstasy	O
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	O
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Compared	O
with	O
MDMA	O
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	O
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	O
use	O
.	O

Phase	O
II	O
study	O
of	O
the	O
amsacrine	O
analogue	O
CI	O
-	O
921	O
(	O
NSC	O
343499	O
)	O
in	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

CI	O
-	O
921	O
(	O
NSC	O
343499	O
;	O
9	O
-	O
[	O
[	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
[	O
(	O
methylsulphonyl	O
)	O
amino	O
]	O
phenyl	O
]	O
amino	O
]	O
-	O
N	O
,	O
5	O
-	O
dimethyl	O
-	O
4	O
-	O
acridinecarboxamide	O
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity	O
.	O

It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
(	O
7	O
with	O
no	O
prior	O
treatment	O
,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery	O
/	O
radiotherapy	O
)	O
at	O
a	O
dose	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phase	O
I	O
trial	O
.	O

Patients	O
had	O
a	O
median	O
performance	O
status	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
median	O
age	O
of	O
61	O
years	O
.	O

The	O
histology	O
comprised	O
squamous	B
carcinoma	I
(	O
11	O
)	O
,	O
adenocarcinoma	B
(	O
1	O
)	O
,	O
mixed	O
histology	O
(	O
2	O
)	O
,	O
bronchio	B
-	I
alveolar	I
carcinoma	I
(	O
1	O
)	O
and	O
large	O
cell	O
undifferentiated	B
carcinoma	I
(	O
1	O
)	O
.	O

Neutropenia	B
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients	O
,	O
infections	B
with	O
recovery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	B
in	O
1	O
patient	O
.	O

Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	B
and	O
vomiting	B
occurred	O
in	O
66	O
%	O
courses	O
and	O
phlebitis	B
in	O
the	O
infusion	O
arm	O
in	O
37	O
%	O
.	O

1	O
patient	O
with	O
squamous	B
cell	I
carcinoma	I
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months	O
.	O

Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	B
types	O
using	O
multiple	O
daily	O
schedules	O
is	O
warranted	O
.	O

Pharmacokinetics	O
of	O
desipramine	O
HCl	O
when	O
administered	O
with	O
cinacalcet	O
HCl	O
.	O

OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	O
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	O
on	O
CYP2D6	O
activity	O
,	O
using	O
desipramine	O
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	O
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	O
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O

RESULTS	O
:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms	O
.	O

Relative	O
to	O
desipramine	O
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	O
increased	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	O
.	O

The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
desipramine	O
was	O
longer	O
when	O
desipramine	O
was	O
coadministered	O
with	O
cinacalcet	O
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O

The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimens	O
.	O

Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	O
alone	O
than	O
when	O
receiving	O
desipramine	O
with	O
cinacalcet	O
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B
and	O
headache	B
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	O
or	O
cinacalcet	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	O
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	O
.	O

These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	O
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O

Case	O
report	O
:	O
acute	O
unintentional	O
carbachol	O
intoxication	O
.	O

INTRODUCTION	O
:	O
Intoxications	O
with	O
carbachol	O
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare	O
.	O

We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(	O
near	O
)	O
fatal	O
poisoning	B
.	O

METHODS	O
:	O
The	O
son	O
of	O
an	O
84	O
-	O
year	O
-	O
old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer	B
'	I
s	I
disease	I
.	O

The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'	O
carbamylcholin	O
'	O
;	O
that	O
is	O
,	O
carbachol	O
.	O

He	O
bought	O
25	O
g	O
of	O
carbachol	O
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	O
.	O

Carbachol	O
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O
2	O
of	O
hospital	O
admission	O
were	O
analysed	O
by	O
HPLC	O
-	O
mass	O
spectrometry	O
.	O

RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	B
,	O
sweating	O
and	O
hypotension	B
,	O
and	O
finally	O
collapsed	O
.	O

Bradycardia	B
,	O
cholinergic	O
symptoms	O
and	O
asystole	B
occurred	O
.	O

Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	O
(	O
epinephrine	O
)	O
,	O
atropine	O
and	O
furosemide	O
was	O
successful	O
.	O

On	O
hospital	O
admission	O
,	O
blood	O
pressure	O
of	O
the	O
intubated	O
,	O
bradyarrhythmic	O
patient	O
was	O
100	O
/	O
65	O
mmHg	O
.	O

Further	O
signs	O
were	O
hyperhidrosis	B
,	O
hypersalivation	B
,	O
bronchorrhoea	B
,	O
and	O
severe	O
miosis	B
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio	B
-	I
ventricular	I
dissociation	I
.	O

High	O
doses	O
of	O
atropine	O
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	O
and	O
dopamine	O
were	O
necessary	O
.	O

The	O
patient	O
was	O
extubated	O
1	O
week	O
later	O
.	O

However	O
,	O
increased	O
dyspnoea	B
and	O
bronchospasm	B
necessitated	O
reintubation	O
.	O

Respiratory	B
insufficiency	I
was	O
further	O
worsened	O
by	O
Proteus	B
mirabilis	I
infection	I
and	O
severe	O
bronchoconstriction	O
.	O

One	O
week	O
later	O
,	O
the	O
patient	O
was	O
again	O
extubated	O
and	O
3	O
days	O
later	O
was	O
transferred	O
to	O
a	O
peripheral	O
ward	O
.	O

On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	O
of	O
heart	B
failure	I
.	O

Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carbachol	O
,	O
respectively	O
.	O

The	O
corresponding	O
urine	O
concentrations	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l	O
.	O

CONCLUSION	O
:	O
This	O
case	O
started	O
with	O
a	O
media	O
report	O
in	O
a	O
popular	O
newspaper	O
,	O
initiated	O
by	O
published	O
,	O
peer	O
-	O
reviewed	O
research	O
on	O
herbals	O
,	O
and	O
involved	O
human	O
failure	O
in	O
a	O
case	O
history	O
,	O
medical	O
examination	O
and	O
clinical	O
treatment	O
.	O

For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	O
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
.	O

The	O
analysed	O
carbachol	O
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
patients	O
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	O
)	O
as	O
a	O
cause	O
of	O
acute	B
cardiovascular	I
failure	I
.	O

Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	B
dysfunctions	I
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	O
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O

The	O
ethanolic	O
extract	O
of	O
Daucus	O
carota	O
seeds	O
(	O
DCE	O
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O

Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory	O
.	O

Diazepam	O
-	O
,	O
scopolamine	O
-	O
and	O
ageing	O
-	O
induced	O
amnesia	B
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O

DCE	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	O
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O

Similarly	O
,	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice	O
.	O

Furthermore	O
,	O
DCE	O
reversed	O
the	O
amnesia	B
induced	O
by	O
scopolamine	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepam	O
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Daucus	O
carota	O
extract	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	O
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	O
.	O

There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	O
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	O
.	O

Therefore	O
,	O
DCE	O
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B
dysfunctions	I
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	O
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O

Valproic	O
acid	O
induced	O
encephalopathy	B
-	O
-	O
19	O
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
effect	O
associated	O
to	O
VPA	O
-	O
therapy	O
not	O
only	O
in	O
young	O
children	O
.	O

Valproic	O
acid	O
(	O
VPA	O
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well	O
-	O
tolerated	O
.	O

Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B
,	O
bone	B
marrow	I
suppression	I
,	O
VPA	O
-	O
induced	O
hepatotoxicity	B
and	O
VPA	O
-	O
induced	O
encephalopathy	B
.	O

The	O
typical	O
signs	O
of	O
VPA	O
-	O
induced	O
encephalopathy	B
are	O
impaired	B
consciousness	I
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	B
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	B
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	O
in	O
patients	O
with	O
encephalopathy	B
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
report	O
19	O
patients	O
with	O
VPA	O
-	O
associated	O
encephalopathy	B
in	O
Germany	O
from	O
the	O
years	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	O
previously	O
.	O

Cerebral	B
haemorrhage	I
induced	O
by	O
warfarin	O
-	O
the	O
influence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
frequency	O
,	O
severity	O
and	O
preventability	O
of	O
warfarin	O
-	O
induced	O
cerebral	B
haemorrhages	I
due	O
to	O
warfarin	O
and	O
warfarin	O
-	O
drug	O
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
tland	O
,	O
Sweden	O
.	O

METHODS	O
:	O
All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	B
haemorrhage	I
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000	O
-	O
2002	O
were	O
identified	O
.	O

Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	O
and	O
warfarin	O
-	O
drug	O
interactions	O
could	O
have	O
caused	O
the	O
cerebral	B
haemorrhage	I
.	O

The	O
proportion	O
of	O
possibly	O
avoidable	O
cases	O
due	O
to	O
drug	O
interactions	O
was	O
estimated	O
.	O

RESULTS	O
:	O
Among	O
593	O
patients	O
with	O
cerebral	B
haemorrhage	I
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	O
treatment	O
.	O

This	O
imply	O
an	O
incidence	O
of	O
1	O
.	O
7	O
/	O
100	O
,	O
000	O
treatment	O
years	O
.	O

Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfarin	O
patients	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
warfarin	O
-	O
drug	O
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	B
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfarin	O
patients	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bleeding	B
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLUSIONS	O
:	O
Warfarin	O
-	O
induced	O
cerebral	B
haemorrhages	I
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	O
-	O
drug	O
interaction	O
.	O

A	O
significant	O
proportion	O
of	O
warfarin	O
-	O
related	O
cerebral	B
haemorrhages	I
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	O
.	O

Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	O
,	O
a	O
selective	O
H3	O
-	O
receptor	O
antagonist	O
in	O
mice	O
.	O

Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	O
H	O
(	O
3	O
)	O
-	O
receptor	O
ligands	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	B
,	O
apomorphine	O
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	O
-	O
induced	O
locomotor	O
activities	O
in	O
mice	O
.	O

Catalepsy	B
was	O
induced	O
by	O
haloperidol	O
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
apomorphine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
amphetamine	O
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O

(	O
R	O
)	O
-	O
alpha	O
-	O
methylhistamine	O
(	O
RAMH	O
)	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thioperamide	O
(	O
THP	O
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B
.	O

Administration	O
of	O
THP	O
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
haloperidol	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
pretreatment	O
with	O
RAMH	O
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RAMH	O
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O

On	O
amphetamine	O
-	O
induced	O
hyperactivity	B
,	O
THP	O
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pretreatment	O
with	O
RAMH	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	O
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Climbing	O
behavior	O
induced	O
by	O
apomorphine	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	O
.	O

Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	O
.	O

THP	O
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	O
-	O
induced	O
catalepsy	B
,	O
reducing	O
amphetamine	O
-	O
induced	O
hyperactivity	B
and	O
reducing	O
apomorphine	O
-	O
induced	O
climbing	O
in	O
mice	O
.	O

Such	O
effects	O
of	O
THP	O
were	O
reversed	O
by	O
RAMH	O
indicating	O
the	O
involvement	O
of	O
histamine	O
H	O
(	O
3	O
)	O
-	O
receptors	O
.	O

Findings	O
suggest	O
a	O
potential	O
for	O
H	O
(	O
3	O
)	O
-	O
receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B
.	O

Cauda	B
equina	I
syndrome	I
after	O
epidural	O
steroid	O
injection	O
:	O
a	O
case	O
report	O
.	O

OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	O
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O

Cauda	B
equina	I
syndrome	I
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O

The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B
equina	I
syndrome	I
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	O
and	O
bupivacaine	O
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
low	B
back	I
and	I
right	I
leg	I
pain	I
was	O
scheduled	O
for	O
epidural	O
steroid	O
injection	O
.	O

INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
level	O
.	O

Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging	O
.	O

After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	O
and	O
triamcinolone	O
diacetate	O
were	O
injected	O
.	O

After	O
the	O
injection	O
,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	B
and	O
lower	B
extremity	I
weakness	I
.	O

The	O
neurologic	O
evaluation	O
revealed	O
loss	B
of	I
sensation	I
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O

There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test	O
.	O

Deep	O
-	O
tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg	O
.	O

She	O
was	O
unable	O
to	O
urinate	O
.	O

The	O
patient	O
'	O
s	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O

She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter	O
.	O

All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O

CONCLUSION	O
:	O
Complications	O
associated	O
with	O
epidural	O
steroid	O
injections	O
are	O
rare	O
.	O

Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	B
deterioration	I
after	O
epidural	O
steroid	O
injections	O
is	O
important	O
.	O

High	O
-	O
dose	O
testosterone	O
is	O
associated	O
with	O
atherosclerosis	B
in	O
postmenopausal	O
women	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
long	O
-	O
term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	B
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
In	O
a	O
population	O
-	O
based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54	O
-	O
67	O
years	O
,	O
we	O
studied	O
the	O
association	O
between	O
self	O
-	O
reported	O
intramuscularly	O
administered	O
high	O
-	O
dose	O
estrogen	O
-	O
testosterone	O
therapy	O
(	O
estradiol	O
-	O
and	O
testosterone	O
esters	O
)	O
and	O
aortic	O
atherosclerosis	B
.	O

Aortic	O
atherosclerosis	B
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	B
.	O

Hormone	O
therapy	O
users	O
were	O
compared	O
with	O
never	O
users	O
.	O

RESULTS	O
:	O
Intramuscular	O
hormone	O
therapy	O
use	O
for	O
1	O
year	O
or	O
longer	O
was	O
reported	O
by	O
25	O
women	O
.	O

In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	B
of	O
the	O
aorta	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	B
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
age	O
,	O
years	O
since	O
menopause	O
,	O
smoking	O
,	O
and	O
body	O
mass	O
index	O
)	O
.	O

The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	B
,	O
cholesterol	O
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	O
use	O
.	O

No	O
association	O
was	O
found	O
for	O
hormone	O
use	O
less	O
than	O
1	O
year	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
testosterone	O
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	B
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O

Optimising	O
stroke	B
prevention	O
in	O
non	O
-	O
valvular	O
atrial	B
fibrillation	I
.	O

Atrial	B
fibrillation	I
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	O
reduces	O
the	O
risk	O
of	O
stroke	B
by	O
62	O
%	O
,	O
and	O
that	O
aspirin	O
alone	O
reduces	O
the	O
risk	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
risk	O
patients	O
,	O
warfarin	O
is	O
superior	O
to	O
aspirin	O
in	O
preventing	O
strokes	B
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36	O
%	O
.	O

Ximelagatran	O
,	O
an	O
oral	O
direct	O
thrombin	O
inhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	O
K	O
antagonist	O
drugs	O
in	O
the	O
prevention	O
of	O
embolic	B
events	I
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	B
liver	I
function	I
tests	O
.	O

The	O
ACTIVE	O
-	O
W	O
(	O
Atrial	B
Fibrillation	I
Clopidogrel	O
Trial	O
with	O
Irbesartan	O
for	O
Prevention	O
of	O
Vascular	O
Events	O
)	O
study	O
has	O
demonstrated	O
that	O
warfarin	O
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	O
plus	O
aspirin	O
)	O
in	O
the	O
prevention	O
af	O
embolic	B
events	I
.	O

Idraparinux	O
,	O
a	O
Factor	O
Xa	O
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B
fibrillation	I
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	O
II	O
receptor	O
-	O
blocking	O
drugs	O
hold	O
promise	O
in	O
atrial	B
fibrillation	I
through	O
cardiac	B
remodelling	I
.	O

Preliminary	O
studies	O
suggest	O
that	O
statins	O
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	O
after	O
electrical	O
cardioversion	O
.	O

Finally	O
,	O
percutaneous	O
methods	O
for	O
the	O
exclusion	O
of	O
left	O
atrial	O
appendage	O
are	O
under	O
investigation	O
in	O
high	O
-	O
risk	O
patients	O
.	O

Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	O
in	O
dexamethasone	O
-	O
induced	O
hypertension	B
in	O
the	O
rat	O
.	O

1	O
.	O

Dexamethasone	O
(	O
Dex	O
)	O
-	O
induced	O
hypertension	B
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	O
oxide	O
(	O
NO	O
)	O
deficiency	O
and	O
increased	O
superoxide	O
(	O
O2	O
-	O
)	O
production	O
.	O

Atorvastatin	O
(	O
Ato	O
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	O
and	O
reduced	O
O2	O
-	O
production	O
in	O
various	O
forms	O
of	O
hypertension	B
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p	O
.	O
o	O
.	O
,	O
Ato	O
could	O
prevent	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2	O
-	O
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O

2	O
.	O

Male	O
SD	O
rats	O
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dexamethasone	O
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	O
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	O
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail	O
-	O
cuff	O
method	O
.	O

Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	O
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	O
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O

Vascular	O
eNOS	O
mRNA	O
was	O
assessed	O
by	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

3	O
.	O

In	O
rats	O
treated	O
with	O
Dex	O
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
Ato	O
+	O
Dex	O
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	O
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	O
+	O
Ato	O
group	O
than	O
in	O
the	O
Dex	O
only	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

Aortic	O
superoxide	O
production	O
was	O
lower	O
in	O
the	O
Dex	O
+	O
Ato	O
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	O
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

4	O
.	O

Treatment	O
with	O
Ato	O
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	O
production	O
and	O
reduced	O
SBP	O
in	O
Dex	O
-	O
treated	O
SD	O
rats	O
.	O

Severe	O
citrate	O
toxicity	B
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
citrate	O
toxicity	B
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection	O
.	O

The	O
donor	O
was	O
a	O
40	O
-	O
year	O
-	O
old	O
female	O
,	O
first	O
-	O
time	O
apheresis	O
platelet	O
donor	O
.	O

Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	B
,	O
hyperlipidemia	B
,	O
and	O
depression	B
.	O

Reported	O
medications	O
included	O
bumetanide	O
,	O
pravastatin	O
,	O
and	O
paroxetine	O
.	O

Thirty	O
minutes	O
from	O
the	O
start	O
of	O
the	O
procedure	O
,	O
the	O
donor	O
noted	O
tingling	O
around	O
the	O
mouth	O
,	O
hands	O
,	O
and	O
feet	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	B
.	O

Empirical	O
treatment	O
with	O
intravenous	O
calcium	O
gluconate	O
was	O
initiated	O
,	O
and	O
muscle	B
contractions	I
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O

The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	O
chelation	O
by	O
sodium	O
citrate	O
anticoagulant	O
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	B
.	O

Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	O
is	O
a	O
loop	O
diuretic	O
that	O
may	O
cause	O
significant	O
hypocalcemia	B
.	O

We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	B
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	O
toxicity	B
.	O

Laboratory	O
measurement	O
of	O
pre	O
-	O
procedure	O
serum	O
calcium	O
levels	O
in	O
selected	O
donors	O
may	O
identify	O
cases	O
requiring	O
heightened	O
vigilance	O
.	O

The	O
case	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparedness	O
for	O
managing	O
rare	O
but	O
serious	O
reactions	O
in	O
volunteer	O
apheresis	O
blood	O
donors	O
.	O

Sirolimus	O
-	O
associated	O
proteinuria	B
and	O
renal	B
dysfunction	I
.	O

Sirolimus	O
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	O
protein	O
kinase	O
.	O

Sirolimus	O
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	B
.	O

Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	B
,	O
autoimmunity	B
,	O
cystic	B
renal	I
diseases	I
and	O
renal	B
cancer	I
is	O
under	O
investigation	O
.	O

Because	O
sirolimus	O
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrotoxic	B
drug	O
'	O
.	O

However	O
,	O
clinical	O
reports	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	O
is	O
associated	O
with	O
proteinuria	B
and	O
acute	B
renal	I
dysfunction	I
.	O

A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre	O
-	O
existing	O
chronic	B
renal	I
damage	I
.	O

The	O
mechanisms	O
of	O
sirolimus	O
-	O
associated	O
proteinuria	B
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	O
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O

The	O
acute	B
renal	I
dysfunction	I
associated	O
with	O
sirolimus	O
(	O
such	O
as	O
in	O
delayed	O
graft	O
function	O
)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival	O
/	O
repair	O
processes	O
.	O

Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients	O
,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	O
on	O
the	O
kidney	O
,	O
the	O
use	O
of	O
sirolimus	O
in	O
appropriate	O
patient	O
populations	O
,	O
close	O
monitoring	O
of	O
proteinuria	B
and	O
renal	O
function	O
,	O
use	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	O
II	O
receptor	O
blockers	O
if	O
proteinuria	B
occurs	O
and	O
withdrawal	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	O
as	O
de	O
novo	O
immunosuppression	O
along	O
with	O
clinical	O
and	O
laboratory	O
studies	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O

Proteinuria	B
after	O
conversion	O
to	O
sirolimus	O
in	O
renal	O
transplant	O
recipients	O
.	O

Sirolimus	O
(	O
SRL	O
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O

More	O
recently	O
,	O
proteinuria	B
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	O
therapy	O
,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear	O
.	O

We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	B
after	O
SRL	O
conversion	O
.	O

The	O
patient	O
cohort	O
(	O
14	O
men	O
,	O
11	O
women	O
)	O
was	O
treated	O
with	O
SRL	O
as	O
conversion	O
therapy	O
,	O
due	O
to	O
chronic	B
allograft	I
nephropathy	I
(	O
CAN	B
)	O
(	O
n	O
=	O
15	O
)	O
neoplasia	B
(	O
n	O
=	O
8	O
)	O
;	O
Kaposi	B
'	I
s	I
sarcoma	I
,	O
Four	O
skin	B
cancers	I
,	O
One	O
intestinal	B
tumors	I
,	O
One	O
renal	B
cell	I
carsinom	I
)	O
or	O
BK	O
virus	O
nephropathy	B
(	O
n	O
=	O
2	O
)	O
.	O

SRL	O
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
months	O
after	O
transplantation	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	O
therapy	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	O
.	O

Proteinuria	B
increased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
conversion	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
conversion	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Before	O
conversion	O
8	O
(	O
32	O
%	O
)	O
patients	O
had	O
no	O
proteinuria	B
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B
.	O

In	O
28	O
%	O
of	O
patients	O
proteinuria	B
remained	O
unchanged	O
,	O
whereas	O
it	O
increased	O
in	O
68	O
%	O
of	O
patients	O
.	O

In	O
40	O
%	O
it	O
increased	O
by	O
more	O
than	O
100	O
%	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	B
to	O
the	O
nephrotic	B
range	O
.	O

Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	B
glomerulopathy	I
and	O
interstitial	B
nephritis	I
.	O

These	O
patients	O
showed	O
persistently	O
good	O
graft	O
function	O
.	O

Serum	O
creatinine	O
values	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	O
therapy	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	O
returned	O
to	O
dialysis	O
.	O

Five	O
patients	O
displayed	O
CAN	B
and	O
Kaposi	B
'	I
s	I
sarcoma	I
.	O

Mean	O
urinary	O
protein	O
of	O
patients	O
who	O
returned	O
to	O
dialysis	O
was	O
1	O
.	O
26	O
(	O
0	O
.	O
5	O
to	O
3	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
and	O
4	O
.	O
7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
conversion	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Mean	O
serum	O
creatinine	O
level	O
before	O
conversion	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

Heavy	O
proteinuria	B
was	O
common	O
after	O
the	O
use	O
of	O
SRL	O
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O

Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	B
and	O
proteinuria	B
.	O

The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	O
treatment	O
requires	O
further	O
investigation	O
by	O
renal	O
biopsy	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfamide	O
renal	B
toxicity	I
in	O
children	O
treated	O
for	O
malignant	B
mesenchymal	I
tumors	I
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report	O
.	O

The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	B
mesenchymal	I
tumors	I
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	O
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	B
Mesenchymal	I
Tumor	I
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	O
.	O

Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	O
(	O
six	O
or	O
10	O
cycles	O
of	O
ifosfamide	O
,	O
vincristine	O
,	O
and	O
dactinomycin	O
[	O
IVA	O
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
cisplatin	O
chemotherapy	O
.	O

Ages	O
ranged	O
from	O
4	O
months	O
to	O
17	O
years	O
;	O
58	O
patients	O
were	O
males	O
and	O
42	O
females	O
.	O

The	O
most	O
common	O
primary	O
tumor	B
site	O
was	O
the	O
head	O
and	O
neck	O
.	O

Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	B
,	O
proteinuria	B
,	O
aminoaciduria	B
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	O
clearance	O
,	O
phosphate	O
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O

Fifty	O
-	O
eight	O
patients	O
(	O
78	O
%	O
)	O
had	O
normal	O
renal	O
tests	O
,	O
whereas	O
16	O
patients	O
(	O
22	O
%	O
)	O
had	O
renal	B
abnormalities	I
.	O

Two	O
subsets	O
of	O
patients	O
were	O
identified	O
from	O
this	O
latter	O
group	O
:	O
the	O
first	O
included	O
four	O
patients	O
(	O
5	O
%	O
of	O
the	O
total	O
population	O
)	O
who	O
developed	O
major	O
toxicity	B
resulting	O
in	O
Fanconi	B
'	I
s	I
syndrome	I
(	O
TDFS	B
)	O
;	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	O
reabsorption	O
.	O

The	O
remaining	O
seven	O
patients	O
had	O
isolated	O
beta	O
2	O
microglobulinuria	O
.	O

Severe	O
toxicity	B
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	O
,	O
a	O
younger	O
age	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
years	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	B
involvement	O
.	O

This	O
low	O
percentage	O
(	O
5	O
%	O
)	O
of	O
TDFS	O
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	O
in	O
the	O
treatment	O
of	O
mesenchymal	B
tumors	I
in	O
children	O
.	O

Progressive	O
myopathy	B
with	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
statin	O
therapy	O
.	O

Statins	O
can	O
cause	O
a	O
necrotizing	O
myopathy	B
and	O
hyperCKaemia	B
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	O
may	O
induce	O
a	O
myopathy	B
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O

We	O
investigated	O
the	O
muscle	O
pathology	O
in	O
8	O
such	O
cases	O
.	O

All	O
had	O
myofibre	O
necrosis	B
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate	O
.	O

In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
even	O
in	O
non	O
-	O
necrotic	B
fibres	O
.	O

Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	O
and	O
methotrexate	O
,	O
and	O
in	O
one	O
case	O
spontaneously	O
.	O

These	O
observations	O
suggest	O
that	O
statins	O
may	O
initiate	O
an	O
immune	O
-	O
mediated	O
myopathy	B
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	O
and	O
responds	O
to	O
immunosuppressive	O
therapy	O
.	O

The	O
mechanism	O
of	O
this	O
myopathy	B
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	O
of	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
with	O
associated	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
and	O
antigen	O
presentation	O
by	O
muscle	O
fibres	O
.	O

Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	B
susceptibility	O
loci	O
in	O
mice	O
.	O

Seizure	B
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains	O
.	O

Chromosome	O
substitution	O
strains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(	O
donor	O
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(	O
host	O
)	O
by	O
repeated	O
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
seizure	B
susceptibility	O
.	O

QTLs	O
for	O
susceptibility	O
to	O
pilocarpine	O
-	O
induced	O
seizures	B
,	O
a	O
model	O
of	O
temporal	B
lobe	I
epilepsy	I
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	B
susceptibility	O
genes	O
.	O

We	O
report	O
QTLs	O
identified	O
using	O
a	O
B6	O
(	O
host	O
)	O
x	O
A	O
/	O
J	O
(	O
donor	O
)	O
CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine	O
-	O
induced	O
seizures	B
.	O

Three	O
hundred	O
fifty	O
-	O
five	O
adult	O
male	O
CSS	O
mice	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine	O
-	O
induced	O
seizures	B
.	O

Highest	O
stage	O
reached	O
and	O
latency	O
to	O
each	O
stage	O
were	O
recorded	O
for	O
all	O
mice	O
.	O

B6	O
mice	O
were	O
resistant	O
to	O
seizures	B
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A	O
/	O
J	O
mice	O
.	O

The	O
CSS	O
for	O
Chromosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
severe	O
stages	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenotype	O
.	O

Latencies	O
to	O
stages	O
were	O
also	O
significantly	O
shorter	O
for	O
CSS10	O
and	O
CSS18	O
mice	O
.	O

CSS	O
mapping	O
suggests	O
seizure	B
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	B
lobe	I
epilepsy	I
.	O

In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	O
-	O
induced	O
cystitis	B
in	O
the	O
rat	O
.	O

In	O
cyclophosphamide	O
-	O
induced	O
cystitis	B
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O

Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B
was	O
presently	O
investigated	O
.	O

Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	O
-	O
pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	O
,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists	O
.	O

Generally	O
,	O
atropine	O
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O

In	O
both	O
types	O
,	O
purinoceptor	O
desensitization	O
with	O
alpha	O
,	O
beta	O
-	O
methylene	O
adenosine	O
-	O
5	O
'	O
-	O
triphosphate	O
(	O
alpha	O
,	O
beta	O
-	O
meATP	O
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
muscarinic	O
receptor	O
antagonists	O
atropine	O
,	O
4	O
-	O
diphenylacetoxy	O
-	O
N	O
-	O
methylpiperidine	O
(	O
4	O
-	O
DAMP	O
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
methoctramine	O
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirenzepine	O
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O

4	O
-	O
DAMP	O
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	O
and	O
pirenzepine	O
.	O

In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	O
and	O
4	O
-	O
DAMP	O
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O

In	O
contrast	O
to	O
controls	O
,	O
methoctramine	O
increased	O
-	O
-	O
instead	O
of	O
decreased	O
-	O
-	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O

While	O
contractions	O
to	O
carbachol	O
and	O
ATP	O
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	O
response	O
,	O
isoprenaline	O
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O

Thus	O
,	O
in	O
cystitis	B
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O

While	O
postjunctional	O
beta	O
-	O
adrenoceptor	O
-	O
mediated	O
relaxations	O
are	O
reduced	O
,	O
effects	O
by	O
prejunctional	O
inhibitory	O
muscarinic	O
receptors	O
may	O
be	O
increased	O
.	O

Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
pacemaker	O
channels	O
by	O
clonidine	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	B
disease	I
,	O
including	O
arrhythmia	B
,	O
coronary	B
heart	I
disease	I
,	O
and	O
chronic	O
heart	B
failure	I
.	O

Activation	O
of	O
presynaptic	O
alpha2	O
-	O
adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	O
clonidine	O
;	O
however	O
,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
whether	O
clonidine	O
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2	O
-	O
adrenoceptors	O
,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2	O
-	O
adrenoceptor	O
subtypes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O

Alpha2ABC	O
-	O
/	O
-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	O
;	O
however	O
,	O
clonidine	O
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC	O
-	O
/	O
-	O
mice	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clonidine	O
-	O
induced	O
bradycardia	B
in	O
conscious	O
alpha2ABC	O
-	O
/	O
-	O
mice	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
microg	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
microg	O
/	O
kg	O
)	O
of	O
the	O
effect	O
in	O
wild	O
-	O
type	O
mice	O
.	O

A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	O
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	O
and	O
wild	O
-	O
type	O
mice	O
.	O

Clonidine	O
inhibited	O
the	O
native	O
pacemaker	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells	O
.	O

As	O
a	O
consequence	O
of	O
blocking	O
I	O
(	O
f	O
)	O
,	O
clonidine	O
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild	O
-	O
type	O
and	O
alpha2ABC	O
-	O
knockout	O
mice	O
.	O

CONCLUSIONS	O
:	O
Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	O
effects	O
of	O
clonidine	O
gene	O
-	O
targeted	O
mice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonidine	O
-	O
like	O
drugs	O
represent	O
novel	O
structures	O
for	O
future	O
HCN	O
channel	O
inhibitors	O
.	O

Granulomatous	B
hepatitis	I
due	O
to	O
combination	O
of	O
amoxicillin	O
and	O
clavulanic	O
acid	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin	O
-	O
clavulanic	O
acid	O
-	O
induced	O
hepatitis	B
with	O
histologic	O
multiple	O
granulomas	B
.	O

This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	B
injury	I
due	O
to	O
this	O
drug	O
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	B
syndrome	I
.	O

The	O
association	O
of	O
granulomas	B
and	O
eosinophilia	B
favor	O
an	O
immunoallergic	O
mechanism	O
.	O

As	O
penicillin	O
derivatives	O
and	O
amoxicillin	O
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions	O
,	O
the	O
amoxicillin	O
component	O
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	O
acid	O
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Dobutamine	O
stress	O
echocardiography	O
:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin	O
-	O
treated	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B
.	O

Doxorubicin	O
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	B
.	O

To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	B
damage	I
due	O
to	O
doxorubicin	O
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	O
infusion	O
to	O
differentiate	O
asymptomatic	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B
treated	O
with	O
doxorubicin	O
from	O
healthy	O
control	O
subjects	O
.	O

Echocardiographic	O
data	O
from	O
the	O
experimental	O
group	O
of	O
21	O
patients	O
(	O
mean	O
age	O
16	O
+	O
/	O
-	O
5	O
years	O
)	O
treated	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
years	O
(	O
median	O
5	O
.	O
3	O
)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxorubicin	O
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

Graded	O
dobutamine	O
infusions	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
were	O
administered	O
.	O

Echocardiographic	O
Doppler	O
studies	O
were	O
performed	O
before	O
infusion	O
and	O
after	O
15	O
min	O
of	O
infusion	O
at	O
each	O
rate	O
.	O

Dobutamine	O
infusion	O
at	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
was	O
discontinued	O
after	O
six	O
studies	O
secondary	O
to	O
a	O
50	O
%	O
incidence	O
rate	O
of	O
adverse	O
symptoms	O
.	O

The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects	O
,	O
end	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin	O
-	O
treated	O
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	O
stimulation	O
.	O

End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin	O
-	O
treated	O
group	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5	O
-	O
micrograms	O
/	O
kg	O
per	O
min	O
dobutamine	O
infusion	O
for	O
the	O
doxorubicin	O
-	O
treated	O
group	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Influence	O
of	O
smoking	O
on	O
developing	O
cochlea	O
.	O

Does	O
smoking	O
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns	O
?	O

OBJECTIVE	O
:	O
Maternal	O
tobacco	O
smoking	O
has	O
negative	O
effects	O
on	O
fetal	O
growth	O
.	O

The	O
influence	O
of	O
smoking	O
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	O
has	O
been	O
positively	O
associated	O
with	O
hearing	B
loss	I
in	O
adults	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	O
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O

METHODS	O
:	O
This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	B
impairment	I
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns	O
.	O

Newborns	O
whose	O
mothers	O
reported	O
smoking	O
during	O
pregnancy	O
(	O
n	O
=	O
200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
newborns	O
(	O
n	O
=	O
200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non	O
-	O
smokers	O
.	O

Exposure	O
to	O
tobacco	O
was	O
characterized	O
as	O
low	O
(	O
<	O
5	O
cigarettes	O
per	O
day	O
,	O
n	O
=	O
88	O
ears	O
)	O
,	O
moderate	O
(	O
5	O
<	O
or	O
=	O
cigarettes	O
per	O
day	O
<	O
10	O
,	O
n	O
=	O
76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
cigarettes	O
per	O
day	O
,	O
n	O
=	O
36	O
)	O
.	O

RESULTS	O
:	O
In	O
exposed	O
neonates	O
,	O
TEOAEs	O
mean	O
response	O
(	O
across	O
frequency	O
)	O
and	O
mean	O
amplitude	O
at	O
4000Hz	O
was	O
significantly	O
lower	O
than	O
in	O
non	O
-	O
exposed	O
neonates	O
.	O

Comparisons	O
between	O
exposed	O
newborns	O
'	O
subgroups	O
revealed	O
no	O
significant	O
differences	O
.	O

However	O
,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group	O
,	O
we	O
found	O
statistically	O
significant	O
decreases	B
of	I
TEOAEs	I
amplitudes	I
at	O
4000Hz	O
for	O
all	O
three	O
groups	O
.	O

Mean	O
TEOAEs	O
responses	O
of	O
highly	O
exposed	O
newborns	O
were	O
also	O
significantly	O
lower	O
in	O
comparison	O
to	O
our	O
control	O
group	O
.	O

CONCLUSION	O
:	O
In	O
utero	O
,	O
exposure	O
to	O
tobacco	O
smoking	O
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells	O
.	O

These	O
effects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
exposed	O
newborns	O
,	O
regardless	O
of	O
the	O
degree	O
of	O
exposure	O
.	O

Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	O
on	O
the	O
neonate	O
'	O
s	O
hearing	O
acuity	O
.	O

Simvastatin	O
-	O
induced	O
bilateral	O
leg	O
compartment	B
syndrome	I
and	O
myonecrosis	B
associated	O
with	O
hypothyroidism	B
.	O

A	O
54	O
-	O
year	O
-	O
old	O
hypothyroid	B
male	O
taking	O
thyroxine	O
and	O
simvastatin	O
presented	O
with	O
bilateral	O
leg	O
compartment	B
syndrome	I
and	O
myonecrosis	B
.	O

Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	O
.	O

It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	O
and	O
its	O
approval	O
for	O
all	O
arteriopathic	B
patients	O
.	O

Neuroinflammation	B
and	O
behavioral	B
abnormalities	I
after	O
neonatal	O
terbutaline	O
treatment	O
in	O
rats	O
:	O
implications	O
for	O
autism	B
.	O

Autism	B
is	O
a	O
neurodevelopmental	B
disorder	I
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	B
in	I
communication	I
and	I
social	I
skills	I
and	O
repetitive	B
behaviors	I
.	O

In	O
addition	O
to	O
genetic	O
influences	O
,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	O
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	B
.	O

Terbutaline	O
,	O
a	O
beta2	O
-	O
adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B
labor	I
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B
in	O
dizygotic	O
twins	O
.	O

We	O
studied	O
the	O
effects	O
of	O
terbutaline	O
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O

Newborn	O
rats	O
were	O
given	O
terbutaline	O
(	O
10	O
mg	O
/	O
kg	O
)	O
daily	O
on	O
postnatal	O
days	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30	O
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	O
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter	O
.	O

None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	O
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	O
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper	O
-	O
reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O

Our	O
findings	O
indicate	O
that	O
beta2	O
-	O
adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	B
abnormalities	I
,	O
similar	O
to	O
those	O
described	O
in	O
autism	B
.	O

This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	B
spectrum	I
disorders	I
.	O

Upregulation	O
of	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
in	O
MRP2	O
-	O
deficient	O
TR	O
(	O
-	O
)	O
rats	O
resembles	O
seizure	B
-	O
induced	O
up	O
-	O
regulation	O
of	O
this	O
drug	O
efflux	O
transporter	O
in	O
normal	O
rats	O
.	O

PURPOSE	O
:	O
The	O
multidrug	O
resistance	O
protein	O
2	O
(	O
MRP2	O
)	O
is	O
a	O
drug	O
efflux	O
transporter	O
that	O
is	O
expressed	O
predominantly	O
at	O
the	O
apical	O
domain	O
of	O
hepatocytes	O
but	O
seems	O
also	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
membrane	O
of	O
brain	O
capillary	O
endothelial	O
cells	O
that	O
form	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

MRP2	O
is	O
absent	O
in	O
the	O
transport	O
-	O
deficient	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wistar	O
rat	O
mutant	O
,	O
so	O
that	O
this	O
rat	O
strain	O
was	O
very	O
helpful	O
in	O
defining	O
substrates	O
of	O
MRP2	O
by	O
comparing	O
tissue	O
concentrations	O
or	O
functional	O
activities	O
of	O
compounds	O
in	O
MRP2	O
-	O
deficient	O
rats	O
with	O
those	O
in	O
transport	O
-	O
competent	O
Wistar	O
rats	O
.	O

By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytoin	O
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O

However	O
,	O
one	O
drawback	O
of	O
such	O
studies	O
in	O
genetically	O
deficient	O
rats	O
is	O
the	O
fact	O
that	O
compensatory	O
changes	O
with	O
upregulation	O
of	O
other	O
transporters	O
can	O
occur	O
.	O

This	O
prompted	O
us	O
to	O
study	O
the	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
)	O
,	O
a	O
major	O
drug	O
efflux	O
transporter	O
in	O
many	O
tissues	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
rats	O
compared	O
with	O
nonmutant	O
(	O
wild	O
-	O
type	O
)	O
Wistar	O
rats	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
MRP2	O
and	O
Pgp	O
in	O
brain	O
and	O
liver	O
sections	O
of	O
TR	O
(	O
-	O
)	O
rats	O
and	O
normal	O
Wistar	O
rats	O
was	O
determined	O
with	O
immunohistochemistry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
monoclonal	O
MRP2	O
antibody	O
and	O
the	O
monoclonal	O
Pgp	O
antibody	O
C219	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Immunofluorescence	O
staining	O
with	O
the	O
MRP2	O
antibody	O
was	O
found	O
to	O
label	O
a	O
high	O
number	O
of	O
microvessels	O
throughout	O
the	O
brain	O
in	O
normal	O
Wistar	O
rats	O
,	O
whereas	O
such	O
labeling	O
was	O
absent	O
in	O
TR	O
(	O
-	O
)	O
rats	O
.	O

TR	O
(	O
-	O
)	O
rats	O
exhibited	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
Pgp	O
in	O
brain	O
capillary	O
endothelial	O
cells	O
compared	O
with	O
wild	O
-	O
type	O
controls	O
.	O

No	O
such	O
obvious	O
upregulation	O
of	O
Pgp	O
was	O
observed	O
in	O
liver	O
sections	O
.	O

A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	O
-	O
induced	O
seizures	B
in	O
wild	O
-	O
type	O
Wistar	O
rats	O
.	O

Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	O
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	O
in	O
TR	O
(	O
-	O
)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	O
lack	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
on	O
TR	O
(	O
-	O
)	O
rats	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	O
compensation	O
of	O
MRP2	O
deficiency	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	B
to	I
the	I
brain	I
from	O
cytotoxic	O
compounds	O
,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	O
in	O
the	O
brain	O
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	B
or	O
other	O
Pgp	O
-	O
enhancing	O
events	O
for	O
this	O
purpose	O
.	O

Role	O
of	O
xanthine	O
oxidase	O
in	O
dexamethasone	O
-	O
induced	O
hypertension	B
in	O
rats	O
.	O

1	O
.	O

Glucocorticoid	O
-	O
induced	O
hypertension	B
(	O
GC	O
-	O
HT	B
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	O
oxide	O
-	O
redox	O
imbalance	O
.	O

2	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthine	O
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
in	O
dexamethasone	O
-	O
induced	O
hypertension	B
(	O
dex	O
-	O
HT	B
)	O
.	O

3	O
.	O

Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	O
(	O
dex	O
)	O
,	O
allopurinol	O
plus	O
saline	O
,	O
and	O
allopurinol	O
plus	O
dex	O
.	O

4	O
.	O

Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
,	O
and	O
serum	O
urate	O
to	O
assess	O
XO	O
inhibition	O
.	O

5	O
.	O

Dex	O
increased	B
SBP	I
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
decreased	B
thymus	I
(	I
P	I
<	I
0	I
.	I
001	I
)	I
and	I
bodyweights	I
(	O
P	O
"	O
<	O
0	O
.	O
01	O
)	O
.	O

Allopurinol	O
decreased	O
serum	O
urate	O
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
saline	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dex	O
-	O
treated	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
groups	O
.	O

6	O
.	O

Allopurinol	O
did	O
not	O
prevent	O
dex	O
-	O
HT	B
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	O
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	B
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	O
-	O
HT	B
in	O
the	O
rat	O
.	O

Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	O
and	O
gentamicin	O
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	O
and	O
gentamicin	O
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	B
surgery	O
.	O

SETTING	O
:	O
St	O
.	O

Luke	O
'	O
s	O
Hospital	O
,	O
Gwardamangia	O
,	O
Malta	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
double	O
-	O
armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub	O
-	O
Tenon	O
'	O
s	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	O
.	O

At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
Group	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methylprednisolone	O
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
gentamicin	O
injected	O
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
and	O
Group	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combination	O
injected	O
into	O
the	O
anterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
.	O

Postoperatively	O
,	O
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea	B
,	I
vomiting	I
,	O
and	O
headache	B
.	O

A	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
assess	O
the	O
statistical	O
significance	O
of	O
results	O
.	O

RESULTS	O
:	O
Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	B
emetic	I
symptoms	I
,	O
headache	B
,	O
or	O
both	O
;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms	O
.	O

CONCLUSIONS	O
:	O
The	O
administration	O
of	O
methylprednisolone	O
and	O
gentamicin	O
in	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea	B
,	I
vomiting	I
,	O
and	O
headache	B
.	O

All	O
adverse	O
effects	O
were	O
self	O
-	O
limiting	O
.	O

Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	O
-	O
induced	O
myocardial	B
ischemia	I
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	O
-	O
induced	O
myocardial	B
ischemia	I
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	O
-	O
induced	O
myocardial	B
ischemia	I
,	O
using	O
Tc99m	O
-	O
Sestamibi	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B
.	O

METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	O
-	O
SPECT	O
/	O
dobutamine	O
stress	O
test	O
.	O

Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	O
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	B
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	O
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O

dP	O
/	O
dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG	O
-	O
enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
positive	O
predictive	O
value	O
increased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negative	O
predictive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
specificity	O
decreased	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B
ischemia	I
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O

Cocaine	O
-	O
induced	O
myocardial	B
infarction	I
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations	O
.	O

Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	O
may	O
result	O
in	O
acute	B
myocardial	I
infarction	I
.	O

In	O
individuals	O
with	O
preexisting	O
,	O
high	O
-	O
grade	O
coronary	O
arterial	O
narrowing	O
,	O
acute	B
myocardial	I
infarction	I
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	O
demand	O
associated	O
with	O
cocaine	O
-	O
induced	O
increase	O
in	O
rate	O
-	O
pressure	O
product	O
.	O

In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B
obstruction	I
,	O
coronary	B
occlusion	I
may	O
be	O
due	O
to	O
spasm	B
,	O
thrombus	B
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spasm	B
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	O
-	O
induced	O
vasoconstriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	B
involves	O
the	O
epicardial	O
,	O
medium	O
-	O
size	O
vessels	O
,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction	O
.	O

Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	B
.	O

Whereas	O
certain	O
in	O
vivo	O
data	O
suggest	O
that	O
these	O
effects	O
are	O
alpha	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
data	O
suggest	O
the	O
opposite	O
.	O

The	O
finding	O
of	O
cocaine	O
-	O
induced	O
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha	O
-	O
mediated	O
effects	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
primary	O
,	O
thrombotic	B
effect	O
of	O
cocaine	O
has	O
not	O
been	O
excluded	O
.	O

Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	B
.	O

L	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	B
(	O
LID	B
)	O
is	O
among	O
the	O
motor	O
complications	O
that	O
arise	O
in	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L	O
-	O
DOPA	O
.	O

To	O
this	O
day	O
,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	B
[	O
Neurobiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
information	O
regarding	O
the	O
proteome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6	O
-	O
hydroxydopamine	O
-	O
lesion	O
rat	O
model	O
of	O
PD	B
treated	O
with	O
saline	O
,	O
L	O
-	O
DOPA	O
or	O
bromocriptine	O
using	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

Rats	O
treated	O
with	O
L	O
-	O
DOPA	O
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	B
.	O

Among	O
the	O
2000	O
spots	O
compared	O
for	O
statistical	O
difference	O
,	O
67	O
spots	O
were	O
significantly	O
changed	O
in	O
abundance	O
and	O
identified	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
MS	O
,	O
atmospheric	O
pressure	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
and	O
HPLC	O
coupled	O
tandem	O
MS	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
.	O

Out	O
of	O
these	O
67	O
proteins	O
,	O
LID	B
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins	O
:	O
alphabeta	O
-	O
crystalin	O
,	O
gamma	O
-	O
enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha	O
-	O
2	O
subunit	O
.	O

Complementary	O
techniques	O
such	O
as	O
western	O
immunoblotting	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
data	O
obtained	O
using	O
the	O
proteomic	O
approach	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	B
.	O

Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
trial	O
of	O
contrast	O
-	O
induced	O
nephropathy	B
in	O
patients	O
with	O
chronic	B
kidney	I
disease	I
.	O

BACKGROUND	O
:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low	O
-	O
osmolality	O
contrast	O
medium	O
iopamidol	O
with	O
that	O
of	O
the	O
iso	O
-	O
osmolality	O
contrast	O
medium	O
iodixanol	O
in	O
high	O
-	O
risk	O
patients	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
comparison	O
of	O
iopamidol	O
and	O
iodixanol	O
in	O
patients	O
with	O
chronic	B
kidney	I
disease	I
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O

Serum	O
creatinine	O
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O

The	O
primary	O
outcome	O
was	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baseline	O
.	O

Secondary	O
outcomes	O
were	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
postdose	O
estimated	O
glomerular	O
filtration	O
rate	O
decrease	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O

In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B
mellitus	I
,	O
use	O
of	O
N	O
-	O
acetylcysteine	O
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O

SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	O
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	O
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
patients	O
with	O
diabetes	B
,	O
SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	O
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	O
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O

Mean	O
post	O
-	O
SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	O
(	O
all	O
patients	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
patients	O
with	O
diabetes	B
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rate	O
of	O
contrast	O
-	O
induced	O
nephropathy	B
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	O
or	O
iodixanol	O
to	O
high	O
-	O
risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B
mellitus	I
.	O

Any	O
true	O
difference	O
between	O
the	O
agents	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O

A	O
novel	O
compound	O
,	O
maltolyl	O
p	O
-	O
coumarate	O
,	O
attenuates	O
cognitive	B
deficits	I
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B
models	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	O
p	O
-	O
coumarate	O
by	O
the	O
esterification	O
of	O
maltol	O
and	O
p	O
-	O
coumaric	O
acid	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	O
p	O
-	O
coumarate	O
could	O
improve	O
cognitive	B
decline	I
in	O
scopolamine	O
-	O
injected	O
rats	O
and	O
in	O
amyloid	O
beta	O
peptide	O
(	O
1	O
-	O
42	O
)	O
-	O
infused	O
rats	O
.	O

Maltolyl	O
p	O
-	O
coumarate	O
was	O
found	O
to	O
attenuate	O
cognitive	B
deficits	I
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	O
beta	O
peptide	O
(	O
1	O
-	O
42	O
)	O
-	O
infused	O
rats	O
.	O

We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	O
p	O
-	O
coumarate	O
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Cells	O
were	O
pretreated	O
with	O
maltolyl	O
p	O
-	O
coumarate	O
,	O
before	O
exposed	O
to	O
amyloid	O
beta	O
peptide	O
(	O
1	O
-	O
42	O
)	O
,	O
glutamate	O
or	O
H2O2	O
.	O

We	O
found	O
that	O
maltolyl	O
p	O
-	O
coumarate	O
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
caspase	O
3	O
activation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	O
p	O
-	O
coumarate	O
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B
'	I
s	I
disease	I
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B
death	I
and	O
progressive	O
decline	B
of	I
cognitive	I
function	I
.	O

Attenuation	O
of	O
methamphetamine	O
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	B
in	O
mice	O
by	O
lipopolysaccharide	O
pretreatment	O
.	O

Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	B
terminal	I
damage	I
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	O
,	O
a	O
pro	O
-	O
inflammatory	O
and	O
inflammatory	O
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	O
-	O
induced	O
nigrostriatal	O
dopamine	O
neurotoxicity	B
.	O

Lipopolysaccharide	O
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	O
-	O
elicited	O
hyperthermia	B
three	O
days	O
later	O
.	O

Such	O
systemic	O
lipopolysaccharide	O
treatment	O
mitigated	O
methamphetamine	O
-	O
induced	O
striatal	O
dopamine	O
and	O
3	O
,	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	O
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	O
dosing	O
regimen	O
,	O
methamphetamine	O
-	O
induced	O
striatal	O
dopamine	O
and	O
3	O
,	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
depletions	O
remained	O
unaltered	O
.	O

Moreover	O
,	O
systemic	O
lipopolysaccharide	O
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	O
infusion	O
-	O
produced	O
dopamine	O
and	O
3	O
,	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	O
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	O
.	O

We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	O
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	O
-	O
induced	O
nigrostriatal	O
dopamine	O
neurotoxicity	B
.	O

Acute	O
myocarditis	B
associated	O
with	O
clozapine	O
.	O

OBJECTIVE	O
:	O
A	O
case	O
of	O
acute	O
myocarditis	B
associated	O
with	O
the	O
commencement	O
of	O
clozapine	O
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
course	O
and	O
possible	O
contributing	O
factors	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	O
use	O
.	O

RESULTS	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
male	O
with	O
schizophrenia	B
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	B
after	O
commencement	O
of	O
clozapine	O
.	O

The	O
patient	O
recovered	O
with	O
intensive	O
medical	O
support	O
.	O

The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	O
in	O
an	O
inpatient	O
setting	O
.	O

Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	O
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O

CONCLUSIONS	O
:	O
Myocarditis	B
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	O
.	O

It	O
can	O
be	O
fatal	O
if	O
not	O
recognized	O
and	O
treated	O
early	O
.	O

Considering	O
that	O
clozapine	O
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	B
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O

There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	O
.	O

Severe	O
rhabdomyolysis	B
and	O
acute	B
renal	I
failure	I
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	O
,	O
amiodarone	O
,	O
and	O
atazanavir	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	O
,	O
amiodarone	O
,	O
and	O
atazanavir	O
resulting	O
in	O
rhabdomyolysis	B
and	O
acute	B
renal	I
failure	I
.	O

BACKGROUND	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
underlying	O
human	B
immunodeficiency	I
virus	I
,	O
atrial	B
fibrillation	I
,	O
coronary	B
artery	I
disease	I
,	O
and	O
hyperlipidemia	B
presented	O
with	O
generalized	O
pain	B
,	O
fatigue	B
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O

The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	O
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	O
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	O
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O

Laboratory	O
evaluation	O
revealed	O
66	O
,	O
680	O
U	O
/	O
L	O
creatine	O
kinase	O
,	O
93	O
mg	O
/	O
dL	O
blood	O
urea	O
nitrogen	O
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatinine	O
,	O
1579	O
U	O
/	O
L	O
aspartate	O
aminotransferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanine	O
aminotransferase	O
.	O

Simvastatin	O
,	O
amiodarone	O
,	O
and	O
the	O
patient	O
'	O
s	O
human	B
immunodeficiency	I
virus	I
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O

Nine	O
days	O
later	O
the	O
patient	O
'	O
s	O
creatine	O
kinase	O
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	O
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O

The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O

DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	O
metabolism	O
.	O

Simvastatin	O
is	O
metabolized	O
by	O
CYP3A4	O
.	O

Amiodarone	O
and	O
atazanavir	O
are	O
recognized	O
CYP3A4	O
inhibitors	O
.	O

CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	O
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O

In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	O
and	O
CYP3A4	O
inhibitors	O
,	O
pravastatin	O
,	O
fluvastatin	O
,	O
and	O
rosuvastatin	O
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
;	O
atorvastatin	O
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	O
and	O
lovastatin	O
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	O
inhibitors	O
.	O

Interaction	O
between	O
warfarin	O
and	O
levofloxacin	O
:	O
case	O
series	O
.	O

Warfarin	O
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O

Levofloxacin	O
,	O
a	O
fluoroquinolone	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
,	O
and	O
atypical	O
bacteria	O
.	O

While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	O
and	O
levofloxacin	O
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	O
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	O
.	O

We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	O
and	O
levofloxacin	O
.	O

Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	O
to	O
patients	O
taking	O
warfarin	O
.	O

Mutations	O
associated	O
with	O
lamivudine	O
-	O
resistance	O
in	O
therapy	O
-	O
na	O
ve	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
infected	I
patients	O
with	O
and	O
without	O
HIV	B
co	I
-	I
infection	I
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B
and	I
HIV	I
co	I
-	I
infected	I
South	O
African	O
patients	O
.	O

This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	O
-	O
resistant	O
hepatitis	B
B	I
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine	O
-	O
na	O
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
co	I
-	I
infection	I
in	O
South	O
African	O
patients	O
.	O

Thirty	O
-	O
five	O
lamivudine	O
-	O
na	O
ve	O
HBV	B
infected	I
patients	O
with	O
or	O
without	O
HIV	B
co	I
-	I
infection	I
were	O
studied	O
:	O
15	O
chronic	O
HBV	B
mono	I
-	I
infected	I
patients	O
and	O
20	O
HBV	B
-	I
HIV	I
co	I
-	I
infected	I
patients	O
.	O

The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	O
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg	O
-	O
positive	O
)	O
patients	O
.	O

HBsAg	O
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	O
-	O
methionine	O
-	O
aspartate	O
-	O
aspartate	O
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O

HBV	O
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	O
Monitor	O
test	O
v2	O
.	O
0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O

HBV	O
lamivudine	O
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B
B	I
patients	O
and	O
10	O
of	O
20	O
HBV	B
-	I
HIV	I
co	I
-	I
infected	I
patients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	O
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	O
ve	O
HBV	B
-	I
HIV	I
co	I
-	I
infected	I
patients	O
.	O

The	O
HBV	O
viral	O
loads	O
for	O
mono	O
-	O
infected	O
and	O
co	O
-	O
infected	O
patients	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
copies	O
/	O
ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	O
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B
-	I
HIV	I
co	I
-	I
infected	I
patients	O
.	O

Rabbit	B
syndrome	I
,	O
antidepressant	O
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O

The	O
rabbit	B
syndrome	I
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy	O
.	O

Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	O
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	O
in	O
conjunction	O
with	O
antidepressants	O
.	O

Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	B
basal	I
ganglia	I
perfusion	I
while	O
the	O
movement	B
disorder	I
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B
syndrome	I
resolved	O
.	O

Estrogen	O
prevents	O
cholesteryl	O
ester	O
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	O
.	O

Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	O
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B
atherosclerosis	I
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	O
treatment	O
increases	O
atherosclerotic	B
lesion	I
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	O
-	O
treated	O
females	O
had	O
less	O
cholesteryl	O
ester	O
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	O
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	O
.	O

We	O
have	O
utilized	O
the	O
human	O
monocyte	O
cell	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
,	O
100	O
nM	O
progesterone	O
or	O
vehicle	O
(	O
0	O
.	O
01	O
%	O
ethanol	O
)	O
.	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	O
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O

Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated	O
.	O

E2	O
decreased	O
the	O
accumulation	O
of	O
cholesteryl	O
esters	O
in	O
macrophages	O
following	O
ritonavir	O
treatment	O
.	O

Ritonavir	O
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	O
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	O
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	O
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	O
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	O
ester	O
accumulation	O
following	O
ritonavir	O
treatment	O
.	O

Acute	O
hepatitis	B
attack	O
after	O
exposure	O
to	O
telithromycin	O
.	O

INTRODUCTION	O
:	O
Antibiotic	O
-	O
associated	O
hepatotoxicity	B
is	O
rare	O
.	O

With	O
widespread	O
use	O
of	O
antimicrobial	O
agents	O
,	O
however	O
,	O
hepatic	B
injury	I
occurs	O
frequently	O
,	O
and	O
among	O
adverse	B
drug	I
reactions	I
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
male	O
patient	O
,	O
with	O
a	O
height	O
of	O
175	O
cm	O
and	O
weight	O
of	O
72	O
kg	O
presented	O
to	O
Marmara	O
University	O
Hospital	O
Emergency	O
Department	O
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	O
'	O
history	O
of	O
jaundice	B
,	O
malaise	O
,	O
nausea	B
,	O
and	O
vomiting	B
.	O

He	O
had	O
been	O
prescribed	O
telithromycin	O
400	O
mg	O
/	O
d	O
PO	O
to	O
treat	O
an	O
upper	B
respiratory	I
tract	I
infection	I
7	O
days	O
prior	O
.	O

Admission	O
laboratory	O
tests	O
were	O
as	O
follows	O
:	O
alanine	O
aminotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
reference	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspartate	O
aminotransferase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkaline	O
phosphatase	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	O
-	O
glutamyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylase	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bilirubin	O
,	O
20	O
.	O

1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilirubin	O
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
albumin	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toxin	O
,	O
alcohol	O
,	O
or	O
other	O
drugs	O
were	O
reported	O
.	O

The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
"	O
acute	O
hepatitis	B
of	O
unknown	O
origin	O
,	O
"	O
that	O
occurred	O
after	O
telithromycin	O
usage	O
.	O

Both	O
incidents	O
occurred	O
within	O
a	O
year	O
.	O

DISCUSSION	O
:	O
Telithromycin	O
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
clinical	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	B
dysfunction	I
.	O

Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B
drug	I
reaction	I
probability	O
scale	O
,	O
telithromycin	O
was	O
the	O
probable	O
cause	O
of	O
acute	O
hepatitis	B
in	O
this	O
patient	O
,	O
and	O
pathological	O
findings	O
suggested	O
drug	O
-	O
induced	O
toxic	B
hepatitis	I
.	O

Recurrence	O
of	O
hepatitis	B
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	O
the	O
second	O
time	O
.	O

CONCLUSION	O
:	O
Here	O
we	O
report	O
a	O
case	O
of	O
acute	O
hepatitis	B
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	O
.	O

A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	O
injection	O
on	O
bruising	B
and	O
pain	B
.	O

AIM	O
:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	B
and	O
pain	B
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	O
.	O

BACKGROUND	O
:	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	B
and	O
pain	B
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	O
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	B
and	O
pain	B
is	O
little	O
documented	O
.	O

DESIGN	O
:	O
This	O
study	O
was	O
designed	O
as	O
within	O
-	O
subject	O
,	O
quasi	O
-	O
experimental	O
research	O
.	O

METHOD	O
:	O
The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	O
was	O
administered	O
.	O

Heparin	O
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site	O
.	O

Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	B
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection	O
.	O

Dimensions	O
of	O
the	O
bruising	B
on	O
the	O
heparin	O
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O

The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	B
intensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	B
period	O
.	O

Data	O
were	O
analysed	O
using	O
chi	O
-	O
square	O
test	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
bruising	B
occurrence	O
was	O
64	O
%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O

It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	B
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O

Pain	B
intensity	O
and	O
pain	B
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30	O
-	O
second	O
injection	O
than	O
for	O
the	O
10	O
-	O
second	O
injection	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	B
and	O
pain	B
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	O
.	O

This	O
study	O
should	O
be	O
repeated	O
on	O
a	O
larger	O
sample	O
.	O

RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
administering	O
subcutaneous	O
heparin	O
injections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duration	O
of	O
the	O
injection	O
.	O

Acute	B
liver	I
failure	I
in	O
two	O
patients	O
with	O
regular	O
alcohol	O
consumption	O
ingesting	O
paracetamol	O
at	O
therapeutic	O
dosage	O
.	O

BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
alcohol	O
in	O
the	O
development	O
of	O
hepatotoxicity	B
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	O
(	O
acetaminophen	O
)	O
is	O
currently	O
debated	O
.	O

CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	O
and	O
who	O
developed	O
liver	B
failure	I
within	O
3	O
-	O
5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	O
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	O
/	O
day	O
.	O

A	O
paracetamol	O
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range	O
.	O

Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	B
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	O
are	O
discussed	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
risk	O
factors	O
,	O
e	O
.	O
g	O
.	O
regular	O
consumption	O
of	O
alcohol	O
,	O
liver	B
failure	I
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested	O
.	O

We	O
propose	O
that	O
the	O
paracetamol	O
dose	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	O
.	O

Associations	O
between	O
use	O
of	O
benzodiazepines	O
or	O
related	O
drugs	O
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non	O
-	O
randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	O
or	O
related	O
drugs	O
(	O
BZDs	O
/	O
RDs	O
)	O
and	O
health	O
,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly	O
.	O

METHODS	O
:	O
A	O
non	O
-	O
randomised	O
clinical	O
study	O
of	O
patients	O
aged	O
>	O
or	O
=	O
65	O
years	O
admitted	O
to	O
acute	O
hospital	O
wards	O
during	O
1	O
month	O
.	O

164	O
patients	O
(	O
mean	O
age	O
+	O
/	O
-	O
standard	O
deviation	O
[	O
SD	O
]	O
81	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
8	O
years	O
)	O
were	O
admitted	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	O
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
users	O
.	O

Cognitive	O
ability	O
was	O
assessed	O
by	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
.	O

Patients	O
scoring	O
>	O
or	O
=	O
20	O
MMSE	O
sum	O
points	O
were	O
interviewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
symptoms	O
and	O
functional	O
abilities	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

Data	O
on	O
use	O
of	O
BZDs	O
/	O
RDs	O
before	O
admission	O
,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records	O
.	O

Health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
were	O
compared	O
between	O
BZD	O
/	O
RD	O
users	O
and	O
non	O
-	O
users	O
,	O
and	O
adjustments	O
were	O
made	O
for	O
confounding	O
variables	O
.	O

The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	O
,	O
temazepam	O
and	O
zopiclone	O
were	O
analysed	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duration	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/	O
-	O
7	O
years	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O

Two	O
or	O
three	O
BZDs	O
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
users	O
(	O
n	O
=	O
20	O
)	O
.	O

Long	O
-	O
term	O
use	O
of	O
these	O
drugs	O
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	O
with	O
effects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	B
.	O

After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders	O
,	O
use	O
of	O
BZDs	O
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE	O
.	O

However	O
,	O
use	O
of	O
BZDs	O
/	O
RDs	O
was	O
associated	O
with	O
dizziness	B
,	O
inability	B
to	I
sleep	I
after	O
awaking	O
at	O
night	O
and	O
tiredness	B
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B
symptoms	I
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O

Use	O
of	O
BZDs	O
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night	O
-	O
time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	O
correlated	O
with	O
a	O
lower	O
MMSE	O
sum	O
score	O
after	O
adjustment	O
for	O
confounding	O
variables	O
.	O

CONCLUSIONS	O
:	O
Long	O
-	O
term	O
use	O
and	O
concomitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
elderly	O
patients	O
hospitalised	O
because	O
of	O
acute	O
illnesses	O
.	O

Long	O
-	O
term	O
use	O
was	O
associated	O
with	O
daytime	O
and	O
night	O
-	O
time	O
symptoms	O
indicative	O
of	O
poorer	O
health	O
and	O
potentially	O
caused	O
by	O
the	O
adverse	O
effects	O
of	O
these	O
drugs	O
.	O

Acute	O
vocal	B
fold	I
palsy	I
after	O
acute	O
disulfiram	O
intoxication	O
.	O

Acute	O
peripheral	B
neuropathy	I
caused	O
by	O
a	O
disulfiram	O
overdose	B
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B
fold	I
palsy	I
.	O

A	O
49	O
-	O
year	O
-	O
old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	B
,	O
lancinating	O
pain	B
,	O
sensory	B
loss	I
,	O
and	O
paresthesia	B
of	O
the	O
distal	O
limbs	O
.	O

One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	O
(	O
130	O
tablets	O
of	O
ALCOHOL	O
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O
Co	O
.	O
,	O
Ansan	O
,	O
Korea	O
)	O
in	O
a	O
suicide	O
attempt	O
.	O

She	O
was	O
not	O
an	O
alcoholic	O
.	O

For	O
the	O
first	O
few	O
days	O
after	O
ingestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	B
and	O
giddiness	B
.	O

She	O
noticed	O
hoarseness	B
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O

A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	B
.	O

Laryngeal	O
electromyography	O
(	O
thyroarytenoid	O
muscle	O
)	O
showed	O
ample	O
denervation	O
potentials	O
.	O

Laryngoscopy	O
revealed	O
asymmetric	O
vocal	O
fold	O
movements	O
during	O
phonation	O
.	O

Her	O
vocal	O
change	O
and	O
weakness	O
began	O
to	O
improve	O
spontaneously	O
about	O
3	O
weeks	O
after	O
transfer	O
.	O

This	O
was	O
a	O
case	O
of	O
acute	O
palsy	B
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	B
caused	O
by	O
high	O
-	O
dose	O
disulfiram	O
intoxication	O
.	O

Encephalopathy	B
induced	O
by	O
levetiracetam	O
added	O
to	O
valproate	O
.	O

BACKGROUND	O
:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	O
(	O
LEV	O
)	O
-	O
induced	O
encephalopathy	B
.	O

FINDINGS	O
:	O
A	O
28	O
-	O
year	O
-	O
old	O
man	O
suffering	O
from	O
idiopathic	B
epilepsy	I
with	O
generalized	O
seizures	B
was	O
treated	O
with	O
LEV	O
(	O
3000	O
mg	O
)	O
added	O
to	O
valproate	O
(	O
VPA	O
)	O
(	O
2000	O
mg	O
)	O
.	O

Frequency	O
of	O
generalized	O
tonic	B
-	I
clonic	I
seizures	I
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month	O
.	O

Neuropsychological	O
testing	O
showed	O
impaired	B
word	I
fluency	I
,	I
psychomotor	I
speed	I
and	I
working	I
memory	I
.	O

The	O
interictal	O
electroencephalogram	O
(	O
EEG	O
)	O
showed	O
a	O
generalized	O
slowing	O
to	O
5	O
per	O
second	O
theta	O
rhythms	O
with	O
bilateral	O
generalized	O
high	O
-	O
amplitude	O
discharges	O
.	O

OUTCOME	O
:	O
Following	O
discontinuation	O
of	O
LEV	O
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	B
frequency	O
decreased	O
.	O

Norepinephrine	O
signaling	O
through	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	O
-	O
induced	O
anxiety	B
.	O

BACKGROUND	O
:	O
Cocaine	O
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O

While	O
the	O
mechanisms	O
underlying	O
cocaine	O
'	O
s	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	O
,	O
such	O
as	O
anxiety	B
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
knockout	O
(	O
Dbh	O
-	O
/	O
-	O
)	O
mice	O
,	O
which	O
lack	O
norepinephrine	O
(	O
NE	O
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	O
-	O
induced	O
anxiety	B
.	O

RESULTS	O
:	O
We	O
found	O
that	O
cocaine	O
dose	O
-	O
dependently	O
increased	O
anxiety	B
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	O
+	O
/	O
-	O
)	O
mice	O
,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O

The	O
Dbh	O
-	O
/	O
-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	O
.	O

Cocaine	O
-	O
induced	O
anxiety	B
was	O
also	O
attenuated	O
in	O
Dbh	O
+	O
/	O
-	O
mice	O
following	O
administration	O
of	O
disulfiram	O
,	O
a	O
dopamine	O
beta	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O

In	O
experiments	O
using	O
specific	O
adrenergic	O
antagonists	O
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
propranolol	O
blocked	O
cocaine	O
-	O
induced	O
anxiety	B
-	O
like	O
behavior	O
in	O
Dbh	O
+	O
/	O
-	O
and	O
wild	O
-	O
type	O
C57BL6	O
/	O
J	O
mice	O
,	O
while	O
the	O
alpha	O
(	O
1	O
)	O
antagonist	O
prazosin	O
and	O
the	O
alpha	O
(	O
2	O
)	O
antagonist	O
yohimbine	O
had	O
no	O
effect	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	O
-	O
induced	O
anxiety	B
in	O
mice	O
.	O

Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	O
acid	O
levels	O
,	O
prolactin	O
signaling	O
,	O
and	O
hyperprolactinemic	B
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	O
.	O

Hyperprolactinemia	B
can	O
reduce	O
fertility	O
and	O
libido	O
.	O

Although	O
central	O
prolactin	O
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	O
-	O
induced	O
LH	O
surge	O
.	O

Chronic	O
hyperprolactinemia	B
induced	O
by	O
the	O
dopamine	O
antagonist	O
sulpiride	O
caused	O
a	O
40	O
%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	O
.	O

Sulpiride	O
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	O
-	O
induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O

Estradiol	O
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
components	O
of	O
prolactin	O
'	O
s	O
signaling	O
pathway	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
estrogen	O
increases	O
PRL	O
-	O
R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	O
greatly	O
augments	O
prolactin	O
-	O
induced	O
STAT5	O
activation	O
.	O

Lastly	O
,	O
we	O
measured	O
PRL	O
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	O
and	O
estradiol	O
.	O

Sulpiride	O
induced	O
only	O
SOCS	O
-	O
1	O
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O

Estradiol	O
enhanced	O
these	O
effects	O
on	O
SOCS	O
-	O
3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estradiol	O
also	O
induced	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O

These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B
in	O
a	O
steroid	O
-	O
dependent	O
manner	O
.	O

They	O
also	O
provide	O
evidence	O
for	O
estradiol	O
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O

Clonidine	O
for	O
attention	B
-	I
deficit	I
/	I
hyperactivity	I
disorder	I
:	O
II	O
.	O

ECG	O
changes	O
and	O
adverse	O
events	O
analysis	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	O
used	O
alone	O
or	O
with	O
methylphenidate	O
in	O
children	O
with	O
attention	B
-	I
deficit	I
/	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
.	O

METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
,	O
122	O
children	O
with	O
ADHD	B
were	O
randomly	O
assigned	O
to	O
clonidine	O
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	O
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	O
and	O
methylphenidate	O
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
30	O
)	O
.	O

Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
day	O
for	O
clonidine	O
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	O
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O

Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	O
.	O

RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B
in	O
subjects	O
treated	O
with	O
clonidine	O
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	O
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O

There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	O
and	O
methylphenidate	O
regarding	O
cardiovascular	O
outcomes	O
.	O

Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	O
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O

Drowsiness	B
was	O
common	O
on	O
clonidine	O
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O

CONCLUSIONS	O
:	O
Clonidine	O
,	O
used	O
alone	O
or	O
with	O
methylphenidate	O
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B
.	O

Physicians	O
prescribing	O
clonidine	O
should	O
monitor	O
for	O
bradycardia	B
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B
.	O

Renal	B
Fanconi	I
syndrome	I
and	O
myopathy	B
after	O
liver	O
transplantation	O
:	O
drug	O
-	O
related	O
mitochondrial	B
cytopathy	I
?	O

Advances	O
in	O
the	O
field	O
of	O
transplantation	O
provide	O
a	O
better	O
quality	O
of	O
life	O
and	O
allow	O
more	O
favorable	O
conditions	O
for	O
growth	O
and	O
development	O
in	O
children	O
.	O

However	O
,	O
combinations	O
of	O
different	O
therapeutic	O
regimens	O
require	O
consideration	O
of	O
potential	O
adverse	O
reactions	O
.	O

We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson	B
'	I
s	I
disease	I
.	O

Tacrolimus	O
,	O
MMF	O
,	O
and	O
steroids	O
were	O
given	O
as	O
immunosuppressant	O
.	O

Lamivudine	O
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	B
B	I
infection	I
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	B
Fanconi	I
syndrome	I
with	O
severe	O
metabolic	B
acidosis	I
,	O
hypophosphatemia	B
,	O
glycosuria	B
,	O
and	O
aminoaciduria	B
.	O

Although	O
tacrolimus	O
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post	O
-	O
transplant	O
renal	O
acidosis	B
and	O
was	O
replaced	O
by	O
sirolimus	O
,	O
acidosis	B
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse	O
.	O

Proximal	O
muscle	B
weakness	I
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Fanconi	B
syndrome	I
,	O
as	O
well	O
as	O
myopathy	B
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	B
disorders	I
and	O
caused	O
by	O
depletion	O
of	O
mtDNA	O
.	O

We	O
suggest	O
that	O
our	O
patient	O
'	O
s	O
tubular	B
dysfunction	I
and	O
myopathy	B
may	O
have	O
resulted	O
from	O
mitochondrial	B
dysfunction	I
which	O
is	O
triggered	O
by	O
tacrolimus	O
and	O
augmented	O
by	O
lamivudine	O
.	O

Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	B
in	O
patients	O
with	O
heparin	O
-	O
induced	O
thrombocytopenia	B
.	O

OBJECTIVES	O
:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two	O
-	O
step	O
heparin	O
-	O
induced	O
thrombocytopenia	B
(	O
HIT	B
)	O
antigen	O
assay	O
with	O
thrombosis	B
;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	O
concentration	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
more	O
than	O
50	O
%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	B
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
exposure	O
to	O
heparin	O
,	O
who	O
had	O
a	O
positive	O
two	O
-	O
step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	O
]	O
were	O
included	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	B
patients	O
had	O
thrombosis	B
at	O
diagnosis	O
;	O
54	O
/	O
94	O
had	O
isolated	O
-	O
HIT	B
without	O
thrombosis	B
.	O

Eight	O
of	O
the	O
isolated	O
-	O
HIT	B
patients	O
developed	O
thrombosis	B
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B
at	O
day	O
30	O
.	O

At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B
patients	O
with	O
thrombosis	B
and	O
those	O
with	O
isolated	O
-	O
HIT	B
.	O

However	O
,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	B
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isolated	O
-	O
HIT	B
patients	O
who	O
later	O
developed	O
thrombosis	B
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
compared	O
to	O
isolated	O
-	O
HIT	B
patients	O
who	O
did	O
not	O
develop	O
thrombosis	B
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
isolated	O
-	O
HIT	B
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	B
by	O
day	O
30	O
.	O

None	O
of	O
these	O
groups	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibition	O
.	O

Multivariate	O
analysis	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
increased	O
risk	O
of	O
thrombosis	B
in	O
females	O
.	O

Similarly	O
,	O
thrombotic	B
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O

CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	B
in	O
patients	O
with	O
isolated	O
-	O
HIT	B
;	O
percent	O
inhibition	O
,	O
however	O
,	O
was	O
not	O
predictive	O
.	O

Thalidomide	O
has	O
limited	O
single	O
-	O
agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non	B
-	I
Hodgkin	I
lymphomas	I
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
.	O

Thalidomide	O
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	B
myeloma	I
,	O
mantle	B
cell	I
lymphoma	I
and	O
lymphoplasmacytic	B
lymphoma	I
.	O

Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	B
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	O
with	O
relapsed	O
/	O
refractory	O
indolent	O
lymphomas	B
received	O
thalidomide	O
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1	O
-	O
2	O
weeks	O
as	O
tolerated	O
,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily	O
.	O

Patients	O
had	O
received	O
a	O
median	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
regimens	O
.	O

Of	O
24	O
evaluable	O
patients	O
,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
partial	O
remission	O
for	O
an	O
overall	O
response	O
rate	O
of	O
12	O
.	O
5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2	O
.	O
6	O
-	O
32	O
.	O
4	O
%	O
)	O
.	O

Eleven	O
patients	O
progressed	O
during	O
therapy	O
.	O

Grade	O
3	O
-	O
4	O
adverse	O
effects	O
included	O
myelosuppression	B
,	O
fatigue	B
,	O
somnolence	B
/	O
depressed	B
mood	I
,	O
neuropathy	B
and	O
dyspnea	B
.	O

Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	B
events	O
.	O

Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	O
in	O
indolent	O
lymphomas	B
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent	O
,	O
lenalidomide	O
.	O

Sex	O
differences	O
in	O
NMDA	O
antagonist	O
enhancement	O
of	O
morphine	O
antihyperalgesia	O
in	O
a	O
capsaicin	O
model	O
of	O
persistent	O
pain	B
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B
pain	I
.	O

In	O
acute	B
pain	I
models	O
,	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	B
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	B
pain	I
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated	O
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus	O
.	O

To	O
this	O
end	O
,	O
persistent	O
hyperalgesia	B
was	O
induced	O
by	O
administration	O
of	O
capsaicin	O
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats	O
,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	O
,	O
and	O
tail	O
-	O
withdrawal	O
latencies	O
measured	O
.	O

For	O
comparison	O
,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	B
pain	I
models	O
,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail	O
-	O
withdrawal	O
procedures	O
.	O

In	O
males	O
,	O
the	O
non	O
-	O
competitive	O
NMDA	O
antagonist	O
dextromethorphan	O
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Across	O
the	O
doses	O
and	O
pretreatment	O
times	O
examined	O
,	O
enhancement	O
was	O
not	O
observed	O
in	O
females	O
.	O

Enhancement	O
of	O
morphine	O
antinociception	O
by	O
dextromethorphan	O
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	B
pain	I
models	O
,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males	O
.	O

These	O
findings	O
demonstrate	O
a	O
sexually	O
-	O
dimorphic	O
interaction	O
between	O
NMDA	O
antagonists	O
and	O
morphine	O
in	O
a	O
persistent	O
pain	B
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B
pain	I
models	O
.	O

Development	O
of	O
proteinuria	B
after	O
switch	O
to	O
sirolimus	O
-	O
based	O
immunosuppression	O
in	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
.	O

Calcineurin	O
-	O
inhibitor	O
therapy	O
can	O
lead	O
to	O
renal	B
dysfunction	I
in	O
heart	O
transplantation	O
patients	O
.	O

The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
drug	O
sirolmus	O
(	O
Srl	O
)	O
lacks	O
nephrotoxic	B
effects	O
;	O
however	O
,	O
proteinuria	B
associated	O
with	O
Srl	O
has	O
been	O
reported	O
following	O
renal	O
transplantation	O
.	O

In	O
cardiac	O
transplantation	O
,	O
the	O
incidence	O
of	O
proteinuria	B
associated	O
with	O
Srl	O
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	O
to	O
Srl	O
-	O
based	O
IS	O
.	O

Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	O
mofetil	O
+	O
/	O
-	O
steroids	O
.	O

Proteinuria	O
increased	O
significantly	O
from	O
a	O
median	O
of	O
0	O
.	O
13	O
g	O
/	O
day	O
(	O
range	O
0	O
-	O
5	O
.	O
7	O
)	O
preswitch	O
to	O
0	O
.	O
23	O
g	O
/	O
day	O
(	O
0	O
-	O
9	O
.	O
88	O
)	O
at	O
24	O
months	O
postswitch	O
(	O
p	O
=	O
0	O
.	O
0024	O
)	O
.	O

Before	O
the	O
switch	O
,	O
11	O
.	O
5	O
%	O
of	O
patients	O
had	O
high	O
-	O
grade	O
proteinuria	B
(	O
>	O
1	O
.	O
0	O
g	O
/	O
day	O
)	O
;	O
this	O
increased	O
to	O
22	O
.	O
9	O
%	O
postswitch	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

ACE	O
inhibitor	O
and	O
angiotensin	O
-	O
releasing	O
blocker	O
(	O
ARB	O
)	O
therapy	O
reduced	O
proteinuria	B
development	O
.	O

Patients	O
without	O
proteinuria	B
had	O
increased	O
renal	O
function	O
(	O
median	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
patients	O
who	O
developed	O
high	O
-	O
grade	O
proteinuria	B
showed	O
decreased	O
renal	O
function	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
median	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O

Thus	O
,	O
proteinuria	B
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	O
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients	O
.	O

Srl	O
should	O
be	O
used	O
with	O
ACEi	O
/	O
ARB	O
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	B
and	O
increased	O
renal	B
dysfunction	I
.	O

Ginsenoside	O
Rg1	O
restores	O
the	O
impairment	B
of	I
learning	I
induced	O
by	O
chronic	O
morphine	O
administration	O
in	O
rats	O
.	O

Rg1	O
,	O
as	O
a	O
ginsenoside	O
extracted	O
from	O
Panax	O
ginseng	O
,	O
could	O
ameliorate	O
spatial	O
learning	B
impairment	I
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	O
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	O
on	O
learning	B
impairment	I
by	O
chronic	O
morphine	O
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O

Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	O
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	O
once	O
a	O
day	O
for	O
10	O
days	O
.	O

Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze	O
.	O

The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	O
/	O
Rg1	O
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O

By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	O
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	O
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O

The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	O
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	O
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline	O
-	O
or	O
morphine	O
/	O
Rg1	O
-	O
treated	O
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
MK801	O
.	O

We	O
conclude	O
that	O
Rg1	O
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	O
administration	O
and	O
restore	O
the	O
morphine	O
-	O
inhibited	O
LTP	O
.	O

This	O
effect	O
is	O
NMDA	O
receptor	O
dependent	O
.	O

Synthesis	O
of	O
N	O
-	O
pyrimidinyl	O
-	O
2	O
-	O
phenoxyacetamides	O
as	O
adenosine	O
A2A	O
receptor	O
antagonists	O
.	O

A	O
series	O
of	O
N	O
-	O
pyrimidinyl	O
-	O
2	O
-	O
phenoxyacetamide	O
adenosine	O
A	O
(	O
2A	O
)	O
antagonists	O
is	O
described	O
.	O

SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selectivity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rat	O
haloperidol	O
-	O
induced	O
catalepsy	B
model	O
for	O
Parkinson	B
'	I
s	I
disease	I
.	O

Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	O
receptors	O
in	O
mediating	O
nicotine	O
-	O
induced	O
hyperactivity	B
in	O
rats	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	O
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	O
-	O
induced	O
locomotor	O
stimulation	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	O
in	O
rats	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dopamine	O
receptors	O
in	O
mediating	O
nicotine	O
-	O
induced	O
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	O
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	O
.	O

Locomotor	O
activity	O
was	O
assessed	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
tested	O
in	O
photocell	O
cages	O
.	O

Nicotine	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
increase	B
in	I
locomotor	I
activity	I
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment	O
.	O

The	O
stimulant	O
action	O
of	O
nicotine	O
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	O
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	O
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors	O
.	O

Nicotine	O
-	O
induced	O
hyperactivity	B
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	O
23390	O
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	O
and	O
the	O
D1	O
/	O
D2	O
antagonist	O
fluphenazine	O
.	O

Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	O
enhanced	O
nicotine	O
-	O
induced	O
hyperactivity	B
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	O
38393	O
had	O
no	O
effect	O
.	O

The	O
results	O
indicate	O
that	O
acute	O
nicotine	O
injection	O
induces	O
a	O
pronounced	O
hyperactivity	B
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment	O
.	O

The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	O
receptors	O
,	O
possibly	O
located	O
on	O
dopaminergic	O
neurons	O
,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	O
receptors	O
.	O

Central	O
retinal	B
vein	I
occlusion	I
associated	O
with	O
clomiphene	O
-	O
induced	O
ovulation	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	B
vein	I
occlusion	I
associated	O
with	O
clomiphene	O
citrate	O
(	O
CC	O
)	O
.	O

DESIGN	O
:	O
Case	O
study	O
.	O

SETTING	O
:	O
Ophthalmology	O
clinic	O
of	O
an	O
academic	O
hospital	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
woman	O
referred	O
from	O
the	O
infertility	B
clinic	O
for	O
blurred	B
vision	I
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Ophthalmic	O
examination	O
after	O
CC	O
therapy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Central	O
retinal	B
vein	I
occlusion	I
after	O
ovulation	O
induction	O
with	O
CC	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
Chinese	O
woman	O
developed	O
central	O
retinal	B
vein	I
occlusion	I
after	O
eight	O
courses	O
of	O
CC	O
.	O

A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	B
complications	O
of	O
CC	O
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication	O
,	O
although	O
mild	O
visual	B
disturbance	I
after	O
CC	O
intake	O
is	O
not	O
uncommon	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B
vein	I
occlusion	I
after	O
treatment	O
with	O
CC	O
.	O

Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	B
patients	O
with	O
CC	O
,	O
and	O
patients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	O
before	O
commencement	O
of	O
therapy	O
.	O

Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	O
bromide	O
and	O
theophylline	O
in	O
chronic	B
obstructive	I
pulmonary	I
disease	I
.	O

The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	O
bromide	O
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short	O
-	O
acting	O
theophylline	O
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10	O
-	O
20	O
micrograms	O
/	O
mL	O
)	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B
obstructive	I
pulmonary	I
disease	I
.	O

Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropium	O
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylline	O
.	O

The	O
average	O
FEV1	O
increases	O
during	O
the	O
6	O
-	O
hour	O
observation	O
period	O
were	O
18	O
%	O
for	O
ipratropium	O
and	O
8	O
%	O
for	O
theophylline	O
.	O

The	O
mean	O
duration	O
of	O
action	O
was	O
3	O
.	O
8	O
hours	O
with	O
ipratropium	O
and	O
2	O
.	O
4	O
hours	O
with	O
theophylline	O
.	O

While	O
side	O
effects	O
were	O
rare	O
,	O
those	O
experienced	O
after	O
theophylline	O
use	O
did	O
involve	O
the	O
cardiovascular	B
and	I
gastrointestinal	I
systems	I
.	O

These	O
results	O
show	O
that	O
ipratropium	O
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	O
in	O
patients	O
with	O
chronic	B
airflow	I
obstruction	I
.	O

Methamphetamine	O
-	O
induced	O
neurotoxicity	B
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O

Methamphetamine	O
(	O
METH	O
)	O
damages	O
dopamine	O
(	O
DA	O
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Cardona	O
et	O
al	O
.	O

[	O
Nat	O
.	O
Neurosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	O
-	O
induced	O
neurodegeneration	B
of	O
DA	O
neurons	O
.	O

Because	O
the	O
CNS	B
damage	I
caused	O
by	O
METH	O
and	O
MPTP	O
is	O
highly	O
selective	O
for	O
the	O
DA	O
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	B
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	O
-	O
induced	O
neurotoxicity	B
and	O
microglial	O
activation	O
.	O

Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	O
and	O
examined	O
for	O
striatal	O
neurotoxicity	B
.	O

METH	O
depleted	O
DA	O
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O

The	O
effects	O
of	O
METH	O
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O

Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	O
that	O
are	O
characteristic	O
of	O
activation	O
.	O

This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	O
neurotoxicity	B
or	O
microglial	O
activation	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	O
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O

Nicotine	O
-	O
induced	O
nystagmus	B
correlates	O
with	O
midpontine	O
activation	O
.	O

The	O
pathomechanism	O
of	O
nicotine	O
-	O
induced	O
nystagmus	B
(	O
NIN	B
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	B
generation	O
.	O

Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	O
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O

NIN	B
correlated	O
with	O
blood	O
oxygen	O
level	O
-	O
dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O

NIN	B
-	O
induced	O
midpontine	O
activation	O
may	O
correspond	O
to	O
activation	O
of	O
the	O
dorsomedial	O
pontine	O
nuclei	O
and	O
the	O
nucleus	O
reticularis	O
tegmenti	O
pontis	O
,	O
structures	O
known	O
to	O
participate	O
in	O
the	O
generation	O
of	O
multidirectional	O
saccades	O
and	O
smooth	O
pursuit	O
eye	O
movements	O
.	O

Acute	O
effects	O
of	O
N	O
-	O
(	O
2	O
-	O
propylpentanoyl	O
)	O
urea	O
on	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
in	O
pilocarpine	O
-	O
induced	O
seizure	B
in	O
rats	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
(	O
glutamate	O
,	O
aspartate	O
,	O
glycine	O
and	O
GABA	O
)	O
of	O
N	O
-	O
(	O
2	O
-	O
propylpentanoyl	O
)	O
urea	O
(	O
VPU	O
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	O
acid	O
(	O
VPA	O
)	O
.	O

VPU	O
was	O
more	O
potent	O
than	O
VPA	O
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	O
-	O
induced	O
seizure	B
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	O
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	O
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	O
and	O
aspartate	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	O
and	O
GABA	O
.	O

Pretreatment	O
with	O
either	O
VPU	O
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	O
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	O
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	O
and	O
aspartate	O
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	O
and	O
glycine	O
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	O
and	O
aspartate	O
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	O
and	O
VPA	O
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	O
-	O
induced	O
seizure	B
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	O
acid	O
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	O
and	O
aspartate	O
.	O

Therefore	O
,	O
like	O
VPA	O
,	O
the	O
finding	O
that	O
VPU	O
could	O
drastically	O
reduce	O
pilocarpine	O
-	O
induced	O
increases	O
in	O
glutamate	O
and	O
aspartate	O
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	O
-	O
induced	O
seizure	B
in	O
experimental	O
animals	O
.	O

Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O

Protective	O
effect	O
of	O
verapamil	O
on	O
gastric	B
hemorrhagic	I
ulcers	B
in	O
severe	O
atherosclerotic	B
rats	O
.	O

Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B
hemorrhage	I
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B
rats	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	O
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B
hemorrhage	I
and	O
ulcer	B
in	O
rats	O
with	O
atherosclerosis	B
induced	O
by	O
coadministration	O
of	O
vitamin	O
D2	O
and	O
cholesterol	O
.	O

Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	O
on	O
this	O
ulcer	B
model	O
was	O
evaluated	O
.	O

Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
corn	O
oil	O
containing	O
vitamin	O
D2	O
and	O
cholesterol	O
to	O
induce	O
atherosclerosis	B
.	O

Control	O
rats	O
received	O
corn	O
oil	O
only	O
.	O

After	O
gastric	O
surgery	O
,	O
rat	O
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline	O
.	O

Gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mucosal	O
LPO	O
generation	O
,	O
histamine	O
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	O
hemoglobin	O
content	O
and	O
ulcer	B
areas	O
were	O
determined	O
.	O

Elevated	O
atherosclerotic	B
parameters	O
,	O
such	O
as	O
serum	O
calcium	O
,	O
total	O
cholesterol	O
and	O
low	O
-	O
density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B
rats	O
.	O

Severe	O
gastric	O
ulcers	B
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
histamine	O
release	O
,	O
LPO	O
generation	O
and	O
luminal	O
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O

Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	O
to	O
gastric	B
hemorrhage	I
and	O
to	O
ulcer	B
was	O
found	O
in	O
those	O
atherosclerotic	B
rats	O
.	O

This	O
hemorrhagic	B
ulcer	B
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	O
.	O

Atherosclerosis	B
could	O
produce	O
gastric	B
hemorrhagic	I
ulcer	B
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	O
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	O
in	O
rats	O
.	O

Lamivudine	O
for	O
the	O
prevention	O
of	O
hepatitis	B
B	I
virus	O
reactivation	O
in	O
hepatitis	O
-	O
B	O
surface	O
antigen	O
(	O
HBSAG	O
)	O
seropositive	O
cancer	B
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O

Hepatitis	B
B	I
virus	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	O
liver	B
disease	I
worldwide	O
.	O

Cancer	B
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	B
complication	I
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation	O
.	O

In	O
this	O
study	O
,	O
cancer	B
patients	O
who	O
have	O
solid	O
and	O
hematological	B
malignancies	I
with	O
chronic	O
HBV	B
infection	I
received	O
the	O
antiviral	O
agent	O
lamivudine	O
prior	O
and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	O
.	O

The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	O
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT	O
.	O

Two	O
groups	O
were	O
compared	O
in	O
this	O
study	O
.	O

The	O
prophylactic	O
lamivudin	O
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	O
treatment	O
.	O

The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	O
.	O

They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT	O
.	O

The	O
outcomes	O
were	O
compared	O
for	O
both	O
groups	O
.	O

Of	O
our	O
control	O
group	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
patients	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatitis	B
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	B
.	O

In	O
the	O
prophylactic	O
lamivudine	O
group	O
severe	O
hepatitis	B
were	O
observed	O
only	O
in	O
1	O
patient	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
patients	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O

Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	O
group	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	O
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	B
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	O
or	O
nucleotide	O
analogue	O
for	O
antiviral	O
prophylaxis	O
during	O
CT	O
and	O
the	O
optimal	O
duration	O
of	O
administration	O
after	O
completion	O
of	O
CT	O
.	O

Recovery	O
of	O
tacrolimus	O
-	O
associated	O
brachial	B
neuritis	I
after	O
conversion	O
to	O
everolimus	O
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
-	O
-	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	O
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	B
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	B
,	O
headaches	B
,	O
seizures	B
,	O
or	O
neurological	B
deficits	I
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B
and	O
right	O
brachial	B
plexitis	I
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	O
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	O
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	O
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	O
.	O

Omitting	O
fentanyl	O
reduces	O
nausea	B
and	O
vomiting	B
,	O
without	O
increasing	O
pain	B
,	O
after	O
sevoflurane	O
for	O
day	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	O
,	O
postoperative	B
nausea	I
and	I
vomiting	I
occurs	O
frequently	O
.	O

Fentanyl	O
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B
nausea	I
and	I
vomiting	I
and	O
pain	B
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	O
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	O
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	O
in	O
addition	O
to	O
fentanyl	O
.	O

RESULTS	O
:	O
Omission	O
of	O
fentanyl	O
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B
nausea	I
and	I
vomiting	I
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	B
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	O
and	O
fentanyl	O
-	O
dexamethasone	O
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamethasone	O
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B
nausea	I
and	I
vomiting	I
.	O

Combining	O
the	O
two	O
fentanyl	O
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B
nausea	I
and	I
vomiting	I
and	O
nausea	B
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Pain	B
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	O
.	O

Fentanyl	O
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	O
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B
depression	I
,	O
hypotension	B
and	O
bradycardia	B
.	O

CONCLUSION	O
:	O
As	O
fentanyl	O
exacerbated	O
postoperative	B
nausea	I
and	I
vomiting	I
without	O
an	O
improvement	O
in	O
postoperative	B
pain	I
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	O
in	O
day	O
surgery	O
.	O

Valvular	B
heart	I
disease	I
in	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
treated	O
with	O
pergolide	O
.	O

Course	O
following	O
treatment	O
modifications	O
.	O

Valvular	B
heart	I
abnormalities	I
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
treated	O
with	O
pergolide	O
.	O

However	O
,	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
abnormalities	O
vary	O
from	O
study	O
to	O
study	O
and	O
their	O
course	O
after	O
drug	O
withdrawal	O
has	O
not	O
been	O
systematically	O
assessed	O
.	O

OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	B
heart	I
abnormality	I
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
All	O
PD	B
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	O
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O

Thirty	O
PD	B
patients	O
participated	O
in	O
the	O
study	O
.	O

A	O
second	O
echocardiography	O
was	O
performed	O
(	O
median	O
interval	O
:	O
13	O
months	O
)	O
after	O
pergolide	O
withdrawal	O
(	O
n	O
=	O
10	O
patients	O
)	O
.	O

Controls	O
were	O
age	O
-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	B
patients	O
referred	O
to	O
the	O
cardiology	O
department	O
.	O

RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B
regurgitation	I
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mitral	B
regurgitation	I
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	B
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
affected	O
valves	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
higher	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	O
group	O
.	O

Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	O
cumulative	O
dose	O
.	O

A	O
restrictive	O
pattern	O
of	O
valvular	B
regurgitation	I
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	O
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
patients	O
including	O
two	O
with	O
heart	B
failure	I
.	O

Pergolide	O
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B
heart	I
disease	I
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B
failure	I
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O

This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	B
regurgitation	I
in	O
PD	B
patients	O
treated	O
with	O
pergolide	O
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non	O
-	O
ergot	O
dopamine	O
agonists	O
.	O

Adriamycin	O
-	O
induced	O
autophagic	O
cardiomyocyte	O
death	B
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	B
failure	I
.	O

BACKGROUND	O
:	O
The	O
mechanisms	O
underlying	O
heart	B
failure	I
induced	O
by	O
adriamycin	O
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	B
failure	I
induced	O
by	O
adriamycin	O
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	B
failure	I
.	O

METHODS	O
:	O
3	O
-	O
methyladenine	O
(	O
3MA	O
)	O
,	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B
failure	I
model	O
of	O
rats	O
induced	O
by	O
adriamycin	O
.	O

Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague	O
-	O
Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin	O
-	O
treated	O
group	O
,	O
and	O
a	O
3MA	O
plus	O
adriamycin	O
-	O
treated	O
group	O
.	O

We	O
then	O
examined	O
the	O
morphology	O
,	O
expression	O
of	O
beclin	O
1	O
gene	O
,	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	O
+	O
ATPase	O
activity	O
in	O
vivo	O
.	O

We	O
also	O
assessed	O
cell	O
viability	O
,	O
mitochondrial	O
membrane	O
potential	O
changes	O
and	O
counted	O
autophagic	O
vacuoles	O
in	O
cultured	O
cardiomyocytes	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
autophagy	O
associated	O
gene	O
,	O
beclin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
in	O
an	O
animal	O
model	O
.	O

RESULTS	O
:	O
3MA	O
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O

Furthermore	O
,	O
adriamycin	O
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	O
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin	O
-	O
induced	O
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
.	O

CONCLUSION	O
:	O
Autophagic	O
cardiomyocyte	O
death	B
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B
failure	I
in	O
rats	O
induced	O
by	O
adriamycin	O
.	O

Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B
failure	I
caused	O
by	O
adriamycin	O
via	O
the	O
autophagy	O
pathway	O
.	O

mToR	O
inhibitors	O
-	O
induced	O
proteinuria	B
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O

Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	O
inhibitors	O
to	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mToR	O
)	O
inhibitors	O
,	O
especially	O
sirolimus	O
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B
allograft	I
nephropathy	I
.	O

Because	O
proteinuria	B
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O

Whether	O
proteinuria	B
was	O
due	O
to	O
sirolimus	O
or	O
only	O
a	O
consequence	O
of	O
calcineurin	O
inhibitors	O
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B
has	O
been	O
observed	O
during	O
sirolimus	O
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	O
de	O
novo	O
.	O

Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade	O
-	O
induced	O
proteinuria	B
.	O

Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	O
.	O

This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	O
.	O

Reactions	O
consisted	O
mainly	O
of	O
seizures	B
,	O
acute	O
psychoses	B
,	O
anxiety	B
neurosis	I
,	O
and	O
major	O
disturbances	B
of	I
sleep	I
-	I
wake	I
rhythm	I
.	O

Side	O
effects	O
occurred	O
after	O
both	O
therapeutic	O
and	O
prophylactic	O
intake	O
and	O
were	O
graded	O
from	O
moderate	O
to	O
severe	O
.	O

In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8	O
,	O
000	O
mefloquine	O
users	O
suffers	O
from	O
such	O
reactions	O
.	O

The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions	O
,	O
compared	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
prophylaxis	O
group	O
,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	O
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis	O
.	O

Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	B
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	O
are	O
recommended	O
.	O

Prenatal	O
protein	O
deprivation	O
alters	O
dopamine	O
-	O
mediated	O
behaviors	O
and	O
dopaminergic	O
and	O
glutamatergic	O
receptor	O
binding	O
.	O

Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	B
.	O

The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	B
.	O

We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(	O
PD	O
)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	O
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	O
in	O
adulthood	O
.	O

These	O
differences	O
were	O
not	O
observed	O
during	O
puberty	O
.	O

No	O
changes	O
in	O
haloperidol	O
-	O
induced	O
catalepsy	B
or	O
MK	O
-	O
801	O
-	O
induced	O
locomotion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
female	O
rats	O
showed	O
increased	O
(	O
3	O
)	O
H	O
-	O
MK	O
-	O
801	O
binding	O
in	O
the	O
striatum	O
and	O
hippocampus	O
,	O
but	O
not	O
in	O
the	O
cortex	O
.	O

PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3	O
)	O
H	O
-	O
haloperidol	O
binding	O
and	O
decreased	O
dopamine	O
transporter	O
binding	O
in	O
striatum	O
.	O

No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(	O
3	O
)	O
H	O
-	O
MK	O
-	O
801	O
binding	O
in	O
cortex	O
.	O

This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	B
deficiency	I
enhances	O
risk	O
for	O
schizophrenia	B
in	O
humans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmental	O
processes	O
leading	O
to	O
differential	O
sensitivity	O
to	O
drugs	O
of	O
abuse	O
.	O

Adverse	O
effects	O
of	O
topical	O
papaverine	O
on	O
auditory	O
nerve	O
function	O
.	O

BACKGROUND	O
:	O
Papaverine	O
hydrochloride	O
is	O
a	O
direct	O
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B
during	O
various	O
neurosurgical	O
operations	O
.	O

Transient	O
cranial	B
nerve	I
dysfunction	I
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	O
.	O

This	O
study	O
supports	O
previous	O
reports	O
and	O
provides	O
neurophysiological	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
the	O
auditory	O
nerve	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	O
for	O
vasospasm	B
.	O

Topical	O
papaverine	O
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	B
in	O
a	O
total	O
of	O
11	O
patients	O
.	O

The	O
timing	O
of	O
papaverine	O
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O

Brainstem	O
auditory	O
evoked	O
potentials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cochlear	O
nerve	O
function	O
during	O
these	O
operations	O
.	O

FINDINGS	O
:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	O
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O

The	O
average	O
temporal	O
delay	O
between	O
papaverine	O
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	O
.	O

Eight	O
of	O
these	O
10	O
patients	O
had	O
complete	O
loss	O
of	O
BAEP	O
waveforms	O
within	O
10	O
min	O
.	O

One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B
hearing	I
loss	I
.	O

The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	O
-	O
papaverine	O
baseline	O
values	O
was	O
39	O
min	O
.	O

CONCLUSIONS	O
:	O
Topical	O
papaverine	O
for	O
the	O
treatment	O
of	O
vasospasm	B
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway	O
.	O

The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	B
effect	I
on	I
the	I
proximal	I
eighth	I
nerve	I
.	O

Recommendations	O
to	O
avoid	O
potential	O
cranial	B
nerve	I
deficits	I
from	O
papaverine	O
are	O
provided	O
.	O

Simvastatin	O
-	O
ezetimibe	O
-	O
induced	O
hepatic	B
failure	I
necessitating	O
liver	O
transplantation	O
.	O

Abstract	O
Serum	O
aminotransferase	O
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	O
)	O
therapy	O
.	O

However	O
,	O
hepatotoxic	B
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	O
or	O
the	O
combination	O
agent	O
simvastatin	O
-	O
ezetimibe	O
.	O

We	O
describe	O
a	O
70	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	B
hepatic	I
failure	I
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	O
40	O
mg	O
/	O
day	O
to	O
simvastatin	O
10	O
mg	O
-	O
ezetimibe	O
40	O
mg	O
/	O
day	O
.	O

The	O
patient	O
'	O
s	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	O
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	B
.	O

A	O
routine	O
laboratory	O
work	O
-	O
up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	O
aminotransferase	O
levels	O
.	O

Simvastatinezetimibe	O
and	O
escitalopram	O
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B
were	O
excluded	O
.	O

A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B
toxicity	I
.	O

She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O

Her	O
aminotransferase	O
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23	O
,	O
and	O
her	O
2	O
-	O
year	O
follow	O
-	O
up	O
showed	O
no	O
adverse	O
events	O
.	O

Ezetimibe	O
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	O
diphosphate	O
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	O
hydroxy	O
acid	O
,	O
resulting	O
in	O
increased	O
simvastatin	O
exposure	O
and	O
subsequent	O
hepatotoxicity	B
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	O
-	O
ezetimibe	O
-	O
induced	O
liver	B
failure	I
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O

We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	O
-	O
induced	O
hepatotoxicity	B
is	O
the	O
increased	O
simvastatin	O
exposure	O
by	O
ezetimibe	O
inhibition	O
of	O
UGT	O
enzymes	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	B
with	O
simvastatin	O
-	O
ezetimibe	O
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	O
aminotransferase	O
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O

Massive	O
proteinuria	B
and	O
acute	B
renal	I
failure	I
after	O
oral	O
bisphosphonate	O
(	O
alendronate	O
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	B
segmental	I
glomerulosclerosis	I
.	O

A	O
61	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
nephrotic	B
syndrome	I
due	O
to	O
focal	B
segmental	I
glomerulosclerosis	I
was	O
initially	O
responding	O
well	O
to	O
steroid	O
therapy	O
.	O

The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O

Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	O
(	O
alendronate	O
sodium	O
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
acute	B
renal	I
failure	I
.	O

After	O
discontinuing	O
the	O
oral	O
alendronate	O
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O

Urinary	O
volume	O
and	O
serum	O
creatinine	O
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O

This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	O
can	O
aggravate	O
proteinuria	B
and	O
acute	B
renal	I
failure	I
.	O

Serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
1	O
in	O
doxorubicin	O
-	O
induced	O
nephrotic	B
syndrome	I
.	O

Doxorubicin	O
-	O
induced	O
nephropathy	B
leads	O
to	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
-	O
dependent	O
volume	B
retention	I
and	O
renal	O
fibrosis	B
.	O

The	O
aldosterone	O
-	O
sensitive	O
serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	B
following	O
mineralocorticoid	O
and	O
salt	O
excess	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	B
retention	I
and	O
fibrosis	B
during	O
nephrotic	B
syndrome	I
.	O

To	O
this	O
end	O
,	O
doxorubicin	O
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Doxorubicin	O
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B
(	O
>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B
syndrome	I
with	O
ascites	B
,	O
lipidemia	B
,	O
and	O
hypoalbuminemia	B
in	O
both	O
genotypes	O
.	O

Plasma	O
aldosterone	O
levels	O
increased	O
in	O
nephrotic	B
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
.	O

Urinary	O
sodium	O
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
15	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
than	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
35	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B
gain	I
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
compared	O
with	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O

During	O
the	O
course	O
of	O
nephrotic	B
syndrome	I
,	O
serum	O
urea	O
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
than	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
leading	O
to	O
uremia	B
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
29	O
vs	O
.	O
40	O
days	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
)	O
.	O

In	O
conclusion	O
,	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	B
retention	I
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	B
during	O
experimental	O
nephrotic	B
syndrome	I
.	O

Severe	O
thrombocytopenia	B
and	O
haemolytic	B
anaemia	I
associated	O
with	O
ciprofloxacin	O
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome	O
.	O

Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	O
.	O

A	O
30	O
-	O
year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	B
pain	I
and	O
jaundice	B
after	O
3	O
-	O
day	O
administration	O
of	O
oral	O
ciprofloxacin	O
for	O
a	O
suspect	O
of	O
urinary	B
tract	I
infection	I
.	O

Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	B
and	O
haemolysis	B
.	O

The	O
patient	O
progressively	O
developed	O
petechiae	B
and	O
purpura	B
on	O
thorax	O
and	O
lower	O
limbs	O
.	O

Despite	O
pharmacological	O
and	O
supportive	O
interventions	O
,	O
laboratory	O
parameters	O
worsened	O
and	O
the	O
patient	O
died	O
17	O
hours	O
after	O
admission	O
.	O

An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	B
.	O

No	O
signs	O
of	O
bone	B
marrow	I
depression	I
were	O
found	O
.	O

No	O
thrombi	B
or	O
signs	O
of	O
microangiopathies	B
were	O
observed	O
in	O
arterial	O
vessels	O
.	O

Blood	O
and	O
urine	O
cultures	O
did	O
not	O
show	O
any	O
bacterial	O
growth	O
.	O

This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	O
may	O
precipitate	O
life	O
-	O
threatening	O
thrombocytopenia	B
and	O
haemolytic	B
anaemia	I
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O

Alpha	O
-	O
lipoic	O
acid	O
prevents	O
mitochondrial	B
damage	I
and	O
neurotoxicity	B
in	O
experimental	O
chemotherapy	O
neuropathy	B
.	O

The	O
study	O
investigates	O
if	O
alpha	O
-	O
lipoic	O
acid	O
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B
,	O
if	O
mitochondrial	B
damage	I
plays	O
a	O
critical	O
role	O
in	O
toxic	B
neurodegenerative	I
cascade	I
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
depend	O
on	O
mitochondria	O
protection	O
.	O

We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B
neuropathy	I
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	O
and	O
cisplatin	O
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O

This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	O
-	O
lipoic	O
acid	O
in	O
preventing	O
axonal	B
damage	I
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	O
-	O
lipoic	O
acid	O
.	O

Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	O
and	O
paclitaxel	O
cause	O
early	O
mitochondrial	B
impairment	I
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O

Alpha	O
-	O
lipoic	O
acid	O
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B
toxicity	I
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O

In	O
conclusion	O
mitochondrial	B
toxicity	I
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	O
and	O
cisplatin	O
induced	O
neurotoxicity	B
.	O

Alpha	O
-	O
lipoic	O
acid	O
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O

These	O
findings	O
suggest	O
that	O
alpha	O
-	O
lipoic	O
acid	O
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B
nerve	I
toxicity	I
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O

Toxicity	B
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8	O
-	O
aminoquinoline	O
8	O
-	O
[	O
(	O
4	O
-	O
amino	O
-	O
l	O
-	O
methylbutyl	O
)	O
amino	O
]	O
-	O
5	O
-	O
(	O
l	O
-	O
hexyloxy	O
)	O
-	O
6	O
-	O
methoxy	O
-	O
4	O
-	O
methylquinoline	O
(	O
WR242511	O
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyanide	O
(	O
CN	O
)	O
toxicity	B
.	O

Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	B
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8	O
-	O
aminoquinoline	O
WR242511	O
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs	O
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
WR242511	O
was	O
administered	O
intravenously	O
(	O
IV	O
)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
male	O
also	O
received	O
WR242511	O
orally	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O

Health	O
status	O
and	O
MHb	O
levels	O
were	O
monitored	O
following	O
exposure	O
.	O

RESULTS	O
:	O
The	O
selected	O
doses	O
of	O
WR242511	O
,	O
which	O
produced	O
significant	O
methemoglobinemia	B
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O

Furthermore	O
,	O
transient	O
hemoglobinuria	B
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	O
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O

Myoglobinuria	B
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O

Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	B
and	I
kidney	I
toxicity	I
,	O
with	O
greater	O
severity	O
in	O
the	O
orally	O
-	O
treated	O
animal	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
direct	O
and	O
/	O
or	O
indirect	O
drug	O
-	O
induced	O
toxicity	B
.	O

It	O
is	O
concluded	O
that	O
WR242511	O
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	B
unless	O
the	O
anti	O
-	O
CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	B
.	O

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	O
-	O
induced	O
dyskinesias	B
in	O
Parkinson	B
'	I
s	I
disease	I
.	O

In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
"	O
real	O
"	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
"	O
sham	O
"	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B
in	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
.	O

Ten	O
patients	O
with	O
PD	B
and	O
prominent	O
dyskinesias	B
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O

Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	B
severity	O
.	O

However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystonia	B
subscore	O
.	O

Similarly	O
,	O
in	O
patient	O
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O

Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	B
symptoms	O
were	O
noted	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	B
in	O
PD	B
.	O

The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	O
therapeutic	O
uses	O
.	O

Intracavernous	O
epinephrine	O
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	B
in	O
the	O
emergency	O
department	O
.	O

Priapism	B
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal	O
.	O

A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	O
user	O
,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	B
after	O
cocaine	O
use	O
.	O

The	O
management	O
options	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	O
instillation	O
,	O
are	O
discussed	O
.	O

Prophylactic	O
use	O
of	O
lamivudine	O
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	B
disorders	I
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	O
in	O
hepatitis	O
B	O
virus	O
surface	O
antigen	O
(	O
HBs	O
Ag	O
)	O
positive	O
patients	O
with	O
rheumatologic	B
disease	I
.	O

From	O
June	O
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	O
Ag	O
positive	O
patients	O
with	O
rheumatologic	B
diseases	I
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	O
therapies	O
,	O
were	O
retrospectively	O
assessed	O
.	O

Liver	O
function	O
tests	O
,	O
hepatitis	B
B	I
virus	O
(	O
HBV	O
)	O
serologic	O
markers	O
,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hospital	O
file	O
records	O
.	O

Eleven	O
patients	O
(	O
six	O
male	O
)	O
with	O
median	O
age	O
47	O
years	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
median	O
disease	O
duration	O
50	O
months	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
median	O
follow	O
-	O
up	O
period	O
of	O
patients	O
13	O
.	O
8	O
months	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Lamivudine	O
therapy	O
was	O
started	O
3	O
-	O
7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O

Baseline	O
,	O
liver	O
function	O
tests	O
were	O
elevated	O
in	O
two	O
patients	O
(	O
fourth	O
patient	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
tenth	O
patient	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
minimal	O
changes	O
in	O
the	O
liver	O
biopsy	O
in	O
both	O
)	O
.	O

Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	B
liver	I
function	I
tests	O
.	O

In	O
four	O
patients	O
HBV	O
DNA	O
levels	O
were	O
higher	O
than	O
normal	O
at	O
baseline	O
.	O

Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
increased	O
later	O
.	O

In	O
three	O
additional	O
patients	O
,	O
HBV	O
DNA	O
levels	O
were	O
increased	O
during	O
follow	O
-	O
up	O
.	O

None	O
of	O
the	O
patients	O
had	O
significant	O
clinical	O
sings	O
of	O
HBV	O
activation	O
.	O

Lamivudine	O
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients	O
.	O

Prophylactic	O
administration	O
of	O
lamivudine	O
in	O
patients	O
who	O
required	O
immunosuppressive	O
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	O
and	O
effective	O
in	O
preventing	O
HBV	O
reactivation	O
.	O

Effect	O
of	O
green	O
tea	O
and	O
vitamin	O
E	O
combination	O
in	O
isoproterenol	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	O
tea	O
and	O
vitamin	O
E	O
on	O
heart	O
weight	O
,	O
body	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
endogenous	O
antioxidants	O
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	O
(	O
ISO	O
)	O
-	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

Adult	O
male	O
albino	O
rats	O
,	O
treated	O
with	O
ISO	O
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
and	O
Ca	O
+	O
2	O
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
Mg	O
+	O
2	O
ATPase	O
levels	O
.	O

Administration	O
of	O
green	O
tea	O
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
vitamin	O
E	O
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	O
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
Ca	O
+	O
2	O
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
Mg	O
+	O
2	O
ATPase	O
when	O
compared	O
with	O
ISO	O
treated	O
group	O
and	O
green	O
tea	O
or	O
vitamin	O
E	O
alone	O
treated	O

groups	O
.	O

These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	O
tea	O
and	O
vitamin	O
E	O
during	O
ISO	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	B
in	O
F344	O
rats	O
.	O

Renal	B
papillary	I
necrosis	I
(	O
RPN	B
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long	O
-	O
term	O
treatment	O
with	O
aspirin	O
and	O
paracetamol	O
in	O
female	O
Fischer	O
344	O
rats	O
.	O

Renal	O
structure	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
recovery	O
period	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
analgesics	O
were	O
given	O
,	O
to	O
investigate	O
whether	O
the	O
analgesic	O
-	O
induced	O
changes	O
were	O
reversible	O
.	O

There	O
was	O
no	O
evidence	O
of	O
repair	O
to	O
the	O
damaged	O
medullary	O
interstitial	O
matrix	O
,	O
or	O
proliferation	O
of	O
remaining	O
undamaged	O
type	O
1	O
medullary	O
interstitial	O
cells	O
after	O
the	O
recovery	O
period	O
following	O
analgesic	O
treatment	O
.	O

The	O
recovery	O
of	O
urinary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
length	O
of	O
analgesic	O
treatment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
structural	O
damage	O
.	O

During	O
the	O
early	O
stages	O
of	O
analgesic	O
treatment	O
,	O
the	O
changes	O
in	O
urinary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prolonged	O
analgesic	O
treatment	O
,	O
maximum	O
urinary	O
concentrating	O
ability	O
failed	O
to	O
recover	O
.	O

This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	B
.	O

The	O
associated	O
urinary	O
concentrating	O
defect	O
is	O
reversible	O
only	O
during	O
the	O
early	O
stages	O
of	O
structural	O
damage	O
to	O
the	O
inner	O
medulla	O
.	O

Testosterone	O
-	O
dependent	O
hypertension	B
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt	O
-	O
sensitive	O
rats	O
.	O

Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
salt	O
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women	O
.	O

In	O
Dahl	O
salt	O
-	O
sensitive	O
rats	O
(	O
DS	O
)	O
,	O
high	O
-	O
salt	O
(	O
HS	O
)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females	O
.	O

In	O
contrast	O
to	O
the	O
systemic	O
renin	O
-	O
angiotensin	O
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS	O
,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased	O
,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	O
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B
injury	I
.	O

On	O
a	O
low	O
-	O
salt	O
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O

HS	O
diet	O
for	O
4	O
wk	O
increased	O
renal	O
cortical	O
angiotensinogen	O
mRNA	O
and	O
protein	O
only	O
in	O
male	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
castration	O
.	O

Ovariectomy	O
of	O
female	O
DS	O
had	O
no	O
effect	O
on	O
intrarenal	O
angiotensinogen	O
expression	O
on	O
either	O
diet	O
.	O

Radiotelemetric	O
BP	O
was	O
similar	O
between	O
males	O
and	O
castrated	O
rats	O
on	O
LS	O
diet	O
.	O

HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP	O
,	O
protein	O
and	O
albumin	O
excretion	O
,	O
and	O
glomerular	B
sclerosis	I
in	O
male	O
DS	O
rats	O
,	O
which	O
were	O
attenuated	O
by	O
castration	O
.	O

Testosterone	O
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP	O
,	O
renal	B
injury	I
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet	O
.	O

Testosterone	O
contributes	O
to	O
the	O
development	O
of	O
hypertension	B
and	O
renal	B
injury	I
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin	O
-	O
angiotensin	O
system	O
.	O

Explicit	O
episodic	O
memory	O
for	O
sensory	O
-	O
discriminative	O
components	O
of	O
capsaicin	O
-	O
induced	O
pain	B
:	O
immediate	O
and	O
delayed	O
ratings	O
.	O

Pain	B
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	B
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	B
conditions	O
.	O

Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	B
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
pain	B
memory	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	O
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
microg	O
,	O
separated	O
by	O
15	O
min	O
breaks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals	O
.	O

Pain	B
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(	O
0	O
-	O
100	O
)	O
digitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection	O
.	O

Subjects	O
also	O
recalled	O
their	O
pains	B
one	O
week	O
later	O
.	O

Capsaicin	O
injection	O
reliably	O
induced	O
a	O
dose	O
-	O
dependent	O
flare	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O

The	O
strong	O
burning	O
pain	B
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	O
.	O

Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	B
magnitude	O
and	O
duration	O
across	O
capsaicin	O
doses	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O

Pain	B
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
duration	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Correlation	O
with	O
rating	O
recall	O
after	O
one	O
week	O
was	O
best	O
when	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
as	O
late	O
as	O
one	O
day	O
after	O
injection	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
)	O
indicating	O
that	O
both	O
rating	O
retrievals	O
utilized	O
similar	O
memory	O
traces	O
.	O

These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B
.	O

The	O
data	O
further	O
suggest	O
that	O
the	O
consolidation	O
of	O
this	O
memory	O
is	O
an	O
important	O
interim	O
stage	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O

Severe	O
and	O
long	O
lasting	O
cholestasis	B
after	O
high	O
-	O
dose	O
co	O
-	O
trimoxazole	O
treatment	O
for	O
Pneumocystis	B
pneumonia	I
in	O
HIV	B
-	I
infected	I
patients	O
-	O
-	O
a	O
report	O
of	O
two	O
cases	O
.	O

Pneumocystis	B
pneumonia	I
(	O
PCP	B
)	O
,	O
a	O
common	O
opportunistic	B
infection	I
in	O
HIV	B
-	I
infected	I
individuals	O
,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co	O
-	O
trimoxazole	O
.	O

However	O
,	O
treatment	O
is	O
often	O
limited	O
by	O
adverse	O
effects	O
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV	B
-	I
infected	I
patients	O
who	O
developed	O
severe	O
intrahepatic	B
cholestasis	I
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B
abscess	I
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	O
-	O
trimoxazole	O
treatment	O
for	O
PCP	B
.	O

Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co	O
-	O
trimoxazole	O
treatment	O
,	O
therapy	O
of	O
patient	O
2	O
was	O
switched	O
early	O
.	O

Bradykinin	O
receptors	O
antagonists	O
and	O
nitric	O
oxide	O
synthase	O
inhibitors	O
in	O
vincristine	O
and	O
streptozotocin	O
induced	O
hyperalgesia	B
in	O
chemotherapy	O
and	O
diabetic	B
neuropathy	I
rat	O
model	O
.	O

PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	O
synthase	O
(	O
L	O
-	O
NOArg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	O
synthase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	O
synthase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D	O
-	O
Arg	O
-	O
[	O
Hyp3	O
,	O

Thi5	O
,	O
D	O
-	O
Tic7	O
,	O
Oic8	O
]	O
bradykinin	O
(	O
HOE	O
140	O
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	O
Arg10	O
HOE	O
140	O
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
model	O
of	O
diabetic	B
(	I
streptozotocin	I
-	I
induced	I
)	I
and	I
toxic	I
(	I
vincristine	I
-	I
induced	I
)	I
neuropathy	I
was	O
investigated	O
.	O

METHODS	O
:	O
The	O
changes	O
in	O
pain	B
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
-	O
-	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O

RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	O
receptors	O
and	O
inducible	O
NO	O
synthase	O
but	O
not	O
neuronal	O
NO	O
synthase	O
activity	O
reduces	O
diabetic	B
hyperalgesia	I
.	O

Pretreatment	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	O
140	O
and	O
des	O
Arg10	O
HOE	O
140	O
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	O
synthase	O
and	O
neuronal	O
NO	O
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	O
are	O
involved	O
in	O
hyperalgesia	B
produced	O
by	O
vincristine	O
.	O

Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	O
140	O
or	O
des	O
-	O
Arg10HOE	O
140	O
in	O
toxic	B
neuropathy	I
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B
and	I
toxic	I
neuropathy	I
.	O

In	O
streptozotocin	O
-	O
induced	O
hyperalgesia	B
,	O
inducible	O
NO	O
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	O
,	O
whereas	O
in	O
vincristine	O
-	O
induced	O
hyperalgesia	B
bradykinin	O
seemed	O
to	O
activate	O
neuronal	O
NO	O
synthase	O
pathway	O
.	O

Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	O
receptor	O
antagonists	O
and	O
NO	O
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B
pain	I
,	O
even	O
in	O
hospital	O
care	O
.	O

Confusion	B
,	O
a	O
rather	O
serious	O
adverse	O
drug	O
reaction	O
with	O
valproic	O
acid	O
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database	O
.	O

INTRODUCTION	O
:	O
Confusion	B
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	O
acid	O
.	O

Some	O
case	O
reports	O
are	O
published	O
in	O
the	O
literature	O
but	O
no	O
systematic	O
study	O
from	O
a	O
sample	O
of	O
patients	O
has	O
been	O
published	O
.	O

We	O
performed	O
this	O
study	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteristics	O
of	O
this	O
adverse	O
drug	O
reaction	O
.	O

METHODS	O
:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database	O
,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	B
reported	O
since	O
1985	O
with	O
valproic	O
acid	O
.	O

RESULTS	O
:	O
272	O
cases	O
of	O
confusion	B
were	O
reported	O
with	O
valproic	O
acid	O
:	O
153	O
women	O
and	O
119	O
men	O
.	O

Confusion	B
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	O
acid	O
exposure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2	O
/	O
3	O
of	O
the	O
patients	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
its	O
outcome	O
favourable	O
in	O
most	O
of	O
the	O
cases	O
(	O
82	O
%	O
)	O
.	O

The	O
occurrence	O
of	O
this	O
ADR	O
was	O
more	O
frequent	O
in	O
patients	O
aged	O
between	O
61	O
and	O
80	O
years	O
.	O

CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confusion	B
with	O
valproic	O
acid	O
is	O
a	O
serious	O
,	O
rather	O
frequent	O
but	O
reversible	O
adverse	O
drug	O
reaction	O
.	O

It	O
occurs	O
especially	O
in	O
older	O
patients	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
treatment	O
.	O

Reversible	O
inferior	B
colliculus	I
lesion	I
in	O
metronidazole	O
-	O
induced	O
encephalopathy	B
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B
colliculus	I
lesions	I
in	O
metronidazole	O
-	O
induced	O
encephalopathy	B
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	O
-	O
induced	O
encephalopathy	B
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O

They	O
had	O
been	O
taking	O
metronidazole	O
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B
in	O
various	O
organs	O
.	O

Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)	O
,	O
FLAIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
image	O
(	O
8	O
/	O
8	O
)	O
.	O

Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	O
administration	O
.	O

Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	O
changes	O
on	O
follow	O
-	O
up	O
images	O
.	O

RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8	O
/	O
8	O
)	O
,	O
inferior	O
colliculus	O
(	O
6	O
/	O
8	O
)	O
,	O
corpus	O
callosum	O
(	O
2	O
/	O
8	O
)	O
,	O
pons	O
(	O
2	O
/	O
8	O
)	O
,	O
medulla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O

High	O
-	O
signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
patient	O
,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O

All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	O
,	O
but	O
in	O
1	O
patient	O
of	O
them	O
,	O
corpus	O
callosal	B
lesion	I
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversible	O
inferior	B
colliculus	I
lesions	I
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	O
-	O
induced	O
encephalopathy	B
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O

Clinically	O
significant	O
proteinuria	B
following	O
the	O
administration	O
of	O
sirolimus	O
to	O
renal	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Sirolimus	O
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	O
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	B
than	O
calcineurin	O
inhibitor	O
(	O
CNI	O
)	O
-	O
based	O
regimens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	B
linked	O
with	O
the	O
use	O
of	O
sirolimus	O
.	O

We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	B
associated	O
with	O
sirolimus	O
use	O
.	O

In	O
each	O
patient	O
,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	O
therapy	O
and	O
proteinuria	B
implicated	O
sirolimus	O
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	B
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimus	O
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen	O
.	O

In	O
these	O
patients	O
,	O
the	O
magnitude	O
of	O
proteinuria	B
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein	O
:	O
creatinine	O
ratios	O
,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria	B
/	O
day	O
.	O

Laboratory	O
results	O
were	O
compared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolimus	O
use	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
eight	O
patients	O
(	O
24	O
%	O
)	O
developed	O
increased	O
proteinuria	B
from	O
baseline	O
during	O
their	O
post	O
-	O
transplantation	O
course	O
.	O

In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	B
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	O
and	O
the	O
development	O
of	O
nephrotic	B
-	O
range	O
proteinuria	B
.	O

Proteinuria	B
correlated	O
most	O
strongly	O
with	O
sirolimus	O
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables	O
.	O

In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	O
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B
.	O

CONCLUSIONS	O
:	O
Sirolimus	O
induces	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteinuria	B
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients	O
.	O

Proteinuria	B
may	O
improve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	O
is	O
withdrawn	O
.	O

Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	B
induced	O
by	O
scopolamine	O
.	O

The	O
anti	O
-	O
dementia	B
effects	O
of	O
s	O
-	O
limonene	O
and	O
s	O
-	O
perillyl	O
alcohol	O
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(	O
OFH	O
)	O
.	O

These	O
lemon	O
essential	O
oils	O
showed	O
strong	O
ability	O
to	O
improve	O
memory	B
impaired	I
by	O
scopolamine	O
;	O
however	O
,	O
s	O
-	O
perillyl	O
alcohol	O
relieved	O
the	O
deficit	B
of	I
associative	I
memory	I
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	O
non	O
-	O
associative	O
memory	O
significantly	O
in	O
OFH	O
.	O

Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	O
concentration	O
of	O
the	O
vehicle	O
/	O
scopolamine	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle	O
/	O
vehicle	O
group	O
,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s	O
-	O
limonene	O
or	O
s	O
-	O
perillyl	O
alcohol	O
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	O
.	O

Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
lemon	O
essential	O
oil	O
components	O
could	O
inhibit	O
acetylcholinesterase	O
activity	O
in	O
vitro	O
using	O
the	O
Ellman	O
method	O
.	O

Attentional	O
modulation	O
of	O
perceived	O
pain	B
intensity	O
in	O
capsaicin	O
-	O
induced	O
secondary	O
hyperalgesia	B
.	O

Perceived	O
pain	B
intensity	O
is	O
modulated	O
by	O
attention	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	B
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin	O
-	O
induced	O
secondary	O
hyperalgesia	B
.	O

Here	O
we	O
show	O
that	O
perceived	O
pain	B
intensity	O
in	O
secondary	O
hyperalgesia	B
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	O
hyperalgesia	B
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin	O
-	O
untreated	O
,	O
control	O
condition	O
.	O

Our	O
findings	O
,	O
showing	O
no	O
interaction	O
between	O
capsaicin	O
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin	O
-	O
induced	O
secondary	O
hyperalgesia	B
and	O
attention	O
might	O
affect	O
mechanical	O
pain	B
through	O
independent	O
mechanisms	O
.	O

Cardioprotective	O
effect	O
of	O
salvianolic	O
acid	O
A	O
on	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	O
acid	O
A	O
on	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
in	O
rats	O
.	O

Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O

Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O

Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O

Isoproterenol	O
-	O
treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	O
dehydrogenase	O
,	O
aspartate	O
transaminase	O
,	O
creatine	O
kinase	O
and	O
malondialdehyde	O
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	O
dismutase	O
,	O
catalase	O
and	O
glutathione	O
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O

These	O
rats	O
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
ST	O
-	O
segment	O
.	O

In	O
addition	O
,	O
mitochondrial	O
respiratory	B
dysfunction	I
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	O
/	O
O	O
was	O
observed	O
in	O
isoproterenol	O
-	O
treated	O
rats	O
.	O

Administration	O
of	O
salvianolic	O
acid	O
A	O
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	O
-	O
induced	O
cardiac	B
dysfunction	I
and	O
myocardial	B
injury	I
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O

The	O
protective	O
role	O
of	O
salvianolic	O
acid	O
A	O
against	O
isoproterenol	O
-	O
induced	O
myocardial	B
damage	I
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	O
acid	O
A	O
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
.	O

Long	O
-	O
term	O
glutamate	O
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	B
neurotoxicity	I
of	O
paclitaxel	O
.	O

Toxic	O
peripheral	B
neuropathy	I
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	O
(	O
PAC	O
)	O
,	O
although	O
glutamate	O
and	O
its	O
closely	O
related	O
amino	O
acid	O
glutamine	O
were	O
claimed	O
to	O
ameliorate	O
PAC	O
neurotoxicity	B
.	O

This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	O
supplementation	O
for	O
preventing	O
PAC	O
-	O
induced	O
peripheral	B
neuropathy	I
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
clinical	O
and	O
electro	O
-	O
diagnostic	O
study	O
.	O

Forty	O
-	O
three	O
ovarian	B
cancer	I
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC	O
-	O
containing	O
regimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	O
all	O
along	O
the	O
treatment	O
period	O
,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(	O
group	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(	O
group	O
P	O
)	O
.	O

Patients	O
were	O
evaluated	O
by	O
neurological	O
examinations	O
,	O
questionnaires	O
and	O
sensory	O
-	O
motor	O
nerve	O
conduction	O
studies	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	B
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G	O
.	O

However	O
,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	B
sensation	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Also	O
the	O
frequency	O
of	O
abnormal	O
electro	O
-	O
diagnostic	O
findings	O
showed	O
similarity	O
between	O
the	O
two	O
groups	O
(	O
G	O
:	O
7	O
/	O
23	O
=	O
30	O
.	O
4	O
%	O
;	O
P	O
:	O
6	O
/	O
20	O
=	O
30	O
%	O
)	O
.	O

This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	O
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	B
neurotoxicity	I
of	O
PAC	O
.	O

Development	O
of	O
ocular	B
myasthenia	I
during	O
pegylated	O
interferon	O
and	O
ribavirin	O
treatment	O
for	O
chronic	B
hepatitis	I
C	I
.	O

A	O
63	O
-	O
year	O
-	O
old	O
male	O
experienced	O
sudden	O
diplopia	B
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	O
interferon	O
(	O
IFN	O
)	O
alpha	O
-	O
2b	O
and	O
ribavirin	O
for	O
chronic	B
hepatitis	I
C	I
(	O
CHC	B
)	O
.	O

Ophthalmologic	O
examinations	O
showed	O
ptosis	B
on	I
the	I
right	I
upper	I
lid	I
and	O
restricted	B
right	I
eye	I
movement	I
without	O
any	O
other	O
neurological	O
signs	O
.	O

A	O
brain	O
imaging	O
study	O
and	O
repetitive	O
nerve	O
stimulation	O
test	O
indicated	O
no	O
abnormality	O
.	O

The	O
acetylcholine	O
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative	O
,	O
and	O
the	O
results	O
of	O
thyroid	O
function	O
tests	O
were	O
normal	O
.	O

The	O
patient	O
'	O
s	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	O
IFN	O
alpha	O
-	O
2b	O
and	O
ribavirin	O
.	O

The	O
ocular	B
myasthenia	I
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	O
IFN	O
alpha	O
-	O
2b	O
and	O
ribavirin	O
for	O
CHC	B
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	O
of	O
IFN	O
therapy	O
.	O

Learning	B
and	I
memory	I
deficits	I
in	O
ecstasy	O
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	O
users	O
display	O
impairments	B
in	I
learning	I
and	I
memory	I
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	O
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O

Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	O
and	O
20	O
controls	O
.	O

To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	O
use	O
of	O
the	O
ecstasy	O
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	O
users	O
(	O
Nestor	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
Deficits	B
in	I
learning	I
and	I
memory	I
:	O
parahippocampal	O
hyperactivity	B
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	O
users	O
.	O
Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecstasy	O
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	O
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	O
-	O
specific	O
hyperactivity	B
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

Ecstasy	O
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

In	O
both	O
ecstasy	O
and	O
cannabis	O
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

These	O
results	O
elucidated	O
ecstasy	O
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	O
use	O
.	O

These	O
ecstasy	O
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B
effects	O
of	O
ecstasy	O
.	O

Disulfiram	O
-	O
like	O
syndrome	O
after	O
hydrogen	O
cyanamide	O
professional	O
skin	O
exposure	O
:	O
two	O
case	O
reports	O
in	O
France	O
.	O

Hydrogen	O
cyanamide	O
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O

Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	O
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	O
syndrome	O
in	O
case	O
of	O
alcohol	O
use	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram	O
-	O
like	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
hydrogen	O
cyanamide	O
.	O

The	O
first	O
case	O
involved	O
a	O
59	O
-	O
year	O
-	O
old	O
man	O
who	O
used	O
Dormex	O
,	O
which	O
contains	O
hydrogen	O
cyanamide	O
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	O
during	O
a	O
meal	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	O
,	O
he	O
developed	O
malaise	O
with	O
flushing	B
of	I
the	I
face	I
,	O
tachycardia	B
,	O
and	O
dyspnea	B
.	O

Manifestations	O
regressed	O
spontaneously	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O

The	O
second	O
case	O
occurred	O
in	O
a	O
55	O
-	O
year	O
-	O
old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	O
.	O

Five	O
hours	O
after	O
exposure	O
,	O
he	O
developed	O
disulfiram	O
-	O
like	O
syndrome	O
with	O
flushing	B
,	O
tachycardia	B
,	O
and	O
arterial	B
hypotension	I
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O

The	O
patient	O
recovered	O
spontaneously	O
in	O
3	O
hours	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O

These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	O
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	O
and	O
of	O
preventing	O
cutaneous	O
contact	O
during	O
use	O
.	O

Sulpiride	O
-	O
induced	O
tardive	B
dystonia	I
.	O

Sulpiride	O
is	O
a	O
selective	O
D2	O
-	O
receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	O
properties	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects	O
,	O
sulpiride	O
-	O
induced	O
tardive	B
dyskinesia	I
and	O
parkinsonism	B
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	B
within	O
2	O
months	O
after	O
starting	O
sulpiride	O
therapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride	O
-	O
induced	O
tardive	B
dystonia	I
.	O

Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate	O
-	O
release	O
oxycodone	O
in	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O

This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	O
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle	O
-	O
aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	B
.	O

Seventy	O
-	O
one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	O
to	O
medication	O
condition	O
(	O
placebo	O
,	O
10	O
-	O
mg	O
oxycodone	O
)	O
.	O

Plasma	O
oxycodone	O
concentration	O
peaked	O
between	O
60	O
and	O
90	O
minutes	O
postdose	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
pupil	O
size	O
,	O
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Significant	O
declines	B
in	I
simple	I
and	I
sustained	I
attention	I
,	I
working	I
memory	I
,	I
and	I
verbal	I
memory	I
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose	O
.	O

For	O
almost	O
all	O
cognitive	O
measures	O
,	O
there	O
were	O
no	O
medication	O
by	O
age	O
-	O
interaction	O
effects	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
groups	O
exhibited	O
similar	O
responses	O
to	O
the	O
medication	O
challenge	O
.	O

This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	B
pain	I
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	O
to	O
a	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	O
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aged	O
adults	O
.	O

PERSPECTIVE	O
:	O
Study	O
findings	O
indicate	O
that	O
the	O
metabolism	O
,	O
neurocognitive	O
effects	O
,	O
and	O
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	O
are	O
similar	O
for	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O

Therefore	O
,	O
clinicians	O
should	O
not	O
avoid	O
prescribing	O
oral	O
opioids	O
to	O
older	O
adults	O
based	O
on	O
the	O
belief	O
that	O
older	O
adults	O
are	O
at	O
higher	O
risk	O
for	O
side	O
effects	O
than	O
younger	O
adults	O
.	O

The	O
glycine	O
transporter	O
-	O
1	O
inhibitor	O
SSR103800	O
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O

Schizophrenia	B
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	O
neurotransmission	O
.	O

However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
produce	O
schizophrenic	B
-	O
like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	O
receptor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	O
receptor	O
.	O

Among	O
them	O
are	O
glycine	O
transporter	O
-	O
1	O
(	O
GlyT1	O
)	O
inhibitors	O
such	O
as	O
SSR103800	O
,	O
which	O
indirectly	O
enhance	O
NMDA	O
receptor	O
function	O
by	O
increasing	O
the	O
glycine	O
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	O
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	O
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	O
and	O
MK	O
-	O
801	O
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	O
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Results	O
showed	O
that	O
SSR103800	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocked	O
hyperactivity	B
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	O
receptor	O
antagonist	O
,	O
MK	O
-	O
801	O
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B
of	O
NMDA	O
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
mice	O
.	O

In	O
contrast	O
,	O
SSR103800	O
failed	O
to	O
affect	O
hyperactivity	B
induced	O
by	O
amphetamine	O
or	O
naturally	O
observed	O
in	O
dopamine	O
transporter	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
knockout	O
mice	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	O
)	O
and	O
atypical	O
(	O
olanzapine	O
,	O
clozapine	O
and	O
aripiprazole	O
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	O
did	O
not	O
produce	O
catalepsy	B
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
,	O
SSR103800	O
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	O
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O

Pyrrolidine	O
dithiocarbamate	O
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	O
status	B
epilepticus	I
model	O
.	O

Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa	O
-	O
beta	O
.	O

Both	O
,	O
production	O
of	O
reactive	O
oxygen	O
species	O
as	O
well	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	B
damage	I
in	O
different	O
sub	O
-	O
regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O

The	O
effect	O
of	O
PDTC	O
on	O
status	B
epilepticus	I
-	O
associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O
piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	O
model	O
.	O

Treatment	O
with	O
150	O
mg	O
/	O
kg	O
PDTC	O
before	O
and	O
following	O
status	B
epilepticus	I
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100	O
%	O
.	O

Administration	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	O
(	O
low	O
-	O
dose	O
)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	B
epilepticus	I
or	O
the	O
mortality	O
rate	O
.	O

In	O
vehicle	O
-	O
treated	O
rats	O
,	O
status	B
epilepticus	I
caused	O
pronounced	O
neuronal	B
damage	I
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons	O
.	O

Low	O
-	O
dose	O
PDTC	O
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex	O
.	O

A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle	O
-	O
and	O
PDTC	O
-	O
treated	O
rats	O
following	O
status	B
epilepticus	I
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	O
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	B
loss	I
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B
-	O
associated	O
neuronal	B
damage	I
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

However	O
,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	O
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piriform	O
cortex	O
.	O

Anaesthetists	O
'	O
nightmare	O
:	O
masseter	B
spasm	I
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B
congenita	I
.	O

We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B
congenita	I
in	O
a	O
24	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
primigravida	O
,	O
who	O
developed	O
life	O
threatening	O
masseter	B
spasm	I
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	O
for	O
induction	O
of	O
anaesthesia	O
.	O

Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
was	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O

Twin	O
preterm	O
neonates	O
with	O
cardiac	B
toxicity	I
related	O
to	O
lopinavir	O
/	O
ritonavir	O
therapy	O
.	O

We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B
immunodeficiency	I
virus	I
infection	I
.	O

One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B
block	I
and	O
dilated	B
cardiomyopathy	I
related	O
to	O
lopinavir	O
/	O
ritonavir	O
therapy	O
,	O
a	O
boosted	O
protease	O
-	O
inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	B
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir	O
/	O
ritonavir	O
in	O
the	O
immediate	O
neonatal	O
period	O
.	O

When	O
drugs	O
disappear	O
from	O
the	O
patient	O
:	O
elimination	O
of	O
intravenous	O
medication	O
by	O
hemodiafiltration	O
.	O

Twenty	O
-	O
three	O
hours	O
after	O
heart	O
transplantation	O
,	O
life	O
-	O
threatening	O
acute	O
right	B
heart	I
failure	I
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O

Increasing	O
doses	O
of	O
catecholamines	O
,	O
sedatives	O
,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective	O
.	O

However	O
,	O
a	O
bolus	O
of	O
epinephrine	O
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	B
crisis	O
.	O

Thus	O
,	O
interference	O
with	O
the	O
central	O
venous	O
infusion	O
by	O
the	O
dialysis	O
catheter	O
was	O
suspected	O
.	O

The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	O
doses	O
.	O

When	O
the	O
effects	O
of	O
IV	O
drugs	O
are	O
inadequate	O
in	O
patients	O
receiving	O
CVVHDF	O
,	O
interference	O
with	O
adjacent	O
catheters	O
resulting	O
in	O
elimination	O
of	O
the	O
drug	O
by	O
CVVHDF	O
should	O
be	O
suspected	O
.	O

Less	O
frequent	O
lithium	O
administration	O
and	O
lower	O
urine	O
volume	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	O
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	O
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O

Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	O
level	O
,	O
creatinine	O
clearance	O
,	O
urine	O
volume	O
,	O
and	O
maximum	O
osmolality	O
.	O

RESULTS	O
:	O
Multiple	O
daily	O
doses	O
of	O
lithium	O
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O

The	O
dosing	O
schedule	O
,	O
duration	O
of	O
lithium	O
treatment	O
,	O
and	O
daily	O
dose	O
of	O
lithium	O
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	O
clearance	O
.	O

CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	O
once	O
daily	O
and	O
/	O
or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O

Lithium	O
-	O
induced	O
polyuria	B
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	O
effects	O
.	O

Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	B
defects	I
:	O
National	O
Birth	B
Defects	I
Prevention	O
Study	O
.	O

OBJECTIVE	O
:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	B
defects	I
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Population	O
-	O
based	O
,	O
multisite	O
,	O
case	O
-	O
control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	B
defects	I
identified	O
via	O
birth	B
defect	I
surveillance	O
programs	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(	O
n	O
=	O
4941	O
)	O
.	O

MAIN	O
EXPOSURE	O
:	O
Reported	O
maternal	O
use	O
of	O
antibacterials	O
(	O
1	O
month	O
before	O
pregnancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimester	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O
Odds	O
ratios	O
(	O
ORs	O
)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B
defects	I
adjusted	O
for	O
potential	O
confounders	O
.	O

RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacterials	O
increased	O
during	O
pregnancy	O
,	O
peaking	O
during	O
the	O
third	O
month	O
.	O

Sulfonamides	O
were	O
associated	O
with	O
anencephaly	B
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hypoplastic	B
left	I
heart	I
syndrome	I
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
coarctation	B
of	I
the	I
aorta	I
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
choanal	B
atresia	I
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O

5	O
)	O
,	O
transverse	B
limb	I
deficiency	I
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diaphragmatic	B
hernia	I
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O

Nitrofurantoins	O
were	O
associated	O
with	O
anophthalmia	B
or	O
microphthalmos	B
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hypoplastic	B
left	I
heart	I
syndrome	I
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
atrial	B
septal	I
defects	I
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
cleft	B
lip	I
with	O
cleft	B
palate	I
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O

-	O
3	O
.	O
9	O
)	O
.	O

Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	O
(	O
2	O
defects	O
)	O
,	O
penicillins	O
(	O
1	O
defect	O
)	O
,	O
cephalosporins	O
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	O
(	O
1	O
defect	O
)	O
.	O

CONCLUSIONS	O
:	O
Reassuringly	O
,	O
penicillins	O
,	O
erythromycins	O
,	O
and	O
cephalosporins	O
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women	O
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B
defects	I
.	O

Sulfonamides	O
and	O
nitrofurantoins	O
were	O
associated	O
with	O
several	O
birth	B
defects	I
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrutiny	O
.	O

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	O
-	O
resistant	O
hepatitis	O
B	O
virus	O
e	O
antigen	O
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O

Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B
B	I
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	O
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O

Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	O
(	O
LAM	O
)	O
and	O
/	O
or	O
HBeAg	O
negativity	O
.	O

Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	O
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	O
-	O
positive	O
and	O
an	O
HBeAg	O
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O

The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	O
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	O
-	O
resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	O
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	O
-	O
resistant	O
clones	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	O
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	O
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O

In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	O
resistance	O
mutations	O
,	O
the	O
nucleotide	O
analogues	O
adefovir	O
and	O
tenofovir	O
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O

These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	O
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O

Hemolytic	B
anemia	I
associated	O
with	O
the	O
use	O
of	O
omeprazole	O
.	O

Omeprazole	O
is	O
the	O
first	O
drug	O
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	B
ulcer	I
disease	I
,	O
reflux	B
esophagitis	I
,	O
and	O
the	O
Zollinger	B
-	I
Ellison	I
syndrome	I
.	O

Although	O
clinical	O
experience	O
with	O
omeprazole	O
is	O
still	O
limited	O
,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short	O
-	O
term	O
safety	O
of	O
this	O
drug	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short	O
-	O
term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	O
:	O
hemolytic	B
anemia	I
.	O

The	O
patient	O
developed	O
weakness	O
,	O
lethargy	B
,	O
and	O
shortness	B
of	I
breath	I
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	O
.	O

Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	O
.	O

After	O
she	O
discontinued	O
the	O
omeprazole	O
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal	O
.	O

The	O
mechanism	O
by	O
which	O
omeprazole	O
caused	O
the	O
patient	O
'	O
s	O
hemolytic	B
anemia	I
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O

Phenylephrine	O
but	O
not	O
ephedrine	O
reduces	B
frontal	I
lobe	I
oxygenation	I
following	O
anesthesia	O
-	O
induced	O
hypotension	B
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	O
and	O
ephedrine	O
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	O
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propofol	O
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	O
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	O
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	B
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registered	O
.	O

RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	B
decrease	I
in	I
MAP	I
,	I
HR	I
,	I
SV	I
,	I
and	I
CO	I
concomitant	O
with	O
an	O
elevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
administration	O
of	O
phenylephrine	O
,	O
MAP	O
increased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/	O
-	O
8	O
%	O
to	O
60	O
+	O
/	O
-	O
7	O
%	O
)	O
reduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
administration	O
of	O
ephedrine	O
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
restored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	O
to	O
correct	O
hypotension	B
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	O
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O

Prolonged	O
elevation	O
of	O
plasma	O
argatroban	O
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
with	O
thrombosis	B
.	O

BACKGROUND	O
:	O
Direct	O
thrombin	O
inhibitors	O
(	O
DTIs	O
)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
(	O
HIT	B
)	O
or	O
HIT	B
with	O
thrombosis	B
(	O
HITT	B
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
report	O
,	O
a	O
65	O
-	O
year	O
-	O
old	O
critically	B
ill	I
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	B
was	O
administered	O
argatroban	O
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation	O
.	O

The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh	O
-	O
frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	B
and	I
postoperative	I
bleeding	I
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	O
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O

RESULTS	O
:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	O
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0	O
-	O
32	O
microg	O
/	O
mL	O
)	O
,	O
and	O
a	O
prolonged	O
plasma	O
argatroban	O
half	O
life	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
minutes	O
[	O
<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	B
impairment	I
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Correlation	O
of	O
plasma	O
argatroban	O
concentration	O
versus	O
the	O
patient	O
'	O
s	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	O
may	O
have	O
contributed	O
to	O
the	O
patient	O
'	O
s	O
extended	O
coagulopathy	B
.	O

Because	O
DTIs	O
do	O
not	O
have	O
reversal	O
agents	O
,	O
surgical	O
teams	O
and	O
transfusion	O
services	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
transfusion	O
events	O
during	O
anticoagulation	O
with	O
these	O
agents	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	O
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	B
.	O

The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	O
on	O
male	O
sexual	B
dysfunction	I
induced	O
by	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
and	O
randomized	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	O
sustained	O
-	O
release	O
(	O
SR	O
)	O
on	O
male	O
sexual	B
dysfunction	I
(	O
SD	B
)	O
induced	O
by	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
,	O
as	O
SD	B
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
SSRIs	O
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	O
.	O

The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	O
SR	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
117	O
)	O
or	O
placebo	O
(	O
twice	O
daily	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Sexual	O
Function	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B
Dysfunction	I
Inventory	O
of	O
Treatment	O
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcome	O
measures	O
)	O
.	O

Participants	O
were	O
followed	O
biweekly	O
during	O
study	O
period	O
.	O

RESULTS	O
:	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patients	O
on	O
bupropion	O
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Men	O
who	O
received	O
bupropion	O
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O

Total	O
ASEX	O
scores	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
men	O
who	O
received	O
bupropion	O
than	O
placebo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
EDITS	O
scores	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
bupropion	O
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
ASEX	O
score	O
and	O
CGI	O
-	O
SF	O
score	O
were	O
correlated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
linear	O
regression	O
analyses	O
the	O
CGI	O
-	O
SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	B
,	O
type	O
of	O
SSRI	O
used	O
and	O
age	O
.	O

CONCLUSIONS	O
:	O
Bupropion	O
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	B
induced	O
by	O
SSRIs	O
.	O

These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	O
.	O

Prevention	O
of	O
seizures	B
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	B
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMCs	O
)	O
in	O
a	O
model	O
of	O
epilepsy	B
induced	O
by	O
pilocarpine	O
in	O
rats	O
.	O

BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	B
epilepticus	I
(	O
SE	B
)	O
.	O

Spontaneous	B
recurrent	I
seizures	I
(	O
SRS	B
)	O
were	O
monitored	O
using	O
Racine	O
'	O
s	O
seizure	B
severity	O
scale	O
.	O

All	O
of	O
the	O
rats	O
in	O
the	O
saline	O
-	O
treated	O
epileptic	B
control	O
group	O
developed	O
SRS	B
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	B
animals	O
had	O
seizures	B
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O

Over	O
the	O
long	O
-	O
term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treated	O
epileptic	B
animals	O
had	O
seizures	B
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	B
control	O
group	O
.	O

The	O
density	O
of	O
hippocampal	O
neurons	O
in	O
the	O
brains	O
of	O
animals	O
treated	O
with	O
BMCs	O
was	O
markedly	O
preserved	O
.	O

At	O
hippocampal	O
Schaeffer	O
collateral	O
-	O
CA1	O
synapses	O
,	O
long	O
-	O
term	O
potentiation	O
was	O
preserved	O
in	O
BMC	O
-	O
transplanted	O
rats	O
compared	O
to	O
epileptic	B
controls	O
.	O

The	O
donor	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	B
rats	O
.	O

In	O
conclusion	O
,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	B
,	O
reduce	O
neuronal	B
loss	I
,	O
and	O
influence	O
the	O
reorganization	O
of	O
the	O
hippocampal	O
neuronal	O
network	O
.	O

Normalizing	O
effects	O
of	O
modafinil	O
on	O
sleep	O
in	O
chronic	O
cocaine	O
users	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	O
on	O
sleep	O
and	O
daytime	B
sleepiness	I
in	O
chronic	O
cocaine	O
users	O
.	O

METHOD	O
:	O
Twenty	O
cocaine	O
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	O
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
placebo	O
(	O
N	O
=	O
10	O
)	O
every	O
morning	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
days	O
in	O
an	O
inpatient	O
,	O
double	O
-	O
blind	O
randomized	O
trial	O
.	O

Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeks	O
of	O
abstinence	O
)	O
.	O

The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.	O
,	O
2	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
on	O
days	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O

For	O
comparison	O
of	O
sleep	O
architecture	O
variables	O
,	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography	O
.	O

RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	O
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O

Compared	O
with	O
placebo	O
,	O
modafinil	O
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	O
-	O
dependent	O
participants	O
.	O

The	O
effect	O
of	O
modafinil	O
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O

Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine	O
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	O
in	O
cocaine	O
-	O
dependent	O
participants	O
.	O

Modafinil	O
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B
sleepiness	I
.	O

CONCLUSIONS	O
:	O
Morning	O
-	O
dosed	O
modafinil	O
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B
sleepiness	I
in	O
abstinent	O
cocaine	O
users	O
.	O

These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	O
dependence	O
.	O

Safety	O
of	O
transesophageal	O
echocardiography	O
in	O
adults	O
:	O
study	O
in	O
a	O
multidisciplinary	O
hospital	O
.	O

BACKGROUND	O
:	O
TEE	O
is	O
a	O
semi	O
-	O
invasive	O
tool	O
broadly	O
used	O
and	O
its	O
utilization	O
associated	O
to	O
sedatives	O
drugs	O
might	O
to	O
affect	O
the	O
procedure	O
safety	O
.	O

OBJECTIVE	O
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	O
(	O
MZ	O
)	O
and	O
Flumazenil	O
(	O
FL	O
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate	O
.	O

METHOD	O
:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	O
associated	O
to	O
moderate	O
sedation	O
.	O

We	O
analyzed	O
the	O
following	O
events	O
:	O
complications	O
related	O
with	O
the	O
topical	O
anesthesia	O
,	O
with	O
MZ	O
use	O
and	O
with	O
the	O
procedure	O
.	O

Uni	O
-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	B
,	O
myocardiopathy	B
(	O
MP	B
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B
regurgitation	I
(	O
MR	B
)	O
and	O
the	O
MZ	O
dose	O
.	O

RESULTS	O
:	O
All	O
patients	O
(	O
65	O
+	O
/	O
-	O
16	O
yrs	O
;	O
58	O
%	O
males	O
)	O
finished	O
the	O
examination	O
.	O

The	O
mean	O
doses	O
of	O
MZ	O
and	O
FL	O
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

The	O
duration	O
of	O
the	O
examination	O
and	O
the	O
mean	O
ejection	O
fraction	O
(	O
EF	O
)	O
were	O
16	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
minutes	O
and	O
60	O
+	O
/	O
-	O
9	O
%	O
,	O
respectively	O
.	O

Mild	O
hypoxia	B
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
event	O
(	O
11	O
patients	O
)	O
;	O
3	O
patients	O
(	O
2	O
%	O
)	O
presented	O
transient	O
hypoxia	B
due	O
to	O
upper	O
airway	B
obstruction	I
by	O
probe	O
introduction	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
hypoxia	B
caused	O
by	O
MZ	O
use	O
.	O

Transient	O
hypotension	B
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
patient	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O

The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	B
,	O
MP	B
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
doses	O
of	O
MZ	O
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
group	O
with	O
MP	B
and	O
44	O
%	O
in	O
the	O
group	O
with	O
severe	O
MR	B
and	O
it	O
can	O
be	O
a	O
factor	O
associated	O
with	O
clinical	O
events	O
in	O
the	O
last	O
group	O
.	O

CONCLUSION	O
:	O
TEE	O
with	O
sedation	O
presents	O
a	O
low	O
rate	O
of	O
events	O
.	O

There	O
were	O
no	O
severe	O
events	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examinations	O
.	O

Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	O
in	O
patients	O
with	O
and	O
without	O
variant	B
angina	I
.	O

The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	O
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	B
angina	I
and	O
22	O
patients	O
with	O
atypical	O
chest	B
pain	I
and	O
in	O
others	O
without	O
angina	B
pectoris	I
(	O
control	O
group	O
)	O
.	O

Methylergonovine	O
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms	O
/	O
min	O
up	O
to	O
50	O
micrograms	O
.	O

In	O
all	O
patients	O
with	O
variant	B
angina	I
,	O
coronary	B
spasm	I
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+	O
/	O
-	O
13	O
micrograms	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

In	O
the	O
control	O
group	O
neither	O
ischemic	O
ST	O
change	O
nor	O
localized	O
spasm	B
occurred	O
.	O

The	O
basal	O
tone	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

The	O
percentage	O
of	O
vasoconstriction	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

These	O
results	O
suggest	O
that	O
spasm	B
provocation	O
tests	O
,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	O
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	B
angina	I
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	O
artery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
coronary	O
arteries	O
.	O

Oral	O
manifestations	O
of	O
"	O
meth	B
mouth	I
"	O
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
"	O
meth	B
mouth	I
"	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O

BACKGROUND	O
:	O
Methamphetamine	O
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	B
dysrhythmias	I
,	O
hypertension	B
,	O
hallucinations	B
,	O
and	O
violent	B
behavior	I
.	O

Dental	O
patients	O
abusing	O
methamphetamine	O
can	O
present	O
with	O
poor	O
oral	O
hygiene	O
,	O
xerostomia	B
,	O
rampant	O
caries	B
(	O
"	O
meth	B
mouth	I
"	O
)	O
,	O
and	O
excessive	O
tooth	B
wear	I
.	O

Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	O
can	O
be	O
challenging	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	B
,	O
bad	B
breath	I
,	O
and	O
self	O
-	O
reported	O
poor	O
esthetics	O
.	O

A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history	O
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	B
lesions	I
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult	O
.	O

She	O
reported	O
her	O
use	O
of	O
methamphetamine	O
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	B
episodes	I
before	O
she	O
started	O
using	O
the	O
drug	O
.	O

SUMMARY	O
:	O
The	O
patient	O
'	O
s	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	O
to	O
a	O
diagnosis	O
of	O
"	O
meth	B
mouth	I
.	O
"	O
Although	O
three	O
different	O
dental	O
treatment	O
modalities	O
(	O
either	O
conventional	O
or	O
implant	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patient	O
since	O
August	O
2007	O
,	O
the	O
patient	O
has	O
yet	O
to	O
initiate	O
any	O
treatment	O
.	O

CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinical	O
case	O
showing	O
oral	O
manifestations	O
of	O
meth	B
mouth	I
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	O
.	O

Dental	O
practitioners	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliability	O
of	O
appointment	O
keeping	O
by	O
these	O
patients	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appointments	O
without	O
reasonable	O
justification	O
.	O

Antituberculosis	O
therapy	O
-	O
induced	O
acute	B
liver	I
failure	I
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O

Antituberculosis	O
therapy	O
(	O
ATT	O
)	O
-	O
associated	O
acute	B
liver	I
failure	I
(	O
ATT	O
-	O
ALF	B
)	O
is	O
the	O
commonest	O
drug	O
-	O
induced	O
ALF	B
in	O
South	O
Asia	O
.	O

Prospective	O
studies	O
on	O
ATT	O
-	O
ALF	B
are	O
lacking	O
.	O

The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT	O
-	O
ALF	B
.	O

From	O
January	O
1986	O
to	O
January	O
2009	O
,	O
1223	O
consecutive	O
ALF	B
patients	O
were	O
evaluated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
patients	O
.	O

Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B
virus	I
infection	I
.	O

In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
patients	O
,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	B
.	O

ATT	O
-	O
ALF	B
patients	O
were	O
younger	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
years	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
women	O
.	O

Most	O
had	O
hyperacute	O
presentation	O
;	O
the	O
median	O
icterus	B
encephalopathy	B
interval	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
days	O
.	O

The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	B
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	O
.	O

At	O
presentation	O
,	O
advanced	O
encephalopathy	B
and	O
cerebral	B
edema	I
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Gastrointestinal	B
bleed	I
,	O
seizures	B
,	O
infection	B
,	O
and	O
acute	B
renal	I
failure	I
were	O
documented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Compared	O
with	O
hepatitis	B
E	I
virus	O
(	O
HEV	O
)	O
and	O
non	O
-	O
A	O
non	O
-	O
E	O
-	O
induced	O
ALF	B
,	O
ATT	O
-	O
ALF	B
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes	O
.	O

The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT	O
-	O
ALF	B
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
patients	O
recovered	O
with	O
medical	O
treatment	O
.	O

In	O
multivariate	O
analysis	O
,	O
three	O
factors	O
independently	O
predicted	O
mortality	O
:	O
serum	O
bilirubin	O
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
grade	O
III	O
/	O
IV	O
encephalopathy	B
at	O
presentation	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	B
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	B
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O

Because	O
the	O
mortality	O
rate	O
is	O
so	O
high	O
,	O
determining	O
which	O
factors	O
are	O
predictors	O
is	O
less	O
important	O
.	O

A	O
high	O
proportion	O
of	O
patients	O
had	O
consumed	O
ATT	O
empirically	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Design	O
and	O
analysis	O
of	O
the	O
HYPREN	O
-	O
trial	O
:	O
safety	O
of	O
enalapril	O
and	O
prazosin	O
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	B
heart	I
failure	I
.	O

Since	O
the	O
introduction	O
of	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	B
heart	I
failure	I
,	O
cases	O
of	O
severe	O
hypotension	B
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	O
inhibitor	O
enalapril	O
a	O
multicenter	O
,	O
randomized	O
,	O
prazosin	O
-	O
controlled	O
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	B
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O

Trial	O
medication	O
was	O
2	O
.	O
5	O
mg	O
enalapril	O
or	O
0	O
.	O
5	O
prazosin	O
.	O

Subjects	O
were	O
1210	O
inpatients	O
with	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
functional	O
class	O
II	O
and	O
III	O
.	O

Patients	O
who	O
received	O
enalapril	O
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	B
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	O
(	O
12	O
.	O
9	O
%	O
)	O
.	O

All	O
patients	O
recovered	O
.	O

It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	O
was	O
well	O
tolerated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	O
to	O
inpatients	O
.	O

Central	B
nervous	I
system	I
complications	I
during	O
treatment	O
of	O
acute	B
lymphoblastic	I
leukemia	I
in	O
a	O
single	O
pediatric	O
institution	O
.	O

Central	B
nervous	I
system	I
(	I
CNS	I
)	I
complications	I
during	O
treatment	O
of	O
childhood	O
acute	B
lymphoblastic	I
leukemia	I
(	O
ALL	B
)	O
remain	O
a	O
challenging	O
clinical	O
problem	O
.	O

Outcome	O
improvement	O
with	O
more	O
intensive	O
chemotherapy	O
has	O
significantly	O
increased	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
events	O
.	O

This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	B
complications	I
during	O
ALL	B
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O

Exclusion	O
criteria	O
included	O
CNS	O
leukemic	B
infiltration	I
at	O
diagnosis	O
,	O
therapy	O
-	O
related	O
peripheral	B
neuropathy	I
,	O
late	O
-	O
onset	O
encephalopathy	B
,	O
or	O
long	O
-	O
term	O
neurocognitive	B
defects	I
.	O

During	O
a	O
9	O
-	O
year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	B
front	O
-	O
line	O
protocol	O
.	O

CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	B
syndrome	O
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B
lobe	I
epilepsy	I
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dose	O
methotrexate	O
toxicity	B
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	O
of	O
inappropriate	B
antidiuretic	I
hormone	I
secretion	I
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	B
therapy	O
,	O
and	O
require	O
rapid	O
detection	O
and	O
prompt	O
treatment	O
to	O
limit	O
permanent	O
damage	O
.	O

Cocaine	O
causes	O
memory	B
and	I
learning	I
impairments	I
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	O
.	O

Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	O
toxicity	B
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	O
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	B
and	O
addiction	O
mechanisms	O
.	O

Therefore	O
NFkappaB	O
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	O
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B
addiction	I
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	O
administration	O
in	O
rats	O
.	O

NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	O
treated	O
rats	O
,	O
as	O
well	O
as	O
GSH	O
concentration	O
and	O
glutathione	O
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	O
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	O
peroxidase	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	O
.	O

Topiramate	O
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O

Efficacy	O
and	O
safety	O
of	O
asenapine	O
in	O
a	O
placebo	O
-	O
and	O
haloperidol	O
-	O
controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B
.	O

Asenapine	O
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B
or	O
of	O
manic	B
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B
I	I
disorder	I
with	O
or	O
without	O
psychotic	B
features	O
.	O

In	O
a	O
double	O
-	O
blind	O
6	O
-	O
week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	B
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	O
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	O
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	O
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O

With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	O
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
haloperidol	O
(	O
-	O
15	O
.	O
4	O
)	O
than	O
placebo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O

haloperidol	O
(	O
-	O
20	O
.	O
0	O
)	O
than	O
placebo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	O
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O

Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	O
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Extrapyramidal	B
symptoms	I
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	O
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Across	O
all	O
groups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	O
had	O
clinically	O
significant	O
weight	O
change	O
.	O

Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	O
and	O
haloperidol	O
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B
symptoms	I
.	O

Salvage	O
therapy	O
with	O
nelarabine	O
,	O
etoposide	O
,	O
and	O
cyclophosphamide	O
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	B
-	I
cell	I
lymphoblastic	I
leukaemia	I
and	I
lymphoma	I
.	O

A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	O
(	O
AraG	O
)	O
with	O
5	O
d	O
of	O
etoposide	O
(	O
VP	O
)	O
and	O
cyclophosphamide	O
(	O
CPM	O
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	B
-	I
cell	I
leukaemia	I
or	I
lymphoma	I
.	O

The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	O
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	B
and	O
musculoskeletal	B
pain	I
.	O

Haematological	B
toxicity	I
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	O
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O

All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	O
/	O
VP	O
/	O
CPM	O
.	O

Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	O
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	O
and	O
cyclophosphamide	O
,	O
although	O
neurological	B
toxicity	I
must	O
be	O
closely	O
monitored	O
.	O

Effect	O
of	O
adriamycin	O
combined	O
with	O
whole	O
body	O
hyperthermia	B
on	O
tumor	B
and	O
normal	O
tissues	O
.	O

Thermal	O
enhancement	O
of	O
Adriamycin	O
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	B
by	O
whole	O
body	O
hyperthermia	B
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O

Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	B
growth	O
delay	O
assay	O
.	O

Acute	O
normal	O
tissue	O
toxicities	B
(	O
i	O
.	O
e	O
.	O
,	O
leukopenia	B
and	O
thrombocytopenia	B
)	O
and	O
late	O
normal	O
tissue	O
toxicities	B
(	O
i	O
.	O
e	O
.	O
,	O
myocardial	B
and	I
kidney	I
injury	I
)	O
were	O
evaluated	O
by	O
functional	O
/	O
physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O

Whole	O
body	O
hyperthermia	B
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degrees	O
C	O
)	O
enhanced	O
both	O
Adriamycin	O
-	O
mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects	O
.	O

The	O
thermal	O
enhancement	O
ratio	O
calculated	O
for	O
antitumor	O
activity	O
was	O
1	O
.	O
6	O
.	O

Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
"	O
acute	O
"	O
hematological	O
changes	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimated	O
for	O
"	O
late	O
"	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	B
and	I
renal	I
lesions	I
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O

Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	B
enhances	O
Adriamycin	O
-	O
mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	B
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O

Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	O
aminonucleoside	O
nephrosis	B
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B
starts	O
.	O

Using	O
puromycin	O
aminonucleoside	O
nephrosis	B
(	O
PAN	O
)	O
rats	O
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	O
,	O
a	O
-	O
actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O

METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O

Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O

Possible	O
effects	O
of	O
ACE	O
inhibition	O
were	O
tested	O
.	O

RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B
,	O
appeared	O
.	O

The	O
amount	O
of	O
nephrin	O
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O

The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O

By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O

Nephrin	O
decreased	O
further	O
,	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	O
but	O
a	O
-	O
actinin	O
remained	O
unchanged	O
.	O

ACE	O
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O

CONCLUSIONS	O
:	O
PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B
.	O

This	O
was	O
preceded	O
by	O
altered	O
nephrin	O
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O

The	O
novel	O
proteins	O
dendrin	O
and	O
plekhh2	O
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
actinin	O
was	O
unchanged	O
.	O

A	O
novel	O
,	O
multiple	O
symptom	O
model	O
of	O
obsessive	B
-	I
compulsive	I
-	I
like	I
behaviors	I
in	O
animals	O
.	O

BACKGROUND	O
:	O
Current	O
animal	O
models	O
of	O
obsessive	B
-	I
compulsive	I
disorder	I
(	O
OCD	B
)	O
typically	O
involve	O
acute	O
,	O
drug	O
-	O
induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	B
.	O

None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD	B
-	O
like	O
behaviors	O
.	O

METHODS	O
:	O
Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	O
clomipramine	O
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood	O
.	O

RESULTS	O
:	O
Clomipramine	O
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	B
(	O
elevated	O
plus	O
maze	O
and	O
marble	O
burying	O
)	O
,	O
behavioral	B
inflexibility	I
(	O
perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning	O
)	O
,	O
working	O
memory	B
impairment	I
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
paradigm	O
)	O
,	O
hoarding	B
,	O
and	O
corticostriatal	B
dysfunction	I
.	O

Dopamine	O
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum	O
,	O
whereas	O
serotonin	O
2C	O
,	O
but	O
not	O
serotonin	O
1A	O
,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD	B
-	O
like	O
profile	O
in	O
animals	O
.	O

Moreover	O
,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	B
.	O

This	O
novel	O
model	O
of	O
OCD	B
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease	O
-	O
like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B
disorders	I
.	O

Elevation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	O
-	O
induced	O
thoracic	B
aortic	I
aneurysm	I
in	O
a	O
rat	O
model	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B
aortic	I
aneurysm	I
(	O
TAA	B
)	O
by	O
calcium	O
chloride	O
(	O
CaCl	O
(	O
2	O
)	O
)	O
-	O
induced	O
arterial	B
injury	I
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B
formation	O
.	O

METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
was	O
exposed	O
to	O
0	O
.	O
5M	O
CaCl	O
(	O
2	O
)	O
or	O
normal	O
saline	O
(	O
NaCl	O
)	O
.	O

After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	O
(	O
2	O
)	O
-	O
treated	O
,	O
CaCl	O
(	O
2	O
)	O
-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	O
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O

MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	O
(	O
2	O
)	O
-	O
treated	O
,	O
non	O
-	O
CaCl	O
(	O
2	O
)	O
-	O
treated	O
and	O
NaCl	O
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl	O
(	O
2	O
)	O
-	O
treated	O
segments	O
.	O

MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	O
(	O
2	O
)	O
-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	O
(	O
2	O
)	O
-	O
untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	O
-	O
treated	O
segments	O
.	O

Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	O
(	O
2	O
)	O
-	O
treated	O
segments	O
.	O

TIMP	O
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O

CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B
model	O
by	O
periarterial	O
CaCl	O
(	O
2	O
)	O
exposure	O
in	O
rats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O

Suxamethonium	O
induced	O
prolonged	O
apnea	B
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy	O
.	O

Suxamethonium	O
causes	O
prolonged	O
apnea	B
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	O
(	O
OP	O
)	O
poisons	O
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	B
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Prolonged	O
apnea	B
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	O
compound	O
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O

Curcumin	O
ameliorates	O
cognitive	B
dysfunction	I
and	O
oxidative	O
damage	O
in	O
phenobarbitone	O
and	O
carbamazepine	O
administered	O
rats	O
.	O

The	O
antiepileptic	O
drugs	O
,	O
phenobarbitone	O
and	O
carbamazepine	O
are	O
well	O
known	O
to	O
cause	O
cognitive	B
impairment	I
on	O
chronic	O
use	O
.	O

The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B
impairment	I
by	O
antiepileptic	O
drugs	O
.	O

Curcumin	O
has	O
shown	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
neuro	O
-	O
protective	O
properties	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	O
administration	O
on	O
phenobarbitone	O
-	O
and	O
carbamazepine	O
-	O
induced	O
cognitive	B
impairment	I
and	O
oxidative	O
stress	O
in	O
rats	O
.	O

Pharmacokinetic	O
interactions	O
of	O
curcumin	O
with	O
phenobarbitone	O
and	O
carbamazepine	O
were	O
also	O
studied	O
.	O

Vehicle	O
/	O
drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats	O
.	O

Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
.	O

At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	O
and	O
carbamazepine	O
,	O
whole	O
brain	O
malondialdehyde	O
and	O
reduced	O
glutathione	O
levels	O
were	O
estimated	O
.	O

The	O
administration	O
of	O
phenobarbitone	O
and	O
carbamazepine	O
for	O
21days	O
caused	O
a	O
significant	O
impairment	B
of	I
learning	I
and	I
memory	I
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O

Concomitant	O
curcumin	O
administration	O
prevented	O
the	O
cognitive	B
impairment	I
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs	O
.	O

Curcumin	O
co	O
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	O
as	O
well	O
as	O
carbamazepine	O
.	O

These	O
results	O
show	O
that	O
curcumin	O
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B
of	I
cognitive	I
functions	I
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	O
and	O
carbamazepine	O
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O

The	O
findings	O
suggest	O
that	O
curcumin	O
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	O
and	O
carbamazepine	O
therapy	O
in	O
preventing	O
cognitive	B
impairment	I
associated	O
with	O
these	O
drugs	O
.	O

Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	O
associated	O
hemolytic	B
anemia	I
?	O

BACKGROUND	O
/	O
AIMS	O
:	O
Recently	O
ribavirin	O
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	O
inhibitors	O
such	O
as	O
sunitinib	O
and	O
sorafenib	O
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	B
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	B
.	O

METHODS	O
:	O
Fourteen	O
patients	O
chronically	B
infected	I
with	I
hepatitis	I
C	I
virus	I
were	O
treated	O
by	O
pegylated	O
interferon	O
alpha	O
2a	O
and	O
ribavirin	O
.	O

Serum	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
markers	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
angiopoetin	O
-	O
2	O
were	O
investigated	O
before	O
and	O
after	O
therapy	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
haptoglobin	O
levels	O
at	O
the	O
end	O
of	O
the	O
treatment	O
period	O
.	O

Hemoglobin	O
levels	O
also	O
decreased	O
but	O
insignificantly	O
by	O
treatment	O
.	O

In	O
contrast	O
with	O
the	O
literature	O
,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	O
interferon	O
and	O
ribavirin	O
therapy	O
.	O

We	O
found	O
no	O
correlation	O
of	O
angiogenesis	O
soluble	O
markers	O
with	O
either	O
hemoglobin	O
or	O
haptoglobin	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	O
induced	O
anemia	B
in	O
patients	O
with	O
hepatitis	B
C	I
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	O
therapy	O
.	O

Reduction	O
in	O
injection	O
pain	B
using	O
buffered	O
lidocaine	O
as	O
a	O
local	O
anesthetic	O
before	O
cardiac	O
catheterization	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
pain	B
associated	O
with	O
the	O
injection	O
of	O
lidocaine	O
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	O
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	B
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O

Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	B
after	O
receiving	O
standard	O
lidocaine	O
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	O
in	O
the	O
opposite	O
femoral	O
area	O
.	O

The	O
mean	O
pain	B
score	O
for	O
buffered	O
lidocaine	O
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	O
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	O
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O

Effect	O
of	O
L	O
-	O
alpha	O
-	O
glyceryl	O
-	O
phosphorylcholine	O
on	O
amnesia	B
caused	O
by	O
scopolamine	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L	O
-	O
alpha	O
-	O
glycerylphosphorylcholine	O
(	O
L	O
-	O
alpha	O
-	O
GFC	O
)	O
on	O
memory	B
impairment	I
induced	O
by	O
scopolamine	O
in	O
man	O
.	O

Thirty	O
-	O
two	O
healthy	O
young	O
volunteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
groups	O
.	O

They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L	O
-	O
alpha	O
-	O
GFC	O
or	O
placebo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	O
or	O
placebo	O
,	O
i	O
.	O
m	O
.	O

Before	O
and	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injection	O
the	O
subjects	O
were	O
given	O
attention	O
and	O
mnemonic	O
tests	O
.	O

The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
the	O
drug	O
is	O
able	O
to	O
antagonize	O
impairment	B
of	I
attention	I
and	I
memory	I
induced	O
by	O
scopolamine	O
.	O

Safety	O
of	O
capecitabine	O
:	O
a	O
review	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	O
,	O
in	O
particular	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B
,	O
including	O
colorectal	B
,	I
breast	I
and	I
head	I
and	I
neck	I
cancers	I
,	O
for	O
>	O
40	O
years	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	O
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	O
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	B
and	I
kidney	I
disease	I
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	O
administration	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	O
is	O
an	O
oral	O
prodrug	O
of	O
5	O
-	O
FU	O
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O

It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B
,	I
breast	I
,	I
pancreaticobiliary	I
,	I
gastric	I
,	I
renal	I
cell	I
and	I
head	I
and	I
neck	I
cancers	I
.	O

The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	O
are	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
stomatitis	B
and	O
hand	B
-	I
foot	I
syndrome	I
.	O

Capecitabine	O
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B
and	I
renal	I
dysfunctions	I
.	O

Levodopa	O
-	O
induced	O
dyskinesias	B
in	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
:	O
filling	O
the	O
bench	O
-	O
to	O
-	O
bedside	O
gap	O
.	O

Levodopa	O
is	O
the	O
most	O
effective	O
drug	O
for	O
the	O
treatment	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamine	O
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	B
.	O

Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa	O
-	O
induced	O
dyskinesias	B
,	O
their	O
pathogenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
years	O
,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson	B
'	I
s	I
disease	I
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post	O
-	O
receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	B
movements	I
.	O

Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms	O
,	O
dopamine	O
receptor	O
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	O
receptors	O
,	O
and	O
non	O
-	O
dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa	O
-	O
induced	O
dyskinesias	B
.	O

Effects	O
of	O
pallidal	O
neurotensin	O
on	O
haloperidol	O
-	O
induced	O
parkinsonian	B
catalepsy	I
:	O
behavioral	O
and	O
electrophysiological	O
studies	O
.	O

OBJECTIVE	O
:	O
The	O
globus	O
pallidus	O
plays	O
a	O
critical	O
role	O
in	O
movement	O
regulation	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	O
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	O
on	O
haloperidol	O
-	O
induced	O
parkinsonian	B
symptoms	I
.	O

METHODS	O
:	O
Behavioral	O
experiments	O
and	O
electrophysiological	O
recordings	O
were	O
performed	O
in	O
the	O
present	O
study	O
.	O

RESULTS	O
:	O
Bilateral	O
infusions	O
of	O
neurotensin	O
into	O
the	O
globus	O
pallidus	O
reversed	O
haloperidol	O
-	O
induced	O
parkinsonian	B
catalepsy	I
in	O
rats	O
.	O

Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	O
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	O
administration	O
.	O

The	O
neurotensin	O
type	O
-	O
1	O
receptor	O
antagonist	O
SR48692	O
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	O
.	O

CONCLUSION	O
:	O
Activation	O
of	O
pallidal	O
neurotensin	O
receptors	O
may	O
be	O
involved	O
in	O
neurotensin	O
-	O
induced	O
antiparkinsonian	O
effects	O
.	O

Carmofur	O
-	O
induced	O
organic	B
mental	I
disorders	I
.	O

Organic	B
mental	I
disorder	I
was	O
observed	O
in	O
a	O
29	O
-	O
year	O
-	O
old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur	O
-	O
induced	O
leukoencephalopathy	B
.	O

Symptoms	O
such	O
as	O
euphoria	O
,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	B
personality	I
syndrome	I
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
frontal	B
lobe	I
syndrome	I
.	O

Brain	O
CT	O
revealed	O
a	O
periventricular	O
low	O
density	O
area	O
in	O
the	O
frontal	O
white	O
matter	O
and	O
moderate	O
dilatation	O
of	O
the	O
lateral	O
ventricles	O
especially	O
at	O
the	O
bilateral	O
anterior	O
horns	O
.	O

Consequently	O
,	O
carmofur	O
-	O
induced	O
leukoencephalopathy	B
may	O
uncommonly	O
result	O
in	O
organic	B
personality	I
syndrome	I
in	O
the	O
residual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
structural	B
damage	I
to	I
the	I
frontal	I
lobe	I
.	O

Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	B
after	O
succinylcholine	O
for	O
electroconvulsive	O
therapy	O
.	O

BACKGROUND	O
:	O
patients	O
undergoing	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholine	O
as	O
part	O
of	O
the	O
anesthetic	O
procedure	O
.	O

The	O
duration	O
of	O
action	O
may	O
be	O
prolonged	O
in	O
patients	O
with	O
genetic	O
variants	O
of	O
the	O
butyrylcholinesterase	O
enzyme	O
(	O
BChE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K	O
-	O
and	O
the	O
A	O
-	O
variants	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(	O
BCHE	O
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	O
after	O
ECT	O
.	O

METHODS	O
:	O
a	O
total	O
of	O
13	O
patients	O
were	O
referred	O
to	O
the	O
Danish	O
Cholinesterase	O
Research	O
Unit	O
after	O
ECT	O
during	O
38	O
months	O
.	O

We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods	O
,	O
the	O
duration	O
of	O
apnea	B
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used	O
.	O

The	O
duration	O
of	O
apnea	B
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O

RESULTS	O
:	O
in	O
11	O
patients	O
,	O
mutations	O
were	O
found	O
in	O
the	O
BCHE	O
gene	O
,	O
the	O
K	O
-	O
variant	O
being	O
the	O
most	O
frequent	O
.	O

The	O
duration	O
of	O
apnea	B
was	O
5	O
-	O
15	O
min	O
compared	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
literature	O
.	O

Severe	O
distress	O
was	O
noted	O
in	O
the	O
recovery	O
phase	O
in	O
two	O
patients	O
.	O

Neuromuscular	O
monitoring	O
was	O
used	O
in	O
two	O
patients	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	O
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B
.	O

We	O
recommend	O
objective	O
neuromuscular	O
monitoring	O
during	O
the	O
first	O
ECT	O
.	O

Perhexiline	O
maleate	O
and	O
peripheral	B
neuropathy	I
.	O

Peripheral	B
neuropathy	I
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	O
maleate	O
,	O
a	O
drug	O
widely	O
used	O
in	O
France	O
(	O
and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	B
pectoris	I
.	O

In	O
24	O
patients	O
with	O
this	O
complication	O
,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B
disorder	I
.	O

Improvement	O
was	O
noted	O
with	O
cessation	O
of	O
therapy	O
.	O

In	O
a	O
few	O
cases	O
the	O
presence	O
of	O
active	O
denervation	O
signified	O
a	O
poor	O
prognosis	O
,	O
with	O
only	O
slight	O
improvement	O
.	O

The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	B
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidence	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	O
storage	O
process	O
.	O

A	O
phase	O
I	O
study	O
of	O
4	O
'	O
-	O
0	O
-	O
tetrahydropyranyladriamycin	O
.	O

Clinical	O
pharmacology	O
and	O
pharmacokinetics	O
.	O

A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
bolus	O
4	O
'	O
-	O
0	O
-	O
tetrahydropyranyladriamycin	O
(	O
Pirarubicin	O
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	B
.	O

Twenty	O
-	O
six	O
had	O
minimal	O
prior	O
therapy	O
(	O
good	O
risk	O
)	O
,	O
23	O
had	O
extensive	O
prior	O
therapy	O
(	O
poor	O
risk	O
)	O
,	O
and	O
six	O
had	O
renal	B
and	I
/	I
or	I
hepatic	I
dysfunction	I
.	O

A	O
total	O
of	O
167	O
courses	O
at	O
doses	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
evaluable	O
.	O

Maximum	O
tolerated	O
dose	O
in	O
good	O
-	O
risk	O
patients	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
poor	O
-	O
risk	O
patients	O
,	O
60	O
mg	O
/	O
m2	O
.	O

The	O
dose	O
-	O
limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	B
.	O

Granulocyte	O
nadir	O
was	O
on	O
day	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O

Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	B
,	O
anemia	B
,	O
nausea	B
,	O
mild	O
alopecia	B
,	O
phlebitis	B
,	O
and	O
mucositis	B
.	O

Myelosuppression	B
was	O
more	O
in	O
patients	O
with	O
hepatic	B
dysfunction	I
.	O

Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	O
plasma	O
T	O
1	O
/	O
2	O
alpha	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minutes	O
,	O
T	O
beta	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
minutes	O
,	O
and	O
T	O
1	O
/	O
2	O
gamma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O

The	O
area	O
under	O
the	O
curve	O
was	O
537	O
+	O
/	O
-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
volume	O
of	O
distribution	O
(	O
Vd	O
)	O
3504	O
+	O
/	O
-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
clearance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39	O
.	O
3	O
l	O
/	O
hour	O
/	O
m2	O
.	O

Adriamycinol	O
,	O
doxorubicin	O
,	O
adriamycinone	O
,	O
and	O
tetrahydropyranyladriamycinol	O
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	O
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O

Urinary	O
excretion	O
of	O
Pirarubicin	O
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
.	O

Activity	O
was	O
noted	O
in	O
mesothelioma	B
,	O
leiomyosarcoma	B
,	O
and	O
basal	B
cell	I
carcinoma	I
.	O

The	O
recommended	O
starting	O
dose	O
for	O
Phase	O
II	O
trials	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
bolus	O
every	O
3	O
weeks	O
.	O

Ocular	B
and	I
auditory	I
toxicity	I
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	O
.	O

During	O
an	O
18	O
-	O
month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	O
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
weekly	O
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	B
toxicity	I
.	O

6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	B
or	I
auditory	I
toxicity	I
.	O

Moreover	O
,	O
detailed	O
ophthalmologic	O
and	O
audiologic	O
studies	O
disclosed	O
abnormalities	O
in	O
7	O
more	O
asymptomatic	O
patients	O
.	O

Visual	B
toxicity	I
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan	O
-	O
type	O
dyschromatopsy	B
,	O
sometimes	O
associated	O
with	O
a	B
loss	I
of	I
visual	I
acuity	I
and	O
pigmentary	B
retinal	I
deposits	I
.	O

Auditory	B
toxicity	I
was	O
characterized	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
frequency	O
neurosensorial	B
hearing	I
loss	I
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type	O
.	O

Desferrioxamine	O
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	B
loss	I
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O

This	O
toxicity	B
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	O
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	O
serum	O
levels	O
.	O

The	O
data	O
indicate	O
that	O
audiovisual	B
toxicity	I
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	O
.	O

Periodical	O
audiovisual	O
monitoring	O
should	O
be	O
performed	O
on	O
hemodialyzed	O
patients	O
receiving	O
the	O
drug	O
in	O
order	O
to	O
detect	O
adverse	O
effects	O
as	O
early	O
as	O
possible	O
.	O

Serial	O
epilepsy	B
caused	O
by	O
levodopa	O
/	O
carbidopa	O
administration	O
in	O
two	O
patients	O
on	O
hemodialysis	O
.	O

Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented	O
:	O
both	O
patients	O
had	O
chronic	B
renal	I
failure	I
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa	O
/	O
levodopa	O
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	B
and	O
recurrent	O
seizures	B
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants	O
.	O

The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	O
B6	O
.	O

Neither	O
patient	O
was	O
considered	O
to	O
have	O
a	O
renal	O
state	O
sufficiently	O
severe	O
enough	O
to	O
explain	O
their	O
presentation	O
.	O

Randomized	O
,	O
double	O
-	O
blind	O
trial	O
of	O
mazindol	O
in	O
Duchenne	B
dystrophy	I
.	O

There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	B
in	O
Duchenne	B
dystrophy	I
.	O

We	O
conducted	O
a	O
12	O
-	O
month	O
controlled	O
trial	O
of	O
mazindol	O
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor	O
,	O
in	O
83	O
boys	O
with	O
Duchenne	B
dystrophy	I
.	O

Muscle	O
strength	O
,	O
contractures	O
,	O
functional	O
ability	O
and	O
pulmonary	O
function	O
were	O
tested	O
at	O
baseline	O
,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	O
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placebo	O
.	O

The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
detect	O
a	O
slowing	O
to	O
25	O
%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	B
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O

Mazindol	O
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O

Side	O
effects	O
attributable	O
to	O
mazindol	O
included	O
decreased	B
appetite	I
(	O
36	O
%	O
)	O
,	O
dry	B
mouth	I
(	O
10	O
%	O
)	O
,	O
behavioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinal	B
symptoms	I
(	O
18	O
%	O
)	O
;	O
mazindol	O
dosage	O
was	O
reduced	O
in	O
43	O
%	O
of	O
patients	O
.	O

The	O
effect	O
of	O
mazindol	O
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF	O
-	O
I	O
levels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
in	O
the	O
mazindol	O
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups	O
.	O

Although	O
mazindol	O
-	O
treated	O
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo	O
-	O
treated	O
patients	O
,	O
no	O
significant	O
effect	O
on	O
IGF	O
-	O
I	O
levels	O
was	O
observed	O
.	O

Mazindol	O
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	B
in	O
Duchenne	B
dystrophy	I
.	O

Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	O
and	O
its	O
state	O
dependency	O
in	O
the	O
step	O
-	O
through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice	O
.	O

Amnesia	B
produced	O
by	O
scopolamine	O
and	O
cycloheximide	O
were	O
reversed	O
by	O
morphine	O
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(	O
pre	O
-	O
test	O
)	O
,	O
and	O
pre	O
-	O
test	O
morphine	O
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	O
during	O
the	O
training	O
trial	O
.	O

Similarly	O
,	O
pre	O
-	O
test	O
scopolamine	O
partially	O
reversed	O
the	O
scopolamine	O
-	O
induced	O
amnesia	B
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
test	O
cycloheximide	O
failed	O
to	O
reverse	O
the	O
cycloheximide	O
-	O
induced	O
amnesia	B
.	O

These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	O
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	O
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O

Naloxone	O
reverses	O
the	O
antihypertensive	O
effect	O
of	O
clonidine	O
.	O

In	O
unanesthetized	O
,	O
spontaneously	O
hypertensive	B
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	O
,	O
5	O
to	O
20	O
micrograms	O
/	O
kg	O
,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	O
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypotensive	B
effect	O
of	O
100	O
mg	O
/	O
kg	O
alpha	O
-	O
methyldopa	O
was	O
also	O
partially	O
reversed	O
by	O
naloxone	O
.	O

Naloxone	O
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	B
rats	O
clonidine	O
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[	O
3H	O
]	O
-	O
naloxone	O
(	O
8	O
nM	O
)	O
,	O
and	O
naloxone	O
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
influence	O
clonidine	O
-	O
suppressible	O
binding	O
of	O
[	O
3H	O
]	O
-	O
dihydroergocryptine	O
(	O
1	O
nM	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	B
rats	O
the	O
effects	O
of	O
central	O
alpha	O
-	O
adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors	O
.	O

As	O
naloxone	O
and	O
clonidine	O
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site	O
,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	O
by	O
clonidine	O
or	O
alpha	O
-	O
methyldopa	O
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	O
in	O
the	O
central	O
control	O
of	O
sympathetic	O
tone	O
.	O

Neurotoxicity	B
of	O
halogenated	O
hydroxyquinolines	O
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan	O
.	O

An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	B
reactions	O
to	O
halogenated	O
hydroxyquinolines	O
reported	O
from	O
outside	O
Japan	O
.	O

In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	O
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
relationship	O
to	O
clioquinol	O
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	O
.	O

In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	B
disturbance	I
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	B
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	O
over	O
a	O
short	O
period	O
.	O

The	O
most	O
common	O
manifestation	O
,	O
observed	O
in	O
15	O
further	O
cases	O
,	O
was	O
isolated	O
optic	B
atrophy	I
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
children	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	O
as	O
treatment	O
for	O
acrodermatitis	B
enteropathica	I
.	O

In	O
the	O
remaining	O
cases	O
,	O
a	O
combination	O
of	O
myelopathy	B
,	O
visual	B
disturbance	I
,	O
and	O
peripheral	B
neuropathy	I
was	O
the	O
most	O
common	O
manifestation	O
.	O

Isolated	O
myelopathy	B
or	O
peripheral	B
neuropathy	I
,	O
or	O
these	O
manifestations	O
occurring	O
together	O
,	O
were	O
infrequent	O
.	O

The	O
onset	O
of	O
all	O
manifestations	O
(	O
except	O
toxic	O
encephalopathy	B
)	O
was	O
usually	O
subacute	O
,	O
with	O
subsequent	O
partial	O
recovery	O
.	O

Older	O
subjects	O
tended	O
to	O
display	O
more	O
side	O
effects	O
.	O

The	O
full	O
syndrome	O
of	O
subacute	O
myelo	B
-	I
optic	I
neuropathy	I
was	O
more	O
frequent	O
in	O
women	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantities	O
of	O
the	O
drug	O
.	O

Prazosin	O
-	O
induced	O
stress	B
incontinence	I
.	O

A	O
case	O
of	O
genuine	O
stress	B
incontinence	I
due	O
to	O
prazosin	O
,	O
a	O
common	O
antihypertensive	O
drug	O
,	O
is	O
presented	O
.	O

Prazosin	O
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha	O
-	O
1	O
adrenergic	O
receptors	O
.	O

As	O
an	O
alpha	O
-	O
blocker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
relaxant	O
effect	O
on	O
the	O
bladder	O
neck	O
and	O
urethra	O
.	O

The	O
patient	O
'	O
s	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	O
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	O
.	O

Her	O
incontinence	B
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O

The	O
restoration	O
of	O
continence	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximum	O
urethral	O
pressure	O
,	O
maximum	O
urethral	O
closure	O
pressure	O
,	O
and	O
functional	O
urethral	O
length	O
.	O

Patients	O
who	O
present	O
with	O
stress	B
incontinence	I
while	O
taking	O
prazosin	O
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	B
may	O
resolve	O
spontaneously	O
with	O
a	O
change	O
in	O
drug	O
therapy	O
.	O

Myocardial	B
infarction	I
following	O
sublingual	O
administration	O
of	O
isosorbide	O
dinitrate	O
.	O

A	O
78	O
-	O
year	O
-	O
old	O
with	O
healed	O
septal	O
necrosis	B
suffered	O
a	O
recurrent	O
myocardial	B
infarction	I
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	O
dinitrate	O
5	O
mg	O
sublingually	O
.	O

After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	B
and	O
hypotension	B
-	O
mediated	O
myocardial	B
ischemia	I
occurring	O
downstream	O
to	O
significant	O
coronary	B
arterial	I
stenosis	I
in	O
the	O
pathophysiology	O
of	O
acute	B
coronary	I
insufficiency	I
.	O

Comparison	O
of	O
the	O
respiratory	O
effects	O
of	O
i	O
.	O
v	O
.	O
infusions	O
of	O
morphine	O
and	O
regional	O
analgesia	O
by	O
extradural	O
block	O
.	O

The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	B
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i	O
.	O
v	O
.	O
infusion	O
of	O
morphine	O
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0	O
.	O
25	O
%	O
bupivacaine	O
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O

Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	O
dioxide	O
analyser	O
,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules	O
,	O
and	O
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor	O
.	O

Both	O
obstructive	B
(	I
P	I
less	I
than	I
0	I
.	I
05	I
)	I
and	I
central	I
apnoea	I
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	O
infusion	O
.	O

There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	B
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
ventricular	B
ectopic	I
beats	I
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
morphine	O
infusion	O
group	O
.	O

Effects	O
of	O
aminophylline	O
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B
fibrillation	I
during	O
respiratory	B
failure	I
.	O

Cardiac	B
arrhythmias	I
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	B
failure	I
.	O

The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	B
disturbances	I
in	O
patients	O
with	O
respiratory	B
failure	I
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
effects	O
of	O
aminophylline	O
on	O
the	O
ventricular	B
fibrillation	I
threshold	O
during	O
normal	O
acid	O
-	O
base	O
conditions	O
and	O
during	O
respiratory	B
failure	I
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs	O
.	O

The	O
ventricular	B
fibrillation	I
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle	O
.	O

During	O
the	O
infusion	O
of	O
aminophylline	O
,	O
the	O
ventricular	B
fibrillation	I
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	O
(	O
PO2	O
)	O
and	O
carbon	O
dioxide	O
(	O
CO2	O
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O

When	O
respiratory	B
failure	I
was	O
produced	O
by	O
hypoventilation	B
(	O
pH	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infusion	O
of	O
aminophylline	O
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	B
fibrillation	I
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level	O
.	O

These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	B
arrhythmias	I
in	O
respiratory	B
failure	I
,	O
pharmacologic	O
agents	O
,	O
particularly	O
aminophylline	O
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Pentoxifylline	O
(	O
Trental	O
)	O
does	O
not	O
inhibit	O
dipyridamole	O
-	O
induced	O
coronary	O
hyperemia	B
:	O
implications	O
for	O
dipyridamole	O
-	O
thallium	O
-	O
201	O
myocardial	O
imaging	O
.	O

Dipyridamole	O
-	O
thallium	O
-	O
201	O
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	B
vascular	I
disease	I
.	O

Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	O
(	O
Trental	O
)	O
,	O
a	O
methylxanthine	O
derivative	O
which	O
may	O
improve	O
intermittent	B
claudication	I
.	O

Whether	O
pentoxifylline	O
inhibits	O
dipyridamole	O
-	O
induced	O
coronary	O
hyperemia	B
like	O
other	O
methylxanthines	O
such	O
as	O
theophylline	O
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole	O
-	O
thallium	O
-	O
201	O
imaging	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	O
in	O
seven	O
open	O
-	O
chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	O
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theophylline	O
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

Baseline	O
circumflex	O
coronary	O
blood	O
flows	O
did	O
not	O
differ	O
significantly	O
among	O
treatment	O
groups	O
.	O

Dipyridamole	O
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pentoxifylline	O
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Neither	O
dose	O
of	O
pentoxifylline	O
significantly	O
decreased	O
the	O
dipyridamole	O
-	O
induced	O
hyperemia	B
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
pentoxyifylline	O
does	O
not	O
inhibit	O
dipyridamole	O
-	O
induced	O
coronary	O
hyperemia	B
even	O
at	O
high	O
doses	O
.	O

Cause	O
of	O
death	B
among	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	B
haemorrhage	I
.	O

Causes	O
of	O
death	B
,	O
with	O
special	O
reference	O
to	O
cerebral	B
haemorrhage	I
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson	B
'	I
s	I
disease	I
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
death	B
were	O
pneumonia	B
and	O
bronchitis	B
(	O
44	O
.	O
1	O
%	O
)	O
,	O
malignant	O
neoplasms	B
(	O
11	O
.	O
6	O
%	O
)	O
,	O
heart	B
diseases	I
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerebral	B
infarction	I
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicaemia	B
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Cerebral	B
haemorrhage	I
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	B
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
deaths	B
among	O
the	O
patients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	B
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985	O
.	O

The	O
low	O
incidence	O
of	O
cerebral	B
haemorrhage	I
as	O
a	O
cause	O
of	O
death	B
in	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
may	O
reflect	O
the	O
hypotensive	B
effect	O
of	O
levodopa	O
and	O
a	O
hypotensive	B
mechanism	O
due	O
to	O
reduced	O
noradrenaline	O
levels	O
in	O
the	O
parkinsonian	B
brain	O
.	O

Possible	O
intramuscular	O
midazolam	O
-	O
associated	O
cardiorespiratory	B
arrest	I
and	O
death	B
.	O

Midazolam	O
hydrochloride	O
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	B
and	I
cardiovascular	I
depression	I
.	O

This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	B
arrest	I
and	O
death	B
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	O
.	O

Information	O
regarding	O
midazolam	O
use	O
is	O
reviewed	O
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O

Myasthenia	B
gravis	I
presenting	O
as	O
weakness	O
after	O
magnesium	O
administration	O
.	O

We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	B
disease	I
who	O
became	O
virtually	O
quadriplegic	B
after	O
parenteral	O
magnesium	O
administration	O
for	O
preeclampsia	B
.	O

The	O
serum	O
magnesium	O
concentration	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O

The	O
magnesium	O
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	O
.	O

While	O
she	O
was	O
weak	O
,	O
2	O
-	O
Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	B
neuromuscular	I
blockade	I
.	O

After	O
her	O
strength	O
returned	O
,	O
repetitive	O
stimulation	O
was	O
normal	O
,	O
but	O
single	O
fiber	O
EMG	O
revealed	O
increased	O
jitter	O
and	O
blocking	O
.	O

Her	O
acetylcholine	O
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O

Although	O
paralysis	B
after	O
magnesium	O
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	B
gravis	I
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease	O
.	O

Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	O
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	B
of	I
neuromuscular	I
transmission	I
.	O

No	O
enhancement	O
by	O
phenobarbital	O
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	O
-	O
devoid	O
diet	O
in	O
the	O
rat	O
.	O

An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	O
in	O
a	O
choline	O
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O

Groups	O
of	O
5	O
-	O
week	O
old	O
male	O
Fischer	O
-	O
344	O
rats	O
were	O
fed	O
for	O
7	O
-	O
25	O
months	O
semipurified	O
choline	O
-	O
devoid	O
or	O
choline	O
-	O
supplemented	O
diets	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phenobarbital	O
.	O

No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	B
carcinomas	I
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline	O
-	O
supplemented	O
diet	O
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	B
carcinoma	I
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	O
.	O

The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	B
carcinomas	I
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
fed	O
the	O
plain	O
choline	O
-	O
devoid	O
diet	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rats	O
fed	O
the	O
phenobarbital	O
-	O
containing	O
choline	O
-	O
devoid	O
diet	O
.	O

The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	O
-	O
devoid	O
diet	O
by	O
phenobarbital	O
.	O

Sporadic	O
neoplastic	O
lesions	O
were	O
observed	O
in	O
organs	O
other	O
than	O
the	O
liver	O
of	O
some	O
of	O
the	O
animals	O
,	O
irrespective	O
of	O
the	O
diet	O
fed	O
.	O

On	O
two	O
paradoxical	O
side	O
-	O
effects	O
of	O
prednisolone	O
in	O
rats	O
,	O
ribosomal	O
RNA	O
biosyntheses	O
,	O
and	O
a	O
mechanism	O
of	O
action	O
.	O

Liver	B
enlargement	I
and	O
muscle	B
wastage	I
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	O
.	O

In	O
the	O
liver	O
both	O
the	O
content	O
of	O
RNA	O
and	O
the	O
biosynthesis	O
of	O
ribosomal	O
RNA	O
increased	O
while	O
both	O
the	O
RNA	O
content	O
and	O
ribosomal	O
RNA	O
biosynthesis	O
were	O
reduced	O
in	O
the	O
gastrocnemius	O
muscle	O
.	O

It	O
is	O
suggested	O
that	O
the	O
drug	O
acted	O
in	O
a	O
selective	O
and	O
tissue	O
-	O
specific	O
manner	O
to	O
enhance	O
ribosomal	O
RNA	O
synthesis	O
in	O
the	O
liver	O
and	O
depress	O
such	O
synthesis	O
in	O
the	O
muscle	O
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	O
action	O
.	O

Differential	O
effects	O
of	O
gamma	O
-	O
hexachlorocyclohexane	O
(	O
lindane	O
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B
.	O

Gamma	O
-	O
hexachlorocyclohexane	O
(	O
gamma	O
-	O
HCH	O
)	O
,	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	O
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	B
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	O
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma	O
-	O
HCH	O
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ	O
-	O
induced	O
seizures	B
24	O
h	O
after	O
exposure	O
to	O
gamma	O
-	O
HCH	O
(	O
Vohland	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure	B
-	O
inducing	O
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg	O
/	O
kg	O
gamma	O
-	O
HCH	O
.	O

One	O
hour	O
after	O
the	O
administration	O
of	O
gamma	O
-	O
HCH	O
,	O
the	O
activity	O
of	O
seizure	B
-	O
inducing	O
agents	O
was	O
increased	O
,	O
regardless	O
of	O
their	O
mechanism	O
,	O
while	O
24	O
h	O
after	O
gamma	O
-	O
HCH	O
a	O
differential	O
response	O
was	O
observed	O
.	O

Seizure	B
activity	O
due	O
to	O
PTZ	O
and	O
picrotoxin	O
(	O
PTX	O
)	O
was	O
significantly	O
decreased	O
;	O
however	O
,	O
seizure	B
activity	O
due	O
to	O
3	O
-	O
mercaptopropionic	O
acid	O
(	O
MPA	O
)	O
,	O
bicuculline	O
(	O
BCC	O
)	O
,	O
methyl	O
6	O
,	O
7	O
-	O
dimethoxy	O
-	O
4	O
-	O
ethyl	O
-	O
B	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
DMCM	O
)	O
,	O
or	O
strychnine	O
(	O
STR	O
)	O
was	O
not	O
different	O
from	O
control	O
.	O

In	O
vitro	O
,	O
gamma	O
-	O
HCH	O
,	O
pentylenetetrazol	O
and	O
picrotoxin	O
were	O
shown	O
to	O
inhibit	O
3H	O
-	O
TBOB	O
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

MPA	O
,	O
BCC	O
,	O
DMCM	O
,	O
and	O
STR	O
showed	O
no	O
inhibition	O
of	O
3H	O
-	O
TBOB	O
(	O
t	O
-	O
butyl	O
bicyclo	O
-	O
orthobenzoate	O
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron	O
.	O

The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B
activity	O
induced	O
by	O
PTZ	O
and	O
PTX	O
24	O
h	O
after	O
gamma	O
-	O
HCH	O
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	B
-	O
inducing	O
agents	O
is	O
decreased	O
.	O

The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	B
activity	O
24	O
h	O
after	O
gamma	O
-	O
HCH	O
may	O
be	O
the	O
GABA	O
-	O
A	O
receptor	O
-	O
linked	O
chloride	O
channel	O
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	O
in	O
patients	O
with	O
Argentine	B
hemorrhagic	I
fever	I
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	O
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	B
hemorrhagic	I
fever	I
(	O
AHF	B
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution	O
.	O

Administration	O
of	O
ribavirin	O
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	B
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers	O
.	O

The	O
average	O
time	O
of	O
death	B
was	O
delayed	O
.	O

A	O
reversible	O
anemia	B
was	O
the	O
only	O
adverse	O
effect	O
observed	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
ribavirin	O
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	B
,	O
and	O
that	O
anemia	B
,	O
the	O
only	O
secondary	O
reaction	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	O
during	O
the	O
initial	O
days	O
of	O
AHF	B
is	O
discussed	O
.	O

Is	O
the	O
treatment	O
of	O
scabies	B
hazardous	O
?	O

Treatment	O
for	O
scabies	B
is	O
usually	O
initiated	O
by	O
general	O
practitioners	O
;	O
most	O
consider	O
lindane	O
(	O
gamma	O
benzene	O
hexachloride	O
)	O
the	O
treatment	O
of	O
choice	O
.	O

Lindane	O
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O

Evidence	O
is	O
accumulating	O
that	O
lindane	O
can	O
be	O
toxic	B
to	I
the	I
central	I
nervous	I
system	I
and	O
may	O
be	O
associated	O
with	O
aplastic	B
anaemia	I
.	O

Preparations	O
containing	O
lindane	O
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O

This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at	O
-	O
risk	O
groups	O
,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	B
.	O

Mouse	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	O
on	O
motility	O
and	O
brain	O
biogenic	O
amines	O
.	O

The	O
effect	O
of	O
amantadine	O
hydrochloride	O
,	O
injected	O
i	O
.	O
p	O
.	O
in	O
6	O
increments	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	O
amines	O
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice	O
.	O

These	O
were	O
the	O
albino	O
Sprague	O
-	O
Dawley	O
ICR	O
and	O
BALB	O
/	O
C	O
,	O
the	O
black	O
C57BL	O
/	O
6	O
and	O
the	O
brown	O
CDF	O
-	O
I	O
mouse	O
strains	O
.	O

Amantadine	O
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility	O
.	O

The	O
initial	O
dose	O
of	O
amantadine	O
depressed	B
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
most	O
sensitive	O
.	O

Subsequent	O
amantadine	O
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
least	O
sensitive	O
.	O

The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	O
,	O
during	O
an	O
overnight	O
drug	O
-	O
free	O
period	O
following	O
the	O
fourth	O
amantadine	O
treatment	O
.	O

Readministration	O
of	O
amantadine	O
,	O
after	O
a	O
drug	O
-	O
free	O
overnight	O
period	O
,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mice	O
where	O
suppression	B
of	I
motility	I
occurred	O
.	O

Treatment	O
with	O
amantadine	O
did	O
not	O
alter	O
whole	O
brain	O
dopamine	O
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3	O
,	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
in	O
the	O
BALB	O
/	O
C	O
mice	O
compared	O
to	O
saline	O
control	O
.	O

Conversely	O
,	O
brain	O
normetanephrine	O
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	O
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O

The	O
results	O
suggest	O
a	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	O
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used	O
.	O

The	O
BALB	O
/	O
C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	O
.	O

The	O
biochemical	O
results	O
of	O
brain	O
biogenic	O
amines	O
of	O
BALB	O
/	O
C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	O
turnover	O
rate	O
and	O
/	O
or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O	O
-	O
methylation	O
of	O
norepinephrine	O
which	O
may	O
account	O
for	O
a	O
behavioral	B
depression	I
caused	O
by	O
amantadine	O
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O

Chloroacetaldehyde	O
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	O
or	O
ifosfamide	O
.	O

An	O
experimental	O
study	O
/	O
short	O
communication	O
.	O

Based	O
on	O
clinical	O
data	O
,	O
indicating	O
that	O
chloroacetaldehyde	O
(	O
CAA	O
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	O
in	O
the	O
development	O
of	O
hemorrhagic	B
cystitis	I
.	O

The	O
data	O
demonstrate	O
that	O
CAA	O
after	O
i	O
.	O
v	O
.	O
administration	O
does	O
not	O
contribute	O
to	O
bladder	B
damage	I
.	O

When	O
instilled	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	O
exerts	O
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	O
.	O

Source	O
of	O
pain	B
and	O
primitive	O
dysfunction	O
in	O
migraine	B
:	O
an	O
identical	O
site	O
?	O

Twenty	O
common	O
migraine	B
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	O
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O

Early	O
onset	O
migraine	B
attacks	O
were	O
induced	O
by	O
nitroglycerin	O
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group	O
.	O

Subsequently	O
20	O
migraine	B
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	O
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O

No	O
early	O
onset	O
migraine	B
was	O
observed	O
.	O

Thus	O
the	O
migraine	B
-	O
inducing	O
effect	O
of	O
nitroglycerin	O
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	B
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	B
crisis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	B
attack	O
.	O

Hypersensitivity	B
to	O
carbamazepine	O
presenting	O
with	O
a	O
leukemoid	B
reaction	I
,	O
eosinophilia	B
,	O
erythroderma	B
,	O
and	O
renal	B
failure	I
.	O

We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	B
to	O
carbamazepine	O
presented	O
with	O
generalized	O
erythroderma	B
,	O
a	O
severe	O
leukemoid	B
reaction	I
,	O
eosinophilia	B
,	O
hyponatremia	B
,	O
and	O
renal	B
failure	I
.	O

This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	O
.	O

Fluoxetine	O
-	O
induced	O
akathisia	B
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O

Five	O
patients	O
receiving	O
fluoxetine	O
for	O
the	O
treatment	O
of	O
obsessive	B
compulsive	I
disorder	I
or	O
major	B
depression	I
developed	O
akathisia	B
.	O

The	O
typical	O
fluoxetine	O
-	O
induced	O
symptoms	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	B
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic	O
-	O
induced	O
akathisia	B
.	O

Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	B
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	O
-	O
induced	O
akathisia	B
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O

Akathisia	B
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	O
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
antagonist	O
propranolol	O
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O

The	O
authors	O
suggest	O
that	O
fluoxetine	O
-	O
induced	O
akathisia	B
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	O
-	O
induced	O
akathisia	B
and	O
tricyclic	O
antidepressant	O
-	O
induced	O
"	O
jitteriness	O
"	O
may	O
be	O
identical	O
.	O

Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin	O
-	O
induced	O
nephropathy	B
.	O

The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(	O
CEI	O
)	O
enalapril	O
was	O
assessed	O
in	O
Munich	O
-	O
Wistar	O
rats	O
with	O
established	O
adriamycin	O
nephrosis	B
.	O

Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	O
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	B
,	O
blood	O
pressure	O
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O

Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	O
.	O

Groups	O
1	O
and	O
2	O
underwent	O
micropuncture	O
studies	O
after	O
10	O
days	O
.	O

These	O
short	O
-	O
term	O
studies	O
showed	O
that	O
enalapril	O
reduced	O
arterial	O
blood	O
pressure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
group	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
glomerular	O
capillary	O
pressure	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
reducing	O
albuminuria	B
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O

11	O
ml	O
/	O
min	O
)	O
.	O

Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	O
on	O
progression	O
of	O
renal	B
injury	I
in	O
adriamycin	O
nephrosis	B
.	O

Chronic	O
enalapril	O
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	B
in	O
group	O
4	O
.	O

Untreated	O
group	O
3	O
rats	O
exhibited	O
a	O
progressive	O
reduction	O
in	O
GFR	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
08	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
ml	O
/	O
min	O
at	O
6	O
months	O
)	O
.	O

Enalapril	O
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
months	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
group	O
3	O
)	O
.	O

Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	B
sclerosis	I
in	O
both	O
treated	O
and	O
untreated	O
rats	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Clotiazepam	O
-	O
induced	O
acute	O
hepatitis	B
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	O
hepatitis	B
with	O
extensive	B
hepatocellular	I
necrosis	I
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	O
,	O
a	O
thienodiazepine	O
derivative	O
.	O

Clotiazepam	O
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O

The	O
administration	O
of	O
several	O
benzodiazepines	O
,	O
chemically	O
related	O
to	O
clotiazepam	O
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	B
.	O

This	O
observation	O
shows	O
that	O
clotiazepam	O
can	O
induce	O
acute	O
hepatitis	B
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	B
between	O
clotiazepam	O
and	O
several	O
benzodiazepines	O
.	O

5	O
-	O
azacytidine	O
potentiates	O
initiation	B
induced	I
by	I
carcinogens	I
in	O
rat	O
liver	O
.	O

To	O
test	O
the	O
validity	O
of	O
the	O
hypothesis	O
that	O
hypomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	B
of	I
carcinogenic	I
process	I
,	O
5	O
-	O
azacytidine	O
(	O
5	O
-	O
AzC	O
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo	O
[	O
a	O
]	O
-	O
pyrene	O
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	O
,	O
2	O
-	O
dimethylhydrazine	O
(	O
1	O
,	O
2	O

-	O
DMH	O
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O

The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma	O
-	O
glutamyltransferase	O
(	O
gamma	O
-	O
GT	O
)	O
positive	O
foci	O
formed	O
following	O
a	O
2	O
-	O
week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0	O
.	O
02	O
%	O
2	O
-	O
acetylaminofluorene	O
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	O
.	O

The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5	O
-	O
AzC	O
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
foci	O
/	O
cm2	O
in	O
5	O
-	O
AzC	O
and	O
carcinogen	O
-	O
treated	O
rats	O
compared	O
with	O
3	O
-	O
5	O
foci	O
/	O
cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only	O
.	O

Administration	O
of	O
[	O
3H	O
]	O
-	O
5	O
-	O
azadeoxycytidine	O
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1	O
,	O
2	O
-	O
DMH	O
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
cytosine	O
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue	O
,	O
indicating	O
that	O
incorporation	O
of	O
5	O
-	O
AzC	O
occurs	O
during	O
repair	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5	O
-	O
AzC	O
given	O
after	O
a	O
two	O
thirds	O
partial	O
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	O
,	O
failed	O
to	O
induce	O
any	O
gamma	O
-	O
GT	O
positive	O
foci	O
.	O

The	O
results	O
suggest	O
that	O
hypomethylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
initiation	O
.	O

Perhaps	O
two	O
events	O
might	O
be	O
necessary	O
for	O
initiation	O
,	O
the	O
first	O
caused	O
by	O
the	O
carcinogen	O
and	O
a	O
second	O
involving	O
hypomethylation	O
of	O
DNA	O
.	O

Antihypertensive	O
drugs	O
and	O
depression	B
:	O
a	O
reappraisal	O
.	O

Eighty	O
-	O
nine	O
new	O
referral	O
hypertensive	B
out	O
-	O
patients	O
and	O
46	O
new	O
referral	O
non	O
-	O
hypertensive	B
chronically	O
physically	O
ill	O
out	O
-	O
patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O

The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	B
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B
group	O
.	O

Hypertensive	B
patients	O
with	O
psychiatric	B
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	B
than	O
the	O
comparison	O
patients	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	B
occurring	O
in	O
methyl	O
dopa	O
treated	O
patients	O
with	O
psychiatric	B
histories	O
.	O

Chronic	B
active	I
hepatitis	I
associated	O
with	O
diclofenac	O
sodium	O
therapy	O
.	O

Diclofenac	O
sodium	O
(	O
Voltarol	O
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	O
acid	O
.	O

Although	O
generally	O
well	O
-	O
tolerated	O
,	O
asymptomatic	O
abnormalities	B
of	I
liver	I
function	I
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	B
induced	O
by	O
diclofenac	O
.	O

The	O
patient	O
described	O
developed	O
chronic	B
active	I
hepatitis	I
after	O
six	O
months	O
therapy	O
with	O
diclofenac	O
sodium	O
which	O
progressed	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	O
,	O
a	O
finding	O
not	O
previously	O
reported	O
.	O

Arterial	O
hypertension	B
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	O
treatment	O
.	O

Two	O
of	O
14	O
patients	O
with	O
Cushing	B
'	I
s	I
syndrome	I
treated	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoconazole	O
developed	O
sustained	O
hypertension	B
.	O

In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	O
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	O
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	B
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O

In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	O
and	O
11	O
-	O
deoxycortisol	O
were	O
elevated	O
.	O

In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	O
and	O
11	O
-	O
deoxycortisol	O
levels	O
,	O
plasma	O
aldosterone	O
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O

Our	O
findings	O
show	O
that	O
long	O
-	O
term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	O
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid	O
-	O
related	O
hypertension	B
.	O

Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	O
converting	O
enzyme	O
(	O
Captopril	O
)	O
on	O
pulmonary	B
and	I
renal	I
insufficiency	I
due	O
to	O
intravascular	B
coagulation	I
in	O
the	O
rat	O
.	O

Induction	O
of	O
intravascular	B
coagulation	I
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	O
acid	O
(	O
AMCA	O
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	B
and	I
renal	I
insufficiency	I
resembling	O
that	O
occurring	O
after	O
trauma	B
or	O
sepsis	B
in	O
man	O
.	O

Injection	O
of	O
Captopril	O
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
,	O
reduced	O
both	O
pulmonary	B
and	I
renal	I
insufficiency	I
in	O
this	O
rat	O
model	O
.	O

The	O
lung	O
weights	O
were	O
lower	O
and	O
PaO2	O
was	O
improved	O
in	O
rats	O
given	O
this	O
enzyme	O
-	O
blocking	O
agent	O
.	O

The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	O
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein	O
.	O

Renal	B
damage	I
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	O
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	O
.	O

The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	O
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	O
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	O
II	O
and	O
an	O
increase	O
in	O
prostacyclin	O
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	O
)	O
.	O

Captopril	O
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	B
damage	I
will	O
be	O
produced	O
.	O

Stroke	B
associated	O
with	O
cocaine	O
use	O
.	O

We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	O
use	O
was	O
related	O
to	O
stroke	B
and	O
review	O
39	O
cases	O
from	O
the	O
literature	O
.	O

Among	O
these	O
47	O
patients	O
the	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
age	O
was	O
32	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
;	O
76	O
%	O
(	O
34	O
/	O
45	O
)	O
were	O
men	O
.	O

Stroke	B
followed	O
cocaine	O
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O

Intracranial	B
aneurysms	I
or	O
arteriovenous	B
malformations	I
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy	O
;	O
cerebral	B
vasculitis	I
was	O
present	O
in	O
two	O
patients	O
.	O

Cerebral	B
infarction	I
occurred	O
in	O
10	O
patients	O
(	O
22	O
%	O
)	O
,	O
intracerebral	B
hemorrhage	I
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachnoid	B
hemorrhage	I
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	O
incidence	O
of	O
stroke	B
related	O
to	O
cocaine	O
use	O
is	O
increasing	O
;	O
(	O
2	O
)	O
cocaine	O
-	O
associated	O
stroke	B
occurs	O
primarily	O
in	O
young	O
adults	O
;	O
(	O
3	O
)	O
stroke	B
may	O
follow	O
any	O
route	O
of	O
cocaine	O
administration	O
;	O
(	O
4	O
)	O
stroke	B
after	O
cocaine	O
use	O
is	O
frequently	O
associated	O
with	O
intracranial	B
aneurysms	I
and	O
arteriovenous	B
malformations	I
;	O
and	O
(	O
5	O
)	O
in	O
cocaine	O
-	O
associated	O
stroke	B
,	O
the	O
frequency	O
of	O
intracranial	B
hemorrhage	I
exceeds	O
that	O
of	O
cerebral	B
infarction	I
.	O

A	O
randomized	O
comparison	O
of	O
labetalol	O
and	O
nitroprusside	O
for	O
induced	O
hypotension	B
.	O

In	O
a	O
randomized	O
study	O
,	O
labetalol	O
-	O
induced	O
hypotension	B
and	O
nitroprusside	O
-	O
induced	O
hypotension	B
were	O
compared	O
in	O
20	O
patients	O
(	O
10	O
in	O
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O

Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug	O
-	O
induced	O
reductions	B
in	I
mean	I
arterial	I
blood	I
pressure	I
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprusside	O
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
increase	B
in	I
heart	I
rate	I
and	I
cardiac	I
output	I
;	O
rebound	O
hypertension	B
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	O
.	O

Labetalol	O
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	O
.	O

Arterial	O
PO2	O
decreased	O
in	O
both	O
groups	O
.	O

It	O
was	O
concluded	O
that	O
labetalol	O
offers	O
advantages	O
over	O
nitroprusside	O
.	O

Sodium	O
status	O
influences	O
chronic	O
amphotericin	O
B	O
nephrotoxicity	B
in	O
rats	O
.	O

The	O
nephrotoxic	B
potential	O
of	O
amphotericin	O
B	O
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
investigated	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
.	O

In	O
salt	O
-	O
depleted	O
rats	O
,	O
amphotericin	O
B	O
decreased	O
creatinine	O
clearance	O
linearly	O
with	O
time	O
,	O
with	O
an	O
85	O
%	O
reduction	O
by	O
week	O
3	O
.	O

In	O
contrast	O
,	O
in	O
normal	O
-	O
salt	O
rats	O
creatinine	O
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt	O
-	O
loaded	O
rats	O
creatinine	O
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O

All	O
rats	O
in	O
the	O
sodium	O
-	O
depleted	O
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal	O
-	O
salt	O
or	O
salt	O
-	O
loaded	O
rat	O
.	O

Concentrations	O
of	O
amphotericin	O
B	O
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
weeks	O
,	O
amphotericin	O
B	O
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt	O
-	O
depleted	O
and	O
normal	O
-	O
salt	O
rats	O
than	O
those	O
in	O
salt	O
-	O
loaded	O
rats	O
,	O
with	O
plasma	O
/	O
kidney	O
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	O
clearance	O
and	O
renal	O
amphotericin	O
B	O
accumulation	O
after	O
chronic	O
amphotericin	O
B	O
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	O
loading	O
in	O
rats	O
.	O

Flestolol	O
:	O
an	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Flestolol	O
(	O
ACC	O
-	O
9089	O
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity	O
.	O

Flestolol	O
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half	O
-	O
life	O
of	O
approximately	O
6	O
.	O
5	O
minutes	O
.	O

This	O
agent	O
was	O
well	O
tolerated	O
in	O
healthy	O
volunteers	O
at	O
doses	O
up	O
to	O
100	O
micrograms	O
/	O
kg	O
/	O
min	O
.	O

In	O
long	O
-	O
term	O
infusion	O
studies	O
,	O
flestolol	O
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta	O
-	O
blocking	O
dose	O
(	O
5	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
days	O
.	O

Flestolol	O
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	O
and	O
beta	O
-	O
adrenergic	O
blockade	O
.	O

Flestolol	O
produced	O
a	O
dose	O
-	O
dependent	O
attenuation	O
of	O
isoproterenol	O
-	O
induced	O
tachycardia	B
.	O

Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	O
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers	O
.	O

In	O
contrast	O
with	O
other	O
beta	O
blockers	O
,	O
flestolol	O
-	O
induced	O
effects	O
reverse	O
rapidly	O
(	O
within	O
30	O
minutes	O
)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half	O
-	O
life	O
.	O

Flestolol	O
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	B
tachyarrhythmia	I
.	O

In	O
patients	O
with	O
unstable	B
angina	I
,	O
flestolol	O
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	B
pain	I
.	O

It	O
is	O
concluded	O
that	O
flestolol	O
is	O
a	O
potent	O
,	O
well	O
-	O
tolerated	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Use	O
of	O
flestolol	O
in	O
the	O
critical	O
care	O
setting	O
is	O
currently	O
undergoing	O
investigation	O
.	O

Immunohistochemical	O
,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen	O
-	O
induced	O
rat	O
prolactinomas	B
after	O
bromocriptine	O
treatment	O
.	O

To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	O
on	O
prolactinoma	B
cells	O
in	O
vivo	O
,	O
immunohistochemical	O
,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen	O
-	O
induced	O
rat	O
prolactinoma	B
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	O
(	O
3	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
.	O

One	O
h	O
after	O
treatment	O
,	O
serum	O
prolactin	O
levels	O
decreased	O
markedly	O
.	O

Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	B
cells	O
.	O

Morphometric	O
analysis	O
revealed	O
that	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
increased	O
,	O
while	O
the	O
volume	O
density	O
of	O
cytoplasmic	O
microtubules	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	O
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules	O
.	O

At	O
6	O
h	O
after	O
injection	O
,	O
serum	O
prolactin	O
levels	O
were	O
still	O
considerably	O
lower	O
than	O
in	O
controls	O
.	O

The	O
prolactinoma	B
cells	O
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae	O
.	O

Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	B
cells	O
.	O

However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	O
treatment	O
of	O
the	O
adenoma	B
cells	O
.	O

An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis	O
,	O
suggesting	O
that	O
bromocriptine	O
inhibits	O
protein	O
synthesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	O
of	O
the	O
prolactin	O
secretion	O
.	O

Sulfasalazine	O
-	O
induced	O
lupus	B
erythematosus	I
.	O

Pneumonitis	B
,	O
bilateral	O
pleural	B
effusions	I
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B
tamponade	I
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulfasalazine	O
therapy	O
for	O
chronic	O
ulcerative	B
colitis	I
.	O

After	O
cessation	O
of	O
the	O
sulfasalazine	O
and	O
completion	O
of	O
a	O
six	O
-	O
week	O
course	O
of	O
corticosteroids	O
,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months	O
.	O

It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	O
-	O
induced	O
lupus	B
,	O
which	O
manifested	O
with	O
serositis	B
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O

Physicians	O
who	O
use	O
sulfasalazine	O
to	O
treat	O
patients	O
with	O
inflammatory	B
bowel	I
disease	I
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	O
-	O
induced	O
lupus	B
syndrome	I
.	O

Chronic	O
carbamazepine	O
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	B
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	O
concentrations	O
.	O

Folate	O
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
.	O

Carbamazepine	O
(	O
CBZ	O
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies	O
.	O

A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	O
treatment	O
on	O
folate	O
concentrations	O
in	O
the	O
rat	O
.	O

In	O
the	O
course	O
of	O
developing	O
this	O
model	O
,	O
a	O
common	O
vehicle	O
,	O
propylene	O
glycol	O
,	O
by	O
itself	O
in	O
high	O
doses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	B
and	O
inhibited	O
weight	B
gain	I
.	O

Seizures	B
induced	O
by	O
hexafluorodiethyl	O
ether	O
(	O
HFDE	O
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	O
than	O
seizures	B
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
.	O

Oral	O
administration	O
of	O
CBZ	O
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	O
-	O
induced	O
seizures	B
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B
gain	I
over	O
8	O
weeks	O
of	O
treatment	O
.	O

The	O
CBZ	O
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
treatment	O
with	O
CBZ	O
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	O
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	O
concentration	O
increased	O
in	O
liver	O
after	O
6	O
weeks	O
of	O
treatment	O
and	O
in	O
plasma	O
at	O
8	O
weeks	O
of	O
treatment	O
.	O

Dipyridamole	O
-	O
induced	O
myocardial	B
ischemia	I
.	O

Angina	B
and	O
ischemic	O
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	O
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	O
therapy	O
,	O
although	O
dipyridamole	O
-	O
induced	O
myocardial	B
ischemia	I
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	B
artery	I
disease	I
.	O

Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients	O
;	O
a	O
coronary	O
"	O
steal	O
"	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole	O
-	O
induced	O
ischemia	B
observed	O
.	O

Inhibition	O
of	O
sympathoadrenal	O
activity	O
by	O
atrial	O
natriuretic	O
factor	O
in	O
dogs	O
.	O

In	O
six	O
conscious	O
,	O
trained	O
dogs	O
,	O
maintained	O
on	O
a	O
normal	O
sodium	O
intake	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	O
and	O
epinephrine	O
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
infusions	O
of	O
human	O
alpha	O
-	O
atrial	O
natriuretic	O
factor	O
.	O

Mean	O
arterial	O
pressure	O
(	O
as	O
a	O
percentage	O
of	O
control	O
+	O
/	O
-	O
SEM	O
)	O
during	O
randomized	O
infusions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
microgram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	B
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	O
release	O
rate	O
(	O
up	O
to	O
0	O
.	O
3	O

microgram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	B
induced	O
by	O
hydralazine	O
or	O
nitroglycerin	O
.	O

The	O
release	O
rate	O
of	O
epinephrine	O
(	O
control	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
declined	O
immediately	O
during	O
infusions	O
of	O
atrial	O
natriuretic	O
factor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
microgram	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
microgram	O
/	O
kg	O
/	O
min	O
.	O

Steady	O
state	O
arterial	O
plasma	O
concentrations	O
of	O
atrial	O
natriuretic	O
factor	O
were	O
39	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infusions	O
of	O
saline	O
and	O
284	O
+	O
/	O
-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/	O
-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0	O
.	O
03	O
and	O
0	O
.	O
1	O
microgram	O
/	O
kg	O
/	O
min	O
infusions	O
of	O
the	O
factor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inhibition	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
secretion	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
by	O
delayed	O
glucocorticoid	O
feedback	O
.	O

Nitroprusside	O
-	O
induced	O
hypotension	B
evokes	O
ACTH	O
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
(	O
irCRF	O
)	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	O
vasopressin	O
nor	O
oxytocin	O
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

Application	O
of	O
a	O
delayed	O
feedback	O
signal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systemic	O
corticosterone	O
infusion	O
in	O
urethane	O
-	O
anesthetized	O
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis	O
,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	O
vasopressin	O
and	O
oxytocin	O
at	O
any	O
corticosterone	O
feedback	O
dose	O
tested	O
.	O

Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	O
infusion	O
rate	O
,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	O
levels	O
of	O
40	O
micrograms	O
/	O
dl	O
.	O

Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside	O
-	O
induced	O
hypotension	B
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	O
level	O
between	O
8	O
-	O
12	O
micrograms	O
/	O
dl	O
.	O

These	O
studies	O
provide	O
further	O
evidence	O
for	O
a	O
strong	O
central	O
component	O
of	O
the	O
delayed	O
feedback	O
process	O
which	O
is	O
mediated	O
by	O
modulation	O
of	O
irCRF	O
release	O
.	O

Noradrenergic	O
involvement	O
in	O
catalepsy	B
induced	O
by	O
delta	O
9	O
-	O
tetrahydrocannabinol	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	O
9	O
-	O
tetrahydrocannabinol	O
(	O
THC	O
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6	O
-	O
hydroxydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
or	O
with	O
desipramine	O
and	O
6	O
-	O
OHDA	O
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
THC	O
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6	O
-	O
OHDA	O
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	O
and	O
6	O
-	O
OHDA	O
,	O
as	O
compared	O
with	O
control	O
rats	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	O
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	O
and	O
6	O
-	O
OHDA	O
but	O
not	O
in	O
rats	O
treated	O
with	O
6	O
-	O
OHDA	O
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
.	O

These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	B
induced	O
by	O
THC	O
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	B
induced	O
by	O
haloperidol	O
.	O

Reversibility	O
of	O
captopril	O
-	O
induced	O
renal	B
insufficiency	I
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	B
hypertension	I
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	B
with	O
an	O
occluded	O
renal	O
artery	O
to	O
a	O
solitary	O
kidney	O
,	O
who	O
developed	O
sudden	B
deterioration	I
of	I
renal	I
function	I
following	O
treatment	O
with	O
captopril	O
.	O

His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years	O
'	O
treatment	O
with	O
captopril	O
but	O
returned	O
to	O
pre	O
-	O
treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug	O
.	O

This	O
indicates	O
reversibility	O
in	O
captopril	O
-	O
induced	O
renal	B
failure	I
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O

HMG	O
CoA	O
reductase	O
inhibitors	O
.	O

Current	O
clinical	O
experience	O
.	O

Lovastatin	O
and	O
simvastatin	O
are	O
the	O
2	O
best	O
-	O
known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O

Clinical	O
experience	O
with	O
lovastatin	O
includes	O
over	O
5000	O
patients	O
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more	O
,	O
and	O
experience	O
with	O
simvastatin	O
includes	O
over	O
3500	O
patients	O
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more	O
.	O

Lovastatin	O
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months	O
.	O

Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy	O
,	O
with	O
reductions	O
in	O
total	O
cholesterol	O
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cholesterol	O
of	O
40	O
%	O
in	O
clinical	O
studies	O
.	O

Modest	O
increases	O
in	O
HDL	O
-	O
cholesterol	O
levels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Clinical	O
tolerability	O
of	O
both	O
agents	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patients	O
withdrawn	O
from	O
treatment	O
because	O
of	O
clinical	O
adverse	O
experiences	O
.	O

Ophthalmological	O
examinations	O
in	O
over	O
1100	O
patients	O
treated	O
with	O
one	O
or	O
the	O
other	O
agent	O
have	O
revealed	O
no	O
evidence	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
years	O
)	O
cataractogenic	O
potential	O
.	O

One	O
to	O
2	O
%	O
of	O
patients	O
have	O
elevations	O
of	O
serum	O
transaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

These	O
episodes	O
are	O
asymptomatic	O
and	O
reversible	O
when	O
therapy	O
is	O
discontinued	O
.	O

Minor	O
elevations	O
of	O
creatine	O
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patients	O
.	O

Myopathy	B
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	B
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	B
failure	I
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	O
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	O
,	O
gemfibrozil	O
or	O
niacin	O
.	O

Lovastatin	O
and	O
simvastatin	O
are	O
both	O
effective	O
and	O
well	O
-	O
tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	O
.	O

As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	B
and	O
its	O
consequences	O
.	O

Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	O
in	O
the	O
United	O
Kingdom	O
.	O

Ketoconazole	O
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O

By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	B
associated	O
with	O
the	O
drug	O
,	O
including	O
five	O
deaths	B
.	O

An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deaths	B
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug	O
.	O

Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatment	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O

The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57	O
.	O
9	O
,	O
with	O
hepatotoxicity	B
being	O
more	O
common	O
in	O
women	O
.	O

The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	B
was	O
61	O
days	O
.	O

None	O
of	O
these	O
well	O
validated	O
cases	O
occurred	O
within	O
the	O
first	O
10	O
days	O
after	O
treatment	O
.	O

The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	B
injury	I
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O

In	O
contrast	O
,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	B
.	O

The	O
characteristics	O
of	O
the	O
48	O
patients	O
in	O
the	O
possible	O
cases	O
were	O
similar	O
.	O

Allergic	O
manifestations	O
such	O
as	O
rash	B
and	O
eosinophilia	B
were	O
rare	O
.	O

Hepatitis	B
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped	O
,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3	O
.	O
1	O
months	O
.	O

In	O
two	O
of	O
the	O
three	O
deaths	B
probably	O
associated	O
with	O
ketoconazole	O
treatment	O
the	O
drug	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	B
and	O
other	O
symptoms	O
of	O
hepatitis	B
.	O

Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	B
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	O
to	O
prevent	O
possible	O
serious	O
hepatic	B
injury	I
.	O

Glyburide	O
-	O
induced	O
hepatitis	B
.	O

Drug	O
-	O
induced	O
hepatotoxicity	B
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	O
.	O

For	O
glyburide	O
,	O
a	O
second	O
-	O
generation	O
sulfonylurea	O
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	B
exist	O
.	O

Two	O
patients	O
with	O
type	B
II	I
diabetes	I
mellitus	I
developed	O
an	O
acute	B
hepatitis	I
-	I
like	I
syndrome	I
soon	O
after	O
initiation	O
of	O
glyburide	O
therapy	O
.	O

There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	B
infection	I
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug	B
-	I
induced	I
hepatitis	I
.	O

Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	O
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
period	O
of	O
1	O
year	O
.	O

Glyburide	O
can	O
produce	O
an	O
acute	B
hepatitis	I
-	I
like	I
illness	I
in	O
some	O
persons	O
.	O

Intracranial	O
pressure	O
increases	O
during	O
alfentanil	O
-	O
induced	O
rigidity	B
.	O

Intracranial	O
pressure	O
(	O
ICP	O
)	O
was	O
measured	O
during	O
alfentanil	O
-	O
induced	O
rigidity	B
in	O
rats	O
.	O

Ten	O
rats	O
had	O
arterial	O
,	O
central	O
venous	O
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	O
anesthesia	O
.	O

The	O
animals	O
were	O
mechanically	O
ventilated	O
to	O
achieve	O
normocarbia	O
(	O
PCO2	O
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

Following	O
instrumentation	O
,	O
halothane	O
was	O
discontinued	O
and	O
alfentanil	O
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	O
anesthesia	O
.	O

In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	B
rigidity	I
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O

These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	B
was	O
abolished	O
with	O
metocurine	O
.	O

In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	O
.	O

These	O
observations	O
suggest	O
that	O
rigidity	B
should	O
be	O
prevented	O
when	O
alfentanil	O
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	O
,	O
are	O
used	O
in	O
the	O
anesthetic	O
management	O
of	O
patients	O
with	O
ICP	O
problems	O
.	O

Verapamil	O
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B
infarction	I
in	O
a	O
hypertensive	B
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O

Verapamil	O
is	O
an	O
effective	O
and	O
relatively	O
-	O
safe	O
antihypertensive	O
drug	O
.	O

Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	B
of	O
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O

We	O
report	O
a	O
case	O
in	O
which	O
myocardial	B
infarction	I
coincided	O
with	O
the	O
introduction	O
of	O
captopril	O
and	O
the	O
withdrawal	O
of	O
verapamil	O
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	B
.	O

Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil	O
-	O
related	O
increase	O
in	O
platelet	O
and	O
/	O
or	O
vascular	O
alpha	O
2	O
-	O
adrenoreceptor	O
affinity	O
for	O
catecholamines	O
are	O
discussed	O
.	O

Haemolytic	B
-	I
uraemic	I
syndrome	I
after	O
treatment	O
with	O
metronidazole	O
.	O

This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic	B
-	I
uraemic	I
syndrome	I
after	O
treatment	O
with	O
metronidazole	O
.	O

These	O
children	O
were	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowel	O
surgery	O
than	O
are	O
other	O
children	O
with	O
this	O
condition	O
.	O

While	O
the	O
involvement	O
of	O
metronidazole	O
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	B
-	I
uraemic	I
syndrome	I
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	B
-	I
uraemic	I
syndrome	I
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	O
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic	B
-	I
uraemic	I
syndrome	I
.	O

Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis	O
-	O
platin	O
and	O
5	O
-	O
fluorouracil	O
.	O

Survival	O
for	O
patients	O
with	O
advanced	O
head	B
and	I
neck	I
carcinoma	I
and	O
esophageal	B
carcinoma	I
is	O
poor	O
with	O
radiotherapy	O
and	O
/	O
or	O
surgery	O
.	O

Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effective	O
chemotherapy	O
.	O

In	O
the	O
present	O
study	O
,	O
cis	O
-	O
platin	O
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5	O
-	O
FU	O
(	O
1000	O
mg	O
/	O
m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
clarify	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
cardiac	O
effects	O
to	O
this	O
treatment	O
.	O

Before	O
treatment	O
all	O
patients	O
had	O
a	O
cardiac	O
evaluation	O
and	O
during	O
treatment	O
serial	O
ECG	O
recordings	O
were	O
performed	O
.	O

In	O
the	O
pre	O
-	O
treatment	O
evaluation	O
,	O
signs	O
of	O
cardiovascular	B
disease	I
were	O
found	O
in	O
33	O
patients	O
(	O
43	O
%	O
)	O
.	O

During	O
treatment	O
,	O
adverse	O
cardiac	O
effects	O
were	O
observed	O
in	O
14	O
patients	O
(	O
18	O
%	O
)	O
.	O

The	O
mean	O
age	O
of	O
these	O
patients	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
group	O
,	O
64	O
years	O
.	O

The	O
incidence	O
of	O
cardiotoxicity	B
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B
disease	I
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treatment	O
evaluation	O
.	O

The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	B
were	O
chest	B
pain	I
,	O
ST	O
-	O
T	O
wave	O
changes	O
and	O
atrial	B
fibrillation	I
.	O

This	O
was	O
followed	O
by	O
ventricular	B
fibrillation	I
in	O
one	O
patient	O
and	O
sudden	B
death	I
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
patients	O
on	O
5	O
-	O
FU	O
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B
pain	I
or	O
tachyarrhythmia	B
is	O
observed	O
.	O

Death	B
from	O
chemotherapy	O
in	O
gestational	B
trophoblastic	I
disease	I
.	O

Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high	O
-	O
risk	O
stage	O
of	O
choriocarcinoma	B
.	O

Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
year	O
old	O
woman	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
risk	O
group	O
(	O
Goldstein	O
and	O
Berkowitz	O
score	O
:	O
11	O
)	O
,	O
was	O
treated	O
with	O
multiple	O
cytotoxic	O
drugs	O
.	O

The	O
multiple	O
drug	O
schema	O
consisted	O
of	O
:	O
Etoposide	O
16	O
.	O
213	O
,	O
Methotrexate	O
,	O
Cyclophosphamide	O
,	O
Actomycin	O
-	O
D	O
,	O
and	O
Cisplatin	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
schedule	O
,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	O
,	O
Etoposide	O
and	O
Cyclophosphamide	O
were	O
administered	O
.	O

Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	B
obstruction	I
due	O
to	O
choriocarcinomic	O
tissue	O
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O

Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	B
necrosis	B
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	B
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	B
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	B
emboli	O
.	O

In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	B
other	O
explanations	O
,	O
such	O
as	O
spontaneous	O
necrosis	B
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patients	O
with	O
large	O
pelvic	B
tumor	I
loads	O
are	O
,	O
according	O
to	O
existing	O
classifications	O
,	O
at	O
high	O
risk	O
to	O
die	O
and	O
to	O
develop	O
drug	O
resistance	O
.	O

Notwithstanding	O
these	O
facts	O
our	O
findings	O
suggest	O
that	O
these	O
patients	O
might	O
benefit	O
from	O
relatively	O
mild	O
initial	O
treatment	O
,	O
especially	O
true	O
for	O
patients	O
not	O
previously	O
exposed	O
to	O
this	O
drug	O
.	O

Close	O
observation	O
of	O
the	O
response	O
status	O
both	O
clinically	O
and	O
with	O
beta	O
-	O
hCG	O
values	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agressive	O
combination	O
chemotherapy	O
should	O
be	O
started	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside	O
-	O
induced	O
hypotension	B
.	O

The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	O
nitroprusside	O
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
nitroprusside	O
infusion	O
,	O
5	O
cm	O
H2O	O
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
systemic	O
vascular	O
resistance	O
,	O
or	O
QS	O
/	O
QT	O
.	O

Ten	O
cm	O
H2O	O
CPAP	O
before	O
nitroprusside	O
infusion	O
produced	O
a	O
further	O
decrease	B
in	I
arterial	I
blood	I
pressure	I
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B
cardiac	I
output	I
and	O
QS	O
/	O
QT	O
.	O

Nitroprusside	O
caused	O
significant	O
decreases	B
in	I
arterial	I
blood	I
pressure	I
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	O
CPAP	O
during	O
nitroprusside	O
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	O
.	O

However	O
,	O
10	O
cm	O
H2O	O
CPAP	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
data	O
indicate	O
that	O
nitroprusside	O
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitroprusside	O
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	O
)	O
,	O
while	O
decreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreases	B
in	I
arterial	I
blood	I
pressure	I
and	I
cardiac	I
output	I
.	O

Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	B
than	O
during	O
sodium	O
nitroprusside	O
-	O
induced	O
hypotension	B
in	O
ventilated	O
dogs	O
.	O

The	O
systolic	O
pressure	O
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
positive	O
-	O
pressure	O
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	B
.	O

Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	B
(	O
HEM	B
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	O
nitroprusside	O
(	O
SNP	O
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	B
-	O
induced	O
hypotension	B
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	O
group	O
.	O

The	O
systemic	O
,	O
central	O
venous	O
,	O
pulmonary	O
capillary	O
wedge	O
pressures	O
,	O
and	O
heart	O
rates	O
,	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Analysis	O
of	O
the	O
respiratory	O
changes	O
in	O
the	O
arterial	O
pressure	O
waveform	O
enabled	O
differentiation	O
between	O
the	O
two	O
groups	O
.	O

The	O
SPV	O
during	O
hypotension	B
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	B
group	O
,	O
compared	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measure	O
of	O
decrease	O
of	O
SBP	O
after	O
a	O
mechanical	O
breath	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	B
and	O
SNP	O
groups	O
,	O
respectively	O
,	O
during	O
hypotension	B
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	B
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	B
than	O
during	O
deliberate	O
hypotension	B
.	O

Ventricular	B
tachyarrhythmias	I
during	O
cesarean	O
section	O
after	O
ritodrine	O
therapy	O
:	O
interaction	O
with	O
anesthetics	O
.	O

This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	O
for	O
preterm	B
labor	I
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	O
and	O
the	O
effects	O
of	O
anesthetics	O
during	O
cesarean	O
section	O
.	O

Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	B
complications	I
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	O
.	O

Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	O
level	O
.	O

Delaying	O
induction	O
of	O
anesthesia	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O

Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	O
are	O
advised	O
.	O

After	O
delivery	O
of	O
the	O
infant	O
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha	O
-	O
adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	O
to	O
treat	O
hypotensive	B
patients	O
with	O
tachycardia	B
.	O

Verapamil	O
-	O
induced	O
carbamazepine	O
neurotoxicity	B
.	O

A	O
report	O
of	O
two	O
cases	O
.	O

Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	O
neurotoxicity	B
after	O
combined	O
treatment	O
with	O
verapamil	O
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	O
entry	O
blocker	O
.	O

Use	O
of	O
verapamil	O
in	O
combination	O
with	O
carbamazepine	O
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	O
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	O
dose	O
by	O
one	O
half	O
)	O
.	O

Paracetamol	O
-	O
associated	O
coma	B
,	O
metabolic	B
acidosis	I
,	O
renal	B
and	I
hepatic	I
failure	I
.	O

A	O
case	O
of	O
metabolic	B
acidosis	I
,	O
acute	B
renal	I
failure	I
and	I
hepatic	I
failure	I
following	O
paracetamol	O
ingestion	O
is	O
presented	O
.	O

The	O
diagnostic	O
difficulty	O
at	O
presentation	O
is	O
highlighted	O
.	O

Continuous	O
arteriovenous	O
haemofiltration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fluid	O
and	O
electrolyte	O
balance	O
.	O

The	O
patient	O
recovered	O
.	O

Sexual	B
dysfunction	I
among	O
patients	O
with	O
arthritis	B
.	O

The	O
relationship	O
of	O
arthritis	B
and	O
sexual	B
dysfunction	I
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B
arthritis	I
,	O
osteoarthritis	B
and	O
spondyloarthropathy	B
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	O
.	O

Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B
mood	I
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(	O
AMHS	O
)	O
.	O

Sexual	B
dysfunctions	I
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls	O
,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions	O
.	O

Impotence	B
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	O
.	O

Depressed	B
mood	I
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B
.	O

Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B
but	O
was	O
associated	O
with	O
sexual	B
dysfunction	I
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O

Does	O
paracetamol	O
cause	O
urothelial	B
cancer	I
or	O
renal	B
papillary	I
necrosis	I
?	O

The	O
risk	O
of	O
developing	O
renal	B
papillary	I
necrosis	I
or	O
cancer	B
of	I
the	I
renal	I
pelvis	I
,	I
ureter	I
or	I
bladder	I
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	O
or	O
paracetamol	O
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O

The	O
risk	O
of	O
renal	B
papillary	I
necrosis	I
was	O
increased	O
nearly	O
20	O
-	O
fold	O
by	O
consumption	O
of	O
phenacetin	O
,	O
which	O
also	O
increased	O
the	O
risk	O
for	O
cancer	B
of	I
the	I
renal	I
pelvis	I
and	I
bladder	I
but	O
not	O
for	O
ureteric	B
cancer	I
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	O
consumption	O
for	O
renal	B
papillary	I
necrosis	I
or	O
any	O
of	O
these	O
cancers	B
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	B
of	I
the	I
ureter	I
.	O

Dapsone	O
-	O
associated	O
Heinz	O
body	O
hemolytic	B
anemia	I
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
.	O

A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B
developed	O
a	O
Heinz	O
body	O
hemolytic	B
anemia	I
while	O
taking	O
a	O
dose	O
of	O
dapsone	O
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	B
.	O

Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
decreased	O
GSH	O
stability	O
.	O

The	O
pentose	O
phosphate	O
shunt	O
activity	O
of	O
the	O
dapsone	O
-	O
exposed	O
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	O
content	O
and	O
GSH	O
stability	O
were	O
normal	O
.	O

The	O
pentose	O
phosphate	O
shunt	O
activity	O
of	O
the	O
non	O
-	O
dapsone	O
-	O
exposed	O
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	O
does	O
not	O
cause	O
hemolytic	B
anemia	I
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O

Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	B
is	O
present	O
,	O
in	O
individuals	O
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	O
prevalence	O
of	O
hemoglobin	O
E	O
.	O

Severe	O
complications	O
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	O
,	O
propafenone	O
,	O
diltiazem	O
,	O
and	O
sparteine	O
.	O

A	O
47	O
-	O
year	O
-	O
old	O
patient	O
suffering	O
from	O
coronary	B
artery	I
disease	I
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	B
with	O
III	O
.	O

AV	B
block	I
,	O
severe	O
hypotension	B
,	O
and	O
impairment	B
of	I
ventricular	I
function	I
.	O

One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	O
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
days	O
before	O
admission	O
diltiazem	O
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
prescribed	O
in	O
addition	O
.	O

Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	O
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
diltiazem	O
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

The	O
patient	O
recovered	O
within	O
1	O
week	O
following	O
discontinuation	O
of	O
antianginal	O
therapy	O
.	O

Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	O
,	O
diltiazem	O
,	O
propafenone	O
(	O
since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past	O
)	O
,	O
and	O
sparteine	O
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	O
/	O
sparteine	O
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism	O
)	O
.	O

It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs	O
,	O
indicating	O
that	O
their	O
metabolism	O
is	O
under	O
the	O
same	O
genetic	O
control	O
.	O

Therefore	O
,	O
patients	O
belonging	O
to	O
the	O
poor	O
-	O
metabolizer	O
phenotype	O
of	O
sparteine	O
/	O
debrisoquine	O
polymorphism	O
in	O
drug	O
metabolism	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
German	O
population	O
,	O
may	O
experience	O
adverse	B
drug	I
reactions	I
when	O
treated	O
with	O
standard	O
doses	O
of	O
one	O
of	O
these	O
drugs	O
alone	O
.	O

Moreover	O
,	O
the	O
coadministration	O
of	O
these	O
frequently	O
used	O
drugs	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O

Clinical	O
experiences	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
blind	O
trial	O
.	O

A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	O
first	O
in	O
open	O
conditions	O
(	O
20	O
patients	O
)	O
,	O
then	O
on	O
a	O
double	O
blind	O
basis	O
(	O
40	O
patients	O
)	O
with	O
haloperidol	O
as	O
the	O
reference	O
substance	O
.	O

The	O
open	O
study	O
lasted	O
for	O
four	O
weeks	O
;	O
the	O
drug	O
was	O
administrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tablets	O
.	O

The	O
daily	O
dose	O
(	O
initial	O
dose	O
:	O
1	O
mg	O
;	O
mean	O
dose	O
at	O
the	O
end	O
of	O
the	O
trial	O
:	O
4	O
.	O
47	O
mg	O
)	O
was	O
always	O
administered	O
in	O
one	O
single	O
dose	O
.	O

Nineteen	O
patients	O
finished	O
the	O
trial	O
,	O
and	O
in	O
18	O
cases	O
the	O
therapeutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
statistical	O
analysis	O
.	O

Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	B
concomitant	I
symptoms	I
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O

The	O
results	O
of	O
detailed	O
laboratory	O
tests	O
and	O
evaluations	O
of	O
various	O
quantitative	O
and	O
qualitative	O
tolerability	O
parameters	O
were	O
not	O
indicative	O
of	O
toxic	O
effects	O
.	O

In	O
the	O
double	O
blind	O
study	O
with	O
haloperidol	O
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
psychotic	B
syndromes	I
belonging	I
predominantly	I
to	I
the	I
schizophrenia	I
group	I
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	O
.	O

No	O
differences	O
were	O
observed	O
with	O
respect	O
to	O
side	O
effects	O
and	O
general	O
tolerability	O
.	O

Prolonged	O
cholestasis	B
after	O
troleandomycin	O
-	O
induced	O
acute	O
hepatitis	B
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin	O
-	O
induced	O
hepatitis	B
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B
.	O

Jaundice	B
occurred	O
after	O
administration	O
of	O
troleandomycin	O
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	B
.	O

Jaundice	B
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B
marked	O
by	O
pruritus	B
and	O
high	O
levels	O
of	O
alkaline	O
phosphatase	O
and	O
gammaglutamyltransferase	O
activities	O
.	O

Finally	O
,	O
pruritus	B
disappeared	O
within	O
19	O
months	O
,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	B
.	O

This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	B
can	O
follow	O
troleandomycin	O
-	O
induced	O
acute	O
hepatitis	B
.	O

Serial	O
studies	O
of	O
auditory	B
neurotoxicity	I
in	O
patients	O
receiving	O
deferoxamine	O
therapy	O
.	O

Visual	B
and	I
auditory	I
neurotoxicity	I
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion	O
-	O
dependent	O
anemia	B
who	O
were	O
receiving	O
iron	O
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	O
.	O

Twenty	O
-	O
two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	B
audiograms	I
with	I
deficits	I
mostly	I
in	I
the	I
high	I
frequency	I
range	I
of	I
4	I
,	I
000	I
to	I
8	I
,	I
000	I
Hz	I
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O

When	O
deferoxamine	O
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed	O
,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic	O
.	O

Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	O
because	O
of	O
permanent	B
disability	I
.	O

Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	O
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	B
abnormality	I
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	B
was	O
demonstrated	O
.	O

Auditory	O
deterioration	O
and	O
improvement	O
,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	O
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relation	O
between	O
deferoxamine	O
administration	O
and	O
ototoxicity	B
.	O

Based	O
on	O
these	O
data	O
,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	O
.	O

A	O
dose	O
of	O
50	O
mg	O
/	O
kg	O
is	O
recommended	O
in	O
those	O
without	O
audiogram	O
abnormalities	O
.	O

With	O
mild	O
toxicity	B
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks	O
.	O

Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O

In	O
those	O
with	O
symptoms	O
of	O
hearing	B
loss	I
,	O
the	O
drug	O
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
.	O

Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	B
dysfunction	I
.	O

Lidocaine	O
-	O
induced	O
cardiac	B
asystole	I
.	O

Intravenous	O
administration	O
of	O
a	O
single	O
50	O
-	O
mg	O
bolus	O
of	O
lidocaine	O
in	O
a	O
67	O
-	O
year	O
-	O
old	O
man	O
resulted	O
in	O
profound	O
depression	B
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers	O
.	O

The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	O
.	O

Flurbiprofen	O
in	O
the	O
treatment	O
of	O
juvenile	B
rheumatoid	I
arthritis	I
.	O

Thirty	O
-	O
four	O
patients	O
with	O
juvenile	B
rheumatoid	I
arthritis	I
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	O
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	B
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	B
joints	I
,	O
the	O
severity	O
of	O
swelling	B
and	O
tenderness	B
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	O
of	O
morning	B
stiffness	I
and	O
the	O
circumference	O
of	O
the	O
left	O
knee	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	B
occult	I
blood	I
(	O
25	O
%	O
of	O
patients	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	B
(	I
GI	I
)	I
bleeding	I
in	O
these	O
patients	O
.	O

One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	B
and	O
abdominal	B
pain	I
.	O

Most	O
side	O
effects	O
were	O
mild	O
and	O
related	O
to	O
the	O
GI	O
tract	O
.	O

Hyperkalemia	B
associated	O
with	O
sulindac	O
therapy	O
.	O

Hyperkalemia	B
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(	O
NSAID	O
)	O
such	O
as	O
indomethacin	O
.	O

Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	O
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	O
synthesis	O
.	O

We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	B
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	O
administration	O
.	O

In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	O
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	O
.	O

As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	O
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	O
and	O
hyperkalemia	B
.	O

These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	O
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	O
renal	O
effects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O

Drug	O
-	O
induced	O
arterial	O
spasm	B
relieved	O
by	O
lidocaine	O
.	O

Case	O
report	O
.	O

Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35	O
-	O
year	O
-	O
old	O
man	O
,	O
sodium	O
pentothal	O
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	B
ischaemia	I
.	O

Intense	O
vasospasm	B
with	O
threatened	O
gangrene	B
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O

Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	O
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B
.	O

The	O
treatment	O
was	O
rapidly	O
successful	O
.	O

Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	O
-	O
induced	O
hyperactivity	B
by	O
intracerebral	O
calcitonin	O
injections	O
.	O

Calcitonin	O
receptors	O
are	O
found	O
in	O
the	O
brain	O
,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	O
can	O
produce	O
behavioral	O
effects	O
.	O

Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine	O
-	O
induced	O
locomotor	O
activity	O
.	O

In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	O
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens	O
.	O

In	O
the	O
present	O
experiment	O
calcitonin	O
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake	O
.	O

The	O
areas	O
where	O
calcitonin	O
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	O
in	O
inhibiting	O
amphetamine	O
-	O
induced	O
locomotor	O
activity	O
.	O

The	O
hematologic	O
effects	O
of	O
cefonicid	O
and	O
cefazedone	O
in	O
the	O
dog	O
:	O
a	O
potential	O
model	O
of	O
cephalosporin	O
hematotoxicity	B
in	O
man	O
.	O

Cephalosporin	O
antibiotics	O
cause	O
a	O
variety	O
of	O
hematologic	B
disturbances	I
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
animal	O
model	O
in	O
which	O
these	O
blood	B
dyscrasias	I
can	O
be	O
studied	O
.	O

In	O
four	O
subacute	O
toxicity	B
studies	O
,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	O
or	O
cefazedone	O
to	O
beagle	O
dogs	O
caused	O
a	O
dose	O
-	O
dependent	O
incidence	O
of	O
anemia	B
,	O
neutropenia	B
,	O
and	O
thrombocytopenia	B
after	O
1	O
-	O
3	O
months	O
of	O
treatment	O
.	O

A	O
nonregenerative	O
anemia	B
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicid	O
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazedone	O
.	O

All	O
three	O
cytopenias	B
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment	O
;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(	O
approximately	O
1	O
month	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	O
to	O
a	O
few	O
days	O
)	O
.	O

Upon	O
rechallenge	O
with	O
either	O
cephalosporin	O
,	O
the	O
hematologic	B
syndrome	I
was	O
reproduced	O
in	O
most	O
dogs	O
tested	O
;	O
cefonicid	O
(	O
but	O
not	O
cefazedone	O
)	O
-	O
treated	O
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(	O
15	O
+	O
/	O
-	O
5	O
days	O
)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	O
to	O
the	O
drug	O
(	O
61	O
+	O
/	O
-	O
24	O
days	O
)	O
.	O

This	O
observation	O
,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs	O
,	O
suggests	O
that	O
a	O
hemolytic	B
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	B
.	O

We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	O
or	O
cefazedone	O
to	O
dogs	O
can	O
induce	O
hematotoxicity	B
similar	O
to	O
the	O
cephalosporin	O
-	O
induced	O
blood	B
dyscrasias	I
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
model	O
for	O
studying	O
the	O
mechanisms	O
of	O
these	O
disorders	O
.	O

Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane	O
-	O
induced	O
hypotension	B
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	B
aneurysms	I
.	O

Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	O
were	O
measured	O
during	O
isoflurane	O
-	O
induced	O
hypotension	B
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B
aneurysm	I
.	O

Flow	O
and	O
metabolism	O
were	O
measured	O
5	O
-	O
13	O
days	O
after	O
the	O
subarachnoid	B
haemorrhage	I
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
technique	O
using	O
xenon	O
-	O
133	O
i	O
.	O
v	O
.	O
Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	O
concentration	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
nitrous	O
oxide	O
in	O
oxygen	O
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PaCO2	O
4	O
.	O
1	O
+	O
/	O

-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

Controlled	O
hypotension	B
to	O
an	O
average	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	O
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	O
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O

This	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
CMRO2	O
(	O
to	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
)	O
,	O
while	O
CBF	O
was	O
unchanged	O
.	O

After	O
the	O
clipping	O
of	O
the	O
aneurysm	B
the	O
isoflurane	O
concentration	O
was	O
reduced	O
to	O
0	O
.	O
75	O
%	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	O
,	O
compared	O
with	O
pre	O
-	O
hypotensive	B
values	O
.	O

These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	B
.	O

Triazolam	O
-	O
induced	O
brief	O
episodes	O
of	O
secondary	O
mania	B
in	O
a	O
depressed	B
patient	O
.	O

Large	O
doses	O
of	O
triazolam	O
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	B
in	O
a	O
depressed	B
elderly	O
woman	O
.	O

Features	O
of	O
organic	B
mental	I
disorder	I
(	O
delirium	B
)	O
were	O
not	O
present	O
.	O

Manic	B
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	O
.	O

The	O
possible	O
contribution	O
of	O
the	O
triazolo	O
group	O
to	O
changes	O
in	O
affective	O
status	O
is	O
discussed	O
.	O

The	O
correlation	O
between	O
neurotoxic	B
esterase	O
inhibition	O
and	O
mipafox	O
-	O
induced	O
neuropathic	B
damage	I
in	O
rats	O
.	O

The	O
correlation	O
between	O
neuropathic	B
damage	I
and	O
inhibition	O
of	O
neurotoxic	B
esterase	O
or	O
neuropathy	B
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	O
(	O
N	O
,	O
N	O
'	O
-	O
diisopropylphosphorodiamidofluoridate	O
)	O
,	O
a	O
neurotoxic	B
organophosphate	O
.	O

Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long	O
-	O
Evans	O
male	O
rats	O
1	O
hr	O
post	O
-	O
exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	O
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	B
damage	I
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14	O
-	O
21	O
days	O
post	O
-	O
exposure	O
.	O

Those	O
dosages	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
the	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
73	O
%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
67	O
%	O
of	O
control	O
values	O
produced	O
severe	O
(	O
greater	O
than	O
or	O
equal	O
to	O
3	O
)	O
cervical	O
cord	O
pathology	O
in	O
85	O
%	O
of	O
the	O
rats	O
.	O

In	O
contrast	O
,	O
dosages	O
of	O
Mipafox	O
(	O
less	O
than	O
or	O
equal	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	O
less	O
than	O
or	O
equal	O
to	O
61	O
%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60	O
%	O
produced	O
this	O
degree	O
of	O
cord	B
damage	I
in	O
only	O
9	O
%	O
of	O
the	O
animals	O
.	O

These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	O
exposure	O
can	O
predict	O
neuropathic	B
damage	I
in	O
rats	O
several	O
weeks	O
later	O
.	O

Allergic	B
reaction	I
to	O
5	O
-	O
fluorouracil	O
infusion	O
.	O

An	O
allergic	B
reaction	I
consisting	O
of	O
angioneurotic	B
edema	I
secondary	O
to	O
continuous	O
infusion	O
5	O
-	O
fluorouracil	O
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	B
of	I
the	I
oral	I
cavity	I
,	O
cirrhosis	B
,	O
and	O
cisplatin	O
-	O
induced	O
impaired	B
renal	I
function	I
.	O

This	O
reaction	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
courses	O
of	O
infusional	O
chemotherapy	O
.	O

Oral	O
diphenhydramine	O
and	O
prednisone	O
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	B
reaction	I
.	O

Discontinuance	O
of	O
effective	O
chemotherapy	O
in	O
this	O
patient	O
during	O
partial	O
remission	O
resulted	O
in	O
fatal	O
disease	O
progression	O
.	O

Myasthenia	B
gravis	I
caused	O
by	O
penicillamine	O
and	O
chloroquine	O
therapy	O
for	O
rheumatoid	B
arthritis	I
.	O

We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose	O
-	O
related	O
myasthenia	B
gravis	I
after	O
penicillamine	O
and	O
chloroquine	O
therapy	O
for	O
rheumatoid	B
arthritis	I
.	O

Although	O
acetylcholine	O
receptor	O
antibodies	O
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	O
with	O
an	O
autoimmune	O
process	O
.	O

On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B
rigidity	I
produced	O
by	O
morphine	O
in	O
rats	O
.	O

The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B
rigidity	I
produced	O
by	O
morphine	O
was	O
studied	O
in	O
rats	O
.	O

Saline	O
-	O
pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidity	B
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram	O
.	O

Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	O
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	B
after	O
the	O
test	O
dose	O
of	O
morphine	O
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	B
(	O
A	O
group	O
)	O
.	O

The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	B
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and	O
/	O
or	O
gnawing	O
in	O
presence	O
of	O
akinetic	B
or	O
hyperkinetic	B
(	O
K	O
)	O
behaviour	O
(	O
AS	O
/	O
KS	O
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation	O
.	O

The	O
rigidity	B
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O

In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	O
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	B
without	O
any	O
dopaminergic	O
interference	O
.	O

Haloperidol	O
enhanced	O
the	O
rigidity	B
in	O
the	O
A	O
group	O
.	O

However	O
,	O
the	O
level	O
in	O
the	O
AS	O
/	O
KS	O
group	O
remained	O
considerably	O
lower	O
than	O
in	O
the	O
A	O
group	O
.	O

The	O
results	O
suggest	O
that	O
rigidity	B
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	O
in	O
the	O
striatum	O
,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	O
activation	O
in	O
the	O
striatum	O
.	O

Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tolerance	O
to	O
this	O
effect	O
.	O

The	O
rapid	O
alternations	O
of	O
rigidity	B
and	O
the	O
signs	O
of	O
dopaminergic	O
activation	O
observed	O
in	O
the	O
animals	O
of	O
the	O
AS	O
/	O
KS	O
group	O
might	O
be	O
due	O
to	O
rapid	O
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
innervated	O
structures	O
.	O

A	O
case	O
of	O
massive	O
rhabdomyolysis	B
following	O
molindone	O
administration	O
.	O

Rhabdomyolysis	B
is	O
a	O
potentially	O
lethal	O
syndrome	O
that	O
psychiatric	B
patients	O
seem	O
predisposed	O
to	O
develop	O
.	O

The	O
clinical	O
signs	O
and	O
symptoms	O
,	O
typical	O
laboratory	O
features	O
,	O
and	O
complications	O
of	O
rhabdomyolysis	B
are	O
presented	O
.	O

The	O
case	O
of	O
a	O
schizophrenic	B
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	B
and	O
subsequent	O
acute	B
renal	I
failure	I
following	O
molindone	O
administration	O
.	O

Physicians	O
who	O
prescribe	O
molindone	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O

Compression	B
neuropathy	I
of	I
the	I
radial	I
nerve	I
due	O
to	O
pentazocine	O
-	O
induced	O
fibrous	B
myopathy	I
.	O

Fibrous	B
myopathy	I
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effect	O
of	O
repeated	O
pentazocine	O
injection	O
.	O

However	O
,	O
compression	B
neuropathy	I
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	O
-	O
induced	O
myopathy	B
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37	O
-	O
year	O
-	O
old	O
woman	O
with	O
documented	O
pentazocine	O
-	O
induced	O
fibrous	B
myopathy	I
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three	O
-	O
week	O
history	O
of	O
right	O
wrist	O
drop	O
,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	O
to	O
the	O
fibrous	B
myopathy	I
.	O

Surgery	O
revealed	O
the	O
right	O
radial	O
nerve	O
to	O
be	O
severely	O
compressed	O
by	O
the	O
densely	O
fibrotic	O
lateral	O
head	O
of	O
the	O
triceps	O
.	O

Decompression	O
and	O
neurolysis	O
were	O
performed	O
with	O
good	O
subsequent	O
recovery	O
of	O
function	O
.	O

Recurrent	O
reversible	O
acute	B
renal	I
failure	I
from	O
amphotericin	O
.	O

A	O
patient	O
with	O
cryptogenic	O
cirrhosis	B
and	O
disseminated	O
sporotrichosis	B
developed	O
acute	B
renal	I
failure	I
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	O
B	O
on	O
four	O
separate	O
occasions	O
.	O

The	O
abruptness	O
of	O
the	O
renal	B
failure	I
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	B
dysfunction	I
.	O

We	O
propose	O
that	O
amphotericin	O
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B
renal	I
failure	I
.	O

Cerebral	B
infarction	I
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	O
.	O

Phenylpropanolamine	O
(	O
PPA	O
)	O
,	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	O
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	O
.	O

Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B
,	O
intracerebral	B
hemorrhage	I
,	O
neuropsychiatric	B
symptoms	I
,	O
and	O
nonhemorrhagic	O
cerebral	B
infarction	I
.	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	B
infarction	I
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	O
.	O

Remission	O
induction	O
of	O
meningeal	B
leukemia	I
with	O
high	O
-	O
dose	O
intravenous	O
methotrexate	O
.	O

Twenty	O
children	O
with	O
acute	B
lymphoblastic	I
leukemia	I
who	O
developed	O
meningeal	B
disease	I
were	O
treated	O
with	O
a	O
high	O
-	O
dose	O
intravenous	O
methotrexate	O
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	O
concentrations	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concomitant	O
intrathecal	O
dosing	O
.	O

The	O
methotrexate	O
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O

Leucovorin	O
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	O
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O

The	O
mean	O
steady	O
-	O
state	O
plasma	O
and	O
CSF	O
methotrexate	O
concentrations	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

All	O
20	O
patients	O
responded	O
to	O
this	O
regimen	O
,	O
16	O
/	O
20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remission	O
,	O
and	O
20	O
%	O
obtained	O
a	O
partial	O
remission	O
.	O

The	O
most	O
common	O
toxicities	B
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	O
elevations	O
,	O
neutropenia	B
,	O
and	O
mucositis	B
.	O

One	O
patient	O
had	O
focal	O
seizures	B
and	O
transient	B
hemiparesis	I
but	O
recovered	O
completely	O
.	O

High	O
-	O
dose	O
intravenous	O
methotrexate	O
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	B
lymphoblastic	I
leukemia	I
.	O

Interaction	O
of	O
cyclosporin	O
A	O
with	O
antineoplastic	O
agents	O
.	O

A	O
synergistic	O
effect	O
of	O
etoposide	O
and	O
cyclosporin	O
A	O
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	B
T	I
-	I
lymphocytic	I
leukemia	I
in	O
relapse	O
.	O

The	O
concomitant	O
administration	O
of	O
etoposide	O
and	O
cyclosporin	O
A	O
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	B
infiltration	I
of	O
bone	O
marrow	O
.	O

Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	B
and	O
progressive	O
hyperbilirubinemia	B
,	O
however	O
,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	B
in	O
normal	O
tissues	O
.	O

This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	O
A	O
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
normal	O
T	O
-	O
cell	O
functions	O
.	O

Incidence	O
of	O
neoplasms	B
in	O
patients	O
with	O
rheumatoid	B
arthritis	I
exposed	O
to	O
different	O
treatment	O
regimens	O
.	O

Immunosuppressive	O
drugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	B
arthritis	I
.	O

The	O
drugs	O
commonly	O
used	O
are	O
cyclophosphamide	O
and	O
chlorambucil	O
(	O
alkylating	O
agents	O
)	O
,	O
azathioprine	O
(	O
purine	O
analogue	O
)	O
,	O
and	O
methotrexate	O
(	O
folic	O
acid	O
analogue	O
)	O
.	O

There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	O
can	O
reduce	O
synovitis	B
,	O
but	O
disease	O
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O

Since	O
adverse	O
reactions	O
are	O
frequent	O
,	O
less	O
than	O
50	O
percent	O
of	O
patients	O
are	O
able	O
to	O
continue	O
a	O
particular	O
drug	O
for	O
more	O
than	O
one	O
year	O
.	O

Since	O
it	O
takes	O
three	O
to	O
12	O
months	O
to	O
achieve	O
maximal	O
effects	O
,	O
those	O
patients	O
who	O
are	O
unable	O
to	O
continue	O
the	O
drug	O
receive	O
little	O
benefit	O
from	O
it	O
.	O

Patients	O
treated	O
with	O
alkylating	O
agents	O
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	B
nonlymphocytic	I
leukemia	I
,	O
and	O
both	O
alkylating	O
agents	O
and	O
azathioprine	O
are	O
associated	O
with	O
the	O
development	O
of	O
non	B
-	I
Hodgkin	I
'	I
s	I
lymphoma	I
.	O

Cyclophosphamide	O
therapy	O
increases	O
the	O
risk	O
of	O
carcinoma	B
of	I
the	I
bladder	I
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
studies	O
of	O
patients	O
with	O
rheumatoid	B
arthritis	I
treated	O
with	O
azathioprine	O
and	O
cyclophosphamide	O
and	O
the	O
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	B
is	O
not	O
increased	O
.	O

Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	B
in	O
rheumatoid	B
arthritis	I
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	O
drugs	O
,	O
particularly	O
alkylating	O
agents	O
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	B
arthritis	I
should	O
be	O
reserved	O
for	O
patients	O
with	O
severe	O
progressive	O
disease	O
or	O
life	O
-	O
threatening	O
complications	O
.	O

Warfarin	O
-	O
induced	O
iliopsoas	O
hemorrhage	B
with	O
subsequent	O
femoral	B
nerve	I
palsy	I
.	O

We	O
present	O
the	O
case	O
of	O
a	O
28	O
-	O
year	O
-	O
old	O
man	O
on	O
chronic	O
warfarin	O
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	B
tear	I
and	O
developed	O
increasing	O
pain	B
and	O
a	O
flexure	O
contracture	B
of	O
the	O
right	O
hip	O
.	O

Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	B
and	O
femoral	O
nerve	B
entrapment	I
,	O
resulting	O
in	O
a	O
femoral	B
nerve	I
palsy	I
and	O
partial	B
loss	I
of	I
quadriceps	I
functions	I
.	O

Anticoagulant	O
-	O
induced	O
femoral	B
nerve	I
palsy	I
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin	O
-	O
induced	O
peripheral	B
neuropathy	I
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	B
in	O
the	O
inguinal	O
region	O
,	O
varying	O
degrees	O
of	O
motor	B
and	I
sensory	I
impairment	I
,	O
and	O
flexure	O
contracture	B
of	O
the	O
involved	O
extremity	O
.	O

Pneumonitis	O
with	O
pleural	B
and	I
pericardial	I
effusion	I
and	O
neuropathy	B
during	O
amiodarone	O
therapy	O
.	O

A	O
patient	O
with	O
sinuatrial	B
disease	I
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	O
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	B
tachyarrhythmias	I
.	O

He	O
developed	O
pneumonitis	B
,	O
pleural	B
and	I
pericardial	I
effusions	I
,	O
and	O
a	O
predominantly	O
proximal	B
motor	I
neuropathy	I
.	O

Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	O
and	O
treatment	O
with	O
prednisolone	O
.	O

Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	O
pneumonitis	B
,	O
immediate	O
withdrawal	O
of	O
amiodarone	O
,	O
and	O
prompt	O
but	O
continued	O
steroid	O
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O

Amiodarone	O
-	O
induced	O
sinoatrial	B
block	I
.	O

We	O
observed	O
sinoatrial	B
block	I
due	O
to	O
chronic	O
amiodarone	O
administration	O
in	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
with	O
primary	B
cardiomyopathy	I
,	O
Wolff	B
-	I
Parkinson	I
-	I
White	I
syndrome	I
and	O
supraventricular	B
tachycardia	I
.	O

Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	O
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B
block	I
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B
bradycardia	I
.	O

Desipramine	O
-	O
induced	O
delirium	B
at	O
"	O
subtherapeutic	O
"	O
concentrations	O
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	O
developed	O
a	O
delirium	B
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
"	O
subtherapeutic	O
"	O
range	O
.	O

Delirium	B
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	O
therapy	O
in	O
the	O
elderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	O
potency	O
.	O

Therapeutic	O
ranges	O
for	O
antidepressants	O
that	O
have	O
been	O
derived	O
from	O
general	O
adult	O
population	O
studies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	O
.	O

Further	O
studies	O
of	O
specifically	O
elderly	O
patients	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidelines	O
for	O
drug	O
therapy	O
.	O

Indomethacin	O
-	O
induced	O
renal	B
insufficiency	I
:	O
recurrence	O
on	O
rechallenge	O
.	O

We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	B
failure	I
with	O
hyperkalemia	B
in	O
a	O
patient	O
with	O
cirrhosis	B
,	O
ascites	B
,	O
and	O
cor	B
pulmonale	I
after	O
indomethacin	O
therapy	O
.	O

Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	O
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	B
.	O

Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	O
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O

Since	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	B
renal	I
failure	I
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
patients	O
.	O

Patterns	O
of	O
hepatic	B
injury	I
induced	O
by	O
methyldopa	O
.	O

Twelve	O
patients	O
with	O
liver	B
disease	I
related	O
to	O
methyldopa	O
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Illness	O
occurred	O
within	O
1	O
-	O
-	O
9	O
weeks	O
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients	O
,	O
the	O
remaining	O
3	O
patients	O
having	O
received	O
the	O
drug	O
for	O
13	O
months	O
,	O
15	O
months	O
and	O
7	O
years	O
before	O
experiencing	O
symptoms	O
.	O

Jaundice	B
with	O
tender	O
hepatomegaly	B
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise	O
,	O
anorexia	B
,	O
nausea	B
and	O
vomiting	B
,	O
and	O
associated	O
with	O
upper	O
abdominal	B
pain	I
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	O
.	O

Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	B
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	B
injury	I
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	B
change	I
and	O
focal	O
hepatocellular	O
necrosis	B
to	O
massive	B
hepatic	I
necrosis	I
.	O

Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	B
hepatitis	I
or	O
chronic	B
active	I
hepatitis	I
with	O
associated	O
cholestasis	B
.	O

The	O
drug	O
was	O
withdrawn	O
on	O
presentation	O
to	O
hospital	O
in	O
11	O
patients	O
,	O
with	O
rapid	O
clinical	O
improvement	O
in	O
9	O
.	O

One	O
patient	O
died	O
,	O
having	O
presented	O
in	O
hepatic	B
failure	I
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopa	O
for	O
7	O
years	O
,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	B
hepatitis	I
when	O
the	O
drug	O
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa	O
-	O
induced	O
hepatitis	B
.	O

In	O
this	O
latter	O
patient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	O
between	O
methyldopa	O
and	O
hepatic	B
dysfunction	I
was	O
proved	O
with	O
the	O
recurrence	O
of	O
hepatitis	B
within	O
2	O
weeks	O
of	O
re	O
-	O
exposure	O
to	O
the	O
drug	O
.	O

Suxamethonium	O
infusion	O
rate	O
and	O
observed	O
fasciculations	B
.	O

A	O
dose	O
-	O
response	O
study	O
.	O

Suxamethonium	O
chloride	O
(	O
Sch	O
)	O
was	O
administered	O
i	O
.	O
v	O
.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	B
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	O
120	O
mg	O
was	O
exceeded	O
.	O

Six	O
additional	O
patients	O
received	O
a	O
30	O
-	O
mg	O
i	O
.	O
v	O
.	O
bolus	O
dose	O
.	O

Fasciculations	B
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	B
score	O
.	O

The	O
times	O
to	O
first	O
fasciculation	B
,	O
twitch	B
suppression	O
and	O
tetanus	B
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates	O
.	O

Fasciculations	B
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	B
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O

Total	O
fasciculation	B
scores	O
in	O
the	O
30	O
-	O
mg	O
bolus	O
group	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
infusion	O
groups	O
were	O
not	O
significantly	O
different	O
.	O

Treatment	O
of	O
psoriasis	B
with	O
azathioprine	O
.	O

Azathioprine	O
treatment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	B
.	O

Haematological	O
complications	O
were	O
not	O
troublesome	O
and	O
results	O
of	O
biochemical	O
liver	O
function	O
tests	O
remained	O
normal	O
.	O

Minimal	O
cholestasis	B
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	B
of	O
a	O
reversible	O
degree	O
in	O
eight	O
.	O

Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	O
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	B
damage	I
may	O
be	O
detected	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
.	O

Angiosarcoma	B
of	I
the	I
liver	I
associated	O
with	O
diethylstilbestrol	O
.	O

Angiosarcoma	B
of	I
the	I
liver	I
occurred	O
in	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well	O
-	O
differentiated	O
adenocarcinoma	B
of	I
the	I
liver	I
with	O
diethylstilbestrol	O
for	O
13	O
years	O
.	O

Angiosarcoma	B
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries	O
.	O

The	O
possibility	O
that	O
the	O
intraarterial	B
lesions	I
might	O
represent	O
independent	O
primary	O
tumors	B
is	O
considered	O
.	O

Galanthamine	O
hydrobromide	O
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	O
,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	O
(	O
Hyoscine	O
)	O
.	O

Galanthamine	O
hydrobromide	O
,	O
an	O
anticholinesterase	O
drug	O
capable	O
of	O
penetrating	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	O
(	O
hyoscine	O
)	O
overdosage	B
.	O

It	O
is	O
longer	O
acting	O
than	O
physostigmine	O
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non	O
-	O
depolarizing	O
neuromuscular	O
block	O
.	O

However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	O
intoxication	O
are	O
indicated	O
.	O

Comparison	O
of	O
the	O
subjective	O
effects	O
and	O
plasma	O
concentrations	O
following	O
oral	O
and	O
i	O
.	O
m	O
.	O
administration	O
of	O
flunitrazepam	O
in	O
volunteers	O
.	O

Flunitrazepam	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i	O
.	O
m	O
.	O
routes	O
to	O
groups	O
of	O
volunteers	O
and	O
its	O
effects	O
compared	O
.	O

Plasma	O
concentrations	O
of	O
the	O
drug	O
were	O
estimated	O
by	O
gas	O
-	O
liquid	O
chromatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjects	O
.	O

The	O
most	O
striking	O
effect	O
was	O
sedation	O
which	O
increased	O
with	O
the	O
dose	O
,	O
2	O
mg	O
producing	O
deep	O
sleep	O
although	O
the	O
subjects	O
could	O
still	O
be	O
aroused	O
.	O

The	O
effects	O
of	O
i	O
.	O
m	O
.	O
administration	O
were	O
apparent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oral	O
administration	O
.	O

Dizziness	B
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O

There	O
was	O
pain	B
on	O
i	O
.	O
m	O
.	O
injection	O
of	O
flunitrazepam	O
significantly	O
more	O
often	O
than	O
with	O
isotonic	O
saline	O
.	O

Plasma	O
concentrations	O
varied	O
with	O
dose	O
and	O
route	O
and	O
corresponded	O
qualitatively	O
with	O
the	O
subjective	O
effects	O
.	O

The	O
drug	O
was	O
still	O
present	O
in	O
measurable	O
quantities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dose	O
.	O

Possible	O
teratogenicity	O
of	O
sulphasalazine	O
.	O

Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	B
bowel	I
disease	I
who	O
received	O
treatment	O
with	O
sulphasalazine	O
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B
anomalies	I
.	O

In	O
the	O
singleton	O
pregnancy	O
,	O
the	O
mother	O
had	O
ulcerative	B
colitis	I
,	O
and	O
the	O
infant	O
,	O
a	O
male	O
,	O
had	O
coarctation	B
of	I
the	I
aorta	I
and	O
a	O
ventricular	B
septal	I
defect	I
.	O

In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn	B
'	I
s	I
disease	I
.	O

The	O
first	O
twin	O
,	O
a	O
female	O
,	O
had	O
a	O
left	O
Potter	B
-	I
type	I
IIa	I
polycystic	I
kidney	I
and	O
a	O
rudimentary	B
left	I
uterine	I
cornu	I
.	O

The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B
'	I
s	I
facies	I
,	O
hypoplastic	B
lungs	I
,	O
absent	B
kidneys	I
and	I
ureters	I
,	O
and	O
talipes	B
equinovarus	I
.	O

Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	O
may	O
be	O
teratogenic	O
.	O

Thrombotic	B
microangiopathy	I
and	O
renal	B
failure	I
associated	O
with	O
antineoplastic	O
chemotherapy	O
.	O

Five	O
patients	O
with	O
carcinoma	B
developed	O
thrombotic	B
microangiopathy	I
(	O
characterized	O
by	O
renal	B
insufficiency	I
,	O
microangiopathic	B
hemolytic	I
anemia	I
,	O
and	O
usually	O
thrombocytopenia	B
)	O
after	O
treatment	O
with	O
cisplatin	O
,	O
bleomycin	O
,	O
and	O
a	O
vinca	O
alkaloid	O
.	O

One	O
patient	O
had	O
thrombotic	B
thrombocytopenic	I
purpura	I
,	O
three	O
the	O
hemolytic	B
-	I
uremic	I
syndrome	I
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	O
.	O

Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	B
coagulation	I
,	O
primarily	O
affecting	O
the	O
small	O
arteries	O
,	O
arterioles	O
,	O
and	O
glomeruli	O
.	O

Because	O
each	O
patient	O
was	O
tumor	B
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tumor	B
at	O
the	O
onset	O
of	O
this	O
syndrome	O
,	O
the	O
thrombotic	B
microangiopathy	I
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O

Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	O
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined	O
,	O
because	O
renal	B
failure	I
may	O
be	O
ascribed	O
to	O
cisplatin	O
nephrotoxicity	B
and	O
the	O
anemia	B
and	O
thrombocytopenia	B
to	O
drug	O
-	O
induced	O
bone	B
marrow	I
suppression	I
.	O

International	O
mexiletine	O
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I	O
.	O

Report	O
on	O
arrhythmia	B
and	O
other	O
findings	O
.	O

Impact	O
Research	O
Group	O
.	O

The	O
antiarrhythmic	O
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	O
(	O
Mexitil	O
-	O
Perlongets	O
)	O
were	O
evaluated	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	B
infarction	I
.	O

The	O
primary	O
response	O
variable	O
was	O
based	O
on	O
central	O
reading	O
of	O
24	O
hour	O
ambulatory	O
electrocardiographic	O
recordings	O
and	O
was	O
defined	O
as	O
the	O
occurrence	O
of	O
30	O
or	O
more	O
single	O
premature	O
ventricular	O
complexes	O
in	O
any	O
two	O
consecutive	O
30	O
minute	O
blocks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
premature	O
ventricular	O
complexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardiographic	O
recording	O
.	O

Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	O
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O

These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	O
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug	O
.	O

There	O
were	O
more	O
deaths	B
in	O
the	O
mexiletine	O
group	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

The	O
incidence	O
of	O
coronary	O
events	O
was	O
similar	O
in	O
both	O
groups	O
.	O

Previously	O
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	B
and	O
gastrointestinal	B
problems	I
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Changes	O
in	O
heart	O
size	O
during	O
long	O
-	O
term	O
timolol	O
treatment	O
after	O
myocardial	B
infarction	I
.	O

The	O
effect	O
of	O
long	O
-	O
term	O
timolol	O
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B
infarction	I
was	O
evaluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blind	O
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	O
115	O
)	O
.	O

The	O
follow	O
-	O
up	O
period	O
was	O
12	O
months	O
.	O

The	O
timolol	O
-	O
treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
timolol	O
-	O
induced	O
bradycardia	B
and	O
a	O
compensatory	O
increase	O
in	O
end	O
-	O
diastolic	O
volume	O
.	O

The	O
timolol	O
-	O
related	O
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size	O
.	O

In	O
patients	O
with	O
cardiomegaly	B
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O

After	O
re	O
-	O
infarction	B
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	O
group	O
.	O

Vitamin	O
D3	O
toxicity	B
in	O
dairy	O
cows	O
.	O

Large	O
parenteral	O
doses	O
of	O
vitamin	O
D3	O
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitamin	O
D3	O
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	B
,	O
hyperphosphatemia	B
,	O
and	O
large	O
increases	O
of	O
vitamin	O
D3	O
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O

Calcium	O
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	O
D3	O
about	O
32	O
days	O
prepartum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
control	O
cows	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O

None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	O
D3	O
showed	O
signs	O
of	O
milk	B
fever	I
during	O
the	O
peripartal	O
period	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	B
fever	I
during	O
this	O
period	O
.	O

Signs	O
of	O
vitamin	O
D3	O
toxicity	B
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	O
D3	O
toxicity	B
and	O
10	O
of	O
17	O
cows	O
died	O
.	O

There	O
was	O
widespread	O
metastatic	O
calcification	O
in	O
the	O
cows	O
that	O
died	O
.	O

Because	O
of	O
the	O
extreme	O
toxicity	B
of	O
vitamin	O
D3	O
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	O
D3	O
that	O
prevent	O
milk	B
fever	I
and	O
doses	O
that	O
induce	O
milk	B
fever	I
,	O
we	O
concluded	O
that	O
vitamin	O
D3	O
cannot	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B
fever	I
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O

Diseases	B
of	I
peripheral	I
nerves	I
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O

The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B
nerve	I
disease	I
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O

There	O
is	O
a	O
male	O
preponderance	O
and	O
the	O
peak	O
incidence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O

Sensori	B
-	I
motor	I
neuropathy	I
was	O
the	O
commonest	O
presentation	O
(	O
50	O
%	O
)	O
.	O

Guillain	B
-	I
Barr	I
syndrome	I
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B
neuropathy	I
.	O

Peripheral	B
neuropathy	I
due	O
to	O
nutritional	B
deficiency	I
of	O
thiamine	O
and	O
riboflavin	O
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori	B
-	I
motor	I
neuropathy	I
.	O

Diabetes	B
mellitus	I
was	O
the	O
major	O
cause	O
of	O
autonomic	B
neuropathy	I
.	O

Isoniazid	O
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	B
.	O

Migraine	B
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B
neuropathy	I
although	O
malignancies	B
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(	O
26	O
%	O
)	O
.	O

In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B
was	O
undetermined	O
.	O

Heredofamilial	O
and	O
connective	B
tissue	I
disorders	I
were	O
rare	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B
are	O
briefly	O
discussed	O
.	O

Reduction	O
in	O
caffeine	O
toxicity	B
by	O
acetaminophen	O
.	O

A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	O
containing	O
sodium	O
acetylsalicylate	O
,	O
caffeine	O
,	O
and	O
acetaminophen	O
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	O
per	O
mL	O
of	O
serum	O
.	O

Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	O
on	O
the	O
CNS	O
,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	O
(	O
52	O
micrograms	O
/	O
mL	O
)	O
reduced	O
the	O
CNS	O
toxicity	B
of	O
caffeine	O
.	O

Studies	O
in	O
DBA	O
/	O
2J	O
mice	O
showed	O
that	O
:	O
1	O
)	O
pretreatment	O
with	O
acetaminophen	O
(	O
100	O
mg	O
/	O
kg	O
)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	O
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	B
by	O
a	O
factor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	O
with	O
acetaminophen	O
(	O
75	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	B
produced	O
in	O
the	O
presence	O
of	O
caffeine	O
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
frequency	O
of	O
sound	O
-	O
induced	O
seizures	B
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
caffeine	O
was	O
reduced	O
from	O
50	O
to	O
5	O
%	O
by	O
acetaminophen	O
.	O

In	O
the	O
absence	O
of	O
caffeine	O
,	O
acetaminophen	O
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizures	B
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	O
in	O
mice	O
(	O
tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS	O
)	O
.	O

Acetaminophen	O
(	O
up	O
to	O
150	O
micrograms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	O
into	O
ATP	O
in	O
slices	O
of	O
rat	O
cerebral	O
cortex	O
.	O

Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	O
antagonizes	O
the	O
actions	O
of	O
caffeine	O
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

A	O
double	O
-	O
blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	O
hydrochloride	O
in	O
the	O
treatment	O
of	O
major	O
depressive	B
disorder	I
.	O

In	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	O
parallel	O
treatment	O
study	O
,	O
dothiepin	O
and	O
amitriptyline	O
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	B
outpatients	O
.	O

Dothiepin	O
and	O
amitriptyline	O
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B
illness	I
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O

The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	B
vision	I
,	O
dry	B
mouth	I
,	O
and	O
drowsiness	O
were	O
significantly	O
less	O
with	O
dothiepin	O
than	O
with	O
amitriptyline	O
.	O

Dothiepin	O
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O

There	O
were	O
no	O
clinically	O
important	O
changes	O
in	O
laboratory	O
parameters	O
.	O

Dothiepin	O
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	O
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	O
in	O
the	O
treatment	O
of	O
depressed	B
outpatients	O
.	O

Behavioral	O
effects	O
of	O
diazepam	O
and	O
propranolol	O
in	O
patients	O
with	O
panic	B
disorder	I
and	O
agoraphobia	B
.	O

The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	O
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	O
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	B
disorders	I
and	O
agoraphobia	B
were	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
crossover	O
design	O
.	O

Both	O
drugs	O
impaired	B
immediate	I
free	I
recall	I
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	O
than	O
propranolol	O
.	O

Delayed	B
free	I
recall	I
was	I
also	I
impaired	I
but	O
the	O
two	O
drugs	O
did	O
not	O
differ	O
.	O

Patients	O
tapped	O
faster	O
after	O
propranolol	O
than	O
diazepam	O
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	O
than	O
propranolol	O
.	O

After	O
2	O
weeks	O
of	O
treatment	O
,	O
patients	O
tested	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
dose	O
of	O
medication	O
did	O
not	O
show	O
any	O
decrement	O
of	O
performance	O
.	O

These	O
results	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healthy	O
subjects	O
.	O

Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B
impairment	I
.	O

Comparison	O
of	O
i	O
.	O
v	O
.	O
glycopyrrolate	O
and	O
atropine	O
in	O
the	O
prevention	O
of	O
bradycardia	B
and	O
arrhythmias	B
following	O
repeated	O
doses	O
of	O
suxamethonium	O
in	O
children	O
.	O

The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	O
5	O
and	O
10	O
micrograms	O
kg	O
-	O
1	O
and	O
atropine	O
10	O
and	O
20	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
induction	O
of	O
anaesthesia	O
,	O
to	O
prevent	O
arrhythmia	B
and	O
bradycardia	B
following	O
repeated	O
doses	O
of	O
suxamethonium	O
in	O
children	O
,	O
was	O
studied	O
.	O

A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	O
and	O
atropine	O
.	O

A	O
frequency	O
of	O
bradycardia	B
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O

Bradycardia	B
(	O
defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	O
was	O
used	O
.	O

It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	O
10	O
micrograms	O
kg	O
-	O
1	O
or	O
atropine	O
20	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia	O
,	O
in	O
children	O
,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	O
is	O
anticipated	O
.	O

Veno	B
-	I
occlusive	I
liver	I
disease	I
after	O
dacarbazine	O
therapy	O
(	O
DTIC	O
)	O
for	O
melanoma	B
.	O

A	O
case	O
of	O
veno	B
-	I
occlusive	I
disease	I
of	I
the	I
liver	I
with	O
fatal	O
outcome	O
after	O
dacarbazine	O
(	O
DTIC	O
)	O
therapy	O
for	O
melanoma	B
is	O
reported	O
.	O

There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	B
.	O

At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B
congestion	I
.	O

Small	O
-	O
and	O
medium	O
-	O
sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	B
.	O

Eosinophilic	O
infiltrations	O
were	O
found	O
around	O
the	O
vessels	O
.	O

Published	O
cases	O
from	O
the	O
literature	O
are	O
reviewed	O
and	O
pertinent	O
features	O
discussed	O
.	O

Maternal	O
lithium	O
and	O
neonatal	O
Ebstein	B
'	I
s	I
anomaly	I
:	O
evaluation	O
with	O
cross	O
-	O
sectional	O
echocardiography	O
.	O

Cross	O
-	O
sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	O
during	O
pregnancy	O
.	O

In	O
one	O
infant	O
,	O
Ebstein	B
'	I
s	I
anomaly	I
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O

In	O
the	O
other	O
infant	O
cross	O
-	O
sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B
'	I
s	I
anomaly	I
.	O

Cross	O
-	O
sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	O
during	O
gestation	O
can	O
provide	O
highly	O
accurate	O
,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	O
-	O
induced	O
cardiac	B
malformations	I
.	O

Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	B
infarction	I
in	O
aging	O
rats	O
.	O

The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	O
-	O
induced	O
myocardial	B
infarction	I
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
weeks	O
of	O
age	O
.	O

The	O
rats	O
were	O
trained	O
to	O
swim	O
for	O
a	O
specific	O
duration	O
and	O
for	O
a	O
particular	O
period	O
.	O

The	O
occurrence	O
of	O
infarcts	B
were	O
confirmed	O
by	O
histological	O
methods	O
.	O

Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary	O
-	O
isoproterenols	O
and	O
minimum	O
in	O
the	O
exercise	O
-	O
controls	O
.	O

These	O
changes	O
in	O
the	O
serum	O
transaminases	O
were	O
associated	O
with	O
corresponding	O
depletions	O
in	O
the	O
cardiac	O
GOT	O
and	O
GPT	O
.	O

However	O
,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
responses	O
exhibited	O
by	O
the	O
young	O
and	O
old	O
rats	O
.	O

Studies	O
dealing	O
with	O
myocardial	B
infarction	I
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	O
.	O

Effect	O
of	O
polyethylene	O
glycol	O
400	O
on	O
adriamycin	O
toxicity	B
in	O
mice	O
.	O

The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent	O
,	O
polyethylene	O
glycol	O
400	O
(	O
PEG	O
400	O
)	O
,	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	O
(	O
ADR	O
)	O
was	O
evaluated	O
in	O
mice	O
.	O

PEG	O
400	O
impressively	O
decreased	O
both	O
acute	O
high	O
-	O
dose	O
and	O
chronic	O
low	O
-	O
dose	O
-	O
ADR	O
-	O
associated	O
lethality	O
.	O

Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR	O
-	O
induced	O
cardiac	B
morphological	I
alterations	I
.	O

Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	O
antitumor	O
activity	O
in	O
L1210	B
leukemia	I
and	O
in	O
Ehrlich	B
ascites	I
tumor	I
.	O

Sublingual	O
absorption	O
of	O
the	O
quaternary	O
ammonium	O
antiarrhythmic	O
agent	O
,	O
UM	O
-	O
272	O
.	O

UM	O
-	O
272	O
(	O
N	O
,	O
N	O
-	O
dimethylpropranolol	O
)	O
,	O
a	O
quaternary	O
antiarrhythmic	O
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	O
-	O
induced	O
ventricular	B
tachycardias	I
.	O

Both	O
anti	O
-	O
arrhythmic	O
efficacy	O
and	O
bioavailability	O
were	O
compared	O
to	O
oral	O
drug	O
.	O

Sublingual	O
UM	O
-	O
272	O
converted	O
ventricular	B
tachycardia	I
to	O
sinus	O
rhythm	O
in	O
all	O
5	O
dogs	O
.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
time	O
curve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
oral	O
drug	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorption	O
-	O
limiting	O
process	O
in	O
the	O
intestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
administration	O
for	O
quaternary	O
drugs	O
.	O

Early	O
adjuvant	O
adriamycin	O
in	O
superficial	O
bladder	B
carcinoma	I
.	O

A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	B
of	I
the	I
bladder	I
.	O

Adriamycin	O
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladder	B
tumors	I
.	O

Instillation	O
was	O
repeated	O
twice	O
during	O
the	O
first	O
week	O
,	O
then	O
weekly	O
during	O
the	O
first	O
month	O
and	O
afterwards	O
monthly	O
for	O
1	O
year	O
.	O

The	O
tolerance	O
was	O
evaluated	O
in	O
these	O
110	O
patients	O
,	O
and	O
29	O
patients	O
presented	O
with	O
local	O
side	O
-	O
effects	O
.	O

In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	B
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study	O
.	O

No	O
systemic	O
side	O
-	O
effects	O
were	O
observed	O
.	O

Recurrence	O
was	O
studied	O
in	O
82	O
evaluable	O
patients	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patients	O
followed	O
for	O
2	O
-	O
3	O
years	O
(	O
mean	O
32	O
months	O
)	O
.	O

Of	O
the	O
82	O
patients	O
studied	O
after	O
1	O
year	O
,	O
23	O
had	O
primary	O
and	O
59	O
recurrent	O
disease	O
.	O

Of	O
the	O
82	O
evaluable	O
patients	O
,	O
50	O
did	O
not	O
show	O
any	O
recurrence	O
after	O
1	O
year	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrences	O
(	O
39	O
%	O
)	O
.	O

Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	B
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions	O
.	O

In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	O
during	O
the	O
first	O
year	O
,	O
80	O
%	O
remained	O
tumor	B
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

Of	O
the	O
patients	O
developing	O
one	O
or	O
more	O
recurrences	O
during	O
the	O
first	O
year	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrence	O
once	O
the	O
instillations	O
were	O
stopped	O
.	O

The	O
beneficial	O
effect	O
of	O
Adriamycin	O
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	O
itself	O
,	O
the	O
early	O
and	O
repeated	O
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O

D	O
-	O
penicillamine	O
-	O
induced	O
angiopathy	B
in	O
rats	O
.	O

The	O
effect	O
of	O
high	O
dose	O
D	O
-	O
penicillamine	O
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
D	O
-	O
penicillamine	O
(	O
D	O
-	O
pen	O
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
days	O
.	O

Pair	O
fed	O
rats	O
served	O
as	O
controls	O
.	O

Changes	O
in	O
aortic	O
morphology	O
were	O
examined	O
by	O
light	O
-	O
and	O
transmission	O
-	O
electron	O
microscopy	O
(	O
TEM	O
)	O
.	O

In	O
addition	O
,	O
the	O
endothelial	O
permeability	O
and	O
the	O
penetration	O
through	O
the	O
aortic	O
wall	O
of	O
albumin	O
were	O
studied	O
10	O
minutes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i	O
.	O
v	O
.	O
injection	O
of	O
human	O
serum	O
131I	O
-	O
albumin	O
(	O
131I	O
-	O
HSA	O
)	O
.	O

TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D	O
-	O
pen	O
-	O
treated	O
rats	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation	O
.	O

In	O
experimental	O
animals	O
excess	O
deposition	O
of	O
collagen	O
and	O
glycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelial	O
and	O
medial	O
layer	O
of	O
the	O
aortic	O
wall	O
,	O
together	O
with	O
prominent	O
basal	O
membrane	O
substance	O
around	O
aortic	O
smooth	O
muscle	O
cells	O
.	O

The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	O
-	O
pen	O
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	O
.	O

The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D	O
-	O
pen	O
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I	O
-	O
HSA	O
radioactivity	O
or	O
aorta	O
/	O
serum	O
-	O
ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection	O
,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D	O
-	O
pen	O
treatment	O
.	O

These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D	O
-	O
pen	O
may	O
induce	O
a	O
fibroproliferative	O
response	O
in	O
rat	O
aorta	O
,	O
possibly	O
by	O
an	O
inhibitory	O
effect	O
on	O
the	O
cross	O
-	O
linking	O
of	O
collagen	O
and	O
elastin	O
.	O

Effect	O
of	O
aspirin	O
on	O
N	O
-	O
[	O
4	O
-	O
(	O
5	O
-	O
nitro	O
-	O
2	O
-	O
furyl	O
)	O
-	O
2	O
-	O
thiazolyl	O
]	O
-	O
formamide	O
-	O
induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O

The	O
co	O
-	O
administration	O
of	O
aspirin	O
with	O
N	O
-	O
[	O
4	O
-	O
(	O
5	O
-	O
nitro	O
-	O
2	O
-	O
furyl	O
)	O
-	O
2	O
-	O
thiazolyl	O
]	O
-	O
formamide	O
(	O
FANFT	O
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	O
-	O
induced	O
bladder	B
carcinomas	I
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	B
tumors	I
.	O

An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F	O
-	O
344	O
rats	O
fed	O
diet	O
containing	O
FANFT	O
at	O
a	O
level	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
aspirin	O
at	O
a	O
level	O
of	O
0	O
.	O
5	O
%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	O
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	O
in	O
the	O
forestomach	O
and	O
bladder	O
.	O

FANFT	O
-	O
induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	O
co	O
-	O
administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O

In	O
the	O
forestomach	O
,	O
and	O
also	O
in	O
the	O
liver	O
,	O
aspirin	O
did	O
not	O
affect	O
the	O
FANFT	O
-	O
induced	O
increase	O
in	O
labeling	O
index	O
.	O

The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	O
carcinogenesis	B
in	O
the	O
bladder	O
and	O
forestomach	O
,	O
and	O
that	O
aspirin	O
'	O
s	O
effect	O
on	O
FANFT	O
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	O
.	O

A	O
case	O
of	O
tardive	B
dyskinesia	I
caused	O
by	O
metoclopramide	O
.	O

Abnormal	B
involuntary	I
movements	I
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	O
for	O
gastrointestinal	B
disorder	I
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O

The	O
symptoms	O
exacerbated	O
to	O
a	O
maximum	O
in	O
a	O
month	O
.	O

When	O
the	O
metoclopramide	O
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B
movements	I
gradually	O
improved	O
to	O
a	O
considerable	O
extent	O
.	O

Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B
dyskinesia	I
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	O
.	O

Intra	O
-	O
arterial	O
BCNU	O
chemotherapy	O
for	O
treatment	O
of	O
malignant	B
gliomas	I
of	O
the	O
central	O
nervous	O
system	O
.	O

Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	O
(	O
1	O
,	O
3	O
-	O
bis	O
-	O
(	O
2	O
-	O
chloroethyl	O
)	O
-	O
1	O
-	O
nitrosourea	O
)	O
,	O
intra	O
-	O
arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	B
gliomas	I
.	O

Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	O
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O

Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	B
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	B
without	O
prior	O
radiation	O
therapy	O
.	O

After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy	O
,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	B
size	O
and	O
surrounding	O
edema	B
on	O
contrast	O
-	O
enhanced	O
computerized	O
tomography	O
scans	O
.	O

In	O
the	O
nine	O
responders	O
,	O
median	O
duration	O
of	O
chemotherapy	O
response	O
from	O
the	O
time	O
of	O
operation	O
was	O
25	O
weeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
weeks	O
)	O
.	O

The	O
median	O
duration	O
of	O
survival	O
in	O
the	O
12	O
patients	O
was	O
54	O
weeks	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
weeks	O
)	O
,	O
with	O
an	O
18	O
-	O
month	O
survival	O
rate	O
of	O
42	O
%	O
.	O

Twenty	O
-	O
four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	B
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra	O
-	O
arterial	O
BCNU	O
therapy	O
.	O

Seventeen	O
of	O
these	O
had	O
a	O
response	O
or	O
were	O
stable	O
for	O
a	O
median	O
of	O
20	O
weeks	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
weeks	O
)	O
.	O

The	O
catheterization	O
procedure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	O
.	O

A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	B
of	I
vision	I
secondary	O
to	O
a	O
retinal	B
vasculitis	I
.	O

The	O
frequency	O
of	O
visual	B
loss	I
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	O
diluent	O
was	O
lowered	O
.	O

Provocation	O
of	O
postural	O
hypotension	B
by	O
nitroglycerin	O
in	O
diabetic	B
autonomic	I
neuropathy	I
?	O

The	O
effect	O
of	O
nitroglycerin	O
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	B
subjects	O
without	O
autonomic	B
neuropathy	I
,	O
and	O
5	O
diabetic	B
subjects	O
with	O
autonomic	B
neuropathy	I
.	O

The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	O
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	B
subjects	O
without	O
autonomic	B
neuropathy	I
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	B
subjects	O
with	O
autonomic	B
neuropathy	I
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	O
in	O
diabetic	B
patients	O
,	O
particularly	O
those	O
with	O
autonomic	B
neuropathy	I
.	O

Blood	O
pressure	O
response	O
to	O
chronic	O
low	O
-	O
dose	O
intrarenal	O
noradrenaline	O
infusion	O
in	O
conscious	O
rats	O
.	O

Sodium	O
chloride	O
solution	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
noradrenaline	O
in	O
doses	O
of	O
4	O
,	O
12	O
and	O
36	O
micrograms	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
infused	O
for	O
five	O
consecutive	O
days	O
,	O
either	O
intrarenally	O
(	O
by	O
a	O
new	O
technique	O
)	O
or	O
intravenously	O
into	O
rats	O
with	O
one	O
kidney	O
removed	O
.	O

Intrarenal	O
infusion	O
of	O
noradrenaline	O
caused	O
hypertension	B
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously	O
.	O

Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	O
caused	O
higher	O
plasma	O
noradrenaline	O
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	O
concentration	O
-	O
blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	O
levels	O
.	O

These	O
results	O
suggest	O
that	O
hypertension	B
after	O
chronic	O
intrarenal	O
noradrenaline	O
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	O
and	O
by	O
triggering	O
of	O
an	O
additional	O
intrarenal	O
pressor	O
mechanism	O
.	O

Characterization	O
of	O
estrogen	O
-	O
induced	O
adenohypophyseal	B
tumors	I
in	O
the	O
Fischer	O
344	O
rat	O
.	O

Pituitary	B
tumors	I
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	O
(	O
DES	O
,	O
8	O
-	O
10	O
mg	O
)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
days	O
of	O
DES	O
treatment	O
,	O
pairs	O
of	O
control	O
and	O
DES	O
-	O
treated	O
rats	O
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single	O
-	O
cell	O
preparations	O
.	O

The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and	O
/	O
or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	O
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O

Total	O
cell	O
yields	O
from	O
DES	O
-	O
treated	O
pituitaries	O
increased	O
from	O
1	O
.	O
3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58	O
.	O
9	O
times	O
control	O
values	O
by	O
day	O
150	O
.	O

Intracellular	O
PRL	O
content	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	O
exposure	O
.	O

Beyond	O
8	O
days	O
of	O
DES	O
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O

Increased	O
density	O
and	O
/	O
or	O
size	O
and	O
PRL	O
content	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cell	O
population	O
in	O
both	O
types	O
of	O
separation	O
protocols	O
.	O

All	O
these	O
effects	O
of	O
DES	O
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O

The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES	O
-	O
induced	O
tumor	B
as	O
a	O
model	O
for	O
study	O
of	O
PRL	O
cellular	O
control	O
mechanisms	O
.	O

Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	O
.	O

In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	O
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	O
.	O

Cimetidine	O
clearance	O
decreased	O
with	O
age	O
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
serum	O
concentration	O
of	O
cimetidine	O
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	O
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O

The	O
ratio	O
of	O
cimetidine	O
clearance	O
to	O
creatinine	O
clearance	O
(	O
Rc	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	O
.	O

Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	O
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	O
is	O
a	O
saturable	O
process	O
.	O

There	O
was	O
only	O
one	O
case	O
of	O
dementia	B
possibly	O
due	O
to	O
cimetidine	O
(	O
with	O
a	O
drug	O
level	O
of	O
1	O
.	O
9	O
microgram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
dose	O
)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	B
or	I
kidney	I
disease	I
who	O
had	O
cimetidine	O
levels	O
above	O
1	O
.	O
25	O
microgram	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cimetidine	O
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	B
.	O

Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	O
therapy	O
.	O

A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra	B
-	I
Hisian	I
block	I
occurring	O
under	O
amiodarone	O
treatment	O
for	O
atrial	B
tachycardia	I
in	O
a	O
patient	O
without	O
clear	O
intraventricular	B
conduction	I
abnormalities	I
.	O

His	O
bundle	O
recordings	O
showed	O
an	O
atrial	B
tachycardia	I
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
days	O
after	O
amiodarone	O
discontinuation	O
,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	B
flutter	I
without	O
intra	O
-	O
Hisian	O
or	O
infra	O
-	O
Hisian	O
delay	O
.	O

Amiodarone	O
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oral	O
therapy	O
in	O
patients	O
with	O
or	O
without	O
clear	O
intraventricular	O
conduction	O
defects	O
.	O

Development	O
of	O
clear	B
cell	I
adenocarcinoma	I
in	O
DES	O
-	O
exposed	O
offspring	O
under	O
observation	O
.	O

Two	O
cases	O
of	O
clear	B
cell	I
adenocarcinoma	I
of	I
the	I
vagina	I
detected	O
at	O
follow	O
-	O
up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	O
are	O
reported	O
.	O

One	O
patient	O
,	O
aged	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	B
was	O
diagnosed	O
;	O
the	O
second	O
patient	O
,	O
aged	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years	O
,	O
8	O
months	O
.	O

In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	B
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	O
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O

Hysterosalpingography	O
was	O
performed	O
on	O
both	O
patients	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnormal	O
x	O
-	O
ray	O
film	O
was	O
reflected	O
by	O
the	O
gross	O
appearance	O
of	O
the	O
uterine	O
cavity	O
found	O
in	O
the	O
surgical	O
specimen	O
.	O

Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2	O
-	O
chloroprocaine	O
-	O
CE	O
,	O
bupivacaine	O
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2	O
-	O
chloroprocaine	O
-	O
CE	O
in	O
experimental	O
animals	O
.	O

The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	B
was	O
evaluated	O
.	O

The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	O
(	O
N	O
=	O
15	O
)	O
,	O
2	O
-	O
chloroprocaine	O
-	O
CE	O
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	O
saline	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2	O
-	O
chloroprocaine	O
-	O
CE	O
seven	O
(	O
35	O
%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	B
.	O

None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	O
,	O
normal	O
saline	O
,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3	O
.	O
0	O
developed	O
hind	O
-	O
limb	O
paralysis	B
.	O

Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2	O
-	O
chloroprocaine	O
-	O
CE	O
,	O
13	O
showed	O
subpial	B
necrosis	I
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal	O
.	O

The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3	O
.	O
0	O
)	O
,	O
or	O
normal	O
saline	O
did	O
not	O
show	O
abnormal	O
findings	O
.	O

Procainamide	O
-	O
induced	O
polymorphous	O
ventricular	B
tachycardia	I
.	O

Seven	O
cases	O
of	O
procainamide	O
-	O
induced	O
polymorphous	O
ventricular	B
tachycardia	I
are	O
presented	O
.	O

In	O
four	O
patients	O
,	O
polymorphous	O
ventricular	B
tachycardia	I
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	O
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	B
tachycardia	I
.	O

In	O
the	O
remaining	O
three	O
patients	O
,	O
procainamide	O
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	B
ventricular	I
contractions	I
or	O
atrial	B
flutter	I
.	O

These	O
patients	O
had	O
Q	B
-	I
T	I
prolongation	I
and	O
recurrent	O
syncope	B
due	O
to	O
polymorphous	O
ventricular	B
tachycardia	I
.	O

In	O
four	O
patients	O
,	O
the	O
arrhythmia	B
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	B
.	O

In	O
two	O
patients	O
,	O
the	O
arrhythmia	B
degenerated	O
into	O
irreversible	O
ventricular	B
fibrillation	I
and	O
both	O
patients	O
died	O
.	O

In	O
the	O
seventh	O
patient	O
,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	O
therapy	O
,	O
polymorphous	O
ventricular	B
tachycardia	I
did	O
not	O
reoccur	O
.	O

These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	O
can	O
produce	O
an	O
acquired	O
prolonged	B
Q	I
-	I
T	I
syndrome	I
with	O
polymorphous	O
ventricular	B
tachycardia	I
.	O

Phenobarbitone	O
-	O
induced	O
enlargement	B
of	I
the	I
liver	I
in	O
the	O
rat	O
:	O
its	O
relationship	O
to	O
carbon	O
tetrachloride	O
-	O
induced	O
cirrhosis	B
.	O

The	O
yield	O
of	O
severe	O
cirrhosis	B
of	I
the	I
liver	I
(	O
defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology	O
,	O
ascites	B
greater	O
than	O
30	O
ml	O
,	O
plasma	O
albumin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
splenomegaly	B
2	O
-	O
3	O
times	O
normal	O
,	O
and	O
testicular	O
atrophy	B
approximately	O
half	O
normal	O
weight	O
)	O
after	O
12	O
doses	O
of	O
carbon	O
tetrachloride	O
given	O
intragastrically	O
in	O
the	O
phenobarbitone	O
-	O
primed	O
rat	O
was	O
increased	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
dose	O
of	O
carbon	O

tetrachloride	O
at	O
the	O
peak	O
of	O
the	O
phenobarbitone	O
-	O
induced	O
enlargement	B
of	I
the	I
liver	I
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450	O
/	O
CCl4	O
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable	O
.	O

The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	O
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47	O
%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	O
weight	O
.	O

The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	O
tetrachloride	O
was	O
after	O
14	O
days	O
on	O
phenobarbitone	O
.	O

Triamterene	O
nephrolithiasis	B
complicating	O
dyazide	O
therapy	O
.	O

A	O
case	O
of	O
triamterene	O
nephrolithiasis	B
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide	O
-	O
triamterene	O
therapy	O
for	O
hypertension	B
.	O

The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	O
metabolite	O
admixed	O
with	O
uric	O
acid	O
salts	O
.	O

Factors	O
affecting	O
triamterene	O
nephrolithiasis	B
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O

Busulfan	O
-	O
induced	O
hemorrhagic	B
cystitis	I
.	O

A	O
case	O
of	O
a	O
busulfan	O
-	O
induced	O
hemorrhage	B
cystitis	I
is	O
reported	O
.	O

Spontaneous	O
resolution	O
occurred	O
following	O
cessation	O
of	O
the	O
drug	O
.	O

The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	O
cystitis	B
and	O
both	O
radiation	O
and	O
cyclophosphamide	O
-	O
induced	O
cystitis	B
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	O
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	B
in	O
other	O
sites	O
,	O
periodic	O
urinary	O
cytology	O
is	O
suggested	O
in	O
patients	O
on	O
long	O
-	O
term	O
therapy	O
.	O

Variant	O
ventricular	B
tachycardia	I
in	O
desipramine	O
toxicity	B
.	O

We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	B
tachycardia	I
induced	O
by	O
desipramine	O
toxicity	B
.	O

Unusual	O
features	O
of	O
the	O
arrhythmia	B
are	O
repetitive	O
group	O
beating	O
,	O
progressive	O
shortening	O
of	O
the	O
R	O
-	O
R	O
interval	O
,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	O
conduction	O
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O

Recognition	O
of	O
variant	O
ventricular	B
tachycardia	I
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	B
tachycardia	I
.	O

Rebound	O
hypertensive	B
after	O
sodium	O
nitroprusside	O
prevented	O
by	O
saralasin	O
in	O
rats	O
.	O

The	O
role	O
of	O
the	O
renin	O
-	O
-	O
angiotensin	O
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	O
anesthesia	O
and	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
-	O
induced	O
hypotension	B
was	O
evaluated	O
.	O

Control	O
rats	O
received	O
halothane	O
anesthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	O
infusion	O
,	O
40	O
microgram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
recovery	O
period	O
.	O

A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	O
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	O
II	O
)	O
throughout	O
the	O
experimental	O
period	O
.	O

In	O
each	O
group	O
,	O
SNP	O
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O

During	O
the	O
SNP	O
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	B
in	I
blood	I
pressure	I
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	O
-	O
treated	O
animals	O
showed	O
no	O
change	O
.	O

Following	O
discontinuation	O
of	O
SNP	O
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	O
-	O
treated	O
rats	O
.	O

This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	O
anesthesia	O
,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	O
infusion	O
and	O
the	O
post	O
-	O
SNP	O
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	O
.	O

This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	O
-	O
-	O
angiotensin	O
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	B
effects	O
of	O
halothane	O
and	O
SNP	O
.	O

Clinical	O
nephrotoxicity	B
of	O
tobramycin	O
and	O
gentamicin	O
.	O

A	O
prospective	O
study	O
.	O

Nearly	O
3	O
.	O
2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	O
antibiotics	O
annually	O
.	O

Gentamicin	O
sulfate	O
and	O
tobramycin	O
sulfate	O
continue	O
to	O
demonstrate	O
ototoxicity	B
and	O
nephrotoxicity	B
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
study	O
,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentamicin	O
sulfate	O
or	O
tobramycin	O
sulfate	O
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside	O
-	O
related	O
renal	B
failure	I
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduction	O
in	O
renal	O
function	O
.	O

In	O
these	O
62	O
patients	O
,	O
no	O
other	O
causes	O
for	O
renal	B
failure	I
could	O
be	O
identified	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycin	O
-	O
treated	O
patients	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
gentamicin	O
-	O
treated	O
patients	O
had	O
renal	B
failure	I
.	O

Thus	O
,	O
gentamicin	O
was	O
associated	O
with	O
renal	B
failure	I
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	O
.	O

Metabolic	O
involvement	O
in	O
adriamycin	O
cardiotoxicity	B
.	O

The	O
cardiotoxic	B
effects	O
of	O
adriamycin	O
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system	O
.	O

Adriamycin	O
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O

A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	O
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin	O
-	O
treated	O
cells	O
.	O

The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	O
mole	O
fraction	O
was	O
unchanged	O
.	O

Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	O
phosphokinase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adenosine	O
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	O
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	O
pool	O
.	O

In	O
the	O
adriamycin	O
-	O
treated	O
cells	O
,	O
the	O
addition	O
of	O
adenosine	O
increased	O
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	O
with	O
this	O
inrcease	O
,	O
the	O
cells	O
'	O
functional	O
integrity	O
,	O
in	O
terms	O
of	O
percentage	O
of	O
beating	O
cells	O
and	O
rate	O
of	O
contractions	O
,	O
was	O
maintained	O
.	O

Age	O
-	O
dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	B
effects	O
of	O
streptomycin	O
.	O

Streptomycin	O
sulfate	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats	O
.	O

Beginning	O
at	O
8	O
days	O
of	O
age	O
,	O
body	O
movement	O
and	O
hearing	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
weeks	O
,	O
respectively	O
.	O

Abnormal	B
movements	I
and	O
deafness	B
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period	O
;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
days	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	O
than	O
the	O
site	O
(	O
vestibular	O
or	O
central	O
)	O
responsible	O
for	O
the	O
dyskinesias	B
.	O

Late	O
,	O
late	O
doxorubicin	O
cardiotoxicity	B
.	O

Cardiac	B
toxicity	I
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	O
as	O
a	O
chemotherapeutic	O
agent	O
.	O

Cardiomyopathy	B
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O

A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	B
two	O
and	O
one	O
-	O
half	O
years	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
late	O
,	O
late	O
cardiotoxicity	B
.	O

Attenuation	O
of	O
the	O
lithium	O
-	O
induced	O
diabetes	B
-	I
insipidus	I
-	I
like	I
syndrome	I
by	O
amiloride	O
in	O
rats	O
.	O

The	O
effect	O
of	O
amiloride	O
on	O
lithium	O
-	O
induced	O
polydipsia	B
and	O
polyuria	B
and	O
on	O
the	O
lithium	O
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	O
.	O

Amiloride	O
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	O
(	O
3	O
days	O
)	O
experiment	O
.	O

6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	O
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	O
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	O
levels	O
.	O

After	O
3	O
days	O
of	O
combined	O
treatment	O
,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	O
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake	O
.	O

In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium	O
-	O
induced	O
diabetes	B
-	I
insipidus	I
-	I
like	I
syndrome	I
by	O
amiloride	O
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	O
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	O
level	O
.	O

It	O
is	O
concluded	O
that	O
acute	O
amiloride	O
administration	O
to	O
lithium	O
-	O
treated	O
patients	O
suffering	O
from	O
polydipsia	B
and	O
polyuria	B
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	O
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	O
levels	O
and	O
might	O
be	O
hazardous	O
.	O

Cardiovascular	B
complications	I
associated	O
with	O
terbutaline	O
treatment	O
for	O
preterm	B
labor	I
.	O

Severe	O
cardiovascular	B
complications	I
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	O
for	O
preterm	B
labor	I
.	O

Associated	O
corticosteroid	O
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O

Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O

Toxic	B
hepatitis	I
induced	O
by	O
antithyroid	O
drugs	O
:	O
four	O
cases	O
including	O
one	O
with	O
cross	O
-	O
reactivity	O
between	O
carbimazole	O
and	O
benzylthiouracil	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	B
adverse	I
effects	I
encountered	O
with	O
antithyroid	O
drugs	O
.	O

METHODS	O
:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	B
admitted	O
in	O
our	O
department	O
(	O
in	O
-	O
or	O
out	O
-	O
patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

RESULTS	O
:	O
Four	O
patients	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identified	O
with	O
toxic	B
hepatitis	I
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent	O
.	O

Two	O
patients	O
had	O
a	O
cholestatic	B
hepatitis	I
induced	O
by	O
carbimazole	O
(	O
N	O
omercazole	O
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	B
and	O
cytolytic	O
)	O
hepatitis	B
following	O
carbimazole	O
.	O

One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	B
which	O
appeared	O
after	O
Benzylthiouracil	O
(	O
Basd	O
ne	O
)	O
had	O
replaced	O
carbimazole	O
.	O

Biological	O
features	O
of	O
hepatitis	B
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	O
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O

Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	B
.	O

CONCLUSION	O
:	O
Toxic	B
hepatitis	I
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	O
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre	O
-	O
therapeutic	O
determination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
relevant	O
biological	O
markers	O
.	O

Moreover	O
,	O
hepatotoxicity	B
may	O
not	O
be	O
restricted	O
to	O
one	O
class	O
of	O
antithyroid	O
agents	O
.	O

Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na	O
]	O
o	O
and	O
[	O
Ca	O
]	O
o	O
on	O
rat	O
atrial	O
spontaneous	O
frequency	O
.	O

The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	O
and	O
Ca	O
(	O
[	O
Na	O
]	O
o	O
and	O
[	O
Ca	O
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	O
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria	O
.	O

Basal	O
frequency	O
(	O
BF	O
)	O
evaluated	O
by	O
surface	O
electrogram	O
was	O
223	O
+	O
/	O
-	O
4	O
beats	O
/	O
min	O
.	O
in	O
control	O
Krebs	O
-	O
Ringer	O
containing	O
137	O
mM	O
Na	O
and	O
1	O
.	O
35	O
mM	O
Ca	O
(	O
N	O
)	O
.	O

It	O
decreased	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
lowering	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
lowering	O
simultaneously	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	O
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNa	O
+	O
LCa	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
lowering	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
plus	O
increasing	O
[	O
Ca	O
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNa	O
+	O
HCa	O
)	O
.	O

At	O
normal	O
[	O
Na	O
]	O
o	O
,	O
decrease	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
increase	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	O
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
normal	O
[	O
Ca	O
]	O
o	O
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O

All	O
negative	O
chronotropic	O
effects	O
were	O
BF	O
-	O
dependent	O
.	O

Dose	O
-	O
dependent	O
bradycardia	B
induced	O
by	O
verapamil	O
was	O
potentiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O

Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	O
and	O
Ca	O
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil	O
]	O
o	O
needed	O
to	O
reduce	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCa	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
verapamil	O
]	O
o	O
that	O
arrested	O
atrial	O
beating	O
(	O
AC	O
)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa	O
+	O
LCa	O
=	O
LNa	O
+	O
HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N	O
.	O

The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na	O
]	O
o	O
than	O
on	O
[	O
Ca	O
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
normal	O
concentration	O
.	O

Also	O
the	O
enhancement	O
of	O
verapamil	O
effects	O
on	O
atrial	O
beating	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pseudo	O
-	O
allergic	B
reactions	I
to	O
corticosteroids	O
:	O
diagnosis	O
and	O
alternatives	O
.	O

Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	O
(	O
Triniol	O
)	O
and	O
dexamethasone	O
(	O
Sedionbel	O
)	O
are	O
described	O
.	O

A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs	O
,	O
they	O
presented	O
urticaria	B
(	O
patients	O
1	O
and	O
2	O
)	O
and	O
conjunctivitis	B
(	O
patient	O
1	O
)	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patients	O
'	O
reactions	O
,	O
the	O
immunological	O
mechanisms	O
involved	O
and	O
whether	O
these	O
patients	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticoid	O
.	O

Clinical	O
examinations	O
and	O
skin	O
,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	O
and	O
ELISA	O
tests	O
were	O
performed	O
.	O

In	O
the	O
two	O
patients	O
,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	O
were	O
negative	O
,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients	O
.	O

A	O
single	O
-	O
blind	O
parenteral	O
challenge	O
with	O
Triniol	O
was	O
positive	O
in	O
both	O
patients	O
after	O
the	O
administration	O
of	O
1	O
ml	O
of	O
the	O
drug	O
,	O
and	O
negative	O
with	O
its	O
excipients	O
.	O

We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	O
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O

These	O
results	O
suggest	O
that	O
paramethasone	O
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O

Corticosteroids	O
different	O
from	O
paramethasone	O
also	O
produced	O
hypersensitivity	B
reactions	O
in	O
these	O
patients	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	O
.	O

The	O
basic	O
mechanisms	O
of	O
those	O
reactions	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo	O
-	O
allergy	B
caused	O
by	O
paramethasone	O
.	O

Study	O
of	O
the	O
role	O
of	O
vitamin	O
B12	O
and	O
folinic	O
acid	O
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	B
of	O
zidovudine	O
.	O

A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	O
B12	O
and	O
folinic	O
acid	O
supplementation	O
in	O
preventing	O
zidovudine	O
(	O
ZDV	O
)	O
-	O
induced	O
bone	B
marrow	I
suppression	I
.	O

Seventy	O
-	O
five	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
-	I
infected	I
patients	O
with	O
CD4	O
+	O
cell	O
counts	O
<	O
500	O
/	O
mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	O
(	O
500	O
mg	O
daily	O
)	O
alone	O
(	O
group	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	O
with	O
folinic	O
acid	O
(	O
15	O
mg	O
daily	O
)	O
and	O
intramascular	O
vitamin	O
B12	O
(	O
1000	O
micrograms	O
monthly	O
)	O
(	O
group	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(	O
noncompliance	O
14	O
,	O
death	B
1	O
)	O
;	O
thus	O
,	O
60	O
patients	O
(	O
31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II	O
)	O
were	O
eligible	O
for	O
analysis	O
.	O

No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
at	O
enrollment	O
.	O

During	O
the	O
study	O
,	O
vitamin	O
B12	O
and	O
folate	O
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white	O
-	O
cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O

Severe	O
hematologic	O
toxicity	B
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

There	O
was	O
no	O
correlation	O
between	O
vitamin	O
B12	O
or	O
folate	O
levels	O
and	O
development	O
of	O
myelosuppression	B
.	O

Vitamin	O
B12	O
and	O
folinic	O
acid	O
supplementation	O
of	O
ZDV	O
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV	O
-	O
induced	O
myelotoxicity	B
in	O
the	O
overall	O
treated	O
population	O
,	O
although	O
a	O
beneficial	O
effect	O
in	O
certain	O
subgroups	O
of	O
patients	O
cannot	O
be	O
excluded	O
.	O

Safety	O
and	O
side	O
-	O
effects	O
of	O
alprazolam	O
.	O

Controlled	O
study	O
in	O
agoraphobia	B
with	O
panic	B
disorder	I
.	O

BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	O
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects	O
.	O

The	O
efficacy	O
of	O
alprazolam	O
and	O
placebo	O
in	O
panic	B
disorder	I
with	O
agoraphobia	B
,	O
and	O
the	O
side	O
-	O
effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	O
groups	O
were	O
measured	O
.	O

METHOD	O
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM	O
-	O
III	O
criteria	O
for	O
panic	B
disorder	I
with	O
agoraphobia	B
were	O
randomised	O
to	O
alprazolam	O
or	O
placebo	O
.	O

Subjects	O
in	O
each	O
drug	O
group	O
also	O
received	O
either	O
exposure	O
or	O
relaxation	O
.	O

Treatment	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tapered	O
from	O
weeks	O
8	O
to	O
16	O
.	O

RESULTS	O
:	O
Mean	O
alprazolam	O
dose	O
was	O
5	O
mg	O
daily	O
.	O

Compared	O
with	O
placebo	O
subjects	O
,	O
alprazolam	O
patients	O
developed	O
more	O
adverse	O
reactions	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
depression	B
,	O
enuresis	B
,	O
disinhibition	O
and	O
aggression	B
;	O
and	O
more	O
side	O
-	O
effects	O
,	O
particularly	O
sedation	O
,	O
irritability	B
,	O
impaired	B
memory	I
,	O
weight	B
loss	I
and	O
ataxia	B
.	O

Side	O
-	O
effects	O
tended	O
to	O
diminish	O
during	O
treatment	O
but	O
remained	O
significant	O
at	O
week	O
8	O
.	O

Despite	O
this	O
,	O
the	O
drop	O
-	O
out	O
rate	O
was	O
low	O
.	O

CONCLUSIONS	O
:	O
Alprazolam	O
caused	O
side	O
-	O
effects	O
and	O
adverse	O
effects	O
during	O
treatment	O
but	O
many	O
patients	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Crescentic	O
fibrillary	O
glomerulonephritis	B
associated	O
with	O
intermittent	O
rifampin	O
therapy	O
for	O
pulmonary	B
tuberculosis	I
.	O

This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	B
in	O
a	O
patient	O
treated	O
with	O
rifampin	O
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease	O
.	O

This	O
patient	O
underwent	O
a	O
10	O
-	O
month	O
regimen	O
of	O
rifampin	O
and	O
isoniazid	O
for	O
pulmonary	B
tuberculosis	I
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B
failure	I
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O

Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	B
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B
were	O
investigated	O
and	O
ruled	O
out	O
.	O

This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	B
in	O
a	O
patient	O
treated	O
with	O
rifampin	O
.	O

Acute	O
confusion	B
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5	O
-	O
fluorouracil	O
and	O
folinic	O
acid	O
.	O

A	O
61	O
-	O
year	O
-	O
old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	O
,	O
etoposide	O
,	O
high	O
-	O
dose	O
5	O
-	O
fluorouracil	O
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
folinic	O
acid	O
for	O
an	O
inoperable	O
gastric	B
adenocarcinoma	I
.	O

He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	B
,	O
disorientation	B
and	O
irritability	B
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	B
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5	O
-	O
fluorouracil	O
and	O
folinic	O
acid	O
infusion	O
.	O

This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5	O
-	O
fluorouracil	O
and	O
folinic	O
acid	O
,	O
which	O
were	O
then	O
the	O
only	O
drugs	O
given	O
.	O

Because	O
folinic	O
acid	O
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	O
,	O
neurotoxicity	B
due	O
to	O
high	O
-	O
dose	O
5	O
-	O
fluorouracil	O
was	O
highly	O
suspected	O
.	O

The	O
pathogenesis	O
of	O
5	O
-	O
fluorouracil	O
neurotoxicity	B
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	O
and	O
fluorocitrate	O
,	O
thiamine	O
deficiency	O
,	O
or	O
dihydrouracil	O
dehydrogenase	O
deficiency	O
.	O

High	O
-	O
dose	O
5	O
-	O
fluorouracil	O
/	O
folinic	O
acid	O
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	B
.	O

It	O
is	O
necessary	O
that	O
both	O
oncologists	O
and	O
neurologists	O
be	O
fully	O
aware	O
of	O
this	O
unusual	O
complication	O
.	O

Effect	O
of	O
switching	O
carbamazepine	O
to	O
oxcarbazepine	O
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	O
.	O

A	O
case	O
report	O
.	O

Carbamazepine	O
was	O
switched	O
to	O
its	O
10	O
-	O
keto	O
analogue	O
oxcarbazepine	O
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	O
schizophrenic	B
or	O
organic	B
psychotic	I
patients	O
using	O
concomitantly	O
haloperidol	O
,	O
chlorpromazine	O
or	O
clozapine	O
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	B
symptoms	I
.	O

None	O
of	O
the	O
patients	O
showed	O
any	O
clinical	O
deteriotation	O
during	O
the	O
following	O
3	O
-	O
6	O
months	O
.	O

The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	O
oxcarbazepine	O
does	O
not	O
induce	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
regulating	O
the	O
inactivation	O
of	O
antipsychotic	O
drugs	O
.	O

Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephropathy	B
.	O

Reactive	O
oxygen	O
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
-	O
induced	O
nephropathy	B
,	O
with	O
antioxidants	O
significantly	O
reducing	O
the	O
proteinuria	B
.	O

The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	B
was	O
examined	O
in	O
this	O
study	O
.	O

Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	O
aminonucleoside	O
,	O
(	O
PAN	O
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
group	O
)	O
.	O

The	O
kidneys	O
were	O
removed	O
,	O
flushed	O
with	O
ice	O
cold	O
TRIS	O
buffer	O
.	O

Kidney	O
cortices	O
from	O
each	O
animal	O
were	O
used	O
to	O
prepare	O
homogenates	O
.	O

Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	O
acid	O
reactive	O
substances	O
.	O

Proteinuria	B
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O

Lipid	O
peroxidation	O
in	O
homogenates	O
was	O
maximal	O
at	O
day	O
3	O
and	O
declined	O
rapidly	O
to	O
control	O
levels	O
by	O
day	O
17	O
.	O

This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	B
injury	I
in	O
PAN	O
nephropathy	B
.	O

Composition	O
of	O
gall	B
bladder	I
stones	I
associated	O
with	O
octreotide	O
:	O
response	O
to	O
oral	O
ursodeoxycholic	O
acid	O
.	O

Octreotide	O
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	B
,	O
induces	O
gall	B
bladder	I
stones	I
in	O
13	O
-	O
60	O
%	O
of	O
patients	O
.	O

Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis	O
,	O
treatment	O
,	O
and	O
prevention	O
,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	O
treated	O
acromegalic	B
patients	O
with	O
gall	B
stones	I
.	O

Chemical	O
analysis	O
of	O
gall	B
stones	I
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholesterol	O
by	O
weight	O
.	O

In	O
the	O
remaining	O
12	O
patients	O
,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(	O
values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	O
rich	O
,	O
dissolvable	O
stones	O
)	O
.	O

Gall	O
bladder	O
bile	O
was	O
obtained	O
by	O
ultrasound	O
guided	O
,	O
fine	O
needle	O
puncture	O
from	O
six	O
patients	O
.	O

All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(	O
mean	O
(	O
SEM	O
)	O
cholesterol	O
saturation	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	O
microcrystal	O
nucleation	O
times	O
(	O
<	O
4	O
days	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bile	O
contained	O
cholesterol	O
microcrystals	O
immediately	O
after	O
sampling	O
.	O

Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	O
acid	O
(	O
UDCA	O
)	O
treatment	O
,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	O
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O

After	O
one	O
year	O
of	O
treatment	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	O
showed	O
either	O
partial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gall	B
stone	I
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	O
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	O
table	O
)	O
analysis	O
,	O
to	O
a	O
combined	O
gall	B
stone	I
dissolution	O
rate	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
octreotide	O
induced	O
gall	B
stones	I
are	O
generally	O
small	O
,	O
multiple	O
,	O
and	O
cholesterol	O
rich	O
although	O
,	O
in	O
common	O
with	O
spontaneous	O
gall	B
stone	I
disease	I
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	B
stones	I
containing	O
calcium	O
.	O

Erythema	B
multiforme	I
and	O
hypersensitivity	B
myocarditis	I
caused	O
by	O
ampicillin	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B
multiforme	I
and	O
hypersensitivity	B
myocarditis	I
caused	O
by	O
ampicillin	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
13	O
-	O
year	O
-	O
old	O
boy	O
was	O
treated	O
with	O
ampicillin	O
and	O
gentamicin	O
because	O
of	O
suspected	O
septicemia	B
.	O

Medications	O
were	O
discontinued	O
when	O
erythema	B
multiforme	I
and	O
congestive	B
heart	I
failure	I
caused	O
by	O
myocarditis	B
occurred	O
.	O

The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	O
and	O
gradually	O
improved	O
.	O

Macrophage	O
-	O
migration	O
inhibition	O
(	O
MIF	O
)	O
test	O
with	O
ampicillin	O
was	O
positive	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infections	B
causing	O
erythema	B
multiforme	I
and	O
myocarditis	B
were	O
ruled	O
out	O
,	O
a	O
drug	B
-	I
induced	I
allergic	I
reaction	I
was	O
suspected	O
.	O

Positive	O
MIF	O
test	O
for	O
ampicillin	O
showed	O
sensitization	O
of	O
the	O
patient	O
'	O
s	O
lymphocytes	O
to	O
ampicillin	O
.	O

CONCLUSIONS	O
:	O
Hypersensitivity	B
myocarditis	I
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	B
to	O
penicillins	O
.	O

Clomipramine	O
-	O
induced	O
sleep	B
disturbance	I
does	O
not	O
impair	O
its	O
prolactin	O
-	O
releasing	O
action	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	B
disturbance	I
,	O
induced	O
by	O
clomipramine	O
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect	O
.	O

Two	O
groups	O
of	O
supine	O
subjects	O
were	O
studied	O
under	O
placebo	O
-	O
controlled	O
conditions	O
,	O
one	O
during	O
the	O
night	O
,	O
when	O
sleeping	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
daytime	O
,	O
when	O
awake	O
(	O
n	O
=	O
6	O
)	O
.	O

Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	O
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection	O
.	O

Plasma	O
PRL	O
concentrations	O
were	O
analysed	O
at	O
10	O
min	O
intervals	O
and	O
underlying	O
secretory	O
rates	O
calculated	O
by	O
a	O
deconvolution	O
procedure	O
.	O

For	O
both	O
experiments	O
the	O
drug	O
intake	O
led	O
to	O
significant	O
increases	O
in	O
PRL	O
secretion	O
,	O
acting	O
preferentially	O
on	O
tonic	O
secretion	O
as	O
pulse	O
amplitude	O
and	O
frequency	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
control	O
values	O
.	O

During	O
the	O
night	O
clomipramine	O
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O

As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B
disturbance	I
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se	O
.	O

The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	O
ingestion	O
.	O

Survey	O
of	O
complications	O
of	O
indocyanine	O
green	O
angiography	O
in	O
Japan	O
.	O

PURPOSE	O
:	O
We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	O
green	O
for	O
use	O
in	O
fundus	O
angiography	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	O
of	O
indocyanine	O
green	O
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	O
green	O
fundus	O
camera	O
.	O

RESULTS	O
:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
indocyanine	O
green	O
angiograms	O
performed	O
on	O
2	O
,	O
820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992	O
.	O

Before	O
angiography	O
,	O
intradermal	O
or	O
intravenous	O
indocyanine	O
green	O
testing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions	O
.	O

For	O
three	O
patients	O
,	O
the	O
decision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiography	O
after	O
positive	O
preangiographic	O
testing	O
.	O

The	O
dosage	O
of	O
indocyanine	O
green	O
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
institution	O
.	O

There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	B
,	O
exanthema	B
,	O
urtication	B
,	O
itchiness	B
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	O
.	O

Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	B
of	O
the	O
vein	O
,	O
which	O
required	O
treatment	O
,	O
and	O
two	O
cases	O
of	O
hypotension	B
.	O

The	O
two	O
hypotensive	B
patients	O
required	O
treatment	O
for	O
shock	B
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	O
green	O
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	O
sodium	O
indicated	O
that	O
indocyanine	O
green	O
is	O
a	O
safe	O
as	O
fluorescein	O
for	O
use	O
in	O
angiography	O
.	O

Angioedema	B
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	O
.	O

A	O
72	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
"	O
flash	O
"	O
pulmonary	B
edema	I
,	O
preceded	O
by	O
chest	B
pain	I
,	O
requiring	O
intubation	O
.	O

Her	O
medical	O
history	O
included	O
coronary	B
artery	I
disease	I
with	O
previous	O
myocardial	B
infarctions	I
,	O
hypertension	B
,	O
and	O
diabetes	B
mellitus	I
.	O

A	O
history	O
of	O
angioedema	B
secondary	O
to	O
lisinopril	O
therapy	O
was	O
elicited	O
.	O

Current	O
medications	O
did	O
not	O
include	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
or	O
beta	O
-	O
blockers	O
.	O

She	O
had	O
no	O
previous	O
beta	O
-	O
blocking	O
drug	O
exposure	O
.	O

During	O
the	O
first	O
day	O
of	O
hospitalization	O
(	O
while	O
intubated	O
)	O
,	O
intravenous	O
metoprolol	O
was	O
given	O
,	O
resulting	O
in	O
severe	O
angioedema	B
.	O

The	O
angioedema	B
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	O
and	O
diphenhydramine	O
hydrochloride	O
.	O

Effect	O
of	O
coniine	O
on	O
the	O
developing	O
chick	O
embryo	O
.	O

Coniine	O
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O

The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	B
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O

However	O
,	O
coniine	O
has	O
failed	O
to	O
produce	O
arthrogryposis	B
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	O
and	O
nicotine	O
in	O
the	O
developing	O
chick	O
.	O

Concentrations	O
of	O
coniine	O
and	O
nicotine	O
sulfate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
compounds	O
caused	O
deformations	B
and	O
lethality	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

All	O
concentrations	O
of	O
nicotine	O
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	O
lethality	O
was	O
0	O
.	O
75	O
%	O
.	O

The	O
deformations	B
caused	O
by	O
both	O
coniine	O
and	O
nicotine	O
sulfate	O
were	O
excessive	B
flexion	I
or	I
extension	I
of	I
one	I
or	I
more	I
toes	I
.	O

No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B
hemorrhage	I
occurred	O
in	O
all	O
nicotine	O
sulfate	O
-	O
treated	O
chicks	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	O
and	O
nicotine	O
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O

Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine	O
-	O
treated	O
chicks	O
were	O
only	O
moving	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	O
sulfate	O
treated	O
chicks	O
.	O

In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	O
-	O
induced	O
arthrogryposis	B
.	O

Data	O
from	O
this	O
model	O
support	O
a	O
mechanism	O
involving	O
nicotinic	O
receptor	O
blockade	O
with	O
subsequent	O
decreased	O
fetal	O
movement	O
.	O

Immediate	O
allergic	B
reactions	I
to	O
amoxicillin	O
.	O

A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B
reactions	I
to	O
beta	O
-	O
lactam	O
antibiotics	O
was	O
evaluated	O
.	O

A	O
detailed	O
clinical	O
history	O
,	O
together	O
with	O
skin	O
tests	O
,	O
RAST	O
(	O
radioallergosorbent	O
test	O
)	O
,	O
and	O
controlled	O
challenge	O
tests	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	B
to	O
beta	O
-	O
lactam	O
antibiotics	O
had	O
selective	O
immediate	O
allergic	B
responses	O
to	O
amoxicillin	O
(	O
AX	O
)	O
or	O
were	O
cross	O
-	O
reacting	O
with	O
other	O
penicillin	O
derivatives	O
.	O

Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl	O
-	O
poly	O
-	O
L	O
-	O
lysine	O
(	O
BPO	O
-	O
PLL	O
)	O
,	O
benzylpenicilloate	O
,	O
benzylpenicillin	O
(	O
PG	O
)	O
,	O
ampicillin	O
(	O
AMP	O
)	O
,	O
and	O
AX	O
.	O

RAST	O
for	O
BPO	O
-	O
PLL	O
and	O
AX	O
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	O
were	O
negative	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	O
or	O
sensitivity	O
to	O
AX	O
.	O

A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B
to	O
beta	O
-	O
lactam	O
antibiotics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
cases	O
of	O
immediate	O
AX	O
allergy	B
with	O
good	O
tolerance	O
of	O
PG	O
.	O

Anaphylaxis	B
was	O
seen	O
in	O
37	O
patients	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
urticaria	B
and	O
/	O
or	O
angioedema	B
.	O

All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	O
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negative	O
to	O
MDM	B
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	O
.	O

Skin	O
tests	O
with	O
AX	O
were	O
positive	O
in	O
34	O
(	O
63	O
%	O
)	O
patients	O
.	O

RAST	O
was	O
positive	O
for	O
AX	O
in	O
22	O
patients	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	O
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	O
were	O
positive	O
to	O
BPO	O
.	O

Challenge	O
tests	O
with	O
AX	O
were	O
performed	O
in	O
23	O
subjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B
reaction	I
to	O
AX	O
,	O
and	O
in	O
15	O
cases	O
(	O
28	O
%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	O
were	O
negative	O
.	O

PG	O
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O

We	O
describe	O
the	O
largest	O
group	O
of	O
AX	O
-	O
allergic	B
patients	O
who	O
have	O
tolerated	O
PG	O
reported	O
so	O
far	O
.	O

Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	O
-	O
related	O
reagents	O
are	O
employed	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
problem	O
and	O
to	O
improve	O
the	O
efficacy	O
of	O
diagnostic	O
methods	O
.	O

Reversal	O
by	O
phenylephrine	O
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	O
in	O
patients	O
with	O
acute	B
myocardial	I
infarction	I
.	O

Nitroglycerin	O
has	O
been	O
shown	O
to	O
reduce	O
ST	O
-	O
segment	O
elevation	O
during	O
acute	B
myocardial	I
infarction	I
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin	O
-	O
induced	O
hypotension	B
.	O

Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	O
and	O
phenylephrine	O
therapy	O
.	O

Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	B
infarctions	I
received	O
intravenous	O
nitroglycerin	O
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
minutes	O
.	O

Left	O
ventricular	O
filling	O
pressure	O
decreased	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

SigmaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
intravenous	O
nitroglycerin	O
.	O

Subsequent	O
addition	O
of	O
phenylephrine	O
infusion	O
,	O
sufficient	O
to	O
re	O
-	O
elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
minutes	O
,	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
increased	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	O
to	O
nitroglycerin	O
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	B
myocardial	I
infarction	I
.	O

Acetazolamide	O
-	O
induced	O
nephrolithiasis	B
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	B
disorders	I
.	O

Carbonic	O
anhydrase	O
inhibitors	O
can	O
cause	O
nephrolithiasis	B
.	O

We	O
studied	O
20	O
patients	O
receiving	O
long	O
-	O
term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	B
and	O
myotonia	B
.	O

Three	O
patients	O
on	O
acetazolamide	O
(	O
15	O
%	O
)	O
developed	O
renal	B
calculi	I
.	O

Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	B
calculus	I
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	B
in	O
another	O
,	O
permitting	O
continued	O
treatment	O
.	O

Renal	O
function	O
remained	O
normal	O
in	O
all	O
patients	O
.	O

Nephrolithiasis	B
is	O
a	O
complication	O
of	O
acetazolamide	O
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Effects	O
of	O
calcium	O
channel	O
blockers	O
on	O
bupivacaine	O
-	O
induced	O
toxicity	B
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	O
channel	O
blockers	O
on	O
bupivacaine	O
-	O
induced	O
acute	O
toxicity	B
.	O

For	O
each	O
of	O
the	O
three	O
tested	O
calcium	O
channel	O
blockers	O
(	O
diltiazem	O
,	O
verapamil	O
and	O
bepridil	O
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	O
later	O
,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
dose	O
of	O
bupivacaine	O
.	O

The	O
convulsant	O
activity	O
,	O
the	O
time	O
of	O
latency	O
to	O
convulse	O
and	O
the	O
mortality	O
rate	O
were	O
assessed	O
in	O
each	O
group	O
.	O

The	O
local	O
anesthetic	O
-	O
induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	O
channel	O
blockers	O
.	O

The	O
convulsant	O
activity	O
of	O
bupivacaine	O
was	O
not	O
significantly	O
modified	O
but	O
calcium	O
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	O
-	O
induced	O
convulsions	B
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	O
.	O

Epidural	O
blood	O
flow	O
during	O
prostaglandin	O
E1	O
or	O
trimethaphan	O
induced	O
hypotension	B
.	O

To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	O
E1	O
(	O
PGE1	O
)	O
or	O
trimethaphan	O
(	O
TMP	O
)	O
induced	O
hypotension	B
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero	O
-	O
lateral	O
interbody	O
fusion	O
under	O
isoflurane	O
anaesthesia	O
.	O

An	O
initial	O
dose	O
of	O
0	O
.	O
1	O
microgram	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PGE1	O
(	O
15	O
patients	O
)	O
,	O
or	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	O
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hypotensive	B
drug	O
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure	O
.	O

After	O
starting	O
PGE1	O
or	O
TMP	O
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(	O
RPP	O
)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
degree	O
of	O
hypotension	B
due	O
to	O
PGE1	O
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
group	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	O
infusion	O
whereas	O
in	O
the	O
TMP	O
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	O
(	O
preinfusion	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O

These	O
results	O
suggest	O
that	O
PGE1	O
may	O
be	O
preferable	O
to	O
TMP	O
for	O
hypotensive	B
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	O
decreased	O
EBF	O
.	O

Dup	O
753	O
prevents	O
the	O
development	O
of	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrosis	B
.	O

The	O
appearance	O
of	O
nephrotic	B
syndromes	I
such	O
as	O
proteinuria	B
,	O
hypoalbuminemia	B
,	O
hypercholesterolemia	B
and	O
increase	O
in	O
blood	O
nitrogen	O
urea	O
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	O
aminonucleoside	O
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	O
753	O
(	O
losartan	O
)	O
,	O
a	O
novel	O
angiotensin	O
II	O
receptor	O
antagonist	O
,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O

The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
in	O
the	O
development	O
of	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrosis	B
.	O

Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	B
loss	I
.	O

Tonotopic	O
organization	O
is	O
an	O
essential	O
feature	O
of	O
the	O
primary	O
auditory	O
area	O
(	O
A1	O
)	O
of	O
primate	O
cortex	O
.	O

In	O
A1	O
of	O
macaque	O
monkeys	O
,	O
low	O
frequencies	O
are	O
represented	O
rostrolaterally	O
and	O
high	O
frequencies	O
are	O
represented	O
caudomedially	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	B
loss	I
.	O

Under	O
anesthesia	O
,	O
the	O
superior	O
temporal	O
gyrus	O
of	O
adult	O
macaque	O
monkeys	O
was	O
exposed	O
,	O
and	O
the	O
tonotopic	O
organization	O
of	O
A1	O
was	O
mapped	O
using	O
conventional	O
microelectrode	O
recording	O
techniques	O
.	O

Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	O
and	O
furosemide	O
.	O

The	O
actual	O
frequencies	O
deafened	O
were	O
determined	O
by	O
the	O
loss	O
of	O
tone	O
-	O
burst	O
elicited	O
auditory	O
brainstem	O
responses	O
.	O

Three	O
months	O
after	O
deafening	O
,	O
A1	O
was	O
remapped	O
.	O

Postmortem	O
cytoarchitectural	O
features	O
identifying	O
A1	O
were	O
correlated	O
with	O
the	O
electrophysiologic	O
data	O
.	O

The	O
results	O
indicate	O
that	O
the	O
deprived	O
area	O
of	O
A1	O
undergoes	O
extensive	O
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	O
cochlear	O
frequencies	O
.	O

The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B
loss	I
.	O

Sodium	O
bicarbonate	O
alleviates	O
penile	B
pain	I
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	B
dysfunction	I
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	B
pain	I
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	B
pain	I
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	O
bicarbonate	O
to	O
the	O
intracorporeal	O
medications	O
.	O

A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	B
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
combination	O
of	O
3	O
drugs	O
:	O
6	O
mg	O
.	O
papaverine	O
,	O
100	O
micrograms	O
.	O
phentolamine	O
and	O
10	O
micrograms	O
.	O
prostaglandin	O
E1	O
with	O
(	O
pH	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
pH	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
sodium	O
bicarbonate	O
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
patients	O
without	O
sodium	O
bicarbonate	O
added	O
to	O
the	O
medication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penile	B
pain	I
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
sodium	O
bicarbonate	O
complained	O
of	O
penile	B
pain	I
.	O

From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	B
pain	I
following	O
intracorporeal	O
injections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	O
to	O
a	O
neutral	O
level	O
.	O

The	O
use	O
and	O
toxicity	B
of	O
didanosine	O
(	O
ddI	O
)	O
in	O
HIV	B
antibody	I
-	I
positive	I
individuals	O
intolerant	O
to	O
zidovudine	O
(	O
AZT	O
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
patients	O
intolerant	O
to	O
zidovudine	O
(	O
AZT	O
)	O
received	O
didanosine	O
(	O
ddI	O
)	O
to	O
a	O
maximum	O
dose	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Patient	O
response	O
was	O
assessed	O
using	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
,	O
HIV	O
p24	O
antigen	O
,	O
weight	O
,	O
and	O
quality	O
of	O
life	O
.	O

Seventy	O
patients	O
developed	O
major	O
opportunistic	B
infections	I
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B
diagnosis	O
in	O
17	O
.	O

Only	O
minor	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	B
patients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease	O
.	O

Of	O
those	O
positive	O
for	O
p24	O
antigen	O
at	O
the	O
commencement	O
of	O
the	O
study	O
67	O
%	O
showed	O
a	O
positive	O
response	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lymphocyte	O
subset	O
counts	O
above	O
100	O
mm3	O
.	O

A	O
positive	O
weight	O
response	O
was	O
seen	O
in	O
16	O
%	O
of	O
patients	O
.	O

Most	O
patients	O
showed	O
improvement	O
in	O
individual	O
parameters	O
and	O
global	O
score	O
of	O
quality	O
of	O
life	O
.	O

Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	O
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
effect	O
was	O
diarrhoea	B
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals	O
.	O

Peripheral	B
neuropathy	I
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	B
in	O
six	O
.	O

Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	O
without	O
abdominal	B
pain	I
.	O

Seven	O
patients	O
developed	O
glucose	B
tolerance	I
curves	I
characteristic	O
of	O
diabetes	B
but	O
these	O
were	O
mild	O
,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	O
.	O

Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B
damage	I
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O

Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(	O
NF	O
)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
study	O
axonal	B
injury	I
in	O
the	O
borderzone	O
of	O
focal	O
lesions	O
in	O
rats	O
.	O

Focal	O
injury	B
in	I
the	I
cortex	I
was	O
produced	O
by	O
infusion	O
of	O
lactate	O
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O

Infarcts	B
in	I
substantia	I
nigra	I
pars	I
reticulata	I
were	O
evoked	O
by	O
prolonged	O
pilocarpine	O
-	O
induced	O
status	B
epilepticus	I
.	O

Immunohistochemical	O
staining	O
for	O
NFs	O
showed	O
characteristic	O
terminal	O
clubs	O
of	O
axons	O
in	O
the	O
borderzone	O
of	O
lesions	O
.	O

Differences	O
in	O
the	O
labelling	O
pattern	O
occurred	O
with	O
different	O
antibodies	O
which	O
apparently	O
depended	O
on	O
molecular	O
weight	O
class	O
of	O
NFs	O
and	O
phosphorylation	O
state	O
.	O

These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B
damage	I
in	O
various	O
experimental	O
traumatic	B
or	O
ischemic	O
lesions	O
.	O

Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	O
-	O
associated	O
mental	O
confusion	B
.	O

15	O
cases	O
of	O
cimetidine	O
-	O
associated	O
mental	O
confusion	B
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrome	O
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients	O
,	O
30	O
patients	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cimetidine	O
and	O
6	O
had	O
moderate	O
to	O
severe	O
changes	O
.	O

These	O
6	O
patients	O
had	O
both	O
renal	B
and	I
liver	I
dysfunction	I
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	O
trough	O
-	O
concentrations	O
of	O
more	O
than	O
1	O
.	O
25	O
microgram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
severity	O
of	O
M	O
.	O
S	O
.	O
changes	O
increased	O
as	O
trough	O
-	O
concentrations	O
rose	O
,	O
5	O
patients	O
had	O
lumbar	O
puncture	O
.	O

The	O
cerebrospinal	O
fluid	O
:	O
serum	O
ratio	O
of	O
cimetidine	O
concentrations	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
cimetidine	O
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	O
H2	O
-	O
receptors	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concentrations	O
and	O
mental	O
confusion	B
are	O
those	O
with	O
both	O
severe	O
renal	B
and	I
hepatic	I
dysfunction	I
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	O
.	O

Prospective	O
study	O
of	O
the	O
long	O
-	O
term	O
effects	O
of	O
somatostatin	O
analog	O
(	O
octreotide	O
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	B
formation	O
in	O
Chinese	O
acromegalic	B
patients	O
.	O

This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	B
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	O
analog	O
octreotide	O
in	O
dosages	O
of	O
300	O
-	O
1500	O
micrograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
months	O
.	O

During	O
treatment	O
with	O
octreotide	O
,	O
17	O
patients	O
developed	O
sludge	O
,	O
10	O
had	O
gallstones	B
,	O
and	O
1	O
developed	O
acute	B
cholecystitis	I
requiring	O
surgery	O
.	O

In	O
all	O
of	O
7	O
patients	O
examined	O
acutely	O
,	O
gallbladder	O
contractility	O
was	O
inhibited	O
after	O
a	O
single	O
100	O
-	O
micrograms	O
injection	O
.	O

In	O
8	O
patients	O
followed	O
for	O
24	O
weeks	O
,	O
gallbladder	O
contractility	O
remained	O
depressed	B
throughout	O
therapy	O
.	O

After	O
withdrawal	O
of	O
octreotide	O
in	O
10	O
patients	O
without	O
gallstones	B
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	B
during	O
treatment	O
,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depressed	B
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge	O
,	O
gallstones	B
,	O
and	O
cholecystitis	B
during	O
octreotide	O
therapy	O
in	O
Chinese	O
acromegalic	B
patients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long	O
-	O
term	O
octreotide	O
therapy	O
of	O
acromegalic	B
patients	O
.	O

Increase	O
of	O
Parkinson	B
disability	I
after	O
fluoxetine	O
medication	O
.	O

Depression	B
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B
disability	I
in	O
four	O
patients	O
with	O
idiopathic	B
Parkinson	I
'	I
s	I
disease	I
after	O
exposure	O
to	O
the	O
antidepressant	O
fluoxetine	O
.	O

The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine	O
-	O
antagonistic	O
capacity	O
of	O
fluoxetine	O
in	O
Parkinson	B
'	I
s	I
disease	I
patients	O
must	O
be	O
considered	O
.	O

Sinus	B
arrest	I
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	O
.	O

The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	O
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	B
.	O

A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
leukemia	B
and	O
no	O
history	O
of	O
cardiac	B
disease	I
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B
arrest	I
while	O
receiving	O
continuous	O
-	O
infusion	O
cimetidine	O
50	O
mg	O
/	O
hour	O
.	O

The	O
arrhythmias	B
were	O
temporally	O
related	O
to	O
cimetidine	O
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	O
treatment	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	B
arrest	I
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	O
.	O

Phase	O
II	O
trial	O
of	O
vinorelbine	O
in	O
metastatic	O
squamous	B
cell	I
esophageal	I
carcinoma	I
.	O

European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B
Gastrointestinal	O
Treat	O
Cancer	B
Cooperative	O
Group	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	O
(	O
VNB	O
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	B
cell	I
esophageal	I
carcinoma	I
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligible	O
patients	O
with	O
measurable	O
lesions	O
were	O
included	O
and	O
were	O
stratified	O
according	O
to	O
previous	O
chemotherapy	O
.	O

Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin	O
-	O
based	O
chemotherapy	O
were	O
assessable	O
for	O
toxicity	B
and	O
response	O
.	O

VNB	O
was	O
administered	O
weekly	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
infusion	O
.	O

RESULTS	O
:	O
Six	O
of	O
30	O
patients	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherapy	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

The	O
median	O
duration	O
of	O
response	O
was	O
21	O
weeks	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O

One	O
of	O
16	O
patients	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemotherapy	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
of	O
31	O
weeks	O
'	O
duration	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O

The	O
overall	O
response	O
rate	O
(	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
criteria	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O

The	O
median	O
dose	O
-	O
intensity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O

VNB	O
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	B
occurred	O
.	O

At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	B
was	O
seen	O
in	O
59	O
%	O
of	O
patients	O
.	O

A	O
grade	O
2	O
or	O
3	O
infection	B
occurred	O
in	O
16	O
%	O
of	O
patients	O
,	O
but	O
no	O
toxic	O
deaths	B
occurred	O
.	O

Other	O
side	O
effects	O
were	O
rare	O
,	O
and	O
peripheral	B
neurotoxicity	I
has	O
been	O
minor	O
(	O
26	O
%	O
grade	O
1	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
VNB	O
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	B
squamous	I
cell	I
carcinoma	I
.	O

Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	B
,	O
further	O
evaluation	O
of	O
VNB	O
in	O
combination	O
therapy	O
is	O
warranted	O
.	O

Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	O
hydrochloride	O
ophthalmic	O
solution	O
.	O

We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	O
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1	O
%	O
apraclonidine	O
in	O
their	O
right	O
eyes	O
.	O

Examinations	O
,	O
including	O
blood	O
pressure	O
,	O
pulse	O
rate	O
,	O
conjunctiva	O
and	O
cornea	O
,	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
pupil	O
diameter	O
,	O
basal	O
tear	O
secretion	O
and	O
margin	O
reflex	O
distance	O
of	O
both	O
upper	O
and	O
lower	O
eyelids	O
,	O
were	O
performed	O
prior	O
to	O
entry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillation	O
.	O

The	O
ocular	B
hypotensive	I
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine	O
-	O
treated	O
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1	O
%	O
apraclonidine	O
.	O

Decreases	B
in	I
systolic	I
blood	I
pressure	I
were	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
.	O

No	O
significant	O
changes	O
in	O
diastolic	O
blood	O
pressure	O
,	O
pulse	O
rate	O
and	O
basal	O
tear	O
secretion	O
were	O
noted	O
.	O

Conjunctival	B
blanching	I
and	O
mydriasis	B
were	O
commonly	O
found	O
.	O

Upper	O
lid	O
retraction	O
was	O
frequently	O
noted	O
.	O

While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance	O
,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	B
and	O
marked	O
corneal	B
abrasion	I
3	O
hours	O
after	O
instillation	O
of	O
the	O
medication	O
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finding	O
in	O
Asian	O
people	O
.	O

Thiopentone	O
pretreatment	O
for	O
propofol	O
injection	O
pain	B
in	O
ambulatory	O
patients	O
.	O

This	O
study	O
investigated	O
propofol	O
injection	O
pain	B
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia	O
.	O

In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	O
.	O

Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline	O
,	O
Group	O
L	O
,	O
2	O
ml	O
,	O
lidocaine	O
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O
thiopentone	O
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
propofol	O
administration	O
using	O
an	O
infusion	O
pump	O
(	O
rate	O
1000	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O

Loss	B
of	I
consciousness	I
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

Visual	O
analogue	O
scores	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
during	O
induction	O
were	O
lower	O
in	O
Groups	O
L	O
(	O
3	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
and	O
T	O
(	O
4	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
than	O
in	O
Group	O
C	O
(	O
5	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
0031	O
.	O

The	O
incidence	O
of	O
venous	O
discomfort	O
was	O
lower	O
in	O
Group	O
L	O
(	O
76	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
Group	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Group	O
T	O
(	O
90	O
%	O
)	O
.	O

The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	B
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Recovery	O
room	O
discharge	O
times	O
were	O
similar	O
:	O
C	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
19	O
.	O
4	O
min	O
)	O
;	O
L	O
73	O
.	O
6	O
+	O
/	O
-	O
21	O
.	O
6	O
min	O
)	O
;	O
T	O
(	O
77	O
.	O
1	O
+	O
/	O
-	O
18	O
.	O
9	O
min	O
)	O
.	O

Assessing	O
their	O
overall	O
satisfaction	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
propofol	O
anaesthesia	O
again	O
.	O

We	O
conclude	O
that	O
lidocaine	O
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	O
injection	O
pain	B
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	O
only	O
reduces	O
its	O
severity	O
.	O

Persistent	O
paralysis	B
after	O
prolonged	O
use	O
of	O
atracurium	O
in	O
the	O
absence	O
of	O
corticosteroids	O
.	O

Neuromuscular	O
blocking	O
agents	O
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patients	O
requiring	O
prolonged	O
mechanical	O
ventilation	O
.	O

Reports	O
of	O
persistent	O
paralysis	B
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecuronium	O
bromide	O
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	O
.	O

Atracurium	O
besylate	O
,	O
a	O
short	O
-	O
acting	O
benzylisoquinolinium	O
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function	O
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	B
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	O
.	O

We	O
report	O
a	O
case	O
of	O
atracurium	O
-	O
related	O
paralysis	B
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	O
.	O

A	O
phase	O
I	O
/	O
II	O
study	O
of	O
paclitaxel	O
plus	O
cisplatin	O
as	O
first	O
-	O
line	O
therapy	O
for	O
head	B
and	I
neck	I
cancers	I
:	O
preliminary	O
results	O
.	O

Improved	O
outcomes	O
among	O
patients	O
with	O
head	B
and	I
neck	I
carcinomas	I
require	O
investigations	O
of	O
new	O
drugs	O
for	O
induction	O
therapy	O
.	O

Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single	O
-	O
agent	O
paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
response	O
rate	O
in	O
patients	O
with	O
head	B
and	I
neck	I
cancer	I
,	O
and	O
the	O
paclitaxel	O
/	O
cisplatin	O
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	B
cancer	I
patients	O
.	O

We	O
initiated	O
a	O
phase	O
I	O
/	O
II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	B
of	O
escalating	O
paclitaxel	O
doses	O
combined	O
with	O
fixed	O
-	O
dose	O
cisplatin	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	B
and	I
neck	I
carcinoma	I
.	O

To	O
date	O
,	O
23	O
men	O
with	O
a	O
median	O
age	O
of	O
50	O
years	O
and	O
good	O
performance	O
status	O
have	O
entered	O
the	O
trial	O
.	O

Primary	O
tumor	B
sites	O
were	O
oropharynx	O
,	O
10	O
patients	O
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	O
cavity	O
,	O
three	O
;	O
unknown	O
primary	O
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O

Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	B
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease	O
.	O

Treatment	O
,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles	O
,	O
consisted	O
of	O
paclitaxel	O
by	O
3	O
-	O
hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	O
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	O
doses	O
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	B
permits	O
.	O

At	O
the	O
time	O
of	O
this	O
writing	O
,	O
dose	O
level	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
evaluated	O
;	O
three	O
patients	O
from	O
this	O
level	O
are	O
evaluable	O
.	O

With	O
paclitaxel	O
doses	O
of	O
200	O
mg	O
/	O
m2	O
and	O
higher	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
5	O
micrograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
days	O
4	O
through	O
12	O
)	O
.	O

Of	O
18	O
patients	O
evaluable	O
for	O
response	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O

Three	O
patients	O
had	O
no	O
change	O
and	O
disease	O
progressed	O
in	O
two	O
.	O

The	O
overall	O
response	O
rate	O
is	O
72	O
%	O
.	O

Eleven	O
responding	O
patients	O
had	O
subsequent	O
surgery	O
/	O
radiotherapy	O
or	O
radical	O
radiotherapy	O
.	O

Two	O
pathologic	O
complete	O
responses	O
were	O
observed	O
in	O
patients	O
who	O
had	O
achieved	O
clinical	O
complete	O
responses	O
.	O

Alopecia	B
,	O
paresthesias	B
,	O
and	O
arthralgias	B
/	O
myalgias	B
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	O
3	O
myalgia	B
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2	O
.	O

No	O
dose	O
-	O
limiting	O
hematologic	O
toxicity	B
has	O
been	O
seen	O
.	O

Paclitaxel	O
/	O
cisplatin	O
is	O
an	O
effective	O
first	O
-	O
line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	B
and	I
neck	I
cancer	I
and	O
continued	O
study	O
is	O
warranted	O
.	O

Results	O
thus	O
far	O
suggest	O
no	O
dose	O
-	O
response	O
effect	O
for	O
paclitaxel	O
doses	O
above	O
200	O
mg	O
/	O
m2	O
.	O

Improvement	O
of	O
levodopa	O
-	O
induced	O
dyskinesia	B
by	O
propranolol	O
in	O
Parkinson	B
'	I
s	I
disease	I
.	O

Seven	O
patients	O
suffering	O
from	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
with	O
severely	O
disabling	O
dyskinesia	B
received	O
low	O
-	O
dose	O
propranolol	O
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
improvement	O
in	O
the	O
dyskinesia	B
score	O
without	O
increase	O
of	O
parkinsonian	B
motor	B
disability	I
.	O

Ballistic	O
and	O
choreic	O
dyskinesia	B
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	B
was	O
not	O
.	O

This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta	O
-	O
blockers	O
may	O
improve	O
levodopa	O
-	O
induced	O
ballistic	O
and	O
choreic	O
dyskinesia	B
in	O
PD	B
.	O

Habitual	O
use	O
of	O
acetaminophen	O
as	O
a	O
risk	O
factor	O
for	O
chronic	B
renal	I
failure	I
:	O
a	O
comparison	O
with	O
phenacetin	O
.	O

Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	O
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B
renal	I
failure	I
and	O
end	B
-	I
stage	I
renal	I
disease	I
(	O
ESRD	B
)	O
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	O
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O

However	O
,	O
three	O
case	O
control	O
studies	O
,	O
one	O
each	O
in	O
North	O
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	O
is	O
also	O
associated	O
with	O
chronic	B
renal	I
failure	I
and	O
ESRD	B
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
studies	O
suggest	O
that	O
both	O
phenacetin	O
and	O
acetaminophen	O
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	B
potential	O
of	O
the	O
drugs	O
themselves	O
.	O

A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	O
if	O
the	O
risk	O
of	O
both	O
drugs	O
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone	O
.	O

Thus	O
,	O
acetaminophen	O
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	O
was	O
available	O
only	O
in	O
combinations	O
.	O

The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	O
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Acetaminophen	O
-	O
induced	O
hypotension	B
.	O

Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	O
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O

The	O
potential	O
for	O
acetaminophen	O
to	O
produce	O
cardiovascular	B
toxicities	I
is	O
very	O
low	O
.	O

However	O
,	O
acetaminophen	O
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	B
,	O
including	O
hypotension	B
,	O
in	O
sensitive	O
individuals	O
.	O

This	O
article	O
describes	O
two	O
critically	B
ill	I
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	B
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	O
.	O

Other	O
symptoms	O
of	O
allergic	B
reactions	I
were	O
not	O
clinically	O
detectable	O
.	O

The	O
hypotensive	B
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O

The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	O
in	O
patients	O
with	O
hypotension	B
of	O
unknown	O
origin	O
.	O

Reduction	O
of	O
heparan	O
sulphate	O
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	O
-	O
induced	O
diabetic	B
nephropathy	I
.	O

Heparan	O
sulphate	O
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	B
by	O
streptozotocin	O
and	O
in	O
age	O
-	O
adn	O
sex	O
-	O
matched	O
control	O
rats	O
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	O
blue	O
.	O

Morphometric	O
analysis	O
at	O
the	O
ultrastructural	O
level	O
was	O
performed	O
using	O
a	O
computerized	O
image	O
processor	O
.	O

The	O
heparan	O
sulphate	O
specificity	O
of	O
the	O
cuprolinic	O
blue	O
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan	O
-	O
degrading	O
enzymes	O
,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining	O
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	O
.	O

The	O
majority	O
of	O
anionic	O
sites	O
(	O
74	O
%	O
in	O
diabetic	B
and	O
81	O
%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
diabetic	B
and	O
control	O
rats	O
,	O
respectively	O
)	O
.	O

Diabetic	B
rats	O
progressively	O
developed	O
albuminuria	B
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
months	O
in	O
contrast	O
to	O
the	O
control	O
animals	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	O
sulphate	O
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Number	O
and	O
total	O
anionic	O
site	O
surface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O

We	O
conclude	O
that	O
in	O
streptozotocin	O
-	O
diabetic	B
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	O
sulphate	O
charge	O
barrier	O
/	O
density	O
is	O
found	O
at	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	B
by	O
L	O
-	O
dopa	O
via	O
central	O
dopamine	O
formation	O
in	O
dogs	O
.	O

L	O
-	O
Dopa	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK	O
-	O
486	O
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anesthetize	O
MAO	O
-	O
inhibited	O
dogs	O
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B
caused	O
by	O
injected	O
norepinephrine	O
was	O
significantly	O
enhanced	O
by	O
L	O
-	O
dopa	O
,	O
DL	O
-	O
Threo	O
-	O
dihydroxyphenylserine	O
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	O
.	O

FLA	O
-	O
63	O
,	O
a	O
dopamine	O
-	O
beta	O
-	O
oxidase	O
inhibitor	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	B
,	O
bradycardia	B
or	O
reflex	O
-	O
enhancing	O
effect	O
of	O
L	O
-	O
dopa	O
.	O

Pimozide	O
did	O
not	O
affect	O
the	O
actions	O
of	O
L	O
-	O
dopa	O
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O

Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	O
.	O

However	O
,	O
L	O
-	O
dopa	O
restored	O
the	O
bradycardia	B
caused	O
by	O
norepinephrine	O
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

5	O
-	O
HTP	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	B
to	O
norepinephrine	O
.	O

It	O
is	O
concluded	O
that	O
L	O
-	O
dopa	O
enhances	O
reflex	O
bradycardia	B
through	O
central	O
alpha	O
-	O
receptor	O
stimulation	O
.	O

Furthermore	O
,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	O
rather	O
than	O
norepinephrine	O
and	O
do	O
not	O
require	O
the	O
carotid	O
sinus	O
baroreceptors	O
.	O

Microangiopathic	B
hemolytic	I
anemia	I
complicating	O
FK506	O
(	O
tacrolimus	O
)	O
therapy	O
.	O

We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	B
hemolytic	I
anemia	I
(	O
MAHA	B
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	O
(	O
tacrolimus	O
)	O
therapy	O
.	O

In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	O
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	O
,	O
aspirin	O
,	O
and	O
dipyridamole	O
led	O
to	O
resolution	O
of	O
MAHA	B
.	O

In	O
one	O
patient	O
,	O
reintroduction	O
of	O
FK506	O
led	O
to	O
rapid	O
recurrence	O
of	O
MAHA	B
.	O

FK506	O
-	O
associated	O
MAHA	B
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication	O
.	O

In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	O
does	O
not	O
seem	O
to	O
cross	O
-	O
react	O
with	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	B
.	O

Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	B
toxicity	I
.	O

The	O
nephrotoxic	B
action	O
of	O
anticancer	O
drugs	O
such	O
as	O
nitrogranulogen	O
(	O
NG	O
)	O
,	O
methotrexate	O
(	O
MTX	O
)	O
,	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
cyclophosphamide	O
(	O
CY	O
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
(	O
CMF	O
)	O
]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats	O
.	O

After	O
drug	O
administration	O
,	O
creatinine	O
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	O
clearance	O
.	O

Histopathologic	O
evaluation	O
of	O
the	O
kidneys	O
was	O
also	O
performed	O
.	O

After	O
MTX	O
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
plasma	O
creatinine	O
concentration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
decrease	O
in	O
creatinine	O
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O

After	O
the	O
administration	O
of	O
NG	O
,	O
5	O
-	O
FU	O
and	O
CY	O
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	O
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	O
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O

Following	O
polytherapy	O
according	O
to	O
the	O
CMF	O
regimen	O
,	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
creatinine	O
clearance	O
was	O
found	O
,	O
but	O
creatinine	O
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O

CY	O
caused	O
hemorrhagic	B
cystitis	I
in	O
40	O
%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5	O
-	O
FU	O
and	O
MTX	O
.	O

Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	O
,	O
CY	O
and	O
NG	O
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	O
-	O
FU	O
and	O
joint	O
administration	O
of	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
compared	O
to	O
controls	O
.	O

Our	O
studies	O
indicate	O
that	O
nephrotoxicity	B
of	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
administered	O
jointly	O
is	O
lower	O
than	O
in	O
monotherapy	O
.	O

The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	O
'	O
s	O
effects	O
on	O
free	O
-	O
field	O
activity	O
.	O

Partial	O
lesions	O
were	O
made	O
with	O
kainic	O
acid	O
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat	O
.	O

Compared	O
with	O
sham	O
-	O
operated	O
controls	O
,	O
lesions	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
blunted	O
the	O
early	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
locomotor	B
hypoactivity	I
caused	O
by	O
nicotine	O
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
enhanced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nicotine	O
-	O
induced	O
hyperactivity	B
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity	O
.	O

Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	O
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	O
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	O
.	O

We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	B
of	O
locomotor	O
activity	O
and	O
dampens	O
nicotinic	O
arousal	O
mechanisms	O
located	O
elsewhere	O
in	O
the	O
brain	O
.	O

Lithium	O
-	O
associated	O
cognitive	B
and	I
functional	I
deficits	I
reduced	O
by	O
a	O
switch	O
to	O
divalproex	O
sodium	O
:	O
a	O
case	O
series	O
.	O

BACKGROUND	O
:	O
Lithium	O
remains	O
a	O
first	O
-	O
line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	B
disorder	I
.	O

Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	O
,	O
such	O
as	O
polyuria	B
and	O
tremor	B
,	O
more	O
subtle	O
lithium	O
side	O
effects	O
such	O
as	O
cognitive	B
deficits	I
,	O
loss	B
of	I
creativity	I
,	O
and	O
functional	B
impairments	I
remain	O
understudied	O
.	O

This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	B
patients	O
from	O
lithium	O
to	O
divalproex	O
sodium	O
to	O
alleviate	O
such	O
cognitive	B
and	I
functional	I
impairments	I
.	O

METHOD	O
:	O
Open	O
,	O
case	O
series	O
design	O
.	O

RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	O
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	O
sodium	O
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B
,	I
motivational	I
,	I
or	I
creative	I
deficits	I
attributed	O
to	O
lithium	O
in	O
our	O
bipolar	B
patients	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
report	O
,	O
divalproex	O
sodium	O
was	O
a	O
superior	O
alternative	O
to	O
lithium	O
in	O
bipolar	B
patients	O
experiencing	O
cognitive	B
deficits	I
,	O
loss	B
of	I
creativity	I
,	O
and	O
functional	B
impairments	I
.	O

Effect	O
of	O
nifedipine	O
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	O
.	O

The	O
effect	O
of	O
nifedipine	O
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	O
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996	O
.	O

Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	O
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year	O
,	O
one	O
group	O
comprising	O
hypertensive	B
patients	O
who	O
were	O
receiving	O
nifedipine	O
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	O
.	O

The	O
time	O
from	O
transplant	O
to	O
baseline	O
was	O
similar	O
in	O
all	O
patients	O
.	O

Nifedipine	O
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	O
levels	O
at	O
6	O
and	O
12	O
months	O
.	O

The	O
observed	O
positive	O
impact	O
of	O
nifedipine	O
on	O
reducing	O
the	O
nephrotoxicity	B
associated	O
with	O
tacrolimus	O
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	B
in	O
this	O
population	O
.	O

Alpha	O
and	O
beta	O
coma	B
in	O
drug	O
intoxication	O
uncomplicated	O
by	O
cerebral	B
hypoxia	I
.	O

Four	O
patients	O
who	O
were	O
rendered	O
comatose	B
or	O
stuporous	B
by	O
drug	O
intoxication	O
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O

Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	O
for	O
alcohol	O
withdrawal	B
symptoms	I
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	B
of	O
nitrazepam	O
.	O

The	O
patient	O
with	O
nitrazepam	O
overdose	B
and	O
two	O
of	O
those	O
with	O
chlormethiazole	O
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'	O
alpha	O
coma	B
'	O
,	O
showing	O
non	O
-	O
reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	O
administration	O
exhibite	O
generalized	O
non	O
-	O
reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range	O
.	O

All	O
four	O
recovered	O
completely	O
without	O
neurological	B
sequelae	I
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents	O
.	O

The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	B
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo	O
-	O
thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	B
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	O
intoxication	O
,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	B
,	O
a	O
favourable	O
outcome	O
may	O
be	O
anticipated	O
.	O

Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	B
patients	O
after	O
phenytoin	O
overdosages	B
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	O
medication	O
and	O
cerebellar	B
atrophy	I
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O

Five	O
females	O
and	O
6	O
males	O
,	O
21	O
-	O
59	O
years	O
of	O
age	O
,	O
were	O
examined	O
with	O
a	O
1	O
.	O
5	O
-	O
T	O
whole	O
-	O
body	O
system	O
using	O
a	O
circular	O
polarized	O
head	O
coil	O
.	O

Conventional	O
spin	O
echo	O
images	O
were	O
acquired	O
in	O
the	O
sagittal	O
and	O
transverse	O
orientation	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
resolution	O
3D	O
gradient	O
echo	O
,	O
T1	O
-	O
weighted	O
sequences	O
at	O
a	O
1	O
-	O
mm	O
slice	O
thickness	O
.	O

The	O
images	O
were	O
subsequently	O
processed	O
to	O
obtain	O
volumetric	O
data	O
for	O
the	O
cerebellum	O
.	O

Cerebellar	O
volume	O
for	O
the	O
patient	O
group	O
ranged	O
between	O
67	O
.	O
66	O
and	O
131	O
.	O
08	O
ml	O
(	O
mean	O
108	O
.	O
9	O
ml	O
)	O
.	O

In	O
addition	O
3D	O
gradient	O
echo	O
data	O
sets	O
from	O
10	O
healthy	O
male	O
and	O
10	O
healthy	O
female	O
age	O
-	O
matched	O
volunteers	O
were	O
used	O
to	O
compare	O
cerebellar	O
volumes	O
.	O

Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	B
duration	O
,	O
elevation	O
of	O
phenytoin	O
serum	O
levels	O
and	O
cerebellar	O
volume	O
.	O

However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	O
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O

We	O
conclude	O
that	O
phenytoin	O
overdosage	B
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B
atrophy	I
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	O
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B
atrophy	I
in	O
the	O
remaining	O
patients	O
.	O

Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	B
disorders	I
.	O

Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	B
uremic	I
syndrome	I
.	O

A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
in	O
a	O
woman	O
taking	O
oral	O
contraceptives	O
.	O

She	O
was	O
treated	O
with	O
heparin	O
,	O
dipyridamole	O
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	B
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O

This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	B
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonged	O
oliguria	B
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	B
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	O
nephrectomy	O
,	O
for	O
treatment	O
of	O
severe	O
hypertension	B
and	O
microangiopathic	B
hemolytic	I
anemia	I
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Morphological	O
features	O
of	O
encephalopathy	B
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	O
valproate	O
to	O
rats	O
.	O

A	O
transmission	O
electron	O
microscopic	O
study	O
of	O
capillaries	O
in	O
the	O
cerebellar	O
cortex	O
.	O

Long	O
-	O
term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	O
sodium	O
valproate	O
(	O
Vupral	O
"	O
Polfa	O
"	O
)	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O

w	O
.	O
once	O
daily	O
to	O
rats	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	B
disorders	I
indicating	O
cerebellum	B
damage	I
(	O
"	O
valproate	O
encephalopathy	B
"	O
)	O
.	O

The	O
first	O
ultrastructural	O
changes	O
in	O
structural	O
elements	O
of	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
in	O
the	O
cerebellar	O
cortex	O
were	O
detectable	O
after	O
3	O
months	O
of	O
the	O
experiment	O
.	O

They	O
became	O
more	O
severe	O
in	O
the	O
later	O
months	O
of	O
the	O
experiment	O
,	O
and	O
were	O
most	O
severe	O
after	O
12	O
months	O
,	O
located	O
mainly	O
in	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellar	O
cortex	O
.	O

Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	B
of	O
endothelial	O
cells	O
.	O

Organelles	O
of	O
these	O
cells	O
,	O
in	O
particular	O
the	O
mitochondria	O
(	O
increased	O
number	O
and	O
size	O
,	O
distinct	O
degeneration	O
of	O
their	O
matrix	O
and	O
cristae	O
)	O
and	O
Golgi	O
apparatus	O
were	O
altered	O
.	O

Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	O
protrusions	O
and	O
swollen	O
microvilli	O
.	O

Pressure	O
on	O
the	O
vessel	O
wall	O
was	O
produced	O
by	O
enlarged	O
perivascular	O
astrocytic	O
processes	O
.	O

Fragments	O
of	O
necrotic	B
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions	O
.	O

Damage	O
to	O
the	O
vascular	O
basement	O
lamina	O
was	O
also	O
observed	O
.	O

Damage	O
to	O
the	O
capillary	O
was	O
accompanied	O
by	O
marked	O
damage	O
to	O
neuroglial	O
cells	O
,	O
mainly	O
to	O
perivascular	O
processes	O
of	O
astrocytes	O
.	O

The	O
proliferation	O
of	O
astrocytes	O
(	O
Bergmann	O
'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodendrocytes	O
was	O
found	O
.	O

Alterations	O
in	O
the	O
structural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesions	O
of	O
neurons	O
of	O
the	O
cerebellum	O
(	O
Purkinje	O
cells	O
are	O
earliest	O
)	O
.	O

In	O
electron	O
micrographs	O
both	O
luminal	O
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions	O
.	O

The	O
possible	O
influence	O
of	O
the	O
hepatic	B
damage	I
,	O
mainly	O
hyperammonemia	B
,	O
upon	O
the	O
development	O
of	O
valproate	O
encephalopathy	B
is	O
discussed	O
.	O

Fatal	O
intracranial	B
bleeding	I
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	O
.	O

We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	B
reaction	I
in	O
a	O
case	O
of	O
pulmonary	B
edema	I
with	O
wheezing	B
.	O

The	O
sudden	O
onset	O
of	O
respiratory	B
distress	I
,	O
rash	B
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	O
.	O

Subsequently	O
,	O
acute	O
cardiac	B
arrest	I
and	O
fatal	O
subarachnoid	B
hemorrhage	I
occurred	O
.	O

Epinephrine	O
has	O
a	O
proven	O
role	O
in	O
cardiac	B
arrest	I
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B
reaction	I
and	O
severe	O
hypertension	B
should	O
be	O
viewed	O
with	O
caution	O
.	O

Role	O
of	O
activation	O
of	O
bradykinin	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B
.	O

Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B
are	O
not	O
clear	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis	O
/	O
release	O
of	O
bradykinin	O
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B
.	O

Permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent	O
-	O
labeled	O
dextran	O
before	O
and	O
during	O
phenylephrine	O
-	O
induced	O
acute	O
hypertension	B
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe	O
-	O
140	O
(	O
0	O
.	O
1	O
microM	O
)	O
.	O

Phenylephrine	O
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	O
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O

These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B
is	O
not	O
related	O
to	O
the	O
synthesis	O
/	O
release	O
of	O
bradykinin	O
to	O
activate	O
B2	O
receptors	O
.	O

Risk	O
factors	O
of	O
sensorineural	B
hearing	I
loss	I
in	O
preterm	O
infants	O
.	O

Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B
hearing	I
loss	I
.	O

Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	B
loss	I
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	O
weight	O
and	O
for	O
perinatal	O
complications	O
.	O

Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	B
loss	I
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications	O
.	O

Ototoxicity	B
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	B
drugs	O
,	O
particularly	O
aminoglycosides	O
and	O
furosemide	O
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B
loss	I
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O

Seizure	B
resulting	O
from	O
a	O
venlafaxine	O
overdose	B
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	O
overdose	B
.	O

CASE	O
SUMMARY	O
:	O
A	O
40	O
-	O
year	O
-	O
old	O
woman	O
with	O
major	B
depression	I
took	O
an	O
overdose	B
of	O
venlafaxine	O
in	O
an	O
apparent	O
suicide	O
attempt	O
.	O

After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	O
50	O
-	O
mg	O
tablets	O
,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	B
.	O

She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
,	O
venlafaxine	O
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	O
overdose	B
that	O
resulted	O
in	O
a	O
generalized	O
seizure	B
.	O

Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	O
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions	O
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O

CONCLUSIONS	O
:	O
The	O
venlafaxine	O
overdose	B
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	B
but	O
elicited	O
no	O
further	O
sequelae	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	O
E1	O
-	O
induced	O
hypotension	B
and	O
haemodilution	B
on	O
human	O
hepatic	O
function	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	O
E1	O
(	O
PGE1	O
)	O
-	O
induced	O
hypotension	B
and	O
haemodilution	B
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery	O
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
;	O
those	O
in	O
group	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	O
hypotension	B
alone	O
,	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	B
alone	O
and	O
those	O
in	O
group	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotension	B
and	O
haemodilution	B
.	O

Haemodilution	B
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	O
solution	O
,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22	O
%	O
.	O

Controlled	O
hypotension	B
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	O
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(	O
AKBR	O
,	O
aceto	O
-	O
acetate	O
/	O
3	O
-	O
hydroxybutyrate	O
)	O
and	O
clinical	O
hepatic	O
function	O
parameters	O
.	O

AKBR	O
and	O
biological	O
hepatic	O
function	O
tests	O
showed	O
no	O
change	O
throughout	O
the	O
time	O
course	O
in	O
groups	O
A	O
and	O
B	O
.	O

In	O
group	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hypotension	B
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
recovery	O
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirubin	O
showed	O
significant	O
increases	O
after	O
operation	O
.	O

The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	O
-	O
induced	O
hypotension	B
and	O
moderate	O
haemodilution	B
would	O
cause	O
impairment	B
of	I
hepatic	I
function	I
.	O

Cardiovascular	B
alterations	I
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	O
channel	O
blockers	O
.	O

Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	O
channel	O
blocker	O
,	O
Ro	O
40	O
-	O
5967	O
,	O
induced	O
cardiovascular	B
alterations	I
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	O
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	B
malformations	I
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O

We	O
studied	O
three	O
calcium	O
channel	O
blockers	O
of	O
different	O
structure	O
,	O
nifedipine	O
,	O
diltiazem	O
,	O
and	O
verapamil	O
,	O
along	O
with	O
the	O
new	O
agent	O
.	O

Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	O
channel	O
blockers	O
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	B
malformations	I
.	O

A	O
low	O
incidence	O
of	O
cardiovascular	B
malformations	I
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	O
channel	O
blockers	O
,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	O
and	O
nifedipine	O
.	O

All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants	O
,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	O
40	O
-	O
5967	O
and	O
verapamil	O
.	O

The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	O
.	O

Atypical	B
sensations	I
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	O
are	O
common	O
,	O
but	O
of	O
uncertain	O
origin	O
.	O

They	O
are	O
almost	O
always	O
benign	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adverse	O
event	O
by	O
the	O
patient	O
.	O

Two	O
patients	O
are	O
presented	O
with	O
tingling	B
or	I
burning	I
sensations	I
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	B
.	O

In	O
these	O
individuals	O
,	O
side	O
effects	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
skin	O
.	O

Macula	O
toxicity	B
after	O
intravitreal	O
amikacin	O
.	O

BACKGROUND	O
:	O
Although	O
intravitreal	O
aminoglycosides	O
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	B
,	O
macular	O
infarction	B
may	O
impair	O
full	O
visual	O
recovery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	O
retinal	B
toxicity	I
following	O
treatment	O
with	O
amikacin	O
and	O
vancomycin	O
for	O
alpha	O
-	O
haemolytic	O
streptococcal	B
endophthalmitis	I
.	O

RESULTS	O
:	O
Endophthalmitis	B
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6	O
/	O
24	O
at	O
three	O
months	O
.	O

Fundus	O
fluorescein	O
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	B
.	O

CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	B
toxicity	I
and	O
macular	O
ischaemia	B
.	O

Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	B
toxicity	I
are	O
discussed	O
.	O

The	O
role	O
of	O
nicotine	O
in	O
smoking	O
-	O
related	O
cardiovascular	B
disease	I
.	O

Nicotine	O
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	B
disease	I
.	O

Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	O
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	B
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	O
.	O

Almost	O
certainly	O
,	O
nicotine	O
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	O
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	O
monoxide	O
.	O

Nicotine	O
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	B
among	O
humans	O
.	O

Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	O
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	O
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events	O
.	O

Finally	O
,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	O
appears	O
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	O
is	O
involved	O
,	O
adverse	O
effects	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
level	O
cigarette	O
exposures	O
.	O

Iatrogenically	O
induced	O
intractable	O
atrioventricular	B
reentrant	I
tachycardia	I
after	O
verapamil	O
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff	B
-	I
Parkinson	I
-	I
White	I
syndrome	I
and	O
idiopathic	B
dilated	I
cardiomyopathy	I
.	O

In	O
a	O
patient	O
with	O
WPW	B
syndrome	I
and	O
idiopathic	B
dilated	I
cardiomyopathy	I
,	O
intractable	O
atrioventricular	B
reentrant	I
tachycardia	I
(	O
AVRT	B
)	O
was	O
iatrogenically	O
induced	O
.	O

QRS	O
without	O
preexcitation	O
,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	O
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation	O
,	O
established	O
frequent	O
AVRT	B
attack	O
.	O

Epidemic	O
of	O
liver	B
disease	I
caused	O
by	O
hydrochlorofluorocarbons	O
used	O
as	O
ozone	O
-	O
sparing	O
substitutes	O
of	O
chlorofluorocarbons	O
.	O

BACKGROUND	O
:	O
Hydrochlorofluorocarbons	O
(	O
HCFCs	O
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	O
-	O
depleting	O
chlorofluorocarbons	O
(	O
CFCs	O
)	O
.	O

Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	B
of	O
some	O
of	O
these	O
compounds	O
.	O

We	O
investigated	O
an	O
epidemic	O
of	O
liver	B
disease	I
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1	O
,	O
1	O
-	O
dichloro	O
-	O
2	O
,	O
2	O
,	O
2	O
-	O
trifluoroethane	O
(	O
HCFC	O
123	O
)	O
and	O
1	O
-	O
chloro	O
-	O
1	O
,	O
2	O
,	O
2	O
,	O
2	O
-	O
tetrafluoroethane	O
(	O
HCFC	O
124	O
)	O
.	O

All	O
nine	O
exposed	O
workers	O
were	O
affected	O
to	O
various	O
degrees	O
.	O

Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1	O
-	O
bromo	O
-	O
1	O
-	O
chloro	O
-	O
2	O
,	O
2	O
,	O
2	O
-	O
trifluoroethane	O
(	O
halothane	O
)	O
to	O
form	O
reactive	O
trifluoroacetyl	O
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	B
of	O
halothane	O
.	O

We	O
aimed	O
to	O
test	O
whether	O
HCFCs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
liver	B
disease	I
.	O

METHODS	O
:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	O
protein	O
adducts	O
were	O
done	O
.	O

The	O
serum	O
of	O
six	O
affected	O
workers	O
and	O
five	O
controls	O
was	O
tested	O
for	O
autoantibodies	O
that	O
react	O
with	O
human	O
liver	O
cytochrome	O
-	O
P450	O
2E1	O
(	O
P450	O
2E1	O
)	O
and	O
P58	O
protein	O
disulphide	O
isomerase	O
isoform	O
(	O
P58	O
)	O
.	O

FINDINGS	O
:	O
The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	B
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(	O
bridging	O
necrosis	B
)	O
.	O

Trifluoroacetyl	O
-	O
adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes	O
.	O

Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothane	B
hepatitis	I
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers	O
.	O

INTERPRETATION	O
:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
liver	B
injury	I
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population	O
.	O

Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	B
of	O
these	O
agents	O
is	O
not	O
known	O
,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl	O
-	O
altered	O
liver	O
proteins	O
are	O
involved	O
.	O

In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
compounds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
alternatives	O
.	O

Bile	B
duct	I
hamartoma	I
occurring	O
in	O
association	O
with	O
long	O
-	O
term	O
treatment	O
with	O
danazol	O
.	O

We	O
report	O
a	O
case	O
of	O
bile	B
duct	I
hamartoma	I
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danazol	O
treatment	O
.	O

Such	O
patients	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
periodic	O
ultrasound	O
examination	O
of	O
the	O
liver	O
.	O

If	O
the	O
patient	O
develops	O
a	O
liver	B
mass	I
,	O
because	O
of	O
non	O
-	O
specific	O
clinical	O
features	O
and	O
imaging	O
appearances	O
,	O
biopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitive	O
diagnosis	O
.	O

Endocrine	O
screening	O
in	O
1	O
,	O
022	O
men	O
with	O
erectile	B
dysfunction	I
:	O
clinical	O
significance	O
and	O
cost	O
-	O
effective	O
strategy	O
.	O

PURPOSE	O
:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	O
and	O
prolactin	O
determination	O
in	O
1	O
,	O
022	O
patients	O
referred	O
because	O
of	O
erectile	B
dysfunction	I
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	O
-	O
effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testosterone	O
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O

Every	O
patient	O
was	O
screened	O
for	O
testosterone	O
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	B
sexual	I
desire	I
,	O
gynecomastia	B
or	O
testosterone	O
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Determination	O
was	O
repeated	O
in	O
case	O
of	O
abnormal	O
first	O
results	O
.	O

Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1	O
,	O
340	O
patients	O
with	O
erectile	B
dysfunction	I
and	O
systematic	O
prolactin	O
determination	O
.	O

Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	B
sexual	I
desire	I
,	O
small	O
testes	O
and	O
gynecomastia	B
.	O

Endocrine	O
therapy	O
consisted	O
of	O
testosterone	O
heptylate	O
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	B
and	O
bromocriptine	O
for	O
hyperprolactinemia	B
.	O

RESULTS	O
:	O
Testosterone	O
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
patients	O
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	O
determination	O
.	O

The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	O
increased	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
years	O
and	O
9	O
%	O
50	O
years	O
or	O
older	O
)	O
.	O

Two	O
pituitary	B
tumors	I
were	O
discovered	O
after	O
testosterone	O
determination	O
.	O

Most	O
of	O
the	O
other	O
low	O
testosterone	O
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	B
dysfunction	I
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	B
dysfunction	I
(	O
definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgen	O
therapy	O
,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30	O
%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42	O
%	O
)	O
.	O

Determining	O
testosterone	O
only	O
in	O
cases	O
of	O
low	B
sexual	I
desire	I
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	O
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy	O
.	O

Prolactin	O
exceeded	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
5	O
men	O
and	O
was	O
normal	O
in	O
2	O
at	O
repeat	O
determination	O
.	O

Only	O
1	O
prolactinoma	B
was	O
discovered	O
.	O

These	O
data	O
are	O
lower	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolactin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
patients	O
,	O
prolactinomas	B
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O

Bromocriptine	O
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

(	O
8	O
of	O
12	O
compared	O
to	O
only	O
9	O
of	O
22	O
cases	O
with	O
prolactin	O
between	O
20	O
and	O
35	O
ng	O
.	O
/	O
ml	O
.	O
)	O
.	O

Testosterone	O
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

CONCLUSIONS	O
:	O
Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	O
and	O
high	O
prolactin	O
in	O
erectile	B
dysfunction	I
cannot	O
justify	O
their	O
routine	O
determination	O
.	O

However	O
,	O
cost	O
-	O
effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50	O
%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B
tumors	I
.	O

We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B
sexual	I
desire	I
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years	O
.	O

Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B
sexual	I
desire	I
,	O
gynecomastia	B
and	O
/	O
or	O
testosterone	O
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Extrapyramidal	O
side	O
effects	O
with	O
risperidone	O
and	O
haloperidol	O
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels	O
.	O

Risperidone	O
is	O
an	O
antipsychotic	O
drug	O
with	O
high	O
affinity	O
at	O
dopamine	O
D2	O
and	O
serotonin	O
5	O
-	O
HT2	O
receptors	O
.	O

Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	O
'	O
s	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	B
symptoms	I
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects	O
;	O
features	O
shared	O
by	O
so	O
-	O
called	O
'	O
atypical	O
'	O
neuroleptics	O
.	O

To	O
determine	O
if	O
routine	O
risperidone	O
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects	O
,	O
we	O
used	O
[	O
123I	O
]	O
IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	O
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	O
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
risperidone	O
and	O
haloperidol	O
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standard	O
clinical	O
doses	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	O
or	O
risperidone	O
.	O

Drug	B
-	I
induced	I
parkinsonism	I
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	O
(	O
42	O
%	O
)	O
and	O
haloperidol	O
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blockade	O
obtained	O
with	O
risperidone	O
at	O
D2	O
occupancy	O
rates	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O

Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B
cancer	I
by	O
mitoxantrone	O
and	O
48	O
-	O
hour	O
continuous	O
infusion	O
of	O
high	O
-	O
dose	O
5	O
-	O
FU	O
and	O
leucovorin	O
(	O
MFL	O
)	O
:	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment	O
-	O
related	O
toxicity	B
.	O

For	O
previously	O
treated	O
advanced	O
breast	B
cancer	I
,	O
there	O
is	O
no	O
standard	O
second	O
-	O
line	O
therapy	O
.	O

Combination	O
chemotherapy	O
with	O
mitoxantrone	O
,	O
high	O
-	O
dose	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
leucovorin	O
(	O
MFL	O
regimen	O
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O

From	O
October	O
1993	O
to	O
November	O
1995	O
,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy	O
-	O
treated	O
metastatic	O
breast	B
cancer	I
by	O
mitoxantrone	O
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5	O
-	O
FU	O
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucovorin	O
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O

Each	O
course	O
of	O
chemotherapy	O
was	O
given	O
every	O
4	O
weeks	O
.	O

Most	O
of	O
these	O
patients	O
had	O
more	O
than	O
two	O
metastatic	O
sites	O
,	O
with	O
lung	O
metastasis	O
predominant	O
.	O

Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	O
.	O

Seven	O
patients	O
had	O
previously	O
received	O
radiotherapy	O
and	O
seven	O
had	O
received	O
hormone	O
therapy	O
.	O

Median	O
number	O
of	O
courses	O
of	O
MFL	O
regimen	O
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	O
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O

One	O
patient	O
had	O
complete	O
response	O
,	O
seven	O
had	O
stable	O
disease	O
,	O
none	O
had	O
partial	O
response	O
and	O
five	O
had	O
progressive	O
disease	O
.	O

The	O
overall	O
objective	O
response	O
rate	O
was	O
7	O
.	O
6	O
%	O
.	O

The	O
median	O
follow	O
-	O
up	O
period	O
was	O
14	O
months	O
.	O

Median	O
survival	O
was	O
16	O
months	O
.	O

Median	O
progression	O
-	O
free	O
survival	O
was	O
5	O
months	O
.	O

A	O
complete	O
responder	O
had	O
relapse	O
-	O
free	O
survival	O
up	O
to	O
17	O
months	O
.	O

Major	O
toxicities	B
were	O
cardiotoxicity	B
and	O
leukopenia	B
.	O

Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment	O
-	O
related	O
toxicity	B
.	O

The	O
MFL	O
regimen	O
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	B
at	O
a	O
fairly	O
high	O
rate	O
.	O

Administration	O
of	O
this	O
regimen	O
to	O
breast	B
cancer	I
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B
heart	I
function	I
requires	O
careful	O
attention	O
.	O

Ticlopidine	O
-	O
induced	O
aplastic	B
anemia	I
:	O
report	O
of	O
three	O
Chinese	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O

In	O
this	O
study	O
,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine	O
-	O
induced	O
aplastic	B
anemia	I
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
.	O

We	O
attempted	O
to	O
find	O
underlying	O
similarities	O
,	O
evaluate	O
the	O
risk	O
factors	O
,	O
and	O
identify	O
appropriate	O
treatment	O
for	O
this	O
complication	O
.	O

All	O
but	O
one	O
of	O
the	O
patients	O
were	O
over	O
60	O
years	O
old	O
,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	O
than	O
65	O
.	O

Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
risk	O
factor	O
for	O
developing	O
this	O
complication	O
.	O

Agranulocytosis	B
occurred	O
3	O
-	O
20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	O
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	B
marrow	I
suppression	I
.	O

Treatment	O
for	O
ticlopidine	O
-	O
induced	O
aplastic	B
anemia	I
with	O
colony	O
-	O
stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	O
channel	O
blockers	O
died	O
,	O
should	O
alert	O
clinicians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	O
simultaneously	O
.	O

Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	O
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium	O
-	O
induced	O
diabetes	B
insipidus	I
rat	O
.	O

The	O
expression	O
of	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	O
(	O
Li	O
)	O
-	O
induced	O
polyuria	B
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O

The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	O
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	B
.	O

The	O
Li	O
-	O
treated	O
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations	O
.	O

Plasma	O
sodium	O
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	O
-	O
treated	O
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O

Plasma	O
concentration	O
of	O
AVP	O
and	O
transcripts	O
of	O
AVP	O
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	O
-	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
dehydration	B
and	O
/	O
or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	O
and	O
the	O
upregulation	O
of	O
AVP	O
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	O
-	O
induced	O
diabetes	B
insipidus	I
rat	O
.	O

Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG	O
-	O
9	O
.	O

The	O
antinociceptive	O
effect	O
of	O
3	O
alpha	O
-	O
tropyl	O
2	O
-	O
(	O
p	O
-	O
bromophenyl	O
)	O
propionate	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
micrograms	O
/	O
mouse	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
mice	O
,	O
rats	O
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot	O
-	O
plate	O
,	O
abdominal	O
-	O
constriction	O
,	O
tail	O
-	O
flick	O
and	O
paw	O
-	O
pressure	O
tests	O

.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
antinociception	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	O
,	O
the	O
M1	O
-	O
selective	O
antagonists	O
pirenzepine	O
and	O
dicyclomine	O
and	O
the	O
acetylcholine	O
depletor	O
hemicholinium	O
-	O
3	O
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	O
,	O
the	O
gamma	O
-	O
aminobutyric	O
acidB	O
antagonist	O
3	O
-	O
aminopropyl	O
-	O
diethoxy	O
-	O
methyl	O
-	O
phosphinic	O
acid	O
,	O
the	O
H3	O
agonist	O
R	O
-	O
(	O
alpha	O
)	O
-	O
methylhistamine	O

,	O
the	O
D2	O
antagonist	O
quinpirole	O
,	O
the	O
5	O
-	O
hydroxytryptamine4	O
antagonist	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
amino	O
-	O
5	O
-	O
chlorobenzoic	O
acid	O
2	O
-	O
(	O
diethylamino	O
)	O
ethyl	O
ester	O
hydrochloride	O
,	O
the	O
5	O
-	O
hydroxytryptamin1A	O
antagonist	O
1	O
-	O
(	O
2	O
-	O
methoxyphenyl	O
)	O
-	O
4	O
-	O
[	O
4	O
-	O
(	O
2	O
-	O
phthalimido	O
)	O
butyl	O
]	O
piperazine	O
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	O
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
prevent	O
amnesia	B
induced	O
by	O
scopolamine	O
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
dicyclomine	O
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
.	O

Affinity	O
profiles	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
for	O
muscarinic	O
receptor	O
subtypes	O
,	O
determined	O
by	O
functional	O
studies	O
(	O
rabbit	O
vas	O
deferens	O
for	O
M1	O
,	O
guinea	O
pig	O
atrium	O
for	O
M2	O
,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectivity	O
ratio	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti	O
-	O
amnesic	B
effect	O
induced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
through	O
an	O
increase	O
in	O

acetylcholine	O
extracellular	O
levels	O
.	O

In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota	O
-	O
rod	O
test	O
and	O
Animex	O
apparatus	O
.	O

The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	B
loss	I
following	O
spinal	O
anaesthesia	O
.	O

The	O
cause	O
of	O
hearing	B
loss	I
after	O
spinal	O
anaesthesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post	O
-	O
operative	O
sensorineural	B
hearing	I
loss	I
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	B
loss	I
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	B
loss	I
.	O

Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied	O
:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	O
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	O
0	O
.	O
5	O
%	O
.	O

Patients	O
given	O
prilocaine	O
were	O
more	O
likely	O
to	O
develop	O
hearing	B
loss	I
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	O
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
average	O
hearing	B
loss	I
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	O
and	O
15	O
dB	O
after	O
bupivacaine	O
.	O

None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	B
loss	I
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
patients	O
was	O
not	O
possible	O
.	O

A	O
transient	O
neurological	B
deficit	I
following	O
intrathecal	O
injection	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	O
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O

We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	B
deficit	I
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	O
slowly	O
injected	O
through	O
a	O
25	O
-	O
gauge	O
pencil	O
-	O
point	O
spinal	O
needle	O
.	O

The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful	O
,	O
but	O
3	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
reported	O
an	O
area	O
of	O
hypoaesthesia	O
over	O
L3	O
-	O
L4	O
dermatomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	B
of	I
pinprick	I
sensation	I
)	O
without	O
reduction	O
in	O
muscular	O
strength	O
.	O

Sensation	O
in	O
this	O
area	O
returned	O
to	O
normal	O
over	O
the	O
following	O
2	O
weeks	O
.	O

Prospective	O
multicentre	O
studies	O
with	O
a	O
large	O
population	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
this	O
unusual	O
side	O
effect	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(	O
if	O
pencil	O
-	O
point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration	O
,	O
which	O
might	O
lead	O
to	O
a	O
transient	O
neurological	B
deficit	I
.	O

Transient	B
neurologic	I
symptoms	I
after	O
spinal	O
anesthesia	O
:	O
a	O
lower	O
incidence	O
with	O
prilocaine	O
and	O
bupivacaine	O
than	O
with	O
lidocaine	O
.	O

BACKGROUND	O
:	O
Recent	O
evidence	O
suggests	O
that	O
transient	B
neurologic	I
symptoms	I
(	O
TNSs	B
)	O
frequently	O
follow	O
lidocaine	O
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	O
.	O

However	O
,	O
identification	O
of	O
a	O
short	O
-	O
acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	O
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O

Prilocaine	O
is	O
an	O
amide	O
local	O
anesthetic	O
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	O
.	O

Accordingly	O
,	O
the	O
present	O
,	O
prospective	O
double	O
-	O
blind	O
study	O
compares	O
prilocaine	O
with	O
lidocaine	O
and	O
bupivacaine	O
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	B
.	O

METHODS	O
:	O
Ninety	O
patients	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
I	O
or	O
II	O
who	O
were	O
scheduled	O
for	O
short	O
gynecologic	O
procedures	O
under	O
spinal	O
anesthesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
lidocaine	O
in	O
7	O
.	O
5	O
%	O
glucose	O
,	O
2	O
%	O
prilocaine	O
in	O
7	O
.	O
5	O
%	O
glucose	O
,	O
or	O
0	O
.	O
5	O
%	O
bupivacaine	O
in	O
7	O
.	O
5	O
%	O
glucose	O
.	O

All	O
solutions	O
were	O
provided	O
in	O
blinded	O
vials	O
by	O
the	O
hospital	O
pharmacy	O
.	O

Details	O
of	O
spinal	O
puncture	O
,	O
extension	O
and	O
regression	O
of	O
spinal	O
block	O
,	O
and	O
the	O
times	O
to	O
reach	O
discharge	O
criteria	O
were	O
noted	O
.	O

In	O
the	O
evening	O
of	O
postoperative	O
day	O
1	O
,	O
patients	O
were	O
evaluated	O
for	O
TNSs	B
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	O
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	O
procedure	O
.	O

RESULTS	O
:	O
Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	O
experienced	O
TNSs	B
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	O
had	O
TNSs	B
.	O

Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	O
and	O
prilocaine	O
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolonged	O
after	O
bupivacaine	O
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Prilocaine	O
may	O
be	O
preferable	O
to	O
lidocaine	O
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B
.	O

Suxamethonium	O
-	O
induced	O
cardiac	B
arrest	I
and	O
death	B
following	O
5	O
days	O
of	O
immobilization	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	B
arrest	I
and	O
subsequent	O
death	B
as	O
a	O
result	O
of	O
hyperkalaemia	B
following	O
the	O
use	O
of	O
suxamethonium	O
in	O
a	O
23	O
-	O
year	O
-	O
old	O
Malawian	O
woman	O
.	O

Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	B
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation	O
.	O

Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	O
,	O
bradycardia	B
and	O
cardiac	B
arrest	I
occurred	O
.	O

Attempts	O
to	O
resuscitate	O
the	O
patient	O
were	O
not	O
successful	O
.	O

The	O
serum	O
level	O
of	O
potassium	O
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O

Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient	O
'	O
s	O
level	O
of	O
consciousness	O
,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	B
following	O
the	O
administration	O
of	O
suxamethonium	O
.	O

It	O
is	O
postulated	O
that	O
her	O
death	B
was	O
caused	O
by	O
hypersensitivity	B
to	O
suxamethonium	O
,	O
associated	O
with	O
her	O
5	O
-	O
day	O
immobilization	O
.	O

Acute	O
hepatitis	B
,	O
autoimmune	B
hemolytic	I
anemia	I
,	O
and	O
erythroblastocytopenia	B
induced	O
by	O
ceftriaxone	O
.	O

An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
acute	O
hepatitis	B
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	O
.	O

Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	O
lactam	O
antibiotic	O
,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	O
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	B
hemolytic	I
anemia	I
and	O
erythroblastocytopenia	B
.	O

These	O
responded	O
to	O
systemic	O
steroids	O
and	O
immunoglobulins	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	O
lactam	O
antibiotics	O
.	O

Thyroxine	O
abuse	O
:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	B
in	O
pregnancy	O
.	O

Eating	B
disorders	I
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	B
abuse	I
are	O
uncommon	O
in	O
pregnancy	O
.	O

When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
risk	O
to	O
both	O
the	O
mother	O
and	O
her	O
fetus	O
.	O

This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	B
disorders	I
in	O
pregnancy	O
,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	O
abuse	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	O
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	B
disorders	I
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	B
remains	O
obscure	O
,	O
thyroxine	O
abuse	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Repeated	O
trimipramine	O
induces	O
dopamine	O
D2	O
/	O
D3	O
and	O
alpha1	O
-	O
adrenergic	O
up	O
-	O
regulation	O
.	O

Trimipramine	O
(	O
TRI	O
)	O
,	O
which	O
shows	O
a	O
clinical	O
antidepressant	O
activity	O
,	O
is	O
chemically	O
related	O
to	O
imipramine	O
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	O
and	O
5	O
-	O
hydroxytryptamine	O
,	O
nor	O
does	O
it	O
induce	O
beta	O
-	O
adrenergic	O
down	O
-	O
regulation	O
.	O

The	O
mechanism	O
of	O
its	O
antidepressant	O
activity	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	O
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	O
and	O
alpha1	O
-	O
adrenergic	O
systems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	O
.	O

TRI	O
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days	O
.	O

In	O
the	O
acute	O
experiment	O
TRI	O
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antagonize	O
the	O
reserpine	O
hypothermia	B
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5	O
-	O
hydroxytryptophan	O
head	O
twitches	O
in	O
rats	O
.	O

TRI	O
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	O
hyperactivity	B
induced	O
by	O
d	O
-	O
amphetamine	O
,	O
quinpirole	O
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hydroxy	O
-	O
dipropyloaminotetralin	O
(	O
dopamine	O
D2	O
and	O
D3	O
effects	O
)	O
.	O

The	O
stereotypies	O
induced	O
by	O
d	O
-	O
amphetamine	O
or	O
apomorphine	O
are	O
not	O
potentiated	O
by	O
TRI	O
.	O

It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	O
(	O
given	O
intraventricularly	O
)	O
in	O
rats	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	B
evoked	O
by	O
clonidine	O
in	O
mice	O
,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1	O
-	O
adrenergic	O
receptor	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	O
antidepressants	O
studied	O
previously	O
,	O
TRI	O
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	O
D2	O
and	O
D3	O
(	O
locomotor	O
activity	O
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1	O
-	O
adrenergic	O
receptors	O
to	O
their	O
agonists	O
.	O

A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	O
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	O
activity	O
.	O

Pethidine	O
-	O
associated	O
seizure	B
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	O
for	O
postoperative	B
pain	I
control	O
.	O

A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	O
via	O
a	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B
pain	I
control	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B
.	O

Both	O
plasma	O
pethidine	O
and	O
norpethidine	O
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	O
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	O
and	O
norpethidine	O
.	O

The	O
routine	O
use	O
of	O
pethidine	O
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	O
analgesia	O
should	O
be	O
reconsidered	O
.	O

An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	O
with	O
adrenaline	O
.	O

An	O
increase	B
in	I
blood	I
pressure	I
,	O
accompanied	O
by	O
atrial	B
fibrillation	I
,	O
agitation	B
,	O
incomprehensible	B
shouts	I
and	O
loss	B
of	I
consciousness	I
,	O
was	O
observed	O
in	O
an	O
elderly	O
,	O
ASA	O
classification	O
group	O
II	O
,	O
cardiovascularly	O
medicated	O
male	O
,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	O
850	O
mg	O
containing	O
adrenaline	O
0	O
.	O
225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren	B
'	I
s	I
contracture	I
.	O

After	O
intravenous	O
administration	O
of	O
labetalol	O
,	O
metoprolol	O
and	O
midazolam	O
the	O
patient	O
'	O
s	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	B
fibrillation	I
.	O

Postoperatively	O
,	O
the	O
patient	O
refused	O
DC	O
cardioversion	O
and	O
was	O
treated	O
medically	O
.	O

Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	O
with	O
adrenaline	O
and	O
/	O
or	O
interaction	O
of	O
these	O
drugs	O
with	O
the	O
patient	O
'	O
s	O
cardiovascular	O
medications	O
were	O
responsible	O
for	O
the	O
perioperative	O
complications	O
.	O

Drug	O
-	O
associated	O
acute	O
-	O
onset	O
vanishing	B
bile	I
duct	I
and	O
Stevens	B
-	I
Johnson	I
syndromes	I
in	O
a	O
child	O
.	O

Acute	O
vanishing	B
bile	I
duct	I
syndrome	O
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	B
in	O
adults	O
,	O
is	O
most	O
often	O
drug	O
or	O
toxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	O
.	O

It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
children	O
.	O

Stevens	B
-	I
Johnson	I
syndrome	I
is	O
a	O
well	O
-	O
recognized	O
immune	O
complex	O
-	O
mediated	O
hypersensitivity	B
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	O
or	O
infection	B
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O

A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute	O
,	O
severe	O
,	O
rapidly	O
progressive	O
vanishing	B
bile	I
duct	I
syndrome	I
shortly	O
after	O
Stevens	B
-	I
Johnson	I
syndrome	I
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	O
use	O
.	O

Despite	O
therapy	O
with	O
ursodeoxycholic	O
acid	O
,	O
prednisone	O
,	O
and	O
then	O
tacrolimus	O
,	O
her	O
cholestatic	B
disease	I
was	O
unrelenting	O
,	O
with	O
cirrhosis	B
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation	O
.	O

This	O
case	O
documents	O
acute	O
drug	O
-	O
related	O
vanishing	B
bile	I
duct	I
syndrome	I
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens	B
-	I
Johnson	I
syndrome	I
and	O
vanishing	B
bile	I
duct	I
syndrome	I
.	O

High	O
incidence	O
of	O
primary	B
pulmonary	I
hypertension	I
associated	O
with	O
appetite	O
suppressants	O
in	O
Belgium	O
.	O

Primary	B
pulmonary	I
hypertension	I
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	O
suppressant	O
drugs	O
.	O

The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	O
suppressants	O
.	O

Thirty	O
-	O
five	O
patients	O
with	O
primary	B
pulmonary	I
hypertension	I
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O

Exposure	O
to	O
appetite	O
-	O
suppressants	O
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	O
suppressants	O
,	O
mainly	O
fenfluramines	O
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Five	O
patients	O
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	O
suppressants	O
.	O

In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	B
pulmonary	I
hypertension	I
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	O
suppressants	O
.	O

The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	O
suppressants	O
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis	O
.	O

A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	O
suppressants	O
may	O
lead	O
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	B
pulmonary	I
hypertension	I
.	O

Intake	O
of	O
appetite	O
suppressants	O
may	O
accelerate	O
the	O
progression	O
of	O
the	O
disease	O
.	O

Inappropriate	O
use	O
of	O
carbamazepine	O
and	O
vigabatrin	O
in	O
typical	O
absence	B
seizures	I
.	O

Carbamazepine	O
and	O
vigabatrin	O
are	O
contraindicated	O
in	O
typical	O
absence	B
seizures	I
.	O

Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	O
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabatrin	O
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	O
and	O
two	O
of	O
these	O
developed	O
myoclonic	B
jerks	I
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	O
.	O

Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	O
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O

Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	O
valproate	O
,	O
lamotrigine	O
,	O
or	O
ethosuximide	O
alone	O
or	O
in	O
combination	O
.	O

Choreoathetoid	B
movements	I
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	O
.	O

Choreatiform	B
hyperkinesias	I
are	O
known	O
to	O
be	O
occasional	O
movement	B
abnormalities	I
during	O
intoxications	O
with	O
cocaine	O
but	O
not	O
opiates	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	B
movements	I
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu	O
-	O
opioid	O
receptor	O
agonist	O
methadone	O
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	O
and	O
cocaine	O
.	O

In	O
addition	O
,	O
minor	O
EEG	O
abnormalities	O
occurred	O
.	O

Possible	O
underlying	O
neurobiological	O
phenomena	O
are	O
discussed	O
.	O

Adverse	O
effects	O
of	O
the	O
atypical	O
antipsychotics	O
.	O

Collaborative	O
Working	O
Group	O
on	O
Clinical	O
Trial	O
Evaluations	O
.	O

Adverse	O
effects	O
of	O
antipsychotics	O
often	O
lead	O
to	O
noncompliance	O
.	O

Thus	O
,	O
clinicians	O
should	O
address	O
patients	O
'	O
concerns	O
about	O
adverse	O
effects	O
and	O
attempt	O
to	O
choose	O
medications	O
that	O
will	O
improve	O
their	O
patients	O
'	O
quality	O
of	O
life	O
as	O
well	O
as	O
overall	O
health	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
the	O
atypical	O
antipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	O
neuroleptics	O
.	O

Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B
symptoms	I
(	O
EPS	B
)	O
,	O
tardive	B
dyskinesia	I
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B
hypotension	I
,	O
hepatic	O
changes	O
,	O
anticholinergic	O
side	O
effects	O
,	O
sexual	B
dysfunction	I
,	O
and	O
weight	B
gain	I
.	O

The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	B
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	O
effects	O
,	O
weight	B
gain	I
,	O
sexual	B
dysfunction	I
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	B
threshold	O
(	O
primarily	O
clozapine	O
)	O
,	O
and	O
agranulocytosis	B
(	O
clozapine	O
only	O
)	O
.	O

Since	O
the	O
incidence	O
and	O
severity	O
of	O
specific	O
adverse	O
effects	O
differ	O
among	O
the	O
various	O
atypicals	O
,	O
the	O
clinician	O
should	O
carefully	O
consider	O
which	O
side	O
effects	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
individual	O
'	O
s	O
dissatisfaction	O
and	O
noncompliance	O
before	O
choosing	O
an	O
antipsychotic	O
for	O
a	O
particular	O
patient	O
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
dose	O
-	O
comparison	O
trial	O
of	O
haloperidol	O
for	O
psychosis	B
and	O
disruptive	B
behaviors	I
in	O
Alzheimer	B
'	I
s	I
disease	I
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	O
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	B
and	O
disruptive	B
behaviors	I
in	O
patients	O
with	O
Alzheimer	B
'	I
s	I
disease	I
.	O

METHOD	O
:	O
In	O
a	O
6	O
-	O
week	O
random	O
-	O
assignment	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
phase	O
A	O
)	O
,	O
haloperidol	O
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
standard	O
dose	O
)	O
,	O
and	O
haloperidol	O
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
day	O
(	O
low	O
dose	O
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer	B
'	I
s	I
disease	I
.	O

For	O
the	O
subsequent	O
6	O
-	O
week	O
double	O
-	O
blind	O
crossover	O
phase	O
(	O
phase	O
B	O
)	O
,	O
patients	O
taking	O
standard	O
-	O
or	O
low	O
-	O
dose	O
haloperidol	O
were	O
switched	O
to	O
placebo	O
,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard	O
-	O
or	O
low	O
-	O
dose	O
haloperidol	O
.	O

RESULTS	O
:	O
For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A	O
,	O
standard	O
-	O
dose	O
haloperidol	O
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dose	O
haloperidol	O
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
psychosis	B
factor	O
and	O
on	O
psychomotor	B
agitation	I
.	O

Response	O
rates	O
according	O
to	O
three	O
sets	O
of	O
criteria	O
were	O
greater	O
with	O
the	O
standard	O
dose	O
(	O
55	O
%	O
-	O
60	O
%	O
)	O
than	O
the	O
low	O
dose	O
(	O
25	O
%	O
-	O
35	O
%	O
)	O
and	O
placebo	O
(	O
25	O
%	O
-	O
30	O
%	O
)	O
.	O

The	O
advantage	O
of	O
standard	O
dose	O
over	O
low	O
dose	O
was	O
replicated	O
in	O
phase	O
B	O
.	O

In	O
phase	O
A	O
,	O
extrapyramidal	B
signs	I
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs	O
.	O

Low	O
-	O
dose	O
haloperidol	O
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	O
in	O
doses	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	B
signs	I
.	O

A	O
starting	O
dose	O
of	O
1	O
mg	O
/	O
day	O
with	O
gradual	O
,	O
upward	O
dose	O
titration	O
is	O
recommended	O
.	O

The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	O
may	O
also	O
apply	O
to	O
other	O
neuroleptics	O
used	O
in	O
Alzheimer	B
'	I
s	I
disease	I
patients	O
with	O
psychosis	B
and	O
disruptive	B
behaviors	I
.	O

Effects	O
of	O
acetylsalicylic	O
acid	O
,	O
dipyridamole	O
,	O
and	O
hydrocortisone	O
on	O
epinephrine	O
-	O
induced	O
myocardial	B
injury	I
in	O
dogs	O
.	O

A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	B
injury	I
(	O
epinephrine	O
infusion	O
)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	O
myocardial	B
infarction	I
.	O

Infusions	O
of	O
epinephrine	O
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increased	O
radiocalcium	O
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline	O
-	O
infused	O
control	O
animals	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction	O
)	O
.	O

Myocardial	O
concentrations	O
of	O
calcium	O
also	O
increased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
)	O
.	O

Infusions	O
of	O
calcium	O
chloride	O
sufficient	O
to	O
raise	O
serum	O
calcium	O
concentrations	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
increase	O
calcium	O
influx	O
into	O
the	O
myocardial	O
cell	O
.	O

Mitochondrial	O
radiocalcium	O
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	O
acid	O
or	O
dipyridamole	O
or	O
when	O
hydrocortisone	O
was	O
added	O
to	O
the	O
epinephrine	O
infusion	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction	O
,	O
respectively	O
)	O
.	O

Myocardial	O
calcium	O
concentrations	O
also	O
were	O
decreased	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatment	O
groups	O
,	O
being	O
significantly	O
decreased	O
only	O
in	O
the	O
last	O
two	O
.	O

Evidence	O
of	O
microscopic	O
damage	O
was	O
graded	O
as	O
less	O
severe	O
in	O
the	O
three	O
treatment	O
groups	O
.	O

Acetylsalicylic	O
acid	O
,	O
dipyridamole	O
,	O
and	O
hydrocortisone	O
all	O
appear	O
to	O
have	O
cardioprotective	O
effects	O
when	O
tested	O
in	O
this	O
model	O
.	O

Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	O
(	O
FK506	O
)	O
for	O
at	O
least	O
one	O
year	O
.	O

BACKGROUND	O
:	O
We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	O
(	O
FK506	O
)	O
for	O
more	O
than	O
1	O
year	O
.	O

METHODS	O
:	O
Twenty	O
-	O
six	O
renal	O
allograft	O
biopsy	O
specimens	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
who	O
underwent	O
transplantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluated	O
.	O

Thirteen	O
biopsies	O
were	O
performed	O
from	O
stable	O
functioning	O
renal	O
allografts	O
with	O
informed	O
consent	O
(	O
nonepisode	O
biopsy	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctional	O
renal	O
allografts	O
with	O
a	O
clinical	O
indication	O
for	O
biopsy	O
(	O
episode	O
biopsy	O
)	O
.	O

RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	B
nephropathy	I
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	O
nephropathy	B
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
biopsies	O
,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal	O
-	O
type	O
and	O
mild	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B
,	O
respectively	O
.	O

Chronic	O
FK506	O
nephropathy	B
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(	O
5	O
biopsies	O
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	O
;	O
20	O
biopsies	O
)	O
,	O
focal	B
segmental	I
glomerulosclerosis	I
(	O
4	O
biopsies	O
)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	B
fibrosis	I
(	O
11	O
biopsies	O
)	O
.	O

The	O
serum	O
creatinine	O
levels	O
of	O
patients	O
in	O
the	O
mild	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
type	O
chronic	O
FK506	O
-	O
nephropathy	B
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	O
nephropathy	B
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	O
,	O
and	O
suggests	O
that	O
mild	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B
is	O
a	O
condition	O
which	O
may	O
lead	O
to	O
deterioration	O
of	O
renal	O
allograft	O
function	O
.	O

Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	B
and	I
extrahepatic	I
cholestasis	I
.	O

Hepatocyte	O
tight	O
junctions	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intercellular	O
barrier	O
between	O
the	O
sinusoidal	O
and	O
the	O
canalicular	O
spaces	O
,	O
play	O
a	O
key	O
role	O
in	O
bile	O
formation	O
.	O

Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	B
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze	O
-	O
fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information	O
.	O

Recently	O
,	O
several	O
TJ	O
-	O
associated	O
proteins	O
like	O
ZO	O
-	O
1	O
and	O
7H6	O
have	O
been	O
identified	O
and	O
characterized	O
.	O

Immunolocalization	O
of	O
7H6	O
appears	O
to	O
closely	O
correlate	O
with	O
paracellular	O
permeability	O
.	O

We	O
used	O
rat	O
models	O
of	O
intrahepatic	B
cholestasis	I
by	O
ethinyl	O
estradiol	O
(	O
EE	O
)	O
treatment	O
and	O
extrahepatic	B
cholestasis	I
by	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage	O
.	O

Alterations	O
in	O
hepatocyte	O
TJs	O
were	O
assessed	O
by	O
double	O
-	O
immunolabeling	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

In	O
control	O
rats	O
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
colocalized	O
to	O
outline	O
bile	O
canaliculi	O
in	O
a	O
continuous	O
fashion	O
.	O

In	O
contrast	O
,	O
7H6	O
and	O
ZO	O
-	O
1	O
immunostaining	O
was	O
more	O
discontinuous	O
,	O
outlining	O
the	O
bile	O
canaliculi	O
after	O
BDL	O
.	O

Immunostaining	O
for	O
7H6	O
,	O
not	O
ZO	O
-	O
1	O
,	O
decreased	O
and	O
predominantly	O
appeared	O
as	O
discrete	O
signals	O
in	O
the	O
submembranous	O
cytoplasm	O
of	O
periportal	O
hepatocytes	O
after	O
BDL	O
.	O

After	O
EE	O
treatment	O
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	O
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O

Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	O
releaser	O
PG	O
-	O
9	O
.	O

The	O
effects	O
of	O
PG	O
-	O
9	O
(	O
3alpha	O
-	O
tropyl	O
2	O
-	O
(	O
p	O
-	O
bromophenyl	O
)	O
propionate	O
)	O
,	O
the	O
acetylcholine	O
releaser	O
,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
synthesis	O
were	O
evaluated	O
.	O

In	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
,	O
PG	O
-	O
9	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
administered	O
20	O
min	O
before	O
the	O
training	O
session	O
,	O
prevented	O
amnesia	B
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	O
scopolamine	O
and	O
the	O
M1	O
-	O
selective	O
antagonist	O
S	O
-	O
(	O
-	O
)	O
-	O
ET	O
-	O
126	O
.	O

In	O
the	O
same	O
experimental	O
conditions	O
,	O
PG	O
-	O
9	O
(	O
5	O
-	O
20	O
microg	O
per	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine	O
-	O
induced	O
amnesia	B
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O

At	O
the	O
highest	O
effective	O
doses	O
,	O
PG	O
-	O
9	O
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	O
.	O

PG	O
-	O
9	O
was	O
also	O
able	O
to	O
increase	O
the	O
amount	O
of	O
NGF	O
secreted	O
in	O
vitro	O
by	O
astrocytes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG	O
-	O
9	O
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
control	O
value	O
.	O

During	O
culture	O
,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG	O
-	O
9	O
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	O
-	O
9	O
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O

Therefore	O
,	O
PG	O
-	O
9	O
could	O
represent	O
a	O
potential	O
useful	O
drug	O
able	O
to	O
improve	O
the	O
function	O
of	O
impaired	O
cognitive	O
processes	O
.	O

Mechanisms	O
of	O
FK	O
506	O
-	O
induced	O
hypertension	B
in	O
the	O
rat	O
.	O

-	O
Tacrolimus	O
(	O
FK	O
506	O
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O

The	O
clinical	O
utility	O
of	O
FK	O
506	O
is	O
complicated	O
by	O
substantial	O
hypertension	B
and	O
nephrotoxicity	B
.	O

To	O
clarify	O
the	O
mechanisms	O
of	O
FK	O
506	O
-	O
induced	O
hypertension	B
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	O
506	O
on	O
the	O
synthesis	O
of	O
endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
expression	O
of	O
mRNA	O
of	O
ET	O
-	O
1	O
and	O
endothelin	O
-	O
converting	O
enzyme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
activity	O
,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C	O
-	O
type	O
natriuretic	O
peptide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vessels	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	O
139317	O
on	O
FK	O
506	O
-	O
induced	O
hypertension	B
in	O
rats	O
was	O
studied	O
.	O

FK	O
506	O
,	O
5	O
mg	O
.	O

kg	O
-	O
1	O
.	O

d	O
-	O
1	O
given	O
for	O
4	O
weeks	O
,	O
elevated	O
blood	O
pressure	O
from	O
102	O
+	O
/	O
-	O
13	O
to	O
152	O
+	O
/	O
-	O
15	O
mm	O
Hg	O
and	O
increased	O
the	O
synthesis	O
of	O
ET	O
-	O
1	O
and	O
the	O
levels	O
of	O
ET	O
-	O
1	O
mRNA	O
in	O
the	O
mesenteric	O
artery	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE	O
-	O
1	O
mRNA	O
and	O
CNP	O
mRNA	O
.	O

FK	O
506	O
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
administration	O
of	O
FR	O
139317	O
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	O
506	O
-	O
induced	O
hypertension	B
in	O
rats	O
.	O

These	O
results	O
indicate	O
that	O
FK	O
506	O
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET	O
-	O
1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	O
synthesis	O
in	O
the	O
vasculature	O
.	O

Identification	O
of	O
APC2	O
,	O
a	O
homologue	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
tumour	I
suppressor	O
.	O

The	O
adenomatous	B
polyposis	I
coli	I
(	I
APC	I
)	I
tumour	I
-	O
suppressor	O
protein	O
controls	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O

Complex	O
formation	O
induces	O
the	O
rapid	O
degradation	O
of	O
betacatenin	O
.	O

In	O
colon	B
carcinoma	I
cells	O
,	O
loss	O
of	O
APC	O
leads	O
to	O
the	O
accumulation	O
of	O
betacatenin	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
Tcf	O
-	O
4	O
transcription	O
factor	O
(	O
reviewed	O
in	O
[	O
1	O
]	O
[	O
2	O
]	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
genomic	O
structure	O
of	O
APC	O
homologues	O
.	O

Mammalian	O
APC2	O
,	O
which	O
closely	O
resembles	O
APC	O
in	O
overall	O
domain	O
structure	O
,	O
was	O
functionally	O
analyzed	O
and	O
shown	O
to	O
contain	O
two	O
SAMP	O
domains	O
,	O
both	O
of	O
which	O
are	O
required	O
for	O
binding	O
to	O
conductin	O
.	O

Like	O
APC	O
,	O
APC2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin	O
-	O
Tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC	O
-	O
/	O
-	O
colon	B
carcinoma	I
cells	O
.	O

Human	O
APC2	O
maps	O
to	O
chromosome	O
19p13	O
.	O

3	O
.	O

APC	O
and	O
APC2	O
may	O
therefore	O
have	O
comparable	O
functions	O
in	O
development	O
and	O
cancer	B
.	O

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	B
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B
cancer	I
.	O

The	O
frequency	O
,	O
origin	O
,	O
and	O
phenotypic	O
expression	O
of	O
a	O
germline	O
MSH2	O
gene	O
mutation	O
previously	O
identified	O
in	O
seven	O
kindreds	O
with	O
hereditary	B
non	I
-	I
polyposis	I
cancer	I
syndrome	I
(	O
HNPCC	B
)	O
was	O
investigated	O
.	O

The	O
mutation	O
(	O
A	O
-	O
-	O
>	O
T	O
at	O
nt943	O
+	O
3	O
)	O
disrupts	O
the	O
3	O
splice	O
site	O
of	O
exon	O
5	O
leading	O
to	O
the	O
deletion	O
of	O
this	O
exon	O
from	O
MSH2	O
mRNA	O
and	O
represents	O
the	O
only	O
frequent	O
MSH2	O
mutation	O
so	O
far	O
reported	O
.	O

Although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	B
cancer	I
families	O
analysed	O
from	O
eastern	O
England	O
,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
English	O
HNPCC	B
kindreds	O
analysed	O
.	O

In	O
contrast	O
,	O
the	O
MSH2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	O
colorectal	B
families	O
from	O
Newfoundland	O
.	O

To	O
investigate	O
the	O
origin	O
of	O
this	O
mutation	O
in	O
colorectal	B
cancer	I
families	O
from	O
England	O
(	O
n	O
=	O
4	O
)	O
,	O
Newfoundland	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
n	O
=	O
3	O
)	O
,	O
haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
linked	O
to	O
MSH2	O
was	O
performed	O
.	O

Within	O
the	O
English	O
and	O
US	O
families	O
there	O
was	O
little	O
evidence	O
for	O
a	O
recent	O
common	O
origin	O
of	O
the	O
MSH2	O
splice	O
site	O
mutation	O
in	O
most	O
families	O
.	O

In	O
contrast	O
,	O
a	O
common	O
haplotype	O
was	O
identified	O
at	O
the	O
two	O
flanking	O
markers	O
(	O
CA5	O
and	O
D2S288	O
)	O
in	O
eight	O
of	O
the	O
Newfoundland	O
families	O
.	O

These	O
findings	O
suggested	O
a	O
founder	O
effect	O
within	O
Newfoundland	O
similar	O
to	O
that	O
reported	O
by	O
others	O
for	O
two	O
MLH1	O
mutations	O
in	O
Finnish	O
HNPCC	B
families	O
.	O

We	O
calculated	O
age	O
related	O
risks	O
of	O
all	O
,	O
colorectal	B
,	I
endometrial	I
,	I
and	I
ovarian	I
cancers	I
in	O
nt943	O
+	O
3	O
A	O
-	O
-	O
>	O
T	O
MSH2	O
mutation	O
carriers	O
(	O
n	O
=	O
76	O
)	O
for	O
all	O
patients	O
and	O
for	O
men	O
and	O
women	O
separately	O
.	O

For	O
both	O
sexes	O
combined	O
,	O
the	O
penetrances	O
at	O
age	O
60	O
years	O
for	O
all	O
cancers	B
and	O
for	O
colorectal	B
cancer	I
were	O
0	O
.	O

86	O
and	O
0	O
.	O

57	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
colorectal	B
cancer	I
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
males	O
than	O
females	O
(	O
0	O
.	O
63	O
v	O
0	O
.	O
30	O
and	O
0	O
.	O
84	O
v	O
0	O
.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O

For	O
females	O
there	O
was	O
a	O
high	O
risk	O
of	O
endometrial	B
cancer	I
(	O
0	O
.	O
5	O
at	O
age	O
60	O
years	O
)	O
and	O
premenopausal	B
ovarian	I
cancer	I
(	O
0	O
.	O
2	O
at	O
50	O
years	O
)	O
.	O

These	O
intersex	O
differences	O
in	O
colorectal	B
cancer	I
risks	O
have	O
implications	O
for	O
screening	O
programmes	O
and	O
for	O
attempts	O
to	O
identify	O
colorectal	B
cancer	I
susceptibility	O
modifiers	O
.	O

Age	O
of	O
onset	O
in	O
Huntington	B
disease	I
:	O
sex	O
specific	O
influence	O
of	O
apolipoprotein	O
E	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
.	O

Age	O
of	O
onset	O
(	O
AO	O
)	O
of	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	B
gene	O
.	O

Apolipoprotein	O
E	O
(	O
APOE	O
)	O
genotype	O
,	O
in	O
turn	O
,	O
is	O
known	O
to	O
influence	O
AO	O
in	O
Alzheimer	B
disease	I
,	O
rendering	O
the	O
APOE	O
gene	O
a	O
likely	O
candidate	O
to	O
affect	O
AO	O
in	O
other	O
neurological	B
diseases	I
too	O
.	O

We	O
therefore	O
determined	O
APOE	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
in	O
the	O
HD	B
gene	O
for	O
138	O
HD	B
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
CAG	O
repeat	O
length	O
.	O

Genotyping	O
for	O
APOE	O
was	O
performed	O
blind	O
to	O
clinical	O
information	O
.	O

In	O
addition	O
to	O
highlighting	O
the	O
effect	O
of	O
the	O
normal	O
repeat	O
length	O
upon	O
AO	O
in	O
maternally	O
inherited	O
HD	B
and	O
in	O
male	O
patients	O
,	O
we	O
show	O
that	O
the	O
APOE	O
epsilon2epsilon3	O
genotype	O
is	O
associated	O
with	O
significantly	O
earlier	O
AO	O
in	O
males	O
than	O
in	O
females	O
.	O

Such	O
a	O
sex	O
difference	O
in	O
AO	O
was	O
not	O
apparent	O
for	O
any	O
of	O
the	O
other	O
APOE	O
genotypes	O
.	O

Our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B
in	O
HD	B
may	O
allow	O
interacting	O
genes	O
to	O
exert	O
gender	O
specific	O
effects	O
upon	O
AO	O
.	O

Familial	B
deficiency	I
of	I
the	I
seventh	I
component	I
of	I
complement	I
associated	O
with	O
recurrent	O
bacteremic	B
infections	I
due	I
to	I
Neisseria	I
.	O

The	O
serum	O
of	O
a	O
29	O
-	O
year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	B
gonococcal	I
infection	I
and	O
a	O
history	O
of	O
meningococcal	B
meningitis	I
and	O
arthritis	B
as	O
a	O
child	O
was	O
found	O
to	O
lack	O
serum	O
hemolytic	O
complement	O
activity	O
.	O

The	O
seventh	O
component	O
of	O
complement	O
(	O
C7	O
)	O
was	O
not	O
detected	O
by	O
functional	O
or	O
immunochemical	O
assays	O
,	O
whereas	O
other	O
components	O
were	O
normal	O
by	O
hemolytic	O
and	O
immunochemical	O
assessment	O
.	O

Her	O
fresh	O
serum	O
lacked	O
complement	O
-	O
mediated	O
bactericidal	O
activity	O
against	O
Neisseria	O
gonorrhoeae	O
,	O
but	O
the	O
addition	O
of	O
fresh	O
normal	O
serum	O
or	O
purified	O
C7	O
restored	O
bactericidal	O
activity	O
as	O
well	O
as	O
hemolytic	O
activity	O
.	O

The	O
absence	B
of	I
functional	I
C7	I
activity	O
could	O
not	O
be	O
accounted	O
for	O
on	O
the	O
basis	O
of	O
an	O
inhibitor	O
.	O

Opsonization	O
and	O
generation	O
of	O
chemotactic	O
activity	O
functioned	O
normally	O
.	O

Complete	B
absence	I
of	I
C7	I
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	O
syndrome	O
of	O
meningococcal	B
meningitis	I
and	O
arthritis	B
as	O
a	O
child	O
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight	O
-	O
year	O
-	O
old	O
son	O
.	O

HLA	O
histocompatibility	O
typing	O
of	O
the	O
family	O
members	O
did	O
not	O
demonstrate	O
evidence	O
for	O
genetic	O
linkage	O
of	O
C7	B
deficiency	I
with	O
the	O
major	O
histocompatibility	O
loci	O
.	O

This	O
report	O
represents	O
the	O
first	O
cases	O
of	O
C7	B
deficiency	I
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	B
neisseria	I
infections	I
.	O

Increased	O
incidence	O
of	O
cancer	B
in	O
patients	O
with	O
cartilage	B
-	I
hair	I
hypoplasia	I
.	O

OBJECTIVE	O
Previous	O
reports	O
have	O
suggested	O
an	O
increased	O
risk	O
of	O
cancer	B
among	O
patients	O
with	O
cartilage	B
-	I
hair	I
hypoplasia	I
(	O
CHH	B
)	O
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	O
among	O
patients	O
with	O
CHH	B
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

STUDY	O
DESIGN	O
One	O
hundred	O
twenty	O
-	O
two	O
patients	O
with	O
CHH	B
were	O
identified	O
through	O
2	O
countrywide	O
epidemiologic	O
surveys	O
in	O
1974	O
and	O
in	O
1986	O
.	O

Their	O
parents	O
and	O
nonaffected	O
siblings	O
were	O
identified	O
through	O
the	O
Population	O
Register	O
Center	O
.	O

This	O
cohort	O
underwent	O
follow	O
-	O
up	O
for	O
cancer	B
incidence	O
through	O
the	O
Finnish	O
Cancer	O
Registry	O
to	O
the	O
end	O
of	O
1995	O
.	O

RESULTS	O
A	O
statistically	O
significant	O
excess	O
risk	O
of	O
cancer	B
was	O
seen	O
among	O
the	O
patients	O
with	O
CHH	B
(	O
standardized	O
incidence	O
ratio	O
6	O
.	O
9	O
,	O
95	O
%	O
confidence	O
interval	O
2	O
.	O
3	O
to	O
16	O
)	O
,	O
which	O
was	O
mainly	O
attributable	O
to	O
non	B
-	I
Hodgkins	I
lymphoma	I
(	O
standardized	O
incidence	O
ratio	O
90	O
,	O
95	O
%	O
confidence	O
interval	O
18	O
to	O
264	O
)	O
.	O

In	O
addition	O
,	O
a	O
significant	O
excess	O
risk	O
of	O
basal	B
cell	I
carcinoma	I
was	O
seen	O
(	O
standardized	O
incidence	O
ratio	O
35	O
,	O
95	O
%	O
confidence	O
interval	O
7	O
.	O
2	O
to	O
102	O
)	O
.	O

The	O
cancer	B
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B
incidence	O
in	O
the	O
Finnish	O
population	O
.	O

CONCLUSIONS	O
This	O
study	O
confirms	O
an	O
increased	O
risk	O
of	O
cancer	B
,	O
especially	O
non	B
-	I
Hodgkins	I
lymphoma	I
,	O
probably	O
attributable	O
to	O
defective	O
immunity	O
,	O
among	O
patients	O
with	O
CHH	B
.	O

Genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
dihydropyrimidine	B
dehydrogenase	I
deficiency	I
.	O

Dihydropyrimidine	B
dehydrogenase	I
(	I
DPD	I
)	I
deficiency	I
is	O
an	O
autosomal	B
recessive	I
disease	I
characterised	O
by	O
thymine	O
-	O
uraciluria	O
in	O
homozygous	O
deficient	O
patients	O
and	O
has	O
been	O
associated	O
with	O
a	O
variable	O
clinical	O
phenotype	O
.	O

In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
DPD	B
deficiency	I
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	B
of	I
DPD	I
.	O

In	O
this	O
group	O
of	O
patients	O
,	O
7	O
different	O
mutations	O
have	O
been	O
identified	O
,	O
including	O
2	O
deletions	O
[	O
295	O
-	O
298delTCAT	O
,	O
1897delC	O
]	O
,	O
1	O
splice	O
-	O
site	O
mutation	O
[	O
IVS14	O
+	O
1G	O
>	O
A	O
)	O
]	O
and	O
4	O
missense	O
mutations	O
(	O
85T	O
>	O
C	O
,	O
703C	O
>	O
T	O
,	O
2658G	O
>	O
A	O
,	O
2983G	O
>	O
T	O
)	O
.	O

Analysis	O
of	O
the	O
prevalence	O
of	O
the	O
various	O
mutations	O
among	O
DPD	B
patients	O
has	O
shown	O
that	O
the	O
G	O
-	O
-	O
>	O
A	O
point	O
mutation	O
in	O
the	O
invariant	O
splice	O
donor	O
site	O
is	O
by	O
far	O
the	O
most	O
common	O
(	O
52	O
%	O
)	O
,	O
whereas	O
the	O
other	O
six	O
mutations	O
are	O
less	O
frequently	O
observed	O
.	O

A	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed	O
,	O
with	O
convulsive	B
disorders	I
,	O
motor	B
retardation	I
and	O
mental	B
retardation	I
being	O
the	O
most	O
abundant	O
manifestations	O
.	O

A	O
clear	O
correlation	O
between	O
the	O
genotype	O
and	O
phenotype	O
has	O
not	O
been	O
established	O
.	O

An	O
altered	O
beta	O
-	O
alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	B
abnormalities	I
encountered	O
in	O
patients	O
with	O
DPD	B
deficiency	I
.	O

Fibroblast	O
growth	O
factor	O
homologous	O
factor	O
2	O
(	O
FHF2	O
)	O
:	O
gene	O
structure	O
,	O
expression	O
and	O
mapping	O
to	O
the	O
Borjeson	B
-	I
Forssman	I
-	I
Lehmann	I
syndrome	I
region	O
in	O
Xq26	O
delineated	O
by	O
a	O
duplication	O
breakpoint	O
in	O
a	O
BFLS	B
-	O
like	O
patient	O
.	O

Borjeson	B
-	I
Forssman	I
-	I
Lehmann	I
syndrome	I
(	O
BFLS	B
)	O
is	O
a	O
syndromal	O
X	B
-	I
linked	I
mental	I
retardation	I
,	O
which	O
maps	O
by	O
linkage	O
to	O
the	O
q26	O
region	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

We	O
have	O
identified	O
a	O
male	O
patient	O
with	O
BFLS	B
-	O
like	O
features	O
and	O
a	O
duplication	O
,	O
46	O
,	O
Y	O
,	O
dup	O
(	O
X	O
)	O
(	O
q26q28	O
)	O
,	O
inherited	O
from	O
his	O
phenotypically	O
normal	O
mother	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
using	O
yeast	O
artificial	O
chromosome	O
clones	O
from	O
Xq26	O
localised	O
the	O
duplication	O
breakpoint	O
to	O
an	O
approximately	O
400	O
-	O
kb	O
interval	O
in	O
the	O
Xq26	O
.	O

3	O
region	O
between	O
DXS155	O
and	O
DXS294	O
/	O
DXS730	O
.	O

Database	O
searches	O
and	O
analysis	O
of	O
available	O
genomic	O
DNA	O
sequence	O
from	O
the	O
region	O
revealed	O
the	O
presence	O
of	O
the	O
fibroblast	O
growth	O
factor	O
homologous	O
factor	O
gene	O
,	O
FHF2	O
,	O
within	O
the	O
duplication	O
breakpoint	O
interval	O
.	O

The	O
gene	O
structure	O
of	O
FHF2	O
was	O
determined	O
and	O
two	O
new	O
exons	O
were	O
identified	O
,	O
including	O
a	O
new	O
5	O
end	O
exon	O
,	O
1B	O
.	O

FHF2	O
is	O
a	O
large	O
gene	O
extending	O
over	O
approximately	O
200	O
kb	O
in	O
Xq26	O
.	O

3	O
and	O
is	O
composed	O
of	O
at	O
least	O
seven	O
exons	O
.	O

It	O
shows	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
and	O
alternative	O
transcription	O
starts	O
.	O

Northern	O
blot	O
hybridisation	O
showed	O
highest	O
expression	O
in	O
brain	O
and	O
skeletal	O
muscle	O
.	O

The	O
FHF2	O
gene	O
localisation	O
and	O
tissue	O
-	O
specific	O
expression	O
pattern	O
suggest	O
it	O
to	O
be	O
a	O
candidate	O
gene	O
for	O
familial	O
cases	O
of	O
the	O
BFLS	B
syndrome	I
and	O
other	O
syndromal	O
and	O
non	O
-	O
specific	O
forms	O
of	O
X	B
-	I
linked	I
mental	I
retardation	I
mapping	O
to	O
the	O
region	O
.	O

Germline	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
mutations	O
predispose	O
to	O
familial	B
gastric	I
cancer	I
and	O
colorectal	B
cancer	I
.	O

Inherited	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
were	O
described	O
recently	O
in	O
three	O
Maori	O
kindreds	O
with	O
familial	B
gastric	I
cancer	I
.	O

Familial	B
gastric	I
cancer	I
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	B
cancer	I
susceptibility	O
in	O
non	O
-	O
Maori	O
populations	O
is	O
due	O
to	O
germline	O
CDH1	O
mutations	O
.	O

Therefore	O
,	O
we	O
screened	O
eight	O
familial	B
gastric	I
cancer	I
kindreds	O
of	O
British	O
and	O
Irish	O
origin	O
for	O
germline	O
CDH1	O
mutations	O
,	O
by	O
SSCP	O
analysis	O
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences	O
.	O

Each	O
family	O
contained	O
(	O
i	O
)	O
two	O
cases	O
of	O
gastric	B
cancer	I
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years	O
;	O
or	O
(	O
ii	O
)	O
three	O
or	O
more	O
cases	O
of	O
gastric	B
cancer	I
.	O

Novel	O
germline	O
CDH1	O
mutations	O
(	O
a	O
nonsense	O
and	O
a	O
splice	O
site	O
)	O
were	O
detected	O
in	O
two	O
families	O
(	O
25	O
%	O
)	O
.	O

Both	O
mutations	O
were	O
predicted	O
to	O
truncate	O
the	O
E	O
-	O
cadherin	O
protein	O
in	O
the	O
signal	O
peptide	O
domain	O
.	O

In	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non	O
-	O
penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	B
and	I
colorectal	I
cancer	I
;	O
thus	O
,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	B
cancer	I
,	O
a	O
CDH1	O
mutation	O
carrier	O
developed	O
colorectal	B
cancer	I
at	O
age	O
30	O
years	O
.	O

We	O
have	O
confirmed	O
that	O
germline	O
mutations	O
in	O
the	O
CDH1	O
gene	O
cause	O
familial	B
gastric	I
cancer	I
in	O
non	O
-	O
Maori	O
populations	O
.	O

However	O
,	O
only	O
a	O
minority	O
of	O
familial	O
gastric	B
cancers	I
can	O
be	O
accounted	O
for	O
by	O
CDH1	O
mutations	O
.	O

Loss	O
of	O
E	O
-	O
cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	B
and	I
other	I
cancers	I
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
CDH1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	B
cancer	I
.	O

Thus	O
,	O
CDH1	O
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	O
susceptibility	O
to	O
both	O
gastric	B
and	I
colorectal	I
cancers	I
.	O

A	O
zinc	O
finger	O
truncation	O
of	O
murine	O
WT1	O
results	O
in	O
the	O
characteristic	O
urogenital	B
abnormalities	I
of	O
Denys	B
-	I
Drash	I
syndrome	I
.	O

The	O
Wilms	B
tumor	I
-	O
suppressor	O
gene	O
,	O
WT1	O
,	O
plays	O
a	O
key	O
role	O
in	O
urogenital	O
development	O
,	O
and	O
WT1	B
dysfunction	I
is	O
implicated	O
in	O
both	O
neoplastic	B
(	O
Wilms	B
tumor	I
,	O
mesothelioma	B
,	O
leukemias	B
,	O
and	O
breast	B
cancer	I
)	O
and	O
nonneoplastic	B
(	O
glomerulosclerosis	B
)	O
disease	O
.	O

The	O
analysis	O
of	O
diseases	O
linked	O
specifically	O
with	O
WT1	O
mutations	O
,	O
such	O
as	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
can	O
provide	O
valuable	O
insight	O
concerning	O
the	O
role	O
of	O
WT1	O
in	O
development	O
and	O
disease	O
.	O

DDS	B
is	O
a	O
rare	O
childhood	O
disease	O
characterized	O
by	O
a	O
nephropathy	B
involving	O
mesangial	B
sclerosis	I
,	O
XY	O
pseudohermaphroditism	B
,	O
and	O
/	O
or	O
Wilms	B
tumor	I
(	O
WT	B
)	O
.	O

DDS	B
patients	O
are	O
constitutionally	O
heterozygous	O
for	O
exonic	O
point	O
mutations	O
in	O
WT1	O
,	O
which	O
include	O
mutations	O
predicted	O
to	O
truncate	O
the	O
protein	O
within	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
(	O
ZF	O
)	O
region	O
.	O

We	O
report	O
that	O
heterozygosity	O
for	O
a	O
targeted	O
murine	O
Wt1	O
allele	O
,	O
Wt1	O
(	O
tmT396	O
)	O
,	O
which	O
truncates	O
ZF3	O
at	O
codon	O
396	O
,	O
induces	O
mesangial	B
sclerosis	I
characteristic	O
of	O
DDS	B
in	O
adult	O
heterozygous	O
and	O
chimeric	O
mice	O
.	O

Male	B
genital	I
defects	I
also	O
were	O
evident	O
and	O
there	O
was	O
a	O
single	O
case	O
of	O
Wilms	B
tumor	I
in	O
which	O
the	O
transcript	O
of	O
the	O
nontargeted	O
allele	O
showed	O
an	O
exon	O
9	O
skipping	O
event	O
,	O
implying	O
a	O
causal	O
link	O
between	O
Wt1	B
dysfunction	I
and	O
Wilms	B
tumorigenesis	I
in	O
mice	O
.	O

However	O
,	O
the	O
mutant	O
WT1	O
(	O
tmT396	O
)	O
protein	O
accounted	O
for	O
only	O
5	O
%	O
of	O
WT1	O
in	O
both	O
heterozygous	O
embryonic	O
stem	O
cells	O
and	O
the	O
WT	B
.	O

This	O
has	O
implications	O
regarding	O
the	O
mechanism	O
by	O
which	O
the	O
mutant	O
allele	O
exerts	O
its	O
effect	O
.	O

Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B
hemochromatosis	I
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1	O
.	O

Hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
a	O
common	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption	O
.	O

We	O
recently	O
reported	O
that	O
HFE	O
,	O
the	O
protein	O
defective	O
in	O
HH	B
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
in	O
duodenal	O
crypt	O
cells	O
and	O
proposed	O
that	O
mutations	O
in	O
HFE	O
attenuate	O
the	O
uptake	O
of	O
transferrin	O
-	O
bound	O
iron	O
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells	O
,	O
leading	O
to	O
up	O
-	O
regulation	O
of	O
transporters	O
for	O
dietary	O
iron	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
HFE	O
-	O
/	O
-	O
mice	O
have	O
increased	O
duodenal	O
expression	O
of	O
the	O
divalent	O
metal	O
transporter	O
(	O
DMT1	O
)	O
.	O

By	O
4	O
weeks	O
of	O
age	O
,	O
the	O
HFE	O
-	O
/	O
-	O
mice	O
demonstrated	O
iron	O
loading	O
when	O
compared	O
with	O
HFE	O
+	O
/	O
+	O
littermates	O
,	O
with	O
elevated	O
transferrin	O
saturations	O
(	O
68	O
.	O
4	O
%	O
vs	O
.	O
49	O
.	O
8	O
%	O
)	O
and	O
elevated	O
liver	O
iron	O
concentrations	O
(	O
985	O
micrograms	O
vs	O
.	O
381	O
micrograms	O
)	O
.	O

By	O
using	O
Northern	O
blot	O
analyses	O
,	O
we	O
quantitated	O
duodenal	O
expression	O
of	O
both	O
classes	O
of	O
DMT1	O
transcripts	O
one	O
containing	O
an	O
iron	O
responsive	O
element	O
(	O
IRE	O
)	O
,	O
called	O
DMT1	O
(	O
IRE	O
)	O
,	O
and	O
one	O
containing	O
no	O
IRE	O
,	O
called	O
DMT1	O
(	O
non	O
-	O
IRE	O
)	O
.	O

The	O
positive	O
control	O
for	O
DMT1	O
up	O
-	O
regulation	O
was	O
a	O
murine	O
model	O
of	O
dietary	B
iron	I
deficiency	I
that	O
demonstrated	O
greatly	O
increased	O
levels	O
of	O
duodenal	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
.	O

HFE	O
-	O
/	O
-	O
mice	O
also	O
demonstrated	O
an	O
increase	O
in	O
duodenal	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
(	O
average	O
7	O
.	O
7	O
-	O
fold	O
)	O
,	O
despite	O
their	O
elevated	O
transferrin	O
saturation	O
and	O
hepatic	O
iron	O
content	O
.	O

Duodenal	O
expression	O
of	O
DMT1	O
(	O
non	O
-	O
IRE	O
)	O
was	O
not	O
increased	O
,	O
nor	O
was	O
hepatic	O
expression	O
of	O
DMT1	O
increased	O
.	O

These	O
data	O
support	O
the	O
model	O
for	O
HH	O
in	O
which	O
HFE	O
mutations	O
lead	O
to	O
inappropriately	O
low	O
crypt	O
cell	O
iron	O
,	O
with	O
resultant	O
stabilization	O
of	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
,	O
up	O
-	O
regulation	O
of	O
DMT1	O
,	O
and	O
increased	O
absorption	O
of	O
dietary	O
iron	O
.	O

Neurophysiologic	O
follow	O
-	O
up	O
of	O
long	O
-	O
term	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B
.	O

OBJECTIVE	O
To	O
monitor	O
the	O
effects	O
of	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
by	O
means	O
of	O
somatosensory	O
evoked	O
potentials	O
(	O
SEPs	O
)	O
and	O
motor	O
evoked	O
potentials	O
(	O
MEPs	O
)	O
.	O

BACKGROUND	O
SEPs	O
and	O
MEPs	O
have	O
proved	O
useful	O
in	O
revealing	O
signs	O
of	O
progressively	O
severe	O
,	O
central	O
dying	B
-	I
back	I
axonopathy	I
in	O
early	O
stages	O
of	O
adult	O
-	O
onset	O
ALD	B
.	O

METHODS	O
Eight	O
patients	O
with	O
adult	O
-	O
onset	O
ALD	B
underwent	O
clinical	O
examination	O
,	O
brain	O
and	O
spine	O
MRI	O
,	O
and	O
SEP	O
and	O
MEP	O
studies	O
before	O
and	O
after	O
3	O
years	O
of	O
Lorenzos	O
oil	O
dietary	O
therapy	O
.	O

RESULTS	O
Before	O
treatment	O
,	O
brain	O
MRI	O
was	O
normal	O
in	O
five	O
patients	O
.	O

Three	O
of	O
these	O
patients	O
had	O
pure	O
spinal	B
SEP	I
abnormalities	I
and	O
in	O
the	O
remaining	O
two	O
patients	O
SEPs	O
showed	O
signs	O
of	O
involvement	O
of	O
both	O
the	O
spinal	O
and	O
cerebral	O
somatosensory	O
tracts	O
.	O

After	O
treatment	O
,	O
the	O
three	O
patients	O
with	O
pure	O
spinal	B
abnormalities	I
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
,	O
whereas	O
the	O
two	O
patients	O
with	O
a	O
more	O
advanced	O
stage	O
of	O
disease	O
(	O
exhibited	O
by	O
SEPs	O
)	O
showed	O
substantially	O
unchanged	O
clinical	O
and	O
neurophysiologic	O
features	O
.	O

The	O
patients	O
with	O
abnormal	O
brain	O
MRI	O
at	O
the	O
onset	O
of	O
treatment	O
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
.	O

CONCLUSIONS	O
Lorenzos	O
oil	O
therapy	O
had	O
no	O
effect	O
on	O
patients	O
with	O
evidence	O
of	O
inflammatory	B
brain	I
lesions	I
.	O

Moreover	O
,	O
in	O
patients	O
without	O
clear	O
signs	O
of	O
inflammatory	O
damage	O
,	O
this	O
treatment	O
does	O
not	O
modify	O
significantly	O
the	O
natural	O
course	O
of	O
the	O
disease	O
.	O

However	O
,	O
because	O
effective	O
treatments	O
should	O
begin	O
before	O
the	O
onset	O
of	O
severe	O
neurologic	O
symptoms	O
,	O
SEPs	O
and	O
MEPs	O
should	O
be	O
considered	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
other	O
experimental	O
treatments	O
in	O
the	O
patient	O
with	O
a	O
negative	O
brain	O
MRI	O
.	O

GCH1	O
mutation	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B
dystonia	I
.	O

The	O
authors	O
report	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
GCH1	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B
dystonia	I
and	O
no	O
obvious	O
family	O
history	O
of	O
dystonia	B
.	O

The	O
patient	O
responded	O
positively	O
to	O
treatment	O
with	O
L	O
-	O
dopa	O
.	O

These	O
findings	O
demonstrate	O
that	O
GCH1	O
mutations	O
must	O
be	O
considered	O
even	O
in	O
patients	O
with	O
dystonic	B
symptoms	O
not	O
typical	O
of	O
dopa	B
-	I
responsive	I
dystonia	I
.	O

Germline	O
mutations	O
of	O
the	O
APC	B
gene	O
in	O
Korean	O
familial	B
adenomatous	I
polyposis	I
patients	O
.	O

We	O
extensively	O
analyzed	O
genomic	O
DNA	O
and	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
from	O
62	O
unrelated	O
Korean	O
patients	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
for	O
identification	O
of	O
germline	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
mutations	O
.	O

We	O
adopted	O
both	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
a	O
method	O
of	O
analysis	O
involving	O
the	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
followed	O
by	O
a	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

DNA	O
sequencing	O
confirmed	O
all	O
alterations	O
represented	O
by	O
aberrant	O
bands	O
.	O

Germline	O
mutations	O
were	O
identified	O
in	O
38	O
patients	O
(	O
61	O
%	O
)	O
.	O

Nineteen	O
of	O
the	O
detected	O
mutations	O
were	O
presumed	O
to	O
be	O
novel	O
,	O
thus	O
emphasizing	O
the	O
heterogeneity	O
of	O
the	O
mutational	O
spectrum	O
in	O
Korean	O
FAP	B
patients	O
.	O

In	O
the	O
initial	O
48	O
patients	O
,	O
SSCP	O
analysis	O
was	O
followed	O
by	O
PTT	O
for	O
those	O
patients	O
for	O
whom	O
no	O
detectable	O
mutations	O
were	O
found	O
by	O
SSCP	O
.	O

Using	O
this	O
combined	O
approach	O
,	O
we	O
identified	O
germline	O
APC	B
gene	O
mutations	O
in	O
29	O
of	O
the	O
48	O
FAP	B
patients	O
(	O
60	O
%	O
)	O
,	O
including	O
6	O
patients	O
in	O
whom	O
SSCP	O
analysis	O
failed	O
to	O
distinguish	O
the	O
mutant	O
allele	O
.	O

In	O
the	O
14	O
later	O
patients	O
,	O
we	O
identified	O
truncating	O
mutations	O
in	O
9	O
patients	O
(	O
64	O
%	O
)	O
using	O
PTT	O
only	O
.	O

Our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
PTT	O
was	O
superior	O
to	O
that	O
with	O
SSCP	O
,	O
and	O
suggest	O
that	O
PTT	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
APC	B
gene	O
in	O
FAP	B
patients	O
.	O

Molecular	O
epidemiology	O
of	O
C9	B
deficiency	I
heterozygotes	O
with	O
an	O
Arg95Stop	O
mutation	O
of	O
the	O
C9	O
gene	O
in	O
Japan	O
.	O

Deficiency	B
of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
deficiency	I
in	O
Japan	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries	O
.	O

Genetic	O
analyses	O
of	O
Japanese	O
C9	B
deficiency	I
have	O
shown	O
that	O
a	O
C	O
-	O
to	O
-	O
T	O
transition	O
leading	O
to	O
TGA	O
stop	O
codon	O
for	O
Arg95	O
in	O
exon	O
4	O
of	O
the	O
C9	O
gene	O
(	O
Arg95Stop	O
)	O
is	O
common	O
in	O
Japanese	O
C9	B
deficiency	I
.	O

To	O
determine	O
the	O
prevalence	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
in	O
a	O
Japanese	O
population	O
,	O
we	O
collected	O
DNA	O
samples	O
from	O
300	O
individuals	O
in	O
two	O
of	O
the	O
four	O
main	O
islands	O
of	O
Japan	O
.	O

Heterozygote	O
detection	O
was	O
performed	O
with	O
an	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
,	O
followed	O
by	O
confirmation	O
with	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Twenty	O
individuals	O
were	O
heterozygous	O
for	O
the	O
Arg95Stop	O
mutation	O
.	O

None	O
was	O
homozygous	O
.	O

The	O
prevalence	O
of	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
was	O
6	O
.	O

7	O
%	O
(	O
20	O
/	O
300	O
)	O
.	O

An	O
estimated	O
frequency	O
(	O
0	O
.	O
12	O
%	O
)	O
of	O
complete	O
C9	B
deficiency	I
due	O
to	O
homozygous	O
Arg95Stop	O
mutation	O
was	O
consistent	O
with	O
frequencies	O
determined	O
by	O
serological	O
studies	O

The	O
hereditary	B
hemochromatosis	I
protein	O
,	O
HFE	O
,	O
specifically	O
regulates	O
transferrin	O
-	O
mediated	O
iron	O
uptake	O
in	O
HeLa	O
cells	O
.	O

HFE	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	B
recessive	I
disease	I
hereditary	B
hemochromatosis	I
(	O
Feder	O
,	O
J	O
.	O

N	O
.	O
,	O
Gnirke	O
,	O
A	O
.	O
,	O
Thomas	O
,	O
W	O
.	O
,	O
Tsuchihashi	O
,	O
Z	O
.	O
,	O
Ruddy	O
,	O
D	O
.	O

A	O
.	O
,	O
Basava	O
,	O
A	O
.	O
,	O
Dormishian	O
,	O
F	O
.	O
,	O
Domingo	O
,	O
R	O
.	O

J	O
.	O
,	O
Ellis	O
,	O
M	O
.	O

C	O
.	O
,	O
Fullan	O
,	O
A	O
.	O
,	O
Hinton	O
,	O
L	O
.	O

M	O
.	O
,	O
Jones	O
,	O
N	O
.	O

L	O
.	O
,	O
Kimmel	O
,	O
B	O
.	O

E	O
.	O
,	O
Kronmal	O
,	O
G	O
.	O

S	O
.	O
,	O
Lauer	O
,	O
P	O
.	O
,	O
Lee	O
,	O
V	O
.	O

K	O
.	O
,	O
Loeb	O
,	O
D	O
.	O

B	O
.	O
,	O
Mapa	O
,	O
F	O
.	O

A	O
.	O
,	O
McClelland	O
,	O
E	O
.	O
,	O
Meyer	O
,	O
N	O
.	O

C	O
.	O
,	O
Mintier	O
,	O
G	O
.	O

A	O
.	O
,	O
Moeller	O
,	O
N	O
.	O
,	O
Moore	O
,	O
T	O
.	O
,	O
Morikang	O
,	O
E	O
.	O
,	O
Prasss	O
,	O
C	O
.	O

E	O
.	O
,	O
Quintana	O
,	O
L	O
.	O
,	O
Starnes	O
,	O
S	O
.	O

M	O
.	O
,	O
Schatzman	O
,	O
R	O
.	O

C	O
.	O
,	O
Brunke	O
,	O
K	O
.	O

J	O
.	O
,	O
Drayna	O
,	O
D	O
.	O

T	O
.	O
,	O
Risch	O
,	O
N	O
.	O

J	O
.	O
,	O
Bacon	O
,	O
B	O
.	O

R	O
.	O
,	O
and	O
Wolff	O
,	O
R	O
.	O

R	O
.	O

(	O
1996	O
)	O
Nat	O
.	O

Genet	O
.	O

13	O
,	O
399	O
-	O
408	O
)	O
.	O

At	O
the	O
cell	O
surface	O
,	O
HFE	O
complexes	O
with	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
,	O
increasing	O
the	O
dissociation	O
constant	O
of	O
transferrin	O
(	O
Tf	O
)	O
for	O
its	O
receptor	O
10	O
-	O
fold	O
(	O
Gross	O
,	O
C	O
.	O

N	O
.	O
,	O
Irrinki	O
,	O
A	O
.	O
,	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
and	O
Enns	O
,	O
C	O
.	O
A	O
.	O
(	O
1998	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
273	O
,	O
22068	O
-	O
22074	O
;	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
Penny	O
,	O
D	O
.	O
M	O
.	O
,	O
Irrinki	O
,	O
A	O
.	O
,	O
Lee	O
,	O
V	O
.	O
K	O
.	O
,	O
Lebron	O
,	O
J	O
.	O
A	O
.	O
,	O
Watson	O
,	O
N	O
.	O
,	O
Tsuchihashi	O
,	O
Z	O
.	O
,	O
Sigal	O
,	O
E	O
.	O
,	O
Bjorkman	O
,	O
P	O
.	O
J	O
.	O
,	O
and	O
Schatzman	O
,	O
R	O
.	O
C	O
.	O

(	O
1998	O
)	O
Proc	O
.	O
Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
S	O
A	O
95	O
,	O
1472	O
-	O
1477	O
)	O
.	O

HFE	O
does	O
not	O
remain	O
at	O
the	O
cell	O
surface	O
,	O
but	O
traffics	O
with	O
TfR	O
to	O
Tf	O
-	O
positive	O
internal	O
compartments	O
(	O
Gross	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Using	O
a	O
HeLa	O
cell	O
line	O
in	O
which	O
the	O
expression	O
of	O
HFE	O
is	O
controlled	O
by	O
tetracycline	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
HFE	O
reduces	O
55Fe	O
uptake	O
from	O
Tf	O
by	O
33	O
%	O
but	O
does	O
not	O
affect	O
the	O
endocytic	O
or	O
exocytic	O
rates	O
of	O
TfR	O
cycling	O
.	O

Therefore	O
,	O
HFE	O
appears	O
to	O
reduce	O
cellular	O
acquisition	O
of	O
iron	O
from	O
Tf	O
within	O
endocytic	O
compartments	O
.	O

HFE	O
specifically	O
reduces	O
iron	O
uptake	O
from	O
Tf	O
,	O
as	O
non	O
-	O
Tf	O
-	O
mediated	O
iron	O
uptake	O
from	O
Fe	O
-	O
nitrilotriacetic	O
acid	O
is	O
not	O
altered	O
.	O

These	O
results	O
explain	O
the	O
decreased	O
ferritin	O
levels	O
seen	O
in	O
our	O
HeLa	O
cell	O
system	O
and	O
demonstrate	O
the	O
specific	O
control	O
of	O
HFE	O
over	O
the	O
Tf	O
-	O
mediated	O
pathway	O
of	O
iron	O
uptake	O
.	O

These	O
results	O
also	O
have	O
implications	O
for	O
the	O
understanding	O
of	O
cellular	O
iron	O
homeostasis	O
in	O
organs	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
heart	O
,	O
and	O
spleen	O
that	O
are	O
iron	O
loaded	O
in	O
hereditary	B
hemochromatotic	I
individuals	O
lacking	O
functional	O
HFE	O
.	O

Mutation	O
and	O
haplotype	O
studies	O
of	O
familial	B
Mediterranean	I
fever	I
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

Familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
is	O
a	O
recessive	B
disorder	I
characterized	O
by	O
episodes	O
of	O
fever	O
with	O
serositis	B
or	O
synovitis	B
.	O

The	O
FMF	B
gene	O
(	O
MEFV	O
)	O
was	O
cloned	O
recently	O
,	O
and	O
four	O
missense	O
mutations	O
were	O
identified	O
.	O

Here	O
we	O
present	O
data	O
from	O
non	O
-	O
Ashkenazi	O
Jewish	O
and	O
Arab	O
patients	O
in	O
whom	O
we	O
had	O
not	O
originally	O
found	O
mutations	O
and	O
from	O
a	O
new	O
,	O
more	O
ethnically	O
diverse	O
panel	O
.	O

Among	O
90	O
symptomatic	O
mutation	O
-	O
positive	O
individuals	O
,	O
11	O
mutations	O
accounted	O
for	O
79	O
%	O
of	O
carrier	O
chromosomes	O
.	O

Of	O
the	O
two	O
mutations	O
that	O
are	O
novel	O
,	O
one	O
alters	O
the	O
same	O
residue	O
(	O
680	O
)	O
as	O
a	O
previously	O
known	O
mutation	O
,	O
and	O
the	O
other	O
(	O
P369S	O
)	O
is	O
located	O
in	O
exon	O
3	O
.	O

Consistent	O
with	O
another	O
recent	O
report	O
,	O
the	O
E148Q	O
mutation	O
was	O
observed	O
in	O
patients	O
of	O
several	O
ethnicities	O
and	O
on	O
multiple	O
microsatellite	O
haplotypes	O
,	O
but	O
haplotype	O
data	O
indicate	O
an	O
ancestral	O
relationships	O
between	O
non	O
-	O
Jewish	O
Italian	O
and	O
Ashkenazi	O
Jewish	O
patients	O
with	O
FMF	B
and	O
other	O
affected	O
populations	O
.	O

Among	O
approximately	O
200	O
anonymous	O
Ashkenazi	O
Jewish	O
DNA	O
samples	O
,	O
the	O
MEFV	O
carrier	O
frequency	O
was	O
21	O
%	O
,	O
with	O
E148Q	O
the	O
most	O
common	O
mutation	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
reduced	O
penetrance	O
among	O
Ashkenazi	O
Jews	O
,	O
especially	O
for	O
E148Q	O
,	O
P369S	O
,	O
and	O
K695R	O
.	O

Nevertheless	O
,	O
E148Q	O
helps	O
account	O
for	O
recessive	O
inheritance	O
in	O
an	O
Ashkenazi	O
family	O
previously	O
reported	O
as	O
an	O
unusual	O
case	O
of	O
dominantly	O
inherited	O
FMF	B
.	O

The	O
presence	O
of	O
three	O
frequent	O
MEFV	O
mutations	O
in	O
multiple	O
Mediterranean	O
populations	O
strongly	O
suggests	O
a	O
heterozygote	O
advantage	O
in	O
this	O
geographic	O
region	O
.	O

Autoimmune	B
lymphoproliferative	I
syndrome	I
with	O
defective	O
Fas	O
:	O
genotype	O
influences	O
penetrance	O
.	O

Autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
is	O
a	O
disorder	B
of	I
lymphocyte	I
homeostasis	I
and	I
immunological	I
tolerance	I
.	O

Most	O
patients	O
have	O
a	O
heterozygous	O
mutation	O
in	O
the	O
APT1	O
gene	O
,	O
which	O
encodes	O
Fas	O
(	O
CD95	O
,	O
APO	O
-	O
1	O
)	O
,	O
mediator	O
of	O
an	O
apoptotic	O
pathway	O
crucial	O
to	O
lymphocyte	O
homeostasis	O
.	O

Of	O
17	O
unique	O
APT1	O
mutations	O
in	O
unrelated	O
ALPS	B
probands	O
,	O
12	O
(	O
71	O
%	O
)	O
occurred	O
in	O
exons	O
7	O
-	O
9	O
,	O
which	O
encode	O
the	O
intracellular	O
portion	O
of	O
Fas	O
.	O

In	O
vitro	O
,	O
activated	O
lymphocytes	O
from	O
all	O
17	O
patients	O
showed	O
apoptotic	O
defects	O
when	O
exposed	O
to	O
an	O
anti	O
-	O
Fas	O
agonist	O
monoclonal	O
antibody	O
.	O

Similar	O
defects	O
were	O
found	O
in	O
a	O
Fas	O
-	O
negative	O
cell	O
line	O
transfected	O
with	O
cDNAs	O
bearing	O
each	O
of	O
the	O
mutations	O
.	O

In	O
cotransfection	O
experiments	O
,	O
Fas	O
constructs	O
with	O
either	O
intra	O
-	O
or	O
extracellular	O
mutations	O
caused	O
dominant	O
inhibition	O
of	O
apoptosis	O
mediated	O
by	O
wild	O
-	O
type	O
Fas	O
.	O

Two	O
missense	O
Fas	O
variants	O
,	O
not	O
restricted	O
to	O
patients	O
with	O
ALPS	B
,	O
were	O
identified	O
.	O

Variant	O
A	O
(	O
-	O
1	O
)	O
T	O
at	O
the	O
Fas	O
signal	O
-	O
sequence	O
cleavage	O
site	O
,	O
which	O
mediates	O
apoptosis	O
less	O
well	O
than	O
wild	O
-	O
type	O
Fas	O
and	O
is	O
partially	O
inhibitory	O
,	O
was	O
present	O
in	O
13	O
%	O
of	O
African	O
American	O
alleles	O
.	O

Among	O
the	O
ALPS	B
-	O
associated	O
Fas	O
mutants	O
,	O
dominant	O
inhibition	O
of	O
apoptosis	O
was	O
much	O
more	O
pronounced	O
in	O
mutants	O
affecting	O
the	O
intracellular	O
,	O
versus	O
extracellular	O
,	O
portion	O
of	O
the	O
Fas	O
receptor	O
.	O

Mutations	O
causing	O
disruption	O
of	O
the	O
intracellular	O
Fas	O
death	O
domain	O
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
ALPS	B
phenotype	O
features	O
in	O
mutation	O
-	O
bearing	O
relatives	O
.	O

Significant	O
ALPS	B
-	O
related	O
morbidity	O
occurred	O
in	O
44	O
%	O
of	O
relatives	O
with	O
intracellular	O
mutations	O
,	O
versus	O
0	O
%	O
of	O
relatives	O
with	O
extracellular	O
mutations	O
.	O

Thus	O
,	O
the	O
location	O
of	O
mutations	O
within	O
APT1	O
strongly	O
influences	O
the	O
development	O
and	O
the	O
severity	O
of	O
ALPS	B
.	O

Multicentric	O
origin	O
of	O
hemochromatosis	B
gene	O
(	O
HFE	O
)	O
mutations	O
.	O

Genetic	B
hemochromatosis	I
(	O
GH	B
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry	O
.	O

In	O
northwestern	O
Europe	O
,	O
>	O
80	O
%	O
of	O
GH	B
patients	O
are	O
homozygous	O
for	O
one	O
mutation	O
,	O
the	O
substitution	O
of	O
tyrosine	O
for	O
cysteine	O
at	O
position	O
282	O
(	O
C282Y	O
)	O
in	O
the	O
unprocessed	O
protein	O
.	O

In	O
a	O
proportion	O
of	O
GH	B
patients	O
,	O
two	O
mutations	O
are	O
present	O
,	O
C282Y	O
and	O
H63D	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
second	O
mutation	O
is	O
such	O
that	O
it	O
appears	O
to	O
predispose	O
1	O
%	O
-	O
2	O
%	O
of	O
compound	O
heterozygotes	O
to	O
expression	O
of	O
the	O
disease	O
.	O

The	O
distribution	O
of	O
the	O
two	O
mutations	O
differ	O
,	O
C282Y	O
being	O
limited	O
to	O
those	O
of	O
northwestern	O
European	O
ancestry	O
and	O
H63D	O
being	O
found	O
at	O
allele	O
frequencies	O
>	O
5	O
%	O
,	O
in	O
Europe	O
,	O
in	O
countries	O
bordering	O
the	O
Mediterranean	O
,	O
in	O
the	O
Middle	O
East	O
,	O
and	O
in	O
the	O
Indian	O
subcontinent	O
.	O

The	O
C282Y	O
mutation	O
occurs	O
on	O
a	O
haplotype	O
that	O
extends	O
<	O
/	O
=	O
6	O
Mb	O
,	O
suggesting	O
that	O
this	O
mutation	O
has	O
arisen	O
during	O
the	O
past	O
2	O
,	O
000	O
years	O
.	O

The	O
H63D	O
mutation	O
is	O
older	O
and	O
does	O
not	O
occur	O
on	O
such	O
a	O
large	O
extended	O
haplotype	O
,	O
the	O
haplotype	O
in	O
this	O
case	O
extending	O
<	O
/	O
=	O
700	O
kb	O
.	O

Here	O
we	O
report	O
the	O
finding	O
of	O
the	O
H63D	O
and	O
C282Y	O
mutations	O
on	O
new	O
haplotypes	O
.	O

In	O
Sri	O
Lanka	O
we	O
have	O
found	O
H63D	O
on	O
three	O
new	O
haplotypes	O
and	O
have	O
found	O
C282Y	O
on	O
one	O
new	O
haplotype	O
,	O
demonstrating	O
that	O
these	O
mutations	O
have	O
arisen	O
independently	O
on	O
this	O
island	O
.	O

These	O
results	O
suggest	O
that	O
the	O
HFE	O
gene	O
has	O
been	O
the	O
subject	O
of	O
selection	O
pressure	O
.	O

These	O
selection	O
pressures	O
could	O
be	O
due	O
to	O
infectious	B
diseases	I
,	O
environmental	O
conditions	O
,	O
or	O
other	O
genetic	B
disorders	I
such	O
as	O
anemia	B
.	O

A	O
retrospective	O
anonymous	O
pilot	O
study	O
in	O
screening	O
newborns	O
for	O
HFE	O
mutations	O
in	O
Scandinavian	O
populations	O
.	O

We	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(	O
DBS	O
)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
Scandinavia	O
for	O
mutations	O
in	O
HFE	O
,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	B
.	O

We	O
have	O
found	O
C282Y	O
allele	O
frequencies	O
of	O
2	O
.	O

3	O
%	O
(	O
+	O
2	O
.	O
0	O
%	O
)	O
(	O
-	O
1	O
.	O
3	O
%	O
)	O
in	O
Greenland	O
,	O
4	O
.	O

5	O
%	O
+	O
/	O
-	O
1	O
.	O

9	O
%	O
in	O
Iceland	O
,	O
5	O
.	O

1	O
%	O
+	O
/	O
-	O
2	O
.	O

3	O
%	O
in	O
the	O
Faeroe	O
Islands	O
,	O
and	O
8	O
.	O

2	O
%	O
+	O
/	O
-	O
2	O
.	O

7	O
%	O
in	O
Denmark	O
.	O

The	O
high	O
prevalence	O
of	O
HFE	O
mutations	O
in	O
Denmark	O
suggests	O
that	O
population	O
screening	O
for	O
the	O
C282Y	O
mutation	O
could	O
be	O
highly	O
advantageous	O
in	O
terms	O
of	O
preventive	O
health	O
care	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
evaluation	O
of	O
C282Y	O
homozygotes	O
and	O
H63D	O
/	O
C282Y	O
compound	O
heterozygotes	O
will	O
give	O
an	O
indication	O
of	O
the	O
penetrance	O
of	O
the	O
mutations	O
.	O

Identification	O
of	O
the	O
mutation	O
in	O
the	O
alkaptonuria	B
mouse	O
model	O
.	O

Alkaptonuria	B
(	O
aku	B
)	O
,	O
an	O
inborn	B
error	I
of	I
metabolism	I
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O

We	O
used	O
RT	O
-	O
PCR	O
to	O
amplify	O
the	O
Hgd	O
cDNA	O
from	O
Hgd	O
(	O
aku	O
)	O
/	O
Hgd	O
(	O
aku	O
)	O
mice	O
.	O

Two	O
products	O
shorter	O
than	O
the	O
wild	O
-	O
type	O
product	O
were	O
amplified	O
.	O

Restriction	O
mapping	O
and	O
DNA	O
sequencing	O
were	O
then	O
used	O
to	O
identify	O
the	O
Hgd	O
(	O
aku	O
)	O
mouse	O
mutation	O
,	O
found	O
to	O
be	O
a	O
single	O
base	O
change	O
in	O
a	O
splice	O
donor	O
consensus	O
sequence	O
,	O
causing	O
exon	O
skipping	O
and	O
frame	O
-	O
shifted	O
products	O
.	O

This	O
base	O
change	O
allowed	O
us	O
to	O
create	O
a	O
non	O
-	O
radioactive	O
genotyping	O
assay	O
for	O
this	O
allele	O
.	O

Non	B
-	I
syndromic	I
hearing	I
loss	I
associated	O
with	O
enlarged	B
vestibular	I
aqueduct	I
is	O
caused	O
by	O
PDS	B
mutations	O
.	O

Enlarged	B
vestibular	I
aqueduct	I
(	O
EVA	B
)	O
,	O
known	O
as	O
the	O
most	O
common	O
form	O
of	O
inner	B
ear	I
abnormality	I
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	O
interest	O
because	O
this	O
anomaly	O
is	O
inherited	O
in	O
a	O
recessive	O
manner	O
.	O

The	O
locus	O
for	O
non	B
-	I
syndromic	I
sensorineural	I
hearing	I
loss	I
with	O
EVA	B
has	O
been	O
mapped	O
to	O
the	O
same	O
chromosomal	O
region	O
,	O
7q31	O
,	O
as	O
the	O
Pendred	B
syndrome	I
locus	O
.	O

In	O
the	O
present	O
study	O
,	O
seven	O
mutations	O
in	O
the	O
PDS	B
gene	O
(	O
PDS	O
)	O
,	O
the	O
gene	O
responsible	O
for	O
Pendred	B
syndrome	I
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non	B
-	I
syndromic	I
sensorineural	I
hearing	I
loss	I
with	O
EVA	B
.	O

One	O
family	O
is	O
homozygous	O
,	O
three	O
families	O
are	O
compound	O
heterozygotes	O
,	O
and	O
two	O
families	O
are	O
heterozygous	O
but	O
with	O
no	O
other	O
mutation	O
detected	O
.	O

The	O
present	O
results	O
provide	O
evidence	O
that	O
mutations	O
in	O
PDS	O
cause	O
both	O
syndromic	B
and	I
non	I
-	I
syndromic	I
hearing	I
loss	I
.	O
.	O

Mutational	O
analysis	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
.	O

BACKGROUND	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
an	O
inherited	B
disease	I
characterized	O
by	O
progressive	O
neurologic	B
dysfunction	I
,	O
occasionally	O
associated	O
with	O
adrenal	B
insufficiency	I
.	O

The	O
classic	O
form	O
of	O
ALD	B
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B
cerebral	I
ALD	I
)	O
,	O
with	O
rapid	O
neurologic	B
deterioration	I
leading	O
to	O
a	O
vegetative	O
state	O
.	O

Adult	O
-	O
onset	O
cerebral	B
ALD	I
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	B
dysfunction	I
.	O

Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B
and	O
Addison	B
disease	I
only	O
also	O
have	O
been	O
recognized	O
.	O

Despite	O
discovery	O
of	O
the	O
causative	O
gene	O
,	O
a	O
molecular	O
basis	O
for	O
the	O
diverse	O
clinical	O
presentations	O
remains	O
to	O
be	O
elucidated	O
.	O

OBJECTIVES	O
To	O
conduct	O
mutational	O
analyses	O
in	O
29	O
Japanese	O
patients	O
with	O
ALD	B
from	O
29	O
unrelated	O
families	O
,	O
to	O
obtain	O
knowledge	O
of	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
,	O
and	O
to	O
study	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
Japanese	O
patients	O
.	O

METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B
cerebral	I
ALD	I
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B
ALD	I
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B
.	O

We	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
ALD	B
by	O
genomic	O
Southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
RNA	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts	O
,	O
lymphoblastoid	O
cells	O
,	O
or	O
peripheral	O
blood	O
leukocytes	O
.	O

RESULTS	O
Three	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B
ALD	I
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O

The	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations	O
,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ALD	B
gene	O
.	O

Eighteen	O
(	O
69	O
%	O
)	O
of	O
26	O
mutations	O
were	O
missense	O
mutations	O
.	O

Most	O
missense	O
mutations	O
involved	O
amino	O
acids	O
conserved	O
in	O
homologous	O
gene	O
products	O
,	O
including	O
PMP70	O
,	O
mALDRP	O
,	O
and	O
Pxa1p	O
.	O

The	O
AG	O
dinucleotide	O
deletion	O
at	O
position	O
1081	O
-	O
1082	O
,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
be	O
the	O
most	O
common	O
mutation	O
in	O
white	O
patients	O
(	O
12	O
%	O
-	O
17	O
%	O
)	O
,	O
was	O
also	O
identified	O
as	O
the	O
most	O
common	O
mutation	O
in	O
Japanese	O
patients	O
(	O
12	O
%	O
)	O
.	O

All	O
phenotypes	O
were	O
associated	O
with	O
mutations	O
resulting	O
in	O
protein	O
truncation	O
or	O
subtle	O
amino	O
acid	O
changes	O
.	O

There	O
were	O
no	O
differences	O
in	O
phenotypic	O
expressions	O
between	O
missense	O
mutations	O
involving	O
conserved	O
amino	O
acids	O
and	O
those	O
involving	O
nonconserved	O
amino	O
acids	O
.	O

CONCLUSIONS	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	B
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	B
.	O
.	O

A	O
common	O
human	O
skin	B
tumour	I
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta	O
-	O
catenin	O
.	O

WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O

In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta	O
-	O
catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O

One	O
of	O
the	O
target	O
genes	O
for	O
beta	O
-	O
catenin	O
/	O
TCF	O
encodes	O
c	O
-	O
MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B
,	O
particularly	O
in	O
the	O
colon	O
.	O

Most	O
colon	B
cancers	I
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta	O
-	O
catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	B
and	I
some	I
other	I
cancers	I
harbour	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B
tumours	I
resembling	O
pilomatricomas	B
.	O

Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O

Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B
tumour	I
.	O

We	O
found	O
nuclear	O
LEF	O
-	O
1	O
in	O
the	O
dividing	O
tumour	B
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	B
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O

At	O
least	O
75	O
%	O
of	O
these	O
tumours	B
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	B
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta	O
-	O
catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
.	O

The	O
Pendred	B
syndrome	I
gene	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O

Pendred	B
syndrome	I
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B
deafness	I
and	O
characterized	O
by	O
congenital	O
sensorineural	B
hearing	I
loss	I
and	O
goitre	B
.	O

This	O
disorder	O
was	O
mapped	O
to	O
chromosome	O
7	O
and	O
the	O
gene	O
causing	O
Pendred	B
syndrome	I
(	O
PDS	B
)	O
was	O
subsequently	O
identified	O
by	O
positional	O
cloning	O
.	O

PDS	O
encodes	O
a	O
putative	O
transmembrane	O
protein	O
designated	O
pendrin	O
.	O

Pendrin	O
is	O
closely	O
related	O
to	O
a	O
family	O
of	O
sulfate	O
transport	O
proteins	O
that	O
includes	O
the	O
rat	O
sulfate	O
-	O
anion	O
transporter	O
(	O
encoded	O
by	O
Sat	O
-	O
1	O
;	O
29	O
%	O
amino	O
acid	O
sequence	O
identity	O
)	O
,	O
the	O
human	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
(	O
encoded	O
by	O
DTD	O
;	O
32	O
%	O
)	O
and	O
the	O
human	O
sulfate	O
transporter	O
downregulated	O
in	O
adenoma	B
(	O
encoded	O
by	O
DRA	O
;	O
45	O
%	O
)	O
.	O

On	O
the	O
basis	O
of	O
this	O
homology	O
and	O
the	O
presence	O
of	O
a	O
slightly	O
modified	O
sulfate	O
-	O
transporter	O
signature	O
sequence	O
comprising	O
its	O
putative	O
second	O
transmembrane	O
domain	O
,	O
pendrin	O
has	O
been	O
proposed	O
to	O
function	O
as	O
a	O
sulfate	O
transporter	O
.	O

We	O
were	O
unable	O
to	O
detect	O
evidence	O
of	O
sulfate	O
transport	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
Xenopus	O
laevis	O
oocytes	O
by	O
microinjection	O
of	O
PDS	O
cRNA	O
or	O
in	O
Sf9	O
cells	O
following	O
infection	O
with	O
PDS	O
-	O
recombinant	O
baculovirus	O
.	O

The	O
rates	O
of	O
transport	O
for	O
iodide	O
and	O
chloride	O
were	O
significantly	O
increased	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
both	O
cell	O
systems	O
.	O

Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B
syndrome	I
.	O
.	O

HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	B
probands	O
:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis	B
.	O

Hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
a	O
common	O
autosomal	B
recessive	I
genetic	I
disorder	I
of	O
iron	O
metabolism	O
.	O

The	O
HFE	O
candidate	O
gene	O
encoding	O
an	O
HLA	O
class	O
I	O
-	O
like	O
protein	O
involved	O
in	O
HH	B
was	O
identified	O
in	O
1996	O
.	O

Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	O
HH	B
chromosomes	O
.	O

We	O
report	O
here	O
on	O
the	O
analysis	O
of	O
C282Y	O
,	O
H63D	O
,	O
and	O
the	O
193A	O
-	O
-	O
>	O
T	O
substitution	O
leading	O
to	O
the	O
S65C	O
missense	O
substitution	O
in	O
a	O
large	O
series	O
of	O
probands	O
and	O
controls	O
.	O

The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	B
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
HH	B
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation	O
.	O

In	O
addition	O
,	O
our	O
screening	O
showed	O
that	O
the	O
S65C	O
substitution	O
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	O
without	O
an	O
assigned	O
mutation	O
.	O

This	O
substitution	O
accounted	O
for	O
7	O
.	O

8	O
%	O
of	O
HH	B
chromosomes	O
that	O
were	O
neither	O
C282Y	O
nor	O
H63D	O
.	O

This	O
enrichment	O
of	O
S65C	O
among	O
HH	B
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	B
.	O

Germline	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
ovarian	B
cancer	I
cases	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
more	O
accurate	O
frequency	O
estimates	O
of	O
breast	B
cancer	I
susceptibility	O
gene	O
1	O
(	O
BRCA1	O
)	O
germline	O
alterations	O
in	O
the	O
ovarian	B
cancer	I
population	O
.	O

To	O
achieve	O
this	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
consecutive	O
ovarian	B
cancer	I
cases	O
.	O

This	O
is	O
the	O
first	O
population	O
-	O
based	O
ovarian	B
cancer	I
study	O
reporting	O
BRCA1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region	O
.	O

One	O
hundred	O
and	O
seven	O
ovarian	B
cancer	I
cases	O
were	O
analyzed	O
for	O
BRCA1	O
alterations	O
using	O
the	O
RNase	O
mismatch	O
cleavage	O
assay	O
followed	O
by	O
direct	O
sequencing	O
.	O

Two	O
truncating	O
mutations	O
,	O
962del4	O
and	O
3600del11	O
,	O
were	O
identified	O
.	O

Both	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B
or	I
ovarian	I
cancer	I
.	O

Several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	B
.	O

The	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
Caucasian	O
cancer	B
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele	O
-	O
specific	O
amplification	O
.	O

The	O
rare	O
form	O
of	O
the	O
Q356R	O
polymorphism	O
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
associated	O
with	O
a	O
family	O
history	O
of	O
ovarian	B
cancer	I
,	O
suggesting	O
that	O
this	O
polymorphism	O
may	O
influence	O
ovarian	B
cancer	I
risk	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
some	O
uncharacterized	O
variants	O
and	O
rare	O
forms	O
of	O
polymorphisms	O
in	O
determining	O
ovarian	B
cancer	I
risk	O
,	O
and	O
highlight	O
the	O
necessity	O
to	O
screen	O
for	O
missense	O
alterations	O
as	O
well	O
as	O
truncating	O
mutations	O
in	O
this	O
population	O
.	O

Adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B
protein	I
deficiency	I
(	O
X	B
-	I
ALD	I
)	O
:	O
implications	O
for	O
therapy	O
.	O

Inherited	B
defects	I
in	O
the	O
peroxisomal	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
adrenoleukodystrophy	B
protein	O
(	O
ALDP	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B
disorder	I
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
X	B
-	I
ALD	I
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

Three	O
other	O
peroxisomal	O
ABC	O
transporters	O
currently	O
are	O
known	O
adrenoleukodystrophy	O
-	O
related	O
protein	O
(	O
ALDRP	O
)	O
,	O
70	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
and	O
PMP70	O
-	O
related	O
protein	O
.	O

By	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cDNAs	O
encoding	O
ALDP	O
and	O
its	O
closest	O
relative	O
ALDRP	O
,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta	O
-	O
oxidation	O
in	O
fibroblasts	O
of	O
X	B
-	I
ALD	I
patients	O
.	O

The	O
pathognomonic	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
could	O
also	O
be	O
prevented	O
by	O
overexpression	O
of	O
ALDRP	O
in	O
immortalized	O
X	O
-	O
ALD	O
cells	O
.	O

Immunofluorescence	O
analysis	O
demonstrated	O
that	O
the	O
functional	O
replacement	O
of	O
ALDP	O
by	O
ALDRP	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
mutated	O
ALDP	O
itself	O
.	O

Moreover	O
,	O
we	O
were	O
able	O
to	O
restore	O
the	O
peroxisomal	O
beta	O
-	O
oxidation	O
defect	O
in	O
the	O
liver	O
of	O
ALDP	O
-	O
deficient	O
mice	O
by	O
stimulation	O
of	O
ALDRP	O
and	O
PMP70	O
gene	O
expression	O
through	O
a	O
dietary	O
treatment	O
with	O
the	O
peroxisome	O
proliferator	O
fenofibrate	O
.	O

These	O
results	O
suggest	O
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	O
in	O
X	B
-	I
ALD	I
could	O
be	O
possible	O
by	O
drug	O
-	O
induced	O
overexpression	O
or	O
ectopic	O
expression	O
of	O
ALDRP	O
.	O
.	O

Centrosome	O
amplification	O
and	O
a	O
defective	O
G2	O
-	O
M	O
cell	O
cycle	O
checkpoint	O
induce	O
genetic	O
instability	O
in	O
BRCA1	O
exon	O
11	O
isoform	O
-	O
deficient	O
cells	O
.	O

Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	B
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B
and	I
ovarian	I
cancers	I
.	O

To	O
study	O
mechanisms	O
underlying	O
BRCA1	O
-	O
related	O
tumorigenesis	O
,	O
we	O
derived	O
mouse	O
embryonic	O
fibroblast	O
cells	O
carrying	O
a	O
targeted	O
deletion	O
of	O
exon	O
11	O
of	O
the	O
Brca1	O
gene	O
.	O

We	O
show	O
that	O
the	O
mutant	O
cells	O
maintain	O
an	O
intact	O
G1	O
-	O
S	O
cell	O
cycle	O
checkpoint	O
and	O
proliferate	O
poorly	O
.	O

However	O
,	O
a	O
defective	O
G2	O
-	O
M	O
checkpoint	O
in	O
these	O
cells	O
is	O
accompanied	O
by	O
extensive	O
chromosomal	B
abnormalities	I
.	O

Mutant	O
fibroblasts	O
contain	O
multiple	O
,	O
functional	O
centrosomes	O
,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation	O
,	O
abnormal	O
nuclear	O
division	O
,	O
and	O
aneuploidy	B
.	O

These	O
data	O
uncover	O
an	O
essential	O
role	O
of	O
BRCA1	O
in	O
maintaining	O
genetic	O
stability	O
through	O
the	O
regulation	O
of	O
centrosome	O
duplication	O
and	O
the	O
G2	O
-	O
M	O
checkpoint	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
role	O
of	O
BRCA1	O
in	O
tumorigenesis	O
.	O
.	O

Defective	O
CD95	O
/	O
APO	O
-	O
1	O
/	O
Fas	O
signal	O
complex	O
formation	O
in	O
the	O
human	O
autoimmune	B
lymphoproliferative	I
syndrome	I
,	I
type	I
Ia	I
.	O

Heterozygous	O
mutations	O
in	O
the	O
CD95	O
(	O
APO	O
-	O
1	O
/	O
Fas	O
)	O
receptor	O
occur	O
in	O
most	O
individuals	O
with	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism	O
.	O

We	O
show	O
that	O
local	O
or	O
global	O
alterations	O
in	O
the	O
structure	O
of	O
the	O
cytoplasmic	O
death	O
domain	O
from	O
nine	O
independent	O
ALPS	B
CD95	O
death	O
-	O
domain	O
mutations	O
result	O
in	O
a	O
failure	O
to	O
bind	O
the	O
FADD	O
/	O
MORT1	O
signaling	O
protein	O
.	O

Despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele	O
,	O
lymphocytes	O
from	O
ALPS	B
patients	O
showed	O
markedly	O
decreased	O
FADD	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking	O
.	O

These	O
data	O
suggest	O
that	O
intracytoplasmic	O
CD95	O
mutations	O
in	O
ALPS	B
impair	O
apoptosis	O
chiefly	O
by	O
disrupting	O
death	O
-	O
domain	O
interactions	O
with	O
the	O
signaling	O
protein	O
FADD	O
/	O
MORT1	O
.	O
.	O

Analysis	O
of	O
alkaptonuria	B
(	O
AKU	B
)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
CCC	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

We	O
recently	O
showed	O
that	O
alkaptonuria	B
(	O
AKU	B
)	O
is	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	B
pedigrees	O
.	O

These	O
analyses	O
identified	O
two	O
novel	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
INV4	O
+	O
31A	O
-	O
-	O
>	O
G	O
and	O
INV11	O
+	O
18A	O
-	O
-	O
>	O
G	O
)	O
and	O
six	O
novel	O
AKU	B
mutations	O
(	O
INV1	O
-	O
1G	O
-	O
-	O
>	O
A	O
,	O
W60G	O
,	O
Y62C	O
,	O
A122D	O
,	O
P230T	O
,	O
and	O
D291E	O
)	O
,	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	O
found	O
in	O
AKU	B
.	O

Reexamination	O
of	O
all	O
29	O
mutations	O
and	O
polymorphisms	O
thus	O
far	O
described	O
in	O
HGO	O
shows	O
that	O
these	O
nucleotide	O
changes	O
are	O
not	O
randomly	O
distributed	O
;	O
the	O
CCC	O
sequence	O
motif	O
and	O
its	O
inverted	O
complement	O
,	O
GGG	O
,	O
are	O
preferentially	O
mutated	O
.	O

These	O
analyses	O
also	O
demonstrated	O
that	O
the	O
nucleotide	O
substitutions	O
in	O
HGO	O
do	O
not	O
involve	O
CpG	O
dinucleotides	O
,	O
which	O
illustrates	O
important	O
differences	O
between	O
HGO	O
and	O
other	O
genes	O
for	O
the	O
occurrence	O
of	O
mutation	O
at	O
specific	O
short	O
-	O
sequence	O
motifs	O
.	O

Because	O
the	O
CCC	O
sequence	O
motifs	O
comprise	O
a	O
significant	O
proportion	O
(	O
34	O
.	O
5	O
%	O
)	O
of	O
all	O
mutated	O
bases	O
that	O
have	O
been	O
observed	O
in	O
HGO	O
,	O
we	O
conclude	O
that	O
the	O
CCC	O
triplet	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
HGO	O
.	O

Fabry	B
disease	I
:	O
identification	O
of	O
novel	O
alpha	O
-	O
galactosidase	O
A	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches	O
.	O

Fabry	B
disease	I
(	O
FD	B
)	O
(	O
angiokeratoma	B
corporis	I
diffusum	I
)	O
is	O
an	O
X	B
-	I
linked	I
inborn	I
error	I
of	I
glycosphingolipid	I
metabolism	I
caused	O
by	O
defects	O
in	O
the	O
lysosomal	O
alpha	O
-	O
galactosidase	O
A	O
gene	O
(	O
GLA	O
)	O
.	O

The	O
enzymatic	O
defect	O
leads	O
to	O
the	O
systemic	O
accumulation	O
of	O
neutral	O
glycosphingolipids	O
with	O
terminal	O
alpha	O
-	O
galactosyl	O
moieties	O
.	O

Clinically	O
,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	B
,	O
severe	B
acroparesthesia	I
,	O
renal	B
failure	I
,	O
and	O
vasculopathy	B
of	I
the	I
heart	I
and	I
brain	I
.	O

While	O
demonstration	O
of	O
alpha	B
-	I
galactosidase	I
deficiency	I
in	O
leukocytes	O
is	O
diagnostic	O
in	O
affected	O
males	O
,	O
enzymatic	O
detection	O
of	O
female	O
carriers	O
is	O
often	O
inconclusive	O
,	O
due	O
to	O
random	O
X	O
-	O
chromosomal	O
inactivation	O
,	O
underlining	O
the	O
need	O
of	O
molecular	O
investigations	O
for	O
accurate	O
genetic	O
counseling	O
.	O

By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence	O
-	O
based	O
detection	O
systems	O
,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha	B
-	I
Gal	I
A	I
deficiency	I
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
FD	B
.	O

The	O
mutational	O
spectrum	O
included	O
five	O
missense	O
mutations	O
(	O
C202W	O
,	O
C223G	O
,	O
N224D	O
,	O
R301Q	O
,	O
and	O
Q327K	O
)	O
and	O
one	O
splice	O
-	O
site	O
mutation	O
[	O
IVS3	O
G	O
(	O
-	O
1	O
)	O
-	O
-	O
>	O
C	O
]	O
.	O

Studies	O
at	O
the	O
mRNA	O
level	O
showed	O
that	O
the	O
latter	O
led	O
to	O
altered	O
pre	O
-	O
mRNA	O
splicing	O
with	O
consequent	O
alteration	O
of	O
the	O
mRNA	O
translational	O
reading	O
frame	O
and	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
of	O
translation	O
.	O

By	O
use	O
of	O
this	O
strategy	O
,	O
carrier	O
status	O
was	O
accurately	O
assessed	O
in	O
all	O
seven	O
at	O
-	O
risk	O
females	O
tested	O
,	O
whereas	O
enzymatic	O
dosages	O
failed	O
to	O
diagnose	O
or	O
exclude	O
heterozygosity	O
.	O
.	O

Prenatal	O
diagnosis	O
by	O
FISH	O
in	O
a	O
family	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
caused	O
by	O
duplication	O
of	O
PLP	O
gene	O
.	O

A	O
diagnosis	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
MIM	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	O
boy	O
.	O

No	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
had	O
been	O
found	O
.	O

The	O
boys	O
maternal	O
aunt	O
came	O
for	O
prenatal	O
diagnosis	O
when	O
16	O
+	O
weeks	O
pregnant	O
and	O
carrying	O
a	O
male	O
fetus	O
.	O

Samples	O
were	O
tested	O
for	O
duplication	O
of	O
the	O
PLP	O
gene	O
,	O
by	O
interphase	O
FISH	O
,	O
in	O
lymphocyte	O
preparations	O
from	O
the	O
proband	O
,	O
his	O
aunt	O
and	O
an	O
amniotic	O
fluid	O
cell	O
preparation	O
from	O
the	O
fetus	O
.	O

The	O
proband	O
was	O
found	O
to	O
carry	O
the	O
duplication	O
,	O
thus	O
confirming	O
the	O
diagnosis	O
of	O
Pelizaeus	B
Merzbacher	I
disease	I
,	O
but	O
neither	O
the	O
aunt	O
nor	O
the	O
fetus	O
carried	O
a	O
duplication	O
.	O
.	O

Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B
adenomatous	I
polyposis	I
.	O

Inactivation	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O

Patients	O
with	O
familial	B
APC	I
(	O
FAP	B
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B
gene	O
and	O
develop	O
multiple	O
colorectal	B
adenomas	I
and	O
subsequent	O
carcinomas	B
early	O
in	O
life	O
.	O

The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	B
mutation	O
(	O
genotype	O
-	O
phenotype	O
correlation	O
)	O
.	O

Together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
APC	B
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B
mutants	O
.	O

Loss	O
of	O
APC	B
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta	O
-	O
catenin	O
-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B
.	O

Wild	O
-	O
type	O
APC	B
activity	O
in	O
beta	O
-	O
catenin	O
-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O

In	O
contrast	O
,	O
mutant	O
APC	B
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B
polyposis	I
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	O
-	O
type	O
APC	B
activity	O
.	O

These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
FAP	B
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B
tumor	I
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
.	O

BRCA1	O
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex	O
.	O

Germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
tumor	O
-	O
suppressor	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
.	O

BRCA1	O
contains	O
a	O
carboxyl	O
-	O
terminal	O
domain	O
(	O
BRCT	O
)	O
that	O
is	O
shared	O
with	O
several	O
other	O
proteins	O
involved	O
in	O
maintaining	O
genome	O
integrity	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
function	O
of	O
BRCA1	O
,	O
we	O
sought	O
to	O
isolate	O
proteins	O
that	O
interact	O
with	O
the	O
BRCT	O
domain	O
.	O

Purified	O
BRCT	O
polypeptide	O
was	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
human	O
placenta	O
cDNA	O
expression	O
library	O
by	O
Far	O
Western	O
analysis	O
.	O

Here	O
we	O
report	O
that	O
BRCA1	O
interacts	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
Rb	O
-	O
binding	O
proteins	O
,	O
RbAp46	O
and	O
RbAp48	O
,	O
as	O
well	O
as	O
with	O
Rb	O
.	O

Moreover	O
,	O
the	O
BRCT	O
domain	O
associates	O
with	O
the	O
histone	O
deacetylases	O
HDAC1	O
and	O
HDAC2	O
.	O

These	O
results	O
demonstrate	O
that	O
BRCA1	O
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex	O
,	O
and	O
therefore	O
may	O
explain	O
the	O
involvement	O
of	O
BRCA1	O
in	O
multiple	O
processes	O
such	O
as	O
transcription	O
,	O
DNA	O
repair	O
,	O
and	O
recombination	O
.	O
.	O

Combined	B
genetic	I
deficiency	I
of	I
C6	I
and	I
C7	I
in	O
man	O
.	O

By	O
routine	O
screening	O
of	O
sera	O
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub	B
-	I
total	I
deficiency	I
of	I
C6	I
and	I
C7	I
.	O

No	O
clinical	O
disease	O
was	O
associated	O
with	O
this	O
deficiency	O
which	O
was	O
transmitted	O
through	O
the	O
subjects	O
family	O
as	O
a	O
single	O
genetic	O
characteristic	O
,	O
the	O
C6	B
deficiency	I
being	O
associated	O
with	O
a	O
silent	O
allele	O
at	O
the	O
structural	O
locus	O
.	O

The	O
propositus	O
was	O
found	O
to	O
have	O
low	O
quantities	O
of	O
an	O
abnormal	O
C6	O
which	O
was	O
both	O
antigenically	O
deficient	O
and	O
smaller	O
in	O
size	O
than	O
normal	O
C6	O
(	O
110	O
,	O
000	O
daltons	O
compared	O
with	O
140	O
,	O
000	O
daltons	O
)	O
and	O
small	O
quantities	O
of	O
apparently	O
normal	O
C7	O
.	O

It	O
is	O
concluded	O
that	O
the	O
most	O
likely	O
explanation	O
for	O
this	O
defect	O
is	O
that	O
the	O
subject	O
has	O
a	O
structural	O
mutation	O
in	O
his	O
C6	O
gene	O
which	O
produces	O
hyopsynthesis	O
not	O
only	O
of	O
C6	O
but	O
also	O
of	O
the	O
closely	O
linked	O
gene	O
for	O
C7	O
.	O

These	O
findings	O
suggest	O
the	O
possibility	O
that	O
C6	O
and	O
C7	O
may	O
function	O
as	O
a	O
single	O
genetic	O
unit	O
and	O
that	O
the	O
primary	O
transcript	O
copied	O
from	O
the	O
genome	O
includes	O
information	O
for	O
both	O
proteins	O
.	O
.	O

Changes	O
at	O
P183	O
of	O
emerin	O
weaken	O
its	O
protein	O
-	O
protein	O
interactions	O
resulting	O
in	O
X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
is	O
an	O
X	B
-	I
linked	I
recessive	I
muscular	I
dystrophy	I
characterized	O
by	O
early	O
contractures	B
of	I
the	I
elbows	I
,	I
Achilles	I
tendons	I
and	I
spine	I
,	O
slowly	O
progressive	O
muscle	B
wasting	I
and	O
weakness	B
,	O
and	O
cardiomyopathy	B
associated	O
with	O
cardiac	B
conduction	I
defects	I
.	O

The	O
emerin	O
gene	O
has	O
been	O
mapped	O
to	O
Xq28	O
and	O
encodes	O
a	O
34	O
-	O
kDa	O
serine	O
-	O
rich	O
protein	O
,	O
emerin	O
,	O
which	O
has	O
been	O
localized	O
to	O
the	O
nuclear	O
envelope	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
and	O
cardiac	O
muscle	O
.	O

Mutations	O
spanning	O
the	O
emerin	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
EDMD	B
.	O

We	O
present	O
here	O
the	O
effect	O
,	O
on	O
emerin	O
protein	O
expression	O
,	O
of	O
two	O
missense	O
mutations	O
identified	O
in	O
unrelated	O
EDMD	B
patients	O
.	O

These	O
alterations	O
predict	O
the	O
replacement	O
of	O
a	O
proline	O
residue	O
at	O
position	O
183	O
with	O
either	O
a	O
histidine	O
or	O
a	O
threonine	O
.	O

Biochemical	O
analysis	O
has	O
demonstrated	O
that	O
the	O
mobility	O
and	O
expression	O
levels	O
of	O
the	O
mutant	O
forms	O
of	O
emerin	O
are	O
indistinguishable	O
from	O
that	O
of	O
wild	O
-	O
type	O
emerin	O
,	O
but	O
that	O
they	O
have	O
weakened	O
interactions	O
with	O
nuclear	O
lamina	O
components	O
.	O

In	O
comparison	O
with	O
the	O
usual	O
EDMD	B
phenotype	O
,	O
patients	O
with	O
P183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms	O
,	O
elbow	B
contractures	I
,	O
ankle	B
contractures	I
,	O
upper	B
limb	I
weakness	I
and	O
lower	B
limb	I
weakness	I
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	B
involvement	I
.	O

This	O
is	O
the	O
first	O
report	O
of	O
protein	O
studies	O
on	O
patients	O
with	O
missense	O
mutations	O
resulting	O
in	O
the	O
clinical	O
features	O
of	O
EDMD	B
.	O

These	O
studies	O
demonstrate	O
the	O
importance	O
of	O
proline	O
183	O
for	O
the	O
proper	O
structure	O
/	O
function	O
of	O
emerin	O
.	O
.	O

Microdeletions	O
at	O
chromosome	O
bands	O
1q32	O
-	O
q41	O
as	O
a	O
cause	O
of	O
Van	B
der	I
Woude	I
syndrome	I
.	O

Van	B
der	I
Woude	I
syndrome	I
(	O
VWS	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
comprising	O
cleft	B
lip	I
and	O
/	O
or	O
cleft	B
palate	I
and	O
lip	B
pits	I
.	O

We	O
reported	O
previously	O
a	O
family	O
whose	O
underlying	O
mutation	O
is	O
a	O
500	O
-	O
800	O
kb	O
deletion	O
localized	O
to	O
chromosome	O
bands	O
1q32	O
-	O
q41	O
[	O
Sander	O
et	O
al	O
.	O
,	O
1994	O
Hum	O
Mol	O
Genet	O
3	O
576	O
-	O
578	O
]	O
.	O

Along	O
with	O
cleft	B
lip	I
/	I
palate	I
and	O
lip	B
pits	I
,	O
affected	O
relatives	O
exhibit	O
developmental	B
delays	I
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted	O
.	O

To	O
further	O
localize	O
the	O
VWS	B
gene	O
we	O
searched	O
for	O
other	O
deletions	O
that	O
cause	O
VWS	B
.	O

An	O
allele	O
loss	O
assay	O
was	O
performed	O
using	O
a	O
novel	O
highly	O
polymorphic	O
marker	O
,	O
D1S3753	O
.	O

From	O
a	O
panel	O
of	O
37	O
unrelated	O
individuals	O
,	O
we	O
detected	O
an	O
allele	O
loss	O
in	O
one	O
family	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
deletion	O
.	O

In	O
this	O
family	O
,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
VWS	B
.	O

Surprisingly	O
,	O
mapping	O
of	O
the	O
new	O
deletion	O
showed	O
that	O
it	O
extended	O
0	O
.	O

2	O
-	O
1	O
Mb	O
beyond	O
the	O
proximal	O
breakpoint	O
for	O
the	O
deletion	O
described	O
previously	O
.	O

No	O
deletions	O
were	O
detected	O
in	O
seven	O
cases	O
of	O
popliteal	B
pterygia	I
syndrome	I
,	O
76	O
cases	O
of	O
mixed	O
syndromic	B
forms	I
of	I
cleft	I
lip	I
and	I
palate	I
,	O
and	O
178	O
cases	O
of	O
nonsyndromic	B
cleft	I
lip	I
and	I
palate	I
.	O

Splicing	O
defects	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
,	O
ATM	O
:	O
underlying	O
mutations	O
and	O
consequences	O
.	O

Mutations	O
resulting	O
in	O
defective	O
splicing	O
constitute	O
a	O
significant	O
proportion	O
(	O
30	O
/	O
62	O
[	O
48	O
%	O
]	O
)	O
of	O
a	O
new	O
series	O
of	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
patients	O
with	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
that	O
were	O
detected	O
by	O
the	O
protein	O
-	O
truncation	O
assay	O
followed	O
by	O
sequence	O
analysis	O
of	O
genomic	O
DNA	O
.	O

Fewer	O
than	O
half	O
of	O
the	O
splicing	O
mutations	O
involved	O
the	O
canonical	O
AG	O
splice	O
-	O
acceptor	O
site	O
or	O
GT	O
splice	O
-	O
donor	O
site	O
.	O

A	O
higher	O
percentage	O
of	O
mutations	O
occurred	O
at	O
less	O
stringently	O
conserved	O
sites	O
,	O
including	O
silent	O
mutations	O
of	O
the	O
last	O
nucleotide	O
of	O
exons	O
,	O
mutations	O
in	O
nucleotides	O
other	O
than	O
the	O
conserved	O
AG	O
and	O
GT	O
in	O
the	O
consensus	O
splice	O
sites	O
,	O
and	O
creation	O
of	O
splice	O
-	O
acceptor	O
or	O
splice	O
-	O
donor	O
sites	O
in	O
either	O
introns	O
or	O
exons	O
.	O

These	O
splicing	O
mutations	O
led	O
to	O
a	O
variety	O
of	O
consequences	O
,	O
including	O
exon	O
skipping	O
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
intron	O
retention	O
,	O
activation	O
of	O
cryptic	O
splice	O
sites	O
,	O
or	O
creation	O
of	O
new	O
splice	O
sites	O
.	O

In	O
addition	O
,	O
5	O
of	O
12	O
nonsense	O
mutations	O
and	O
1	O
missense	O
mutation	O
were	O
associated	O
with	O
deletion	O
in	O
the	O
cDNA	O
of	O
the	O
exons	O
in	O
which	O
the	O
mutations	O
occurred	O
.	O

No	O
ATM	O
protein	O
was	O
detected	O
by	O
western	O
blotting	O
in	O
any	O
AT	B
cell	O
line	O
in	O
which	O
splicing	O
mutations	O
were	O
identified	O
.	O

Several	O
cases	O
of	O
exon	O
skipping	O
in	O
both	O
normal	O
controls	O
and	O
patients	O
for	O
whom	O
no	O
underlying	O
defect	O
could	O
be	O
found	O
in	O
genomic	O
DNA	O
were	O
also	O
observed	O
,	O
suggesting	O
caution	O
in	O
the	O
interpretation	O
of	O
exon	O
deletions	O
observed	O
in	O
ATM	O
cDNA	O
when	O
there	O
is	O
no	O
accompanying	O
identification	O
of	O
genomic	O
mutations	O
.	O
.	O

Alpha	O
-	O
cardiac	O
actin	O
is	O
a	O
novel	O
disease	O
gene	O
in	O
familial	B
hypertrophic	I
cardiomyopathy	I
.	O

We	O
identified	O
the	O
alpha	O
-	O
cardiac	O
actin	O
gene	O
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B
hypertrophic	I
cardiomyopathy	I
(	O
FHC	B
)	O
.	O

Linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
FHC	B
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied	O
,	O
with	O
lod	O
scores	O
varying	O
between	O
-	O
2	O
.	O

5	O
and	O
-	O
6	O
.	O

0	O
0	O
.	O

Further	O
linkage	O
analyses	O
of	O
plausible	O
candidate	O
genes	O
highly	O
expressed	O
in	O
the	O
adult	O
human	O
heart	O
identified	O
ACTC	O
as	O
the	O
most	O
likely	O
disease	O
gene	O
,	O
showing	O
a	O
maximal	O
lod	O
score	O
of	O
3	O
.	O

6	O
6	O
.	O

Mutation	O
analysis	O
of	O
ACTC	O
revealed	O
an	O
Ala295Ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	B
dilated	I
cardiomyopathy	I
(	O
IDC	B
)	O
.	O

Overgrowth	B
of	I
oral	I
mucosa	I
and	I
facial	I
skin	I
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
lysosomal	B
storage	I
disorder	I
caused	O
by	O
deficiency	B
of	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

The	O
main	O
symptom	O
is	O
progressive	O
mental	B
retardation	I
.	O

A	O
spectrum	O
of	O
different	O
mutations	O
has	O
been	O
reported	O
in	O
this	O
disease	O
,	O
one	O
missense	O
mutation	O
(	O
Cys163Ser	O
)	O
being	O
responsible	O
for	O
the	O
majority	O
of	O
Finnish	O
cases	O
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	B
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O

Biopsy	O
specimens	O
of	O
16	O
oral	O
lesions	O
,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth	O
,	O
plus	O
two	O
facial	B
lesions	I
were	O
studied	O
histologically	O
.	O

Immunohistochemical	O
staining	O
for	O
AGA	O
was	O
performed	O
on	O
15	O
oral	O
specimens	O
.	O

Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B
of	I
the	I
facial	I
skin	I
already	O
common	O
in	O
childhood	O
.	O

Of	O
44	O
patients	O
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B
angiofibromas	I
,	O
tumours	B
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	B
sclerosis	I
.	O

Oedemic	B
buccal	I
mucosa	I
(	O
leucoedema	B
)	O
and	O
gingival	B
overgrowths	I
were	O
more	O
frequent	O
in	O
AGU	B
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Of	O
16	O
oral	B
mucosal	I
lesions	I
studied	O
histologically	O
,	O
15	O
represented	O
fibroepithelial	B
or	I
epithelial	I
hyperplasias	I
and	O
were	O
reactive	O
in	O
nature	O
.	O

Cytoplasmic	O
vacuolisation	O
was	O
evident	O
in	O
four	O
.	O

Immunohistochemically	O
,	O
expression	O
of	O
AGA	O
in	O
AGU	B
patients	O
mucosal	B
lesions	I
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O

Thus	O
,	O
the	O
high	O
frequency	O
of	O
mucosal	B
overgrowth	I
in	O
AGU	B
patients	O
does	O
not	O
appear	O
to	O
be	O
directly	O
associated	O
with	O
lysosomal	O
storage	O
or	O
with	O
alterations	O
in	O
the	O
level	O
of	O
AGA	O
expression	O
.	O

Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	B
syndrome	I
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene	O
.	O

The	O
oculocerebrorenal	B
syndrome	I
of	I
Lowe	I
(	O
OCRL	B
)	O
is	O
an	O
X	B
-	I
linked	I
disorder	I
characterized	O
by	O
major	O
abnormalities	B
of	I
eyes	I
,	I
nervous	I
system	I
,	I
and	I
kidneys	I
.	O

Mutations	O
in	O
the	O
OCRL1	O
gene	O
have	O
been	O
associated	O
with	O
the	O
disease	O
.	O

OCRL1	O
encodes	O
a	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
biphosphate	O
(	O
PtdIns	O
[	O
4	O
,	O
5	O
]	O
P2	O
)	O
5	O
-	O
phosphatase	O
.	O

We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	B
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in	O
-	O
frame	O
deletion	O
.	O

Among	O
the	O
new	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
(	O
R317X	O
and	O
E558X	O
)	O
and	O
three	O
other	O
frameshift	O
mutations	O
caused	O
premature	O
termination	O
of	O
the	O
protein	O
.	O

A	O
missense	O
mutation	O
,	O
R483G	O
,	O
was	O
located	O
in	O
the	O
highly	O
conserved	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
5	O
-	O
phosphatase	O
domain	O
.	O

Finally	O
,	O
one	O
frameshift	O
mutation	O
,	O
2799delC	O
,	O
modifies	O
the	O
C	O
-	O
terminal	O
part	O
of	O
OCRL1	O
,	O
with	O
an	O
extension	O
of	O
six	O
amino	O
acids	O
.	O

Altogether	O
,	O
70	O
%	O
of	O
missense	O
mutations	O
are	O
located	O
in	O
exon	O
15	O
,	O
and	O
52	O
%	O
of	O
all	O
mutations	O
cluster	O
in	O
exons	O
11	O
-	O
15	O
.	O

We	O
also	O
identified	O
two	O
new	O
microsatellite	O
markers	O
for	O
the	O
OCRL1	O
locus	O
,	O
and	O
we	O
detected	O
a	O
germline	O
mosaicism	O
in	O
one	O
family	O
.	O

This	O
observation	O
has	O
direct	O
implications	O
for	O
genetic	O
counseling	O
of	O
Lowe	B
syndrome	I
families	O
.	O
.	O

MEFV	O
-	O
Gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
Familial	B
Mediterranean	I
fever	I
:	O
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
M694V	O
homozygous	O
genotype	O
-	O
genetic	O
and	O
therapeutic	O
implications	O
.	O

Familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
is	O
a	O
recessively	B
inherited	I
disorder	I
that	O
is	O
common	O
in	O
patients	O
of	O
Armenian	O
ancestry	O
.	O

To	O
date	O
,	O
its	O
diagnosis	O
,	O
which	O
can	O
be	O
made	O
only	O
retrospectively	O
,	O
is	O
one	O
of	O
exclusion	O
,	O
based	O
entirely	O
on	O
nonspecific	O
clinical	O
signs	O
that	O
result	O
from	O
serosal	B
inflammation	I
and	O
that	O
may	O
lead	O
to	O
unnecessary	O
surgery	O
.	O

Renal	B
amyloidosis	I
,	O
prevented	O
by	O
colchicine	O
,	O
is	O
the	O
most	O
severe	O
complication	O
of	O
FMF	B
,	O
a	O
disorder	O
associated	O
with	O
mutations	O
in	O
the	O
MEFV	O
gene	O
.	O

To	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV	O
-	O
gene	O
analysis	O
,	O
we	O
investigated	O
90	O
Armenian	O
FMF	B
patients	O
from	O
77	O
unrelated	O
families	O
that	O
were	O
not	O
selected	O
through	O
genetic	O
-	O
linkage	O
analysis	O
.	O

Eight	O
mutations	O
,	O
one	O
of	O
which	O
(	O
R408Q	O
)	O
is	O
new	O
,	O
were	O
found	O
to	O
account	O
for	O
93	O
%	O
of	O
the	O
163	O
independent	O
FMF	B
alleles	O
,	O
with	O
both	O
FMF	B
alleles	O
identified	O
in	O
89	O
%	O
of	O
the	O
patients	O
.	O

In	O
several	O
instances	O
,	O
family	O
studies	O
provided	O
molecular	O
evidence	O
for	O
pseudodominant	O
transmission	O
and	O
incomplete	O
penetrance	O
of	O
the	O
disease	O
phenotype	O
.	O

The	O
M694V	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	B
amyloidosis	I
and	O
arthritis	B
,	O
compared	O
with	O
other	O
genotypes	O
(	O
P	O
=	O
.	O
0002	O
and	O
P	O
=	O
.	O
006	O
,	O
respectively	O
)	O
.	O

The	O
demonstration	O
of	O
both	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV	O
analysis	O
and	O
particular	O
modes	O
of	O
inheritance	O
should	O
lead	O
to	O
new	O
ways	O
for	O
management	O
of	O
FMF	O
-	O
including	O
genetic	O
counseling	O
and	O
therapeutic	O
decisions	O
in	O
affected	O
families	O
.	O

Noninvasive	O
test	O
for	O
fragile	B
X	I
syndrome	I
,	O
using	O
hair	O
root	O
analysis	O
.	O

Identification	O
of	O
the	O
FMR1	O
gene	O
and	O
the	O
repeat	O
-	O
amplification	O
mechanism	O
causing	O
fragile	B
X	I
syndrome	I
led	O
to	O
development	O
of	O
reliable	O
DNA	O
-	O
based	O
diagnostic	O
methods	O
,	O
including	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
.	O

Both	O
methods	O
are	O
performed	O
on	O
DNA	O
isolated	O
from	O
peripheral	O
blood	O
cells	O
and	O
measure	O
the	O
repeat	O
size	O
in	O
FMR1	O
.	O

Using	O
an	O
immunocytochemical	O
technique	O
on	O
blood	O
smears	O
,	O
we	O
recently	O
developed	O
a	O
novel	O
test	O
for	O
identification	O
of	O
patients	O
with	O
fragile	B
X	I
syndrome	I
.	O

This	O
method	O
,	O
also	O
called	O
"	O
antibody	O
test	O
,	O
"	O
uses	O
monoclonal	O
antibodies	O
against	O
the	O
FMR1	O
gene	O
product	O
(	O
FMRP	O
)	O
and	O
is	O
based	O
on	O
absence	O
of	O
FMRP	O
in	O
patients	O
cells	O
.	O

Here	O
we	O
describe	O
a	O
new	O
diagnostic	O
test	O
to	O
identify	O
male	O
patients	O
with	O
fragile	B
X	I
syndrome	I
,	O
on	O
the	O
basis	O
of	O
lack	O
of	O
FMRP	O
in	O
their	O
hair	O
roots	O
.	O

Expression	O
of	O
FMRP	O
in	O
hair	O
roots	O
was	O
studied	O
by	O
use	O
of	O
an	O
FMRP	O
-	O
specific	O
antibody	O
test	O
,	O
and	O
the	O
percentage	O
of	O
FMRP	O
-	O
expressing	O
hair	O
roots	O
in	O
controls	O
and	O
in	O
male	O
fragile	B
X	I
patients	O
was	O
determined	O
.	O

Control	O
individuals	O
showed	O
clear	O
expression	O
of	O
FMRP	O
in	O
nearly	O
every	O
hair	O
root	O
,	O
whereas	O
male	O
fragile	B
X	I
patients	O
lacked	O
expression	O
of	O
FMRP	O
in	O
almost	O
all	O
their	O
hair	O
roots	O
.	O

Mentally	B
retarded	I
female	O
patients	O
with	O
a	O
full	O
mutation	O
showed	O
FMRP	O
expression	O
in	O
only	O
some	O
of	O
their	O
hair	O
roots	O
(	O
<	O
55	O
%	O
)	O
,	O
and	O
no	O
overlap	O
with	O
normal	O
female	O
controls	O
was	O
observed	O
.	O

The	O
advantages	O
of	O
this	O
test	O
are	O
(	O
1	O
)	O
plucking	O
of	O
hair	O
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	B
retarded	I
patient	O
,	O
(	O
2	O
)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	O
center	O
,	O
and	O
(	O
3	O
)	O
the	O
result	O
of	O
the	O
test	O
is	O
available	O
within	O
5	O
h	O
of	O
plucking	O
.	O

In	O
addition	O
,	O
this	O
test	O
enabled	O
us	O
to	O
identify	O
two	O
fragile	B
X	I
patients	O
who	O
did	O
not	O
show	O
the	O
full	O
mutation	O
by	O
analysis	O
of	O
DNA	O
isolated	O
from	O
blood	O
cells	O
.	O
.	O

In	O
Swedish	O
families	O
with	O
hereditary	B
prostate	I
cancer	I
,	O
linkage	O
to	O
the	O
HPC1	O
locus	O
on	O
chromosome	O
1q24	O
-	O
25	O
is	O
restricted	O
to	O
families	O
with	O
early	O
-	O
onset	O
prostate	B
cancer	I
.	O

Prostate	B
cancer	I
clusters	O
in	O
some	O
families	O
,	O
and	O
an	O
estimated	O
5	O
%	O
-	O
10	O
%	O
of	O
all	O
cases	O
are	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
prostate	O
cancer	O
-	O
susceptibility	O
genes	O
.	O

We	O
previously	O
reported	O
evidence	O
of	O
linkage	O
to	O
the	O
1q24	O
-	O
25	O
region	O
(	O
HPC1	O
)	O
in	O
91	O
North	O
American	O
and	O
Swedish	O
families	O
each	O
with	O
multiple	O
cases	O
of	O
prostate	B
cancer	I
(	O
Smith	O
et	O
al	O
.	O
1996	O
)	O
.	O

In	O
the	O
present	O
report	O
we	O
analyze	O
40	O
(	O
12	O
original	O
and	O
28	O
newly	O
identified	O
)	O
Swedish	O
families	O
with	O
hereditary	B
prostate	I
cancer	I
(	O
HPC	B
)	O
that	O
,	O
on	O
the	O
basis	O
of	O
40	O
markers	O
spanning	O
a	O
25	O
-	O
cM	O
interval	O
within	O
1q24	O
-	O
25	O
,	O
have	O
evidence	O
of	O
linkage	O
.	O

In	O
the	O
complete	O
set	O
of	O
families	O
,	O
a	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
of	O
1	O
.	O

10	O
was	O
observed	O
at	O
D1S413	O
(	O
at	O
a	O
recombination	O
fraction	O
[	O
theta	O
]	O
of	O
.	O
1	O
)	O
,	O
with	O
a	O
maximum	O
NPL	O
(	O
nonparametric	O
linkage	O
)	O
Z	O
score	O
of	O
1	O
.	O

64	O
at	O
D1S202	O
(	O
P	O
=	O
.	O
05	O
)	O
.	O

The	O
evidence	O
of	O
linkage	O
to	O
this	O
region	O
originated	O
almost	O
exclusively	O
from	O
the	O
subset	O
of	O
12	O
early	O
-	O
onset	O
(	O
age	O
<	O
65	O
years	O
)	O
families	O
,	O
which	O
yielded	O
a	O
maximum	O
LOD	O
score	O
of	O
2	O
.	O

38	O
at	O
D1S413	O
(	O
straight	O
theta	O
=	O
0	O
)	O
and	O
an	O
NPL	O
Z	O
score	O
of	O
1	O
.	O

95	O
at	O
D1S422	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

Estimates	O
from	O
heterogeneity	O
tests	O
suggest	O
that	O
,	O
within	O
Sweden	O
,	O
as	O
many	O
as	O
50	O
%	O
of	O
early	O
-	O
onset	O
families	O
had	O
evidence	O
of	O
linkage	O
to	O
the	O
HPC1	O
region	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
of	O
linkage	O
to	O
HPC1	O
in	O
a	O
subset	O
of	O
families	O
with	O
prostate	B
cancer	I
,	O
particularly	O
those	O
with	O
an	O
early	O
age	O
at	O
diagnosis	O
.	O

Molecular	O
basis	O
of	O
feline	O
beta	B
-	I
glucuronidase	I
deficiency	I
:	O
an	O
animal	O
model	O
of	O
mucopolysaccharidosis	B
VII	I
.	O

A	O
family	O
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	O
and	O
biochemical	O
abnormalities	O
consistent	O
with	O
mucopolysaccharidosis	B
VII	I
,	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
beta	B
-	I
glucuronidase	I
deficiency	I
.	O

beta	O
-	O
Glucuronidase	O
activity	O
was	O
undetectable	O
in	O
affected	O
cat	O
fibroblasts	O
and	O
restored	O
by	O
retroviral	O
gene	O
transfer	O
of	O
rat	O
beta	O
-	O
glucuronidase	O
cDNA	O
.	O

beta	O
-	O
Glucuronidase	O
mRNA	O
was	O
normal	O
in	O
affected	O
cat	O
testis	O
by	O
Northern	O
blot	O
analysis	O
.	O

Normal	O
feline	O
beta	O
-	O
glucuronidase	O
cDNA	O
was	O
cloned	O
and	O
characterized	O
,	O
and	O
amplified	O
from	O
affected	O
cat	O
fibroblasts	O
by	O
reverse	O
transcription	O
coupled	O
polymerase	O
chain	O
reaction	O
.	O

There	O
was	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
the	O
affected	O
cat	O
cDNA	O
that	O
predicted	O
an	O
E351K	O
substitution	O
,	O
destroyed	O
a	O
BssSI	O
site	O
,	O
and	O
eliminated	O
GUSB	O
enzymatic	O
activity	O
in	O
expression	O
studies	O
.	O

Multiple	O
species	O
comparison	O
and	O
the	O
crystal	O
structure	O
of	O
human	O
beta	O
-	O
glucuronidase	O
indicated	O
that	O
E351	O
is	O
a	O
highly	O
conserved	O
residue	O
most	O
likely	O
essential	O
in	O
maintenance	O
of	O
the	O
enzymes	O
conformation	O
.	O

BssSI	O
digestion	O
of	O
polymerase	O
chain	O
reaction	O
products	O
amplified	O
from	O
genomic	O
DNA	O
indicated	O
that	O
affected	O
cats	O
were	O
homozygous	O
and	O
cats	O
with	O
half	O
-	O
normal	O
beta	O
-	O
glucuronidase	O
activity	O
were	O
heterozygous	O
for	O
the	O
missense	O
mutation	O
.	O

Carriers	O
identified	O
in	O
this	O
manner	O
produced	O
affected	O
kittens	O
in	O
prospective	O
breedings	O
,	O
and	O
a	O
feline	O
MPS	B
VII	I
breeding	O
colony	O
has	O
been	O
established	O
.	O
.	O

A	O
common	O
molecular	O
basis	O
for	O
rearrangement	B
disorders	I
on	O
chromosome	O
22q11	O
.	O

The	O
chromosome	O
22q11	O
region	O
is	O
susceptible	O
to	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B
anomaly	I
disorders	I
and	O
malignant	B
tumors	I
.	O

Three	O
congenital	B
anomaly	I
disorders	I
,	O
cat	B
-	I
eye	I
syndrome	I
,	O
der	B
(	I
)	I
syndrome	I
and	O
velo	B
-	I
cardio	I
-	I
facial	I
syndrome	I
/	O
DiGeorge	B
syndrome	I
(	O
VCFS	B
/	O
DGS	B
)	O
are	O
associated	O
with	O
tetrasomy	O
,	O
trisomy	O
or	O
monosomy	O
,	O
respectively	O
,	O
for	O
part	O
of	O
chromosome	O
22q11	O
.	O

VCFS	B
/	O
DGS	B
is	O
the	O
most	O
common	O
syndrome	O
associated	O
with	O
22q11	O
rearrangements	O
.	O

In	O
order	O
to	O
determine	O
whether	O
there	O
are	O
particular	O
regions	O
on	O
22q11	O
that	O
are	O
prone	O
to	O
rearrangements	O
,	O
the	O
deletion	O
end	O
-	O
points	O
in	O
a	O
large	O
number	O
of	O
VCFS	B
/	O
DGS	B
patients	O
were	O
defined	O
by	O
haplotype	O
analysis	O
.	O

Most	O
VCFS	B
/	O
DGS	B
patients	O
have	O
a	O
similar	O
3	O
Mb	O
deletion	O
,	O
some	O
have	O
a	O
nested	O
distal	O
deletion	O
breakpoint	O
resulting	O
in	O
a	O
1	O
.	O

5	O
Mb	O
deletion	O
and	O
a	O
few	O
rare	O
patients	O
have	O
unique	O
deletions	O
or	O
translocations	O
.	O

The	O
high	O
prevalence	O
of	O
the	O
disorder	O
in	O
the	O
population	O
and	O
the	O
fact	O
that	O
most	O
cases	O
occur	O
sporadically	O
suggest	O
that	O
sequences	O
at	O
or	O
near	O
the	O
breakpoints	O
confer	O
susceptibility	O
to	O
chromosome	O
rearrangements	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
developed	O
hamster	O
-	O
human	O
somatic	O
hybrid	O
cell	O
lines	O
from	O
VCFS	B
/	O
DGS	B
patients	O
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	O
within	O
similar	O
low	O
copy	O
repeats	O
,	O
termed	O
LCR22s	O
.	O

To	O
support	O
this	O
idea	O
further	O
,	O
we	O
identified	O
a	O
family	O
that	O
carries	O
an	O
interstitial	O
duplication	O
of	O
the	O
same	O
3	O
Mb	O
region	O
that	O
is	O
deleted	O
in	O
VCFS	B
/	O
DGS	B
patients	O
.	O

We	O
present	O
models	O
to	O
explain	O
how	O
the	O
LCR22s	O
can	O
mediate	O
different	O
homologous	O
recombination	O
events	O
,	O
thereby	O
generating	O
a	O
number	O
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B
anomaly	I
disorders	I
.	O

We	O
identified	O
five	O
additional	O
copies	O
of	O
the	O
LCR22	O
on	O
22q11	O
that	O
may	O
mediate	O
other	O
rearrangements	O
leading	O
to	O
disease	O
.	O

Functional	O
consequences	O
of	O
mutations	O
in	O
the	O
early	O
growth	O
response	O
2	O
gene	O
(	O
EGR2	O
)	O
correlate	O
with	O
severity	O
of	O
human	O
myelinopathies	B
.	O

The	O
early	O
growth	O
response	O
2	O
gene	O
(	O
EGR2	O
)	O
is	O
a	O
Cys2His2zinc	O
finger	O
transcription	O
factor	O
which	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
peripheral	O
nervous	O
system	O
myelination	O
.	O

This	O
idea	O
is	O
based	O
partly	O
on	O
the	O
phenotype	O
of	O
homozygous	O
Krox20	O
(	O
Egr2	O
)	O
knockout	O
mice	O
,	O
which	O
display	O
hypomyelination	B
of	I
the	I
PNS	I
and	O
a	O
block	O
of	O
Schwann	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

Mutations	O
in	O
the	O
human	O
EGR2	O
gene	O
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	B
peripheral	I
neuropathies	I
Charcot	B
-	I
Marie	I
-	I
Tooth	I
type	I
1	I
,	O
Dejerine	B
-	I
Sottas	I
syndrome	I
and	O
congenital	B
hypomyelinating	I
neuropathy	I
.	O

Three	O
of	O
the	O
four	O
EGR2	O
mutations	O
are	O
dominant	O
and	O
occur	O
within	O
the	O
zinc	O
finger	O
DNA	O
-	O
binding	O
domain	O
.	O

The	O
fourth	O
mutation	O
is	O
recessive	O
and	O
affects	O
the	O
inhibitory	O
domain	O
(	O
R1	O
)	O
that	O
binds	O
the	O
NAB	O
transcriptional	O
co	O
-	O
repressors	O
.	O

A	O
combination	O
of	O
DNA	O
-	O
binding	O
assays	O
and	O
transcriptional	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
functional	O
consequences	O
of	O
these	O
mutations	O
.	O

The	O
zinc	O
finger	O
mutations	O
affect	O
DNA	O
binding	O
and	O
the	O
amount	O
of	O
residual	O
binding	O
directly	O
correlates	O
with	O
disease	O
severity	O
.	O

The	O
R1	O
domain	O
mutation	O
prevents	O
interaction	O
of	O
EGR2	O
with	O
the	O
NAB	O
co	O
-	O
repressors	O
and	O
thereby	O
increases	O
transcriptional	O
activity	O
.	O

These	O
data	O
provide	O
insight	O
into	O
the	O
possible	O
disease	O
mechanisms	O
underlying	O
EGR2	O
mutations	O
and	O
the	O
reason	O
for	O
varying	O
severity	O
and	O
differences	O
in	O
inheritance	O
patterns	O
.	O
.	O

Autosomal	B
recessive	I
familial	I
neurohypophyseal	I
diabetes	I
insipidus	I
with	O
continued	O
secretion	O
of	O
mutant	O
weakly	O
active	O
vasopressin	O
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
is	O
an	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
post	O
-	O
natal	O
development	O
of	O
arginine	B
vasopressin	I
(	I
AVP	I
)	I
deficiency	I
due	O
to	O
mutations	O
in	O
the	O
AVP	O
gene	O
.	O

All	O
published	O
mutations	O
affect	O
the	O
signal	O
peptide	O
or	O
the	O
neurophysin	O
-	O
II	O
carrier	O
protein	O
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone	O
,	O
leading	O
to	O
neuronal	B
damage	I
.	O

We	O
studied	O
an	O
unusual	O
Palestinian	O
family	O
consisting	O
of	O
asymptomatic	O
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	O
with	O
neurohypophyseal	B
diabetes	I
insipidus	I
,	O
suggesting	O
autosomal	O
recessive	O
inheritance	O
.	O

All	O
three	O
affected	O
children	O
were	O
homozygous	O
and	O
the	O
parents	O
heterozygous	O
for	O
a	O
single	O
novel	O
mutation	O
(	O
C301	O
-	O
>	O
T	O
)	O
in	O
exon	O
1	O
,	O
replacing	O
Pro7	O
of	O
mature	O
AVP	O
with	O
Leu	O
(	O
Leu	O
-	O
AVP	O
)	O
.	O

Leu	O
-	O
AVP	O
was	O
a	O
weak	O
agonist	O
with	O
approximately	O
30	O
-	O
fold	O
reduced	O
binding	O
to	O
the	O
human	O
V2	O
receptor	O
.	O

Measured	O
by	O
radioimmunoassay	O
with	O
a	O
synthetic	O
Leu	O
-	O
AVP	O
standard	O
,	O
serum	O
Leu	O
-	O
AVP	O
levels	O
were	O
elevated	O
in	O
all	O
three	O
children	O
and	O
further	O
increased	O
during	O
water	O
deprivation	O
to	O
as	O
high	O
as	O
30	O
times	O
normal	O
.	O

The	O
youngest	O
child	O
(	O
2	O
years	O
old	O
)	O
was	O
only	O
mildly	O
affected	O
but	O
had	O
Leu	O
-	O
AVP	O
levels	O
similar	O
to	O
her	O
severely	O
affected	O
8	O
-	O
year	O
-	O
old	O
brother	O
,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	B
of	I
active	I
AVP	I
in	O
very	O
young	O
children	O
.	O
.	O

X	O
inactivation	O
and	O
somatic	O
cell	O
selection	O
rescue	O
female	O
mice	O
carrying	O
a	O
Piga	O
-	O
null	O
mutation	O
.	O

A	O
somatic	O
mutation	O
in	O
the	O
X	O
linked	O
PIGA	O
gene	O
is	O
responsible	O
for	O
the	O
deficiency	B
of	I
glycosyl	I
phosphatidylinositol	I
(	I
GPI	I
)	I
-	I
anchored	I
proteins	I
on	O
blood	O
cells	O
from	O
patients	O
with	O
paroxysmal	B
nocturnal	I
hemoglobinuria	I
.	O

No	O
inherited	O
form	O
of	O
GPI	B
-	I
anchor	I
deficiency	I
has	O
been	O
described	O
.	O

Because	O
conventional	O
Piga	O
gene	O
knockout	O
is	O
associated	O
with	O
high	O
embryonic	B
lethality	I
in	O
chimeric	O
mice	O
,	O
we	O
used	O
the	O
Cre	O
/	O
loxP	O
system	O
.	O

We	O
generated	O
mice	O
in	O
which	O
two	O
loxP	O
sites	O
flank	O
part	O
of	O
Piga	O
exon	O
2	O
.	O

After	O
crossbreeding	O
with	O
female	O
mice	O
of	O
the	O
EIIa	O
-	O
cre	O
strain	O
,	O
the	O
floxed	O
allele	O
undergoes	O
Cre	O
-	O
mediated	O
recombination	O
with	O
high	O
efficiency	O
during	O
early	O
embryonic	O
development	O
.	O

Because	O
of	O
X	O
chromosome	O
inactivation	O
,	O
female	O
offspring	O
are	O
mosaic	O
for	O
cells	O
that	O
express	O
or	O
lack	O
GPI	O
-	O
linked	O
proteins	O
.	O

Analysis	O
of	O
mosaic	O
mice	O
showed	O
that	O
in	O
heart	O
,	O
lung	O
,	O
kidney	O
,	O
brain	O
,	O
and	O
liver	O
,	O
mainly	O
wild	O
-	O
type	O
Piga	O
is	O
active	O
,	O
suggesting	O
that	O
these	O
tissues	O
require	O
GPI	O
-	O
linked	O
proteins	O
.	O

The	O
salient	O
exceptions	O
were	O
spleen	O
,	O
thymus	O
,	O
and	O
red	O
blood	O
cells	O
,	O
which	O
had	O
almost	O
equal	O
numbers	O
of	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
or	O
the	O
recombined	O
allele	O
,	O
implying	O
that	O
GPI	O
-	O
linked	O
proteins	O
are	O
not	O
essential	O
for	O
the	O
derivation	O
of	O
these	O
tissues	O
.	O

PIGA	O
(	O
-	O
)	O
cells	O
had	O
no	O
growth	O
advantage	O
,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	O
with	O
paroxysmal	B
nocturnal	I
hemoglobinuria	I
.	O
.	O

The	O
C282Y	O
mutation	O
causing	O
hereditary	B
hemochromatosis	I
does	O
not	O
produce	O
a	O
null	O
allele	O
.	O

Targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	B
gene	O
(	O
Hfe	O
)	O
locus	O
.	O

The	O
first	O
mutation	O
deletes	O
a	O
large	O
portion	O
of	O
the	O
coding	O
sequence	O
,	O
generating	O
a	O
null	O
allele	O
.	O

The	O
second	O
mutation	O
introduces	O
a	O
missense	O
mutation	O
(	O
C282Y	O
)	O
into	O
the	O
Hfe	O
locus	O
,	O
but	O
otherwise	O
leaves	O
the	O
gene	O
intact	O
.	O

This	O
mutation	O
is	O
identical	O
to	O
the	O
disease	O
-	O
causing	O
mutation	O
in	O
patients	O
with	O
hereditary	B
hemochromatosis	I
.	O

Mice	O
carrying	O
each	O
of	O
the	O
two	O
mutations	O
were	O
bred	O
and	O
analyzed	O
.	O

Homozygosity	O
for	O
either	O
mutation	O
results	O
in	O
postnatal	O
iron	O
loading	O
.	O

The	O
effects	O
of	O
the	O
null	O
mutation	O
are	O
more	O
severe	O
than	O
the	O
effects	O
of	O
the	O
C282Y	O
mutation	O
.	O

Mice	O
heterozygous	O
for	O
either	O
mutation	O
accumulate	O
more	O
iron	O
than	O
normal	O
controls	O
.	O

Interestingly	O
,	O
although	O
liver	O
iron	O
stores	O
are	O
greatly	O
increased	O
,	O
splenic	O
iron	O
is	O
decreased	O
.	O

We	O
conclude	O
that	O
the	O
C282Y	O
mutation	O
does	O
not	O
result	O
in	O
a	O
null	O
allele	O
.	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
in	O
X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
and	O
identification	O
of	O
a	O
missense	O
mutation	O
associated	O
with	O
a	O
milder	O
phenotype	O
.	O

Direct	O
sequencing	O
of	O
the	O
emerin	O
gene	O
in	O
22	O
families	O
with	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EMD	B
)	O
revealed	O
mutations	O
in	O
21	O
(	O
95	O
%	O
)	O
,	O
confirming	O
that	O
emerin	O
mutations	O
can	O
be	O
identified	O
in	O
the	O
majority	O
of	O
families	O
with	O
X	B
-	I
linked	I
EMD	I
.	O

Most	O
emerin	O
mutations	O
result	O
in	O
absence	O
of	O
the	O
protein	O
.	O

In	O
this	O
study	O
three	O
mutations	O
(	O
a	O
missense	O
mutation	O
Pro183Thr	O
and	O
two	O
in	O
-	O
frame	O
deletions	O
removing	O
residues	O
95	O
-	O
99	O
and	O
236	O
-	O
241	O
,	O
respectively	O
)	O
were	O
unusual	O
in	O
being	O
associated	O
with	O
expression	O
of	O
mutant	O
protein	O
.	O

The	O
phenotype	O
in	O
these	O
families	O
was	O
compared	O
in	O
detail	O
with	O
the	O
clinical	O
features	O
in	O
cases	O
with	O
typical	O
null	O
mutations	O
.	O

For	O
the	O
in	O
-	O
frame	O
deletions	O
there	O
were	O
no	O
significant	O
differences	O
.	O

In	O
the	O
family	O
with	O
the	O
missense	O
mutation	O
the	O
phenotype	O
was	O
milder	O
.	O

Age	O
at	O
onset	O
was	O
later	O
for	O
first	O
symptoms	O
and	O
for	O
development	O
of	O
ankle	B
contractures	I
and	O
muscle	B
weakness	I
.	O

These	O
findings	O
have	O
diagnostic	O
implications	O
as	O
well	O
as	O
pointing	O
to	O
functionally	O
important	O
regions	O
of	O
the	O
emerin	O
protein	O
.	O
.	O

Severe	O
clinical	O
expression	O
in	O
X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
is	O
a	O
relatively	O
rare	O
benign	B
neuromuscular	I
disorder	I
which	O
can	O
vary	O
remarkably	O
in	O
onset	O
,	O
course	O
and	O
severity	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
TCTAC	O
deletion	O
spanning	O
the	O
nucleotides	O
631	O
-	O
635	O
of	O
the	O
emerin	O
gene	O
caused	O
an	O
unusually	O
severe	O
disease	O
phenotype	O
including	O
loss	B
of	I
ambulation	I
and	O
severe	O
muscle	B
wasting	I
in	O
two	O
affected	O
brothers	O
.	O

The	O
same	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
an	O
unrelated	O
family	O
showing	O
a	O
significantly	O
milder	O
phenotype	O
.	O

The	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O
.	O

Common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
do	O
not	O
contribute	O
to	O
early	O
prostate	B
cancer	I
in	O
Jewish	O
men	O
.	O

BACKGROUND	O
Families	O
with	O
a	O
high	O
incidence	O
of	O
hereditary	B
breast	I
cancer	I
,	O
and	O
subsequently	O
shown	O
to	O
have	O
terminating	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
,	O
appear	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
prostate	B
cancer	I
among	O
male	O
relatives	O
.	O

We	O
aimed	O
to	O
determine	O
whether	O
the	O
common	O
germline	O
mutations	O
of	O
BRCA1	O
or	O
BRCA2	O
in	O
Ashkenazi	O
Jewish	O
men	O
predisposed	O
them	O
to	O
prostate	B
cancer	I
.	O

METHODS	O
We	O
examined	O
genomic	O
DNA	O
from	O
83	O
(	O
for	O
BRCA1	O
185delAG	O
)	O
or	O
82	O
(	O
for	O
BRCA2	O
6174delT	O
)	O
Ashkenazi	O
Jewish	O
prostate	B
cancer	I
patients	O
,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	O
age	O
,	O
for	O
the	O
most	O
common	O
germline	O
mutation	O
in	O
each	O
gene	O
seen	O
in	O
the	O
Ashkenazi	O
population	O
.	O

RESULTS	O
Our	O
study	O
should	O
have	O
been	O
able	O
to	O
detect	O
a	O
4	O
-	O
5	O
-	O
fold	O
increase	O
in	O
the	O
risk	O
of	O
prostate	B
cancer	I
due	O
to	O
mutation	O
of	O
BRCA1	O
or	O
BRCA2	O
.	O

However	O
,	O
only	O
one	O
(	O
1	O
.	O
15	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
-	O
3	O
.	O
6	O
%	O
)	O
of	O
the	O
patients	O
was	O
heterozygous	O
for	O
the	O
BRCA1	O
mutant	O
allele	O
,	O
and	O
only	O
two	O
were	O
heterozygous	O
for	O
the	O
BRCA2	O
mutation	O
(	O
2	O
.	O
4	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
-	O
6	O
.	O
2	O
%	O
)	O
.	O

CONCLUSIONS	O
The	O
incidence	O
of	O
each	O
of	O
the	O
germline	O
mutations	O
in	O
these	O
prostate	B
cancer	I
patients	O
closely	O
matched	O
their	O
incidence	O
(	O
about	O
1	O
%	O
)	O
in	O
the	O
general	O
Ashkenazi	O
Jewish	O
population	O
.	O

This	O
suggests	O
that	O
unlike	O
cases	O
of	O
breast	B
and	I
ovarian	I
cancers	I
,	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
do	O
not	O
significantly	O
predispose	O
men	O
to	O
prostate	B
cancer	I

Beta	O
-	O
catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B
.	O

Hepatoblastoma	B
is	O
a	O
rare	O
malignant	B
tumor	I
of	I
the	I
liver	I
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O

Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B
type	O
in	O
families	O
affected	O
by	O
adenomatous	B
polyposis	I
coli	I
.	O

In	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	B
tumor	I
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	B
tumorigenesis	O
.	O

A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta	O
-	O
catenin	O
,	O
a	O
transcription	O
-	O
activating	O
protein	O
with	O
oncogenic	O
potential	O
.	O

In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta	O
-	O
catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B
types	O
that	O
are	O
associated	O
with	O
adenomatous	B
polyposis	I
coli	I
,	O
we	O
observed	O
increased	O
beta	O
-	O
catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B
.	O

Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
(	O
CTNNB1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	B
samples	O
.	O

Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta	O
-	O
catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	B
type	O
.	O

Genes	O
Chromosomes	O
Cancer	O
25	O
399	O
-	O
402	O
,	O
1999	O
.	O
.	O

Decrease	O
in	O
GTP	O
cyclohydrolase	O
I	O
gene	O
expression	O
caused	O
by	O
inactivation	O
of	O
one	O
allele	O
in	O
hereditary	B
progressive	I
dystonia	I
with	O
marked	O
diurnal	O
fluctuation	O
.	O

Hereditary	B
progressive	I
dystonia	I
with	O
marked	O
diurnal	O
fluctuation	O
(	O
HPD	B
;	O
dopa	B
-	I
responsive	I
dystonia	I
,	O
DRD	B
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	O
by	O
a	O
genetic	B
defect	I
in	O
the	O
GTP	O
cyclohydrolase	O
I	O
(	O
GCH1	O
)	O
gene	O
.	O

In	O
this	O
study	O
,	O
we	O
quantified	O
the	O
mRNA	O
level	O
of	O
GCH1	O
in	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-	O
stimulated	O
mononuclear	O
blood	O
cells	O
from	O
one	O
Japanese	O
family	O
that	O
do	O
not	O
have	O
a	O
mutation	O
in	O
the	O
coding	O
region	O
or	O
splice	O
junctions	O
of	O
the	O
gene	O
.	O

The	O
results	O
showed	O
that	O
the	O
amounts	O
of	O
the	O
GCH1	O
mRNA	O
were	O
decreased	O
to	O
about	O
40	O
%	O
of	O
the	O
normal	O
level	O
in	O
both	O
patients	O
and	O
carriers	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
GCH1	O
mRNA	O
was	O
transcribed	O
from	O
only	O
one	O
allele	O
,	O
indicating	O
that	O
the	O
other	O
allele	O
was	O
in	O
an	O
inactive	O
state	O
.	O

These	O
results	O
suggest	O
that	O
some	O
novel	O
mutations	O
should	O
exist	O
on	O
one	O
of	O
the	O
alleles	O
in	O
some	O
unknown	O
region	O
of	O
the	O
GCH1	O
gene	O
,	O
and	O
may	O
decrease	O
the	O
GCH1	O
mRNA	O
causing	O
the	O
HPD	B
/	O
DRD	B
symptoms	O
.	O
.	O

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B
syndrome	I
thyrocytes	O
.	O

Pendred	B
syndrome	I
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B
deafness	I
,	O
characterized	O
by	O
dyshormonogenic	B
goiter	I
associated	O
with	O
sensory	B
-	I
neural	I
deafness	I
.	O

The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	B
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B
goiter	I
and	O
sensory	B
-	I
neural	I
deafness	I
remains	O
an	O
enigma	O
.	O

PDS	O
codes	O
for	O
a	O
novel	O
protein	O
,	O
pendrin	O
,	O
which	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
sufate	O
transporters	O
.	O

Mechanisms	O
by	O
which	O
abnormal	O
sulfate	O
transport	O
could	O
deleteriously	O
affect	O
iodide	O
organification	O
have	O
been	O
proposed	O
.	O

We	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
Pendred	B
syndrome	I
patients	O
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O

This	O
suggests	O
that	O
pendrin	O
in	O
fact	O
may	O
not	O
be	O
a	O
sulfate	O
transporter	O
,	O
and	O
emphasizes	O
the	O
importance	O
of	O
functional	O
studies	O
on	O
this	O
novel	O
protein	O
.	O
.	O

Small	O
deletions	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produce	O
kniest	B
dysplasia	I
.	O

Kniest	B
dysplasia	I
is	O
a	O
moderately	O
severe	O
type	B
II	I
collagenopathy	I
,	O
characterized	O
by	O
short	O
trunk	O
and	O
limbs	O
,	O
kyphoscoliosis	B
,	O
midface	B
hypoplasia	I
,	O
severe	O
myopia	B
,	O
and	O
hearing	B
loss	I
.	O

Mutations	O
in	O
the	O
gene	O
that	O
encodes	O
type	O
II	O
collagen	O
(	O
COL2A1	O
)	O
,	O
the	O
predominant	O
protein	O
of	O
cartilage	O
,	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
individuals	O
with	O
Kniest	B
dysplasia	I
.	O

All	O
but	O
two	O
of	O
these	O
previously	O
described	O
mutations	O
cause	O
in	O
-	O
frame	O
deletions	O
in	O
type	O
II	O
collagen	O
,	O
either	O
by	O
small	O
deletions	O
in	O
the	O
gene	O
or	O
splice	O
site	O
alterations	O
.	O

Furthermore	O
,	O
all	O
but	O
one	O
of	O
these	O
mutations	O
is	O
located	O
between	O
exons	O
12	O
and	O
24	O
in	O
the	O
COL2A1	O
gene	O
.	O

We	O
used	O
heteroduplex	O
analysis	O
to	O
identify	O
sequence	O
anomalies	O
in	O
five	O
individuals	O
with	O
Kniest	B
dysplasia	I
.	O

Sequencing	O
of	O
the	O
index	O
patients	O
genomic	O
DNA	O
identified	O
four	O
new	O
dominant	O
mutations	O
in	O
COL2A1	O
that	O
result	O
in	O
Kniest	B
dysplasia	I
a	O
21	O
-	O
bp	O
deletion	O
in	O
exon	O
16	O
,	O
an	O
18	O
-	O
bp	O
deletion	O
in	O
exon	O
19	O
,	O
and	O
4	O
-	O
bp	O
deletions	O
in	O
the	O
splice	O
donor	O
sites	O
of	O
introns	O
14	O
and	O
20	O
.	O

A	O
previously	O
described	O
28	O
-	O
bp	O
deletion	O
at	O
the	O
COL2A1	O
exon	O
12	O
-	O
intron	O
12	O
junction	O
,	O
deleting	O
the	O
splice	O
donor	O
site	O
,	O
was	O
identified	O
in	O
the	O
fifth	O
case	O
.	O

The	O
latter	O
three	O
mutations	O
are	O
predicted	O
to	O
result	O
in	O
exon	O
skipping	O
in	O
the	O
mRNA	O
encoded	O
from	O
the	O
mutant	O
allele	O
.	O

These	O
data	O
suggest	O
that	O
Kniest	B
dysplasia	I
results	O
from	O
shorter	O
type	O
II	O
collagen	O
monomers	O
,	O
and	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
specific	O
COL2A1	O
domain	O
,	O
which	O
may	O
span	O
from	O
exons	O
12	O
to	O
24	O
,	O
leads	O
to	O
the	O
Kniest	B
dysplasia	I
phenotype	O
.	O
.	O

Classical	B
galactosemia	I
and	O
mutations	O
at	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
gene	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
by	O
a	O
deficiency	O
in	O
activity	O
of	O
the	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
caused	O
by	O
mutations	O
at	O
the	O
GALT	O
gene	O
.	O

The	O
disorder	O
exhibits	O
considerable	O
allelic	O
heterogeneity	O
and	O
,	O
at	O
the	O
end	O
of	O
1998	O
,	O
more	O
than	O
150	O
different	O
base	O
changes	O
were	O
recorded	O
in	O
24	O
different	O
populations	O
and	O
ethnic	O
groups	O
in	O
15	O
countries	O
worldwide	O
.	O

The	O
mutations	O
most	O
frequently	O
cited	O
are	O
Q188R	O
,	O
K285N	O
,	O
S135L	O
,	O
and	O
N314D	O
.	O

Q188R	O
is	O
the	O
most	O
common	O
mutation	O
in	O
European	O
populations	O
or	O
in	O
those	O
predominantly	O
of	O
European	O
descent	O
.	O

Overall	O
,	O
it	O
accounts	O
for	O
60	O
-	O
70	O
%	O
of	O
mutant	O
chromosomes	O
,	O
but	O
there	O
are	O
significant	O
differences	O
in	O
its	O
relative	O
frequency	O
in	O
individual	O
populations	O
.	O

Individuals	O
homoallelic	O
for	O
Q188R	O
tend	O
to	O
have	O
a	O
severe	O
phenotype	O
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
virtually	O
complete	O
loss	O
of	O
enzyme	O
activity	O
observed	O
in	O
in	O
vitro	O
expression	O
systems	O
.	O

Globally	O
,	O
K285N	O
is	O
rarer	O
,	O
but	O
in	O
many	O
European	O
populations	O
it	O
can	O
be	O
found	O
on	O
25	O
-	O
40	O
%	O
of	O
mutant	O
chromosomes	O
.	O

It	O
is	O
invariably	O
associated	O
with	O
a	O
severe	O
phenotype	O
.	O

S135L	O
is	O
found	O
almost	O
exclusively	O
in	O
African	O
Americans	O
.	O

In	O
vitro	O
expression	O
results	O
are	O
discrepant	O
,	O
but	O
some	O
individuals	O
carrying	O
S135L	O
appear	O
to	O
exhibit	O
GALT	O
activity	O
in	O
some	O
tissues	O
.	O

Duarte	O
1	O
(	O
or	O
Los	O
Angeles	O
)	O
and	O
Duarte	O
2	O
(	O
or	O
Duarte	O
)	O
variants	O
carry	O
the	O
same	O
amino	O
acid	O
substitution	O
,	O
N314D	O
,	O
even	O
though	O
D1	O
is	O
associated	O
with	O
increased	O
erythrocyte	O
GALT	O
activity	O
and	O
D2	O
with	O
reduced	O
activity	O
.	O

N314D	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
other	O
base	O
changes	O
that	O
differ	O
on	O
the	O
D1	O
and	O
D2	O
alleles	O
.	O

N314D	O
does	O
not	O
impair	O
GALT	O
activity	O
in	O
in	O
vitro	O
expression	O
systems	O
.	O

However	O
,	O
there	O
are	O
differences	O
in	O
the	O
abundance	O
of	O
GALT	O
protein	O
in	O
lymphoblastoid	O
cells	O
lines	O
from	O
D2	O
and	O
D1	O
individuals	O
.	O

It	O
is	O
unclear	O
whether	O
the	O
specific	O
molecular	O
changes	O
that	O
distinguish	O
the	O
D1	O
and	O
D2	O
alleles	O
account	O
for	O
the	O
different	O
activities	O
.	O

The	O
considerable	O
genetic	O
heterogeneity	O
documented	O
to	O
date	O
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	O
heterogeneity	O
that	O
is	O
observed	O
in	O
galactosemia	B
.	O

The	O
additional	O
effects	O
of	O
nonallelic	O
variation	O
and	O
other	O
constitutional	O
factors	O
on	O
phenotypic	O
variability	O
remain	O
to	O
be	O
elucidated	O
.	O
.	O

Mutations	O
of	O
the	O
VHL	B
gene	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
:	O
definition	O
of	O
a	O
risk	O
factor	O
for	O
VHL	B
patients	O
to	O
develop	O
an	O
RCC	B
.	O

To	O
investigate	O
the	O
nature	O
of	O
somatic	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
mutations	O
,	O
we	O
analyzed	O
173	O
primary	O
sporadic	O
human	O
renal	B
cell	I
carcinomas	I
for	O
mutations	O
of	O
the	O
VHL	B
tumor	I
suppressor	O
gene	O
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
of	O
DNA	O
.	O

We	O
detected	O
abnormal	O
SSCP	O
pattern	O
in	O
73	O
samples	O
.	O

After	O
sequencing	O
,	O
we	O
identified	O
microdeletions	O
in	O
58	O
%	O
of	O
cases	O
,	O
microinsertions	O
in	O
17	O
%	O
,	O
nonsense	O
mutations	O
in	O
8	O
%	O
,	O
and	O
missense	O
mutations	O
in	O
17	O
%	O
.	O

Among	O
these	O
mutations	O
,	O
50	O
%	O
correspond	O
to	O
new	O
mutations	O
.	O

VHL	B
mutations	O
were	O
found	O
only	O
in	O
the	O
nonpapillary	B
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
subtype	O
,	O
as	O
previously	O
reported	O
.	O

To	O
compare	O
somatic	O
and	O
germline	O
mutations	O
,	O
we	O
used	O
the	O
VHL	B
database	O
,	O
which	O
includes	O
507	O
mutations	O
.	O

The	O
study	O
of	O
mutational	O
events	O
revealed	O
a	O
significant	O
difference	O
between	O
somatic	O
and	O
germline	O
mutations	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
observed	O
in	O
78	O
%	O
of	O
somatic	O
mutations	O
vs	O
only	O
37	O
%	O
in	O
germline	O
mutations	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
postulated	O
that	O
a	O
specific	O
pattern	O
of	O
VHL	B
mutations	O
is	O
associated	O
with	O
sporadic	B
RCC	I
.	O

This	O
pattern	O
corresponds	O
to	O
mutations	O
leading	O
mainly	O
to	O
truncated	O
proteins	O
with	O
few	O
specific	O
missense	O
mutations	O
.	O

We	O
then	O
analyzed	O
the	O
occurrence	O
of	O
RCC	B
in	O
VHL	B
families	O
,	O
based	O
on	O
the	O
nature	O
of	O
mutations	O
.	O

We	O
observed	O
RCC	B
in	O
at	O
least	O
one	O
member	O
of	O
the	O
VHL	B
families	O
in	O
77	O
%	O
of	O
cases	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
versus	O
55	O
%	O
in	O
cases	O
with	O
missense	O
mutations	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Thus	O
,	O
mutations	O
resulting	O
in	O
truncated	O
proteins	O
may	O
lead	O
to	O
a	O
higher	O
risk	O
of	O
RCC	B
in	O
VHL	B
patients	O

Defective	O
CTLA	O
-	O
4	O
cycling	O
pathway	O
in	O
Chediak	B
-	I
Higashi	I
syndrome	I
:	O
a	O
possible	O
mechanism	O
for	O
deregulation	O
of	O
T	O
lymphocyte	O
activation	O
.	O

Cytotoxic	O
T	O
lymphocyte	O
-	O
associated	O
antigen	O
4	O
(	O
CTLA	O
-	O
4	O
,	O
also	O
known	O
as	O
CD152	O
)	O
has	O
been	O
shown	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
activation	O
.	O

Its	O
membrane	O
expression	O
is	O
highly	O
regulated	O
by	O
endocytosis	O
and	O
trafficking	O
through	O
the	O
secretory	O
lysosome	O
pathway	O
.	O

Chediak	B
-	I
Higashi	I
syndrome	I
(	O
CHS	B
)	O
is	O
an	O
inherited	B
disorder	I
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
trafficking	O
regulator	O
gene	O
,	O
LYST	O
.	O

It	O
results	O
in	O
defective	O
membrane	O
targeting	O
of	O
the	O
proteins	O
present	O
in	O
secretory	O
lysosomes	O
,	O
and	O
it	O
is	O
associated	O
with	O
a	O
variety	O
of	O
features	O
,	O
including	O
a	O
lymphoproliferative	B
syndrome	I
with	O
hemophagocytosis	B
.	O

The	O
murine	O
equivalent	O
of	O
CHS	B
,	O
beige	O
mice	O
,	O
present	O
similar	O
characteristics	O
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	B
syndrome	I
.	O

We	O
show	O
herein	O
that	O
CTLA	O
-	O
4	O
is	O
present	O
in	O
enlarged	O
,	O
abnormal	O
vesicles	O
in	O
CHS	B
T	O
cells	O
and	O
is	O
not	O
properly	O
expressed	O
at	O
the	O
cell	O
surface	O
after	O
T	O
cell	O
activation	O
,	O
whereas	O
its	O
surface	O
expression	O
is	O
not	O
impaired	O
.	O

It	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	O
of	O
CTLA	O
-	O
4	O
by	O
CHS	B
T	O
cells	O
is	O
involved	O
in	O
the	O
generation	O
of	O
lymphoproliferative	B
disease	I
.	O

This	O
observation	O
may	O
provide	O
insight	O
into	O
the	O
role	O
of	O
CTLA	O
-	O
4	O
in	O
humans	O
.	O
.	O

Proteolipoprotein	O
gene	O
analysis	O
in	O
82	O
patients	O
with	O
sporadic	O
Pelizaeus	B
-	I
Merzbacher	I
Disease	I
:	O
duplications	O
,	O
the	O
major	O
cause	O
of	O
the	O
disease	O
,	O
originate	O
more	O
frequently	O
in	O
male	O
germ	O
cells	O
,	O
but	O
point	O
mutations	O
do	O
not	O
.	O

The	O
Clinical	O
European	O
Network	O
on	O
Brain	B
Dysmyelinating	I
Disease	I
.	O

Pelizaeus	B
-	I
Merzbacher	I
Disease	I
(	O
PMD	B
)	O
is	O
an	O
X	B
-	I
linked	I
developmental	I
defect	I
of	I
myelination	I
affecting	O
the	O
central	O
nervous	O
system	O
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(	O
PLP	O
)	O
locus	O
.	O

Investigating	O
82	O
strictly	O
selected	O
sporadic	O
cases	O
of	O
PMD	B
,	O
we	O
found	O
PLP	O
mutations	O
in	O
77	O
%	O
;	O
complete	O
PLP	O
-	O
gene	O
duplications	O
were	O
the	O
most	O
frequent	O
abnormality	O
(	O
62	O
%	O
)	O
,	O
whereas	O
point	O
mutations	O
in	O
coding	O
or	O
splice	O
-	O
site	O
regions	O
of	O
the	O
gene	O
were	O
involved	O
less	O
frequently	O
(	O
38	O
%	O
)	O
.	O

We	O
analyzed	O
the	O
maternal	O
status	O
of	O
56	O
cases	O
to	O
determine	O
the	O
origin	O
of	O
both	O
types	O
of	O
PLP	O
mutation	O
,	O
since	O
this	O
is	O
relevant	O
to	O
genetic	O
counseling	O
.	O

In	O
the	O
22	O
point	O
mutations	O
,	O
68	O
%	O
of	O
mothers	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
a	O
value	O
identical	O
to	O
the	O
two	O
-	O
thirds	O
of	O
carrier	O
mothers	O
that	O
would	O
be	O
expected	O
if	O
there	O
were	O
an	O
equal	O
mutation	O
rate	O
in	O
male	O
and	O
female	O
germ	O
cells	O
.	O

In	O
sharp	O
contrast	O
,	O
among	O
the	O
34	O
duplicated	O
cases	O
,	O
91	O
%	O
of	O
mothers	O
were	O
carriers	O
,	O
a	O
value	O
significantly	O
(	O
chi2	O
=	O
9	O
.	O
20	O
,	O
P	O
<	O
.	O
01	O
)	O
in	O
favor	O
of	O
a	O
male	O
bias	O
,	O
with	O
an	O
estimation	O
of	O
the	O
male	O
/	O
female	O
mutation	O
frequency	O
(	O
k	O
)	O
of	O
9	O
.	O

3	O
3	O
.	O

Moreover	O
,	O
we	O
observed	O
the	O
occurrence	O
of	O
de	O
novo	O
mutations	O
between	O
parental	O
and	O
grandparental	O
generations	O
in	O
17	O
three	O
-	O
generation	O
families	O
,	O
which	O
allowed	O
a	O
direct	O
estimation	O
of	O
the	O
k	O
value	O
(	O
k	O
=	O
11	O
)	O
.	O

Again	O
,	O
a	O
significant	O
male	O
mutation	O
imbalance	O
was	O
observed	O
only	O
for	O
the	O
duplications	O
.	O

Chromosome	O
breakage	O
in	O
the	O
Prader	B
-	I
Willi	I
and	I
Angelman	I
syndromes	I
involves	O
recombination	O
between	O
large	O
,	O
transcribed	O
repeats	O
at	O
proximal	O
and	O
distal	O
breakpoints	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
and	O
Angelman	B
syndrome	I
(	O
AS	B
)	O
are	O
distinct	O
neurobehavioral	B
disorders	I
that	O
most	O
often	O
arise	O
from	O
a	O
4	O
-	O
Mb	O
deletion	O
of	O
chromosome	O
15q11	O
-	O
q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis	O
,	O
respectively	O
.	O

At	O
a	O
de	O
novo	O
frequency	O
of	O
approximately	O
.	O

67	O
-	O
1	O
/	O
10	O
,	O
000	O
births	O
,	O
these	O
deletions	O
represent	O
a	O
common	O
structural	O
chromosome	O
change	O
in	O
the	O
human	O
genome	O
.	O

To	O
elucidate	O
the	O
mechanism	O
underlying	O
these	O
events	O
,	O
we	O
characterized	O
the	O
regions	O
that	O
contain	O
two	O
proximal	O
breakpoint	O
clusters	O
and	O
a	O
distal	O
cluster	O
.	O

Novel	O
DNA	O
sequences	O
potentially	O
associated	O
with	O
the	O
breakpoints	O
were	O
positionally	O
cloned	O
from	O
YACs	O
within	O
or	O
near	O
these	O
regions	O
.	O

Analyses	O
of	O
rodent	O
-	O
human	O
somatic	O
-	O
cell	O
hybrids	O
,	O
YAC	O
contigs	O
,	O
and	O
FISH	O
of	O
normal	O
or	O
rearranged	O
chromosomes	O
15	O
identified	O
duplicated	O
sequences	O
(	O
the	O
END	O
repeats	O
)	O
at	O
or	O
near	O
the	O
breakpoints	O
.	O

The	O
END	O
-	O
repeat	O
units	O
are	O
derived	O
from	O
large	O
genomic	O
duplications	O
of	O
a	O
novel	O
gene	O
(	O
HERC2	O
)	O
,	O
many	O
copies	O
of	O
which	O
are	O
transcriptionally	O
active	O
in	O
germline	O
tissues	O
.	O

One	O
of	O
five	O
PWS	B
/	O
AS	B
patients	O
analyzed	O
to	O
date	O
has	O
an	O
identifiable	O
,	O
rearranged	O
HERC2	O
transcript	O
derived	O
from	O
the	O
deletion	O
event	O
.	O

We	O
postulate	O
that	O
the	O
END	O
repeats	O
flanking	O
15q11	O
-	O
q13	O
mediate	O
homologous	O
recombination	O
resulting	O
in	O
deletion	O
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
active	O
transcription	O
of	O
these	O
repeats	O
in	O
male	O
and	O
female	O
germ	O
cells	O
may	O
facilitate	O
the	O
homologous	O
recombination	O
process	O
.	O

Linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
family	O
with	O
van	B
der	I
Woude	I
syndrome	I
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	O
locus	O
for	O
cleft	B
palate	I
at	O
17p11	O
.	O
2	O
-	O
11	O
.	O
1	O
.	O

van	B
der	I
Woude	I
syndrome	I
(	O
VWS	B
)	O
,	O
which	O
has	O
been	O
mapped	O
to	O
1q32	O
-	O
41	O
,	O
is	O
characterized	O
by	O
pits	B
and	I
/	I
or	I
sinuses	I
of	I
the	I
lower	I
lip	I
,	O
cleft	B
lip	I
/	I
palate	I
(	O
CL	B
/	I
P	I
)	O
,	O
cleft	B
palate	I
(	O
CP	B
)	O
,	O
bifid	B
uvula	I
,	O
and	O
hypodontia	B
(	O
H	B
)	O
.	O

The	O
expression	O
of	O
VWS	B
,	O
which	O
has	O
incomplete	O
penetrance	O
,	O
is	O
highly	O
variable	O
.	O

Both	O
the	O
occurrence	O
of	O
CL	B
/	I
P	I
and	O
CP	B
within	O
the	O
same	O
genealogy	O
and	O
a	O
recurrence	O
risk	O
<	O
40	O
%	O
for	O
CP	B
among	O
descendants	O
with	O
VWS	B
have	O
suggested	O
that	O
the	O
development	O
of	O
clefts	B
in	O
this	O
syndrome	O
is	O
influenced	O
by	O
modifying	O
genes	O
at	O
other	O
loci	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
conducted	O
linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
kindred	O
with	O
VWS	B
,	O
considering	O
as	O
affected	O
the	O
individuals	O
with	O
CP	B
,	O
regardless	O
of	O
whether	O
it	O
is	O
associated	O
with	O
other	O
clinical	O
signs	O
of	O
VWS	B
.	O

Our	O
results	O
suggest	O
that	O
a	O
gene	O
at	O
17p11	O
.	O

2	O
-	O
11	O
2	O
-	O
11	O
.	O

1	O
,	O
together	O
with	O
the	O
VWS	B
gene	O
at	O
1p32	O
-	O
41	O
,	O
enhances	O
the	O
probability	O
of	O
CP	B
in	O
an	O
individual	O
carrying	O
the	O
two	O
at	O
-	O
risk	O
genes	O
.	O

If	O
this	O
hypothesis	O
is	O
confirmed	O
in	O
other	O
VWS	B
pedigrees	O
,	O
it	O
will	O
represent	O
one	O
of	O
the	O
first	O
examples	O
of	O
a	O
gene	O
,	O
mapped	O
through	O
linkage	O
analysis	O
,	O
which	O
modifies	O
the	O
expression	O
of	O
a	O
major	O
gene	O
.	O

New	O
mutations	O
,	O
polymorphisms	O
,	O
and	O
rare	O
variants	O
in	O
the	O
ATM	O
gene	O
detected	O
by	O
a	O
novel	O
SSCP	O
strategy	O
.	O

The	O
gene	O
for	O
ataxia	B
-	I
telangiectasia	I
,	O
ATM	O
,	O
spans	O
about	O
150	O
kb	O
of	O
genomic	O
DNA	O
.	O

ATM	O
mutations	O
are	O
found	O
along	O
the	O
entire	O
gene	O
,	O
with	O
no	O
evidence	O
of	O
a	O
mutational	O
hot	O
spot	O
.	O

Using	O
DNA	O
as	O
the	O
starting	O
material	O
,	O
we	O
screened	O
the	O
ATM	O
gene	O
in	O
92	O
A	B
-	I
T	I
patients	O
,	O
using	O
an	O
optimized	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
that	O
detected	O
all	O
previously	O
known	O
mutations	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
segments	O
being	O
analyzed	O
.	O

To	O
expedite	O
screening	O
,	O
we	O
sequentially	O
loaded	O
the	O
SSCP	O
gels	O
with	O
three	O
different	O
sets	O
of	O
PCR	O
products	O
that	O
were	O
pretested	O
to	O
avoid	O
overlapping	O
patterns	O
.	O

Many	O
of	O
the	O
DNA	O
changes	O
we	O
detected	O
were	O
intragenic	O
polymorphisms	O
.	O

Of	O
an	O
expected	O
177	O
unknown	O
mutations	O
,	O
we	O
detected	O
approximately	O
70	O
%	O
,	O
mostly	O
protein	O
truncating	O
mutations	O
(	O
that	O
would	O
have	O
been	O
detectable	O
by	O
protein	O
truncation	O
testing	O
if	O
RNA	O
starting	O
material	O
had	O
been	O
available	O
)	O
.	O

Mutations	O
have	O
now	O
been	O
defined	O
for	O
every	O
exon	O
of	O
the	O
ATM	O
gene	O
.	O

Herein	O
,	O
we	O
present	O
35	O
new	O
mutations	O
and	O
34	O
new	O
intragenic	O
polymorphisms	O
or	O
rare	O
variants	O
within	O
the	O
ATM	O
gene	O
.	O

This	O
is	O
the	O
most	O
comprehensive	O
compilation	O
of	O
ATM	O
polymorphisms	O
assembled	O
to	O
date	O
.	O

Defining	O
polymorphic	O
sites	O
as	O
well	O
as	O
mutations	O
in	O
the	O
ATM	O
gene	O
will	O
be	O
of	O
great	O
importance	O
in	O
designing	O
automated	O
methods	O
for	O
detecting	O
mutations	O
.	O
.	O

A	O
novel	O
frameshift	O
mutation	O
in	O
the	O
McLeod	B
syndrome	I
gene	O
in	O
a	O
Japanese	O
family	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
XK	O
gene	O
(	O
XK	O
)	O
in	O
a	O
Japanese	O
patient	O
with	O
McLeod	B
syndrome	I
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	O
showed	O
progressive	O
muscular	B
atrophy	I
,	O
choreic	B
movement	I
,	O
elevated	O
level	O
of	O
serum	O
creatinine	O
kinase	O
,	O
and	O
acanthocytosis	B
.	O

The	O
expression	O
level	O
of	O
all	O
the	O
Kell	O
antigens	O
in	O
erythrocyte	O
was	O
decreased	O
and	O
molecular	O
analysis	O
revealed	O
a	O
single	O
-	O
base	O
(	O
T	O
)	O
deletion	O
at	O
the	O
nucleotide	O
position	O
1095	O
in	O
XK	O
.	O

This	O
deletion	O
caused	O
a	O
frameshift	O
in	O
translation	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
the	O
amino	O
acid	O
position	O
408	O
.	O

We	O
conclude	O
this	O
single	O
-	O
base	O
deletion	O
causes	O
defective	O
Kx	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
the	O
McLeod	B
phenotype	O
in	O
this	O
patient	O
.	O
.	O

Association	O
of	O
BRCA1	O
with	O
the	O
hRad50	O
-	O
hMre11	O
-	O
p95	O
complex	O
and	O
the	O
DNA	O
damage	O
response	O
.	O

BRCA1	O
encodes	O
a	O
tumor	B
suppressor	O
that	O
is	O
mutated	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancers	I
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
BRCA1	O
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
hRad50	O
,	O
which	O
forms	O
a	O
complex	O
with	O
hMre11	O
and	O
p95	O
/	O
nibrin	O
.	O

Upon	O
irradiation	O
,	O
BRCA1	O
was	O
detected	O
in	O
discrete	O
foci	O
in	O
the	O
nucleus	O
,	O
which	O
colocalize	O
with	O
hRad50	O
.	O

Formation	O
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
BRCA1	O
,	O
hRad50	O
,	O
hMre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC	O
/	O
1937	O
breast	B
cancer	I
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
BRCA1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	O
-	O
type	O
BRCA1	O
.	O

Ectopic	O
expression	O
of	O
wild	O
-	O
type	O
,	O
but	O
not	O
mutated	O
,	O
BRCA1	O
in	O
these	O
cells	O
rendered	O
them	O
less	O
sensitive	O
to	O
the	O
DNA	O
damage	O
agent	O
,	O
methyl	O
methanesulfonate	O
.	O

These	O
data	O
suggest	O
that	O
BRCA1	O
is	O
important	O
for	O
the	O
cellular	O
responses	O
to	O
DNA	O
damage	O
that	O
are	O
mediated	O
by	O
the	O
hRad50	O
-	O
hMre11	O
-	O
p95	O
complex	O
.	O
.	O

Relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
in	O
females	O
with	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
report	O
from	O
the	O
Maternal	B
Phenylketonuria	I
Collaborative	O
Study	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	B
phenylketonuria	I
(	O
PKU	B
)	O
.	O

METHODOLOGY	O
PAH	O
gene	O
mutations	O
were	O
examined	O
in	O
222	O
hyperphenylalaninemic	B
females	O
enrolled	O
in	O
the	O
Maternal	B
PKU	I
Collaborative	O
Study	O
(	O
MPKUCS	O
)	O
.	O

A	O
total	O
of	O
84	O
different	O
mutations	O
were	O
detected	O
,	O
and	O
complete	O
genotype	O
was	O
obtained	O
in	O
199	O
individuals	O
.	O

Based	O
on	O
previous	O
knowledge	O
about	O
mutation	O
-	O
phenotype	O
associations	O
,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(	O
severe	O
PKU	B
,	O
moderate	O
PKU	B
,	O
mild	O
PKU	B
,	O
and	O
mild	B
hyperphenylalaninemia	I
[	O
MHP	B
]	O
)	O
.	O

Then	O
,	O
189	O
MPKUCS	O
subjects	O
were	O
grouped	O
according	O
to	O
the	O
various	O
combinations	O
of	O
mutation	O
classifications	O
.	O

The	O
sample	O
sizes	O
were	O
large	O
enough	O
for	O
statistical	O
testing	O
in	O
four	O
groups	O
with	O
at	O
least	O
one	O
mutation	O
that	O
completely	O
abolishes	O
enzyme	O
activity	O
.	O

These	O
patients	O
are	O
considered	O
functionally	O
hemizygous	O
.	O

RESULTS	O
The	O
biochemical	O
phenotype	O
predicted	O
from	O
the	O
genotype	O
in	O
functionally	O
hemizygous	O
patients	O
was	O
related	O
significantly	O
to	O
the	O
assigned	O
phenylalanine	O
level	O
.	O

Cognitive	O
performance	O
(	O
IQ	O
)	O
was	O
also	O
significantly	O
related	O
to	O
genotype	O
.	O

The	O
IQ	O
of	O
PAH	B
-	I
deficient	I
mothers	O
with	O
a	O
severe	O
PKU	B
mutation	O
in	O
combination	O
with	O
a	O
MHP	B
mutation	O
or	O
a	O
mild	O
PKU	B
mutation	O
was	O
99	O
and	O
96	O
,	O
respectively	O
,	O
whereas	O
the	O
IQ	O
of	O
PKU	B
mothers	O
with	O
two	O
severe	O
PKU	B
mutations	O
or	O
with	O
one	O
severe	O
and	O
one	O
moderate	O
PKU	B
mutation	O
was	O
83	O
and	O
84	O
,	O
respectively	O
.	O

Of	O
the	O
patients	O
with	O
PKU	B
,	O
92	O
%	O
had	O
been	O
treated	O
during	O
childhood	O
.	O

Those	O
who	O
were	O
untreated	O
or	O
treated	O
late	O
had	O
lower	O
than	O
average	O
IQ	O
scores	O
for	O
their	O
group	O
of	O
mutation	O
combinations	O
.	O

Females	O
with	O
moderate	O
or	O
mild	O
PKU	B
who	O
were	O
treated	O
early	O
and	O
treated	O
for	O
>	O
6	O
years	O
showed	O
IQ	O
scores	O
10	O
points	O
above	O
average	O
for	O
their	O
group	O
.	O

CONCLUSIONS	O
The	O
reproductive	O
outcome	O
in	O
maternal	B
phenylketonuria	I
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances	O
.	O

Both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
PKU	B
.	O

The	O
significant	O
relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
observed	O
in	O
the	O
present	O
study	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
PKU	B
who	O
plan	O
pregnancy	O
.	O
.	O

Spinal	B
xanthomatosis	I
:	O
a	O
variant	O
of	O
cerebrotendinous	B
xanthomatosis	I
.	O

We	O
describe	O
seven	O
Dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive	O
,	O
mainly	O
spinal	B
cord	I
syndrome	I
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

MRI	O
demonstrated	O
white	B
matter	I
abnormalities	I
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	O
cord	O
.	O

Post	O
-	O
mortem	O
examination	O
of	O
one	O
of	O
the	O
patients	O
showed	O
extensive	O
myelin	O
loss	O
in	O
these	O
columns	O
.	O

An	O
array	O
of	O
genotypes	O
was	O
found	O
in	O
these	O
patients	O
.	O

We	O
conclude	O
that	O
spinal	B
xanthomatosis	I
is	O
a	O
clinical	O
and	O
radiological	O
separate	O
entity	O
of	O
CTX	B
that	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
chronic	B
myelopathy	I
.	O
.	O

A	O
transgene	O
insertion	O
creating	O
a	O
heritable	O
chromosome	O
deletion	O
mouse	O
model	O
of	O
Prader	B
-	I
Willi	I
and	I
angelman	I
syndromes	I
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
and	O
Angelman	B
syndrome	I
(	O
AS	B
)	O
result	O
from	O
the	O
loss	O
of	O
function	O
of	O
imprinted	O
genes	O
in	O
human	O
chromosome	O
15q11	O
-	O
q13	O
.	O

The	O
central	O
part	O
of	O
mouse	O
chromosome	O
7	O
is	O
homologous	O
to	O
human	O
15q11	O
-	O
q13	O
,	O
with	O
conservation	O
of	O
both	O
gene	O
order	O
and	O
imprinted	O
features	O
.	O

We	O
report	O
here	O
the	O
characterization	O
of	O
a	O
transgene	O
insertion	O
(	O
Epstein	O
-	O
Barr	O
virus	O
Latent	O
Membrane	O
Protein	O
2A	O
,	O
LMP2A	O
)	O
into	O
mouse	O
chromosome	O
7C	O
,	O
which	O
has	O
resulted	O
in	O
mouse	O
models	O
for	O
PWS	B
and	O
AS	B
dependent	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

Epigenotype	O
(	O
allelic	O
expression	O
and	O
DNA	O
methylation	O
)	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
analyses	O
indicate	O
that	O
the	O
transgene	O
-	O
induced	O
mutation	O
has	O
generated	O
a	O
complete	O
deletion	O
of	O
the	O
PWS	B
/	O
AS	B
-	O
homologous	O
region	O
but	O
has	O
not	O
deleted	O
flanking	O
loci	O
.	O

Because	O
the	O
intact	O
chromosome	O
7	O
,	O
opposite	O
the	O
deleted	O
homolog	O
,	O
maintains	O
the	O
correct	O
imprint	O
in	O
somatic	O
cells	O
of	O
PWS	B
and	O
AS	B
mice	O
and	O
establishes	O
the	O
correct	O
imprint	O
in	O
male	O
and	O
female	O
germ	O
cells	O
of	O
AS	B
mice	O
,	O
homologous	O
association	O
and	O
replication	O
asynchrony	O
are	O
not	O
part	O
of	O
the	O
imprinting	O
mechanism	O
.	O

This	O
heritable	O
-	O
deletion	O
mouse	O
model	O
will	O
be	O
particularly	O
useful	O
for	O
the	O
identification	O
of	O
the	O
etiological	O
genes	O
and	O
mechanisms	O
,	O
phenotypic	O
basis	O
,	O
and	O
investigation	O
of	O
therapeutic	O
approaches	O
for	O
PWS	B
.	O
.	O

Linkage	O
analysis	O
of	O
5	O
novel	O
van	B
der	I
Woude	I
syndrome	I
kindreds	O
to	O
1q32	O
-	O
q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait	O
.	O

van	B
der	I
Woude	I
syndrome	I
(	O
vWS	B
,	O
MIM	O
119300	O
)	O
is	O
a	O
rare	O
autosomal	B
dominant	I
clefting	I
condition	I
with	O
cardinal	O
features	O
of	O
mucous	B
cysts	I
(	O
lower	B
-	I
lip	I
pits	I
)	O
and	O
clefts	B
to	I
the	I
lip	I
and	I
/	I
or	I
palate	I
.	O

The	O
vWS	B
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32	O
-	O
q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping	O
.	O

We	O
have	O
investigated	O
5	O
novel	O
vWS	B
families	O
through	O
probands	O
attended	O
for	O
cleft	B
lip	I
and	I
/	I
or	I
palate	I
repair	O
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau	O
,	O
Paris	O
,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vWS	B
region	O
in	O
1q32	O
-	O
q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees	O
.	O

Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
6	O
microsatellite	O
markers	O
(	O
D1S249	O
,	O
D1S425	O
,	O
D1S491	O
,	O
D1S205	O
,	O
D1S414	O
,	O
D1S425	O
)	O
,	O
yielding	O
a	O
maximum	O
cumulative	O
LOD	O
score	O
of	O
Z	O
=	O
3	O
.	O

27	O
at	O
theta	O
=	O
0	O
.	O

00	O
for	O
D1S245	O
.	O

The	O
innermost	O
four	O
markers	O
were	O
found	O
to	O
be	O
tightly	O
linked	O
to	O
one	O
another	O
,	O
with	O
no	O
evidence	O
for	O
recombination	O
.	O

Our	O
results	O
support	O
linkage	O
of	O
vWS	B
within	O
a	O
region	O
of	O
tightly	O
linked	O
markers	O
and	O
do	O
not	O
favour	O
locus	O
heterogeneity	O
of	O
the	O
disease	O
trait	O
.	O

Null	O
mutation	O
of	O
the	O
murine	O
ATP7B	O
(	O
Wilson	B
disease	I
)	O
gene	O
results	O
in	O
intracellular	B
copper	I
accumulation	I
and	O
late	B
-	I
onset	I
hepatic	I
nodular	I
transformation	I
.	O

The	O
Atp7b	O
protein	O
is	O
a	O
copper	O
-	O
transporting	O
ATPase	O
expressed	O
predominantly	O
in	O
the	O
liver	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
most	O
other	O
tissues	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
gene	O
lead	O
to	O
Wilson	B
disease	I
,	O
a	O
copper	B
toxicity	I
disorder	I
characterized	O
by	O
dramatic	O
build	O
-	O
up	O
of	O
intracellular	O
hepatic	O
copper	O
with	O
subsequent	O
hepatic	B
and	I
neuro	I
-	I
logical	I
abnormalities	I
.	O

Using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
ATP7B	O
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(	O
null	O
)	O
for	O
the	O
Wilson	B
disease	I
gene	O
.	O

The	O
ATP7B	O
null	O
mice	O
display	O
a	O
gradual	O
accumulation	O
of	O
hepatic	O
copper	O
that	O
increases	O
to	O
a	O
level	O
60	O
-	O
fold	O
greater	O
than	O
normal	O
by	O
5	O
months	O
of	O
age	O
.	O

An	O
increase	O
in	O
copper	O
concentration	O
was	O
also	O
observed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo	O
-	O
zygous	O
mutants	O
,	O
although	O
milk	O
from	O
the	O
mutant	O
glands	O
was	O
copper	B
deficient	I
.	O

Morphological	B
abnormalities	I
resembling	O
cirrhosis	B
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	O
mutants	O
older	O
than	O
7	O
months	O
of	O
age	O
.	O

Progeny	O
of	O
the	O
homozygous	O
mutant	O
females	O
demonstrated	O
neurological	B
abnormalities	I
and	O
growth	B
retardation	I
characteristic	O
of	O
copper	B
deficiency	I
.	O

Copper	O
concentration	O
in	O
the	O
livers	O
of	O
the	O
newborn	O
homozygous	O
null	O
mutants	O
was	O
decreased	O
dramatically	O
.	O

In	O
summary	O
,	O
inactivation	O
of	O
the	O
murine	O
ATP7B	O
gene	O
produces	O
a	O
form	O
of	O
cirrhotic	B
liver	I
disease	I
that	O
resembles	O
Wilson	B
disease	I
in	O
humans	O
and	O
the	O
toxic	O
milk	O
phenotype	O
in	O
the	O
mouse	O
.	O
.	O

French	O
Machado	B
-	I
Joseph	I
disease	I
patients	O
do	O
not	O
exhibit	O
gametic	O
segregation	O
distortion	O
:	O
a	O
sperm	O
typing	O
analysis	O
.	O

Segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	B
repeat	I
disorders	I
.	O

On	O
the	O
basis	O
of	O
a	O
sperm	O
typing	O
study	O
performed	O
in	O
patients	O
of	O
Japanese	O
descent	O
with	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
,	O
it	O
was	O
reported	O
that	O
disease	O
alleles	O
are	O
preferentially	O
transmitted	O
during	O
meiosis	O
.	O

We	O
performed	O
a	O
sperm	O
typing	O
study	O
of	O
five	O
MJD	B
patients	O
of	O
French	O
descent	O
and	O
analysis	O
of	O
the	O
pooled	O
data	O
shows	O
a	O
ratio	O
of	O
mutant	O
to	O
normal	O
alleles	O
of	O
379	O
436	O
(	O
46	O
.	O
5	O
53	O
.	O
5	O
%	O
)	O
,	O
which	O
does	O
not	O
support	O
meiotic	O
segregation	O
distortion	O
.	O

To	O
confirm	O
these	O
results	O
,	O
sperm	O
typing	O
analysis	O
was	O
also	O
performed	O
using	O
a	O
polymorphic	O
marker	O
,	O
D14S1050	O
,	O
closely	O
linked	O
to	O
the	O
MJD1	O
gene	O
.	O

Among	O
910	O
sperm	O
analyzed	O
,	O
the	O
allele	O
linked	O
to	O
the	O
disease	O
chromosome	O
was	O
detected	O
in	O
50	O
.	O

3	O
%	O
of	O
the	O
samples	O
and	O
the	O
allele	O
linked	O
to	O
the	O
normal	O
chromosome	O
was	O
found	O
in	O
49	O
.	O

6	O
%	O
of	O
the	O
sperm	O
.	O

The	O
difference	O
in	O
frequency	O
of	O
these	O
two	O
alleles	O
is	O
not	O
significant	O
(	O
P	O
=	O
0	O
.	O
8423	O
)	O
.	O

Likelihood	O
-	O
based	O
analysis	O
of	O
segregation	O
distortion	O
in	O
the	O
single	O
sperm	O
data	O
using	O
the	O
SPERMSEG	O
program	O
also	O
showed	O
no	O
support	O
for	O
segregation	O
distortion	O
at	O
the	O
gamete	O
level	O
in	O
this	O
patient	O
population	O
.	O

The	O
previous	O
report	O
on	O
the	O
Japanese	O
patients	O
also	O
suggested	O
that	O
disease	O
allele	O
stability	O
may	O
be	O
influenced	O
by	O
a	O
trans	O
effect	O
of	O
an	O
intragenic	O
polymorphism	O
(	O
987	O
G	O
/	O
C	O
)	O
in	O
the	O
wild	O
-	O
type	O
allele	O
.	O

All	O
of	O
the	O
French	O
patients	O
were	O
heterozygous	O
for	O
this	O
polymorphism	O
.	O

However	O
,	O
analysis	O
of	O
the	O
variance	O
in	O
repeat	O
number	O
in	O
sperm	O
from	O
the	O
French	O
MJD	B
patients	O
overlapped	O
significantly	O
with	O
the	O
variance	O
in	O
repeat	O
number	O
observed	O
in	O
the	O
C	O
/	O
C	O
homozygous	O
Japanese	O
patients	O
.	O

Missense	O
mutation	O
in	O
the	O
alternative	O
splice	O
region	O
of	O
the	O
PAX6	O
gene	O
in	O
eye	B
anomalies	I
.	O

The	O
PAX6	O
gene	O
is	O
involved	O
in	O
ocular	O
morphogenesis	O
,	O
and	O
PAX6	O
mutations	O
have	O
been	O
detected	O
in	O
various	O
types	O
of	O
ocular	B
anomalies	I
,	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
corneal	B
dystrophy	I
,	O
congenital	B
cataract	I
,	O
and	O
foveal	B
hypoplasia	I
.	O

The	O
gene	O
encodes	O
a	O
transcriptional	O
regulator	O
that	O
recognizes	O
target	O
genes	O
through	O
its	O
paired	O
-	O
type	O
DNA	O
-	O
binding	O
domain	O
.	O

The	O
paired	O
domain	O
is	O
composed	O
of	O
two	O
distinct	O
DNA	O
-	O
binding	O
subdomains	O
,	O
the	O
N	O
-	O
terminal	O
subdomain	O
(	O
NTS	O
)	O
and	O
the	O
C	O
-	O
terminal	O
subdomain	O
(	O
CTS	O
)	O
,	O
which	O
bind	O
respective	O
consensus	O
DNA	O
sequences	O
.	O

The	O
human	O
PAX6	O
gene	O
produces	O
two	O
alternative	O
splice	O
isoforms	O
that	O
have	O
the	O
distinct	O
structure	O
of	O
the	O
paired	O
domain	O
.	O

The	O
insertion	O
,	O
into	O
the	O
NTS	O
,	O
of	O
14	O
additional	O
amino	O
acids	O
encoded	O
by	O
exon	O
5a	O
abolishes	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
NTS	O
and	O
unmasks	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
the	O
CTS	O
.	O

Thus	O
,	O
exon	O
5a	O
appears	O
to	O
function	O
as	O
a	O
molecular	O
switch	O
that	O
specifies	O
target	O
genes	O
.	O

We	O
ascertained	O
a	O
novel	O
missense	O
mutation	O
in	O
four	O
pedigrees	O
with	O
Peters	B
anomaly	I
,	O
congenital	B
cataract	I
,	O
Axenfeldt	B
anomaly	I
,	O
and	O
/	O
or	O
foveal	B
hypoplasia	I
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
is	O
the	O
first	O
mutation	O
identified	O
in	O
the	O
splice	O
-	O
variant	O
region	O
.	O

A	O
T	O
-	O
-	O
>	O
A	O
transition	O
at	O
the	O
20th	O
nucleotide	O
position	O
of	O
exon	O
5a	O
results	O
in	O
a	O
Val	O
-	O
-	O
>	O
Asp	O
(	O
GTC	O
-	O
-	O
>	O
GAC	O
)	O
substitution	O
at	O
the	O
7th	O
codon	O
of	O
the	O
alternative	O
splice	O
region	O
.	O

Functional	O
analyses	O
demonstrated	O
that	O
the	O
V54D	O
mutation	O
slightly	O
increased	O
NTS	O
binding	O
and	O
decreased	O
CTS	O
transactivation	O
activity	O
to	O
almost	O
half	O
.	O
.	O

Penetrances	O
of	O
BRCA1	O
1675delA	O
and	O
1135insA	O
with	O
respect	O
to	O
breast	B
cancer	I
and	O
ovarian	B
cancer	I
.	O

For	O
genetic	O
counseling	O
and	O
predictive	O
testing	O
in	O
families	O
with	O
inherited	B
breast	I
-	I
ovarian	I
cancer	I
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	O
should	O
be	O
known	O
.	O

We	O
have	O
previously	O
reported	O
two	O
BRCA1	O
founder	O
mutations	O
in	O
the	O
Norwegian	O
population	O
.	O

Index	O
cases	O
for	O
the	O
present	O
study	O
were	O
found	O
two	O
different	O
ways	O
through	O
a	O
series	O
of	O
consecutive	O
ovarian	B
cancers	I
(	O
n	O
=	O
16	O
)	O
and	O
through	O
our	O
family	O
cancer	B
clinic	O
(	O
n	O
=	O
14	O
)	O
.	O

Altogether	O
,	O
20	O
of	O
the	O
patients	O
had	O
BRCA1	O
1675delA	O
,	O
and	O
10	O
had	O
1135insA	O
.	O

Their	O
relatives	O
were	O
described	O
with	O
respect	O
to	O
absence	O
/	O
presence	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
.	O

Of	O
133	O
living	O
female	O
relatives	O
,	O
83	O
(	O
62	O
%	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
a	O
mutation	O
.	O

No	O
difference	O
,	O
in	O
penetrance	O
and	O
expression	O
,	O
between	O
the	O
two	O
mutations	O
were	O
found	O
,	O
whereas	O
differences	O
according	O
to	O
method	O
of	O
ascertainment	O
were	O
seen	O
.	O

The	O
overall	O
findings	O
were	O
that	O
disease	O
started	O
to	O
occur	O
at	O
age	O
30	O
years	O
and	O
that	O
by	O
age	O
50	O
years	O
48	O
%	O
of	O
the	O
mutation	O
-	O
carrying	O
women	O
had	O
experienced	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
.	O

More	O
ovarian	B
cancers	I
than	O
breast	B
cancers	I
were	O
recorded	O
.	O

Both	O
penetrance	O
and	O
expression	O
(	O
breast	B
cancer	I
vs	O
.	O
ovarian	B
cancer	I
)	O
were	O
different	O
from	O
those	O
in	O
reports	O
of	O
the	O
Ashkenazi	O
founder	O
mutations	O
.	O

Whether	O
the	O
reported	O
differences	O
reflect	O
true	O
differences	O
and	O
/	O
or	O
methodological	O
problems	O
is	O
discussed	O
.	O

An	O
observed	O
excess	O
of	O
mutation	O
carriers	O
could	O
not	O
be	O
accounted	O
for	O
by	O
methodological	O
problems	O
;	O
possible	O
explanations	O
were	O
a	O
"	O
true	O
"	O
low	O
penetrance	O
or	O
preferential	O
segregation	O
.	O
.	O

The	O
dermatofibrosarcoma	B
protuberans	I
-	O
associated	O
collagen	O
type	O
Ialpha1	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
B	O
-	O
chain	O
fusion	O
gene	O
generates	O
a	O
transforming	O
protein	O
that	O
is	O
processed	O
to	O
functional	O
PDGF	O
-	O
BB	O
.	O

Dermatofibrosarcoma	B
protuberans	I
(	O
DFSP	B
)	O
displays	O
chromosomal	O
rearrangements	O
involving	O
chromosome	O
17	O
and	O
22	O
,	O
which	O
fuse	O
the	O
collagen	O
type	O
Ialpha1	O
(	O
COLIA1	O
)	O
gene	O
to	O
the	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
B	O
-	O
chain	O
(	O
PDGFB	O
)	O
gene	O
.	O

To	O
characterize	O
the	O
functional	O
and	O
structural	O
properties	O
of	O
the	O
COLIA1	O
/	O
PDGFB	O
fusion	O
protein	O
,	O
we	O
generated	O
a	O
stable	O
NIH3T3	O
cell	O
line	O
that	O
contained	O
a	O
tumor	O
-	O
derived	O
chimeric	O
gene	O
resulting	O
from	O
a	O
COIA1	O
intron	O
7	O
-	O
PDGFB	O
intron	O
1	O
fusion	O
.	O

Expression	O
of	O
the	O
fusion	O
protein	O
led	O
to	O
morphological	O
transformation	O
and	O
increased	O
growth	O
rate	O
of	O
these	O
cells	O
.	O

The	O
PDGF	O
receptor	O
kinase	O
inhibitor	O
CGP57148B	O
reversed	O
the	O
transformed	O
phenotype	O
and	O
reduced	O
the	O
growth	O
rate	O
of	O
COLIA1	O
/	O
PDGFB	O
-	O
expressing	O
cells	O
but	O
had	O
no	O
effects	O
on	O
control	O
cells	O
.	O

The	O
presence	O
of	O
dimeric	O
COLIA1	O
/	O
PDGFB	O
precursors	O
was	O
demonstrated	O
through	O
PDGFB	O
immunoprecipitations	O
of	O
metabolically	O
labeled	O
cells	O
and	O
also	O
by	O
PDGFB	O
immunoprecipitations	O
followed	O
by	O
immunoblotting	O
with	O
COLIA1	O
antibodies	O
.	O

Pulse	O
-	O
chase	O
studies	O
demonstrated	O
that	O
the	O
COLIA1	O
/	O
PDGFB	O
precursor	O
was	O
processed	O
to	O
an	O
end	O
product	O
that	O
was	O
indistinguishable	O
from	O
wild	O
-	O
type	O
PDGF	O
-	O
BB	O
.	O

Finally	O
,	O
COLIA1	O
/	O
PDGFB	O
-	O
expressing	O
cells	O
generated	O
tumors	B
after	O
s	O
.	O

c	O
c	O
.	O
injection	O
into	O
nude	O
mice	O
,	O
and	O
tumor	B
growth	O
was	O
reduced	O
by	O
treatment	O
with	O
CGP57148B	O
.	O

We	O
conclude	O
that	O
the	O
COLIA1	O
/	O
PDGFB	O
fusion	O
associated	O
with	O
DFSP	B
contributes	O
to	O
tumor	B
development	O
through	O
ectopic	O
production	O
of	O
PDGF	O
-	O
BB	O
and	O
the	O
formation	O
of	O
an	O
autocrine	O
loop	O
.	O

Our	O
findings	O
,	O
thus	O
,	O
suggest	O
that	O
PDGF	O
receptors	O
could	O
be	O
a	O
target	O
for	O
pharmacological	O
treatment	O
of	O
DFSP	B
and	O
giant	B
cell	I
fibroblastoma	I
,	O
e	O
.	O
g	O
.	O
,	O
through	O
the	O
use	O
of	O
PDGF	O
receptor	O
kinase	O
inhibitors	O
such	O
as	O
CGP57148B	O
.	O

Identification	O
of	O
a	O
common	O
PEX1	O
mutation	O
in	O
Zellweger	B
syndrome	I
.	O

The	O
Zellweger	B
spectrum	I
of	I
disease	I
,	O
encompassing	O
Zellweger	B
syndrome	I
and	O
the	O
progressively	O
milder	O
phenotypes	O
of	O
neonatal	B
adrenoleukodystrophy	I
and	O
infantile	B
Refsum	I
disease	I
,	O
is	O
due	O
to	O
a	O
failure	O
to	O
form	O
functional	O
peroxisomes	O
.	O

Cell	O
fusion	O
complementation	O
studies	O
demonstrated	O
that	O
these	O
diseases	O
are	O
genetically	O
heterogeneous	O
,	O
with	O
two	O
-	O
thirds	O
of	O
all	O
patients	O
lying	O
within	O
a	O
single	O
complementation	O
group	O
,	O
CG1	O
.	O

Molecular	O
genetic	O
and	O
cell	O
biology	O
studies	O
have	O
shown	O
that	O
PEX1	O
is	O
deficient	O
in	O
many	O
CG1	O
patients	O
.	O

However	O
,	O
previous	O
studies	O
have	O
focused	O
on	O
mildly	O
affected	O
patients	O
and	O
there	O
is	O
still	O
no	O
report	O
of	O
two	O
mutant	O
PEX1	O
alleles	O
in	O
any	O
Zellweger	B
syndrome	I
patient	O
.	O

Furthermore	O
,	O
mutations	O
in	O
the	O
PMP70	O
gene	O
have	O
also	O
been	O
identified	O
in	O
two	O
Zellweger	B
syndrome	I
patients	O
from	O
CG1	O
,	O
raising	O
the	O
possibility	O
that	O
CG1	O
patients	O
may	O
represent	O
a	O
mixture	O
of	O
PEX1	O
-	O
deficient	O
and	O
PMP70	O
-	O
deficient	O
individuals	O
.	O

To	O
address	O
the	O
molecular	O
basis	O
of	O
disease	O
in	O
Zellweger	B
syndrome	I
patients	O
from	O
CG1	O
,	O
we	O
examined	O
all	O
24	O
PEX1	O
exons	O
in	O
four	O
patients	O
,	O
including	O
both	O
patients	O
that	O
have	O
mutations	O
in	O
PMP70	O
.	O

PEX1	O
mutations	O
were	O
detected	O
in	O
all	O
four	O
patients	O
,	O
including	O
a	O
1	O
-	O
bp	O
insertion	O
(	O
c	O
.	O
2097insT	O
)	O
in	O
exon	O
13	O
that	O
was	O
present	O
in	O
three	O
of	O
the	O
four	O
patients	O
.	O

Subsequent	O
studies	O
demonstrated	O
that	O
this	O
mutation	O
is	O
present	O
in	O
one	O
-	O
half	O
of	O
all	O
CG1	O
patients	O
and	O
correlates	O
with	O
the	O
Zellweger	B
syndrome	I
phenotype	O
.	O

As	O
this	O
mutation	O
leads	O
to	O
a	O
loss	O
of	O
protein	O
function	O
its	O
frequency	O
makes	O
it	O
the	O
most	O
common	O
cause	O
of	O
Zellweger	B
syndrome	I
,	O
helping	O
to	O
explain	O
the	O
high	O
percentage	O
of	O
patients	O
that	O
belong	O
to	O
CG1	O
.	O

Novel	O
mutations	O
in	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
gene	O
and	O
their	O
effects	O
on	O
transcriptional	O
,	O
translational	O
,	O
and	O
clinical	O
phenotypes	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
is	O
an	O
X	B
-	I
linked	I
recessive	I
immunodeficiency	I
characterized	O
by	O
thrombocytopenia	B
,	O
eczema	B
,	O
and	O
recurrent	O
infections	O
,	O
and	O
caused	O
by	O
mutations	O
in	O
the	O
WAS	B
protein	O
(	O
WASP	O
)	O
gene	O
.	O

WASP	O
contains	O
several	O
functional	O
domains	O
through	O
which	O
it	O
interacts	O
with	O
proteins	O
involved	O
in	O
intracellular	O
signaling	O
and	O
regulation	O
of	O
the	O
actin	O
cytoskeleton	O
.	O

In	O
this	O
report	O
,	O
17	O
WASP	O
gene	O
mutations	O
were	O
identified	O
,	O
12	O
of	O
which	O
are	O
novel	O
.	O

DNA	O
of	O
affected	O
males	O
and	O
obligate	O
carriers	O
was	O
PCR	O
amplified	O
and	O
analyzed	O
by	O
SSCA	O
,	O
heteroduplex	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O

The	O
effects	O
of	O
the	O
mutations	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
were	O
ascertained	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analyses	O
.	O

All	O
missense	O
mutations	O
were	O
located	O
in	O
exons	O
1	O
-	O
4	O
.	O

Most	O
of	O
the	O
nonsense	O
,	O
frameshift	O
and	O
splice	O
site	O
mutations	O
were	O
found	O
in	O
exons	O
6	O
-	O
11	O
.	O

Mutations	O
that	O
alter	O
splice	O
sites	O
led	O
to	O
the	O
synthesis	O
of	O
several	O
types	O
of	O
mRNAs	O
,	O
a	O
fraction	O
of	O
which	O
represented	O
the	O
normally	O
spliced	O
product	O
.	O

The	O
presence	O
of	O
normally	O
spliced	O
transcripts	O
was	O
correlated	O
with	O
a	O
milder	O
phenotype	O
.	O

When	O
one	O
such	O
case	O
was	O
studied	O
by	O
Western	O
blotting	O
,	O
reduced	O
amounts	O
of	O
normal	O
-	O
size	O
WASP	O
were	O
present	O
.	O

In	O
other	O
cases	O
as	O
well	O
,	O
a	O
correlation	O
was	O
found	O
between	O
the	O
amount	O
of	O
normal	O
or	O
mutant	O
WASP	O
present	O
and	O
the	O
phenotypes	O
of	O
the	O
affected	O
individuals	O
.	O

No	O
protein	O
was	O
detected	O
in	O
two	O
individuals	O
with	O
severe	O
WAS	B
.	O

Reduced	O
levels	O
of	O
a	O
normal	O
-	O
size	O
WASP	O
with	O
a	O
missense	O
mutation	O
were	O
seen	O
in	O
two	O
individuals	O
with	O
XLT	B
.	O

It	O
is	O
concluded	O
that	O
mutation	O
analysis	O
at	O
the	O
DNA	O
level	O
is	O
not	O
sufficient	O
for	O
predicting	O
clinical	O
course	O
.	O

Studies	O
at	O
the	O
transcript	O
and	O
protein	O
level	O
are	O
needed	O
for	O
a	O
better	O
assessment	O
.	O
.	O

Aminoglycoside	O
antibiotics	O
restore	O
dystrophin	O
function	O
to	O
skeletal	O
muscles	O
of	O
mdx	O
mice	O
.	O

Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene	O
,	O
leading	O
to	O
the	O
absence	O
of	O
the	O
dystrophin	O
protein	O
in	O
striated	O
muscle	O
.	O

A	O
significant	O
number	O
of	O
these	O
mutations	O
are	O
premature	O
stop	O
codons	O
.	O

On	O
the	O
basis	O
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	O
codons	O
in	O
cultured	O
cells	O
,	O
we	O
tested	O
the	O
effect	O
of	O
gentamicin	O
on	O
cultured	O
muscle	O
cells	O
from	O
the	O
mdx	O
mouse	O
-	O
an	O
animal	O
model	O
for	O
DMD	B
that	O
possesses	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
dystrophin	O
gene	O
.	O

Exposure	O
of	O
mdx	O
myotubes	O
to	O
gentamicin	O
led	O
to	O
the	O
expression	O
and	O
localization	O
of	O
dystrophin	O
to	O
the	O
cell	O
membrane	O
.	O

We	O
then	O
evaluated	O
the	O
effects	O
of	O
differing	O
dosages	O
of	O
gentamicin	O
on	O
expression	O
and	O
functional	O
protection	O
of	O
the	O
muscles	O
of	O
mdx	O
mice	O
.	O

We	O
identified	O
a	O
treatment	O
regimen	O
that	O
resulted	O
in	O
the	O
presence	O
of	O
dystrophin	O
in	O
the	O
cell	O
membrane	O
in	O
all	O
striated	O
muscles	O
examined	O
and	O
that	O
provided	O
functional	O
protection	O
against	O
muscular	B
injury	I
.	O

To	O
our	O
knowledge	O
,	O
our	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
aminoglycosides	O
can	O
suppress	O
stop	O
codons	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	O
.	O

Furthermore	O
,	O
these	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	B
dystrophy	I
and	O
other	O
diseases	O
caused	O
by	O
premature	O
stop	O
codon	O
mutations	O
.	O

This	O
treatment	O
could	O
prove	O
effective	O
in	O
up	O
to	O
15	O
%	O
of	O
patients	O
with	O
DMD	B
.	O
.	O

Loss	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
causes	O
oxidative	O
damage	O
in	O
target	O
organs	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
characterized	O
by	O
a	O
markedly	O
increased	O
sensitivity	O
to	O
ionizing	O
radiation	O
,	O
increased	O
incidence	O
of	O
cancer	B
,	O
and	O
neurodegeneration	B
,	O
especially	O
of	O
the	O
cerebellar	O
Purkinje	O
cells	O
.	O

Ionizing	O
radiation	O
oxidizes	O
macromolecules	O
and	O
causes	O
tissue	O
damage	O
through	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

We	O
therefore	O
hypothesized	O
that	O
A	B
-	I
T	I
is	O
due	O
to	O
oxidative	O
damage	O
resulting	O
from	O
loss	O
of	O
function	O
of	O
the	O
A	B
-	I
T	I
gene	O
product	O
.	O

To	O
assess	O
this	O
hypothesis	O
,	O
we	O
employed	O
an	O
animal	O
model	O
of	O
A	B
-	I
T	I
,	O
the	O
mouse	O
with	O
a	O
disrupted	O
Atm	O
gene	O
.	O

We	O
show	O
that	O
organs	O
which	O
develop	O
pathologic	O
changes	O
in	O
the	O
Atm	O
-	O
deficient	O
mice	O
are	O
targets	O
of	O
oxidative	O
damage	O
,	O
and	O
that	O
cerebellar	O
Purkinje	O
cells	O
are	O
particularly	O
affected	O
.	O

These	O
observations	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
A	B
-	I
T	I
phenotype	O
and	O
lay	O
a	O
rational	O
foundation	O
for	O
therapeutic	O
intervention	O
.	O
.	O

Recessively	O
inherited	O
multiple	B
epiphyseal	I
dysplasia	I
with	O
normal	O
stature	O
,	O
club	B
foot	I
,	O
and	O
double	B
layered	I
patella	I
caused	O
by	O
a	O
DTDST	O
mutation	O
.	O

We	O
have	O
observed	O
over	O
25	O
different	O
mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulphate	O
transporter	O
gene	O
(	O
DTDST	O
)	O
in	O
association	O
with	O
the	O
recessive	B
disorders	I
achondrogenesis	B
1B	I
,	O
atelosteogenesis	B
2	I
,	O
and	O
diastrophic	B
dysplasia	I
.	O

The	O
c862t	O
(	O
R279W	O
)	O
transition	O
is	O
the	O
most	O
common	O
mutation	O
in	O
non	O
-	O
Finnish	O
patients	O
,	O
but	O
in	O
these	O
disorders	O
it	O
is	O
usually	O
combined	O
with	O
other	O
DTDST	O
mutations	O
.	O

We	O
had	O
not	O
seen	O
a	O
case	O
of	O
homozygosity	O
for	O
c862t	O
(	O
R279W	O
)	O
until	O
we	O
analysed	O
DNA	O
from	O
a	O
36	O
year	O
old	O
male	O
with	O
tall	O
-	O
normal	O
stature	O
(	O
180	O
cm	O
)	O
who	O
asked	O
for	O
genetic	O
counselling	O
for	O
suspected	O
multiple	B
epiphyseal	I
dysplasia	I
.	O

He	O
was	O
treated	O
for	O
club	B
foot	I
and	O
hip	B
dysplasia	I
at	O
birth	O
.	O

Skeletal	O
changes	O
consistent	O
with	O
multiple	B
epiphyseal	I
dysplasia	I
,	O
with	O
the	O
peculiar	O
finding	O
of	O
a	O
double	B
layered	I
patella	I
,	O
were	O
recognised	O
during	O
childhood	O
.	O

Cleft	B
palate	I
,	O
swelling	B
of	I
the	I
ear	I
pinna	I
,	O
and	O
hitch	B
hiker	I
thumb	I
were	O
absent	O
.	O

He	O
was	O
found	O
to	O
be	O
homozygous	O
,	O
and	O
both	O
healthy	O
parents	O
heterozygous	O
,	O
for	O
the	O
R279W	O
mutation	O
in	O
DTDST	O
,	O
and	O
his	O
fibroblasts	O
showed	O
a	O
sulphate	O
incorporation	O
defect	O
typical	O
of	O
DTDST	B
disorders	I
.	O

Counselling	O
was	O
given	O
for	O
a	O
recessive	B
disorder	I
,	O
thereby	O
considerably	O
reducing	O
the	O
probability	O
of	O
affected	O
offspring	O
.	O

Multiple	B
epiphyseal	I
dysplasia	I
is	O
more	O
frequently	O
caused	O
by	O
dominant	O
mutations	O
in	O
the	O
COMP	O
(	O
EDM1	B
,	O
McKusick	O
132400	O
)	O
and	O
COL9A2	O
genes	O
(	O
EDM2	B
,	O
McKusick	O
600204	O
)	O
.	O

A	O
few	O
other	O
patients	O
and	O
families	O
with	O
features	O
similar	O
to	O
our	O
proband	O
have	O
been	O
described	O
previously	O
and	O
considered	O
to	O
have	O
autosomal	O
recessive	O
MED	B
(	O
EDM4	B
,	O
McKusick	O
226900	O
)	O
.	O

This	O
observation	O
confirms	O
the	O
existence	O
of	O
this	O
entity	O
and	O
assigns	O
it	O
to	O
the	O
phenotypic	O
spectrum	O
associated	O
with	O
mutations	O
at	O
the	O
DTDST	O
locus	O
.	O
.	O

Homozygosity	O
for	O
a	O
novel	O
DTDST	O
mutation	O
in	O
a	O
child	O
with	O
a	O
'	O
broad	O
bone	O
-	O
platyspondylic	O
'	O
variant	O
of	O
diastrophic	B
dysplasia	I
.	O

Atypical	O
or	O
variant	O
forms	O
of	O
well	O
-	O
known	O
chondrodysplasias	B
may	O
pose	O
diagnostic	O
problems	O
.	O

We	O
report	O
on	O
a	O
girl	O
with	O
clinical	O
features	O
suggesting	O
diastrophic	B
dysplasia	I
but	O
with	O
unusual	O
radiographic	O
features	O
including	O
severe	O
platyspondyly	B
,	O
wide	O
metaphyses	O
,	O
and	O
fibular	O
overgrowth	O
,	O
which	O
are	O
partially	O
reminiscent	O
of	O
metatropic	B
dysplasia	I
.	O

The	O
diagnosis	O
was	O
clarified	O
by	O
molecular	O
analysis	O
of	O
the	O
DTDST	O
gene	O
,	O
which	O
revealed	O
homozygosity	O
for	O
a	O
previously	O
undescribed	O
mutation	O
leading	O
to	O
a	O
Q454P	O
substitution	O
in	O
the	O
10th	O
transmembrane	O
domain	O
of	O
the	O
DTDST	O
sulfate	O
transporter	O
.	O

Molecular	O
analysis	O
may	O
be	O
of	O
particular	O
value	O
in	O
such	O
atypical	O
cases	O
.	O
.	O

The	O
type	O
of	O
somatic	O
mutation	O
at	O
APC	O
in	O
familial	B
adenomatous	I
polyposis	I
is	O
determined	O
by	O
the	O
site	O
of	O
the	O
germline	O
mutation	O
:	O
a	O
new	O
facet	O
to	O
Knudson	O
'	O
s	O
'	O
two	O
-	O
hit	O
'	O
hypothesis	O
.	O

APC	O
is	O
often	O
cited	O
as	O
a	O
prime	O
example	O
of	O
a	O
tumor	B
suppressor	O
gene	O
.	O

Truncating	O
germline	O
and	O
somatic	O
mutations	O
(	O
or	O
,	O
infrequently	O
,	O
allelic	O
loss	O
)	O
occur	O
in	O
tumors	B
in	O
FAP	B
(	O
familial	B
adenomatous	I
polyposis	I
)	O
.	O

Most	O
sporadic	B
colorectal	I
cancers	I
also	O
have	O
two	O
APC	B
mutations	O
.	O

Clues	O
from	O
attenuated	B
polyposis	I
,	O
missense	O
germline	O
variants	O
with	O
mild	O
disease	O
and	O
the	O
somatic	O
mutation	O
cluster	O
region	O
(	O
codons	O
1	O
,	O
250	O
-	O
1	O
,	O
450	O
)	O
indicate	O
,	O
however	O
,	O
that	O
APC	B
mutations	O
might	O
not	O
result	O
in	O
simple	O
loss	O
of	O
protein	O
function	O
.	O

We	O
have	O
found	O
that	O
FAP	B
patients	O
with	O
germline	O
APC	B
mutations	O
within	O
a	O
small	O
region	O
(	O
codons	O
1	O
,	O
194	O
-	O
1	O
,	O
392	O
at	O
most	O
)	O
mainly	O
show	O
allelic	O
loss	O
in	O
their	O
colorectal	B
adenomas	I
,	O
in	O
contrast	O
to	O
other	O
FAP	B
patients	O
,	O
whose	O
second	O
hits	O
tend	O
to	O
occur	O
by	O
truncating	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O

Our	O
results	O
indicate	O
that	O
different	O
APC	B
mutations	O
provide	O
cells	O
with	O
different	O
selective	O
advantages	O
,	O
with	O
mutations	O
close	O
to	O
codon	O
1	O
,	O
300	O
providing	O
the	O
greatest	O
advantage	O
.	O

Allelic	O
loss	O
is	O
selected	O
strongly	O
in	O
cells	O
with	O
one	O
mutation	O
near	O
codon	O
1	O
,	O
300	O
.	O

A	O
different	O
germline	O
-	O
somatic	O
APC	B
mutation	O
association	O
exists	O
in	O
FAP	B
desmoids	I
.	O

APC	O
is	O
not	O
,	O
therefore	O
,	O
a	O
classical	O
tumor	B
suppressor	O
.	O

Our	O
findings	O
also	O
indicate	O
a	O
new	O
mechanism	O
for	O
disease	O
severity	O
if	O
a	O
broader	O
spectrum	O
of	O
mutations	O
is	O
selected	O
in	O
tumors	B
,	O
the	O
somatic	O
mutation	O
rate	O
is	O
effectively	O
higher	O
and	O
more	O
tumors	B
grow	O
.	O
.	O

Mxi1	O
mutations	O
in	O
human	O
neurofibrosarcomas	B
.	O

Mxi1	O
is	O
thought	O
to	O
negatively	O
regulate	O
Myc	O
function	O
and	O
may	O
therefore	O
be	O
a	O
potential	O
tumor	B
suppressor	O
gene	O
.	O

Little	O
effort	O
has	O
yet	O
been	O
made	O
to	O
find	O
alterations	O
involving	O
this	O
gene	O
in	O
human	O
solid	B
tumors	I
.	O

We	O
screened	O
31	O
human	O
gastric	B
cancers	I
,	O
7	O
esophageal	B
cancers	I
,	O
85	O
bone	B
and	I
soft	I
tissue	I
tumors	I
of	O
various	O
types	O
,	O
including	O
4	O
neurofibrosarcomas	B
.	O

We	O
also	O
examined	O
29	O
human	O
tumor	B
cell	O
lines	O
consisting	O
of	O
12	O
esophageal	B
cancers	I
,	O
7	O
glioma	B
/	O
glioblastomas	B
and	O
10	O
others	O
for	O
Mxi1	O
mutations	O
in	O
exons	O
1	O
,	O
2	O
,	O
4	O
(	O
HLH	O
domain	O
)	O
,	O
5	O
and	O
6	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
subsequent	O
sequencing	O
revealed	O
three	O
distinct	O
polymorphisms	O
in	O
the	O
intron	O
-	O
exon	O
boundary	O
upstream	O
from	O
exon	O
6	O
.	O

We	O
discovered	O
a	O
missense	O
mutation	O
,	O
GCA	O
to	O
GTA	O
(	O
Ala	O
54	O
Val	O
)	O
,	O
in	O
exon	O
2	O
in	O
a	O
neurofibrosarcoma	B
patient	O
(	O
case	O
1	O
)	O
,	O
two	O
missense	O
mutations	O
,	O
AAA	O
to	O
CAA	O
(	O
Lys	O
118	O
Gln	O
)	O
and	O
GAA	O
to	O
GGA	O
(	O
Glu	O
154	O
Gly	O
)	O
in	O
exon	O
5	O
of	O
another	O
neurofibrosarcoma	B
patient	O
(	O
case	O
2	O
)	O
,	O
and	O
3	O
amino	O
acid	O
substitutions	O
,	O
GTG	O
to	O
GCG	O
(	O
Val	O
179	O
Ala	O
)	O
,	O
GTT	O
to	O
GCT	O
(	O
Val	O
181	O
Ala	O
)	O
and	O
TTC	O
to	O
CTC	O
(	O
Phe	O
186	O

Leu	O
)	O
,	O
in	O
a	O
third	O
neurofibrosarcoma	B
patient	O
(	O
case	O
3	O
)	O
.	O

In	O
case	O
3	O
,	O
loss	O
of	O
heterozygosity	O
was	O
also	O
demonstrated	O
by	O
informative	O
(	O
TTC	O
)	O
3	O
/	O
(	O
TTC	O
)	O
2	O
polymorphism	O
.	O

Our	O
data	O
demonstrate	O
that	O
mutations	O
occur	O
in	O
the	O
Mxi1	O
gene	O
in	O
neurofibrosarcoma	B
.	O

Missense	O
mutations	O
in	O
the	O
functional	O
domain	O
of	O
Mxi1	O
in	O
these	O
cases	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neurofibrosarcoma	B
.	O
.	O

A	O
population	O
-	O
based	O
study	O
of	O
the	O
clinical	O
expression	O
of	O
the	O
hemochromatosis	B
gene	O
.	O

BACKGROUND	O
AND	O
METHODS	O
Hereditary	B
hemochromatosis	I
is	O
associated	O
with	O
homozygosity	O
for	O
the	O
C282Y	O
mutation	O
in	O
the	O
hemochromatosis	B
(	O
HFE	O
)	O
gene	O
on	O
chromosome	O
6	O
,	O
elevated	O
serum	O
transferrin	O
saturation	O
,	O
and	O
excess	B
iron	I
deposits	I
throughout	O
the	O
body	O
.	O

To	O
assess	O
the	O
prevalence	O
and	O
clinical	O
expression	O
of	O
the	O
HFE	O
gene	O
,	O
we	O
conducted	O
a	O
population	O
-	O
based	O
study	O
in	O
Busselton	O
,	O
Australia	O
.	O

In	O
1994	O
,	O
we	O
obtained	O
blood	O
samples	O
for	O
the	O
determination	O
of	O
serum	O
transferrin	O
saturation	O
and	O
ferritin	O
levels	O
and	O
the	O
presence	O
or	O
absence	O
of	O
the	O
C282Y	O
mutation	O
and	O
the	O
H63D	O
mutation	O
(	O
which	O
may	O
contribute	O
to	O
increased	O
hepatic	O
iron	O
levels	O
)	O
in	O
3011	O
unrelated	O
white	O
adults	O
.	O

We	O
evaluated	O
all	O
subjects	O
who	O
had	O
persistently	O
elevated	O
transferrin	O
-	O
saturation	O
values	O
(	O
45	O
percent	O
or	O
higher	O
)	O
or	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
.	O

We	O
recommended	O
liver	O
biopsy	O
for	O
subjects	O
with	O
serum	O
ferritin	O
levels	O
of	O
300	O
ng	O
per	O
milliliter	O
or	O
higher	O
.	O

The	O
subjects	O
were	O
followed	O
for	O
up	O
to	O
four	O
years	O
.	O

RESULTS	O
Sixteen	O
of	O
the	O
subjects	O
(	O
0	O
.	O
5	O
percent	O
)	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
,	O
and	O
424	O
(	O
14	O
.	O
1	O
percent	O
)	O
were	O
heterozygous	O
.	O

The	O
serum	O
transferrin	O
saturation	O
was	O
45	O
percent	O
or	O
higher	O
in	O
15	O
of	O
the	O
16	O
who	O
were	O
homozygous	O
;	O
in	O
1	O
subject	O
it	O
was	O
43	O
percent	O
.	O

Four	O
of	O
the	O
homozygous	O
subjects	O
had	O
previously	O
been	O
given	O
a	O
diagnosis	O
of	O
hemochromatosis	B
,	O
and	O
12	O
had	O
not	O
.	O

Seven	O
of	O
these	O
12	O
patients	O
had	O
elevated	O
serum	O
ferritin	O
levels	O
in	O
1994	O
;	O
6	O
of	O
the	O
7	O
had	O
further	O
increases	O
in	O
1998	O
,	O
and	O
1	O
had	O
a	O
decrease	O
,	O
although	O
the	O
value	O
remained	O
elevated	O
.	O

The	O
serum	O
ferritin	O
levels	O
in	O
the	O
four	O
other	O
homozygous	O
patients	O
remained	O
in	O
the	O
normal	O
range	O
.	O

Eleven	O
of	O
the	O
16	O
homozygous	O
subjects	O
underwent	O
liver	O
biopsy	O
;	O
3	O
had	O
hepatic	B
fibrosis	I
,	O
and	O
1	O
,	O
who	O
had	O
a	O
history	O
of	O
excessive	B
alcohol	I
consumption	I
,	O
had	O
cirrhosis	B
and	O
mild	O
microvesicular	B
steatosis	I
.	O

Eight	O
of	O
the	O
16	O
homozygous	O
subjects	O
had	O
clinical	O
findings	O
that	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
hereditary	B
hemochromatosis	I
,	O
such	O
as	O
hepatomegaly	B
,	O
skin	B
pigmentation	I
,	O
and	O
arthritis	B
.	O

CONCLUSIONS	O
In	O
a	O
population	O
of	O
white	O
adults	O
of	O
northern	O
European	O
ancestry	O
,	O
0	O
.	O

5	O
percent	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
in	O
the	O
HFE	O
gene	O
.	O

However	O
,	O
only	O
half	O
of	O
those	O
who	O
were	O
homozygous	O
had	O
clinical	O
features	O
of	O
hemochromatosis	B
,	O
and	O
one	O
quarter	O
had	O
serum	O
ferritin	O
levels	O
that	O
remained	O
normal	O
over	O
a	O
four	O
-	O
year	O
period	O
.	O

Large	O
heterozygous	O
deletion	O
masquerading	O
as	O
homozygous	O
missense	O
mutation	O
:	O
a	O
pitfall	O
in	O
diagnostic	O
mutation	O
analysis	O
.	O

The	O
clinical	O
use	O
of	O
molecular	O
analyses	O
in	O
recessive	B
disorders	I
relies	O
on	O
the	O
exact	O
characterization	O
of	O
both	O
mutant	O
alleles	O
in	O
the	O
affected	O
patient	O
.	O

This	O
can	O
be	O
problematic	O
when	O
only	O
part	O
of	O
the	O
gene	O
is	O
examined	O
or	O
when	O
relevant	O
DNA	O
alterations	O
are	O
not	O
recognized	O
by	O
standard	O
methods	O
.	O

We	O
present	O
a	O
child	O
in	O
whom	O
phenylketonuria	B
was	O
apparently	O
caused	O
by	O
homozygosity	O
for	O
the	O
mutation	O
E390G	O
in	O
exon	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
.	O

However	O
,	O
the	O
clinical	O
severity	O
of	O
the	O
disease	O
was	O
not	O
quite	O
as	O
mild	O
as	O
expected	O
,	O
the	O
mutation	O
was	O
not	O
identified	O
in	O
the	O
father	O
despite	O
confirmed	O
paternity	O
,	O
and	O
the	O
paternal	O
allele	O
showed	O
a	O
highly	O
unusual	O
pattern	O
of	O
polymorphic	O
markers	O
in	O
the	O
PAH	O
gene	O
.	O

Presence	O
of	O
a	O
large	O
deletion	O
involving	O
exons	O
9	O
,	O
10	O
and	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
was	O
confirmed	O
by	O
long	O
-	O
range	O
PCR	O
.	O

Diagnostic	O
DNA	O
analyses	O
should	O
include	O
a	O
comprehensive	O
examination	O
of	O
the	O
whole	O
relevant	O
gene	O
in	O
the	O
patient	O
and	O
confirmation	O
of	O
carrier	O
status	O
in	O
both	O
parents	O
.	O
.	O

Early	O
onset	O
of	O
X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
in	O
a	O
boy	O
with	O
emerin	O
gene	O
deletion	O
.	O

A	O
boy	O
developed	O
contractures	B
of	I
the	I
Achilles	I
tendons	I
at	O
3	O
years	O
and	O
of	O
the	O
postcervical	O
muscles	O
at	O
7	O
years	O
,	O
although	O
neither	O
contractures	B
of	I
the	I
elbows	I
nor	O
cardiac	B
abnormality	I
were	O
recognized	O
by	O
the	O
age	O
of	O
9	O
years	O
.	O

Muscle	O
computed	O
tomography	O
scanning	O
revealed	O
changes	O
characteristic	O
of	O
muscle	O
involvement	O
.	O

Emerin	O
was	O
not	O
detected	O
in	O
the	O
biopsied	O
muscle	O
,	O
and	O
RT	O
-	O
PCR	O
and	O
PCR	O
-	O
based	O
genomic	O
DNA	O
analyses	O
of	O
the	O
emerin	O
gene	O
demonstrated	O
no	O
amplification	O
product	O
in	O
the	O
patient	O
.	O

These	O
results	O
confirmed	O
the	O
diagnosis	O
of	O
X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
,	O
and	O
reinforce	O
the	O
necessity	O
of	O
molecular	O
genetic	O
diagnosis	O
of	O
the	O
membrane	O
protein	O
emerin	O
in	O
younger	O
patients	O
with	O
possible	O
EDMD	B
before	O
appearance	O
of	O
the	O
typical	O
symptoms	O
,	O
to	O
avoid	O
sudden	B
cardiac	I
death	I
.	O
.	O

Duchenne	B
/	I
Becker	I
muscular	I
dystrophy	I
:	O
correlation	O
of	O
phenotype	O
by	O
electroretinography	O
with	O
sites	O
of	O
dystrophin	O
mutations	O
.	O

The	O
dark	O
-	O
adapted	O
electroretinogram	O
(	O
ERG	O
)	O
of	O
patients	O
with	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
/	O
BMD	B
)	O
shows	O
a	O
marked	O
reduction	O
in	O
b	O
-	O
wave	O
amplitude	O
.	O

Genotype	O
-	O
phenotype	O
studies	O
of	O
mouse	O
models	O
for	O
DMD	B
show	O
position	O
-	O
specific	O
effects	O
of	O
the	O
mutations	O
upon	O
the	O
phenotype	O
mice	O
with	O
5	O
defects	O
of	O
dystrophin	O
have	O
normal	O
ERGs	O
,	O
those	O
with	O
defects	O
in	O
the	O
central	O
region	O
have	O
a	O
normal	O
b	O
-	O
wave	O
amplitude	O
associated	O
with	O
prolonged	O
implicit	O
times	O
for	O
both	O
the	O
b	O
-	O
wave	O
and	O
oscillatory	O
potentials	O
,	O
and	O
mice	O
with	O
3	O
defects	O
have	O
a	O
phenotype	O
similar	O
to	O
that	O
seen	O
in	O
DMD	B
/	O
BMD	B
patients	O
.	O

The	O
mouse	O
studies	O
suggest	O
a	O
key	O
role	O
for	O
the	O
carboxyl	O
terminal	O
dystrophin	O
isoform	O
,	O
Dp260	O
,	O
in	O
retinal	O
electrophysiology	O
.	O

We	O
have	O
undertaken	O
a	O
systematic	O
evaluation	O
of	O
DMD	B
/	O
BMD	B
patients	O
through	O
clinical	O
examination	O
and	O
review	O
of	O
the	O
literature	O
in	O
order	O
to	O
determine	O
whether	O
the	O
position	O
-	O
specific	O
effects	O
of	O
mutations	O
noted	O
in	O
the	O
mouse	O
are	O
present	O
in	O
man	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
man	O
,	O
a	O
wider	O
variation	O
of	O
DMD	B
defects	I
correlate	O
with	O
reductions	O
in	O
the	O
b	O
-	O
wave	O
amplitude	O
.	O

Individuals	O
with	O
normal	O
ERGs	O
have	O
mutations	O
predominantly	O
located	O
5	O
of	O
the	O
transcript	O
initiation	O
site	O
of	O
Dp260	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
ERG	O
b	O
-	O
wave	O
phenotype	O
is	O
the	O
mutation	O
position	O
,	O
rather	O
than	O
muscle	B
disease	I
severity	O
.	O

Forty	O
-	O
six	O
per	O
cent	O
of	O
patients	O
with	O
mutations	O
5	O
of	O
the	O
Dp260	O
transcript	O
start	O
site	O
have	O
abnormal	O
ERGs	O
,	O
as	O
opposed	O
to	O
94	O
%	O
with	O
more	O
distal	O
mutations	O
.	O

The	O
human	O
genotype	O
-	O
phenotype	O
correlations	O
are	O
consistent	O
with	O
a	O
role	O
for	O
Dp260	O
in	O
normal	O
retinal	O
electrophysiology	O
and	O
may	O
also	O
reflect	O
the	O
expression	O
of	O
other	O
C	O
-	O
terminal	O
dystrophin	O
isoforms	O
and	O
their	O
contributions	O
to	O
retinal	O
signal	O
transmission	O
.	O
.	O

Cis	O
and	O
trans	O
effects	O
of	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
in	O
a	O
cell	O
culture	O
model	O
.	O

The	O
mutation	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
has	O
been	O
identified	O
as	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
3	O
-	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
pathogenesis	O
remain	O
unknown	O
.	O

Studies	O
using	O
DM	B
patient	O
materials	O
have	O
often	O
produced	O
confusing	O
results	O
.	O

Therefore	O
,	O
to	O
study	O
the	O
effects	O
of	O
the	O
DM	B
mutation	O
in	O
a	O
controlled	O
environment	O
,	O
we	O
have	O
established	O
a	O
cell	O
culture	O
model	O
system	O
using	O
C2C12	O
mouse	O
myoblasts	O
.	O

By	O
expressing	O
chimeric	O
reporter	O
constructs	O
containing	O
a	O
reporter	O
gene	O
fused	O
to	O
a	O
human	O
DMPK	O
3	O
-	O
UTR	O
,	O
we	O
identified	O
both	O
cis	O
and	O
trans	O
effects	O
that	O
are	O
mediated	O
by	O
the	O
DM	B
mutation	O
.	O

Our	O
data	O
show	O
that	O
a	O
mutant	O
DMPK	O
3	O
-	O
UTR	O
,	O
with	O
as	O
few	O
as	O
57	O
CTGs	O
,	O
had	O
a	O
negative	O
cis	O
effect	O
on	O
protein	O
expression	O
and	O
resulted	O
in	O
the	O
aggregation	O
of	O
reporter	O
transcripts	O
into	O
discrete	O
nuclear	O
foci	O
.	O

We	O
determined	O
by	O
deletion	O
analysis	O
that	O
an	O
expanded	O
(	O
CTG	O
)	O
(	O
n	O
)	O
tract	O
alone	O
was	O
sufficient	O
to	O
mediate	O
these	O
cis	O
effects	O
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
the	O
normal	O
DMPK	O
3	O
-	O
UTR	O
mRNA	O
,	O
a	O
mutant	O
DMPK	O
3	O
-	O
UTR	O
mRNA	O
with	O
(	O
CUG	O
)	O
(	O
200	O
)	O
selectively	O
inhibited	O
myogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
.	O

Genetic	O
analysis	O
and	O
the	O
Cre	O
-	O
loxP	O
system	O
were	O
used	O
to	O
clearly	O
demonstrate	O
that	O
the	O
myoblast	O
fusion	O
defect	O
could	O
be	O
rescued	O
by	O
eliminating	O
the	O
expression	O
of	O
the	O
mutant	O
DMPK	O
3	O
-	O
UTR	O
transcript	O
.	O

Characterization	O
of	O
spontaneous	O
deletion	O
events	O
mapped	O
the	O
inhibitory	O
effect	O
to	O
the	O
(	O
CTG	O
)	O
(	O
n	O
)	O
expansion	O
and	O
/	O
or	O
the	O
3	O
end	O
of	O
the	O
DMPK	O
3	O
-	O
UTR	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
the	O
DM	B
mutation	O
acts	O
in	O
cis	O
to	O
reduce	O
protein	O
production	O
(	O
consistent	O
with	O
DMPK	B
haploinsufficiency	I
)	O
and	O
in	O
trans	O
as	O
a	O
riboregulator	O
to	O
inhibit	O
myogenesis	O
.	O
.	O

Coats	B
'	I
disease	I
of	O
the	O
retina	O
(	O
unilateral	B
retinal	I
telangiectasis	I
)	O
caused	O
by	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
:	O
a	O
role	O
for	O
norrin	O
in	O
retinal	O
angiogenesis	O
.	O

Coats	B
disease	I
is	O
characterized	O
by	O
abnormal	B
retinal	I
vascular	I
development	I
(	O
so	O
-	O
called	O
retinal	B
telangiectasis	I
)	O
which	O
results	O
in	O
massive	O
intraretinal	B
and	I
subretinal	I
lipid	I
accumulation	I
(	O
exudative	B
retinal	I
detachment	I
)	O
.	O

The	O
classical	O
form	O
of	O
Coats	B
disease	I
is	O
almost	O
invariably	O
isolated	O
,	O
unilateral	O
and	O
seen	O
in	O
males	O
.	O

A	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
Coats	B
disease	I
gave	O
birth	O
to	O
a	O
son	O
affected	O
by	O
Norrie	B
disease	I
.	O

Both	O
carried	O
a	O
missense	O
mutation	O
within	O
the	O
NDP	O
gene	O
on	O
chromosome	O
Xp11	O
.	O

2	O
2	O
.	O

Subsequently	O
analysis	O
of	O
the	O
retinas	O
of	O
nine	O
enucleated	O
eyes	O
from	O
males	O
with	O
Coats	B
disease	I
demonstrated	O
in	O
one	O
a	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
was	O
not	O
present	O
within	O
non	O
-	O
retinal	O
tissue	O
.	O

We	O
suggest	O
that	O
Coats	B
telangiectasis	I
is	O
secondary	O
to	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
results	O
in	O
a	O
deficiency	B
of	I
norrin	I
(	O
the	O
protein	O
product	O
of	O
the	O
NDP	O
gene	O
)	O
within	O
the	O
developing	O
retina	O
.	O

This	O
supports	O
recent	O
observations	O
that	O
the	O
protein	O
is	O
critical	O
for	O
normal	O
retinal	O
vasculogenesis	O
.	O

Hereditary	O
TP53	O
codon	O
292	O
and	O
somatic	O
P16INK4A	O
codon	O
94	O
mutations	O
in	O
a	O
Li	B
-	I
Fraumeni	I
syndrome	I
family	O
.	O

Li	B
-	I
Fraumeni	I
syndrome	I
is	O
an	O
autosomal	B
dominant	I
disorder	I
that	O
is	O
characterized	O
by	O
various	O
types	O
of	O
cancer	B
in	O
childhood	O
and	O
adult	O
cases	O
.	O

Although	O
hereditary	O
TP53	O
mutation	O
is	O
very	O
rare	O
in	O
different	O
human	O
cancers	B
,	O
it	O
has	O
been	O
frequently	O
reported	O
in	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

On	O
the	O
other	O
hand	O
,	O
hereditary	O
mutations	O
of	O
TP57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
,	O
which	O
affect	O
the	O
cell	O
cycle	O
similar	O
to	O
TP53	O
,	O
were	O
observed	O
in	O
some	O
types	O
of	O
cancer	B
.	O

In	O
a	O
Turkish	O
family	O
with	O
the	O
diagnosis	O
of	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
we	O
analyzed	O
the	O
mutation	O
pattern	O
of	O
TP53	O
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
in	O
the	O
peripheral	O
blood	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
homo	O
/	O
hemizygous	O
deletion	O
)	O
pattern	O
of	O
TP53	O
and	O
P15INK4B	O
/	O
P16INK4A	O
in	O
two	O
tumor	B
tissues	O
.	O

The	O
propositus	O
had	O
a	O
seminoma	B
,	O
his	O
daughter	O
a	O
medulloblastoma	B
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins	O
,	O
a	O
TP53	O
codon	O
292	O
missense	O
point	O
mutation	O
(	O
AAA	O
-	O
-	O
>	O
ATA	O
;	O
Lys	O
-	O
-	O
>	O
Ile	O
)	O
in	O
the	O
peripheral	O
blood	O
cells	O
.	O

Tumor	O
tissue	O
obtained	O
from	O
the	O
propositus	O
with	O
the	O
seminoma	B
revealed	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
.	O

In	O
the	O
analyses	O
of	O
tumor	B
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter	O
,	O
a	O
P16INK4A	O
codon	O
94	O
missense	O
point	O
mutation	O
(	O
GCG	O
-	O
-	O
>	O
GAG	O
;	O
Ala	O
-	O
-	O
>	O
Glu	O
)	O
was	O
observed	O
with	O
the	O
hereditary	O
TP53	O
mutation	O
.	O

P16INK4A	O
codon	O
94	O
mutation	O
observed	O
in	O
our	O
family	O
is	O
a	O
novel	O
mutation	O
in	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

No	O
other	O
gene	O
alteration	O
in	O
TP53	O
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
was	O
observed	O
.	O

Existence	O
of	O
the	O
P16INK4A	O
mutation	O
and	O
the	O
hereditary	O
TP53	O
mutation	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
(	O
seminoma	B
/	O
medulloblastoma	B
)	O
may	O
be	O
evidence	O
for	O
a	O
common	O
mechanism	O
involved	O
in	O
tumorogenesis	B
.	O

The	O
gene	O
alterations	O
in	O
TP53	O
and	O
P16INK4A	O
genes	O
may	O
be	O
used	O
as	O
tumor	B
markers	O
in	O
our	O
family	O
.	O
.	O

A	O
novel	O
mutation	O
in	O
the	O
sodium	O
/	O
iodide	O
symporter	O
gene	O
in	O
the	O
largest	O
family	O
with	O
iodide	B
transport	I
defect	I
.	O

We	O
previously	O
reported	O
nine	O
children	O
with	O
an	O
autosomally	O
recessive	O
form	O
of	O
congenital	B
hypothyroidism	I
due	O
to	O
an	O
iodide	B
transport	I
defect	I
in	O
a	O
large	O
Hutterite	O
family	O
with	O
extensive	O
consanguinity	O
living	O
in	O
central	O
Canada	O
.	O

Since	O
the	O
original	O
report	O
,	O
we	O
have	O
diagnosed	O
congenital	B
hypothyroidism	I
by	O
newborn	O
TSH	O
screening	O
in	O
9	O
additional	O
children	O
from	O
the	O
family	O
.	O

We	O
performed	O
direct	O
sequencing	O
of	O
the	O
PCR	O
products	O
of	O
each	O
NIS	O
(	O
sodium	O
/	O
iodide	O
symporter	O
)	O
gene	O
exon	O
with	O
flanking	O
introns	O
amplified	O
from	O
genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
cells	O
of	O
the	O
patients	O
.	O

We	O
identified	O
a	O
novel	O
NIS	O
gene	O
mutation	O
,	O
G395R	O
(	O
Gly395	O
-	O
-	O
>	O
Arg	O
;	O
GGA	O
-	O
-	O
>	O
AGA	O
)	O
,	O
in	O
10	O
patients	O
examined	O
in	O
the	O
present	O
study	O
.	O

All	O
of	O
the	O
parents	O
tested	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
suggesting	O
that	O
the	O
patients	O
were	O
homozygous	O
.	O

The	O
mutation	O
was	O
located	O
in	O
the	O
10th	O
transmembrane	O
helix	O
.	O

Expression	O
experiments	O
by	O
transfection	O
of	O
the	O
mutant	O
NIS	O
complimentary	O
DNA	O
into	O
COS	O
-	O
7	O
cells	O
showed	O
no	O
perchlorate	O
-	O
sensitive	O
iodide	O
uptake	O
,	O
confirming	O
that	O
the	O
mutation	O
is	O
the	O
direct	O
cause	O
of	O
the	O
iodide	B
transport	I
defect	I
in	O
these	O
patients	O
.	O

A	O
patient	O
who	O
showed	O
an	O
intermediate	O
saliva	O
/	O
serum	O
technetium	O
ratio	O
(	O
14	O
.	O
0	O
;	O
normal	O
,	O
>	O
or	O
=	O
20	O
)	O
and	O
was	O
considered	O
to	O
have	O
a	O
partial	O
or	O
less	O
severe	O
defect	O
in	O
the	O
previous	O
report	O
(	O
IX	O
-	O
24	O
)	O
did	O
not	O
have	O
a	O
NIS	O
gene	O
mutation	O
.	O

It	O
is	O
now	O
possible	O
to	O
use	O
gene	O
diagnostics	O
of	O
this	O
unique	O
NIS	O
mutation	O
to	O
identify	O
patients	O
with	O
congenital	B
hypothyroidism	I
due	O
to	O
an	O
iodide	B
transport	I
defect	I
in	O
this	O
family	O
and	O
to	O
determine	O
the	O
carrier	O
state	O
of	O
potential	O
parents	O
for	O
genetic	O
counseling	O
and	O
arranging	O
rapid	O
and	O
early	O
diagnosis	O
of	O
their	O
infants	O
.	O

Molecular	O
analysis	O
in	O
familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
:	O
early	O
diagnosis	O
of	O
an	O
asymptomatic	O
carrier	O
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
inherited	O
deficiency	B
of	I
the	I
hormone	I
arginine	I
vasopressin	I
(	O
AVP	O
)	O
and	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
analyzed	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
in	O
a	O
Spanish	O
kindred	O
.	O

Studies	O
were	O
performed	O
on	O
seven	O
members	O
(	O
four	O
clinically	O
affected	O
)	O
of	O
the	O
family	O
.	O

Patients	O
were	O
diagnosed	O
at	O
the	O
Hospital	O
Universitario	O
Gregorio	O
Maranon	O
(	O
Madrid	O
,	O
Spain	O
)	O
.	O

The	O
entire	O
coding	O
region	O
of	O
the	O
AVP	O
-	O
NPII	O
gene	O
of	O
all	O
family	O
members	O
was	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
.	O

All	O
affected	O
individuals	O
presented	O
a	O
missense	O
mutation	O
(	O
G1757	O
-	O
-	O
>	O
A	O
)	O
that	O
replaces	O
glycine	O
at	O
position	O
23	O
with	O
arginine	O
within	O
the	O
NPII	O
domain	O
.	O

The	O
substitution	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
and	O
was	O
present	O
in	O
heterozygosis	O
.	O

Additionally	O
,	O
one	O
of	O
the	O
asymptomatic	O
relatives	O
(	O
a	O
girl	O
8	O
months	O
old	O
at	O
the	O
time	O
of	O
study	O
)	O
was	O
identified	O
as	O
carrier	O
of	O
the	O
same	O
mutation	O
and	O
developed	O
the	O
disease	O
3	O
months	O
later	O
.	O

The	O
alteration	O
found	O
in	O
the	O
second	O
exon	O
of	O
the	O
gene	O
in	O
this	O
family	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
disease	O
,	O
as	O
all	O
individuals	O
harboring	O
the	O
mutation	O
had	O
been	O
previously	O
diagnosed	O
or	O
have	O
eventually	O
developed	O
FNDI	B
.	O

Identification	O
of	O
the	O
molecular	O
defect	O
underlying	O
FNDI	B
in	O
affected	O
families	O
is	O
a	O
powerful	O
tool	O
for	O
early	O
asymptomatic	O
diagnosis	O
in	O
infants	O
.	O
.	O

Deficit	O
of	O
in	O
vivo	O
mitochondrial	O
ATP	O
production	O
in	O
patients	O
with	O
Friedreich	B
ataxia	I
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
,	O
the	O
most	O
common	O
of	O
the	O
inherited	B
ataxias	I
,	O
is	O
an	O
autosomal	B
recessive	I
degenerative	I
disorder	I
,	O
characterized	O
clinically	O
by	O
onset	O
before	O
the	O
age	O
of	O
25	O
of	O
progressive	B
gait	I
and	I
limb	I
ataxia	I
,	O
absence	B
of	I
deep	I
tendon	I
reflexes	I
,	O
extensor	B
plantar	I
responses	I
,	O
and	O
loss	B
of	I
position	I
and	I
vibration	I
sense	I
in	O
the	O
lower	O
limbs	O
.	O

FRDA	B
is	O
caused	O
by	O
a	O
GAA	O
triplet	O
expansion	O
in	O
the	O
first	O
intron	O
of	O
the	O
FRDA	B
gene	O
on	O
chromosome	O
9q13	O
in	O
97	O
%	O
of	O
patients	O
.	O

The	O
FRDA	B
gene	O
encodes	O
a	O
widely	O
expressed	O
210	O
-	O
aa	O
protein	O
,	O
frataxin	O
,	O
which	O
is	O
located	O
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
FRDA	B
patients	O
.	O

Frataxin	O
function	O
is	O
still	O
unknown	O
but	O
the	O
knockout	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
gene	O
(	O
YFH1	O
)	O
showed	O
a	O
severe	O
defect	O
of	O
mitochondrial	O
respiration	O
and	O
loss	O
of	O
mtDNA	O
associated	O
with	O
elevated	O
intramitochondrial	O
iron	O
.	O

Here	O
we	O
report	O
in	O
vivo	O
evidence	O
of	O
impaired	O
mitochondrial	O
respiration	O
in	O
skeletal	O
muscle	O
of	O
FRDA	B
patients	O
.	O

Using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	O
rate	O
of	O
muscle	O
mitochondrial	O
ATP	O
production	O
(	O
V	O
(	O
max	O
)	O
)	O
below	O
the	O
normal	O
range	O
in	O
all	O
12	O
FRDA	B
patients	O
and	O
a	O
strong	O
negative	O
correlation	O
between	O
mitochondrial	O
V	O
(	O
max	O
)	O
and	O
the	O
number	O
of	O
GAA	O
repeats	O
in	O
the	O
smaller	O
allele	O
.	O

Our	O
results	O
show	O
that	O
FRDA	B
is	O
a	O
nuclear	O
-	O
encoded	O
mitochondrial	B
disorder	I
affecting	O
oxidative	O
phosphorylation	O
and	O
give	O
a	O
rationale	O
for	O
treatments	O
aimed	O
to	O
improve	O
mitochondrial	O
function	O
in	O
this	O
condition	O
.	O
.	O

Identification	O
of	O
a	O
novel	O
R21X	O
mutation	O
in	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
ARG1	O
)	O
in	O
four	O
Portuguese	O
patients	O
with	O
argininemia	B
.	O

Argininemia	B
is	O
a	O
rare	O
autossomal	B
recessive	I
disorder	I
caused	O
by	O
deficiency	B
in	I
the	I
cytosolic	I
liver	I
-	I
type	I
arginase	I
enzyme	I
(	O
L	O
-	O
arginine	O
urea	O
-	O
hydrolase	O
;	O
E	O
.	O
C	O
.	O
3	O
.	O
5	O
.	O
3	O
.	O
1	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
molecular	O
basis	O
for	O
argininemia	B
in	O
four	O
unrelated	O
Portuguese	O
patients	O
(	O
two	O
from	O
northern	O
Portugal	O
and	O
two	O
from	O
Madeira	O
Island	O
)	O
we	O
performed	O
a	O
DNA	O
sequence	O
analysis	O
of	O
all	O
the	O
exons	O
and	O
exon	O
/	O
intron	O
boundaries	O
of	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
ARG1	O
)	O
.	O

All	O
patients	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
newly	O
identified	O
C	O
-	O
>	O
T	O
transition	O
in	O
codon	O
21	O
(	O
exon	O
2	O
)	O
substituting	O
arginine	O
for	O
a	O
premature	O
stop	O
codon	O
(	O
R21X	O
CGA	O
to	O
TGA	O
)	O
and	O
generating	O
a	O
NlaIII	O
restriction	O
site	O
.	O

Restriction	O
digestion	O
following	O
PCR	O
amplification	O
of	O
ARG1	O
exon	O
2	O
confirmed	O
the	O
presence	O
of	O
the	O
mutation	O
.	O

Mutation	O
of	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
results	O
in	O
truncation	O
of	O
mRNA	O
expressed	O
in	O
leucocytes	O
in	O
a	O
Japanese	O
family	O
with	O
cerebrotendinous	B
xanthomatosis	I
.	O

OBJECTIVES	O
A	O
Japanese	O
family	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
was	O
investigated	O
for	O
a	O
sequence	O
alteration	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
.	O

The	O
expression	O
of	O
CYP27	O
has	O
been	O
mostly	O
explored	O
using	O
cultured	O
fibroblasts	O
,	O
prompting	O
the	O
examination	O
of	O
the	O
transcripts	O
from	O
blood	O
leucocytes	O
as	O
a	O
simple	O
and	O
rapid	O
technique	O
.	O

METHODS	O
An	O
alteration	O
in	O
CYP27	O
of	O
the	O
proband	O
was	O
searched	O
for	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
subsequent	O
sequencing	O
.	O

Samples	O
of	O
RNA	O
were	O
subjected	O
to	O
reverse	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
the	O
product	O
of	O
the	O
proband	O
was	O
amplified	O
with	O
nested	O
primers	O
and	O
sequenced	O
.	O

RESULTS	O
A	O
homozygous	O
G	O
to	O
A	O
transition	O
at	O
the	O
5	O
end	O
of	O
intron	O
7	O
was	O
detected	O
in	O
the	O
patient	O
.	O

In	O
RT	O
-	O
PCR	O
analysis	O
,	O
only	O
a	O
truncated	O
transcript	O
was	O
detected	O
in	O
the	O
patient	O
,	O
whereas	O
both	O
normal	O
and	O
truncated	O
transcripts	O
were	O
detected	O
in	O
the	O
siblings	O
.	O

The	O
sequencing	O
of	O
the	O
patients	O
cDNA	O
fragment	O
disclosed	O
a	O
direct	O
conjuction	O
of	O
exon	O
6	O
and	O
exon	O
8	O
.	O

CONCLUSION	O
The	O
mutation	O
at	O
splice	O
donor	O
site	O
and	O
the	O
truncation	O
of	O
mRNA	O
were	O
identical	O
with	O
those	O
of	O
a	O
recently	O
reported	O
Italian	O
patient	O
,	O
although	O
different	O
in	O
symptomatology	O
.	O

The	O
application	O
of	O
blood	O
leucocytes	O
can	O
be	O
a	O
simple	O
technique	O
on	O
analysing	O
a	O
constructive	O
abnormality	B
of	I
CYP27	I
mRNA	O
.	O
.	O

Clinical	O
and	O
molecular	O
genetic	O
analysis	O
of	O
19	O
Wolfram	B
syndrome	I
kindreds	O
demonstrating	O
a	O
wide	O
spectrum	O
of	O
mutations	O
in	O
WFS1	O
.	O

Wolfram	B
syndrome	I
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
characterized	O
by	O
juvenile	B
-	I
onset	I
diabetes	I
mellitus	I
and	O
progressive	O
optic	B
atrophy	I
.	O

mtDNA	O
deletions	O
have	O
been	O
described	O
,	O
and	O
a	O
gene	O
(	O
WFS1	O
)	O
recently	O
has	O
been	O
identified	O
,	O
on	O
chromosome	O
4p16	O
,	O
encoding	O
a	O
predicted	O
890	O
amino	O
acid	O
transmembrane	O
protein	O
.	O

Direct	O
DNA	O
sequencing	O
was	O
done	O
to	O
screen	O
the	O
entire	O
coding	O
region	O
of	O
the	O
WFS1	O
gene	O
in	O
30	O
patients	O
from	O
19	O
British	O
kindreds	O
with	O
Wolfram	B
syndrome	I
.	O

DNA	O
was	O
also	O
screened	O
for	O
structural	O
rearrangements	O
(	O
deletions	O
and	O
duplications	O
)	O
and	O
point	O
mutations	O
in	O
mtDNA	O
.	O

No	O
pathogenic	O
mtDNA	O
mutations	O
were	O
found	O
in	O
our	O
cohort	O
.	O

We	O
identified	O
24	O
mutations	O
in	O
the	O
WFS1	O
gene	O
8	O
nonsense	O
mutations	O
,	O
8	O
missense	O
mutations	O
,	O
3	O
in	O
-	O
frame	O
deletions	O
,	O
1	O
in	O
-	O
frame	O
insertion	O
,	O
and	O
4	O
frameshift	O
mutations	O
.	O

Of	O
these	O
,	O
23	O
were	O
novel	O
mutations	O
,	O
and	O
most	O
occurred	O
in	O
exon	O
8	O
.	O

The	O
majority	O
of	O
patients	O
were	O
compound	O
heterozygotes	O
for	O
two	O
mutations	O
,	O
and	O
there	O
was	O
no	O
common	O
founder	O
mutation	O
.	O

The	O
data	O
were	O
also	O
analyzed	O
for	O
genotype	O
-	O
phenotype	O
relationships	O
.	O

Although	O
some	O
interesting	O
cases	O
were	O
noted	O
,	O
consideration	O
of	O
the	O
small	O
sample	O
size	O
and	O
frequency	O
of	O
each	O
mutation	O
indicated	O
no	O
clear	O
-	O
cut	O
correlations	O
between	O
any	O
of	O
the	O
observed	O
mutations	O
and	O
disease	O
severity	O
.	O

There	O
were	O
no	O
obvious	O
mutation	O
hot	O
spots	O
or	O
clusters	O
.	O

Hence	O
,	O
molecular	O
screening	O
for	O
Wolfram	B
syndrome	I
in	O
affected	O
families	O
and	O
for	O
Wolfram	B
syndrome	I
-	O
carrier	O
status	O
in	O
subjects	O
with	O
psychiatric	B
disorders	I
or	O
diabetes	B
mellitus	I
will	O
require	O
complete	O
analysis	O
of	O
exon	O
8	O
and	O
upstream	O
exons	O
.	O
.	O

Late	O
-	O
onset	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
:	O
a	O
subset	O
with	O
distinct	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O
.	O

To	O
determine	O
the	O
prevalence	O
and	O
characterize	O
demographic	O
,	O
clinical	O
,	O
and	O
genetic	O
features	O
of	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
of	O
late	O
onset	O
,	O
all	O
patients	O
experiencing	O
their	O
first	O
FMF	B
attack	O
at	O
age	O
40	O
years	O
or	O
more	O
were	O
identified	O
using	O
the	O
computerized	O
registry	O
of	O
our	O
FMF	B
clinic	O
,	O
and	O
then	O
thoroughly	O
interviewed	O
and	O
examined	O
.	O

The	O
control	O
group	O
consisted	O
of	O
40	O
consecutive	O
FMF	B
patients	O
,	O
who	O
arrived	O
at	O
the	O
FMF	B
clinic	O
for	O
their	O
regular	O
follow	O
-	O
up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	O
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination	O
.	O

The	O
severity	O
of	O
the	O
disease	O
in	O
patients	O
and	O
controls	O
was	O
determined	O
using	O
a	O
modified	O
score	O
,	O
developed	O
previously	O
.	O

Mutational	O
analysis	O
in	O
the	O
FMF	B
gene	O
was	O
performed	O
using	O
a	O
commercial	O
kit	O
.	O

Only	O
20	O
of	O
4000	O
(	O
0	O
.	O
5	O
%	O
)	O
patients	O
had	O
late	O
-	O
onset	O
FMF	B
.	O

These	O
patients	O
were	O
mostly	O
men	O
,	O
of	O
non	O
-	O
North	O
African	O
origin	O
,	O
P	O
<	O
0	O
.	O

05	O
compared	O
to	O
controls	O
.	O

All	O
had	O
abdominal	O
attacks	O
and	O
in	O
most	O
these	O
were	O
the	O
only	O
manifestation	O
of	O
their	O
disease	O
,	O
P	O
<	O
0	O
.	O

001	O
001	O
.	O

None	O
had	O
chronic	O
or	O
prolonged	O
manifestations	O
of	O
FMF	B
,	O
for	O
example	O
,	O
amyloidosis	B
,	O
chronic	B
arthritis	I
,	O
or	O
protracted	O
myalgia	B
,	O
P	O
<	O
0	O
.	O

001	O
.	O

The	O
response	O
to	O
treatment	O
was	O
good	O
despite	O
using	O
low	O
colchicine	O
dose	O
,	O
P	O
<	O
0	O
.	O

05	O
.	O

The	O
overall	O
severity	O
score	O
indicated	O
a	O
mild	O
disease	O
,	O
P	O
<	O
0	O
.	O

001	O
.	O

Mutational	O
analysis	O
revealed	O
absence	O
of	O
M694V	O
homozygosity	O
,	O
P	O
<	O
0	O
.	O

01	O
,	O
compared	O
to	O
our	O
regular	O
FMF	B
population	O
.	O

We	O
conclude	O
that	O
the	O
onset	O
of	O
FMF	B
in	O
a	O
late	O
age	O
defines	O
a	O
milder	O
form	O
of	O
disease	O
with	O
typical	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O

A	O
highly	O
accurate	O
,	O
low	O
cost	O
test	O
for	O
BRCA1	O
mutations	O
.	O

The	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
syndrome	I
is	O
associated	O
with	O
a	O
high	O
frequency	O
of	O
BRCA1	O
mutations	O
.	O

However	O
,	O
the	O
widespread	O
use	O
of	O
BRCA1	O
testing	O
has	O
been	O
limited	O
to	O
date	O
by	O
three	O
principal	O
concerns	O
the	O
fear	O
of	O
loss	O
of	O
health	O
and	O
life	O
insurance	O
,	O
the	O
uncertain	O
clinical	O
value	O
of	O
a	O
positive	O
test	O
result	O
,	O
and	O
the	O
current	O
lack	O
of	O
an	O
inexpensive	O
and	O
sensitive	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
.	O

We	O
have	O
developed	O
an	O
inexpensive	O
system	O
for	O
gene	O
mutational	O
scanning	O
,	O
based	O
on	O
a	O
combination	O
of	O
extensive	O
multiplex	O
PCR	O
amplification	O
and	O
two	O
dimensional	O
electrophoresis	O
.	O

The	O
efficiency	O
of	O
this	O
system	O
,	O
as	O
a	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
,	O
was	O
evaluated	O
in	O
a	O
panel	O
of	O
60	O
samples	O
from	O
high	O
risk	O
women	O
,	O
14	O
of	O
which	O
contained	O
a	O
previously	O
identified	O
mutation	O
in	O
BRCA1	O
.	O

All	O
14	O
mutations	O
were	O
identified	O
,	O
as	O
well	O
as	O
an	O
additional	O
five	O
that	O
had	O
previously	O
escaped	O
detection	O
.	O

In	O
addition	O
to	O
the	O
19	O
mutations	O
,	O
a	O
total	O
of	O
15	O
different	O
polymorphic	O
variants	O
were	O
scored	O
,	O
most	O
of	O
which	O
were	O
recurring	O
.	O

All	O
were	O
confirmed	O
by	O
nucleotide	O
sequencing	O
.	O

The	O
cost	O
of	O
screening	O
per	O
sample	O
was	O
calculated	O
to	O
be	O
approximately	O
US	O
$	O
70	O
for	O
the	O
manual	O
technique	O
used	O
in	O
this	O
study	O
,	O
and	O
may	O
be	O
reduced	O
to	O
approximately	O
US	O
$	O
10	O
with	O
the	O
introduction	O
of	O
commercially	O
available	O
PCR	O
robotics	O
and	O
fluorescent	O
imaging	O
.	O

Implementation	O
of	O
this	O
method	O
of	O
mutation	O
screening	O
in	O
the	O
research	O
and	O
clinical	O
setting	O
should	O
permit	O
rapid	O
accrual	O
of	O
quantitative	O
data	O
on	O
genotype	O
-	O
phenotype	O
associations	O
for	O
the	O
evaluation	O
of	O
diagnostic	O
testing	O
.	O
.	O

Maternal	B
uniparental	I
disomy	I
for	I
chromosome	I
14	I
in	O
a	O
boy	O
with	O
a	O
normal	O
karyotype	O
.	O

We	O
report	O
on	O
a	O
boy	O
with	O
a	O
maternal	B
uniparental	I
disomy	I
for	I
chromosome	I
14	I
(	O
UPD	B
(	O
14	O
)	O
)	O
.	O

At	O
7	O
years	O
of	O
age	O
he	O
was	O
referred	O
to	O
us	O
by	O
the	O
paediatrician	O
because	O
of	O
symptoms	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

He	O
showed	O
short	B
stature	I
,	O
obesity	B
,	O
mild	O
developmental	B
delay	I
,	O
cryptorchidism	B
,	O
and	O
some	O
mild	O
dysmorphic	B
features	I
.	O

The	O
history	O
further	O
indicated	O
intrauterine	B
growth	I
retardation	I
at	O
the	O
end	O
of	O
the	O
pregnancy	O
.	O

His	O
mother	O
was	O
44	O
years	O
of	O
age	O
at	O
the	O
time	O
of	O
his	O
birth	O
.	O

After	O
birth	O
he	O
showed	O
hypotonia	B
with	O
poor	O
sucking	O
,	O
for	O
which	O
gavage	O
feeding	O
was	O
needed	O
.	O

Motor	O
development	O
was	O
delayed	O
.	O

After	O
1	O
year	O
he	O
became	O
obese	B
despite	O
a	O
normal	O
appetite	O
.	O

Recurrent	O
middle	B
ear	I
infections	I
,	O
a	O
high	O
pain	O
threshold	O
,	O
and	O
a	O
great	O
skill	O
with	O
jigsaw	O
puzzles	O
were	O
reported	O
.	O

There	O
were	O
no	O
behavioural	O
problems	O
or	O
sleep	O
disturbance	O
.	O

Chromosomal	O
analysis	O
was	O
normal	O
(	O
46	O
,	O
XY	O
)	O
.	O

DNA	O
analysis	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
showed	O
no	O
abnormalities	O
.	O

Two	O
years	O
later	O
he	O
was	O
re	O
-	O
examined	O
because	O
we	O
thought	O
his	O
features	O
fitted	O
the	O
PWS	B
-	O
like	O
phenotype	O
associated	O
with	O
maternal	O
UPD	B
(	O
14	O
)	O
.	O

At	O
that	O
time	O
precocious	O
puberty	O
was	O
evident	O
.	O

DNA	O
analysis	O
showed	O
maternal	B
heterodisomy	I
for	O
chromosome	O
14	O
.	O

In	O
all	O
the	O
previously	O
described	O
11	O
cases	O
with	O
maternal	O
UPD	B
(	O
14	O
)	O
,	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
was	O
detected	O
cytogenetically	O
before	O
DNA	O
analysis	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
diagnosis	O
of	O
maternal	O
UPD	B
(	O
14	O
)	O
based	O
on	O
clinical	O
features	O
.	O

This	O
finding	O
underlines	O
the	O
importance	O
of	O
DNA	O
analysis	O
for	O
maternal	O
UPD	O
(	O
14	O
)	O
in	O
patients	O
with	O
a	O
similar	O
PWS	B
-	O
like	O
phenotype	O
even	O
without	O
previous	O
identification	O
of	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
.	O
.	O

Clinical	O
and	O
genetic	O
study	O
of	O
Friedreich	B
ataxia	I
in	O
an	O
Australian	O
population	O
.	O

Friedreich	B
ataxia	I
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
mutations	O
in	O
the	O
FRDA	B
gene	O
that	O
encodes	O
a	O
210	O
-	O
amino	O
acid	O
protein	O
called	O
frataxin	O
.	O

An	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene	O
is	O
present	O
in	O
more	O
than	O
95	O
%	O
of	O
mutant	O
alleles	O
.	O

Of	O
the	O
83	O
people	O
we	O
studied	O
who	O
have	O
mutations	O
in	O
FRDA	O
,	O
78	O
are	O
homozygous	O
for	O
an	O
expanded	O
GAA	O
repeat	O
;	O
the	O
other	O
five	O
patients	O
have	O
an	O
expansion	O
in	O
one	O
allele	O
and	O
a	O
point	O
mutation	O
in	O
the	O
other	O
.	O

Here	O
we	O
present	O
a	O
detailed	O
clinical	O
and	O
genetic	O
study	O
of	O
a	O
subset	O
of	O
51	O
patients	O
homozygous	O
for	O
an	O
expansion	O
of	O
the	O
GAA	O
repeat	O
.	O

We	O
found	O
a	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
of	O
the	O
two	O
expanded	O
alleles	O
and	O
age	O
at	O
onset	O
,	O
age	O
into	O
wheelchair	O
,	O
scoliosis	B
,	O
impaired	O
vibration	O
sense	O
,	O
and	O
the	O
presence	O
of	O
foot	B
deformity	I
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
allele	O
and	O
cardiomyopathy	B
,	O
diabetes	B
mellitus	I
,	O
loss	B
of	I
proprioception	I
,	O
or	O
bladder	B
symptoms	I
.	O

The	O
larger	O
allele	O
size	O
correlated	O
with	O
bladder	B
symptoms	I
and	O
the	O
presence	O
of	O
foot	B
deformity	I
.	O

The	O
duration	O
of	O
disease	O
is	O
correlated	O
with	O
wheelchair	O
use	O
and	O
the	O
presence	O
of	O
diabetes	B
,	O
scoliosis	B
,	O
bladder	B
symptoms	I
and	O
impaired	B
proprioception	I
,	O
and	O
vibration	O
sense	O
but	O
no	O
other	O
complications	O
studied	O
.	O
.	O

Novel	O
mutations	O
in	O
XLRS1	O
causing	O
retinoschisis	B
,	O
including	O
first	O
evidence	O
of	O
putative	O
leader	O
sequence	O
change	O
.	O

Juvenile	B
retinoschisis	I
is	O
an	O
X	B
-	I
linked	I
recessive	I
disease	I
caused	O
by	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O

We	O
screened	O
31	O
new	O
unrelated	O
patients	O
and	O
families	O
for	O
XLRS1	O
mutations	O
in	O
addition	O
to	O
previously	O
reported	O
mutations	O
for	O
60	O
of	O
our	O
families	O
(	O
Retinoschisis	B
Consortium	O
,	O
Hum	O
Mol	O
Genet	O
1998	O
;	O
7	O
1185	O
-	O
1192	O
)	O
.	O

Twenty	O
-	O
three	O
different	O
mutations	O
including	O
12	O
novel	O
ones	O
were	O
identified	O
in	O
28	O
patients	O
.	O

Mutations	O
identified	O
in	O
this	O
study	O
include	O
19	O
missense	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
,	O
one	O
intragenic	O
deletion	O
,	O
four	O
microdeletions	O
,	O
one	O
insertion	O
,	O
and	O
one	O
intronic	O
sequence	O
substitution	O
that	O
is	O
likely	O
to	O
result	O
in	O
a	O
splice	O
site	O
defect	O
.	O

Two	O
novel	O
mutations	O
,	O
c	O
.	O

38T	O
-	O
-	O
>	O
C	O
(	O
L13P	O
)	O
and	O
c	O
.	O

667T	O
-	O
-	O
>	O
C	O
(	O
C223R	O
)	O
,	O
respectively	O
,	O
present	O
the	O
first	O
genetic	O
evidence	O
for	O
the	O
functional	O
significance	O
of	O
the	O
putative	O
leader	O
peptide	O
sequence	O
and	O
for	O
the	O
functional	O
significance	O
at	O
the	O
carboxyl	O
terminal	O
of	O
the	O
XLRS1	O
protein	O
beyond	O
the	O
discoidin	O
domain	O
.	O

Mutations	O
in	O
25	O
of	O
the	O
families	O
were	O
localized	O
to	O
exons	O
4	O
-	O
6	O
,	O
emphasizing	O
the	O
critical	O
functional	O
significance	O
of	O
the	O
discoidin	O
domain	O
of	O
the	O
XLRS1	O
protein	O

Growth	O
hormone	O
treatment	O
increases	O
CO	O
(	O
2	O
)	O
response	O
,	O
ventilation	O
and	O
central	O
inspiratory	O
drive	O
in	O
children	O
with	O
Prader	B
-	I
Willi	I
syndrome	I
.	O

We	O
studied	O
whether	O
the	O
beneficial	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
treatment	O
on	O
growth	O
and	O
body	O
composition	O
in	O
PWS	B
are	O
accompanied	O
by	O
an	O
improvement	O
in	O
respiratory	O
function	O
.	O

We	O
measured	O
resting	O
ventilation	O
,	O
airway	O
occlusion	O
pressure	O
(	O
P	O
(	O
0	O
.	O
1	O
)	O
)	O
and	O
ventilatory	O
response	O
to	O
CO	O
(	O
2	O
)	O
in	O
nine	O
children	O
,	O
aged	O
7	O
-	O
14	O
years	O
,	O
before	O
and	O
6	O
-	O
9	O
months	O
after	O
the	O
start	O
of	O
GH	O
treatment	O
.	O

During	O
GH	O
treatment	O
,	O
resting	O
ventilation	O
increased	O
by	O
26	O
%	O
,	O
P	O
(	O
0	O
.	O
1	O
)	O
by	O
72	O
%	O
and	O
the	O
response	O
to	O
CO	O
(	O
2	O
)	O
by	O
65	O
%	O
(	O
P	O
<	O
0	O
.	O
002	O
,	O
<	O
0	O
.	O
04	O
and	O
<	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

This	O
observed	O
increase	O
in	O
ventilatory	O
output	O
was	O
not	O
correlated	O
to	O
changes	O
in	O
body	O
mass	O
index	O
.	O

CONCLUSION	O
Treatment	O
of	O
children	O
with	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	O
on	O
central	O
respiratory	O
structures	O
.	O

The	O
observed	O
increase	O
in	O
ventilation	O
and	O
inspiratory	O
drive	O
may	O
contribute	O
to	O
the	O
improved	O
activity	O
level	O
reported	O
by	O
parents	O
of	O
PWS	B
children	O
during	O
growth	O
hormone	O
therapy	O

G130V	O
,	O
a	O
common	O
FRDA	B
point	O
mutation	O
,	O
appears	O
to	O
have	O
arisen	O
from	O
a	O
common	O
founder	O
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
is	O
the	O
most	O
common	O
inherited	B
ataxia	I
.	O

About	O
98	O
%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
affected	O
gene	O
,	O
FRDA	O
.	O

The	O
other	O
2	O
%	O
are	O
point	O
mutations	O
.	O

Of	O
the	O
17	O
point	O
mutations	O
so	O
far	O
described	O
,	O
three	O
appear	O
to	O
be	O
more	O
common	O
.	O

One	O
of	O
these	O
is	O
the	O
G130V	O
mutation	O
in	O
exon	O
4	O
of	O
FRDA	O
.	O

G130V	O
,	O
when	O
present	O
with	O
an	O
expanded	O
GAA	O
repeat	O
on	O
the	O
other	O
allele	O
,	O
is	O
associated	O
with	O
an	O
atypical	O
FRDA	B
phenotype	O
.	O

Haplotype	O
analysis	O
was	O
undertaken	O
on	O
the	O
four	O
families	O
who	O
have	O
been	O
described	O
with	O
this	O
mutation	O
.	O

The	O
results	O
suggest	O
a	O
common	O
founder	O
for	O
this	O
mutation	O
.	O

Although	O
marked	O
differences	O
in	O
extragenic	O
marker	O
haplotypes	O
were	O
seen	O
in	O
one	O
family	O
,	O
similar	O
intragenic	O
haplotyping	O
suggests	O
the	O
same	O
mutation	O
founder	O
for	O
this	O
family	O
with	O
the	O
differences	O
explicable	O
by	O
two	O
recombination	O
events	O
.	O
.	O

Synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
the	O
FMR1	O
gene	O
.	O

Most	O
fragile	B
X	I
syndrome	I
patients	O
have	O
expansion	O
of	O
a	O
(	O
CGG	O
)	O
(	O
n	O
)	O
sequence	O
with	O
>	O
200	O
repeats	O
(	O
full	O
mutation	O
)	O
in	O
the	O
FMR1	O
gene	O
responsible	O
for	O
this	O
condition	O
.	O

Hypermethylation	O
of	O
the	O
expanded	O
repeat	O
and	O
of	O
the	O
FMR1	O
promoter	O
is	O
almost	O
always	O
present	O
and	O
apparently	O
suppresses	O
transcription	O
,	O
resulting	O
in	O
absence	O
of	O
the	O
FMR1	O
protein	O
.	O

We	O
recently	O
showed	O
that	O
transcriptional	O
reactivation	O
of	O
FMR1	O
full	O
mutations	O
can	O
be	O
achieved	O
by	O
inducing	O
DNA	O
demethylation	O
with	O
5	O
-	O
azadeoxycytidine	O
(	O
5	O
-	O
azadC	O
)	O
.	O

The	O
level	O
of	O
histone	O
acetylation	O
is	O
another	O
important	O
factor	O
in	O
regulating	O
gene	O
expression	O
;	O
therefore	O
,	O
we	O
treated	O
lymphoblastoid	O
cell	O
lines	O
of	O
non	O
-	O
mosaic	O
full	O
mutation	O
patients	O
with	O
three	O
drugs	O
capable	O
of	O
inducing	O
histone	O
hyperacetylation	O
.	O

We	O
observed	O
a	O
consistent	O
,	O
although	O
modest	O
,	O
reactivation	O
of	O
the	O
FMR1	O
gene	O
with	O
4	O
-	O
phenylbutyrate	O
,	O
sodium	O
butyrate	O
and	O
trichostatin	O
A	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
.	O

However	O
,	O
we	O
report	O
that	O
combining	O
these	O
drugs	O
with	O
5	O
-	O
azadC	O
results	O
in	O
a	O
2	O
-	O
to	O
5	O
-	O
fold	O
increase	O
in	O
FMR1	O
mRNA	O
levels	O
obtained	O
with	O
5	O
-	O
azadC	O
alone	O
,	O
thus	O
showing	O
a	O
marked	O
synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
FMR1	O
full	O
mutations	O
.	O
.	O

Constitutional	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
gene	O
deletions	O
detected	O
in	O
VHL	B
families	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
is	O
an	O
autosomal	B
dominantly	I
inherited	I
cancer	I
syndrome	I
predisposing	O
to	O
a	O
variety	O
of	O
tumor	B
types	O
that	O
include	O
retinal	O
hemangioblastomas	B
,	O
hemangioblastomas	B
of	O
the	O
central	O
nervous	O
system	O
,	O
renal	B
cell	I
carcinomas	I
,	O
pancreatic	B
cysts	I
and	I
tumors	I
,	O
pheochromocytomas	B
,	O
endolymphatic	B
sac	I
tumors	I
,	O
and	O
epididymal	B
cystadenomas	I
[	O
W	O
.	O

M	O
.	O

Linehan	O
et	O
al	O
.	O
,	O
J	O
.	O

Am	O
.	O
Med	O
.	O
Assoc	O
.	O
,	O
273	O
564	O
-	O
570	O
,	O
1995	O
;	O
E	O
.	O
A	O
.	O
Maher	O
and	O
W	O
.	O
G	O
.	O
Kaelin	O
,	O
Jr	O
.	O
,	O
Medicine	O
(	O
Baltimore	O
)	O
,	O
76	O
381	O
-	O
391	O
,	O
1997	O
;	O
W	O
.	O
M	O
.	O
Linehan	O
and	O
R	O
.	O
D	O
.	O
Klausner	O
,	O
In	O
B	O
.	O
Vogelstein	O
and	O
K	O
.	O
Kinzler	O
(	O
eds	O
.	O
)	O
,	O
The	O
Genetic	O
Basis	O
of	O
Human	O
Cancer	O
,	O
pp	O
.	O

455	O
-	O
473	O
,	O
McGraw	O
-	O
Hill	O
,	O
1998	O
]	O
.	O

The	O
VHL	B
gene	O
was	O
localized	O
to	O
chromosome	O
3p25	O
-	O
26	O
and	O
cloned	O
[	O
F	O
.	O
Latif	O
et	O
al	O
.	O
,	O
Science	O
(	O
Washington	O
DC	O
)	O
,	O
260	O
1317	O
-	O
1320	O
,	O
1993	O
]	O
.	O

Germline	O
mutations	O
in	O
the	O
VHL	B
gene	O
have	O
been	O
detected	O
in	O
the	O
majority	O
of	O
VHL	B
kindreds	O
.	O

The	O
reported	O
frequency	O
of	O
detection	O
of	O
VHL	B
germline	O
mutations	O
has	O
varied	O
from	O
39	O
to	O
80	O
%	O
(	O
J	O
.	O
M	O
.	O
Whaley	O
et	O
al	O
.	O
,	O
Am	O
.	O
J	O
.	O
Hum	O
.	O
Genet	O
.	O
,	O
55	O
1092	O
-	O
1102	O
,	O
1994	O
;	O
Clinical	O
Research	O
Group	O
for	O
Japan	O
,	O
Hum	O
.	O
Mol	O
.	O
Genet	O
.	O
,	O
4	O
2233	O
-	O
2237	O
,	O
1995	O
;	O
F	O
.	O
Chen	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
5	O
66	O
-	O
75	O
,	O
1995	O
;	O
E	O
.	O
R	O
.	O
Maher	O
et	O
al	O
.	O
,	O
J	O
.	O
Med	O
.	O
Genet	O
.	O
,	O
33	O
328	O
-	O
332	O
,	O
1996	O
;	O

B	O
.	O
Zbar	O
,	O
Cancer	O
Surv	O
.	O
,	O
25	O
219	O
-	O
232	O
,	O
1995	O
)	O
.	O

Recently	O
a	O
quantitative	O
Southern	O
blotting	O
procedure	O
was	O
found	O
to	O
improve	O
this	O
frequency	O
(	O
C	O
.	O
Stolle	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
12	O
417	O
-	O
423	O
,	O
1998	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
use	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
as	O
a	O
method	O
to	O
detect	O
and	O
characterize	O
VHL	B
germline	O
deletions	O
.	O

We	O
reexamined	O
a	O
group	O
of	O
VHL	B
patients	O
shown	O
previously	O
by	O
single	O
-	O
strand	O
conformation	O
and	O
sequencing	O
analysis	O
not	O
to	O
harbor	O
point	O
mutations	O
in	O
the	O
VHL	B
locus	O
.	O

We	O
found	O
constitutional	O
deletions	O
in	O
29	O
of	O
30	O
VHL	B
patients	O
in	O
this	O
group	O
using	O
cosmid	O
and	O
P1	O
probes	O
that	O
cover	O
the	O
VHL	B
locus	O
.	O

We	O
then	O
tested	O
six	O
phenotypically	O
normal	O
offspring	O
from	O
four	O
of	O
these	O
VHL	B
families	O
two	O
were	O
found	O
to	O
carry	O
the	O
deletion	O
and	O
the	O
other	O
four	O
were	O
deletion	O
-	O
free	O
.	O

In	O
addition	O
,	O
germline	O
mosaicism	O
of	O
the	O
VHL	B
gene	O
was	O
identified	O
in	O
one	O
family	O
.	O

In	O
sum	O
,	O
FISH	O
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	O
VHL	B
germline	O
deletions	O
and	O
practically	O
useful	O
in	O
cases	O
where	O
other	O
methods	O
of	O
screening	O
have	O
failed	O
to	O
detect	O
a	O
VHL	B
gene	I
abnormality	I

Spectrum	O
of	O
hSNF5	O
/	O
INI1	O
somatic	O
mutations	O
in	O
human	O
cancer	B
and	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

The	O
hSNF5	O
/	O
INI1	O
gene	O
which	O
encodes	O
a	O
member	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
ATP	O
-	O
dependent	O
remodeling	O
complex	O
,	O
is	O
a	O
new	O
tumor	B
suppressor	O
gene	O
localized	O
on	O
chromosome	O
22q11	O
.	O

2	O
and	O
recently	O
shown	O
to	O
be	O
mutated	O
in	O
malignant	B
rhabdoid	I
tumors	I
.	O

We	O
have	O
searched	O
for	O
hSNF5	O
/	O
INI1	O
mutations	O
in	O
229	O
tumors	B
of	O
various	O
origins	O
using	O
a	O
screening	O
method	O
based	O
on	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

A	O
total	O
of	O
31	O
homozygous	O
deletions	O
and	O
36	O
point	O
alterations	O
were	O
identified	O
.	O

Point	O
mutations	O
were	O
scattered	O
along	O
the	O
coding	O
sequence	O
and	O
included	O
15	O
nonsense	O
,	O
15	O
frameshift	O
,	O
three	O
splice	O
site	O
,	O
two	O
missense	O
and	O
one	O
editing	O
mutations	O
.	O

Mutations	O
were	O
retrieved	O
in	O
most	O
rhabdoid	B
tumors	I
,	O
whatever	O
their	O
sites	O
of	O
occurrence	O
,	O
indicating	O
the	O
common	O
pathogenetic	O
origin	O
of	O
these	O
tumors	B
.	O

Recurrent	O
hSNF5	O
/	O
INI1	O
alterations	O
were	O
also	O
observed	O
in	O
choroid	B
plexus	I
carcinomas	I
and	O
in	O
a	O
subset	O
of	O
central	O
primitive	O
neuroectodermal	B
tumors	I
(	O
cPNETs	O
)	O
and	O
medulloblastomas	B
.	O

In	O
contrast	O
,	O
hSNF5	O
/	O
INI1	O
point	O
mutations	O
were	O
not	O
detected	O
in	O
breast	B
cancers	I
,	O
Wilms	B
tumors	I
,	O
gliomas	B
,	O
ependymomas	B
,	O
sarcomas	B
and	O
other	O
tumor	B
types	O
,	O
even	O
though	O
most	O
analyzed	O
cases	O
harbored	O
loss	O
of	O
heterozygosity	O
at	O
22q11	O
.	O

2	O
loci	O
.	O

These	O
results	O
suggest	O
that	O
rhabdoid	B
tumors	I
,	O
choroid	B
plexus	I
carcinomas	I
and	O
a	O
subset	O
of	O
medulloblastomas	B
and	O
cPNETs	O
share	O
common	O
pathways	O
of	O
oncogenesis	O
related	O
to	O
hSNF5	O
/	O
INI1	O
alteration	O
and	O
that	O
hSNF5	O
/	O
INI1	O
mutations	O
define	O
a	O
genetically	O
homogeneous	O
family	O
of	O
highly	O
aggressive	O
cancers	B
mainly	O
occurring	O
in	O
young	O
children	O
and	O
frequently	O
,	O
but	O
not	O
always	O
,	O
exhibiting	O
a	O
rhabdoid	B
phenotype	O

Ataxin	O
-	O
3	O
with	O
an	O
altered	O
conformation	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
is	O
associated	O
with	O
the	O
nuclear	O
matrix	O
.	O

Spinocerebellar	B
ataxia	I
type	I
-	I
3	I
or	O
Machado	B
-	I
Joseph	I
disease	I
(	O
SCA3	B
/	O
MJD	B
)	O
is	O
a	O
member	O
of	O
the	O
CAG	B
/	I
polyglutamine	I
repeat	I
disease	I
family	O
.	O

In	O
this	O
family	O
of	O
disorders	O
,	O
a	O
normally	O
polymorphic	O
CAG	O
repeat	O
becomes	O
expanded	O
,	O
resulting	O
in	O
expression	O
of	O
an	O
expanded	O
polyglutamine	O
domain	O
in	O
the	O
disease	O
gene	O
product	O
.	O

Experimental	O
models	O
of	O
polyglutamine	B
disease	I
implicate	O
the	O
nucleus	O
in	O
pathogenesis	O
;	O
however	O
,	O
the	O
link	O
between	O
intranuclear	O
expression	O
of	O
expanded	O
polyglutamine	O
and	O
neuronal	B
dysfunction	I
remains	O
unclear	O
.	O

Here	O
we	O
demonstrate	O
that	O
ataxin	O
-	O
3	O
,	O
the	O
disease	O
protein	O
in	O
SCA3	B
/	O
MJD	B
,	O
adopts	O
a	O
unique	O
conformation	O
when	O
expressed	O
within	O
the	O
nucleus	O
of	O
transfected	O
cells	O
.	O

The	O
monoclonal	O
antibody	O
1C2	O
is	O
known	O
preferentially	O
to	O
bind	O
expanded	O
polyglutamine	O
,	O
but	O
we	O
find	O
that	O
it	O
also	O
binds	O
a	O
fragment	O
of	O
ataxin	O
-	O
3	O
containing	O
a	O
normal	O
glutamine	O
repeat	O
.	O

In	O
addition	O
,	O
expression	O
of	O
ataxin	O
-	O
3	O
within	O
the	O
nucleus	O
exposes	O
the	O
glutamine	O
domain	O
of	O
the	O
full	O
-	O
length	O
non	O
-	O
pathological	O
protein	O
,	O
allowing	O
it	O
to	O
bind	O
the	O
monoclonal	O
antibody	O
1C2	O
.	O

Fractionation	O
and	O
immunochemical	O
experiments	O
indicate	O
that	O
this	O
novel	O
conformation	O
of	O
intranuclear	O
ataxin	O
-	O
3	O
is	O
not	O
due	O
to	O
proteolysis	O
,	O
suggesting	O
instead	O
that	O
association	O
with	O
nuclear	O
protein	O
(	O
s	O
)	O
alters	O
the	O
structure	O
of	O
full	O
-	O
length	O
ataxin	O
-	O
3	O
which	O
exposes	O
the	O
polyglutamine	O
domain	O
.	O

This	O
conformationally	O
altered	O
ataxin	O
-	O
3	O
is	O
bound	O
to	O
the	O
nuclear	O
matrix	O
.	O

The	O
pathological	O
form	O
of	O
ataxin	O
-	O
3	O
with	O
an	O
expanded	O
polyglutamine	O
domain	O
also	O
associates	O
with	O
the	O
nuclear	O
matrix	O
.	O

These	O
data	O
suggest	O
that	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
SCA3	B
/	O
MJD	B
may	O
be	O
an	O
altered	O
conformation	O
of	O
ataxin	O
-	O
3	O
within	O
the	O
nucleus	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
.	O
.	O

The	O
human	O
MAGEL2	O
gene	O
and	O
its	O
mouse	O
homologue	O
are	O
paternally	O
expressed	O
and	O
mapped	O
to	O
the	O
Prader	B
-	I
Willi	I
region	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
is	O
a	O
complex	O
neurogenetic	B
disorder	I
.	O

The	O
phenotype	O
is	O
likely	O
to	O
be	O
a	O
contiguous	B
gene	I
syndrome	I
involving	O
genes	O
which	O
are	O
paternally	O
expressed	O
only	O
,	O
located	O
in	O
the	O
human	O
15q11	O
-	O
q13	O
region	O
.	O

Four	O
mouse	O
models	O
of	O
PWS	B
have	O
been	O
reported	O
but	O
these	O
do	O
not	O
definitively	O
allow	O
the	O
delineation	O
of	O
the	O
critical	O
region	O
and	O
the	O
associated	O
genes	O
involved	O
in	O
the	O
aetiology	O
of	O
PWS	B
.	O

Moreover	O
,	O
targeted	O
mutagenesis	O
of	O
mouse	O
homologues	O
of	O
the	O
human	O
candidate	O
PWS	B
genes	O
does	O
not	O
appear	O
to	O
result	O
in	O
any	O
of	O
the	O
features	O
of	O
PWS	B
.	O

Therefore	O
,	O
the	O
isolation	O
of	O
new	O
genes	O
in	O
this	O
region	O
remains	O
crucial	O
for	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
PWS	B
.	O

In	O
this	O
manuscript	O
,	O
we	O
report	O
the	O
characterization	O
of	O
MAGEL2	O
and	O
its	O
mouse	O
homologue	O
Magel2	O
.	O

These	O
are	O
located	O
in	O
the	O
human	O
15q11	O
-	O
q13	O
and	O
mouse	O
7C	O
regions	O
,	O
in	O
close	O
proximity	O
to	O
NDN	O
/	O
Ndn	O
.	O

By	O
northern	O
blot	O
analysis	O
we	O
did	O
not	O
detect	O
any	O
expression	O
of	O
MAGEL2	O
/	O
Magel2	O
but	O
by	O
RT	O
-	O
PCR	O
analysis	O
,	O
specific	O
expression	O
was	O
detected	O
in	O
fetal	O
and	O
adult	O
brain	O
and	O
in	O
placenta	O
.	O

Both	O
genes	O
are	O
intronless	O
with	O
tandem	O
direct	O
repeat	O
sequences	O
contained	O
within	O
a	O
CpG	O
island	O
in	O
the	O
5	O
-	O
untranscribed	O
region	O
.	O

The	O
transcripts	O
encode	O
putative	O
proteins	O
that	O
are	O
homologous	O
to	O
the	O
MAGE	O
proteins	O
and	O
NDN	O
.	O

Moreover	O
,	O
MAGEL2	O
/	O
Magel2	O
are	O
expressed	O
only	O
from	O
the	O
paternal	O
allele	O
in	O
brain	O
,	O
suggesting	O
a	O
potential	O
role	O
in	O
the	O
aetiology	O
of	O
PWS	B
and	O
its	O
mouse	O
model	O
,	O
respectively	O
.	O
.	O

cDNA	O
microarrays	O
detect	O
activation	O
of	O
a	O
myogenic	O
transcription	O
program	O
by	O
the	O
PAX3	O
-	O
FKHR	O
fusion	O
oncogene	O
.	O

Alveolar	B
rhabdomyosarcoma	I
is	O
an	O
aggressive	O
pediatric	B
cancer	I
of	I
striated	I
muscle	I
characterized	O
in	O
60	O
%	O
of	O
cases	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
.	O

This	O
results	O
in	O
the	O
fusion	O
of	O
PAX3	O
,	O
a	O
developmental	O
transcription	O
factor	O
required	O
for	O
limb	O
myogenesis	O
,	O
with	O
FKHR	O
,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors	O
.	O

The	O
resultant	O
PAX3	O
-	O
FKHR	O
gene	O
possesses	O
transforming	O
properties	O
;	O
however	O
,	O
the	O
effects	O
of	O
this	O
chimeric	O
oncogene	O
on	O
gene	O
expression	O
are	O
largely	O
unknown	O
.	O

To	O
investigate	O
the	O
actions	O
of	O
these	O
transcription	O
factors	O
,	O
both	O
Pax3	O
and	O
PAX3	O
-	O
FKHR	O
were	O
introduced	O
into	O
NIH	O
3T3	O
cells	O
,	O
and	O
the	O
resultant	O
gene	O
expression	O
changes	O
were	O
analyzed	O
with	O
a	O
murine	O
cDNA	O
microarray	O
containing	O
2	O
,	O
225	O
elements	O
.	O

We	O
found	O
that	O
PAX3	O
-	O
FKHR	O
but	O
not	O
PAX3	O
activated	O
a	O
myogenic	O
transcription	O
program	O
including	O
the	O
induction	O
of	O
transcription	O
factors	O
MyoD	O
,	O
Myogenin	O
,	O
Six1	O
,	O
and	O
Slug	O
as	O
well	O
as	O
a	O
battery	O
of	O
genes	O
involved	O
in	O
several	O
aspects	O
of	O
muscle	O
function	O
.	O

Notable	O
among	O
this	O
group	O
were	O
the	O
growth	O
factor	O
gene	O
Igf2	O
and	O
its	O
binding	O
protein	O
Igfbp5	O
.	O

Relevance	O
of	O
this	O
model	O
was	O
suggested	O
by	O
verification	O
that	O
three	O
of	O
these	O
genes	O
(	O
IGFBP5	O
,	O
HSIX1	O
,	O
and	O
Slug	O
)	O
were	O
also	O
expressed	O
in	O
alveolar	B
rhabdomyosarcoma	I
cell	O
lines	O
.	O

This	O
study	O
utilizes	O
cDNA	O
microarrays	O
to	O
elucidate	O
the	O
pattern	O
of	O
gene	O
expression	O
induced	O
by	O
an	O
oncogenic	O
transcription	O
factor	O
and	O
demonstrates	O
the	O
profound	O
myogenic	O
properties	O
of	O
PAX3	O
-	O
FKHR	O
in	O
NIH	O
3T3	O
cells	O
.	O
.	O

Experimental	O
hemochromatosis	B
due	O
to	O
MHC	O
class	O
I	O
HFE	B
deficiency	I
:	O
immune	O
status	O
and	O
iron	O
metabolism	O
.	O

The	O
puzzling	O
linkage	O
between	O
genetic	O
hemochromatosis	B
and	O
histocompatibility	O
loci	O
became	O
even	O
more	O
so	O
when	O
the	O
gene	O
involved	O
,	O
HFE	O
,	O
was	O
identified	O
.	O

Indeed	O
,	O
within	O
the	O
well	O
defined	O
,	O
mainly	O
peptide	O
-	O
binding	O
,	O
MHC	O
class	O
I	O
family	O
of	O
molecules	O
,	O
HFE	O
seems	O
to	O
perform	O
an	O
unusual	O
yet	O
essential	O
function	O
.	O

As	O
yet	O
,	O
our	O
understanding	O
of	O
HFE	O
function	O
in	O
iron	O
homeostasis	O
is	O
only	O
partial	O
;	O
an	O
even	O
more	O
open	O
question	O
is	O
its	O
possible	O
role	O
in	O
the	O
immune	O
system	O
.	O

To	O
advance	O
on	O
both	O
of	O
these	O
avenues	O
,	O
we	O
report	O
the	O
deletion	O
of	O
HFE	O
alpha1	O
and	O
alpha2	O
putative	O
ligand	O
binding	O
domains	O
in	O
vivo	O
.	O

HFE	B
-	I
deficient	I
animals	O
were	O
analyzed	O
for	O
a	O
comprehensive	O
set	O
of	O
metabolic	O
and	O
immune	O
parameters	O
.	O

Faithfully	O
mimicking	O
human	O
hemochromatosis	B
,	O
mice	O
homozygous	O
for	O
this	O
deletion	O
develop	O
iron	O
overload	O
,	O
characterized	O
by	O
a	O
higher	O
plasma	O
iron	O
content	O
and	O
a	O
raised	O
transferrin	O
saturation	O
as	O
well	O
as	O
an	O
elevated	O
hepatic	O
iron	O
load	O
.	O

The	O
primary	O
defect	O
could	O
,	O
indeed	O
,	O
be	O
traced	O
to	O
an	O
augmented	O
duodenal	O
iron	O
absorption	O
.	O

In	O
parallel	O
,	O
measurement	O
of	O
the	O
gut	O
mucosal	O
iron	O
content	O
as	O
well	O
as	O
iron	O
regulatory	O
proteins	O
allows	O
a	O
more	O
informed	O
evaluation	O
of	O
various	O
hypotheses	O
regarding	O
the	O
precise	O
role	O
of	O
HFE	O
in	O
iron	O
homeostasis	O
.	O

Finally	O
,	O
an	O
extensive	O
phenotyping	O
of	O
primary	O
and	O
secondary	O
lymphoid	O
organs	O
including	O
the	O
gut	O
provides	O
no	O
compelling	O
evidence	O
for	O
an	O
obvious	O
immune	O
-	O
linked	O
function	O
for	O
HFE	O
.	O
.	O

Somatic	O
rearrangement	O
of	O
chromosome	O
14	O
in	O
human	O
lymphocytes	O
.	O

Ataxia	B
-	I
telangiectasia	I
is	O
a	O
rare	O
genetic	B
disorder	I
associated	O
with	O
immune	B
deficiency	I
,	O
chromosome	B
instability	I
,	O
and	O
a	O
predisposition	O
to	O
lymphoid	B
malignancy	I
.	O

We	O
have	O
detected	O
chromosomally	O
anomalous	O
clones	O
of	O
lymphocytes	O
in	O
eight	O
patients	O
with	O
this	O
disorder	O
.	O

Chromosome	O
banding	O
disclosed	O
that	O
the	O
clones	O
are	O
consistently	O
marked	O
by	O
structural	O
rearrangement	O
of	O
the	O
long	O
arm	O
(	O
q	O
)	O
of	O
chromosome	O
14	O
.	O

A	O
translocation	O
involving	O
14q	O
was	O
found	O
in	O
clones	O
obtained	O
from	O
seven	O
of	O
the	O
eight	O
patients	O
whereas	O
a	O
ring	O
14	O
chromosome	O
was	O
found	O
in	O
a	O
clone	O
obtained	O
from	O
the	O
other	O
.	O

These	O
findings	O
as	O
well	O
as	O
data	O
obtained	O
by	O
others	O
for	O
patients	O
with	O
ataxia	B
-	I
telangiectasia	I
suggest	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
the	O
initial	O
chromosomal	O
change	O
in	O
lymphocyte	O
clones	O
of	O
patients	O
with	O
this	O
disorder	O
.	O

Chromosomes	O
of	O
lymphocytes	O
from	O
one	O
of	O
the	O
patients	O
were	O
studied	O
before	O
and	O
after	O
the	O
onset	O
of	O
chronic	B
lymphocytic	I
leukemia	I
.	O

Before	O
leukemia	B
was	O
diagnosed	O
,	O
the	O
patient	O
had	O
a	O
lymphocyte	O
clone	O
with	O
a	O
14q	O
translocation	O
.	O

This	O
clone	O
appears	O
to	O
have	O
given	O
rise	O
to	O
the	O
leukemic	B
cells	O
.	O

We	O
hypothesize	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
directly	O
related	O
to	O
abnormal	O
growth	O
of	O
lymphocytes	O
and	O
that	O
it	O
may	O
be	O
a	O
step	O
toward	O
the	O
development	O
of	O
lymphoid	B
malignancies	I
.	O

Increasing	O
evidence	O
,	O
provided	O
by	O
others	O
,	O
for	O
the	O
nonrandom	O
involvement	O
of	O
14q	O
in	O
African	O
-	O
type	O
Burkitts	B
lymphoma	I
and	O
other	O
lymphoid	B
neoplasms	I
further	O
strengthens	O
this	O
hypothesis	O
.	O
.	O

Exon	O
9	O
mutations	O
in	O
the	O
WT1	O
gene	O
,	O
without	O
influencing	O
KTS	O
splice	O
isoforms	O
,	O
are	O
also	O
responsible	O
for	O
Frasier	B
syndrome	I
.	O

We	O
report	O
new	O
mutations	O
in	O
exon	O
9	O
of	O
the	O
WT1	O
gene	O
that	O
did	O
not	O
alter	O
the	O
ratio	O
of	O
+	O
/	O
-	O
KTS	O
splice	O
isoforms	O
in	O
two	O
unrelated	O
patients	O
with	O
Frasier	B
syndrome	I
(	O
FS	B
)	O
.	O

The	O
mutation	O
of	O
intron	O
9	O
inducing	O
defective	O
alternative	O
splicing	O
was	O
reported	O
to	O
be	O
responsible	O
for	O
this	O
syndrome	O
.	O

The	O
mutations	O
found	O
in	O
our	O
cases	O
occurred	O
in	O
the	O
same	O
exon	O
of	O
the	O
WT1	O
gene	O
as	O
detected	O
in	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
and	O
could	O
not	O
be	O
explained	O
by	O
the	O
previously	O
proposed	O
mechanism	O
.	O

The	O
results	O
suggest	O
that	O
the	O
two	O
syndromes	O
originate	O
from	O
the	O
same	O
WT1	B
gene	I
abnormality	I
.	O

From	O
a	O
molecular	O
biological	O
point	O
of	O
view	O
,	O
we	O
concluded	O
that	O
the	O
two	O
diseases	O
were	O
not	O
separable	O
,	O
and	O
that	O
FS	B
should	O
be	O
included	O
as	O
an	O
atypical	O
form	O
of	O
DDS	B
.	O
.	O

Splice	O
-	O
site	O
mutation	O
in	O
the	O
PDS	B
gene	O
may	O
result	O
in	O
intrafamilial	O
variability	O
for	O
deafness	B
in	O
Pendred	B
syndrome	I
.	O

Pendred	B
syndrome	I
is	O
a	O
recessive	B
inherited	I
disorder	I
that	O
consists	O
of	O
developmental	B
abnormalities	I
of	I
the	I
cochlea	I
,	O
sensorineural	B
hearing	I
loss	I
,	O
and	O
diffuse	B
thyroid	I
enlargement	I
(	O
goiter	B
)	O
.	O

This	O
disorder	O
may	O
account	O
for	O
up	O
to	O
10	O
%	O
of	O
cases	O
of	O
hereditary	B
deafness	I
.	O

The	O
disease	O
gene	O
(	O
PDS	B
)	O
has	O
been	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
,	O
and	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
individual	O
exons	O
of	O
the	O
PDS	B
gene	O
in	O
one	O
Spanish	O
family	O
that	O
shows	O
intrafamilial	O
variability	O
of	O
the	O
deafness	B
phenotype	O
(	O
two	O
patients	O
with	O
profound	O
and	O
one	O
with	O
moderate	O
-	O
severe	O
deafness	B
)	O
.	O

We	O
identified	O
a	O
new	O
splice	O
-	O
site	O
mutation	O
affecting	O
intron	O
4	O
of	O
the	O
PDS	B
gene	O
,	O
at	O
nucleotide	O
position	O
639	O
+	O
7	O
.	O

RNA	O
analysis	O
from	O
lymphocytes	O
of	O
the	O
affected	O
patients	O
showed	O
that	O
mutation	O
639	O
+	O
7A	O
-	O
-	O
>	O
G	O
generates	O
a	O
new	O
donor	O
splice	O
site	O
,	O
leading	O
to	O
an	O
mRNA	O
with	O
an	O
insertion	O
of	O
six	O
nucleotides	O
from	O
intron	O
4	O
of	O
PDS	O
.	O

Since	O
the	O
newly	O
created	O
donor	O
splice	O
site	O
is	O
likely	O
to	O
compete	O
with	O
the	O
normal	O
one	O
,	O
variations	O
of	O
the	O
levels	O
of	O
normal	O
and	O
aberrant	O
transcripts	O
of	O
the	O
PDS	B
gene	O
in	O
the	O
cochlea	O
may	O
explain	O
the	O
variability	O
in	O
the	O
deafness	B
presentation	O
.	O
.	O

The	O
molecular	O
basis	O
of	O
Sjogren	B
-	I
Larsson	I
syndrome	I
:	O
mutation	O
analysis	O
of	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene	O
.	O

Sjogren	B
-	I
Larsson	I
syndrome	I
(	O
SLS	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
ichthyosis	B
,	O
mental	B
retardation	I
,	O
spasticity	B
,	O
and	O
deficient	B
activity	I
of	I
fatty	I
aldehyde	I
dehydrogenase	I
(	O
FALDH	O
)	O
.	O

To	O
define	O
the	O
molecular	O
defects	O
causing	O
SLS	B
,	O
we	O
performed	O
mutation	O
analysis	O
of	O
the	O
FALDH	O
gene	O
in	O
probands	O
from	O
63	O
kindreds	O
with	O
SLS	B
.	O

Among	O
these	O
patients	O
,	O
49	O
different	O
mutations	O
-	O
including	O
10	O
deletions	O
,	O
2	O
insertions	O
,	O
22	O
amino	O
acid	O
substitutions	O
,	O
3	O
nonsense	O
mutations	O
,	O
9	O
splice	O
-	O
site	O
defects	O
,	O
and	O
3	O
complex	O
mutations	O
-	O
were	O
found	O
.	O

All	O
of	O
the	O
patients	O
with	O
SLS	B
were	O
found	O
to	O
carry	O
mutations	O
.	O

Nineteen	O
of	O
the	O
missense	O
mutations	O
resulted	O
in	O
a	O
severe	O
reduction	O
of	O
FALDH	O
enzyme	O
catalytic	O
activity	O
when	O
expressed	O
in	O
mammalian	O
cells	O
,	O
but	O
one	O
mutation	O
(	O
798G	O
-	O
-	O
>	O
C	O
[	O
K266N	O
]	O
)	O
seemed	O
to	O
have	O
a	O
greater	O
effect	O
on	O
mRNA	O
stability	O
.	O

The	O
splice	O
-	O
site	O
mutations	O
led	O
to	O
exon	O
skipping	O
or	O
utilization	O
of	O
cryptic	O
acceptor	O
-	O
splice	O
sites	O
.	O

Thirty	O
-	O
seven	O
mutations	O
were	O
private	O
,	O
and	O
12	O
mutations	O
were	O
seen	O
in	O
two	O
or	O
more	O
probands	O
of	O
European	O
or	O
Middle	O
Eastern	O
descent	O
.	O

Four	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
found	O
in	O
the	O
FALDH	O
gene	O
.	O

At	O
least	O
four	O
of	O
the	O
common	O
mutations	O
(	O
551C	O
-	O
-	O
>	O
T	O
,	O
682C	O
-	O
-	O
>	O
T	O
,	O
733G	O
-	O
-	O
>	O
A	O
,	O
and	O
798	O
+	O
1delG	O
)	O
were	O
associated	O
with	O
multiple	O
SNP	O
haplotypes	O
,	O
suggesting	O
that	O
these	O
mutations	O
originated	O
independently	O
on	O
more	O
than	O
one	O
occasion	O
or	O
were	O
ancient	O
SLS	B
genes	O
that	O
had	O
undergone	O
intragenic	O
recombination	O
.	O

Our	O
results	O
demonstrate	O
that	O
SLS	B
is	O
caused	O
by	O
a	O
strikingly	O
heterogeneous	O
group	O
of	O
mutations	O
in	O
the	O
FALDH	O
gene	O
and	O
provide	O
a	O
framework	O
for	O
understanding	O
the	O
genetic	O
basis	O
of	O
SLS	B
and	O
the	O
development	O
of	O
DNA	O
-	O
based	O
diagnostic	O
tests	O
.	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
cathepsin	O
C	O
gene	O
result	O
in	O
periodontal	B
disease	I
and	O
palmoplantar	B
keratosis	I
.	O

Papillon	B
-	I
Lefevre	I
syndrome	I
,	O
or	O
keratosis	B
palmoplantaris	I
with	O
periodontopathia	B
(	O
PLS	B
,	O
MIM	O
245000	O
)	O
,	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	O
periodontitis	B
that	O
afflicts	O
patients	O
.	O

Both	O
the	O
deciduous	O
and	O
permanent	O
dentitions	O
are	O
affected	O
,	O
resulting	O
in	O
premature	O
tooth	B
loss	I
.	O

Palmoplantar	B
keratosis	I
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	O
to	O
overt	O
hyperkeratosis	B
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life	O
.	O

Keratosis	B
also	O
affects	O
other	O
sites	O
such	O
as	O
elbows	O
and	O
knees	O
.	O

Most	O
PLS	B
patients	O
display	O
both	O
periodontitis	B
and	O
hyperkeratosis	B
.	O

Some	O
patients	O
have	O
only	O
palmoplantar	B
keratosis	I
or	O
periodontitis	B
,	O
and	O
in	O
rare	O
individuals	O
the	O
periodontitis	B
is	O
mild	O
and	O
of	O
late	O
onset	O
.	O

The	O
PLS	O
locus	O
has	O
been	O
mapped	O
to	O
chromosome	O
11q14	O
-	O
q21	O
(	O
refs	O
7	O
,	O
8	O
,	O
9	O
)	O
.	O

Using	O
homozygosity	O
mapping	O
in	O
eight	O
small	O
consanguineous	O
families	O
,	O
we	O
have	O
narrowed	O
the	O
candidate	O
region	O
to	O
a	O
1	O
.	O

2	O
-	O
cM	O
interval	O
between	O
D11S4082	O
and	O
D11S931	O
.	O

The	O
gene	O
(	O
CTSC	O
)	O
encoding	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
(	O
or	O
dipeptidyl	O
aminopeptidase	O
I	O
)	O
lies	O
within	O
this	O
interval	O
.	O

We	O
defined	O
the	O
genomic	O
structure	O
of	O
CTSC	O
and	O
found	O
mutations	O
in	O
all	O
eight	O
families	O
.	O

In	O
two	O
of	O
these	O
families	O
we	O
used	O
a	O
functional	O
assay	O
to	O
demonstrate	O
an	O
almost	O
total	O
loss	O
of	O
cathepsin	O
C	O
activity	O
in	O
PLS	B
patients	O
and	O
reduced	O
activity	O
in	O
obligate	O
carriers	O
.	O

Confirmation	O
of	O
linkage	O
of	O
Van	B
der	I
Woude	I
syndrome	I
to	O
chromosome	O
1q32	O
:	O
evidence	O
of	O
association	O
with	O
STR	O
alleles	O
suggests	O
possible	O
unique	O
origin	O
of	O
the	O
disease	O
mutation	O
.	O

Van	B
der	I
Woude	I
syndrome	I
(	O
VWS	B
)	O
is	O
an	O
autosomal	B
dominant	I
craniofacial	I
disorder	I
with	O
high	O
penetrance	O
and	O
variable	O
expression	O
.	O

Its	O
clinical	O
features	O
are	O
variably	O
expressed	O
,	O
but	O
include	O
cleft	B
lip	I
and	O
/	O
or	O
cleft	B
palate	I
,	O
lip	B
pits	I
and	O
hypodontia	B
.	O

All	O
VWS	B
families	O
studied	O
to	O
date	O
map	O
the	O
disease	O
gene	O
to	O
a	O
<	O
2	O
cM	O
region	O
of	O
chromosome	O
1q32	O
,	O
with	O
no	O
evidence	O
of	O
locus	O
heterogeneity	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
refine	O
the	O
localization	O
of	O
the	O
VWS	B
gene	O
and	O
to	O
further	O
assess	O
possible	O
heterogeneity	O
.	O

We	O
analyzed	O
four	O
multiplex	O
VWS	B
families	O
.	O

All	O
available	O
members	O
were	O
clinically	O
assessed	O
and	O
genotyped	O
for	O
19	O
short	O
tandem	O
repeat	O
markers	O
on	O
chromosome	O
1	O
in	O
the	O
VWS	B
candidate	O
gene	O
region	O
.	O

We	O
performed	O
two	O
-	O
point	O
and	O
multipoint	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
score	O
analyses	O
using	O
a	O
high	O
penetrance	O
autosomal	O
dominant	O
model	O
.	O

All	O
families	O
showed	O
positive	O
LOD	O
scores	O
without	O
any	O
recombination	O
in	O
the	O
candidate	O
region	O
.	O

The	O
largest	O
two	O
-	O
point	O
LOD	O
score	O
was	O
5	O
.	O

87	O
87	O
.	O

Our	O
assay	O
method	O
for	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
provided	O
highly	O
accurate	O
size	O
estimation	O
of	O
marker	O
allele	O
fragment	O
sizes	O
,	O
and	O
therefore	O
enabled	O
us	O
to	O
determine	O
the	O
specific	O
alleles	O
segregating	O
with	O
the	O
VWS	B
gene	O
in	O
each	O
of	O
our	O
four	O
families	O
.	O

We	O
observed	O
a	O
striking	O
pattern	O
of	O
STR	O
allele	O
sharing	O
at	O
several	O
closely	O
linked	O
loci	O
among	O
our	O
four	O
Caucasian	O
VWS	B
families	O
recruited	O
at	O
three	O
different	O
locations	O
in	O
the	O
US	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
of	O
a	O
unique	O
origin	O
for	O
a	O
mutation	O
responsible	O
for	O
many	O
or	O
most	O
cases	O
of	O
VWS	B
.	O

A	O
point	O
mutation	O
Thr	O
(	O
799	O
)	O
Met	O
on	O
the	O
alpha	O
(	O
2	O
)	O
integrin	O
leads	O
to	O
the	O
formation	O
of	O
new	O
human	O
platelet	O
alloantigen	O
Sit	O
(	O
a	O
)	O
and	O
affects	O
collagen	O
-	O
induced	O
aggregation	O
.	O

A	O
new	O
platelet	O
-	O
specific	O
alloantigen	O
,	O
termed	O
Sit	O
(	O
a	O
)	O
,	O
was	O
identified	O
in	O
a	O
severe	O
case	O
of	O
neonatal	B
alloimmune	I
thrombocytopenia	I
.	O

The	O
Sit	O
(	O
a	O
)	O
alloantigen	O
is	O
of	O
low	O
frequency	O
(	O
1	O
/	O
400	O
)	O
in	O
the	O
German	O
population	O
.	O

Immunochemical	O
studies	O
demonstrated	O
that	O
the	O
Sit	O
(	O
a	O
)	O
epitopes	O
reside	O
on	O
platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ia	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
GPIa	O
cDNA	O
derived	O
from	O
Sit	O
(	O
a	O
)	O
-	O
positive	O
platelets	O
showed	O
C	O
(	O
2531	O
)	O
-	O
-	O
>	O
T	O
(	O
2531	O
)	O
point	O
mutation	O
,	O
resulting	O
in	O
Thr	O
(	O
799	O
)	O
Met	O
dimorphism	O
.	O

Analysis	O
of	O
genomic	O
DNA	O
from	O
22	O
Sit	O
(	O
a	O
)	O
-	O
negative	O
normal	O
individuals	O
showed	O
that	O
the	O
Thr	O
(	O
799	O
)	O
is	O
encoded	O
by	O
ACG	O
(	O
2532	O
)	O
(	O
90	O
.	O
9	O
%	O
)	O
or	O
ACA	O
(	O
2532	O
)	O
(	O
9	O
.	O
1	O
%	O
)	O
.	O

To	O
establish	O
a	O
DNA	O
typing	O
technique	O
,	O
we	O
elucidated	O
the	O
organization	O
of	O
the	O
GPIa	O
gene	O
adjacent	O
to	O
the	O
polymorphic	O
bases	O
.	O

The	O
introns	O
(	O
421	O
bp	O
and	O
1	O
.	O
2	O
kb	O
)	O
encompass	O
a	O
142	O
-	O
bp	O
exon	O
with	O
the	O
2	O
polymorphic	O
bases	O
2531	O
and	O
2532	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
on	O
DNA	O
derived	O
from	O
100	O
donors	O
using	O
the	O
restriction	O
enzyme	O
Mae	O
III	O
showed	O
that	O
the	O
Met	O
(	O
799	O
)	O
form	O
of	O
GPIa	O
is	O
restricted	O
to	O
Sit	O
(	O
a	O
)	O
(	O
+	O
)	O
phenotype	O
.	O

Analysis	O
of	O
stable	O
Chinese	O
hamster	O
ovary	O
transfectants	O
expressing	O
allele	O
-	O
specific	O
recombinant	O
forms	O
of	O
GPIa	O
showed	O
that	O
anti	O
-	O
Sit	O
(	O
a	O
)	O
exclusively	O
reacted	O
with	O
the	O
Glu	O
(	O
505	O
)	O
Met	O
(	O
799	O
)	O
,	O
but	O
not	O
with	O
the	O
Glu	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
and	O
the	O
Lys	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
isoforms	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
Br	O
(	O
a	O
)	O
(	O
HPA	O
-	O
5b	O
)	O
only	O
recognized	O
the	O
Lys	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
form	O
,	O
whereas	O
anti	O
-	O
Br	O
(	O
b	O
)	O
(	O
HPA	O
-	O
5a	O
)	O
reacted	O
with	O
both	O
Glu	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
and	O
Glu	O
(	O
505	O
)	O
Met	O
(	O
799	O
)	O
isoforms	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
Met	O
(	O
799	O
)	O
is	O
responsible	O
for	O
formation	O
of	O
the	O
Sit	O
(	O
a	O
)	O
alloantigenic	O
determinants	O
,	O
whereas	O
amino	O
acid	O
505	O
(	O
Lys	O
or	O
Glu	O
)	O
specifically	O
controls	O
the	O
expression	O
of	O
Br	O
(	O
a	O
)	O
and	O
Br	O
(	O
b	O
)	O
epitopes	O
,	O
respectively	O
.	O

Platelet	O
aggregation	O
responses	O
of	O
Sit	O
(	O
a	O
)	O
(	O
+	O
)	O
individuals	O
were	O
diminished	O
in	O
response	O
to	O
collagen	O
,	O
indicating	O
that	O
the	O
Thr	O
(	O
799	O
)	O
Met	O
mutation	O
affects	O
the	O
function	O
of	O
the	O
GPIa	O
/	O
IIa	O
complex	O

Mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
are	O
responsible	O
for	O
Papillon	B
-	I
Lefevre	I
syndrome	I
.	O

Papillon	B
-	I
Lefevre	I
syndrome	I
(	O
PLS	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterised	O
by	O
palmoplantar	B
hyperkeratosis	I
and	O
severe	O
early	O
onset	O
periodontitis	B
that	O
results	O
in	O
the	O
premature	O
loss	O
of	O
the	O
primary	O
and	O
secondary	O
dentitions	O
.	O

A	O
major	O
gene	O
locus	O
for	O
PLS	B
has	O
been	O
mapped	O
to	O
a	O
2	O
.	O

8	O
cM	O
interval	O
on	O
chromosome	O
11q14	O
.	O

Correlation	O
of	O
physical	O
and	O
genetic	O
maps	O
of	O
this	O
interval	O
indicate	O
it	O
includes	O
at	O
least	O
40	O
ESTs	O
and	O
six	O
known	O
genes	O
including	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
gene	O
(	O
CTSC	O
)	O
.	O

The	O
CTSC	O
message	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
a	O
variety	O
of	O
immune	O
cells	O
including	O
polymorphonuclear	O
leucocytes	O
,	O
macrophages	O
,	O
and	O
their	O
precursors	O
.	O

By	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
CTSC	O
is	O
also	O
expressed	O
in	O
epithelial	O
regions	O
commonly	O
affected	O
by	O
PLS	B
,	O
including	O
the	O
palms	O
,	O
soles	O
,	O
knees	O
,	O
and	O
oral	O
keratinised	O
gingiva	O
.	O

The	O
4	O
.	O

7	O
kb	O
CTSC	O
gene	O
consists	O
of	O
two	O
exons	O
.	O

Sequence	O
analysis	O
of	O
CTSC	O
from	O
subjects	O
affected	O
with	O
PLS	B
from	O
five	O
consanguineous	O
Turkish	O
families	O
identified	O
four	O
different	O
mutations	O
.	O

An	O
exon	O
1	O
nonsense	O
mutation	O
(	O
856C	O
-	O
-	O
>	O
T	O
)	O
introduces	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
286	O
.	O

Three	O
exon	O
2	O
mutations	O
were	O
identified	O
,	O
including	O
a	O
single	O
nucleotide	O
deletion	O
(	O
2692delA	O
)	O
of	O
codon	O
349	O
introducing	O
a	O
frameshift	O
and	O
premature	O
termination	O
codon	O
,	O
a	O
2	O
bp	O
deletion	O
(	O
2673	O
-	O
2674delCT	O
)	O
that	O
results	O
in	O
introduction	O
of	O
a	O
stop	O
codon	O
at	O
amino	O
acid	O
343	O
,	O
and	O
a	O
G	O
-	O
-	O
>	O
A	O
substitution	O
in	O
codon	O
429	O
(	O
2931G	O
-	O
-	O
>	O
A	O
)	O
introducing	O
a	O
premature	O
termination	O
codon	O
.	O

All	O
PLS	B
patients	O
were	O
homozygous	O
for	O
cathepsin	O
C	O
mutations	O
inherited	O
from	O
a	O
common	O
ancestor	O
.	O

Parents	O
and	O
sibs	O
heterozygous	O
for	O
cathepsin	O
C	O
mutations	O
do	O
not	O
show	O
either	O
the	O
palmoplantar	B
hyperkeratosis	I
or	O
severe	O
early	O
onset	O
periodontitis	B
characteristic	O
of	O
PLS	B
.	O

A	O
more	O
complete	O
understanding	O
of	O
the	O
functional	O
physiology	O
of	O
cathepsin	O
C	O
carries	O
significant	O
implications	O
for	O
understanding	O
normal	O
and	O
abnormal	O
skin	O
development	O
and	O
periodontal	B
disease	I
susceptibility	O

Mutational	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
Finnish	O
alkaptonuria	B
patients	O
.	O

Alkaptonuria	B
(	O
AKU	B
)	O
,	O
the	O
prototypic	O
inborn	B
error	I
of	I
metabolism	I
,	O
has	O
recently	O
been	O
shown	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
homogentisate	O
-	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

So	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
AKU	B
patients	O
of	O
different	O
ethnic	O
origin	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
(	O
R58fs	O
,	O
R330S	O
,	O
and	O
H371R	O
)	O
and	O
one	O
common	O
AKU	B
mutation	O
(	O
M368V	O
)	O
,	O
detected	O
by	O
mutational	O
and	O
polymorphism	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
five	O
Finnish	O
AKU	B
pedigrees	O
.	O

The	O
three	O
novel	O
AKU	B
mutations	O
are	O
most	O
likely	O
specific	O
for	O
the	O
Finnish	O
population	O
and	O
have	O
originated	O
recently	O
.	O
.	O

The	O
identical	O
5	O
'	O
splice	O
-	O
site	O
acceptor	O
mutation	O
in	O
five	O
attenuated	B
APC	I
families	O
from	O
Newfoundland	O
demonstrates	O
a	O
founder	O
effect	O
.	O

Inherited	O
mutations	O
of	O
the	O
APC	B
gene	O
predispose	O
carriers	O
to	O
multiple	O
adenomatous	B
polyps	I
of	I
the	I
colon	I
and	I
rectum	I
and	O
to	O
colorectal	B
cancer	I
.	O

Mutations	O
located	O
at	O
the	O
extreme	O
5	O
end	O
of	O
the	O
APC	B
gene	O
,	O
however	O
,	O
are	O
associated	O
with	O
a	O
less	O
severe	O
disease	O
known	O
as	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

Many	O
individuals	O
with	O
AAPC	B
develop	O
relatively	O
few	O
colorectal	B
polyps	I
but	O
are	O
still	O
at	O
high	O
risk	O
for	O
colorectal	B
cancer	I
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
5	O
APC	B
germline	O
mutation	O
in	O
five	O
separately	O
ascertained	O
AAPC	B
families	O
from	O
Newfoundland	O
,	O
Canada	O
.	O

This	O
disease	O
-	O
causing	O
mutation	O
is	O
a	O
single	O
basepair	O
change	O
(	O
G	O
to	O
A	O
)	O
in	O
the	O
splice	O
-	O
acceptor	O
region	O
of	O
APC	B
intron	O
3	O
that	O
creates	O
a	O
mutant	O
RNA	O
without	O
exon	O
4	O
of	O
APC	O
.	O

The	O
observation	O
of	O
the	O
same	O
APC	B
mutation	O
in	O
five	O
families	O
from	O
the	O
same	O
geographic	O
area	O
demonstrates	O
a	O
founder	O
effect	O
.	O

Furthermore	O
,	O
the	O
identification	O
of	O
this	O
germline	O
mutation	O
strengthens	O
the	O
correlation	O
between	O
the	O
5	O
location	O
of	O
an	O
APC	B
disease	O
-	O
causing	O
mutation	O
and	O
the	O
attenuated	B
polyposis	I
phenotype	O
.	O
.	O

Alstrom	B
syndrome	I
:	O
further	O
evidence	O
for	O
linkage	O
to	O
human	O
chromosome	O
2p13	O
.	O

Alstrom	B
syndrome	I
is	O
a	O
rare	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
retinal	B
degeneration	I
,	O
sensorineural	B
hearing	I
loss	I
,	O
early	O
-	O
onset	O
obesity	B
,	O
and	O
non	B
-	I
insulin	I
-	I
dependent	I
diabetes	I
mellitus	I
.	O

The	O
gene	O
for	O
Alstrom	B
syndrome	I
(	O
ALMS1	O
)	O
has	O
been	O
previously	O
localized	O
to	O
human	O
chromosome	O
2p13	O
by	O
homozygosity	O
mapping	O
in	O
two	O
distinct	O
isolated	O
populations	O
-	O
French	O
Acadian	O
and	O
North	O
African	O
.	O

Pair	O
-	O
wise	O
analyses	O
resulted	O
in	O
maximum	O
lod	O
(	O
logarithm	O
of	O
the	O
odds	O
ratio	O
)	O
scores	O
of	O
3	O
.	O

84	O
and	O
2	O
.	O

9	O
,	O
respectively	O
.	O

To	O
confirm	O
these	O
findings	O
,	O
a	O
large	O
linkage	O
study	O
was	O
performed	O
in	O
twelve	O
additional	O
families	O
segregating	O
for	O
Alstrom	B
syndrome	I
.	O

A	O
maximum	O
two	O
-	O
point	O
lod	O
score	O
of	O
7	O
.	O

13	O
(	O
theta	O
=	O
0	O
.	O
00	O
)	O
for	O
marker	O
D2S2110	O
and	O
a	O
maximum	O
cumulative	O
multipoint	O
lod	O
score	O
of	O
9	O
.	O

16	O
for	O
marker	O
D2S2110	O
were	O
observed	O
,	O
further	O
supporting	O
linkage	O
to	O
chromosome	O
2p13	O
.	O

No	O
evidence	O
of	O
genetic	O
heterogeneity	O
was	O
observed	O
in	O
these	O
families	O
.	O

Meiotic	O
recombination	O
events	O
have	O
localized	O
the	O
critical	O
region	O
containing	O
ALMS1	O
to	O
a	O
6	O
.	O

1	O
-	O
cM	O
interval	O
flanked	O
by	O
markers	O
D2S327	O
and	O
D2S286	O
.	O

A	O
fine	O
resolution	O
radiation	O
hybrid	O
map	O
of	O
31	O
genes	O
and	O
markers	O
has	O
been	O
constructed	O
.	O

Pendred	B
syndrome	I
:	O
phenotypic	O
variability	O
in	O
two	O
families	O
carrying	O
the	O
same	O
PDS	B
missense	O
mutation	O
.	O

Pendred	B
syndrome	I
comprises	O
congenital	B
sensorineural	I
hearing	I
loss	I
,	O
thyroid	B
goiter	I
,	O
and	O
positive	O
perchlorate	O
discharge	O
test	O
.	O

Recently	O
,	O
this	O
autosomal	B
recessive	I
disorder	I
was	O
shown	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
PDS	B
gene	O
,	O
which	O
encodes	O
an	O
anion	O
transporter	O
called	O
pendrin	O
.	O

Molecular	O
analysis	O
of	O
the	O
PDS	B
gene	O
was	O
performed	O
in	O
two	O
consanguineous	O
large	O
families	O
from	O
Southern	O
Tunisia	O
comprising	O
a	O
total	O
of	O
23	O
individuals	O
affected	O
with	O
profound	O
congenital	B
deafness	I
;	O
the	O
same	O
missense	O
mutation	O
,	O
L445W	O
,	O
was	O
identified	O
in	O
all	O
affected	O
individuals	O
.	O

A	O
widened	B
vestibular	I
aqueduct	I
was	O
found	O
in	O
all	O
patients	O
who	O
underwent	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
exploration	O
of	O
the	O
inner	O
ear	O
.	O

In	O
contrast	O
,	O
goiter	B
was	O
present	O
in	O
only	O
11	O
affected	O
individuals	O
,	O
who	O
interestingly	O
had	O
a	O
normal	O
result	O
of	O
the	O
perchlorate	O
discharge	O
test	O
whenever	O
performed	O
.	O

The	O
present	O
results	O
question	O
the	O
sensitivity	O
of	O
the	O
perchlorate	O
test	O
for	O
the	O
diagnosis	O
of	O
Pendred	B
syndrome	I
and	O
support	O
the	O
use	O
of	O
a	O
molecular	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
the	O
assessment	O
of	O
individuals	O
with	O
severe	O
to	O
profound	O
congenital	B
hearing	I
loss	I
associated	O
with	O
inner	B
ear	I
morphological	I
anomaly	I
even	O
in	O
the	O
absence	O
of	O
a	O
thyroid	B
goiter	I
.	O
.	O

Knobloch	B
syndrome	I
involving	O
midline	B
scalp	I
defect	I
of	I
the	I
frontal	I
region	I
.	O

We	O
report	O
on	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
Knobloch	B
syndrome	I
.	O

He	O
has	O
vitreoretinal	B
degeneration	I
,	O
high	B
myopia	I
,	O
cataract	B
,	O
telecanthus	B
,	O
hypertelorism	B
,	O
and	O
a	O
high	B
-	I
arched	I
palate	I
.	O

He	O
also	O
has	O
a	O
defect	B
of	I
the	I
anterior	I
midline	I
scalp	I
with	O
involvement	O
of	O
the	O
frontal	O
bone	O
as	O
documented	O
by	O
a	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
.	O

The	O
brain	O
was	O
normal	O
on	O
CT	O
scan	O
and	O
magnetic	O
resonance	O
imaging	O
.	O

We	O
present	O
a	O
review	O
of	O
the	O
23	O
published	O
cases	O
with	O
this	O
syndrome	O
.	O

Our	O
patient	O
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	O
nervous	O
system	O
pathology	O
whenever	O
midline	B
scalp	I
defects	I
are	O
present	O
.	O
.	O

The	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
gene	O
hMRE11	O
is	O
mutated	O
in	O
individuals	O
with	O
an	O
ataxia	B
-	I
telangiectasia	I
-	I
like	I
disorder	I
.	O

We	O
show	O
that	O
hypomorphic	O
mutations	O
in	O
hMRE11	O
,	O
but	O
not	O
in	O
ATM	O
,	O
are	O
present	O
in	O
certain	O
individuals	O
with	O
an	O
ataxia	B
-	I
telangiectasia	I
-	I
like	I
disorder	I
(	O
ATLD	B
)	O
.	O

The	O
cellular	O
features	O
resulting	O
from	O
these	O
hMRE11	O
mutations	O
are	O
similar	O
to	O
those	O
seen	O
in	O
A	B
-	I
T	I
as	O
well	O
as	O
NBS	B
and	O
include	O
hypersensitivity	B
to	I
ionizing	I
radiation	I
,	O
radioresistant	O
DNA	O
synthesis	O
,	O
and	O
abrogation	O
of	O
ATM	O
-	O
dependent	O
events	O
,	O
such	O
as	O
the	O
activation	O
of	O
Jun	O
kinase	O
following	O
exposure	O
to	O
gamma	O
irradiation	O
.	O

Although	O
the	O
mutant	O
hMre11	O
proteins	O
retain	O
some	O
ability	O
to	O
interact	O
with	O
hRad50	O
and	O
Nbs1	O
,	O
formation	O
of	O
ionizing	O
radiation	O
-	O
induced	O
hMre11	O
and	O
Nbs1	O
foci	O
was	O
absent	O
in	O
hMRE11	O
mutant	O
cells	O
.	O

These	O
data	O
demonstrate	O
that	O
ATM	O
and	O
the	O
hMre11	O
/	O
hRad50	O
/	O
Nbs1	O
protein	O
complex	O
act	O
in	O
the	O
same	O
DNA	O
damage	O
response	O
pathway	O
and	O
link	O
hMre11	O
to	O
the	O
complex	O
pathology	O
of	O
A	B
-	I
T	I
.	O
.	O

Mutations	O
in	O
TNFRSF11A	O
,	O
affecting	O
the	O
signal	O
peptide	O
of	O
RANK	O
,	O
cause	O
familial	B
expansile	I
osteolysis	I
.	O

Familial	B
expansile	I
osteolysis	I
(	O
FEO	B
,	O
MIM	O
174810	O
)	O
is	O
a	O
rare	O
,	O
autosomal	B
dominant	I
bone	I
disorder	I
characterized	O
by	O
focal	O
areas	O
of	O
increased	B
bone	I
remodelling	I
.	O

The	O
osteolytic	B
lesions	I
,	O
which	O
develop	O
usually	O
in	O
the	O
long	O
bones	O
during	O
early	O
adulthood	O
,	O
show	O
increased	O
osteoblast	O
and	O
osteoclast	O
activity	O
.	O

Our	O
previous	O
linkage	O
studies	O
mapped	O
the	O
gene	O
responsible	O
for	O
FEO	B
to	O
an	O
interval	O
of	O
less	O
than	O
5	O
cM	O
between	O
D18S64	O
and	O
D18S51	O
on	O
chromosome	O
18q21	O
.	O

2	O
-	O
21	O
2	O
-	O
21	O
.	O

3	O
in	O
a	O
large	O
Northern	O
Irish	O
family	O
.	O

The	O
gene	O
encoding	O
receptor	O
activator	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
RANK	O
;	O
ref	O
.	O
5	O
)	O
,	O
TNFRSF11A	O
,	O
maps	O
to	O
this	O
region	O
.	O

RANK	O
is	O
essential	O
in	O
osteoclast	O
formation	O
.	O

We	O
identified	O
two	O
heterozygous	O
insertion	O
mutations	O
in	O
exon	O
1	O
of	O
TNFRSF11A	O
in	O
affected	O
members	O
of	O
four	O
families	O
with	O
FEO	B
or	O
familial	B
Paget	I
disease	I
of	I
bone	I
(	O
PDB	B
)	O
.	O

One	O
was	O
a	O
duplication	O
of	O
18	O
bases	O
and	O
the	O
other	O
a	O
duplication	O
of	O
27	O
bases	O
,	O
both	O
of	O
which	O
affected	O
the	O
signal	O
peptide	O
region	O
of	O
the	O
RANK	O
molecule	O
.	O

Expression	O
of	O
recombinant	O
forms	O
of	O
the	O
mutant	O
RANK	O
proteins	O
revealed	O
perturbations	O
in	O
expression	O
levels	O
and	O
lack	O
of	O
normal	O
cleavage	O
of	O
the	O
signal	O
peptide	O
.	O

Both	O
mutations	O
caused	O
an	O
increase	O
in	O
RANK	O
-	O
mediated	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
signalling	O
in	O
vitro	O
,	O
consistent	O
with	O
the	O
presence	O
of	O
an	O
activating	O
mutation	O
.	O

Cardiac	O
Na	O
(	O
+	O
)	O
channel	O
dysfunction	O
in	O
Brugada	B
syndrome	I
is	O
aggravated	O
by	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
.	O

BACKGROUND	O
Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	O
cardiac	O
Na	O
(	O
+	O
)	O
channel	O
alpha	O
-	O
subunit	O
(	O
hH1	O
)	O
are	O
responsible	O
for	O
chromosome	O
3	O
-	O
linked	O
congenital	B
long	I
-	I
QT	I
syndrome	I
(	O
LQT3	B
)	O
and	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O
.	O

An	O
auxiliary	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
,	O
widely	O
expressed	O
in	O
excitable	O
tissues	O
,	O
shifts	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	O
inactivation	O
toward	O
more	O
negative	O
potentials	O
and	O
restores	O
normal	O
gating	O
kinetics	O
of	O
brain	O
and	O
skeletal	O
muscle	O
Na	O
(	O
+	O
)	O
channels	O
expressed	O
in	O
Xenopus	O
oocytes	O
but	O
has	O
little	O
if	O
any	O
functional	O
effect	O
on	O
the	O
cardiac	O
isoform	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
altered	O
effects	O
of	O
a	O
human	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
(	O
hbeta	O
(	O
1	O
)	O
)	O
on	O
the	O
heterologously	O
expressed	O
hH1	O
mutation	O
(	O
T1620M	O
)	O
previously	O
associated	O
with	O
IVF	B
.	O

METHODS	O
AND	O
RESULTS	O
When	O
expressed	O
alone	O
in	O
Xenopus	O
oocytes	O
,	O
T1620M	O
exhibited	O
no	O
persistent	O
currents	O
,	O
in	O
contrast	O
to	O
the	O
LQT3	B
mutant	O
channels	O
,	O
but	O
the	O
midpoint	O
of	O
steady	O
-	O
state	O
inactivation	O
(	O
V	O
(	O
1	O
/	O
2	O
)	O
)	O
was	O
significantly	O
shifted	O
toward	O
more	O
positive	O
potentials	O
than	O
for	O
wild	O
-	O
type	O
hH1	O
.	O

Coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
did	O
not	O
significantly	O
alter	O
current	O
decay	O
or	O
recovery	O
from	O
inactivation	O
of	O
wild	O
-	O
type	O
hH1	O
;	O
however	O
,	O
it	O
further	O
shifted	O
the	O
V	O
(	O
1	O
/	O
2	O
)	O
and	O
accelerated	O
the	O
recovery	O
from	O
inactivation	O
of	O
T1620M	O
.	O

Oocyte	O
macropatch	O
analysis	O
revealed	O
that	O
the	O
activation	O
kinetics	O
of	O
T1620M	O
were	O
normal	O
.	O

CONCLUSIONS	O
It	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
exposes	O
a	O
more	O
severe	O
functional	O
defect	O
that	O
results	O
in	O
a	O
greater	O
overlap	O
in	O
the	O
relationship	O
between	O
channel	O
inactivation	O
and	O
activation	O
(	O
window	O
current	O
)	O
in	O
T1620M	O
,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
pathophysiological	O
mechanism	O
of	O
IVF	B
in	O
vivo	O
.	O

One	O
possible	O
explanation	O
for	O
our	O
finding	O
is	O
an	O
altered	O
alpha	O
-	O
/	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
association	O
in	O
the	O
mutant	O
.	O
.	O

Meiotic	O
segregation	O
analysis	O
of	O
RB1	O
alleles	O
in	O
retinoblastoma	B
pedigrees	O
by	O
use	O
of	O
single	O
-	O
sperm	O
typing	O
.	O

In	O
hereditary	B
retinoblastoma	I
,	O
different	O
epidemiological	O
studies	O
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	O
of	O
mutant	O
retinoblastoma	B
alleles	O
to	O
offspring	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
meiotic	O
drive	O
.	O

To	O
investigate	O
this	O
mechanism	O
,	O
we	O
analyzed	O
sperm	O
samples	O
from	O
six	O
individuals	O
from	O
five	O
unrelated	O
families	O
affected	O
with	O
hereditary	B
retinoblastoma	I
.	O

Single	O
-	O
sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	O
of	O
two	O
informative	O
short	O
tandem	O
repeats	O
located	O
either	O
in	O
or	O
close	O
to	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

The	O
segregation	O
probability	O
of	O
mutant	O
RB1	O
alleles	O
in	O
sperm	O
samples	O
was	O
assessed	O
by	O
use	O
of	O
the	O
SPERMSEG	O
program	O
,	O
which	O
includes	O
experimental	O
parameters	O
,	O
recombination	O
fractions	O
between	O
the	O
markers	O
,	O
and	O
segregation	O
parameters	O
.	O

A	O
total	O
of	O
2	O
,	O
952	O
single	O
sperm	O
from	O
the	O
six	O
donors	O
were	O
analyzed	O
.	O

We	O
detected	O
a	O
significant	O
segregation	O
distortion	O
in	O
the	O
data	O
as	O
a	O
whole	O
(	O
P	O
=	O
.	O
0099	O
)	O
and	O
a	O
significant	O
heterogeneity	O
in	O
the	O
segregation	O
rate	O
across	O
donors	O
(	O
.	O
0092	O
)	O
.	O

Further	O
analysis	O
shows	O
that	O
this	O
result	O
can	O
be	O
explained	O
by	O
segregation	O
distortion	O
in	O
favor	O
of	O
the	O
normal	O
allele	O
in	O
one	O
donor	O
only	O
and	O
that	O
it	O
does	O
not	O
provide	O
evidence	O
of	O
a	O
significant	O
segregation	O
distortion	O
in	O
the	O
other	O
donors	O
.	O

The	O
segregation	O
distortion	O
favoring	O
the	O
mutant	O
RB1	O
allele	O
does	O
not	O
seem	O
to	O
occur	O
during	O
spermatogenesis	O
,	O
and	O
,	O
thus	O
,	O
meiotic	O
drive	O
may	O
result	O
either	O
from	O
various	O
mechanisms	O
,	O
including	O
a	O
fertilization	O
advantage	O
or	O
a	O
better	O
mobility	O
in	O
sperm	O
bearing	O
a	O
mutant	O
RB1	O
gene	O
,	O
or	O
from	O
the	O
existence	O
of	O
a	O
defectively	O
imprinted	O
gene	O
located	O
on	O
the	O
human	O
X	O
chromosome	O
.	O

Friedreich	B
ataxia	I
:	O
an	O
overview	O
.	O

Friedreich	B
ataxia	I
,	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disease	I
,	O
is	O
the	O
most	O
common	O
of	O
the	O
inherited	B
ataxias	I
.	O

The	O
recent	O
discovery	O
of	O
the	O
gene	O
that	O
is	O
mutated	O
in	O
this	O
condition	O
,	O
FRDA	O
,	O
has	O
led	O
to	O
rapid	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
Friedreich	B
ataxia	I
.	O

About	O
98	O
%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene	O
.	O

This	O
leads	O
to	O
reduced	O
levels	O
of	O
the	O
protein	O
,	O
frataxin	O
.	O

There	O
is	O
mounting	O
evidence	O
to	O
suggest	O
that	O
Friedreich	B
ataxia	I
is	O
the	O
result	O
of	O
accumulation	O
of	O
iron	O
in	O
mitochondria	O
leading	O
to	O
excess	O
production	O
of	O
free	O
radicals	O
,	O
which	O
then	O
results	O
in	O
cellular	O
damage	O
and	O
death	O
.	O

Currently	O
there	O
is	O
no	O
known	O
treatment	O
that	O
alters	O
the	O
natural	O
course	O
of	O
the	O
disease	O
.	O

The	O
discovery	O
of	O
the	O
FRDA	B
gene	O
and	O
its	O
possible	O
function	O
has	O
raised	O
hope	O
that	O
rational	O
therapeutic	O
strategies	O
will	O
be	O
developed	O
.	O
.	O

X	B
-	I
linked	I
retinoschisis	I
with	O
point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O

BACKGROUND	O
X	B
-	I
linked	I
retinoschisis	I
(	O
XLRS	B
)	O
is	O
a	O
relatively	O
rare	O
vitreoretinal	B
dystrophy	I
that	O
causes	O
visual	B
loss	I
in	O
young	O
men	O
.	O

Recently	O
,	O
a	O
gene	O
responsible	O
for	O
this	O
disease	O
,	O
designated	O
XLRS1	O
,	O
was	O
identified	O
,	O
and	O
several	O
deleterious	O
gene	O
mutations	O
were	O
reported	O
.	O

OBJECTIVE	O
To	O
analyze	O
Japanese	O
patients	O
clinically	O
diagnosed	O
as	O
having	O
XLRS	B
formutational	O
changes	O
in	O
the	O
XLRS1	O
gene	O
.	O

METHODS	O
Ten	O
patients	O
with	O
XLRS	B
underwent	O
full	O
ophthalmologic	O
examination	O
,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
dilated	O
funduscopy	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
,	O
and	O
all	O
exons	O
of	O
the	O
XLRS1	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
using	O
a	O
direct	O
sequencing	O
method	O
.	O

RESULTS	O
Point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
were	O
identified	O
in	O
all	O
10	O
patients	O
.	O

The	O
mutations	O
were	O
identical	O
in	O
each	O
of	O
2	O
pairs	O
of	O
brothers	O
.	O

Six	O
of	O
the	O
point	O
mutations	O
represented	O
missense	O
mutations	O
,	O
1	O
was	O
a	O
nonsense	O
mutation	O
,	O
and	O
1	O
was	O
a	O
frameshift	O
mutation	O
.	O

Five	O
of	O
the	O
mutations	O
are	O
newly	O
reported	O
herein	O
.	O

CONCLUSIONS	O
The	O
discovery	O
of	O
new	O
point	O
mutations	O
in	O
this	O
study	O
increases	O
the	O
available	O
information	O
regarding	O
the	O
spectrum	O
of	O
genetic	B
abnormalities	I
and	O
clinical	O
manifestations	O
of	O
XLRS	B
.	O

However	O
,	O
the	O
limited	O
data	O
failed	O
to	O
reveal	O
a	O
correlation	O
between	O
mutation	O
and	O
disease	O
phenotype	O
.	O

CLINICAL	O
RELEVANCE	O
Identification	O
of	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
and	O
expanded	O
information	O
on	O
clinical	O
manifestations	O
will	O
facilitate	O
early	O
diagnosis	O
,	O
appropriate	O
early	O
therapy	O
,	O
and	O
genetic	O
counseling	O
regarding	O
the	O
prognosis	O
of	O
XLRS	B
.	O
.	O

Atm	O
and	O
Bax	O
cooperate	O
in	O
ionizing	O
radiation	O
-	O
induced	O
apoptosis	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Ataxia	B
-	I
telangiectasia	I
is	O
a	O
hereditary	B
multisystemic	I
disease	I
resulting	O
from	O
mutations	O
of	O
ataxia	B
telangiectasia	I
,	O
mutated	O
(	O
ATM	O
)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	B
,	O
cancer	B
,	O
immune	B
defects	I
,	O
and	O
hypersensitivity	B
to	I
ionizing	I
radiation	I
.	O

The	O
molecular	O
details	O
of	O
ATM	O
function	O
in	O
the	O
nervous	O
system	O
are	O
unclear	O
,	O
although	O
the	O
neurological	B
lesion	I
in	O
ataxia	B
-	I
telangiectasia	I
becomes	O
apparent	O
early	O
in	O
life	O
,	O
suggesting	O
a	O
developmental	O
origin	O
.	O

The	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
Atm	O
-	O
null	O
mice	O
shows	O
a	O
pronounced	O
defect	O
in	O
apoptosis	O
induced	O
by	O
genotoxic	O
stress	O
,	O
suggesting	O
ATM	O
functions	O
to	O
eliminate	O
neurons	O
with	O
excessive	O
genomic	O
damage	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
death	O
effector	O
Bax	O
is	O
required	O
for	O
a	O
large	O
proportion	O
of	O
Atm	O
-	O
dependent	O
apoptosis	O
in	O
the	O
developing	O
CNS	O
after	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O

Although	O
many	O
of	O
the	O
same	O
regions	O
of	O
the	O
CNS	O
in	O
both	O
Bax	O
-	O
/	O
-	O
and	O
Atm	O
-	O
/	O
-	O
mice	O
were	O
radioresistant	O
,	O
mice	O
nullizygous	O
for	O
both	O
Bax	O
and	O
Atm	O
showed	O
additional	O
reduction	O
in	O
IR	O
-	O
induced	O
apoptosis	O
in	O
the	O
CNS	O
.	O

Therefore	O
,	O
although	O
the	O
major	O
IR	O
-	O
induced	O
apoptotic	O
pathway	O
in	O
the	O
CNS	O
requires	O
Atm	O
and	O
Bax	O
,	O
a	O
p53	O
-	O
dependent	O
collateral	O
pathway	O
exists	O
that	O
has	O
both	O
Atm	O
-	O
and	O
Bax	O
-	O
independent	O
branches	O
.	O

Further	O
,	O
Atm	O
-	O
and	O
Bax	O
-	O
dependent	O
apoptosis	O
in	O
the	O
CNS	O
also	O
required	O
caspase	O
-	O
3	O
activation	O
.	O

These	O
data	O
implicate	O
Bax	O
and	O
caspase	O
-	O
3	O
as	O
death	O
effectors	O
in	O
neurodegenerative	O
pathways	O
.	O
.	O

Haim	B
-	I
Munk	I
syndrome	I
and	O
Papillon	B
-	I
Lefevre	I
syndrome	I
are	O
allelic	O
mutations	O
in	O
cathepsin	O
C	O
.	O

Of	O
the	O
many	O
palmoplantar	B
keratoderma	I
(	I
PPK	I
)	I
conditions	I
,	O
only	O
Papillon	B
-	I
Lefevre	I
syndrome	I
(	O
PLS	B
)	O
and	O
Haim	B
-	I
Munk	I
syndrome	I
(	O
HMS	B
)	O
are	O
associated	O
with	O
premature	O
periodontal	O
destruction	O
.	O

Although	O
both	O
PLS	B
and	O
HMS	B
share	O
the	O
cardinal	O
features	O
of	O
PPK	B
and	O
severe	O
periodontitis	B
,	O
a	O
number	O
of	O
additional	O
findings	O
are	O
reported	O
in	O
HMS	B
including	O
arachnodactyly	B
,	O
acro	B
-	I
osteolysis	I
,	O
atrophic	B
changes	I
of	I
the	I
nails	I
,	O
and	O
a	O
radiographic	B
deformity	I
of	I
the	I
fingers	I
.	O

While	O
PLS	B
cases	O
have	O
been	O
identified	O
throughout	O
the	O
world	O
,	O
HMS	B
has	O
only	O
been	O
described	O
among	O
descendants	O
of	O
a	O
religious	O
isolate	O
originally	O
from	O
Cochin	O
,	O
India	O
.	O

Parental	O
consanguinity	O
is	O
a	O
characteristic	O
of	O
many	O
cases	O
of	O
both	O
conditions	O
.	O

Although	O
autosomal	O
recessive	O
transmission	O
of	O
PLS	B
is	O
evident	O
,	O
a	O
more	O
"	O
complex	O
"	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
with	O
phenotypic	O
influences	O
from	O
a	O
closely	O
linked	O
modifying	O
locus	O
has	O
been	O
hypothesised	O
for	O
HMS	B
.	O

Recently	O
,	O
mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
have	O
been	O
identified	O
as	O
the	O
underlying	O
genetic	B
defect	I
in	O
PLS	B
.	O

To	O
determine	O
if	O
a	O
cathepsin	O
C	O
mutation	O
is	O
also	O
responsible	O
for	O
HMS	B
,	O
we	O
sequenced	O
the	O
gene	O
in	O
affected	O
and	O
unaffected	O
subjects	O
from	O
the	O
Cochin	O
isolate	O
in	O
which	O
both	O
the	O
PLS	B
and	O
HMS	B
phenotypes	O
appear	O
.	O

Here	O
we	O
report	O
identification	O
of	O
a	O
mutation	O
of	O
cathepsin	O
C	O
(	O
exon	O
6	O
,	O
2127A	O
-	O
-	O
>	O
G	O
)	O
that	O
changes	O
a	O
highly	O
conserved	O
amino	O
acid	O
in	O
the	O
cathepsin	O
C	O
peptide	O
.	O

This	O
mutation	O
segregates	O
with	O
HMS	B
in	O
four	O
nuclear	O
families	O
.	O

Additionally	O
,	O
the	O
existence	O
of	O
a	O
shared	O
common	O
haplotype	O
for	O
genetic	O
loci	O
flanking	O
the	O
cathepsin	O
C	O
gene	O
suggests	O
that	O
affected	O
subjects	O
descended	O
from	O
the	O
Cochin	O
isolate	O
are	O
homozygous	O
for	O
a	O
mutation	O
inherited	O
"	O
identical	O
by	O
descent	O
"	O
from	O
a	O
common	O
ancestor	O
.	O

This	O
finding	O
supports	O
simple	O
autosomal	O
recessive	O
inheritance	O
for	O
HMS	B
in	O
these	O
families	O
.	O

We	O
also	O
report	O
a	O
mutation	O
of	O
the	O
same	O
exon	O
6	O
CTSC	O
codon	O
(	O
2126C	O
-	O
-	O
>	O
T	O
)	O
in	O
a	O
Turkish	O
family	O
with	O
classical	O
PLS	B
.	O

These	O
findings	O
provide	O
evidence	O
that	O
PLS	B
and	O
HMS	B
are	O
allelic	O
variants	O
of	O
cathepsin	O
C	O
gene	O
mutations	O
.	O
.	O

ATM	O
-	O
heterozygous	O
germline	O
mutations	O
contribute	O
to	O
breast	B
cancer	I
-	O
susceptibility	O
.	O

Approximately	O
0	O
.	O

5	O
%	O
-	O
1	O
%	O
of	O
the	O
general	O
population	O
has	O
been	O
estimated	O
to	O
be	O
heterozygous	O
for	O
a	O
germline	O
mutation	O
in	O
the	O
ATM	O
gene	O
.	O

Mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
(	O
MIM	O
208900	O
)	O
.	O

The	O
finding	O
that	O
ATM	O
-	O
heterozygotes	O
have	O
an	O
increased	O
relative	O
risk	O
for	O
breast	B
cancer	I
was	O
supported	O
by	O
some	O
studies	O
but	O
not	O
confirmed	O
by	O
others	O
.	O

In	O
view	O
of	O
this	O
discrepancy	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
ATM	O
germline	O
mutations	O
in	O
a	O
selected	O
group	O
of	O
Dutch	O
patients	O
with	O
breast	B
cancer	I
.	O

We	O
have	O
analyzed	O
ATM	O
germline	O
mutations	O
in	O
normal	O
blood	O
lymphocytes	O
,	O
using	O
the	O
protein	O
-	O
truncation	O
test	O
followed	O
by	O
genomic	O
-	O
sequence	O
analysis	O
.	O

A	O
high	O
percentage	O
of	O
ATM	O
germline	O
mutations	O
was	O
demonstrated	O
among	O
patients	O
with	O
sporadic	B
breast	I
cancer	I
.	O

The	O
82	O
patients	O
included	O
in	O
this	O
study	O
had	O
developed	O
breast	B
cancer	I
at	O
age	O
<	O
45	O
and	O
had	O
survived	O
>	O
/	O
=	O
5	O
years	O
(	O
mean	O
15	O
years	O
)	O
,	O
and	O
in	O
33	O
(	O
40	O
%	O
)	O
of	O
the	O
patients	O
a	O
contralateral	O
breast	O
tumor	O
had	O
been	O
diagnosed	O
.	O

Among	O
these	O
patients	O
we	O
identified	O
seven	O
(	O
8	O
.	O
5	O
%	O
)	O
ATM	O
germline	O
mutations	O
,	O
of	O
which	O
five	O
are	O
distinct	O
.	O

One	O
splice	O
-	O
site	O
mutation	O
(	O
IVS10	O
-	O
6T	O
-	O
-	O
>	O
G	O
)	O
was	O
detected	O
three	O
times	O
in	O
our	O
series	O
.	O

Four	O
heterozygous	O
carriers	O
were	O
patients	O
with	O
bilateral	O
breast	O
cancer	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
"	O
A	O
-	O
T	O
disease	O
-	O
causing	O
"	O
mutations	O
that	O
might	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
in	O
heterozygotes	O
.	O

We	O
conclude	O
that	O
ATM	O
heterozygotes	O
have	O
an	O
approximately	O
ninefold	O
-	O
increased	O
risk	O
of	O
developing	O
a	O
type	O
of	O
breast	O
cancer	O
characterized	O
by	O
frequent	O
bilateral	O
occurrence	O
,	O
early	O
age	O
at	O
onset	O
,	O
and	O
long	O
-	O
term	O
survival	O
.	O

The	O
specific	O
characteristics	O
of	O
our	O
population	O
of	O
patients	O
may	O
explain	O
why	O
such	O
a	O
high	O
frequency	O
was	O
not	O
found	O
in	O
other	O
series	O
.	O

Human	O
mutations	O
in	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
reflect	O
evolutionary	O
history	O
.	O

Glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
is	O
a	O
cytosolic	O
enzyme	O
encoded	O
by	O
a	O
housekeeping	O
X	O
-	O
linked	O
gene	O
whose	O
main	O
function	O
is	O
to	O
produce	O
NADPH	O
,	O
a	O
key	O
electron	O
donor	O
in	O
the	O
defense	O
against	O
oxidizing	O
agents	O
and	O
in	O
reductive	O
biosynthetic	O
reactions	O
.	O

Inherited	O
G6PD	B
deficiency	I
is	O
associated	O
with	O
either	O
episodic	B
hemolytic	I
anemia	I
(	O
triggered	O
by	O
fava	O
beans	O
or	O
other	O
agents	O
)	O
or	O
life	B
-	I
long	I
hemolytic	I
anemia	I
.	O

We	O
show	O
here	O
that	O
an	O
evolutionary	O
analysis	O
is	O
a	O
key	O
to	O
understanding	O
the	O
biology	O
of	O
a	O
housekeeping	O
gene	O
.	O

From	O
the	O
alignment	O
of	O
the	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
of	O
52	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
species	O
from	O
42	O
different	O
organisms	O
,	O
we	O
found	O
a	O
striking	O
correlation	O
between	O
the	O
aa	O
replacements	O
that	O
cause	O
G6PD	B
deficiency	I
in	O
humans	O
and	O
the	O
sequence	O
conservation	O
of	O
G6PD	O
two	O
-	O
thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	O
and	O
moderately	O
conserved	O
(	O
50	O
-	O
99	O
%	O
)	O
aa	O
;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	O
aa	O
(	O
where	O
they	O
might	O
be	O
lethal	O
)	O
or	O
in	O
poorly	O
conserved	O
aa	O
,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
G6PD	B
deficiency	I
.	O

This	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
all	O
human	O
mutants	O
have	O
residual	O
enzyme	O
activity	O
and	O
that	O
null	O
mutations	O
are	O
lethal	O
at	O
some	O
stage	O
of	O
development	O
.	O

Comparing	O
the	O
distribution	O
of	O
mutations	O
in	O
a	O
human	O
housekeeping	O
gene	O
with	O
evolutionary	O
conservation	O
is	O
a	O
useful	O
tool	O
for	O
pinpointing	O
amino	O
acid	O
residues	O
important	O
for	O
the	O
stability	O
or	O
the	O
function	O
of	O
the	O
corresponding	O
protein	O
.	O

In	O
view	O
of	O
the	O
current	O
explosive	O
increase	O
in	O
full	O
genome	O
sequencing	O
projects	O
,	O
this	O
tool	O
will	O
become	O
rapidly	O
available	O
for	O
numerous	O
other	O
genes	O
.	O
.	O

Constitutive	O
and	O
regulated	O
modes	O
of	O
splicing	O
produce	O
six	O
major	O
myotonic	B
dystrophy	I
protein	O
kinase	O
(	O
DMPK	O
)	O
isoforms	O
with	O
distinct	O
properties	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
the	O
most	O
prevalent	O
inherited	B
neuromuscular	I
disease	I
in	O
adults	O
.	O

The	O
genetic	B
defect	I
is	O
a	O
CTG	O
triplet	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
(	O
DMPK	O
)	O
gene	O
,	O
consisting	O
of	O
15	O
exons	O
.	O

Using	O
a	O
transgenic	O
DMPK	O
-	O
overexpressor	O
mouse	O
model	O
,	O
we	O
demonstrate	O
here	O
that	O
the	O
endogenous	O
mouse	O
DMPK	O
gene	O
and	O
the	O
human	O
DMPK	O
transgene	O
produce	O
six	O
major	O
alternatively	O
spliced	O
mRNAs	O
which	O
have	O
almost	O
identical	O
cell	O
type	O
-	O
dependent	O
distribution	O
frequencies	O
and	O
expression	O
patterns	O
.	O

Use	O
of	O
a	O
cryptic	O
5	O
splice	O
site	O
in	O
exon	O
8	O
,	O
which	O
results	O
in	O
absence	O
or	O
presence	O
of	O
15	O
nucleotides	O
specifying	O
a	O
VSGGG	O
peptide	O
motif	O
,	O
and	O
/	O
or	O
use	O
of	O
a	O
cryptic	O
3	O
splice	O
site	O
in	O
exon	O
14	O
,	O
which	O
leads	O
to	O
a	O
frameshift	O
in	O
the	O
mRNA	O
reading	O
frame	O
,	O
occur	O
as	O
independent	O
stochastic	O
events	O
in	O
all	O
tissues	O
examined	O
.	O

In	O
contrast	O
,	O
the	O
excision	O
of	O
exons	O
13	O
/	O
14	O
that	O
causes	O
a	O
frameshift	O
and	O
creates	O
a	O
C	O
-	O
terminally	O
truncated	O
protein	O
is	O
clearly	O
cell	O
type	O
dependent	O
and	O
occurs	O
predominantly	O
in	O
smooth	O
muscle	O
.	O

We	O
generated	O
all	O
six	O
full	O
-	O
length	O
mouse	O
cDNAs	O
that	O
result	O
from	O
combinations	O
of	O
these	O
three	O
major	O
splicing	O
events	O
and	O
show	O
that	O
their	O
transfection	O
into	O
cells	O
in	O
culture	O
leads	O
to	O
production	O
of	O
four	O
different	O
approximately	O
74	O
kDa	O
full	O
-	O
length	O
(	O
heart	O
-	O
,	O
skeletal	O
muscle	O
-	O
or	O
brain	O
-	O
specific	O
)	O
and	O
two	O
C	O
-	O
terminally	O
truncated	O
approximately	O
68	O
kDa	O
(	O
smooth	O
muscle	O
-	O
specific	O
)	O
isoforms	O
.	O

Information	O
on	O
DMPK	O
mRNA	O
and	O
protein	O
isoform	O
expression	O
patterns	O
will	O
be	O
useful	O
for	O
recognizing	O
differential	O
effects	O
of	O
(	O
CTG	O
)	O
(	O
n	O
)	O
expansion	O
in	O
DM	B
manifestation	O
.	O
.	O

Genetic	O
analysis	O
,	O
phenotypic	O
diagnosis	O
,	O
and	O
risk	O
of	O
venous	B
thrombosis	I
in	O
families	O
with	O
inherited	O
deficiencies	B
of	I
protein	I
S	I
.	O

Protein	B
S	I
deficiency	I
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	B
thrombosis	I
.	O

Of	O
all	O
the	O
inherited	O
thrombophilic	B
conditions	I
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	O
variability	O
,	O
which	O
can	O
lead	O
to	O
inconclusive	O
results	O
.	O

We	O
have	O
overcome	O
this	O
problem	O
by	O
studying	O
a	O
cohort	O
of	O
patients	O
from	O
a	O
single	O
center	O
where	O
the	O
diagnosis	O
was	O
confirmed	O
at	O
the	O
genetic	O
level	O
.	O

Twenty	O
-	O
eight	O
index	O
patients	O
with	O
protein	B
S	I
deficiency	I
and	O
a	O
PROS1	B
gene	I
defect	I
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	O
relatives	O
.	O

To	O
avoid	O
selection	O
bias	O
,	O
we	O
confined	O
analysis	O
of	O
total	O
and	O
free	O
protein	O
S	O
levels	O
and	O
thrombotic	O
risk	O
to	O
the	O
patients	O
relatives	O
.	O

In	O
this	O
group	O
of	O
relatives	O
,	O
a	O
low	O
free	O
protein	O
S	O
level	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
PROS1	B
gene	I
defect	I
(	O
sensitivity	O
97	O
.	O
7	O
%	O
,	O
specificity	O
100	O
%	O
)	O
.	O

First	O
-	O
degree	O
relatives	O
with	O
a	O
PROS1	B
gene	I
defect	I
had	O
a	O
5	O
.	O

0	O
-	O
fold	O
higher	O
risk	O
of	O
thrombosis	B
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
-	O
16	O
.	O
8	O
)	O
than	O
those	O
with	O
a	O
normal	O
PROS1	O
gene	O
and	O
no	O
other	O
recognized	O
thrombophilic	B
defect	I
.	O

Although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous	O
.	O

Relatives	O
with	O
splice	O
-	O
site	O
or	O
major	O
structural	O
defects	B
in	I
the	I
PROS1	I
gene	I
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	O
event	O
and	O
had	O
significantly	O
lower	O
total	O
and	O
free	O
protein	O
S	O
levels	O
than	O
those	O
relatives	O
having	O
missense	O
mutations	O
.	O

We	O
conclude	O
that	O
persons	O
with	O
PROS1	B
gene	I
defects	I
and	O
protein	B
S	I
deficiency	I
are	O
at	O
increased	O
risk	O
of	O
thrombosis	B
and	O
that	O
free	O
protein	O
S	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	O
.	O

(	O
Blood	O
.	O
2000	O
;	O
95	O
1935	O
-	O
1941	O
)	O
.	O

Autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
in	O
a	O
child	O
from	O
consanguineous	O
parents	O
:	O
a	O
dominant	O
or	O
recessive	O
disease	O
?	O

Autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
is	O
characterized	O
by	O
autoimmune	O
features	O
and	O
lymphoproliferations	O
and	O
is	O
generally	O
caused	O
by	O
defective	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

This	O
report	O
describes	O
a	O
child	O
with	O
clinical	O
features	O
of	O
ALPS	B
without	O
detectable	O
Fas	O
expression	O
on	O
freshly	O
isolated	O
blood	O
leukocytes	O
.	O

Detection	O
of	O
FAS	O
transcripts	O
via	O
real	O
-	O
time	O
quantitative	O
PCR	O
made	O
a	O
severe	O
transcriptional	O
defect	O
unlikely	O
.	O

Sequencing	O
of	O
the	O
FAS	O
gene	O
revealed	O
a	O
20	O
-	O
nucleotide	O
duplication	O
in	O
the	O
last	O
exon	O
affecting	O
the	O
cytoplasmic	O
signaling	O
domain	O
.	O

The	O
patient	O
was	O
homozygous	O
for	O
this	O
mutation	O
,	O
whereas	O
the	O
consanguineous	O
parents	O
and	O
the	O
siblings	O
were	O
heterozygous	O
.	O

The	O
patient	O
reported	O
here	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Fas	O
-	O
null	O
mouse	O
,	O
inasmuch	O
as	O
she	O
carries	O
an	O
autosomal	O
homozygous	O
mutation	O
in	O
the	O
FAS	O
gene	O
and	O
she	O
shows	O
the	O
severe	O
and	O
accelerated	O
ALPS	B
phenotype	O
.	O

The	O
heterozygous	O
family	O
members	O
did	O
not	O
have	O
the	O
ALPS	B
phenotype	O
,	O
indicating	O
that	O
the	O
disease	O
-	O
causing	O
FAS	O
mutation	O
in	O
this	O
family	O
is	O
autosomal	O
recessive	O
.	O
.	O

Identification	O
of	O
novel	O
imprinted	O
transcripts	O
in	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
and	O
Angelman	B
syndrome	I
deletion	O
region	O
:	O
further	O
evidence	O
for	O
regional	O
imprinting	O
control	O
.	O

Deletions	O
and	O
other	O
abnormalities	O
of	O
human	O
chromosome	O
15q11	O
-	O
q13	O
are	O
associated	O
with	O
two	O
developmental	O
disorders	O
,	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
and	O
Angelman	B
syndrome	I
(	O
AS	B
)	O
.	O

Loss	O
of	O
expression	O
of	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
has	O
been	O
implicated	O
in	O
PWS	B
.	O

However	O
,	O
the	O
number	O
of	O
imprinted	O
genes	O
that	O
contribute	O
to	O
PWS	B
,	O
and	O
the	O
range	O
over	O
which	O
the	O
imprinting	O
signal	O
acts	O
to	O
silence	O
one	O
copy	O
of	O
the	O
gene	O
in	O
a	O
parent	O
-	O
of	O
-	O
origin	O
-	O
specific	O
manner	O
,	O
are	O
unknown	O
.	O

To	O
identify	O
additional	O
imprinted	O
genes	O
that	O
could	O
contribute	O
to	O
the	O
PWS	B
phenotype	O
and	O
to	O
understand	O
the	O
regional	O
control	O
of	O
imprinting	O
in	O
15q11	O
-	O
q13	O
,	O
we	O
have	O
constructed	O
an	O
imprinted	O
transcript	O
map	O
of	O
the	O
PWS	O
-	O
AS	O
deletion	O
interval	O
.	O

The	O
imprinting	O
status	O
of	O
22	O
expressed	O
sequence	O
tags	O
derived	O
from	O
the	O
radiation	O
-	O
hybrid	O
human	O
transcript	O
maps	O
or	O
physical	O
maps	O
was	O
determined	O
in	O
a	O
reverse	O
transcriptase	O
-	O
PCR	O
assay	O
and	O
correlated	O
with	O
the	O
position	O
of	O
the	O
transcripts	O
on	O
the	O
physical	O
map	O
.	O

Seven	O
new	O
paternally	O
expressed	O
transcripts	O
localize	O
to	O
an	O
approximately	O
1	O
.	O

5	O
-	O
Mb	O
domain	O
surrounding	O
the	O
SNRPN	O
-	O
associated	O
imprinting	O
center	O
,	O
which	O
already	O
includes	O
four	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
.	O

All	O
other	O
tested	O
new	O
transcripts	O
in	O
the	O
deletion	O
region	O
were	O
expressed	O
from	O
both	O
alleles	O
.	O

A	O
domain	O
of	O
exclusive	O
paternal	O
expression	O
surrounding	O
the	O
imprinting	O
center	O
suggests	O
strong	O
regional	O
control	O
of	O
the	O
imprinting	O
process	O
.	O

This	O
study	O
provides	O
the	O
means	O
for	O
further	O
investigation	O
of	O
additional	O
genes	O
that	O
cause	O
or	O
modify	O
the	O
phenotypes	O
associated	O
with	O
rearrangements	O
of	O
15q11	O
-	O
q13	O
.	O

Combined	O
analysis	O
of	O
hereditary	B
prostate	I
cancer	I
linkage	O
to	O
1q24	O
-	O
25	O
:	O
results	O
from	O
772	O
hereditary	B
prostate	I
cancer	I
families	O
from	O
the	O
International	O
Consortium	O
for	O
Prostate	B
Cancer	I
Genetics	O
.	O

A	O
previous	O
linkage	O
study	O
provided	O
evidence	O
for	O
a	O
prostate	B
cancer	I
-	O
susceptibility	O
locus	O
at	O
1q24	O
-	O
25	O
.	O

Subsequent	O
reports	O
in	O
additional	O
collections	O
of	O
families	O
have	O
yielded	O
conflicting	O
results	O
.	O

In	O
addition	O
,	O
evidence	O
for	O
locus	O
heterogeneity	O
has	O
been	O
provided	O
by	O
the	O
identification	O
of	O
other	O
putative	O
hereditary	B
prostate	I
cancer	I
loci	O
on	O
Xq27	O
-	O
28	O
,	O
1q42	O
-	O
43	O
,	O
and	O
1p36	O
.	O

The	O
present	O
study	O
describes	O
a	O
combined	O
analysis	O
for	O
six	O
markers	O
in	O
the	O
1q24	O
-	O
25	O
region	O
in	O
772	O
families	O
affected	O
by	O
hereditary	B
prostate	I
cancer	I
and	O
ascertained	O
by	O
the	O
members	O
of	O
the	O
International	O
Consortium	O
for	O
Prostate	B
Cancer	I
Genetics	O
(	O
ICPCG	O
)	O
from	O
North	O
America	O
,	O
Australia	O
,	O
Finland	O
,	O
Norway	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
Kingdom	O
.	O

Overall	O
,	O
there	O
was	O
some	O
evidence	O
for	O
linkage	O
,	O
with	O
a	O
peak	O
parametric	O
multipoint	O
LOD	O
score	O
assuming	O
heterogeneity	O
(	O
HLOD	O
)	O
of	O
1	O
.	O

40	O
(	O
P	O
=	O
.	O
01	O
)	O
at	O
D1S212	O
.	O

The	O
estimated	O
proportion	O
of	O
families	O
(	O
alpha	O
)	O
linked	O
to	O
the	O
locus	O
was	O
.	O

06	O
(	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
01	O
-	O
.	O
12	O
)	O
.	O

This	O
evidence	O
was	O
not	O
observed	O
by	O
a	O
nonparametric	O
approach	O
,	O
presumably	O
because	O
of	O
the	O
extensive	O
heterogeneity	O
.	O

Further	O
parametric	O
analysis	O
revealed	O
a	O
significant	O
effect	O
of	O
the	O
presence	O
of	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
within	O
the	O
families	O
.	O

In	O
the	O
subset	O
of	O
491	O
such	O
families	O
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O

In	O
the	O
subset	O
of	O
491	O
such	O
families	O
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O

56	O
(	O
P	O
=	O
.	O
0006	O
)	O
and	O
alpha	O
=	O
.	O

11	O
(	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
04	O
-	O
.	O
19	O
)	O
,	O
compared	O
with	O
HLODs	O
of	O
0	O
in	O
the	O
remaining	O
281	O
families	O
.	O

Within	O
the	O
families	O
with	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
,	O
alpha	O
increased	O
with	O
the	O
early	O
mean	O
age	O
at	O
diagnosis	O
(	O
<	O
65	O
years	O
,	O
alpha	O
=	O
.	O
19	O
,	O
with	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
06	O
-	O
.	O
34	O
)	O
and	O
the	O
number	O
of	O
affected	O
family	O
members	O
(	O
five	O
or	O
more	O
family	O
members	O
,	O
alpha	O
=	O
.	O
15	O
,	O
with	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
04	O
-	O
.	O
28	O
)	O
.	O

The	O
highest	O
value	O
of	O
alpha	O
was	O
observed	O
for	O
the	O
48	O
families	O
that	O
met	O
all	O
three	O
criteria	O
(	O
peak	O
HLOD	O
=	O
2	O
.	O
25	O
,	O
P	O
=	O
.	O
001	O
,	O
alpha	O
=	O
.	O
29	O
,	O
with	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
08	O
-	O
.	O
53	O
)	O
.	O

These	O
results	O
support	O
the	O
finding	O
of	O
a	O
prostate	B
cancer	I
-	O
susceptibility	O
gene	O
linked	O
to	O
1q24	O
-	O
25	O
,	O
albeit	O
in	O
a	O
defined	O
subset	O
of	O
prostate	B
cancer	I
families	O
.	O

Although	O
HPC1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	O
of	O
all	O
families	O
affected	O
by	O
hereditary	B
prostate	I
cancer	I
,	O
it	O
appears	O
to	O
play	O
a	O
more	O
prominent	O
role	O
in	O
the	O
subset	O
of	O
families	O
with	O
several	O
members	O
affected	O
at	O
an	O
early	O
age	O
and	O
with	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
.	O

A	O
recurrent	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
CAG	O
repeats	O
causes	O
Huntington	B
disease	I
in	O
two	O
sisters	O
.	O

Large	O
intergenerational	O
repeat	O
expansions	O
of	O
the	O
CAG	O
trinucleotide	O
repeat	O
in	O
the	O
HD	B
gene	O
have	O
been	O
well	O
documented	O
for	O
the	O
male	O
germline	O
.	O

We	O
describe	O
a	O
recurrent	O
large	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
CAG	O
repeats	O
(	O
to	O
66	O
and	O
57	O
repeats	O
,	O
respectively	O
,	O
in	O
two	O
daughters	O
)	O
associated	O
with	O
onset	O
of	O
Huntington	B
disease	I
(	O
HD	B
)	O
in	O
the	O
second	O
and	O
third	O
decade	O
in	O
a	O
family	O
without	O
history	O
of	O
HD	B
.	O

Our	O
findings	O
give	O
evidence	O
of	O
a	O
gonadal	O
mosaicism	O
in	O
the	O
unaffected	O
mother	O
.	O

We	O
hypothesize	O
that	O
large	O
expansions	O
also	O
occur	O
in	O
the	O
female	O
germline	O
and	O
that	O
a	O
negative	O
selection	O
of	O
oocytes	O
with	O
long	O
repeats	O
might	O
explain	O
the	O
different	O
instability	O
behavior	O
of	O
the	O
male	O
and	O
the	O
female	O
germlines	O
.	O
.	O

Abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
in	O
Atm	O
mutant	O
mice	O
.	O

Motor	B
incoordination	I
,	O
immune	B
deficiencies	I
,	O
and	O
an	O
increased	O
risk	O
of	O
cancer	B
are	O
the	O
characteristic	O
features	O
of	O
the	O
hereditary	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
.	O

Through	O
gene	O
targeting	O
,	O
we	O
have	O
generated	O
a	O
line	O
of	O
Atm	O
mutant	O
mice	O
,	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
.	O

In	O
contrast	O
to	O
other	O
Atm	O
mutant	O
mice	O
,	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
show	O
a	O
lower	O
incidence	O
of	O
thymic	B
lymphoma	I
and	O
survive	O
beyond	O
a	O
few	O
months	O
of	O
age	O
.	O

Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	B
dysfunction	I
.	O

Even	O
though	O
we	O
found	O
no	O
gross	O
cerebellar	B
degeneration	I
in	O
older	O
Atm	O
(	O
y	O
/	O
y	O
)	O
animals	O
,	O
ectopic	O
and	O
abnormally	O
differentiated	O
Purkinje	O
cells	O
were	O
apparent	O
in	O
mutant	O
mice	O
of	O
all	O
ages	O
.	O

These	O
findings	O
establish	O
that	O
some	O
neuropathological	B
abnormalities	I
seen	O
in	O
A	B
-	I
T	I
patients	O
also	O
are	O
present	O
in	O
Atm	O
mutant	O
mice	O
.	O

In	O
addition	O
,	O
we	O
report	O
a	O
previously	O
unrecognized	O
effect	O
of	O
Atm	B
deficiency	I
on	O
development	O
or	O
maintenance	O
of	O
CD4	O
(	O
+	O
)	O
8	O
(	O
+	O
)	O
thymocytes	O
.	O

We	O
discuss	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
hypothesis	O
that	O
abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
A	B
-	I
T	I
.	O
.	O

Novel	O
mutations	O
of	O
the	O
ATP7B	O
gene	O
in	O
Japanese	O
patients	O
with	O
Wilson	B
disease	I
.	O

Wilson	B
disease	I
(	O
WD	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
copper	O
accumulation	O
in	O
the	O
liver	O
,	O
brain	O
,	O
kidneys	O
,	O
and	O
corneas	O
,	O
and	O
culminating	O
in	O
copper	O
toxication	O
in	O
these	O
organs	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
mutations	O
of	O
the	O
responsible	O
gene	O
,	O
ATP7B	O
,	O
in	O
four	O
Japanese	O
patients	O
with	O
WD	B
.	O

By	O
direct	O
sequencing	O
,	O
we	O
identified	O
five	O
mutations	O
,	O
of	O
which	O
two	O
were	O
novel	O
,	O
and	O
16	O
polymorphisms	O
,	O
of	O
which	O
6	O
were	O
novel	O
.	O

The	O
mutations	O
2871delC	O
and	O
2513delA	O
shift	O
the	O
reading	O
frame	O
so	O
that	O
truncated	O
abnormal	O
protein	O
is	O
expected	O
.	O

In	O
contrast	O
to	O
these	O
mutations	O
found	O
in	O
patients	O
with	O
hepatic	O
-	O
type	O
of	O
early	O
onset	O
,	O
the	O
mutations	O
A874V	O
,	O
R778L	O
,	O
and	O
3892delGTC	O
were	O
either	O
missense	O
mutations	O
or	O
in	O
frame	O
1	O
-	O
amino	O
acid	O
deletion	O
,	O
and	O
occurred	O
in	O
the	O
patients	O
with	O
hepato	O
-	O
neurologic	O
type	O
of	O
late	O
onset	O
.	O

The	O
mutations	O
2871delC	O
and	O
R778L	O
have	O
been	O
previously	O
reported	O
in	O
a	O
relatively	O
large	O
number	O
of	O
Japanese	O
patients	O
.	O

In	O
particular	O
,	O
R778L	O
is	O
known	O
to	O
be	O
more	O
prevalent	O
in	O
Asian	O
countries	O
than	O
in	O
other	O
countries	O
of	O
the	O
world	O
.	O

Our	O
data	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
the	O
mutations	O
tend	O
to	O
occur	O
in	O
a	O
population	O
-	O
specific	O
manner	O
.	O

Therefore	O
,	O
the	O
accumulation	O
of	O
the	O
types	O
of	O
mutations	O
in	O
Japanese	O
patients	O
with	O
WD	B
will	O
facilitate	O
the	O
fast	O
and	O
effective	O
genetic	O
diagnosis	O
of	O
WD	B
in	O
Japanese	O
patients	O
.	O
.	O

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
.	O

The	O
Rho	O
-	O
family	O
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
family	O
members	O
.	O

Activation	O
relieves	O
an	O
autoinhibitory	O
contact	O
between	O
the	O
GTPase	O
-	O
binding	O
domain	O
and	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
WASP	O
proteins	O
.	O

Here	O
we	O
report	O
the	O
autoinhibited	O
structure	O
of	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
,	O
which	O
can	O
be	O
induced	O
by	O
the	O
C	O
-	O
terminal	O
region	O
or	O
by	O
organic	O
co	O
-	O
solvents	O
.	O

In	O
the	O
autoinhibited	O
complex	O
,	O
intramolecular	O
interactions	O
with	O
the	O
GTPase	O
-	O
binding	O
domain	O
occlude	O
residues	O
of	O
the	O
C	O
terminus	O
that	O
regulate	O
the	O
Arp2	O
/	O
3	O
actin	O
-	O
nucleating	O
complex	O
.	O

Binding	O
of	O
Cdc42	O
to	O
the	O
GTPase	O
-	O
binding	O
domain	O
causes	O
a	O
dramatic	O
conformational	O
change	O
,	O
resulting	O
in	O
disruption	O
of	O
the	O
hydrophobic	O
core	O
and	O
release	O
of	O
the	O
C	O
terminus	O
,	O
enabling	O
its	O
interaction	O
with	O
the	O
actin	O
regulatory	O
machinery	O
.	O

These	O
data	O
show	O
that	O
intrinsically	O
unstructured	O
peptides	O
such	O
as	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
can	O
be	O
induced	O
into	O
distinct	O
structural	O
and	O
functional	O
states	O
depending	O
on	O
context	O
.	O
.	O

hCds1	O
-	O
mediated	O
phosphorylation	O
of	O
BRCA1	O
regulates	O
the	O
DNA	O
damage	O
response	O
.	O

Mutations	O
in	O
the	O
BRCA1	O
(	O
ref	O
.	O
1	O
)	O
tumour	B
suppressor	O
gene	O
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	O
with	O
inherited	B
breast	I
and	I
ovarian	I
cancers	I
and	O
about	O
half	O
of	O
the	O
families	O
with	O
only	O
breast	B
cancer	I
.	O

Although	O
the	O
biochemical	O
function	O
of	O
BRCA1	O
is	O
not	O
well	O
understood	O
,	O
it	O
is	O
important	O
for	O
DNA	O
damage	O
repair	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
.	O

BRCA1	O
exists	O
in	O
nuclear	O
foci	O
but	O
is	O
hyperphosphorylated	O
and	O
disperses	O
after	O
DNA	O
damage	O
.	O

It	O
is	O
not	O
known	O
whether	O
BRCA1	O
phosphorylation	O
and	O
dispersion	O
and	O
its	O
function	O
in	O
DNA	O
damage	O
response	O
are	O
related	O
.	O

In	O
yeast	O
the	O
DNA	O
damage	O
response	O
and	O
the	O
replication	O
-	O
block	O
checkpoint	O
are	O
mediated	O
partly	O
through	O
the	O
Cds1	O
kinase	O
family	O
.	O

Here	O
we	O
report	O
that	O
the	O
human	O
Cds1	O
kinase	O
(	O
hCds1	O
/	O
Chk2	O
)	O
regulates	O
BRCA1	O
function	O
after	O
DNA	O
damage	O
by	O
phosphorylating	O
serine	O
988	O
of	O
BRCA1	O
.	O

We	O
show	O
that	O
hCds1	O
and	O
BRCA1	O
interact	O
and	O
co	O
-	O
localize	O
within	O
discrete	O
nuclear	O
foci	O
but	O
separate	O
after	O
gamma	O
irradiation	O
.	O

Phosphorylation	O
of	O
BRCA1	O
at	O
serine	O
988	O
is	O
required	O
for	O
the	O
release	O
of	O
BRCA1	O
from	O
hCds1	O
.	O

This	O
phosphorylation	O
is	O
also	O
important	O
for	O
the	O
ability	O
of	O
BRCA1	O
to	O
restore	O
survival	O
after	O
DNA	O
damage	O
in	O
the	O
BRCA1	O
-	O
mutated	O
cell	O
line	O
HCC1937	O
.	O
.	O

Characterization	O
of	O
the	O
rat	O
spinocerebellar	O
ataxia	O
type	O
3	O
gene	O
.	O

Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
belongs	O
to	O
a	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
neurodegenerative	B
disorders	I
characterized	O
by	O
progressive	B
cerebellar	I
ataxia	I
.	O

The	O
disease	O
-	O
causing	O
mutation	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
and	O
expanded	O
(	O
CAG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
a	O
novel	O
gene	O
of	O
unknown	O
function	O
.	O

In	O
Caucasians	O
,	O
repeat	O
expansions	O
in	O
the	O
MJD1	O
gene	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
the	O
clinically	O
distinct	O
autosomal	O
dominant	O
spinocerebellar	B
ataxia	I
type	I
3	I
(	O
SCA3	B
)	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
biology	O
of	O
the	O
MJD1	O
/	O
SCA3	O
gene	O
we	O
cloned	O
the	O
rat	O
homologue	O
and	O
studied	O
its	O
expression	O
.	O

The	O
rat	O
and	O
human	O
ataxin	O
-	O
3	O
genes	O
are	O
highly	O
homologous	O
with	O
an	O
overall	O
sequence	O
identity	O
of	O
approximately	O
88	O
%	O
.	O

However	O
,	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
putative	O
protein	O
differs	O
strongly	O
from	O
the	O
published	O
human	O
sequence	O
.	O

The	O
(	O
CAG	O
)	O
n	O
block	O
in	O
the	O
rat	O
cDNA	O
consists	O
of	O
just	O
three	O
interrupted	O
units	O
suggesting	O
that	O
a	O
long	O
polyglutamine	O
stretch	O
is	O
not	O
essential	O
for	O
the	O
normal	O
function	O
of	O
the	O
ataxin	O
-	O
3	O
protein	O
in	O
rodents	O
.	O

The	O
expression	O
pattern	O
of	O
the	O
SCA3	O
gene	O
in	O
various	O
rat	O
and	O
human	O
tissues	O
was	O
investigated	O
by	O
Northern	O
blot	O
analyses	O
.	O

The	O
mature	O
transcript	O
is	O
approximately	O
6	O
kb	O
in	O
length	O
.	O

In	O
rat	O
testis	O
,	O
a	O
smaller	O
transcript	O
of	O
1	O
.	O

3	O
kb	O
was	O
identified	O
.	O

Transcription	O
of	O
rsca3	O
was	O
detected	O
in	O
most	O
rat	O
tissues	O
including	O
brain	O
.	O

Analyzing	O
the	O
expression	O
level	O
of	O
the	O
SCA3	O
gene	O
in	O
several	O
human	O
brain	O
sections	O
revealed	O
no	O
significant	O
higher	O
mRNA	O
level	O
in	O
regions	O
predominantly	O
affected	O
in	O
MJD	B
.	O

Thus	O
additional	O
molecules	O
and	O
/	O
or	O
regulatory	O
events	O
are	O
necessary	O
to	O
explain	O
the	O
exclusive	O
degeneration	B
of	I
certain	I
brain	I
areas	I
.	O

Emerin	B
,	I
deficiency	I
of	O
which	O
causes	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
,	O
is	O
localized	O
at	O
the	O
inner	O
nuclear	O
membrane	O
.	O

X	B
-	I
linked	I
recessive	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
is	O
an	O
inherited	B
muscle	I
disorder	I
characterized	O
by	O
the	O
clinical	O
triad	O
of	O
progressive	O
wasting	B
of	I
humero	I
-	I
peroneal	I
muscles	I
,	O
early	O
contractures	B
of	I
the	I
elbows	I
,	I
Achilles	I
tendons	I
and	I
postcervical	I
muscles	I
,	O
and	O
cardiac	B
conduction	I
block	I
with	O
a	O
high	O
risk	O
of	O
sudden	B
death	I
.	O

The	O
gene	O
for	O
EDMD	B
on	O
Xq28	O
encodes	O
a	O
novel	O
protein	O
named	O
emerin	O
that	O
localizes	O
at	O
the	O
nuclear	O
membrane	O
of	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
and	O
some	O
other	O
non	O
-	O
muscle	O
tissues	O
.	O

To	O
investigate	O
a	O
possible	O
physiological	O
role	O
for	O
emerin	O
,	O
we	O
examined	O
the	O
ultrastructural	O
localization	O
of	O
the	O
protein	O
in	O
human	O
skeletal	O
muscle	O
and	O
HeLa	O
cells	O
,	O
using	O
ultrathin	O
cryosections	O
.	O

We	O
found	O
that	O
the	O
immune	O
-	O
labeled	O
colloidal	O
gold	O
particles	O
were	O
localized	O
on	O
the	O
nucleoplasmic	O
surface	O
of	O
the	O
inner	O
nuclear	O
membrane	O
,	O
but	O
not	O
on	O
the	O
nuclear	O
pore	O
.	O

Emerin	O
stayed	O
on	O
the	O
cytoplasmic	O
surface	O
of	O
the	O
nuclear	O
lamina	O
,	O
even	O
after	O
detergent	O
treatment	O
that	O
solubilizes	O
membrane	O
lipids	O
and	O
washes	O
out	O
membrane	O
proteins	O
.	O

These	O
results	O
suggest	O
that	O
emerin	O
anchors	O
at	O
the	O
inner	O
nuclear	O
membrane	O
through	O
the	O
hydrophobic	O
stretch	O
,	O
and	O
protrudes	O
from	O
the	O
hydrophilic	O
region	O
to	O
the	O
nucleoplasm	O
where	O
it	O
interacts	O
with	O
the	O
nuclear	O
lamina	O
.	O

We	O
speculate	O
that	O
emerin	O
contributes	O
to	O
maintain	O
the	O
nuclear	O
structure	O
and	O
stability	O
,	O
as	O
well	O
as	O
nuclear	O
functions	O
,	O
particularly	O
in	O
muscle	O
tissues	O
that	O
have	O
severe	O
stress	O
with	O
rigorous	O
contraction	O
-	O
relaxation	O
movements	O
and	O
calcium	O
flux	O
.	O
.	O

Locus	O
heterogeneity	O
in	O
Friedreich	B
ataxia	I
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B
recessive	I
ataxia	I
.	O

The	O
disease	O
locus	O
was	O
assigned	O
to	O
chromosome	O
9	O
and	O
the	O
disease	O
gene	O
,	O
STM7	O
/	O
X25	O
,	O
has	O
been	O
isolated	O
.	O

To	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
FRDA	B
.	O

We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	B
locus	O
.	O

Studying	O
two	O
siblings	O
with	O
FRDA	B
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
STM7	O
/	O
X25	O
.	O

Haplotype	O
analysis	O
of	O
the	O
STM7	O
/	O
X25	O
region	O
of	O
chromosome	O
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	O
of	O
chromosome	O
9	O
differs	O
in	O
the	O
patients	O
.	O

Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	B
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	O
of	O
FRDA	B
caused	O
by	O
the	O
second	O
locus	O
,	O
FRDA2	O
,	O
we	O
studied	O
an	O
unrelated	O
FRDA	B
patient	O
with	O
retained	O
tendon	O
reflexes	O
.	O

The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7	O
/	O
X25	O
(	O
GAA	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	B
cannot	O
be	O
distinguished	O
clinically	O
.	O
.	O

Glycerol	O
as	O
a	O
correlate	O
of	O
impaired	B
glucose	I
tolerance	I
:	O
dissection	O
of	O
a	O
complex	O
system	O
by	O
use	O
of	O
a	O
simple	O
genetic	O
trait	O
.	O

Glycerol	O
kinase	O
(	O
GK	O
)	O
represents	O
the	O
primary	O
entry	O
of	O
glycerol	O
into	O
glucose	O
and	O
triglyceride	O
metabolism	O
.	O

Impaired	B
glucose	I
tolerance	I
(	O
IGT	B
)	O
and	O
hypertriglyceridemia	B
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	B
mellitus	I
and	O
cardiovascular	B
disease	I
.	O

The	O
relationship	O
between	O
glycerol	O
and	O
the	O
risk	O
of	O
IGT	B
,	O
however	O
,	O
is	O
poorly	O
understood	O
.	O

We	O
therefore	O
undertook	O
the	O
study	O
of	O
fasting	O
plasma	O
glycerol	O
levels	O
in	O
a	O
cohort	O
of	O
1	O
,	O
056	O
unrelated	O
men	O
and	O
women	O
of	O
French	O
-	O
Canadian	O
descent	O
.	O

Family	O
screening	O
in	O
the	O
initial	O
cohort	O
identified	O
18	O
men	O
from	O
five	O
families	O
with	O
severe	O
hyperglycerolemia	B
(	O
values	O
above	O
2	O
.	O
0	O
mmol	O
/	O
liter	O
)	O
and	O
demonstrated	O
an	O
X	O
-	O
linked	O
pattern	O
of	O
inheritance	O
.	O

Linkage	O
analysis	O
of	O
the	O
data	O
from	O
12	O
microsatellite	O
markers	O
surrounding	O
the	O
Xp21	O
.	O

3	O
GK	O
gene	O
resulted	O
in	O
a	O
peak	O
LOD	O
score	O
of	O
3	O
.	O

46	O
,	O
centered	O
around	O
marker	O
DXS8039	O
.	O

In	O
addition	O
,	O
since	O
all	O
of	O
the	O
families	O
originated	O
in	O
a	O
population	O
with	O
a	O
proven	O
founder	O
effect	O
-	O
the	O
Saguenay	O
Lac	O
-	O
St	O
.	O

-	O
Jean	O
region	O
of	O
Quebec	O
-	O
a	O
common	O
disease	O
haplotype	O
was	O
sought	O
.	O

Indeed	O
,	O
a	O
six	O
-	O
marker	O
haplotype	O
extending	O
over	O
a	O
region	O
of	O
5	O
.	O

5	O
cM	O
was	O
observed	O
in	O
all	O
families	O
.	O

Resequencing	O
of	O
the	O
GK	O
gene	O
in	O
family	O
members	O
led	O
to	O
the	O
discovery	O
of	O
a	O
N288D	O
missense	O
mutation	O
in	O
exon	O
10	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
asparagine	O
residue	O
by	O
a	O
negatively	O
charged	O
aspartic	O
acid	O
.	O

Clinical	O
and	O
molecular	O
genetics	O
of	O
primary	B
dystonias	I
.	O

Primary	B
dystonias	I
are	O
movement	B
disorders	I
with	O
dystonia	B
as	O
a	O
major	O
symptom	O
.	O

They	O
are	O
frequently	O
inherited	O
as	O
Mendelian	O
traits	O
.	O

There	O
are	O
at	O
least	O
eight	O
clinically	O
distinct	O
autosomal	O
dominant	O
and	O
two	O
X	O
-	O
linked	O
recessive	O
forms	O
.	O

In	O
addition	O
,	O
pedigree	O
analyses	O
suggest	O
the	O
occurrence	O
of	O
an	O
autosomal	O
recessive	O
variant	O
.	O

The	O
clinical	O
classification	O
is	O
increasingly	O
being	O
replaced	O
by	O
a	O
genetic	O
one	O
.	O

To	O
date	O
gene	O
loci	O
have	O
been	O
identified	O
in	O
at	O
least	O
six	O
autosomal	O
dominant	O
forms	O
,	O
i	O
.	O
e	O
.	O
,	O
in	O
idiopathic	B
torsion	I
dystonia	I
(	O
9q34	O
)	O
,	O
focal	B
dystonia	I
(	O
18p	O
)	O
,	O
adult	O
-	O
onset	O
idiopathic	B
torsion	I
dystonia	I
of	O
mixed	O
type	O
(	O
8p21	O
-	O
q22	O
)	O
,	O
dopa	B
-	I
responsive	I
dystonia	I
(	O
14q22	O
.	O
1	O
-	O
q22	O
.	O
2	O
)	O
,	O
and	O
paroxysmal	B
dystonic	I
choreoathetosis	I
(	O
2q25	O
-	O
q33	O
;	O
1p21	O
-	O

p13	O
.	O
3	O
)	O
.	O

Gene	O
loci	O
in	O
the	O
X	O
-	O
linked	O
recessive	O
forms	O
have	O
been	O
assigned	O
to	O
Xq13	O
.	O

1	O
in	O
the	O
X	B
-	I
linked	I
dystonia	I
parkinsonism	I
syndrome	I
and	O
to	O
Xq22	O
in	O
X	B
-	I
linked	I
sensorineural	I
deafness	I
,	O
dystonia	B
,	O
and	O
mental	B
retardation	I
.	O

The	O
disease	O
genes	O
have	O
been	O
identified	O
in	O
two	O
autosomal	O
dominant	O
forms	O
and	O
in	O
one	O
X	O
-	O
linked	O
recessive	O
form	O
.	O

Mutations	O
in	O
a	O
gene	O
coding	O
for	O
an	O
ATP	O
-	O
binding	O
protein	O
were	O
detected	O
in	O
idiopathic	B
torsion	I
dystonia	I
(	O
DYT1	O
)	O
,	O
and	O
the	O
GTP	O
cyclohydrolase	O
1	O
gene	O
is	O
mutated	O
in	O
dopa	B
-	I
responsive	I
dystonia	I
(	O
DYT5	O
)	O
.	O

In	O
sensorineural	B
deafness	I
,	O
dystonia	B
,	O
and	O
mental	B
retardation	I
,	O
mutations	O
were	O
found	O
in	O
the	O
gene	O
DDP	O
coding	O
for	O
a	O
polypeptide	O
of	O
unknown	O
function	O
.	O

This	O
article	O
reviews	O
the	O
clinical	O
and	O
molecular	O
genetics	O
of	O
primary	B
dystonias	I
,	O
critically	O
discusses	O
present	O
findings	O
,	O
and	O
proposes	O
referring	O
to	O
the	O
known	O
forms	O
,	O
most	O
of	O
which	O
can	O
be	O
distinguished	O
by	O
genetic	O
criteria	O
,	O
as	O
dystonias	B
1	I
-	I
12	I
.	O

Determination	O
of	O
30	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
mutations	O
,	O
including	O
15	O
not	O
previously	O
described	O
.	O

X	B
-	I
linked	I
Adrenoleukodystrophy	I
(	O
X	B
-	I
ALD	I
)	O
is	O
the	O
most	O
frequent	O
peroxisomal	B
disease	I
.	O

It	O
mainly	O
involves	O
the	O
nervous	O
system	O
white	O
matter	O
,	O
adrenal	O
cortex	O
and	O
testes	O
.	O

Several	O
distinct	O
clinical	O
phenotypes	O
are	O
known	O
.	O

The	O
principal	O
biochemical	O
abnormality	O
is	O
the	O
accumulation	O
of	O
saturated	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
VLCFAs	O
>	O
C22	O
0	O
,	O
mainly	O
C26	O
0	O
)	O
,	O
which	O
is	O
due	O
to	O
impaired	O
capacity	O
for	O
beta	O
-	O
oxidation	O
in	O
peroxisomes	O
.	O

Diagnosis	O
is	O
usually	O
based	O
on	O
the	O
VLCFA	O
levels	O
in	O
plasma	O
or	O
cultured	O
skin	O
fibroblasts	O
in	O
both	O
patients	O
and	O
carriers	O
.	O

In	O
0	O
.	O

1	O
%	O
of	O
affected	O
males	O
,	O
however	O
,	O
the	O
plasma	O
C26	O
0	O
level	O
is	O
borderline	O
normal	O
,	O
and	O
15	O
%	O
of	O
obligate	O
female	O
carriers	O
have	O
normal	O
results	O
.	O

Effective	O
mutation	O
detection	O
in	O
these	O
families	O
is	O
therefore	O
fundamental	O
to	O
unambiguously	O
determine	O
the	O
genetic	O
status	O
of	O
each	O
individual	O
at	O
risk	O
.	O

Of	O
particular	O
concern	O
are	O
female	O
members	O
of	O
kindreds	O
segregating	O
X	B
-	I
ALD	I
mutations	O
,	O
because	O
normal	O
VLCFA	O
levels	O
do	O
not	O
guarantee	O
lack	O
of	O
carrier	O
status	O
.	O

We	O
describe	O
a	O
fast	O
method	O
for	O
detection	O
of	O
X	B
-	I
ALD	I
mutations	O
.	O

The	O
method	O
is	O
based	O
on	O
SSCP	O
analysis	O
of	O
nested	O
PCR	O
fragments	O
followed	O
by	O
sequence	O
-	O
determination	O
reactions	O
.	O

Using	O
this	O
methodology	O
we	O
have	O
found	O
X	B
-	I
ALD	I
mutations	O
in	O
30	O
kindreds	O
,	O
including	O
15	O
not	O
previously	O
reported	O
.	O

beta	O
-	O
galactosidase	O
gene	O
mutations	O
affecting	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
elastin	O
-	O
binding	O
protein	O
in	O
GM1	B
-	I
gangliosidosis	I
patients	O
with	O
cardiac	B
involvement	I
.	O

GM1	B
-	I
gangliosidosis	I
is	O
a	O
lysosomal	B
storage	I
disorder	I
caused	O
by	O
deficiency	B
of	I
acid	I
beta	I
-	I
galactosidase	I
(	O
GLB1	O
)	O
.	O

We	O
report	O
five	O
new	O
beta	O
-	O
galactosidase	O
gene	O
mutations	O
in	O
nine	O
Italian	O
patients	O
and	O
one	O
fetus	O
,	O
segregating	O
in	O
seven	O
unrelated	O
families	O
.	O

Six	O
of	O
the	O
eight	O
patients	O
with	O
the	O
infantile	O
,	O
severe	O
form	O
of	O
the	O
disease	O
presented	O
cardiac	B
involvement	I
,	O
a	O
feature	O
rarely	O
associated	O
with	O
GM1	B
-	I
gangliosidosis	I
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
RNA	O
and	O
DNA	O
identified	O
two	O
new	O
RNA	O
splicing	O
defects	O
,	O
three	O
new	O
and	O
three	O
previously	O
described	O
amino	O
acid	O
substitutions	O
.	O

Interestingly	O
,	O
all	O
patients	O
with	O
cardiac	B
involvement	I
were	O
homozygous	O
for	O
one	O
of	O
these	O
mutations	O
R59H	O
,	O
Y591C	O
,	O
Y591N	O
,	O
or	O
IVS14	O
-	O
2A	O
>	O
G	O
.	O

In	O
contrast	O
,	O
all	O
other	O
patients	O
were	O
compound	O
heterozygous	O
for	O
one	O
of	O
the	O
following	O
mutations	O
R201H	O
,	O
R482H	O
,	O
G579D	O
,	O
IVS8	O
+	O
2T	O
>	O
C	O
.	O

Although	O
we	O
could	O
not	O
directly	O
correlate	O
the	O
presence	O
of	O
cardiac	B
abnormalities	I
with	O
specific	O
genetic	B
lesions	I
,	O
the	O
mutations	O
identified	O
in	O
patients	O
with	O
cardiomyopathy	B
fell	O
in	O
the	O
GLB1	O
cDNA	O
region	O
common	O
to	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
Hbeta	O
-	O
Gal	O
-	O
related	O
protein	O
,	O
also	O
known	O
as	O
the	O
elastin	O
binding	O
protein	O
(	O
EBP	O
)	O
.	O

Consequently	O
,	O
both	O
molecules	O
are	O
affected	O
by	O
the	O
mutations	O
,	O
and	O
they	O
may	O
contribute	O
differently	O
to	O
the	O
occurrence	O
of	O
specific	O
clinical	O
manifestations	O
.	O
.	O

In	O
vivo	O
modulation	O
of	O
Hmgic	O
reduces	O
obesity	B
.	O

The	O
HMGI	O
family	O
of	O
proteins	O
consists	O
of	O
three	O
members	O
,	O
HMGIC	O
,	O
HMGI	O
and	O
HMGI	O
(	O
Y	O
)	O
,	O
that	O
function	O
as	O
architectural	O
factors	O
and	O
are	O
essential	O
components	O
of	O
the	O
enhancesome	O
.	O

HMGIC	O
is	O
predominantly	O
expressed	O
in	O
proliferating	O
,	O
undifferentiated	O
mesenchymal	O
cells	O
and	O
is	O
not	O
detected	O
in	O
adult	O
tissues	O
.	O

It	O
is	O
disrupted	O
and	O
misexpressed	O
in	O
a	O
number	O
of	O
mesenchymal	B
tumour	I
cell	O
types	O
,	O
including	O
fat	B
-	I
cell	I
tumours	I
(	O
lipomas	B
)	O
.	O

In	O
addition	O
Hmgic	O
-	O
/	O
-	O
mice	O
have	O
a	O
deficiency	O
in	O
fat	O
tissue	O
.	O

To	O
study	O
its	O
role	O
in	O
adipogenesis	O
and	O
obesity	B
,	O
we	O
examined	O
Hmgic	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
adult	O
,	O
obese	B
mice	O
.	O

Mice	O
with	O
a	O
partial	B
or	I
complete	I
deficiency	I
of	I
Hmgic	I
resisted	O
diet	O
-	O
induced	O
obesity	B
.	O

Disruption	O
of	O
Hmgic	O
caused	O
a	O
reduction	O
in	O
the	O
obesity	B
induced	O
by	O
leptin	B
deficiency	I
(	O
Lepob	O
/	O
Lepob	O
)	O
in	O
a	O
gene	O
-	O
dose	O
-	O
dependent	O
manner	O
.	O

Our	O
studies	O
implicate	O
a	O
role	O
for	O
HMGIC	O
in	O
fat	O
-	O
cell	O
proliferation	O
,	O
indicating	O
that	O
it	O
may	O
be	O
an	O
adipose	O
-	O
specific	O
target	O
for	O
the	O
treatment	O
of	O
obesity	B
.	O
.	O

Molecular	O
analysis	O
of	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
in	O
factor	B
X	I
deficiency	I
.	O

Factor	B
X	I
deficiency	I
is	O
a	O
rare	O
haemorrhagic	B
condition	I
,	O
normally	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
in	O
which	O
a	O
variable	O
clinical	O
presentation	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype	O
.	O

The	O
factor	O
X	O
(	O
F10	O
)	O
genes	O
of	O
14	O
unrelated	O
individuals	O
with	O
factor	B
X	I
deficiency	I
(	O
12	O
familial	O
and	O
two	O
sporadic	O
cases	O
)	O
were	O
sequenced	O
yielding	O
a	O
total	O
of	O
13	O
novel	O
mutations	O
.	O

Family	O
studies	O
were	O
performed	O
in	O
order	O
to	O
distinguish	O
the	O
contributions	O
of	O
individual	O
mutant	O
F10	O
alleles	O
to	O
the	O
clinical	O
and	O
laboratory	O
phenotypes	O
.	O

Missense	O
mutations	O
were	O
studied	O
by	O
means	O
of	O
molecular	O
modelling	O
,	O
whereas	O
single	O
basepair	O
substitutions	O
in	O
splice	O
sites	O
and	O
the	O
5	O
flanking	O
region	O
were	O
examined	O
by	O
in	O
vitro	O
splicing	O
assay	O
and	O
luciferase	O
reporter	O
gene	O
assay	O
respectively	O
.	O

The	O
deletion	O
allele	O
of	O
a	O
novel	O
hexanucleotide	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
F10	O
gene	O
promoter	O
region	O
was	O
shown	O
by	O
reporter	O
gene	O
assay	O
,	O
to	O
reduce	O
promoter	O
activity	O
by	O
approximately	O
20	O
%	O
.	O

One	O
family	O
manifesting	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
possessed	O
three	O
clinically	O
affected	O
members	O
who	O
were	O
heterozygous	O
for	O
a	O
splice	O
-	O
site	O
mutation	O
that	O
was	O
predicted	O
to	O
lead	O
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
product	O
.	O

A	O
model	O
which	O
accounts	O
for	O
the	O
dominant	O
negative	O
effect	O
of	O
this	O
lesion	O
is	O
presented	O
.	O

Variation	O
in	O
the	O
antigen	O
level	O
of	O
heterozygous	O
relatives	O
of	O
probands	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
between	O
families	O
than	O
within	O
families	O
,	O
consistent	O
with	O
the	O
view	O
that	O
the	O
nature	O
of	O
the	O
F10	O
lesion	O
(	O
s	O
)	O
segregating	O
in	O
a	O
given	O
family	O
is	O
a	O
prime	O
determinant	O
of	O
the	O
laboratory	O
phenotype	O
.	O

By	O
contrast	O
,	O
no	O
such	O
relationship	O
could	O
be	O
discerned	O
between	O
laboratory	O
phenotype	O
and	O
polymorphism	O
genotype	O
.	O
.	O

Transgenic	O
mice	O
expressing	O
a	O
truncated	O
form	O
of	O
the	O
high	O
mobility	O
group	O
I	O
-	O
C	O
protein	O
develop	O
adiposity	O
and	O
an	O
abnormally	O
high	O
prevalence	O
of	O
lipomas	B
.	O

Chromosomal	O
translocations	O
in	O
human	O
lipomas	B
frequently	O
create	O
fusion	O
transcripts	O
encoding	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
I	O
-	O
C	O
DNA	O
-	O
binding	O
domains	O
and	O
C	O
-	O
terminal	O
sequences	O
from	O
different	O
presumed	O
transcription	O
factors	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
HMG	O
I	O
-	O
C	O
in	O
the	O
development	O
of	O
lipomas	B
.	O

To	O
evaluate	O
the	O
role	O
of	O
the	O
HMG	O
I	O
-	O
C	O
component	O
,	O
the	O
three	O
DNA	O
-	O
binding	O
domains	O
of	O
HMG	O
I	O
-	O
C	O
have	O
now	O
been	O
expressed	O
in	O
transgenic	O
mice	O
.	O

Despite	O
the	O
ubiquitous	O
expression	O
of	O
the	O
truncated	O
HMG	O
I	O
-	O
C	O
protein	O
,	O
the	O
transgenic	O
mice	O
develop	O
a	O
selective	O
abundance	O
of	O
fat	O
tissue	O
early	O
in	O
life	O
,	O
show	O
marked	O
adipose	B
tissue	I
inflammation	I
,	O
and	O
have	O
an	O
abnormally	O
high	O
incidence	O
of	O
lipomas	B
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
DNA	O
-	O
binding	O
domains	O
of	O
HMG	O
I	O
-	O
C	O
,	O
in	O
the	O
absence	O
of	O
a	O
C	O
-	O
terminal	O
fusion	O
partner	O
,	O
are	O
sufficient	O
to	O
perturb	O
adipogenesis	O
and	O
predispose	O
to	O
lipomas	B
.	O

We	O
provide	O
data	O
supporting	O
the	O
central	O
utility	O
of	O
this	O
animal	O
model	O
as	O
a	O
tool	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
one	O
of	O
the	O
most	O
common	O
kind	O
of	O
human	O
benign	B
tumors	I
.	O
.	O

ATM	O
phosphorylates	O
p95	O
/	O
nbs1	O
in	O
an	O
S	O
-	O
phase	O
checkpoint	O
pathway	O
.	O

The	O
rare	B
diseases	I
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
,	O
and	O
Nijmegen	B
breakage	I
syndrome	I
(	O
NBS	B
)	O
,	O
with	O
mutations	O
in	O
the	O
p95	O
/	O
nbs1	O
gene	O
,	O
share	O
a	O
variety	O
of	O
phenotypic	B
abnormalities	I
such	O
as	O
chromosomal	B
instability	I
,	O
radiation	O
sensitivity	O
and	O
defects	O
in	O
cell	O
-	O
cycle	O
checkpoints	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O

The	O
ATM	O
gene	O
encodes	O
a	O
protein	O
kinase	O
that	O
is	O
activated	O
by	O
ionizing	O
radiation	O
or	O
radiomimetic	O
drugs	O
,	O
whereas	O
p95	O
/	O
nbs1	O
is	O
part	O
of	O
a	O
protein	O
complex	O
that	O
is	O
involved	O
in	O
responses	O
to	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

Here	O
,	O
because	O
of	O
the	O
similarities	O
between	O
AT	B
and	O
NBS	B
,	O
we	O
evaluated	O
the	O
functional	O
interactions	O
between	O
ATM	O
and	O
p95	O
/	O
nbs1	O
.	O

Activation	O
of	O
the	O
ATM	O
kinase	O
by	O
ionizing	O
radiation	O
and	O
induction	O
of	O
ATM	O
-	O
dependent	O
responses	O
in	O
NBS	B
cells	O
indicated	O
that	O
p95	O
/	O
nbs1	O
may	O
not	O
be	O
required	O
for	O
signalling	O
to	O
ATM	O
after	O
ionizing	O
radiation	O
.	O

However	O
,	O
p95	O
/	O
nbs1	O
was	O
phosphorylated	O
on	O
serine	O
343	O
in	O
an	O
ATM	O
-	O
dependent	O
manner	O
in	O
vitro	O
and	O
in	O
vivo	O
after	O
ionizing	O
radiation	O
.	O

A	O
p95	O
/	O
nbs1	O
construct	O
mutated	O
at	O
the	O
ATM	O
phosphorylation	O
site	O
abrogated	O
an	O
S	O
-	O
phase	O
checkpoint	O
induced	O
by	O
ionizing	O
radiation	O
in	O
normal	O
cells	O
and	O
failed	O
to	O
compensate	O
for	O
this	O
functional	O
deficiency	O
in	O
NBS	B
cells	O
.	O

These	O
observations	O
link	O
ATM	O
and	O
p95	O
/	O
nbs1	O
in	O
a	O
common	O
signalling	O
pathway	O
and	O
provide	O
an	O
explanation	O
for	O
phenotypic	O
similarities	O
in	O
these	O
two	O
diseases	O
.	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
fragile	B
X	I
syndrome	I
.	O

Fragile	B
X	I
syndrome	I
,	O
a	O
common	O
form	O
of	O
inherited	B
mental	I
retardation	I
,	O
is	O
mainly	O
caused	O
by	O
massive	O
expansion	O
of	O
CGG	O
triplet	O
repeats	O
located	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
of	O
the	O
fragile	B
X	I
mental	I
retardation	I
-	O
1	O
(	O
FMR1	O
)	O
gene	O
.	O

In	O
patients	O
with	O
fragile	B
X	I
syndrome	I
,	O
the	O
expanded	O
CGG	O
triplet	O
repeats	O
are	O
hypermethylated	O
and	O
the	O
expression	O
of	O
the	O
FMR1	O
gene	O
is	O
repressed	O
,	O
which	O
leads	O
to	O
the	O
absence	O
of	O
FMR1	O
protein	O
(	O
FMRP	O
)	O
and	O
subsequent	O
mental	B
retardation	I
.	O

FMRP	O
is	O
an	O
RNA	O
-	O
binding	O
protein	O
that	O
shuttles	O
between	O
the	O
nucleus	O
and	O
cytoplasm	O
.	O

This	O
protein	O
has	O
been	O
implicated	O
in	O
protein	O
translation	O
as	O
it	O
is	O
found	O
associated	O
with	O
polyribosomes	O
and	O
the	O
rough	O
endoplasmic	O
reticulum	O
.	O

We	O
discuss	O
here	O
the	O
recent	O
progress	O
made	O
towards	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
CGG	O
repeat	O
expansion	O
and	O
physiological	O
function	O
(	O
s	O
)	O
of	O
FMRP	O
.	O

These	O
studies	O
will	O
not	O
only	O
help	O
to	O
illuminate	O
the	O
molecular	O
basis	O
of	O
the	O
general	O
class	O
of	O
human	O
diseases	O
with	O
trinucleotide	O
repeat	O
expansion	O
but	O
also	O
provide	O
an	O
avenue	O
to	O
understand	O
aspects	O
of	O
human	O
cognition	O
and	O
intelligence	O
.	O
.	O

Haploinsufficiency	B
of	I
the	I
transcription	I
factors	I
FOXC1	I
and	I
FOXC2	I
results	O
in	O
aberrant	O
ocular	O
development	O
.	O

Anterior	B
segment	I
developmental	I
disorders	I
,	O
including	O
Axenfeld	B
-	I
Rieger	I
anomaly	I
(	O
ARA	B
)	O
,	O
variably	O
associate	O
with	O
harmfully	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
which	O
causes	O
glaucoma	B
.	O

Clinically	O
observed	O
dysgenesis	O
does	O
not	O
correlate	O
with	O
IOP	O
,	O
however	O
,	O
and	O
the	O
etiology	O
of	O
glaucoma	B
development	O
is	O
not	O
understood	O
.	O

The	O
forkhead	O
transcription	O
factor	O
genes	O
Foxc1	O
(	O
formerly	O
Mf1	O
)	O
and	O
Foxc2	O
(	O
formerly	O
Mfh1	O
)	O
are	O
expressed	O
in	O
the	O
mesenchyme	O
from	O
which	O
the	O
ocular	O
drainage	O
structures	O
derive	O
.	O

Mutations	O
in	O
the	O
human	O
homolog	O
of	O
Foxc1	O
,	O
FKHL7	O
,	O
cause	O
dominant	O
anterior	B
segment	I
defects	I
and	O
glaucoma	B
in	O
various	O
families	O
.	O

We	O
show	O
that	O
Foxc1	O
(	O
+	O
/	O
-	O
)	O
mice	O
have	O
anterior	B
segment	I
abnormalities	I
similar	O
to	O
those	O
reported	O
in	O
human	O
patients	O
.	O

These	O
abnormalities	O
include	O
small	O
or	O
absent	O
Schlemms	O
canal	O
,	O
aberrantly	O
developed	O
trabecular	O
meshwork	O
,	O
iris	B
hypoplasia	I
,	O
severely	O
eccentric	O
pupils	O
and	O
displaced	O
Schwalbes	O
line	O
.	O

The	O
penetrance	O
of	O
clinically	O
obvious	O
abnormalities	O
varies	O
with	O
genetic	O
background	O
.	O

In	O
some	O
affected	O
eyes	O
,	O
collagen	O
bundles	O
were	O
half	O
normal	O
diameter	O
,	O
or	O
collagen	O
and	O
elastic	O
tissue	O
were	O
very	O
sparse	O
.	O

Thus	O
,	O
abnormalities	O
in	O
extracellular	O
matrix	O
synthesis	O
or	O
organization	O
may	O
contribute	O
to	O
development	O
of	O
the	O
ocular	O
phenotypes	O
.	O

Despite	O
the	O
abnormalities	O
in	O
ocular	O
drainage	O
structures	O
in	O
Foxc1	O
(	O
+	O
/	O
-	O
)	O
mice	O
,	O
IOP	O
was	O
normal	O
in	O
almost	O
all	O
mice	O
analyzed	O
,	O
on	O
all	O
genetic	O
backgrounds	O
and	O
at	O
all	O
ages	O
.	O

Similar	O
abnormalities	O
were	O
found	O
in	O
Foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
,	O
but	O
no	O
disease	O
-	O
associated	O
mutations	O
were	O
identified	O
in	O
the	O
human	O
homolog	O
FKHL14	O
in	O
32	O
ARA	B
patients	O
.	O

Foxc1	O
(	O
+	O
/	O
-	O
)	O
and	O
Foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
are	O
useful	O
models	O
for	O
studying	O
anterior	O
segment	O
development	O
and	O
its	O
anomalies	O
,	O
and	O
may	O
allow	O
identification	O
of	O
genes	O
that	O
interact	O
with	O
Foxc1	O
and	O
Foxc2	O
(	O
or	O
FKHL7	O
and	O
FKHL14	O
)	O
to	O
produce	O
a	O
phenotype	O
with	O
elevated	O
IOP	O
and	O
glaucoma	B
.	O
.	O

(	O
Over	O
)	O
correction	O
of	O
FMR1	B
deficiency	I
with	O
YAC	O
transgenics	O
:	O
behavioral	O
and	O
physical	O
features	O
.	O

Fragile	B
X	I
syndrome	I
is	O
a	O
common	O
cause	O
of	O
mental	B
retardation	I
involving	O
loss	O
of	O
expression	O
of	O
the	O
FMR1	O
gene	O
.	O

The	O
role	O
of	O
FMR1	O
remains	O
undetermined	O
but	O
the	O
protein	O
appears	O
to	O
be	O
involved	O
in	O
RNA	O
metabolism	O
.	O

Fmr1	O
knockout	O
mice	O
exhibit	O
a	O
phenotype	O
with	O
some	O
similarities	O
to	O
humans	O
,	O
such	O
as	O
macroorchidism	B
and	O
behavioral	O
abnormalities	O
.	O

As	O
a	O
step	O
toward	O
understanding	O
the	O
function	O
of	O
FMR1	O
and	O
the	O
determination	O
of	O
the	O
potential	O
for	O
therapeutic	O
approaches	O
to	O
fragile	B
X	I
syndrome	I
,	O
yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
transgenic	O
mice	O
were	O
generated	O
in	O
order	O
to	O
determine	O
whether	O
the	O
Fmr1	O
knockout	O
mouse	O
phenotype	O
could	O
be	O
rescued	O
.	O

Several	O
transgenic	O
lines	O
were	O
generated	O
that	O
carried	O
the	O
entire	O
FMR1	O
locus	O
with	O
extensive	O
amounts	O
of	O
flanking	O
sequence	O
.	O

We	O
observed	O
that	O
the	O
YAC	O
transgene	O
supported	O
production	O
of	O
the	O
human	O
protein	O
(	O
FMRP	O
)	O
which	O
was	O
present	O
at	O
levels	O
10	O
to	O
15	O
times	O
that	O
of	O
endogenous	O
protein	O
and	O
was	O
expressed	O
in	O
a	O
cell	O
-	O
and	O
tissue	O
-	O
specific	O
manner	O
.	O

Macro	O
-	O
orchidism	O
was	O
absent	O
in	O
knockout	O
mice	O
carrying	O
the	O
YAC	O
transgene	O
indicating	O
functional	O
rescue	O
by	O
the	O
human	O
protein	O
.	O

Given	O
the	O
complex	O
behavioral	O
phenotype	O
in	O
fragile	B
X	I
patients	O
and	O
the	O
mild	O
phenotype	O
previously	O
reported	O
for	O
the	O
Fmr1	O
knockout	O
mouse	O
,	O
we	O
performed	O
a	O
more	O
thorough	O
evaluation	O
of	O
the	O
Fmr1	O
knockout	O
phenotype	O
using	O
additional	O
behavioral	O
assays	O
that	O
had	O
not	O
previously	O
been	O
reported	O
for	O
this	O
animal	O
model	O
.	O

The	O
mouse	O
displayed	O
reduced	O
anxiety	B
-	O
related	O
responses	O
with	O
increased	O
exploratory	O
behavior	O
.	O

FMR1	O
YAC	O
transgenic	O
mice	O
overexpressing	O
the	O
human	O
protein	O
did	O
produce	O
opposing	O
behavioral	O
responses	O
and	O
additional	O
abnormal	O
behaviors	O
were	O
also	O
observed	O
.	O

These	O
findings	O
have	O
significant	O
implications	O
for	O
gene	O
therapy	O
for	O
fragile	B
X	I
syndrome	I
since	O
overexpression	O
of	O
the	O
gene	O
may	O
harbor	O
its	O
own	O
phenotype	O
.	O
.	O

Transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
expanded	O
CTG	O
repeat	O
mimic	O
closely	O
the	O
DM	B
CTG	O
repeat	O
intergenerational	O
and	O
somatic	O
instability	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
repeat	O
expansion	O
in	O
the	O
3UTR	O
of	O
the	O
DM	B
protein	O
kinase	O
(	O
DMPK	O
)	O
gene	O
.	O

A	O
very	O
high	O
level	O
of	O
instability	O
is	O
observed	O
through	O
successive	O
generations	O
and	O
the	O
size	O
of	O
the	O
repeat	O
is	O
generally	O
correlated	O
with	O
the	O
severity	O
of	O
the	O
disease	O
and	O
with	O
age	O
at	O
onset	O
.	O

Furthermore	O
,	O
tissues	O
from	O
DM	B
patients	O
exhibit	O
somatic	O
mosaicism	O
that	O
increases	O
with	O
age	O
.	O

We	O
generated	O
transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
20	O
,	O
55	O
or	O
>	O
300	O
CTG	O
,	O
cloned	O
from	O
patients	O
from	O
the	O
same	O
affected	O
DM	B
family	O
.	O

Using	O
large	O
human	O
flanking	O
sequences	O
and	O
a	O
large	O
amplification	O
,	O
we	O
demonstrate	O
that	O
the	O
intergenerational	O
CTG	O
repeat	O
instability	O
is	O
reproduced	O
in	O
mice	O
,	O
with	O
a	O
strong	O
bias	O
towards	O
expansions	O
and	O
with	O
the	O
same	O
sex	O
-	O
and	O
size	O
-	O
dependent	O
characteristics	O
as	O
in	O
humans	O
.	O

Moreover	O
,	O
a	O
high	O
level	O
of	O
instability	O
,	O
increasing	O
with	O
age	O
,	O
can	O
be	O
observed	O
in	O
tissues	O
and	O
in	O
sperm	O
.	O

Although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(	O
or	O
big	O
jumps	O
over	O
several	O
hundred	O
CTG	O
repeats	O
)	O
as	O
in	O
congenital	O
forms	O
of	O
DM	B
,	O
our	O
model	O
carrying	O
>	O
300	O
CTG	O
is	O
the	O
first	O
to	O
show	O
instability	O
so	O
close	O
to	O
the	O
human	O
DM	B
situation	O
.	O

Our	O
three	O
models	O
carrying	O
different	O
sizes	O
of	O
CTG	O
repeat	O
provide	O
insight	O
on	O
the	O
different	O
factors	O
modulating	O
the	O
CTG	O
repeat	O
instability	O
.	O
.	O

Inactivation	O
of	O
the	O
Friedreich	B
ataxia	I
mouse	O
gene	O
leads	O
to	O
early	O
embryonic	B
lethality	I
without	O
iron	O
accumulation	O
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
,	O
the	O
most	O
common	O
autosomal	B
recessive	I
ataxia	I
,	O
is	O
caused	O
in	O
almost	O
all	O
cases	O
by	O
homozygous	O
intronic	O
expansions	O
resulting	O
in	O
the	O
loss	O
of	O
frataxin	O
,	O
a	O
mitochondrial	O
protein	O
conserved	O
through	O
evolution	O
,	O
and	O
involved	O
in	O
mitochondrial	O
iron	O
homeostasis	O
.	O

Yeast	O
knockout	O
models	O
,	O
and	O
histological	O
and	O
biochemical	O
data	O
from	O
patient	O
heart	O
biopsies	O
or	O
autopsies	O
indicate	O
that	O
the	O
frataxin	O
defect	O
causes	O
a	O
specific	O
iron	B
-	I
sulfur	I
protein	I
deficiency	I
and	O
mitochondrial	O
iron	O
accumulation	O
leading	O
to	O
the	O
pathological	O
changes	O
.	O

Affected	O
human	O
tissues	O
are	O
rarely	O
available	O
to	O
further	O
examine	O
this	O
hypothesis	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
the	O
disease	O
,	O
we	O
generated	O
a	O
mouse	O
model	O
by	O
deletion	O
of	O
exon	O
4	O
leading	O
to	O
inactivation	O
of	O
the	O
Frda	B
gene	O
product	O
.	O

We	O
show	O
that	O
homozygous	O
deletions	O
cause	O
embryonic	B
lethality	I
a	O
few	O
days	O
after	O
implantation	O
,	O
demonstrating	O
an	O
important	O
role	O
for	O
frataxin	O
during	O
early	O
development	O
.	O

These	O
results	O
suggest	O
that	O
the	O
milder	O
phenotype	O
in	O
humans	O
is	O
due	O
to	O
residual	O
frataxin	O
expression	O
associated	O
with	O
the	O
expansion	O
mutations	O
.	O

Surprisingly	O
,	O
in	O
the	O
frataxin	O
knockout	O
mouse	O
,	O
no	O
iron	O
accumulation	O
was	O
observed	O
during	O
embryonic	O
resorption	O
,	O
suggesting	O
that	O
cell	O
death	O
could	O
be	O
due	O
to	O
a	O
mechanism	O
independent	O
of	O
iron	O
accumulation	O
.	O
.	O

Gaucher	B
disease	I
:	O
the	O
origins	O
of	O
the	O
Ashkenazi	O
Jewish	O
N370S	O
and	O
84GG	O
acid	O
beta	O
-	O
glucosidase	O
mutations	O
.	O

Type	O
1	O
Gaucher	B
disease	I
(	O
GD	B
)	O
,	O
a	O
non	O
-	O
neuronopathic	O
lysosomal	B
storage	I
disorder	I
,	O
results	O
from	O
the	O
deficient	O
activity	O
of	O
acid	O
beta	O
-	O
glucosidase	O
(	O
GBA	O
)	O
.	O

Type	O
1	O
disease	O
is	O
panethnic	O
but	O
is	O
more	O
prevalent	O
in	O
individuals	O
of	O
Ashkenazi	O
Jewish	O
(	O
AJ	O
)	O
descent	O
.	O

Of	O
the	O
causative	O
GBA	O
mutations	O
,	O
N370S	O
is	O
particularly	O
frequent	O
in	O
the	O
AJ	O
population	O
,	O
(	O
q	O
approximately	O
.	O
03	O
)	O
,	O
whereas	O
the	O
84GG	O
insertion	O
(	O
q	O
approximately	O
.	O
003	O
)	O
occurs	O
exclusively	O
in	O
the	O
Ashkenazim	O
.	O

To	O
investigate	O
the	O
genetic	O
history	O
of	O
these	O
mutations	O
in	O
the	O
AJ	O
population	O
,	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
were	O
used	O
to	O
map	O
a	O
9	O
.	O

3	O
-	O
cM	O
region	O
containing	O
the	O
GBA	O
locus	O
and	O
to	O
genotype	O
261	O
AJ	O
N370S	O
chromosomes	O
,	O
60	O
European	O
non	O
-	O
Jewish	O
N370S	O
chromosomes	O
,	O
and	O
62	O
AJ	O
84GG	O
chromosomes	O
.	O

A	O
highly	O
conserved	O
haplotype	O
at	O
four	O
markers	O
flanking	O
GBA	O
(	O
PKLR	O
,	O
D1S1595	O
,	O
D1S2721	O
,	O
and	O
D1S2777	O
)	O
was	O
observed	O
on	O
both	O
the	O
AJ	O
chromosomes	O
and	O
the	O
non	O
-	O
Jewish	O
N370S	O
chromosomes	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
founder	O
common	O
to	O
both	O
populations	O
.	O

Of	O
note	O
,	O
the	O
presence	O
of	O
different	O
divergent	O
haplotypes	O
suggested	O
the	O
occurrence	O
of	O
de	O
novo	O
,	O
recurrent	O
N370S	O
mutations	O
.	O

In	O
contrast	O
,	O
a	O
different	O
conserved	O
haplotype	O
at	O
these	O
markers	O
was	O
identified	O
on	O
the	O
84GG	O
chromosomes	O
,	O
which	O
was	O
unique	O
to	O
the	O
AJ	O
population	O
.	O

On	O
the	O
basis	O
of	O
the	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
delta	O
values	O
,	O
the	O
non	O
-	O
Jewish	O
European	O
N370S	O
chromosomes	O
had	O
greater	O
haplotype	O
diversity	O
and	O
less	O
LD	O
at	O
the	O
markers	O
flanking	O
the	O
conserved	O
haplotype	O
than	O
did	O
the	O
AJ	O
N370S	O
chromosomes	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
the	O
N370S	O
mutation	O
in	O
the	O
non	O
-	O
Jewish	O
European	O
population	O
prior	O
to	O
the	O
founding	O
of	O
the	O
AJ	O
population	O
.	O

Coalescence	O
analyses	O
for	O
the	O
N370S	O
and	O
84GG	O
mutations	O
estimated	O
similar	O
coalescence	O
times	O
,	O
of	O
48	O
and	O
55	O
.	O
5	O
generations	O
ago	O
,	O
respectively	O
.	O

The	O
results	O
of	O
these	O
studies	O
are	O
consistent	O
with	O
a	O
significant	O
bottleneck	O
occurring	O
in	O
the	O
AJ	O
population	O
during	O
the	O
first	O
millennium	O
,	O
when	O
the	O
population	O
became	O
established	O
in	O
Europe	O
.	O

HLA	O
B27	O
and	O
the	O
genetics	O
of	O
ankylosing	B
spondylitis	I
.	O

One	O
hundred	O
and	O
twenty	O
-	O
eight	O
of	O
145	O
patients	O
with	O
ankylosing	B
spondylitis	I
(	O
AS	B
)	O
were	O
found	O
to	O
be	O
HLA	O
B27	O
positive	O
.	O

Five	O
patients	O
had	O
evidence	O
of	O
a	O
sero	O
-	O
negative	O
peripheral	B
arthritis	I
resembling	O
peripheral	B
psoriatic	I
arthritis	I
and	O
3	O
of	O
these	O
were	O
B27	O
negative	O
.	O

One	O
further	O
B27	O
negative	O
patients	O
had	O
a	O
sister	O
with	O
ankylosing	B
spondylitis	I
and	O
ulcerative	B
colitis	I
and	O
a	O
mother	O
with	O
ulcerative	B
colitis	I
.	O

There	O
was	O
evidence	O
of	O
a	O
somewhat	O
later	O
age	O
of	O
onset	O
of	O
symptoms	O
in	O
B27	O
negative	O
patients	O
.	O

These	O
findings	O
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	O
of	O
clinical	O
and	O
genetic	O
heterogeneity	O
in	O
ankylosing	B
spondylitis	I
with	O
genes	O
for	O
psoriasis	B
and	O
inflammatory	B
bowel	I
disease	I
being	O
important	O
in	O
some	O
individuals	O
,	O
particularly	O
those	O
who	O
are	O
B27	O
negative	O
.	O

Twenty	O
-	O
five	O
first	O
-	O
degree	O
relatives	O
with	O
ankylosing	B
spondylitis	I
were	O
all	O
B27	O
positive	O
.	O

The	O
only	O
instance	O
of	O
disassociation	O
of	O
B27	O
and	O
spondylitis	B
in	O
a	O
family	O
was	O
where	O
the	O
proband	O
had	O
ulcerative	B
colitis	I
as	O
well	O
as	O
spondylitis	B
.	O

Of	O
13	O
B27	O
positive	O
fathers	O
3	O
could	O
be	O
diagnosed	O
as	O
having	O
definite	O
ankylosing	B
spondylitis	I
(	O
23	O
%	O
)	O
.	O

These	O
findings	O
are	O
thought	O
to	O
provide	O
evidence	O
against	O
the	O
concept	O
that	O
the	O
gene	O
for	O
ankylosing	B
spondylitis	I
is	O
not	O
B27	O
but	O
a	O
closely	O
linked	O
gene	O
and	O
favour	O
the	O
occurrence	O
of	O
an	O
environmental	O
event	O
affecting	O
approximately	O
one	O
-	O
fifth	O
of	O
B27	O
positive	O
males	O
to	O
result	O
in	O
disease	O
.	O
.	O

Founder	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
Polish	O
families	O
with	O
breast	B
-	I
ovarian	I
cancer	I
.	O

We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	O
study	O
,	O
to	O
identify	O
possible	O
BRCA1	O
and	O
BRCA2	O
founder	O
mutations	O
in	O
the	O
Polish	O
population	O
.	O

The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	B
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B
or	I
ovarian	I
cancer	I
and	O
who	O
had	O
cancer	B
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O

A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	B
and	I
ovarian	I
cancers	I
,	O
4	O
families	O
had	O
ovarian	B
cancers	I
only	O
,	O
and	O
36	O
families	O
had	O
breast	B
cancers	I
only	O
.	O

Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	O
from	O
each	O
family	O
.	O

The	O
entire	O
coding	O
region	O
of	O
BRCA1	O
and	O
BRCA2	O
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations	O
,	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
.	O

Mutations	O
were	O
found	O
in	O
35	O
(	O
53	O
%	O
)	O
of	O
the	O
66	O
families	O
studied	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	O
gene	O
.	O

BRCA1	B
abnormalities	I
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B
cancer	I
only	O
,	O
in	O
67	O
%	O
of	O
27	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
,	O
and	O
in	O
34	O
%	O
of	O
35	O
families	O
with	O
breast	B
cancer	I
only	O
.	O

The	O
single	O
family	O
with	O
a	O
BRCA2	O
mutation	O
had	O
the	O
breast	B
-	I
ovarian	I
cancer	I
syndrome	I
.	O

Seven	O
distinct	O
mutations	O
were	O
identified	O
;	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families	O
.	O

In	O
total	O
,	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(	O
94	O
%	O
)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations	O
.	O

Three	O
BRCA1	B
abnormalities	I
-	O
5382insC	O
,	O
C61G	O
,	O
and	O
4153delA	O
-	O
accounted	O
for	O
51	O
%	O
,	O
20	O
%	O
,	O
and	O
11	O
%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
.	O
.	O

Molecular	O
basis	O
of	O
very	B
long	I
chain	I
acyl	I
-	I
CoA	I
dehydrogenase	I
deficiency	I
in	O
three	O
Israeli	O
patients	O
:	O
identification	O
of	O
a	O
complex	O
mutant	O
allele	O
with	O
P65L	O
and	O
K247Q	O
mutations	O
,	O
the	O
former	O
being	O
an	O
exonic	O
mutation	O
causing	O
exon	O
3	O
skipping	O
.	O

Very	B
long	I
chain	I
acyl	I
-	I
CoA	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
a	O
life	O
-	O
threatening	O
disorder	O
of	O
mitochondrial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

We	O
identified	O
four	O
novel	O
mutations	O
in	O
three	O
unrelated	O
patients	O
.	O

All	O
patients	O
had	O
the	O
severe	O
childhood	O
form	O
of	O
VLCAD	B
deficiency	I
with	O
early	O
onset	O
and	O
high	O
mortality	O
.	O

Immunoblot	O
analysis	O
revealed	O
that	O
VLCAD	O
protein	O
was	O
undetectable	O
in	O
patients	O
2	O
and	O
3	O
,	O
whereas	O
normal	O
-	O
size	O
VLCAD	O
protein	O
and	O
an	O
aberrant	O
form	O
of	O
VLCAD	O
(	O
4kDa	O
smaller	O
)	O
were	O
detected	O
in	O
patient	O
1	O
.	O

As	O
expected	O
,	O
null	O
mutations	O
were	O
found	O
in	O
patients	O
2	O
and	O
3	O
patient	O
2	O
is	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
del	O
4	O
bp	O
at	O
798	O
-	O
801	O
,	O
and	O
patient	O
3	O
is	O
homozygous	O
for	O
a	O
nonsense	O
mutation	O
65C	O
>	O
A	O
(	O
S22X	O
)	O
.	O

Patient	O
1	O
was	O
homozygous	O
for	O
a	O
complex	O
mutant	O
allele	O
containing	O
two	O
alterations	O
,	O
including	O
a	O
194C	O
>	O
T	O
transition	O
(	O
P65L	O
)	O
and	O
739A	O
>	O
C	O
transversion	O
(	O
K247Q	O
)	O
;	O
in	O
the	O
case	O
of	O
P65L	O
,	O
the	O
amino	O
acid	O
change	O
does	O
not	O
reduce	O
enzyme	O
activity	O
.	O

However	O
,	O
the	O
nucleotide	O
change	O
resulted	O
in	O
exon	O
3	O
skipping	O
,	O
whereas	O
the	O
latter	O
K247Q	O
mutation	O
had	O
a	O
drastic	O
effect	O
on	O
enzyme	O
activity	O
.	O

We	O
verified	O
these	O
events	O
by	O
in	O
vivo	O
splicing	O
experiments	O
and	O
transient	O
expression	O
analysis	O
of	O
mutant	O
cDNAs	O
.	O

The	O
P65L	O
mutation	O
locates	O
11	O
bases	O
upstream	O
of	O
a	O
splice	O
donor	O
site	O
of	O
intron	O
3	O
.	O

This	O
is	O
an	O
example	O
of	O
an	O
exonic	O
mutation	O
which	O
affects	O
exon	O
-	O
splicing	O
.	O
.	O

Submicroscopic	O
deletion	O
in	O
cousins	O
with	O
Prader	B
-	I
Willi	I
syndrome	I
causes	O
a	O
grandmatrilineal	O
inheritance	O
pattern	O
:	O
effects	O
of	O
imprinting	O
.	O

The	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
critical	O
region	O
on	O
15q11	O
-	O
q13	O
is	O
subject	O
to	O
imprinting	O
.	O

PWS	B
becomes	O
apparent	O
when	O
genes	O
on	O
the	O
paternally	O
inherited	O
chromosome	O
are	O
not	O
expressed	O
.	O

Familial	B
PWS	I
is	O
rare	O
.	O

We	O
report	O
on	O
a	O
family	O
in	O
which	O
a	O
male	O
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
PWS	B
with	O
cytogenetically	O
normal	O
karyotypes	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
shows	O
a	O
submicroscopic	O
deletion	O
of	O
SNRPN	O
,	O
but	O
not	O
the	O
closely	O
associated	O
loci	O
D15S10	O
,	O
D15S11	O
,	O
D15S63	O
,	O
and	O
GABRB3	O
.	O

The	O
cousins	O
fathers	O
and	O
two	O
paternal	O
aunts	O
have	O
the	O
same	O
deletion	O
and	O
are	O
clinically	O
normal	O
.	O

The	O
grandmother	O
of	O
the	O
cousins	O
is	O
deceased	O
and	O
not	O
available	O
for	O
study	O
,	O
and	O
their	O
grandfather	O
is	O
not	O
deleted	O
for	O
SNRPN	O
.	O

DNA	O
methylation	O
analysis	O
of	O
D15S63	O
is	O
consistent	O
with	O
an	O
abnormality	O
of	O
the	O
imprinting	O
center	O
associated	O
with	O
PWS	B
.	O

"	O
Grandmatrilineal	O
"	O
inheritance	O
occurs	O
when	O
a	O
woman	O
with	O
deletion	O
of	O
an	O
imprinted	O
,	O
paternally	O
expressed	O
gene	O
is	O
at	O
risk	O
of	O
having	O
affected	O
grandchildren	O
through	O
her	O
sons	O
.	O

In	O
this	O
case	O
,	O
PWS	B
does	O
not	O
become	O
evident	O
as	O
long	O
as	O
the	O
deletion	O
is	O
passed	O
through	O
the	O
matrilineal	O
line	O
.	O

This	O
represents	O
a	O
unique	O
inheritance	O
pattern	O
due	O
to	O
imprinting	O
.	O
.	O

Human	O
glycine	O
decarboxylase	O
gene	O
(	O
GLDC	O
)	O
and	O
its	O
highly	O
conserved	O
processed	O
pseudogene	O
(	O
psiGLDC	O
)	O
:	O
their	O
structure	O
and	O
expression	O
,	O
and	O
the	O
identification	O
of	O
a	O
large	O
deletion	O
in	O
a	O
family	O
with	O
nonketotic	B
hyperglycinemia	I
.	O

Mutations	O
in	O
the	O
glycine	O
decarboxylase	O
gene	O
(	O
GLDC	O
)	O
cause	O
nonketotic	B
hyperglycinemia	I
(	O
NKH	B
)	O
,	O
an	O
in	B
-	I
born	I
error	I
of	I
metabolism	I
characterized	O
by	O
severe	O
neurological	B
disturbance	I
.	O

We	O
have	O
determined	O
the	O
structure	O
of	O
GLDC	O
and	O
of	O
its	O
pseudogene	O
(	O
psiGLDC	O
)	O
and	O
studied	O
their	O
expression	O
for	O
a	O
molecular	O
analysis	O
of	O
NKH	B
.	O

The	O
GLDC	O
gene	O
spans	O
at	O
least	O
135	O
kb	O
and	O
consists	O
of	O
25	O
exons	O
.	O

All	O
donor	O
and	O
acceptor	O
sites	O
adhere	O
to	O
the	O
canonical	O
GT	O
-	O
AG	O
rule	O
,	O
except	O
for	O
the	O
donor	O
site	O
of	O
intron	O
21	O
,	O
where	O
a	O
variant	O
form	O
GC	O
is	O
used	O
instead	O
of	O
GT	O
.	O

The	O
transcription	O
initiation	O
site	O
has	O
been	O
assigned	O
to	O
a	O
residue	O
163	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
triplet	O
by	O
primer	O
extension	O
analysis	O
.	O

The	O
psiGLDC	O
gene	O
has	O
no	O
intron	O
and	O
shares	O
97	O
.	O

5	O
%	O
homology	O
with	O
the	O
coding	O
region	O
of	O
functional	O
GLDC	O
,	O
suggesting	O
that	O
psiGLDC	O
is	O
a	O
processed	O
pseudogene	O
that	O
arose	O
from	O
the	O
GLDC	O
transcript	O
about	O
4	O
-	O
8	O
million	O
years	O
ago	O
.	O

RNA	O
blotting	O
analysis	O
has	O
revealed	O
that	O
GLDC	O
is	O
expressed	O
in	O
human	O
liver	O
,	O
kidney	O
,	O
brain	O
,	O
and	O
placenta	O
.	O

We	O
have	O
also	O
examined	O
a	O
patient	O
with	O
NKH	B
with	O
no	O
detectable	O
GLDC	O
mRNA	O
in	O
his	O
lymphoblasts	O
.	O

Exons	O
1	O
-	O
3	O
of	O
the	O
functional	O
GLDC	O
gene	O
from	O
this	O
patient	O
are	O
not	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
whereas	O
those	O
from	O
control	O
subjects	O
are	O
.	O

These	O
results	O
suggest	O
a	O
large	O
homozygous	O
deletion	O
(	O
at	O
least	O
30	O
kb	O
)	O
in	O
the	O
patient	O
.	O

Furthermore	O
,	O
we	O
have	O
devised	O
a	O
semi	O
-	O
quantitative	O
PCR	O
to	O
estimate	O
the	O
number	O
of	O
GLDC	O
alleles	O
by	O
using	O
psiGLDC	O
as	O
an	O
internal	O
control	O
and	O
have	O
confirmed	O
the	O
homozygosity	O
and	O
heterozygosity	O
of	O
the	O
deletion	O
in	O
the	O
patient	O
and	O
his	O
parents	O
,	O
respectively	O
.	O

Structural	O
information	O
of	O
GLDC	O
and	O
psiGLDC	O
should	O
facilitate	O
the	O
molecular	O
analysis	O
of	O
NKH	B
.	O

De	O
novo	O
deletions	O
of	O
SNRPN	O
exon	O
1	O
in	O
early	O
human	O
and	O
mouse	O
embryos	O
result	O
in	O
a	O
paternal	O
to	O
maternal	O
imprint	O
switch	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
is	O
a	O
neurogenetic	B
disease	I
characterized	O
by	O
infantile	B
hypotonia	I
,	O
gonadal	B
hypoplasia	I
,	O
obsessive	O
behaviour	O
and	O
neonatal	O
feeding	O
difficulties	O
followed	O
by	O
hyperphagia	B
,	O
leading	O
to	O
profound	O
obesity	B
.	O

PWS	B
is	O
due	O
to	O
a	O
lack	O
of	O
paternal	O
genetic	O
information	O
at	O
15q11	O
-	O
q13	O
(	O
ref	O
.	O
2	O
)	O
.	O

Five	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
map	O
to	O
the	O
PWS	B
region	O
,	O
MKRN3	O
(	O
ref	O
.	O
3	O
)	O
,	O
NDN	O
(	O
ref	O
.	O
4	O
)	O
,	O
NDNL1	O
(	O
ref	O
.	O
5	O
)	O
,	O
SNRPN	O
(	O
refs	O
6	O
-	O
8	O
)	O
and	O
IPW	O
(	O
ref	O
.	O
9	O
)	O
,	O
as	O
well	O
as	O
two	O
poorly	O
characterized	O
framents	O
designated	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
5	O
(	O
ref	O
.	O
10	O
)	O
.	O

Imprinting	O
of	O
this	O
region	O
involves	O
a	O
bipartite	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
which	O
overlaps	O
SNRPN	O
(	O
refs	O
10	O
,	O
11	O
)	O
.	O

Deletion	O
of	O
the	O
SNRPN	O
promoter	O
/	O
exon	O
1	O
region	O
(	O
the	O
PWS	B
IC	O
element	O
)	O
appears	O
to	O
impair	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
in	O
the	O
male	O
germ	O
line	O
and	O
leads	O
to	O
PWS	B
.	O

Here	O
we	O
report	O
a	O
PWS	B
family	O
in	O
which	O
the	O
father	O
is	O
mosaic	O
for	O
an	O
IC	O
deletion	O
on	O
his	O
paternal	O
chromosome	O
.	O

The	O
deletion	O
chromosome	O
has	O
acquired	O
a	O
maternal	O
methylation	O
imprint	O
in	O
his	O
somatic	O
cells	O
.	O

We	O
have	O
made	O
identical	O
findings	O
in	O
chimaeric	O
mice	O
generated	O
from	O
two	O
independent	O
embryonic	O
stem	O
(	O
ES	O
)	O
cell	O
lines	O
harbouring	O
a	O
similar	O
deletion	O
.	O

Our	O
studies	O
demonstrate	O
that	O
the	O
PWS	B
IC	O
element	O
is	O
not	O
only	O
required	O
for	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
,	O
but	O
also	O
for	O
its	O
postzygotic	O
maintenance	O
.	O
.	O

Mice	O
deficient	B
in	I
Six5	I
develop	O
cataracts	B
:	O
implications	O
for	O
myotonic	B
dystrophy	I
.	O

Expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
UTR	O
of	O
the	O
gene	O
DMPK	O
at	O
the	O
DM1	O
locus	O
on	O
chromosome	O
19	O
causes	O
myotonic	B
dystrophy	I
,	O
a	O
dominantly	B
inherited	I
disease	I
characterized	O
by	O
skeletal	O
muscle	B
dystrophy	I
and	O
myotonia	B
,	O
cataracts	B
and	O
cardiac	B
conduction	I
defects	I
.	O

Targeted	O
deletion	O
of	O
Dm15	O
,	O
the	O
mouse	O
orthologue	O
of	O
human	O
DMPK	O
,	O
produced	O
mice	O
with	O
a	O
mild	O
myopathy	B
and	O
cardiac	B
conduction	I
abnormalities	I
,	O
but	O
without	O
other	O
features	O
of	O
myotonic	B
dystrophy	I
,	O
such	O
as	O
myotonia	B
and	O
cataracts	B
.	O

We	O
,	O
and	O
others	O
,	O
have	O
demonstrated	O
that	O
repeat	O
expansion	O
decreases	O
expression	O
of	O
the	O
adjacent	O
gene	O
SIX5	O
(	O
refs	O
7	O
,	O
8	O
)	O
,	O
which	O
encodes	O
a	O
homeodomain	O
transcription	O
factor	O
.	O

To	O
determine	O
whether	O
SIX5	B
deficiency	I
contributes	O
to	O
the	O
myotonic	B
dystrophy	I
phenotype	O
,	O
we	O
disrupted	O
mouse	O
Six5	O
by	O
replacing	O
the	O
first	O
exon	O
with	O
a	O
beta	O
-	O
galactosidase	O
reporter	O
.	O

Six5	O
-	O
mutant	O
mice	O
showed	O
reporter	O
expression	O
in	O
multiple	O
tissues	O
,	O
including	O
the	O
developing	O
lens	O
.	O

Homozygous	O
mutant	O
mice	O
had	O
no	O
apparent	O
abnormalities	B
of	I
skeletal	I
muscle	I
function	I
,	O
but	O
developed	O
lenticular	B
opacities	I
at	O
a	O
higher	O
rate	O
than	O
controls	O
.	O

Our	O
results	O
suggest	O
that	O
SIX5	B
deficiency	I
contributes	O
to	O
the	O
cataract	B
phenotype	O
in	O
myotonic	B
dystrophy	I
,	O
and	O
that	O
myotonic	B
dystrophy	I
represents	O
a	O
multigenic	B
disorder	I
.	O
.	O

Heterozygous	O
loss	O
of	O
Six5	O
in	O
mice	O
is	O
sufficient	O
to	O
cause	O
ocular	O
cataracts	B
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
skeletal	O
muscle	B
wasting	I
,	O
myotonia	B
,	O
cardiac	B
arrhythmia	I
,	O
hyperinsulinaemia	B
,	O
mental	B
retardation	I
and	O
ocular	O
cataracts	B
.	O

The	O
genetic	B
defect	I
in	O
DM	B
is	O
a	O
CTG	O
repeat	O
expansion	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
DMPK	O
and	O
5	O
of	O
a	O
homeodomain	O
-	O
encoding	O
gene	O
,	O
SIX5	O
(	O
formerly	O
DMAHP	O
;	O
refs	O
2	O
-	O
5	O
)	O
.	O

There	O
are	O
three	O
mechanisms	O
by	O
which	O
CTG	O
expansion	O
can	O
result	O
in	O
DM	B
.	O

First	O
,	O
repeat	O
expansion	O
may	O
alter	O
the	O
processing	O
or	O
transport	O
of	O
the	O
mutant	O
DMPK	O
mRNA	O
and	O
consequently	O
reduce	O
DMPK	O
levels	O
.	O

Second	O
,	O
CTG	O
expansion	O
may	O
establish	O
a	O
region	O
of	O
heterochromatin	O
3	O
of	O
the	O
repeat	O
sequence	O
and	O
decrease	O
SIX5	O
transcription	O
.	O

Third	O
,	O
toxic	O
effects	O
of	O
the	O
repeat	O
expansion	O
may	O
be	O
intrinsic	O
to	O
the	O
repeated	O
elements	O
at	O
the	O
level	O
of	O
DNA	O
or	O
RNA	O
(	O
refs	O
10	O
,	O
11	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
dose	O
-	O
dependent	O
loss	O
of	O
Dm15	O
(	O
the	O
mouse	O
DMPK	O
homologue	O
)	O
in	O
mice	O
produces	O
a	O
partial	O
DM	B
phenotype	O
characterized	O
by	O
decreased	O
development	O
of	O
skeletal	O
muscle	O
force	O
and	O
cardiac	B
conduction	I
disorders	I
.	O

To	O
test	O
the	O
role	O
of	O
Six5	O
loss	O
in	O
DM	B
,	O
we	O
have	O
analysed	O
a	O
strain	O
of	O
mice	O
in	O
which	O
Six5	O
was	O
deleted	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
rate	O
and	O
severity	O
of	O
cataract	B
formation	O
is	O
inversely	O
related	O
to	O
Six5	O
dosage	O
and	O
is	O
temporally	O
progressive	O
.	O

Six5	O
+	O
/	O
-	O
and	O
Six5	O
-	O
/	O
-	O
mice	O
show	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
the	O
Na	O
+	O
/	O
K	O
+	O
-	O
ATPase	O
alpha	O
-	O
1	O
subunit	O
and	O
decreased	O
Dm15	O
mRNA	O
levels	O
.	O

Thus	O
,	O
altered	O
ion	O
homeostasis	O
within	O
the	O
lens	O
may	O
contribute	O
to	O
cataract	B
formation	O
.	O

As	O
ocular	O
cataracts	B
are	O
a	O
characteristic	O
feature	O
of	O
DM	B
,	O
these	O
results	O
demonstrate	O
that	O
decreased	O
SIX5	O
transcription	O
is	O
important	O
in	O
the	O
aetiology	O
of	O
DM	B
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
DM	B
is	O
a	O
contiguous	O
gene	O
syndrome	O
associated	O
with	O
the	O
partial	O
loss	O
of	O
both	O
DMPK	O
and	O
SIX5	O
.	O
.	O

ATM	O
-	O
dependent	O
phosphorylation	O
of	O
nibrin	O
in	O
response	O
to	O
radiation	O
exposure	O
.	O

Mutations	O
in	O
the	O
gene	O
ATM	O
are	O
responsible	O
for	O
the	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
which	O
is	O
characterized	O
by	O
cerebellar	B
dysfunction	I
,	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B
predisposition	O
.	O

Both	O
the	O
A	B
-	I
T	I
phenotype	O
and	O
the	O
similarity	O
of	O
the	O
ATM	O
protein	O
to	O
other	O
DNA	O
-	O
damage	O
sensors	O
suggests	O
a	O
role	O
for	O
ATM	O
in	O
biochemical	O
pathways	O
involved	O
in	O
the	O
recognition	O
,	O
signalling	O
and	O
repair	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

There	O
are	O
strong	O
parallels	O
between	O
the	O
pattern	O
of	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B
predisposition	O
in	O
A	B
-	I
T	I
patients	O
and	O
that	O
in	O
patients	O
with	O
Nijmegen	B
breakage	I
syndrome	I
(	O
NBS	B
)	O
.	O

The	O
protein	O
defective	O
in	O
NBS	B
,	O
nibrin	O
(	O
encoded	O
by	O
NBS1	O
)	O
,	O
forms	O
a	O
complex	O
with	O
MRE11	O
and	O
RAD50	O
(	O
refs	O
1	O
,	O
2	O
)	O
.	O

This	O
complex	O
localizes	O
to	O
DSBs	O
within	O
30	O
minutes	O
after	O
cellular	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
and	O
is	O
observed	O
in	O
brightly	O
staining	O
nuclear	O
foci	O
after	O
a	O
longer	O
period	O
of	O
time	O
.	O

The	O
overlap	O
between	O
clinical	O
and	O
cellular	O
phenotypes	O
in	O
A	B
-	I
T	I
and	O
NBS	B
suggests	O
that	O
ATM	O
and	O
nibrin	O
may	O
function	O
in	O
the	O
same	O
biochemical	O
pathway	O
.	O

Here	O
we	O
demonstrate	O
that	O
nibrin	O
is	O
phosphorylated	O
within	O
one	O
hour	O
of	O
treatment	O
of	O
cells	O
with	O
IR	O
.	O

This	O
response	O
is	O
abrogated	O
in	O
A	B
-	I
T	I
cells	O
that	O
either	O
do	O
not	O
express	O
ATM	O
protein	O
or	O
express	O
near	O
full	O
-	O
length	O
mutant	O
protein	O
.	O

We	O
also	O
show	O
that	O
ATM	O
physically	O
interacts	O
with	O
and	O
phosphorylates	O
nibrin	O
on	O
serine	O
343	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Phosphorylation	O
of	O
this	O
site	O
appears	O
to	O
be	O
functionally	O
important	O
because	O
mutated	O
nibrin	O
(	O
S343A	O
)	O
does	O
not	O
completely	O
complement	O
radiosensitivity	O
in	O
NBS	B
cells	O
.	O

ATM	O
phosphorylation	O
of	O
nibrin	O
does	O
not	O
affect	O
nibrin	O
-	O
MRE11	O
-	O
RAD50	O
association	O
as	O
revealed	O
by	O
radiation	O
-	O
induced	O
foci	O
formation	O
.	O

Our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
A	B
-	I
T	I
and	O
NBS	B
.	O
.	O

Clinicopathologic	O
features	O
of	O
BRCA	B
-	I
linked	I
and	I
sporadic	I
ovarian	I
cancer	I
.	O

CONTEXT	O
Most	O
hereditary	B
ovarian	I
cancers	I
are	O
associated	O
with	O
germline	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O

Attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
BRCA	O
mutation	O
status	O
in	O
ovarian	B
cancer	I
have	O
produced	O
conflicting	O
results	O
,	O
especially	O
regarding	O
survival	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
hereditary	B
ovarian	I
cancers	I
have	O
distinct	O
clinical	O
and	O
pathological	O
features	O
compared	O
with	O
sporadic	B
(	I
nonhereditary	I
)	I
ovarian	I
cancers	I
.	O

DESIGN	O
AND	O
SETTING	O
Retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	B
cancers	I
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	B
Institute	O
,	O
over	O
a	O
12	O
-	O
year	O
period	O
(	O
December	O
1986	O
to	O
August	O
1998	O
)	O
.	O

PATIENTS	O
The	O
study	O
was	O
restricted	O
to	O
patients	O
of	O
Jewish	O
origin	O
because	O
of	O
the	O
ease	O
of	O
BRCA1	O
and	O
BRCA2	O
genotyping	O
in	O
this	O
ethnic	O
group	O
.	O

From	O
the	O
189	O
patients	O
who	O
identified	O
themselves	O
as	O
Jewish	O
,	O
88	O
hereditary	O
cases	O
were	O
identified	O
with	O
the	O
presence	O
of	O
a	O
germline	O
founder	O
mutation	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O

The	O
remaining	O
101	O
cases	O
from	O
the	O
same	O
series	O
not	O
associated	O
with	O
a	O
BRCA	O
mutation	O
and	O
2	O
additional	O
groups	O
(	O
Gynecologic	O
Oncology	O
Group	O
protocols	O
52	O
and	O
111	O
)	O
with	O
ovarian	B
cancer	I
from	O
clinical	O
trials	O
(	O
for	O
the	O
survival	O
analysis	O
)	O
were	O
included	O
for	O
comparison	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Age	O
at	O
diagnosis	O
,	O
surgical	O
stage	O
,	O
histologic	O
cell	O
type	O
and	O
grade	O
,	O
and	O
surgical	O
outcome	O
;	O
and	O
response	O
to	O
chemotherapy	O
and	O
survival	O
for	O
advanced	O
-	O
stage	O
(	O
II	O
and	O
IV	O
)	O
cases	O
.	O

RESULTS	O
Hereditary	B
cancers	I
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years	O
,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
BRCA1	O
-	O
vs	O
BRCA2	O
-	O
linked	O
patients	O
(	O
54	O
vs	O
62	O
years	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

Histology	O
,	O
grade	O
,	O
stage	O
,	O
and	O
success	O
of	O
cytoreductive	O
surgery	O
were	O
similar	O
for	O
hereditary	O
and	O
sporadic	O
cases	O
.	O

The	O
hereditary	O
group	O
had	O
a	O
longer	O
disease	O
-	O
free	O
interval	O
following	O
primary	O
chemotherapy	O
in	O
comparison	O
with	O
the	O
nonhereditary	O
group	O
,	O
with	O
a	O
median	O
time	O
to	O
recurrence	O
of	O
14	O
months	O
and	O
7	O
months	O
,	O
respectively	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Those	O
with	O
hereditary	B
cancers	I
had	O
improved	O
survival	O
compared	O
with	O
the	O
nonhereditary	O
group	O
(	O
P	O
=	O
.	O
004	O
)	O
.	O

For	O
stage	B
III	I
cancers	I
,	O
BRCA	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
Although	O
BRCA	B
-	I
associated	I
hereditary	I
ovarian	I
cancers	I
in	O
this	O
population	O
have	O
surgical	O
and	O
pathological	O
characteristics	O
similar	O
to	O
those	O
of	O
sporadic	B
cancers	I
,	O
advanced	B
-	I
stage	I
hereditary	I
cancer	I
patients	O
survive	O
longer	O
than	O
nonhereditary	B
cancer	I
patients	O
.	O

Age	O
penetrance	O
is	O
greater	O
for	O
BRCA1	B
-	I
linked	I
than	I
for	I
BRCA2	I
-	I
linked	I
cancers	I
in	O
this	O
population	O
.	O

The	O
gene	O
for	O
familial	B
Mediterranean	I
fever	I
,	O
MEFV	O
,	O
is	O
expressed	O
in	O
early	O
leukocyte	O
development	O
and	O
is	O
regulated	O
in	O
response	O
to	O
inflammatory	O
mediators	O
.	O

Familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
is	O
a	O
recessive	B
disorder	I
characterized	O
by	O
episodes	O
of	O
fever	B
and	O
neutrophil	B
-	I
mediated	I
serosal	I
inflammation	I
.	O

We	O
recently	O
identified	O
the	O
gene	O
causing	O
FMF	B
,	O
designated	O
MEFV	O
,	O
and	O
found	O
it	O
to	O
be	O
expressed	O
in	O
mature	O
neutrophils	O
,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
inflammatory	O
regulator	O
.	O

To	O
facilitate	O
our	O
understanding	O
of	O
the	O
normal	O
function	O
of	O
MEFV	O
,	O
we	O
extended	O
our	O
previous	O
studies	O
.	O

MEFV	O
messenger	O
RNA	O
was	O
detected	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
in	O
bone	O
marrow	O
leukocytes	O
,	O
with	O
differential	O
expression	O
observed	O
among	O
cells	O
by	O
in	O
situ	O
hybridization	O
.	O

CD34	O
hematopoietic	O
stem	O
-	O
cell	O
cultures	O
induced	O
toward	O
the	O
granulocytic	O
lineage	O
expressed	O
MEFV	O
at	O
the	O
myelocyte	O
stage	O
,	O
concurrently	O
with	O
lineage	O
commitment	O
.	O

The	O
prepromyelocytic	O
cell	O
line	O
HL60	O
expressed	O
MEFV	O
only	O
at	O
granulocytic	O
and	O
monocytic	O
differentiation	O
.	O

MEFV	O
was	O
also	O
expressed	O
in	O
the	O
monocytic	O
cell	O
lines	O
U937	O
and	O
THP	O
-	O
1	O
.	O

Among	O
peripheral	O
blood	O
leukocytes	O
,	O
MEFV	O
expression	O
was	O
detected	O
in	O
neutrophils	O
,	O
eosinophils	O
,	O
and	O
to	O
varying	O
degrees	O
,	O
monocytes	O
.	O

Consistent	O
with	O
the	O
tissue	O
specificity	O
of	O
expression	O
,	O
complete	O
sequencing	O
and	O
analysis	O
of	O
upstream	O
regulatory	O
regions	O
of	O
MEFV	O
revealed	O
homology	O
to	O
myeloid	O
-	O
specific	O
promoters	O
and	O
to	O
more	O
broadly	O
expressed	O
inflammatory	O
promoter	O
elements	O
.	O

In	O
vitro	O
stimulation	O
of	O
monocytes	O
with	O
the	O
proinflammatory	O
agents	O
interferon	O
(	O
IFN	O
)	O
gamma	O
,	O
tumor	B
necrosis	O
factor	O
,	O
and	O
lipopolysaccharide	O
induced	O
MEFV	O
expression	O
,	O
whereas	O
the	O
antiinflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
4	O
,	O
IL	O
-	O
10	O
,	O
and	O
transforming	O
growth	O
factor	O
beta	O
inhibited	O
such	O
expression	O
.	O

Induction	O
by	O
IFN	O
-	O
gamma	O
occurred	O
rapidly	O
and	O
was	O
resistant	O
to	O
cycloheximide	O
.	O

IFN	O
-	O
alpha	O
also	O
induced	O
MEFV	O
expression	O
.	O

In	O
granulocytes	O
,	O
MEFV	O
was	O
up	O
-	O
regulated	O
by	O
IFN	O
-	O
gamma	O
and	O
the	O
combination	O
of	O
IFN	O
-	O
alpha	O
and	O
colchicine	O
.	O

These	O
results	O
refine	O
understanding	O
of	O
MEFV	O
by	O
placing	O
the	O
gene	O
in	O
the	O
myelomonocytic	O
-	O
specific	O
proinflammatory	O
pathway	O
and	O
identifying	O
it	O
as	O
an	O
IFN	O
-	O
gamma	O
immediate	O
early	O
gene	O
.	O
.	O

Biochemical	O
and	O
structural	O
analysis	O
of	O
missense	O
mutations	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
causing	O
mucopolysaccharidosis	B
IVA	I
phenotypes	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
;	O
OMIM	O
#	O
253000	O
)	O
,	O
a	O
lysosomal	B
storage	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
N	I
-	I
acetylgalactosamine	I
-	I
6	I
-	I
sulfate	I
sulfatase	I
(	O
GALNS	O
)	O
,	O
has	O
variable	O
clinical	O
phenotypes	O
.	O

To	O
date	O
we	O
have	O
identified	O
65	O
missense	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
MPS	B
IVA	I
patients	O
,	O
but	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
has	O
remained	O
unclear	O
.	O

We	O
studied	O
17	O
missense	O
mutations	O
using	O
biochemical	O
approaches	O
and	O
32	O
missense	O
mutations	O
,	O
using	O
structural	O
analyses	O
.	O

Fifteen	O
missense	O
mutations	O
and	O
two	O
newly	O
engineered	O
active	O
site	O
mutations	O
(	O
C79S	O
,	O
C79T	O
)	O
were	O
characterized	O
by	O
transient	O
expression	O
analysis	O
.	O

Mutant	O
proteins	O
,	O
except	O
for	O
C79S	O
and	O
C79T	O
,	O
were	O
destabilized	O
and	O
detected	O
as	O
insoluble	O
precursor	O
forms	O
while	O
the	O
C79S	O
and	O
C79T	O
mutants	O
were	O
of	O
a	O
soluble	O
mature	O
size	O
.	O

Mutants	O
found	O
in	O
the	O
severe	O
phenotype	O
had	O
no	O
activity	O
.	O

Mutants	O
found	O
in	O
the	O
mild	O
phenotype	O
had	O
a	O
considerable	O
residual	O
activity	O
(	O
1	O
.	O
3	O
-	O
13	O
.	O
3	O
%	O
of	O
wild	O
-	O
type	O
GALNS	O
activity	O
)	O
.	O

Sulfatases	O
,	O
including	O
GALNS	O
,	O
are	O
members	O
of	O
a	O
highly	O
conserved	O
gene	O
family	O
sharing	O
an	O
extensive	O
sequence	O
homology	O
.	O

Thus	O
,	O
a	O
tertiary	O
structural	O
model	O
of	O
human	O
GALNS	O
was	O
constructed	O
from	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
N	O
-	O
acetylgalacto	O
-	O
samine	O
-	O
4	O
-	O
sulfatase	O
and	O
arylsulfatase	O
A	O
,	O
using	O
homology	O
modeling	O
,	O
and	O
32	O
missense	O
mutations	O
were	O
investigated	O
.	O

Consequently	O
,	O
we	O
propose	O
that	O
there	O
are	O
at	O
least	O
three	O
different	O
reasons	O
for	O
the	O
severe	O
phenotype	O
(	O
i	O
)	O
destruction	O
of	O
the	O
hydrophobic	O
core	O
or	O
modification	O
of	O
the	O
packing	O
;	O
(	O
ii	O
)	O
removal	O
of	O
a	O
salt	O
bridge	O
to	O
destabilize	O
the	O
entire	O
conformation	O
;	O
(	O
iii	O
)	O
modification	O
of	O
the	O
active	O
site	O
.	O

In	O
contrast	O
,	O
mild	O
mutations	O
were	O
mostly	O
located	O
on	O
the	O
surface	O
of	O
the	O
GALNS	O
protein	O
.	O

These	O
studies	O
shed	O
further	O
light	O
on	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
MPS	B
IVA	I
and	O
structure	O
-	O
function	O
relationship	O
in	O
the	O
sulfatase	O
family	O
.	O

Mutations	O
at	O
the	O
ataxia	B
-	I
telangiectasia	I
locus	O
and	O
clinical	O
phenotypes	O
of	O
A	B
-	I
T	I
patients	O
.	O

Mutations	O
at	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
locus	O
on	O
chromosome	O
band	O
11q22	O
cause	O
a	O
distinctive	O
autosomal	B
recessive	I
syndrome	I
in	O
homozygotes	O
and	O
predispose	O
heterozygotes	O
to	O
cancer	B
,	O
ischemic	B
heart	I
disease	I
,	O
and	O
early	O
mortality	O
.	O

PCR	O
amplification	O
from	O
genomic	O
DNA	O
and	O
automated	O
sequencing	O
of	O
the	O
entire	O
coding	O
region	O
(	O
66	O
exons	O
)	O
and	O
splice	O
junctions	O
detected	O
77	O
mutations	O
(	O
85	O
%	O
)	O
in	O
90	O
A	B
-	I
T	I
chromosomes	O
.	O

Heteroduplex	O
analysis	O
detected	O
another	O
42	O
mutations	O
at	O
the	O
A	B
-	I
T	I
locus	O
.	O

Out	O
of	O
a	O
total	O
of	O
71	O
unique	O
mutations	O
,	O
50	O
were	O
found	O
only	O
in	O
a	O
single	O
family	O
,	O
and	O
51	O
had	O
not	O
been	O
reported	O
previously	O
.	O

Most	O
(	O
58	O
/	O
71	O
,	O
82	O
%	O
)	O
mutations	O
were	O
frameshift	O
and	O
nonsense	O
mutations	O
that	O
are	O
predicted	O
to	O
cause	O
truncation	O
of	O
the	O
A	B
-	I
T	I
protein	O
;	O
the	O
less	O
common	O
mutation	O
types	O
were	O
missense	O
(	O
9	O
/	O
71	O
,	O
13	O
%	O
)	O
,	O
splicing	O
(	O
3	O
/	O
71	O
,	O
4	O
%	O
)	O
and	O
one	O
in	O
-	O
frame	O
deletion	O
,	O
2546	O
3	O
(	O
1	O
/	O
71	O
,	O
1	O
%	O
)	O
.	O

The	O
mean	O
survival	O
and	O
height	O
distribution	O
of	O
134	O
A	B
-	I
T	I
patients	O
correlated	O
significantly	O
with	O
the	O
specific	O
mutations	O
present	O
in	O
the	O
patients	O
.	O

Patients	O
homozygous	O
for	O
a	O
single	O
truncating	O
mutation	O
,	O
typically	O
near	O
the	O
N	O
-	O
terminal	O
end	O
of	O
the	O
gene	O
,	O
or	O
heterozygous	O
for	O
the	O
in	O
-	O
frame	O
deletion	O
2546	O
3	O
,	O
were	O
shorter	O
and	O
had	O
significantly	O
shorter	O
survival	O
than	O
those	O
heterozygous	O
for	O
a	O
splice	O
site	O
or	O
missense	O
mutation	O
,	O
or	O
heterozygous	O
for	O
two	O
truncating	O
mutations	O
.	O

Alterations	O
of	O
the	O
length	O
or	O
amino	O
acid	O
composition	O
of	O
the	O
A	B
-	I
T	I
gene	O
product	O
affect	O
the	O
A	B
-	I
T	I
clinical	O
phenotype	O
in	O
different	O
ways	O
.	O

Mutation	O
analysis	O
at	O
the	O
A	B
-	I
T	I
locus	O
may	O
help	O
estimate	O
the	O
prognosis	O
of	O
A	B
-	I
T	I
patients	O
.	O
.	O

Isolation	O
,	O
genomic	O
organization	O
,	O
and	O
expression	O
analysis	O
of	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
MEFV	O
,	O
the	O
gene	O
for	O
familial	B
mediterranean	I
fever	I
.	O

Familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
is	O
a	O
recessive	B
disorder	I
characterized	O
by	O
episodes	O
of	O
fever	B
with	O
serositis	B
or	O
synovitis	B
.	O

Recently	O
the	O
FMF	B
gene	O
(	O
MEFV	O
)	O
was	O
cloned	O
;	O
the	O
protein	O
product	O
,	O
pyrin	O
/	O
marenostrin	O
,	O
is	O
thought	O
to	O
regulate	O
inflammation	O
in	O
myeloid	O
cells	O
.	O

In	O
this	O
manuscript	O
we	O
report	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
MEFV	O
.	O

The	O
murine	O
gene	O
contains	O
ten	O
exons	O
with	O
a	O
coding	O
sequence	O
of	O
2304	O
bp	O
,	O
while	O
the	O
rat	O
homolog	O
has	O
nine	O
exons	O
with	O
a	O
coding	O
sequence	O
of	O
2253	O
bp	O
.	O

A	O
considerable	O
amino	O
acid	O
sequence	O
homology	O
was	O
observed	O
between	O
the	O
mouse	O
and	O
human	O
(	O
47	O
.	O
6	O
%	O
identity	O
and	O
65	O
.	O
5	O
%	O
similarity	O
)	O
and	O
between	O
the	O
mouse	O
and	O
rat	O
genes	O
(	O
73	O
.	O
5	O
%	O
identity	O
and	O
82	O
.	O
1	O
%	O
similarity	O
)	O
.	O

The	O
predicted	O
rodent	O
proteins	O
have	O
several	O
important	O
domains	O
and	O
signals	O
found	O
in	O
human	O
pyrin	O
,	O
including	O
a	O
B	O
-	O
box	O
zinc	O
finger	O
domain	O
,	O
Robbins	O
-	O
Dingwall	O
nuclear	O
localization	O
signal	O
,	O
and	O
coiled	O
-	O
coil	O
domain	O
.	O

However	O
,	O
perhaps	O
because	O
of	O
an	O
ancient	O
frame	O
-	O
shift	O
mutation	O
,	O
neither	O
the	O
mouse	O
nor	O
the	O
rat	O
protein	O
has	O
an	O
intact	O
C	O
-	O
terminal	O
B30	O
.	O

2	O
domain	O
,	O
in	O
which	O
most	O
FMF	B
-	O
associated	O
mutations	O
have	O
been	O
found	O
in	O
human	O
MEFV	O
.	O

Nevertheless	O
,	O
like	O
the	O
human	O
gene	O
,	O
mouse	O
Mefv	O
is	O
expressed	O
in	O
peripheral	O
blood	O
granulocytes	O
but	O
not	O
lymphocytes	O
.	O

Consistent	O
with	O
its	O
expression	O
in	O
granulocytes	O
,	O
Mefv	O
was	O
detected	O
at	O
high	O
levels	O
in	O
the	O
primary	O
follicles	O
and	O
marginal	O
zones	O
of	O
the	O
splenic	O
white	O
pulp	O
.	O

Mefv	O
is	O
localized	O
on	O
mouse	O
Chromosome	O
(	O
Chr	O
)	O
16	O
,	O
region	O
A3	O
-	O
B1	O
,	O
extending	O
a	O
region	O
of	O
synteny	O
with	O
human	O
Chr	O
16p13	O
.	O

3	O
.	O

Development	O
of	O
knockout	O
and	O
knockin	O
mouse	O
models	O
may	O
provide	O
further	O
insights	O
into	O
the	O
functional	O
evolution	O
of	O
this	O
gene	O
.	O

Additional	O
copies	O
of	O
the	O
proteolipid	O
protein	O
gene	O
causing	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
arise	O
by	O
separate	O
integration	O
into	O
the	O
X	O
chromosome	O
.	O

The	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
is	O
normally	O
present	O
at	O
chromosome	O
Xq22	O
.	O

Mutations	O
and	O
duplications	O
of	O
this	O
gene	O
are	O
associated	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

Here	O
we	O
describe	O
two	O
new	O
families	O
in	O
which	O
males	O
affected	O
with	O
PMD	B
were	O
found	O
to	O
have	O
a	O
copy	O
of	O
PLP	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
in	O
addition	O
to	O
a	O
normal	O
copy	O
on	O
Xq22	O
.	O

In	O
the	O
first	O
family	O
,	O
the	O
extra	O
copy	O
was	O
first	O
detected	O
by	O
the	O
presence	O
of	O
heterozygosity	O
of	O
the	O
AhaII	O
dimorphism	O
within	O
the	O
PLP	O
gene	O
.	O

The	O
results	O
of	O
FISH	O
analysis	O
showed	O
an	O
additional	O
copy	O
of	O
PLP	O
in	O
Xp22	O
.	O

1	O
,	O
although	O
no	O
chromosomal	O
rearrangements	O
could	O
be	O
detected	O
by	O
standard	O
karyotype	O
analysis	O
.	O

Another	O
three	O
affected	O
males	O
from	O
the	O
family	O
had	O
similar	O
findings	O
.	O

In	O
a	O
second	O
unrelated	O
family	O
with	O
signs	O
of	O
PMD	B
,	O
cytogenetic	O
analysis	O
showed	O
a	O
pericentric	O
inversion	O
of	O
the	O
X	O
chromosome	O
.	O

In	O
the	O
inv	O
(	O
X	O
)	O
carried	O
by	O
several	O
affected	O
family	O
members	O
,	O
FISH	O
showed	O
PLP	O
signals	O
at	O
Xp11	O
.	O

4	O
and	O
Xq22	O
.	O

A	O
third	O
family	O
has	O
previously	O
been	O
reported	O
,	O
in	O
which	O
affected	O
members	O
had	O
an	O
extra	O
copy	O
of	O
the	O
PLP	O
gene	O
detected	O
at	O
Xq26	O
in	O
a	O
chromosome	O
with	O
an	O
otherwise	O
normal	O
banding	O
pattern	O
.	O

The	O
identification	O
of	O
three	O
separate	O
families	O
in	O
which	O
PLP	O
is	O
duplicated	O
at	O
a	O
noncontiguous	O
site	O
suggests	O
that	O
such	O
duplications	O
could	O
be	O
a	O
relatively	O
common	O
but	O
previously	O
undetected	O
cause	O
of	O
genetic	B
disorders	I
.	O

The	O
exon	O
13	O
duplication	O
in	O
the	O
BRCA1	O
gene	O
is	O
a	O
founder	O
mutation	O
present	O
in	O
geographically	O
diverse	O
populations	O
.	O

The	O
BRCA1	O
Exon	O
13	O
Duplication	O
Screening	O
Group	O
.	O

Recently	O
,	O
a	O
6	O
-	O
kb	O
duplication	O
of	O
exon	O
13	O
,	O
which	O
creates	O
a	O
frameshift	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
BRCA1	O
gene	O
,	O
has	O
been	O
described	O
in	O
three	O
unrelated	O
U	O
.	O

S	O
S	O
.	O
families	O
of	O
European	O
ancestry	O
and	O
in	O
one	O
Portuguese	O
family	O
.	O

Here	O
,	O
our	O
goal	O
was	O
to	O
estimate	O
the	O
frequency	O
and	O
geographic	O
diversity	O
of	O
carriers	O
of	O
this	O
duplication	O
.	O

To	O
do	O
this	O
,	O
a	O
collaborative	O
screening	O
study	O
was	O
set	O
up	O
that	O
involved	O
39	O
institutions	O
from	O
19	O
countries	O
and	O
included	O
3	O
,	O
580	O
unrelated	O
individuals	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
and	O
934	O
early	O
-	O
onset	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
cases	O
.	O

A	O
total	O
of	O
11	O
additional	O
families	O
carrying	O
this	O
mutation	O
were	O
identified	O
in	O
Australia	O
(	O
1	O
)	O
,	O
Belgium	O
(	O
1	O
)	O
,	O
Canada	O
(	O
1	O
)	O
,	O
Great	O
Britain	O
(	O
6	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
2	O
)	O
.	O

Haplotyping	O
showed	O
that	O
they	O
are	O
likely	O
to	O
derive	O
from	O
a	O
common	O
ancestor	O
,	O
possibly	O
of	O
northern	O
British	O
origin	O
.	O

Our	O
results	O
demonstrate	O
that	O
it	O
is	O
strongly	O
advisable	O
,	O
for	O
laboratories	O
carrying	O
out	O
screening	O
either	O
in	O
English	O
-	O
speaking	O
countries	O
or	O
in	O
countries	O
with	O
historical	O
links	O
with	O
Britain	O
,	O
to	O
include	O
within	O
their	O
BRCA1	O
screening	O
protocols	O
the	O
polymerase	O
chain	O
reaction	O
-	O
based	O
assay	O
described	O
in	O
this	O
report	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
families	O
with	O
deletions	O
in	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
gene	O
.	O

Von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
is	O
a	O
hereditary	B
tumor	I
syndrome	I
characterized	O
by	O
predisposition	O
for	O
bilateral	B
and	I
multi	I
-	I
centric	I
hemangioblastoma	I
in	O
the	O
retina	O
and	O
central	O
nervous	O
system	O
,	O
pheochromocytoma	B
,	O
renal	B
cell	I
carcinoma	I
,	O
and	O
cysts	B
in	I
the	I
kidney	I
,	I
pancreas	I
,	I
and	I
epididymis	I
.	O

We	O
describe	O
five	O
families	O
for	O
which	O
direct	O
sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
VHL	B
gene	O
had	O
failed	O
to	O
identify	O
the	O
family	O
-	O
specific	O
mutation	O
.	O

Further	O
molecular	O
analysis	O
revealed	O
deletions	O
involving	O
the	O
VHL	B
gene	O
in	O
each	O
of	O
these	O
families	O
.	O

In	O
four	O
families	O
,	O
partial	O
deletions	O
of	O
one	O
or	O
more	O
exons	O
were	O
detected	O
by	O
Southern	O
blot	O
analysis	O
.	O

In	O
the	O
fifth	O
family	O
,	O
FISH	O
analysis	O
demonstrated	O
the	O
deletion	O
of	O
the	O
entire	O
VHL	B
gene	O
.	O

Our	O
results	O
show	O
that	O
(	O
quantitative	O
)	O
Southern	O
blot	O
analysis	O
is	O
a	O
sensitive	O
method	O
for	O
detecting	O
germline	O
deletions	O
of	O
the	O
VHL	B
gene	O
and	O
should	O
be	O
implemented	O
in	O
routine	O
DNA	O
diagnosis	O
for	O
VHL	B
disease	I
.	O

Our	O
data	O
support	O
the	O
previously	O
established	O
observation	O
that	O
families	O
with	O
a	O
germline	O
deletion	O
have	O
a	O
low	O
risk	O
for	O
pheochromocytoma	B
.	O

Further	O
unraveling	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
VHL	B
disease	I
has	O
revealed	O
that	O
families	O
with	O
a	O
full	O
or	O
partial	O
deletion	O
of	O
the	O
VHL	B
gene	O
exhibit	O
a	O
phenotype	O
with	O
a	O
preponderance	O
of	O
central	B
nervous	I
system	I
hemangioblastoma	I
.	O
.	O

Age	O
of	O
the	O
intronic	O
GAA	O
triplet	O
repeat	O
expansion	O
mutation	O
in	O
Friedreich	B
ataxia	I
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
,	O
the	O
most	O
frequently	O
inherited	B
ataxia	I
,	O
is	O
due	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
to	O
a	O
large	O
expansion	O
of	O
an	O
intronic	O
GAA	O
repeat	O
.	O

Using	O
linkage	O
disequilibrium	O
analysis	O
based	O
on	O
haplotype	O
data	O
of	O
seven	O
polymorphic	O
markers	O
close	O
to	O
the	O
frataxin	O
gene	O
,	O
the	O
age	O
of	O
FRDA	B
founding	O
mutational	O
event	O
(	O
s	O
)	O
is	O
estimated	O
to	O
be	O
at	O
least	O
682	O
+	O
/	O
-	O
203	O
generations	O
(	O
95	O
%	O
confidence	O
interval	O
564	O
-	O
801	O
g	O
)	O
,	O
a	O
dating	O
which	O
is	O
consistent	O
with	O
little	O
or	O
no	O
negative	O
selection	O
and	O
provides	O
further	O
evidence	O
for	O
an	O
ancient	O
spread	O
of	O
a	O
pre	O
-	O
mutation	O
(	O
at	O
-	O
risk	O
alleles	O
)	O
in	O
western	O
Europe	O
.	O
.	O

Functional	O
link	O
between	O
ataxia	B
-	I
telangiectasia	I
and	O
Nijmegen	B
breakage	I
syndrome	I
gene	O
products	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
and	O
Nijmegen	B
breakage	I
syndrome	I
(	O
NBS	B
)	O
are	O
recessive	B
genetic	I
disorders	I
with	O
susceptibility	O
to	O
cancer	B
and	O
similar	O
cellular	O
phenotypes	O
.	O

The	O
protein	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
A	B
-	I
T	I
,	O
designated	O
ATM	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
characterized	O
by	O
a	O
carboxy	O
-	O
terminal	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
like	O
domain	O
.	O

The	O
NBS1	O
protein	O
is	O
specifically	O
mutated	O
in	O
patients	O
with	O
Nijmegen	B
breakage	I
syndrome	I
and	O
forms	O
a	O
complex	O
with	O
the	O
DNA	O
repair	O
proteins	O
Rad50	O
and	O
Mrel1	O
.	O

Here	O
we	O
show	O
that	O
phosphorylation	O
of	O
NBS1	O
,	O
induced	O
by	O
ionizing	O
radiation	O
,	O
requires	O
catalytically	O
active	O
ATM	O
.	O

Complexes	O
containing	O
ATM	O
and	O
NBS1	O
exist	O
in	O
vivo	O
in	O
both	O
untreated	O
cells	O
and	O
cells	O
treated	O
with	O
ionizing	O
radiation	O
.	O

We	O
have	O
identified	O
two	O
residues	O
of	O
NBS1	O
,	O
Ser	O
278	O
and	O
Ser	O
343	O
that	O
are	O
phosphorylated	O
in	O
vitro	O
by	O
ATM	O
and	O
whose	O
modification	O
in	O
vivo	O
is	O
essential	O
for	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

This	O
response	O
includes	O
S	O
-	O
phase	O
checkpoint	O
activation	O
,	O
formation	O
of	O
the	O
NBS1	O
/	O
Mrel1	O
/	O
Rad50	O
nuclear	O
foci	O
and	O
rescue	O
of	O
hypersensitivity	B
to	I
ionizing	I
radiation	I
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
a	O
biochemical	O
link	O
between	O
cell	O
-	O
cycle	O
checkpoints	O
activated	O
by	O
DNA	O
damage	O
and	O
DNA	O
repair	O
in	O
two	O
genetic	B
diseases	I
with	O
overlapping	O
phenotypes	O
.	O
.	O

Homozygosity	O
mapping	O
in	O
a	O
family	O
with	O
microcephaly	B
,	O
mental	B
retardation	I
,	O
and	O
short	B
stature	I
to	O
a	O
Cohen	B
syndrome	I
region	O
on	O
8q21	O
.	O
3	O
-	O
8q22	O
.	O
1	O
:	O
redefining	O
a	O
clinical	O
entity	O
.	O

A	O
syndrome	O
of	O
microcephaly	B
,	O
progressive	O
postnatal	B
growth	I
deficiency	I
,	O
and	O
mental	B
retardation	I
was	O
observed	O
in	O
two	O
brothers	O
and	O
their	O
cousin	O
from	O
a	O
multiply	O
consanguineous	O
kindred	O
of	O
Lebanese	O
descent	O
.	O

Hypotonia	B
,	O
chorioretinal	B
dystrophy	I
,	O
and	O
myopia	B
were	O
also	O
identified	O
.	O

The	O
severity	O
of	O
the	O
condition	O
varied	O
among	O
the	O
closely	O
related	O
patients	O
.	O

Because	O
of	O
absence	O
of	O
a	O
distinctive	O
facial	O
appearance	O
,	O
the	O
degree	O
of	O
mental	B
retardation	I
,	O
and	O
short	B
stature	I
,	O
the	O
initially	O
considered	O
clinical	O
diagnosis	O
of	O
Cohen	B
syndrome	I
was	O
withdrawn	O
and	O
a	O
novel	O
genetic	O
entity	O
was	O
assumed	O
.	O

Homozygosity	O
mapping	O
in	O
this	O
family	O
assigned	O
the	O
gene	O
to	O
a	O
26	O
.	O

8	O
-	O
cM	O
region	O
on	O
the	O
chromosome	O
band	O
8q21	O
.	O

3	O
-	O
22	O
.	O

1	O
,	O
between	O
the	O
microsatellites	O
at	O
D8S270	O
and	O
D8S514	O
.	O

The	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
was	O
found	O
for	O
marker	O
at	O
D8S267	O
(	O
Zmax	O
=	O
3	O
.	O
.	O
237	O
at	O
Omax	O
=	O
0	O
.	O
00	O
)	O
.	O

Intriguingly	O
enough	O
,	O
the	O
identified	O
gene	O
region	O
overlaps	O
the	O
refined	O
gene	O
region	O
for	O
Cohen	B
syndrome	I
(	O
COH1	O
)	O
[	O
Kolehmainen	O
et	O
al	O
.	O
,	O
1997	O
Euro	O
J	O
Hum	O
Genet	O
5	O
206	O
-	O
213	O
]	O
.	O

This	O
fact	O
encourages	O
the	O
hypothesis	O
that	O
the	O
described	O
kindred	O
segregates	O
for	O
a	O
variant	O
of	O
Cohen	B
syndrome	I
and	O
suggests	O
a	O
redefinition	O
of	O
its	O
phenotype	O

Polymorphisms	O
of	O
the	O
CYP2D6	O
gene	O
increase	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
.	O

Ankylosing	B
spondylitis	I
(	O
AS	B
)	O
is	O
a	O
common	O
and	O
highly	O
familial	O
rheumatic	B
disorder	I
.	O

The	O
sibling	O
recurrence	O
risk	O
ratio	O
for	O
the	O
disease	O
is	O
63	O
and	O
heritability	O
assessed	O
in	O
twins	O
>	O
90	O
%	O
.	O

Although	O
MHC	O
genes	O
,	O
including	O
HLA	O
-	O
B27	O
,	O
contribute	O
only	O
20	O
-	O
50	O
%	O
of	O
the	O
genetic	O
risk	O
for	O
the	O
disease	O
,	O
no	O
non	O
-	O
MHC	O
gene	O
has	O
yet	O
been	O
convincingly	O
demonstrated	O
to	O
influence	O
either	O
susceptibility	O
to	O
the	O
disease	O
or	O
its	O
phenotypic	O
expression	O
.	O

Previous	O
linkage	O
and	O
association	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	O
gene	O
for	O
AS	B
close	O
to	O
,	O
or	O
within	O
,	O
the	O
cytochrome	O
P450	O
2D6	O
gene	O
(	O
CYP2D6	O
,	O
debrisoquine	O
hydroxylase	O
)	O
located	O
at	O
chromosome	O
22q13	O
.	O
1	O
.	O

We	O
performed	O
a	O
linkage	O
study	O
of	O
chromosome	O
22	O
in	O
200	O
families	O
with	O
AS	B
affected	O
sibling	O
-	O
pairs	O
.	O

Association	O
of	O
alleles	O
of	O
the	O
CYP2D6	O
gene	O
was	O
examined	O
by	O
both	O
case	O
-	O
control	O
and	O
within	O
-	O
family	O
means	O
.	O

For	O
case	O
-	O
control	O
studies	O
,	O
617	O
unrelated	O
individuals	O
with	O
AS	B
(	O
361	O
probands	O
from	O
sibling	O
-	O
pair	O
and	O
parent	O
-	O
case	O
trio	O
families	O
and	O
256	O
unrelated	O
non	O
-	O
familial	O
sporadic	O
cases	O
)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed	O
.	O

For	O
within	O
-	O
family	O
association	O
studies	O
,	O
361	O
families	O
including	O
161	O
parent	O
-	O
case	O
trios	O
and	O
200	O
affected	O
sibling	O
-	O
pair	O
families	O
were	O
employed	O
.	O

Homozygosity	O
for	O
poor	O
metabolizer	O
alleles	O
was	O
found	O
to	O
be	O
associated	O
with	O
AS	B
.	O

Heterozygosity	O
for	O
the	O
most	O
frequent	O
poor	O
metabolizer	O
allele	O
(	O
CYP2D6	O
*	O
4	O
)	O
was	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
AS	B
.	O

Significant	O
within	O
-	O
family	O
association	O
of	O
CYP2D6	O
*	O
4	O
alleles	O
and	O
AS	B
was	O
demonstrated	O
.	O

Weak	O
linkage	O
was	O
also	O
demonstrated	O
between	O
CYP2D6	O
and	O
AS	B
.	O

We	O
postulate	O
that	O
altered	O
metabolism	O
of	O
a	O
natural	O
toxin	O
or	O
antigen	O
by	O
the	O
CYP2D6	O
gene	O
may	O
increase	O
susceptibility	O
to	O
AS	B
.	O

Functional	O
differences	O
of	O
the	O
PDS	B
gene	O
product	O
are	O
associated	O
with	O
phenotypic	O
variation	O
in	O
patients	O
with	O
Pendred	B
syndrome	I
and	O
non	B
-	I
syndromic	I
hearing	I
loss	I
(	O
DFNB4	B
)	O
.	O

The	O
PDS	B
gene	O
encodes	O
a	O
transmembrane	O
protein	O
,	O
known	O
as	O
pendrin	O
,	O
which	O
functions	O
as	O
a	O
transporter	O
of	O
iodide	O
and	O
chloride	O
.	O

Mutations	O
in	O
this	O
gene	O
are	O
responsible	O
for	O
Pendred	B
syndrome	I
and	O
autosomal	B
recessive	I
non	I
-	I
syndromic	I
hearing	I
loss	I
at	O
the	O
DFNB4	B
locus	O
on	O
chromosome	O
7q31	O
.	O

A	O
screen	O
of	O
20	O
individuals	O
from	O
the	O
midwestern	O
USA	O
with	O
non	B
-	I
syndromic	I
hearing	I
loss	I
and	O
dilated	O
vestibular	O
aqueducts	O
identified	O
three	O
people	O
(	O
15	O
%	O
)	O
with	O
PDS	B
mutations	O
.	O

To	O
determine	O
whether	O
PDS	B
mutations	O
in	O
individuals	O
with	O
Pendred	B
syndrome	I
differ	O
functionally	O
from	O
PDS	B
mutations	O
in	O
individuals	O
with	O
non	B
-	I
syndromic	I
hearing	I
loss	I
,	O
we	O
compared	O
three	O
common	O
Pendred	B
syndrome	I
allele	O
variants	O
(	O
L236P	O
,	O
T416P	O
and	O
E384G	O
)	O
,	O
with	O
three	O
PDS	B
mutations	O
reported	O
only	O
in	O
individuals	O
with	O
non	B
-	I
syndromic	I
hearing	I
loss	I
(	O
V480D	O
,	O
V653A	O
and	O
I490L	O
/	O
G497S	O
)	O
.	O

The	O
mutations	O
associated	O
with	O
Pendred	B
syndrome	I
have	O
complete	O
loss	O
of	O
pendrin	O
-	O
induced	O
chloride	O
and	O
iodide	O
transport	O
,	O
while	O
alleles	O
unique	O
to	O
people	O
with	O
DFNB4	B
are	O
able	O
to	O
transport	O
both	O
iodide	O
and	O
chloride	O
,	O
albeit	O
at	O
a	O
much	O
lower	O
level	O
than	O
wild	O
-	O
type	O
pendrin	O
.	O

We	O
hypothesize	O
that	O
this	O
residual	O
level	O
of	O
anion	O
transport	O
is	O
sufficient	O
to	O
eliminate	O
or	O
postpone	O
the	O
onset	O
of	O
goiter	B
in	O
individuals	O
with	O
DFNB4	B
.	O

We	O
propose	O
a	O
model	O
for	O
pendrin	O
function	O
in	O
the	O
thyroid	O
in	O
which	O
pendrin	O
transports	O
iodide	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
thyrocyte	O
into	O
the	O
colloid	O
space	O
.	O
.	O

The	O
human	O
factor	O
IX	O
gene	O
as	O
germline	O
mutagen	O
test	O
:	O
samples	O
from	O
Mainland	O
China	O
have	O
the	O
putatively	O
endogenous	O
pattern	O
of	O
mutation	O
.	O

Germline	O
mutations	O
are	O
the	O
major	O
source	O
of	O
genetic	O
variation	O
that	O
allows	O
a	O
species	O
to	O
evolve	O
over	O
time	O
but	O
at	O
the	O
cost	O
of	O
Mendelian	B
disease	I
and	O
genetic	O
predisposition	O
to	O
multifactorial	B
diseases	I
.	O

Previous	O
analyses	O
have	O
revealed	O
that	O
the	O
pattern	O
of	O
germline	O
mutations	O
in	O
the	O
factor	O
IX	O
gene	O
(	O
F9	O
)	O
is	O
similar	O
among	O
a	O
variety	O
of	O
ethnically	O
and	O
geographically	O
diverse	O
populations	O
and	O
compatible	O
with	O
the	O
ancient	O
pattern	O
that	O
has	O
shaped	O
the	O
mammalian	O
genome	O
.	O

Here	O
,	O
we	O
compare	O
the	O
pattern	O
of	O
germline	O
mutation	O
in	O
a	O
population	O
of	O
hemophilia	B
B	I
patients	O
from	O
Mainland	O
China	O
(	O
n	O
=	O
66	O
)	O
to	O
that	O
in	O
U	O
.	O

S	O
.	O

Caucasians	O
,	O
Blacks	O
,	O
and	O
Mexican	O
Hispanics	O
and	O
stratify	O
by	O
disease	O
severity	O
and	O
ethnicity	O
.	O

The	O
similar	O
pattern	O
of	O
germline	O
mutation	O
in	O
all	O
ethnic	O
groups	O
studied	O
to	O
date	O
provides	O
additional	O
data	O
compatible	O
with	O
the	O
inference	O
that	O
endogenous	O
processes	O
predominate	O
in	O
germline	O
mutations	O
.	O

Fas	O
preassociation	O
required	O
for	O
apoptosis	O
signaling	O
and	O
dominant	O
inhibition	O
by	O
pathogenic	O
mutations	O
.	O

Heterozygous	O
mutations	O
encoding	O
abnormal	O
forms	O
of	O
the	O
death	O
receptor	O
Fas	O
dominantly	O
interfere	O
with	O
Fas	O
-	O
induced	O
lymphocyte	O
apoptosis	O
in	O
human	O
autoimmune	B
lymphoproliferative	I
syndrome	I
.	O

This	O
effect	O
,	O
rather	O
than	O
depending	O
on	O
ligand	O
-	O
induced	O
receptor	O
oligomerization	O
,	O
was	O
found	O
to	O
stem	O
from	O
ligand	O
-	O
independent	O
interaction	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
Fas	O
receptors	O
through	O
a	O
specific	O
region	O
in	O
the	O
extracellular	O
domain	O
.	O

Preassociated	O
Fas	O
complexes	O
were	O
found	O
in	O
living	O
cells	O
by	O
means	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
between	O
variants	O
of	O
green	O
fluorescent	O
protein	O
.	O

These	O
results	O
show	O
that	O
formation	O
of	O
preassociated	O
receptor	O
complexes	O
is	O
necessary	O
for	O
Fas	O
signaling	O
and	O
dominant	O
interference	O
in	O
human	O
disease	O
.	O
.	O

Determination	O
of	O
carrier	O
status	O
for	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
by	O
flow	O
cytometric	O
analysis	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
is	O
caused	O
by	O
defects	O
in	O
the	O
WAS	B
protein	O
(	O
WASP	O
)	O
gene	O
on	O
the	O
X	O
chromosome	O
.	O

Previous	O
study	O
disclosed	O
that	O
flow	O
cytometric	O
analysis	O
of	O
intracellular	O
WASP	O
expression	O
(	O
FCM	O
-	O
WASP	O
analysis	O
)	O
in	O
lymphocytes	O
was	O
useful	O
for	O
the	O
diagnosis	O
of	O
WAS	B
patients	O
.	O

Lymphocytes	O
from	O
all	O
WAS	B
patients	O
showed	O
WASPdim	O
instead	O
of	O
WASPbright	O
.	O

Here	O
we	O
report	O
that	O
FCM	O
-	O
WASP	O
analysis	O
in	O
monocytes	O
could	O
be	O
a	O
useful	O
tool	O
for	O
the	O
WAS	B
carrier	O
diagnosis	O
.	O

Monocytes	O
from	O
all	O
nine	O
WAS	B
carriers	O
showed	O
varied	O
population	O
of	O
WASPdim	O
together	O
with	O
WASPbright	O
.	O

None	O
of	O
control	O
individuals	O
possessed	O
the	O
WASPdim	O
population	O
.	O

In	O
contrast	O
,	O
lymphocytes	O
from	O
all	O
the	O
carriers	O
except	O
two	O
lacked	O
the	O
WASPdim	O
population	O
.	O

The	O
difference	O
of	O
the	O
WASPdim	O
population	O
in	O
monocytes	O
and	O
lymphocytes	O
observed	O
in	O
WAS	B
carriers	O
suggests	O
that	O
WASP	O
plays	O
a	O
more	O
critical	O
role	O
in	O
the	O
development	O
of	O
lymphocytes	O
than	O
in	O
that	O
of	O
monocytes	O
.	O

The	O
present	O
studies	O
suggest	O
that	O
a	O
skewed	O
X	O
-	O
chromosomal	O
inactivation	O
pattern	O
observed	O
in	O
WAS	B
carrier	O
peripheral	O
blood	O
cells	O
is	O
not	O
fixed	O
at	O
the	O
hemopoietic	O
stem	O
cell	O
level	O
but	O
progresses	O
after	O
the	O
lineage	O
commitment	O
.	O
.	O

Restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	B
degeneration	I
slow	O
mice	O
by	O
gene	O
therapy	O
.	O

The	O
gene	O
Prph2	O
encodes	O
a	O
photoreceptor	O
-	O
specific	O
membrane	O
glycoprotein	O
,	O
peripherin	O
-	O
2	O
(	O
also	O
known	O
as	O
peripherin	O
/	O
rds	O
)	O
,	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	O
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom	O
-	O
1	O
(	O
ref	O
.	O
2	O
)	O
.	O

The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs	O
,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life	O
,	O
and	O
which	O
contain	O
the	O
visual	O
pigments	O
necessary	O
for	O
photon	O
capture	O
.	O

Mutations	O
in	O
Prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	B
dystrophies	I
,	O
including	O
autosomal	B
dominant	I
retinitis	I
pigmentosa	I
and	O
macular	B
dystrophy	I
.	O

A	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function	O
,	O
also	O
seen	O
in	O
the	O
retinal	B
degeneration	I
slow	O
(	O
rds	O
or	O
Prph2	O
Rd2	O
/	O
Rd2	O
)	O
mouse	O
,	O
which	O
is	O
homozygous	O
for	O
a	O
null	O
mutation	O
in	O
Prph2	O
.	O

It	O
is	O
characterized	O
by	O
a	O
complete	O
failure	O
to	O
develop	O
photoreceptor	O
discs	O
and	O
outer	O
segments	O
,	O
downregulation	O
of	O
rhodopsin	O
and	O
apoptotic	O
loss	O
of	O
photoreceptor	O
cells	O
.	O

The	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
Prph2Rd2	O
/	O
Rd2	O
mice	O
have	O
greatly	O
diminished	O
a	O
-	O
wave	O
and	O
b	O
-	O
wave	O
amplitudes	O
,	O
which	O
decline	O
to	O
virtually	O
undetectable	O
concentrations	O
by	O
two	O
months	O
.	O

Subretinal	O
injection	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
encoding	O
a	O
Prph2	O
transgene	O
results	O
in	O
stable	O
generation	O
of	O
outer	O
segment	O
structures	O
and	O
formation	O
of	O
new	O
stacks	O
of	O
discs	O
containing	O
both	O
perpherin	O
-	O
2	O
and	O
rhodopsin	O
,	O
which	O
in	O
many	O
cases	O
are	O
morphologically	O
similar	O
to	O
normal	O
outer	O
segments	O
.	O

Moreover	O
,	O
the	O
re	O
-	O
establishment	O
of	O
the	O
structural	O
integrity	O
of	O
the	O
photoreceptor	O
layer	O
also	O
results	O
in	O
electrophysiological	O
correction	O
.	O

These	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
complex	O
ultrastructural	O
cell	O
defect	O
can	O
be	O
corrected	O
both	O
morphologically	O
and	O
functionally	O
by	O
in	O
vivo	O
gene	O
transfer	O
.	O
.	O

Mutations	O
in	O
the	O
fibrinogen	O
aalpha	O
gene	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
congenital	B
afibrinogenemia	I
.	O

Congenital	B
afibrinogenemia	I
is	O
a	O
rare	O
,	O
autosomal	B
,	I
recessive	I
disorder	I
characterized	O
by	O
the	O
complete	O
absence	O
of	O
detectable	O
fibrinogen	O
.	O

We	O
previously	O
identified	O
the	O
first	O
causative	O
mutations	O
in	O
a	O
nonconsanguineous	O
Swiss	O
family	O
;	O
the	O
4	O
affected	O
persons	O
have	O
homozygous	O
deletions	O
of	O
approximately	O
11	O
kb	O
of	O
the	O
fibrinogen	O
alpha	O
(	O
FGA	O
)	O
gene	O
.	O

Haplotype	O
data	O
implied	O
that	O
these	O
deletions	O
occurred	O
on	O
distinct	O
ancestral	O
chromosomes	O
,	O
suggesting	O
that	O
this	O
region	O
may	O
be	O
susceptible	O
to	O
deletion	O
by	O
a	O
common	O
mechanism	O
.	O

We	O
subsequently	O
showed	O
that	O
all	O
the	O
deletions	O
were	O
identical	O
to	O
the	O
base	O
pair	O
and	O
probably	O
resulted	O
from	O
a	O
nonhomologous	O
recombination	O
mediated	O
by	O
7	O
-	O
bp	O
direct	O
repeats	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
collected	O
data	O
on	O
13	O
additional	O
unrelated	O
patients	O
to	O
identify	O
the	O
causative	O
mutations	O
and	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
11	O
-	O
kb	O
deletion	O
.	O

A	O
common	O
recurrent	O
mutation	O
,	O
at	O
the	O
donor	O
splice	O
site	O
of	O
FGA	O
intron	O
4	O
(	O
IVS4	O
+	O
1	O
G	O
>	O
T	O
)	O
,	O
accounted	O
for	O
14	O
of	O
the	O
26	O
(	O
54	O
%	O
)	O
alleles	O
.	O

One	O
patient	O
was	O
heterozygous	O
for	O
the	O
previously	O
identified	O
deletion	O
.	O

Three	O
more	O
frameshift	O
mutations	O
,	O
2	O
nonsense	O
mutations	O
,	O
and	O
a	O
second	O
splice	O
site	O
mutation	O
were	O
also	O
identified	O
.	O

Consequently	O
,	O
86	O
%	O
of	O
afibrinogenemia	B
alleles	O
analyzed	O
to	O
date	O
have	O
truncating	O
mutations	O
of	O
FGA	O
,	O
though	O
mutations	O
in	O
all	O
3	O
fibrinogen	O
genes	O
,	O
FGG	O
,	O
FGA	O
,	O
and	O
FGB	O
,	O
might	O
be	O
predicted	O
to	O
cause	O
congenital	B
afibrinogenemia	I
.	O
.	O

Myotonic	B
dystrophy	I
:	O
the	O
role	O
of	O
the	O
CUG	O
triplet	O
repeats	O
in	O
splicing	O
of	O
a	O
novel	O
DMPK	O
exon	O
and	O
altered	O
cytoplasmic	O
DMPK	O
mRNA	O
isoform	O
ratios	O
.	O

The	O
mechanism	O
by	O
which	O
(	O
CTG	O
)	O
n	O
expansion	O
in	O
the	O
3	O
UTR	O
of	O
the	O
DMPK	O
gene	O
causes	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
unknown	O
.	O

We	O
identified	O
four	O
RNA	O
splicing	O
factors	O
-	O
-	O
hnRNP	O
C	O
,	O
U2AF	O
(	O
U2	O
auxiliary	O
factor	O
)	O
,	O
PTB	O
(	O
polypyrimidine	O
tract	O
binding	O
protein	O
)	O
,	O
and	O
PSF	O
(	O
PTB	O
associated	O
splicing	O
factor	O
)	O
-	O
-	O
that	O
bind	O
to	O
two	O
short	O
regions	O
3	O
of	O
the	O
(	O
CUG	O
)	O
n	O
,	O
and	O
found	O
a	O
novel	O
3	O
DMPK	O
exon	O
resulting	O
in	O
an	O
mRNA	O
lacking	O
the	O
repeats	O
.	O

We	O
propose	O
that	O
the	O
(	O
CUG	O
)	O
n	O
is	O
an	O
essential	O
cis	O
acting	O
element	O
for	O
this	O
splicing	O
event	O
.	O

In	O
contrast	O
to	O
(	O
CUG	O
)	O
n	O
containing	O
mRNAs	O
,	O
the	O
novel	O
isoform	O
is	O
not	O
retained	O
in	O
the	O
nucleus	O
in	O
DM	B
cells	O
,	O
resulting	O
in	O
imbalances	O
in	O
relative	O
levels	O
of	O
cytoplasmic	O
DMPK	O
mRNA	O
isoforms	O
and	O
a	O
new	O
dominant	O
effect	O
of	O
the	O
mutation	O
on	O
DMPK	O
.	O
.	O

Expression	O
and	O
imprinting	O
of	O
MAGEL2	O
suggest	O
a	O
role	O
in	O
Prader	B
-	I
willi	I
syndrome	I
and	O
the	O
homologous	O
murine	O
imprinting	O
phenotype	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
is	O
caused	O
by	O
the	O
loss	O
of	O
expression	O
of	O
imprinted	O
genes	O
in	O
chromosome	O
15q11	O
-	O
q13	O
.	O

Affected	O
individuals	O
exhibit	O
neonatal	B
hypotonia	I
,	O
developmental	B
delay	I
and	O
childhood	B
-	I
onset	I
obesity	I
.	O

Necdin	O
,	O
a	O
protein	O
implicated	O
in	O
the	O
terminal	O
differentiation	O
of	O
neurons	O
,	O
is	O
the	O
only	O
PWS	B
candidate	O
gene	O
to	O
reduce	O
viability	O
when	O
disrupted	O
in	O
a	O
mouse	O
model	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
MAGEL2	O
(	O
also	O
known	O
as	O
NDNL1	O
)	O
,	O
a	O
gene	O
with	O
51	O
%	O
amino	O
acid	O
sequence	O
similarity	O
to	O
necdin	O
and	O
located	O
41	O
kb	O
distal	O
to	O
NDN	O
in	O
the	O
PWS	B
deletion	O
region	O
.	O

MAGEL2	O
is	O
expressed	O
predominantly	O
in	O
brain	O
,	O
the	O
primary	O
tissue	O
affected	O
in	O
PWS	B
and	O
in	O
several	O
fetal	O
tissues	O
as	O
shown	O
by	O
northern	O
blot	O
analysis	O
.	O

MAGEL2	O
is	O
imprinted	O
with	O
monoallelic	O
expression	O
in	O
control	O
brain	O
,	O
and	O
paternal	O
-	O
only	O
expression	O
in	O
the	O
central	O
nervous	O
system	O
as	O
demonstrated	O
by	O
its	O
lack	O
of	O
expression	O
in	O
brain	O
from	O
a	O
PWS	B
-	O
affected	O
individual	O
.	O

The	O
orthologous	O
mouse	O
gene	O
(	O
Magel2	O
)	O
is	O
located	O
within	O
150	O
kb	O
of	O
NDN	O
,	O
is	O
imprinted	O
with	O
paternal	O
-	O
only	O
expression	O
and	O
is	O
expressed	O
predominantly	O
in	O
late	O
developmental	O
stages	O
and	O
adult	O
brain	O
as	O
shown	O
by	O
northern	O
blotting	O
,	O
RT	O
-	O
PCR	O
and	O
whole	O
-	O
mount	O
RNA	O
in	O
situ	O
hybridization	O
.	O

Magel2	O
distribution	O
partially	O
overlaps	O
that	O
of	O
NDN	O
,	O
with	O
strong	O
expression	O
being	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
in	O
mid	O
-	O
gestation	O
mouse	O
embryos	O
by	O
in	O
situ	O
hybridization	O
.	O

We	O
hypothesize	O
that	O
,	O
although	O
loss	O
of	O
necdin	O
expression	O
may	O
be	O
important	O
in	O
the	O
neonatal	O
presentation	O
of	O
PWS	B
,	O
loss	O
of	O
MAGEL2	O
may	O
be	O
critical	O
to	O
abnormalities	B
in	I
brain	I
development	I
and	O
dysmorphic	B
features	I
in	O
individuals	O
with	O
PWS	B
.	O
.	O

Retinoschisin	O
,	O
the	O
X	B
-	I
linked	I
retinoschisis	I
protein	O
,	O
is	O
a	O
secreted	O
photoreceptor	O
protein	O
,	O
and	O
is	O
expressed	O
and	O
released	O
by	O
Weri	O
-	O
Rb1	O
cells	O
.	O

X	B
-	I
linked	I
retinoschisis	I
is	O
characterized	O
by	O
microcystic	O
-	O
like	O
changes	O
of	O
the	O
macular	O
region	O
and	O
schisis	O
within	O
the	O
inner	O
retinal	O
layers	O
,	O
leading	O
to	O
visual	B
deterioration	I
in	O
males	O
.	O

Many	O
missense	O
and	O
protein	O
-	O
truncating	O
mutations	O
of	O
the	O
causative	O
gene	O
RS1	O
have	O
now	O
been	O
identified	O
and	O
are	O
thought	O
to	O
be	O
inactivating	O
.	O

RS1	O
encodes	O
a	O
224	O
amino	O
acid	O
protein	O
,	O
retinoschisin	O
,	O
which	O
contains	O
a	O
discoidin	O
domain	O
but	O
is	O
of	O
unknown	O
function	O
.	O

We	O
have	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
a	O
peptide	O
from	O
a	O
unique	O
region	O
within	O
retinoschisin	O
,	O
which	O
detects	O
a	O
protein	O
of	O
approximately	O
28	O
kDa	O
in	O
retinal	O
samples	O
reduced	O
with	O
dithiothreitol	O
,	O
but	O
multimers	O
sized	O
>	O
40	O
kDa	O
under	O
non	O
-	O
reducing	O
conditions	O
.	O

A	O
screen	O
of	O
human	O
tissues	O
with	O
this	O
antibody	O
reveals	O
retinoschisin	O
to	O
be	O
retina	O
specific	O
and	O
the	O
antibody	O
detects	O
a	O
protein	O
of	O
similar	O
size	O
in	O
bovine	O
and	O
murine	O
retinae	O
.	O

We	O
investigated	O
the	O
expression	O
pattern	O
in	O
the	O
retina	O
of	O
both	O
RS1	O
mRNA	O
(	O
using	O
in	O
situ	O
hybridization	O
with	O
riboprobes	O
)	O
and	O
retinoschisin	O
(	O
using	O
immunohistochemistry	O
)	O
.	O

The	O
antisense	O
riboprobe	O
detected	O
RS1	O
mRNA	O
only	O
in	O
the	O
photoreceptor	O
layer	O
but	O
the	O
protein	O
product	O
of	O
the	O
gene	O
was	O
present	O
both	O
in	O
the	O
photoreceptors	O
and	O
within	O
the	O
inner	O
portions	O
of	O
the	O
retina	O
.	O

Furthermore	O
,	O
differentiated	O
retinoblastoma	B
cells	O
(	O
Weri	O
-	O
Rb1	O
cells	O
)	O
were	O
found	O
to	O
express	O
RS1	O
mRNA	O
and	O
to	O
release	O
retinoschisin	O
.	O

These	O
results	O
suggest	O
that	O
retinoschisin	O
is	O
released	O
by	O
photo	O
-	O
receptors	O
and	O
has	O
functions	O
within	O
the	O
inner	O
retinal	O
layers	O
.	O

Thus	O
,	O
X	B
-	I
linked	I
retinoschisis	I
is	O
caused	O
by	O
abnormalities	O
in	O
a	O
putative	O
secreted	O
photoreceptor	O
protein	O
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo	O
-	O
receptor	O
protein	O
associated	O
with	O
a	O
retinal	B
dystrophy	I
.	O
.	O

Study	O
of	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
beta	O
1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
in	O
the	O
benign	B
familial	I
infantile	I
convulsions	I
syndrome	I
(	O
BFIC	B
)	O
.	O

Benign	B
familial	I
infantile	I
convulsions	I
(	O
BFIC	B
)	O
is	O
a	O
rare	O
autosomal	B
dominant	I
epilepsy	I
syndrome	I
.	O

This	O
syndrome	O
has	O
been	O
recently	O
described	O
in	O
Italian	O
and	O
French	O
pedigrees	O
.	O

Patients	O
present	O
with	O
partial	O
,	O
then	O
generalized	O
seizures	O
,	O
with	O
onset	O
at	O
age	O
three	O
months	O
.	O

The	O
seizures	O
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment	O
,	O
leaving	O
no	O
neurological	B
abnormalities	I
.	O

We	O
have	O
mapped	O
BFIC	B
to	O
chromosome	O
19q	O
in	O
five	O
Italian	O
pedigrees	O
.	O

The	O
sodium	O
channel	O
beta1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
maps	O
to	O
this	O
candidate	O
region	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
one	O
Australian	O
pedigree	O
with	O
generalized	B
epilepsy	I
and	I
febrile	I
seizures	I
"	I
plus	I
"	I
(	O
GEFS	O
+	O
)	O
.	O

In	O
this	O
family	O
,	O
a	O
missense	O
mutation	O
in	O
SCN1B	O
cosegregates	O
with	O
the	O
GEFS	O
+	O
phenotype	O
.	O

BFIC	B
and	O
GEFS	O
+	O
have	O
clinical	O
features	O
in	O
common	O
,	O
therefore	O
SCN1B	O
is	O
a	O
candidate	O
gene	O
for	O
BFIC	B
.	O

We	O
studied	O
SCN1B	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
using	O
four	O
SSCP	O
methods	O
in	O
10	O
Caucasian	O
BFIC	B
probands	O
of	O
Western	O
Europe	O
.	O

We	O
found	O
no	O
exon	O
variants	O
.	O

One	O
variant	O
was	O
identified	O
in	O
intron	O
5	O
(	O
IVS5	O
-	O
10C	O
>	O
G	O
)	O
,	O
which	O
did	O
not	O
segregate	O
with	O
BFIC	B
and	O
was	O
observed	O
in	O
9	O
.	O

2	O
%	O
controls	O
.	O

A	O
second	O
variant	O
in	O
intron	O
5	O
was	O
identified	O
(	O
IVS5	O
+	O
30G	O
>	O
A	O
)	O
.	O

It	O
was	O
rare	O
,	O
as	O
not	O
observed	O
in	O
controls	O
,	O
but	O
not	O
segregating	O
with	O
the	O
BFIC	B
phenotype	O
.	O

Inactivation	O
of	O
germline	O
mutant	O
APC	B
alleles	O
by	O
attenuated	O
somatic	O
mutations	O
:	O
a	O
molecular	O
genetic	O
mechanism	O
for	O
attenuated	B
familial	I
adenomatous	I
polyposis	I
.	O

Germline	O
mutations	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	I
APC	I
)	I
tumor	I
-	O
suppressor	O
gene	O
result	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

Patients	O
with	O
FAP	B
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	B
colorectal	I
tumors	I
and	O
early	O
-	O
onset	O
colorectal	B
cancer	I
.	O

A	O
subset	O
of	O
germline	O
APC	B
mutations	O
results	O
in	O
an	O
attenuated	B
FAP	I
(	O
AFAP	B
)	O
phenotype	O
,	O
in	O
which	O
patients	O
develop	O
fewer	O
tumors	B
and	O
develop	O
them	O
at	O
an	O
older	O
age	O
.	O

Although	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
locations	O
of	O
APC	B
germline	O
mutations	O
and	O
the	O
development	O
of	O
AFAP	B
has	O
been	O
well	O
documented	O
,	O
the	O
mechanism	O
for	O
AFAP	B
has	O
not	O
been	O
well	O
defined	O
.	O

We	O
investigated	O
the	O
mechanism	O
for	O
AFAP	B
in	O
patients	O
carrying	O
a	O
mutant	O
APC	B
allele	O
(	O
APC	O
(	O
AS9	O
)	O
)	O
that	O
has	O
a	O
mutation	O
in	O
the	O
alternatively	O
spliced	O
region	O
of	O
exon	O
9	O
.	O

APC	O
(	O
AS9	O
)	O
was	O
found	O
to	O
down	O
-	O
regulate	O
beta	O
-	O
catenin	O
-	O
regulated	O
transcription	O
,	O
the	O
major	O
tumor	B
-	O
suppressor	O
function	O
of	O
APC	O
,	O
as	O
did	O
the	O
wild	O
-	O
type	O
APC	O
.	O

Mutation	O
analysis	O
showed	O
that	O
both	O
APC	O
(	O
AS9	O
)	O
and	O
the	O
wild	O
-	O
type	O
APC	B
alleles	O
were	O
somatically	O
mutated	O
in	O
most	O
colorectal	B
tumors	I
from	O
these	O
patients	O
.	O

Functional	O
analysis	O
showed	O
that	O
4666insA	O
,	O
a	O
common	O
somatic	O
mutation	O
in	O
APC	O
(	O
AS9	O
)	O
in	O
these	O
tumors	B
,	O
did	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
APC	O
.	O

Our	O
results	O
indicate	O
that	O
carriers	O
of	O
APC	O
(	O
AS9	O
)	O
develop	O
fewer	O
colorectal	B
tumors	I
than	O
do	O
typical	O
patients	O
with	O
FAP	B
because	O
somatic	O
inactivation	O
of	O
both	O
APC	B
alleles	O
is	O
necessary	O
for	O
colorectal	O
tumorigenesis	O
.	O

However	O
,	O
these	O
patients	O
develop	O
colorectal	B
tumors	I
more	O
frequently	O
than	O
does	O
the	O
general	O
population	O
because	O
APC	O
(	O
AS9	O
)	O
is	O
inactivated	O
by	O
mutations	O
that	O
do	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
APC	O
.	O
.	O

Iron	O
-	O
dependent	O
self	O
-	O
assembly	O
of	O
recombinant	O
yeast	O
frataxin	O
:	O
implications	O
for	O
Friedreich	B
ataxia	I
.	O

Frataxin	B
deficiency	I
is	O
the	O
primary	O
cause	O
of	O
Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
,	O
an	O
autosomal	B
recessive	I
cardiodegenerative	I
and	I
neurodegenerative	I
disease	I
.	O

Frataxin	O
is	O
a	O
nuclear	O
-	O
encoded	O
mitochondrial	O
protein	O
that	O
is	O
widely	O
conserved	O
among	O
eukaryotes	O
.	O

Genetic	O
inactivation	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
(	O
Yfh1p	O
)	O
results	O
in	O
mitochondrial	B
iron	I
accumulation	I
and	O
hypersensitivity	B
to	I
oxidative	I
stress	I
.	O

Increased	O
iron	O
deposition	O
and	O
evidence	O
of	O
oxidative	O
damage	O
have	O
also	O
been	O
observed	O
in	O
cardiac	O
tissue	O
and	O
cultured	O
fibroblasts	O
from	O
patients	O
with	O
FRDA	B
.	O

These	O
findings	O
indicate	O
that	O
frataxin	O
is	O
essential	O
for	O
mitochondrial	O
iron	O
homeostasis	O
and	O
protection	O
from	O
iron	O
-	O
induced	O
formation	O
of	O
free	O
radicals	O
.	O

The	O
functional	O
mechanism	O
of	O
frataxin	O
,	O
however	O
,	O
is	O
still	O
unknown	O
.	O

We	O
have	O
expressed	O
the	O
mature	O
form	O
of	O
Yfh1p	O
(	O
mYfh1p	O
)	O
in	O
Escherichia	O
coli	O
and	O
have	O
analyzed	O
its	O
function	O
in	O
vitro	O
.	O

Isolated	O
mYfh1p	O
is	O
a	O
soluble	O
monomer	O
(	O
13	O
,	O
783	O
Da	O
)	O
that	O
contains	O
no	O
iron	O
and	O
shows	O
no	O
significant	O
tendency	O
to	O
self	O
-	O
associate	O
.	O

Aerobic	O
addition	O
of	O
ferrous	O
iron	O
to	O
mYfh1p	O
results	O
in	O
assembly	O
of	O
regular	O
spherical	O
multimers	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
1	O
.	O

1	O
MDa	O
(	O
megadaltons	O
)	O
and	O
a	O
diameter	O
of	O
13	O
+	O
/	O
-	O
2	O
nm	O
.	O

Each	O
multimer	O
consists	O
of	O
approximately	O
60	O
subunits	O
and	O
can	O
sequester	O
>	O
3	O
,	O
000	O
atoms	O
of	O
iron	O
.	O

Titration	O
of	O
mYfh1p	O
with	O
increasing	O
iron	O
concentrations	O
supports	O
a	O
stepwise	O
mechanism	O
of	O
multimer	O
assembly	O
.	O

Sequential	O
addition	O
of	O
an	O
iron	O
chelator	O
and	O
a	O
reducing	O
agent	O
results	O
in	O
quantitative	O
iron	O
release	O
with	O
concomitant	O
disassembly	O
of	O
the	O
multimer	O
,	O
indicating	O
that	O
mYfh1p	O
sequesters	O
iron	O
in	O
an	O
available	O
form	O
.	O

In	O
yeast	O
mitochondria	O
,	O
native	O
mYfh1p	O
exists	O
as	O
monomer	O
and	O
a	O
higher	O
-	O
order	O
species	O
with	O
a	O
molecular	O
weight	O
>	O
600	O
,	O
000	O
.	O

After	O
addition	O
of	O
(	O
55	O
)	O
Fe	O
to	O
the	O
medium	O
,	O
immunoprecipitates	O
of	O
this	O
species	O
contain	O
>	O
16	O
atoms	O
of	O
(	O
55	O
)	O
Fe	O
per	O
molecule	O
of	O
mYfh1p	O
.	O

We	O
propose	O
that	O
iron	O
-	O
dependent	O
self	O
-	O
assembly	O
of	O
recombinant	O
mYfh1p	O
reflects	O
a	O
physiological	O
role	O
for	O
frataxin	O
in	O
mitochondrial	O
iron	O
sequestration	O
and	O
bioavailability	O
.	O
.	O

A	O
mutation	O
in	O
the	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domain	O
of	O
the	O
FGD1	O
gene	O
in	O
an	O
Italian	O
family	O
with	O
faciogenital	B
dysplasia	I
(	O
Aarskog	B
-	I
Scott	I
syndrome	I
)	O
.	O

Aarskog	B
-	I
Scott	I
Syndrome	I
(	O
AAS	B
)	O
is	O
an	O
X	B
-	I
linked	I
disorder	I
characterised	O
by	O
short	B
stature	I
and	O
multiple	O
facial	B
,	I
limb	I
and	I
genital	I
abnormalities	I
.	O

A	O
gene	O
,	O
FGD1	O
,	O
altered	O
in	O
a	O
patient	O
with	O
AAS	B
phenotype	O
,	O
has	O
been	O
identified	O
and	O
found	O
to	O
encode	O
a	O
protein	O
with	O
homology	O
to	O
Rho	O
/	O
Rac	O
guanine	O
nucleotide	O
exchange	O
factors	O
(	O
Rho	O
/	O
Rac	O
GEF	O
)	O
.	O

However	O
,	O
since	O
this	O
original	O
report	O
on	O
identification	O
of	O
a	O
mutated	O
FGD1	O
gene	O
in	O
an	O
AAS	B
patient	O
,	O
no	O
additional	O
mutations	O
in	O
the	O
FGD1	O
gene	O
have	O
been	O
described	O
.	O

We	O
analysed	O
13	O
independent	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
AAS	B
.	O

One	O
patient	O
presented	O
a	O
mutation	O
that	O
results	O
in	O
a	O
nucleotide	O
change	O
in	O
exon	O
10	O
of	O
the	O
FGD1	O
gene	O
(	O
G2559	O
>	O
A	O
)	O
substituting	O
a	O
Gln	O
for	O
Arg	O
in	O
position	O
610	O
.	O

The	O
mutation	O
was	O
found	O
to	O
segregate	O
with	O
the	O
AAS	B
phenotype	O
in	O
affected	O
males	O
and	O
carrier	O
females	O
in	O
the	O
family	O
of	O
this	O
patient	O
.	O

Interestingly	O
,	O
Arg	O
-	O
610	O
is	O
located	O
within	O
one	O
of	O
the	O
two	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domains	O
of	O
the	O
FGD1	O
gene	O
and	O
it	O
corresponds	O
to	O
a	O
highly	O
conserved	O
residue	O
which	O
has	O
been	O
involved	O
in	O
InsP	O
binding	O
in	O
PH	O
domains	O
of	O
other	O
proteins	O
.	O

The	O
same	O
residue	O
is	O
often	O
mutated	O
in	O
the	O
Brutons	O
tyrosine	O
kinase	O
(	O
Btk	O
)	O
gene	O
in	O
patients	O
with	O
an	O
X	B
-	I
linked	I
agammaglobulinemia	I
.	O

The	O
Arg610Gln	O
mutation	O
represents	O
the	O
first	O
case	O
of	O
a	O
mutation	O
in	O
the	O
PH	O
domain	O
of	O
the	O
FGD1	O
gene	O
and	O
additional	O
evidence	O
that	O
mutations	O
in	O
PH	O
domains	O
can	O
be	O
associated	O
to	O
human	O
diseases	O
.	O
.	O

Amino	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
show	O
selective	O
accumulation	O
in	O
striatal	O
neurons	O
and	O
synaptic	O
toxicity	O
.	O

Huntington	B
disease	I
(	O
HD	B
)	O
is	O
caused	O
by	O
expansion	O
of	O
a	O
glutamine	O
repeat	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
huntingtin	O
.	O

Despite	O
its	O
widespread	O
expression	O
,	O
mutant	O
huntingtin	O
induces	O
selective	O
neuronal	O
loss	O
in	O
striatal	O
neurons	O
.	O

Here	O
we	O
report	O
that	O
,	O
in	O
mutant	O
mice	O
expressing	O
HD	B
repeats	O
,	O
the	O
production	O
and	O
aggregation	O
of	O
N	O
-	O
terminal	O
huntingtin	O
fragments	O
preferentially	O
occur	O
in	O
HD	B
-	O
affected	O
neurons	O
and	O
their	O
processes	O
and	O
axonal	O
terminals	O
.	O

N	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
form	O
aggregates	O
and	O
induce	O
neuritic	B
degeneration	I
in	O
cultured	O
striatal	O
neurons	O
.	O

N	O
-	O
terminal	O
mutant	O
huntingtin	O
also	O
binds	O
to	O
synaptic	O
vesicles	O
and	O
inhibits	O
their	O
glutamate	O
uptake	O
in	O
vitro	O
.	O

The	O
specific	O
processing	O
and	O
accumulation	O
of	O
toxic	O
fragments	O
of	O
N	O
-	O
terminal	O
huntingtin	O
in	O
HD	B
-	O
affected	O
striatal	O
neurons	O
,	O
especially	O
in	O
their	O
neuronal	O
processes	O
and	O
axonal	O
terminals	O
,	O
may	O
contribute	O
to	O
the	O
selective	O
neuropathology	O
of	O
HD	B
.	O
.	O

BRCA1	O
is	O
associated	O
with	O
a	O
human	O
SWI	O
/	O
SNF	O
-	O
related	O
complex	O
:	O
linking	O
chromatin	O
remodeling	O
to	O
breast	B
cancer	I
.	O

Germline	O
mutations	O
in	O
the	O
tumor	B
suppressor	O
gene	O
,	O
BRCA1	O
,	O
predispose	O
individuals	O
to	O
breast	B
and	I
ovarian	I
cancers	I
.	O

Using	O
a	O
combination	O
of	O
affinity	O
-	O
and	O
conventional	O
chromatographic	O
techniques	O
,	O
we	O
have	O
isolated	O
a	O
predominant	O
form	O
of	O
a	O
multiprotein	O
BRCA1	O
-	O
containing	O
complex	O
from	O
human	O
cells	O
displaying	O
chromatin	O
-	O
remodeling	O
activity	O
.	O

Mass	O
spectrometric	O
sequencing	O
of	O
components	O
of	O
this	O
complex	O
indicated	O
that	O
BRCA1	O
is	O
associated	O
with	O
a	O
SWI	O
/	O
SNF	O
-	O
related	O
complex	O
.	O

We	O
show	O
that	O
BRCA1	O
can	O
directly	O
interact	O
with	O
the	O
BRG1	O
subunit	O
of	O
the	O
SWI	O
/	O
SNF	O
complex	O
.	O

Moreover	O
,	O
p53	O
-	O
mediated	O
stimulation	O
of	O
transcription	O
by	O
BRCA1	O
was	O
completely	O
abrogated	O
by	O
either	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
BRG1	O
or	O
the	O
cancer	B
-	O
causing	O
deletion	O
in	O
exon	O
11	O
of	O
BRCA1	O
.	O

These	O
findings	O
reveal	O
a	O
direct	O
function	O
for	O
BRCA1	O
in	O
transcriptional	O
control	O
through	O
modulation	O
of	O
chromatin	O
structure	O
.	O
.	O

Asef	O
,	O
a	O
link	O
between	O
the	O
tumor	B
suppressor	O
APC	O
and	O
G	O
-	O
protein	O
signaling	O
.	O

The	O
adenomatous	B
polyposis	I
coli	I
gene	O
(	O
APC	O
)	O
is	O
mutated	O
in	O
familial	B
adenomatous	I
polyposis	I
and	O
in	O
sporadic	O
colorectal	B
tumors	I
.	O

Here	O
the	O
APC	B
gene	O
product	O
is	O
shown	O
to	O
bind	O
through	O
its	O
armadillo	O
repeat	O
domain	O
to	O
a	O
Rac	O
-	O
specific	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	O
GEF	O
)	O
,	O
termed	O
Asef	O
.	O

Endogenous	O
APC	O
colocalized	O
with	O
Asef	O
in	O
mouse	O
colon	O
epithelial	O
cells	O
and	O
neuronal	O
cells	O
.	O

Furthermore	O
,	O
APC	O
enhanced	O
the	O
GEF	O
activity	O
of	O
Asef	O
and	O
stimulated	O
Asef	O
-	O
mediated	O
cell	O
flattening	O
,	O
membrane	O
ruffling	O
,	O
and	O
lamellipodia	O
formation	O
in	O
MDCK	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
APC	O
-	O
Asef	O
complex	O
may	O
regulate	O
the	O
actin	O
cytoskeletal	O
network	O
,	O
cell	O
morphology	O
and	O
migration	O
,	O
and	O
neuronal	O
function	O
.	O
.	O

Function	O
of	O
an	O
axonal	O
chemoattractant	O
modulated	O
by	O
metalloprotease	O
activity	O
.	O

The	O
axonal	O
chemoattractant	O
netrin	O
-	O
1	O
guides	O
spinal	O
commissural	O
axons	O
by	O
activating	O
its	O
receptor	O
DCC	O
(	O
Deleted	O
in	O
Colorectal	B
Cancer	I
)	O
.	O

We	O
have	O
found	O
that	O
chemical	O
inhibitors	O
of	O
metalloproteases	O
potentiate	O
netrin	O
-	O
mediated	O
axon	O
outgrowth	O
in	O
vitro	O
.	O

We	O
have	O
also	O
found	O
that	O
DCC	O
is	O
a	O
substrate	O
for	O
metalloprotease	O
-	O
dependent	O
ectodomain	O
shedding	O
,	O
and	O
that	O
the	O
inhibitors	O
block	O
proteolytic	O
processing	O
of	O
DCC	O
and	O
cause	O
an	O
increase	O
in	O
DCC	O
protein	O
levels	O
on	O
axons	O
within	O
spinal	O
cord	O
explants	O
.	O

Thus	O
,	O
potentiation	O
of	O
netrin	O
activity	O
by	O
inhibitors	O
may	O
result	O
from	O
stabilization	O
of	O
DCC	O
on	O
the	O
axons	O
,	O
and	O
proteolytic	O
activity	O
may	O
regulate	O
axon	O
migration	O
by	O
controlling	O
the	O
number	O
of	O
functional	O
extracellular	O
axon	O
guidance	O
receptors	O
.	O
.	O

Myotonic	B
dystrophy	I
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
CUG	O
repeat	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
common	O
form	O
of	O
muscular	B
dystrophy	I
in	O
adult	O
humans	O
,	O
results	O
from	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
gene	O
.	O

The	O
mutant	O
DMPK	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
contains	O
an	O
expanded	O
CUG	O
repeat	O
and	O
is	O
retained	O
in	O
the	O
nucleus	O
.	O

We	O
have	O
expressed	O
an	O
untranslated	O
CUG	O
repeat	O
in	O
an	O
unrelated	O
mRNA	O
in	O
transgenic	O
mice	O
.	O

Mice	O
that	O
expressed	O
expanded	O
CUG	O
repeats	O
developed	O
myotonia	B
and	O
myopathy	B
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not	O
.	O

Thus	O
,	O
transcripts	O
with	O
expanded	O
CUG	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
DM	B
phenotype	O
.	O

This	O
result	O
supports	O
a	O
role	O
for	O
RNA	O
gain	O
of	O
function	O
in	O
disease	O
pathogenesis	O
.	O
.	O

Genomic	O
rearrangements	O
of	O
the	O
APC	B
tumor	I
-	O
suppressor	O
gene	O
in	O
familial	B
adenomatous	I
polyposis	I
.	O

Germline	O
mutations	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	I
APC	I
)	I
tumor	I
-	O
suppressor	O
gene	O
result	O
in	O
the	O
hereditary	B
colorectal	I
cancer	I
syndrome	I
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

Almost	O
all	O
APC	B
mutations	O
that	O
have	O
been	O
identified	O
are	O
single	O
-	O
nucleotide	O
alterations	O
,	O
small	O
insertions	O
,	O
or	O
small	O
deletions	O
that	O
would	O
truncate	O
the	O
protein	O
product	O
of	O
the	O
gene	O
.	O

No	O
well	O
-	O
characterized	O
intragenic	O
rearrangement	O
of	O
APC	O
has	O
been	O
described	O
,	O
and	O
the	O
prevalence	O
of	O
this	O
type	O
of	O
mutation	O
in	O
FAP	B
patients	O
is	O
not	O
clear	O
.	O

We	O
screened	O
49	O
potential	O
FAP	B
families	O
and	O
identified	O
26	O
different	O
germline	O
APC	B
mutations	O
in	O
30	O
families	O
.	O

Four	O
of	O
these	O
mutations	O
were	O
genomic	O
rearrangements	O
resulting	O
from	O
homologous	O
and	O
nonhomologous	O
recombinations	O
mediated	O
by	O
Alu	O
elements	O
.	O

Two	O
of	O
these	O
four	O
rearrangements	O
were	O
complex	O
,	O
involving	O
deletion	O
and	O
insertion	O
of	O
nucleotides	O
.	O

Of	O
these	O
four	O
rearrangements	O
,	O
one	O
resulted	O
in	O
the	O
deletion	O
of	O
exons	O
11	O
and	O
12	O
and	O
two	O
others	O
resulted	O
in	O
either	O
complete	O
or	O
partial	O
deletion	O
of	O
exon	O
14	O
.	O

The	O
fourth	O
rearrangement	O
grossly	O
altered	O
the	O
sequence	O
within	O
intron	O
14	O
.	O

Although	O
this	O
rearrangement	O
did	O
not	O
affect	O
any	O
coding	O
sequence	O
of	O
APC	O
at	O
the	O
genomic	O
DNA	O
level	O
,	O
it	O
caused	O
inappropriate	O
splicing	O
of	O
exon	O
14	O
.	O

These	O
rearrangements	O
were	O
initially	O
revealed	O
by	O
analyzing	O
cDNAs	O
and	O
could	O
not	O
have	O
been	O
identified	O
by	O
using	O
mutation	O
detection	O
methods	O
that	O
screened	O
each	O
exon	O
individually	O
.	O

The	O
identification	O
of	O
a	O
rearrangement	O
that	O
did	O
not	O
alter	O
any	O
coding	O
exons	O
yet	O
affected	O
the	O
splicing	O
further	O
underscores	O
the	O
importance	O
of	O
using	O
cDNA	O
for	O
mutation	O
analysis	O
.	O

The	O
identification	O
of	O
four	O
genomic	O
rearrangements	O
among	O
30	O
mutations	O
suggests	O
that	O
genomic	O
rearrangements	O
are	O
frequent	O
germline	O
APC	B
mutations	O
.	O
.	O

Detection	O
of	O
a	O
novel	O
missense	O
mutation	O
and	O
second	O
recurrent	O
mutation	O
in	O
the	O
CACNA1A	O
gene	O
in	O
individuals	O
with	O
EA	B
-	I
2	I
and	O
FHM	B
.	O

Mutations	O
in	O
the	O
brain	O
specific	O
P	O
/	O
Q	O
type	O
Ca2	O
+	O
channel	O
alpha1	O
subunit	O
gene	O
,	O
CACNA1A	O
,	O
have	O
been	O
identified	O
in	O
three	O
clinically	O
distinct	O
disorders	O
,	O
viz	O
.	O
episodic	B
ataxia	I
type	I
2	I
(	O
EA	B
-	I
2	I
)	O
,	O
familial	B
hemiplegic	I
migraine	I
(	O
FHM	B
)	O
and	O
spinocerebellar	B
ataxia	I
6	I
(	O
SCA6	B
)	O
.	O

For	O
individuals	O
with	O
EA	B
-	I
2	I
,	O
the	O
mutations	O
described	O
thus	O
far	O
are	O
presumed	O
to	O
result	O
in	O
a	O
truncated	O
protein	O
product	O
.	O

Several	O
different	O
missense	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
FHM	B
.	O

At	O
least	O
two	O
of	O
these	O
mutations	O
have	O
been	O
identified	O
on	O
two	O
different	O
chromosome	O
19p13	O
haplotypes	O
and	O
thus	O
represent	O
recurrent	O
mutations	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
screened	O
several	O
individuals	O
for	O
mutations	O
in	O
all	O
47	O
exons	O
in	O
the	O
CACNA1A	O
gene	O
by	O
single	O
-	O
strand	O
conformation	O
analysis	O
.	O

We	O
have	O
characterised	O
a	O
novel	O
missense	O
mutation	O
,	O
G5260A	O
,	O
in	O
exon	O
32	O
in	O
a	O
family	O
segregating	O
for	O
EA	B
-	I
2	I
.	O

The	O
consequence	O
of	O
this	O
mutation	O
is	O
an	O
amino	O
acid	O
substitution	O
at	O
a	O
highly	O
conserved	O
position	O
within	O
the	O
CACNA1A	O
gene	O
.	O

This	O
represents	O
the	O
first	O
point	O
mutation	O
not	O
resulting	O
in	O
a	O
proposed	O
truncated	O
protein	O
.	O

Furthermore	O
,	O
this	O
mutation	O
has	O
been	O
detected	O
in	O
a	O
family	O
member	O
with	O
mild	O
clinical	O
signs	O
including	O
only	O
migraine	B
.	O

Additionally	O
,	O
a	O
second	O
previously	O
identified	O
recurrent	O
muta	O
tion	O
,	O
C2272T	O
,	O
in	O
exon	O
16	O
has	O
been	O
discovered	O
in	O
a	O
patient	O
with	O
FHM	B
.	O
.	O

Analbuminemia	B
in	O
a	O
neonate	O
.	O

A	O
small	O
-	O
for	O
-	O
gestational	O
-	O
age	O
infant	O
,	O
found	O
to	O
have	O
analbuminemia	B
in	O
the	O
neonatal	O
period	O
,	O
is	O
reported	O
and	O
the	O
twelve	O
cases	O
recorded	O
in	O
the	O
world	O
literature	O
are	O
reviewed	O
.	O

Patients	O
lacking	O
this	O
serum	O
protein	O
are	O
essentially	O
asymptomatic	O
,	O
apart	O
from	O
minimal	O
ankle	B
edema	I
and	O
ease	B
of	I
fatigue	I
.	O

Apparent	O
compensatory	O
mechanisms	O
which	O
come	O
into	O
play	O
when	O
serum	O
albumin	O
is	O
low	O
include	O
prolonged	O
half	O
-	O
life	O
of	O
albumin	O
and	O
transferrin	O
,	O
an	O
increase	O
in	O
serum	O
globulins	O
,	O
beta	O
lipoprotein	O
,	O
and	O
glycoproteins	O
,	O
arterial	B
hypotension	I
with	O
reduced	O
capillary	O
hydrostatic	O
pressure	O
,	O
and	O
the	O
ability	O
to	O
respond	O
with	O
rapid	O
sodium	O
and	O
chloride	O
diuresis	O
in	O
response	O
to	O
small	O
volume	O
changes	O
.	O

Examination	O
of	O
plasma	O
amino	O
acids	O
,	O
an	O
investigation	O
not	O
previously	O
reported	O
,	O
revealed	O
an	O
extremely	O
low	O
plasma	O
tryptophan	O
level	O
,	O
a	O
finding	O
which	O
may	O
be	O
important	O
in	O
view	O
of	O
the	O
role	O
of	O
tryptophan	O
in	O
albumin	O
synthesis	O
.	O
.	O

Histidinemia	B
.	O

Classical	O
and	O
atypical	O
form	O
in	O
siblings	O
.	O

Two	O
brothers	O
,	O
6	O
and	O
13	O
years	O
old	O
,	O
had	O
histidinemia	B
.	O

On	O
the	O
basis	O
of	O
clinical	O
and	O
biochemical	O
observations	O
,	O
the	O
younger	O
boy	O
was	O
considered	O
to	O
have	O
a	O
classical	O
type	O
of	O
the	O
disease	O
,	O
while	O
the	O
older	O
boy	O
had	O
an	O
atypical	O
form	O
characterized	O
by	O
partial	O
impairment	O
of	O
the	O
skin	O
histidase	O
activity	O
and	O
a	O
moderately	O
prolonged	O
half	O
-	O
life	O
of	O
blood	O
histidine	O
.	O

The	O
mother	O
is	O
a	O
heterozygous	O
carrier	O
,	O
while	O
the	O
father	O
and	O
sister	O
seem	O
to	O
be	O
normal	O
.	O
.	O

Carrier	O
detection	O
of	O
pyruvate	B
carboxylase	I
deficiency	I
in	O
fibroblasts	O
and	O
lymphocytes	O
.	O

Pyruvate	O
carboxylase	O
(	O
E	O
.	O
C	O
.	O
6	O
.	O
4	O
.	O
1	O
.	O
1	O
)	O
activity	O
was	O
determined	O
in	O
the	O
circulating	O
peripheral	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
family	O
of	O
a	O
patient	O
with	O
hepatic	O
,	O
cerebral	O
,	O
renal	O
cortical	O
,	O
leukocyte	O
,	O
and	O
fibroblast	O
pyruvate	B
carboxylase	I
deficiency	I
(	O
PC	B
Portland	I
deficiency	I
)	O
.	O

Lymphocyte	O
activities	O
were	O
mother	O
,	O
33	O
-	O
-	O
39	O
%	O
;	O
father	O
,	O
11	O
-	O
-	O
29	O
%	O
;	O
brother	O
,	O
82	O
-	O
-	O
103	O
%	O
;	O
and	O
sister	O
,	O
38	O
-	O
-	O
48	O
%	O
of	O
the	O
lowest	O
normal	O
.	O

Fibroblasts	O
from	O
the	O
patients	O
mother	O
and	O
father	O
had	O
42	O
and	O
34	O
%	O
,	O
respectively	O
,	O
of	O
the	O
activity	O
of	O
the	O
lowest	O
normal	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
disease	O
is	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
and	O
that	O
lymphocytes	O
and	O
fibroblasts	O
can	O
be	O
used	O
to	O
detect	O
carriers	O
.	O

Neither	O
pyruvate	O
carboxylase	O
nor	O
mitochondrial	O
PEPCK	O
activity	O
in	O
lymphocytes	O
was	O
increased	O
by	O
a	O
21	O
-	O
hr	O
fast	O
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
from	O
Italian	O
subjects	O
associated	O
with	O
severe	B
neonatal	I
jaundice	I
.	O

Screening	O
for	O
the	O
G6PD	B
deficiency	I
was	O
carried	O
out	O
at	O
the	O
Maternity	O
Division	O
of	O
the	O
Galliera	O
Hospital	O
in	O
Genoa	O
,	O
Italy	O
.	O

Two	O
groups	O
of	O
subjects	O
with	O
hyperbilirubinaemia	B
of	O
non	O
-	O
immunological	O
origin	O
were	O
examined	O
(	O
a	O
)	O
302	O
newborn	O
babies	O
of	O
Sardinian	O
extraction	O
(	O
on	O
cord	O
blood	O
)	O
and	O
(	O
b	O
)	O
201	O
newborn	O
babies	O
of	O
south	O
Italian	O
ancestry	O
(	O
on	O
peripheral	O
blood	O
)	O
.	O

Among	O
503	O
subjects	O
,	O
43	O
showed	O
an	O
enzyme	O
deficiency	O
;	O
in	O
39	O
the	O
defect	O
was	O
of	O
the	O
Mediterranean	O
type	O
.	O

In	O
one	O
case	O
,	O
previously	O
described	O
,	O
the	O
enzyme	O
was	O
of	O
the	O
A	O
-	O
type	O
.	O

In	O
the	O
remaining	O
cases	O
three	O
different	O
variants	O
were	O
identified	O
.	O

In	O
the	O
present	O
work	O
these	O
three	O
cases	O
,	O
each	O
with	O
severe	B
neonatal	I
jaundice	I
,	O
are	O
reported	O
.	O

Their	O
parents	O
originated	O
from	O
Calabria	O
,	O
from	O
Sardinia	O
and	O
from	O
Sicily	O
.	O

The	O
abnormal	O
enzymes	O
are	O
respectively	O
designated	O
as	O
GdDcbrousse	O
-	O
like	O
,	O
GdGallura	O
and	O
GdAgrigento	O
.	O
.	O

Cytogenetic	O
investigations	O
in	O
families	O
with	O
ataxia	B
-	I
telangiectasia	I
.	O

Chromosomal	O
studies	O
were	O
performed	O
on	O
peripheral	O
blood	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
five	O
Israeli	O
-	O
Moroccan	O
families	O
with	O
ataxia	B
-	I
telangiectasia	I
.	O

A	O
total	O
of	O
24	O
individuals	O
,	O
including	O
seven	O
propositi	O
,	O
was	O
investigated	O
.	O

Among	O
the	O
probands	O
,	O
significantly	O
elevated	O
rates	O
of	O
chromosome	O
damage	O
were	O
observed	O
in	O
both	O
blood	O
and	O
skin	O
.	O

Skin	O
fibroblasts	O
of	O
affected	O
individuals	O
showed	O
several	O
orders	O
of	O
magnitude	O
more	O
chromosome	O
breakage	O
than	O
lymphocytes	O
.	O

Increased	O
rates	O
of	O
chromosome	O
damage	O
were	O
also	O
observed	O
in	O
the	O
fibroblasts	O
of	O
some	O
phenotypically	O
normal	O
family	O
members	O
(	O
obligate	O
heterozygotes	O
and	O
sibs	O
)	O
when	O
compared	O
to	O
normal	O
controls	O
.	O

An	O
apparent	O
abnormal	O
clone	O
of	O
cells	O
,	O
possessing	O
a	O
large	O
acrocentric	O
marker	O
chromosome	O
(	O
14q	O
+	O
)	O
,	O
was	O
observed	O
in	O
varying	O
proportions	O
among	O
cells	O
of	O
all	O
the	O
propositi	O
(	O
2	O
-	O
5	O
%	O
of	O
lymphocytes	O
;	O
1	O
-	O
9	O
%	O
of	O
fibroblasts	O
)	O
.	O
.	O

Prenatal	O
diagnosis	O
of	O
Wolman	B
disease	I
.	O

Two	O
pregnancies	O
at	O
risk	O
for	O
Wolman	B
disease	I
were	O
monitored	O
by	O
assay	O
and	O
electrophoresis	O
of	O
acid	O
lipase	O
in	O
cultured	O
amniotic	O
-	O
fluid	O
cells	O
.	O

Cells	O
from	O
patient	O
1	O
had	O
5	O
%	O
of	O
control	O
levels	O
of	O
acid	O
lipase	O
,	O
using	O
14C	O
-	O
triolein	O
as	O
substrate	O
;	O
however	O
,	O
when	O
artificial	O
substrates	O
(	O
esters	O
of	O
4	O
-	O
methylumbelliferone	O
and	O
p	O
-	O
nitrophenol	O
)	O
were	O
used	O
to	O
measure	O
acid	O
lipase	O
,	O
these	O
cells	O
had	O
30	O
%	O
of	O
control	O
levels	O
.	O

Electrophoresis	O
of	O
cell	O
extracts	O
revealed	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Wolman	B
disease	I
.	O

Analysis	O
of	O
fetal	O
tissues	O
following	O
prostaglandin	O
termination	O
of	O
this	O
pregnancy	O
confirmed	O
the	O
diagnosis	O
.	O

Assay	O
of	O
fetal	O
-	O
skin	O
fibroblasts	O
with	O
14C	O
-	O
triolein	O
,	O
as	O
well	O
as	O
with	O
artificial	O
substrates	O
,	O
showed	O
marked	O
deficiency	O
of	O
acid	O
lipase	O
activity	O
.	O

Electrophoresis	O
of	O
fetal	O
-	O
tissue	O
extracts	O
also	O
demonstrated	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase	O
.	O

Amniotic	O
-	O
fluid	O
cells	O
from	O
patient	O
2	O
showed	O
normal	O
levels	O
of	O
acid	O
lipase	O
with	O
all	O
substrates	O
tested	O
;	O
the	O
electrophoretic	O
pattern	O
of	O
acid	O
lipase	O
was	O
normal	O
.	O

The	O
results	O
suggest	O
that	O
the	O
prenatal	O
diagnosis	O
of	O
Wolman	B
disease	I
be	O
made	O
using	O
the	O
radioassay	O
of	O
acid	O
lipase	O
and	O
/	O
or	O
electrophoresis	O
.	O
.	O

Malignant	B
neoplasms	I
in	O
the	O
families	O
of	O
patients	O
with	O
ataxia	B
-	I
telangiectasia	I
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
an	O
autosomal	B
recessive	I
syndrome	I
associated	O
with	O
a	O
greatly	O
increased	O
incidence	O
of	O
malignant	B
neoplasms	I
in	O
homozygous	O
affected	O
individuals	O
.	O

Heterozygotes	O
for	O
the	O
gene	O
for	O
A	B
-	I
T	I
are	O
thought	O
to	O
comprise	O
about	O
1	O
%	O
of	O
the	O
general	O
population	O
and	O
,	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	O
also	O
predisposes	O
the	O
heterozygous	O
carrier	O
to	O
cancers	B
.	O

Heterozygous	O
carriers	O
of	O
this	O
gene	O
are	O
common	O
among	O
the	O
close	O
relatives	O
of	O
patients	O
with	O
A	B
-	I
T	I
,	O
although	O
individual	O
carriers	O
cannot	O
be	O
identified	O
by	O
any	O
clinical	O
criterion	O
or	O
laboratory	O
test	O
.	O

For	O
this	O
reason	O
,	O
we	O
compared	O
the	O
incidence	O
of	O
death	O
from	O
malignant	B
neoplasms	I
in	O
2	O
families	O
of	O
patients	O
with	O
A	B
-	I
T	I
to	O
that	O
expected	O
in	O
a	O
random	O
sample	O
of	O
the	O
general	O
population	O
.	O

There	O
were	O
59	O
deaths	O
from	O
malignant	B
neoplasms	I
in	O
relatives	O
dying	O
before	O
age	O
75	O
,	O
compared	O
to	O
42	O
.	O

6	O
expected	O
(	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

For	O
A	B
-	I
T	I
heterozygotes	O
younger	O
than	O
age	O
45	O
,	O
the	O
risk	O
of	O
dying	O
from	O
a	O
malignant	B
neoplasm	I
was	O
estimated	O
to	O
be	O
greater	O
than	O
5	O
times	O
the	O
risk	O
for	O
the	O
general	O
population	O
.	O

A	B
-	I
T	I
heterozygotes	O
may	O
comprise	O
more	O
than	O
5	O
%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	B
before	O
age	O
45	O
.	O

The	O
incidence	O
of	O
ovarian	B
,	I
gastric	I
,	I
and	I
biliary	I
system	I
carcinomas	I
and	O
of	O
leukemia	B
and	O
lymphoma	B
was	O
increased	O
in	O
these	O
A	B
-	I
T	I
families	O
.	O

Other	O
neoplasms	B
that	O
may	O
be	O
associated	O
with	O
this	O
gene	O
in	O
heterozygotes	O
include	O
pancreatic	B
,	I
basal	I
cell	I
,	I
colonic	I
,	I
breast	I
,	I
and	I
cervical	I
carcinomas	I
.	O

Striking	O
prevalence	O
of	O
ankylosing	B
spondylitis	I
in	O
"	O
healthy	O
"	O
w27	O
positive	O
males	O
and	O
females	O
.	O

Ankylosing	B
spondylitis	I
is	O
diagnosed	O
once	O
or	O
twice	O
in	O
each	O
1000	O
males	O
and	O
one	O
tenth	O
as	O
frequently	O
in	O
females	O
,	O
but	O
the	O
true	O
prevalence	O
is	O
unknown	O
.	O

Indentification	O
of	O
genetic	O
marker	O
,	O
HL	O
-	O
A	O
W27	O
,	O
for	O
susceptible	O
persons	O
has	O
provided	O
a	O
tool	O
facilitating	O
epidemiologic	O
studies	O
and	O
allowing	O
identification	O
of	O
"	O
control	O
"	O
populations	O
without	O
the	O
marker	O
.	O

Evaluation	O
by	O
postal	O
questionnaires	O
,	O
and	O
pelvic	O
radiography	O
of	O
78	O
HL	O
-	O
A	O
27W	O
-	O
positive	O
blood	O
donors	O
selected	O
from	O
a	O
group	O
of	O
apparently	O
healthy	O
subjects	O
revealed	O
14	O
who	O
satisfied	O
the	O
criteria	O
for	O
definite	O
ankylosing	B
spondylitis	I
.	O

The	O
prevalence	O
was	O
similar	O
in	O
both	O
sexes	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
six	O
W27	O
-	O
negative	O
controls	O
matched	O
for	O
race	O
,	O
sex	O
,	O
and	O
age	O
failed	O
to	O
yield	O
a	O
single	O
case	O
.	O

For	O
a	O
person	O
of	O
either	O
sex	O
with	O
HL	O
-	O
A	O
W27	O
,	O
there	O
appears	O
to	O
be	O
about	O
a	O
20	O
per	O
cent	O
chance	O
that	O
ankylosing	B
spondylitis	I
will	O
develop	O
,	O
suggesting	O
a	O
prevalence	O
of	O
10	O
to	O
15	O
per	O
thousand	O
.	O

Hitherto	O
accepted	O
figures	O
may	O
underestimate	O
the	O
frequency	O
by	O
a	O
factor	O
of	O
10	O
to	O
20	O
.	O
.	O

Analbuminemia	B
in	O
an	O
American	O
Indian	O
girl	O
.	O

Analbuminemia	B
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12	O
-	O
year	O
-	O
old	O
American	O
Indian	O
girl	O
with	O
atopic	B
dermatitis	I
,	O
mild	O
bronchial	B
asthma	I
,	O
a	O
mild	O
seizure	B
disorder	I
,	O
and	O
hyperlipoproteinemia	B
with	O
a	O
corneal	B
arcus	I
.	O

Immunologic	O
methods	O
revealed	O
trace	O
amounts	O
(	O
17	O
mg	O
/	O
100	O
ml	O
)	O
of	O
apparently	O
normal	O
serum	O
albumin	O
.	O

The	O
patients	O
parents	O
were	O
remotely	O
related	O
.	O

The	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	B
.	O

Heterozygotes	O
had	O
subnormal	O
levels	O
of	O
serum	O
albumin	O
.	O

The	O
Gc	O
-	O
locus	O
is	O
closely	O
linked	O
to	O
the	O
structural	O
albumin	O
locus	O
.	O

Gc	O
-	O
protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	B
.	O

Gc	O
-	O
types	O
in	O
the	O
family	O
were	O
compatible	O
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	O
of	O
analbuminemia	B
to	O
the	O
Gc	O
-	O
locus	O
.	O

These	O
findings	O
suggest	O
a	O
"	O
thalassemia	B
"	O
-	O
like	O
mutation	O
for	O
this	O
disorder	O
.	O
.	O

Deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
in	O
a	O
patient	O
with	O
piebaldism	B
.	O

We	O
have	O
previously	O
shown	O
that	O
human	O
piebaldism	B
results	O
from	O
mutations	O
of	O
the	O
KIT	O
gene	O
,	O
which	O
encodes	O
the	O
receptor	O
for	O
the	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
and	O
is	O
located	O
in	O
chromosome	O
segment	O
4q12	O
.	O

Using	O
DNA	O
of	O
a	O
patient	O
with	O
piebaldism	B
,	O
mental	B
retardation	I
,	O
and	O
multiple	B
congenital	I
anomalies	I
associated	O
with	O
a	O
46	O
,	O
XY	O
,	O
del	O
(	O
4	O
)	O
(	O
q12q21	O
.	O
1	O
)	O
karyotype	O
,	O
we	O
carried	O
out	O
quantitative	O
Southern	O
blot	O
hybridization	O
analyses	O
of	O
the	O
KIT	O
gene	O
and	O
the	O
adjacent	O
PDGFRA	O
(	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
alpha	O
subunit	O
)	O
genes	O
.	O

The	O
patient	O
was	O
hemizygous	O
for	O
both	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
,	O
indicating	O
that	O
both	O
of	O
these	O
genes	O
are	O
included	O
within	O
the	O
deleted	O
region	O
.	O

Therefore	O
,	O
deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
may	O
account	O
for	O
the	O
piebald	B
phenotype	O
in	O
this	O
patient	O
.	O

A	O
germ	O
line	O
mutation	O
within	O
the	O
coding	O
sequence	O
for	O
the	O
putative	O
5	O
-	O
phosphoribosyl	O
-	O
1	O
-	O
pyrophosphate	O
binding	O
site	O
of	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
in	O
a	O
Lesch	B
-	I
Nyhan	I
patient	O
:	O
missense	O
mutations	O
within	O
a	O
functionally	O
important	O
region	O
probably	O
cause	O
disease	O
.	O

Lesch	B
-	I
Nyhan	I
syndrome	I
caused	O
by	O
a	O
complete	B
deficiency	I
of	I
hypoxanthine	I
guanine	I
phosphoribosyltransferase	I
(	O
HPRT	O
)	O
is	O
the	O
result	O
of	O
a	O
heterogeneous	O
group	O
of	O
germ	O
line	O
mutations	O
.	O

Identification	O
of	O
each	O
mutant	O
gene	O
provides	O
valuable	O
information	O
as	O
to	O
the	O
type	O
of	O
mutation	O
that	O
occurs	O
spontaneously	O
.	O

We	O
report	O
here	O
a	O
newly	O
identified	O
HPRT	O
mutation	O
in	O
a	O
Japanese	O
patient	O
with	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

This	O
gene	O
,	O
designated	O
HPRT	O
Tokyo	O
,	O
had	O
a	O
single	O
nucleotide	O
change	O
from	O
G	O
to	O
A	O
,	O
as	O
identified	O
by	O
sequencing	O
cDNA	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O

Allele	O
specific	O
oligonucleotide	O
hybridization	O
analysis	O
using	O
amplified	O
genomic	O
DNA	O
showed	O
that	O
the	O
mutant	O
gene	O
was	O
transmitted	O
from	O
the	O
maternal	O
germ	O
line	O
.	O

This	O
mutation	O
would	O
lead	O
to	O
an	O
amino	O
acid	O
substitution	O
of	O
Asp	O
for	O
Gly	O
at	O
the	O
amino	O
acid	O
position	O
140	O
located	O
within	O
the	O
putative	O
5	O
-	O
phosphoribosyl	O
-	O
1	O
-	O
pyrophosphate	O
(	O
PRPP	O
)	O
binding	O
region	O
.	O

Missense	O
mutations	O
in	O
human	O
HPRT	B
deficient	I
patients	O
thus	O
far	O
reported	O
tend	O
to	O
accumulate	O
in	O
this	O
functionally	O
active	O
region	O
.	O

However	O
,	O
a	O
comparison	O
of	O
the	O
data	O
suggested	O
that	O
both	O
missense	O
and	O
synonymous	O
mutations	O
can	O
occur	O
at	O
any	O
coding	O
sequence	O
of	O
the	O
human	O
germ	O
line	O
HPRT	O
gene	O
,	O
but	O
that	O
a	O
limited	O
percentage	O
of	O
all	O
the	O
missense	O
mutations	O
cause	O
disease	O
.	O

The	O
probability	O
that	O
a	O
mutation	O
will	O
cause	O
disease	O
tends	O
to	O
be	O
higher	O
when	O
the	O
missense	O
mutation	O
is	O
within	O
a	O
functionally	O
important	O
sequence	O
.	O
.	O

Characterisation	O
of	O
a	O
new	O
rare	O
fragile	O
site	O
easily	O
confused	O
with	O
the	O
fragile	B
X	I
.	O

A	O
new	O
fragile	O
site	O
(	O
FRAXE	O
)	O
in	O
Xq28	O
is	O
described	O
.	O

It	O
appears	O
to	O
be	O
a	O
typical	O
folate	O
sensitive	O
fragile	O
site	O
.	O

The	O
fragile	O
site	O
is	O
not	O
associated	O
with	O
mental	B
retardation	I
,	O
it	O
does	O
not	O
give	O
abnormal	O
results	O
when	O
subjected	O
to	O
Southern	O
analysis	O
with	O
probe	O
pfxa3	O
which	O
detects	O
the	O
unstable	O
DNA	O
sequence	O
characteristic	O
of	O
fragile	B
X	I
syndrome	I
.	O

In	O
situ	O
hybridization	O
mapping	O
locates	O
the	O
fragile	O
site	O
between	O
150	O
kb	O
and	O
600	O
kb	O
distal	O
to	O
FRAXA	O
.	O

The	O
distinction	O
between	O
the	O
two	O
fragile	O
sites	O
is	O
important	O
clinically	O
since	O
cytogenetic	O
detection	O
of	O
FRAXE	O
,	O
without	O
molecular	O
analysis	O
,	O
could	O
result	O
in	O
misdiagnosis	O
of	O
fragile	B
X	I
syndrome	I
.	O
.	O

The	O
Norrie	B
disease	I
gene	O
maps	O
to	O
a	O
150	O
kb	O
region	O
on	O
chromosome	O
Xp11	O
.	O
3	O
.	O

Norrie	B
disease	I
is	O
a	O
human	O
X	B
-	I
linked	I
recessive	I
disorder	I
of	O
unknown	O
etiology	O
characterized	O
by	O
congenital	B
blindness	I
,	O
sensory	B
neural	I
deafness	I
and	O
mental	B
retardation	I
.	O

This	O
disease	O
gene	O
was	O
previously	O
linked	O
to	O
the	O
DXS7	O
(	O
L1	O
.	O
28	O
)	O
locus	O
and	O
the	O
MAO	O
genes	O
in	O
band	O
Xp11	O
.	O

3	O
3	O
.	O

We	O
report	O
here	O
fine	O
physical	O
mapping	O
of	O
the	O
obligate	O
region	O
containing	O
the	O
Norrie	B
disease	I
gene	O
(	O
NDP	O
)	O
defined	O
by	O
a	O
recombination	O
and	O
by	O
the	O
smallest	O
submicroscopic	O
chromosomal	O
deletion	O
associated	O
with	O
Norrie	B
disease	I
identified	O
to	O
date	O
.	O

Analysis	O
,	O
using	O
in	O
addition	O
two	O
overlapping	O
YAC	O
clones	O
from	O
this	O
region	O
,	O
allowed	O
orientation	O
of	O
the	O
MAOA	O
and	O
MAOB	O
genes	O
in	O
a	O
5	O
-	O
3	O
-	O
3	O
-	O
5	O
configuration	O
.	O

A	O
recombination	O
event	O
between	O
a	O
(	O
GT	O
)	O
n	O
polymorphism	O
in	O
intron	O
2	O
of	O
the	O
MAOB	O
gene	O
and	O
the	O
NDP	O
locus	O
,	O
in	O
a	O
family	O
previously	O
reported	O
to	O
have	O
a	O
recombination	O
between	O
DXS7	O
and	O
NDP	O
,	O
delineates	O
a	O
flanking	O
marker	O
telomeric	O
to	O
this	O
disease	O
gene	O
.	O

An	O
anonymous	O
DNA	O
probe	O
,	O
dc12	O
,	O
present	O
in	O
one	O
of	O
the	O
YACs	O
and	O
in	O
a	O
patient	O
with	O
a	O
submicroscopic	O
deletion	O
which	O
includes	O
MAOA	O
and	O
MAOB	O
but	O
not	O
L1	O
.	O

28	O
,	O
serves	O
as	O
a	O
flanking	O
marker	O
centromeric	O
to	O
the	O
disease	O
gene	O
.	O

An	O
Alu	O
-	O
PCR	O
fragment	O
from	O
the	O
right	O
arm	O
of	O
the	O
MAO	O
YAC	O
(	O
YMAO	O
.	O
AluR	O
)	O
is	O
not	O
deleted	O
in	O
this	O
patient	O
and	O
also	O
delineates	O
the	O
centromeric	O
extent	O
of	O
the	O
obligate	O
disease	O
region	O
.	O

The	O
apparent	O
order	O
of	O
these	O
loci	O
is	O
telomere	O
.	O

DXS7	O
-	O
MAOA	O
-	O
MAOB	O
-	O
NDP	O
-	O
dc12	O
-	O
YMAO	O
DXS7	O
-	O
MAOA	O
-	O
MAOB	O
-	O
NDP	O
-	O
dc12	O
-	O
YMAO	O
.	O

AluR	O
.	O
centromere	O
.	O

Together	O
these	O
data	O
define	O
the	O
obligate	O
region	O
containing	O
the	O
NDP	O
gene	O
to	O
a	O
chromosomal	O
segment	O
less	O
than	O
150	O
kb	O
.	O

Molecular	O
basis	O
of	O
phenylketonuria	B
and	O
related	O
hyperphenylalaninemias	B
:	O
mutations	O
and	O
polymorphisms	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
.	O

Mutations	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
producing	O
phenylketonuria	B
or	O
hyperphenylalaninemia	B
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O

These	O
mutations	O
all	O
exhibit	O
a	O
high	O
degree	O
of	O
association	O
with	O
specific	O
restriction	O
fragment	O
-	O
length	O
polymorphism	O
haplotypes	O
at	O
the	O
PAH	O
locus	O
.	O

About	O
50	O
of	O
these	O
mutations	O
are	O
single	O
-	O
base	O
substitutions	O
,	O
including	O
six	O
nonsense	O
mutations	O
and	O
eight	O
splicing	O
mutations	O
,	O
with	O
the	O
remainder	O
being	O
missense	O
mutations	O
.	O

One	O
splicing	O
mutation	O
results	O
in	O
a	O
3	O
amino	O
acid	O
in	O
-	O
frame	O
insertion	O
.	O

Two	O
or	O
3	O
large	O
deletions	O
,	O
2	O
single	O
codon	O
deletions	O
,	O
and	O
2	O
single	O
base	O
deletions	O
have	O
been	O
found	O
.	O

Twelve	O
of	O
the	O
missense	O
mutations	O
apparently	O
result	O
from	O
the	O
methylation	O
and	O
subsequent	O
deamination	O
of	O
highly	O
mutagenic	O
CpG	O
dinucleotides	O
.	O

Recurrent	O
mutation	O
has	O
been	O
observed	O
at	O
several	O
of	O
these	O
sites	O
,	O
producing	O
associations	O
with	O
different	O
haplotypes	O
in	O
different	O
populations	O
.	O

About	O
half	O
of	O
all	O
missense	O
mutations	O
have	O
been	O
examined	O
by	O
in	O
vitro	O
expression	O
analysis	O
,	O
and	O
a	O
significant	O
correlation	O
has	O
been	O
observed	O
between	O
residual	O
PAH	O
activity	O
and	O
disease	O
phenotype	O
.	O

Since	O
continuing	O
advances	O
in	O
molecular	O
methodologies	O
have	O
dramatically	O
accelerated	O
the	O
rate	O
in	O
which	O
new	O
mutations	O
are	O
being	O
identified	O
and	O
characterized	O
,	O
this	O
register	O
of	O
mutations	O
will	O
be	O
updated	O
periodically	O
.	O
.	O

A	O
glycine250	O
-	O
-	O
>	O
aspartate	O
substitution	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
hexosaminidase	O
A	O
causes	O
juvenile	O
-	O
onset	O
Tay	B
-	I
Sachs	I
disease	I
in	O
a	O
Lebanese	O
-	O
Canadian	O
family	O
.	O

The	O
mutation	O
causing	O
juvenile	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
in	O
two	O
sibs	O
of	O
Lebanese	O
-	O
Maronite	O
origin	O
is	O
described	O
.	O

An	O
mRNA	O
-	O
containing	O
extract	O
of	O
cultured	O
fibroblasts	O
obtained	O
from	O
one	O
of	O
the	O
probands	O
was	O
used	O
as	O
a	O
template	O
to	O
amplify	O
the	O
coding	O
sequence	O
of	O
the	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
alpha	O
-	O
subunit	O
.	O

Sequencing	O
of	O
amplified	O
cDNA	O
fragments	O
revealed	O
a	O
single	O
alteration	O
,	O
guanine	O
to	O
adenine	O
at	O
nt	O
749	O
creating	O
a	O
G250D	O
mutation	O
.	O

The	O
mutation	O
introduces	O
a	O
new	O
recognition	O
site	O
for	O
the	O
restriction	O
enzyme	O
Eco	O
RV	O
,	O
permitting	O
identification	O
of	O
heterozygotes	O
for	O
this	O
allele	O
following	O
PCR	O
amplification	O
and	O
Eco	O
RV	O
digestion	O
of	O
exon	O
7	O
sequences	O
from	O
genomic	O
DNA	O
templates	O
.	O

In	O
order	O
to	O
test	O
the	O
effect	O
of	O
this	O
substitution	O
,	O
an	O
in	O
vitro	O
mutagenized	O
cDNA	O
construct	O
was	O
introduced	O
into	O
a	O
mammalian	O
expression	O
vector	O
and	O
transfected	O
into	O
monkey	O
Cos	O
-	O
1	O
cells	O
separately	O
or	O
along	O
with	O
a	O
beta	O
-	O
cDNA	O
expression	O
vector	O
.	O

When	O
the	O
mutant	O
alpha	O
-	O
cDNA	O
was	O
the	O
only	O
gene	O
introduced	O
into	O
COS	O
cells	O
no	O
enzymatic	O
activity	O
above	O
endogenous	O
COS	O
cell	O
activity	O
was	O
detected	O
.	O

Cotransfection	O
of	O
normal	O
alpha	O
-	O
cDNA	O
and	O
beta	O
-	O
cDNA	O
followed	O
by	O
immunoprecipitation	O
of	O
human	O
Hex	O
A	O
resulted	O
in	O
20	O
-	O
fold	O
increase	O
in	O
the	O
ratio	O
between	O
positive	O
and	O
negative	O
(	O
mock	O
transfection	O
)	O
control	O
values	O
.	O

This	O
allowed	O
the	O
detection	O
of	O
some	O
residual	O
activity	O
(	O
12	O
%	O
of	O
the	O
positive	O
control	O
)	O
when	O
the	O
mutant	O
alpha	O
-	O
cDNA	O
replaced	O
its	O
wild	O
-	O
type	O
counterpart	O
.	O

The	O
predicted	O
protein	O
environment	O
in	O
which	O
the	O
mutation	O
occurs	O
is	O
compared	O
to	O
that	O
of	O
the	O
adult	O
-	O
onset	O
Tay	B
-	I
Sachs	I
disease	I
mutation	O
caused	O
by	O
a	O
Gly269	O
-	O
-	O
>	O
Ser	O
substitution	O
in	O
exon	O
7	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Novel	O
Tay	B
-	I
Sachs	I
disease	I
mutations	O
from	O
China	O
.	O

We	O
describe	O
three	O
HEXA	O
mutations	O
associated	O
with	O
infantile	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
in	O
three	O
unrelated	O
nonconsanguineous	O
Chinese	O
families	O
.	O

Novel	O
mutations	O
were	O
found	O
in	O
two	O
of	O
these	O
families	O
.	O

The	O
third	O
is	O
a	O
previously	O
reported	O
mutation	O
(	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nt	O
1444	O
)	O
(	O
Nakano	O
et	O
al	O
.	O
,	O
1988	O
)	O
.	O

Direct	O
sequencing	O
of	O
PCR	O
products	O
identified	O
a	O
novel	O
insertion	O
of	O
an	O
A	O
after	O
nt	O
547	O
in	O
family	O
1	O
.	O

This	O
change	O
generates	O
an	O
early	O
termination	O
codon	O
6	O
bp	O
downstream	O
from	O
the	O
insertion	O
site	O
.	O

Allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
confirmed	O
homozygosity	O
in	O
the	O
proband	O
.	O

Single	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
amplified	O
exon	O
13	O
revealed	O
a	O
T	O
-	O
-	O
>	O
C	O
transition	O
at	O
nt	O
1453	O
with	O
the	O
corresponding	O
amino	O
acid	O
substitution	O
W485R	O
in	O
the	O
second	O
family	O
.	O

This	O
mutation	O
creates	O
an	O
Fnu4HI	O
restriction	O
site	O
.	O

The	O
proband	O
is	O
homozygous	O
for	O
this	O
allele	O
.	O

When	O
the	O
site	O
-	O
specific	O
mutagenized	O
alpha	O
cDNA	O
carrying	O
the	O
T	O
-	O
-	O
>	O
C	O
transition	O
at	O
nt	O
1453	O
was	O
expressed	O
in	O
COS	O
1	O
cells	O
hexosaminidase	O
S	O
activity	O
was	O
not	O
detectable	O
above	O
background	O
.	O

A	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nt	O
1444	O
(	O
exon	O
13	O
)	O
corresponding	O
to	O
the	O
E482K	O
substitution	O
was	O
found	O
in	O
the	O
third	O
family	O
.	O

This	O
mutation	O
occurs	O
at	O
a	O
CpG	O
dinucleotide	O
.	O

It	O
has	O
been	O
reported	O
in	O
an	O
Italian	O
TSD	B
proband	O
and	O
causes	O
defective	O
intracellular	O
transport	O
of	O
the	O
alpha	O
-	O
subunit	O
from	O
the	O
rough	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Two	O
missense	O
mutations	O
causing	O
mild	O
hyperphenylalaninemia	B
associated	O
with	O
DNA	O
haplotype	O
12	O
.	O

The	O
genetic	B
defects	I
responsible	O
for	O
most	O
phenylketonuria	B
(	O
PKU	B
)	O
and	O
hyperphenylalaninemia	B
(	O
HPA	B
)	O
cases	O
are	O
located	O
in	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
.	O

Approximately	O
50	O
-	O
60	O
mutations	O
have	O
been	O
reported	O
in	O
Caucasians	O
and	O
are	O
reflected	O
in	O
a	O
wide	O
range	O
of	O
clinical	O
severities	O
.	O

Most	O
mutations	O
are	O
linked	O
to	O
specific	O
haplotypes	O
,	O
as	O
defined	O
by	O
eight	O
polymorphic	O
restriction	O
sites	O
in	O
the	O
PAH	O
gene	O
.	O

We	O
hypothesized	O
that	O
there	O
is	O
at	O
least	O
one	O
mild	O
mutation	O
linked	O
to	O
haplotype	O
12	O
in	O
the	O
Swedish	O
PKU	B
/	O
HPA	B
population	O
,	O
since	O
7	O
of	O
8	O
patients	O
carrying	O
haplotype	O
12	O
had	O
mild	O
HPA	B
.	O

Sequence	O
analysis	O
revealed	O
a	O
C	O
-	O
to	O
-	O
G	O
transversion	O
at	O
the	O
second	O
base	O
of	O
codon	O
322	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
glycine	O
for	O
alanine	O
,	O
in	O
four	O
mutant	O
haplotype	O
12	O
genes	O
,	O
and	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
408	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
glutamine	O
for	O
arginine	O
,	O
in	O
another	O
three	O
mutant	O
haplotype	O
12	O
genes	O
.	O

These	O
mutations	O
segregated	O
with	O
mutant	O
haplotype	O
12	O
alleles	O
in	O
nuclear	O
families	O
but	O
were	O
not	O
present	O
on	O
normal	O
or	O
other	O
mutant	O
alleles	O
.	O

Both	O
mutations	O
were	O
tested	O
in	O
a	O
eukaryotic	O
expression	O
system	O
in	O
which	O
enzyme	O
activities	O
of	O
different	O
mutant	O
PAH	O
enzymes	O
reflect	O
the	O
relative	O
severities	O
of	O
the	O
mutations	O
,	O
although	O
these	O
in	O
vitro	O
activities	O
cannot	O
be	O
translated	O
directly	O
into	O
in	O
vivo	O
hepatic	O
activities	O
.	O

The	O
A322G	O
mutant	O
PAH	O
had	O
about	O
75	O
%	O
and	O
the	O
R408Q	O
mutant	O
PAH	O
about	O
55	O
%	O
of	O
the	O
wild	O
-	O
type	O
PAH	O
enzyme	O
activity	O
.	O

These	O
in	O
vitro	O
activities	O
are	O
the	O
highest	O
reported	O
for	O
mutant	O
PAH	O
enzymes	O
produced	O
in	O
the	O
same	O
expression	O
system	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
correlations	O
for	O
I65T	O
and	O
M1V	O
mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
locus	O
.	O

Mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
locus	O
are	O
the	O
major	O
cause	O
of	O
hyperphenylalaninemia	B
.	O

We	O
have	O
previously	O
described	O
four	O
mutations	O
(	O
M1V	O
,	O
IVS12nt1	O
,	O
R408W	O
,	O
and	O
S349P	O
)	O
at	O
the	O
PAH	O
locus	O
in	O
French	O
Canadians	O
with	O
ancestry	O
in	O
eastern	O
Quebec	O
.	O

Here	O
we	O
report	O
(	O
1	O
)	O
identification	O
of	O
another	O
mutation	O
,	O
on	O
a	O
haplotype	O
9	O
chromosome	O
,	O
which	O
converts	O
codon	O
65	O
from	O
isoleucine	O
(	O
ATT	O
)	O
to	O
threonine	O
(	O
ACT	O
)	O
,	O
(	O
2	O
)	O
expression	O
analysis	O
of	O
the	O
I65T	O
mutation	O
in	O
COS	O
cells	O
demonstrating	O
75	O
%	O
loss	O
of	O
both	O
immunoreactive	O
protein	O
and	O
enzyme	O
activity	O
,	O
and	O
(	O
3	O
)	O
expression	O
analysis	O
of	O
the	O
most	O
prevalent	O
PKU	B
allele	O
(	O
M1V	O
)	O
in	O
eastern	O
Quebec	O
,	O
showing	O
nondetectable	O
levels	O
of	O
PAH	O
protein	O
and	O
activity	O
,	O
a	O
finding	O
compatible	O
with	O
a	O
mutation	O
in	O
the	O
translation	O
initiation	O
codon	O
.	O

Homozygosity	O
for	O
M1V	O
and	O
codominant	O
inheritance	O
of	O
I65T	O
/	O
R408W	O
were	O
both	O
associated	O
with	O
classical	B
phenylketonuria	I
.	O
.	O

Molecular	O
basis	O
of	O
hexosaminidase	B
A	I
deficiency	I
and	O
pseudodeficiency	O
in	O
the	O
Berks	O
County	O
Pennsylvania	O
Dutch	O
.	O

Following	O
the	O
birth	O
of	O
two	O
infants	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
a	O
non	O
-	O
Jewish	O
,	O
Pennsylvania	O
Dutch	O
kindred	O
was	O
screened	O
for	O
TSD	B
carriers	O
using	O
the	O
biochemical	O
assay	O
.	O

A	O
high	O
frequency	O
of	O
individuals	O
who	O
appeared	O
to	O
be	O
TSD	B
heterozygotes	O
was	O
detected	O
(	O
Kelly	O
et	O
al	O
.	O
,	O
1975	O
)	O
.	O

Clinical	O
and	O
biochemical	O
evidence	O
suggested	O
that	O
the	O
increased	O
carrier	O
frequency	O
was	O
due	O
to	O
at	O
least	O
two	O
altered	O
alleles	O
for	O
the	O
hexosaminidase	O
A	O
alpha	O
-	O
subunit	O
.	O

We	O
now	O
report	O
two	O
mutant	O
alleles	O
in	O
this	O
Pennsylvania	O
Dutch	O
kindred	O
,	O
and	O
one	O
polymorphism	O
.	O

One	O
allele	O
,	O
reported	O
originally	O
in	O
a	O
French	O
TSD	B
patient	O
(	O
Akli	O
et	O
al	O
.	O
,	O
1991	O
)	O
,	O
is	O
a	O
GT	O
-	O
-	O
>	O
AT	O
transition	O
at	O
the	O
donor	O
splice	O
-	O
site	O
of	O
intron	O
9	O
.	O

The	O
second	O
,	O
a	O
C	O
-	O
-	O
>	O
T	O
transition	O
at	O
nucleotide	O
739	O
(	O
Arg247Trp	O
)	O
,	O
has	O
been	O
shown	O
by	O
Triggs	O
-	O
Raine	O
et	O
al	O
.	O

(	O
1992	O
)	O
to	O
be	O
a	O
clinically	O
benign	O
"	O
pseudodeficient	O
"	O
allele	O
associated	O
with	O
reduced	O
enzyme	O
activity	O
against	O
artificial	O
substrate	O
.	O

Finally	O
,	O
a	O
polymorphism	O
[	O
G	O
-	O
-	O
>	O
A	O
(	O
759	O
)	O
]	O
,	O
which	O
leaves	O
valine	O
at	O
codon	O
253	O
unchanged	O
,	O
is	O
described	O
.	O

A	O
mutation	O
common	O
in	O
non	O
-	O
Jewish	O
Tay	B
-	I
Sachs	I
disease	I
:	O
frequency	O
and	O
RNA	O
studies	O
.	O

Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
is	O
an	O
autosomal	B
recessive	I
genetic	I
disorder	I
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
N	O
-	O
acetylhexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
.	O

We	O
have	O
discovered	O
that	O
a	O
Tay	B
-	I
Sachs	I
mutation	O
,	O
IVS	O
-	O
9	O
+	O
1	O
G	O
-	O
-	O
>	O
A	O
,	O
first	O
detected	O
by	O
Akli	O
et	O
al	O
.	O

(	O
Genomics	O
11	O
124	O
-	O
134	O
,	O
1991	O
)	O
,	O
is	O
a	O
common	O
disease	O
allele	O
in	O
non	O
-	O
Jewish	O
Caucasians	O
(	O
10	O
/	O
58	O
alleles	O
examined	O
)	O
.	O

A	O
PCR	O
-	O
based	O
diagnostic	O
test	O
,	O
which	O
detects	O
an	O
NlaIII	O
site	O
generated	O
by	O
the	O
mutation	O
,	O
revealed	O
a	O
frequency	O
among	O
enzyme	O
-	O
defined	O
carriers	O
of	O
9	O
/	O
64	O
(	O
14	O
%	O
)	O
.	O

Most	O
of	O
those	O
carrying	O
the	O
allele	O
trace	O
their	O
origins	O
to	O
the	O
United	O
Kingdom	O
,	O
Ireland	O
,	O
or	O
Western	O
Europe	O
.	O

It	O
was	O
not	O
identified	O
among	O
12	O
Black	O
American	O
TSD	B
alleles	O
or	O
in	O
any	O
of	O
18	O
Ashkenazi	O
Jewish	O
,	O
enzyme	O
-	O
defined	O
carriers	O
who	O
did	O
not	O
carry	O
any	O
of	O
the	O
mutations	O
common	O
to	O
this	O
population	O
.	O

No	O
normally	O
spliced	O
RNA	O
was	O
detected	O
in	O
PCR	O
products	O
generated	O
from	O
reverse	O
transcription	O
of	O
RNA	O
carrying	O
the	O
IVS	O
-	O
9	O
mutation	O
.	O

Instead	O
,	O
the	O
low	O
levels	O
of	O
mRNA	O
from	O
this	O
allele	O
were	O
comprised	O
of	O
aberrant	O
species	O
resulting	O
from	O
the	O
use	O
of	O
either	O
of	O
two	O
cryptic	O
donor	O
sites	O
,	O
one	O
truncating	O
exon	O
9	O
and	O
the	O
other	O
within	O
IVS	O
-	O
9	O
,	O
spliced	O
to	O
exon	O
10	O
.	O

Numerous	O
additional	O
splice	O
products	O
were	O
detected	O
,	O
most	O
involving	O
skipping	O
of	O
one	O
or	O
more	O
surrounding	O
exons	O
.	O

Together	O
with	O
a	O
recently	O
identified	O
allele	O
responsible	O
for	O
Hex	O
A	O
pseudodeficiency	O
(	O
Triggs	O
-	O
Raine	O
et	O
al	O
.	O
Am	O
J	O
Hum	O
Genet	O
,	O
1992	O
)	O
,	O
these	O
two	O
alleles	O
accounted	O
for	O
almost	O
50	O
%	O
(	O
29	O
/	O
64	O
)	O
of	O
TSD	B
or	O
carrier	O
alleles	O
ascertained	O
by	O
enzyme	O
screening	O
tests	O
in	O
non	O
-	O
Jewish	O
Caucasians	O
.	O
.	O

Aberrant	O
splicing	O
of	O
the	O
CHM	B
gene	O
is	O
a	O
significant	O
cause	O
of	O
choroideremia	B
.	O

Choroideremia	B
(	O
CHM	B
)	O
is	O
an	O
X	B
-	I
linked	I
progressive	I
degeneration	I
of	I
the	I
choroid	I
and	I
retina	I
.	O

12	O
%	O
of	O
unrelated	O
male	O
patients	O
carry	O
deletions	O
of	O
the	O
partially	O
cloned	O
CHM	B
gene	O
.	O

In	O
Finland	O
,	O
there	O
are	O
more	O
than	O
120	O
living	O
CHM	B
patients	O
belonging	O
to	O
eight	O
apparently	O
unrelated	O
pedigrees	O
.	O

Molecular	O
deletions	O
involving	O
the	O
CHM	B
gene	O
have	O
been	O
detected	O
in	O
three	O
families	O
.	O

We	O
have	O
screened	O
the	O
remaining	O
five	O
families	O
for	O
point	O
mutations	O
.	O

In	O
one	O
large	O
family	O
a	O
single	O
nucleotide	O
(	O
T	O
)	O
insertion	O
into	O
the	O
donor	O
splice	O
site	O
of	O
exon	O
C	O
leads	O
to	O
two	O
aberrantly	O
spliced	O
mRNAs	O
both	O
producing	O
a	O
premature	O
stop	O
codon	O
.	O

The	O
mutation	O
can	O
be	O
assayed	O
easily	O
by	O
amplification	O
and	O
digestion	O
with	O
Msel	O
.	O

Our	O
findings	O
provide	O
additional	O
evidence	O
for	O
the	O
pathogenetic	O
role	O
of	O
CHM	B
mutations	O
and	O
provide	O
a	O
diagnostic	O
tool	O
for	O
one	O
fifth	O
of	O
the	O
worlds	O
known	O
CHM	B
patients	O
.	O
.	O

Germline	O
intronic	O
and	O
exonic	O
mutations	O
in	O
the	O
Wilms	B
'	I
tumour	I
gene	O
(	O
WT1	O
)	O
affecting	O
urogenital	O
development	O
.	O

Denys	B
-	I
Drash	I
syndrome	I
is	O
a	O
rare	O
human	O
developmental	B
disorder	I
affecting	O
the	O
urogenital	O
system	O
and	O
leading	O
to	O
renal	B
failure	I
,	O
intersex	B
disorders	I
and	O
Wilms	B
tumour	I
.	O

In	O
this	O
report	O
,	O
four	O
individuals	O
with	O
this	O
syndrome	O
are	O
described	O
carrying	O
germline	O
point	O
mutations	O
in	O
the	O
Wilms	B
tumour	I
suppressor	O
gene	O
,	O
WT1	O
.	O

Three	O
of	O
these	O
mutations	O
were	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
WT1	O
.	O

The	O
fourth	O
occurred	O
within	O
intron	O
9	O
,	O
preventing	O
splicing	O
at	O
one	O
of	O
the	O
alternatively	O
chosen	O
splice	O
donor	O
sites	O
of	O
exon	O
9	O
when	O
assayed	O
in	O
vitro	O
.	O

These	O
results	O
provide	O
genetic	O
evidence	O
for	O
distinct	O
functional	O
roles	O
of	O
the	O
WT1	O
isoforms	O
in	O
urogenital	O
development	O
.	O
.	O

Characterization	O
of	O
the	O
myotonic	B
dystrophy	I
region	O
predicts	O
multiple	O
protein	O
isoform	O
-	O
encoding	O
mRNAs	O
.	O

The	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
has	O
been	O
identified	O
as	O
an	O
expansion	O
of	O
a	O
polymorphic	O
CTG	O
-	O
repeat	O
in	O
a	O
gene	O
encoding	O
protein	O
kinase	O
activity	O
.	O

Brain	O
and	O
heart	O
transcripts	O
of	O
the	O
DM	O
-	O
kinase	O
(	O
DMR	O
-	O
B15	O
)	O
gene	O
are	O
subject	O
to	O
alternative	O
RNA	O
splicing	O
in	O
both	O
human	O
and	O
mouse	O
.	O

The	O
unstable	O
[	O
CTG	O
]	O
5	O
-	O
30	O
motif	O
is	O
found	O
uniquely	O
in	O
humans	O
,	O
although	O
the	O
flanking	O
nucleotides	O
are	O
also	O
present	O
in	O
mouse	O
.	O

Characterization	O
of	O
the	O
DM	B
region	O
of	O
both	O
species	O
reveals	O
another	O
active	O
gene	O
(	O
DMR	O
-	O
N9	O
)	O
in	O
close	O
proximity	O
to	O
the	O
kinase	O
gene	O
.	O

DMR	O
-	O
N9	O
transcripts	O
,	O
mainly	O
expressed	O
in	O
brain	O
and	O
testis	O
,	O
possess	O
a	O
single	O
,	O
large	O
open	O
reading	O
frame	O
,	O
but	O
the	O
function	O
of	O
its	O
protein	O
product	O
is	O
unknown	O
.	O

Clinical	O
manifestation	O
of	O
DM	B
may	O
be	O
caused	O
by	O
the	O
expanded	O
CTG	O
-	O
repeat	O
compromising	O
the	O
(	O
alternative	O
)	O
expression	O
of	O
DM	O
-	O
kinase	O
or	O
DMR	O
-	O
N9	O
proteins	O
.	O
.	O

Fragile	B
X	I
syndrome	I
without	O
CCG	O
amplification	O
has	O
an	O
FMR1	O
deletion	O
.	O

We	O
describe	O
a	O
patient	O
with	O
typical	O
clinical	O
features	O
of	O
the	O
fragile	B
X	I
syndrome	I
,	O
but	O
without	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B
X	I
or	O
an	O
amplified	O
CCG	O
trinucleotide	O
repeat	O
fragment	O
.	O

The	O
patient	O
has	O
a	O
previously	O
uncharacterized	O
submicroscopic	O
deletion	O
encompassing	O
the	O
CCG	O
repeat	O
,	O
the	O
entire	O
FMR1	O
gene	O
and	O
about	O
2	O
.	O

5	O
megabases	O
of	O
flanking	O
sequences	O
.	O

This	O
finding	O
confirms	O
that	O
the	O
fragile	B
X	I
phenotype	O
can	O
exist	O
,	O
without	O
amplification	O
of	O
the	O
CCG	O
repeat	O
or	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B
X	I
,	O
and	O
that	O
fragile	B
X	I
syndrome	I
is	O
a	O
genetically	O
homogeneous	O
disorder	O
involving	O
FMR1	O
.	O

We	O
also	O
found	O
random	O
X	O
-	O
inactivation	O
in	O
the	O
mother	O
of	O
the	O
patient	O
who	O
was	O
shown	O
to	O
be	O
a	O
carrier	O
of	O
this	O
deletion	O
.	O

Cloning	O
of	O
the	O
Huntington	B
disease	I
region	O
in	O
yeast	O
artificial	O
chromosomes	O
.	O

The	O
gene	O
responsible	O
for	O
Huntington	B
disease	I
has	O
been	O
localized	O
to	O
a	O
2	O
.	O

5	O
million	O
base	O
pair	O
(	O
Mb	O
)	O
region	O
between	O
the	O
loci	O
D4S10	O
and	O
D4S168	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
4	O
.	O

As	O
part	O
of	O
a	O
strategy	O
to	O
clone	O
the	O
HD	B
gene	O
on	O
the	O
basis	O
of	O
its	O
chromosomal	O
location	O
,	O
we	O
isolated	O
genomic	O
DNA	O
from	O
the	O
HD	B
region	O
as	O
a	O
set	O
of	O
overlapping	O
yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
clones	O
.	O

Twenty	O
-	O
eight	O
YAC	O
clones	O
were	O
identified	O
by	O
screening	O
human	O
YAC	O
libraries	O
with	O
twelve	O
PCR	O
-	O
based	O
sequence	O
-	O
tagged	O
sites	O
(	O
STSs	O
)	O
from	O
the	O
region	O
.	O

We	O
assembled	O
the	O
YAC	O
clones	O
into	O
overlapping	O
sets	O
by	O
hybridizing	O
them	O
to	O
a	O
large	O
number	O
of	O
DNA	O
probes	O
from	O
the	O
HD	B
region	O
,	O
including	O
the	O
STSs	O
.	O

In	O
addition	O
,	O
we	O
isolated	O
the	O
ends	O
of	O
the	O
human	O
DNA	O
inserts	O
of	O
most	O
of	O
the	O
YAC	O
clones	O
to	O
assist	O
in	O
the	O
construction	O
of	O
the	O
contig	O
.	O

Although	O
almost	O
half	O
of	O
the	O
YACs	O
appear	O
to	O
contain	O
chimeric	O
inserts	O
and	O
several	O
contain	O
internal	O
deletions	O
or	O
other	O
rearrangements	O
,	O
we	O
were	O
able	O
to	O
obtain	O
over	O
2	O
.	O

2	O
Mb	O
of	O
the	O
HD	B
region	O
in	O
YACs	O
,	O
including	O
one	O
continuous	O
segment	O
of	O
2	O
.	O

0	O
Mb	O
covering	O
the	O
region	O
that	O
most	O
likely	O
contains	O
the	O
HD	B
gene	O
.	O

Ten	O
of	O
the	O
twenty	O
eight	O
YAC	O
clones	O
comprise	O
a	O
minimal	O
set	O
spanning	O
the	O
2	O
.	O

2	O
Mb	O
.	O

These	O
clones	O
provide	O
reagents	O
for	O
the	O
complete	O
characterization	O
of	O
this	O
region	O
of	O
the	O
genome	O
and	O
for	O
the	O
eventual	O
isolation	O
of	O
the	O
HD	B
gene	O
.	O

Characterization	O
of	O
a	O
YAC	O
containing	O
part	O
or	O
all	O
of	O
the	O
Norrie	B
disease	I
locus	O
.	O

It	O
has	O
been	O
shown	O
from	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
that	O
the	O
monoamine	O
oxidase	O
genes	O
A	O
and	O
B	O
(	O
MAOA	O
&	O
MAOB	O
)	O
and	O
DXS7	O
loci	O
are	O
physically	O
very	O
close	O
.	O

We	O
have	O
therefore	O
extended	O
studies	O
on	O
their	O
relationship	O
through	O
the	O
characterisation	O
of	O
a	O
650	O
kb	O
YAC	O
isolated	O
using	O
L1	O
.	O

28	O
(	O
recognising	O
the	O
DXS7	O
locus	O
)	O
as	O
a	O
probe	O
.	O

Restriction	O
mapping	O
of	O
the	O
YAC	O
indicates	O
that	O
it	O
contains	O
both	O
MAOA	O
and	O
MAOB	O
genes	O
in	O
addition	O
to	O
the	O
DXS7	O
locus	O
.	O

The	O
map	O
derived	O
from	O
the	O
YL1	O
.	O

28	O
-	O
YAC	O
is	O
compatible	O
both	O
with	O
the	O
map	O
from	O
an	O
independently	O
derived	O
YAC	O
carrying	O
MAOA	O
and	O
B	O
genes	O
and	O
with	O
the	O
long	O
range	O
genomic	O
map	O
for	O
the	O
region	O
.	O

A	O
series	O
of	O
subclones	O
prepared	O
from	O
a	O
phage	O
library	O
(	O
lambda	O
DASH	O
II	O
)	O
of	O
the	O
YAC	O
have	O
been	O
characterised	O
and	O
have	O
been	O
employed	O
to	O
determine	O
the	O
end	O
point	O
of	O
the	O
deletion	O
of	O
a	O
Norrie	B
disease	I
(	O
NDP	B
)	O
patient	O
who	O
has	O
been	O
shown	O
to	O
lack	O
both	O
DXS7	O
and	O
MAO	O
coding	O
sequences	O
.	O

The	O
pattern	O
of	O
retention	O
of	O
subclones	O
in	O
the	O
deletion	O
patient	O
place	O
the	O
end	O
point	O
of	O
the	O
deletion	O
within	O
30	O
-	O
130	O
kb	O
of	O
the	O
proximal	O
end	O
of	O
the	O
YAC	O
.	O

By	O
combining	O
the	O
data	O
with	O
established	O
recombination	O
analysis	O
,	O
we	O
provide	O
evidence	O
that	O
all	O
or	O
part	O
of	O
the	O
NDP	O
lies	O
in	O
the	O
interval	O
of	O
approximately	O
250kb	O
within	O
the	O
YAC	O
.	O

Both	O
mutations	O
in	O
G6PD	O
A	O
-	O
are	O
necessary	O
to	O
produce	O
the	O
G6PD	B
deficient	I
phenotype	O
.	O

The	O
high	O
prevalence	O
of	O
glucose	B
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
African	O
populations	O
is	O
due	O
almost	O
entirely	O
to	O
the	O
enzyme	O
variant	O
A	O
-	O
,	O
which	O
differs	O
from	O
the	O
wild	O
-	O
type	O
G6PD	O
B	O
by	O
two	O
amino	O
acid	O
replacements	O
,	O
68	O
Val	O
-	O
-	O
>	O
Met	O
and	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
.	O

The	O
non	O
-	O
deficient	O
polymorphic	O
variant	O
G6PD	O
A	O
contains	O
only	O
the	O
mutation	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
.	O

The	O
frequencies	O
of	O
the	O
G6PD	O
A	O
and	O
of	O
the	O
G6PD	O
A	O
-	O
genes	O
in	O
parts	O
of	O
Africa	O
are	O
both	O
about	O
0	O
.	O

2	O
.	O

The	O
68	O
Val	O
-	O
-	O
>	O
Met	O
mutation	O
has	O
not	O
been	O
found	O
in	O
a	O
B	O
background	O
.	O

This	O
could	O
be	O
because	O
the	O
68	O
Val	O
-	O
-	O
>	O
Met	O
mutation	O
happened	O
to	O
arise	O
in	O
an	O
A	O
gene	O
in	O
the	O
first	O
instance	O
,	O
or	O
because	O
the	O
68	O
Val	O
-	O
-	O
>	O
Met	O
mutation	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
G6PD	B
deficiency	I
.	O

We	O
have	O
approached	O
this	O
question	O
by	O
producing	O
G6PD	O
B	O
,	O
A	O
,	O
A	O
-	O
,	O
and	O
G6PD	O
68	O
Val	O
-	O
-	O
>	O
Met	O
in	O
a	O
bacterial	O
expression	O
system	O
and	O
analysing	O
their	O
biochemical	O
properties	O
.	O

With	O
each	O
single	O
mutation	O
we	O
found	O
a	O
slight	O
decrease	O
in	O
both	O
the	O
specific	O
activity	O
and	O
the	O
yield	O
of	O
enzyme	O
when	O
compared	O
to	O
G6PD	O
B	O
.	O

When	O
both	O
mutations	O
were	O
introduced	O
together	O
,	O
there	O
was	O
a	O
roughly	O
additive	O
effect	O
on	O
specific	O
activity	O
,	O
but	O
a	O
much	O
more	O
drastic	O
effect	O
on	O
enzyme	O
yield	O
(	O
4	O
%	O
of	O
normal	O
)	O
.	O

This	O
synergistic	O
effect	O
was	O
also	O
demonstrated	O
on	O
thermal	O
stability	O
,	O
especially	O
at	O
low	O
NADP	O
concentrations	O
.	O

Comparable	O
results	O
were	O
produced	O
when	O
the	O
replacement	O
119	O
Gln	O
-	O
-	O
>	O
Glu	O
was	O
studied	O
instead	O
of	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
.	O

We	O
infer	O
that	O
the	O
coexistence	O
of	O
the	O
two	O
mutations	O
is	O
responsible	O
for	O
enzyme	B
deficiency	I
in	I
G6PD	I
A	O
-	O
because	O
they	O
act	O
synergistically	O
in	O
causing	O
instability	O
of	O
the	O
enzyme	O
.	O

Small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
,	O
an	O
expressed	O
gene	O
in	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
critical	O
region	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
is	O
associated	O
with	O
paternally	O
derived	O
chromosomal	O
deletions	O
in	O
region	O
15q11	O
-	O
13	O
or	O
with	O
maternal	B
disomy	I
for	I
chromosome	I
15	I
.	O

Therefore	O
,	O
loss	O
of	O
the	O
expressed	O
paternal	O
alleles	O
of	O
maternally	O
imprinted	O
genes	O
must	O
be	O
responsible	O
for	O
the	O
PWS	B
phenotype	O
.	O

We	O
have	O
mapped	O
the	O
gene	O
encoding	O
the	O
small	O
nuclear	O
RNA	O
associated	O
polypeptide	O
SmN	O
(	O
SNRPN	O
)	O
to	O
human	O
chromosome	O
15q12	O
and	O
a	O
processed	O
pseudogene	O
SNRPNP1	O
to	O
chromosome	O
region	O
6pter	O
-	O
p21	O
.	O

Furthermore	O
,	O
SNRPN	O
was	O
mapped	O
to	O
the	O
minimal	O
deletion	O
interval	O
that	O
is	O
critical	O
for	O
PWS	B
.	O

The	O
fact	O
that	O
the	O
mouse	O
Snrpn	O
gene	O
is	O
maternally	O
imprinted	O
in	O
brain	O
suggests	O
that	O
loss	O
of	O
the	O
paternally	O
derived	O
SNRPN	O
allele	O
may	O
be	O
involved	O
in	O
the	O
PWS	B
phenotype	O
.	O
.	O

The	O
presence	O
of	O
two	O
different	O
infantile	O
Tay	B
-	I
Sachs	I
disease	I
mutations	O
in	O
a	O
Cajun	O
population	O
.	O

A	O
study	O
was	O
undertaken	O
to	O
characterize	O
the	O
mutation	O
(	O
s	O
)	O
responsible	O
for	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
in	O
a	O
Cajun	O
population	O
in	O
southwest	O
Louisiana	O
and	O
to	O
identify	O
the	O
origins	O
of	O
these	O
mutations	O
.	O

Eleven	O
of	O
12	O
infantile	O
TSD	B
alleles	O
examined	O
in	O
six	O
families	O
had	O
the	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
alpha	O
-	O
subunit	O
exon	O
11	O
insertion	O
mutation	O
that	O
is	O
present	O
in	O
approximately	O
70	O
%	O
of	O
Ashkenazi	O
Jewish	O
TSD	B
heterozygotes	O
.	O

The	O
mutation	O
in	O
the	O
remaining	O
allele	O
was	O
a	O
single	O
-	O
base	O
transition	O
in	O
the	O
donor	O
splice	O
site	O
of	O
the	O
alpha	O
-	O
subunit	O
intron	O
9	O
.	O

To	O
determine	O
the	O
origins	O
of	O
these	O
two	O
mutations	O
in	O
the	O
Cajun	O
population	O
,	O
the	O
TSD	B
carrier	O
status	O
was	O
enzymatically	O
determined	O
for	O
90	O
members	O
of	O
four	O
of	O
the	O
six	O
families	O
,	O
and	O
extensive	O
pedigrees	O
were	O
constructed	O
for	O
all	O
carriers	O
.	O

A	O
single	O
ancestral	O
couple	O
from	O
France	O
was	O
found	O
to	O
be	O
common	O
to	O
most	O
of	O
the	O
carriers	O
of	O
the	O
exon	O
11	O
insertion	O
.	O

Pedigree	O
data	O
suggest	O
that	O
this	O
mutation	O
has	O
been	O
in	O
the	O
Cajun	O
population	O
since	O
its	O
founding	O
over	O
2	O
centuries	O
ago	O
and	O
that	O
it	O
may	O
be	O
widely	O
distributed	O
within	O
the	O
population	O
.	O

In	O
contrast	O
,	O
the	O
intron	O
9	O
mutation	O
apparently	O
was	O
introduced	O
within	O
the	O
last	O
century	O
and	O
probably	O
is	O
limited	O
to	O
a	O
few	O
Louisiana	O
families	O
.	O
.	O

Mutations	O
in	O
the	O
candidate	O
gene	O
for	O
Norrie	B
disease	I
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
isolated	O
a	O
candidate	O
gene	O
for	O
X	B
linked	I
Norrie	I
disease	I
(	O
ND	B
)	O
which	O
was	O
found	O
to	O
be	O
deleted	O
or	O
disrupted	O
in	O
several	O
patients	O
.	O

As	O
a	O
prerequisite	O
for	O
the	O
identification	O
of	O
point	O
mutations	O
in	O
the	O
ND	B
gene	O
we	O
have	O
established	O
the	O
exon	O
-	O
intron	O
structure	O
of	O
this	O
gene	O
.	O

In	O
17	O
unrelated	O
patients	O
and	O
15	O
controls	O
,	O
PCR	O
products	O
derived	O
from	O
the	O
promoter	O
region	O
,	O
exons	O
1	O
and	O
2	O
as	O
well	O
as	O
the	O
coding	O
part	O
of	O
exon	O
3	O
were	O
analysed	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
.	O

In	O
12	O
patients	O
altered	O
PCR	O
fragments	O
were	O
detected	O
which	O
were	O
studied	O
in	O
detail	O
by	O
direct	O
sequencing	O
.	O

Eleven	O
different	O
mutations	O
were	O
found	O
,	O
and	O
all	O
but	O
one	O
are	O
likely	O
to	O
give	O
rise	O
to	O
significant	O
structural	O
changes	O
in	O
the	O
predicted	O
protein	O
.	O

These	O
findings	O
,	O
and	O
the	O
absence	O
of	O
functionally	O
relevant	O
base	O
changes	O
in	O
healthy	O
controls	O
,	O
emphasize	O
the	O
causal	O
role	O
of	O
this	O
candidate	O
gene	O
in	O
Norrie	B
disease	I
and	O
pave	O
the	O
way	O
for	O
reliable	O
diagnosis	O
and	O
carrier	O
detection	O
.	O
.	O

Detection	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
dystrophin	O
gene	O
by	O
multiple	O
SSCP	O
.	O

A	O
combination	O
of	O
multiplex	O
PCR	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
was	O
employed	O
to	O
screen	O
for	O
point	O
mutations	O
in	O
the	O
human	O
dystrophin	O
gene	O
.	O

Co	O
-	O
amplification	O
of	O
11	O
exons	O
from	O
genomic	O
DNA	O
of	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
/	O
BMD	B
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
SSCP	O
analysis	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
Duchenne	B
patient	O
identified	O
by	O
this	O
approach	O
.	O

The	O
mutation	O
introduces	O
a	O
termination	O
codon	O
within	O
exon	O
8	O
of	O
the	O
dystrophin	O
gene	O
.	O

It	O
is	O
predicted	O
to	O
cause	O
a	O
very	O
premature	O
translational	O
termination	O
accounting	O
for	O
the	O
severe	O
phenotype	O
observed	O
.	O

The	O
patient	O
inherited	O
this	O
mutation	O
from	O
his	O
mother	O
.	O

In	O
addition	O
the	O
analysis	O
revealed	O
5	O
polymorphisms	O
useful	O
for	O
internal	O
control	O
.	O
.	O

Proliferation	O
-	O
related	O
expression	O
of	O
p19	O
/	O
nm23	O
nucleoside	O
diphosphate	O
kinase	O
.	O

High	O
level	O
expression	O
of	O
the	O
nm23	O
-	O
H1	O
gene	O
,	O
which	O
encodes	O
for	O
a	O
nucleoside	O
diphosphate	O
kinase	O
,	O
has	O
been	O
found	O
to	O
correlate	O
with	O
diminished	O
metastasis	O
in	O
some	O
tumors	B
but	O
not	O
in	O
others	O
.	O

We	O
have	O
previously	O
identified	O
the	O
protein	O
product	O
of	O
the	O
nm23	O
-	O
H1	O
gene	O
in	O
two	O
-	O
dimensional	O
electrophoretic	O
gels	O
and	O
have	O
designated	O
it	O
p19	O
/	O
nm23	O
.	O

In	O
neuroblastoma	B
,	O
higher	O
levels	O
of	O
p19	O
/	O
nm23	O
,	O
which	O
are	O
associated	O
with	O
amplification	O
of	O
the	O
N	O
-	O
myc	O
oncogene	O
,	O
large	O
tumor	B
mass	O
,	O
and	O
metastasis	O
,	O
were	O
observed	O
in	O
advanced	O
stage	O
tumors	B
compared	O
with	O
limited	O
stage	O
disease	O
.	O

Because	O
of	O
the	O
variable	O
expression	O
of	O
nm23	O
-	O
H1	O
in	O
different	O
tumors	B
,	O
we	O
have	O
investigated	O
the	O
relationship	O
between	O
amounts	O
of	O
the	O
protein	O
and	O
cell	O
proliferation	O
.	O

The	O
levels	O
of	O
p19	O
/	O
nm23	O
were	O
compared	O
between	O
resting	O
and	O
mitotically	O
stimulated	O
normal	O
human	O
PBLs	O
and	O
in	O
leukemia	B
cells	O
.	O

The	O
amount	O
of	O
p19	O
/	O
nm23	O
increased	O
in	O
normal	O
lymphocytes	O
in	O
response	O
to	O
mitotic	O
stimulation	O
and	O
paralleled	O
the	O
increase	O
in	O
DNA	O
synthesis	O
.	O

In	O
leukemia	B
cells	O
obtained	O
from	O
patients	O
with	O
different	O
subtypes	O
of	O
acute	B
leukemia	I
,	O
p19	O
/	O
nm23	O
levels	O
were	O
also	O
increased	O
relative	O
to	O
resting	O
normal	O
lymphocytes	O
.	O

Treatment	O
of	O
mitotically	O
stimulated	O
lymphocytes	O
with	O
cyclosporin	O
,	O
which	O
inhibits	O
proliferation	O
,	O
blocked	O
the	O
increase	O
in	O
p19	O
/	O
nm23	O
;	O
treatment	O
of	O
the	O
leukemia	B
cell	O
line	O
HL	O
-	O
60	O
with	O
dimethylsulfoxide	O
,	O
which	O
induces	O
terminal	O
differentiation	O
,	O
resulted	O
in	O
diminished	O
levels	O
of	O
p19	O
/	O
nm23	O
.	O

Our	O
data	O
therefore	O
provide	O
evidence	O
that	O
nm23	O
-	O
H1	O
expression	O
is	O
related	O
to	O
cell	O
proliferative	O
activity	O
.	O
.	O

An	O
intrachromosomal	O
insertion	O
causing	O
5q22	O
deletion	O
and	O
familial	B
adenomatous	I
polyposis	I
coli	I
in	O
two	O
generations	O
.	O

We	O
report	O
familial	B
adenomatous	I
polyposis	I
coli	I
(	O
FAPC	B
)	O
with	O
epidermoid	B
cysts	I
,	O
osteomata	B
,	O
and	O
areas	O
of	O
congenital	B
hypertrophy	I
of	I
the	I
retinal	I
pigment	I
epithelium	I
(	O
CHRPEs	B
)	O
in	O
a	O
male	O
patient	O
and	O
his	O
maternal	O
aunt	O
,	O
both	O
of	O
whom	O
suffered	O
a	O
mild	O
to	O
moderate	O
degree	O
of	O
mental	B
handicap	I
.	O

Both	O
had	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
(	O
del	O
(	O
5	O
)	O
(	O
q22q23	O
.	O
2	O
)	O
)	O
.	O

Two	O
other	O
normal	O
family	O
members	O
had	O
the	O
underlying	O
direct	O
insertion	O
of	O
chromosome	O
5	O
(	O
dir	O
ins	O
(	O
5	O
)	O
(	O
q31	O
.	O
3q22q23	O
3q22q23	O
.	O
2	O
)	O
)	O
.	O

Molecular	O
genetic	O
and	O
fluorescent	O
hybridisation	O
studies	O
have	O
shown	O
that	O
loci	O
D5S37	O
and	O
D5S98	O
are	O
outside	O
the	O
deletion	O
whereas	O
loci	O
detected	O
by	O
probes	O
EF5	O
.	O

44	O
and	O
YN5	O
.	O

48	O
are	O
lost	O
.	O

As	O
expected	O
,	O
the	O
molecular	O
analyses	O
indicate	O
loss	O
of	O
one	O
allele	O
at	O
the	O
MCC	O
and	O
APC	B
loci	O
.	O

The	O
APC	B
gene	O
is	O
located	O
within	O
band	O
5q22	O
.	O

Familial	O
direct	O
insertions	O
should	O
be	O
considered	O
as	O
a	O
cause	O
of	O
recurrent	O
microdeletion	O
syndromes	O
.	O

Chromosome	O
mapping	O
of	O
the	O
rod	O
photoreceptor	O
cGMP	O
phosphodiesterase	O
beta	O
-	O
subunit	O
gene	O
in	O
mouse	O
and	O
human	O
:	O
tight	O
linkage	O
to	O
the	O
Huntington	B
disease	I
region	O
(	O
4p16	O
.	O
3	O
)	O
.	O

The	O
retinal	B
degeneration	I
mouse	O
(	O
gene	O
symbol	O
,	O
rd	O
)	O
is	O
an	O
animal	O
model	O
for	O
certain	O
forms	O
of	O
human	O
hereditary	B
retinopathies	I
.	O

Recent	O
findings	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
rd	O
mouse	O
PDE	O
beta	O
-	O
subunit	O
gene	O
(	O
Pdeb	O
)	O
prompted	O
us	O
to	O
investigate	O
the	O
chromosome	O
locations	O
of	O
the	O
mouse	O
and	O
human	O
genes	O
.	O

We	O
have	O
utilized	O
backcross	O
analysis	O
in	O
mice	O
to	O
verify	O
and	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
Pdeb	O
locus	O
6	O
.	O

1	O
+	O
/	O
-	O
2	O
.	O

3	O
cM	O
distal	O
of	O
Mgsa	O
on	O
mouse	O
chromosome	O
5	O
.	O

We	O
have	O
determined	O
that	O
the	O
human	O
gene	O
(	O
PDEB	O
)	O
maps	O
to	O
4p16	O
.	O

3	O
,	O
very	O
close	O
to	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
region	O
.	O

Analysis	O
of	O
the	O
comparative	O
map	O
for	O
mice	O
and	O
humans	O
shows	O
that	O
the	O
mouse	O
homologue	O
of	O
the	O
HD	B
gene	O
will	O
reside	O
on	O
chromosome	O
5	O
.	O

Linkage	O
of	O
the	O
mouse	O
Pdeb	O
locus	O
with	O
other	O
homologues	O
in	O
the	O
human	O
4p16	O
.	O

3	O
region	O
is	O
maintained	O
but	O
gene	O
order	O
is	O
not	O
,	O
suggesting	O
at	O
least	O
three	O
possible	O
sites	O
for	O
the	O
corresponding	O
mouse	O
HD	B
gene	O
.	O

Coincident	O
Kaposi	B
sarcoma	I
and	O
T	B
-	I
cell	I
lymphoma	I
in	O
a	O
patient	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

A	O
24	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
eczema	B
,	O
recurrent	O
mild	O
infections	O
,	O
and	O
thrombocytopenia	B
consistent	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
presented	O
with	O
a	O
mediastinal	O
mass	O
,	O
generalized	O
lymphadenopathy	B
,	O
splenomegaly	B
,	O
and	O
severe	O
thrombocytopenia	B
.	O

Studies	O
of	O
immune	O
function	O
including	O
immunoglobulin	O
levels	O
and	O
T	O
-	O
cell	O
subsets	O
were	O
normal	O
.	O

Furthermore	O
,	O
his	O
T	O
lymphocytes	O
proliferated	O
normally	O
in	O
response	O
to	O
phytohemagglutinin	O
,	O
concanavalin	O
A	O
,	O
and	O
the	O
combination	O
of	O
neuraminidase	O
/	O
galactose	O
oxidase	O
.	O

However	O
,	O
their	O
proliferative	O
responses	O
to	O
anti	O
-	O
CD43	O
antibody	O
and	O
periodate	O
were	O
diminished	O
,	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
WAS	B
.	O

An	O
initial	O
inguinal	O
lymph	O
node	O
biopsy	O
surprisingly	O
revealed	O
Kaposi	B
sarcoma	I
.	O

However	O
,	O
following	O
splenectomy	O
to	O
increase	O
the	O
platelet	O
count	O
,	O
biopsy	O
of	O
the	O
mediastinal	O
mass	O
revealed	O
T	B
-	I
cell	I
large	I
cell	I
lymphoma	I
.	O

Studies	O
of	O
biopsied	O
tissue	O
for	O
the	O
presence	O
of	O
Epstein	B
-	I
Barr	I
virus	I
and	O
cytomegalovirus	B
were	O
negative	O
,	O
as	O
were	O
studies	O
of	O
blood	O
,	O
including	O
the	O
polymerase	O
chain	O
reaction	O
,	O
for	O
the	O
presence	O
of	O
the	O
human	B
immunodeficiency	I
virus	I
(	O
HIV	B
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
Kaposi	B
sarcoma	I
arising	O
in	O
a	O
patient	O
with	O
a	O
congenital	B
immunodeficiency	I
syndrome	I
.	O

Although	O
Kaposi	B
sarcoma	I
can	O
arise	O
in	O
the	O
face	O
of	O
the	O
severe	O
immunosuppression	O
that	O
follows	O
allograft	O
transplantation	O
and	O
in	O
patients	O
infected	O
with	O
HIV	B
,	O
we	O
postulate	O
that	O
longevity	O
in	O
the	O
face	O
of	O
mild	O
immunosuppression	O
was	O
the	O
major	O
factor	O
in	O
the	O
development	O
of	O
Kaposi	B
sarcoma	I
in	O
this	O
patient	O
.	O
.	O

The	O
APC	B
gene	O
,	O
responsible	O
for	O
familial	B
adenomatous	I
polyposis	I
,	O
is	O
mutated	O
in	O
human	O
gastric	B
cancer	I
.	O

Although	O
gastric	B
cancer	I
is	O
the	O
most	O
common	O
cancer	B
in	O
the	O
world	O
,	O
genetic	O
changes	O
during	O
its	O
carcinogenesis	O
are	O
not	O
well	O
understood	O
.	O

Since	O
some	O
gastric	B
cancers	I
are	O
considered	O
to	O
originate	O
from	O
the	O
intestinal	O
metaplasia	O
,	O
it	O
is	O
likely	O
that	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
,	O
the	O
mutation	O
of	O
which	O
causes	O
adenomatous	B
polyps	I
in	I
the	I
colon	I
,	O
is	O
associated	O
with	O
carcinogenesis	O
of	O
gastric	B
cancer	I
.	O

Based	O
on	O
this	O
idea	O
,	O
DNAs	O
isolated	O
from	O
gastric	B
cancers	I
were	O
examined	O
by	O
means	O
of	O
a	O
RNase	O
protection	O
analysis	O
coupled	O
with	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products	O
.	O

By	O
screening	O
nearly	O
one	O
-	O
half	O
of	O
the	O
coding	O
region	O
of	O
the	O
APC	B
gene	O
in	O
44	O
tumors	B
,	O
somatic	O
mutations	O
were	O
detected	O
in	O
three	O
tumors	B
a	O
missense	O
mutation	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
5	O
-	O
base	O
pair	O
deletion	O
resulting	O
in	O
a	O
frame	O
shift	O
which	O
causes	O
truncation	O
of	O
the	O
gene	O
product	O
.	O

These	O
results	O
suggest	O
that	O
the	O
mutation	O
of	O
the	O
APC	B
gene	O
also	O
plays	O
an	O
important	O
role	O
during	O
the	O
carcinogenesis	O
of	O
at	O
least	O
some	O
gastric	B
cancers	I
.	O
.	O

A	O
71	O
-	O
kilodalton	O
protein	O
is	O
a	O
major	O
product	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
.	O

The	O
known	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
products	O
,	O
the	O
muscle	O
-	O
and	O
brain	O
-	O
type	O
dystrophin	O
isoforms	O
,	O
are	O
427	O
-	O
kDa	O
proteins	O
translated	O
from	O
14	O
-	O
kilobase	O
(	O
kb	O
)	O
mRNAs	O
.	O

Recently	O
we	O
described	O
a	O
6	O
.	O

5	O
-	O
kb	O
mRNA	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
DMD	B
gene	O
.	O

Cloning	O
and	O
in	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
entire	O
coding	O
region	O
show	O
that	O
the	O
6	O
.	O

5	O
-	O
kb	O
mRNA	O
encodes	O
a	O
70	O
.	O

8	O
-	O
kDa	O
protein	O
that	O
is	O
a	O
major	O
product	O
of	O
the	O
DMD	B
gene	O
.	O

It	O
contains	O
the	O
C	O
-	O
terminal	O
and	O
the	O
cysteine	O
-	O
rich	O
domains	O
of	O
dystrophin	O
,	O
seven	O
additional	O
amino	O
acids	O
at	O
the	O
N	O
terminus	O
,	O
and	O
some	O
modifications	O
formed	O
by	O
alternative	O
splicing	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

It	O
lacks	O
the	O
entire	O
large	O
domain	O
of	O
spectrin	O
-	O
like	O
repeats	O
and	O
the	O
actin	O
-	O
binding	O
N	O
-	O
terminal	O
domain	O
of	O
dystrophin	O
.	O

This	O
protein	O
is	O
the	O
major	O
DMD	B
gene	O
product	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
but	O
is	O
undetectable	O
in	O
skeletal	O
muscle	O
extracts	O
.	O

Correlation	O
between	O
the	O
location	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B
gene	O
and	O
the	O
number	O
of	O
colorectal	B
polyps	I
in	O
familial	B
adenomatous	I
polyposis	I
patients	O
.	O

Recently	O
we	O
have	O
isolated	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
which	O
causes	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
and	O
its	O
germ	O
-	O
line	O
mutations	O
in	O
a	O
substantial	O
number	O
of	O
FAP	B
patients	O
have	O
been	O
identified	O
.	O

On	O
the	O
basis	O
of	O
this	O
information	O
,	O
we	O
compared	O
the	O
location	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B
gene	O
in	O
22	O
unrelated	O
patients	O
(	O
12	O
of	O
whom	O
have	O
been	O
reported	O
previously	O
)	O
with	O
the	O
number	O
of	O
colorectal	B
polyps	I
developed	O
in	O
FAP	B
patients	O
;	O
17	O
were	O
sparse	O
types	O
and	O
five	O
were	O
profuse	O
types	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
considered	O
to	O
cause	O
truncation	O
of	O
the	O
gene	O
product	O
by	O
frame	O
-	O
shift	O
due	O
to	O
deletion	O
(	O
14	O
cases	O
)	O
or	O
nonsense	O
mutation	O
(	O
seven	O
cases	O
)	O
.	O

The	O
location	O
of	O
the	O
germ	O
-	O
line	O
mutations	O
seems	O
to	O
correlate	O
with	O
the	O
two	O
clinical	O
types	O
;	O
germ	O
-	O
line	O
mutations	O
in	O
five	O
FAP	B
patients	O
with	O
profuse	O
polyps	B
were	O
observed	O
between	O
codon	O
1250	O
and	O
codon	O
1464	O
,	O
whereas	O
mutations	O
in	O
17	O
FAP	B
patients	O
with	O
fewer	O
polyps	B
were	O
observed	O
in	O
the	O
other	O
regions	O
of	O
the	O
APC	B
gene	O
.	O

The	O
result	O
suggests	O
that	O
the	O
number	O
of	O
colorectal	B
polyps	I
in	O
FAP	B
patients	O
may	O
be	O
associated	O
with	O
a	O
difference	O
in	O
the	O
stability	O
or	O
biological	O
function	O
of	O
the	O
truncated	O
APC	B
protein	O
.	O
.	O

Identification	O
and	O
rapid	O
detection	O
of	O
three	O
Tay	B
-	I
Sachs	I
mutations	O
in	O
the	O
Moroccan	O
Jewish	O
population	O
.	O

Infantile	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
result	O
in	O
the	O
complete	O
absence	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
activity	O
.	O

It	O
is	O
well	O
known	O
that	O
an	O
elevated	O
frequency	O
of	O
TSD	B
mutations	O
exists	O
among	O
Ashkenazi	O
Jews	O
.	O

More	O
recently	O
it	O
has	O
become	O
apparent	O
that	O
elevated	O
carrier	O
frequencies	O
for	O
TSD	B
also	O
occur	O
in	O
several	O
other	O
ethnic	O
groups	O
,	O
including	O
Moroccan	O
Jews	O
,	O
a	O
subgroup	O
of	O
Sephardic	O
Jews	O
.	O

Elsewhere	O
we	O
reported	O
an	O
in	O
-	O
frame	O
deletion	O
of	O
one	O
of	O
the	O
two	O
adjacent	O
phenylalanine	O
codons	O
at	O
position	O
304	O
or	O
305	O
(	O
delta	O
F304	O
/	O
305	O
)	O
in	O
one	O
HEXA	O
allele	O
of	O
a	O
Moroccan	O
Jewish	O
TSD	B
patient	O
and	O
in	O
three	O
obligate	O
carriers	O
from	O
six	O
unrelated	O
Moroccan	O
Jewish	O
families	O
.	O

We	O
have	O
now	O
identified	O
two	O
additional	O
mutations	O
within	O
exon	O
5	O
of	O
the	O
HEXA	O
gene	O
that	O
account	O
for	O
the	O
remaining	O
TSD	B
alleles	O
in	O
the	O
patient	O
and	O
carriers	O
.	O

One	O
of	O
the	O
mutations	O
is	O
a	O
novel	O
C	O
-	O
to	O
-	O
G	O
transversion	O
,	O
resulting	O
in	O
a	O
replacement	O
of	O
Tyr180	O
by	O
a	O
stop	O
codon	O
.	O

The	O
other	O
mutation	O
is	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
resulting	O
in	O
an	O
Arg170	O
-	O
to	O
-	O
Gln	O
substitution	O
.	O

This	O
mutation	O
is	O
at	O
a	O
CpG	O
site	O
in	O
a	O
Japanese	O
infant	O
with	O
Tay	B
-	I
Sachs	I
disease	I
and	O
was	O
described	O
elsewhere	O
.	O

Analysis	O
of	O
nine	O
obligate	O
carriers	O
from	O
seven	O
unrelated	O
families	O
showed	O
that	O
four	O
harbor	O
the	O
delta	O
F304	O
/	O
305	O
mutation	O
,	O
two	O
the	O
Arg170	O
-	O
-	O
-	O
-	O
Gln	O
mutation	O
,	O
and	O
one	O
the	O
Tyr180	O
-	O
-	O
-	O
-	O
Stop	O
mutation	O
.	O

We	O
also	O
have	O
developed	O
rapid	O
,	O
nonradioactive	O
assays	O
for	O
the	O
detection	O
of	O
each	O
mutation	O
,	O
which	O
should	O
be	O
helpful	O
for	O
carrier	O
screening	O
.	O
.	O

Molecular	O
characterization	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
by	O
natural	O
and	O
amplification	O
created	O
restriction	O
sites	O
:	O
five	O
mutations	O
account	O
for	O
most	O
G6PD	B
deficiency	I
cases	O
in	O
Taiwan	O
.	O

We	O
have	O
developed	O
a	O
rapid	O
and	O
simple	O
method	O
to	O
diagnose	O
the	O
molecular	O
defects	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
Chinese	O
in	O
Taiwan	O
.	O

This	O
method	O
involves	O
the	O
selective	O
amplification	O
of	O
a	O
DNA	O
fragment	O
from	O
human	O
G6PD	O
gene	O
with	O
specific	O
oligonucleotide	O
primers	O
followed	O
by	O
digestion	O
with	O
restriction	O
enzymes	O
that	O
recognize	O
artificially	O
created	O
or	O
naturally	O
occurring	O
restriction	O
sites	O
.	O

Ninety	O
-	O
four	O
Chinese	O
males	O
with	O
G6PD	B
deficiency	I
were	O
studied	O
.	O

The	O
results	O
show	O
that	O
50	O
%	O
(	O
47	O
of	O
94	O
)	O
were	O
G	O
to	O
T	O
mutation	O
at	O
nucleotide	O
(	O
nt	O
)	O
1376	O
,	O
21	O
.	O

3	O
%	O
(	O
20	O
of	O
94	O
)	O
were	O
G	O
to	O
A	O
mutation	O
at	O
nt	O
1388	O
,	O
7	O
.	O

4	O
%	O
(	O
7	O
of	O
94	O
)	O
were	O
A	O
to	O
G	O
mutation	O
at	O
nt	O
493	O
,	O
7	O
.	O

4	O
%	O
(	O
7	O
of	O
94	O
)	O
were	O
A	O
to	O
G	O
mutation	O
at	O
nt	O
95	O
,	O
4	O
.	O

2	O
%	O
(	O
4	O
of	O
94	O
)	O
were	O
C	O
to	O
T	O
mutation	O
at	O
nt	O
1024	O
,	O
1	O
.	O

1	O
%	O
(	O
1	O
of	O
94	O
)	O
was	O
G	O
to	O
T	O
mutation	O
at	O
nt	O
392	O
,	O
and	O
1	O
.	O

1	O
%	O
(	O
1	O
of	O
94	O
)	O
was	O
G	O
to	O
A	O
mutation	O
at	O
nt	O
487	O
.	O

These	O
results	O
show	O
that	O
the	O
former	O
five	O
mutations	O
account	O
for	O
more	O
than	O
90	O
%	O
of	O
G6PD	B
deficiency	I
cases	O
in	O
Taiwan	O
.	O

Aside	O
from	O
showing	O
that	O
G	O
to	O
T	O
change	O
at	O
nt	O
1376	O
is	O
the	O
most	O
common	O
mutation	O
,	O
our	O
research	O
indicates	O
that	O
nt	O
493	O
mutation	O
is	O
a	O
frequent	O
mutation	O
among	O
Chinese	O
in	O
Taiwan	O
.	O

We	O
compared	O
G6PD	O
activity	O
among	O
different	O
mutations	O
,	O
without	O
discovering	O
significant	O
differences	O
between	O
them	O
.	O

Eight	O
novel	O
inactivating	O
germ	O
line	O
mutations	O
at	O
the	O
APC	B
gene	O
identified	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
dominantly	O
inherited	O
condition	O
predisposing	O
to	O
colorectal	B
cancer	I
.	O

The	O
recent	O
isolation	O
of	O
the	O
responsible	O
gene	O
(	O
adenomatous	B
polyposis	I
coli	I
or	O
APC	B
)	O
has	O
facilitated	O
the	O
search	O
for	O
germ	O
line	O
mutations	O
in	O
affected	O
individuals	O
.	O

Previous	O
authors	O
have	O
used	O
the	O
RNase	O
protection	O
assay	O
and	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphisms	O
procedure	O
to	O
screen	O
for	O
mutations	O
.	O

In	O
this	O
study	O
we	O
used	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

DGGE	O
analysis	O
of	O
10	O
APC	B
exons	O
(	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
and	O
part	O
of	O
15	O
)	O
in	O
33	O
unrelated	O
Dutch	O
FAP	B
patients	O
has	O
led	O
to	O
the	O
identification	O
of	O
eight	O
novel	O
germ	O
line	O
mutations	O
resulting	O
in	O
stop	O
codons	O
or	O
frameshifts	O
.	O

The	O
results	O
reported	O
here	O
indicate	O
that	O
(	O
1	O
)	O
familial	B
adenomatous	I
polyposis	I
is	O
caused	O
by	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
point	O
mutations	O
;	O
(	O
2	O
)	O
all	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
chain	O
terminating	O
;	O
and	O
(	O
3	O
)	O
DGGE	O
represents	O
a	O
rapid	O
and	O
sensitive	O
technique	O
for	O
the	O
detection	O
of	O
mutations	O
in	O
the	O
unusually	O
large	O
APC	B
gene	O
.	O

An	O
extension	O
of	O
the	O
DGGE	O
analysis	O
to	O
the	O
entire	O
coding	O
region	O
in	O
a	O
sufficient	O
number	O
of	O
clinically	O
well	O
-	O
characterized	O
,	O
unrelated	O
patients	O
will	O
facilitate	O
the	O
establishment	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
occurrence	O
of	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
mutations	O
spread	O
throughout	O
the	O
entire	O
length	O
of	O
the	O
large	O
APC	B
gene	O
among	O
the	O
FAP	B
patients	O
indicates	O
that	O
this	O
approach	O
may	O
not	O
be	O
useful	O
as	O
a	O
rapid	O
presymptomatic	O
diagnostic	O
procedure	O
in	O
a	O
routine	O
laboratory	O
.	O

Nevertheless	O
,	O
the	O
above	O
DGGE	O
approach	O
has	O
incidentally	O
led	O
to	O
the	O
identification	O
of	O
a	O
common	O
polymorphism	O
in	O
exon	O
13	O
.	O

Such	O
intragenic	O
polymorphisms	O
offer	O
a	O
practical	O
approach	O
to	O
a	O
more	O
rapid	O
procedure	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	B
by	O
linkage	O
analysis	O
in	O
informative	O
families	O
.	O
.	O

Yeast	O
artificial	O
chromosomes	O
for	O
the	O
molecular	O
analysis	O
of	O
the	O
familial	B
polyposis	I
APC	I
gene	O
region	O
.	O

Two	O
yeast	O
artificial	O
chromosomes	O
(	O
YACs	O
)	O
spanning	O
a	O
total	O
distance	O
of	O
1	O
.	O

1	O
megabase	O
pairs	O
of	O
DNA	O
around	O
the	O
MCC	O
(	O
for	O
mutated	O
in	O
colorectal	B
carcinoma	I
)	O
and	O
APC	B
(	O
for	O
adenomatous	B
polyposis	I
coli	I
)	O
genes	O
at	O
5q21	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

Starting	O
from	O
the	O
MCC	O
gene	O
,	O
a	O
strategy	O
was	O
undertaken	O
to	O
identify	O
constitutional	O
submicroscopic	O
deletions	O
in	O
familial	B
adenomatous	I
polyposis	I
patients	O
that	O
might	O
considerably	O
narrow	O
down	O
the	O
position	O
of	O
the	O
APC	B
gene	O
.	O

To	O
this	O
end	O
,	O
YACs	O
identified	O
by	O
the	O
MCC	O
gene	O
were	O
screened	O
across	O
a	O
chromosome	O
5	O
-	O
specific	O
cosmid	O
library	O
to	O
provide	O
a	O
source	O
of	O
DNA	O
probes	O
for	O
genomic	O
scanning	O
.	O

The	O
cosmids	O
isolated	O
from	O
these	O
experiments	O
were	O
used	O
to	O
screen	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
containing	O
chromosome	O
5	O
segregated	O
from	O
patients	O
suspected	O
to	O
carry	O
putative	O
interstitial	O
deletions	O
.	O

This	O
screening	O
approach	O
led	O
to	O
the	O
confirmation	O
of	O
a	O
small	O
heterozygous	O
deletion	O
in	O
a	O
polyposis	B
patient	O
that	O
overlaps	O
one	O
of	O
the	O
two	O
isolated	O
YACs	O
.	O

This	O
YAC	O
has	O
been	O
shown	O
to	O
contain	O
the	O
entire	O
APC	B
gene	O
,	O
in	O
addition	O
to	O
a	O
significant	O
portion	O
of	O
DNA	O
flanking	O
the	O
5	O
end	O
of	O
the	O
gene	O
,	O
and	O
should	O
therefore	O
prove	O
a	O
valuable	O
resource	O
for	O
functional	O
studies	O
by	O
transfer	O
to	O
colorectal	B
tumor	I
-	O
derived	O
cell	O
lines	O
.	O

Inherited	O
WT1	O
mutation	O
in	O
Denys	B
-	I
Drash	I
syndrome	I
.	O

Patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
Wilms	B
tumor	I
,	O
genital	B
anomalies	I
,	O
and	O
nephropathy	B
)	O
have	O
been	O
demonstrated	O
to	O
carry	O
de	O
novo	O
constitutional	O
mutations	O
in	O
WT1	O
,	O
the	O
Wilms	B
tumor	I
gene	O
at	O
chromosome	O
11p13	O
.	O

We	O
report	O
three	O
new	O
cases	O
,	O
two	O
carrying	O
a	O
previously	O
described	O
WT1	O
exon	O
9	O
mutation	O
and	O
one	O
with	O
a	O
novel	O
WT1	O
exon	O
8	O
mutation	O
.	O

However	O
,	O
unlike	O
patients	O
in	O
previous	O
reports	O
,	O
one	O
of	O
our	O
three	O
patients	O
inherited	O
the	O
affected	O
allele	O
from	O
his	O
phenotypically	O
unaffected	O
father	O
.	O

This	O
observation	O
indicates	O
that	O
the	O
WT1	O
exon	O
9	O
mutation	O
affecting	O
394Arg	O
demonstrated	O
in	O
over	O
one	O
-	O
half	O
of	O
the	O
patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
may	O
exhibit	O
incomplete	O
penetrance	O
.	O

Consequently	O
,	O
familial	O
studies	O
in	O
patients	O
affected	O
by	O
this	O
syndrome	O
are	O
recommended	O
.	O
.	O

Submicroscopic	O
deletions	O
at	O
the	O
WAGR	B
locus	O
,	O
revealed	O
by	O
nonradioactive	O
in	O
situ	O
hybridization	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
biotin	O
-	O
labeled	O
probes	O
mapping	O
to	O
11p13	O
has	O
been	O
used	O
for	O
the	O
molecular	O
analysis	O
of	O
deletions	O
of	O
the	O
WAGR	B
(	O
Wilms	B
tumor	I
,	O
aniridia	B
,	O
genitourinary	B
abnormalities	I
,	O
and	O
mental	B
retardation	I
)	O
locus	O
.	O

We	O
have	O
detected	O
a	O
submicroscopic	O
11p13	O
deletion	O
in	O
a	O
child	O
with	O
inherited	O
aniridia	B
who	O
subsequently	O
presented	O
with	O
Wilms	B
tumor	I
in	O
a	O
horseshoe	O
kidney	O
,	O
only	O
revealed	O
at	O
surgery	O
.	O

The	O
mother	O
,	O
who	O
has	O
aniridia	B
,	O
was	O
also	O
found	O
to	O
carry	O
a	O
deletion	O
including	O
both	O
the	O
aniridia	B
candidate	O
gene	O
(	O
AN2	O
)	O
and	O
the	O
Wilms	B
tumor	I
predisposition	O
gene	O
(	O
WT1	O
)	O
.	O

This	O
is	O
therefore	O
a	O
rare	O
case	O
of	O
an	O
inherited	O
WAGR	B
deletion	O
.	O

Wilms	B
tumor	I
has	O
so	O
far	O
only	O
been	O
associated	O
with	O
sporadic	O
de	O
novo	O
aniridia	B
cases	O
.	O

We	O
have	O
shown	O
that	O
a	O
cosmid	O
probe	O
for	O
a	O
candidate	O
aniridia	B
gene	O
,	O
homologous	O
to	O
the	O
mouse	O
Pax	O
-	O
6	O
gene	O
,	O
is	O
deleted	O
in	O
cell	O
lines	O
from	O
aniridia	B
patients	O
with	O
previously	O
characterized	O
deletions	O
at	O
11p13	O
,	O
while	O
another	O
cosmid	O
marker	O
mapping	O
between	O
two	O
aniridia	B
-	O
associated	O
translocation	O
breakpoints	O
(	O
and	O
hence	O
a	O
second	O
candidate	O
marker	O
)	O
is	O
present	O
on	O
both	O
chromosomes	O
.	O

These	O
results	O
support	O
the	O
Pax	O
-	O
6	O
homologue	O
as	O
a	O
strong	O
candidate	O
for	O
the	O
AN2	O
gene	O
.	O

FISH	O
with	O
cosmid	O
probes	O
has	O
proved	O
to	O
be	O
a	O
fast	O
and	O
reliable	O
technique	O
for	O
the	O
molecular	O
analysis	O
of	O
deletions	O
.	O

It	O
can	O
be	O
used	O
with	O
limited	O
amounts	O
of	O
material	O
and	O
has	O
strong	O
potential	O
for	O
clinical	O
applications	O
.	O
.	O

Linkage	O
of	O
gene	O
for	O
C2	B
deficiency	I
and	O
the	O
major	O
histocompatibility	O
complex	O
MHC	O
in	O
man	O
.	O

Family	O
study	O
of	O
a	O
further	O
case	O
.	O

Close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B
deficiency	I
was	O
first	O
reported	O
by	O
FU	O
and	O
co	O
-	O
workers	O
in	O
1974	O
.	O

We	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
C2	B
-	I
deficient	I
individual	O
with	O
clinical	O
manifestations	O
of	O
Hodgkins	B
disease	I
.	O

The	O
following	O
markers	O
were	O
tested	O
C2	O
levels	O
,	O
factor	O
B	O
polymorphism	O
,	O
blood	O
groups	O
,	O
and	O
enzyme	O
typing	O
.	O

In	O
addition	O
to	O
close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B
deficiency	I
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
Bf	O
(	O
HL	O
-	O
A	O
linked	O
,	O
electrophoretic	O
variation	O
of	O
B	O
)	O
.	O

The	O
two	O
HL	O
-	O
A	O
haplotypes	O
closely	O
linked	O
to	O
C2	B
deficiency	I
are	O
different	O
2	O
,	O
W18	O
and	O
W24	O
,	O
W18	O
.	O

They	O
share	O
,	O
however	O
,	O
the	O
SD2	O
antigen	O
W18	O
and	O
the	O
LD	O
type	O
7a	O
.	O
.	O

Screening	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
familial	B
adenomatous	I
polyposis	I
patients	O
:	O
61	O
new	O
patients	O
and	O
a	O
summary	O
of	O
150	O
unrelated	O
patients	O
.	O

We	O
report	O
here	O
the	O
result	O
of	O
a	O
screening	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
in	O
61	O
new	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
patients	O
as	O
well	O
as	O
a	O
summary	O
of	O
the	O
results	O
of	O
150	O
patients	O
.	O

Examination	O
of	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B
gene	O
,	O
based	O
on	O
a	O
ribonuclease	O
protection	O
assay	O
coupled	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
disclosed	O
mutations	O
that	O
were	O
considered	O
to	O
cause	O
significant	O
defects	O
in	O
the	O
APC	B
product	O
in	O
97	O
of	O
150	O
unrelated	O
FAP	B
patients	O
.	O

Our	O
findings	O
revealed	O
the	O
following	O
characteristics	O
of	O
the	O
germ	O
-	O
line	O
mutations	O
of	O
APC	O
1	O
)	O
the	O
great	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
to	O
truncate	O
the	O
APC	B
product	O
;	O
2	O
)	O
almost	O
all	O
of	O
the	O
mutations	O
were	O
located	O
within	O
the	O
first	O
half	O
of	O
the	O
coding	O
region	O
;	O
3	O
)	O
no	O
correlation	O
was	O
observed	O
between	O
the	O
locations	O
of	O
germ	O
-	O
line	O
mutations	O
and	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
;	O
4	O
)	O
more	O
than	O
80	O
%	O
of	O
base	O
substitutions	O
in	O
the	O
APC	B
gene	O
were	O
from	O
cytosine	O
to	O
other	O
nucleotides	O
,	O
nearly	O
one	O
-	O
third	O
of	O
which	O
occurred	O
at	O
the	O
GpG	O
site	O
.	O

Our	O
results	O
provide	O
information	O
helpful	O
to	O
an	O
understanding	O
of	O
the	O
APC	B
gene	O
and	O
will	O
also	O
contribute	O
to	O
presymptomatic	O
diagnosis	O
of	O
members	O
in	O
FAP	B
families	O
.	O
.	O

Somatic	O
mutations	O
of	O
the	O
APC	B
gene	O
in	O
colorectal	B
tumors	I
:	O
mutation	O
cluster	O
region	O
in	O
the	O
APC	B
gene	O
.	O

We	O
examined	O
somatic	O
mutations	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
in	O
63	O
colorectal	B
tumors	I
(	O
16	O
adenomas	B
and	O
47	O
carcinomas	B
)	O
developed	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
and	O
non	O
-	O
FAP	O
patients	O
.	O

In	O
addition	O
to	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
APC	B
locus	O
in	O
30	O
tumors	B
,	O
43	O
other	O
somatic	O
mutations	O
were	O
detected	O
.	O

Twenty	O
-	O
one	O
of	O
them	O
were	O
point	O
mutations	O
;	O
16	O
nonsense	O
and	O
two	O
missense	O
mutations	O
,	O
and	O
three	O
occurred	O
in	O
introns	O
at	O
the	O
splicing	O
site	O
.	O

Twenty	O
-	O
two	O
tumors	B
had	O
frameshift	O
mutations	O
due	O
to	O
deletion	O
or	O
insertion	O
;	O
nineteen	O
of	O
them	O
were	O
deletions	O
of	O
one	O
to	O
31	O
bp	O
and	O
three	O
were	O
a	O
1	O
-	O
bp	O
insertion	O
.	O

One	O
tumor	B
had	O
a	O
1	O
-	O
bp	O
deletion	O
in	O
an	O
intron	O
near	O
the	O
splicing	O
site	O
.	O

Hence	O
,	O
41	O
(	O
95	O
%	O
)	O
of	O
43	O
mutations	O
resulted	O
in	O
truncation	O
of	O
the	O
APC	B
protein	O
.	O

Over	O
60	O
%	O
of	O
the	O
somatic	O
mutations	O
in	O
the	O
APC	B
gene	O
were	O
clustered	O
within	O
a	O
small	O
region	O
of	O
exon	O
15	O
,	O
designated	O
as	O
MCR	O
(	O
mutation	O
cluster	O
region	O
)	O
,	O
which	O
accounted	O
for	O
less	O
than	O
10	O
%	O
of	O
the	O
coding	O
region	O
.	O

Combining	O
these	O
data	O
and	O
the	O
results	O
of	O
LOH	O
,	O
more	O
than	O
80	O
%	O
of	O
tumors	B
(	O
14	O
adenomas	B
and	O
39	O
carcinomas	B
)	O
had	O
at	O
least	O
one	O
mutation	O
in	O
the	O
APC	B
gene	O
,	O
of	O
which	O
more	O
than	O
60	O
%	O
(	O
9	O
adenomas	B
and	O
23	O
carcinomas	B
)	O
had	O
two	O
mutations	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
somatic	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
associated	O
with	O
development	O
of	O
a	O
great	O
majority	O
of	O
colorectal	B
tumors	I
.	O
.	O

Constitutional	O
mutations	O
in	O
the	O
WT1	O
gene	O
in	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
.	O

The	O
Denys	B
-	I
Drash	I
syndrome	I
is	O
characterised	O
by	O
a	O
typical	O
nephropathy	B
,	O
genital	B
abnormalities	I
and	O
also	O
predisposes	O
to	O
the	O
development	O
of	O
Wilms	B
tumor	I
.	O

These	O
patients	O
eventually	O
go	O
into	O
end	O
stage	O
renal	B
failure	I
.	O

A	O
candidate	O
Wilms	B
tumor	I
gene	O
,	O
WT1	O
,	O
from	O
the	O
11p13	O
chromosome	O
region	O
has	O
recently	O
been	O
cloned	O
.	O

We	O
have	O
analysed	O
the	O
DNA	O
sequence	O
in	O
constitutional	O
cells	O
from	O
eight	O
patients	O
and	O
have	O
shown	O
heterozygous	O
mutations	O
in	O
six	O
of	O
them	O
.	O

Four	O
of	O
the	O
mutations	O
were	O
in	O
exon	O
9	O
,	O
all	O
resulting	O
in	O
missense	O
mutations	O
.	O

Three	O
were	O
at	O
nucleotide	O
position	O
1180	O
resulting	O
in	O
an	O
arg	O
>	O
trp	O
amino	O
acid	O
change	O
.	O

The	O
other	O
was	O
at	O
position	O
1186	O
converting	O
an	O
asp	O
>	O
asn	O
in	O
the	O
predicted	O
resultant	O
protein	O
.	O

One	O
patient	O
had	O
a	O
missense	O
mutation	O
in	O
exon	O
8	O
,	O
converting	O
an	O
arg	O
>	O
his	O
.	O

A	O
single	O
base	O
pair	O
insertion	O
at	O
nucleotide	O
position	O
821	O
in	O
exon	O
6	O
resulted	O
in	O
the	O
generation	O
of	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
last	O
patient	O
.	O

We	O
were	O
unable	O
to	O
find	O
a	O
mutation	O
in	O
one	O
patient	O
despite	O
complete	O
sequencing	O
of	O
the	O
genomic	O
sequence	O
of	O
the	O
gene	O
.	O

The	O
last	O
patient	O
carried	O
a	O
constitutional	O
deletion	O
of	O
the	O
11p13	O
region	O
and	O
no	O
additional	O
mutation	O
was	O
found	O
.	O

There	O
was	O
no	O
obvious	O
correlation	O
between	O
the	O
type	O
of	O
mutation	O
and	O
phenotypic	O
expression	O
.	O

These	O
results	O
further	O
demonstrate	O
that	O
the	O
WT1	O
gene	O
is	O
important	O
in	O
both	O
the	O
development	O
of	O
the	O
kidney	O
and	O
the	O
genito	O
-	O
urinary	O
system	O
.	O
.	O

Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
founder	O
populations	O
:	O
diastrophic	B
dysplasia	I
in	O
Finland	O
.	O

Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
populations	O
provides	O
a	O
powerful	O
tool	O
for	O
fine	O
structure	O
localization	O
of	O
disease	O
genes	O
.	O

Here	O
,	O
Luria	O
and	O
Delbrucks	O
classical	O
methods	O
for	O
analysing	O
bacterial	O
cultures	O
are	O
adapted	O
to	O
the	O
study	O
of	O
human	O
isolated	O
founder	O
populations	O
in	O
order	O
to	O
estimate	O
(	O
i	O
)	O
the	O
recombination	O
fraction	O
between	O
a	O
disease	O
locus	O
and	O
a	O
marker	O
;	O
(	O
ii	O
)	O
the	O
expected	O
degree	O
of	O
allelic	O
homogeneity	O
in	O
a	O
population	O
;	O
and	O
(	O
iii	O
)	O
the	O
mutation	O
rate	O
of	O
marker	O
loci	O
.	O

Using	O
these	O
methods	O
,	O
we	O
report	O
striking	O
linkage	O
disequilibrium	O
for	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
in	O
Finland	O
indicating	O
that	O
the	O
DTD	B
gene	O
should	O
lie	O
within	O
0	O
.	O

06	O
centimorgans	O
(	O
or	O
about	O
60	O
kilobases	O
)	O
of	O
the	O
CSF1R	O
gene	O
.	O

Predictions	O
about	O
allelic	O
homogeneity	O
in	O
Finland	O
and	O
mutation	O
rates	O
in	O
simple	O
sequence	O
repeats	O
are	O
confirmed	O
by	O
independent	O
observations	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
refinement	O
of	O
the	O
localization	O
on	O
Xp	O
and	O
identification	O
of	O
another	O
closely	O
linked	O
marker	O
locus	O
,	O
OATL1	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
has	O
previously	O
been	O
mapped	O
to	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
between	O
the	O
DXS14	O
and	O
DXS7	O
loci	O
.	O

In	O
this	O
study	O
,	O
further	O
segregation	O
analysis	O
has	O
been	O
performed	O
using	O
a	O
newly	O
identified	O
WAS	B
family	O
as	O
well	O
as	O
an	O
additional	O
marker	O
probe	O
,	O
HOATL1	O
.	O

The	O
results	O
indicate	O
close	O
linkage	O
between	O
the	O
WAS	B
and	O
OATL1	O
loci	O
(	O
Z	O
=	O
6	O
.	O
08	O
at	O
theta	O
=	O
0	O
.	O
00	O
)	O
and	O
localize	O
the	O
TIMP	O
,	O
OATL1	O
,	O
DXS255	O
,	O
and	O
WAS	B
loci	O
distal	O
to	O
DXS146	O
and	O
the	O
OATL1	O
and	O
WAS	B
loci	O
proximal	O
to	O
TIMP	O
.	O

These	O
linkage	O
data	O
narrow	O
the	O
boundaries	O
within	O
which	O
the	O
WAS	B
locus	O
maps	O
to	O
the	O
chromosomal	O
region	O
bracketed	O
by	O
TIMP	O
and	O
DXS146	O
and	O
support	O
the	O
loci	O
order	O
Xpter	O
-	O
DXS7	O
-	O
TIMP	O
-	O
(	O
OATL1	O
,	O
WAS	O
,	O
DXS255	O
)	O
-	O
DXS146	O
.	O

Detection	O
of	O
an	O
unstable	O
fragment	O
of	O
DNA	O
specific	O
to	O
individuals	O
with	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B
dystrophy	I
,	O
with	O
a	O
prevalence	O
of	O
2	O
-	O
14	O
per	O
100	O
,	O
000	O
individuals	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
progressive	O
muscle	B
weakness	I
and	O
sustained	B
muscle	I
contraction	I
,	O
often	O
with	O
a	O
wide	O
range	O
of	O
accompanying	O
symptoms	O
.	O

The	O
age	O
at	O
onset	O
and	O
severity	O
of	O
the	O
disease	O
show	O
extreme	O
variation	O
,	O
both	O
within	O
and	O
between	O
families	O
.	O

Despite	O
its	O
clinical	O
variability	O
,	O
this	O
dominant	O
condition	O
segregates	O
as	O
a	O
single	O
locus	O
at	O
chromosome	O
19q13	O
.	O

3	O
in	O
every	O
population	O
studied	O
.	O

It	O
is	O
flanked	O
by	O
the	O
tightly	O
linked	O
genetic	O
markers	O
ERCC1	O
proximally	O
and	O
D19S51	O
distally	O
;	O
these	O
define	O
the	O
DM	B
critical	O
region	O
.	O

We	O
report	O
the	O
isolation	O
of	O
an	O
expressed	O
sequence	O
from	O
this	O
region	O
which	O
detects	O
a	O
DNA	O
fragment	O
that	O
is	O
larger	O
in	O
affected	O
individuals	O
than	O
in	O
normal	O
siblings	O
or	O
unaffected	O
controls	O
.	O

The	O
size	O
of	O
this	O
fragment	O
varies	O
between	O
affected	O
siblings	O
,	O
and	O
increases	O
in	O
size	O
through	O
generations	O
in	O
parallel	O
with	O
increasing	O
severity	O
of	O
the	O
disease	O
.	O

We	O
postulate	O
that	O
this	O
unstable	O
DNA	O
sequence	O
is	O
the	O
molecular	O
feature	O
that	O
underlies	O
DM	B
.	O

Common	O
sequence	O
motifs	O
at	O
the	O
rearrangement	O
sites	O
of	O
a	O
constitutional	O
X	O
/	O
autosome	O
translocation	O
and	O
associated	O
deletion	O
.	O

Reciprocal	O
chromosome	O
translocations	O
are	O
common	O
de	O
novo	O
rearrangements	O
that	O
occur	O
randomly	O
throughout	O
the	O
human	O
genome	O
.	O

To	O
learn	O
about	O
causative	O
mechanisms	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
breakpoints	O
of	O
a	O
cytologically	O
balanced	O
constitutional	O
reciprocal	O
translocation	O
,	O
t	O
(	O
X	O
;	O
4	O
)	O
(	O
p21	O
.	O
2	O
;	O
q31	O
.	O
22	O
)	O
,	O
present	O
in	O
a	O
girl	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

Physical	O
mapping	O
of	O
the	O
derivative	O
chromosomes	O
,	O
after	O
their	O
separation	O
in	O
somatic	O
cell	O
hybrids	O
,	O
reveals	O
that	O
the	O
translocation	O
disrupts	O
the	O
DMD	B
gene	O
in	O
Xp21	O
within	O
the	O
18	O
-	O
kb	O
intron	O
16	O
.	O

Restriction	O
mapping	O
and	O
sequencing	O
of	O
clones	O
that	O
span	O
both	O
translocation	O
breakpoints	O
as	O
well	O
as	O
the	O
corresponding	O
normal	O
regions	O
indicate	O
the	O
loss	O
of	O
approximately	O
5	O
kb	O
in	O
the	O
formation	O
of	O
the	O
derivative	O
X	O
chromosome	O
,	O
with	O
4	O
-	O
6	O
bp	O
deleted	O
from	O
chromosome	O
4	O
.	O

RFLP	O
and	O
Southern	O
analyses	O
indicate	O
that	O
the	O
de	O
novo	O
translocation	O
is	O
a	O
paternal	O
origin	O
and	O
that	O
the	O
fathers	O
X	O
chromosome	O
contains	O
the	O
DNA	O
that	O
is	O
deleted	O
in	O
the	O
derivative	O
X	O
.	O

Most	O
likely	O
,	O
deletion	O
and	O
translation	O
arose	O
simultaneously	O
from	O
a	O
complex	O
rearrangement	O
event	O
that	O
involves	O
three	O
chromosomal	O
breakpoints	O
.	O

Short	O
regions	O
of	O
sequence	O
homology	O
were	O
present	O
at	O
the	O
three	O
sites	O
.	O

A	O
5	O
-	O
bp	O
sequence	O
,	O
GGAAT	O
,	O
found	O
exactly	O
at	O
the	O
translocation	O
breakpoints	O
on	O
both	O
normal	O
chromosomes	O
X	O
and	O
4	O
,	O
has	O
been	O
preserved	O
only	O
on	O
the	O
der	O
(	O
4	O
)	O
chromosome	O
.	O

It	O
is	O
likely	O
that	O
the	O
X	O
-	O
derived	O
sequence	O
GGAATCA	O
has	O
been	O
lost	O
in	O
the	O
formation	O
of	O
the	O
der	O
(	O
X	O
)	O
chromosome	O
,	O
as	O
it	O
matches	O
an	O
inverted	O
GAATCA	O
sequence	O
present	O
on	O
the	O
opposite	O
strand	O
exactly	O
at	O
the	O
other	O
end	O
of	O
the	O
deleted	O
5	O
-	O
kb	O
fragment	O
.	O

A	O
genetic	O
etiology	O
for	O
DiGeorge	B
syndrome	I
:	O
consistent	O
deletions	O
and	O
microdeletions	O
of	O
22q11	O
.	O

DiGeorge	B
syndrome	I
(	O
DGS	B
)	O
,	O
a	O
developmental	O
field	O
defect	O
of	O
the	O
third	O
and	O
fourth	O
pharyngeal	O
pouches	O
,	O
is	O
characterized	O
by	O
aplasia	B
or	I
hypoplasia	I
of	I
the	I
thymus	I
and	I
parathyroid	I
glands	I
and	O
by	O
conotruncal	B
cardiac	I
malformations	I
.	O

Cytogenetic	O
studies	O
support	O
the	O
presence	O
of	O
a	O
DGS	B
critical	O
region	O
in	O
band	O
22q11	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
results	O
of	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
studies	O
of	O
14	O
patients	O
with	O
DGS	B
.	O

Chromosome	O
analysis	O
,	O
utilizing	O
high	O
-	O
resolution	O
banding	O
techniques	O
,	O
detected	O
interstitial	O
deletions	O
in	O
five	O
probands	O
and	O
was	O
inconclusive	O
for	O
a	O
deletion	O
in	O
three	O
probands	O
.	O

The	O
remaining	O
six	O
patients	O
had	O
normal	O
karyotypes	O
.	O

In	O
contrast	O
,	O
molecular	O
analysis	O
detected	O
DNA	O
deletions	O
in	O
all	O
14	O
probands	O
.	O

Two	O
of	O
10	O
loci	O
tested	O
,	O
D22S75	O
and	O
D22S259	O
,	O
are	O
deleted	O
in	O
all	O
14	O
patients	O
.	O

A	O
third	O
locus	O
,	O
D22S66	O
,	O
is	O
deleted	O
in	O
the	O
eight	O
DGS	B
probands	O
tested	O
.	O

Physical	O
mapping	O
using	O
somatic	O
cell	O
hybrids	O
places	O
D22S66	O
between	O
D22S75	O
and	O
D22S259	O
,	O
suggesting	O
that	O
it	O
should	O
be	O
deleted	O
in	O
the	O
remaining	O
six	O
cases	O
.	O

Parent	O
-	O
of	O
-	O
origin	O
studies	O
were	O
performed	O
in	O
five	O
families	O
.	O

Four	O
probands	O
failed	O
to	O
inherit	O
a	O
maternal	O
allele	O
,	O
and	O
one	O
failed	O
to	O
inherit	O
a	O
paternal	O
allele	O
.	O

On	O
the	O
basis	O
of	O
these	O
families	O
,	O
and	O
of	O
six	O
maternally	O
and	O
five	O
paternally	O
derived	O
unbalanced	O
-	O
translocation	O
DGS	B
probands	O
in	O
the	O
literature	O
,	O
parent	O
of	O
origin	O
or	O
imprinting	O
does	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
DGS	B
.	O

Deletion	O
of	O
the	O
same	O
three	O
loci	O
in	O
all	O
14	O
DGS	B
probands	O
begins	O
to	O
delineate	O
the	O
region	O
of	O
chromosome	O
22	O
critical	O
for	O
DGS	B
and	O
confirms	O
the	O
hypothesis	O
that	O
submicroscopic	O
deletions	O
of	O
22q11	O
are	O
etiologic	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
.	O
.	O

Loss	O
of	O
normal	O
allele	O
of	O
the	O
APC	B
gene	O
in	O
an	O
adrenocortical	B
carcinoma	I
from	O
a	O
patient	O
with	O
familial	B
adenomatous	I
polyposis	I
.	O

Endocrine	B
neoplasms	I
have	O
been	O
reported	O
occasionally	O
in	O
patients	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

An	O
adrenocorotical	B
carcinoma	I
was	O
studied	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
FAP	B
.	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
the	O
region	O
close	O
to	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
was	O
detected	O
in	O
this	O
carcinoma	B
,	O
and	O
evidence	O
was	O
obtained	O
that	O
there	O
was	O
a	O
loss	O
of	O
the	O
normal	O
allele	O
of	O
the	O
APC	B
gene	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
LOH	O
at	O
the	O
APC	B
locus	O
in	O
adrenocortical	B
tumors	I
.	O

The	O
present	O
results	O
and	O
our	O
previous	O
data	O
on	O
LOH	O
in	O
a	O
recurring	O
desmoid	B
tumor	I
suggest	O
that	O
the	O
heterozygous	O
mutant	O
/	O
wild	O
-	O
type	O
condition	O
of	O
the	O
APC	B
gene	O
may	O
give	O
rise	O
to	O
benign	B
tumors	I
,	O
and	O
that	O
functional	O
loss	O
of	O
this	O
gene	O
leads	O
to	O
development	O
of	O
tumors	B
not	O
only	O
in	O
the	O
colon	O
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
FAP	B
patients	O
.	O
.	O

Oncogenic	O
point	O
mutations	O
in	O
exon	O
20	O
of	O
the	O
RB1	O
gene	O
in	O
families	O
showing	O
incomplete	O
penetrance	O
and	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

The	O
retinoblastoma	B
-	O
predisposition	O
gene	O
,	O
RB1	O
,	O
segregates	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
high	O
(	O
90	O
%	O
)	O
penetrance	O
.	O

Certain	O
families	O
,	O
however	O
,	O
show	O
an	O
unusual	O
low	O
-	O
penetrance	O
phenotype	O
with	O
many	O
individuals	O
being	O
unaffected	O
,	O
unilaterally	O
affected	O
,	O
or	O
with	O
evidence	O
of	O
spontaneously	O
regressed	O
tumors	B
.	O

We	O
have	O
used	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
PCR	O
sequencing	O
to	O
study	O
two	O
such	O
families	O
.	O

Mutations	O
were	O
found	O
in	O
exon	O
20	O
of	O
RB1	O
in	O
both	O
cases	O
.	O

In	O
one	O
family	O
a	O
C	O
-	O
-	O
-	O
-	O
T	O
transition	O
in	O
codon	O
661	O
converts	O
an	O
arginine	O
(	O
CGG	O
)	O
to	O
a	O
tryptophan	O
(	O
TGG	O
)	O
codon	O
.	O

In	O
this	O
family	O
,	O
incomplete	O
penetrance	O
and	O
mild	O
phenotypic	O
expression	O
were	O
observed	O
in	O
virtually	O
all	O
patients	O
,	O
possibly	O
indicating	O
that	O
single	O
amino	O
acid	O
changes	O
may	O
modify	O
protein	O
structure	O
/	O
function	O
such	O
that	O
tumorigenesis	O
is	O
not	O
inevitable	O
.	O

In	O
the	O
second	O
family	O
the	O
mutation	O
in	O
codon	O
675	O
is	O
a	O
G	O
-	O
-	O
-	O
-	O
T	O
transversion	O
that	O
converts	O
a	O
glutamine	O
(	O
GAA	O
)	O
to	O
a	O
stop	O
(	O
TAA	O
)	O
codon	O
.	O

However	O
,	O
this	O
mutation	O
also	O
occurs	O
near	O
a	O
potential	O
cryptic	O
splice	O
acceptor	O
site	O
,	O
raising	O
the	O
possibility	O
of	O
alternative	O
splicing	O
resulting	O
in	O
a	O
less	O
severely	O
disrupted	O
protein	O
.	O
.	O

Late	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

In	O
that	O
allele	O
arginine84	O
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	O
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	O
activity	O
.	O

A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	O
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
MLD	B
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B
.	O
.	O

Trisomy	B
15	I
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
due	O
to	O
maternal	B
disomy	I
.	O

Uniparental	B
disomy	I
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B
disomy	I
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	B
disomy	I
in	O
a	O
fetus	O
.	O

Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	B
15	I
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O

Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied	O
.	O

The	O
child	O
was	O
hypotonic	B
at	O
birth	O
,	O
and	O
high	O
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11	O
-	O
13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-	O
70	O
%	O
of	O
patients	O
with	O
PWS	B
.	O

Over	O
time	O
,	O
typical	O
features	O
of	O
PWS	B
developed	O
.	O

Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy	O
.	O

Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B
disomy	I
in	O
this	O
case	O
of	O
PWS	B
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
.	O
.	O

Genetic	O
heterogeneity	O
in	O
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
.	O

The	O
AMELX	O
gene	O
located	O
at	O
Xp22	O
.	O

1	O
-	O
p22	O
.	O

3	O
encodes	O
for	O
the	O
enamel	O
protein	O
amelogenin	O
and	O
has	O
been	O
implicated	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
inherited	B
dental	I
abnormality	I
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
(	O
XAI	B
)	O
.	O

Three	O
families	O
with	O
XAI	B
have	O
been	O
investigated	O
using	O
polymorphic	O
DNA	O
markers	O
flanking	O
the	O
position	O
of	O
AMELX	O
.	O

Using	O
two	O
-	O
point	O
linkage	O
analysis	O
,	O
linkage	O
was	O
established	O
between	O
XAI	B
and	O
several	O
of	O
these	O
markers	O
in	O
two	O
families	O
,	O
with	O
a	O
combined	O
lod	O
score	O
of	O
6	O
.	O

05	O
for	O
DXS16	O
at	O
theta	O
=	O
0	O
.	O

04	O
04	O
.	O

This	O
supports	O
the	O
involvement	O
of	O
AMELX	O
,	O
located	O
close	O
to	O
DXS16	O
,	O
in	O
the	O
XAI	B
disease	I
process	O
(	O
AIH1	O
)	O
in	O
those	O
families	O
.	O

Using	O
multipoint	O
linkage	O
analysis	O
,	O
the	O
combined	O
maximum	O
lod	O
score	O
for	O
these	O
two	O
families	O
was	O
7	O
.	O

30	O
for	O
a	O
location	O
of	O
AIH1	O
at	O
2	O
cM	O
distal	O
to	O
DXS16	O
.	O

The	O
support	O
interval	O
around	O
this	O
location	O
extended	O
about	O
8	O
cM	O
proximal	O
to	O
DXS92	O
,	O
and	O
the	O
AIH1	O
location	O
could	O
not	O
be	O
precisely	O
defined	O
by	O
multipoint	O
mapping	O
.	O

Study	O
of	O
recombination	O
events	O
indicated	O
that	O
AIH1	O
lies	O
in	O
the	O
interval	O
between	O
DXS143	O
and	O
DXS85	O
.	O

There	O
was	O
significant	O
evidence	O
against	O
linkage	O
to	O
this	O
region	O
in	O
the	O
third	O
family	O
,	O
indicating	O
locus	O
heterogeneity	O
in	O
XAI	B
.	O

Further	O
analysis	O
with	O
markers	O
on	O
the	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
showed	O
evidence	O
of	O
linkage	O
to	O
DXS144E	O
and	O
F9	O
with	O
no	O
recombination	O
with	O
either	O
of	O
these	O
markers	O
.	O

Two	O
-	O
point	O
analysis	O
gave	O
a	O
peak	O
lod	O
score	O
at	O
DXS144E	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
2	O
.	O

83	O
at	O
theta	O
=	O
0	O
,	O
with	O
a	O
peak	O
lod	O
score	O
in	O
multipoint	O
linkage	O
analysis	O
of	O
2	O
.	O

84	O
at	O
theta	O
=	O
0	O
.	O

The	O
support	O
interval	O
extended	O
9	O
cM	O
proximal	O
to	O
DXS144E	O
and	O
14	O
cM	O
distal	O
to	O
F9	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Multiple	O
origins	O
for	O
phenylketonuria	B
in	O
Europe	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
,	O
a	O
disorder	B
of	I
amino	I
acid	I
metabolism	I
prevalent	O
among	O
Caucasians	O
and	O
other	O
ethnic	O
groups	O
,	O
is	O
caused	O
primarily	O
by	O
a	O
deficiency	B
of	I
the	I
hepatic	I
enzyme	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

PKU	B
is	O
a	O
highly	O
heterogeneous	O
disorder	O
,	O
with	O
more	O
than	O
60	O
molecular	O
lesions	O
identified	O
in	O
the	O
PAH	O
gene	O
.	O

The	O
haplotype	O
associations	O
,	O
relative	O
frequencies	O
,	O
and	O
distributions	O
of	O
five	O
prevalent	O
PAH	O
mutations	O
(	O
R158Q	O
,	O
R261Q	O
,	O
IVS10nt546	O
,	O
R408W	O
,	O
and	O
IVS12n1	O
)	O
were	O
established	O
in	O
a	O
comprehensive	O
European	O
sample	O
population	O
and	O
subsequently	O
were	O
examined	O
to	O
determine	O
the	O
potential	O
roles	O
of	O
several	O
genetic	O
mechanisms	O
in	O
explaining	O
the	O
present	O
distribution	O
of	O
the	O
major	O
PKU	B
alleles	O
.	O

Each	O
of	O
these	O
five	O
mutations	O
was	O
strongly	O
associated	O
with	O
only	O
one	O
of	O
the	O
more	O
than	O
70	O
chromosomal	O
haplotypes	O
defined	O
by	O
eight	O
RFLPs	O
in	O
or	O
near	O
the	O
PAH	O
gene	O
.	O

These	O
findings	O
suggest	O
that	O
each	O
of	O
these	O
mutations	O
arose	O
through	O
a	O
single	O
founding	O
event	O
that	O
occurred	O
within	O
time	O
periods	O
ranging	O
from	O
several	O
hundred	O
to	O
several	O
thousand	O
years	O
ago	O
.	O

From	O
the	O
significant	O
differences	O
observed	O
in	O
the	O
relative	O
frequencies	O
and	O
distributions	O
of	O
these	O
five	O
alleles	O
throughout	O
Europe	O
,	O
four	O
of	O
these	O
putative	O
founding	O
events	O
could	O
be	O
localized	O
to	O
specific	O
ethnic	O
subgroups	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
there	O
were	O
multiple	O
,	O
geographically	O
and	O
ethnically	O
distinct	O
origins	O
for	O
PKU	B
within	O
the	O
European	O
population	O
.	O
.	O

Complement	B
factor	I
2	I
deficiency	I
:	O
a	O
clinical	O
and	O
serological	O
family	O
study	O
.	O

Inherited	B
complement	I
deficiencies	I
are	O
associated	O
with	O
a	O
variety	O
of	O
connective	O
tissue	O
diseases	O
.	O

A	O
family	O
with	O
inherited	B
deficiency	I
of	I
complement	I
factor	I
2	I
(	O
C2	O
)	O
is	O
described	O
in	O
which	O
two	O
family	O
members	O
with	O
homozygous	O
C2	B
deficiency	I
developed	O
cutaneous	B
vasculitis	I
and	O
sicca	B
syndrome	I
.	O

The	O
other	O
family	O
members	O
had	O
heterozygous	O
C2	B
deficiency	I
and	O
each	O
member	O
had	O
the	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
DR2	O
(	O
w15	O
)	O
haplotype	O
.	O

The	O
mother	O
had	O
seropositive	B
rheumatoid	I
arthritis	I
.	O

Further	O
studies	O
showed	O
the	O
presence	O
of	O
cryoglobulins	O
,	O
antibodies	O
against	O
endothelial	O
cells	O
,	O
and	O
anticardiolipin	O
antibodies	O
.	O
.	O

New	O
variant	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
a	O
family	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

A	O
C	O
-	O
-	O
greater	O
than	O
G	O
transversion	O
has	O
been	O
found	O
in	O
exon	O
3	O
of	O
the	O
PLP	O
gene	O
of	O
affected	O
males	O
and	O
their	O
mother	O
in	O
a	O
single	O
sibship	O
with	O
Pelizaeus	B
-	I
merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

The	O
transversion	O
should	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
in	O
the	O
protein	O
but	O
it	O
does	O
result	O
in	O
the	O
loss	O
of	O
a	O
HaeIII	O
restriction	O
endonuclease	O
cleavage	O
site	O
.	O

It	O
is	O
concordant	O
with	O
the	O
disease	O
in	O
this	O
family	O
.	O

One	O
-	O
hundred	O
-	O
ten	O
unrelated	O
X	O
chromosomes	O
are	O
negative	O
for	O
this	O
mutation	O
.	O

No	O
other	O
sequence	O
defect	O
was	O
found	O
in	O
the	O
PLP	O
exons	O
of	O
the	O
affected	O
males	O
.	O

The	O
cause	O
of	O
disease	O
in	O
this	O
family	O
remains	O
unknown	O
,	O
but	O
the	O
association	O
between	O
this	O
rare	O
mutation	O
and	O
PMD	B
is	O
intriguing	O
.	O

The	O
mutation	O
can	O
serve	O
as	O
a	O
marker	O
for	O
following	O
segregation	O
of	O
the	O
PLP	O
gene	O
.	O
.	O

Uncoupling	O
of	O
hypomyelination	B
and	O
glial	B
cell	I
death	I
by	O
a	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
gene	O
.	O

Proteolipid	O
protein	O
(	O
PLP	O
;	O
M	O
(	O
r	O
)	O
30	O
,	O
000	O
)	O
is	O
a	O
highly	O
conserved	O
major	O
polytopic	O
membrane	O
protein	O
in	O
myelin	O
but	O
its	O
cellular	O
function	O
remains	O
obscure	O
.	O

Neurological	O
mutant	O
mice	O
can	O
often	O
provide	O
model	O
systems	O
for	O
human	O
genetic	B
disorders	I
.	O

Mutations	O
of	O
the	O
X	O
-	O
chromosome	O
-	O
linked	O
PLP	O
gene	O
are	O
lethal	O
,	O
identified	O
first	O
in	O
the	O
jimpy	O
mouse	O
and	O
subsequently	O
in	O
patients	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

The	O
unexplained	O
phenotype	O
of	O
these	O
mutations	O
includes	O
degeneration	B
and	I
premature	I
cell	I
death	I
of	I
oligodendrocytes	I
with	O
associated	O
hypomyelination	B
.	O

Here	O
we	O
show	O
that	O
a	O
new	O
mouse	O
mutant	O
rumpshaker	O
is	O
defined	O
by	O
the	O
amino	O
-	O
acid	O
substitution	O
Ile	O
-	O
to	O
-	O
Thr	O
at	O
residue	O
186	O
in	O
a	O
membrane	O
-	O
embedded	O
domain	O
of	O
PLP	O
.	O

Surprisingly	O
,	O
rumpshaker	O
mice	O
,	O
although	O
myelin	B
-	I
deficient	I
,	O
have	O
normal	O
longevity	O
and	O
a	O
full	O
complement	O
of	O
morphologically	O
normal	O
oligodendrocytes	O
.	O

Hypomyelination	B
can	O
thus	O
be	O
genetically	O
separated	O
from	O
the	O
PLP	O
-	O
dependent	O
oligodendrocyte	B
degeneration	I
.	O

We	O
suggest	O
that	O
PLP	O
has	O
a	O
vital	O
function	O
in	O
glial	O
cell	O
development	O
,	O
distinct	O
from	O
its	O
later	O
role	O
in	O
myelin	O
assembly	O
,	O
and	O
that	O
this	O
dichotomy	O
of	O
action	O
may	O
explain	O
the	O
clinical	O
spectrum	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O
.	O

A	O
pseudodeficiency	O
allele	O
common	O
in	O
non	O
-	O
Jewish	O
Tay	B
-	I
Sachs	I
carriers	O
:	O
implications	O
for	O
carrier	O
screening	O
.	O

Deficiency	B
of	I
beta	I
-	I
hexosaminidase	I
A	I
(	O
Hex	O
A	O
)	O
activity	O
typically	O
results	O
in	O
Tay	B
-	I
Sachs	I
disease	I
.	O

However	O
,	O
healthy	O
subjects	O
found	O
to	O
be	O
deficient	B
in	I
Hex	I
A	I
activity	O
(	O
i	O
.	O
e	O
.	O
,	O
pseudodeficient	O
)	O
by	O
means	O
of	O
in	O
vitro	O
biochemical	O
tests	O
have	O
been	O
described	O
.	O

We	O
analyzed	O
the	O
HEXA	O
gene	O
of	O
one	O
pseudodeficient	O
subject	O
and	O
identified	O
both	O
a	O
C739	O
-	O
to	O
-	O
T	O
substitution	O
that	O
changes	O
Arg247	O
-	O
-	O
-	O
-	O
Trp	O
on	O
one	O
allele	O
and	O
a	O
previously	O
identified	O
Tay	B
-	I
Sachs	I
disease	I
mutation	O
on	O
the	O
second	O
allele	O
.	O

Six	O
additional	O
pseudodeficient	O
subjects	O
were	O
found	O
to	O
have	O
the	O
C739	O
-	O
to	O
-	O
T	O
mutation	O
.	O

This	O
allele	O
accounted	O
for	O
32	O
%	O
(	O
20	O
/	O
62	O
)	O
of	O
non	O
-	O
Jewish	O
enzyme	O
-	O
defined	O
Tay	B
-	I
Sachs	I
disease	I
carriers	O
but	O
for	O
none	O
of	O
36	O
Jewish	O
enzyme	O
-	O
defined	O
carriers	O
who	O
did	O
not	O
have	O
one	O
of	O
three	O
known	O
mutations	O
common	O
to	O
this	O
group	O
.	O

The	O
C739	O
-	O
to	O
-	O
T	O
allele	O
,	O
together	O
with	O
a	O
"	O
true	O
"	O
Tay	B
-	I
Sachs	I
disease	I
allele	O
,	O
causes	O
Hex	O
A	O
pseudodeficiency	O
.	O

Given	O
both	O
the	O
large	O
proportion	O
of	O
non	O
-	O
Jewish	O
carriers	O
with	O
this	O
allele	O
and	O
that	O
standard	O
biochemical	O
screening	O
cannot	O
differentiate	O
between	O
heterozygotes	O
for	O
the	O
C739	O
-	O
to	O
-	O
T	O
mutations	O
and	O
Tay	B
-	I
Sachs	I
disease	I
carriers	O
,	O
DNA	O
testing	O
for	O
this	O
mutation	O
in	O
at	O
-	O
risk	O
couples	O
is	O
essential	O
.	O

Pelizaeus	B
-	I
Merzbacher	I
disease	I
:	O
detection	O
of	O
mutations	O
Thr181	O
-	O
-	O
-	O
-	O
Pro	O
and	O
Leu223	O
-	O
-	O
-	O
-	O
Pro	O
in	O
the	O
proteolipid	O
protein	O
gene	O
,	O
and	O
prenatal	O
diagnosis	O
.	O

A	O
family	O
with	O
an	O
apparent	O
history	O
of	O
X	O
-	O
linked	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
presented	O
for	O
genetic	O
counseling	O
,	O
requesting	O
carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
.	O

RFLP	O
analysis	O
using	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
probe	O
was	O
uninformative	O
in	O
this	O
family	O
.	O

A	O
prenatal	O
diagnosis	O
on	O
a	O
chorionic	O
villus	O
sample	O
(	O
CVS	O
)	O
was	O
carried	O
out	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
of	O
a	O
variant	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
.	O

The	O
fetus	O
was	O
predicted	O
to	O
be	O
unaffected	O
.	O

Sequencing	O
of	O
the	O
exon	O
from	O
the	O
CVS	O
,	O
the	O
predicted	O
-	O
carrier	O
mother	O
,	O
and	O
the	O
obligate	O
-	O
carrier	O
grandmother	O
revealed	O
an	O
A	O
-	O
to	O
-	O
C	O
change	O
at	O
nucleotide	O
541	O
in	O
the	O
two	O
women	O
but	O
not	O
in	O
the	O
fetus	O
.	O

As	O
this	O
change	O
results	O
in	O
a	O
Thr	O
-	O
to	O
-	O
Pro	O
change	O
at	O
amino	O
acid	O
181	O
in	O
a	O
region	O
of	O
the	O
gene	O
predicted	O
to	O
be	O
part	O
of	O
a	O
transmembrane	O
segment	O
,	O
it	O
was	O
concluded	O
that	O
this	O
was	O
the	O
mutation	O
causing	O
the	O
disease	O
in	O
this	O
family	O
.	O

In	O
addition	O
,	O
in	O
a	O
second	O
family	O
,	O
an	O
exon	O
5	O
variant	O
band	O
pattern	O
on	O
SSCP	O
analysis	O
was	O
shown	O
by	O
sequencing	O
to	O
be	O
due	O
to	O
a	O
T	O
-	O
to	O
-	O
C	O
change	O
at	O
nucleotide	O
668	O
.	O

This	O
results	O
in	O
a	O
Leu	O
-	O
to	O
-	O
Pro	O
change	O
in	O
a	O
carrier	O
mother	O
and	O
in	O
her	O
two	O
affected	O
sons	O
.	O

These	O
results	O
provide	O
further	O
examples	O
of	O
mutations	O
in	O
PLP	O
that	O
cause	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
and	O
illustrate	O
the	O
value	O
of	O
SSCP	O
in	O
genetic	O
analysis	O
.	O
.	O

von	B
Willebrand	I
disease	I
type	I
B	I
:	O
a	O
missense	O
mutation	O
selectively	O
abolishes	O
ristocetin	O
-	O
induced	O
von	B
Willebrand	I
factor	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib	O
.	O

von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
mediates	O
the	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
by	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib	O
.	O

For	O
human	O
vWF	O
,	O
this	O
interaction	O
can	O
be	O
induced	O
in	O
vitro	O
by	O
the	O
antibiotic	O
ristocetin	O
or	O
the	O
snake	O
venom	O
protein	O
botrocetin	O
.	O

A	O
missense	O
mutation	O
,	O
Gly	O
-	O
561	O
-	O
-	O
>	O
Ser	O
,	O
was	O
identified	O
within	O
the	O
proposed	O
glycoprotein	O
Ib	O
binding	O
domain	O
of	O
vWF	O
in	O
the	O
proband	O
with	O
von	B
Willebrand	I
disease	I
type	I
B	I
,	O
a	O
unique	O
variant	O
characterized	O
by	O
no	O
ristocetin	O
-	O
induced	O
,	O
but	O
normal	O
botrocetin	O
-	O
induced	O
,	O
binding	O
to	O
glycoprotein	O
Ib	O
.	O

The	O
corresponding	O
mutant	O
recombinant	O
protein	O
,	O
rvWF	O
(	O
G561S	O
)	O
,	O
formed	O
normal	O
multimers	O
and	O
exhibited	O
the	O
same	O
functional	O
defect	O
as	O
the	O
patients	O
plasma	O
vWF	O
,	O
confirming	O
that	O
this	O
mutation	O
causes	O
von	B
Willebrand	I
disease	I
type	I
B	I
.	O

These	O
data	O
show	O
that	O
botrocetin	O
and	O
ristocetin	O
cofactor	O
activities	O
of	O
vWF	O
can	O
be	O
dissociated	O
by	O
a	O
point	O
mutation	O
and	O
confirm	O
that	O
these	O
mediators	O
promote	O
vWF	O
binding	O
to	O
platelets	O
by	O
different	O
mechanisms	O
.	O

The	O
normal	O
botrocetin	O
-	O
induced	O
binding	O
and	O
the	O
defective	O
ristocetin	O
-	O
induced	O
binding	O
of	O
rvWF	O
(	O
G561S	O
)	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
von	B
Willebrand	I
disease	I
type	I
B	I
may	O
be	O
a	O
failure	O
of	O
normal	O
allosteric	O
regulation	O
of	O
the	O
glycoprotein	O
Ib	O
binding	O
function	O
of	O
vWF	O
.	O
.	O

Typical	O
and	O
partial	O
cat	B
eye	I
syndrome	I
:	O
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
FISH	O
.	O

Three	O
children	O
are	O
reported	O
with	O
typical	O
cat	B
eye	I
syndrome	I
(	O
CES	B
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	B
because	O
of	O
absence	O
of	O
coloboma	O
,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
FISH	O
.	O

Using	O
a	O
genomic	O
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B
was	O
shown	O
in	O
all	O
cases	O
.	O
.	O

[	O
Genetic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
:	O
mutant	O
alleles	O
of	O
G6PD	O
in	O
the	O
Shekii	O
district	O
of	O
Azerbaijan	O
]	O

Examination	O
on	O
G6PD	B
deficiency	I
in	O
349	O
patients	O
of	O
Shekii	O
district	O
hospital	O
(	O
Azerbaijan	O
)	O
revealed	O
16	O
hemi	O
-	O
,	O
4	O
homo	O
-	O
and	O
9	O
heterozygotic	O
carriers	O
of	O
the	O
defect	O
.	O

Gd	O
-	O
frequency	O
,	O
calculated	O
from	O
the	O
data	O
obtained	O
(	O
7	O
.	O
7	O
%	O
)	O
,	O
may	O
be	O
compared	O
to	O
neighbouring	O
regions	O
frequencies	O
(	O
6	O
-	O
30	O
%	O
)	O
.	O

Carriers	O
of	O
G6PD	B
deficiency	I
are	O
residents	O
of	O
11	O
villages	O
located	O
in	O
Alasani	O
-	O
Aphtalan	O
valley	O
,	O
highly	O
endemic	O
with	O
malaria	B
in	O
the	O
past	O
;	O
nearly	O
all	O
marriages	O
are	O
endogamic	O
.	O

Physico	O
-	O
chemical	O
and	O
kinetic	O
study	O
of	O
10	O
mutant	O
forms	O
of	O
G6PD	O
,	O
according	O
to	O
WHO	O
program	O
,	O
led	O
to	O
identification	O
of	O
5	O
variants	O
of	O
the	O
II	O
class	O
(	O
Shekii	O
,	O
Bideiz	O
,	O
Shirin	O
-	O
Bulakh	O
,	O
Okhut	O
I	O
and	O
Zakataly	O
)	O
and	O
2	O
variants	O
of	O
the	O
III	O
class	O
(	O
Okhut	O
II	O
and	O
Martinique	O
-	O
like	O
)	O
.	O

Resemblance	O
of	O
the	O
majority	O
of	O
variants	O
in	O
electrophoretic	O
mobility	O
and	O
the	O
level	O
of	O
erythrocyte	O
enzyme	O
activity	O
permit	O
to	O
suggest	O
the	O
existence	O
of	O
a	O
common	O
parental	O
mutant	O
G6PD	O
allele	O
distributed	O
in	O
this	O
area	O
.	O

Craniofrontonasal	B
dysplasia	I
.	O

We	O
report	O
on	O
nine	O
patients	O
with	O
craniofrontonasal	B
dysplasia	I
(	O
CFND	B
)	O
.	O

Seven	O
classical	O
cases	O
had	O
facial	O
features	O
suggestive	O
of	O
frontonasal	B
dysplasia	I
and	O
coronal	B
craniosynostosis	I
.	O

Extracranial	B
abnormalities	I
such	O
as	O
brittle	B
nails	I
with	I
prominent	I
longitudinal	I
grooves	I
or	O
syndactyly	B
of	I
fingers	I
and	I
toes	I
were	O
observed	O
in	O
individual	O
patients	O
.	O

In	O
two	O
families	O
the	O
father	O
of	O
classical	O
cases	O
showed	O
a	O
milder	O
pattern	O
of	O
abnormalities	O
,	O
consistent	O
with	O
the	O
diagnosis	O
.	O

We	O
present	O
a	O
2	O
-	O
to	O
13	O
-	O
year	O
follow	O
-	O
up	O
on	O
our	O
patients	O
.	O

Hypotonia	B
and	O
laxity	B
of	I
joints	I
are	O
common	O
and	O
may	O
necessitate	O
supportive	O
measures	O
.	O

Mild	O
developmental	B
delay	I
was	O
noted	O
in	O
three	O
out	O
of	O
six	O
classical	O
cases	O
studied	O
in	O
detail	O
.	O

Unlike	O
almost	O
all	O
other	O
X	B
-	I
linked	I
disorders	I
,	O
clinical	O
expression	O
in	O
CFND	B
is	O
generally	O
much	O
more	O
severe	O
in	O
females	O
than	O
in	O
males	O
.	O

In	O
contrast	O
to	O
previous	O
reports	O
of	O
this	O
condition	O
,	O
one	O
of	O
our	O
severely	O
affected	O
cases	O
is	O
a	O
male	O
.	O
.	O

The	O
intron	O
7	O
donor	O
splice	O
site	O
transition	O
:	O
a	O
second	O
Tay	B
-	I
Sachs	I
disease	I
mutation	O
in	O
French	O
Canada	O
.	O

Mutations	O
at	O
the	O
hexosaminidase	O
A	O
(	O
HEXA	O
)	O
gene	O
which	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
have	O
elevated	O
frequency	O
in	O
the	O
Ashkenazi	O
Jewish	O
and	O
French	O
-	O
Canadian	O
populations	O
.	O

We	O
report	O
a	O
novel	O
TSD	B
allele	O
in	O
the	O
French	O
-	O
Canadian	O
population	O
associated	O
with	O
the	O
infantile	O
form	O
of	O
the	O
disease	O
.	O

The	O
mutation	O
,	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
the	O
+	O
1	O
position	O
of	O
intron	O
7	O
,	O
abolishes	O
the	O
donor	O
splice	O
site	O
.	O

Cultured	O
human	O
fibroblasts	O
from	O
a	O
compound	O
heterozygote	O
for	O
this	O
transition	O
(	O
and	O
for	O
a	O
deletion	O
mutation	O
)	O
produce	O
no	O
detectable	O
HEXA	O
mRNA	O
.	O

The	O
intron	O
7	O
+	O
1	O
mutation	O
occurs	O
in	O
the	O
base	O
adjacent	O
to	O
the	O
site	O
of	O
the	O
adult	O
-	O
onset	O
TSD	B
mutation	O
(	O
G805A	O
)	O
.	O

In	O
both	O
mutations	O
a	O
restriction	O
site	O
for	O
the	O
endonuclease	O
EcoRII	O
is	O
abolished	O
.	O

Unambiguous	O
diagnosis	O
,	O
therefore	O
,	O
requires	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
to	O
distinguish	O
between	O
these	O
two	O
mutant	O
alleles	O
.	O

The	O
intron	O
7	O
+	O
1	O
mutation	O
has	O
been	O
detected	O
in	O
three	O
unrelated	O
families	O
.	O

Obligate	O
heterozygotes	O
for	O
the	O
intron	O
7	O
+	O
1	O
mutation	O
were	O
born	O
in	O
the	O
Saguenay	O
-	O
Lac	O
-	O
St	O
-	O
Jean	O
region	O
of	O
Quebec	O
.	O

The	O
most	O
recent	O
ancestors	O
common	O
to	O
obligate	O
carriers	O
of	O
this	O
mutation	O
were	O
from	O
the	O
Charlevoix	O
region	O
of	O
the	O
province	O
of	O
Quebec	O
.	O

This	O
mutation	O
thus	O
has	O
a	O
different	O
geographic	O
centre	O
of	O
diffusion	O
and	O
is	O
probably	O
less	O
common	O
than	O
the	O
exon	O
1	O
deletion	O
TSD	B
mutation	O
in	O
French	O
Canadians	O
.	O

Neither	O
mutation	O
has	O
been	O
detected	O
in	O
France	O
,	O
the	O
ancestral	O
homeland	O
of	O
French	O
Canada	O
.	O
.	O

Assignment	O
of	O
the	O
aspartylglucosaminidase	O
gene	O
(	O
AGA	O
)	O
to	O
4q33	O
-	O
-	O
-	O
-	O
q35	O
based	O
on	O
decreased	O
activity	O
in	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
recessive	O
autosomally	O
inherited	O
lysosomal	B
storage	I
disorder	I
due	O
to	O
deficiency	B
of	I
the	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
this	O
human	O
enzyme	O
(	O
AGA	O
)	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21	O
-	O
-	O
-	O
-	O
qter	O
.	O

We	O
determined	O
the	O
AGA	O
activity	O
in	O
cultured	O
fibroblasts	O
of	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

The	O
results	O
indicate	O
that	O
the	O
girl	O
is	O
a	O
hemizygote	O
for	O
AGA	O
,	O
permitting	O
the	O
assignment	O
of	O
human	O
AGA	O
to	O
the	O
region	O
4q33	O
-	O
-	O
-	O
-	O
qter	O
.	O
.	O

Resolution	O
of	O
the	O
two	O
loci	O
for	O
autosomal	O
dominant	O
aniridia	B
,	O
AN1	O
and	O
AN2	O
,	O
to	O
a	O
single	O
locus	O
on	O
chromosome	O
11p13	O
.	O

Two	O
distinct	O
loci	O
have	O
been	O
proposed	O
for	O
aniridia	B
;	O
AN1	O
for	O
autosomal	O
dominant	O
aniridia	B
on	O
chromosome	O
2p	O
and	O
AN2	O
for	O
the	O
aniridia	B
in	O
the	O
WAGR	B
contiguous	I
gene	I
syndrome	I
on	O
chromosome	O
11p13	O
.	O

In	O
this	O
report	O
,	O
the	O
kindred	O
segregating	O
for	O
autosomal	O
dominant	O
aniridia	B
,	O
which	O
suggested	O
linkage	O
to	O
acid	O
phosphatase	O
-	O
1	O
(	O
ACP1	O
)	O
and	O
led	O
to	O
the	O
assignment	O
of	O
the	O
AN1	O
locus	O
on	O
chromosome	O
2p	O
,	O
has	O
been	O
updated	O
and	O
expanded	O
.	O

Linkage	O
analysis	O
between	O
the	O
aniridia	B
phenotype	O
and	O
ACP1	O
does	O
not	O
support	O
the	O
original	O
linkage	O
results	O
,	O
excluding	O
linkage	O
up	O
to	O
theta	O
=	O
0	O
.	O

17	O
with	O
Z	O
=	O
-	O
2	O
.	O

Tests	O
for	O
linkage	O
to	O
other	O
chromosome	O
2p	O
markers	O
.	O

APOB	O
,	O
D2S71	O
,	O
D2S5	O
,	O
and	O
D2S1	O
,	O
also	O
excluded	O
linkage	O
to	O
aniridia	B
.	O

Markers	O
that	O
have	O
been	O
isolated	O
from	O
the	O
chromosome	O
11p13	O
region	O
were	O
then	O
analyzed	O
in	O
this	O
aniridia	B
family	O
.	O

Two	O
RFLPs	O
at	O
the	O
D11S323	O
locus	O
give	O
significant	O
evidence	O
for	O
linkage	O
.	O

The	O
PvuII	O
polymorphism	O
detected	O
by	O
probe	O
p5S1	O
.	O

6	O
detects	O
no	O
recombinants	O
,	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
6	O
.	O

97	O
at	O
theta	O
=	O
0	O
.	O

00	O
00	O
.	O

The	O
HaeIII	O
polymorphism	O
detected	O
by	O
the	O
probe	O
p5BE1	O
.	O

2	O
gives	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
2	O
.	O

57	O
at	O
theta	O
=	O
0	O
.	O

00	O
00	O
.	O

Locus	O
D11S325	O
gives	O
a	O
lod	O
score	O
of	O
Z	O
=	O
1	O
.	O

53	O
at	O
theta	O
=	O
0	O
.	O

00	O
00	O
.	O

These	O
data	O
suggest	O
that	O
a	O
locus	O
for	O
aniridia	B
(	O
AN1	O
)	O
on	O
chromosome	O
2p	O
has	O
been	O
misassigned	O
and	O
that	O
this	O
autosomal	O
dominant	O
aniridia	B
family	O
is	O
segregating	O
for	O
an	O
aniridia	B
mutation	O
linked	O
to	O
markers	O
in	O
the	O
11p13	O
region	O
.	O

Fatal	O
pyoderma	B
gangrenosum	I
in	O
association	O
with	O
C7	B
deficiency	I
.	O

Although	O
pyoderma	B
gangrenosum	I
(	O
PG	B
)	O
is	O
often	O
associated	O
with	O
systemic	B
diseases	I
,	O
it	O
has	O
not	O
been	O
reported	O
in	O
association	O
with	O
congenital	B
complement	I
deficiencies	I
.	O

We	O
describe	O
an	O
aggressive	O
and	O
ultimately	O
fatal	O
case	O
of	O
PG	B
in	O
a	O
patient	O
with	O
a	O
congenital	O
C7	B
deficiency	I
.	O

Deficiencies	B
of	I
C7	I
can	O
be	O
associated	O
with	O
decreased	O
neutrophil	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
opsonization	O
,	O
similar	O
to	O
the	O
immunologic	B
abnormalities	I
described	O
in	O
patients	O
with	O
PG	B
.	O

Our	O
patients	O
decreased	O
complement	O
level	O
,	O
if	O
not	O
directly	O
related	O
to	O
the	O
development	O
of	O
PG	B
,	O
may	O
have	O
contributed	O
to	O
the	O
aggressive	O
nature	O
of	O
her	O
disease	O
.	O
.	O

Diverse	O
point	O
mutations	O
result	O
in	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
polymorphism	O
in	O
Taiwan	O
.	O

Glucose	B
-	I
6	I
-	I
PHOSPHATE	I
dehydrogenase	I
(	I
G6PD	I
;	I
EC	I
1	I
.	I
1	I
.	I
1	I
.	I
49	I
)	I
deficiency	I
is	O
the	O
most	O
common	O
human	O
enzymopathy	B
,	O
affecting	O
more	O
than	O
200	O
million	O
people	O
worldwide	O
.	O

Although	O
greater	O
than	O
400	O
variants	O
have	O
been	O
described	O
based	O
on	O
clinical	O
and	O
biochemical	O
criteria	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
basis	O
of	O
these	O
G6PD	B
deficiencies	I
.	O

Recently	O
,	O
the	O
gene	O
that	O
encodes	O
human	O
G6PD	O
has	O
been	O
cloned	O
and	O
sequenced	O
,	O
which	O
enables	O
us	O
to	O
examine	O
directly	O
the	O
heterogeneity	O
of	O
G6PD	O
at	O
the	O
DNA	O
level	O
.	O

During	O
the	O
past	O
10	O
years	O
,	O
we	O
examined	O
the	O
G6PD	O
activity	O
in	O
21	O
,	O
271	O
newborn	O
Chinese	O
infants	O
(	O
11	O
,	O
400	O
males	O
and	O
9	O
,	O
871	O
females	O
)	O
and	O
identified	O
314	O
(	O
2	O
.	O
8	O
%	O
)	O
males	O
and	O
246	O
(	O
2	O
.	O
5	O
%	O
)	O
females	O
having	O
low	O
G6PD	O
activity	O
.	O

The	O
G6PD	O
gene	O
from	O
10	O
randomly	O
selected	O
affected	O
individuals	O
and	O
their	O
relatives	O
was	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
,	O
subcloned	O
,	O
and	O
sequenced	O
.	O

Our	O
results	O
indicate	O
that	O
at	O
least	O
four	O
types	O
of	O
mutation	O
are	O
responsible	O
for	O
the	O
G6PD	O
polymorphism	O
in	O
Taiwan	O
.	O

The	O
first	O
type	O
of	O
mutation	O
(	O
487	O
G	O
-	O
-	O
-	O
-	O
A	O
)	O
was	O
found	O
in	O
an	O
affected	O
Chinese	O
with	O
a	O
G	O
to	O
A	O
change	O
at	O
nucleotide	O
487	O
,	O
which	O
results	O
in	O
a	O
(	O
163	O
)	O
Gly	O
to	O
Ser	O
substitution	O
.	O

The	O
second	O
type	O
of	O
mutation	O
(	O
493	O
A	O
-	O
-	O
-	O
-	O
G	O
)	O
is	O
a	O
novel	O
mutation	O
that	O
has	O
not	O
been	O
reported	O
in	O
any	O
other	O
ethnic	O
group	O
and	O
was	O
identified	O
in	O
two	O
affected	O
Chinese	O
.	O

This	O
mutation	O
causes	O
an	O
A	O
to	O
G	O
change	O
at	O
nucleotide	O
position	O
493	O
,	O
producing	O
an	O
(	O
165	O
)	O
Asn	O
to	O
Asp	O
substitution	O
.	O

Interestingly	O
,	O
the	O
487	O
G	O
-	O
-	O
-	O
-	O
A	O
and	O
493	O
A	O
-	O
-	O
-	O
-	O
G	O
mutations	O
create	O
Alu	O
I	O
and	O
Ava	O
II	O
recognition	O
sites	O
,	O
respectively	O
,	O
which	O
enabled	O
us	O
to	O
rapidly	O
detect	O
these	O
two	O
mutations	O
by	O
PCR	O
/	O
restriction	O
enzyme	O
(	O
RE	O
)	O
digestion	O
method	O
.	O

The	O
third	O
mutation	O
(	O
1376	O
G	O
-	O
-	O
-	O
-	O
T	O
)	O
was	O
found	O
in	O
four	O
affected	O
Chinese	O
.	O

This	O
mutation	O
causes	O
a	O
G	O
to	O
T	O
change	O
at	O
nucleotide	O
position	O
1376	O
that	O
results	O
in	O
an	O
(	O
459	O
)	O
Arg	O
to	O
Leu	O
substitution	O
.	O

The	O
1376	O
G	O
-	O
-	O
-	O
-	O
T	O
mutation	O
seems	O
to	O
be	O
the	O
dominant	O
allele	O
that	O
causes	O
G6PD	B
deficiency	I
in	O
Taiwan	O
.	O

Finally	O
,	O
two	O
affected	O
Chinese	O
were	O
identified	O
as	O
having	O
the	O
fourth	O
mutation	O
(	O
1388	O
G	O
-	O
-	O
-	O
-	O
A	O
)	O
.	O

This	O
mutation	O
causes	O
a	O
G	O
to	O
A	O
change	O
at	O
nucleotide	O
1388	O
that	O
produces	O
an	O
(	O
463	O
)	O
Arg	O
to	O
His	O
substitution	O
.	O

Our	O
studies	O
provide	O
the	O
direct	O
proof	O
of	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
in	O
the	O
Chinese	O
populations	O
of	O
Taiwan	O
and	O
the	O
PCR	O
/	O
RE	O
digestion	O
method	O
is	O
suitable	O
for	O
simultaneous	O
detection	O
of	O
the	O
487	O
G	O
-	O
-	O
-	O
-	O
A	O
and	O
493	O
A	O
-	O
-	O
-	O
-	O
G	O
mutations	O
.	O

An	O
error	O
in	O
dystrophin	O
mRNA	O
processing	O
in	O
golden	B
retriever	I
muscular	I
dystrophy	I
,	O
an	O
animal	O
homologue	O
of	O
Duchenne	B
muscular	I
dystrophy	I
.	O

Golden	B
retriever	I
muscular	I
dystrophy	I
(	O
GRMD	B
)	O
is	O
a	O
spontaneous	O
,	O
X	O
-	O
linked	O
,	O
progressively	O
fatal	O
disease	O
of	O
dogs	O
and	O
is	O
also	O
a	O
homologue	O
of	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

Two	O
-	O
thirds	O
of	O
DMD	B
patients	O
carry	O
detectable	O
deletions	O
in	O
their	O
dystrophin	O
gene	O
.	O

The	O
defect	O
underlying	O
the	O
remaining	O
one	O
-	O
third	O
of	O
DMD	B
patients	O
is	O
undetermined	O
.	O

Analysis	O
of	O
the	O
canine	O
dystrophin	O
gene	O
in	O
normal	O
and	O
GRMD	B
dogs	O
has	O
failed	O
to	O
demonstrate	O
any	O
detectable	O
loss	O
of	O
exons	O
.	O

Here	O
,	O
we	O
have	O
demonstrated	O
a	O
RNA	O
processing	O
error	O
in	O
GRMD	B
that	O
results	O
from	O
a	O
single	O
base	O
change	O
in	O
the	O
3	O
consensus	O
splice	O
site	O
of	O
intron	O
6	O
.	O

The	O
seventh	O
exon	O
is	O
then	O
skipped	O
,	O
which	O
predicts	O
a	O
termination	O
of	O
the	O
dystrophin	O
reading	O
frame	O
within	O
its	O
N	O
-	O
terminal	O
domain	O
in	O
exon	O
8	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
dystrophin	B
deficiency	I
caused	O
by	O
a	O
splice	O
-	O
site	O
mutation	O
.	O
.	O

Type	B
I	I
human	I
complement	I
C2	I
deficiency	I
.	O

A	O
28	O
-	O
base	O
pair	O
gene	O
deletion	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing	O
.	O

Two	O
variants	O
of	O
a	O
genetic	O
deficiency	B
of	I
complement	I
protein	I
C2	I
(	O
C2D	O
)	O
have	O
been	O
previously	O
identified	O
.	O

No	O
C2	O
protein	O
translation	O
is	O
detected	O
in	O
type	O
I	O
deficiency	O
,	O
while	O
type	O
II	O
deficiency	O
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

Type	B
I	I
C2	I
deficiency	I
was	O
described	O
in	O
a	O
family	O
in	O
which	O
the	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
associated	O
with	O
the	O
major	O
histocompatibility	O
haplotype	O
/	O
complotype	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
C2Q0	O
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
;	O
this	O
extended	O
haplotype	O
occurs	O
in	O
over	O
90	O
%	O
of	O
C2	B
-	I
deficient	I
individuals	O
(	O
common	O
complotype	O
/	O
haplotype	O
)	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
type	B
I	I
C2	I
deficiency	I
,	O
the	O
C2	O
gene	O
and	O
cDNA	O
were	O
characterized	O
from	O
a	O
homozygous	O
type	B
I	I
C2	I
-	I
deficient	I
individual	O
with	O
the	O
common	O
associated	O
haplotype	O
/	O
complotype	O
.	O

We	O
found	O
a	O
28	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
,	O
beginning	O
9	O
base	O
pairs	O
upstream	O
of	O
the	O
3	O
-	O
end	O
of	O
exon	O
6	O
,	O
that	O
generates	O
a	O
C2	O
transcript	O
with	O
a	O
complete	O
deletion	O
of	O
exon	O
6	O
(	O
134	O
base	O
pair	O
)	O
and	O
a	O
premature	O
termination	O
codon	O
.	O

In	O
studies	O
of	O
eight	O
kindred	O
,	O
the	O
28	O
-	O
base	O
pair	O
deletion	O
was	O
observed	O
in	O
all	O
C2Q0	O
alleles	O
associated	O
with	O
the	O
common	O
type	O
I	O
deficient	O
complotype	O
/	O
haplotype	O
;	O
this	O
deletion	O
was	O
not	O
present	O
in	O
normal	O
C2	O
nor	O
in	O
type	B
II	I
C2	I
-	I
deficient	I
genes	O
.	O

These	O
data	O
demonstrate	O
that	O
1	O
)	O
type	B
I	I
human	I
complement	I
C2	I
deficiency	I
is	O
caused	O
by	O
a	O
28	O
-	O
base	O
pair	O
genomic	O
deletion	O
that	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing	O
,	O
resulting	O
in	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
,	O
2	O
)	O
the	O
28	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
is	O
strongly	O
associated	O
with	O
the	O
HLA	O
haplotype	O
/	O
complotype	O
A25	O
,	O
B18	O
,	O
C2Q0	O
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
,	O
suggesting	O
that	O
all	O
C2	B
-	I
deficient	I
individuals	O
with	O
this	O

haplotype	O
/	O
complotype	O
will	O
harbor	O
the	O
28	O
-	O
base	O
pair	O
C2	O
gene	O
deletion	O
,	O
and	O
3	O
)	O
type	B
II	I
C2	I
deficiency	I
is	O
caused	O
by	O
a	O
different	O
,	O
as	O
yet	O
uncharacterized	O
,	O
molecular	O
genetic	B
defect	I
.	O
.	O

Molecular	O
characterization	O
of	O
two	O
galactosemia	B
mutations	O
and	O
one	O
polymorphism	O
:	O
implications	O
for	O
structure	O
-	O
function	O
analysis	O
of	O
human	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
.	O

We	O
report	O
here	O
the	O
molecular	O
characterization	O
of	O
two	O
galactosemia	B
mutations	O
,	O
L74P	O
and	O
F171S	O
,	O
and	O
one	O
polymorphism	O
,	O
S135L	O
,	O
in	O
human	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
.	O

Both	O
galactosemia	B
mutations	O
result	O
in	O
reduced	O
enzymatic	O
activity	O
when	O
reconstructed	O
in	O
the	O
cDNA	O
and	O
overexpressed	O
.	O

The	O
polymorphism	O
,	O
in	O
contrast	O
,	O
has	O
near	O
normal	O
activity	O
.	O

Both	O
mutations	O
affect	O
evolutionarily	O
conserved	O
residues	O
,	O
suggesting	O
that	O
they	O
are	O
functionally	O
important	O
,	O
while	O
the	O
polymorphism	O
occurs	O
in	O
a	O
nonconserved	O
domain	O
which	O
is	O
presumably	O
not	O
critical	O
for	O
enzymatic	O
function	O
.	O

The	O
F171S	O
mutation	O
is	O
close	O
to	O
the	O
putative	O
active	O
-	O
site	O
nucleophile	O
.	O

Our	O
data	O
further	O
support	O
the	O
notion	O
of	O
molecular	O
heterogeneity	O
of	O
galactosemia	B
and	O
suggest	O
that	O
galactosemia	B
mutations	O
and	O
GALT	O
polymorphisms	O
may	O
be	O
useful	O
tools	O
in	O
highlighting	O
different	O
functional	O
domains	O
in	O
human	O
GALT	O
.	O
.	O

Linkage	O
relationship	O
of	O
C2	B
deficiency	I
,	O
HLA	O
and	O
glyoxalase	O
I	O
loci	O
.	O

Immunogenetic	O
analysis	O
of	O
a	O
homozygous	O
C2	B
-	I
deficient	I
individual	O
and	O
family	O
members	O
demonstrated	O
linkage	O
of	O
HLA	O
-	O
A25	O
,	O
B18	O
and	O
C2o	O
.	O

HLA	O
-	O
D	O
typing	O
showed	O
that	O
5	O
members	O
typed	O
with	O
homozygous	O
Dw2	O
typing	O
cells	O
from	O
an	O
individual	O
with	O
C2	B
deficiency	I
but	O
not	O
with	O
Dw2	O
typing	O
cells	O
from	O
2	O
individuals	O
with	O
normal	O
C2	O
.	O

The	O
homozygous	O
C2	B
-	I
deficient	I
propositus	O
and	O
brother	O
were	O
HLA	O
-	O
A	O
and	O
B	O
homozygous	O
but	O
heterozygous	O
at	O
the	O
HLA	O
-	O
D	O
and	O
glyoxalase	O
I	O
loci	O
.	O

Therefore	O
,	O
in	O
this	O
family	O
,	O
the	O
C2o	O
gene	O
is	O
linked	O
with	O
two	O
distinct	O
haplotypes	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
Dw2	O
,	O
GLO1	O
and	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
D	O
unknown	O
,	O
GL02	O
.	O

These	O
results	O
could	O
be	O
explained	O
by	O
an	O
ancestral	O
recombinant	O
event	O
,	O
which	O
occurred	O
between	O
the	O
C2o	O
locus	O
and	O
HLA	O
-	O
D	O
locus	O
in	O
which	O
C2o	O
segregated	O
with	O
HLA	O
-	O
B	O
.	O

This	O
would	O
suggest	O
that	O
the	O
locus	O
for	O
the	O
C2o	O
gene	O
maps	O
between	O
HLA	O
-	O
B	O
and	O
HLA	O
-	O
D	O
on	O
the	O
sixth	O
chromosome	O
.	O
.	O

Germline	O
mutations	O
in	O
the	O
Wilms	B
'	I
tumor	I
suppressor	O
gene	O
are	O
associated	O
with	O
abnormal	O
urogenital	O
development	O
in	O
Denys	B
-	I
Drash	I
syndrome	I
.	O

Denys	B
-	I
Drash	I
syndrome	I
is	O
a	O
rare	O
human	O
condition	O
in	O
which	O
severe	O
urogenital	B
aberrations	I
result	O
in	O
renal	B
failure	I
,	O
pseudohermaphroditism	B
,	O
and	O
Wilms	B
tumor	I
(	O
nephroblastoma	B
)	O
.	O

To	O
investigate	O
its	O
possible	O
role	O
,	O
we	O
have	O
analyzed	O
the	O
coding	O
exons	O
of	O
the	O
Wilms	B
tumor	I
suppressor	O
gene	O
(	O
WT1	O
)	O
for	O
germline	O
mutations	O
.	O

In	O
ten	O
independent	O
cases	O
of	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
point	O
mutations	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
one	O
WT1	O
gene	O
copy	O
were	O
found	O
.	O

Nine	O
of	O
these	O
mutations	O
are	O
found	O
within	O
exon	O
9	O
(	O
zinc	O
finger	O
III	O
)	O
;	O
the	O
remaining	O
mutation	O
is	O
in	O
exon	O
8	O
(	O
zinc	O
finger	O
II	O
)	O
.	O

These	O
mutations	O
directly	O
affect	O
DNA	O
sequence	O
recognition	O
.	O

In	O
two	O
families	O
analyzed	O
,	O
the	O
mutations	O
were	O
shown	O
to	O
arise	O
de	O
novo	O
.	O

Wilms	B
tumors	I
from	O
three	O
individuals	O
and	O
one	O
juvenile	O
granulosa	O
cell	O
tumor	B
demonstrate	O
reduction	O
to	O
homozygosity	O
for	O
the	O
mutated	O
WT1	O
allele	O
.	O

Our	O
results	O
provide	O
evidence	O
of	O
a	O
direct	O
role	O
for	O
WT1	O
in	O
Denys	B
-	I
Drash	I
syndrome	I
and	O
thus	O
urogenital	O
system	O
development	O
.	O
.	O

Linkage	O
analysis	O
in	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
and	O
application	O
in	O
post	O
-	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
DNA	O
markers	O
DXS52	O
and	O
the	O
clotting	O
factor	O
VIII	O
gene	O
(	O
F8C	O
)	O
,	O
in	O
several	O
large	O
families	O
with	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
.	O

The	O
tight	O
linkage	O
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	O
score	O
of	O
22	O
.	O

5	O
at	O
1	O
cM	O
.	O

F8C	O
was	O
also	O
tightly	O
linked	O
to	O
ALD	B
with	O
a	O
maximal	O
LOD	O
score	O
of	O
7	O
.	O

8	O
without	O
recombination	O
.	O

Multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
DXS304	O
,	O
DXS52	O
,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ALD	B
and	O
for	O
F8C	O
are	O
distal	O
to	O
DXS52	O
.	O

In	O
four	O
patients	O
with	O
ALD	B
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
Xqter	O
region	O
was	O
observed	O
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B
in	I
the	I
vision	I
blindness	I
genes	I
.	O

DNA	O
analysis	O
appeared	O
to	O
be	O
of	O
use	O
in	O
determination	O
of	O
the	O
carrier	O
status	O
of	O
females	O
at	O
risk	O
,	O
for	O
the	O
determination	O
of	O
the	O
origin	O
of	O
the	O
mutation	O
in	O
a	O
particular	O
family	O
,	O
and	O
for	O
prenatal	O
diagnosis	O
.	O

Two	O
distinct	O
mutations	O
at	O
a	O
single	O
BamHI	O
site	O
in	O
phenylketonuria	B
.	O

Classical	B
phenylketonuria	I
is	O
an	O
autosomal	B
recessive	I
disease	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	O
located	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
PAH	O
gene	O
(	O
exon	O
7	O
)	O
led	O
to	O
the	O
recognition	O
of	O
two	O
new	O
point	O
mutations	O
at	O
codon	O
272	O
and	O
273	O
(	O
272gly	O
-	O
-	O
-	O
-	O
stop	O
and	O
273ser	O
-	O
-	O
-	O
-	O
phe	O
,	O
respectively	O
)	O
.	O

Both	O
mutations	O
were	O
detected	O
in	O
north	O
eastern	O
France	O
or	O
Belgium	O
and	O
occurred	O
on	O
the	O
background	O
of	O
RFLP	O
haplotype	O
7	O
alleles	O
.	O

The	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
PKU	B
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
PAH	B
deficiencies	I
.	O
.	O

A	O
detailed	O
multipoint	O
map	O
of	O
human	O
chromosome	O
4	O
provides	O
evidence	O
for	O
linkage	O
heterogeneity	O
and	O
position	O
-	O
specific	O
recombination	O
rates	O
.	O

Utilizing	O
the	O
CEPH	O
reference	O
panel	O
and	O
genotypic	O
data	O
for	O
53	O
markers	O
,	O
we	O
have	O
constructed	O
a	O
20	O
-	O
locus	O
multipoint	O
genetic	O
map	O
of	O
human	O
chromosome	O
4	O
.	O

New	O
RFLPs	O
are	O
reported	O
for	O
four	O
loci	O
.	O

The	O
map	O
integrates	O
a	O
high	O
-	O
resolution	O
genetic	O
map	O
of	O
4p16	O
into	O
a	O
continuous	O
map	O
extending	O
to	O
4q31	O
and	O
an	O
unlinked	O
cluster	O
of	O
three	O
loci	O
at	O
4q35	O
.	O

The	O
20	O
linked	O
markers	O
form	O
a	O
continuous	O
linkage	O
group	O
of	O
152	O
cM	O
in	O
males	O
and	O
202	O
cM	O
in	O
females	O
.	O

Likely	O
genetic	O
locations	O
are	O
provided	O
for	O
25	O
polymorphic	O
anonymous	O
sequences	O
and	O
28	O
gene	O
-	O
specific	O
RFLPs	O
.	O

The	O
map	O
was	O
constructed	O
employing	O
the	O
LINKAGE	O
and	O
CRIMAP	O
computational	O
methodologies	O
to	O
build	O
the	O
multipoint	O
map	O
via	O
a	O
stepwise	O
algorithm	O
.	O

A	O
detailed	O
10	O
-	O
point	O
map	O
of	O
the	O
4p16	O
region	O
constructed	O
from	O
the	O
CEPH	O
panel	O
provides	O
evidence	O
for	O
heterogeneity	O
in	O
the	O
linkage	O
maps	O
constructed	O
from	O
families	O
segregating	O
for	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

It	O
additionally	O
provides	O
evidence	O
for	O
position	O
-	O
specific	O
recombination	O
frequencies	O
in	O
the	O
telomeric	O
region	O
of	O
4p	O
.	O
.	O

Carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
using	O
a	O
combination	O
of	O
anonymous	O
DNA	O
polymorphisms	O
and	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
cDNA	O
.	O

We	O
report	O
carrier	O
identification	O
and	O
a	O
prenatal	O
diagnosis	O
using	O
DNA	O
polymorphisms	O
in	O
2	O
families	O
with	O
X	B
-	I
linked	I
Pelizaeus	I
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

In	O
both	O
families	O
,	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
the	O
single	O
affected	O
male	O
could	O
be	O
traced	O
back	O
to	O
his	O
unaffected	O
maternal	O
grandfather	O
.	O

Therefore	O
,	O
each	O
family	O
contains	O
a	O
new	O
mutation	O
.	O

In	O
the	O
case	O
of	O
the	O
prenatal	O
diagnosis	O
,	O
the	O
fetus	O
was	O
shown	O
by	O
cytogenetic	O
analysis	O
to	O
be	O
a	O
female	O
,	O
who	O
we	O
predict	O
will	O
be	O
a	O
noncarrier	O
of	O
PMD	B
based	O
on	O
her	O
genotype	O
with	O
the	O
PLP	O
intragenic	O
polymorphism	O
.	O
.	O

Identification	O
of	O
deletion	O
mutations	O
and	O
three	O
new	O
genes	O
at	O
the	O
familial	B
polyposis	I
locus	O
.	O

Small	O
(	O
100	O
-	O
260	O
kb	O
)	O
,	O
nested	O
deletions	O
were	O
characterized	O
in	O
DNA	O
from	O
two	O
unrelated	O
patients	O
with	O
familial	B
adenomatous	I
polyposis	I
coli	I
(	O
APC	B
)	O
.	O

Three	O
candidate	O
genes	O
located	O
within	O
the	O
deleted	O
region	O
were	O
ascertained	O
and	O
a	O
previous	O
candidate	O
gene	O
,	O
MCC	O
,	O
was	O
shown	O
to	O
be	O
located	O
outside	O
the	O
deleted	O
region	O
.	O

One	O
of	O
the	O
new	O
genes	O
contained	O
sequence	O
identical	O
to	O
SRP19	O
,	O
the	O
gene	O
coding	O
for	O
the	O
19	O
kd	O
component	O
of	O
the	O
ribosomal	O
signal	O
recognition	O
particle	O
.	O

The	O
second	O
,	O
provisionally	O
designated	O
DP1	O
(	O
deleted	O
in	O
polyposis	O
1	O
)	O
,	O
was	O
found	O
to	O
be	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
MCC	O
.	O

Two	O
other	O
cDNAs	O
,	O
DP2	O
and	O
DP3	O
,	O
were	O
found	O
to	O
overlap	O
,	O
forming	O
a	O
single	O
gene	O
,	O
DP2	O
.	O

5	O
,	O
that	O
is	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
SRP19	O
.	O

Exclusion	O
of	O
linkage	O
between	O
familial	B
Mediterranean	I
fever	I
and	O
the	O
human	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
gene	O
cluster	O
.	O

We	O
studied	O
the	O
relationship	O
between	O
the	O
autosomal	O
recessive	O
trait	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
and	O
the	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
genes	O
by	O
comparing	O
alleles	O
of	O
a	O
highly	O
polymorphic	O
dinucleotide	O
repeat	O
and	O
a	O
conventional	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
in	O
the	O
SAA	O
gene	O
cluster	O
in	O
Israeli	O
FMF	B
kindreds	O
.	O

By	O
haplotype	O
analysis	O
,	O
our	O
data	O
indicate	O
a	O
minimum	O
crossover	O
frequency	O
of	O
22	O
%	O
between	O
the	O
SAA	O
gene	O
marker	O
and	O
FMF	B
.	O

By	O
conventional	O
linkage	O
analysis	O
this	O
eliminates	O
a	O
minimum	O
of	O
10	O
.	O

4	O
cM	O
including	O
and	O
surrounding	O
the	O
SAA	O
gene	O
cluster	O
as	O
the	O
site	O
of	O
the	O
FMF	B
mutation	O
although	O
SAA	O
proteins	O
are	O
prominent	O
physiologic	O
markers	O
of	O
the	O
acute	O
attacks	O
.	O

PRAD1	O
,	O
a	O
candidate	O
BCL1	O
oncogene	O
:	O
mapping	O
and	O
expression	O
in	O
centrocytic	B
lymphoma	I
.	O

Rearrangement	O
of	O
the	O
BCL1	O
(	O
B	O
-	O
cell	O
lymphoma	O
1	O
)	O
region	O
on	O
chromosome	O
11q13	O
appears	O
to	O
be	O
highly	O
characteristic	O
of	O
centrocytic	B
lymphoma	I
and	O
also	O
is	O
found	O
infrequently	O
in	O
other	O
B	B
-	I
cell	I
neoplasms	I
.	O

Rearrangement	O
is	O
thought	O
to	O
deregulate	O
a	O
nearby	O
protooncogene	O
,	O
but	O
transcribed	O
sequences	O
in	O
the	O
immediate	O
vicinity	O
of	O
BCL1	O
breakpoints	O
had	O
not	O
been	O
identified	O
.	O

PRAD1	O
,	O
previously	O
designated	O
D11S287E	O
,	O
was	O
identified	O
on	O
11q13	O
as	O
a	O
chromosomal	O
breakpoint	O
region	O
rearranged	O
with	O
the	O
parathyroid	O
hormone	O
gene	O
in	O
a	O
subset	O
of	O
parathyroid	B
adenomas	I
;	O
this	O
highly	O
conserved	O
putative	O
oncogene	O
,	O
which	O
encodes	O
a	O
novel	O
cyclin	O
,	O
has	O
been	O
linked	O
to	O
BCL1	O
and	O
implicated	O
also	O
in	O
subsets	O
of	O
breast	B
and	I
squamous	I
cell	I
neoplasms	I
with	O
11q13	O
amplification	O
.	O

We	O
report	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
data	O
showing	O
BCL1	O
and	O
PRAD1	O
to	O
be	O
no	O
more	O
than	O
130	O
kilobases	O
apart	O
.	O

PRAD1	O
mRNA	O
is	O
abundantly	O
expressed	O
in	O
seven	O
of	O
seven	O
centrocytic	B
lymphomas	I
(	O
Kiel	O
classification	O
)	O
,	O
in	O
contrast	O
to	O
13	O
closely	O
related	O
but	O
noncentrocytic	B
lymphomas	I
.	O

Three	O
of	O
the	O
seven	O
centrocytic	B
lymphomas	I
had	O
detectable	O
BCL1	O
DNA	O
rearrangement	O
.	O

Also	O
,	O
two	O
unusual	O
cases	O
of	O
CLL	O
with	O
BCL1	O
rearrangement	O
overexpressed	O
PRAD1	O
,	O
in	O
contrast	O
to	O
five	O
CLL	O
controls	O
.	O

Thus	O
,	O
PRAD1	O
is	O
an	O
excellent	O
candidate	O
"	O
BCL1	O
oncogene	O
.	O

"	O
Its	O
overexpression	O
may	O
be	O
a	O
key	O
consequence	O
of	O
rearrangement	O
of	O
the	O
BCL1	O
vicinity	O
in	O
B	B
-	I
cell	I
neoplasms	I
and	O
a	O
unifying	O
pathogenetic	O
feature	O
in	O
centrocytic	B
lymphoma	I
.	O

Two	O
new	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
mutations	O
in	O
a	O
juvenile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
patient	O
.	O

Fragments	O
of	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
gene	O
from	O
a	O
patient	O
with	O
juvenile	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
were	O
amplified	O
by	O
PCR	O
and	O
ligated	O
into	O
MP13	O
cloning	O
vectors	O
.	O

Clones	O
hybridizing	O
with	O
cDNA	O
for	O
human	O
ARSA	O
were	O
selected	O
,	O
examined	O
for	O
appropriate	O
size	O
inserts	O
,	O
and	O
used	O
to	O
prepare	O
single	O
-	O
stranded	O
phage	O
DNA	O
.	O

Examination	O
of	O
the	O
entire	O
coding	O
and	O
most	O
of	O
the	O
intronic	O
sequence	O
revealed	O
two	O
putative	O
disease	O
-	O
related	O
mutations	O
.	O

One	O
,	O
a	O
point	O
mutation	O
in	O
exon	O
3	O
,	O
resulted	O
in	O
the	O
substitution	O
of	O
isoleucine	O
by	O
serine	O
.	O

Introduction	O
of	O
this	O
alteration	O
into	O
the	O
normal	O
ARSA	O
cDNA	O
sequence	O
resulted	O
in	O
a	O
substantial	O
decrease	O
in	O
ARSA	O
activity	O
on	O
transient	O
expression	O
in	O
cultured	O
baby	O
hamster	O
kidney	O
cells	O
.	O

About	O
5	O
%	O
of	O
the	O
control	O
expression	O
was	O
observed	O
,	O
suggesting	O
a	O
small	O
residual	O
activity	O
in	O
the	O
mutated	O
ARSA	O
.	O

The	O
second	O
mutation	O
,	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
,	O
occurred	O
in	O
the	O
other	O
allele	O
and	O
resulted	O
in	O
an	O
altered	O
splice	O
-	O
recognition	O
sequence	O
between	O
exon	O
7	O
and	O
the	O
following	O
intron	O
.	O

The	O
mutation	O
also	O
resulted	O
in	O
the	O
loss	O
of	O
a	O
restriction	O
site	O
.	O

Apparently	O
normal	O
levels	O
of	O
mRNA	O
were	O
generated	O
from	O
this	O
allele	O
,	O
but	O
no	O
ARSA	O
activity	O
or	O
immuno	O
-	O
cross	O
-	O
reactive	O
material	O
could	O
be	O
detected	O
.	O

A	O
collection	O
of	O
DNA	O
samples	O
from	O
known	O
or	O
suspected	O
MLD	B
patients	O
,	O
members	O
of	O
their	O
families	O
,	O
and	O
normal	O
controls	O
was	O
screened	O
for	O
these	O
mutations	O
.	O

Four	O
additional	O
individuals	O
carrying	O
each	O
of	O
the	O
mutations	O
were	O
found	O
among	O
the	O
nearly	O
100	O
MLD	B
patients	O
in	O
the	O
sample	O
.	O

Gene	O
segregation	O
in	O
the	O
original	O
patients	O
family	O
was	O
consistent	O
with	O
available	O
clinical	O
and	O
biochemical	O
data	O
.	O

No	O
individuals	O
homozygous	O
for	O
either	O
of	O
these	O
two	O
mutations	O
were	O
identified	O
.	O

However	O
,	O
combinations	O
with	O
other	O
MLD	B
mutations	O
suggest	O
that	O
the	O
point	O
mutation	O
in	O
exon	O
3	O
does	O
result	O
in	O
some	O
residual	O
enzyme	O
activity	O
and	O
is	O
associated	O
with	O
late	O
-	O
onset	O
forms	O
of	O
the	O
disease	O
.	O

The	O
splice	O
-	O
site	O
mutation	O
following	O
exon	O
7	O
produces	O
late	O
-	O
infantile	O
MLD	B
when	O
combined	O
with	O
other	O
enzyme	O
-	O
null	O
mutations	O
,	O
implying	O
that	O
it	O
is	O
completely	O
silent	O
enzymatically	O
.	O
.	O

Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
and	O
presumptive	O
expression	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
gene	O
in	O
hematopoietic	O
cell	O
lineages	O
of	O
a	O
thrombocytopenic	O
carrier	O
female	O
of	O
WAS	B
.	O

We	O
report	O
on	O
a	O
thrombocytopenic	B
female	O
belonging	O
to	O
a	O
pedigree	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
with	O
probe	O
M27	O
beta	O
,	O
closely	O
linked	O
to	O
the	O
WAS	B
gene	O
,	O
demonstrated	O
that	O
she	O
is	O
a	O
carrier	O
of	O
WAS	B
.	O

Both	O
small	O
-	O
sized	O
and	O
normal	O
-	O
sized	O
platelets	O
were	O
present	O
,	O
suggesting	O
that	O
,	O
unlike	O
the	O
vast	O
majority	O
of	O
WAS	B
carriers	O
,	O
she	O
does	O
not	O
manifest	O
nonrandom	O
X	O
-	O
chromosome	O
inactivation	O
in	O
the	O
thrombopoietic	O
cell	O
lineage	O
.	O

Study	O
of	O
X	O
-	O
chromosome	O
inactivation	O
by	O
means	O
of	O
RFLP	O
and	O
methylation	O
analysis	O
demonstrated	O
that	O
the	O
pattern	O
of	O
X	O
-	O
chromosome	O
inactivation	O
was	O
nonrandom	O
in	O
T	O
lymphocytes	O
,	O
but	O
random	O
in	O
granulocytes	O
.	O

While	O
this	O
is	O
the	O
first	O
complete	O
report	O
on	O
the	O
occurrence	O
of	O
thrombocytopenia	B
in	O
a	O
carrier	O
female	O
of	O
WAS	B
as	O
the	O
result	O
of	O
atypical	O
lyonization	O
,	O
it	O
also	O
suggests	O
that	O
expression	O
of	O
the	O
WAS	B
gene	O
occurs	O
at	O
(	O
or	O
extends	O
up	O
to	O
)	O
a	O
later	O
stage	O
than	O
the	O
multipotent	O
stem	O
cell	O
along	O
the	O
hematopoietic	O
differentiation	O
pathway	O
.	O
.	O

A	O
new	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

A	O
C	O
-	O
to	O
-	O
T	O
transition	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
was	O
found	O
in	O
2	O
affected	O
males	O
and	O
two	O
obligate	O
carriers	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

The	O
mutation	O
,	O
which	O
causes	O
loss	O
of	O
an	O
HphI	O
site	O
and	O
changes	O
amino	O
acid	O
155	O
from	O
threonine	O
to	O
isoleucine	O
,	O
was	O
absent	O
from	O
108	O
normal	O
chromosomes	O
.	O

There	O
are	O
5	O
concordances	O
and	O
1	O
discrepancy	O
between	O
these	O
results	O
and	O
those	O
obtained	O
by	O
magnetic	O
resonance	O
imaging	O
in	O
this	O
family	O
.	O
.	O

A	O
3	O
-	O
base	O
pair	O
in	O
-	O
frame	O
deletion	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
results	O
in	O
a	O
kinetic	O
variant	O
of	O
phenylketonuria	B
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disease	I
due	O
to	O
deficiency	B
of	I
a	I
hepatic	I
enzyme	I
,	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

The	O
absence	O
of	O
PAH	O
activity	O
results	O
in	O
typical	O
PKU	B
while	O
persistence	O
of	O
a	O
residual	O
enzyme	O
activity	O
gives	O
rise	O
to	O
variant	O
forms	O
of	O
the	O
disease	O
.	O

We	O
report	O
here	O
a	O
3	O
-	O
base	O
pair	O
in	O
-	O
frame	O
deletion	O
of	O
the	O
PAH	O
gene	O
(	O
delta	O
194	O
)	O
in	O
a	O
mild	O
variant	O
,	O
with	O
markedly	O
reduced	O
affinity	O
of	O
the	O
enzyme	O
for	O
phenylalanine	O
(	O
Km	O
=	O
160	O
nM	O
)	O
,	O
and	O
we	O
provide	O
functional	O
evidence	O
for	O
responsibility	O
of	O
the	O
deletion	O
in	O
the	O
mutant	O
phenotype	O
.	O

Since	O
the	O
deletion	O
was	O
located	O
in	O
the	O
third	O
exon	O
of	O
the	O
gene	O
,	O
which	O
presents	O
no	O
homology	O
with	O
other	O
hydroxylases	O
,	O
we	O
suggest	O
that	O
exon	O
3	O
is	O
involved	O
in	O
the	O
specificity	O
of	O
the	O
enzyme	O
for	O
phenylalanine	O
.	O

Finally	O
,	O
since	O
none	O
of	O
the	O
98	O
PKU	B
patients	O
tested	O
were	O
found	O
to	O
carry	O
this	O
particular	O
deletion	O
,	O
our	O
study	O
suggests	O
that	O
this	O
molecular	O
event	O
probably	O
occurred	O
recently	O
on	O
the	O
background	O
of	O
a	O
haplotype	O
2	O
gene	O
in	O
Portugal	O
.	O
.	O

Mutation	O
of	O
the	O
KIT	O
(	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
receptor	O
)	O
protooncogene	O
in	O
human	O
piebaldism	B
.	O

Piebaldism	B
is	O
an	O
autosomal	B
dominant	I
genetic	I
disorder	I
characterized	O
by	O
cogenital	O
patches	O
of	O
skin	O
and	O
hair	O
from	O
which	O
melanocytes	O
are	O
completely	O
absent	O
.	O

A	O
similar	O
disorder	O
of	O
mouse	O
,	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
,	O
results	O
from	O
mutations	O
of	O
the	O
c	O
-	O
Kit	O
protooncogene	O
,	O
which	O
encodes	O
and	O
receptor	O
for	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
.	O

We	O
identified	O
a	O
KIT	O
gene	O
mutation	O
in	O
a	O
proband	O
with	O
classic	O
autosomal	O
dominant	O
piebaldism	B
.	O

This	O
mutation	O
results	O
in	O
a	O
Gly	O
-	O
-	O
-	O
-	O
Arg	O
substitution	O
at	O
codon	O
664	O
,	O
within	O
the	O
tyrosine	O
kinase	O
domain	O
.	O

This	O
substitution	O
was	O
not	O
seen	O
in	O
any	O
normal	O
individuals	O
and	O
was	O
completely	O
linked	O
to	O
the	O
piebald	B
phenotype	O
in	O
the	O
probands	O
family	O
.	O

Piebaldism	B
in	O
this	O
family	O
thus	O
appears	O
to	O
be	O
the	O
human	O
homologue	O
to	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
of	O
the	O
mouse	O
.	O
.	O

Genetic	O
analysis	O
of	O
a	O
Japanese	O
family	O
with	O
normotriglyceridemic	B
abetalipoproteinemia	I
indicates	O
a	O
lack	O
of	O
linkage	O
to	O
the	O
apolipoprotein	O
B	O
gene	O
.	O

Normotriglyceridemic	B
abetalipoproteinemia	I
is	O
a	O
rare	O
familial	B
disorder	I
characterized	O
by	O
an	O
isolated	O
deficiency	B
of	I
apoB	I
-	I
100	I
.	O

We	O
have	O
previously	O
reported	O
a	O
patient	O
with	O
this	O
disease	O
,	O
who	O
had	O
normal	O
apoB	O
-	O
48	O
but	O
no	O
apoB	O
-	O
100	O
.	O

To	O
elucidate	O
the	O
genetic	B
abnormalities	I
in	O
this	O
family	O
,	O
we	O
studied	O
the	O
linkage	O
of	O
apoB	O
gene	O
using	O
three	O
genetic	O
markers	O
.	O

The	O
proband	O
and	O
her	O
affected	O
brother	O
showed	O
completely	O
different	O
apoB	O
gene	O
alleles	O
,	O
suggesting	O
that	O
the	O
apoB	O
gene	O
itself	O
is	O
not	O
related	O
to	O
this	O
disorder	O
in	O
this	O
family	O
.	O

By	O
contrast	O
,	O
an	O
American	O
case	O
had	O
a	O
point	O
substitution	O
in	O
the	O
apoB	O
gene	O
generating	O
an	O
in	O
-	O
frame	O
stop	O
codon	O
.	O

These	O
results	O
indicate	O
that	O
this	O
disorder	O
can	O
be	O
caused	O
by	O
defect	O
(	O
s	O
)	O
of	O
either	O
an	O
apoB	O
gene	O
or	O
other	O
genes	O
.	O
.	O

Localisation	O
of	O
the	O
gene	O
for	O
Norrie	B
disease	I
to	O
between	O
DXS7	O
and	O
DXS426	O
on	O
Xp	O
.	O

A	O
highly	O
informative	O
microsatellite	O
marker	O
,	O
DXS426	O
,	O
which	O
maps	O
proximal	O
to	O
DXS7	O
in	O
the	O
interval	O
Xp11	O
.	O

4	O
-	O
Xp11	O
4	O
-	O
Xp11	O
.	O

23	O
,	O
has	O
been	O
used	O
to	O
refine	O
further	O
the	O
localisation	O
of	O
the	O
gene	O
for	O
Norrie	B
disease	I
(	O
NDP	B
)	O
.	O

The	O
results	O
from	O
a	O
multiply	O
informative	O
crossover	O
localize	O
the	O
NDP	B
gene	O
proximal	O
to	O
DXS7	O
.	O

In	O
conjunction	O
with	O
information	O
from	O
2	O
NDP	B
patients	O
who	O
have	O
a	O
deletion	O
for	O
DXS7	O
but	O
not	O
for	O
DSX426	O
,	O
our	O
data	O
indicate	O
that	O
the	O
NDP	B
gene	O
lies	O
between	O
DXS7	O
and	O
DXS426	O
on	O
proximal	O
Xp	O
.	O

Aberrant	O
splicing	O
of	O
phenylalanine	O
hydroxylase	O
mRNA	O
:	O
the	O
major	O
cause	O
for	O
phenylketonuria	B
in	O
parts	O
of	O
southern	O
Europe	O
.	O

We	O
report	O
a	O
mutation	O
within	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
that	O
causes	O
aberrant	O
splicing	O
of	O
the	O
mRNA	O
and	O
that	O
is	O
in	O
tight	O
association	O
with	O
chromosomal	O
haplotypes	O
6	O
,	O
10	O
,	O
and	O
36	O
.	O

Because	O
of	O
the	O
high	O
frequency	O
of	O
these	O
particular	O
haplotypes	O
in	O
Bulgaria	O
,	O
Italy	O
,	O
and	O
Turkey	O
,	O
it	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequent	O
defects	O
in	O
the	O
PAH	O
gene	O
causing	O
classical	O
phenylketonuria	B
in	O
this	O
part	O
of	O
Europe	O
.	O

The	O
mutation	O
is	O
a	O
G	O
to	O
A	O
transition	O
at	O
position	O
546	O
in	O
intron	O
10	O
of	O
the	O
PAH	O
gene	O
,	O
11	O
bp	O
upstream	O
from	O
the	O
intron	O
10	O
/	O
exon	O
11	O
boundary	O
.	O

It	O
activates	O
a	O
cryptic	O
splice	O
site	O
and	O
results	O
in	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
9	O
nucleotides	O
between	O
exon	O
10	O
and	O
exon	O
11	O
of	O
the	O
processed	O
mRNA	O
.	O

Normal	O
amounts	O
of	O
liver	O
PAH	O
protein	O
are	O
present	O
in	O
homozygous	O
patients	O
,	O
but	O
no	O
catalytic	O
activity	O
can	O
be	O
detected	O
.	O

This	O
loss	O
of	O
enzyme	O
activity	O
is	O
probably	O
caused	O
by	O
conformational	O
changes	O
resulting	O
from	O
the	O
insertion	O
of	O
three	O
additional	O
amino	O
acids	O
(	O
Gly	O
-	O
Leu	O
-	O
Gln	O
)	O
between	O
the	O
normal	O
sequences	O
encoded	O
by	O
exon	O
10	O
and	O
exon	O
11	O
.	O
.	O

Gardner	B
syndrome	I
in	O
a	O
boy	O
with	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

We	O
described	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
Gardner	B
syndrome	I
(	O
GS	B
)	O
,	O
mental	B
retardation	I
,	O
and	O
craniofacial	B
abnormalities	I
.	O

High	O
-	O
resolution	O
banding	O
analysis	O
showed	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
(	O
q22	O
.	O
1	O
-	O
-	O
-	O
-	O
q31	O
1	O
-	O
-	O
-	O
-	O
q31	O
.	O
1	O
)	O
.	O

The	O
breakpoints	O
in	O
the	O
present	O
case	O
and	O
in	O
3	O
previously	O
reported	O
5q	O
-	O
patients	O
with	O
adenomatous	B
polyposis	I
coli	I
suggest	O
that	O
the	O
gene	O
responsible	O
for	O
GS	B
/	O
or	O
familial	B
polyposis	I
coli	I
(	O
FPC	B
)	O
is	O
in	O
the	O
5q22	O
region	O
,	O
a	O
result	O
consistent	O
with	O
the	O
findings	O
of	O
linkage	O
studies	O

Huntington	B
disease	I
and	O
childhood	O
-	O
onset	O
Tourette	B
syndrome	I
.	O

A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
childhood	O
-	O
onset	O
Tourette	B
syndrome	I
(	O
TS	B
)	O
developed	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood	O
-	O
onset	O
TS	B
with	O
adult	O
onset	O
HD	B
.	O

Discovery	O
of	O
other	O
cases	O
with	O
both	O
disorders	O
may	O
provide	O
clues	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
.	O
.	O

Sequence	O
of	O
DNA	O
flanking	O
the	O
exons	O
of	O
the	O
HEXA	O
gene	O
,	O
and	O
identification	O
of	O
mutations	O
in	O
Tay	B
-	I
Sachs	I
disease	I
.	O

The	O
rapid	O
identification	O
of	O
mutations	O
causing	O
Tay	B
-	I
Sachs	I
disease	I
requires	O
the	O
capacity	O
to	O
readily	O
screen	O
the	O
regions	O
of	O
the	O
HEXA	O
gene	O
most	O
likely	O
to	O
be	O
affected	O
by	O
mutation	O
.	O

We	O
have	O
sequenced	O
the	O
portions	O
of	O
the	O
introns	O
flanking	O
each	O
of	O
the	O
14	O
HEXA	O
exons	O
in	O
order	O
to	O
specify	O
oligonucleotide	O
primers	O
for	O
the	O
PCR	O
-	O
dependent	O
amplification	O
of	O
each	O
exon	O
and	O
splice	O
-	O
junction	O
sequence	O
.	O

The	O
amplified	O
products	O
were	O
analyzed	O
,	O
by	O
electrophoresis	O
in	O
nondenaturing	O
polyacrylamide	O
gels	O
,	O
for	O
the	O
presence	O
of	O
either	O
heteroduplexes	O
,	O
derived	O
from	O
the	O
annealing	O
of	O
normal	O
and	O
mutant	O
DNA	O
strands	O
,	O
or	O
single	O
-	O
strand	O
conformational	O
polymorphisms	O
(	O
SSCP	O
)	O
,	O
derived	O
from	O
the	O
renaturation	O
of	O
single	O
-	O
stranded	O
DNA	O
.	O

Five	O
novel	O
mutations	O
from	O
Tay	B
-	I
Sachs	I
disease	I
patients	O
were	O
detected	O
a	O
5	O
-	O
bp	O
deletion	O
of	O
TCTCC	O
in	O
IVS	O
-	O
9	O
;	O
a	O
2	O
-	O
bp	O
deletion	O
of	O
TG	O
in	O
exon	O
5	O
;	O
G78	O
to	O
A	O
,	O
giving	O
a	O
stop	O
codon	O
in	O
exon	O
1	O
;	O
G533	O
to	O
T	O
in	O
exon	O
5	O
,	O
producing	O
the	O
third	O
amino	O
acid	O
substitution	O
detected	O
at	O
this	O
site	O
;	O
and	O
G	O
to	O
C	O
at	O
position	O
1	O
of	O
IVS	O
-	O
2	O
,	O
expected	O
to	O
produce	O
abnormal	O
splicing	O
.	O

In	O
addition	O
,	O
two	O
mutations	O
,	O
(	O
G1496	O
to	O
A	O
in	O
exon	O
13	O
and	O
a	O
4	O
-	O
bp	O
insertion	O
in	O
exon	O
11	O
)	O
that	O
have	O
previously	O
been	O
reported	O
were	O
identified	O
.	O
.	O

Molecular	O
characterization	O
of	O
two	O
galactosemia	B
mutations	O
:	O
correlation	O
of	O
mutations	O
with	O
highly	O
conserved	O
domains	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
.	O

Galactosemia	B
is	O
an	O
autosomal	B
recessive	I
disorder	I
of	I
human	I
galactose	I
metabolism	I
caused	O
by	O
deficiency	B
of	I
the	I
enzyme	I
galactose	I
-	I
1	I
-	I
phosphate	I
uridyl	I
transferase	I
(	O
GALT	O
)	O
.	O

The	O
molecular	O
basis	O
of	O
this	O
disorder	O
is	O
at	O
present	O
not	O
well	O
understood	O
.	O

We	O
report	O
here	O
two	O
missense	O
mutations	O
which	O
result	O
in	O
low	O
or	O
undetectable	O
enzymatic	O
activity	O
.	O

First	O
,	O
we	O
identified	O
at	O
nucleotide	O
591	O
a	O
transition	O
which	O
substitutes	O
glutamine	O
188	O
by	O
arginine	O
.	O

The	O
mutated	O
glutamine	O
is	O
not	O
only	O
highly	O
conserved	O
in	O
evolution	O
(	O
conserved	O
also	O
in	O
Escherichia	O
coli	O
and	O
Saccharomyces	O
cerevisiae	O
)	O
,	O
but	O
is	O
also	O
two	O
amino	O
acid	O
residues	O
downstream	O
from	O
the	O
active	O
site	O
histidine	O
-	O
proline	O
-	O
histidine	O
triad	O
and	O
results	O
in	O
about	O
10	O
%	O
of	O
normal	O
enzymatic	O
activity	O
.	O

The	O
arginine	O
188	O
mutation	O
is	O
the	O
most	O
common	O
galactosemia	B
mutation	O
characterized	O
to	O
date	O
.	O

It	O
accounts	O
for	O
one	O
-	O
fourth	O
of	O
the	O
galactosemia	B
alleles	O
studied	O
.	O

Second	O
,	O
we	O
report	O
the	O
substitution	O
of	O
arginine	O
333	O
by	O
tryptophan	O
,	O
caused	O
by	O
a	O
transition	O
at	O
nucleotide	O
1025	O
.	O

The	O
area	O
surrounding	O
this	O
missense	O
mutation	O
is	O
the	O
most	O
highly	O
conserved	O
domain	O
in	O
the	O
homologous	O
enzymes	O
from	O
E	O
.	O
coli	O
,	O
yeast	O
,	O
and	O
humans	O
,	O
and	O
this	O
mutation	O
results	O
in	O
undetectable	O
enzymatic	O
activity	O
,	O
suggesting	O
that	O
this	O
is	O
a	O
severe	O
mutation	O
.	O

This	O
second	O
mutation	O
appears	O
to	O
be	O
rare	O
,	O
since	O
it	O
was	O
found	O
only	O
in	O
the	O
patient	O
we	O
sequenced	O
.	O

Our	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
heterogeneity	O
of	O
galactosemia	B
at	O
the	O
molecular	O
level	O
,	O
heterogeneity	O
which	O
might	O
be	O
related	O
to	O
the	O
variable	O
clinical	O
outcome	O
observed	O
in	O
this	O
disorder	O
.	O
.	O

Hypoxanthine	B
-	I
guanine	I
phosphoribosyltransferase	I
deficiency	I
:	O
analysis	O
of	O
HPRT	O
mutations	O
by	O
direct	O
sequencing	O
and	O
allele	O
-	O
specific	O
amplification	O
.	O

The	O
Lesch	B
-	I
Nyhan	I
syndrome	I
is	O
a	O
severe	O
X	B
chromosome	I
-	I
linked	I
human	I
disease	I
caused	O
by	O
a	O
virtual	O
absence	B
of	I
hypoxanthine	I
-	I
guanine	I
phosphoribosyltransferase	I
(	I
HPRT	I
)	I
activity	I
.	O

A	O
partial	O
deficiency	O
in	O
the	O
activity	O
of	O
this	O
enzyme	O
can	O
result	O
in	O
gouty	B
arthritis	I
.	O

To	O
determine	O
the	O
genetic	O
basis	O
for	O
reduction	O
or	O
loss	O
of	O
enzyme	O
activity	O
,	O
we	O
have	O
amplified	O
and	O
sequenced	O
the	O
coding	O
region	O
of	O
HPRT	O
cDNA	O
from	O
four	O
patients	O
one	O
with	O
Lesch	B
-	I
Nyhan	I
syndrome	I
(	O
HPRTPerth	O
)	O
and	O
three	O
with	O
partial	B
deficiencies	I
of	I
HPRT	I
activity	I
,	O
which	O
have	O
been	O
designated	O
HPRTUrangan	O
,	O
HPRTSwan	O
and	O
HPRTToowong	O
.	O

In	O
all	O
four	O
patients	O
,	O
the	O
only	O
mutation	O
identified	O
was	O
a	O
single	O
base	O
substitution	O
in	O
exons	O
2	O
or	O
3	O
of	O
the	O
coding	O
region	O
,	O
which	O
in	O
each	O
case	O
predicts	O
a	O
single	O
amino	O
acid	O
substitution	O
in	O
the	O
translated	O
protein	O
.	O

Each	O
base	O
change	O
was	O
confirmed	O
by	O
allele	O
-	O
specific	O
amplification	O
of	O
the	O
patients	O
genomic	O
DNA	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
mutation	O
found	O
for	O
HPRTPerth	O
is	O
identical	O
to	O
that	O
reported	O
for	O
HPRTFlint	O
.	O

It	O
appears	O
that	O
the	O
two	O
mutations	O
are	O
de	O
novo	O
events	O
.	O
.	O

Molecular	O
and	O
metabolic	O
basis	O
for	O
the	O
metabolic	B
disorder	I
normotriglyceridemic	B
abetalipoproteinemia	I
.	O

We	O
have	O
previously	O
described	O
a	O
disorder	O
,	O
normotriglyceridemic	B
abetalipoproteinemia	I
,	O
that	O
is	O
characterized	O
by	O
the	O
virtual	O
absence	O
of	O
plasma	O
low	O
density	O
lipoproteins	O
and	O
complete	O
absence	O
of	O
apoB	O
-	O
100	O
,	O
but	O
with	O
apparently	O
normal	O
secretion	O
of	O
triglyceride	O
-	O
rich	O
lipoproteins	O
containing	O
apoB	O
-	O
48	O
.	O

The	O
patients	O
plasma	O
lipoproteins	O
were	O
shown	O
on	O
polyacrylamide	O
gels	O
and	O
by	O
antibody	O
mapping	O
to	O
have	O
a	O
new	O
truncated	O
apoB	O
variant	O
,	O
apoB	O
-	O
50	O
,	O
circulating	O
along	O
with	O
her	O
apoB	O
-	O
48	O
.	O

We	O
have	O
found	O
this	O
individual	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
C	O
-	O
to	O
-	O
T	O
nucleotide	O
substitution	O
at	O
apoB	O
codon	O
2252	O
,	O
which	O
produces	O
a	O
premature	O
in	O
-	O
frame	O
stop	O
codon	O
.	O

Thus	O
,	O
this	O
is	O
a	O
rare	O
example	O
of	O
homozygous	B
hypobetalipoproteinemia	I
.	O

Electron	O
photomicrographs	O
revealed	O
that	O
the	O
diameters	O
of	O
particles	O
in	O
the	O
d	O
less	O
than	O
1	O
.	O

006	O
g	O
/	O
ml	O
lipoprotein	O
fraction	O
,	O
in	O
both	O
the	O
postprandial	O
and	O
postabsorptive	O
state	O
,	O
are	O
bimodally	O
distributed	O
.	O

The	O
molar	O
ratio	O
of	O
apoE	O
to	O
apoB	O
in	O
these	O
particles	O
is	O
3	O
.	O

5	O
1	O
,	O
similar	O
to	O
normal	O
VLDL	O
.	O

The	O
plasma	O
LDL	O
interval	O
contains	O
both	O
spherical	O
and	O
cuboidal	O
particles	O
.	O

Autologous	O
reinfusion	O
of	O
labeled	O
d	O
less	O
than	O
1	O
.	O

006	O
g	O
/	O
ml	O
lipoproteins	O
showed	O
exponential	O
disappearance	O
from	O
plasma	O
,	O
with	O
an	O
apparent	O
half	O
-	O
removal	O
time	O
of	O
50	O
min	O
,	O
somewhat	O
slower	O
than	O
for	O
normal	O
chylomicrons	O
but	O
within	O
the	O
normal	O
range	O
for	O
VLDL	O
.	O

The	O
calculated	O
production	O
rate	O
for	O
apoB	O
was	O
within	O
the	O
normal	O
range	O
in	O
this	O
subject	O
.	O

A	O
single	O
origin	O
of	O
phenylketonuria	B
in	O
Yemenite	O
Jews	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
a	O
metabolic	B
disease	I
caused	O
by	O
recessive	O
mutations	O
of	O
the	O
gene	O
encoding	O
the	O
hepatic	O
enzyme	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

The	O
incidence	O
of	O
PKU	B
varies	O
widely	O
across	O
different	O
geographic	O
areas	O
,	O
and	O
is	O
highest	O
(	O
about	O
1	O
in	O
5	O
,	O
000	O
live	O
births	O
)	O
in	O
Ireland	O
and	O
western	O
Scotland	O
,	O
and	O
among	O
Yemenite	O
Jews	O
.	O

A	O
limited	O
number	O
of	O
point	O
mutations	O
account	O
for	O
most	O
of	O
the	O
PKU	B
cases	O
in	O
the	O
European	O
population	O
.	O

Here	O
we	O
report	O
that	O
a	O
single	O
molecular	O
defect	O
-	O
-	O
a	O
deletion	O
spanning	O
the	O
third	O
exon	O
of	O
the	O
PAH	O
gene	O
-	O
-	O
is	O
responsible	O
for	O
all	O
the	O
PKU	B
cases	O
among	O
the	O
Yemenite	O
Jews	O
.	O

Examination	O
of	O
a	O
random	O
sample	O
of	O
Yemenite	O
Jews	O
using	O
a	O
molecular	O
probe	O
that	O
detects	O
the	O
carriers	O
of	O
this	O
deletion	O
indicated	O
a	O
high	O
frequency	O
of	O
the	O
defective	O
gene	O
in	O
this	O
community	O
.	O

Although	O
the	O
deleted	O
PAH	O
gene	O
was	O
traced	O
to	O
25	O
different	O
locations	O
throughout	O
Yemen	O
,	O
family	O
histories	O
and	O
official	O
documents	O
of	O
the	O
Yemenite	O
Jewish	O
community	O
showed	O
that	O
the	O
common	O
ancestor	O
of	O
all	O
the	O
carriers	O
of	O
this	O
genetic	B
defect	I
lived	O
in	O
Sana	O
,	O
the	O
capital	O
of	O
Yemen	O
,	O
before	O
the	O
eighteenth	O
century	O
.	O
.	O

Linkage	O
of	O
aspartylglucosaminuria	B
(	O
AGU	B
)	O
to	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
enzyme	O
aspartylglucosaminidase	O
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
AGA	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21	O
-	O
qter	O
of	O
chromosome	O
4	O
.	O

We	O
have	O
studied	O
the	O
map	O
position	O
of	O
the	O
AGU	O
locus	O
in	O
relation	O
to	O
other	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
using	O
linkage	O
analyses	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
alleles	O
for	O
the	O
ADH2	O
,	O
ADH3	O
,	O
EGF	O
,	O
FG	O
alpha	O
and	O
FG	O
beta	O
loci	O
and	O
blood	O
group	O
antigens	O
for	O
the	O
MNS	O
locus	O
were	O
determined	O
in	O
a	O
panel	O
of	O
12	O
Finnish	O
AGU	B
families	O
.	O

The	O
heterozygous	O
family	O
members	O
were	O
identified	O
by	O
reduced	O
activity	O
of	O
AGA	O
in	O
lymphocytes	O
.	O

Linkage	O
studies	O
were	O
performed	O
using	O
both	O
pairwise	O
and	O
multipoint	O
analyses	O
.	O

Loose	O
linkage	O
of	O
the	O
AGU	B
locus	O
to	O
the	O
FG	O
and	O
MNS	O
loci	O
was	O
observed	O
(	O
z	O
=	O
1	O
.	O
16	O
,	O
z	O
=	O
1	O
.	O
39	O
,	O
respectively	O
)	O
.	O

Multipoint	O
analysis	O
to	O
the	O
fixed	O
map	O
[	O
ADH	O
-	O
(	O
0	O
.	O
03	O
)	O
-	O
EGF	O
-	O
(	O
0	O
.	O
35	O
)	O
-	O
FG	O
-	O
(	O
0	O
.	O
11	O
)	O
-	O
MNS	O
]	O
suggests	O
that	O
the	O
location	O
of	O
the	O
AGU	O
locus	O
is	O
0	O
.	O

05	O
-	O
0	O
.	O

30	O
recombination	O
units	O
distal	O
to	O
MNS	O
(	O
z	O
=	O
3	O
.	O
03	O
)	O
.	O

The	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
FG	O
-	O
MNS	O
-	O
AGU	O
is	O
35	O
times	O
more	O
likely	O
than	O
the	O
next	O
best	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
AGU	O
-	O
FG	O
-	O
MNS	O
.	O

Linkage	O
relationships	O
of	O
the	O
apolipoprotein	O
C1	O
gene	O
and	O
a	O
cytochrome	O
P450	O
gene	O
(	O
CYP2A	O
)	O
to	O
myotonic	B
dystrophy	I
.	O

We	O
have	O
studied	O
the	O
genetic	O
linkage	O
of	O
two	O
markers	O
,	O
the	O
apolipoprotein	O
C1	O
(	O
APOC1	O
)	O
gene	O
and	O
a	O
cytochrome	O
P450	O
(	O
CYP2A	O
)	O
gene	O
,	O
in	O
relation	O
to	O
the	O
gene	O
for	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

A	O
peak	O
lod	O
score	O
of	O
9	O
.	O

29	O
at	O
2	O
cM	O
was	O
observed	O
for	O
APOC1	O
-	O
DM	O
,	O
with	O
a	O
lod	O
score	O
of	O
8	O
.	O

55	O
at	O
4	O
cM	O
for	O
CYP2A	O
-	O
DM	O
.	O

These	O
two	O
markers	O
also	O
show	O
close	O
linkage	O
to	O
each	O
other	O
(	O
theta	O
max	O
=	O
0	O
.	O
05	O
,	O
Zmax	O
=	O
9	O
.	O
09	O
)	O
.	O

From	O
examination	O
of	O
the	O
genotypes	O
of	O
the	O
recombinant	O
individuals	O
,	O
CYP2A	O
appears	O
to	O
map	O
proximal	O
to	O
DM	O
because	O
in	O
one	O
recombinant	O
individual	O
CYP2A	O
,	O
APOC2	O
and	O
CKMM	O
had	O
all	O
recombined	O
with	O
DM	O
.	O

Evidence	O
from	O
another	O
CYP2A	O
-	O
DM	O
recombinant	O
individual	O
places	O
CYP2A	O
proximal	O
to	O
APOC2	O
and	O
CKMM	O
.	O

Localisation	O
of	O
CYP2A	O
on	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
also	O
suggests	O
that	O
it	O
is	O
proximal	O
to	O
DM	O
and	O
APOC2	O
/	O
C1	O
/	O
E	O
gene	O
cluster	O
.	O

Genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
around	O
the	O
gene	O
for	O
familial	B
adenomatous	I
polyposis	I
on	O
chromosome	O
5	O
.	O

A	O
genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
close	O
to	O
the	O
gene	O
(	O
APC	O
)	O
for	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
on	O
chromosome	O
5q	O
is	O
reported	O
.	O

One	O
hundred	O
fifty	O
-	O
five	O
typed	O
members	O
of	O
nine	O
FAP	B
kindred	O
provided	O
more	O
than	O
90	O
meioses	O
for	O
linkage	O
analysis	O
.	O

A	O
number	O
of	O
crucial	O
recombination	O
events	O
have	O
been	O
identified	O
which	O
are	O
informative	O
at	O
three	O
or	O
more	O
loci	O
,	O
allowing	O
confident	O
ordering	O
of	O
parts	O
of	O
the	O
map	O
.	O

There	O
was	O
no	O
evidence	O
of	O
genetic	O
heterogeneity	O
,	O
with	O
all	O
families	O
showing	O
linkage	O
of	O
at	O
least	O
one	O
chromosome	O
5	O
marker	O
to	O
the	O
gene	O
.	O

Recombination	O
data	O
and	O
two	O
-	O
point	O
linkage	O
analysis	O
support	O
a	O
locus	O
order	O
of	O
centromere	O
-	O
pi	O
227	O
-	O
C11P11	O
-	O
ECB27	O
-	O
L5	O
.	O

62	O
-	O
APC	O
-	O
EF5	O
62	O
-	O
APC	O
-	O
EF5	O
.	O

44	O
-	O
YN5	O
44	O
-	O
YN5	O
.	O

48	O
-	O
telomer	O
e	O
,	O
although	O
EF5	O
.	O

44	O
could	O
lie	O
in	O
the	O
interval	O
L5	O
.	O

62	O
-	O
APC	O
or	O
ECB27	O
-	O
L5	O
.	O

62	O
.	O

No	O
recombinants	O
were	O
identified	O
between	O
APC	O
and	O
either	O
EF5	O
.	O

44	O
or	O
YN5	O
.	O

48	O
,	O
but	O
published	O
deletion	O
mapping	O
in	O
colorectal	B
carcinomas	I
and	O
linkage	O
analysis	O
in	O
FAP	B
suggest	O
that	O
YN5	O
.	O

48	O
is	O
1	O
-	O
3	O
cM	O
from	O
APC	O
.	O

The	O
present	O
study	O
suggests	O
that	O
YN5	O
.	O

48	O
and	O
L5	O
.	O

62	O
delineate	O
a	O
small	O
region	O
of	O
chromosome	O
5	O
within	O
which	O
the	O
EF5	O
.	O

44	O
locus	O
lies	O
very	O
close	O
to	O
the	O
APC	B
gene	O
.	O

These	O
data	O
not	O
only	O
allow	O
use	O
of	O
flanking	O
markers	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	B
but	O
also	O
provide	O
a	O
high	O
-	O
density	O
map	O
of	O
the	O
region	O
for	O
isolation	O
of	O
the	O
APC	B
gene	O
itself	O
and	O
for	O
further	O
assessment	O
of	O
the	O
role	O
of	O
chromosome	O
5	O
deletions	O
in	O
the	O
biology	O
of	O
sporadic	O
colorectal	B
cancer	I
.	O

Serum	O
amyloid	O
A	O
and	O
P	O
protein	O
genes	O
in	O
familial	B
Mediterranean	I
fever	I
.	O

Two	O
recent	O
studies	O
have	O
suggested	O
the	O
involvement	O
of	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
and	O
P	O
(	O
APCS	O
)	O
genes	O
in	O
familial	B
Mediterranean	I
fever	I
(	O
MEF	B
)	O
.	O

To	O
test	O
the	O
role	O
of	O
SAA	O
and	O
APCS	O
in	O
MEF	B
and	O
MEF	B
-	I
amyloidosis	I
,	O
we	O
studied	O
17	O
informative	O
families	O
(	O
15	O
Armenians	O
,	O
2	O
non	O
-	O
Ashkenazi	O
Jews	O
)	O
and	O
8	O
MEF	B
patients	O
with	O
amyloidosis	B
using	O
a	O
candidate	O
gene	O
approach	O
.	O

No	O
evidence	O
for	O
any	O
MEF	B
-	O
associated	O
polymorphism	O
was	O
found	O
in	O
any	O
of	O
the	O
41	O
Armenian	O
and	O
Jewish	O
MEF	B
patients	O
tested	O
.	O

Our	O
family	O
studies	O
allowed	O
us	O
to	O
rule	O
out	O
tight	O
linkage	O
between	O
SAA	O
and	O
MEF	B
(	O
lod	O
score	O
=	O
-	O
2	O
.	O
16	O
,	O
theta	O
less	O
than	O
or	O
equal	O
to	O
0	O
.	O
06	O
)	O
.	O

For	O
APCS	O
we	O
found	O
that	O
the	O
allele	O
frequency	O
in	O
the	O
MEF	B
-	I
amyloidosis	I
patients	O
was	O
similar	O
to	O
that	O
in	O
18	O
unrelated	O
MEF	B
patients	O
without	O
amyloidosis	B
and	O
their	O
33	O
healthy	O
parents	O
.	O

Some	O
Mexican	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
revisited	O
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
appears	O
to	O
be	O
fairly	O
common	O
in	O
Mexico	O
.	O

We	O
have	O
now	O
examined	O
the	O
DNA	O
of	O
three	O
previously	O
reported	O
electrophoretically	O
fast	O
Mexican	O
G6PD	O
variants	O
,	O
-	O
G6PD	O
Distrito	O
Federal	O
,	O
G6PD	O
Tepic	O
,	O
and	O
G6PD	O
Castilla	O
.	O

All	O
three	O
of	O
these	O
variants	O
,	O
believed	O
on	O
the	O
basis	O
of	O
biochemical	O
characterization	O
and	O
population	O
origin	O
to	O
be	O
unique	O
,	O
have	O
the	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
at	O
nucleotide	O
202	O
and	O
the	O
A	O
-	O
-	O
-	O
-	O
G	O
transition	O
at	O
nucleotide	O
376	O
,	O
mutations	O
that	O
we	O
now	O
recognize	O
to	O
be	O
characteristic	O
of	O
G6PD	O
A	O
-	O
.	O

Two	O
other	O
Mexican	O
males	O
with	O
G6PD	B
deficiency	I
were	O
found	O
to	O
have	O
the	O
same	O
mutation	O
.	O

All	O
five	O
have	O
the	O
(	O
NlaIII	O
/	O
FokI	O
/	O
PvuII	O
/	O
PstI	O
)	O
haplotype	O
characteristic	O
of	O
G6PD	O
A	O
-	O
in	O
Africa	O
.	O

Since	O
the	O
PvuII	O
+	O
genotype	O
seems	O
to	O
be	O
rare	O
in	O
Europe	O
,	O
we	O
conclude	O
that	O
all	O
of	O
these	O
G6PD	O
A	O
-	O
genes	O
had	O
their	O
ancient	O
origin	O
in	O
Africa	O
,	O
although	O
in	O
many	O
of	O
the	O
Mexican	O
patients	O
with	O
G6PD	O
A	O
-	O
202A	O
/	O
376G	O
the	O
gene	O
may	O
have	O
been	O
imported	O
more	O
recently	O
from	O
Spain	O
,	O
where	O
this	O
variant	O
,	O
formerly	O
known	O
as	O
G6PD	O
Betica	O
,	O
is	O
also	O
prevalent	O
.	O
.	O

Hereditary	O
deficiency	B
of	I
C5	I
in	O
association	O
with	O
discoid	B
lupus	I
erythematosus	I
.	O

A	O
29	O
-	O
year	O
-	O
old	O
woman	O
with	O
discoid	B
lupus	I
erythematosus	I
had	O
undetectable	O
classic	O
pathway	O
complement	O
activity	O
.	O

Hypocomplementemia	B
was	O
due	O
to	O
selective	O
deficiency	B
of	I
C5	I
.	O

One	O
of	O
her	O
children	O
was	O
also	O
deficient	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
documented	O
case	O
of	O
an	O
association	O
between	O
discoid	B
lupus	I
erythematosus	I
and	O
C5	B
deficiency	I
.	O
.	O

Founder	O
effect	O
of	O
a	O
prevalent	O
phenylketonuria	B
mutation	O
in	O
the	O
Oriental	O
population	O
.	O

A	O
missense	O
mutation	O
has	O
been	O
identified	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
[	O
PAH	O
;	O
phenylalanine	O
4	O
-	O
monooxygenase	O
;	O
L	O
-	O
phenylalanine	O
,	O
tetrahydrobiopterin	O
oxygen	O
oxidoreductase	O
(	O
4	O
-	O
hydroxylating	O
)	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
]	O
gene	O
in	O
a	O
Chinese	O
patient	O
with	O
classic	O
phenylketonuria	B
(	O
PKU	B
)	O
.	O

A	O
G	O
-	O
to	O
-	O
C	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
413	O
in	O
exon	O
12	O
of	O
the	O
gene	O
results	O
in	O
the	O
substitution	O
of	O
Pro413	O
for	O
Arg413	O
in	O
the	O
mutant	O
protein	O
.	O

This	O
mutation	O
(	O
R413P	O
)	O
results	O
in	O
negligible	O
enzymatic	O
activity	O
when	O
expressed	O
in	O
heterologous	O
mammalian	O
cells	O
and	O
is	O
compatible	O
with	O
a	O
classic	O
PKU	B
phenotype	O
in	O
the	O
patient	O
.	O

Population	O
genetic	O
studies	O
reveal	O
that	O
this	O
mutation	O
is	O
tightly	O
linked	O
to	O
restriction	O
fragment	O
length	O
polymorphism	O
haplotype	O
4	O
,	O
which	O
is	O
the	O
predominant	O
haplotype	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
Oriental	O
population	O
.	O

It	O
accounts	O
for	O
13	O
.	O

8	O
%	O
of	O
northern	O
Chinese	O
and	O
27	O
%	O
of	O
Japanese	O
PKU	B
alleles	O
,	O
but	O
it	O
is	O
rare	O
in	O
southern	O
Chinese	O
(	O
2	O
.	O
2	O
%	O
)	O
and	O
is	O
absent	O
in	O
the	O
Caucasian	O
population	O
.	O

The	O
data	O
demonstrate	O
unambiguously	O
that	O
the	O
mutation	O
occurred	O
after	O
racial	O
divergence	O
of	O
Orientals	O
and	O
Caucasians	O
and	O
suggest	O
that	O
the	O
allele	O
has	O
spread	O
throughout	O
the	O
Orient	O
by	O
a	O
founder	O
effect	O
.	O

Previous	O
protein	O
polymorphism	O
studies	O
in	O
eastern	O
Asia	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
"	O
northern	O
Mongoloids	O
"	O
represented	O
a	O
founding	O
population	O
in	O
Asia	O
.	O

Our	O
results	O
are	O
compatible	O
with	O
this	O
hypothesis	O
in	O
that	O
the	O
PKU	B
mutation	O
might	O
have	O
occurred	O
in	O
northern	O
Mongoloids	O
and	O
subsequently	O
spread	O
to	O
the	O
Chinese	O
and	O
Japanese	O
populations	O
.	O

Glucose	B
/	I
galactose	I
malabsorption	I
caused	O
by	O
a	O
defect	O
in	O
the	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
.	O

Glucose	B
/	I
galactose	I
malabsorption	I
(	O
GGM	B
)	O
is	O
an	O
autosomal	B
recessive	I
disease	I
manifesting	O
within	O
the	O
first	O
weeks	O
of	O
life	O
and	O
characterized	O
by	O
a	O
selective	O
failure	O
to	O
absorb	O
dietary	O
glucose	O
and	O
galactose	O
from	O
the	O
intestine	O
.	O

The	O
consequent	O
severe	O
diarrhoea	B
and	O
dehydration	B
are	O
usually	O
fatal	O
unless	O
these	O
sugars	O
are	O
eliminated	O
from	O
the	O
diet	O
.	O

Intestinal	O
biopsies	O
of	O
GGM	B
patients	O
have	O
revealed	O
a	O
specific	O
defect	O
in	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
absorption	O
of	O
glucose	O
in	O
the	O
brush	O
border	O
.	O

Normal	O
glucose	O
absorption	O
is	O
mediated	O
by	O
the	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
in	O
the	O
brush	O
border	O
membrane	O
of	O
the	O
intestinal	O
epithelium	O
.	O

Cellular	O
influx	O
is	O
driven	O
by	O
the	O
transmembrane	O
Na	O
+	O
electrochemical	O
potential	O
gradient	O
;	O
thereafter	O
the	O
sugar	O
moves	O
to	O
the	O
blood	O
across	O
the	O
basolateral	O
membrane	O
via	O
the	O
facilitated	O
glucose	O
carrier	O
.	O

We	O
have	O
previously	O
cloned	O
and	O
sequenced	O
a	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
from	O
normal	O
human	O
ileum	O
and	O
shown	O
that	O
this	O
gene	O
,	O
SGLT1	O
,	O
resides	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
.	O

We	O
have	O
now	O
amplified	O
SGLT1	O
complementary	O
DNA	O
and	O
genomic	O
DNA	O
from	O
members	O
of	O
a	O
family	O
affected	O
with	O
GGM	B
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O

Sequence	O
analysis	O
of	O
the	O
amplified	O
products	O
has	O
revealed	O
a	O
single	O
missense	O
mutation	O
in	O
SGLT1	O
which	O
cosegregates	O
with	O
the	O
GGM	B
phenotype	O
and	O
results	O
in	O
a	O
complete	O
loss	O
of	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
glucose	O
transport	O
in	O
Xenopus	O
oocytes	O
injected	O
with	O
this	O
complementary	O
RNA	O
.	O
.	O

A	O
de	O
novo	O
unbalanced	O
reciprocal	O
translocation	O
identified	O
as	O
paternal	O
in	O
origin	O
in	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
.	O

Interstitial	O
cytogenetic	O
deletions	O
involving	O
the	O
paternally	O
derived	O
chromosome	O
15q11	O
-	O
13	O
have	O
been	O
described	O
in	O
patients	O
with	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
report	O
a	O
child	O
with	O
PWS	B
and	O
a	O
de	O
novo	O
unbalanced	O
karyotype	O
-	O
45	O
,	O
XY	O
,	O
-	O
9	O
,	O
-	O
15	O
,	O
+	O
der	O
(	O
9	O
)	O
t	O
(	O
9	O
;	O
15	O
)	O
(	O
q34	O
;	O
q13	O
)	O
.	O

Molecular	O
studies	O
with	O
the	O
DNA	O
probe	O
pML34	O
confirmed	O
that	O
only	O
a	O
single	O
Prader	B
Willi	I
critical	O
region	O
(	O
PWCR	O
15q11	O
.	O
2	O
-	O
q12	O
)	O
copy	O
was	O
present	O
.	O

Hybridisation	O
of	O
patient	O
and	O
parental	O
DNA	O
with	O
the	O
multi	O
-	O
allelic	O
probe	O
CMW1	O
,	O
which	O
maps	O
to	O
pter	O
-	O
15q13	O
,	O
showed	O
that	O
the	O
chromosome	O
involved	O
in	O
the	O
translocation	O
was	O
paternal	O
in	O
origin	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
paternally	O
-	O
derived	O
PWCR	O
allele	O
loss	O
caused	O
by	O
an	O
unbalanced	O
translocation	O
that	O
has	O
arisen	O
de	O
novo	O
.	O

Localisation	O
of	O
the	O
myotonic	B
dystrophy	I
locus	O
to	O
19q13	O
.	O
2	O
-	O
19q13	O
.	O
3	O
and	O
its	O
relationship	O
to	O
twelve	O
polymorphic	O
loci	O
on	O
19q	O
.	O

The	O
order	O
of	O
fourteen	O
polymorphic	O
markers	O
localised	O
to	O
the	O
long	O
arm	O
of	O
human	O
chromosome	O
19	O
has	O
been	O
established	O
by	O
multipoint	O
mapping	O
in	O
a	O
set	O
of	O
40	O
CEPH	O
(	O
Centre	O
dEtude	O
de	O
Polymorphisme	O
Humain	O
,	O
Paris	O
)	O
reference	O
families	O
.	O

We	O
report	O
here	O
the	O
linkage	O
relationship	O
of	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
to	O
twelve	O
of	O
these	O
markers	O
as	O
studied	O
in	O
45	O
families	O
with	O
DM	B
.	O

The	O
resulting	O
genetic	O
map	O
is	O
supported	O
by	O
the	O
localisation	O
of	O
the	O
DNA	O
markers	O
in	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
.	O

Ten	O
of	O
the	O
twelve	O
markers	O
have	O
been	O
shown	O
to	O
be	O
proximal	O
to	O
the	O
DM	B
gene	O
and	O
two	O
,	O
PRKCG	O
and	O
D19S22	O
,	O
distal	O
but	O
at	O
distances	O
of	O
approximately	O
25	O
cM	O
and	O
15	O
cM	O
,	O
respectively	O
.	O

The	O
closest	O
proximal	O
markers	O
are	O
APOC2	O
(	O
apolipoprotein	O
C	O
-	O
II	O
)	O
and	O
CKM	O
(	O
creatine	O
kinase	O
,	O
muscle	O
)	O
approximately	O
3	O
cM	O
and	O
2	O
cM	O
from	O
the	O
DM	B
gene	O
respectively	O
,	O
in	O
the	O
order	O
APOC2	O
-	O
CKM	O
-	O
DM	O
.	O

The	O
distance	O
between	O
APOC2	O
,	O
CKM	O
and	O
DM	B
(	O
of	O
the	O
order	O
of	O
2	O
million	O
base	O
pairs	O
)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	O
walking	O
and	O
jumping	O
.	O

The	O
data	O
presented	O
here	O
should	O
enable	O
us	O
to	O
determine	O
whether	O
or	O
not	O
new	O
markers	O
are	O
distal	O
to	O
APOC2	O
/	O
CKM	O
and	O
thus	O
potentially	O
flank	O
the	O
DM	B
gene	O
.	O
.	O

Localization	O
of	O
histidase	O
to	O
human	O
chromosome	O
region	O
12q22	O
-	O
-	O
-	O
-	O
q24	O
.	O
1	O
and	O
mouse	O
chromosome	O
region	O
10C2	O
-	O
-	O
-	O
-	O
D1	O
.	O

The	O
human	O
gene	O
for	O
histidase	O
(	O
histidine	O
ammonia	O
-	O
lyase	O
;	O
HAL	O
)	O
,	O
the	O
enzyme	O
deficient	O
in	O
histidinemia	B
,	O
was	O
assigned	O
to	O
human	O
chromosome	O
12	O
by	O
Southern	O
blot	O
analysis	O
of	O
human	O
X	O
mouse	O
somatic	O
cell	O
hybrid	O
DNA	O
.	O

The	O
gene	O
was	O
sublocalized	O
to	O
region	O
12q22	O
-	O
-	O
-	O
-	O
q24	O
.	O

1	O
by	O
in	O
situ	O
hybridization	O
,	O
using	O
a	O
human	O
histidase	O
cDNA	O
.	O

The	O
homologous	O
locus	O
in	O
the	O
mouse	O
(	O
Hal	O
)	O
was	O
mapped	O
to	O
region	O
10C2	O
-	O
-	O
-	O
-	O
D1	O
by	O
in	O
situ	O
hybridization	O
,	O
using	O
a	O
cell	O
line	O
from	O
a	O
mouse	O
homozygous	O
for	O
a	O
1	O
.	O

10	O
Robertsonian	O
translocation	O
.	O

These	O
assignments	O
extend	O
the	O
conserved	O
syntenic	O
region	O
between	O
human	O
chromosome	O
12	O
and	O
mouse	O
chromosome	O
10	O
that	O
includes	O
the	O
genes	O
for	O
phenylalanine	O
hydroxylase	O
,	O
gamma	O
interferon	O
,	O
peptidase	O
,	O
and	O
citrate	O
synthase	O
.	O

The	O
localization	O
of	O
histidase	O
to	O
mouse	O
chromosome	O
10	O
suggests	O
that	O
the	O
histidase	O
regulatory	O
locus	O
(	O
Hsd	O
)	O
and	O
the	O
histidinemia	O
mutation	O
(	O
his	O
)	O
,	O
which	O
are	O
both	O
known	O
to	O
be	O
on	O
chromosome	O
10	O
,	O
may	O
be	O
alleles	O
of	O
the	O
histidase	O
structural	O
gene	O
locus	O
.	O

Determination	O
of	O
the	O
mutations	O
responsible	O
for	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
in	O
17	O
subjects	O
.	O

Hypoxanthine	O
-	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
is	O
a	O
purine	O
salvage	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
hypoxanthine	O
to	O
inosine	O
monophosphate	O
and	O
guanine	O
to	O
guanosine	O
monophosphate	O
.	O

Previous	O
studies	O
of	O
mutant	O
HPRT	O
proteins	O
analyzed	O
at	O
the	O
molecular	O
level	O
have	O
shown	O
a	O
significant	O
heterogeneity	O
.	O

This	O
investigation	O
further	O
verifies	O
this	O
heterogeneity	O
and	O
identifies	O
insertions	O
,	O
deletions	O
,	O
and	O
point	O
mutations	O
.	O

The	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
product	O
of	O
reverse	O
-	O
transcribed	O
HPRT	O
mRNA	O
enabled	O
the	O
rapid	O
identification	O
of	O
the	O
mutations	O
found	O
in	O
17	O
previously	O
uncharacterized	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O
.	O

Linkage	O
of	O
DNA	O
markers	O
at	O
Xq28	O
to	O
adrenoleukodystrophy	B
and	O
adrenomyeloneuropathy	B
present	O
within	O
the	O
same	O
family	O
.	O

We	O
present	O
a	O
large	O
kindred	O
that	O
contained	O
patients	O
with	O
either	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
or	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
.	O

The	O
pedigree	O
clearly	O
supported	O
the	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
of	O
the	O
nonneonatal	O
form	O
of	O
ALD	B
/	O
AMN	B
.	O

Analysis	O
with	O
DNA	O
markers	O
at	O
Xq28	O
suggested	O
segregation	O
of	O
both	O
ALD	B
and	O
AMN	B
with	O
an	O
identical	O
haplotype	O
.	O

This	O
indicated	O
that	O
nonneonatal	O
ALD	B
and	O
AMN	B
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
same	O
gene	O
at	O
Xq28	O
.	O

It	O
showed	O
,	O
furthermore	O
,	O
that	O
phenotypic	O
differences	O
between	O
ALD	B
and	O
AMN	B
are	O
not	O
necessarily	O
the	O
consequence	O
of	O
allelic	O
heterogeneity	O
due	O
to	O
different	O
mutations	O
within	O
the	O
same	O
gene	O
.	O

The	O
maximal	O
lod	O
score	O
for	O
linkage	O
of	O
the	O
ALD	B
/	O
AMN	B
gene	O
and	O
the	O
multiallelic	O
anonymous	O
DNA	O
marker	O
at	O
DXS52	O
was	O
3	O
.	O

0	O
at	O
a	O
recombination	O
fraction	O
of	O
0	O
.	O

00	O
.	O

This	O
made	O
a	O
prenatal	O
or	O
presymptomatic	O
diagnosis	O
and	O
heterozygote	O
detection	O
by	O
DNA	O
analysis	O
with	O
this	O
marker	O
reliable	O
.	O

Skewed	O
X	O
inactivation	O
in	O
a	O
female	O
MZ	O
twin	O
results	O
in	O
Duchenne	B
muscular	I
dystrophy	I
.	O

One	O
of	O
female	O
MZ	O
twins	O
presented	O
with	O
muscular	B
dystrophy	I
.	O

Physical	O
examination	O
,	O
creatine	O
phosphokinase	O
levels	O
,	O
and	O
muscle	O
biopsy	O
were	O
consistent	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

However	O
,	O
because	O
of	O
her	O
sex	O
she	O
was	O
diagnosed	O
as	O
having	O
limb	B
-	I
girdle	I
muscular	I
dystrophy	I
.	O

With	O
cDNA	O
probes	O
to	O
the	O
DMD	B
gene	O
,	O
a	O
gene	O
deletion	O
was	O
detected	O
in	O
the	O
twins	O
and	O
their	O
mother	O
.	O

The	O
de	O
novo	O
mutation	O
which	O
arose	O
in	O
the	O
mother	O
was	O
shown	O
by	O
novel	O
junction	O
fragments	O
generated	O
by	O
HindIII	O
,	O
PstI	O
,	O
or	O
TaqI	O
when	O
probed	O
with	O
cDNA8	O
.	O

Additional	O
evidence	O
of	O
a	O
large	O
gene	O
deletion	O
was	O
given	O
by	O
novel	O
SfiI	O
junction	O
fragments	O
detected	O
by	O
probes	O
p20	O
,	O
J	O
-	O
Bir	O
,	O
and	O
J	O
-	O
66	O
on	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
.	O

Immunoblot	O
analysis	O
of	O
muscle	O
from	O
the	O
affected	O
twin	O
showed	O
dystrophin	O
of	O
normal	O
size	O
but	O
of	O
reduced	O
amount	O
.	O

Immunofluorescent	O
visualization	O
of	O
dystrophin	O
revealed	O
foci	O
of	O
dystrophin	O
-	O
positive	O
fibers	O
adjacent	O
to	O
foci	O
of	O
dystrophin	O
-	O
negative	O
fibers	O
.	O

These	O
data	O
indicate	O
that	O
the	O
affected	O
twin	O
is	O
a	O
manifesting	O
carrier	O
of	O
an	O
abnormal	O
DMD	B
gene	O
,	O
her	O
myopathy	B
being	O
a	O
direct	O
result	O
of	O
underexpression	O
of	O
dystrophin	O
.	O

Cytogenetic	O
analysis	O
revealed	O
normal	O
karyotypes	O
,	O
eliminating	O
the	O
possibility	O
of	O
a	O
translocation	O
affecting	O
DMD	B
gene	O
function	O
.	O

Both	O
linkage	O
analysis	O
and	O
DNA	O
fingerprint	O
analysis	O
revealed	O
that	O
each	O
twin	O
has	O
two	O
different	O
X	O
chromosomes	O
,	O
eliminating	O
the	O
possibility	O
of	O
uniparental	B
disomy	I
as	O
a	O
mechanism	O
for	O
DMD	B
expression	O
.	O

On	O
the	O
basis	O
of	O
methylation	O
differences	O
of	O
the	O
paternal	O
and	O
maternal	O
X	O
chromosomes	O
in	O
these	O
MZ	O
twins	O
,	O
we	O
propose	O
uneven	O
lyonization	O
(	O
X	O
chromosome	O
inactivation	O
)	O
as	O
the	O
underlying	O
mechanism	O
for	O
disease	O
expression	O
in	O
the	O
affected	O
female	O
.	O
.	O

Adrenoleukodystrophy	B
and	O
adrenomyeloneuropathy	B
associated	O
with	O
partial	O
adrenal	B
insufficiency	I
in	O
three	O
generations	O
of	O
a	O
kindred	O
.	O

Four	O
cases	O
of	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
and	O
one	O
case	O
of	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
have	O
developed	O
in	O
a	O
kindred	O
over	O
three	O
generations	O
demonstrating	O
that	O
AMN	B
is	O
a	O
clinical	O
variant	O
of	O
ALD	B
.	O

Pituitary	O
-	O
adrenal	O
function	O
studies	O
were	O
performed	O
in	O
10	O
family	O
members	O
,	O
including	O
two	O
affected	O
males	O
and	O
four	O
females	O
identified	O
as	O
carriers	O
of	O
ALD	B
/	O
AMN	B
.	O

No	O
pituitary	B
-	I
adrenal	I
abnormality	I
was	O
found	O
in	O
the	O
carriers	O
.	O

However	O
,	O
basal	O
morning	O
plasma	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
levels	O
were	O
markedly	O
elevated	O
in	O
the	O
two	O
males	O
with	O
ALD	B
and	O
AMN	B
,	O
despite	O
the	O
fact	O
that	O
they	O
had	O
no	O
clinical	O
signs	O
of	O
adrenal	B
insufficiency	I
and	O
that	O
morning	O
plasma	O
cortisol	O
levels	O
and	O
their	O
response	O
to	O
maximal	O
exogenous	O
ACTH	O
stimulation	O
appeared	O
to	O
be	O
normal	O
.	O

In	O
addition	O
,	O
the	O
integrated	O
24	O
-	O
hour	O
response	O
to	O
the	O
administration	O
were	O
also	O
subnormal	O
in	O
these	O
two	O
cases	O
.	O

Thus	O
,	O
people	O
with	O
ALD	B
and	O
AMN	B
may	O
have	O
subclinical	O
partial	O
adrenocrotical	B
insufficiency	I
.	O

No	O
other	O
endocrinologic	B
dysfunction	I
was	O
identified	O
.	O
.	O

Regional	O
localisation	O
of	O
the	O
Friedreich	B
ataxia	I
locus	O
to	O
human	O
chromosome	O
9q13	O
-	O
-	O
-	O
-	O
q21	O
.	O
1	O
.	O

We	O
have	O
previously	O
assigned	O
the	O
Friedreich	B
ataxia	I
locus	O
(	O
FRDA	O
)	O
to	O
chromosome	O
9	O
;	O
the	O
current	O
maximal	O
lod	O
score	O
between	O
FRDA	O
and	O
MCT112	O
(	O
D9S15	O
)	O
is	O
greater	O
than	O
50	O
at	O
a	O
recombination	O
fraction	O
of	O
theta	O
=	O
0	O
.	O

The	O
physical	O
assignment	O
of	O
the	O
locus	O
defined	O
by	O
MCT112	O
,	O
and	O
hence	O
FRDA	O
,	O
has	O
not	O
been	O
determined	O
,	O
although	O
linkage	O
analysis	O
of	O
MCT112	O
with	O
other	O
chromosome	O
9	O
markers	O
inferred	O
a	O
location	O
close	O
to	O
the	O
centromere	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridisation	O
with	O
MCT112	O
,	O
a	O
corresponding	O
cosmid	O
MJ1	O
,	O
and	O
DR47	O
(	O
D9S5	O
)	O
,	O
coupled	O
with	O
mapping	O
studies	O
on	O
hybrid	O
cell	O
panels	O
,	O
to	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
disease	O
locus	O
.	O

The	O
in	O
situ	O
location	O
of	O
all	O
three	O
probes	O
is	O
9q13	O
-	O
-	O
-	O
-	O
q21	O
.	O

1	O
,	O
distal	O
to	O
the	O
variable	O
heterochromatin	O
region	O
.	O

Physical	O
assignment	O
of	O
FRDA	O
will	O
allow	O
us	O
to	O
identify	O
hybrid	O
cell	O
lines	O
containing	O
the	O
mutated	O
gene	O
.	O

Increased	O
high	O
-	O
density	O
lipoprotein	O
levels	O
caused	O
by	O
a	O
common	O
cholesteryl	O
-	O
ester	O
transfer	O
protein	O
gene	O
mutation	O
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
plasma	O
cholesteryl	O
-	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
catalyzes	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
to	O
other	O
lipoproteins	O
.	O

We	O
recently	O
described	O
a	O
Japanese	O
family	O
with	O
increased	O
HDL	O
levels	O
and	O
CETP	B
deficiency	I
due	O
to	O
a	O
splicing	O
defect	O
of	O
the	O
CETP	O
gene	O
.	O

To	O
assess	O
the	O
frequency	O
and	O
phenotype	O
of	O
this	O
condition	O
,	O
we	O
screened	O
11	O
additional	O
families	O
with	O
high	O
HDL	O
levels	O
by	O
means	O
of	O
a	O
radioimmunoassay	O
for	O
CETP	O
and	O
DNA	O
analysis	O
.	O

RESULTS	O
.	O

We	O
found	O
the	O
same	O
CETP	O
gene	O
mutation	O
in	O
four	O
families	O
from	O
three	O
different	O
regions	O
of	O
Japan	O
.	O

Analysis	O
of	O
restriction	O
-	O
fragment	O
-	O
length	O
polymorphisms	O
of	O
the	O
mutant	O
CETP	O
allele	O
showed	O
that	O
all	O
probands	O
were	O
homozygous	O
for	O
the	O
identical	O
haplotype	O
.	O

Family	O
members	O
homozygous	O
for	O
CETP	B
deficiency	I
(	O
n	O
=	O
10	O
)	O
had	O
moderate	O
hypercholesterolemia	B
(	O
mean	O
total	O
cholesterol	O
level	O
[	O
+	O
/	O
-	O
SD	O
]	O
,	O
7	O
.	O
01	O
+	O
/	O
-	O
0	O
.	O
83	O
mmol	O
per	O
liter	O
)	O
,	O
markedly	O
increased	O
levels	O
of	O
HDL	O
cholesterol	O
(	O
4	O
.	O
24	O
+	O
/	O
-	O
1	O
.	O
01	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	O
A	O
-	O
I	O
,	O
and	O
decreased	O
levels	O
of	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
80	O
mmol	O
per	O
liter	O
)	O
and	O

apolipoprotein	O
B	O
.	O

Members	O
heterozygous	O
for	O
the	O
deficiency	O
(	O
n	O
=	O
20	O
)	O
,	O
whose	O
CETP	O
levels	O
were	O
in	O
the	O
lower	O
part	O
of	O
the	O
normal	O
range	O
,	O
had	O
moderately	O
increased	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
apolipoprotein	O
A	O
-	O
I	O
and	O
an	O
increased	O
ratio	O
of	O
HDL	O
subclass	O
2	O
to	O
HDL	O
subclass	O
3	O
,	O
as	O
compared	O
with	O
unaffected	O
family	O
members	O
(	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
.	O

CETP	B
deficiency	I
was	O
not	O
found	O
in	O
six	O
unrelated	O
subjects	O
with	O
elevated	O
HDL	O
cholesterol	O
levels	O
who	O
were	O
from	O
different	O
parts	O
of	O
the	O
United	O
States	O
.	O

CONCLUSIONS	O
.	O

CETP	B
deficiency	I
appears	O
to	O
be	O
a	O
frequent	O
cause	O
of	O
increased	O
HDL	O
levels	O
in	O
the	O
population	O
of	O
Japan	O
,	O
possibly	O
because	O
of	O
a	O
founder	O
effect	O
.	O

The	O
results	O
that	O
we	O
observed	O
in	O
heterozygotes	O
suggest	O
that	O
CETP	O
normally	O
plays	O
a	O
part	O
in	O
the	O
regulation	O
of	O
levels	O
of	O
HDL	O
subclass	O
2	O
.	O

There	O
was	O
no	O
evidence	O
of	O
premature	B
atherosclerosis	I
in	O
the	O
families	O
with	O
CETP	B
deficiency	I
.	O

In	O
fact	O
,	O
the	O
lipoprotein	O
profile	O
of	O
persons	O
with	O
CETP	B
deficiency	I
is	O
potentially	O
antiatherogenic	O
and	O
may	O
be	O
associated	O
with	O
an	O
increased	O
life	O
span	O
.	O

Further	O
mapping	O
of	O
an	O
ataxia	B
-	I
telangiectasia	I
locus	O
to	O
the	O
chromosome	O
11q23	O
region	O
.	O

We	O
recently	O
mapped	O
the	O
gene	O
for	O
ataxia	B
-	I
telangiectasia	I
group	O
A	O
(	O
ATA	O
)	O
to	O
chromosome	O
11q22	O
-	O
23	O
by	O
linkage	O
analysis	O
,	O
using	O
the	O
genetic	O
markers	O
THY1	O
and	O
pYNB3	O
.	O

12	O
(	O
D11S144	O
)	O
.	O

The	O
most	O
likely	O
order	O
was	O
cent	O
-	O
AT	O
-	O
S144	O
-	O
THY1	O
.	O

The	O
present	O
paper	O
describes	O
further	O
mapping	O
of	O
the	O
AT	B
locus	O
by	O
means	O
of	O
a	O
panel	O
of	O
10	O
markers	O
that	O
span	O
approximately	O
60	O
cM	O
in	O
the	O
11q22	O
-	O
23	O
region	O
centered	O
around	O
S144	O
and	O
THY1	O
.	O

Location	O
scores	O
indicate	O
that	O
three	O
contiguous	O
subsegments	O
within	O
the	O
[	O
S144	O
-	O
THY1	O
]	O
segment	O
,	O
as	O
well	O
as	O
three	O
contiguous	O
segments	O
telomeric	O
to	O
THY1	O
,	O
are	O
each	O
unlikely	O
to	O
contain	O
the	O
AT	B
locus	O
,	O
while	O
the	O
more	O
centromeric	O
[	O
STMY	O
-	O
S144	O
]	O
segment	O
is	O
most	O
likely	O
to	O
contain	O
the	O
AT	B
locus	O
.	O

These	O
data	O
,	O
together	O
with	O
recent	O
refinements	O
in	O
the	O
linkage	O
and	O
physical	O
maps	O
of	O
11q22	O
-	O
23	O
,	O
place	O
the	O
AT	B
locus	O
at	O
11q23	O
.	O

Recurrent	O
meningitis	B
in	O
a	O
patient	O
with	O
congenital	B
deficiency	I
of	I
the	I
C9	I
component	I
of	I
complement	I
.	O

First	O
case	O
of	O
C9	B
deficiency	I
in	O
Europe	O
.	O

We	O
describe	O
the	O
first	O
cases	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
C9	B
deficiency	I
in	O
Europe	O
that	O
were	O
detected	O
in	O
a	O
Swiss	O
family	O
,	O
of	O
which	O
two	O
members	O
-	O
-	O
one	O
with	O
a	O
complete	O
deficiency	O
and	O
the	O
other	O
with	O
approximately	O
half	O
-	O
normal	O
C9	O
levels	O
-	O
-	O
experienced	O
bacterial	B
meningitis	I
.	O

The	O
index	O
patient	O
,	O
a	O
56	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
a	O
history	O
of	O
purulent	B
meningitis	I
at	O
the	O
age	O
of	O
23	O
years	O
,	O
presented	O
with	O
an	O
acute	B
meningococcal	I
meningitis	I
.	O

No	O
impairment	B
of	I
cellular	I
immunity	I
or	O
immunoglobulin	B
deficiency	I
could	O
be	O
found	O
.	O

Complement	O
assays	O
showed	O
a	O
complete	B
deficiency	I
of	I
the	I
C9	I
component	I
,	O
while	O
the	O
other	O
individual	O
component	O
levels	O
were	O
normal	O
and	O
the	O
hemolytic	O
activity	O
(	O
measured	O
using	O
the	O
CH50	O
assay	O
)	O
was	O
only	O
slightly	O
reduced	O
.	O

A	O
family	O
study	O
revealed	O
complete	B
C9	I
deficiency	I
in	O
the	O
patients	O
healthy	O
brother	O
and	O
half	O
-	O
normal	O
C9	O
concentrations	O
in	O
his	O
sister	O
,	O
his	O
son	O
(	O
who	O
also	O
had	O
experienced	O
an	O
episode	O
of	O
bacterial	B
meningitis	I
)	O
,	O
and	O
his	O
niece	O
,	O
consistent	O
with	O
an	O
inherited	O
C9	B
deficiency	I
.	O

This	O
first	O
case	O
of	O
recurrent	B
meningitis	I
in	O
a	O
white	O
patient	O
with	O
complete	B
C9	I
deficiency	I
suggests	O
that	O
this	O
complement	B
defect	I
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
bacterial	B
,	I
especially	I
neisserial	I
,	I
infections	I
.	O
.	O

Detection	O
of	O
98	O
%	O
of	O
DMD	B
/	O
BMD	B
gene	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
.	O

We	O
describe	O
oligonucleotide	O
primer	O
sequences	O
that	O
can	O
be	O
used	O
to	O
amplify	O
eight	O
exons	O
plus	O
the	O
muscle	O
promoter	O
of	O
the	O
dystrophin	O
gene	O
in	O
a	O
single	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

When	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set	O
,	O
these	O
two	O
multiplex	O
reactions	O
detect	O
about	O
98	O
%	O
of	O
deletions	O
in	O
patients	O
with	O
Duchenne	B
or	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
,	O
BMD	B
)	O
.	O

Furthermore	O
,	O
these	O
primers	O
amplify	O
most	O
of	O
the	O
exons	O
in	O
the	O
deletion	O
prone	O
"	O
hot	O
spot	O
"	O
region	O
around	O
exons	O
44	O
to	O
53	O
,	O
allowing	O
determination	O
of	O
deletion	O
endpoints	O
and	O
prediction	O
of	O
mutational	O
effects	O
on	O
the	O
translational	O
reading	O
frame	O
.	O

Thus	O
,	O
use	O
of	O
these	O
PCR	O
-	O
based	O
assays	O
will	O
allow	O
deletion	O
detection	O
and	O
prenatal	O
diagnosis	O
for	O
most	O
DMD	B
/	O
BMD	B
patients	O
in	O
a	O
fraction	O
of	O
the	O
time	O
required	O
for	O
Southern	O
blot	O
analysis	O
.	O
.	O

Genetic	O
heterogeneity	O
at	O
the	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
locus	O
in	O
southern	O
Italy	O
:	O
a	O
study	O
on	O
a	O
population	O
from	O
the	O
Matera	O
district	O
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
has	O
been	O
analyzed	O
by	O
gel	O
electrophoresis	O
and	O
by	O
quantitative	O
assay	O
in	O
an	O
unselected	O
sample	O
of	O
1524	O
schoolboys	O
from	O
the	O
province	O
of	O
Matera	O
(	O
Lucania	O
)	O
in	O
southern	O
Italy	O
.	O

We	O
have	O
identified	O
43	O
subjects	O
with	O
a	O
G6PD	O
variant	O
.	O

Of	O
these	O
,	O
31	O
had	O
severe	O
G6PD	B
deficiency	I
,	O
nine	O
had	O
mild	O
to	O
moderate	O
deficiency	O
,	O
and	O
three	O
had	O
a	O
non	O
-	O
deficient	O
electrophoretic	O
variant	O
.	O

The	O
overall	O
rate	O
of	O
G6PD	B
deficiency	I
was	O
2	O
.	O

6	O
%	O
.	O

The	O
frequency	O
of	O
G6PD	B
deficiency	I
,	O
ranging	O
from	O
7	O
.	O

2	O
%	O
on	O
the	O
Ionian	O
Coast	O
to	O
zero	O
on	O
the	O
eastern	O
side	O
of	O
the	O
Lucanian	O
Apennines	O
,	O
appears	O
to	O
be	O
inversely	O
related	O
to	O
the	O
distance	O
of	O
each	O
town	O
examined	O
from	O
the	O
Ionian	O
Coast	O
,	O
suggesting	O
that	O
this	O
geographic	O
distribution	O
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
gene	O
flow	O
from	O
Greek	O
settlers	O
.	O

Biochemical	O
characterization	O
has	O
shown	O
that	O
most	O
of	O
the	O
G6PD	B
deficiency	I
in	O
this	O
population	O
is	O
accounted	O
for	O
by	O
G6PD	O
Mediterranean	O
.	O

In	O
addition	O
,	O
we	O
have	O
found	O
several	O
examples	O
of	O
two	O
other	O
known	O
polymorphic	O
variants	O
(	O
G6PD	O
Cagliari	O
and	O
G6PD	O
A	O
-	O
)	O
;	O
three	O
new	O
polymorphic	O
variants	O
,	O
G6PD	O
Metaponto	O
(	O
class	O
III	O
)	O
,	O
G6PD	O
Montalbano	O
(	O
class	O
III	O
)	O
,	O
and	O
G6PD	O
Pisticci	O
(	O
class	O
IV	O
)	O
;	O
and	O
two	O
sporadic	O
variants	O
,	O
G6PD	O
Tursi	O
(	O
class	O
III	O
)	O
and	O
G6PD	O
Ferrandina	O
(	O
class	O
II	O
)	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
marked	O
genetic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
within	O
a	O
relatively	O
narrow	O
geographic	O
area	O
and	O
they	O
prove	O
the	O
presence	O
in	O
the	O
Italian	O
peninsula	O
of	O
a	O
gene	O
(	O
GdA	O
-	O
)	O
regarded	O
as	O
characteristically	O
African	O
.	O

Deficiency	B
of	I
the	I
murine	I
fifth	I
complement	I
component	I
(	I
C5	I
)	I
.	O

A	O
2	O
-	O
base	O
pair	O
gene	O
deletion	O
in	O
a	O
5	O
'	O
-	O
exon	O
.	O

To	O
ascertain	O
the	O
molecular	O
mechanism	O
that	O
causes	O
murine	O
C5	B
deficiency	I
,	O
genomic	O
and	O
cDNA	O
libraries	O
were	O
constructed	O
from	O
mouse	O
liver	O
DNA	O
and	O
mRNA	O
employing	O
the	O
congenic	O
strains	O
B10	O
.	O

D2	O
/	O
nSnJ	O
and	O
B10	O
.	O

D2	O
/	O
oSnJ	O
that	O
are	O
sufficient	O
and	O
deficient	B
for	I
C5	I
,	O
respectively	O
.	O

Genomic	O
fragments	O
were	O
isolated	O
which	O
correspond	O
to	O
PvuII	O
and	O
HindIII	O
restriction	O
fragment	O
length	O
polymorphisms	O
associated	O
with	O
C5	B
deficiency	I
.	O

Sequence	O
analyses	O
demonstrated	O
that	O
each	O
of	O
these	O
polymorphisms	O
resulted	O
from	O
single	O
base	O
pair	O
substitutions	O
and	O
that	O
neither	O
substitution	O
would	O
probably	O
cause	O
or	O
contribute	O
to	O
the	O
C5	B
deficiency	I
.	O

Sequence	O
analyses	O
of	O
C5	O
sufficient	O
and	O
deficient	O
cDNAs	O
revealed	O
a	O
2	O
base	O
-	O
pair	O
deletion	O
in	O
the	O
deficient	O
cDNAs	O
.	O

The	O
"	O
TA	O
"	O
deletion	O
was	O
located	O
near	O
the	O
5	O
end	O
of	O
the	O
cDNA	O
.	O

This	O
deletion	O
shifts	O
the	O
reading	O
frame	O
of	O
the	O
C5	O
mRNA	O
so	O
that	O
the	O
termination	O
codon	O
UGA	O
is	O
present	O
4	O
base	O
pairs	O
downstream	O
from	O
the	O
deletion	O
.	O

Genomic	O
DNA	O
was	O
amplified	O
and	O
sequenced	O
corresponding	O
to	O
the	O
area	O
surrounding	O
the	O
2	O
-	O
base	O
pair	O
deletion	O
.	O

Six	O
C5	B
-	I
deficient	I
strains	O
,	O
A	O
/	O
HeJ	O
,	O
AKR	O
/	O
J	O
,	O
DBA	O
/	O
2J	O
,	O
NZB	O
/	O
B1NJ	O
,	O
SWR	O
/	O
J	O
,	O
and	O
B10	O
.	O

D2	O
/	O
oSnJ	O
,	O
and	O
four	O
C5	O
-	O
sufficient	O
strains	O
,	O
Balb	O
/	O
CJ	O
,	O
C57Bl	O
/	O
6J	O
,	O
DBA	O
/	O
1J	O
,	O
and	O
B10	O
.	O

D2	O
/	O
nSnJ	O
,	O
were	O
analyzed	O
.	O

The	O
sequencing	O
data	O
revealed	O
that	O
the	O
2	O
base	O
pairs	O
were	O
deleted	O
from	O
the	O
C5	O
gene	O
of	O
each	O
deficient	O
mouse	O
tested	O
but	O
not	O
from	O
the	O
C5	O
gene	O
of	O
any	O
sufficient	O
mouse	O
.	O

These	O
data	O
demonstrate	O
that	O
1	O
)	O
there	O
is	O
an	O
identical	O
2	O
-	O
base	O
pair	O
deletion	O
in	O
an	O
exon	O
of	O
the	O
C5	O
gene	O
in	O
several	O
different	O
C5	B
-	I
deficient	I
mouse	O
strains	O
;	O
2	O
)	O
the	O
mRNA	O
transcribed	O
from	O
the	O
C5D	O
gene	O
retains	O
this	O
deletion	O
;	O
and	O
3	O
)	O
this	O
mutation	O
should	O
result	O
in	O
C5	B
protein	I
deficiency	I
.	O

Molecular	O
genetics	O
of	O
PKU	B
in	O
eastern	O
Europe	O
:	O
a	O
nonsense	O
mutation	O
associated	O
with	O
haplotype	O
4	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
a	O
genetic	B
disorder	I
secondary	O
to	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

Several	O
mutations	O
in	O
the	O
PAH	O
gene	O
have	O
recently	O
been	O
reported	O
,	O
and	O
linkage	O
disequilibrium	O
was	O
observed	O
between	O
RFLP	O
haplotypes	O
and	O
specific	O
mutations	O
.	O

A	O
new	O
molecular	B
lesion	I
has	O
been	O
identified	O
in	O
exon	O
7	O
of	O
the	O
PAH	O
gene	O
in	O
a	O
Hungarian	O
PKU	B
patient	O
by	O
direct	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
DNA	O
.	O

The	O
C	O
-	O
to	O
-	O
T	O
transition	O
causes	O
the	O
substitution	O
of	O
Arg243	O
to	O
a	O
termination	O
codon	O
,	O
and	O
the	O
mutant	O
allele	O
is	O
associated	O
with	O
haplotype	O
4	O
of	O
the	O
PAH	O
gene	O
.	O

The	O
mutation	O
is	O
present	O
in	O
two	O
of	O
nine	O
mutant	O
haplotype	O
4	O
alleles	O
among	O
Eastern	O
Europeans	O
and	O
is	O
not	O
present	O
among	O
Western	O
Europeans	O
and	O
Asians	O
.	O

The	O
rarity	O
of	O
this	O
mutant	O
allele	O
and	O
its	O
restricted	O
geographic	O
distribution	O
suggest	O
that	O
the	O
mutational	O
event	O
occurred	O
recently	O
on	O
a	O
normal	O
haplotype	O
4	O
background	O
in	O
Eastern	O
Europe	O
.	O
.	O

The	O
red	O
-	O
green	O
visual	O
pigment	O
gene	O
region	O
in	O
adrenoleukodystrophy	B
.	O

Although	O
recent	O
data	O
established	O
that	O
a	O
specific	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acyl	O
-	O
CoA	O
synthetase	O
is	O
defective	O
in	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
,	O
the	O
ALD	B
gene	O
is	O
still	O
unidentified	O
.	O

The	O
ALD	B
locus	O
has	O
been	O
mapped	O
to	O
Xq28	O
,	O
like	O
the	O
red	O
and	O
green	O
color	O
pigment	O
genes	O
.	O

Abnormal	B
color	I
vision	I
has	O
been	O
observed	O
in	O
12	O
of	O
27	O
patients	O
with	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
,	O
a	O
milder	O
form	O
of	O
ALD	B
.	O

Furthermore	O
,	O
rearrangements	O
of	O
the	O
color	O
vision	O
gene	O
cluster	O
were	O
found	O
in	O
four	O
of	O
eight	O
ALD	B
kindreds	O
.	O

This	O
led	O
us	O
to	O
propose	O
that	O
a	O
single	O
DNA	O
rearrangement	O
could	O
underlie	O
both	O
ALD	B
and	O
abnormal	B
color	I
vision	I
in	O
these	O
patients	O
.	O

Study	O
of	O
34	O
French	O
ALD	B
patients	O
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	O
of	O
green	O
/	O
red	O
visual	O
pigment	O
rearrangements	O
3	O
to	O
the	O
red	O
/	O
green	O
color	O
vision	O
gene	O
complex	O
.	O

The	O
previous	O
report	O
of	O
such	O
rearrangements	O
was	O
based	O
on	O
small	O
numbers	O
and	O
lack	O
of	O
knowledge	O
that	O
the	O
frequency	O
of	O
"	O
abnormal	O
"	O
color	O
vision	O
arrays	O
on	O
molecular	O
analysis	O
was	O
twice	O
as	O
high	O
as	O
expected	O
on	O
the	O
basis	O
of	O
the	O
frequency	O
of	O
phenotypic	B
color	I
vision	I
defects	I
.	O

The	O
red	O
/	O
green	O
color	O
pigment	O
(	O
R	O
/	O
GCP	O
)	O
region	O
was	O
studied	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
in	O
14	O
of	O
these	O
patients	O
,	O
and	O
we	O
did	O
not	O
find	O
any	O
fragment	O
size	O
difference	O
between	O
the	O
patients	O
and	O
normal	O
individuals	O
who	O
have	O
the	O
same	O
number	O
of	O
pigment	O
genes	O
.	O

The	O
R	O
/	O
GCP	O
region	O
was	O
also	O
analyzed	O
in	O
29	O
French	O
and	O
seven	O
North	O
American	O
ALD	B
patients	O
by	O
using	O
six	O
genomic	O
DNA	O
probes	O
,	O
isolated	O
from	O
a	O
cosmid	O
walk	O
,	O
that	O
flank	O
the	O
color	O
vision	O
genes	O
.	O

No	O
deletions	O
were	O
found	O
with	O
probes	O
that	O
lie	O
3	O
of	O
the	O
green	O
pigment	O
genes	O
.	O

One	O
of	O
the	O
eight	O
previously	O
reported	O
ALD	B
individuals	O
has	O
a	O
long	O
deletion	O
5	O
of	O
the	O
red	O
pigment	O
gene	O
,	O
a	O
deletion	O
causing	O
blue	O
cone	O
monochromacy	O
.	O

This	O
finding	O
and	O
the	O
previous	O
findings	O
of	O
a	O
45	O
%	O
frequency	O
of	O
phenotypic	O
color	O
vision	O
defects	O
in	O
patients	O
with	O
AMN	B
may	O
suggest	O
that	O
the	O
ALD	B
/	O
AMN	B
gene	O
lies	O
5	O
to	O
the	O
red	O
pigment	O
gene	O
and	O
that	O
the	O
frequent	O
phenotypic	O
color	B
vision	I
anomalies	I
owe	O
their	O
origin	O
to	O
deleted	O
DNA	O
that	O
includes	O
regulatory	O
genes	O
for	O
color	O
vision	O
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
phenotypic	O
color	B
vision	I
anomalies	I
in	O
AMN	B
may	O
be	O
phenocopies	O
secondary	O
to	O
retinal	O
or	O
neural	O
involvement	O
by	O
the	O
disease	O
.	O

The	O
single	O
case	O
of	O
blue	O
cone	O
monochromacy	O
may	O
therefore	O
be	O
a	O
fortuitous	O
coincidence	O
of	O
two	O
diseases	O
.	O
.	O

Paroxysmal	B
nocturnal	I
haemoglobinuria	I
with	O
coexisting	O
deficiency	B
of	I
the	I
ninth	I
component	I
of	I
complement	I
:	O
lack	O
of	O
massive	O
haemolytic	B
attack	I
.	O

A	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
paroxysmal	B
nocturnal	I
haemoglobinuria	I
(	O
PNH	B
)	O
was	O
found	O
to	O
have	O
an	O
inherited	B
deficiency	I
in	I
the	I
ninth	I
complement	I
component	I
(	O
C9	O
)	O
.	O

In	O
complement	O
-	O
sensitivity	O
lysis	O
tests	O
,	O
80	O
%	O
of	O
her	O
erythrocytes	O
were	O
markedly	O
complement	O
-	O
sensitive	O
(	O
PNH	O
-	O
III	O
)	O
.	O

Laser	O
cytofluorimetry	O
with	O
a	O
monoclonal	O
antibody	O
against	O
decay	O
-	O
accelerating	O
factor	O
(	O
DAF	O
)	O
revealed	O
that	O
95	O
%	O
of	O
her	O
erythrocytes	O
were	O
DAF	O
-	O
negative	O
.	O

Surprisingly	O
,	O
she	O
has	O
suffered	O
only	O
mild	O
haemolysis	B
and	O
has	O
never	O
experienced	O
massive	O
spontaneous	O
haemolysis	B
.	O

Gross	O
haemoglobinuria	B
and	O
jaundice	B
occurred	O
only	O
after	O
receiving	O
postoperative	O
transfusion	O
of	O
whole	O
blood	O
.	O

In	O
her	O
serum	O
,	O
C9	O
was	O
not	O
detectable	O
either	O
by	O
immunological	O
or	O
by	O
functional	O
assays	O
.	O

Both	O
the	O
Ham	O
test	O
and	O
the	O
sugar	O
water	O
test	O
using	O
normal	O
human	O
serum	O
or	O
plasma	O
yielded	O
marked	O
haemolysis	O
of	O
the	O
patients	O
erythrocytes	O
.	O

When	O
the	O
patients	O
serum	O
or	O
plasma	O
was	O
used	O
,	O
only	O
a	O
trace	O
of	O
lysis	O
was	O
detected	O
.	O

Addition	O
of	O
purified	O
human	O
C9	O
to	O
her	O
plasma	O
fully	O
restored	O
haemolysis	O
.	O

These	O
observations	O
indicated	O
that	O
C9	O
may	O
play	O
a	O
critical	O
role	O
in	O
haemolytic	B
attacks	I
in	O
patients	O
with	O
PNH	B
and	O
that	O
characteristic	O
haemolysis	B
in	O
PNH	B
may	O
be	O
tempered	O
by	O
coexisting	O
C9	B
deficiency	I
.	O
.	O

Duplicational	O
mutation	O
at	O
the	O
Duchenne	B
muscular	I
dystrophy	I
locus	O
:	O
its	O
frequency	O
,	O
distribution	O
,	O
origin	O
,	O
and	O
phenotypegenotype	O
correlation	O
.	O

Partial	O
gene	O
deletion	O
is	O
the	O
major	O
cause	O
of	O
mutation	O
leading	O
to	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
and	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
.	O

Partial	O
gene	O
duplication	O
has	O
also	O
been	O
recognized	O
in	O
a	O
few	O
cases	O
.	O

We	O
have	O
conducted	O
a	O
survey	O
for	O
duplication	O
in	O
72	O
unrelated	O
nondeletion	O
patients	O
,	O
analyzed	O
by	O
Southern	O
blot	O
hybridization	O
with	O
clones	O
representing	O
the	O
entire	O
DMD	B
cDNA	O
.	O

With	O
careful	O
quantitative	O
analysis	O
of	O
hybridization	O
band	O
intensity	O
,	O
10	O
cases	O
were	O
found	O
to	O
carry	O
a	O
duplication	O
of	O
part	O
of	O
the	O
gene	O
,	O
a	O
frequency	O
of	O
14	O
%	O
for	O
nondeletion	O
cases	O
(	O
10	O
/	O
72	O
)	O
,	O
or	O
6	O
%	O
for	O
all	O
cases	O
(	O
10	O
/	O
181	O
)	O
.	O

The	O
extent	O
of	O
these	O
duplications	O
has	O
been	O
characterized	O
according	O
to	O
the	O
published	O
exon	O
-	O
containing	O
HindIII	O
fragment	O
map	O
,	O
and	O
in	O
six	O
of	O
the	O
10	O
duplications	O
a	O
novel	O
restriction	O
fragment	O
that	O
spanned	O
the	O
duplication	O
junction	O
was	O
detected	O
.	O

The	O
resulting	O
translational	O
reading	O
frame	O
of	O
mRNA	O
has	O
been	O
predicted	O
for	O
nine	O
duplications	O
.	O

A	O
shift	O
of	O
the	O
reading	O
frame	O
was	O
predicted	O
in	O
four	O
of	O
the	O
six	O
DMD	B
cases	O
and	O
in	O
one	O
of	O
the	O
two	O
intermediate	O
cases	O
,	O
while	O
the	O
reading	O
frame	O
remained	O
uninterrupted	O
in	O
both	O
BMD	B
cases	O
.	O

RFLP	O
and	O
quantitative	O
Southern	O
blot	O
analyses	O
revealed	O
a	O
grandpaternal	O
origin	O
of	O
duplication	O
in	O
four	O
families	O
and	O
grandmaternal	O
origin	O
in	O
one	O
family	O
.	O

In	O
all	O
five	O
families	O
,	O
the	O
duplication	O
was	O
found	O
to	O
originate	O
from	O
a	O
single	O
X	O
chromosome	O
.	O

Unequal	O
sister	O
-	O
chromatid	O
exchange	O
is	O
proposed	O
to	O
be	O
the	O
mechanism	O
for	O
the	O
formation	O
of	O
these	O
duplications	O
.	O
.	O

Glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
:	O
Gd	O
(	O
+	O
)	O
Alexandra	O
associated	O
with	O
neonatal	B
jaundice	I
and	O
Gd	O
(	O
-	O
)	O
Camperdown	O
in	O
a	O
young	O
man	O
with	O
lamellar	B
cataracts	I
.	O

Two	O
male	O
subjects	O
are	O
described	O
,	O
with	O
unusual	O
clinical	O
presentations	O
and	O
with	O
hitherto	O
undescribed	O
G6PD	O
variants	O
.	O

The	O
first	O
,	O
of	O
Italian	O
extraction	O
,	O
suffered	O
from	O
severe	O
neonatal	B
jaundice	I
following	O
maternal	O
ingestion	O
of	O
fresh	O
broad	O
beans	O
(	O
Vicia	O
fava	O
)	O
both	O
prenatally	O
and	O
postnatally	O
the	O
expression	O
of	O
the	O
enzymatic	O
defect	O
was	O
much	O
more	O
severe	O
in	O
the	O
neonatal	O
period	O
than	O
on	O
retesting	O
in	O
adolescence	O
,	O
when	O
biochemical	O
characterization	O
showed	O
unique	O
features	O
which	O
justify	O
designation	O
as	O
a	O
new	O
variant	O
Gd	O
(	O
+	O
)	O
Alexandra	O
.	O

The	O
second	O
patient	O
,	O
a	O
boy	O
of	O
Maltese	O
extraction	O
who	O
was	O
found	O
to	O
have	O
bilateral	B
lamellar	I
cataracts	I
at	O
the	O
age	O
of	O
4	O
years	O
,	O
was	O
identified	O
as	O
G6PD	B
deficient	I
only	O
as	O
a	O
result	O
of	O
a	O
survey	O
of	O
children	O
of	O
Mediterranean	O
origin	O
with	O
unexplained	O
cataract	B
formation	O
;	O
he	O
has	O
approximately	O
15	O
%	O
of	O
normal	O
enzyme	O
activity	O
,	O
with	O
another	O
unique	O
combination	O
of	O
biochemical	O
characteristics	O
which	O
has	O
led	O
to	O
its	O
designation	O
as	O
Gd	O
(	O
-	O
)	O
Camperdown	O
.	O

Although	O
this	O
association	O
may	O
be	O
coincidental	O
,	O
it	O
prompts	O
further	O
attention	O
to	O
the	O
possibility	O
that	O
under	O
certain	O
circumstances	O
G6PD	B
deficiency	I
may	O
favor	O
cataract	B
formation	O
.	O

The	O
two	O
cases	O
illustrate	O
the	O
value	O
of	O
characterization	O
of	O
the	O
mutant	O
enzyme	O
whenever	O
unexpected	O
clinical	O
or	O
laboratory	O
results	O
are	O
obtained	O
.	O
.	O

Statistical	O
analysis	O
of	O
the	O
two	O
stage	O
mutation	O
model	O
in	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
,	O
and	O
in	O
sporadic	B
cerebellar	I
haemangioblastoma	I
and	O
renal	B
cell	I
carcinoma	I
.	O

Analysis	O
of	O
the	O
age	O
incidence	O
curves	O
for	O
unilateral	B
and	I
bilateral	I
retinoblastoma	I
led	O
Knudson	O
to	O
propose	O
that	O
hereditary	B
tumours	I
may	O
arise	O
by	O
a	O
single	O
event	O
and	O
sporadic	B
tumours	I
by	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

It	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	B
renal	I
cell	I
carcinoma	I
may	O
arise	O
from	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

We	O
analysed	O
the	O
age	O
incidence	O
curves	O
for	O
symptomatic	O
renal	B
cell	I
carcinoma	I
(	O
n	O
=	O
26	O
)	O
and	O
cerebellar	B
haemangioblastoma	I
(	O
n	O
=	O
68	O
)	O
in	O
109	O
patients	O
with	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
,	O
and	O
compared	O
them	O
to	O
104	O
patients	O
with	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
43	O
patients	O
with	O
sporadic	B
cerebellar	I
haemangioblastoma	I
.	O

The	O
age	O
incidence	O
curves	O
for	O
renal	B
cell	I
carcinoma	I
and	O
cerebellar	B
haemangioblastoma	I
in	O
VHL	B
disease	I
were	O
compatible	O
with	O
a	O
single	O
mutation	O
model	O
,	O
whereas	O
the	O
age	O
incidence	O
curves	O
for	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
cerebellar	B
haemangioblastoma	I
suggested	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

These	O
data	O
are	O
compatible	O
with	O
the	O
VHL	B
gene	O
functioning	O
as	O
a	O
recessive	O
tumour	B
suppressor	O
gene	O
.	O

Sporadic	B
cerebellar	I
haemangioblastoma	I
and	O
some	O
renal	B
cell	I
carcinoma	I
may	O
arise	O
from	O
somatic	O
mutations	O
inactivating	O
both	O
alleles	O
at	O
the	O
VHL	B
locus	O
.	O
.	O

Screening	O
for	O
carriers	O
of	O
Tay	B
-	I
Sachs	I
disease	I
among	O
Ashkenazi	O
Jews	O
.	O

A	O
comparison	O
of	O
DNA	O
-	O
based	O
and	O
enzyme	O
-	O
based	O
tests	O
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
prevention	O
of	O
Tay	B
-	I
Sachs	I
disease	I
(	O
GM2	B
gangliosidosis	I
,	I
type	I
1	I
)	O
depends	O
on	O
the	O
identification	O
of	O
carriers	O
of	O
the	O
gene	O
for	O
this	O
autosomal	B
recessive	I
disorder	I
.	O

We	O
compared	O
the	O
enzyme	O
-	O
based	O
test	O
widely	O
used	O
in	O
screening	O
for	O
Tay	B
-	I
Sachs	I
disease	I
with	O
a	O
test	O
based	O
on	O
analysis	O
of	O
DNA	O
.	O

We	O
developed	O
methods	O
to	O
detect	O
the	O
three	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
occur	O
with	O
high	O
frequency	O
among	O
Ashkenazi	O
Jews	O
two	O
mutations	O
cause	O
infantile	O
Tay	B
-	I
Sachs	I
disease	I
,	O
and	O
the	O
third	O
causes	O
the	O
adult	O
-	O
onset	O
form	O
of	O
the	O
disease	O
.	O

DNA	O
segments	O
containing	O
these	O
mutation	O
sites	O
were	O
amplified	O
with	O
the	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
mutations	O
.	O

RESULTS	O
.	O

Among	O
62	O
Ashkenazi	O
obligate	O
carriers	O
of	O
Tay	B
-	I
Sachs	I
disease	I
,	O
the	O
three	O
specific	O
mutations	O
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	O
alleles	O
(	O
98	O
percent	O
)	O
.	O

In	O
216	O
Ashkenazi	O
carriers	O
identified	O
by	O
the	O
enzyme	O
test	O
,	O
DNA	O
analysis	O
showed	O
that	O
177	O
(	O
82	O
percent	O
)	O
had	O
one	O
of	O
the	O
identified	O
mutations	O
.	O

Of	O
the	O
177	O
,	O
79	O
percent	O
had	O
the	O
exon	O
11	O
insertion	O
mutation	O
,	O
18	O
percent	O
had	O
the	O
intron	O
12	O
splice	O
-	O
junction	O
mutation	O
,	O
and	O
3	O
percent	O
had	O
the	O
less	O
severe	O
exon	O
7	O
mutation	O
associated	O
with	O
adult	O
-	O
onset	O
disease	O
.	O

The	O
results	O
of	O
the	O
enzyme	O
tests	O
in	O
the	O
39	O
subjects	O
(	O
18	O
percent	O
)	O
who	O
were	O
defined	O
as	O
carriers	O
but	O
in	O
whom	O
DNA	O
analysis	O
did	O
not	O
identify	O
a	O
mutant	O
allele	O
were	O
probably	O
false	O
positive	O
(	O
although	O
there	O
remains	O
some	O
possibility	O
of	O
unidentified	O
mutations	O
)	O
.	O

In	O
addition	O
,	O
of	O
152	O
persons	O
defined	O
as	O
noncarriers	O
by	O
the	O
enzyme	O
-	O
based	O
test	O
,	O
1	O
was	O
identified	O
as	O
a	O
carrier	O
by	O
DNA	O
analysis	O
(	O
i	O
.	O
e	O
e	O
.	O
,	O
a	O
false	O
negative	O
enzyme	O
-	O
test	O
result	O
)	O
.	O

CONCLUSIONS	O
.	O

The	O
increased	O
specificity	O
and	O
predictive	O
value	O
of	O
the	O
DNA	O
-	O
based	O
test	O
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	O
tests	O
currently	O
used	O
to	O
screen	O
for	O
carriers	O
of	O
Tay	B
-	I
Sachs	I
disease	I
.	O

Total	B
deficiency	I
of	I
plasma	I
cholesteryl	I
ester	I
transfer	I
protein	I
in	O
subjects	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
intron	O
14	O
splicing	O
defect	O
.	O

The	O
molecular	O
basis	O
of	O
cholesteryl	B
ester	I
transfer	I
protein	I
(	I
CETP	I
)	I
deficiency	I
was	O
investigated	O
in	O
4	O
unrelated	O
CETP	B
-	I
deficient	I
families	O
.	O

The	O
high	O
density	O
lipoprotein	O
-	O
cholesterol	O
levels	O
of	O
the	O
probands	O
exceeded	O
150	O
mg	O
/	O
dl	O
.	O

The	O
plasma	O
of	O
the	O
probands	O
was	O
totally	O
deficient	O
in	O
CETP	O
activity	O
and	O
mass	O
.	O

The	O
genomic	O
DNA	O
of	O
the	O
patients	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
,	O
using	O
two	O
oligonucleotide	O
primers	O
located	O
in	O
the	O
intron	O
12	O
and	O
14	O
of	O
the	O
CETP	O
gene	O
,	O
and	O
the	O
amplified	O
products	O
were	O
directly	O
sequenced	O
.	O

Two	O
patients	O
were	O
homozygous	O
for	O
a	O
G	O
-	O
to	O
-	O
A	O
change	O
at	O
the	O
5	O
-	O
splice	O
donor	O
site	O
of	O
the	O
intron	O
14	O
.	O

The	O
G	O
-	O
to	O
-	O
A	O
change	O
would	O
cause	O
impaired	O
splicing	O
of	O
pre	O
-	O
messenger	O
RNA	O
.	O

The	O
other	O
two	O
probands	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
but	O
totally	O
lacked	O
CETP	O
.	O

Their	O
lipoprotein	O
patterns	O
were	O
also	O
similar	O
to	O
those	O
of	O
the	O
two	O
homozygotes	O
.	O

Thus	O
,	O
other	O
genetic	B
defects	I
or	O
metabolic	O
factors	O
influencing	O
CETP	O
expression	O
are	O
implicated	O
.	O

The	O
data	O
suggest	O
that	O
the	O
G	O
-	O
to	O
-	O
A	O
mutation	O
may	O
be	O
common	O
in	O
human	O
plasma	O
CETP	B
deficiency	I
.	O

Furthermore	O
,	O
there	O
could	O
be	O
compound	O
heterozygotes	O
who	O
totally	O
lack	O
plasma	O
CETP	O
and	O
have	O
lipoprotein	O
profiles	O
similar	O
to	O
those	O
of	O
homozygotes	O
.	O
.	O

Molecular	O
genetics	O
of	O
the	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
Mediterranean	O
variant	O
and	O
description	O
of	O
a	O
new	O
G6PD	O
mutant	O
,	O
G6PD	O
Andalus1361A	O
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
;	I
E	I
.	I
C	I
.	I
1	I
.	I
1	I
.	I
1	I
.	I
49	I
)	I
deficiency	I
is	O
the	O
most	O
common	O
human	O
enzymopathy	B
;	O
more	O
than	O
300	O
different	O
biochemical	O
variants	O
of	O
the	O
enzyme	O
have	O
been	O
described	O
.	O

In	O
many	O
parts	O
of	O
the	O
world	O
the	O
Mediterranean	O
type	O
of	O
G6PD	B
deficiency	I
is	O
prevalent	O
.	O

However	O
,	O
G6PD	O
Mediterranean	O
has	O
come	O
to	O
be	O
regarded	O
as	O
a	O
generic	O
term	O
applied	O
to	O
similar	O
G6PD	O
mutations	O
thought	O
,	O
however	O
,	O
to	O
represent	O
a	O
somewhat	O
heterogeneous	O
group	O
.	O

A	O
C	O
-	O
-	O
-	O
-	O
T	O
mutation	O
at	O
nucleotide	O
563	O
of	O
G6PD	O
Mediterranean	O
has	O
been	O
identified	O
by	O
Vulliamy	O
et	O
al	O
.	O
,	O
and	O
the	O
same	O
mutation	O
has	O
been	O
found	O
by	O
De	O
Vita	O
et	O
al	O
.	O
in	O
G6PD	O
Mediterranean	O
,	O
G6PD	O
Sassari	O
,	O
and	O
G6PD	O
Cagliari	O
.	O

The	O
latter	O
subjects	O
had	O
an	O
additional	O
mutation	O
,	O
at	O
nucleotide	O
1311	O
,	O
that	O
did	O
not	O
produce	O
a	O
coding	O
change	O
.	O

We	O
have	O
examined	O
genomic	O
DNA	O
of	O
five	O
patients	O
-	O
-	O
four	O
of	O
Spanish	O
origin	O
and	O
one	O
of	O
Jewish	O
origin	O
-	O
-	O
having	O
enzymatically	O
documented	O
G6PD	O
Mediterranean	O
.	O

All	O
had	O
both	O
the	O
mutation	O
at	O
nucleotide	O
563	O
and	O
that	O
at	O
nucleotide	O
1311	O
.	O

A	O
sixth	O
sample	O
,	O
resembling	O
G6PD	O
Mediterranean	O
kinetically	O
but	O
with	O
a	O
slightly	O
rapid	O
electrophoretic	O
mobility	O
,	O
was	O
designated	O
G6PD	O
Andalus	O
and	O
was	O
found	O
to	O
have	O
a	O
different	O
mutation	O
,	O
a	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
at	O
nucleotide	O
1361	O
,	O
producing	O
an	O
arginine	O
-	O
to	O
-	O
histidine	O
substitution	O
.	O

These	O
studies	O
suggest	O
that	O
G6PD	O
Mediterranean	O
is	O
,	O
after	O
all	O
,	O
relatively	O
homogeneous	O
.	O

A	O
normal	O
male	O
with	O
an	O
inherited	O
deletion	O
of	O
one	O
exon	O
within	O
the	O
DMD	B
gene	O
.	O

We	O
describe	O
two	O
brothers	O
with	O
identical	O
inherited	O
deletions	O
of	O
one	O
single	O
exon	O
within	O
the	O
middle	O
of	O
the	O
DMD	B
gene	O
;	O
one	O
brother	O
has	O
Becker	B
muscular	I
dystrophy	I
diagnosed	O
at	O
11	O
years	O
of	O
age	O
,	O
whereas	O
the	O
older	O
brother	O
is	O
normal	O
at	O
18	O
.	O

These	O
results	O
have	O
implications	O
for	O
genetic	O
counselling	O
and	O
prenatal	O
diagnosis	O
in	O
families	O
with	O
Becker	B
muscular	I
dystrophy	I
.	O
.	O

Duchenne	B
muscular	I
dystrophy	I
gene	O
expression	O
in	O
normal	O
and	O
diseased	O
human	O
muscle	O
.	O

A	O
probe	O
for	O
the	O
5	O
end	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
was	O
used	O
to	O
study	O
expression	O
of	O
the	O
gene	O
in	O
normal	O
human	O
muscle	O
,	O
myogenic	O
cell	O
cultures	O
,	O
and	O
muscle	O
from	O
patients	O
with	O
DMD	B
.	O

Expression	O
was	O
found	O
in	O
RNA	O
from	O
normal	O
fetal	O
muscle	O
,	O
adult	O
cardiac	O
and	O
skeletal	O
muscle	O
,	O
and	O
cultured	O
muscle	O
after	O
myoblast	O
fusion	O
.	O

In	O
DMD	B
muscle	O
,	O
expression	O
of	O
this	O
portion	O
of	O
the	O
gene	O
was	O
also	O
revealed	O
by	O
in	O
situ	O
RNA	O
hybridization	O
,	O
particularly	O
in	O
regenerating	O
muscle	O
fibers	O
.	O
.	O

Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
.	O

Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
or	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
DMD	B
locus	O
.	O

This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b	O
-	O
7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O

These	O
80	O
individuals	O
account	O
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al	O
.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
)	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O

Thirty	O
-	O
eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B
,	O
BMD	B
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
BMD	B
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in	O
-	O
frame	O
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al	O
.	O
and	O
Koenig	O
et	O
al	O
.	O
but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al	O
.	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

Cloning	O
of	O
breakpoints	O
of	O
a	O
chromosome	O
translocation	O
identifies	O
the	O
AN2	O
locus	O
.	O

Chromosome	O
translocations	O
involving	O
11p13	O
have	O
been	O
associated	O
with	O
familial	B
aniridia	I
in	O
two	O
kindreds	O
highlighting	O
the	O
chromosomal	O
localization	O
of	O
the	O
AN2	O
locus	O
.	O

This	O
locus	O
is	O
also	O
part	O
of	O
the	O
WAGR	B
complex	O
(	O
Wilms	B
tumor	I
,	O
aniridia	B
,	O
genitourinary	B
abnormalities	I
,	O
and	O
mental	B
retardation	I
)	O
.	O

In	O
one	O
kindred	O
,	O
the	O
translocation	O
is	O
associated	O
with	O
a	O
deletion	O
,	O
and	O
probes	O
for	O
this	O
region	O
were	O
used	O
to	O
identify	O
and	O
clone	O
the	O
breakpoints	O
of	O
the	O
translocation	O
in	O
the	O
second	O
kindred	O
.	O

Comparison	O
of	O
phage	O
restriction	O
maps	O
exclude	O
the	O
presence	O
of	O
any	O
sizable	O
deletion	O
in	O
this	O
case	O
.	O

Sequences	O
at	O
the	O
chromosome	O
11	O
breakpoint	O
are	O
conserved	O
in	O
multiple	O
species	O
,	O
suggesting	O
that	O
the	O
translocation	O
falls	O
within	O
the	O
AN2	O
gene	O
.	O
.	O

Linkage	O
analysis	O
of	O
the	O
apolipoprotein	O
C2	O
gene	O
and	O
myotonic	B
dystrophy	I
on	O
human	O
chromosome	O
19	O
reveals	O
linkage	O
disequilibrium	O
in	O
a	O
French	O
-	O
Canadian	O
population	O
.	O

The	O
gene	O
for	O
human	O
apolipoprotein	O
C2	O
(	O
APOC2	O
)	O
,	O
situated	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
19	O
,	O
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B
dystrophy	I
,	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

Six	O
APOC2	O
RFLPs	O
(	O
TaqI	O
,	O
BglI	O
,	O
BanI	O
,	O
BamHI	O
,	O
NcoI	O
,	O
and	O
AvaII	O
)	O
have	O
been	O
identified	O
to	O
date	O
.	O

We	O
have	O
conducted	O
a	O
comprehensive	O
DM	B
linkage	O
study	O
utilizing	O
all	O
six	O
RFLPs	O
and	O
involving	O
50	O
families	O
and	O
372	O
individuals	O
.	O

The	O
most	O
informative	O
RFLPs	O
are	O
,	O
in	O
descending	O
order	O
,	O
NcoI	O
(	O
lod	O
=	O
6	O
.	O
64	O
,	O
theta	O
=	O
0	O
.	O
05	O
)	O
,	O
BglI	O
(	O
lod	O
=	O
6	O
.	O
12	O
,	O
theta	O
=	O
0	O
.	O
05	O
)	O
,	O
AvaII	O
(	O
lod	O
=	O
6	O
.	O
02	O
,	O
theta	O
=	O
0	O
.	O
03	O
)	O
,	O
BanI	O
(	O
lod	O
=	O
5	O
.	O
76	O
,	O
theta	O
=	O
0	O
.	O
04	O
)	O
,	O
TaqI	O
(	O
lod	O
=	O
4	O
.	O
29	O
,	O
theta	O
=	O
0	O
.	O
06	O
)	O
,	O
and	O
BamHI	O
(	O
lod	O
=	O
1	O
.	O
75	O
,	O
theta	O
=	O
0	O
.	O
01	O

)	O
.	O

A	O
substantial	O
increase	O
in	O
the	O
lod	O
scores	O
over	O
those	O
seen	O
with	O
the	O
individual	O
RFLPs	O
was	O
obtained	O
when	O
the	O
linkage	O
of	O
the	O
entire	O
APOC2	O
haplotype	O
(	O
composed	O
of	O
the	O
six	O
RFLPs	O
)	O
was	O
studied	O
(	O
lod	O
=	O
17	O
.	O
87	O
,	O
theta	O
=	O
0	O
.	O
04	O
)	O
.	O

We	O
have	O
observed	O
significant	O
inter	O
-	O
APOC2	O
RFLP	O
linkage	O
disequilibrium	O
.	O

Consequently	O
,	O
the	O
three	O
most	O
informative	O
RFLPs	O
have	O
been	O
found	O
to	O
be	O
BanI	O
,	O
TaqI	O
,	O
and	O
either	O
BglI	O
,	O
AvaII	O
,	O
or	O
NcoI	O
polymorphisms	O
.	O

We	O
also	O
demonstrate	O
linkage	O
disequilibrium	O
between	O
DM	O
and	O
APOC2	O
in	O
our	O
French	O
-	O
Canadian	O
population	O
(	O
standardized	O
disequilibrium	O
constant	O
phi	O
=	O
.	O
22	O
,	O
chi	O
2	O
=	O
5	O
.	O
12	O
,	O
df	O
=	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
04	O
)	O
.	O

This	O
represents	O
the	O
first	O
evidence	O
of	O
linkage	O
disequilibrium	O
between	O
APOC2	O
and	O
the	O
DM	B
locus	O
.	O

Phenylalanine	O
hydroxylase	O
gene	O
haplotypes	O
in	O
Polynesians	O
:	O
evolutionary	O
origins	O
and	O
absence	O
of	O
alleles	O
associated	O
with	O
severe	O
phenylketonuria	B
.	O

A	O
total	O
of	O
630	O
haplotypes	O
for	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
locus	O
were	O
established	O
in	O
five	O
groups	O
of	O
Polynesians	O
comprising	O
Samoans	O
,	O
Tongans	O
,	O
Cook	O
Islanders	O
,	O
Maori	O
,	O
and	O
Niueans	O
.	O

Considerable	O
genetic	O
continuity	O
was	O
demonstrated	O
between	O
these	O
widely	O
dispersed	O
populations	O
,	O
since	O
three	O
common	O
haplotypes	O
(	O
4	O
,	O
1	O
,	O
and	O
7	O
)	O
constituted	O
over	O
95	O
%	O
of	O
alleles	O
.	O

A	O
control	O
group	O
of	O
individuals	O
from	O
Southeast	O
Asia	O
shared	O
the	O
same	O
major	O
haplotypes	O
,	O
4	O
,	O
1	O
,	O
and	O
7	O
,	O
with	O
Polynesians	O
.	O

These	O
data	O
provide	O
further	O
support	O
for	O
the	O
theories	O
of	O
genetic	O
homogeneity	O
and	O
of	O
Asian	O
affinities	O
of	O
the	O
Polynesian	O
precursor	O
populations	O
.	O

The	O
absence	O
of	O
severe	O
phenylketonuria	B
(	O
PKU	B
)	O
in	O
both	O
Polynesians	O
and	O
Southeast	O
Asians	O
is	O
consistent	O
with	O
the	O
lack	O
of	O
PAH	O
haplotypes	O
2	O
and	O
3	O
,	O
on	O
which	O
the	O
severe	O
PKU	B
mutants	O
have	O
arisen	O
among	O
Caucasians	O
.	O
.	O

Preferential	O
germline	O
mutation	O
of	O
the	O
paternal	O
allele	O
in	O
retinoblastoma	B
.	O

The	O
event	O
triggering	O
malignant	O
proliferation	O
in	O
70	O
%	O
of	O
retinoblastoma	B
tumours	I
is	O
loss	O
of	O
heterozygosity	O
for	O
chromosome	O
13q14	O
,	O
whereby	O
the	O
normal	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
allele	O
is	O
lost	O
and	O
an	O
already	O
mutated	O
RB1	O
allele	O
remains	O
in	O
the	O
tumour	B
.	O

The	O
first	O
allele	O
suffers	O
a	O
mutational	O
event	O
-	O
-	O
deletion	O
,	O
duplication	O
or	O
point	O
mutation	O
(	O
manuscript	O
in	O
preparation	O
)	O
-	O
-	O
either	O
in	O
the	O
germ	O
line	O
(	O
all	O
bilateral	O
patients	O
)	O
or	O
in	O
a	O
somatic	O
retinal	O
cell	O
(	O
most	O
unilateral	O
patients	O
)	O
.	O

Most	O
bilateral	O
patients	O
have	O
no	O
family	O
history	O
of	O
retinoblastoma	B
and	O
are	O
presumed	O
to	O
have	O
new	O
germline	O
mutations	O
which	O
arose	O
in	O
the	O
egg	O
,	O
sperm	O
or	O
early	O
embryo	O
.	O

We	O
have	O
determined	O
the	O
parental	O
origin	O
of	O
the	O
retained	O
allele	O
in	O
nine	O
retinoblastoma	B
tumours	I
from	O
eight	O
unrelated	O
non	O
-	O
familial	O
cases	O
by	O
using	O
RB1	O
-	O
linked	O
genetic	O
markers	O
.	O

Six	O
tumours	B
retained	O
the	O
paternal	O
allele	O
and	O
three	O
retained	O
the	O
maternal	O
allele	O
.	O

Of	O
the	O
three	O
unilateral	B
tumours	I
,	O
only	O
one	O
retained	O
the	O
paternal	O
RB1	O
allele	O
.	O

Thus	O
,	O
there	O
is	O
no	O
evidence	O
that	O
the	O
paternal	O
RB1	O
allele	O
is	O
preferentially	O
retained	O
in	O
retinoblastoma	B
,	O
as	O
has	O
been	O
suggested	O
to	O
be	O
the	O
case	O
in	O
osteosarcoma	B
.	O

By	O
contrast	O
,	O
tumours	B
from	O
four	O
of	O
the	O
five	O
bilateral	O
patients	O
retained	O
the	O
paternal	O
RB1	O
allele	O
.	O

This	O
suggests	O
either	O
that	O
new	O
germline	O
RB1	O
mutations	O
arise	O
more	O
frequently	O
during	O
spermatogenesis	O
than	O
during	O
oogenesis	O
,	O
or	O
that	O
imprinting	O
in	O
the	O
early	O
embryo	O
affects	O
chromosomal	O
susceptibility	O
to	O
mutation	O
.	O
.	O

Haplotype	O
analysis	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
Turkish	O
phenylketonuria	B
families	O
.	O

We	O
have	O
estimated	O
the	O
haplotype	O
distribution	O
of	O
mutant	O
and	O
normal	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
alleles	O
for	O
17	O
Turkish	O
phenylketonuria	B
(	O
PKU	B
)	O
families	O
20	O
normal	O
and	O
27	O
mutated	O
PAH	O
alleles	O
could	O
be	O
identified	O
.	O

Of	O
the	O
latter	O
,	O
the	O
most	O
prevalent	O
were	O
associated	O
with	O
haplotype	O
6	O
(	O
29	O
.	O
6	O
%	O
)	O
,	O
1	O
(	O
18	O
.	O
5	O
%	O
)	O
and	O
36	O
(	O
11	O
.	O
1	O
%	O
)	O
,	O
while	O
the	O
normal	O
alleles	O
were	O
preferentially	O
associated	O
with	O
haplotype	O
1	O
(	O
20	O
%	O
)	O
.	O

Of	O
the	O
19	O
different	O
haplotypes	O
observed	O
,	O
5	O
have	O
not	O
been	O
described	O
previously	O
.	O

The	O
haplotype	O
distribution	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
Northern	O
European	O
population	O
.	O

Two	O
of	O
the	O
eight	O
polymorphic	O
sites	O
were	O
in	O
association	O
with	O
PKU	B
.	O

No	O
deletions	O
of	O
exon	O
sequences	O
were	O
found	O
in	O
the	O
families	O
analysed	O
.	O

Huntington	B
disease	I
:	O
no	O
evidence	O
for	O
locus	O
heterogeneity	O
.	O

A	O
total	O
of	O
63	O
families	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
were	O
examined	O
for	O
linkage	O
between	O
HD	B
and	O
G8	O
(	O
D4S10	O
)	O
.	O

The	O
families	O
included	O
57	O
Caucasian	O
,	O
four	O
Black	O
American	O
,	O
and	O
two	O
Japanese	O
.	O

The	O
combined	O
maximum	O
lod	O
score	O
was	O
87	O
.	O

69	O
at	O
theta	O
=	O
0	O
.	O

04	O
(	O
99	O
%	O
confidence	O
interval	O
0	O
.	O
018	O
-	O
0	O
.	O
071	O
)	O
.	O

The	O
maximum	O
frequency	O
of	O
recombination	O
was	O
0	O
.	O

03	O
in	O
males	O
and	O
0	O
.	O

05	O
in	O
females	O
.	O

Fifty	O
-	O
seven	O
families	O
gave	O
positive	O
lod	O
scores	O
;	O
five	O
small	O
families	O
gave	O
mildly	O
negative	O
lod	O
scores	O
.	O

The	O
maximum	O
likelihood	O
estimate	O
of	O
alpha	O
,	O
the	O
proportion	O
of	O
linked	O
loci	O
,	O
was	O
1	O
.	O

0	O
with	O
a	O
lower	O
99	O
%	O
confidence	O
interval	O
of	O
0	O
.	O

88	O
.	O

These	O
data	O
suggest	O
that	O
there	O
is	O
only	O
one	O
HD	B
locus	O
,	O
although	O
a	O
second	O
rare	O
locus	O
cannot	O
be	O
ruled	O
out	O
.	O

Haplotype	O
and	O
multipoint	O
linkage	O
analysis	O
in	O
Finnish	O
choroideremia	B
families	O
.	O

Multipoint	O
linkage	O
analysis	O
of	O
choroideremia	B
(	O
TCD	B
)	O
and	O
seven	O
X	O
chromosomal	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
was	O
carried	O
out	O
in	O
18	O
Finnish	O
TCD	B
families	O
.	O

The	O
data	O
place	O
TCD	B
distal	O
to	O
PGK	O
and	O
DXS72	O
,	O
very	O
close	O
to	O
DXYS1	O
and	O
DXYS5	O
(	O
Zmax	O
=	O
24	O
at	O
theta	O
=	O
0	O
)	O
and	O
proximal	O
to	O
DXYS4	O
and	O
DXYS12	O
.	O

This	O
agrees	O
with	O
the	O
data	O
obtained	O
from	O
other	O
linkage	O
studies	O
and	O
from	O
physical	O
mapping	O
.	O

All	O
the	O
TCD	B
males	O
and	O
carrier	O
females	O
studied	O
have	O
the	O
same	O
DXYS1	O
allele	O
in	O
coupling	O
with	O
TCD	B
.	O

In	O
Northeastern	O
Finland	O
,	O
66	O
/	O
69	O
chromosomes	O
carrying	O
TCD	B
had	O
the	O
same	O
haplotype	O
at	O
loci	O
DXS72	O
,	O
DXYS1	O
,	O
DXYS4	O
,	O
and	O
DXYS12	O
.	O

The	O
same	O
haplotype	O
is	O
seen	O
in	O
only	O
15	O
/	O
99	O
chromosomes	O
not	O
carrying	O
TCD	B
.	O

Moreover	O
,	O
in	O
71	O
/	O
104	O
non	O
-	O
TCD	O
chromosomes	O
,	O
the	O
haplotype	O
at	O
six	O
marker	O
loci	O
is	O
different	O
from	O
those	O
seen	O
in	O
any	O
of	O
the	O
76	O
TCD	B
chromosomes	O
.	O

This	O
supports	O
the	O
previously	O
described	O
hypothesis	O
that	O
the	O
large	O
Northern	O
Finnish	O
choroideremia	B
pedigrees	O
,	O
comprising	O
a	O
total	O
of	O
over	O
80	O
living	O
patients	O
representing	O
more	O
than	O
a	O
fifth	O
of	O
all	O
TCD	B
patients	O
described	O
worldwide	O
,	O
carry	O
the	O
same	O
mutation	O
.	O

These	O
linkage	O
and	O
haplotype	O
data	O
provide	O
improved	O
opportunities	O
for	O
prenatal	O
diagnosis	O
based	O
on	O
RFLP	O
studies	O
.	O
.	O

Autosomal	O
dominant	O
aniridia	B
linked	O
to	O
the	O
chromosome	O
11p13	O
markers	O
catalase	O
and	O
D11S151	O
in	O
a	O
large	O
Dutch	O
family	O
.	O

In	O
a	O
large	O
pedigree	O
with	O
autosomal	O
dominant	O
aniridia	B
,	O
we	O
found	O
close	O
linkage	O
between	O
the	O
aniridia	B
locus	O
AN2	O
and	O
the	O
markers	O
catalase	O
(	O
CAT	O
)	O
(	O
zeta	O
=	O
7	O
.	O
27	O
at	O
theta	O
=	O
0	O
.	O
00	O
)	O
and	O
D11S151	O
(	O
zeta	O
=	O
3	O
.	O
86	O
at	O
theta	O
=	O
0	O
.	O
10	O
)	O
flanking	O
the	O
AN2	O
locus	O
on	O
11p13	O
.	O

Positive	O
lod	O
scores	O
were	O
also	O
obtained	O
for	O
the	O
11p13	O
-	O
-	O
-	O
-	O
11p14	O
markers	O
D11S16	O
and	O
FSHB	O
with	O
the	O
linkage	O
group	O
CAT	O
/	O
AN2	O
/	O
D11S151	O
.	O

We	O
conclude	O
that	O
the	O
autosomal	O
dominant	O
aniridia	B
in	O
this	O
family	O
is	O
due	O
to	O
a	O
mutation	O
at	O
the	O
AN2	O
locus	O
on	O
11p13	O
.	O

We	O
have	O
excluded	O
linkage	O
(	O
zeta	O
less	O
than	O
-	O
2	O
at	O
theta	O
less	O
than	O
0	O
.	O
18	O
)	O
between	O
the	O
aniridia	B
and	O
the	O
chromosome	O
2p25	O
marker	O
D2S1	O
(	O
linked	O
to	O
ACP1	O
)	O
.	O

Recombination	O
events	O
that	O
locate	O
myotonic	B
dystrophy	I
distal	O
to	O
APOC2	O
on	O
19q	O
.	O

We	O
previously	O
reported	O
a	O
recombination	O
in	O
an	O
individual	O
with	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
which	O
placed	O
the	O
markers	O
D19S19	O
and	O
APOC2	O
on	O
the	O
same	O
side	O
of	O
the	O
DM	B
locus	O
.	O

Haplotyping	O
of	O
this	O
family	O
with	O
more	O
recently	O
characterized	O
probes	O
which	O
are	O
either	O
tightly	O
linked	O
to	O
DM	B
or	O
distal	O
to	O
the	O
linkage	O
group	O
at	O
q13	O
.	O

2	O
shows	O
that	O
the	O
DM	B
locus	O
is	O
distal	O
to	O
APOC2	O
.	O

This	O
is	O
confirmed	O
by	O
other	O
recombinants	O
where	O
DM	B
segregates	O
with	O
distal	O
probes	O
.	O

Additional	O
marker	O
to	O
marker	O
recombinations	O
in	O
unaffected	O
individuals	O
are	O
reported	O
and	O
support	O
the	O
order	O
and	O
orientation	O
of	O
the	O
DM	B
linkage	O
group	O
as	O
pter	O
-	O
(	O
INSR	O
,	O
LDLR	O
,	O
S9	O
)	O
-	O
(	O
S19	O
,	O
BCL3	O
,	O
APOC2	O
)	O
-	O
(	O
CKMM	O
,	O
DM	O
)	O
-	O
(	O
S22	O
,	O
+	O
+	O
+	O
PRKCG	O
)	O
-	O
qter	O
.	O

The	O
data	O
presented	O
here	O
cannot	O
determine	O
whether	O
DM	B
is	O
proximal	O
or	O
distal	O
to	O
CKMM	O
.	O

The	O
consequences	O
of	O
this	O
probe	O
order	O
for	O
antenatal	O
diagnosis	O
and	O
future	O
research	O
aiming	O
to	O
isolate	O
the	O
gene	O
which	O
is	O
affected	O
in	O
DM	B
are	O
discussed	O
.	O

Mutations	O
in	O
the	O
RB1	O
gene	O
and	O
their	O
effects	O
on	O
transcription	O
.	O

Inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
during	O
normal	O
retinal	O
development	O
initiates	O
the	O
formation	O
of	O
a	O
retinoblastoma	B
(	I
RB	I
)	I
tumor	I
.	O

To	O
identify	O
the	O
mutations	O
which	O
inactivate	O
RB1	O
,	O
21	O
RB	B
tumors	I
isolated	O
from	O
19	O
patients	O
were	O
analyzed	O
with	O
the	O
polymerase	O
chain	O
reaction	O
or	O
an	O
RNase	O
protection	O
assay	O
or	O
both	O
.	O

Mutations	O
were	O
identified	O
in	O
13	O
of	O
21	O
RB	B
tumors	I
;	O
in	O
8	O
tumors	B
,	O
the	O
precise	O
errors	O
in	O
nucleotide	O
sequence	O
were	O
characterized	O
.	O

Each	O
of	O
four	O
germ	O
line	O
mutations	O
involved	O
a	O
small	O
deletion	O
or	O
duplication	O
,	O
while	O
three	O
somatic	O
mutations	O
were	O
point	O
mutations	O
leading	O
to	O
splice	O
alterations	O
and	O
loss	O
of	O
an	O
exon	O
from	O
the	O
mature	O
RB1	O
mRNA	O
.	O

We	O
were	O
unable	O
to	O
detect	O
expression	O
of	O
the	O
mutant	O
allele	O
in	O
lymphoblasts	O
of	O
three	O
bilaterally	O
affected	O
patients	O
,	O
although	O
the	O
mutation	O
was	O
present	O
in	O
the	O
genomic	O
DNA	O
and	O
transcripts	O
containing	O
the	O
mutations	O
were	O
obvious	O
in	O
the	O
RB	B
tumors	I
in	O
the	O
absence	O
of	O
a	O
normal	O
RB1	O
allele	O
.	O

The	O
variations	O
in	O
the	O
level	O
of	O
expression	O
of	O
mutant	O
transcripts	O
suggest	O
deregulation	O
of	O
RB1	O
transcription	O
in	O
the	O
absence	O
of	O
a	O
functional	O
RB1	O
gene	O
product	O
.	O
.	O

Partial	O
deletion	O
8q	O
without	O
Langer	B
-	I
Giedion	I
syndrome	I
:	O
a	O
recognisable	O
syndrome	O
.	O

We	O
report	O
two	O
de	O
novo	O
cases	O
of	O
del	O
(	O
8	O
)	O
(	O
pter	O
-	O
-	O
-	O
-	O
q24	O
.	O
1	O
)	O
with	O
breakpoints	O
involving	O
the	O
distal	O
part	O
of	O
band	O
8q24	O
.	O

1	O
1	O
.	O

The	O
clinical	O
features	O
were	O
similar	O
and	O
there	O
were	O
no	O
obvious	O
stigmata	O
of	O
Langer	B
-	I
Giedion	I
syndrome	I
(	O
LGS	B
)	O
.	O

There	O
are	O
three	O
other	O
cases	O
reported	O
with	O
a	O
deletion	O
of	O
chromosome	O
8	O
at	O
approximately	O
the	O
same	O
breakpoint	O
,	O
one	O
without	O
LGS	B
and	O
some	O
similarities	O
to	O
our	O
cases	O
,	O
the	O
other	O
two	O
with	O
LGS	B
.	O

Our	O
findings	O
would	O
support	O
the	O
observation	O
that	O
the	O
critical	O
segment	O
for	O
the	O
assignment	O
of	O
LGS	B
is	O
proximal	O
to	O
or	O
involves	O
the	O
proximal	O
part	O
of	O
8q24	O
.	O

1	O
,	O
but	O
a	O
review	O
of	O
published	O
reports	O
suggests	O
that	O
the	O
aetiology	O
of	O
LGS	B
may	O
be	O
a	O
more	O
complex	O
issue	O

Myotonic	B
dystrophy	I
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
muscle	O
-	O
type	O
creatine	O
kinase	O
(	O
CKMM	O
)	O
.	O

We	O
have	O
studied	O
genetic	O
linkage	O
between	O
the	O
gene	O
for	O
creatine	O
kinase	O
muscle	O
type	O
(	O
CKMM	O
)	O
and	O
the	O
gene	O
for	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

In	O
a	O
panel	O
of	O
65	O
myotonic	B
dystrophy	I
families	O
from	O
Canada	O
and	O
the	O
Netherlands	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
Zmax	O
)	O
of	O
22	O
.	O

8	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O

03	O
was	O
obtained	O
.	O

Tight	O
linkage	O
was	O
also	O
demonstrated	O
for	O
CKMM	O
and	O
the	O
gene	O
for	O
apolipoprotein	O
C2	O
(	O
ApoC2	O
)	O
.	O

This	O
establishes	O
CKMM	O
as	O
a	O
useful	O
marker	O
for	O
myotonic	B
dystrophy	I

Color	B
vision	I
defects	I
in	O
adrenomyeloneuropathy	B
.	O

The	O
relationship	O
between	O
abnormal	B
color	I
vision	I
and	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
was	O
investigated	O
in	O
27	O
AMN	B
patients	O
and	O
31	O
age	O
-	O
matched	O
controls	O
by	O
using	O
the	O
Farnsworth	O
-	O
Munsell	O
100	O
Hue	O
test	O
.	O

Twelve	O
(	O
44	O
%	O
)	O
of	O
27	O
patients	O
showed	O
test	O
scores	O
significantly	O
above	O
normal	O
.	O

The	O
axes	O
of	O
bipolarity	O
determined	O
by	O
the	O
testing	O
differed	O
widely	O
between	O
the	O
patients	O
with	O
abnormal	O
scores	O
,	O
compatible	O
with	O
the	O
notion	O
that	O
different	O
alterations	O
in	O
visual	O
pigment	O
genes	O
occur	O
in	O
different	O
AMN	B
kindreds	O
.	O

These	O
observations	O
confirm	O
our	O
earlier	O
impression	O
that	O
the	O
frequency	O
of	O
abnormal	B
color	I
vision	I
is	O
increased	O
in	O
these	O
kindreds	O
,	O
and	O
it	O
supports	O
our	O
contentions	O
that	O
(	O
1	O
)	O
AMN	B
(	O
and	O
its	O
companion	O
,	O
adrenoleukodystrophy	B
)	O
are	O
very	O
closely	O
linked	O
to	O
the	O
visual	O
pigment	O
loci	O
at	O
Xq28	O
and	O
(	O
2	O
)	O
this	O
proximity	O
might	O
provide	O
the	O
opportunity	O
to	O
observe	O
contiguous	B
gene	I
defects	I
.	O
.	O

Molecular	O
analysis	O
of	O
a	O
female	O
Lesch	B
-	I
Nyhan	I
patient	O
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
female	O
patient	O
with	O
the	O
X	O
-	O
linked	O
recessive	O
Lesch	B
-	I
Nyhan	I
syndrome	I
(	O
hypoxanthine	B
phosphoribosyltransferase	I
[	I
HPRT	I
]	I
deficiency	I
)	O
.	O

Cytogenetic	O
and	O
carrier	O
studies	O
revealed	O
structurally	O
normal	O
chromosomes	O
for	O
this	O
patient	O
and	O
her	O
parents	O
and	O
demonstrated	O
that	O
this	O
mutation	O
arose	O
through	O
a	O
de	O
novo	O
gametic	O
event	O
.	O

Comparison	O
of	O
this	O
patients	O
DNA	O
with	O
the	O
DNA	O
of	O
her	O
parents	O
revealed	O
that	O
a	O
microdeletion	O
,	O
which	O
occurred	O
within	O
a	O
maternal	O
gamete	O
and	O
involved	O
the	O
entire	O
HPRT	O
gene	O
,	O
was	O
partially	O
responsible	O
for	O
the	O
disease	O
in	O
this	O
patient	O
.	O

Somatic	O
cell	O
hybrids	O
,	O
generated	O
to	O
separate	O
maternal	O
and	O
paternal	O
X	O
chromosomes	O
,	O
showed	O
that	O
expression	O
of	O
two	O
additional	O
X	O
-	O
linked	O
enzymes	O
,	O
phosphoglycerate	O
kinase	O
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
,	O
were	O
expressed	O
only	O
in	O
cells	O
that	O
contained	O
the	O
maternal	O
X	O
chromosome	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
functionally	O
inactive	O
paternal	O
X	O
chromosome	O
.	O

Furthermore	O
,	O
comparison	O
of	O
methylation	O
patterns	O
within	O
a	O
region	O
of	O
the	O
HPRT	O
gene	O
known	O
to	O
be	O
important	O
in	O
gene	O
regulation	O
revealed	O
differences	O
between	O
DNA	O
from	O
the	O
father	O
and	O
the	O
patient	O
,	O
in	O
keeping	O
with	O
an	O
active	O
HPRT	O
locus	O
in	O
the	O
father	O
and	O
an	O
inactive	O
HPRT	O
locus	O
in	O
the	O
patient	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
nonrandom	O
inactivation	O
of	O
the	O
cytogenetically	O
normal	O
paternal	O
X	O
chromosome	O
and	O
a	O
microdeletion	O
of	O
the	O
HPRT	O
gene	O
on	O
an	O
active	O
maternal	O
X	O
chromosome	O
were	O
responsible	O
for	O
the	O
absence	O
of	O
HPRT	O
in	O
this	O
patient	O
.	O
.	O

Pelizaeus	B
-	I
Merzbacher	I
disease	I
:	O
an	O
X	B
-	I
linked	I
neurologic	I
disorder	I
of	I
myelin	I
metabolism	I
with	O
a	O
novel	O
mutation	O
in	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
.	O

The	O
nosology	O
of	O
the	O
inborn	B
errors	I
of	I
myelin	I
metabolism	I
has	O
been	O
stymied	O
by	O
the	O
lack	O
of	O
molecular	O
genetic	O
analysis	O
.	O

Historically	O
,	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
has	O
encompassed	O
a	O
host	O
of	O
neurologic	B
disorders	I
that	O
present	O
with	O
a	O
deficit	B
of	I
myelin	I
,	O
the	O
membrane	O
elaborated	O
by	O
glial	O
cells	O
that	O
encircles	O
and	O
successively	O
enwraps	O
axons	O
.	O

We	O
describe	O
here	O
a	O
Pelizaeus	B
-	I
Merzbacher	I
pedigree	O
of	O
the	O
classical	O
type	O
,	O
with	O
X	O
-	O
linked	O
inheritance	O
,	O
a	O
typical	O
clinical	O
progression	O
,	O
and	O
a	O
pathologic	O
loss	O
of	O
myelinating	O
cells	O
and	O
myelin	O
in	O
the	O
central	O
nervous	O
system	O
.	O

To	O
discriminate	O
variants	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
,	O
a	O
set	O
of	O
oligonucleotide	O
primers	O
was	O
constructed	O
to	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
PCR	O
)	O
amplify	O
and	O
sequence	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
,	O
a	O
structural	O
protein	O
that	O
comprises	O
half	O
of	O
the	O
protein	O
of	O
the	O
myelin	O
sheath	O
.	O

The	O
PLP	O
gene	O
in	O
one	O
of	O
two	O
affected	O
males	O
and	O
the	O
carrier	O
mother	O
of	O
this	O
family	O
exhibited	O
a	O
single	O
base	O
difference	O
in	O
the	O
more	O
than	O
2	O
kb	O
of	O
the	O
PLP	O
gene	O
sequenced	O
,	O
a	O
C	O
-	O
-	O
-	O
-	O
T	O
transition	O
that	O
would	O
create	O
a	O
serine	O
substitution	O
for	O
proline	O
at	O
the	O
carboxy	O
end	O
of	O
the	O
protein	O
.	O

Our	O
results	O
delineate	O
the	O
clinical	O
features	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
,	O
define	O
the	O
possible	O
molecular	O
pathology	O
of	O
this	O
dysmyelinating	B
disorder	I
,	O
and	O
address	O
the	O
molecular	O
classification	O
of	O
inborn	B
errors	I
of	I
myelin	I
metabolism	I
.	O

Patients	O
with	O
the	O
classical	O
form	O
(	O
type	O
I	O
)	O
and	O
the	O
more	O
severely	O
affected	O
,	O
connatal	O
variant	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	I
type	I
II	I
)	I
would	O
be	O
predicted	O
to	O
display	O
mutation	O
at	O
the	O
PLP	O
locus	O
.	O

The	O
other	O
variants	O
(	O
types	O
III	O
-	O
VI	O
)	O
,	O
which	O
have	O
sometimes	O
been	O
categorized	O
as	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
,	O
may	O
represent	O
mutations	O
in	O
genes	O
encoding	O
other	O
structural	O
myelin	O
proteins	O
or	O
proteins	O
critical	O
to	O
myelination	O
.	O
.	O

Molecular	O
basis	O
of	O
human	O
von	B
Willebrand	I
disease	I
:	O
analysis	O
of	O
platelet	O
von	B
Willebrand	I
factor	O
mRNA	O
.	O

von	B
Willebrand	I
disease	I
(	O
vWD	B
)	O
,	O
the	O
most	O
common	O
inherited	B
bleeding	I
disorder	I
in	O
humans	O
,	O
can	O
result	O
from	O
either	O
a	O
quantitative	O
or	O
a	O
qualitative	O
defect	O
in	O
the	O
adhesive	O
glycoprotein	O
,	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
.	O

Molecular	O
studies	O
of	O
vWD	B
have	O
been	O
limited	O
by	O
the	O
large	O
size	O
of	O
the	O
vWF	O
gene	O
and	O
difficulty	O
in	O
obtaining	O
the	O
vWF	O
mRNA	O
from	O
patients	O
.	O

By	O
use	O
of	O
an	O
adaptation	O
of	O
the	O
polymerase	O
chain	O
reaction	O
,	O
vWF	O
mRNA	O
was	O
amplified	O
and	O
sequenced	O
from	O
peripheral	O
blood	O
platelets	O
.	O

A	O
silent	O
vWF	O
allele	O
was	O
identified	O
,	O
resulting	O
from	O
a	O
cis	O
defect	O
in	O
vWF	O
mRNA	O
transcription	O
or	O
processing	O
.	O

In	O
two	O
type	B
IIA	I
vWD	I
patients	O
,	O
two	O
different	O
but	O
adjacent	O
missense	O
mutations	O
were	O
identified	O
,	O
the	O
locations	O
of	O
which	O
may	O
identify	O
an	O
important	O
vWF	O
functional	O
domain	O
.	O

Expression	O
in	O
heterologous	O
cells	O
of	O
recombinant	O
vWF	O
containing	O
one	O
of	O
these	O
latter	O
mutations	O
reproduced	O
the	O
characteristic	O
structural	O
abnormality	O
seen	O
in	O
type	B
IIA	I
vWD	I
plasma	O
.	O
.	O

Familial	B
deficiency	I
of	I
the	I
seventh	I
component	I
of	I
complement	I
associated	O
with	O
recurrent	O
meningococcal	B
infections	I
.	O

We	O
describe	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
suffering	O
from	O
recurrent	B
meningitis	I
with	O
a	O
complete	O
absence	B
of	I
the	I
seventh	I
component	I
of	I
complement	I
(	O
C7	O
)	O
.	O

Diagnosis	O
was	O
established	O
by	O
haemolytic	O
titration	O
and	O
western	O
blotting	O
.	O

The	O
patients	O
serum	O
lacked	O
the	O
85	O
kDa	O
C7	O
chain	O
.	O

Haemolytic	O
activity	O
of	O
serum	O
was	O
reconstituted	O
with	O
either	O
pooled	O
normal	O
human	O
serum	O
or	O
with	O
purified	O
C7	O
.	O

The	O
relatives	O
(	O
parents	O
and	O
one	O
sister	O
)	O
had	O
half	O
-	O
normal	O
levels	O
of	O
both	O
immunochemically	O
and	O
functionally	O
determined	O
C7	O
,	O
indicating	O
a	O
heterozygous	O
state	O
for	O
C7	B
deficiency	I
.	O
.	O

Translocation	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
1	O
;	O
p13	O
)	O
associated	O
with	O
familial	O
isolated	B
aniridia	I
.	O

A	O
father	O
and	O
daughter	O
with	O
isolated	B
aniridia	I
were	O
observed	O
to	O
have	O
an	O
apparently	O
balanced	O
,	O
reciprocal	O
translocation	O
involving	O
chromosomes	O
5	O
and	O
11	O
[	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
1	O
;	O
p13	O
)	O
]	O
.	O

No	O
other	O
clinical	O
characteristics	O
often	O
associated	O
with	O
the	O
deletion	O
of	O
11p13	O
were	O
observed	O
in	O
this	O
family	O
.	O

This	O
finding	O
,	O
in	O
association	O
with	O
3	O
other	O
instances	O
of	O
single	O
breaks	O
at	O
11p13	O
and	O
aniridia	B
,	O
supports	O
the	O
assignment	O
of	O
AN2	O
to	O
11p13	O
.	O

Homozygous	B
hypobetalipoproteinemia	I
:	O
a	O
disease	O
distinct	O
from	O
abetalipoproproteinemia	B
at	O
the	O
molecular	O
level	O
.	O

apoB	O
DNA	O
,	O
RNA	O
,	O
and	O
protein	O
from	O
two	O
patients	O
with	O
homozygous	B
hypobetalipoproteinemia	I
(	O
HBL	B
)	O
were	O
evaluated	O
and	O
compared	O
with	O
normal	O
individuals	O
.	O

Southern	O
blot	O
analysis	O
with	O
10	O
different	O
cDNA	O
probes	O
revealed	O
a	O
normal	O
gene	O
without	O
major	O
insertions	O
,	O
deletions	O
,	O
or	O
rearrangements	O
.	O

Northern	O
and	O
slot	O
blot	O
analyses	O
of	O
total	O
liver	O
mRNA	O
from	O
HBL	B
patients	O
documented	O
a	O
normal	O
size	O
apoB	O
mRNA	O
that	O
was	O
present	O
in	O
greatly	O
reduced	O
quantities	O
.	O

ApoB	O
protein	O
was	O
detected	O
within	O
HBL	B
hepatocytes	O
utilizing	O
immunohistochemical	O
techniques	O
;	O
however	O
,	O
it	O
was	O
markedly	O
reduced	O
in	O
quantity	O
when	O
compared	O
with	O
control	O
samples	O
.	O

No	O
apoB	O
was	O
detectable	O
in	O
the	O
plasma	O
of	O
HBL	B
individuals	O
with	O
an	O
ELISA	O
assay	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
a	O
mutation	O
in	O
the	O
coding	O
portion	O
of	O
the	O
apoB	O
gene	O
in	O
HBL	B
patients	O
,	O
leading	O
to	O
an	O
abnormal	O
apoB	O
protein	O
and	O
apoB	O
mRNA	O
instability	O
.	O

These	O
results	O
are	O
distinct	O
from	O
those	O
previously	O
noted	O
in	O
abetalipoproteinemia	B
,	O
which	O
was	O
characterized	O
by	O
an	O
elevated	O
level	O
of	O
hepatic	O
apoB	O
mRNA	O
and	O
accumulation	O
of	O
intracellular	O
hepatic	O
apoB	O
protein	O
.	O
.	O

Spontaneous	O
reversion	O
of	O
novel	O
Lesch	B
-	I
Nyhan	I
mutation	O
by	O
HPRT	O
gene	O
rearrangement	O
.	O

Molecular	O
analysis	O
of	O
an	O
unusual	O
patient	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
has	O
suggested	O
that	O
the	O
mutation	O
is	O
due	O
to	O
a	O
partial	O
HPRT	O
gene	O
duplication	O
.	O

We	O
now	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
mutant	O
HPRT	O
cDNA	O
which	O
shows	O
the	O
precise	O
duplication	O
of	O
exons	O
2	O
and	O
3	O
.	O

This	O
mutation	O
is	O
the	O
result	O
of	O
an	O
internal	O
duplication	O
of	O
16	O
-	O
20	O
kilobases	O
of	O
the	O
gene	O
.	O

The	O
structure	O
of	O
the	O
mutant	O
gene	O
suggests	O
that	O
the	O
duplication	O
was	O
not	O
generated	O
by	O
a	O
single	O
unequal	O
crossing	O
-	O
over	O
event	O
between	O
two	O
normal	O
HPRT	O
alleles	O
.	O

Growth	O
of	O
Epstein	B
-	I
Barr	I
virus	O
-	O
transformed	O
lymphoblasts	O
from	O
this	O
patient	O
in	O
selective	O
medium	O
has	O
permitted	O
isolation	O
of	O
spontaneous	O
HPRT	O
+	O
revertants	O
of	O
this	O
mutation	O
.	O

The	O
reversion	O
event	O
involves	O
a	O
second	O
major	O
HPRT	O
gene	O
rearrangement	O
where	O
most	O
or	O
all	O
of	O
the	O
duplicated	O
portion	O
of	O
the	O
mutant	O
gene	O
is	O
deleted	O
.	O

The	O
original	O
mutation	O
therefore	O
has	O
the	O
potential	O
for	O
spontaneous	O
somatic	O
reversion	O
.	O

This	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	O
of	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
exhibited	O
by	O
this	O
patient	O
.	O
.	O

Complex	B
glycerol	I
kinase	I
deficiency	I
:	O
molecular	O
-	O
genetic	O
,	O
cytogenetic	O
,	O
and	O
clinical	O
studies	O
of	O
five	O
Japanese	O
patients	O
.	O

Five	O
male	O
Japanese	O
patients	O
with	O
complex	B
glycerol	I
kinase	I
deficiency	I
(	O
CGKD	B
)	O
and	O
their	O
relatives	O
were	O
studied	O
clinically	O
,	O
cytogenetically	O
,	O
and	O
molecular	O
-	O
genetically	O
.	O

All	O
patients	O
had	O
muscular	B
dystrophy	I
or	O
muscle	B
weakness	I
,	O
mental	B
retardation	I
,	O
congenital	B
adrenal	I
hypoplasia	I
,	O
and	O
glycerol	B
kinase	I
deficiency	I
.	O

High	O
-	O
resolution	O
GTG	O
-	O
banded	O
chromosomes	O
showed	O
a	O
microdeletion	O
in	O
the	O
Xp21	O
region	O
in	O
all	O
four	O
patients	O
examined	O
and	O
in	O
all	O
five	O
mothers	O
.	O

Southern	O
hybridizations	O
,	O
after	O
digestions	O
by	O
restriction	O
endonucleases	O
,	O
with	O
various	O
cloned	O
DNAs	O
(	O
D2	O
,	O
99	O
-	O
6	O
,	O
B24	O
,	O
C7	O
,	O
L1	O
-	O
4	O
,	O
cDMD13	O
-	O
14	O
,	O
J66	O
-	O
HI	O
,	O
P20	O
,	O
J	O
-	O
Bir	O
,	O
ERT87	O
-	O
30	O
,	O
ERT87	O
-	O
15	O
,	O
ERT87	O
-	O
8	O
,	O
ERT87	O
-	O
1	O
,	O
XJ	O
-	O
1	O
.	O
1	O
,	O
754	O
,	O
cx5	O
.	O
7	O
,	O
and	O
OTC	O
-	O
1	O
)	O
that	O
are	O
located	O
around	O
Xp21	O
also	O
showed	O
a	O
deletion	O

in	O
the	O
genome	O
of	O
all	O
patients	O
and	O
mothers	O
.	O

Although	O
the	O
deletion	O
differed	O
in	O
size	O
among	O
patients	O
,	O
a	O
segment	O
commonly	O
absent	O
was	O
located	O
between	O
the	O
genomic	O
sequences	O
corresponding	O
to	O
L1	O
-	O
4	O
and	O
cDMD13	O
-	O
14	O
.	O

This	O
finding	O
indicated	O
that	O
the	O
gene	O
coding	O
for	O
glycerol	O
kinase	O
(	O
GK	O
)	O
is	O
located	O
within	O
this	O
segment	O
.	O

A	O
comparison	O
of	O
the	O
clinical	O
manifestations	O
of	O
the	O
present	O
five	O
patients	O
and	O
reported	O
CGKD	B
or	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
patients	O
with	O
DNA	O
deletion	O
suggests	O
the	O
existence	O
of	O
a	O
certain	O
gene	O
responsible	O
for	O
gonadotropin	B
deficiency	I
(	O
GTD	B
)	O
.	O

The	O
result	O
of	O
the	O
present	O
study	O
and	O
results	O
of	O
previous	O
studies	O
suggest	O
that	O
genes	O
for	O
ornithine	O
transcarbamylase	O
(	O
OTC	O
)	O
,	O
DMD	B
,	O
and	O
GK	O
and	O
putative	O
genes	O
responsible	O
for	O
congenital	B
adrenal	I
hypoplasia	I
(	O
AHC	B
)	O
and	O
GTD	B
are	O
arranged	O
from	O
telomere	O
to	O
centromere	O
as	O
pter	O
-	O
-	O
GTD	O
-	O
-	O
AHC	O
-	O
-	O
GK	O
-	O
-	O
DMD	O
-	O
-	O
OTC	O
-	O
-	O
cen	O

Genetically	O
determined	O
low	O
C4	O
:	O
a	O
predisposing	O
factor	O
to	O
autoimmune	B
chronic	I
active	I
hepatitis	I
.	O

Of	O
26	O
patients	O
with	O
autoimmune	B
chronic	I
active	I
hepatitis	I
(	O
CAH	B
)	O
starting	O
in	O
childhood	O
18	O
(	O
69	O
%	O
)	O
had	O
low	O
C4	O
and	O
5	O
(	O
19	O
%	O
)	O
had	O
low	O
C3	O
serum	O
levels	O
.	O

Impaired	O
hepatic	O
synthesis	O
and	O
immune	O
-	O
consumption	O
were	O
unlikely	O
since	O
transferrin	O
levels	O
were	O
normal	O
in	O
all	O
patients	O
,	O
albumin	O
levels	O
were	O
persistently	O
low	O
in	O
only	O
3	O
,	O
and	O
only	O
3	O
had	O
raised	O
levels	O
of	O
activation	O
fragment	O
C3d	O
.	O

C4d	O
was	O
normal	O
in	O
all	O
patients	O
studied	O
.	O

In	O
the	O
families	O
of	O
12	O
probands	O
with	O
low	O
C4	O
,	O
7	O
parents	O
had	O
low	O
C4	O
and	O
2	O
had	O
levels	O
which	O
were	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O

5	O
of	O
10	O
siblings	O
from	O
5	O
families	O
had	O
low	O
C4	O
.	O

These	O
results	O
suggest	O
that	O
low	O
C4	O
levels	O
in	O
CAH	B
are	O
genetically	O
determined	O
.	O

C4	O
phenotyping	O
in	O
20	O
patients	O
and	O
in	O
26	O
parents	O
showed	O
that	O
90	O
%	O
and	O
81	O
%	O
,	O
respectively	O
,	O
had	O
null	O
allotypes	O
at	O
either	O
the	O
C4A	O
or	O
C4B	O
locus	O
compared	O
with	O
59	O
%	O
in	O
controls	O
,	O
indicating	O
that	O
defective	O
expression	O
of	O
structural	O
genes	O
may	O
contribute	O
to	O
the	O
observed	O
C4	B
deficiency	I
.	O
.	O

An	O
amino	O
-	O
acid	O
substitution	O
involved	O
in	O
phenylketonuria	B
is	O
in	O
linkage	O
disequilibrium	O
with	O
DNA	O
haplotype	O
2	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
human	I
genetic	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
,	O
phenylalanine	O
4	O
-	O
monooxygenase	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O

PKU	B
is	O
a	O
common	O
inborn	B
error	I
of	I
amino	I
-	I
acid	I
metabolism	I
in	O
caucasian	O
populations	O
and	O
approximately	O
1	O
in	O
50	O
individuals	O
are	O
carriers	O
of	O
a	O
PKU	B
allele	O
.	O

To	O
define	O
the	O
molecular	O
basis	O
of	O
PKU	B
,	O
we	O
characterized	O
twelve	O
restriction	O
fragment	O
-	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
haplotypes	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
northern	O
European	O
population	O
and	O
observed	O
that	O
90	O
%	O
of	O
the	O
PKU	B
alleles	O
in	O
this	O
population	O
are	O
confined	O
to	O
four	O
common	O
RFLP	O
haplotypes	O
.	O

We	O
have	O
recently	O
reported	O
a	O
splicing	O
mutation	O
in	O
the	O
PAH	O
gene	O
that	O
is	O
associated	O
with	O
RFLP	O
haplotype	O
3	O
which	O
is	O
present	O
at	O
about	O
40	O
%	O
of	O
mutant	O
alleles	O
.	O

We	O
now	O
report	O
the	O
molecular	B
lesion	I
associated	O
with	O
the	O
RFLP	O
haplotype	O
2	O
mutant	O
allele	O
.	O

This	O
defect	O
is	O
caused	O
by	O
a	O
C	O
-	O
to	O
-	O
T	O
transition	O
in	O
exon	O
12	O
resulting	O
in	O
an	O
amino	O
-	O
acid	O
substitution	O
(	O
Arg	O
to	O
Trp	O
)	O
at	O
residue	O
408	O
of	O
PAH	O
.	O

Direct	O
hybridization	O
analysis	O
of	O
the	O
point	O
mutation	O
using	O
a	O
specific	O
oligonucleotide	O
probe	O
demonstrated	O
that	O
this	O
mutation	O
is	O
also	O
in	O
linkage	O
disequilibrium	O
with	O
RFLP	O
haplotype	O
2	O
alleles	O
that	O
make	O
up	O
about	O
20	O
%	O
of	O
mutant	O
PAH	O
genes	O

Choroideremia	B
:	O
close	O
linkage	O
to	O
DXYS1	O
and	O
DXYS12	O
demonstrated	O
by	O
segregation	O
analysis	O
and	O
historical	O
-	O
genealogical	O
evidence	O
.	O

Linkage	O
studies	O
using	O
restriction	O
fragment	O
length	O
polymorphisms	O
were	O
conducted	O
in	O
the	O
X	B
-	I
linked	I
disorder	I
,	O
choroideremia	B
,	O
designated	O
TCD	B
for	O
Progressive	B
Tapeto	I
-	I
Choroidal	I
Dystrophy	I
.	O

Previously	O
demonstrated	O
close	O
linkage	O
with	O
locus	O
DXYS1	O
was	O
confirmed	O
(	O
lod	O
11	O
.	O
44	O
at	O
0	O
recombination	O
distance	O
)	O
.	O

In	O
addition	O
,	O
locus	O
DXYS12	O
was	O
found	O
to	O
be	O
closely	O
linked	O
with	O
TCD	B
(	O
lod	O
3	O
.	O
31	O
at	O
0	O
recombination	O
distance	O
)	O
.	O

The	O
disease	O
mainly	O
occurs	O
in	O
three	O
large	O
kindreds	O
in	O
remote	O
Northern	O
Finland	O
.	O

While	O
formal	O
genealogical	O
proof	O
is	O
lacking	O
,	O
all	O
presently	O
living	O
(	O
more	O
than	O
80	O
affected	O
males	O
and	O
120	O
carrier	O
females	O
)	O
probably	O
originate	O
from	O
a	O
common	O
founder	O
couple	O
born	O
in	O
1644	O
and	O
1646	O
,	O
twelve	O
generations	O
ago	O
.	O

All	O
36	O
patients	O
and	O
48	O
carriers	O
tested	O
from	O
the	O
three	O
kindreds	O
had	O
the	O
same	O
haplotype	O
(	O
TCD	B
/	O
DXYS1	O
,	O
11kb	O
/	O
DXYS12	O
,	O
1	O
.	O
6kb	O
)	O
.	O

Given	O
that	O
at	O
least	O
105	O
female	O
meioses	O
transmitting	O
TCD	B
have	O
occurred	O
since	O
1650	O
in	O
these	O
kindreds	O
,	O
extremely	O
close	O
linkage	O
between	O
TCD	B
,	O
DXYS1	O
and	O
DXYS12	O
is	O
suggested	O
.	O

The	O
above	O
haplotype	O
is	O
a	O
very	O
useful	O
diagnostic	O
tool	O
in	O
these	O
TCD	B
families	O
.	O

We	O
suggest	O
that	O
our	O
historical	O
-	O
genealogical	O
approach	O
to	O
linkage	O
analysis	O
may	O
be	O
possible	O
elsewhere	O
in	O
similar	O
isolated	O
populations	O

Von	B
Hippel	I
-	I
Lindau	I
disease	I
maps	O
to	O
the	O
region	O
of	O
chromosome	O
3	O
associated	O
with	O
renal	B
cell	I
carcinoma	I
.	O

Von	B
Hippel	I
-	I
Lindau	I
disease	I
(	O
VHL	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
with	O
inherited	O
susceptibility	O
to	O
various	O
forms	O
of	O
cancer	B
,	O
including	O
hemangioblastomas	B
of	O
the	O
central	O
nervous	O
system	O
,	O
phaeochromocytomas	B
,	O
pancreatic	B
malignancies	I
,	O
and	O
renal	B
cell	I
carcinomas	I
.	O

Renal	B
cell	I
carcinomas	I
constitute	O
a	O
particularly	O
frequent	O
cause	O
of	O
death	O
in	O
this	O
disorder	O
,	O
occurring	O
as	O
bilateral	B
and	I
multifocal	I
tumours	I
,	O
and	O
presenting	O
at	O
an	O
earlier	O
age	O
than	O
in	O
sporadic	O
,	O
non	O
-	O
familial	O
cases	O
of	O
this	O
tumour	B
type	O
.	O

We	O
report	O
here	O
that	O
the	O
VHL	B
gene	O
is	O
linked	O
to	O
the	O
locus	O
encoding	O
the	O
human	O
homologoue	O
of	O
the	O
RAF1	O
oncogene	O
,	O
which	O
maps	O
to	O
chromosome	O
3p25	O
(	O
ref	O
.	O
4	O
)	O
.	O

Crossovers	O
with	O
the	O
VHL	B
locus	O
suggest	O
that	O
the	O
defect	O
responsible	O
for	O
the	O
VHL	B
phenotype	O
is	O
not	O
a	O
mutation	O
in	O
the	O
RAF1	O
gene	O
itself	O
.	O

An	O
alternative	O
or	O
prior	O
event	O
to	O
oncogene	O
activation	O
in	O
tumour	B
formation	O
may	O
be	O
the	O
inactivation	O
of	O
a	O
putative	O
tumour	B
suppressor	O
which	O
can	O
be	O
associated	O
with	O
both	O
the	O
inherited	B
and	I
sporadic	I
forms	I
of	I
the	I
cancer	I
.	O

Sporadic	B
renal	I
cell	I
carcinomas	I
have	O
previously	O
been	O
associated	O
with	O
the	O
loss	O
of	O
regions	O
on	O
chromosome	O
3p	O
(	O
refs	O
5	O
,	O
6	O
)	O
.	O

Consequently	O
,	O
sporadic	O
and	O
VHL	O
-	O
associated	O
forms	O
of	O
renal	B
cell	I
carcinoma	I
might	O
both	O
result	O
from	O
alterations	O
causing	O
loss	O
of	O
function	O
of	O
the	O
same	O
tumour	B
suppressor	O
gene	O
on	O
this	O
chromosome	O
.	O
.	O

Tightly	O
linked	O
flanking	O
markers	O
for	O
the	O
Lowe	B
oculocerebrorenal	I
syndrome	I
,	O
with	O
application	O
to	O
carrier	O
assessment	O
.	O

The	O
Lowe	B
oculocerebrorenal	I
syndrome	I
(	O
OCRL	B
)	O
is	O
characterized	O
by	O
congenital	O
cataract	B
,	O
mental	B
retardation	I
,	O
and	O
defective	B
renal	I
tubular	I
function	I
.	O

A	O
map	O
assignment	O
of	O
OCRL	B
to	O
Xq24	O
-	O
q26	O
has	O
been	O
made	O
previously	O
by	O
linkage	O
analysis	O
with	O
DXS42	O
at	O
Xq24	O
-	O
q26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
5	O
.	O
09	O
)	O
and	O
with	O
DXS10	O
at	O
Xq26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
6	O
.	O
45	O
)	O
.	O

Two	O
additional	O
families	O
were	O
studied	O
and	O
three	O
additional	O
polymorphisms	O
were	O
identified	O
at	O
DXS42	O
by	O
using	O
a	O
35	O
-	O
kb	O
sequence	O
isolated	O
with	O
the	O
probe	O
detecting	O
the	O
original	O
polymorphism	O
at	O
DXS42	O
.	O

With	O
additional	O
OCRL	B
families	O
made	O
informative	O
for	O
DXS42	O
,	O
theta	O
remained	O
0	O
with	O
z	O
=	O
6	O
.	O

63	O
;	O
and	O
for	O
DXS10	O
theta	O
=	O
0	O
.	O

03	O
and	O
z	O
=	O
7	O
.	O

07	O
.	O

Evidence	O
for	O
placing	O
OCRL	O
at	O
Xq25	O
also	O
comes	O
from	O
a	O
female	O
with	O
Lowe	B
syndrome	I
and	O
an	O
X	O
;	O
3	O
translocation	O
.	O

We	O
have	O
used	O
the	O
Xq25	O
breakpoint	O
in	O
this	O
patient	O
to	O
determine	O
the	O
position	O
of	O
OCRL	O
relative	O
to	O
the	O
two	O
linked	O
markers	O
.	O

Each	O
derivative	O
chromosome	O
was	O
isolated	O
away	O
from	O
its	O
normal	O
counterpart	O
in	O
somatic	O
cell	O
hybrids	O
.	O

DXS42	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
X	O
containing	O
Xpterq25	O
,	O
and	O
DXS10	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
3	O
containing	O
Xq25	O
-	O
qter	O
.	O

The	O
markers	O
DXS10	O
and	O
DXS42	O
therefore	O
show	O
tight	O
linkage	O
with	O
OCRL	B
in	O
six	O
families	O
and	O
flank	O
the	O
Xq25	O
breakpoint	O
in	O
a	O
female	O
patient	O
with	O
an	O
X	O
;	O
3	O
translocation	O
.	O

Linkage	O
analysis	O
with	O
flanking	O
markers	O
was	O
used	O
to	O
assess	O
OCRL	B
carrier	O
status	O
in	O
women	O
at	O
risk	O
.	O

Results	O
,	O
when	O
compared	O
with	O
carrier	O
determination	O
by	O
ophthalmologic	O
examination	O
,	O
indicated	O
that	O
the	O
slit	O
-	O
lamp	O
exam	O
can	O
be	O
a	O
sensitive	O
and	O
specific	O
method	O
of	O
carrier	O
determination	O
in	O
many	O
cases	O

Identification	O
of	O
a	O
single	O
nucleotide	O
change	O
in	O
the	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
gene	O
(	O
HPRTYale	O
)	O
responsible	O
for	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Complete	O
deficiency	B
of	I
hypoxanthine	I
-	I
guanine	I
phosphoribosyltransferase	I
(	O
HPRT	O
)	O
causes	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Previous	O
characterization	O
of	O
a	O
mutant	O
form	O
of	O
HPRT	O
,	O
HPRTYale	O
,	O
from	O
a	O
subject	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
revealed	O
normal	O
mRNA	O
and	O
protein	O
concentrations	O
,	O
no	O
residual	O
catalytic	O
activity	O
,	O
and	O
cathodal	O
migration	O
upon	O
PAGE	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
HPRTYale	O
cDNA	O
.	O

The	O
nucleotide	O
sequence	O
of	O
full	O
-	O
length	O
HPRTYale	O
cDNA	O
revealed	O
a	O
single	O
nucleotide	O
substitution	O
compared	O
with	O
normal	O
HPRT	O
cDNA	O
G	O
-	O
-	O
-	O
-	O
C	O
at	O
nucleotide	O
position	O
211	O
.	O

This	O
transversion	O
predicts	O
substitution	O
of	O
arginine	O
for	O
glycine	O
at	O
amino	O
acid	O
position	O
71	O
,	O
explaining	O
the	O
cathodal	O
migration	O
of	O
HPRTYale	O
.	O

Chou	O
-	O
Fasman	O
secondary	O
structure	O
analysis	O
predicts	O
a	O
change	O
in	O
the	O
probability	O
of	O
beta	O
-	O
turn	O
formation	O
in	O
the	O
region	O
containing	O
the	O
mutation	O
.	O

Inclusion	O
of	O
the	O
bulky	O
arginine	O
side	O
chain	O
in	O
place	O
of	O
glycine	O
probably	O
disrupts	O
protein	O
folding	O
as	O
well	O
.	O

Cloning	O
mutant	O
forms	O
of	O
cDNA	O
allows	O
identification	O
of	O
specific	O
mutations	O
,	O
provides	O
insight	O
into	O
mutational	O
mechanisms	O
,	O
and	O
facilitates	O
structure	O
-	O
function	O
analysis	O
of	O
mutant	O
proteins	O
.	O
.	O

Two	O
point	O
mutations	O
are	O
responsible	O
for	O
G6PD	O
polymorphism	O
in	O
Sardinia	O
.	O

The	O
human	O
X	O
-	O
linked	O
gene	O
encoding	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
is	O
highly	O
polymorphic	O
;	O
more	O
than	O
300	O
G6PD	O
variants	O
have	O
been	O
identified	O
.	O

G6PD	B
deficiency	I
in	O
different	O
geographical	O
areas	O
appears	O
to	O
have	O
arisen	O
through	O
independent	O
mutational	O
events	O
,	O
but	O
within	O
the	O
same	O
population	O
it	O
may	O
also	O
be	O
heterogeneous	O
.	O

One	O
example	O
is	O
the	O
island	O
of	O
Sardinia	O
,	O
where	O
careful	O
clinical	O
and	O
biochemical	O
studies	O
have	O
identified	O
four	O
different	O
G6PD	O
variants	O
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
four	O
G6PD	O
variants	O
from	O
Sardinia	O
and	O
found	O
that	O
only	O
two	O
mutations	O
are	O
responsible	O
for	O
G6PD	B
deficiency	I
in	O
this	O
area	O
one	O
mutation	O
is	O
the	O
cause	O
of	O
the	O
G6PD	B
Seattle	I
-	I
like	I
phenotype	I
,	O
a	O
milder	O
form	O
of	O
G6PD	B
deficiency	I
;	O
the	O
other	O
mutation	O
is	O
responsible	O
for	O
all	O
forms	O
of	O
very	O
severe	O
G6PD	B
deficiency	I
in	O
Sardinia	O
and	O
,	O
possibly	O
,	O
in	O
the	O
Mediterranean	O
.	O
.	O

Chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
(	O
CNSHA	B
)	O
and	O
glucose	B
6	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
a	O
patient	O
with	O
familial	B
amyloidotic	I
polyneuropathy	I
(	O
FAP	B
)	O
.	O

Molecular	O
study	O
of	O
a	O
new	O
variant	O
(	O
G6PD	O
Clinic	O
)	O
with	O
markedly	O
acidic	O
pH	O
optimum	O
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
variant	O
with	O
severe	O
erythrocytic	B
G6PD	I
deficiency	I
and	O
a	O
unique	O
pH	O
optimum	O
is	O
described	O
in	O
a	O
young	O
patient	O
with	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
(	O
CNSHA	B
)	O
and	O
familial	B
amyloidotic	I
polyneuropathy	I
(	O
FAP	B
)	O
.	O

Chronic	B
hemolysis	I
was	O
present	O
in	O
the	O
absence	O
of	O
infections	O
,	O
oxidant	O
drugs	O
or	O
ingestion	O
of	O
faba	O
beans	O
.	O

Residual	O
enzyme	O
activity	O
was	O
about	O
2	O
.	O

6	O
%	O
and	O
63	O
%	O
of	O
normal	O
activity	O
in	O
erythrocytes	O
and	O
leucocytes	O
,	O
respectively	O
.	O

A	O
molecular	O
study	O
using	O
standard	O
methods	O
showed	O
G6PD	O
in	O
the	O
patient	O
to	O
have	O
normal	O
electrophoretic	O
mobility	O
(	O
at	O
pH	O
7	O
.	O
0	O
,	O
8	O
.	O
0	O
and	O
8	O
.	O
8	O
)	O
,	O
normal	O
apparent	O
affinity	O
for	O
substrates	O
(	O
Km	O
,	O
G6P	O
and	O
NADP	O
)	O
and	O
a	O
slightly	O
abnormal	O
utilization	O
of	O
substrate	O
analogues	O
(	O
decreased	O
deamino	O
-	O
NADP	O
and	O
increased	O
2	O
-	O
deoxyglucose	O
-	O
6	O
-	O
phosphate	O
utilization	O
)	O
.	O

Heat	O
stability	O
was	O
found	O
to	O
be	O
markedly	O
decreased	O
(	O
8	O
%	O
of	O
residual	O
activity	O
after	O
20	O
min	O
of	O
incubation	O
at	O
46	O
degrees	O
C	O
)	O
and	O
a	O
particular	O
characteristic	O
of	O
this	O
enzyme	O
was	O
a	O
biphasic	O
pH	O
curve	O
with	O
a	O
greatly	O
increased	O
activity	O
at	O
low	O
pH	O
.	O

Although	O
molecular	O
characteristics	O
of	O
this	O
variant	O
closely	O
resemble	O
those	O
of	O
G6PD	O
Bangkok	O
and	O
G6PD	O
Duarte	O
,	O
it	O
can	O
be	O
distinguished	O
from	O
these	O
and	O
all	O
other	O
previously	O
reported	O
variants	O
by	O
virtue	O
of	O
its	O
unusual	O
pH	O
curve	O
.	O

Therefore	O
the	O
present	O
variant	O
has	O
been	O
designated	O
G6PD	O
Clinic	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	O
variants	O
previously	O
described	O

Molecular	O
detection	O
of	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
putative	O
retinoblastoma	B
susceptibility	O
locus	O
.	O

A	O
candidate	O
DNA	O
sequence	O
with	O
many	O
of	O
the	O
properties	O
predicted	O
for	O
the	O
retinoblastoma	B
susceptibility	O
(	O
RB1	O
)	O
locus	O
has	O
been	O
cloned	O
(	O
S	O
.	O
H	O
.	O
Friend	O
,	O
R	O
.	O
Bernards	O
,	O
S	O
.	O
Rogelj	O
,	O
R	O
.	O
A	O
.	O
Weinberg	O
,	O
J	O
.	O
M	O
.	O
Rapaport	O
,	O
D	O
.	O
M	O
.	O
Albert	O
,	O
and	O
T	O
.	O
P	O
.	O
Dryja	O
,	O
Nature	O
[	O
London	O
]	O
323	O
643	O
-	O
645	O
,	O
1986	O
)	O
.	O

The	O
large	O
size	O
of	O
this	O
gene	O
(	O
ca	O
.	O
200	O
kilobases	O
[	O
kb	O
]	O
)	O
and	O
its	O
multiple	O
dispersed	O
exons	O
(	O
Wiggs	O
et	O
al	O
.	O
,	O
N	O
.	O
Engl	O
.	O
J	O
.	O
Med	O
.	O
318	O
151	O
-	O
157	O
,	O
1988	O
)	O
complicate	O
molecular	O
screening	O
strategies	O
important	O
in	O
prenatal	O
and	O
presymptomatic	O
diagnosis	O
and	O
in	O
carrier	O
detection	O
.	O

Here	O
we	O
used	O
field	O
inversion	O
gel	O
electrophoresis	O
(	O
FIGE	O
)	O
to	O
construct	O
a	O
restriction	O
map	O
of	O
approximately	O
1	O
,	O
000	O
kb	O
of	O
DNA	O
surrounding	O
the	O
RB1	O
locus	O
and	O
to	O
detect	O
the	O
translocation	O
breakpoints	O
in	O
three	O
retinoblastoma	B
patients	O
.	O

DNA	O
probes	O
from	O
either	O
the	O
5	O
or	O
3	O
end	O
of	O
the	O
gene	O
were	O
used	O
to	O
detect	O
a	O
250	O
-	O
kb	O
EagI	O
restriction	O
fragment	O
in	O
DNA	O
from	O
unaffected	O
individuals	O
.	O

Both	O
probes	O
identified	O
an	O
additional	O
hybridizing	O
fragment	O
in	O
the	O
DNA	O
from	O
each	O
patient	O
,	O
permitting	O
the	O
breakpoints	O
in	O
all	O
three	O
to	O
be	O
mapped	O
within	O
the	O
cloned	O
RB1	O
gene	O
.	O

Analysis	O
of	O
the	O
breakpoint	O
in	O
one	O
translocation	O
cell	O
line	O
allowed	O
the	O
RB1	O
gene	O
to	O
be	O
oriented	O
with	O
its	O
5	O
end	O
toward	O
the	O
centromere	O
.	O

The	O
5	O
end	O
of	O
the	O
gene	O
also	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
clustering	O
of	O
sites	O
for	O
several	O
infrequently	O
cleaving	O
restriction	O
enzymes	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
HpaII	O
tiny	O
fragment	O
island	O
.	O

The	O
detection	O
and	O
mapping	O
of	O
the	O
translocation	O
breakpoints	O
of	O
all	O
three	O
retinoblastoma	B
patients	O
to	O
within	O
the	O
putative	O
RB1	O
gene	O
substantiated	O
the	O
authenticity	O
of	O
this	O
candidate	O
sequence	O
and	O
demonstrated	O
the	O
utility	O
of	O
FIGE	O
in	O
detecting	O
chromosomal	O
rearrangements	O
affecting	O
this	O
locus	O
.	O

Inherited	O
C3	B
deficiency	I
with	O
recurrent	O
infections	O
and	O
glomerulonephritis	B
.	O

A	O
10	O
-	O
year	O
-	O
old	O
Laotian	O
boy	O
had	O
homozygous	O
deficiency	B
of	I
the	I
third	I
component	I
of	I
complement	I
and	O
recurrent	O
bacterial	B
infections	I
beginning	O
at	O
age	O
5	O
months	O
.	O

Cellular	O
and	O
humoral	O
immunity	O
were	O
normal	O
,	O
as	O
were	O
polymorphonuclear	O
leukocyte	O
chemotaxis	O
and	O
bactericidal	O
activities	O
.	O

Serum	O
complement	O
-	O
mediated	O
hemolytic	O
,	O
chemotactic	O
,	O
and	O
opsonic	O
activities	O
were	O
deficient	O
.	O

In	O
vitro	O
addition	O
of	O
purified	O
C3	O
to	O
patient	O
serum	O
restored	O
hemolytic	O
complement	O
to	O
normal	O
levels	O
,	O
and	O
plasma	O
infusion	O
during	O
each	O
of	O
four	O
episodes	O
of	O
pneumonia	B
significantly	O
enhanced	O
serum	O
opsonic	O
activity	O
for	O
as	O
long	O
as	O
36	O
hours	O
.	O

A	O
renal	O
biopsy	O
specimen	O
revealed	O
mesangiopathic	B
glomerulonephritis	I
,	O
although	O
significant	O
levels	O
of	O
circulating	O
IgG	O
immune	O
complexes	O
were	O
not	O
detected	O
.	O

These	O
findings	O
further	O
support	O
the	O
association	O
of	O
C3	B
deficiency	I
with	O
immune	B
-	I
complex	I
disease	I
and	O
suggest	O
that	O
plasma	O
infusion	O
may	O
be	O
an	O
adjunct	O
to	O
antibiotic	O
therapy	O
in	O
the	O
management	O
of	O
severe	O
pyogenic	B
infections	I
in	O
patients	O
with	O
C3	B
deficiency	I
.	O
.	O

DNA	O
restriction	O
fragments	O
associated	O
with	O
alpha	O
1	O
-	O
antitrypsin	O
indicate	O
a	O
single	O
origin	O
for	O
deficiency	O
allele	O
PI	O
Z	O
.	O

The	O
alpha	O
1	O
-	O
protease	O
inhibitor	O
,	O
or	O
alpha	O
-	O
antitrypsin	O
(	O
AAT	O
)	O
,	O
a	O
major	O
plasma	O
inhibitor	O
of	O
leukocyte	O
elastase	O
and	O
bacterial	O
proteases	O
,	O
is	O
encoded	O
at	O
the	O
PI	O
locus	O
on	O
chromosome	O
14	O
(	O
14q24	O
.	O
3	O
-	O
q32	O
.	O
1	O
)	O
.	O

A	O
deficiency	B
of	I
AAT	I
in	O
individuals	O
homozygous	O
for	O
the	O
PI	O
Z	O
allele	O
occurs	O
in	O
about	O
1	O
in	O
2	O
,	O
000	O
-	O
8	O
,	O
000	O
caucasians	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
early	O
adult	O
onset	O
emphysema	B
and	O
liver	B
disease	I
in	O
childhood	O
.	O

We	O
have	O
now	O
used	O
DNA	O
polymorphisms	O
associated	O
with	O
the	O
AAT	O
gene	O
to	O
investigate	O
the	O
origin	O
of	O
the	O
PI	O
Z	O
allele	O
.	O

Using	O
two	O
genomic	O
probes	O
extending	O
into	O
the	O
5	O
and	O
3	O
flanking	O
regions	O
,	O
respectively	O
,	O
we	O
have	O
identified	O
eight	O
polymorphic	O
restriction	O
sites	O
.	O

Extensive	O
linkage	O
disequilibrium	O
occurs	O
throughout	O
the	O
probed	O
region	O
with	O
the	O
PI	O
Z	O
allele	O
,	O
but	O
not	O
with	O
normal	O
PI	O
M	O
alleles	O
.	O

The	O
Z	O
allele	O
occurs	O
mainly	O
with	O
one	O
haplotype	O
,	O
indicating	O
a	O
single	O
,	O
relatively	O
recent	O
,	O
origin	O
in	O
caucasians	O

Segregation	O
analysis	O
of	O
a	O
marker	O
localised	O
Xp21	O
.	O
2	O
-	O
Xp21	O
.	O
3	O
in	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
families	O
.	O

A	O
DNA	O
marker	O
C7	O
,	O
localised	O
Xp21	O
.	O

1	O
-	O
Xp21	O
.	O

3	O
,	O
has	O
been	O
studied	O
in	O
kindreds	O
segregating	O
for	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
and	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
.	O

In	O
DMD	B
families	O
four	O
crossovers	O
were	O
observed	O
in	O
38	O
informative	O
meioses	O
between	O
C7	O
and	O
the	O
DMD	B
locus	O
(	O
theta	O
=	O
0	O
.	O
12	O
,	O
z	O
max	O
=	O
+	O
2	O
.	O
72	O
)	O
.	O

In	O
BMD	B
families	O
no	O
recombinants	O
were	O
observed	O
in	O
the	O
16	O
informative	O
meioses	O
studied	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
localisation	O
of	O
the	O
mutations	O
in	O
these	O
disorders	O
being	O
in	O
the	O
same	O
region	O
of	O
Xp21	O
.	O

Studies	O
in	O
families	O
also	O
segregating	O
for	O
the	O
DNA	O
marker	O
754	O
support	O
the	O
previously	O
reported	O
physical	O
order	O
of	O
these	O
loci	O
as	O
X	O
centromere	O
-	O
754	O
-	O
DMD	O
-	O
BMD	O
-	O
C7	O
-	O
X	O
telomere	O
.	O

A	O
recombination	O
fraction	O
of	O
0	O
.	O

11	O
(	O
z	O
max	O
=	O
+	O
5	O
.	O
58	O
)	O
was	O
found	O
between	O
DMD	O
-	O
754	O
by	O
combining	O
our	O
previously	O
published	O
data	O
with	O
the	O
data	O
presented	O
here	O
.	O

C7	O
and	O
754	O
thus	O
provide	O
good	O
bridging	O
markers	O
for	O
the	O
diagnosis	O
of	O
DMD	B
and	O
BMD	B

Isolation	O
of	O
molecular	O
probes	O
associated	O
with	O
the	O
chromosome	O
15	O
instability	O
in	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
.	O

Flow	O
cytometry	O
and	O
recombinant	O
DNA	O
techniques	O
have	O
been	O
used	O
to	O
obtain	O
reagents	O
for	O
a	O
molecular	O
analysis	O
of	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

HindIII	O
total	O
-	O
digest	O
libraries	O
were	O
prepared	O
in	O
lambda	O
phage	O
Charon	O
21A	O
from	O
flow	O
-	O
sorted	O
inverted	O
duplicated	O
no	O
.	O
15	O
human	O
chromosomes	O
and	O
propagated	O
on	O
recombination	O
-	O
proficient	O
(	O
LE392	O
)	O
and	O
recBC	O
-	O
,	O
sbcB	O
-	O
(	O
DB1257	O
)	O
bacteria	O
.	O

Twelve	O
distinct	O
chromosome	O
15	O
-	O
specific	O
probes	O
have	O
been	O
isolated	O
.	O

Eight	O
localized	O
to	O
the	O
region	O
15q11	O
-	O
-	O
-	O
-	O
13	O
.	O

Four	O
of	O
these	O
eight	O
sublocalized	O
to	O
band	O
15q11	O
.	O

2	O
and	O
are	O
shown	O
to	O
be	O
deleted	O
in	O
DNA	O
of	O
one	O
of	O
two	O
patients	O
examined	O
with	O
the	O
PWS	B
.	O

Heteroduplex	O
analysis	O
of	O
two	O
of	O
these	O
clones	O
,	O
which	O
grew	O
on	O
DB1257	O
but	O
not	O
on	O
LE392	O
,	O
revealed	O
stem	O
-	O
loop	O
structures	O
in	O
the	O
inserts	O
,	O
indicative	O
of	O
inverted	O
,	O
repeated	O
DNA	O
elements	O
.	O

Such	O
DNA	O
repeats	O
might	O
account	O
for	O
some	O
of	O
the	O
cloning	O
instability	O
of	O
DNA	O
segments	O
from	O
proximal	O
15q	O
.	O

Analysis	O
of	O
the	O
genetic	O
and	O
physical	O
instability	O
associated	O
with	O
the	O
repeated	O
sequences	O
we	O
have	O
isolated	O
from	O
band	O
15q11	O
.	O

2	O
may	O
elucidate	O
the	O
molecular	O
basis	O
for	O
the	O
instability	O
of	O
this	O
chromosomal	O
region	O
in	O
patients	O
with	O
the	O
PWS	B
or	O
other	O
diseases	O
associated	O
with	O
chromosomal	B
abnormalities	I
in	O
the	O
proximal	O
long	O
arm	O
of	O
human	O
chromosome	O
15	O

Analysis	O
of	O
deletions	O
in	O
DNA	O
from	O
patients	O
with	O
Becker	B
and	I
Duchenne	I
muscular	I
dystrophy	I
.	O

Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
is	O
an	O
X	B
-	I
linked	I
recessive	I
genetic	I
disorder	I
for	O
which	O
the	O
biochemical	O
defect	O
is	O
as	O
yet	O
unknown	O
.	O

Recently	O
,	O
two	O
cloned	O
segments	O
of	O
human	O
X	O
-	O
chromosome	O
DNA	O
have	O
been	O
described	O
which	O
detect	O
structural	O
alterations	O
within	O
or	O
near	O
the	O
genetic	O
locus	O
responsible	O
for	O
the	O
disorder	O
.	O

Both	O
of	O
these	O
cloned	O
segments	O
were	O
described	O
as	O
tightly	O
linked	O
to	O
the	O
locus	O
and	O
were	O
capable	O
of	O
detecting	O
deletions	O
in	O
the	O
DNA	O
of	O
boys	O
affected	O
with	O
DMD	B
.	O

In	O
an	O
attempt	O
to	O
determine	O
more	O
precisely	O
the	O
occurrence	O
of	O
these	O
deletions	O
within	O
a	O
large	O
population	O
of	O
DMD	B
patients	O
and	O
the	O
accuracy	O
of	O
one	O
of	O
the	O
segments	O
,	O
DXS164	O
(	O
pERT87	O
)	O
,	O
in	O
determining	O
the	O
inheritance	O
of	O
the	O
DMD	B
X	O
chromosome	O
,	O
the	O
subclones	O
1	O
,	O
8	O
and	O
15	O
were	O
made	O
available	O
to	O
many	O
investigators	O
throughout	O
the	O
world	O
.	O

Here	O
we	O
describe	O
the	O
combined	O
results	O
of	O
more	O
than	O
20	O
research	O
laboratories	O
with	O
respect	O
to	O
the	O
occurrence	O
of	O
deletions	O
at	O
the	O
DXS164	O
locus	O
in	O
DNA	O
samples	O
isolated	O
from	O
patients	O
with	O
DMD	B
and	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
.	O

The	O
results	O
indicate	O
that	O
the	O
DXS164	O
locus	O
apparently	O
recombines	O
with	O
DMD	B
5	O
%	O
of	O
the	O
time	O
,	O
but	O
is	O
probably	O
located	O
between	O
independent	O
sites	O
of	O
mutation	O
which	O
yield	O
DMD	B
.	O

The	O
breakpoints	O
of	O
some	O
deletions	O
are	O
delineated	O
within	O
the	O
DXS164	O
locus	O
,	O
and	O
it	O
is	O
evident	O
that	O
the	O
deletions	O
at	O
the	O
DMD	B
locus	O
are	O
frequent	O
and	O
extremely	O
large	O
.	O
.	O

A	O
potential	O
animal	O
model	O
for	O
Lesch	B
-	I
Nyhan	I
syndrome	I
through	O
introduction	O
of	O
HPRT	O
mutations	O
into	O
mice	O
.	O

The	O
human	O
Lesch	B
-	I
Nyhan	I
syndrome	I
is	O
a	O
rare	O
neurological	B
and	I
behavioural	I
disorder	I
,	O
affecting	O
only	O
males	O
,	O
which	O
is	O
caused	O
by	O
an	O
inherited	B
deficiency	I
in	O
the	O
level	O
of	O
activity	O
of	O
the	O
purine	O
salvage	O
enzyme	O
hypoxanthine	O
-	O
guanosine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
)	O
.	O

How	O
the	O
resulting	O
alterations	O
in	O
purine	O
metabolism	O
lead	O
to	O
the	O
severe	O
symptoms	O
characteristic	O
of	O
Lesch	B
-	I
Nyhan	I
patients	O
is	O
still	O
not	O
understood	O
.	O

No	O
mutations	O
at	O
the	O
Hprt	O
locus	O
leading	O
to	O
loss	O
of	O
activity	O
have	O
been	O
described	O
in	O
laboratory	O
animals	O
.	O

To	O
derive	O
an	O
animal	O
model	O
for	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
,	O
we	O
have	O
used	O
cultured	O
mouse	O
embryonic	O
stem	O
cells	O
,	O
mutagenized	O
by	O
retroviral	O
insertion	O
and	O
selected	O
for	O
loss	O
of	O
HPRT	O
activity	O
,	O
to	O
construct	O
chimaeric	O
mice	O
.	O

Two	O
clonal	O
lines	O
carrying	O
different	O
mutant	O
Hprt	O
alleles	O
have	O
given	O
rise	O
to	O
germ	O
cells	O
in	O
chimaeras	O
,	O
allowing	O
the	O
derivation	O
of	O
strains	O
of	O
mutant	O
mice	O
having	O
the	O
same	O
biochemical	O
defect	O
as	O
Lesch	B
-	I
Nyhan	I
patients	O
.	O

Male	O
mice	O
carrying	O
the	O
mutant	O
alleles	O
are	O
viable	O
and	O
analysis	O
of	O
their	O
cells	O
shows	O
a	O
total	O
lack	O
of	O
HPRT	O
activity	O
.	O
.	O

Re	O
-	O
evaluation	O
of	O
the	O
sublocalization	O
of	O
esterase	O
D	O
and	O
its	O
relation	O
to	O
the	O
retinoblastoma	B
locus	O
by	O
in	O
situ	O
hybridization	O
.	O

In	O
situ	O
hybridization	O
of	O
a	O
cDNA	O
probe	O
for	O
the	O
esterase	O
D	O
gene	O
(	O
ESD	O
)	O
was	O
carried	O
out	O
on	O
human	O
chromosomes	O
.	O

The	O
probe	O
hybridized	O
most	O
strongly	O
to	O
13q14	O
.	O

2	O
and	O
13q14	O
.	O

3	O
.	O

This	O
observation	O
raises	O
doubts	O
concerning	O
the	O
most	O
recently	O
published	O
assignment	O
of	O
ESD	O
to	O
13q14	O
.	O

1	O
.	O

A	O
deletion	O
in	O
an	O
individual	O
with	O
retinoblastoma	B
was	O
reported	O
to	O
separate	O
the	O
closely	O
linked	O
ESD	O
and	O
retinoblastoma	B
(	O
RB1	O
)	O
loci	O
,	O
placing	O
ESD	O
proximal	O
to	O
RB1	O
.	O

Quantitative	O
in	O
situ	O
hybridization	O
studies	O
of	O
this	O
deletion	O
do	O
not	O
confirm	O
this	O
interpretation	O
.	O

Rather	O
,	O
they	O
suggest	O
that	O
ESD	O
is	O
missing	O
from	O
the	O
deleted	O
chromosome	O
13	O
and	O
duplicated	O
on	O
the	O
normal	O
homolog	O
.	O

From	O
these	O
findings	O
,	O
we	O
conclude	O
that	O
the	O
deletion	O
in	O
this	O
individual	O
cannot	O
be	O
used	O
to	O
determine	O
the	O
orientation	O
nor	O
the	O
sublocalization	O
of	O
ESD	O
and	O
RB1	O
within	O
the	O
13q14	O
region	O
.	O

Hereditary	B
C2	I
deficiency	I
associated	O
with	O
common	O
variable	O
immunodeficiency	B
.	O

Homozygous	O
C2	B
deficiency	I
in	O
a	O
19	O
-	O
year	O
-	O
old	O
boy	O
was	O
associated	O
with	O
variable	O
immunodeficiency	B
manifested	O
by	O
marked	O
hypoimmunoglobulinemia	B
and	O
impaired	O
antibody	O
responses	O
,	O
normal	O
circulating	O
B	O
lymphocytes	O
,	O
and	O
subnormal	O
T	O
-	O
cell	O
functions	O
.	O

Neither	O
antilymphocytic	O
autoantibodies	O
nor	O
chromosomal	B
abnormalities	I
were	O
found	O
.	O

Serum	O
immunoglobulin	O
levels	O
were	O
within	O
normal	O
limits	O
in	O
his	O
parents	O
and	O
brother	O
who	O
were	O
heterozygous	O
for	O
C2	B
deficiency	I
.	O

The	O
patients	O
lymphocytes	O
were	O
homozygous	O
at	O
the	O
HLA	O
-	O
D	O
locus	O
but	O
expressed	O
an	O
antigen	O
different	O
from	O
DW2	O
.	O
.	O

Mild	O
and	O
severe	O
muscular	B
dystrophy	I
associated	O
with	O
deletions	O
in	O
Xp21	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

We	O
have	O
analysed	O
over	O
300	O
patients	O
suffering	O
from	O
Duchenne	B
or	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
or	O
BMD	B
)	O
.	O

Deletions	O
have	O
been	O
characterised	O
which	O
encompass	O
either	O
the	O
pERT87	O
(	O
DXS164	O
)	O
locus	O
only	O
,	O
the	O
XJ1	O
.	O

1	O
(	O
DXS206	O
)	O
and	O
HIP25	O
loci	O
only	O
,	O
or	O
all	O
three	O
loci	O
.	O

These	O
loci	O
have	O
been	O
shown	O
to	O
lie	O
within	O
the	O
DMD	B
region	O
covering	O
several	O
hundred	O
kilobases	O
(	O
kb	O
)	O
of	O
DNA	O
.	O

One	O
mildly	O
affected	O
BMD	B
patient	O
possesses	O
a	O
deletion	O
of	O
at	O
least	O
110	O
kb	O
including	O
exons	O
of	O
the	O
DMD	B
gene	O
.	O

Other	O
patients	O
with	O
similar	O
exon	O
deletions	O
,	O
or	O
smaller	O
deletions	O
,	O
show	O
the	O
more	O
severe	O
phenotype	O
typical	O
of	O
DMD	B
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
severity	O
of	O
the	O
clinical	O
phenotype	O
cannot	O
be	O
explained	O
on	O
the	O
basis	O
of	O
the	O
size	O
of	O
the	O
deletion	O
.	O

We	O
discuss	O
this	O
in	O
the	O
context	O
of	O
candidate	O
gene	O
sequences	O
.	O

Patterns	O
of	O
exon	O
deletions	O
in	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
.	O

A	O
panel	O
of	O
patients	O
with	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
and	O
BMD	B
)	O
has	O
been	O
screened	O
with	O
the	O
cDNA	O
probes	O
Cf56a	O
and	O
Cf23a	O
,	O
which	O
detect	O
exons	O
in	O
the	O
central	O
part	O
of	O
the	O
DMD	B
gene	O
.	O

One	O
or	O
more	O
exons	O
were	O
deleted	O
in	O
60	O
%	O
of	O
patients	O
.	O

The	O
deletions	O
were	O
mapped	O
and	O
prove	O
to	O
be	O
heterogeneous	O
in	O
size	O
and	O
extent	O
,	O
particularly	O
in	O
DMD	B
.	O

Deletions	O
specific	O
to	O
DMD	B
and	O
to	O
BMD	B
are	O
described	O
.	O

Half	O
of	O
all	O
BMD	B
patients	O
have	O
a	O
deletion	O
of	O
one	O
particular	O
small	O
group	O
of	O
exons	O
;	O
smaller	O
deletions	O
within	O
this	O
same	O
group	O
produce	O
the	O
more	O
severe	O
DMD	B
.	O
.	O

Hereditary	B
deficiency	I
of	I
the	I
third	I
component	I
of	I
complement	I
in	O
a	O
child	O
with	O
fever	B
,	O
skin	B
rash	I
,	O
and	O
arthralgias	B
:	O
response	O
to	O
transfusion	O
of	O
whole	O
blood	O
.	O

A	O
previously	O
well	O
34	O
-	O
month	O
-	O
old	O
male	O
presenting	O
with	O
fever	B
,	O
skin	B
rash	I
,	O
and	O
arthralgias	B
was	O
found	O
to	O
lack	O
C3	O
by	O
immunochemical	O
(	O
undetectable	O
)	O
and	O
hemolytic	O
(	O
1	O
%	O
normal	O
)	O
assays	O
.	O

No	O
infectious	O
agent	O
could	O
be	O
demonstrated	O
.	O

Protein	O
levels	O
of	O
Clq	O
.	O

C4	O
,	O
C5	O
,	O
properdin	O
,	O
and	O
C3b	O
-	O
INA	O
and	O
hemolytic	O
activities	O
of	O
complement	O
components	O
C1	O
to	O
C9	O
except	O
C3	O
were	O
normal	O
or	O
elevated	O
;	O
total	O
hemolytic	O
complement	O
activity	O
was	O
13	O
%	O
of	O
normal	O
and	O
was	O
reconstituted	O
by	O
purified	O
C3	O
.	O

Properdin	O
factor	O
B	O
was	O
702	O
(	O
normal	O
175	O
to	O
275	O
)	O
mug	O
/	O
ml	O
,	O
and	O
was	O
not	O
cleaver	O
upon	O
addition	O
of	O
zymosan	O
or	O
cobra	O
venom	O
factor	O
.	O

The	O
serum	O
had	O
normal	O
immune	O
adherence	O
activity	O
,	O
but	O
was	O
deficient	O
in	O
ability	O
to	O
opsonize	O
Candida	O
albicans	O
for	O
uptake	O
and	O
Escherichia	O
coli	O
for	O
killing	O
by	O
neurophils	O
,	O
generate	O
neutrophil	O
chemotactic	O
factors	O
and	O
inhibit	O
the	O
growth	O
of	O
E	O
.	O
coli	O
;	O
these	O
activities	O
were	O
restored	O
by	O
purified	O
C3	O
.	O

A	O
transfusion	O
of	O
320	O
ml	O
1	O
-	O
hour	O
-	O
old	O
normal	O
whole	O
blood	O
on	O
the	O
fifty	O
-	O
second	O
day	O
resulted	O
in	O
transitory	O
elevation	O
of	O
the	O
C3	O
level	O
to	O
25	O
mg	O
/	O
dl	O
with	O
a	O
fall	O
-	O
off	O
(	O
approximately	O
2	O
1	O
/	O
2	O
%	O
per	O
hour	O
)	O
to	O
undetectable	O
levels	O
by	O
69	O
hours	O
;	O
it	O
was	O
followed	O
by	O
disappearance	O
of	O
the	O
skin	B
rash	I
and	O
arthralgias	B
and	O
return	O
to	O
normal	O
of	O
the	O
previously	O
elevated	O
temperature	O
and	O
CRP	O
levels	O
.	O

C3	O
levels	O
in	O
family	O
members	O
(	O
seven	O
of	O
24	O
half	O
-	O
normal	O
)	O
,	O
lack	O
of	O
anti	O
-	O
C3	O
activity	O
,	O
normal	O
C3b	O
-	O
INA	O
levels	O
and	O
a	O
normal	O
rate	O
of	O
catabolism	O
of	O
transfused	O
C3	O
indicated	O
that	O
the	O
deficiency	O
was	O
inherited	O
with	O
autosomal	O
codominance	O
and	O
involved	O
decreased	B
synthesis	I
of	I
C3	I
.	O

Thus	O
,	O
this	O
child	O
is	O
a	O
unique	O
individual	O
with	O
inherited	B
C3	I
deficiency	I
presenting	O
with	O
absence	O
of	O
repeated	O
infections	O
,	O
whose	O
symptoms	O
of	O
fever	B
,	O
skin	B
rash	I
,	O
and	O
arthralgia	B
were	O
abated	O
by	O
whole	O
blood	O
transfusion	O
.	O
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
and	O
their	O
frequency	O
in	O
Guangdong	O
,	O
China	O
.	O

Erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
was	O
characterized	O
in	O
blood	O
samples	O
obtained	O
from	O
97	O
randomly	O
selected	O
males	O
with	O
enzyme	B
deficiency	I
from	O
various	O
regions	O
of	O
Guangdong	O
Province	O
,	O
China	O
.	O

Nine	O
new	O
variants	O
(	O
Gd	O
Kaiping	O
,	O
Gd	O
Boluo	O
,	O
Gd	O
Huiyang	O
,	O
Gd	O
Gaomin	O
,	O
Gd	O
Qing	O
-	O
Baijiang	O
,	O
Gd	O
Gaozhou	O
,	O
Gd	O
Huazhou	O
,	O
Gd	O
Nanhai	O
,	O
and	O
Gd	O
Guangzhou	O
)	O
were	O
identified	O
.	O

Of	O
the	O
31	O
variants	O
found	O
in	O
this	O
province	O
,	O
Gd	O
Kaiping	O
,	O
Gd	O
Taiwan	O
-	O
Hakka	O
,	O
Gd	O
Haad	O
Yai	O
,	O
Gd	O
Haad	O
Yai	O
-	O
like	O
and	O
Gd	O
Huiyang	O
occurred	O
most	O
frequently	O
.	O

The	O
frequency	O
of	O
each	O
variant	O
was	O
calculated	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
was	O
high	O
in	O
this	O
area	O
.	O
.	O

Homozygous	O
and	O
heterozygous	O
deletions	O
of	O
the	O
von	B
Willebrand	I
factor	O
gene	O
in	O
patients	O
and	O
carriers	O
of	O
severe	B
von	I
Willebrand	I
disease	I
.	O

Severe	B
von	I
Willebrand	I
disease	I
is	O
characterized	O
by	O
undetectable	O
or	O
trace	O
quantities	O
of	O
von	B
Willebrand	I
factor	O
in	O
plasma	O
and	O
tissue	O
stores	O
.	O

We	O
have	O
studied	O
the	O
genomic	O
DNA	O
of	O
10	O
affected	O
individuals	O
from	O
six	O
families	O
with	O
this	O
disorder	O
using	O
probes	O
from	O
the	O
5	O
and	O
3	O
ends	O
of	O
the	O
vWF	O
cDNA	O
and	O
with	O
a	O
probe	O
extending	O
from	O
the	O
5	O
end	O
into	O
the	O
central	O
region	O
.	O

Southern	O
blots	O
of	O
restriction	O
endonuclease	O
digests	O
and	O
gene	O
dosage	O
analysis	O
measurements	O
carried	O
out	O
with	O
quantitative	O
slot	O
blots	O
of	O
undigested	O
genomic	O
DNA	O
separated	O
these	O
patients	O
into	O
three	O
groups	O
.	O

The	O
first	O
group	O
consisted	O
of	O
a	O
family	O
with	O
complete	O
homozygous	O
deletions	O
of	O
the	O
vWF	O
gene	O
in	O
the	O
four	O
probands	O
.	O

Gene	O
dosage	O
analysis	O
was	O
consistent	O
with	O
heterozygous	O
deletions	O
in	O
both	O
of	O
the	O
asymptomatic	O
parents	O
and	O
four	O
asymptomatic	O
siblings	O
of	O
this	O
kindred	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
second	O
group	O
was	O
comprised	O
of	O
a	O
family	O
in	O
which	O
there	O
was	O
a	O
complete	O
heterozygous	O
deletion	O
of	O
the	O
vWF	O
gene	O
in	O
the	O
proband	O
and	O
one	O
asymptomatic	O
parent	O
,	O
suggesting	O
that	O
a	O
different	O
type	O
of	O
genetic	B
abnormality	I
was	O
inherited	O
from	O
the	O
other	O
parent	O
.	O

Thus	O
,	O
the	O
patient	O
appeared	O
to	O
be	O
doubly	O
heterozygous	O
for	O
interacting	O
genetic	B
abnormalities	I
affecting	O
vWF	O
expression	O
.	O

In	O
the	O
third	O
group	O
,	O
no	O
gene	O
deletions	O
could	O
be	O
detected	O
.	O

Alloantibodies	O
developed	O
only	O
in	O
the	O
kindred	O
with	O
homozygous	O
deletions	O
.	O

These	O
techniques	O
should	O
prove	O
useful	O
in	O
identifying	O
carriers	O
of	O
severe	B
von	I
Willebrand	I
disease	I
and	O
also	O
in	O
defining	O
patients	O
predictably	O
at	O
risk	O
of	O
developing	O
alloantibodies	O
to	O
vWF	O
.	O

Sjogren	B
-	I
Larsson	I
syndrome	I
.	O

Impaired	O
fatty	O
alcohol	O
oxidation	O
in	O
cultured	O
fibroblasts	O
due	O
to	O
deficient	O
fatty	O
alcohol	O
:	O
nicotinamide	O
adenine	O
dinucleotide	O
oxidoreductase	O
activity	O
.	O

Lipid	O
metabolism	O
was	O
studied	O
in	O
cultured	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
the	O
inherited	B
disorder	I
,	O
Sjogren	B
-	I
Larsson	I
syndrome	I
(	O
SLS	B
)	O
.	O

Intact	O
SLS	B
fibroblasts	O
incubated	O
in	O
the	O
presence	O
of	O
[	O
1	O
-	O
14C	O
]	O
palmitate	O
accumulated	O
more	O
radioactive	O
hexadecanol	O
than	O
did	O
normal	O
cells	O
,	O
whereas	O
incorporation	O
of	O
radioactivity	O
into	O
other	O
cellular	O
lipids	O
was	O
unaltered	O
.	O

The	O
hexadecanol	O
content	O
of	O
SLS	B
fibroblasts	O
was	O
abnormally	O
elevated	O
.	O

Hexadecanol	O
accumulation	O
was	O
not	O
due	O
to	O
increased	O
fatty	O
alcohol	O
synthesis	O
nor	O
its	O
deficient	O
utilization	O
for	O
glycerol	O
ether	O
synthesis	O
.	O

The	O
half	O
-	O
life	O
of	O
intracellular	O
hexadecanol	O
loaded	O
into	O
SLS	B
fibroblasts	O
was	O
increased	O
(	O
70	O
min	O
)	O
compared	O
with	O
normal	O
(	O
15	O
min	O
)	O
,	O
and	O
intact	O
SLS	B
fibroblasts	O
showed	O
impaired	O
oxidation	O
of	O
[	O
14C	O
]	O
-	O
hexadecanol	O
to	O
fatty	O
acid	O
.	O

Fatty	O
alcohol	O
NAD	O
+	O
oxidoreductase	O
,	O
the	O
enzyme	O
catalyzing	O
this	O
reaction	O
,	O
was	O
deficient	O
in	O
SLS	B
fibroblasts	O
.	O

Mean	O
total	O
activity	O
in	O
SLS	B
fibroblasts	O
(	O
n	O
=	O
5	O
)	O
was	O
13	O
%	O
of	O
that	O
in	O
normal	O
fibroblasts	O
,	O
and	O
palmitoyl	O
CoA	O
-	O
inhibitable	O
activity	O
was	O
1	O
%	O
of	O
normal	O
.	O

Fibroblasts	O
from	O
two	O
obligate	O
SLS	B
heterozygotes	O
had	O
enzyme	O
activities	O
intermediate	O
between	O
that	O
in	O
normal	O
fibroblasts	O
and	O
individuals	O
with	O
SLS	B
.	O

These	O
results	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
SLS	B
is	O
deficiency	B
of	I
fatty	I
alcohol	I
NAD	I
+	I
oxidoreductase	I
.	O

SLS	B
represents	O
the	O
first	O
inherited	B
disorder	I
in	O
man	O
associated	O
with	O
an	O
isolated	O
abnormality	B
in	I
fatty	I
alcohol	I
metabolism	I
.	O
.	O

Germinal	O
mosaicism	O
in	O
Duchenne	B
muscular	I
dystrophy	I
.	O

We	O
have	O
identified	O
a	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
pedigree	O
where	O
the	O
disease	O
is	O
associated	O
with	O
a	O
molecular	O
deletion	O
within	O
the	O
DMD	B
locus	O
.	O

We	O
have	O
examined	O
the	O
meiotic	O
segregation	O
products	O
of	O
the	O
common	O
female	O
ancestor	O
using	O
marker	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
detected	O
by	O
probes	O
that	O
lie	O
within	O
this	O
deletion	O
.	O

These	O
studies	O
show	O
that	O
this	O
female	O
has	O
transmitted	O
three	O
distinct	O
types	O
of	O
X	O
chromosome	O
to	O
her	O
offspring	O
.	O

This	O
observation	O
may	O
be	O
explained	O
by	O
postulating	O
that	O
the	O
mutation	O
arose	O
as	O
a	O
postzygotic	O
deletion	O
within	O
this	O
common	O
ancestor	O
,	O
who	O
was	O
consequently	O
germinally	O
mosaic	O
.	O
.	O

Nebulin	O
seen	O
in	O
DMD	B
males	O
including	O
one	O
patient	O
with	O
a	O
large	O
DNA	O
deletion	O
encompassing	O
the	O
DMD	B
gene	O
.	O

The	O
presence	O
of	O
nebulin	O
in	O
a	O
muscle	O
specimen	O
from	O
a	O
patient	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
due	O
to	O
a	O
large	O
deletion	O
precludes	O
the	O
possibility	O
that	O
this	O
protein	O
is	O
the	O
DMD	B
gene	O
product	O
.	O
.	O

Expression	O
of	O
the	O
murine	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
in	O
muscle	O
and	O
brain	O
.	O

Complementary	O
DNA	O
clones	O
were	O
isolated	O
that	O
represent	O
the	O
5	O
terminal	O
2	O
.	O

5	O
kilobases	O
of	O
the	O
murine	O
Duchenne	B
muscular	I
dystrophy	I
(	O
Dmd	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
.	O

Mouse	O
Dmd	O
mRNA	O
was	O
detectable	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
and	O
at	O
a	O
level	O
approximately	O
90	O
percent	O
lower	O
in	O
brain	O
.	O

Dmd	O
mRNA	O
is	O
also	O
present	O
,	O
but	O
at	O
much	O
lower	O
than	O
normal	O
levels	O
,	O
in	O
both	O
the	O
muscle	O
and	O
brain	O
of	O
three	O
different	O
strains	O
of	O
dystrophic	B
mdx	O
mice	O
.	O

The	O
identification	O
of	O
Dmd	O
mRNA	O
in	O
brain	O
raises	O
the	O
possibility	O
of	O
a	O
relation	O
between	O
human	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
expression	O
and	O
the	O
mental	B
retardation	I
found	O
in	O
some	O
DMD	B
males	O
.	O

These	O
results	O
also	O
provide	O
evidence	O
that	O
the	O
mdx	O
mutations	O
are	O
allelic	O
variants	O
of	O
mouse	O
Dmd	O
gene	O
mutations	O
.	O

Glucose	B
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
and	O
incidence	O
of	O
hematologic	B
malignancy	I
.	O

We	O
have	O
evaluated	O
the	O
hypothesis	O
of	O
a	O
negative	O
association	O
between	O
glucose	B
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
and	O
cancer	B
in	O
a	O
cohort	O
of	O
481	O
Sardinian	O
males	O
with	O
hematological	B
malignancies	I
.	O

The	O
frequency	O
of	O
G6PD	B
deficiency	I
in	O
the	O
patients	O
was	O
not	O
different	O
from	O
the	O
incidence	O
in	O
a	O
group	O
of	O
16	O
,	O
219	O
controls	O
.	O

The	O
same	O
conclusion	O
resulted	O
from	O
the	O
comparison	O
of	O
the	O
frequency	O
of	O
expression	O
of	O
the	O
GdB	O
gene	O
in	O
23	O
heterozygous	O
women	O
having	O
a	O
clonal	O
hematologic	B
disease	I
and	O
a	O
control	O
group	O
of	O
37	O
healthy	O
heterozygotes	O
.	O

Therefore	O
at	O
present	O
there	O
is	O
no	O
evidence	O
that	O
G6PD	B
deficiency	I
has	O
a	O
protective	O
effect	O
against	O
development	O
of	O
hematologic	B
neoplasms	I
.	O
.	O

Hepatoblastoma	B
,	O
pigmented	B
ocular	I
fundus	I
lesions	I
and	O
jaw	B
lesions	I
in	O
Gardner	B
syndrome	I
.	O

Hepatoblastoma	B
is	O
a	O
rare	O
neoplasm	B
of	O
infants	O
and	O
children	O
only	O
recently	O
documented	O
in	O
association	O
with	O
hereditary	B
adenomatous	I
polyposis	I
of	I
the	I
colon	I
[	O
Kingston	O
et	O
al	O
.	O
,	O
1983	O
]	O
.	O

We	O
report	O
four	O
children	O
with	O
hepatoblastoma	B
from	O
four	O
unrelated	O
families	O
with	O
Gardner	B
syndrome	I
(	O
GS	B
)	O
.	O

One	O
child	O
,	O
now	O
19	O
years	O
old	O
,	O
survived	O
after	O
a	O
resection	O
of	O
a	O
hepatoblastoma	B
in	O
infancy	O
and	O
recently	O
was	O
found	O
to	O
have	O
GS	B
.	O

He	O
has	O
an	O
associated	O
odontoma	B
and	O
pigmented	B
ocular	I
fundus	I
lesions	I
,	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
be	O
clinical	O
markers	O
of	O
GS	B
.	O

Many	O
individuals	O
in	O
these	O
four	O
GS	B
families	O
,	O
both	O
affected	O
and	O
at	O
risk	O
,	O
have	O
osteomatous	B
jaw	I
lesions	I
and	O
pigmented	B
ocular	I
fundus	I
lesions	I
.	O

A	O
search	O
for	O
colonic	B
polyps	I
should	O
be	O
made	O
in	O
families	O
of	O
infants	O
and	O
children	O
with	O
hepatoblastoma	B
.	O

If	O
the	O
child	O
survives	O
,	O
he	O
or	O
she	O
should	O
be	O
monitored	O
for	O
the	O
later	O
appearance	O
of	O
colonic	B
polyps	I
.	O

The	O
finding	O
of	O
jaw	B
lesions	I
and	O
/	O
or	O
pigmented	B
ocular	I
fundus	I
lesions	I
in	O
relatives	O
at	O
risk	O
are	O
indications	O
of	O
the	O
possible	O
presence	O
of	O
the	O
GS	B
gene	O
.	O

Identification	O
of	O
an	O
altered	O
splice	O
site	O
in	O
Ashkenazi	O
Tay	B
-	I
Sachs	I
disease	I
.	O

Tay	B
-	I
Sachs	I
disease	I
is	O
an	O
autosomal	B
recessive	I
genetic	I
disorder	I
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
N	O
-	O
acetylhexosaminidase	O
A	O
(	O
ref	O
.	O
1	O
)	O
.	O

A	O
relatively	O
high	O
frequency	O
of	O
carriers	O
(	O
1	O
/	O
27	O
)	O
of	O
a	O
lethal	O
,	O
infantile	O
form	O
of	O
the	O
disease	O
is	O
found	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
it	O
is	O
not	O
yet	O
evident	O
whether	O
this	O
has	O
resulted	O
from	O
a	O
founder	O
effect	O
and	O
random	O
genetic	O
drift	O
or	O
from	O
a	O
selective	O
advantage	O
of	O
heterozygotes	O
.	O

We	O
have	O
identified	O
a	O
single	O
-	O
base	O
mutation	O
in	O
a	O
cloned	O
fragment	O
of	O
the	O
HEXA	O
gene	O
from	O
an	O
Ashkenazi	O
Jewish	O
patient	O
.	O

This	O
change	O
,	O
the	O
substitution	O
of	O
a	O
C	O
for	O
G	O
in	O
the	O
first	O
nucleotide	O
of	O
intron	O
12	O
is	O
expected	O
to	O
result	O
in	O
defective	O
splicing	O
of	O
the	O
messenger	O
RNA	O
.	O

A	O
test	O
for	O
the	O
mutant	O
allele	O
based	O
on	O
amplification	O
of	O
DNA	O
by	O
the	O
polymerase	O
chain	O
rection	O
and	O
cleavage	O
of	O
a	O
DdeI	O
restriction	O
site	O
generated	O
by	O
the	O
mutation	O
revealed	O
that	O
this	O
case	O
and	O
two	O
other	O
cases	O
of	O
the	O
Ashkenazi	O
,	O
infantile	O
form	O
of	O
Tay	B
-	I
Sachs	I
disease	I
are	O
heterozygous	O
for	O
two	O
different	O
mutations	O
.	O

The	O
occurrence	O
of	O
multiple	O
mutant	O
alleles	O
warrants	O
further	O
examination	O
of	O
the	O
selective	O
advantage	O
hypothesis	O
.	O
.	O

X	B
-	I
linked	I
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
Mus	O
musculus	O
.	O

A	O
mouse	O
with	O
X	B
-	I
linked	I
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1	O
-	O
ethyl	O
-	O
1	O
-	O
nitrosourea	O
-	O
treated	O
male	O
mice	O
.	O

The	O
activity	O
alteration	O
was	O
detected	O
in	O
blood	O
but	O
can	O
also	O
be	O
observed	O
in	O
other	O
tissue	O
extracts	O
.	O

Hemizygous	O
,	O
heterozygous	O
,	O
and	O
homozygous	O
mutants	O
have	O
,	O
respectively	O
,	O
about	O
15	O
,	O
60	O
,	O
and	O
15	O
%	O
G6PD	O
remaining	O
activity	O
in	O
the	O
blood	O
as	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Erythrocyte	O
indices	O
did	O
not	O
show	O
differences	O
between	O
mutants	O
and	O
wild	O
types	O
.	O

The	O
mutation	O
does	O
not	O
affect	O
the	O
electrophoretic	O
migration	O
,	O
the	O
isoelectric	O
point	O
,	O
or	O
the	O
thermal	O
stability	O
.	O

Kinetic	O
properties	O
,	O
such	O
as	O
the	O
Km	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	O
utilization	O
of	O
substrate	O
analogues	O
,	O
showed	O
no	O
differences	O
between	O
wild	O
types	O
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	O
utilization	O
of	O
deamino	O
-	O
NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants	O
.	O

This	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
X	B
-	I
linked	I
G6PD	I
deficiency	I
in	O
humans	O
.	O
.	O

Diverse	O
point	O
mutations	O
in	O
the	O
human	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
cause	O
enzyme	B
deficiency	I
and	O
mild	O
or	O
severe	O
hemolytic	B
anemia	I
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
;	I
EC	I
1	I
.	I
1	I
.	I
1	I
.	I
49	I
)	I
deficiency	I
is	O
a	O
common	O
genetic	B
abnormality	I
affecting	O
an	O
estimated	O
400	O
million	O
people	O
worldwide	O
.	O

Clinical	O
and	O
biochemical	O
analyses	O
have	O
identified	O
many	O
variants	O
exhibiting	O
a	O
range	O
of	O
phenotypes	O
,	O
which	O
have	O
been	O
well	O
characterized	O
from	O
the	O
hematological	O
point	O
of	O
view	O
.	O

However	O
,	O
until	O
now	O
,	O
their	O
precise	O
molecular	O
basis	O
has	O
remained	O
unknown	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
seven	O
mutant	O
G6PD	O
alleles	O
.	O

In	O
the	O
nondeficient	O
polymorphic	O
African	O
variant	O
G6PD	O
A	O
we	O
have	O
found	O
a	O
single	O
point	O
mutation	O
.	O

The	O
other	O
six	O
mutants	O
investigated	O
were	O
all	O
associated	O
with	O
enzyme	B
deficiency	I
.	O

In	O
one	O
of	O
the	O
commonest	O
,	O
G6PD	O
Mediterranean	O
,	O
which	O
is	O
associated	O
with	O
favism	B
among	O
other	O
clinical	O
manifestations	O
,	O
a	O
single	O
amino	O
acid	O
replacement	O
was	O
found	O
(	O
serine	O
-	O
-	O
-	O
-	O
phenylalanine	O
)	O
it	O
must	O
be	O
responsible	O
for	O
the	O
decreased	O
stability	O
and	O
the	O
reduced	O
catalytic	O
efficiency	O
of	O
this	O
enzyme	O
.	O

Single	O
point	O
mutations	O
were	O
also	O
found	O
in	O
G6PD	O
Metaponto	O
(	O
Southern	O
Italy	O
)	O
and	O
in	O
G6PD	O
Ilesha	O
(	O
Nigeria	O
)	O
,	O
which	O
are	O
asymptomatic	O
,	O
and	O
in	O
G6PD	O
Chatham	O
,	O
which	O
was	O
observed	O
in	O
an	O
Indian	O
boy	O
with	O
neonatal	B
jaundice	I
.	O

In	O
G6PD	O
"	O
Matera	O
,	O
"	O
which	O
is	O
now	O
known	O
to	O
be	O
the	O
same	O
as	O
G6PD	O
A	O
-	O
,	O
two	O
separate	O
point	O
mutations	O
were	O
found	O
,	O
one	O
of	O
which	O
is	O
the	O
same	O
as	O
in	O
G6PD	O
A	O
.	O

In	O
G6PD	O
Santiago	O
,	O
a	O
de	O
novo	O
mutation	O
(	O
glycine	O
-	O
-	O
-	O
-	O
arginine	O
)	O
is	O
associated	O
with	O
severe	O
chronic	O
hemolytic	B
anemia	I
.	O

The	O
mutations	O
observed	O
show	O
a	O
striking	O
predominance	O
of	O
C	O
-	O
-	O
-	O
-	O
T	O
transitions	O
,	O
with	O
CG	O
doublets	O
involved	O
in	O
four	O
of	O
seven	O
cases	O
.	O

Thus	O
,	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
.	O

Tight	O
linkage	O
between	O
myotonic	B
dystrophy	I
and	O
apolipoprotein	O
E	O
genes	O
revealed	O
with	O
allele	O
-	O
specific	O
oligonucleotides	O
.	O

In	O
16	O
families	O
with	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
a	O
novel	O
approach	O
based	O
on	O
use	O
of	O
allele	O
-	O
specific	O
oligonucleotides	O
has	O
been	O
employed	O
to	O
study	O
the	O
linkage	O
relationship	O
between	O
the	O
apolipoprotein	O
E	O
(	O
APOE	O
)	O
gene	O
and	O
DM	B
.	O

Synthetic	O
oligonucleotides	O
,	O
designed	O
to	O
discriminate	O
between	O
APOE	O
alleles	O
epsilon	O
3	O
and	O
epsilon	O
4	O
,	O
enabled	O
us	O
to	O
distinguish	O
heterozygous	O
carriers	O
in	O
a	O
hybridization	O
assay	O
.	O

In	O
a	O
subset	O
of	O
families	O
,	O
the	O
relevant	O
segment	O
of	O
the	O
APOE	O
gene	O
was	O
enzymatically	O
amplified	O
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
method	O
.	O

For	O
DM	O
and	O
APOE	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
zmax	O
of	O
7	O
.	O

47	O
was	O
obtained	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O

047	O
(	O
male	O
theta	O
=	O
female	O
theta	O
)	O
.	O

No	O
recombination	O
(	O
maximum	O
lod	O
score	O
of	O
5	O
.	O
61	O
at	O
theta	O
=	O
0	O
.	O
0	O
)	O
was	O
found	O
between	O
APOE	O
and	O
the	O
apolipoprotein	O
CII	O
(	O
APOC2	O
)	O
gene	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
APOC2	O
,	O
APOE	O
is	O
a	O
useful	O
marker	O
for	O
presymptomatic	O
DM	B
diagnosis	O
.	O

Regional	O
localization	O
of	O
polymorphic	O
DNA	O
loci	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
using	O
deletions	O
associated	O
with	O
choroideremia	B
.	O

In	O
two	O
unrelated	O
families	O
,	O
males	O
have	O
been	O
identified	O
who	O
suffer	O
from	O
choroideremia	B
and	O
at	O
the	O
same	O
time	O
have	O
an	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
.	O

By	O
high	O
-	O
resolution	O
banding	O
we	O
have	O
characterized	O
the	O
deletion	O
chromosomes	O
as	O
del	O
(	O
X	O
)	O
(	O
q21	O
.	O
1	O
-	O
q21	O
1	O
-	O
q21	O
.	O
33	O
)	O
and	O
del	O
(	O
X	O
)	O
(	O
q21	O
.	O
2	O
-	O
q21	O
2	O
-	O
q21	O
.	O
31	O
)	O
respectively	O
.	O

By	O
Southern	O
blot	O
analysis	O
we	O
have	O
mapped	O
ten	O
different	O
polymorphic	O
DNA	O
loci	O
relative	O
to	O
the	O
position	O
of	O
the	O
deletion	O
and	O
the	O
choroideremia	B
locus	O
TCD	O
.	O

One	O
probe	O
,	O
p31	O
,	O
was	O
shown	O
to	O
cover	O
one	O
of	O
the	O
breakpoints	O
of	O
the	O
smallest	O
deletion	O
.	O

The	O
following	O
order	O
of	O
the	O
loci	O
was	O
suggested	O
by	O
deletion	O
mapping	O
cen	O
-	O
DXS106	O
-	O
DXS72	O
-	O
TCD	O
-	O
(	O
DXYS1	O
/	O
DXYS23	O
/	O
DXYS5	O
)	O
-	O
DXYS2	O
-	O
(	O
DXYS12	O
/	O
DXS3	O
)	O
-	O
(	O
DXS17	O
/	O
DXS101	O
)	O
-	O
Xqter	O
.	O

Retroviral	O
-	O
mediated	O
gene	O
transfer	O
of	O
human	O
phenylalanine	O
hydroxylase	O
into	O
NIH	O
3T3	O
and	O
hepatoma	B
cells	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
caused	O
by	O
deficiency	B
of	I
the	I
hepatic	I
enzyme	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

A	O
full	O
-	O
length	O
human	O
PAH	O
cDNA	O
sequence	O
has	O
been	O
inserted	O
into	O
pzip	O
-	O
neoSV	O
(	O
X	O
)	O
,	O
which	O
is	O
a	O
retroviral	O
vector	O
containing	O
the	O
bacterial	O
neo	O
gene	O
.	O

The	O
recombinant	O
has	O
been	O
transfected	O
into	O
psi	O
2	O
cells	O
,	O
which	O
provide	O
synthesis	O
of	O
the	O
retroviral	O
capsid	O
.	O

Recombinant	O
virus	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
of	O
the	O
transfected	O
psi	O
2	O
cells	O
,	O
which	O
is	O
capable	O
of	O
transmitting	O
the	O
human	O
PAH	O
gene	O
into	O
mouse	O
NIH	O
3T3	O
cells	O
by	O
infection	O
leading	O
to	O
stable	O
incorporation	O
of	O
the	O
recombinant	O
provirus	O
.	O

Infected	O
cells	O
express	O
PAH	O
mRNA	O
,	O
immunoreactive	O
PAH	O
protein	O
,	O
and	O
exhibit	O
pterin	O
-	O
dependent	O
phenylalanine	O
hydroxylase	O
activity	O
.	O

The	O
recombinant	O
virus	O
is	O
also	O
capable	O
of	O
infecting	O
a	O
mouse	O
hepatoma	B
cell	O
line	O
that	O
does	O
not	O
normally	O
synthesize	O
PAH	O
.	O

PAH	O
activity	O
is	O
present	O
in	O
the	O
cellular	O
extracts	O
and	O
the	O
entire	O
hydroxylation	O
system	O
is	O
reconstituted	O
in	O
the	O
hepatoma	B
cells	O
infected	O
with	O
the	O
recombinant	O
viruses	O
.	O

Thus	O
,	O
recombinant	O
viruses	O
containing	O
human	O
PAH	O
cDNA	O
provide	O
a	O
means	O
for	O
introducing	O
functional	O
PAH	O
into	O
mammalian	O
cells	O
of	O
hepatic	O
origin	O
and	O
can	O
potentially	O
be	O
introduced	O
into	O
whole	O
animals	O
as	O
a	O
model	O
for	O
somatic	O
gene	O
therapy	O
for	O
PKU	B
.	O
.	O

Estimation	O
of	O
the	O
male	O
to	O
female	O
ratio	O
of	O
mutation	O
rates	O
from	O
the	O
segregation	O
of	O
X	O
-	O
chromosomal	O
DNA	O
haplotypes	O
in	O
Duchenne	B
muscular	I
dystrophy	I
families	O
.	O

A	O
novel	O
procedure	O
is	O
presented	O
to	O
estimate	O
the	O
ratio	O
of	O
male	O
to	O
female	O
mutation	O
rates	O
for	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

X	O
-	O
specific	O
restriction	O
fragment	O
length	O
polymorphisms	O
are	O
used	O
to	O
establish	O
DNA	O
haplotypes	O
in	O
three	O
-	O
generation	O
DMD	B
families	O
.	O

From	O
the	O
proportion	O
of	O
DMD	B
patients	O
who	O
have	O
inherited	O
their	O
maternal	O
grandfathers	O
X	O
chromosome	O
,	O
the	O
ratio	O
of	O
mutation	O
rates	O
can	O
be	O
calculated	O
.	O

In	O
contrast	O
to	O
classical	O
methods	O
,	O
the	O
proposed	O
procedure	O
is	O
not	O
restricted	O
to	O
sporadic	O
or	O
familiar	O
cases	O
nor	O
is	O
any	O
information	O
on	O
the	O
carrier	O
status	O
of	O
female	O
relatives	O
required	O
.	O
.	O

Deletions	O
of	O
a	O
DNA	O
sequence	O
in	O
retinoblastomas	B
and	O
mesenchymal	B
tumors	I
:	O
organization	O
of	O
the	O
sequence	O
and	O
its	O
encoded	O
protein	O
.	O

Retinoblastoma	B
is	O
a	O
childhood	B
tumor	I
that	O
can	O
arise	O
because	O
of	O
mutant	O
alleles	O
acquired	O
as	O
somatic	O
or	O
germinal	O
mutations	O
.	O

The	O
mutant	O
allele	O
can	O
be	O
carried	O
in	O
the	O
germ	O
line	O
.	O

The	O
mutations	O
creating	O
these	O
alleles	O
act	O
by	O
inactivating	O
copies	O
of	O
a	O
recessive	O
oncogene	O
located	O
within	O
band	O
q14	O
of	O
chromosome	O
13	O
and	O
termed	O
the	O
RB1	O
locus	O
.	O

We	O
have	O
reported	O
isolation	O
of	O
a	O
cDNA	O
fragment	O
that	O
recognizes	O
chromosomal	O
sequences	O
possessing	O
many	O
of	O
the	O
attributes	O
of	O
the	O
retinoblastoma	B
gene	O
associated	O
with	O
the	O
RB1	O
locus	O
.	O

We	O
now	O
report	O
that	O
this	O
segment	O
is	O
additionally	O
the	O
target	O
of	O
somatic	O
mutations	O
in	O
mesenchymal	B
tumors	I
among	O
patients	O
having	O
no	O
apparent	O
predisposition	O
to	O
retinoblastoma	B
and	O
no	O
previous	O
evidence	O
of	O
retinoblastoma	B
.	O

These	O
tumors	B
provide	O
additional	O
evidence	O
that	O
the	O
cloned	O
sequences	O
are	O
representative	O
of	O
a	O
gene	O
that	O
is	O
a	O
frequent	O
target	O
of	O
inactivation	O
during	O
tumorigenesis	O
.	O

Sequence	O
analysis	O
of	O
this	O
cDNA	O
provides	O
little	O
insight	O
into	O
its	O
normal	O
functional	O
role	O
.	O
.	O

Treatment	O
of	O
Duchenne	B
muscular	I
dystrophy	I
with	O
growth	O
hormone	O
inhibitors	O
.	O

A	O
controlled	O
,	O
double	O
-	O
blind	O
therapeutic	O
trial	O
with	O
the	O
drug	O
mazindol	O
,	O
a	O
growth	O
hormone	O
inhibitor	O
,	O
was	O
performed	O
in	O
a	O
pair	O
of	O
7	O
1	O
/	O
2	O
year	O
-	O
old	O
monozygotic	O
twins	O
,	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

The	O
rationale	O
for	O
this	O
trial	O
was	O
based	O
on	O
a	O
patient	O
(	O
reported	O
previously	O
)	O
affected	O
simultaneously	O
with	O
DMD	B
and	O
growth	B
hormone	I
(	I
GH	I
)	I
deficiency	I
,	O
who	O
is	O
showing	O
a	O
benign	O
course	O
of	O
the	O
dystrophic	B
process	I
and	O
is	O
still	O
walking	O
at	O
18	O
years	O
.	O

One	O
of	O
the	O
twins	O
received	O
2	O
mg	O
of	O
mazindol	O
daily	O
,	O
while	O
the	O
other	O
received	O
a	O
placebo	O
.	O

The	O
assessment	O
,	O
repeated	O
every	O
2	O
months	O
,	O
included	O
weight	O
and	O
height	O
measurements	O
,	O
functional	O
and	O
motor	O
ability	O
tests	O
,	O
ergometry	O
and	O
determinations	O
of	O
serum	O
enzymes	O
and	O
GH	O
levels	O
.	O

After	O
one	O
year	O
of	O
trial	O
the	O
code	O
was	O
broken	O
and	O
it	O
was	O
seen	O
that	O
the	O
twin	O
under	O
placebo	O
treatment	O
was	O
strikingly	O
worse	O
than	O
his	O
brother	O
,	O
the	O
progression	O
of	O
whose	O
condition	O
was	O
practically	O
arrested	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
treatment	O
with	O
a	O
GH	O
inhibitor	O
is	O
beneficial	O
for	O
DMD	B
patients	O
.	O
.	O

Identification	O
and	O
localization	O
of	O
mutations	O
at	O
the	O
Lesch	B
-	I
Nyhan	I
locus	O
by	O
ribonuclease	O
A	O
cleavage	O
.	O

Many	O
mutations	O
leading	O
to	O
human	O
disease	O
are	O
the	O
result	O
of	O
single	O
DNA	O
base	O
pair	O
changes	O
that	O
cannot	O
be	O
identified	O
by	O
Southern	O
analysis	O
.	O

This	O
has	O
prompted	O
the	O
development	O
of	O
alternative	O
assays	O
for	O
point	O
mutation	O
detection	O
.	O

The	O
recently	O
described	O
ribonuclease	O
A	O
cleavage	O
procedure	O
,	O
with	O
a	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
chromatography	O
step	O
,	O
has	O
been	O
used	O
to	O
identify	O
the	O
mutational	O
lesions	O
in	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
messenger	O
RNAs	O
of	O
patients	O
with	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Distinctive	O
ribonuclease	O
A	O
cleavage	O
patterns	O
were	O
identified	O
in	O
messenger	O
RNA	O
from	O
5	O
of	O
14	O
Lesch	B
-	I
Nyhan	I
patients	O
who	O
were	O
chosen	O
because	O
no	O
HPRT	O
Southern	O
or	O
Northern	O
blotting	O
pattern	O
changes	O
had	O
been	O
found	O
.	O

This	O
approach	O
now	O
allows	O
HPRT	O
mutation	O
detection	O
in	O
50	O
percent	O
of	O
the	O
cases	O
of	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

The	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
procedure	O
provides	O
a	O
general	O
method	O
for	O
analysis	O
of	O
low	O
abundance	O
messenger	O
RNAs	O
.	O
.	O

Two	O
new	O
variants	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
associated	O
with	O
hereditary	B
non	I
-	I
spherocytic	I
hemolytic	I
anemia	I
:	O
G6PD	O
Wayne	O
and	O
G6PD	O
Huron	O
.	O

Two	O
new	O
deficient	O
variants	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
causing	O
hereditary	B
nonspherocytic	I
hemolytic	I
anemia	I
(	O
HNSHA	B
)	O
are	O
described	O
.	O

Both	O
of	O
these	O
are	O
unique	O
and	O
they	O
have	O
been	O
named	O
G6PD	O
Wayne	O
and	O
G6PD	O
Huron	O
.	O

Patients	O
with	O
G6PD	O
Wayne	O
underwent	O
splenectomy	O
and	O
no	O
objective	O
improvement	O
was	O
noted	O
.	O

The	O
patients	O
with	O
G6PD	O
Huron	O
were	O
under	O
medical	O
observation	O
for	O
a	O
considerable	O
period	O
of	O
time	O
without	O
the	O
diagnosis	O
of	O
G6PD	B
deficiency	I
being	O
entertained	O
because	O
the	O
family	O
was	O
of	O
Northern	O
European	O
origin	O
.	O

Since	O
sporadic	O
variants	O
of	O
G6PD	O
causing	O
HNSHA	B
show	O
no	O
special	O
racial	O
predilection	O
,	O
the	O
diagnosis	O
of	O
G6PD	B
deficiency	I
should	O
always	O
be	O
considered	O
in	O
patients	O
with	O
this	O
syndrome	O
.	O
.	O

Sialophorin	O
,	O
a	O
surface	O
sialoglycoprotein	O
defective	O
in	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
is	O
involved	O
in	O
human	O
T	O
lymphocyte	O
proliferation	O
.	O

The	O
mAb	O
L10	O
was	O
used	O
to	O
determine	O
the	O
distribution	O
and	O
the	O
function	O
of	O
sialophorin	O
,	O
the	O
heavily	O
glycosylated	O
surface	O
molecule	O
that	O
is	O
deficient	O
/	O
defective	O
in	O
lymphocytes	O
of	O
patients	O
with	O
the	O
X	B
-	I
linked	I
immunodeficiency	I
Wiskott	I
-	I
Aldrich	I
syndrome	I
.	O

Dual	O
-	O
parameter	O
FACS	O
analysis	O
indicated	O
that	O
sialophorin	O
is	O
expressed	O
on	O
CD4	O
+	O
and	O
CD8	O
+	O
lymphocytes	O
,	O
on	O
a	O
subpopulation	O
of	O
peripheral	O
blood	O
B	O
lymphocytes	O
,	O
on	O
all	O
thymocytes	O
,	O
and	O
on	O
a	O
subpopulation	O
of	O
bone	O
marrow	O
cells	O
.	O

Functional	O
studies	O
demonstrated	O
that	O
L10	O
mAb	O
stimulates	O
the	O
proliferation	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
as	O
measured	O
by	O
stimulation	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
.	O

The	O
time	O
course	O
and	O
magnitude	O
of	O
increased	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
by	O
T	O
lymphocytes	O
in	O
response	O
to	O
L10	O
mAb	O
paralleled	O
that	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
.	O

Effective	O
stimulation	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
monocytes	O
and	O
the	O
Fc	O
portion	O
of	O
L10	O
mAb	O
.	O

Stimulation	O
of	O
lymphocytes	O
by	O
L10	O
,	O
like	O
stimulation	O
by	O
anti	O
-	O
CD3	O
mAb	O
,	O
involves	O
increased	O
expression	O
of	O
4F2	O
,	O
HLA	O
-	O
DR	O
,	O
and	O
IL	O
-	O
2	O
-	O
R	O
.	O

These	O
observations	O
suggest	O
that	O
sialophorin	O
functions	O
in	O
T	O
cell	O
activation	O
.	O
.	O

Hypopigmentation	B
in	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
.	O

Cutaneous	B
and	I
ocular	I
pigmentation	I
were	O
evaluated	O
in	O
29	O
individuals	O
with	O
the	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Criteria	O
for	O
hypopigmentation	B
included	O
the	O
presence	O
of	O
type	O
I	O
or	O
II	O
skin	O
,	O
the	O
lightest	O
skin	O
type	O
in	O
the	O
family	O
by	O
history	O
,	O
and	O
iris	O
translucency	O
on	O
globe	O
transillumination	O
.	O

On	O
the	O
basis	O
of	O
these	O
criteria	O
,	O
48	O
%	O
of	O
the	O
PWS	B
individuals	O
were	O
hypopigmented	B
.	O

The	O
presence	O
of	O
hypopigmentation	B
correlated	O
with	O
a	O
small	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
;	O
however	O
,	O
this	O
deletion	O
was	O
also	O
found	O
in	O
individuals	O
who	O
did	O
not	O
meet	O
the	O
full	O
criteria	O
for	O
hypopigmentation	B
.	O

Hairbulb	O
tyrosinase	O
activity	O
and	O
glutathione	O
content	O
,	O
as	O
well	O
as	O
urine	O
cysteinyldopa	O
excretion	O
,	O
were	O
low	O
in	O
PWS	B
individuals	O
with	O
and	O
without	O
hypopigmentation	B
and	O
did	O
not	O
separate	O
these	O
two	O
groups	O
.	O

We	O
conclude	O
that	O
hypopigmentation	B
is	O
found	O
in	O
a	O
significant	O
proportion	O
of	O
individuals	O
with	O
PWS	B
and	O
that	O
the	O
hypopigmentation	B
may	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
15	O
.	O

The	O
mechanism	O
for	O
the	O
hypopigmentation	B
is	O
unknown	O
.	O
.	O

Phenotype	O
heterogeneity	O
among	O
hemizygotes	O
in	O
a	O
family	O
biochemically	O
screened	O
for	O
adrenoleukodystrophy	B
.	O

We	O
report	O
on	O
two	O
clinically	O
,	O
neurologically	O
normal	O
relatives	O
of	O
a	O
boy	O
affected	O
by	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
;	O
they	O
were	O
found	O
repeatedly	O
to	O
have	O
the	O
biochemical	O
defect	O
of	O
an	O
ALD	B
hemizygote	O
.	O

The	O
assay	O
consisted	O
in	O
the	O
determination	O
of	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
in	O
lyophilized	O
and	O
reconstituted	O
plasma	O
.	O

While	O
no	O
evidence	O
of	O
neurologic	B
disease	I
(	O
leukodystrophy	B
or	O
myeloneuropathy	B
)	O
was	O
present	O
in	O
these	O
hemizygotes	O
,	O
adrenocortical	B
insufficiency	I
provoking	O
compensatory	O
high	O
ACTH	O
release	O
was	O
found	O
in	O
both	O
.	O

These	O
findings	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
counseling	O
families	O
in	O
which	O
cases	O
with	O
clinically	O
expressed	O
ALD	B
are	O
represented	O
in	O
several	O
generations	O
.	O
.	O

The	O
mapping	O
of	O
a	O
cDNA	O
from	O
the	O
human	O
X	B
-	I
linked	I
Duchenne	I
muscular	I
dystrophy	I
gene	O
to	O
the	O
mouse	O
X	O
chromosome	O
.	O

The	O
recent	O
discovery	O
of	O
sequences	O
at	O
the	O
site	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
in	O
humans	O
has	O
opened	O
up	O
the	O
possibility	O
of	O
a	O
detailed	O
molecular	O
analysis	O
of	O
the	O
genes	O
in	O
humans	O
and	O
in	O
related	O
mammalian	O
species	O
.	O

Until	O
relatively	O
recently	O
,	O
there	O
was	O
no	O
obvious	O
mouse	O
model	O
of	O
this	O
genetic	B
disease	I
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
.	O

The	O
identification	O
of	O
a	O
mouse	O
X	O
-	O
linked	O
mutant	O
showing	O
muscular	B
dystrophy	I
,	O
mdx	O
,	O
has	O
provided	O
a	O
candidate	O
mouse	O
genetic	O
homologue	O
to	O
the	O
DMD	B
locus	O
;	O
the	O
relatively	O
mild	O
pathological	O
features	O
of	O
mdx	O
suggest	O
it	O
may	O
have	O
more	O
in	O
common	O
with	O
mutations	O
of	O
the	O
Becker	B
muscular	I
dystrophy	I
type	O
at	O
the	O
same	O
human	O
locus	O
,	O
however	O
.	O

But	O
the	O
close	O
genetic	O
linkage	O
of	O
mdx	O
to	O
G6PD	O
and	O
Hprt	O
on	O
the	O
mouse	O
X	O
chromosome	O
,	O
coupled	O
with	O
its	O
comparatively	O
mild	O
pathology	O
,	O
have	O
suggested	O
that	O
the	O
mdx	O
mutation	O
may	O
instead	O
correspond	O
to	O
Emery	B
Dreifuss	I
muscular	I
dystrophy	I
which	O
itself	O
is	O
closely	O
linked	O
to	O
DNA	O
markers	O
at	O
Xq28	O
-	O
qter	O
in	O
the	O
region	O
of	O
G6PD	O
on	O
the	O
human	O
X	O
chromosome	O
.	O

Using	O
an	O
interspecific	O
mouse	O
domesticus	O
/	O
spretus	O
cross	O
,	O
segregating	O
for	O
a	O
variety	O
of	O
markers	O
on	O
the	O
mouse	O
X	O
chromosome	O
,	O
we	O
have	O
positioned	O
on	O
the	O
mouse	O
X	O
chromosome	O
sequences	O
homologous	O
to	O
a	O
DMD	B
cDNA	O
clone	O
.	O

These	O
sequences	O
map	O
provocatively	O
close	O
to	O
the	O
mdx	O
mutation	O
and	O
unexpectedly	O
distant	O
from	O
sparse	O
fur	O
,	O
spf	O
,	O
the	O
mouse	O
homologue	O
of	O
OTC	O
(	O
ornithine	O
transcarbamylase	O
)	O
which	O
is	O
closely	O
linked	O
to	O
DMD	B
on	O
the	O
human	O
X	O
chromosome	O
.	O
.	O

Localization	O
of	O
the	O
region	O
homologous	O
to	O
the	O
Duchenne	B
muscular	I
dystrophy	I
locus	O
on	O
the	O
mouse	O
X	O
chromosome	O
.	O

Recent	O
progress	O
has	O
resulted	O
in	O
part	O
of	O
the	O
gene	O
mutated	O
in	O
Duchenne	B
and	I
the	I
milder	I
Becker	I
muscular	I
dystrophies	I
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	O
itself	O
extends	O
over	O
1	O
,	O
000	O
to	O
2	O
,	O
000	O
kilobases	O
(	O
kb	O
)	O
.	O

To	O
study	O
how	O
mutations	O
in	O
this	O
gene	O
affect	O
muscle	O
development	O
and	O
integrity	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
have	O
available	O
a	O
mouse	O
model	O
of	O
the	O
human	O
disease	O
.	O

The	O
mouse	O
mdx	O
mutation	O
affects	O
muscle	O
and	O
confers	O
a	O
mild	O
dystrophic	B
syndrome	I
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	O
is	O
equivalent	O
to	O
Duchenne	B
/	I
Becker	I
muscular	I
dystrophy	I
in	O
man	O
.	O

Here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
that	O
cross	O
-	O
hybridize	O
to	O
mouse	O
X	O
-	O
linked	O
sequences	O
to	O
localize	O
the	O
gene	O
homologous	O
to	O
DMD	B
in	O
the	O
mouse	O
.	O

Both	O
sequences	O
map	O
to	O
the	O
region	O
of	O
10	O
centimorgan	O
lying	O
between	O
the	O
Tabby	O
(	O
Ta	O
)	O
and	O
St14	O
-	O
1	O
(	O
DxPas8	O
)	O
loci	O
,	O
close	O
to	O
the	O
phosphorylase	O
b	O
kinase	O
locus	O
(	O
Phk	O
)	O
.	O

By	O
analogy	O
with	O
the	O
human	O
X	O
-	O
chromosome	O
,	O
we	O
conclude	O
that	O
the	O
region	O
in	O
the	O
mouse	O
around	O
the	O
G6pd	O
and	O
St14	O
-	O
1	O
loci	O
may	O
contain	O
two	O
genes	O
corresponding	O
to	O
distinct	O
human	O
myopathies	B
Emery	B
Dreifuss	I
muscular	I
dystrophy	I
which	O
is	O
known	O
to	O
be	O
closely	O
linked	O
to	O
St14	O
-	O
1	O
in	O
man	O
and	O
the	O
DMD	B
homologue	O
described	O
here	O
.	O
.	O

GT	O
to	O
AT	O
transition	O
at	O
a	O
splice	O
donor	O
site	O
causes	O
skipping	O
of	O
the	O
preceding	O
exon	O
in	O
phenylketonuria	B
.	O

Classical	B
Phenylketonuria	I
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
human	I
genetic	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

We	O
isolated	O
several	O
mutant	O
PAH	O
cDNA	O
clones	O
from	O
a	O
PKU	B
carrier	O
individual	O
and	O
showed	O
that	O
they	O
contained	O
an	O
internal	O
116	O
base	O
pair	O
deletion	O
,	O
corresponding	O
precisely	O
to	O
exon	O
12	O
of	O
the	O
human	O
chromosomal	O
PAH	O
gene	O
.	O

The	O
deletion	O
causes	O
the	O
synthesis	O
of	O
a	O
truncated	O
protein	O
lacking	O
the	O
C	O
-	O
terminal	O
52	O
amino	O
acids	O
.	O

Gene	O
transfer	O
and	O
expression	O
studies	O
using	O
the	O
mutant	O
PAH	O
cDNA	O
indicated	O
that	O
the	O
deletion	O
abolishes	O
PAH	O
activity	O
in	O
the	O
cell	O
as	O
a	O
result	O
of	O
protein	O
instability	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
the	O
deletion	O
,	O
the	O
mutant	O
chromosomal	O
PAH	O
gene	O
was	O
isolated	O
from	O
this	O
individual	O
and	O
shown	O
to	O
contain	O
a	O
GT	O
-	O
-	O
greater	O
than	O
AT	O
substitution	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
12	O
.	O

Thus	O
,	O
the	O
consequence	O
of	O
the	O
splice	O
donor	O
site	O
mutation	O
in	O
the	O
human	O
liver	O
is	O
the	O
skipping	O
of	O
the	O
preceding	O
exon	O
during	O
RNA	O
splicing	O
.	O
.	O

Conservation	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
in	O
mice	O
and	O
humans	O
.	O

A	O
portion	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
transcript	O
from	O
human	O
fetal	O
skeletal	O
muscle	O
and	O
mouse	O
adult	O
heart	O
was	O
sequenced	O
,	O
representing	O
approximately	O
25	O
percent	O
of	O
the	O
total	O
,	O
14	O
-	O
kb	O
DMD	B
transcript	O
.	O

The	O
nucleic	O
acid	O
and	O
predicted	O
amino	O
acid	O
sequences	O
from	O
the	O
two	O
species	O
are	O
nearly	O
90	O
percent	O
homologous	O
.	O

The	O
amino	O
acid	O
sequence	O
that	O
is	O
predicted	O
from	O
this	O
portion	O
of	O
the	O
DMD	B
gene	O
indicates	O
that	O
the	O
protein	O
product	O
might	O
serve	O
a	O
structural	O
role	O
in	O
muscle	O
,	O
but	O
the	O
abundance	O
and	O
tissue	O
distribution	O
of	O
the	O
messenger	O
RNA	O
suggests	O
that	O
the	O
DMD	B
protein	O
is	O
not	O
nebulin	O
.	O
.	O

Familial	O
Prader	B
-	I
Willi	I
syndrome	I
with	O
apparently	O
normal	O
chromosomes	O
.	O

We	O
report	O
on	O
4	O
sibs	O
(	O
2F	O
,	O
2M	O
)	O
with	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Diagnosis	O
was	O
made	O
clinically	O
on	O
the	O
basis	O
of	O
history	O
,	O
behavior	O
,	O
and	O
physical	O
findings	O
in	O
3	O
of	O
the	O
sibs	O
.	O

The	O
other	O
child	O
had	O
died	O
at	O
age	O
10	O
months	O
with	O
a	O
history	O
and	O
clinical	O
findings	O
typical	O
of	O
first	O
phase	O
of	O
PWS	B
.	O

Results	O
of	O
chromosome	O
studies	O
on	O
the	O
parents	O
and	O
surviving	O
sibs	O
were	O
normal	O
.	O

The	O
implications	O
of	O
this	O
unusual	O
familial	O
occurrence	O
for	O
our	O
understanding	O
of	O
PWS	B
are	O
discussed	O
.	O
.	O

Nebulin	O
and	O
titin	O
expression	O
in	O
Duchenne	B
muscular	I
dystrophy	I
appears	O
normal	O
.	O

Monoclonal	O
antibodies	O
which	O
recognize	O
different	O
epitopes	O
on	O
either	O
titin	O
or	O
nebulin	O
show	O
normal	O
staining	O
patterns	O
on	O
frozen	O
sections	O
of	O
three	O
muscle	O
biopsies	O
of	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

Gel	O
electrophoresis	O
and	O
immunoblotting	O
performed	O
on	O
two	O
of	O
these	O
muscle	O
biopsies	O
show	O
the	O
normal	O
pattern	O
of	O
titin	O
and	O
nebulin	O
polypeptides	O
.	O

Since	O
the	O
donor	O
of	O
one	O
of	O
these	O
biopsies	O
has	O
a	O
large	O
deletion	O
of	O
the	O
5	O
-	O
region	O
of	O
the	O
DMD	B
gene	O
,	O
our	O
results	O
argue	O
against	O
the	O
recent	O
proposal	O
that	O
nebulin	O
is	O
the	O
gene	O
mutated	O
in	O
DMD	B
.	O
.	O

Heterozygous	B
C2	I
deficiency	I
associated	O
with	O
angioedema	B
,	O
myasthenia	B
gravis	I
,	O
and	O
systemic	B
lupus	I
erythematosus	I
.	O

We	O
describe	O
a	O
patient	O
with	O
myasthenia	B
gravis	I
,	O
systemic	B
lupus	I
erythematosus	I
,	O
and	O
angioedema	B
associated	O
with	O
heterozygous	O
complement	B
factor	I
2	I
(	I
C2	I
)	I
deficiency	I
.	O

The	O
significance	O
of	O
this	O
association	O
is	O
controversial	O
,	O
though	O
the	O
association	O
of	O
C2	B
deficiency	I
with	O
certain	O
histocompatibility	O
antigens	O
suggests	O
possible	O
linkage	O
to	O
immune	O
response	O
genes	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
heterozygous	O
C2	B
deficiency	I
in	O
association	O
with	O
this	O
combination	O
of	O
autoimmune	B
disorders	I
,	O
and	O
we	O
discuss	O
the	O
aetiological	O
implications	O
.	O
.	O

Genetic	O
analysis	O
of	O
an	O
inherited	O
deficiency	B
of	I
the	I
third	I
component	I
of	I
complement	I
in	O
Brittany	O
spaniel	O
dogs	O
.	O

Genetically	O
determined	O
C3	B
deficiency	I
in	O
Brittany	O
spaniel	O
dogs	O
shares	O
a	O
number	O
of	O
biochemical	O
and	O
clinical	O
characteristics	O
with	O
the	O
human	O
disorder	O
.	O

In	O
humans	O
,	O
the	O
gene	O
for	O
C3	B
deficiency	I
is	O
a	O
null	O
gene	O
that	O
is	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
C3	O
and	O
is	O
not	O
linked	O
to	O
the	O
major	O
histocompatibility	O
locus	O
.	O

The	O
current	O
study	O
used	O
allotype	O
analysis	O
of	O
canine	O
C3	O
in	O
order	O
to	O
demonstrate	O
that	O
the	O
gene	O
for	O
C3	B
deficiency	I
in	O
these	O
dogs	O
is	O
also	O
a	O
null	O
gene	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
C3	O
.	O

In	O
addition	O
,	O
preliminary	O
pedigree	O
analysis	O
suggests	O
that	O
the	O
gene	O
for	O
canine	O
C3	B
deficiency	I
is	O
apparently	O
not	O
closely	O
linked	O
to	O
the	O
major	O
histocompatibility	O
complex	O
of	O
the	O
dog	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
C3	B
deficiency	I
in	O
Brittany	O
spaniel	O
dogs	O
not	O
only	O
shares	O
biochemical	O
and	O
clinical	O
features	O
with	O
C3	B
deficiency	I
in	O
humans	O
,	O
but	O
also	O
shares	O
some	O
genetic	O
characteristics	O
with	O
the	O
human	O
disorder	O
.	O
.	O

Gene	O
transfer	O
and	O
expression	O
of	O
human	O
phenylalanine	O
hydroxylase	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
caused	O
by	O
a	O
genetic	O
deficiency	B
of	I
the	I
enzyme	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

A	O
full	O
-	O
length	O
complementary	O
DNA	O
clone	O
of	O
human	O
PAH	O
was	O
inserted	O
into	O
a	O
eukaryotic	O
expression	O
vector	O
and	O
transferred	O
into	O
mouse	O
NIH3T3	O
cells	O
which	O
do	O
not	O
normally	O
express	O
PAH	O
.	O

The	O
transformed	O
mouse	O
cells	O
expressed	O
PAH	O
messenger	O
RNA	O
,	O
immunoreactive	O
protein	O
,	O
and	O
enzymatic	O
activity	O
that	O
are	O
characteristic	O
of	O
the	O
normal	O
human	O
liver	O
products	O
,	O
demonstrating	O
that	O
a	O
single	O
gene	O
contains	O
all	O
of	O
the	O
necessary	O
genetic	O
information	O
to	O
code	O
for	O
functional	O
PAH	O
.	O

These	O
results	O
support	O
the	O
use	O
of	O
the	O
human	O
PAH	O
probe	O
in	O
prenatal	O
diagnosis	O
and	O
detection	O
of	O
carriers	O
,	O
to	O
provide	O
new	O
opportunities	O
for	O
the	O
biochemical	O
characterization	O
of	O
normal	O
and	O
mutant	O
enzymes	O
,	O
and	O
in	O
the	O
investigation	O
of	O
alternative	O
genetic	O
therapies	O
for	O
PKU	B
.	O
.	O

Regional	O
mapping	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
and	O
the	O
phenylketonuria	B
locus	O
in	O
the	O
human	O
genome	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
of	O
amino	O
acid	O
metabolism	O
caused	O
by	O
a	O
deficiency	B
of	I
the	I
hepatic	I
enzyme	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
;	O
phenylalanine	O
4	O
-	O
monooxygenase	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O

A	O
cDNA	O
clone	O
for	O
human	O
PAH	O
has	O
previously	O
been	O
used	O
to	O
assign	O
the	O
corresponding	O
gene	O
to	O
human	O
chromosome	O
12	O
.	O

To	O
define	O
the	O
regional	O
map	O
position	O
of	O
the	O
disease	O
locus	O
and	O
the	O
PAH	O
gene	O
on	O
human	O
chromosome	O
12	O
,	O
DNA	O
was	O
isolated	O
from	O
human	O
-	O
hamster	O
somatic	O
cell	O
hybrids	O
with	O
various	O
deletions	O
of	O
human	O
chromosome	O
12	O
and	O
was	O
analyzed	O
by	O
Southern	O
blot	O
analysis	O
using	O
the	O
human	O
cDNA	O
PAH	O
clone	O
as	O
a	O
hybridization	O
probe	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
detailed	O
biochemical	O
and	O
cytogenetic	O
characterization	O
of	O
the	O
hybrid	O
cells	O
,	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
human	O
PAH	O
gene	O
has	O
been	O
defined	O
as	O
12q14	O
.	O

3	O
-	O
-	O
-	O
-	O
qter	O
3	O
-	O
-	O
-	O
-	O
qter	O
.	O

The	O
PAH	O
map	O
position	O
on	O
chromosome	O
12	O
was	O
further	O
localized	O
by	O
in	O
situ	O
hybridization	O
of	O
125I	O
-	O
labeled	O
human	O
PAH	O
cDNA	O
to	O
chromosomes	O
prepared	O
from	O
a	O
human	O
lymphoblastoid	O
cell	O
line	O
.	O

Results	O
of	O
these	O
experiments	O
demonstrated	O
that	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
PAH	O
gene	O
and	O
the	O
PKU	B
locus	O
in	O
man	O
is	O
12q22	O
-	O
-	O
-	O
-	O
12q24	O
.	O

1	O
.	O

These	O
results	O
not	O
only	O
provide	O
a	O
regionalized	O
map	O
position	O
for	O
a	O
major	O
human	O
disease	O
locus	O
but	O
also	O
can	O
serve	O
as	O
a	O
reference	O
point	O
for	O
linkage	O
analysis	O
with	O
other	O
DNA	O
markers	O
on	O
human	O
chromosome	O
12	O

Heterogeneity	O
of	O
type	B
I	I
von	I
Willebrand	I
disease	I
:	O
evidence	O
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	B
Willebrand	I
factor	O
.	O

Type	B
I	I
von	I
Willebrand	I
disease	I
(	O
vWD	B
)	O
is	O
characterized	O
by	O
equally	O
low	O
plasma	O
concentrations	O
of	O
von	B
Willebrand	I
factor	O
antigen	O
(	O
vWF	O
Ag	O
)	O
and	O
ristocetin	O
cofactor	O
(	O
RiCof	O
)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vWF	O
multimers	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
agarose	O
gel	O
electrophoresis	O
.	O

For	O
17	O
patients	O
(	O
13	O
kindreds	O
)	O
diagnosed	O
with	O
these	O
criteria	O
,	O
we	O
have	O
studied	O
the	O
platelet	O
contents	O
of	O
vWF	O
Ag	O
and	O
RiCof	O
and	O
the	O
changes	O
of	O
these	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
.	O

Platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
normal	O
in	O
four	O
kindreds	O
(	O
called	O
"	O
platelet	O
normal	O
"	O
subgroup	O
)	O
;	O
following	O
1	O
-	O
deamino	O
-	O
8	O
-	O
D	O
-	O
arginine	O
vasopressin	O
;	O
plasma	O
vWF	O
Ag	O
,	O
RiCof	O
and	O
the	O
bleeding	O
time	O
(	O
BT	O
)	O
became	O
normal	O
.	O

In	O
six	O
kindreds	O
,	O
platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
equally	O
low	O
(	O
platelet	O
low	O
)	O
;	O
after	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
and	O
RiCof	O
remained	O
low	O
,	O
and	O
the	O
BT	O
was	O
prolonged	O
.	O

In	O
three	O
additional	O
kindreds	O
,	O
platelets	O
contained	O
normal	O
concentrations	O
of	O
vWF	O
Ag	O
,	O
but	O
RiCof	O
was	O
very	O
low	O
(	O
platelet	O
discordant	O
)	O
;	O
even	O
though	O
a	O
complete	O
set	O
of	O
multimers	O
was	O
found	O
in	O
plasma	O
and	O
platelets	O
,	O
there	O
was	O
a	O
relatively	O
small	O
amount	O
of	O
large	O
multimers	O
.	O

After	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
became	O
normal	O
,	O
but	O
RiCof	O
remained	O
low	O
and	O
the	O
BT	O
was	O
very	O
prolonged	O
.	O

These	O
findings	O
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vWF	O
(	O
RiCof	O
less	O
than	O
vWF	O
Ag	O
)	O
even	O
in	O
type	B
I	I
vWD	I
,	O
coexisting	O
with	O
a	O
complete	O
set	O
of	O
vWF	O
multimers	O
(	O
platelet	O
discordant	O
)	O
;	O
that	O
the	O
abnormal	O
vWF	O
can	O
be	O
shown	O
more	O
clearly	O
in	O
platelets	O
than	O
in	O
plasma	O
or	O
else	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
;	O
and	O
that	O
DDAVP	O
normalizes	O
the	O
BT	O
only	O
in	O
those	O
patients	O
with	O
normal	O
platelet	O
levels	O
of	O
both	O
vWF	O
Ag	O
and	O
RiCof	O
(	O
platelet	O
normal	O
)	O
.	O
.	O

Genetic	O
analysis	O
in	O
families	O
with	O
van	B
der	I
Woude	I
syndrome	I
.	O

We	O
have	O
brought	O
together	O
information	O
on	O
864	O
affected	O
individuals	O
in	O
164	O
families	O
(	O
including	O
three	O
new	O
pedigrees	O
)	O
reported	O
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
Demarquay	O
first	O
described	O
a	O
family	O
with	O
what	O
was	O
later	O
called	O
van	B
der	I
Woude	I
syndrome	I
(	O
VWS	B
)	O
.	O

Both	O
types	O
of	O
oral	B
cleft	I
,	O
cleft	B
palate	I
(	O
CP	B
)	O
and	O
cleft	B
lip	I
with	O
or	O
without	O
CP	B
(	O
CLP	B
)	O
,	O
segregate	O
in	O
these	O
families	O
together	O
with	O
lower	O
lip	B
pits	I
or	O
fistulae	B
in	O
an	O
autosomal	O
dominant	O
mode	O
with	O
high	O
penetrance	O
estimated	O
to	O
be	O
K	O
=	O
.	O

89	O
and	O
.	O

99	O
by	O
different	O
methods	O
.	O

Cleft	O
types	O
(	O
CLP	B
and	O
CP	B
)	O
occur	O
in	O
VWS	B
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	O
non	O
-	O
VWS	O
population	O
,	O
ie	O
,	O
about	O
twice	O
as	O
many	O
cleft	O
-	O
bearing	O
individuals	O
have	O
CLP	B
as	O
have	O
CP	B
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	O
excess	O
of	O
females	O
with	O
CP	B
and	O
excess	O
of	O
males	O
with	O
CLP	B
;	O
in	O
VWS	B
the	O
sex	O
ratios	O
are	O
more	O
nearly	O
equal	O
.	O

Lip	B
pits	I
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes	O
.	O

Affected	O
males	O
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
VWS	B
.	O

However	O
,	O
there	O
is	O
an	O
excess	O
of	O
less	O
severely	O
affected	O
individuals	O
among	O
transmitters	O
and	O
a	O
deficiency	O
of	O
more	O
severely	O
affected	O
,	O
brought	O
about	O
by	O
a	O
proband	O
bias	O
and	O
differential	O
fecundity	O
.	O

The	O
expression	O
of	O
VWS	B
is	O
significantly	O
modified	O
by	O
the	O
genetic	O
background	O
More	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	O
more	O
extreme	O
expression	O
in	O
their	O
children	O
.	O

For	O
a	O
VWS	B
gene	O
carrier	O
the	O
relative	O
risk	O
of	O
transmitting	O
a	O
cleft	O
is	O
26	O
.	O

45	O
%	O
;	O
that	O
of	O
transmitting	O
lower	O
lip	B
pits	I
is	O
23	O
.	O

55	O
%	O
.	O

Three	O
pedigrees	O
of	O
lip	B
pits	I
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	O
number	O
of	O
affected	O
individuals	O
.	O

Control	O
of	O
gene	O
expression	O
in	O
VWS	B
in	O
the	O
three	O
target	O
tissues	O
appears	O
to	O
be	O
independent	O
and	O
separately	O
designated	O
.	O

Mutation	O
rate	O
of	O
the	O
VWS	B
gene	O
is	O
calculated	O
to	O
be	O
1	O
.	O

8	O
X	O
10	O
(	O
-	O
5	O
)	O

Hereditary	B
C7	I
deficiency	I
.	O

Diagnosis	O
and	O
HLA	O
studies	O
in	O
a	O
French	O
-	O
Canadian	O
family	O
.	O

The	O
serum	O
of	O
a	O
44	O
-	O
yr	O
-	O
old	O
woman	O
of	O
French	O
-	O
Canadian	O
descent	O
having	O
a	O
B	O
-	O
27	O
positive	O
ankylosing	B
spondylitis	I
was	O
deficient	B
in	I
the	I
seventh	I
component	I
of	I
complement	I
(	O
C7	O
)	O
as	O
determined	O
by	O
hemolytic	O
and	O
immunochemical	O
methods	O
.	O

No	O
inhibitor	O
against	O
C7	O
was	O
detected	O
,	O
and	O
the	O
levels	O
of	O
all	O
other	O
complement	O
components	O
were	O
normal	O
.	O

No	O
deficiency	O
in	O
the	O
opsonic	O
activity	O
of	O
the	O
serum	O
was	O
found	O
,	O
and	O
the	O
results	O
of	O
basic	O
coagulation	O
studies	O
of	O
the	O
plasma	O
were	O
normal	O
.	O

On	O
investigation	O
of	O
the	O
patients	O
family	O
,	O
two	O
sisters	O
were	O
found	O
to	O
have	O
the	O
same	O
deficiency	O
but	O
were	O
otherwise	O
in	O
good	O
health	O
.	O

The	O
seven	O
other	O
siblings	O
were	O
heterozygous	O
for	O
C7	B
deficiency	I
,	O
while	O
the	O
paternal	O
aunt	O
had	O
a	O
normal	O
C7	O
level	O
.	O

In	O
the	O
third	O
generation	O
,	O
six	O
children	O
of	O
the	O
three	O
homozygous	O
sisters	O
and	O
five	O
children	O
of	O
heterozygotes	O
were	O
available	O
for	O
testing	O
.	O

Studies	O
of	O
the	O
HLA	O
antigens	O
in	O
all	O
the	O
22	O
subjects	O
and	O
in	O
three	O
spouses	O
indicated	O
no	O
close	O
linkage	O
between	O
the	O
CM	B
deficienty	I
and	O
the	O
HLA	O
system	O
.	O

In	O
addition	O
,	O
the	O
simultaneous	O
occurrence	O
of	O
two	O
hereditary	O
complement	B
deficiencies	I
(	I
C2	I
and	I
C7	I
)	I
was	O
discovered	O
in	O
one	O
family	O
of	O
this	O
remarkable	O
kindred	O
.	O
.	O

Genetic	O
defect	B
in	I
secretion	I
of	I
complement	I
C5	I
in	O
mice	O
.	O

A	O
genetic	O
deficiency	B
of	I
the	I
fifth	I
(	I
C5	I
)	I
component	I
of	I
complement1	I
-	I
3	I
,	O
a	O
serum	O
glycoprotein	O
of	O
molecular	O
weight	O
(	O
MW	O
)	O
220	O
,	O
000	O
(	O
ref	O
.	O
4	O
)	O
,	O
has	O
been	O
found	O
in	O
39	O
%	O
of	O
inbred	O
strains	O
of	O
mice3	O
.	O

Sera	O
of	O
deficient	O
mice	O
lack	O
detectable	O
C5	O
activity	O
and	O
protein2	O
,	O
3	O
.	O

In	O
addition	O
deficient	O
mice	O
produce	O
antibody	O
to	O
mouse	O
C5	O
when	O
injected	O
with	O
sera	O
from	O
C5	O
sufficient	O
(	O
normal	O
)	O
strains	O
.	O

Levy	O
et	O
al	O
.	O

5	O
showed	O
that	O
somatic	O
cell	O
hybrids	O
between	O
C5	O
deficient	O
(	O
B10	O
.	O
D2	O
/	O
old	O
line	O
)	O
macrophages	O
and	O
either	O
C5	O
sufficient	O
(	O
B10	O
.	O
D2	O
/	O
new	O
line	O
)	O
mouse	O
kidney	O
or	O
chicken	O
erythroblasts	O
secreted	O
haemolytically	O
active	O
mouse	O
C5	O
in	O
vitro	O
.	O

Several	O
possible	O
molecular	O
mechanisms	O
to	O
account	O
for	O
the	O
findings	O
were	O
considered	O
,	O
but	O
insufficient	O
direct	O
data	O
were	O
available	O
to	O
choose	O
among	O
them	O
.	O

We	O
recently	O
reported	O
that	O
mouse	O
(	O
CD	O
.	O
1	O
strain	O
)	O
peritoneal	O
cells	O
in	O
culture	O
synthesise	O
and	O
secrete	O
a	O
single	O
chain	O
precursor	O
,	O
pro	O
-	O
C5	O
(	O
MW	O
approximately	O
210	O
,	O
000	O
)	O
,	O
of	O
the	O
two	O
-	O
chain	O
(	O
alpha	O
chain	O
,	O
125	O
,	O
000	O
and	O
beta	O
chain	O
83	O
,	O
000	O
MW	O
)	O
C5	O
protein6	O
.	O

Radiolabelled	O
precursor	O
C5	O
was	O
contained	O
within	O
the	O
cells	O
and	O
was	O
secreted	O
into	O
the	O
tissue	O
culture	O
media	O
.	O

Using	O
similar	O
methods	O
,	O
we	O
now	O
find	O
that	O
C5	B
deficiency	I
in	O
each	O
of	O
five	O
different	O
mouse	O
strains	O
(	O
AKR	O
,	O
SWR	O
,	O
DBA	O
/	O
2J8	O
A	O
/	O
HeJ	O
and	O
B10	O
.	O
D2	O
/	O
old	O
line	O
)	O
is	O
due	O
to	O
a	O
failure	O
in	O
secretion	O
of	O
C5	O
protein	O
and	O
not	O
to	O
a	O
failure	O
in	O
biosynthesis	O
of	O
pro	O
-	O
C5	O

Recurrent	O
meningococcal	B
meningitis	I
with	O
absence	B
of	I
the	I
sixth	I
component	I
of	I
complement	I
:	O
an	O
evaluation	O
of	O
underlying	O
immunologic	O
mechanisms	O
.	O

A	O
51	O
/	O
2	O
-	O
year	O
-	O
old	O
black	O
girl	O
with	O
recurrent	O
meningococcal	B
meningitis	I
and	O
absence	B
of	I
the	I
sixth	I
component	I
of	I
complement	I
(	O
C6	O
)	O
is	O
reported	O
.	O

To	O
explore	O
the	O
pathogenesis	O
of	O
recurrent	O
neisserial	B
infections	I
in	O
C6	B
deficiency	I
,	O
a	O
detailed	O
analysis	O
of	O
her	O
immune	O
competence	O
was	O
conducted	O
.	O

Her	O
serum	O
had	O
normal	O
chemotactic	O
,	O
opsonic	O
,	O
alternative	O
complement	O
pathway	O
,	O
and	O
specific	O
antibody	O
activity	O
,	O
but	O
lacked	O
complement	O
-	O
mediated	O
bacteriolytic	O
activity	O
.	O

In	O
addition	O
,	O
her	O
C6	B
-	I
deficient	I
serum	O
was	O
indistinguishable	O
from	O
normal	O
serum	O
in	O
a	O
complement	O
-	O
dependent	O
assay	O
of	O
phagocyte	O
bactericidal	O
activity	O
.	O

Absent	O
bacteriolysis	O
remains	O
the	O
only	O
consistent	O
defect	O
associated	O
with	O
recurrent	O
neisserial	B
infections	I
and	O
absence	O
of	O
one	O
of	O
the	O
late	O
-	O
acting	O
complement	O
components	O
.	O
.	O

Deficiency	B
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
human	O
subjects	O
.	O

Clinical	O
,	O
genetic	O
and	O
immunologic	O
studies	O
in	O
a	O
large	O
kindred	O
.	O

The	O
discovery	O
of	O
a	O
large	O
kindred	O
with	O
a	O
heritable	O
deficiency	B
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
has	O
permitted	O
the	O
accumulation	O
of	O
new	O
clinical	O
,	O
genetic	O
and	O
immunologic	O
data	O
concerning	O
the	O
role	O
of	O
C5	O
in	O
human	O
subjects	O
.	O

The	O
proband	O
,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	B
infection	I
,	O
has	O
a	O
hemolytic	O
C5	O
level	O
of	O
approximately	O
0	O
.	O

5	O
per	O
cent	O
of	O
normal	O
.	O

No	O
C5	O
protein	O
was	O
detectable	O
,	O
but	O
low	O
levels	O
of	O
functional	O
C5	O
activity	O
could	O
be	O
found	O
using	O
a	O
sensitive	O
bactericidal	O
assay	O
.	O

The	O
probands	O
twin	O
as	O
well	O
as	O
another	O
sister	O
also	O
had	O
extremely	O
low	O
levels	O
of	O
hemolytic	O
C5	O
(	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
normal	O
)	O
,	O
but	O
both	O
these	O
subjects	O
have	O
been	O
healthy	O
.	O

Hemolytic	O
complement	O
and	O
bacteriolytic	O
activity	O
could	O
be	O
restored	O
by	O
the	O
addition	O
of	O
purified	O
C5	O
.	O

No	O
chemotactic	O
activity	O
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
C5	B
-	I
deficient	I
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	O
or	O
alternative	O
pathways	O
,	O
again	O
demonstrating	O
the	O
importance	O
of	O
C5	O
in	O
human	O
subjects	O
for	O
the	O
production	O
of	O
chemotactic	O
factors	O
.	O

The	O
chemotactic	O
responsiveness	O
of	O
the	O
patients	O
polymorphonuclear	O
leukocytes	O
and	O
monocytes	O
to	O
preformed	O
chemotactic	O
factors	O
was	O
not	O
depressed	O
.	O

Twenty	O
-	O
two	O
of	O
32	O
other	O
family	O
members	O
from	O
three	O
generations	O
had	O
depressed	O
whole	O
hemolytic	O
complement	O
levels	O
.	O

In	O
19	O
of	O
30	O
family	O
members	O
,	O
levels	O
of	O
hemolytic	O
C5	O
ranged	O
from	O
13	O
to	O
64	O
per	O
cent	O
of	O
normal	O
.	O

No	O
linkage	O
for	O
C5	B
deficiency	I
and	O
the	O
A	O
or	O
B	O
loci	O
of	O
the	O
major	O
histocompatibility	O
complex	O
could	O
be	O
found	O
.	O

These	O
data	O
suggest	O
an	O
autosomal	O
codominant	O
mode	O
of	O
inheritance	O
of	O
C5	B
deficiency	I
.	O

Deficiency	B
of	I
C5	I
is	O
compatible	O
with	O
good	O
health	O
,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	B
infection	I

Incidence	O
and	O
characteristics	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
in	O
Japan	O
.	O

A	O
total	O
of	O
3000	O
men	O
living	O
in	O
Yamaguchi	O
were	O
screened	O
for	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
using	O
Beutlers	O
spot	O
test	O
and	O
three	O
types	O
of	O
starch	O
gel	O
electrophoresis	O
.	O

These	O
electrophoresis	O
used	O
a	O
phosphate	O
buffer	O
system	O
at	O
pH	O
7	O
.	O

0	O
,	O
a	O
TRIS	O
-	O
EDTA	O
-	O
borate	O
buffer	O
system	O
at	O
pH	O
8	O
.	O

6	O
,	O
and	O
a	O
TRIS	O
-	O
hydrochloride	O
buffer	O
system	O
at	O
pH	O
8	O
.	O
.	O

Fifteen	O
G6PD	B
-	I
deficient	I
variants	O
were	O
found	O
at	O
the	O
rate	O
of	O
0	O
.	O

5	O
%	O
and	O
classified	O
into	O
four	O
groups	O
.	O

As	O
new	O
variants	O
,	O
G6PD	O
Konan	O
,	O
Kamiube	O
,	O
and	O
Kiwa	O
were	O
identified	O
.	O

These	O
three	O
variants	O
had	O
a	O
mild	O
to	O
moderate	O
G6PD	B
deficiency	I
and	O
were	O
not	O
associated	O
with	O
any	O
clinical	O
signs	O
.	O

G6PD	O
Konan	O
had	O
fast	O
electrophoretic	O
mobility	O
as	O
compared	O
with	O
normal	O
levels	O
,	O
G6PD	O
Kiwa	O
had	O
slightly	O
elevated	O
electrophoretic	O
mobility	O
,	O
and	O
G6PD	O
Kamiube	O
had	O
normal	O
electrophoretic	O
mobility	O
.	O

These	O
three	O
variants	O
had	O
normal	O
levels	O
of	O
Km	O
G6P	O
,	O
Km	O
NADP	O
,	O
and	O
Ki	O
NADPH	O
,	O
normal	O
utilizations	O
of	O
both	O
2	O
-	O
deoxy	O
-	O
G6P	O
and	O
deamino	O
-	O
NAPD	O
,	O
normal	O
heat	O
stability	O
,	O
and	O
a	O
normal	O
pH	O
curve	O
.	O

The	O
other	O
variant	O
was	O
G6PD	O
Ube	O
,	O
which	O
we	O
had	O
previously	O
found	O
in	O
Yamaguchi	O
(	O
Nakashima	O
et	O
al	O
.	O
,	O
1977	O
)	O
.	O

One	O
boy	O
with	O
G6PD	O
Ube	O
was	O
Korean	O

Utilization	O
of	O
purines	O
by	O
an	O
HPRT	O
variant	O
in	O
an	O
intelligent	O
,	O
nonmutilative	O
patient	O
with	O
features	O
of	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

The	O
patient	O
,	O
H	O
.	O

Chr	O
.	O

B	O
.	O
,	O
was	O
among	O
the	O
first	O
reported	O
with	O
hyperuricemia	B
and	O
central	B
nervous	I
system	I
symptoms	I
.	O

He	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
;	O
E	O
.	O
C	O
.	O
2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
distinct	O
from	O
the	O
enzyme	O
present	O
in	O
patients	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

The	O
patient	O
had	O
chroeoathetosis	B
,	O
spasticity	B
,	O
dysarthric	B
speech	I
,	O
and	O
hyperuricemia	B
.	O

However	O
,	O
his	O
intelligence	O
was	O
normal	O
and	O
he	O
had	O
no	O
evidence	O
of	O
self	O
-	O
mutilation	O
.	O

There	O
was	O
no	O
activity	O
of	O
HPRT	O
in	O
the	O
lysates	O
of	O
erythrocytes	O
and	O
cultured	O
fibroblasts	O
when	O
analyzed	O
in	O
the	O
usual	O
manner	O
.	O

Using	O
a	O
newly	O
developed	O
method	O
for	O
the	O
study	O
of	O
purine	O
metabolism	O
in	O
intact	O
cultured	O
cells	O
,	O
this	O
patient	O
was	O
found	O
to	O
metabolize	O
some	O
9	O
%	O
of	O
8	O
-	O
14C	O
-	O
hypoxanthine	O
,	O
and	O
90	O
%	O
of	O
the	O
isotope	O
utilized	O
was	O
converted	O
to	O
adenine	O
and	O
guanine	O
nucleotides	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
patients	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	O
to	O
nucleotides	O
.	O

The	O
patients	O
fibroblasts	O
were	O
even	O
more	O
efficient	O
in	O
the	O
metabolism	O
of	O
8	O
-	O
14C	O
-	O
guanine	O
,	O
which	O
was	O
utilized	O
to	O
the	O
extent	O
of	O
27	O
%	O
,	O
over	O
80	O
%	O
of	O
which	O
was	O
converted	O
to	O
guanine	O
and	O
adenine	O
nucleotides	O
.	O

The	O
growth	O
of	O
the	O
cultured	O
fibroblasts	O
of	O
this	O
patient	O
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	O
aminopterin	O
thymidine	O
(	O
HAT	O
)	O
,	O
whereas	O
the	O
growth	O
of	O
Lesch	B
-	I
Nyhan	I
cells	O
was	O
inhibited	O
and	O
normal	O
cells	O
grew	O
normally	O
.	O

Similarly	O
in	O
8	O
-	O
azaguanine	O
,	O
6	O
-	O
thioguanine	O
,	O
and	O
8	O
-	O
azahypoxanthine	O
,	O
the	O
growth	O
of	O
the	O
patients	O
cells	O
was	O
intermediate	O
between	O
normal	O
and	O
Lesch	B
-	I
Nyhan	I
cells	O
.	O

These	O
observations	O
provide	O
further	O
evidence	O
for	O
genetic	O
heterogeneity	O
among	O
patients	O
with	O
disorders	O
in	O
purine	O
metabolism	O
involving	O
the	O
HPRT	O
gene	O
.	O

They	O
document	O
that	O
this	O
famous	O
patient	O
did	O
not	O
have	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I

Localisation	O
of	O
the	O
Becker	B
muscular	I
dystrophy	I
gene	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
DNA	O
sequences	O
.	O

A	O
linkage	O
study	O
in	O
30	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	O
sequences	O
from	O
the	O
X	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
,	O
suggests	O
that	O
the	O
BMD	B
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
in	O
the	O
p21	O
region	O
.	O

The	O
genes	O
for	O
Becker	B
and	I
Duchenne	I
dystrophies	I
must	O
therefore	O
be	O
closely	O
linked	O
,	O
if	O
not	O
allelic	O
,	O
and	O
any	O
future	O
DNA	O
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	O
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O

The	O
linkage	O
analysis	O
also	O
provides	O
data	O
on	O
the	O
frequency	O
of	O
recombination	O
along	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
and	O
across	O
the	O
centromeric	O
region	O
.	O
.	O

Molecular	O
evidence	O
for	O
new	O
mutation	O
at	O
the	O
hprt	O
locus	O
in	O
Lesch	B
-	I
Nyhan	I
patients	O
.	O

Hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
;	O
EC2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
,	O
which	O
functions	O
in	O
the	O
metabolic	O
salvage	O
of	O
purines	O
,	O
is	O
encoded	O
by	O
an	O
X	O
-	O
linked	O
gene	O
in	O
man	O
.	O

Partial	O
HPRT	B
deficiencies	I
are	O
associated	O
with	O
gouty	B
arthritis	I
,	O
while	O
absence	O
of	O
activity	O
results	O
in	O
Lesch	B
-	I
Nyhan	I
syndrome	I
(	O
L	B
-	I
N	I
)	O
.	O

L	B
-	I
N	I
patients	O
fail	O
to	O
reproduce	O
and	O
the	O
heterozygous	O
state	O
appears	O
to	O
confer	O
no	O
selective	O
advantage	O
.	O

Thus	O
,	O
Haldanes	O
principle	O
predicts	O
that	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
must	O
occur	O
frequently	O
in	O
order	O
for	O
L	B
-	I
N	I
syndrome	I
to	O
be	O
maintained	O
in	O
the	O
population	O
.	O

This	O
constant	O
introduction	O
of	O
new	O
mutations	O
would	O
be	O
expected	O
to	O
result	O
in	O
a	O
heterogeneous	O
collection	O
of	O
genetic	B
lesions	I
,	O
some	O
of	O
which	O
may	O
be	O
novel	O
.	O

As	O
we	O
report	O
here	O
,	O
the	O
mutations	O
in	O
the	O
hprt	O
gene	O
of	O
seven	O
L	B
-	I
N	I
patients	O
,	O
selected	O
from	O
an	O
initial	O
survey	O
of	O
28	O
patients	O
,	O
have	O
been	O
characterized	O
and	O
all	O
were	O
found	O
to	O
be	O
distinctly	O
different	O
,	O
as	O
predicted	O
.	O

The	O
origin	O
of	O
one	O
unusual	O
mutation	O
has	O
been	O
identified	O
by	O
analysis	O
of	O
DNA	O
from	O
four	O
generations	O
of	O
family	O
members	O
.	O

Further	O
molecular	O
analysis	O
of	O
the	O
origin	O
of	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
should	O
aid	O
in	O
resolving	O
the	O
issue	O
of	O
an	O
apparent	O
difference	O
in	O
the	O
frequency	O
of	O
hprt	O
mutations	O
in	O
males	O
and	O
females	O

Allelic	O
exclusion	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
T	O
lymphocytes	O
from	O
a	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
carrier	O
.	O

An	O
obligate	O
carrier	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
who	O
was	O
also	O
heterozygous	O
for	O
the	O
A	O
and	O
B	O
types	O
of	O
X	O
-	O
linked	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
was	O
found	O
.	O

With	O
her	O
it	O
became	O
possible	O
to	O
determine	O
whether	O
allelic	O
exclusion	O
occurs	O
in	O
particular	O
cell	O
-	O
types	O
of	O
the	O
WAS	B
carrier	O
.	O

If	O
so	O
,	O
the	O
remaining	O
cells	O
of	O
a	O
particular	O
cell	O
-	O
type	O
would	O
express	O
only	O
the	O
normal	O
X	O
chromosome	O
and	O
only	O
one	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
isoenzyme	O
would	O
be	O
demonstrable	O
.	O

This	O
carrier	O
had	O
only	O
the	O
B	O
isoenzyme	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
T	O
lymphocytes	O
,	O
although	O
both	O
isoenzymes	O
A	O
and	O
B	O
were	O
present	O
in	O
erythrocytes	O
and	O
neutrophils	O
.	O

These	O
findings	O
suggest	O
that	O
selection	O
against	O
the	O
WAS	B
gene	O
occurs	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
T	O
lymphocytes	O
and	O
that	O
the	O
defects	O
associated	O
with	O
WAS	B
expressed	O
in	O
these	O
cell	O
-	O
types	O
may	O
be	O
implicated	O
in	O
the	O
genesis	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O
.	O

Complement	B
deficiency	I
and	O
nephritis	B
.	O

A	O
report	O
of	O
a	O
family	O
.	O

A	O
family	O
is	O
described	O
in	O
which	O
three	O
children	O
had	O
homozygous	O
deficiency	B
of	I
C3	I
and	O
in	O
which	O
both	O
parents	O
and	O
two	O
other	O
children	O
were	O
heterozygous	O
for	O
the	O
C3	O
null	O
gene	O
.	O

One	O
child	O
with	O
heterozygous	O
C3	B
deficiency	I
was	O
found	O
to	O
have	O
membranoproliferative	O
glomerulonephritis	B
;	O
proteinuria	B
and	O
/	O
or	O
microscopical	O
haematuria	B
was	O
present	O
in	O
all	O
three	O
homozygous	O
C3	B
-	I
deficient	I
children	O
.	O

All	O
children	O
with	O
homozygous	O
or	O
heterozygous	O
C3	B
deficiency	I
were	O
,	O
to	O
a	O
varying	O
degree	O
,	O
susceptible	O
to	O
infection	O
.	O

The	O
only	O
child	O
of	O
the	O
family	O
with	O
normal	O
complement	O
had	O
no	O
increased	O
risk	O
of	O
infection	O
and	O
no	O
renal	B
disease	I
.	O

This	O
family	O
study	O
provides	O
further	O
support	O
for	O
the	O
proposal	O
that	O
C3	B
deficiency	I
predisposes	O
to	O
nephritis	B
.	O
.	O

Heterogeneity	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
Algeria	O
.	O

Study	O
in	O
Northern	O
Algeria	O
with	O
description	O
of	O
five	O
new	O
variants	O
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
was	O
found	O
in	O
3	O
.	O

2	O
%	O
of	O
the	O
male	O
population	O
living	O
in	O
the	O
urban	O
area	O
of	O
Algiers	O
.	O

The	O
deficient	O
subjects	O
originated	O
from	O
multiple	O
geographic	O
regions	O
of	O
Northern	O
Algeria	O
,	O
with	O
prevalence	O
of	O
individuals	O
of	O
Berber	O
-	O
Kabyle	O
origin	O
.	O

Red	O
blood	O
cell	O
G6PD	O
was	O
partially	O
purified	O
and	O
characterized	O
in	O
deficient	O
males	O
from	O
17	O
families	O
,	O
and	O
six	O
different	O
variants	O
were	O
found	O
.	O

Among	O
them	O
,	O
only	O
one	O
,	O
the	O
Gd	O
(	O
-	O
)	O
Kabyle	O
variant	O
,	O
had	O
been	O
previously	O
described	O
.	O

It	O
was	O
detected	O
in	O
nine	O
families	O
.	O

The	O
other	O
five	O
variants	O
were	O
new	O
Gd	O
(	O
-	O
)	O
Laghouat	O
(	O
four	O
cases	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Blida	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Thenia	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Titteri	O
(	O
one	O
case	O
)	O
,	O
and	O
Gd	O
(	O
-	O
)	O
Alger	O
(	O
two	O
brothers	O
)	O
.	O

Strikingly	O
,	O
the	O
common	O
Mediterranean	O
variant	O
was	O
not	O
found	O
.	O

G6PD	B
deficiency	I
is	O
heterogeneous	O
in	O
northern	O
Algeria	O
where	O
autochtonous	O
variants	O
seem	O
to	O
prevail	O
.	O

The	O
Kabyle	O
variant	O
may	O
be	O
common	O
in	O
this	O
country	O
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
inhibits	O
in	O
vitro	O
growth	O
of	O
Plasmodium	O
falciparum	O
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
;	I
EC	I
1	I
.	I
1	I
.	I
1	I
.	I
49	I
)	I
-	I
deficient	I
red	O
blood	O
cells	O
from	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
from	O
the	O
island	O
of	O
Sardinia	O
were	O
studied	O
for	O
their	O
ability	O
to	O
support	O
growth	O
in	O
vitro	O
of	O
the	O
malaria	B
-	O
causing	O
organism	O
Plasmodium	O
falciparum	O
.	O

Parasite	O
growth	O
was	O
approximately	O
one	O
-	O
third	O
of	O
normal	O
in	O
both	O
hemi	O
-	O
and	O
heterozygotes	O
for	O
G6PD	B
deficiency	I
.	O

In	O
Sardinians	O
with	O
the	O
beta	O
0	O
-	O
thalassemia	O
trait	O
,	O
parasite	O
growth	O
was	O
normal	O
except	O
when	O
G6PD	B
deficiency	I
occurred	O
together	O
with	O
the	O
thalassemia	B
trait	O
.	O

The	O
data	O
support	O
the	O
hypothesis	O
that	O
G6PD	B
deficiency	I
may	O
confer	O
a	O
selective	O
advantage	O
in	O
a	O
malarious	B
area	O
;	O
the	O
female	O
heterozygote	O
may	O
be	O
at	O
a	O
particular	O
advantage	O
because	O
resistance	O
to	O
malaria	B
equals	O
that	O
of	O
male	O
hemizygotes	O
,	O
but	O
the	O
risk	O
of	O
fatal	B
hemolysis	I
may	O
be	O
less	O
.	O

However	O
,	O
more	O
female	O
heterozygotes	O
must	O
be	O
studied	O
to	O
confirm	O
this	O
hypothesis	O
.	O

No	O
protective	O
effect	O
of	O
beta	O
0	O
-	O
thalassemia	O
trait	O
could	O
be	O
demonstrated	O
in	O
vitro	O
.	O

Bone	O
marrow	O
transplant	O
in	O
adrenoleukodystrophy	B
.	O

An	O
allogeneic	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
from	O
a	O
normal	O
HLA	O
identical	O
sibling	O
donor	O
was	O
performed	O
in	O
a	O
13	O
-	O
year	O
-	O
old	O
boy	O
with	O
rapidly	O
progressive	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
.	O

Engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	O
within	O
4	O
weeks	O
,	O
but	O
neurologic	B
deterioration	I
continued	O
.	O

The	O
patient	O
died	O
of	O
an	O
adenovirus	B
infection	I
141	O
days	O
after	O
BMT	O
.	O

ALD	B
is	O
characterized	O
by	O
abnormally	O
high	O
plasma	O
levels	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
as	O
a	O
result	O
of	O
impaired	O
capacity	O
to	O
degrade	O
them	O
.	O

Ten	O
days	O
after	O
BMT	O
,	O
the	O
white	O
blood	O
cell	O
VLCFA	O
levels	O
and	O
enzyme	O
activity	O
became	O
normal	O
;	O
after	O
3	O
months	O
,	O
there	O
was	O
progressive	O
reduction	O
of	O
plasma	O
VLCFA	O
to	O
levels	O
only	O
slightly	O
above	O
normal	O
.	O
.	O

[	O
Gd	O
-	O
allele	O
distribution	O
patterns	O
in	O
Azerbaijan	O
.	O
III	O
.	O
The	O
identification	O
of	O
mutant	O
forms	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
]	O

In	O
28	O
families	O
with	O
G6PD	B
deficiency	I
living	O
in	O
3	O
settlements	O
of	O
Shekii	O
district	O
of	O
Azerbaijan	O
11	O
G6PD	O
variants	O
of	O
II	O
and	O
III	O
classes	O
differing	O
by	O
kinetic	O
properties	O
were	O
identified	O
according	O
WHO	O
program	O
.	O

9	O
of	O
them	O
are	O
characterized	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
.	O

Comparison	O
of	O
G6PD	O
spectra	O
in	O
two	O
subpopulations	O
and	O
in	O
a	O
mixed	O
group	O
permits	O
to	O
make	O
a	O
conclusion	O
about	O
existence	O
of	O
common	O
and	O
rare	O
G6PD	O
alleles	O
in	O
examined	O
population	O
.	O

They	O
distribute	O
by	O
gene	O
drift	O
supported	O
by	O
natural	O
selection	O
.	O

Among	O
7	O
samples	O
of	O
G6PD	O
with	O
normal	O
and	O
increased	O
activity	O
two	O
new	O
variants	O
of	O
IV	O
class	O
-	O
-	O
Nukha	O
and	O
Bash	O
-	O
Kungut	O
-	O
-	O
were	O
found	O
.	O
.	O

Adrenoleukodystrophy	B
:	O
survey	O
of	O
303	O
cases	O
:	O
biochemistry	O
,	O
diagnosis	O
,	O
and	O
therapy	O
.	O

Adrenoleukodystrophy	B
(	O
ALD	B
)	O
is	O
a	O
genetically	O
determined	O
disorder	O
associated	O
with	O
progressive	B
central	I
demyelination	I
and	O
adrenal	B
cortical	I
insufficiency	I
.	O

All	O
affected	O
persons	O
show	O
increased	O
levels	O
of	O
saturated	O
unbranched	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
particularly	O
hexacosanoate	O
(	O
C26	O
0	O
)	O
,	O
because	O
of	O
impaired	O
capacity	O
to	O
degrade	O
these	O
acids	O
.	O

This	O
degradation	O
normally	O
takes	O
place	O
in	O
a	O
subcellular	O
organelle	O
called	O
the	O
peroxisome	O
,	O
and	O
ALD	B
,	O
together	O
with	O
Zellwegers	B
cerebrohepatorenal	I
syndrome	I
,	O
is	O
now	O
considered	O
to	O
belong	O
to	O
the	O
newly	O
formed	O
category	O
of	O
peroxisomal	B
disorders	I
.	O

Biochemical	O
assays	O
permit	O
prenatal	O
diagnosis	O
,	O
as	O
well	O
as	O
identification	O
of	O
most	O
heterozygotes	O
.	O

We	O
have	O
identified	O
303	O
patients	O
with	O
ALD	B
in	O
217	O
kindreds	O
.	O

These	O
patients	O
show	O
a	O
wide	O
phenotypic	O
variation	O
.	O

Sixty	O
percent	O
of	O
patients	O
had	O
childhood	O
ALD	B
and	O
17	O
%	O
adrenomyeloneuropathy	B
,	O
both	O
of	O
which	O
are	O
X	O
-	O
linked	O
,	O
with	O
the	O
gene	O
mapped	O
to	O
Xq28	O
.	O

Neonatal	B
ALD	I
,	O
a	O
distinct	O
entity	O
with	O
autosomal	O
recessive	O
inheritance	O
and	O
points	O
of	O
resemblance	O
to	O
Zellwegers	B
syndrome	I
,	O
accounted	O
for	O
7	O
%	O
of	O
the	O
cases	O
.	O

Although	O
excess	O
C26	O
0	O
in	O
the	O
brain	O
of	O
patients	O
with	O
ALD	B
is	O
partially	O
of	O
dietary	O
origin	O
,	O
dietary	O
C26	O
0	O
restriction	O
did	O
not	O
produce	O
clear	O
benefit	O
.	O

Bone	O
marrow	O
transplant	O
lowered	O
the	O
plasma	O
C26	O
0	O
level	O
but	O
failed	O
to	O
arrest	O
neurological	O
progression	O
.	O
.	O

Genetic	O
polymorphism	O
of	O
G6PD	O
in	O
a	O
Bulgarian	O
population	O
.	O

Considerable	O
genetic	O
heterogeneity	O
in	O
G6PD	O
was	O
found	O
in	O
the	O
Bulgarian	O
population	O
-	O
14	O
G6PD	O
variants	O
isolated	O
from	O
117	O
hemizygous	O
carriers	O
of	O
G6PD	B
deficiency	I
.	O

Of	O
these	O
,	O
G6PD	O
Mediterranean	O
type	O
was	O
a	O
polymorphic	O
variant	O
and	O
G6PD	O
Corinth	O
occurred	O
with	O
high	O
frequency	O
.	O

Two	O
new	O
variants	O
were	O
identified	O
-	O
G6PD	O
Rudosem	O
and	O
G6PD	O
Nedelino	O
.	O

In	O
a	O
selected	O
group	O
of	O
78	O
subjects	O
with	O
clinical	O
manifestations	O
,	O
four	O
variants	O
were	O
established	O
G6PD	O
Mediterranian	O
,	O
G6PD	O
Corinth	O
,	O
G6PD	O
Seattle	O
and	O
G6PD	O
Ohut	O
II	O
.	O
.	O

Clinical	O
use	O
of	O
DNA	O
markers	O
linked	O
to	O
the	O
gene	O
for	O
Duchenne	B
muscular	I
dystrophy	I
.	O

Seventy	O
families	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
known	O
to	O
the	O
Institute	O
of	O
Child	O
Health	O
fall	O
into	O
three	O
categories	O
with	O
respect	O
to	O
potential	O
linkage	O
analysis	O
with	O
the	O
X	O
chromosome	O
DNA	O
markers	O
RC8	O
and	O
L1	O
.	O

28	O
that	O
bridge	O
the	O
DMD	B
gene	O
.	O

Families	O
in	O
which	O
there	O
is	O
at	O
least	O
one	O
obligatory	O
female	O
heterozygote	O
(	O
n	O
=	O
13	O
)	O
.	O

Here	O
prediction	O
and	O
exclusion	O
of	O
DMD	B
gene	O
transmission	O
may	O
be	O
possible	O
,	O
the	O
accuracy	O
being	O
dependent	O
on	O
the	O
closeness	O
of	O
the	O
linkage	O
of	O
the	O
DNA	O
marker	O
(	O
s	O
)	O
to	O
the	O
DMD	B
gene	O
;	O
an	O
illustrative	O
case	O
is	O
reported	O
.	O

Families	O
in	O
which	O
there	O
is	O
a	O
single	O
affected	O
boy	O
,	O
who	O
also	O
has	O
one	O
or	O
more	O
healthy	O
brothers	O
(	O
n	O
=	O
26	O
)	O
.	O

Given	O
an	O
informative	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
,	O
the	O
probability	O
that	O
the	O
boy	O
represents	O
a	O
new	O
mutation	O
can	O
be	O
reassessed	O
;	O
it	O
is	O
also	O
possible	O
to	O
exclude	O
the	O
DMD	B
gene	O
in	O
a	O
sister	O
.	O

Families	O
with	O
a	O
single	O
affected	O
boy	O
with	O
no	O
brother	O
(	O
n	O
=	O
30	O
)	O
.	O

Here	O
exclusion	O
of	O
the	O
DMD	B
gene	O
in	O
a	O
sister	O
may	O
be	O
possible	O
.	O

Only	O
in	O
one	O
family	O
was	O
there	O
no	O
possibility	O
of	O
useful	O
linkage	O
analysis	O
.	O

The	O
linkage	O
analysis	O
required	O
is	O
described	O
,	O
and	O
the	O
need	O
to	O
check	O
DMD	B
families	O
for	O
informative	O
RFLPs	O
is	O
stressed	O
.	O

Family	O
studies	O
in	O
Bechterew	B
'	I
s	I
syndrome	I
(	O
ankylosing	B
spondylitis	I
)	O
III	O
.	O

Genetics	O
.	O

The	O
results	O
of	O
segregation	O
analyses	O
in	O
75	O
families	O
where	O
the	O
proband	O
had	O
ankylosing	B
spondylitis	I
,	O
are	O
presented	O
.	O

Of	O
the	O
278	O
adult	O
,	O
living	O
first	O
degree	O
relatives	O
,	O
approximately	O
85	O
%	O
cooperated	O
in	O
the	O
study	O
.	O

Clinical	O
and	O
radiographical	O
examinations	O
were	O
performed	O
and	O
HLA	O
typing	O
was	O
conducted	O
.	O

The	O
results	O
were	O
in	O
agreement	O
with	O
our	O
hypothesis	O
that	O
ankylosing	B
spondylitis	I
is	O
part	O
of	O
a	O
syndrome	O
where	O
different	O
genetic	O
factors	O
interact	O
.	O

Such	O
known	O
factors	O
are	O
HLA	O
B27	O
associated	O
disease	O
susceptibility	O
,	O
susceptibility	O
to	O
psoriatic	B
arthropathy	I
and	O
susceptibility	O
to	O
entero	B
-	I
arthropathy	I
.	O

Radiographical	O
sacro	B
-	I
iliitis	I
was	O
restricted	O
to	O
HLA	O
B27	O
positive	O
relatives	O
,	O
and	O
was	O
more	O
frequently	O
found	O
in	O
relatives	O
to	O
probands	O
with	O
psoriasis	B
than	O
in	O
relatives	O
to	O
probands	O
without	O
psoriasis	B
.	O

Environmental	O
factors	O
(	O
intestinal	O
bacteria	O
)	O
are	O
known	O
to	O
trigger	O
the	O
disease	O
at	O
least	O
in	O
some	O
persons	O
,	O
and	O
we	O
have	O
postulated	O
that	O
all	O
or	O
most	O
of	O
them	O
have	O
the	O
predisposition	O
to	O
develop	O
disease	O
.	O

Thus	O
,	O
the	O
syndrome	O
has	O
a	O
multifactorial	O
etiology	O
.	O

The	O
phenotypic	O
expressions	O
of	O
the	O
different	O
genetic	O
predispositions	O
involved	O
,	O
include	O
sacro	B
-	I
iliitis	I
,	O
psoriasis	B
,	O
acute	B
anterior	I
uveitis	I
,	O
peripheral	O
arthropathy	B
and	O
inflammatory	B
bowel	I
disease	I
.	O

We	O
suggest	O
the	O
descriptive	O
name	O
HEREDITARY	B
MULTIFOCAL	I
RELAPSING	I
INFLAMMATION	I
(	O
HEMRI	B
)	O
for	O
this	O
syndrome	O
.	O

Ankylosing	B
spondylitis	I
,	O
psoriatic	B
arthropathy	I
and	O
entero	B
-	I
arthropathy	I
may	O
be	O
regarded	O
as	O
clinical	O
sub	O
-	O
types	O
of	O
the	O
syndrome	O
.	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
and	O
chromosome	O
15	O
.	O

A	O
clinical	O
discussion	O
of	O
20	O
cases	O
.	O

A	O
chromosome	B
15	I
anomaly	I
was	O
observed	O
in	O
12	O
of	O
20	O
patients	O
,	O
17	O
of	O
whom	O
were	O
clinically	O
suspected	O
of	O
having	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

The	O
clinical	O
features	O
of	O
eight	O
cases	O
with	O
15q11	O
-	O
12	O
deletion	O
were	O
very	O
similar	O
to	O
those	O
originally	O
described	O
in	O
PWS	B
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
group	O
of	O
normal	O
karyotype	O
patients	O
is	O
heterogeneous	O
,	O
and	O
their	O
features	O
do	O
not	O
strictly	O
correspond	O
to	O
the	O
clinical	O
definition	O
of	O
PWS	B
.	O

However	O
,	O
the	O
hypothesis	O
that	O
PWS	B
is	O
associated	O
with	O
deletion	O
of	O
15q11	O
-	O
12	O
can	O
neither	O
explain	O
the	O
apparently	O
balanced	O
translocations	O
of	O
chromosome	O
15	O
nor	O
account	O
for	O
the	O
small	O
supernumerary	O
metacentric	O
chromosomes	O
corresponding	O
to	O
an	O
isochromosome	O
15	O
for	O
band	O
15q11	O
observed	O
in	O
some	O
cases	O
.	O
.	O

The	O
Tay	B
-	I
Sachs	I
disease	I
gene	O
in	O
North	O
American	O
Jewish	O
populations	O
:	O
geographic	O
variations	O
and	O
origin	O
.	O

From	O
data	O
collected	O
in	O
a	O
North	O
American	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
heterozygote	O
screening	O
program	O
,	O
the	O
TSD	B
carrier	O
frequency	O
among	O
46	O
,	O
304	O
Jewish	O
individuals	O
was	O
found	O
to	O
be	O
.	O

0324	O
(	O
1	O
in	O
31	O
individuals	O
)	O
.	O

This	O
frequency	O
is	O
consistent	O
with	O
earlier	O
estimates	O
based	O
on	O
TSD	B
incidence	O
data	O
.	O

TSD	B
carrier	O
frequencies	O
were	O
then	O
examined	O
by	O
single	O
country	O
and	O
single	O
region	O
of	O
origin	O
in	O
28	O
,	O
029	O
Jews	O
within	O
this	O
sample	O
for	O
whom	O
such	O
data	O
were	O
available	O
for	O
analysis	O
.	O

Jews	O
with	O
Polish	O
and	O
/	O
or	O
Russian	O
ancestry	O
constituted	O
88	O
%	O
of	O
this	O
sample	O
and	O
had	O
a	O
TSD	B
carrier	O
frequency	O
of	O
.	O

0327	O
.	O

No	O
TSD	B
carriers	O
were	O
observed	O
among	O
the	O
166	O
Jews	O
of	O
Near	O
Eastern	O
origins	O
.	O

Relative	O
to	O
Jews	O
of	O
Polish	O
and	O
Russian	O
origins	O
,	O
there	O
was	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
the	O
TSD	B
carrier	O
frequency	O
in	O
Jews	O
of	O
Austrian	O
,	O
Hungarian	O
,	O
and	O
Czechoslovakian	O
origins	O
(	O
P	O
less	O
than	O
.	O
005	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
TSD	B
gene	O
proliferated	O
among	O
the	O
antecedents	O
of	O
modern	O
Ashkenazi	O
Jewry	O
after	O
the	O
Second	O
Diaspora	O
(	O
70	O
A	O
.	O
D	O
.	O
)	O
and	O
before	O
their	O
major	O
migrations	O
to	O
regions	O
of	O
Poland	O
and	O
Russia	O
(	O
before	O
1100	O
A	O
.	O
D	O
.	O
)	O
.	O

Human	O
deficiency	B
of	I
the	I
sixth	I
component	I
of	I
complement	I
in	O
a	O
patient	O
with	O
meningococcal	B
meningitis	I
and	O
no	O
haemostasis	B
abnormality	I
.	O

A	O
case	O
of	O
human	O
complete	O
C6	B
deficiency	I
is	O
reported	O
.	O

The	O
patient	O
,	O
a	O
31	O
year	O
old	O
white	O
male	O
,	O
was	O
seen	O
on	O
the	O
occasion	O
of	O
an	O
isolated	O
episode	O
of	O
meningococcal	B
meningitis	I
.	O

Serum	O
complement	O
hemolytic	O
and	O
bactericidal	O
activities	O
were	O
lacking	O
and	O
could	O
be	O
restored	O
to	O
normal	O
by	O
addition	O
of	O
appropriate	O
amounts	O
of	O
purified	O
C6	O
.	O

No	O
hemostatic	B
abnormalities	I
were	O
observed	O
.	O
.	O

Absence	B
of	I
the	I
seventh	I
component	I
of	I
complement	I
in	O
a	O
patient	O
with	O
chronic	B
meningococcemia	I
presenting	O
as	O
vasculitis	B
.	O

A	O
previously	O
healthy	O
40	O
-	O
year	O
-	O
old	O
man	O
presenting	O
with	O
fever	B
,	O
arthritis	B
,	O
and	O
cutaneous	B
vasculitis	I
was	O
found	O
to	O
have	O
chronic	B
meningococcemia	I
.	O

Evaluation	O
of	O
his	O
complement	O
system	O
showed	O
an	O
absence	O
of	O
functional	O
and	O
antigenic	O
C7	O
,	O
compatible	O
with	O
a	O
complete	O
deficiency	B
of	I
the	I
seventh	I
component	I
of	I
complement	I
.	O

Study	O
of	O
the	O
patients	O
family	O
spanning	O
four	O
generations	O
showed	O
heterozygous	O
deficiency	B
of	I
C7	I
in	O
five	O
members	O
.	O

Chronic	B
neisserial	I
infection	I
can	O
be	O
associated	O
with	O
C7	B
deficiency	I
and	O
must	O
be	O
distinguished	O
from	O
other	O
causes	O
of	O
cutaneous	B
vasculitis	I
.	O
.	O

Familial	B
discoid	I
lupus	I
erythematosus	I
associated	O
with	O
heterozygote	O
C2	B
deficiency	I
.	O

Two	O
siblings	O
with	O
chronic	B
discoid	I
lupus	I
erythematosus	I
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
C2	B
deficiency	I
.	O

An	O
association	O
with	O
histocompatibility	O
markers	O
HLA	O
-	O
B18	O
and	O
HLA	O
-	O
Dw2	O
was	O
demonstrated	O
,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	O
B	O
was	O
present	O
.	O

Linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
genes	O
coding	O
for	O
B18	O
,	O
Dw2	O
,	O
and	O
BfS	O
antigens	O
.	O

One	O
HLA	O
-	O
ACB	O
/	O
DBf	O
recombinant	O
was	O
observed	O
showing	O
closer	O
linkage	O
between	O
HLA	O
-	O
D	O
and	O
Bf	O
than	O
between	O
HLA	O
-	O
B	O
and	O
Bf	O
.	O
.	O

Severe	B
-	I
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
associated	O
with	O
chronic	O
hemolytic	B
anemia	I
,	O
granulocyte	B
dysfunction	I
,	O
and	O
increased	O
susceptibility	O
to	O
infections	O
:	O
description	O
of	O
a	O
new	O
molecular	O
variant	O
(	O
G6PD	O
Barcelona	O
)	O
.	O

Molecular	O
,	O
kinetic	O
,	O
and	O
functional	O
studies	O
were	O
carried	O
out	O
on	O
erythrocytes	O
and	O
leukocytes	O
in	O
a	O
Spanish	O
male	O
with	O
G6PD	B
deficiency	I
,	O
congenital	B
nonspherocytic	I
hemolytic	I
anemia	I
(	O
CNSHA	B
)	O
,	O
and	O
increased	O
susceptibility	O
to	O
infections	O
.	O

G6PD	O
activity	O
was	O
absent	O
in	O
patients	O
red	O
cells	O
and	O
was	O
about	O
2	O
%	O
of	O
normal	O
in	O
leukocytes	O
.	O

Molecular	O
studies	O
using	O
standard	O
methods	O
(	O
WHO	O
,	O
1967	O
)	O
showed	O
G6PD	O
in	O
the	O
patient	O
to	O
have	O
a	O
slightly	O
fast	O
electrophoretic	O
mobility	O
at	O
pH	O
8	O
.	O

0	O
with	O
otherwise	O
normal	O
properties	O
(	O
heat	O
stability	O
at	O
46	O
degrees	O
C	O
,	O
apparent	O
affinity	O
for	O
substrates	O
,	O
optimum	O
pH	O
,	O
and	O
utilization	O
of	O
substrate	O
analogues	O
)	O
.	O

Other	O
tests	O
showed	O
the	O
patients	O
granulocytes	O
to	O
engulf	O
latex	O
particles	O
normally	O
,	O
but	O
to	O
have	O
impaired	O
reduction	O
of	O
nitroblue	O
tetrazolium	O
and	O
ferricytochrome	O
-	O
c	O
as	O
well	O
as	O
reduced	O
iodination	O
.	O

Chemotaxis	O
and	O
random	O
migration	O
of	O
the	O
patients	O
granulocytes	O
were	O
normal	O
as	O
were	O
myeloperoxidase	O
,	O
leukocyte	O
alkaline	O
phosphatase	O
(	O
LAP	O
)	O
,	O
and	O
ultrastructural	O
features	O
.	O

The	O
molecular	O
characteristics	O
of	O
G6PD	O
in	O
the	O
patient	O
differed	O
from	O
those	O
of	O
all	O
previously	O
reported	O
variants	O
associated	O
with	O
CNSHA	B
,	O
so	O
the	O
present	O
variant	O
was	O
provisionally	O
called	O
G6PD	O
Barcelona	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	O
variants	O
previously	O
described	O
.	O

Possible	O
mechanisms	O
for	O
the	O
severe	O
deficiency	B
of	I
G6PD	I
in	O
erythrocytes	O
and	O
granulocytes	O
was	O
investigated	O
by	O
studies	O
on	O
the	O
immunologic	O
specific	O
activity	O
of	O
the	O
mutant	O
enzyme	O
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
Papua	O
New	O
Guinea	O
.	O

The	O
description	O
of	O
13	O
new	O
variants	O
.	O

A	O
total	O
of	O
362	O
males	O
from	O
various	O
regions	O
of	O
Papua	O
New	O
Guinea	O
were	O
screened	O
for	O
red	O
cell	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
activity	O
.	O

Twenty	O
-	O
six	O
G6PD	B
deficient	I
individuals	O
were	O
identified	O
.	O

Biochemical	O
characterization	O
of	O
G6PD	O
purified	O
from	O
these	O
subjects	O
has	O
revealed	O
13	O
new	O
variants	O
and	O
several	O
copies	O
of	O
previously	O
described	O
forms	O
of	O
G6PD	O
.	O

This	O
study	O
illustrates	O
the	O
extreme	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
among	O
the	O
people	O
of	O
Papua	O
New	O
Guinea	O
.	O
.	O

Heterogeneity	O
of	O
"	O
Mediterranean	O
type	O
"	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
Spain	O
and	O
description	O
of	O
two	O
new	O
variants	O
associated	O
with	O
favism	B
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
;	O
EC	O
1	O
.	O

1	O
.	O

1	O
.	O

49	O
from	O
thirty	O
-	O
six	O
unrelated	O
Spanish	O
males	O
was	O
partially	O
purified	O
from	O
blood	O
,	O
and	O
the	O
variants	O
were	O
characterized	O
biochemically	O
and	O
electrophoretically	O
according	O
to	O
the	O
methods	O
recommended	O
by	O
the	O
world	O
Health	O
Organization	O
.	O

Subjects	O
were	O
from	O
multiple	O
geographic	O
regions	O
within	O
Spain	O
,	O
and	O
all	O
suffered	O
from	O
hemolytic	B
anemia	I
,	O
either	O
acute	O
(	O
34	O
cases	O
)	O
or	O
chronic	O
nonspherocytic	O
(	O
2	O
cases	O
)	O
.	O

Almost	O
all	O
the	O
variants	O
studied	O
presented	O
residual	O
erythrocyte	O
G6PD	O
activity	O
ranging	O
from	O
0	O
to	O
10	O
%	O
of	O
normal	O
,	O
and	O
five	O
different	O
mutants	O
were	O
responsible	O
for	O
the	O
deficient	O
phenotype	O
.	O

Three	O
variants	O
were	O
similar	O
to	O
others	O
previously	O
described	O
G6PD	O
Mediterranean	O
(	O
11	O
cases	O
)	O
,	O
G6PD	O
Athens	O
-	O
like	O
(	O
3	O
cases	O
)	O
,	O
and	O
G6PD	O
Union	O
(	O
2	O
cases	O
)	O
.	O

The	O
remaining	O
variants	O
were	O
different	O
from	O
the	O
numerous	O
variants	O
already	O
reported	O
and	O
have	O
been	O
considered	O
as	O
new	O
mutants	O
.	O

Provisionally	O
they	O
are	O
called	O
G6PD	O
Betica	O
(	O
19	O
cases	O
)	O
and	O
G6PD	O
Menorca	O
(	O
1	O
case	O
)	O
.	O

The	O
present	O
study	O
constitutes	O
the	O
first	O
attempt	O
to	O
characterize	O
the	O
deficient	B
G6PD	I
variants	O
found	O
in	O
Spain	O
and	O
supplies	O
new	O
data	O
on	O
the	O
relationship	O
between	O
molecular	O
characteristics	O
of	O
deficient	O
variants	O
and	O
their	O
clinical	O
manifestations	O
.	O

The	O
most	O
important	O
findings	O
can	O
be	O
summarized	O
as	O
follows	O
(	O
1	O
)	O
The	O
Spanish	O
population	O
is	O
characterized	O
by	O
an	O
important	O
heterogeneity	O
in	O
G6PD	B
deficiency	I
.	O

(	O
2	O
)	O
Although	O
G6PD	O
Mediterranean	O
is	O
very	O
frequent	O
,	O
it	O
presents	O
a	O
relatively	O
high	O
degree	O
of	O
polymorphism	O
.	O

(	O
3	O
)	O
Favism	B
has	O
been	O
observed	O
associated	O
with	O
all	O
kinds	O
of	O
variants	O
described	O
here	O
.	O

(	O
4	O
)	O
G6PD	O
Betica	O
,	O
which	O
is	O
the	O
most	O
frequent	O
variant	O
found	O
in	O
subjects	O
of	O
Southern	O
Spanish	O
origin	O
,	O
has	O
been	O
observed	O
associated	O
with	O
favism	B
in	O
all	O
cases	O
except	O
one	O
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variant	O
(	O
G6PD	O
Nagano	O
)	O
associated	O
with	O
congenital	B
hemolytic	I
anemia	I
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
variant	O
associated	O
with	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
was	O
reported	O
.	O

The	O
patient	O
,	O
a	O
6	O
-	O
year	O
-	O
old	O
Japanese	O
male	O
,	O
was	O
noticed	O
to	O
have	O
hemolytic	B
anemia	I
soon	O
after	O
birth	O
,	O
and	O
a	O
diagnosis	O
of	O
G6PD	B
deficiency	I
was	O
made	O
at	O
the	O
age	O
of	O
2	O
.	O

He	O
had	O
episodes	O
of	O
hemolytic	B
crisis	I
several	O
times	O
after	O
upper	B
respiratory	I
infection	I
.	O

G6PD	O
activity	O
of	O
the	O
patient	O
was	O
5	O
.	O

5	O
%	O
of	O
normal	O
.	O

The	O
enzymatic	O
characteristics	O
were	O
examined	O
when	O
he	O
was	O
5	O
years	O
old	O
,	O
and	O
his	O
G6PD	O
showed	O
faster	O
-	O
than	O
-	O
normal	O
electrophoretic	O
mobility	O
,	O
low	O
Km	O
G6P	O
,	O
high	O
Km	O
NADP	O
,	O
low	O
Ki	O
NADPH	O
,	O
normal	O
utilization	O
of	O
substrate	O
analogues	O
,	O
heat	O
instability	O
,	O
and	O
a	O
normal	O
pH	O
optimum	O
curve	O
.	O

From	O
these	O
results	O
,	O
this	O
was	O
considered	O
to	O
be	O
a	O
new	O
variant	O
and	O
was	O
designated	O
G6PD	O
Nagano	O
.	O

Infection	O
-	O
induced	O
hemolysis	B
and	O
chronic	B
hemolytic	I
anemia	I
seem	O
to	O
be	O
due	O
to	O
markedly	O
impaired	O
enzyme	O
activity	O
and	O
thermal	O
instability	O
.	O

Heterozygous	O
C2	B
-	I
deficiency	I
and	O
myasthenia	B
gravis	I
.	O

Complement	B
deficiency	I
states	O
in	O
myasthenia	B
gravis	I
(	O
MG	B
)	O
have	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
a	O
19	O
-	O
year	O
-	O
old	O
woman	O
with	O
typical	O
MG	B
and	O
heterozygous	O
C2	B
deficiency	I
,	O
along	O
with	O
HLA	O
typing	O
of	O
the	O
patient	O
and	O
her	O
immediate	O
family	O
.	O
.	O

Adrenoleukodystrophy	B
:	O
increased	O
plasma	O
content	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
.	O

With	O
a	O
new	O
method	O
we	O
measured	O
the	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
the	O
plasma	O
of	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
hemizygotes	O
,	O
ALD	B
heterozygotes	O
,	O
and	O
controls	O
.	O

ALD	B
hemizygotes	O
showed	O
increased	O
levels	O
of	O
hexacosanoate	O
(	O
C26	O
fatty	O
acid	O
)	O
which	O
represented	O
0	O
.	O

081	O
+	O
/	O
-	O
0	O
.	O

0066	O
%	O
(	O
SEM	O
)	O
of	O
total	O
fatty	O
acids	O
,	O
compared	O
to	O
0	O
.	O

015	O
+	O
/	O
-	O
0	O
.	O

0032	O
%	O
in	O
the	O
controls	O
.	O

C25	O
,	O
C24	O
,	O
and	O
C23	O
fatty	O
acids	O
were	O
also	O
increased	O
,	O
but	O
the	O
C22	O
and	O
C20	O
fatty	O
acids	O
were	O
normal	O
.	O

C26	O
levels	O
were	O
also	O
increased	O
in	O
most	O
ALD	B
heterozygotes	O
,	O
with	O
a	O
mean	O
level	O
0	O
.	O

057	O
+	O
/	O
-	O
0	O
.	O

0063	O
%	O
of	O
total	O
fatty	O
acids	O
.	O

The	O
technique	O
can	O
be	O
used	O
for	O
diagnosis	O
and	O
carrier	O
identification	O
,	O
and	O
in	O
the	O
evaluation	O
of	O
therapy	O
.	O

Abnormal	O
high	O
density	O
lipoproteins	O
in	O
cerebrotendinous	B
xanthomatosis	I
.	O

The	O
plasma	O
lipoprotein	O
profiles	O
and	O
high	O
density	O
lipoproteins	O
(	O
HDL	O
)	O
were	O
characterized	O
in	O
patients	O
with	O
the	O
genetic	B
disease	I
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

Abnormalities	B
in	I
the	I
HDL	I
may	O
contribute	O
to	O
their	O
increased	O
atherogenesis	O
and	O
excessive	O
deposits	O
of	O
tissue	O
sterols	O
in	O
the	O
presence	O
of	O
low	O
or	O
low	O
-	O
normal	O
concentrations	O
of	O
plasma	O
cholesterol	O
(	O
165	O
+	O
/	O
-	O
25	O
mg	O
/	O
dl	O
)	O
and	O
low	O
density	O
lipoproteins	O
(	O
LDL	O
)	O
.	O

The	O
mean	O
HDL	O
-	O
cholesterol	O
concentration	O
in	O
the	O
CTX	B
plasmas	O
was	O
14	O
.	O

5	O
+	O
/	O
-	O
3	O
.	O

2	O
mg	O
/	O
dl	O
,	O
about	O
one	O
-	O
third	O
the	O
normal	O
value	O
.	O

The	O
low	O
HDL	O
-	O
cholesterol	O
reflects	O
a	O
low	O
concentration	O
and	O
an	O
abnormal	O
lipid	O
composition	O
of	O
the	O
plasma	O
HDL	O
.	O

Relative	O
to	O
normal	O
HDL	O
,	O
the	O
cholesteryl	O
esters	O
are	O
low	O
,	O
free	O
cholesterol	O
and	O
phospholipids	O
essentially	O
normal	O
,	O
and	O
triglycerides	O
increased	O
.	O

The	O
ratio	O
of	O
apoprotein	O
(	O
apo	O
)	O
to	O
total	O
cholesterol	O
in	O
the	O
HDL	O
of	O
CTX	B
was	O
two	O
to	O
three	O
times	O
greater	O
than	O
normal	O
.	O

In	O
the	O
CTX	B
HDL	O
,	O
the	O
ratio	O
of	O
apoAI	O
to	O
apoAII	O
was	O
high	O
,	O
the	O
proportion	O
of	O
apoC	O
low	O
,	O
and	O
a	O
normally	O
minor	O
form	O
of	O
apoAI	O
increased	O
relative	O
to	O
other	O
forms	O
.	O

The	O
HDL	O
in	O
electron	O
micrographs	O
appeared	O
normal	O
morphologically	O
and	O
in	O
particle	O
size	O
.	O

The	O
abnormalities	O
in	O
lipoprotein	O
distribution	O
profile	O
and	O
composition	O
of	O
the	O
plasma	O
HDL	O
result	O
from	O
metabolic	O
defects	O
that	O
are	O
not	O
understood	O
but	O
may	O
be	O
linked	O
to	O
the	O
genetic	B
defect	I
in	O
bile	O
acid	O
synthesis	O
in	O
CTX	B
.	O

As	O
a	O
consequence	O
,	O
it	O
is	O
probable	O
that	O
the	O
normal	O
functions	O
of	O
the	O
HDL	O
,	O
possibly	O
including	O
modulation	O
of	O
LDL	O
-	O
cholesterol	O
uptake	O
and	O
the	O
removal	O
of	O
excess	O
cholesterol	O
from	O
peripheral	O
tissues	O
,	O
are	O
perturbed	O
significantly	O
in	O
this	O
disease	O
.	O

Genetics	O
of	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
:	O
an	O
autosomal	O
recessive	O
trait	O
with	O
high	O
gene	O
frequency	O
in	O
Sephardim	O
of	O
Moroccan	O
origin	O
.	O

We	O
described	O
6	O
patients	O
(	O
from	O
3	O
families	O
)	O
affected	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

All	O
are	O
Sephardic	O
Jews	O
of	O
Moroccan	O
extraction	O
.	O

In	O
view	O
of	O
the	O
small	O
number	O
of	O
CTX	B
patients	O
diagnosed	O
in	O
the	O
world	O
(	O
a	O
total	O
of	O
50	O
including	O
our	O
6	O
patients	O
)	O
,	O
we	O
are	O
probably	O
dealing	O
with	O
an	O
ethnic	O
subgroup	O
with	O
a	O
high	O
CTX	O
gene	O
frequency	O
,	O
which	O
we	O
have	O
estimated	O
to	O
be	O
1	O
/	O
108	O
.	O

Since	O
there	O
are	O
differences	O
in	O
expression	O
in	O
this	O
disease	O
,	O
we	O
recommend	O
cholestanol	O
study	O
in	O
cases	O
of	O
undiagnosed	O
cataract	B
or	O
tendinous	B
xanthomas	I
in	O
childhood	O
or	O
early	O
adolescence	O
.	O

The	O
diagnosis	O
in	O
CTX	B
is	O
important	O
not	O
only	O
for	O
genetic	O
counseling	O
,	O
but	O
also	O
in	O
veiw	O
of	O
possible	O
treatment	O
.	O
.	O

New	O
genetic	O
variants	O
of	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
in	O
Italy	O
.	O

Six	O
new	O
variants	O
of	O
human	O
erythrocyte	O
G6PD	O
have	O
been	O
characterized	O
.	O

All	O
of	O
them	O
were	O
found	O
in	O
Italian	O
males	O
and	O
all	O
were	O
associated	O
with	O
enzyme	B
deficiency	I
,	O
but	O
only	O
two	O
with	O
signs	O
of	O
haemolysis	B
.	O

These	O
and	O
other	O
variants	O
reported	O
in	O
the	O
literature	O
,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic	O
,	O
are	O
found	O
to	O
map	O
in	O
parts	O
of	O
Italy	O
where	O
common	O
types	O
of	O
G6PD	B
deficiency	I
are	O
also	O
prevalent	O
.	O
.	O

Variants	O
of	O
erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
in	O
Bulgarian	O
populations	O
.	O

Ten	O
variants	O
of	O
erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
were	O
identified	O
in	O
22	O
patients	O
with	O
G6PD	B
deficiency	I
from	O
three	O
districts	O
of	O
Bulgaria	O
.	O

Corinth	O
-	O
like	O
and	O
Fayoum	O
-	O
like	O
variants	O
were	O
the	O
most	O
frequent	O
;	O
Mediterranean	O
,	O
Ohut	O
II	O
,	O
Kilgore	O
,	O
Boston	O
,	O
Poznan	O
,	O
and	O
Panay	O
variants	O
and	O
two	O
new	O
variants	O
,	O
Petrich	O
and	O
Gotze	O
Delchev	O
,	O
were	O
each	O
found	O
in	O
one	O
or	O
two	O
carriers	O
.	O

No	O
correlation	O
was	O
revealed	O
between	O
clinical	O
and	O
biochemical	O
polymorphism	O
.	O
.	O

Nephropathy	B
in	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

Nephropathy	B
was	O
detected	O
in	O
five	O
of	O
32	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
who	O
were	O
participating	O
in	O
a	O
study	O
of	O
transfer	O
factor	O
(	O
TF	O
)	O
therapy	O
.	O

In	O
two	O
patients	O
,	O
nephropathy	B
was	O
present	O
before	O
TF	O
and	O
did	O
not	O
appear	O
changed	O
by	O
TF	O
therapy	O
.	O

One	O
of	O
these	O
patients	O
subsequently	O
developed	O
progressive	O
renal	B
failure	I
requiring	O
dialysis	O
beginning	O
5	O
1	O
/	O
2	O
years	O
after	O
TF	O
therapy	O
.	O

In	O
two	O
patients	O
,	O
decreased	O
renal	O
function	O
appeared	O
very	O
soon	O
after	O
the	O
administration	O
of	O
TF	O
.	O

One	O
patient	O
showed	O
gradually	O
decreasing	O
renal	O
function	O
beginning	O
after	O
two	O
years	O
of	O
TF	O
therapy	O
.	O

An	O
additional	O
patient	O
was	O
identified	O
who	O
died	O
with	O
renal	B
failure	I
without	O
having	O
received	O
TF	O
.	O

The	O
results	O
suggest	O
that	O
renal	B
failure	I
occurs	O
in	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
TF	O
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	B
disease	I
in	O
patients	O
with	O
this	O
syndrome	O
.	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
cellular	O
impairments	O
and	O
their	O
implication	O
for	O
carrier	O
detection	O
.	O

A	O
family	O
in	O
which	O
two	O
male	O
siblings	O
were	O
affected	O
with	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
was	O
studied	O
using	O
G	O
-	O
6	O
-	O
PD	O
isoenzymes	O
as	O
an	O
X	O
-	O
linked	O
marker	O
in	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
cellular	O
abnormalities	O
.	O

Isolated	O
peripheral	O
blood	O
cell	O
types	O
from	O
the	O
doubly	O
heterozygous	O
mother	O
of	O
the	O
affected	O
males	O
seemingly	O
failed	O
to	O
express	O
the	O
G	O
-	O
6	O
-	O
PD	O
allele	O
in	O
cis	O
position	O
with	O
the	O
WAS	B
allele	O
while	O
her	O
cultured	O
skin	O
fibroblasts	O
expressed	O
both	O
G	O
-	O
6	O
-	O
PD	O
alleles	O
.	O

Additionally	O
,	O
a	O
histogram	O
analysis	O
of	O
platelet	O
size	O
revealed	O
a	O
single	O
population	O
of	O
abnormally	O
small	O
platelets	O
in	O
the	O
affected	O
propositus	O
,	O
whereas	O
the	O
heterozygous	O
mother	O
had	O
no	O
appreciable	O
small	O
platelet	O
subpopulation	O
.	O

In	O
vitro	O
culture	O
of	O
hemopoietic	O
progenitor	O
cells	O
of	O
the	O
heterozygous	O
mother	O
showed	O
that	O
the	O
majority	O
of	O
progenitor	O
cells	O
did	O
not	O
express	O
the	O
WAS	B
allele	O
.	O

However	O
,	O
a	O
small	O
number	O
of	O
cells	O
expressing	O
the	O
G	O
-	O
6	O
-	O
PD	O
type	O
linked	O
with	O
the	O
WAS	B
allele	O
were	O
detected	O
.	O

The	O
proportion	O
of	O
the	O
latter	O
progenitors	O
was	O
significantly	O
higher	O
among	O
more	O
primitive	O
progenitors	O
(	O
those	O
giving	O
rise	O
to	O
later	O
appearing	O
colonies	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
selection	O
against	O
cells	O
expressing	O
the	O
Wiskott	B
-	I
Aldrich	I
defect	I
takes	O
place	O
in	O
the	O
hemopoietic	O
system	O
of	O
the	O
heterozygous	O
female	O
and	O
offers	O
a	O
possible	O
means	O
of	O
carrier	O
detection	O
in	O
some	O
women	O
.	O

Linkage	O
studies	O
in	O
this	O
family	O
revealed	O
one	O
example	O
of	O
probable	O
recombination	O
between	O
the	O
loci	O
for	O
WAS	B
and	O
G	O
-	O
6	O
-	O
PD	O
among	O
three	O
informative	O
subjects	O
,	O
suggesting	O
that	O
these	O
two	O
loci	O
may	O
not	O
be	O
closely	O
linked	O
on	O
the	O
X	O
-	O
chromosome	O
.	O
.	O

A	O
new	O
CT	O
pattern	O
in	O
adrenoleukodystrophy	B
.	O

A	O
new	O
CT	O
pattern	O
was	O
observed	O
in	O
2	O
patients	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
.	O

This	O
pattern	O
,	O
which	O
the	O
authors	O
call	O
Type	O
II	O
,	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
posterior	O
periventricular	O
areas	O
of	O
decreased	O
attenuation	O
around	O
the	O
trigone	O
on	O
non	O
-	O
contrast	O
scans	O
after	O
contrast	O
infusion	O
,	O
however	O
,	O
there	O
is	O
striking	O
enhancement	O
of	O
various	O
white	O
-	O
matter	O
structures	O
(	O
tracts	O
or	O
fiber	O
systems	O
)	O
such	O
as	O
the	O
internal	O
capsules	O
,	O
corpus	O
callosum	O
,	O
corona	O
radiata	O
,	O
forceps	O
major	O
,	O
and	O
cerebral	O
peduncles	O
.	O

This	O
is	O
different	O
from	O
numerous	O
previous	O
descriptions	O
of	O
the	O
CT	O
pattern	O
in	O
ALD	B
.	O

Type	B
II	I
ALD	I
does	O
not	O
appear	O
to	O
have	O
been	O
seen	O
in	O
any	O
other	O
leukoencephalopathy	B
and	O
is	O
probably	O
specific	O
for	O
a	O
phenotypic	O
variant	O
or	O
an	O
evolving	O
stage	O
of	O
ALD	B
.	O
.	O

Further	O
evidence	O
for	O
heterogeneity	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
Papua	O
New	O
Guinea	O
.	O

Four	O
new	O
G6PD	O
variants	O
have	O
been	O
characterized	O
in	O
individuals	O
from	O
Papua	O
New	O
Guinea	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
previously	O
reported	O
Markham	O
variant	O
and	O
the	O
newly	O
characterized	O
Salata	O
variant	O
may	O
be	O
widely	O
distributed	O
in	O
Papua	O
New	O
Guinea	O
.	O

Th	O
data	O
presented	O
here	O
together	O
with	O
those	O
of	O
previously	O
published	O
studies	O
demonstrate	O
a	O
degree	O
of	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
that	O
is	O
much	O
higher	O
than	O
that	O
in	O
other	O
regions	O
of	O
the	O
world	O
where	O
G6PD	B
deficiency	I
is	O
common	O
.	O
.	O

Increased	O
incidence	O
of	O
cataracts	B
in	O
male	O
subjects	O
deficient	B
in	I
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
RBCs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	O
cataractous	B
patients	O
than	O
in	O
672	O
control	O
subjects	O
of	O
Sardinian	O
origin	O
.	O

The	O
frequency	O
of	O
the	O
deficiency	O
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	B
.	O

In	O
the	O
G6PD	B
-	I
deficient	I
group	O
,	O
the	O
incidence	O
of	O
cortical	B
and	I
total	I
cataracts	I
was	O
also	O
increased	O
.	O

It	O
is	O
suggested	O
that	O
decrease	O
of	O
the	O
G6PD	O
activity	O
in	O
the	O
lens	O
,	O
which	O
accompanies	O
its	O
deficiency	O
in	O
the	O
erythrocyte	O
,	O
might	O
play	O
a	O
role	O
in	O
the	O
cataracto	O
-	O
genesis	O
of	O
these	O
patients	O
.	O

Moreover	O
,	O
G6PD	B
deficiency	I
should	O
be	O
added	O
to	O
other	O
conditions	O
,	O
such	O
as	O
the	O
galactosemic	B
states	O
and	O
riboflavin	B
deficiency	I
,	O
where	O
cataracts	B
represent	O
a	O
sensitive	O
indicator	O
of	O
metabolic	B
abnormalities	I
of	O
the	O
RBC	O
.	O
.	O

Molecular	O
basis	O
of	O
human	O
mitochondrial	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
CoA	I
dehydrogenase	I
deficiency	I
causing	O
cardiomyopathy	B
and	O
sudden	B
death	I
in	O
childhood	O
.	O

beta	O
-	O
Oxidation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
provides	O
the	O
major	O
source	O
of	O
energy	O
in	O
the	O
heart	O
.	O

Defects	O
in	O
enzymes	O
of	O
the	O
beta	O
-	O
oxidation	O
pathway	O
cause	O
sudden	B
,	I
unexplained	I
death	I
in	O
childhood	O
,	O
acute	O
hepatic	B
encephalopathy	I
or	O
liver	B
failure	I
,	O
skeletal	B
myopathy	I
,	O
and	O
cardiomyopathy	B
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
[	O
VLCAD	O
;	O
very	O
-	O
long	O
-	O
chain	O
-	O
acyl	O
-	O
CoA	O
(	O
acceptor	O
)	O
2	O
,	O
3	O
-	O
oxidoreductase	O
,	O
EC	O
1	O
.	O
3	O
3	O
.	O
99	O
99	O
.	O
13	O
]	O
catalyzes	O
the	O
first	O
step	O
in	O
beta	O
-	O
oxidation	O
.	O

We	O
have	O
isolated	O
the	O
human	O
VLCAD	O
cDNA	O
and	O
gene	O
and	O
determined	O
the	O
complete	O
nucleotide	O
sequences	O
.	O

Polymerase	O
chain	O
reaction	O
amplification	O
of	O
VLCAD	O
mRNA	O
and	O
genomic	O
exons	O
defined	O
the	O
molecular	O
defects	O
in	O
two	O
patients	O
with	O
VLCAD	B
deficiency	I
who	O
presented	O
with	O
unexplained	O
cardiac	B
arrest	I
and	O
cardiomyopathy	B
.	O

In	O
one	O
,	O
a	O
homozygous	O
mutation	O
in	O
the	O
consensus	O
dinucleotide	O
of	O
the	O
donor	O
splice	O
site	O
(	O
g	O
+	O
1	O
-	O
-	O
>	O
a	O
)	O
was	O
associated	O
with	O
universal	O
skipping	O
of	O
the	O
prior	O
exon	O
(	O
exon	O
11	O
)	O
.	O

The	O
second	O
patient	O
was	O
a	O
compound	O
heterozygote	O
,	O
with	O
a	O
missense	O
mutation	O
,	O
C1837	O
-	O
-	O
>	O
T	O
,	O
changing	O
the	O
arginine	O
at	O
residue	O
613	O
to	O
tryptophan	O
on	O
one	O
allele	O
and	O
a	O
single	O
base	O
deletion	O
at	O
the	O
intron	O
-	O
exon	O
6	O
boundary	O
as	O
the	O
second	O
mutation	O
.	O

This	O
initial	O
delineation	O
of	O
human	O
mutations	O
in	O
VLCAD	O
suggests	O
that	O
VLCAD	B
deficiency	I
reduces	O
myocardial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
and	O
energy	O
production	O
and	O
is	O
associated	O
with	O
cardiomyopathy	B
and	O
sudden	B
death	I
in	O
childhood	O
.	O

Aberrant	O
subcellular	O
localization	O
of	O
BRCA1	O
in	O
breast	B
cancer	I
.	O

The	O
BRCA1	O
gene	O
product	O
was	O
identified	O
as	O
a	O
220	O
-	O
kilodalton	O
nuclear	O
phosphoprotein	O
in	O
normal	O
cells	O
,	O
including	O
breast	O
ductal	O
epithelial	O
cells	O
,	O
and	O
in	O
18	O
of	O
20	O
tumor	B
cell	O
lines	O
derived	O
from	O
tissues	O
other	O
than	O
breast	O
and	O
ovary	O
.	O

In	O
16	O
of	O
17	O
breast	B
and	I
ovarian	I
cancer	I
lines	O
and	O
17	O
of	O
17	O
samples	O
of	O
cells	O
obtained	O
from	O
malignant	O
effusions	O
,	O
however	O
,	O
BRCA1	O
localized	O
mainly	O
in	O
cytoplasm	O
.	O

Absence	O
of	O
BRCA1	O
or	O
aberrant	O
subcellular	O
location	O
was	O
also	O
observed	O
to	O
a	O
variable	O
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	B
cancer	I
biopsies	O
.	O

These	O
findings	O
suggest	O
that	O
BRCA1	B
abnormalities	I
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
breast	B
cancers	I
,	O
sporadic	O
as	O
well	O
as	O
familial	O
.	O
.	O

Mapping	O
of	O
the	O
mouse	O
homologue	O
of	O
the	O
Wilson	B
disease	I
gene	O
to	O
mouse	O
chromosome	O
8	O
.	O

ATP7B	O
,	O
the	O
gene	O
altered	O
in	O
Wilson	B
disease	I
(	O
WD	B
)	O
patients	O
,	O
lies	O
in	O
a	O
block	O
of	O
homology	O
shared	O
between	O
human	O
chromosome	O
13q14	O
and	O
the	O
central	O
region	O
of	O
mouse	O
chromosome	O
14	O
.	O

However	O
,	O
we	O
have	O
mapped	O
the	O
murine	O
homologue	O
of	O
ATP7B	O
(	O
Atp7b	O
)	O
to	O
mouse	O
chromosome	O
8	O
by	O
somatic	O
cell	O
hybrid	O
analysis	O
.	O

Analysis	O
of	O
80	O
interspecific	O
backcross	O
offspring	O
was	O
used	O
to	O
position	O
Atp7b	O
close	O
to	O
D8Mit3	O
and	O
another	O
ATPase	O
locus	O
,	O
Atp4b	O
,	O
on	O
mouse	O
chromosome	O
8	O
.	O

ATP4B	O
lies	O
in	O
13q34	O
and	O
is	O
separated	O
from	O
ATP7B	O
by	O
several	O
loci	O
whose	O
mouse	O
homologues	O
map	O
to	O
mouse	O
chromosome	O
14	O
.	O

The	O
assignment	O
of	O
Atp7b	O
to	O
mouse	O
chromosome	O
8	O
identifies	O
a	O
previously	O
unrecognized	O
region	O
of	O
homology	O
between	O
this	O
chromosome	O
and	O
human	O
chromosome	O
13	O
.	O

This	O
assignment	O
suggests	O
a	O
possible	O
location	O
for	O
the	O
toxic	O
milk	O
mutation	O
in	O
the	O
mouse	O
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
homologue	O
of	O
WD	B
.	O
.	O

Germline	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
in	O
breast	B
and	I
ovarian	I
cancer	I
families	O
provide	O
evidence	O
for	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Mutations	O
in	O
the	O
BRCA1	O
gene	O
,	O
discovered	O
in	O
1994	O
,	O
are	O
associated	O
with	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
.	O

We	O
have	O
analysed	O
60	O
families	O
with	O
a	O
history	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
for	O
germline	O
mutations	O
in	O
BRCA1	O
.	O

Twenty	O
-	O
two	O
different	O
mutations	O
were	O
detected	O
in	O
32	O
families	O
(	O
53	O
%	O
)	O
,	O
of	O
which	O
14	O
are	O
previously	O
unreported	O
.	O

We	O
observed	O
a	O
significant	O
correlation	O
between	O
the	O
location	O
of	O
the	O
mutation	O
in	O
the	O
gene	O
and	O
the	O
ratio	O
of	O
breast	B
to	I
ovarian	I
cancer	I
incidence	O
within	O
each	O
family	O
.	O

Our	O
data	O
suggest	O
a	O
transition	O
in	O
risk	O
such	O
that	O
mutations	O
in	O
the	O
3	O
third	O
of	O
the	O
gene	O
are	O
associated	O
with	O
a	O
lower	O
proportion	O
of	O
ovarian	B
cancer	I
.	O

Haplotype	O
analysis	O
supports	O
previous	O
data	O
which	O
suggest	O
some	O
BRCA1	O
mutation	O
carriers	O
have	O
common	O
ancestors	O
;	O
however	O
,	O
we	O
have	O
found	O
at	O
least	O
two	O
examples	O
where	O
recurrent	O
mutations	O
appear	O
to	O
have	O
arisen	O
independently	O
.	O
.	O

Hereditary	O
deficiency	B
of	I
the	I
seventh	I
component	I
of	I
complement	I
and	O
recurrent	O
meningococcal	B
infection	I
:	O
investigations	O
of	O
an	O
Irish	O
family	O
using	O
a	O
novel	O
haemolytic	O
screening	O
assay	O
for	O
complement	O
activity	O
and	O
C7	O
M	O
/	O
N	O
allotyping	O
.	O

Terminal	B
complement	I
component	I
deficiency	I
predisposes	O
to	O
meningococcal	B
infection	I
and	O
is	O
inherited	O
in	O
an	O
autosomal	O
co	O
-	O
dominant	O
manner	O
.	O

An	O
Irish	O
family	O
is	O
described	O
,	O
in	O
which	O
2	O
of	O
3	O
brothers	O
had	O
recurrent	O
meningococcal	B
infection	I
.	O

A	O
novel	O
screening	O
assay	O
was	O
used	O
to	O
investigate	O
for	O
terminal	B
complement	I
deficiency	I
and	O
the	O
2	O
affected	O
brothers	O
were	O
found	O
to	O
be	O
completely	B
deficient	I
in	I
the	I
seventh	I
component	I
of	I
complement	I
(	O
C7	O
)	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
C7	O
revealed	O
lower	O
than	O
normal	O
levels	O
in	O
the	O
remaining	O
brother	O
and	O
parents	O
.	O

C7	O
M	O
/	O
N	O
protein	O
polymorphism	O
allotyping	O
,	O
used	O
to	O
investigate	O
the	O
segregation	O
of	O
the	O
C7	B
deficiency	I
genes	O
,	O
showed	O
that	O
the	O
apparently	O
complement	O
sufficient	O
brother	O
was	O
heterozygous	O
C7	B
deficient	I
and	O
a	O
carrier	O
of	O
one	O
of	O
the	O
deficiency	O
genes	O
.	O

Complement	O
screening	O
should	O
be	O
carried	O
out	O
in	O
any	O
individual	O
suffering	O
recurrent	O
meningococcal	B
infection	I
or	O
infection	O
with	O
an	O
uncommon	O
meningococcal	B
serogroup	O
.	O

Identification	O
of	O
complement	B
deficient	I
patients	O
allows	O
the	O
implementation	O
of	O
strategies	O
to	O
prevent	O
recurrent	O
infection	O
.	O
.	O

Molecular	O
basis	O
of	O
subtotal	B
complement	I
C6	I
deficiency	I
.	O

A	O
carboxy	O
-	O
terminally	O
truncated	O
but	O
functionally	O
active	O
C6	O
.	O

Individuals	O
with	O
subtotal	B
complement	I
C6	I
deficiency	I
possess	O
a	O
C6	O
molecule	O
that	O
is	O
14	O
%	O
shorter	O
than	O
normal	O
C6	O
and	O
present	O
in	O
low	O
but	O
detectable	O
concentrations	O
(	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
mean	O
)	O
.	O

We	O
now	O
show	O
that	O
this	O
dysmorphic	O
C6	O
is	O
bactericidally	O
active	O
and	O
lacks	O
an	O
epitope	O
that	O
was	O
mapped	O
to	O
the	O
most	O
carboxy	O
-	O
terminal	O
part	O
of	O
C6	O
using	O
C6	O
cDNA	O
fragments	O
expressed	O
as	O
fusion	O
proteins	O
in	O
the	O
pUEX	O
expression	O
system	O
.	O

We	O
thus	O
predicted	O
that	O
the	O
abnormal	O
C6	O
molecule	O
might	O
be	O
carboxy	O
-	O
terminally	O
truncated	O
and	O
sought	O
a	O
mutation	O
in	O
an	O
area	O
approximately	O
14	O
%	O
from	O
the	O
carboxy	O
-	O
terminal	O
end	O
of	O
the	O
coding	O
sequence	O
.	O

By	O
sequencing	O
PCR	O
-	O
amplified	O
products	O
from	O
this	O
region	O
,	O
we	O
found	O
,	O
in	O
three	O
individuals	O
from	O
two	O
families	O
,	O
a	O
mutation	O
that	O
might	O
plausibly	O
be	O
responsible	O
for	O
the	O
defect	O
.	O

All	O
three	O
have	O
an	O
abnormal	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
,	O
which	O
would	O
probably	O
prevent	O
splicing	O
.	O

An	O
in	O
-	O
frame	O
stop	O
codon	O
is	O
found	O
17	O
codons	O
downstream	O
from	O
the	O
intron	O
boundary	O
,	O
which	O
would	O
lead	O
to	O
a	O
truncated	O
polypeptide	O
13	O
.	O

5	O
%	O
smaller	O
than	O
normal	O
C6	O
.	O

This	O
result	O
was	O
unexpected	O
,	O
as	O
earlier	O
studies	O
mapped	O
the	O
C5b	O
binding	O
site	O
,	O
or	O
a	O
putative	O
enzymatic	O
region	O
,	O
to	O
this	O
part	O
of	O
C6	O
.	O

Interestingly	O
,	O
all	O
three	O
subjects	O
were	O
probably	O
heterozygous	O
for	O
both	O
subtotal	B
C6	I
and	I
complete	I
C6	I
deficiency	I
.	O

Myotonic	B
dystrophy	I
:	O
evidence	O
for	O
a	O
possible	O
dominant	O
-	O
negative	O
RNA	O
mutation	O
.	O

The	O
trinucleotide	O
expansion	O
mutation	O
causing	O
myotonic	B
dystrophy	I
is	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
gene	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
the	O
expanded	O
repeat	O
causes	O
the	O
clinically	O
variable	O
and	O
multisystemic	B
disease	I
,	O
myotonic	B
dystrophy	I
,	O
are	O
not	O
understood	O
.	O

It	O
has	O
been	O
particularly	O
difficult	O
to	O
rationalize	O
the	O
dominant	O
inheritance	O
with	O
the	O
fact	O
that	O
the	O
expansion	O
mutation	O
lies	O
outside	O
of	O
the	O
protein	O
-	O
encoding	O
gene	O
elements	O
,	O
and	O
should	O
not	O
be	O
translated	O
into	O
protein	O
.	O

Here	O
we	O
use	O
muscle	O
biopsies	O
from	O
classical	O
adult	O
-	O
onset	O
myotonic	B
dystrophy	I
patients	O
to	O
study	O
the	O
accumulation	O
of	O
transcripts	O
from	O
both	O
the	O
normal	O
and	O
expanded	O
DM	B
kinase	O
genes	O
in	O
patient	O
muscle	O
,	O
and	O
compare	O
the	O
results	O
to	O
normal	O
and	O
myopathic	B
controls	O
.	O

We	O
found	O
relatively	O
small	O
decreases	O
of	O
DM	B
kinase	O
RNA	O
in	O
the	O
total	O
RNA	O
pool	O
from	O
muscle	O
;	O
however	O
,	O
these	O
reductions	O
were	O
not	O
disease	O
specific	O
.	O

Analysis	O
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
showed	O
dramatic	O
decreases	O
of	O
both	O
the	O
mutant	O
and	O
normal	O
DM	B
kinase	O
RNAs	O
,	O
and	O
these	O
changes	O
were	O
disease	O
-	O
specific	O
.	O

Our	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
molecular	O
pathogenetic	O
mechanism	O
for	O
myotonic	B
dystrophy	I
both	O
the	O
normal	O
and	O
expanded	O
DM	B
kinase	O
genes	O
are	O
transcribed	O
in	O
patient	O
muscle	O
,	O
but	O
the	O
abnormal	O
expansion	O
-	O
containing	O
RNA	O
has	O
a	O
dominant	O
effect	O
on	O
RNA	O
metabolism	O
by	O
preventing	O
the	O
accumulation	O
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
.	O

The	O
ability	O
of	O
the	O
expansion	O
mutation	O
to	O
alter	O
accumulation	O
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
in	O
trans	O
suggests	O
that	O
myotonic	B
dystrophy	I
may	O
be	O
the	O
first	O
example	O
of	O
a	O
dominant	O
-	O
negative	O
mutation	O
manifested	O
at	O
the	O
RNA	O
level	O
.	O
.	O

A	O
strong	O
candidate	O
for	O
the	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
.	O

A	O
strong	O
candidate	O
for	O
the	O
17q	O
-	O
linked	O
BRCA1	O
gene	O
,	O
which	O
influences	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
,	O
has	O
been	O
identified	O
by	O
positional	O
cloning	O
methods	O
.	O

Probable	O
predisposing	O
mutations	O
have	O
been	O
detected	O
in	O
five	O
of	O
eight	O
kindreds	O
presumed	O
to	O
segregate	O
BRCA1	O
susceptibility	O
alleles	O
.	O

The	O
mutations	O
include	O
an	O
11	O
-	O
base	O
pair	O
deletion	O
,	O
a	O
1	O
-	O
base	O
pair	O
insertion	O
,	O
a	O
stop	O
codon	O
,	O
a	O
missense	O
substitution	O
,	O
and	O
an	O
inferred	O
regulatory	O
mutation	O
.	O

The	O
BRCA1	O
gene	O
is	O
expressed	O
in	O
numerous	O
tissues	O
,	O
including	O
breast	O
and	O
ovary	O
,	O
and	O
encodes	O
a	O
predicted	O
protein	O
of	O
1863	O
amino	O
acids	O
.	O

This	O
protein	O
contains	O
a	O
zinc	O
finger	O
domain	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
,	O
but	O
is	O
otherwise	O
unrelated	O
to	O
previously	O
described	O
proteins	O
.	O

Identification	O
of	O
BRCA1	O
should	O
facilitate	O
early	O
diagnosis	O
of	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
in	O
some	O
individuals	O
as	O
well	O
as	O
a	O
better	O
understanding	O
of	O
breast	B
cancer	I
biology	O
.	O
.	O

Molecular	O
characterization	O
of	O
galactosemia	B
(	O
type	O
1	O
)	O
mutations	O
in	O
Japanese	O
.	O

We	O
characterized	O
two	O
novel	O
mutations	O
of	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
in	O
two	O
Japanese	O
patients	O
with	O
GALT	B
deficiency	I
and	O
identified	O
N314D	O
and	O
R333W	O
mutations	O
,	O
previously	O
found	O
in	O
Caucasians	O
.	O

One	O
novel	O
missense	O
mutation	O
was	O
an	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
by	O
histidine	O
at	O
the	O
codon	O
231	O
(	O
R231H	O
)	O
.	O

GALT	O
activity	O
of	O
the	O
R231H	O
mutant	O
construct	O
was	O
reduced	O
to	O
15	O
%	O
of	O
normal	O
controls	O
in	O
a	O
COS	O
cell	O
expression	O
system	O
.	O

The	O
other	O
was	O
a	O
splicing	O
mutation	O
,	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	O
at	O
the	O
38th	O
nucleotide	O
in	O
exon	O
3	O
(	O
318A	O
-	O
-	O
>	O
G	O
)	O
,	O
resulting	O
in	O
a	O
38	O
-	O
bp	O
deletion	O
in	O
the	O
GALT	O
cDNA	O
by	O
activating	O
a	O
cryptic	O
splice	O
acceptor	O
site	O
.	O

In	O
seven	O
Japanese	O
families	O
(	O
14	O
alleles	O
for	O
classic	O
form	O
and	O
one	O
allele	O
for	O
Duarte	O
variant	O
)	O
with	O
GALT	B
deficiency	I
,	O
the	O
R231H	O
and	O
318A	O
-	O
-	O
>	O
G	O
mutations	O
were	O
found	O
only	O
on	O
both	O
alleles	O
of	O
the	O
proband	O
.	O

The	O
N314D	O
and	O
R333W	O
mutations	O
were	O
found	O
on	O
one	O
allele	O
each	O
.	O

The	O
Q188R	O
was	O
prevalent	O
in	O
the	O
United	O
States	O
but	O
not	O
in	O
Japanese	O
patients	O
.	O

The	O
N314D	O
mutation	O
was	O
associated	O
with	O
the	O
Duarte	O
variant	O
in	O
Japanese	O
persons	O
,	O
as	O
well	O
as	O
in	O
the	O
United	O
States	O
.	O

We	O
speculate	O
that	O
classic	B
galactosemia	I
mutations	O
appear	O
to	O
differ	O
between	O
Japanese	O
and	O
Caucasian	O
patients	O
.	O

Our	O
limited	O
data	O
set	O
on	O
galactosemia	B
mutations	O
in	O
Japanese	O
suggests	O
that	O
the	O
N314D	O
GALT	O
mutation	O
encoding	O
the	O
Duarte	O
variant	O
arose	O
before	O
Asian	O
and	O
Caucasian	O
people	O
diverged	O
and	O
that	O
classic	B
galactosemia	I
mutations	O
arose	O
and	O
/	O
or	O
accumulated	O
after	O
the	O
divergence	O
of	O
Asian	O
and	O
Caucasian	O
populations	O
.	O
.	O

Three	O
novel	O
aniridia	B
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

Aniridia	B
(	O
iris	B
hypoplasia	I
)	O
is	O
an	O
autosomal	B
dominant	I
congenital	I
disorder	I
of	I
the	I
eye	I
.	O

Mutations	O
in	O
the	O
human	O
aniridia	B
(	O
PAX6	O
)	O
gene	O
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O

In	O
the	O
study	O
reported	O
here	O
we	O
describe	O
PAX6	O
mutations	O
in	O
one	O
sporadic	O
and	O
five	O
familial	O
cases	O
with	O
aniridia	B
.	O

Of	O
the	O
four	O
different	O
mutations	O
identified	O
,	O
one	O
was	O
identical	O
to	O
a	O
previously	O
reported	O
mutation	O
(	O
C	O
-	O
-	O
>	O
T	O
transition	O
at	O
codon	O
240	O
)	O
,	O
and	O
three	O
were	O
novel	O
two	O
in	O
the	O
glycine	O
-	O
rich	O
region	O
and	O
one	O
in	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
(	O
PST	O
)	O
region	O
.	O

One	O
PAX6	O
mutation	O
found	O
in	O
the	O
PST	O
region	O
was	O
associated	O
with	O
cataracts	B
in	O
an	O
aniridia	B
family	O
.	O

Another	O
splice	O
mutation	O
in	O
the	O
PST	O
domain	O
occurred	O
in	O
an	O
aniridia	B
patient	O
with	O
anosmia	B
(	O
inability	O
to	O
smell	O
)	O
.	O

The	O
six	O
new	O
aniridia	B
cases	O
reported	O
here	O
have	O
mutations	O
predicted	O
to	O
generate	O
incomplete	O
PAX6	O
proteins	O
.	O

These	O
results	O
support	O
the	O
theory	O
that	O
human	O
aniridia	B
is	O
caused	O
by	O
haploinsufficiency	B
of	I
PAX6	I
.	O
.	O

The	O
carrier	O
frequency	O
of	O
the	O
BRCA1	O
185delAG	O
mutation	O
is	O
approximately	O
1	O
percent	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
.	O

Since	O
BRCA1	O
,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	B
breast	I
cancer	I
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	B
and	I
ovarian	I
cancer	I
.	O

In	O
high	O
-	O
risk	O
pedigrees	O
,	O
female	O
carriers	O
of	O
BRCA1	O
mutations	O
have	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
,	O
and	O
a	O
40	O
-	O
50	O
%	O
risk	O
of	O
ovarian	B
cancer	I
.	O

However	O
,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	B
or	I
ovarian	I
cancer	I
has	O
not	O
been	O
determined	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	B
as	O
in	O
individuals	O
from	O
the	O
high	O
-	O
risk	O
families	O
studied	O
so	O
far	O
.	O

Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	O
mutation	O
in	O
several	O
Ashkenazi	O
Jewish	O
breast	O
/	O
ovarian	O
families	O
,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
Ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	B
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin	O
.	O

We	O
observed	O
the	O
185delAG	O
mutation	O
in	O
0	O
.	O

9	O
%	O
of	O
Ashkenazim	O
(	O
95	O
%	O
confidence	O
limit	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
8	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples	O
.	O

Our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
Ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
.	O

Identification	O
and	O
localization	O
of	O
huntingtin	O
in	O
brain	O
and	O
human	O
lymphoblastoid	O
cell	O
lines	O
with	O
anti	O
-	O
fusion	O
protein	O
antibodies	O
.	O

The	O
Huntington	B
disease	I
(	O
HD	B
)	O
phenotype	O
is	O
associated	O
with	O
expansion	O
of	O
a	O
trinucleotide	O
repeat	O
in	O
the	O
IT15	O
gene	O
,	O
which	O
is	O
predicted	O
to	O
encode	O
a	O
348	O
-	O
kDa	O
protein	O
named	O
huntington	O
.	O

We	O
used	O
polyclonal	O
and	O
monoclonal	O
anti	O
-	O
fusion	O
protein	O
antibodies	O
to	O
identify	O
native	O
huntingtin	O
in	O
rat	O
,	O
monkey	O
,	O
and	O
human	O
.	O

Western	O
blots	O
revealed	O
a	O
protein	O
with	O
the	O
expected	O
molecular	O
weight	O
which	O
is	O
present	O
in	O
the	O
soluble	O
fraction	O
of	O
rat	O
and	O
monkey	O
brain	O
tissues	O
and	O
lymphoblastoid	O
cells	O
from	O
control	O
cases	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
from	O
juvenile	O
-	O
onset	O
heterozygote	O
HD	B
cases	O
,	O
both	O
normal	O
and	O
mutant	O
huntingtin	O
are	O
expressed	O
,	O
and	O
increasing	O
repeat	O
expansion	O
leads	O
to	O
lower	O
levels	O
of	O
the	O
mutant	O
protein	O
.	O

Immunocytochemistry	O
indicates	O
that	O
huntingtin	O
is	O
located	O
in	O
neurons	O
throughout	O
the	O
brain	O
,	O
with	O
the	O
highest	O
levels	O
evident	O
in	O
larger	O
neurons	O
.	O

In	O
the	O
human	O
striatum	O
,	O
huntingtin	O
is	O
enriched	O
in	O
a	O
patch	O
-	O
like	O
distribution	O
,	O
potentially	O
corresponding	O
to	O
the	O
first	O
areas	O
affected	O
in	O
HD	B
.	O

Subcellular	O
localization	O
of	O
huntingtin	O
is	O
consistent	O
with	O
a	O
cytosolic	O
protein	O
primarily	O
found	O
in	O
somatodendritic	O
regions	O
.	O

Huntingtin	O
appears	O
to	O
particularly	O
associate	O
with	O
microtubules	O
,	O
although	O
some	O
is	O
also	O
associated	O
with	O
synaptic	O
vesicles	O
.	O

On	O
the	O
basis	O
of	O
the	O
localization	O
of	O
huntingtin	O
in	O
association	O
with	O
microtubules	O
,	O
we	O
speculate	O
that	O
the	O
mutation	O
impairs	O
the	O
cytoskeletal	O
anchoring	O
or	O
transport	O
of	O
mitochondria	O
,	O
vesicles	O
,	O
or	O
other	O
organelles	O
or	O
molecules	O
.	O
.	O

Marked	O
phenotypic	O
heterogeneity	O
associated	O
with	O
expansion	O
of	O
a	O
CAG	O
repeat	O
sequence	O
at	O
the	O
spinocerebellar	B
ataxia	I
3	I
/	I
Machado	I
-	I
Joseph	I
disease	I
locus	O
.	O

The	O
spinocerebellar	B
ataxia	I
3	I
locus	O
(	O
SCA3	B
)	O
for	O
type	B
I	I
autosomal	I
dominant	I
cerebellar	I
ataxia	I
(	O
ADCA	B
type	I
I	I
)	O
,	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	B
disorders	I
,	O
has	O
been	O
mapped	O
to	O
chromosome	O
14q32	O
.	O

1	O
1	O
.	O

ADCA	B
type	I
I	I
patients	O
from	O
families	O
segregating	O
SCA3	B
share	O
clinical	O
features	O
in	O
common	O
with	O
those	O
with	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
,	O
the	O
gene	O
of	O
which	O
maps	O
to	O
the	O
same	O
region	O
.	O

We	O
show	O
here	O
that	O
the	O
disease	O
gene	O
segregating	O
in	O
each	O
of	O
three	O
French	O
ADCA	B
type	I
I	I
kindreds	O
and	O
in	O
a	O
French	O
family	O
with	O
neuropathological	O
findings	O
suggesting	O
the	O
ataxochoreic	O
form	O
of	O
dentatorubropallidoluysian	B
atrophy	I
carries	O
an	O
expanded	O
CAG	O
repeat	O
sequence	O
located	O
at	O
the	O
same	O
locus	O
as	O
that	O
for	O
MJD	B
.	O

Analysis	O
of	O
the	O
mutation	O
in	O
these	O
families	O
shows	O
a	O
strong	O
negative	O
correlation	O
between	O
size	O
of	O
the	O
expanded	O
CAG	O
repeat	O
and	O
age	O
at	O
onset	O
of	O
clinical	O
disease	O
.	O

Instability	O
of	O
the	O
expanded	O
triplet	O
repeat	O
was	O
not	O
found	O
to	O
be	O
affected	O
by	O
sex	O
of	O
the	O
parent	O
transmitting	O
the	O
mutation	O
.	O

Evidence	O
was	O
found	O
for	O
somatic	O
and	O
gonadal	O
mosaicism	O
for	O
alleles	O
carrying	O
expanded	O
trinucleotide	O
repeats	O
.	O

Overexpression	O
of	O
DM20	O
messenger	O
RNA	O
in	O
two	O
brothers	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

Pelizaeus	B
-	I
Merzbacher	I
disease	I
is	O
a	O
rare	B
,	I
sex	I
-	I
linked	I
recessive	I
,	I
dysmyelinating	I
disease	I
of	I
the	I
central	I
nervous	I
system	I
that	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
myelin	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
.	O

Only	O
25	O
%	O
of	O
patients	O
studied	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
have	O
exonic	O
mutations	O
in	O
this	O
gene	O
,	O
the	O
underlying	O
cause	O
of	O
the	O
disease	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O

The	O
PLP	O
gene	O
encodes	O
two	O
major	O
alternatively	O
spliced	O
transcripts	O
called	O
PLP	O
and	O
DM20	O
.	O

PLP	O
messenger	O
RNA	O
is	O
specifically	O
expressed	O
in	O
central	O
nervous	O
system	O
tissue	O
,	O
whereas	O
DM20	O
messenger	O
RNA	O
is	O
found	O
in	O
central	O
nervous	O
system	O
,	O
cardiac	O
,	O
and	O
other	O
tissues	O
.	O

We	O
studied	O
cultured	O
skin	O
fibroblasts	O
from	O
2	O
brothers	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
who	O
exhibited	O
no	O
detectable	O
exonic	O
mutation	O
of	O
the	O
PLP	O
gene	O
.	O

Examination	O
of	O
RNA	O
from	O
these	O
cells	O
showed	O
that	O
the	O
level	O
of	O
DM20	O
messenger	O
RNA	O
is	O
elevated	O
sixfold	O
relative	O
to	O
male	O
control	O
skin	O
fibroblasts	O
.	O

An	O
unrelated	O
female	O
carrier	O
,	O
also	O
with	O
no	O
detectable	O
exonic	O
mutation	O
,	O
showed	O
a	O
threefold	O
increase	O
in	O
DM20	O
messenger	O
RNA	O
in	O
cultured	O
skin	O
fibroblasts	O
.	O

Our	O
findings	O
suggest	O
that	O
in	O
some	O
patients	O
,	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
is	O
caused	O
by	O
overexpression	O
of	O
PLP	O
gene	O
transcripts	O
,	O
and	O
that	O
in	O
these	O
families	O
a	O
50	O
%	O
increase	O
of	O
DM20	O
messenger	O
RNA	O
in	O
females	O
,	O
relative	O
to	O
the	O
increase	O
in	O
affected	O
males	O
,	O
can	O
identify	O
a	O
female	O
carrier	O
.	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
and	O
X	B
-	I
linked	I
congenital	I
thrombocytopenia	I
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
is	O
an	O
X	B
-	I
linked	I
recessive	I
disorder	I
characterized	O
by	O
thrombocytopenia	B
,	O
small	O
platelets	O
,	O
eczema	B
,	O
recurrent	O
infections	O
,	O
and	O
immunodeficiency	B
.	O

Besides	O
the	O
classic	O
WAS	B
phenotype	O
,	O
there	O
is	O
a	O
group	O
of	O
patients	O
with	O
congenital	B
X	I
-	I
linked	I
thrombocytopenia	I
(	O
XLT	B
)	O
who	O
have	O
small	O
platelets	O
but	O
only	O
transient	O
eczema	B
,	O
if	O
any	O
,	O
and	O
minimal	O
immune	B
deficiency	I
.	O

Because	O
the	O
gene	O
responsible	O
for	O
WAS	B
has	O
been	O
sequenced	O
,	O
it	O
was	O
possible	O
to	O
correlate	O
the	O
WAS	B
phenotypes	O
with	O
WAS	B
gene	O
mutations	O
.	O

Using	O
a	O
fingerprinting	O
screening	O
technique	O
,	O
we	O
determined	O
the	O
approximate	O
location	O
of	O
the	O
mutation	O
in	O
13	O
unrelated	O
WAS	B
patients	O
with	O
mild	O
to	O
severe	O
clinical	O
symptoms	O
.	O

Direct	O
sequence	O
analysis	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
obtained	O
from	O
patient	O
-	O
derived	O
cell	O
lines	O
showed	O
12	O
unique	O
mutations	O
distributed	O
throughout	O
the	O
WAS	B
gene	O
,	O
including	O
insertions	O
,	O
deletions	O
,	O
and	O
point	O
mutations	O
resulting	O
in	O
amino	O
acid	O
substitutions	O
,	O
termination	O
,	O
exon	O
skipping	O
,	O
or	O
splicing	O
defects	O
.	O

Of	O
4	O
unrelated	O
patients	O
with	O
the	O
XLT	B
phenotype	O
,	O
3	O
had	O
missense	O
mutations	O
affecting	O
exon	O
2	O
and	O
1	O
had	O
a	O
splice	O
-	O
site	O
mutation	O
affecting	O
exon	O
9	O
.	O

Patients	O
with	O
classic	O
WAS	B
had	O
more	O
complex	O
mutations	O
,	O
resulting	O
in	O
termination	O
codons	O
,	O
frameshift	O
,	O
and	O
early	O
termination	O
.	O

These	O
findings	O
provide	O
direct	O
evidence	O
that	O
XLT	B
and	O
WAS	B
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene	O
and	O
suggest	O
that	O
severe	O
clinical	O
phenotypes	O
are	O
associated	O
with	O
complex	O
mutations	O
.	O
.	O

Myotonia	B
levior	I
is	O
a	O
chloride	B
channel	I
disorder	I
.	O

The	O
group	O
of	O
dominant	B
non	I
-	I
dystrophic	I
myotonias	I
,	O
comprising	O
disorders	O
characterized	O
by	O
clinically	O
similar	O
forms	O
of	O
myogenic	O
muscle	O
stiffness	O
,	O
is	O
genetically	O
inhomogeneous	O
.	O

Dominant	B
myotonia	I
congenita	I
(	O
Thomsens	B
disease	I
)	O
is	O
linked	O
to	O
CLCN1	O
,	O
the	O
gene	O
encoding	O
the	O
major	O
muscle	O
chloride	O
channel	O
,	O
localized	O
on	O
chromosome	O
7q35	O
.	O

In	O
contrast	O
,	O
dominant	B
myotonias	I
sensitive	O
to	O
potassium	O
are	O
caused	O
by	O
point	O
mutations	O
in	O
SCN4A	O
on	O
chromosome	O
17q	O
,	O
the	O
gene	O
for	O
the	O
alpha	O
subunit	O
of	O
the	O
adult	O
skeletal	O
muscle	O
sodium	O
channel	O
.	O

No	O
linkage	O
or	O
molecular	O
genetic	O
data	O
are	O
as	O
yet	O
available	O
on	O
myotonia	B
levior	I
characterized	O
by	O
milder	O
symptoms	O
and	O
later	O
onset	O
of	O
myotonia	B
than	O
in	O
Thomsens	B
disease	I
,	O
and	O
absence	O
of	O
muscle	B
hypertrophy	I
.	O

We	O
report	O
a	O
CLCN1	O
Gln	O
-	O
552	O
-	O
Arg	O
substitution	O
for	O
a	O
family	O
with	O
dominant	O
inheritance	O
previously	O
diagnosed	O
to	O
have	O
myotonia	B
levior	I
.	O

Thus	O
,	O
this	O
disorder	O
appears	O
as	O
a	O
variant	O
of	O
Thomsens	B
disease	I
due	O
to	O
mutations	O
leading	O
to	O
low	O
clinical	O
expressivity	O
.	O

In	O
addition	O
,	O
we	O
report	O
a	O
novel	O
Ile	O
-	O
290	O
-	O
Met	O
CLCN1	O
mutation	O
for	O
a	O
typical	O
Thomsen	O
pedigree	O
.	O

In	O
another	O
family	O
previously	O
diagnosed	O
as	O
having	O
Thomsens	B
disease	I
,	O
we	O
unexpectedly	O
found	O
a	O
CLCN1	O
14	O
bp	O
deletion	O
known	O
to	O
cause	O
recessive	B
myotonia	I
,	O
and	O
a	O
rare	O
Trp	O
-	O
118	O
-	O
Gly	O
polymorphism	O
.	O
.	O

Southern	O
analysis	O
reveals	O
a	O
large	O
deletion	O
at	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
locus	O
in	O
a	O
patient	O
with	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Whole	O
genomic	O
hprt	O
clones	O
were	O
used	O
in	O
Southern	O
analysis	O
to	O
screen	O
the	O
integrity	O
of	O
the	O
hprt	O
gene	O
in	O
a	O
family	O
that	O
includes	O
a	O
patient	O
with	O
HPRT	B
enzyme	I
deficiency	I
causal	O
to	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

A	O
5	O
kb	O
DNA	O
sequence	O
deletion	O
was	O
found	O
to	O
have	O
its	O
endpoints	O
in	O
the	O
first	O
and	O
third	O
introns	O
.	O

The	O
probes	O
identified	O
the	O
carrier	O
status	O
of	O
female	O
family	O
members	O
,	O
aided	O
by	O
an	O
RFLP	O
carried	O
by	O
the	O
mothers	O
normal	O
X	O
-	O
chromosome	O
.	O
.	O

Characterisation	O
of	O
molecular	O
defects	O
in	O
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
(	O
AIH1	O
)	O
.	O

Amelogenins	O
are	O
an	O
heterogenous	O
family	O
of	O
proteins	O
produced	O
by	O
ameloblasts	O
of	O
the	O
enamel	O
organ	O
during	O
tooth	O
development	O
.	O

Disturbances	O
of	O
enamel	O
formation	O
occur	O
in	O
amelogenesis	B
imperfecta	I
,	O
a	O
clinically	O
heterogenous	O
group	O
of	O
inherited	B
disorders	I
characterised	O
by	O
defective	O
enamel	O
biomineralisation	O
.	O

An	O
amelogenin	O
gene	O
,	O
AMGX	O
,	O
has	O
been	O
mapped	O
to	O
the	O
short	O
of	O
the	O
X	O
chromosome	O
(	O
Xp22	O
.	O
1	O
-	O
p22	O
.	O
3	O
)	O
and	O
has	O
been	O
implicated	O
in	O
the	O
molecular	O
pathology	O
of	O
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
(	O
AIH1	B
)	O
.	O

We	O
have	O
identified	O
three	O
families	O
exhibiting	O
AIH1	B
and	O
screened	O
the	O
AMGX	O
gene	O
for	O
mutations	O
using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
DNA	O
sequencing	O
.	O

Three	O
novel	O
mutations	O
were	O
identified	O
a	O
C	O
-	O
T	O
substitution	O
in	O
exon	O
5	O
,	O
and	O
a	O
G	O
-	O
T	O
substitution	O
and	O
single	O
cytosine	O
deletion	O
in	O
exon	O
6	O
,	O
confirming	O
the	O
existence	O
of	O
extensive	O
allelic	O
heterogeneity	O
in	O
this	O
condition	O
.	O

The	O
identification	O
of	O
family	O
-	O
specific	O
mutations	O
will	O
enable	O
early	O
identification	O
of	O
affected	O
individuals	O
and	O
correlation	O
of	O
clinical	O
phenotype	O
with	O
genotype	O
will	O
facilitate	O
an	O
objective	O
system	O
of	O
disease	O
classification	O
.	O

Frequency	O
of	O
exon	O
15	O
missense	O
mutation	O
(	O
442D	O
:	O
G	O
)	O
in	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
in	O
hyperalphalipoproteinemic	B
Japanese	O
subjects	O
.	O

Cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
transfers	O
cholesteryl	O
ester	O
from	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
to	O
apo	O
B	O
-	O
containing	O
lipoproteins	O
.	O

The	O
hyperalphalipoproteinemia	B
caused	O
by	O
CETP	B
deficiency	I
is	O
fairly	O
common	O
in	O
Japan	O
and	O
one	O
of	O
the	O
most	O
common	O
mutations	O
in	O
the	O
CETP	O
gene	O
is	O
the	O
splicing	O
defect	O
of	O
the	O
intron	O
14	O
,	O
the	O
allelic	O
frequency	O
of	O
which	O
has	O
been	O
shown	O
to	O
be	O
0	O
.	O

0049	O
in	O
the	O
Japanese	O
general	O
population	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
a	O
missense	O
mutation	O
in	O
exon	O
15	O
of	O
the	O
CETP	O
gene	O
(	O
442D	O
G	O
)	O
,	O
showing	O
a	O
dominant	O
effect	O
on	O
the	O
CETP	O
activity	O
and	O
HDL	O
-	O
cholesterol	O
level	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
determined	O
the	O
frequency	O
of	O
this	O
new	O
mutation	O
in	O
Japanese	O
hyperalphalipoproteinemic	B
(	O
HDL	O
-	O
cholesterol	O
>	O
or	O
=	O
100	O
mg	O
/	O
dl	O
)	O
subjects	O
.	O

A	O
rapid	O
and	O
easy	O
screening	O
method	O
for	O
this	O
new	O
mutation	O
was	O
developed	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
mediated	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Among	O
117	O
Japanese	O
hyperalphalipoproteinemic	B
subjects	O
(	O
HDL	O
-	O
cholesterol	O
;	O
116	O
.	O
7	O
+	O
/	O
-	O
16	O
.	O
5	O
mg	O
/	O
dl	O
,	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
)	O
without	O
the	O
intron	O
14	O
splice	O
defect	O
,	O
three	O
homozygotes	O
(	O
2	O
.	O
5	O
%	O
)	O
and	O
34	O
heterozygotes	O
(	O
29	O
.	O
1	O
%	O
)	O
were	O
found	O
to	O
have	O
the	O
442D	O
G	O
mutation	O
.	O

The	O
relative	O
allelic	O
frequency	O
of	O
this	O
mutation	O
was	O
calculated	O
to	O
be	O
0	O
.	O

17	O
.	O

One	O
of	O
the	O
homozygotes	O
for	O
the	O
442D	O
G	O
mutation	O
was	O
the	O
patient	O
previously	O
described	O
by	O
us	O
as	O
having	O
hyperalphalipoproteinemia	B
with	O
corneal	B
opacity	I
and	O
coronary	B
heart	I
disease	I
.	O

This	O
was	O
the	O
first	O
reported	O
subject	O
homozygous	O
for	O
the	O
CETP	B
deficiency	I
who	O
also	O
demonstrated	O
atherosclerotic	B
symptoms	I
.	O

In	O
homozygous	O
subjects	O
,	O
CETP	O
activity	O
ranged	O
from	O
37	O
%	O
to	O
62	O
%	O
of	O
the	O
normal	O
value	O
,	O
which	O
was	O
consistent	O
with	O
the	O
results	O
obtained	O
from	O
the	O
transient	O
expression	O
experiment	O
previously	O
reported	O
;	O
however	O
,	O
the	O
specific	O
activity	O
of	O
CETP	O
was	O
not	O
as	O
low	O
as	O
expected	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mucopolysaccharidosis	B
type	I
IVA	I
:	O
common	O
double	O
deletion	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfatase	O
gene	O
(	O
GALNS	O
)	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
in	I
N	I
-	I
acetylgalactosamine	I
-	I
6	I
-	I
sulfatase	I
(	O
GALNS	O
)	O
.	O

We	O
found	O
two	O
separate	O
deletions	O
of	O
nearly	O
8	O
.	O

0	O
and	O
6	O
.	O

0	O
kb	O
in	O
the	O
GALNS	O
gene	O
,	O
including	O
some	O
exons	O
.	O

There	O
are	O
Alu	O
repetitive	O
elements	O
near	O
the	O
breakpoints	O
of	O
the	O
8	O
.	O

0	O
-	O
kb	O
deletion	O
,	O
and	O
this	O
deletion	O
resulted	O
from	O
an	O
Alu	O
-	O
Alu	O
recombination	O
.	O

The	O
other	O
6	O
.	O

0	O
-	O
kb	O
deletion	O
involved	O
illegitimate	O
recombinational	O
events	O
between	O
incomplete	O
short	O
direct	O
repeats	O
of	O
8	O
bp	O
at	O
deletion	O
breakpoints	O
.	O

The	O
same	O
rearrangement	O
has	O
been	O
observed	O
in	O
a	O
heteroallelic	O
state	O
in	O
four	O
unrelated	O
patients	O
.	O

This	O
is	O
the	O
first	O
documentation	O
of	O
a	O
common	O
double	O
deletion	O
a	O
gene	O
that	O
is	O
not	O
a	O
member	O
of	O
a	O
gene	O
cluster	O
.	O

Detection	O
of	O
eight	O
BRCA1	O
mutations	O
in	O
10	O
breast	B
/	I
ovarian	I
cancer	I
families	O
,	O
including	O
1	O
family	O
with	O
male	B
breast	I
cancer	I
.	O

Genetic	O
epidemiological	O
evidence	O
suggests	O
that	O
mutations	O
in	O
BRCA1	O
may	O
be	O
responsible	O
for	O
approximately	O
one	O
half	O
of	O
early	O
onset	O
familial	B
breast	I
cancer	I
and	O
the	O
majority	O
of	O
familial	B
breast	I
/	I
ovarian	I
cancer	I
.	O

The	O
recent	O
cloning	O
of	O
BRCA1	O
allows	O
for	O
the	O
direct	O
detection	O
of	O
mutations	O
,	O
but	O
the	O
feasibility	O
of	O
presymptomatic	O
screening	O
for	O
cancer	B
susceptibility	O
is	O
unknown	O
.	O

We	O
analyzed	O
genomic	O
DNA	O
from	O
one	O
affected	O
individual	O
from	O
each	O
of	O
24	O
families	O
with	O
at	O
least	O
three	O
cases	O
of	O
ovarian	B
or	I
breast	I
cancer	I
,	O
using	O
SSCP	O
assays	O
.	O

Variant	O
SSCP	O
bands	O
were	O
subcloned	O
and	O
sequenced	O
.	O

Allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
was	O
used	O
to	O
verify	O
sequence	O
changes	O
and	O
to	O
screen	O
DNA	O
from	O
control	O
individuals	O
.	O

Six	O
frameshift	O
and	O
two	O
missense	O
mutations	O
were	O
detected	O
in	O
10	O
different	O
families	O
.	O

A	O
frameshift	O
mutation	O
was	O
detected	O
in	O
a	O
male	O
proband	O
affected	O
with	O
both	O
breast	B
and	I
prostate	I
cancer	I
.	O

A	O
40	O
-	O
bp	O
deletion	O
was	O
detected	O
in	O
a	O
patient	O
who	O
developed	O
intra	B
-	I
abdominal	I
carcinomatosis	I
1	O
year	O
after	O
prophylactic	O
oophorectomy	O
.	O

Mutations	O
were	O
detected	O
throughout	O
the	O
gene	O
,	O
and	O
only	O
one	O
was	O
detected	O
in	O
more	O
than	O
a	O
single	O
family	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
that	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
can	O
occur	O
as	O
a	O
consequence	O
of	O
a	O
wide	O
array	O
of	O
BRCA1	O
mutations	O
.	O

These	O
results	O
suggests	O
that	O
development	O
of	O
a	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
will	O
be	O
technically	O
challenging	O
.	O

The	O
finding	O
of	O
a	O
mutation	O
in	O
a	O
family	O
with	O
male	B
breast	I
cancer	I
,	O
not	O
previously	O
thought	O
to	O
be	O
related	O
to	O
BRCA1	O
,	O
also	O
illustrates	O
the	O
potential	O
difficulties	O
of	O
genetic	O
counseling	O
for	O
individuals	O
known	O
to	O
carry	O
mutations	O
.	O
.	O

Natural	O
selection	O
of	O
hemi	O
-	O
and	O
heterozygotes	O
for	O
G6PD	B
deficiency	I
in	O
Africa	O
by	O
resistance	O
to	O
severe	O
malaria	B
.	O

Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
,	O
the	O
most	O
common	O
enzymopathy	B
of	O
humans	O
,	O
affects	O
over	O
400	O
million	O
people	O
.	O

The	O
geographical	O
correlation	O
of	O
its	O
distribution	O
with	O
the	O
historical	O
endemicity	O
of	O
malaria	B
suggests	O
that	O
this	O
disorder	O
has	O
risen	O
in	O
frequency	O
through	O
natural	O
selection	O
by	O
malaria	B
.	O

However	O
,	O
attempts	O
to	O
confirm	O
that	O
G6PD	B
deficiency	I
is	O
protective	O
in	O
case	O
-	O
control	O
studies	O
of	O
malaria	B
have	O
yielded	O
conflicting	O
results	O
.	O

Hence	O
,	O
for	O
this	O
X	B
-	I
linked	I
disorder	I
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
are	O
protected	O
or	O
,	O
as	O
frequently	O
suggested	O
,	O
only	O
females	O
.	O

Furthermore	O
,	O
how	O
much	O
protection	O
may	O
be	O
afforded	O
is	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
,	O
in	O
two	O
large	O
case	O
-	O
control	O
studies	O
of	O
over	O
2	O
,	O
000	O
African	O
children	O
,	O
the	O
common	O
African	O
form	O
of	O
G6PD	B
deficiency	I
(	O
G6PD	B
A	I
-	I
)	O
is	O
associated	O
with	O
a	O
46	O
-	O
58	O
%	O
reduction	O
in	O
risk	O
of	O
severe	O
malaria	B
for	O
both	O
female	O
heterozygotes	O
and	O
male	O
hemizygotes	O
.	O

A	O
mathematical	O
model	O
incorporating	O
the	O
measured	O
selective	O
advantage	O
against	O
malaria	B
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage	O
,	O
associated	O
with	O
this	O
enzyme	B
deficiency	I
,	O
has	O
retarded	O
its	O
rise	O
in	O
frequency	O
in	O
malaria	B
-	O
endemic	O
regions	O
.	O

Although	O
G6PD	B
deficiency	I
is	O
now	O
regarded	O
as	O
a	O
generally	O
benign	O
disorder	O
,	O
in	O
earlier	O
environmental	O
conditions	O
it	O
could	O
have	O
been	O
significantly	O
disadvantageous	O
.	O
.	O

The	O
alveolar	B
rhabdomyosarcoma	I
PAX3	O
/	O
FKHR	O
fusion	O
protein	O
is	O
a	O
transcriptional	O
activator	O
.	O

Chimeric	O
transcription	O
factors	O
,	O
created	O
by	O
gene	O
fusions	O
as	O
the	O
result	O
of	O
chromosomal	O
translocations	O
,	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
pathologically	O
disparate	O
solid	B
tumors	I
.	O

The	O
PAX3	O
/	O
FKHR	O
fusion	O
gene	O
,	O
formed	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
encodes	O
a	O
hybrid	O
protein	O
that	O
contains	O
both	O
PAX3	O
DNA	O
binding	O
domains	O
,	O
the	O
paired	O
box	O
and	O
homeodomain	O
,	O
linked	O
to	O
the	O
bisected	O
DNA	O
binding	O
domain	O
of	O
FKHR	O
,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors	O
.	O

Here	O
we	O
report	O
that	O
PAX3	O
and	O
PAX3	O
/	O
FKHR	O
display	O
similar	O
,	O
but	O
not	O
identical	O
transactivation	O
activities	O
when	O
tested	O
with	O
model	O
Pax	O
recognition	O
sequences	O
.	O

No	O
functional	O
role	O
could	O
be	O
ascribed	O
solely	O
to	O
the	O
residual	O
FKHR	O
binding	O
domain	O
present	O
in	O
the	O
fusion	O
protein	O
,	O
but	O
FKHR	O
was	O
found	O
to	O
contribute	O
a	O
strong	O
carboxyl	O
terminal	O
activation	O
domain	O
replacing	O
the	O
one	O
located	O
in	O
the	O
unrearranged	O
PAX3	O
gene	O
.	O

We	O
show	O
that	O
the	O
native	O
PAX3	O
/	O
FKHR	O
protein	O
present	O
in	O
tumor	B
cells	O
with	O
this	O
translocation	O
has	O
transcriptional	O
characteristics	O
similar	O
to	O
the	O
in	O
vitro	O
expressed	O
protein	O
.	O

The	O
ability	O
of	O
the	O
PAX3	O
/	O
FKHR	O
hybrid	O
protein	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
specific	O
manner	O
and	O
to	O
transactivate	O
the	O
expression	O
of	O
artificial	O
reporter	O
genes	O
suggests	O
that	O
its	O
aberrant	O
expression	O
could	O
subvert	O
the	O
transcriptional	O
programs	O
that	O
normally	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
survival	O
of	O
primitive	O
myogenic	O
precursors	O
in	O
vivo	O
.	O
.	O

A	O
p16INK4a	O
-	O
insensitive	O
CDK4	O
mutant	O
targeted	O
by	O
cytolytic	O
T	O
lymphocytes	O
in	O
a	O
human	O
melanoma	B
.	O

A	O
mutated	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
(	O
CDK4	O
)	O
was	O
identified	O
as	O
a	O
tumor	B
-	O
specific	O
antigen	O
recognized	O
by	O
HLA	O
-	O
A2	O
.	O

1	O
-	O
restricted	O
autologous	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
in	O
a	O
human	O
melanoma	B
.	O

The	O
mutated	O
CDK4	O
allele	O
was	O
present	O
in	O
autologous	O
cultured	O
melanoma	B
cells	O
and	O
metastasis	O
tissue	O
,	O
but	O
not	O
in	O
the	O
patients	O
lymphocytes	O
.	O

The	O
mutation	O
,	O
an	O
arginine	O
-	O
to	O
-	O
cysteine	O
exchange	O
at	O
residue	O
24	O
,	O
was	O
part	O
of	O
the	O
CDK4	O
peptide	O
recognized	O
by	O
CTLs	O
and	O
prevented	O
binding	O
of	O
the	O
CDK4	O
inhibitor	O
p16INK4a	O
,	O
but	O
not	O
of	O
p21	O
or	O
of	O
p27KIP1	O
.	O

The	O
same	O
mutation	O
was	O
found	O
in	O
one	O
additional	O
melanoma	B
among	O
28	O
melanomas	B
analyzed	O
.	O

These	O
results	O
suggest	O
that	O
mutation	O
of	O
CDK4	O
can	O
create	O
a	O
tumor	B
-	O
specific	O
antigen	O
and	O
can	O
disrupt	O
the	O
cell	O
-	O
cycle	O
regulation	O
exerted	O
by	O
the	O
tumor	B
suppressor	O
p16INK4a	O
.	O
.	O

Rapid	O
detection	O
of	O
BRCA1	O
mutations	O
by	O
the	O
protein	O
truncation	O
test	O
.	O

More	O
than	O
75	O
%	O
of	O
the	O
reported	O
mutations	O
in	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
result	O
in	O
truncated	O
proteins	O
.	O

We	O
have	O
used	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
11	O
,	O
which	O
encodes	O
61	O
%	O
of	O
BRCA1	O
.	O

In	O
45	O
patients	O
from	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
families	O
we	O
found	O
six	O
novel	O
mutations	O
two	O
single	O
nucleotide	O
insertions	O
,	O
three	O
small	O
deletions	O
(	O
1	O
-	O
5	O
bp	O
)	O
and	O
a	O
nonsense	O
mutation	O
identified	O
two	O
unrelated	O
families	O
.	O

Furthermore	O
,	O
we	O
were	O
able	O
to	O
amplify	O
the	O
remaining	O
coding	O
region	O
by	O
RT	O
-	O
PCR	O
using	O
lymphocyte	O
RNA	O
.	O

Combined	O
with	O
PTT	O
,	O
we	O
detected	O
aberrantly	O
spliced	O
products	O
affecting	O
exons	O
5	O
and	O
6	O
in	O
one	O
of	O
two	O
BRCA1	O
-	O
linked	O
families	O
examined	O
.	O

The	O
protein	O
truncation	O
test	O
promises	O
to	O
become	O
a	O
valuable	O
technique	O
in	O
detecting	O
BRCA1	O
mutations	O
.	O
.	O

Cloning	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients	O
.	O

Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	O
and	O
736	O
bp	O
,	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	O
mitochondrial	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
VLCAD	O
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
,	O
including	O
a	O
40	O
-	O
amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615	O
-	O
amino	O
acid	O
mature	O
polypeptide	O
.	O

PCR	O
-	O
amplified	O
VLCAD	O
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD	B
-	I
deficient	I
patients	O
.	O

In	O
both	O
patients	O
,	O
a	O
105	O
-	O
bp	O
deletion	O
encompassing	O
bases	O
1078	O
-	O
1182	O
in	O
VLCAD	O
cDNA	O
was	O
identified	O
.	O

The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	O
pre	O
-	O
mRNA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	B
deficiency	I
.	O

Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	O
VLCAD	O
was	O
performed	O
in	O
the	O
patients	O
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B
of	I
the	I
normal	I
VLCAD	I
protein	I
causes	O
impaired	O
long	O
-	O
chain	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	O
fibroblasts	O
.	O

In	O
patient	O
fibroblasts	O
,	O
raising	O
VLCAD	O
activity	O
to	O
approximately	O
20	O
%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	O
acid	O
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	B
deficiency	I
.	O
.	O

Brain	B
disease	I
and	O
molecular	O
analysis	O
in	O
myotonic	B
dystrophy	I
.	O

Abnormal	O
amplification	O
of	O
a	O
CTG	O
repeat	O
on	O
chromosome	O
19	O
is	O
the	O
molecular	O
basis	O
of	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

Expansion	O
of	O
the	O
repeat	O
has	O
been	O
correlated	O
with	O
severity	O
of	O
several	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

We	O
performed	O
extensive	O
cognitive	O
testing	O
,	O
cerebral	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
a	O
molecular	O
analysis	O
in	O
28	O
cases	O
of	O
DM	B
to	O
determine	O
the	O
relationship	O
between	O
the	O
molecular	O
defect	O
and	O
brain	B
disease	I
.	O

Performance	O
in	O
two	O
or	O
more	O
cognitive	O
tests	O
was	O
pathological	O
in	O
10	O
cases	O
.	O

Fourteen	O
patients	O
had	O
subcortical	O
white	B
matter	I
lesions	I
on	O
MRI	O
,	O
14	O
had	O
cerebral	B
atrophy	I
.	O

Amplification	O
of	O
the	O
CTG	O
repeat	O
showed	O
a	O
strong	O
correlation	O
with	O
cognitive	O
test	O
deficits	O
when	O
exceeding	O
a	O
length	O
of	O
over	O
1000	O
trinucleotides	O
.	O

MRI	O
lesions	O
were	O
associated	O
with	O
impaired	O
psychometric	O
performance	O
,	O
but	O
MRI	O
and	O
molecular	O
findings	O
were	O
only	O
weakly	O
related	O
.	O

Disease	O
duration	O
influenced	O
the	O
appearance	O
and	O
amount	O
of	O
white	B
matter	I
lesions	I
on	O
MRI	O
.	O

Quantification	O
of	O
CTG	O
repeat	O
size	O
may	O
allow	O
an	O
early	O
estimate	O
on	O
the	O
probability	O
of	O
brain	O
involvement	O
in	O
DM	B
;	O
cognitive	B
dysfunction	I
is	O
associated	O
with	O
white	B
matter	I
lesions	I
and	O
cerebral	B
atrophy	I
later	O
on	O
in	O
the	O
course	O
.	O
.	O

Mutations	O
in	O
the	O
gene	O
for	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
in	O
patients	O
with	O
different	O
clinical	O
phenotypes	O
.	O

Recently	O
,	O
the	O
gene	O
for	O
the	O
most	O
common	O
peroxisomal	B
disorder	I
,	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
X	B
-	I
ALD	I
)	O
,	O
has	O
been	O
described	O
encoding	O
a	O
peroxisomal	O
membrane	O
transporter	O
protein	O
.	O

We	O
analyzed	O
the	O
entire	O
protein	O
-	O
coding	O
sequence	O
of	O
this	O
gene	O
by	O
reverse	O
-	O
transcription	O
PCR	O
,	O
SSCP	O
,	O
and	O
DNA	O
sequencing	O
in	O
five	O
patients	O
with	O
different	O
clinical	O
expression	O
of	O
X	B
-	I
ALD	I
and	O
in	O
their	O
female	O
relatives	O
;	O
these	O
clinical	O
expressions	O
were	O
cerebral	O
childhood	O
ALD	B
,	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
,	O
and	O
"	O
Addison	B
disease	I
only	I
"	O
(	O
ADO	B
)	O
phenotype	O
.	O

In	O
the	O
three	O
patients	O
exhibiting	O
the	O
classical	O
picture	O
of	O
severe	O
childhood	O
ALD	B
we	O
identified	O
in	O
the	O
5	O
portion	O
of	O
the	O
X	B
-	I
ALD	I
gene	O
a	O
38	O
-	O
bp	O
deletion	O
that	O
causes	O
a	O
frameshift	O
mutation	O
,	O
a	O
3	O
-	O
bp	O
deletion	O
leading	O
to	O
a	O
deletion	O
of	O
an	O
amino	O
acid	O
in	O
the	O
ATP	O
-	O
binding	O
domain	O
of	O
the	O
ALD	B
protein	O
,	O
and	O
a	O
missense	O
mutation	O
.	O

In	O
the	O
patient	O
with	O
the	O
clinical	O
phenotype	O
of	O
AMN	B
,	O
a	O
nonsense	O
mutation	O
in	O
codon	O
212	O
,	O
along	O
with	O
a	O
second	O
site	O
mutation	O
at	O
codon	O
178	O
,	O
was	O
observed	O
.	O

Analysis	O
of	O
the	O
patient	O
with	O
the	O
ADO	B
phenotype	O
revealed	O
a	O
further	O
missense	O
mutation	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
ALDP	O
/	O
PMP70	O
comparison	O
.	O

The	O
disruptive	O
nature	O
of	O
two	O
mutations	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
frameshift	O
and	O
the	O
nonsense	O
mutation	O
)	O
in	O
patients	O
with	O
biochemically	O
proved	O
childhood	O
ALD	B
and	O
AMN	B
further	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
alterations	O
in	O
this	O
gene	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
X	B
-	I
ALD	I
.	O

Since	O
the	O
current	O
biochemical	O
techniques	O
for	O
X	B
-	I
ALD	I
carrier	O
detection	O
in	O
affected	O
families	O
lack	O
sufficient	O
reliability	O
,	O
our	O
procedure	O
described	O
for	O
systematic	O
mutation	O
scanning	O
is	O
also	O
capable	O
of	O
improving	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O

Duchenne	B
muscular	I
dystrophy	I
and	O
myotonic	B
dystrophy	I
in	O
the	O
same	O
patient	O
.	O

We	O
report	O
on	O
the	O
first	O
patient	O
identified	O
with	O
myotonic	B
dystrophy	I
and	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

The	O
family	O
of	O
the	O
propositus	O
had	O
a	O
strong	O
history	O
of	O
myotonic	B
dystrophy	I
,	O
and	O
there	O
was	O
an	O
intrafamilial	O
pathological	O
expansion	O
of	O
the	O
responsible	O
CTG	O
repeat	O
between	O
the	O
mildly	O
affected	O
mother	O
(	O
160	O
repeats	O
;	O
normal	O
27	O
repeats	O
)	O
and	O
her	O
more	O
severely	O
affected	O
son	O
(	O
650	O
repeats	O
)	O
,	O
and	O
his	O
sister	O
(	O
650	O
repeats	O
)	O
.	O

The	O
propositus	O
was	O
an	O
isolated	O
case	O
of	O
Duchenne	B
muscular	I
dystrophy	I
with	O
marked	O
dystrophin	B
deficiency	I
in	O
muscle	O
biopsy	O
.	O

The	O
patient	O
was	O
still	O
ambulatory	O
post	O
age	O
16	O
.	O

Myotonic	B
dystrophy	I
could	O
interfere	O
to	O
some	O
extent	O
with	O
the	O
progression	O
of	O
Duchenne	B
dystrophy	I
.	O

However	O
,	O
other	O
interpretations	O
are	O
possible	O
.	O

Twelve	O
percent	O
of	O
dystrophin	O
revertant	O
fibers	O
as	O
observed	O
by	O
immunohistochemistry	O
could	O
be	O
sufficient	O
to	O
ameliorate	O
typical	O
DMD	B
clinical	O
severity	O
,	O
or	O
the	O
patient	O
may	O
present	O
a	O
somatic	O
mosaic	O
.	O

The	O
pathophysiological	O
interactions	O
of	O
these	O
two	O
unlinked	O
disorders	O
are	O
discussed	O
at	O
the	O
clinical	O
and	O
histopathological	O
levels	O
.	O
.	O

Age	O
at	O
diagnosis	O
as	O
an	O
indicator	O
of	O
eligibility	O
for	O
BRCA1	O
DNA	O
testing	O
in	O
familial	B
breast	I
cancer	I
.	O

We	O
searched	O
for	O
criteria	O
that	O
could	O
indicate	O
breast	B
cancer	I
families	O
with	O
a	O
high	O
prior	O
probability	O
of	O
being	O
caused	O
by	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
locus	O
BRCA1	O
on	O
chromosome	O
17	O
.	O

To	O
this	O
end	O
,	O
we	O
performed	O
a	O
linkage	O
study	O
with	O
59	O
consecutively	O
collected	O
Dutch	O
breast	B
cancer	I
families	O
,	O
including	O
16	O
with	O
at	O
least	O
one	O
case	O
of	O
ovarian	B
cancer	I
.	O

We	O
used	O
an	O
intake	O
cut	O
-	O
off	O
of	O
at	O
least	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
at	O
any	O
age	O
.	O

Significant	O
evidence	O
for	O
linkage	O
was	O
found	O
only	O
among	O
the	O
13	O
breast	B
cancer	I
families	O
with	O
a	O
mean	O
age	O
at	O
diagnosis	O
of	O
less	O
than	O
45	O
years	O
.	O

An	O
unexpectedly	O
low	O
proportion	O
of	O
the	O
breast	B
-	I
ovarian	I
cancer	I
families	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1	O
,	O
which	O
could	O
be	O
due	O
to	O
a	O
founder	O
effect	O
in	O
the	O
Dutch	O
population	O
.	O

Given	O
the	O
expected	O
logistical	O
problems	O
in	O
clinical	O
management	O
now	O
that	O
BRCA1	O
has	O
been	O
identified	O
,	O
we	O
propose	O
an	O
interim	O
period	O
in	O
which	O
only	O
families	O
with	O
a	O
strong	O
positive	O
family	O
history	O
for	O
early	O
onset	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
will	O
be	O
offered	O
BRCA1	O
mutation	O
testing	O
.	O
.	O

Linkage	O
analysis	O
of	O
26	O
Canadian	O
breast	B
and	I
breast	I
-	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
examined	O
26	O
Canadian	O
families	O
with	O
hereditary	B
breast	I
or	I
ovarian	I
cancer	I
for	O
linkage	O
to	O
markers	O
flanking	O
the	O
BRCA1	O
gene	O
on	O
chromosome	O
17q12	O
-	O
q21	O
.	O

Of	O
the	O
15	O
families	O
that	O
contain	O
cases	O
of	O
ovarian	B
cancer	I
,	O
94	O
%	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
overall	O
evidence	O
of	O
linkage	O
in	O
the	O
group	O
of	O
10	O
families	O
with	O
breast	B
cancer	I
without	O
ovarian	B
cancer	I
.	O

A	O
genetic	O
recombinant	O
in	O
a	O
breast	B
-	I
ovarian	I
cancer	I
family	O
indicates	O
a	O
placement	O
of	O
BRCA1	O
telomeric	O
to	O
D17S776	O
,	O
and	O
helps	O
to	O
define	O
the	O
region	O
of	O
assignment	O
of	O
the	O
cancer	B
susceptibility	O
gene	O
.	O

Other	O
cancers	B
of	O
interest	O
that	O
appeared	O
in	O
the	O
BRCA1	O
-	O
linked	O
families	O
included	O
primary	B
peritoneal	I
cancer	I
,	O
cancer	B
of	I
the	I
fallopian	I
tube	I
,	O
and	O
malignant	B
melanoma	I
.	O
.	O

Structural	O
analysis	O
of	O
the	O
5	O
'	O
region	O
of	O
mouse	O
and	O
human	O
Huntington	B
disease	I
genes	O
reveals	O
conservation	O
of	O
putative	O
promoter	O
region	O
and	O
di	O
-	O
and	O
trinucleotide	O
polymorphisms	O
.	O

We	O
have	O
previously	O
cloned	O
and	O
characterized	O
the	O
murine	O
homologue	O
of	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
and	O
shown	O
that	O
it	O
maps	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O

3	O
3	O
.	O

Here	O
we	O
present	O
a	O
detailed	O
comparison	O
of	O
the	O
sequence	O
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	O
of	O
the	O
5	O
genomic	O
region	O
of	O
the	O
murine	O
(	O
Hdh	O
)	O
and	O
human	O
HD	B
genes	O
encompassing	O
the	O
first	O
five	O
exons	O
.	O

We	O
show	O
that	O
in	O
this	O
region	O
these	O
two	O
genes	O
share	O
identical	O
exon	O
boundaries	O
,	O
but	O
have	O
different	O
-	O
size	O
introns	O
.	O

Two	O
dinucleotide	O
(	O
CT	O
)	O
and	O
one	O
trinucleotide	O
intronic	O
polymorphism	O
in	O
Hdh	O
and	O
an	O
intronic	O
CA	O
polymorphism	O
in	O
the	O
HD	B
gene	O
were	O
identified	O
.	O

Comparison	O
of	O
940	O
-	O
bp	O
sequence	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
reveals	O
a	O
highly	O
conserved	O
region	O
(	O
78	O
.	O
8	O
%	O
nucleotide	O
identity	O
)	O
between	O
Hdh	O
and	O
the	O
HD	B
gene	O
from	O
nucleotide	O
-	O
56	O
to	O
-	O
206	O
(	O
of	O
Hdh	O
)	O
.	O

Neither	O
Hdh	O
nor	O
the	O
HD	B
gene	O
have	O
typical	O
TATA	O
or	O
CCAAT	O
elements	O
,	O
but	O
both	O
show	O
one	O
putative	O
AP2	O
binding	O
site	O
and	O
numerous	O
potential	O
Sp1	O
binding	O
sites	O
.	O

The	O
high	O
sequence	O
identity	O
between	O
Hdh	O
and	O
the	O
HD	B
gene	O
for	O
approximately	O
200	O
bp	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
the	O
Huntington	B
disease	I
gene	O

The	O
protein	O
deficient	O
in	O
Lowe	B
syndrome	I
is	O
a	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
5	O
-	O
phosphatase	O
.	O

Lowe	B
syndrome	I
,	O
also	O
known	O
as	O
oculocerebrorenal	B
syndrome	I
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
X	O
chromosome	O
-	O
encoded	O
OCRL	O
gene	O
.	O

The	O
OCRL	O
protein	O
is	O
51	O
%	O
identical	O
to	O
inositol	O
polyphosphate	O
5	O
-	O
phosphatase	O
II	O
(	O
5	O
-	O
phosphatase	O
II	O
)	O
from	O
human	O
platelets	O
over	O
a	O
span	O
of	O
744	O
aa	O
,	O
suggesting	O
that	O
OCRL	O
may	O
be	O
a	O
similar	O
enzyme	O
.	O

We	O
engineered	O
a	O
construct	O
of	O
the	O
OCRL	O
cDNA	O
that	O
encodes	O
amino	O
acids	O
homologous	O
to	O
the	O
platelet	O
5	O
-	O
phosphatase	O
for	O
expression	O
in	O
baculovirus	O
-	O
infected	O
Sf9	O
insect	O
cells	O
.	O

This	O
cDNA	O
encodes	O
aa	O
264	O
-	O
968	O
of	O
the	O
OCRL	O
protein	O
.	O

The	O
recombinant	O
protein	O
was	O
found	O
to	O
catalyze	O
the	O
reactions	O
also	O
carried	O
out	O
by	O
platelet	O
5	O
-	O
phosphatase	O
II	O
.	O

Thus	O
OCRL	O
converts	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
to	O
inositol	O
1	O
,	O
4	O
-	O
bisphosphate	O
,	O
and	O
it	O
converts	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrakisphosphate	O
to	O
inositol	O
1	O
,	O
3	O
,	O
4	O
-	O
trisphosphate	O
.	O

Most	O
important	O
,	O
the	O
enzyme	O
converts	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
to	O
phosphatidylinositol	O
4	O
-	O
phosphate	O
.	O

The	O
relative	O
ability	O
of	O
OCRL	O
to	O
catalyze	O
the	O
three	O
reactions	O
is	O
different	O
from	O
that	O
of	O
5	O
-	O
phosphatase	O
II	O
and	O
from	O
that	O
of	O
another	O
5	O
-	O
phosphatase	O
isoenzyme	O
from	O
platelets	O
,	O
5	O
-	O
phosphatase	O
I	O
.	O

The	O
recombinant	O
OCRL	O
protein	O
hydrolyzes	O
the	O
phospholipid	O
substrate	O
10	O
-	O
to	O
30	O
-	O
fold	O
better	O
than	O
5	O
-	O
phosphatase	O
II	O
,	O
and	O
5	O
-	O
phosphatase	O
I	O
does	O
not	O
cleave	O
the	O
lipid	O
at	O
all	O
.	O

We	O
also	O
show	O
that	O
OCRL	O
functions	O
as	O
a	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
5	O
-	O
phosphatase	O
in	O
OCRL	O
-	O
expressing	O
Sf9	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
OCRL	O
is	O
mainly	O
a	O
lipid	O
phosphatase	O
that	O
may	O
control	O
cellular	O
levels	O
of	O
a	O
critical	O
metabolite	O
,	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
.	O

Deficiency	O
of	O
this	O
enzyme	O
apparently	O
causes	O
the	O
protean	O
manifestations	O
of	O
Lowe	B
syndrome	I
.	O
.	O

New	O
founder	O
haplotypes	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
in	O
southern	O
Africa	O
.	O

The	O
association	O
between	O
normal	O
alleles	O
at	O
the	O
CTG	O
repeat	O
and	O
two	O
nearby	O
polymorphisms	O
in	O
the	O
myotonin	O
protein	O
kinase	O
gene	O
,	O
the	O
Alu	O
insertion	O
/	O
deletion	O
polymorphism	O
and	O
the	O
myotonic	B
dystrophy	I
kinase	O
(	O
DMK	O
)	O
(	O
G	O
/	O
T	O
)	O
intron	O
9	O
/	O
HinfI	O
polymorphism	O
,	O
has	O
been	O
analyzed	O
in	O
South	O
African	O
Negroids	O
,	O
a	O
population	O
in	O
which	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
has	O
not	O
been	O
described	O
.	O

South	O
African	O
Negroids	O
have	O
a	O
CTG	O
allelic	O
distribution	O
that	O
is	O
significantly	O
different	O
from	O
that	O
in	O
Caucasoids	O
and	O
Japanese	O
the	O
CTG	O
repeat	O
lengths	O
of	O
>	O
or	O
=	O
19	O
are	O
very	O
rare	O
.	O

The	O
striking	O
linkage	O
disequilibrium	O
between	O
specific	O
alleles	O
at	O
the	O
Alu	O
polymorphism	O
(	O
Alu	O
(	O
ins	O
)	O
and	O
Alu	O
(	O
del	O
)	O
)	O
,	O
the	O
HinfI	O
polymorphism	O
(	O
HinfI	O
-	O
1	O
and	O
HinfI	O
-	O
2	O
)	O
,	O
and	O
the	O
CTG	O
repeat	O
polymorphism	O
seen	O
in	O
Caucasoid	O
(	O
Europeans	O
and	O
Canadians	O
)	O
populations	O
was	O
also	O
found	O
in	O
the	O
South	O
African	O
Negroid	O
population	O
.	O

Numerous	O
haplotypes	O
,	O
not	O
previously	O
described	O
in	O
Europeans	O
,	O
were	O
,	O
however	O
,	O
found	O
.	O

It	O
thus	O
seems	O
likely	O
that	O
only	O
a	O
small	O
number	O
of	O
these	O
"	O
African	O
"	O
chromosomes	O
were	O
present	O
in	O
the	O
progenitors	O
of	O
all	O
non	O
-	O
African	O
peoples	O
.	O

These	O
data	O
provide	O
support	O
for	O
the	O
"	O
out	O
of	O
Africa	O
"	O
model	O
for	O
the	O
origin	O
of	O
modern	O
humans	O
and	O
suggest	O
that	O
the	O
rare	O
ancestral	O
DM	B
mutation	O
event	O
may	O
have	O
occurred	O
after	O
the	O
migration	O
from	O
Africa	O
,	O
hence	O
the	O
absence	O
of	O
DM	B
in	O
sub	O
-	O
Saharan	O
Negroid	O
peoples	O
.	O
.	O

Discordant	O
clinical	O
outcome	O
in	O
myotonic	B
dystrophy	I
relatives	O
showing	O
(	O
CTG	O
)	O
n	O
>	O
700	O
repeats	O
.	O

A	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
family	O
is	O
described	O
in	O
which	O
discordant	O
DM	B
phenotypes	O
were	O
found	O
in	O
the	O
children	O
of	O
two	O
affected	O
sisters	O
with	O
similar	O
CTG	O
expansion	O
and	O
clinical	O
manifestations	O
.	O

In	O
this	O
family	O
,	O
congenital	O
as	O
well	O
as	O
early	O
severe	O
childhood	O
and	O
later	O
childhood	O
onset	O
DM	B
coexist	O
.	O

This	O
observation	O
strengthens	O
the	O
limited	O
ability	O
of	O
lymphocytes	O
CTG	O
repeat	O
number	O
analysis	O
in	O
predicting	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
DM	B
patients	O
.	O
.	O

Purification	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
and	O
characterization	O
of	O
its	O
deficiency	O
in	O
seven	O
patients	O
.	O

Mitochondrial	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
VLCAD	O
)	O
was	O
purified	O
from	O
human	O
liver	O
.	O

The	O
molecular	O
masses	O
of	O
the	O
native	O
enzyme	O
and	O
the	O
subunit	O
were	O
estimated	O
to	O
be	O
154	O
and	O
70	O
kD	O
,	O
respectively	O
.	O

The	O
enzyme	O
was	O
found	O
to	O
catalyze	O
the	O
major	O
part	O
of	O
mitochondrial	O
palmitoylcoenzyme	O
A	O
dehydrogenation	O
in	O
liver	O
,	O
heart	O
,	O
skeletal	O
muscle	O
,	O
and	O
skin	O
fibroblasts	O
(	O
89	O
-	O
97	O
,	O
86	O
-	O
99	O
,	O
96	O
-	O
99	O
,	O
and	O
78	O
-	O
87	O
%	O
,	O
respectively	O
)	O
.	O

Skin	O
fibroblasts	O
from	O
26	O
patients	O
suspected	O
of	O
having	O
a	O
disorder	O
of	O
mitochondrial	O
beta	O
-	O
oxidation	O
were	O
analyzed	O
for	O
VLCAD	O
protein	O
using	O
immunoblotting	O
,	O
and	O
7	O
of	O
them	O
contained	O
undetectable	O
or	O
trace	O
levels	O
of	O
the	O
enzyme	O
.	O

The	O
seven	O
deficient	O
fibroblast	O
lines	O
were	O
characterized	O
by	O
measuring	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenation	O
activities	O
,	O
overall	O
palmitic	O
acid	O
oxidation	O
,	O
and	O
VLCAD	O
protein	O
synthesis	O
using	O
pulse	O
-	O
chase	O
,	O
further	O
confirming	O
the	O
diagnosis	O
of	O
VLCAD	B
deficiency	I
.	O

These	O
results	O
suggested	O
the	O
heterogenous	O
nature	O
of	O
the	O
mutations	O
causing	O
the	O
deficiency	O
in	O
the	O
seven	O
patients	O
.	O

Clinically	O
,	O
all	O
patients	O
with	O
VLCAD	B
deficiency	I
exhibited	O
cardiac	B
disease	I
.	O

At	O
least	O
four	O
of	O
them	O
presented	O
with	O
hypertrophic	B
cardiomyopathy	I
.	O

This	O
frequency	O
(	O
>	O
57	O
%	O
)	O
was	O
much	O
higher	O
than	O
that	O
observed	O
in	O
patients	O
with	O
other	O
disorders	O
of	O
mitochondrial	O
long	O
-	O
chain	O
fatty	O
acid	O
oxidation	O
that	O
may	O
be	O
accompanied	O
by	O
cardiac	B
disease	I
in	O
infants	O
.	O
.	O

Hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
man	O
.	O

II	O
.	O

Biological	O
properties	O
of	O
C5	B
-	I
deficient	I
human	O
serum	O
.	O

The	O
first	O
known	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
was	O
documented	O
in	O
the	O
accompanying	O
report	O
.	O

This	O
study	O
examines	O
several	O
biological	O
properties	O
of	O
C5	B
-	I
deficient	I
(	O
C5D	B
)	O
human	O
serum	O
,	O
particularly	O
sera	O
obtained	O
from	O
two	O
C5D	B
homozygotes	O
.	O

The	O
proband	O
,	O
who	O
has	O
inactive	O
systemic	B
lupus	I
erythematosus	I
is	O
completely	O
lacking	O
C5	O
,	O
while	O
her	O
healthy	O
half	O
-	O
sister	O
has	O
1	O
-	O
2	O
%	O
of	O
normal	O
levels	O
.	O

Both	O
sera	O
were	O
severely	O
impaired	O
in	O
their	O
ability	O
to	O
generate	O
chemotactic	O
activity	O
for	O
normal	O
human	O
neutrophils	O
upon	O
incubation	O
with	O
aggregated	O
human	O
gamma	O
-	O
globulin	O
or	O
Escherichia	O
coli	O
endotoxin	O
.	O

This	O
function	O
was	O
fully	O
restored	O
in	O
the	O
siblings	O
serum	O
,	O
and	O
substantially	O
improved	O
in	O
the	O
probands	O
serum	O
,	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
to	O
normal	O
serum	O
concentrations	O
.	O

Sera	O
from	O
eight	O
family	O
members	O
who	O
were	O
apparently	O
heterozygous	O
for	O
C5	B
deficiency	I
gave	O
normal	O
chemotactic	O
scores	O
.	O

The	O
ability	O
of	O
C5D	B
serum	O
to	O
opsonize	O
Saccharomyces	O
cerevisiae	O
(	O
bakers	O
yeast	O
)	O
or	O
Candida	O
albicans	O
for	O
ingestion	O
by	O
normal	O
neutrophils	O
was	O
completely	O
normal	O
.	O

In	O
addition	O
,	O
C5D	B
serum	O
was	O
capable	O
of	O
promoting	O
normal	O
phagocytosis	O
and	O
intracellular	O
killing	O
of	O
Staphylococcus	O
aureus	O
.	O

The	O
probands	O
serum	O
was	O
incapable	O
of	O
mediating	O
lysis	O
of	O
erythrocytes	O
from	O
a	O
patient	O
with	O
paroxysmal	B
nocturnal	I
hemoglobinuria	I
in	O
both	O
the	O
sucrose	O
hemolysia	O
and	O
acid	O
hemolysis	O
tests	O
,	O
and	O
also	O
lacked	O
bactericidal	O
activity	O
against	O
sensitized	O
or	O
unsensitized	O
Salmonella	O
typhi	O
.	O

The	O
siblings	O
serum	O
,	O
containing	O
only	O
1	O
-	O
2	O
%	O
of	O
normal	O
C5	O
,	O
effectively	O
lysed	O
S	O
.	O
typhi	O
,	O
but	O
only	O
at	O
eightfold	O
lower	O
serum	O
dilutions	O
as	O
compared	O
to	O
normals	O
.	O

These	O
findings	O
underscore	O
the	O
critical	O
role	O
of	O
C5	O
in	O
the	O
generation	O
of	O
chemotactic	O
activity	O
and	O
in	O
cytolytic	O
reactions	O
,	O
as	O
opposed	O
to	O
a	O
nonobligatory	O
or	O
minimal	O
role	O
in	O
opsonization	O
,	O
at	O
least	O
for	O
the	O
organisms	O
under	O
study	O
.	O
.	O

Human	O
peroxisomal	O
targeting	O
signal	O
-	O
1	O
receptor	O
restores	O
peroxisomal	O
protein	O
import	O
in	O
cells	O
from	O
patients	O
with	O
fatal	O
peroxisomal	B
disorders	I
.	O

Two	O
peroxisomal	O
targeting	O
signals	O
,	O
PTS1	O
and	O
PTS2	O
,	O
are	O
involved	O
in	O
the	O
import	O
of	O
proteins	O
into	O
the	O
peroxisome	O
matrix	O
.	O

Human	O
patients	O
with	O
fatal	O
generalized	O
peroxisomal	B
deficiency	I
disorders	I
fall	O
into	O
at	O
least	O
nine	O
genetic	O
complementation	O
groups	O
.	O

Cells	O
from	O
many	O
of	O
these	O
patients	O
are	O
deficient	O
in	O
the	O
import	O
of	O
PTS1	O
-	O
containing	O
proteins	O
,	O
but	O
the	O
causes	O
of	O
the	O
protein	O
-	O
import	O
defect	O
in	O
these	O
patients	O
are	O
unknown	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	O
cDNA	O
homologue	O
(	O
PTS1R	O
)	O
of	O
the	O
Pichia	O
pastoris	O
PAS8	O
gene	O
,	O
the	O
PTS1	O
receptor	O
(	O
McCollum	O
,	O
D	O
.	O
,	O
E	O
.	O
Monosov	O
,	O
and	O
S	O
.	O
Subramani	O
.	O
1993	O
.	O
J	O
.	O
Cell	O
Biol	O
.	O
121	O
761	O
-	O
774	O
)	O
.	O

The	O
PTS1R	O
mRNA	O
is	O
expressed	O
in	O
all	O
human	O
tissues	O
examined	O
.	O

Antibodies	O
to	O
the	O
human	O
PTS1R	O
recognize	O
this	O
protein	O
in	O
human	O
,	O
monkey	O
,	O
rat	O
,	O
and	O
hamster	O
cells	O
.	O

The	O
protein	O
is	O
localized	O
mainly	O
in	O
the	O
cytosol	O
but	O
is	O
also	O
found	O
to	O
be	O
associated	O
with	O
peroxisomes	O
.	O

Part	O
of	O
the	O
peroxisomal	O
PTS1R	O
protein	O
is	O
tightly	O
bound	O
to	O
the	O
peroxisomal	O
membrane	O
.	O

Antibodies	O
to	O
PTS1R	O
inhibit	O
peroxisomal	O
protein	O
-	O
import	O
of	O
PTS1	O
-	O
containing	O
proteins	O
in	O
a	O
permeabilized	O
CHO	O
cell	O
system	O
.	O

In	O
vitro	O
-	O
translated	O
PTS1R	O
protein	O
specifically	O
binds	O
a	O
serine	O
-	O
lysine	O
-	O
leucine	O
-	O
peptide	O
.	O

A	O
PAS8	O
-	O
PTS1R	O
fusion	O
protein	O
complements	O
the	O
P	O
.	O
pastoris	O
pas8	O
mutant	O
.	O

The	O
PTS1R	O
cDNA	O
also	O
complements	O
the	O
PTS1	B
protein	I
-	I
import	I
defect	I
in	O
skin	O
fibroblasts	O
from	O
patients	O
-	O
-	O
belonging	O
to	O
complementation	O
group	O
two	O
-	O
-	O
diagnosed	O
as	O
having	O
neonatal	B
adrenoleukodystrophy	I
or	O
Zellweger	B
syndrome	I
.	O

The	O
PTS1R	O
gene	O
has	O
been	O
localized	O
to	O
a	O
chromosomal	O
location	O
where	O
no	O
other	O
peroxisomal	B
disorder	I
genes	O
are	O
known	O
to	O
map	O
.	O

Our	O
findings	O
represent	O
the	O
only	O
case	O
in	O
which	O
the	O
molecular	O
basis	O
of	O
the	O
protein	B
-	I
import	I
deficiency	I
in	O
human	O
peroxisomal	B
disorders	I
is	O
understood	O
.	O

Spectrum	O
of	O
germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
:	O
a	O
study	O
of	O
232	O
patients	O
with	O
hereditary	B
and	I
non	I
hereditary	I
retinoblastoma	I
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
confer	O
hereditary	O
predisposition	O
to	O
retinoblastoma	B
.	O

We	O
have	O
performed	O
a	O
mutation	O
survey	O
of	O
the	O
RB1	O
gene	O
in	O
232	O
patients	O
with	O
hereditary	B
or	I
non	I
hereditary	I
retinoblastoma	I
.	O

We	O
systematically	O
explored	O
all	O
27	O
exons	O
and	O
flanking	O
sequences	O
as	O
well	O
as	O
the	O
promotor	O
.	O

All	O
types	O
of	O
point	O
mutations	O
are	O
represented	O
and	O
are	O
found	O
unequally	O
distributed	O
along	O
the	O
RB1	O
gene	O
sequence	O
.	O

In	O
the	O
population	O
we	O
studied	O
,	O
exons	O
3	O
,	O
8	O
,	O
18	O
and	O
19	O
are	O
preferentially	O
altered	O
.	O

The	O
range	O
of	O
frequency	O
of	O
detection	O
of	O
germline	O
mutations	O
is	O
about	O
20	O
%	O
,	O
indicating	O
that	O
other	O
mechanisms	O
of	O
inactivation	O
of	O
RB1	O
should	O
be	O
involved	O
.	O

The	O
spectrum	O
of	O
mutations	O
presented	O
here	O
should	O
help	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
retinoblastoma	B
and	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
leading	O
to	O
tumorigenesis	O
.	O
.	O

Aniridia	B
-	O
associated	O
cytogenetic	O
rearrangements	O
suggest	O
that	O
a	O
position	O
effect	O
may	O
cause	O
the	O
mutant	O
phenotype	O
.	O

Current	O
evidence	O
suggests	O
that	O
aniridia	B
(	O
absence	B
of	I
iris	I
)	O
is	O
caused	O
by	O
loss	O
of	O
function	O
of	O
one	O
copy	O
of	O
the	O
PAX6	O
gene	O
,	O
which	O
maps	O
to	O
11p13	O
.	O

We	O
present	O
the	O
further	O
characterisation	O
of	O
two	O
aniridia	B
pedigrees	O
in	O
which	O
the	O
disease	O
segregates	O
with	O
chromosomal	O
rearrangements	O
which	O
involve	O
11p13	O
but	O
do	O
not	O
disrupt	O
the	O
PAX6	O
gene	O
.	O

We	O
have	O
isolated	O
three	O
human	O
YAC	O
clones	O
which	O
encompass	O
the	O
PAX6	O
locus	O
and	O
we	O
have	O
used	O
these	O
to	O
show	O
that	O
in	O
both	O
cases	O
the	O
chromosomal	O
breakpoint	O
is	O
at	O
least	O
85	O
kb	O
distal	O
of	O
the	O
3	O
end	O
of	O
PAX6	O
.	O

In	O
addition	O
,	O
the	O
open	O
reading	O
frame	O
of	O
PAX6	O
is	O
apparently	O
free	O
of	O
mutations	O
.	O

We	O
propose	O
that	O
the	O
PAX6	O
gene	O
on	O
the	O
rearranged	O
chromosome	O
11	O
is	O
in	O
an	O
inappropriate	O
chromatin	O
environment	O
for	O
normal	O
expression	O
and	O
therefore	O
that	O
a	O
position	O
effect	O
is	O
the	O
underlying	O
mechanism	O
of	O
disease	O
in	O
these	O
families	O
.	O
.	O

Somatic	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
sporadic	B
ovarian	I
tumours	I
.	O

The	O
BRCA1	O
gene	O
on	O
chromosome	O
17q21	O
is	O
responsible	O
for	O
an	O
autosomal	B
dominant	I
syndrome	I
of	O
increased	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
but	O
no	O
somatic	O
mutations	O
in	O
tumours	B
have	O
yet	O
been	O
described	O
.	O

To	O
study	O
the	O
potential	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
carcinogenesis	O
,	O
we	O
analysed	O
the	O
genomic	O
DNA	O
of	O
tumour	B
and	O
normal	O
fractions	O
of	O
47	O
ovarian	B
cancers	I
for	O
mutations	O
in	O
BRCA1	O
using	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O

We	O
now	O
describe	O
somatic	O
mutations	O
in	O
the	O
DNA	O
of	O
four	O
tumours	B
which	O
also	O
had	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
a	O
BRCA1	O
intragenic	O
marker	O
.	O

Our	O
data	O
support	O
a	O
tumour	B
suppressor	O
mechanism	O
for	O
BRCA1	O
;	O
somatic	O
mutations	O
and	O
LOH	O
may	O
result	O
in	O
inactivation	O
of	O
BRCA1	O
in	O
at	O
least	O
a	O
small	O
number	O
of	O
ovarian	B
cancers	I
.	O
.	O

Decreased	O
expression	O
of	O
BRCA1	O
accelerates	O
growth	O
and	O
is	O
often	O
present	O
during	O
sporadic	B
breast	I
cancer	I
progression	O
.	O

We	O
have	O
characterized	O
expression	O
of	O
the	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
in	O
cases	O
of	O
non	B
-	I
hereditary	I
(	I
sporadic	I
)	I
breast	I
cancer	I
and	O
analyzed	O
the	O
effect	O
of	O
antisense	O
inhibition	O
of	O
BRCA1	O
on	O
the	O
proliferative	O
rate	O
of	O
mammary	O
epithelial	O
cells	O
.	O

BRCA1	O
mRNA	O
levels	O
are	O
markedly	O
decreased	O
during	O
the	O
transition	O
from	O
carcinoma	B
in	I
situ	I
to	O
invasive	B
cancer	I
.	O

Experimental	O
inhibition	O
of	O
BRCA1	O
expression	O
with	O
antisense	O
oligonucleotides	O
produced	O
accelerated	O
growth	O
of	O
normal	O
and	O
malignant	O
mammary	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
non	O
-	O
mammary	O
epithelial	O
cells	O
.	O

These	O
studies	O
suggest	O
that	O
BRCA1	O
may	O
normally	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
mammary	O
epithelial	O
cell	O
growth	O
whose	O
function	O
is	O
compromised	O
in	O
breast	B
cancer	I
either	O
by	O
direct	O
mutation	O
or	O
alterations	O
in	O
gene	O
expression	O
.	O
.	O

Additional	O
case	O
of	O
female	O
monozygotic	O
twins	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	B
muscular	I
dystrophy	I
due	O
to	O
opposite	O
X	O
-	O
chromosome	O
inactivation	O
.	O

A	O
pair	O
of	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
,	O
heterozygous	O
carriers	O
for	O
a	O
deletion	O
in	O
the	O
DMD	B
gene	O
and	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	B
muscular	I
dystrophy	I
,	O
were	O
analyzed	O
by	O
molecular	O
studies	O
,	O
in	O
situ	O
hybridization	O
,	O
and	O
methylation	O
pattern	O
of	O
X	O
chromosomes	O
to	O
search	O
for	O
opposite	O
X	O
inactivation	O
as	O
an	O
explanation	O
of	O
their	O
clinical	O
discordance	O
.	O

Results	O
in	O
lymphocytes	O
and	O
skin	O
fibroblast	O
cell	O
lines	O
suggest	O
a	O
partial	O
mirror	O
inactivation	O
with	O
the	O
normal	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
unaffected	O
twin	O
,	O
and	O
the	O
maternal	O
deleted	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
affected	O
twin	O
.	O

A	O
review	O
shows	O
that	O
MZ	O
female	O
twins	O
discordant	O
for	O
X	B
-	I
linked	I
diseases	I
are	O
not	O
uncommon	O
.	O

Twinning	O
and	O
X	O
inactivation	O
may	O
be	O
interrelated	O
and	O
could	O
explain	O
the	O
female	O
twins	O
discordant	O
for	O
X	O
-	O
linked	O
traits	O
.	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
:	O
a	O
novel	O
mutation	O
of	O
the	O
ALD	B
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes	O
.	O

Fragments	O
of	O
the	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
cDNA	O
from	O
a	O
patient	O
with	O
adolescent	B
ALD	I
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned	O
.	O

Bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ALD	B
gene	O
disclosed	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
at	O
nucleotide	O
1451	O
in	O
exon	O
five	O
,	O
resulting	O
in	O
substitution	O
of	O
proline	O
484	O
by	O
arginine	O
.	O

Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	O
,	O
comprising	O
two	O
cerebral	B
ALD	I
,	O
one	O
adrenomyeloneuropathy	B
,	O
one	O
Addison	B
only	I
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	O
long	O
chain	O
fatty	O
acids	O
)	O
carried	O
this	O
mutation	O
,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
,	O
in	O
five	O
unrelated	O
ALD	B
patients	O
,	O
and	O
in	O
twenty	O
controls	O
.	O

We	O
propose	O
that	O
this	O
missense	O
mutation	O
generated	O
the	O
disease	O
per	O
se	O
as	O
well	O
as	O
the	O
metabolic	O
defect	O
;	O
the	O
different	O
phenotypes	O
,	O
however	O
,	O
must	O
have	O
originated	O
by	O
means	O
of	O
additional	O
pathogenetic	O
factors	O
.	O
.	O

Novel	O
mutation	O
at	O
the	O
initiation	O
codon	O
in	O
the	O
Norrie	B
disease	I
gene	O
in	O
two	O
Japanese	O
families	O
.	O

We	O
have	O
identified	O
a	O
new	O
mutation	O
of	O
Norrie	B
disease	I
(	O
ND	B
)	O
gene	O
in	O
two	O
Japanese	O
males	O
from	O
unrelated	O
families	O
;	O
they	O
showed	O
typical	O
ocular	O
features	O
of	O
ND	B
but	O
no	O
mental	B
retardation	I
or	O
hearing	B
impairment	I
.	O

A	O
mutation	O
was	O
found	O
in	O
both	O
patients	O
at	O
the	O
initiation	O
codon	O
of	O
exon	O
2	O
of	O
the	O
ND	B
gene	O
(	O
ATG	O
to	O
GTG	O
)	O
,	O
with	O
otherwise	O
normal	O
nucleotide	O
sequences	O
.	O

Their	O
mothers	O
had	O
the	O
normal	O
and	O
mutant	O
types	O
of	O
the	O
gene	O
,	O
which	O
was	O
expected	O
for	O
heterozygotes	O
of	O
the	O
disease	O
.	O

The	O
mutation	O
of	O
the	O
initiation	O
codon	O
would	O
cause	O
the	O
failure	O
of	O
ND	B
gene	O
expression	O
or	O
a	O
defect	O
in	O
translation	O
thereby	O
truncating	O
the	O
amino	O
terminus	O
of	O
ND	B
protein	O
.	O

In	O
view	O
of	O
the	O
rarity	O
and	O
marked	O
heterogeneity	O
of	O
mutations	O
in	O
the	O
ND	B
gene	O
,	O
the	O
present	O
apparently	O
unrelated	O
Japanese	O
families	O
who	O
have	O
lived	O
in	O
the	O
same	O
area	O
for	O
over	O
two	O
centuries	O
presumably	O
share	O
the	O
origin	O
of	O
the	O
mutation	O
.	O
.	O

Anticipation	O
resulting	O
in	O
elimination	O
of	O
the	O
myotonic	B
dystrophy	I
gene	O
:	O
a	O
follow	O
up	O
study	O
of	O
one	O
extended	O
family	O
.	O

We	O
have	O
re	O
-	O
examined	O
an	O
extended	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
family	O
,	O
previously	O
described	O
in	O
1955	O
,	O
in	O
order	O
to	O
study	O
the	O
long	O
term	O
effects	O
of	O
anticipation	O
in	O
DM	B
and	O
in	O
particular	O
the	O
implications	O
for	O
families	O
affected	O
by	O
this	O
disease	O
.	O

This	O
follow	O
up	O
study	O
provides	O
data	O
on	O
35	O
gene	O
carriers	O
and	O
46	O
asymptomatic	O
at	O
risk	O
family	O
members	O
in	O
five	O
generations	O
.	O

Clinical	O
anticipation	O
,	O
defined	O
as	O
the	O
cascade	O
of	O
mild	O
,	O
adult	O
,	O
childhood	O
,	O
or	O
congenital	B
disease	I
in	O
subsequent	O
generations	O
,	O
appeared	O
to	O
be	O
a	O
relentless	O
process	O
,	O
occurring	O
in	O
all	O
affected	O
branches	O
of	O
the	O
family	O
.	O

The	O
cascade	O
was	O
found	O
to	O
proceed	O
asynchronously	O
in	O
the	O
different	O
branches	O
,	O
mainly	O
because	O
of	O
an	O
unequal	O
number	O
of	O
generations	O
with	O
mild	O
disease	O
.	O

The	O
transition	O
from	O
the	O
mild	O
to	O
the	O
adult	O
type	O
was	O
associated	O
with	O
transmission	O
through	O
a	O
male	O
parent	O
.	O

Stable	O
transmission	O
of	O
the	O
asymptomatic	O
/	O
mild	O
phenotype	O
showed	O
a	O
female	O
transmission	O
bias	O
.	O

We	O
further	O
examined	O
the	O
extent	O
and	O
causes	O
of	O
gene	O
loss	O
in	O
this	O
pedigree	O
.	O

Gene	O
loss	O
in	O
the	O
patient	O
group	O
was	O
complete	O
,	O
owing	O
to	O
infertility	B
of	O
the	O
male	O
patients	O
with	O
adult	O
onset	O
disease	O
and	O
the	O
fact	O
that	O
mentally	B
retarded	I
patients	O
did	O
not	O
procreate	O
.	O

Out	O
of	O
the	O
46	O
at	O
risk	O
subjects	O
in	O
the	O
two	O
youngest	O
generations	O
,	O
only	O
one	O
was	O
found	O
to	O
have	O
a	O
full	O
mutation	O
.	O

This	O
is	O
the	O
only	O
subject	O
who	O
may	O
transmit	O
the	O
gene	O
to	O
the	O
sixth	O
generation	O
.	O

No	O
protomutation	O
carriers	O
were	O
found	O
in	O
the	O
fourth	O
and	O
fifth	O
generations	O
.	O

Therefore	O
it	O
is	O
highly	O
probable	O
that	O
the	O
DM	B
gene	O
will	O
be	O
eliminated	O
from	O
this	O
pedigree	O
within	O
one	O
generation	O
.	O

The	O
high	O
population	O
frequency	O
of	O
DM	B
can	O
at	O
present	O
not	O
be	O
explained	O
by	O
the	O
contribution	O
of	O
asymptomatic	O
cases	O
in	O
the	O
younger	O
generations	O
of	O
known	O
families	O
,	O
but	O
is	O
probably	O
caused	O
by	O
the	O
events	O
in	O
the	O
ancestral	O
generations	O
.	O
.	O

The	O
gene	O
for	O
spinal	B
cerebellar	I
ataxia	I
3	O
(	O
SCA3	O
)	O
is	O
located	O
in	O
a	O
region	O
of	O
approximately	O
3	O
cM	O
on	O
chromosome	O
14q24	O
.	O
3	O
-	O
q32	O
.	O
2	O
.	O

SCA3	O
,	O
the	O
gene	O
for	O
spinal	B
cerebellar	I
ataxia	I
3	O
,	O
was	O
recently	O
mapped	O
to	O
a	O
15	O
-	O
cM	O
interval	O
between	O
D14S67	O
and	O
D14S81	O
on	O
chromosome	O
14q	O
,	O
by	O
linkage	O
analysis	O
in	O
two	O
families	O
of	O
French	O
ancestry	O
.	O

The	O
SCA3	O
candidate	O
region	O
has	O
now	O
been	O
refined	O
by	O
linkage	O
analysis	O
with	O
four	O
new	O
microsatellite	O
markers	O
(	O
D14S256	O
,	O
D14S291	O
,	O
D14S280	O
,	O
and	O
AFM343vf1	O
)	O
in	O
the	O
same	O
two	O
families	O
,	O
in	O
which	O
19	O
additional	O
individuals	O
were	O
genotyped	O
,	O
and	O
in	O
a	O
third	O
French	O
family	O
.	O

Combined	O
two	O
-	O
point	O
linkage	O
analyses	O
show	O
that	O
the	O
new	O
markers	O
,	O
D14S280	O
and	O
AFM343vf1	O
,	O
are	O
tightly	O
linked	O
to	O
the	O
SCA3	O
locus	O
,	O
with	O
maximal	O
lod	O
scores	O
,	O
at	O
recombination	O
fraction	O
,	O
(	O
theta	O
)	O
=	O
.	O

00	O
,	O
of	O
7	O
.	O

05	O
and	O
13	O
.	O

70	O
,	O
respectively	O
.	O

Combined	O
multipoint	O
and	O
recombinant	O
haplotype	O
analyses	O
localize	O
the	O
SCA3	O
locus	O
to	O
a	O
3	O
-	O
cM	O
interval	O
flanked	O
by	O
D14S291	O
and	O
D14S81	O
.	O

The	O
same	O
allele	O
for	O
D14S280	O
segregates	O
with	O
the	O
disease	O
locus	O
in	O
the	O
three	O
kindreds	O
.	O

This	O
allele	O
is	O
frequent	O
in	O
the	O
French	O
population	O
,	O
however	O
,	O
and	O
linkage	O
disequilibrium	O
is	O
not	O
clearly	O
established	O
.	O

The	O
SCA3	O
locus	O
remains	O
within	O
the	O
29	O
-	O
cM	O
region	O
on	O
14q24	O
.	O

3	O
-	O
q32	O
.	O

2	O
containing	O
the	O
gene	O
for	O
the	O
Machado	B
-	I
Joseph	I
disease	I
,	O
which	O
is	O
clinically	O
related	O
to	O
the	O
phenotype	O
determined	O
by	O
SCA3	O
,	O
but	O
it	O
cannot	O
yet	O
be	O
concluded	O
that	O
both	O
diseases	O
result	O
from	O
alterations	O
of	O
the	O
same	O
gene	O

An	O
evaluation	O
of	O
genetic	O
heterogeneity	O
in	O
145	O
breast	B
-	I
ovarian	I
cancer	I
families	O
.	O

Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

The	O
breast	B
-	I
ovary	I
cancer	I
-	I
family	I
syndrome	I
is	O
a	O
dominant	O
predisposition	O
to	O
cancer	B
of	I
the	I
breast	I
and	I
ovaries	I
which	O
has	O
been	O
mapped	O
to	O
chromosome	O
region	O
17q12	O
-	O
q21	O
.	O

The	O
majority	O
,	O
but	O
not	O
all	O
,	O
of	O
breast	B
-	I
ovary	I
cancer	I
families	O
show	O
linkage	O
to	O
this	O
susceptibility	O
locus	O
,	O
designated	O
BRCA1	O
.	O

We	O
report	O
here	O
the	O
results	O
of	O
a	O
linkage	O
analysis	O
of	O
145	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
.	O

These	O
families	O
contain	O
either	O
a	O
total	O
of	O
three	O
or	O
more	O
cases	O
of	O
early	O
-	O
onset	O
(	O
before	O
age	O
60	O
years	O
)	O
breast	B
cancer	I
or	O
ovarian	B
cancer	I
.	O

All	O
families	O
contained	O
at	O
least	O
one	O
case	O
of	O
ovarian	B
cancer	I
.	O

Overall	O
,	O
an	O
estimated	O
76	O
%	O
of	O
the	O
145	O
families	O
are	O
linked	O
to	O
the	O
BRCA1	O
locus	O
.	O

None	O
of	O
the	O
13	O
families	O
with	O
cases	O
of	O
male	B
breast	I
cancer	I
appear	O
to	O
be	O
linked	O
,	O
but	O
it	O
is	O
estimated	O
that	O
92	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
76	O
%	O
-	O
100	O
%	O
)	O
of	O
families	O
with	O
no	O
male	B
breast	I
cancer	I
and	O
with	O
two	O
or	O
more	O
ovarian	B
cancers	I
are	O
linked	O
to	O
BRCA1	O
.	O

These	O
data	O
suggest	O
that	O
the	O
breast	B
-	I
ovarian	I
cancer	I
-	I
family	I
syndrome	I
is	O
genetically	O
heterogeneous	O
.	O

However	O
,	O
the	O
large	O
majority	O
of	O
families	O
with	O
early	O
-	O
onset	O
breast	B
cancer	I
and	O
with	O
two	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
are	O
likely	O
to	O
be	O
due	O
to	O
BRCA1	O
mutations	O
.	O
.	O

Molecular	O
basis	O
of	O
essential	B
fructosuria	I
:	O
molecular	O
cloning	O
and	O
mutational	O
analysis	O
of	O
human	O
ketohexokinase	O
(	O
fructokinase	O
)	O
.	O

Essential	B
fructosuria	I
is	O
one	O
of	O
the	O
oldest	O
known	O
inborn	B
errors	I
of	I
metabolism	I
.	O

It	O
is	O
a	O
benign	O
condition	O
which	O
is	O
believed	O
to	O
result	O
from	O
deficiency	B
of	I
hepatic	I
fructokinase	I
(	O
ketohexokinase	O
,	O
KHK	O
,	O
E	O
.	O
C	O
.	O
2	O
.	O
7	O
.	O
1	O
.	O
3	O
)	O
.	O

This	O
enzyme	O
catalyses	O
the	O
first	O
step	O
of	O
metabolism	O
of	O
dietary	O
fructose	O
,	O
conversion	O
of	O
fructose	O
to	O
fructose	O
-	O
1	O
-	O
phosphate	O
.	O

Despite	O
the	O
early	O
recognition	O
of	O
this	O
disorder	O
,	O
the	O
primary	O
structure	O
of	O
human	O
KHK	O
and	O
the	O
molecular	O
basis	O
of	O
essential	B
fructosuria	I
have	O
not	O
been	O
previously	O
defined	O
.	O

In	O
this	O
report	O
,	O
the	O
isolation	O
and	O
sequencing	O
of	O
full	O
-	O
length	O
cDNA	O
clones	O
encoding	O
human	O
ketohexokinase	O
are	O
described	O
.	O

Alternative	O
mRNA	O
species	O
and	O
alternative	O
KHK	O
isozymes	O
are	O
produced	O
by	O
alternative	O
polyadenylation	O
and	O
splicing	O
of	O
the	O
KHK	O
gene	O
.	O

The	O
KHK	O
proteins	O
show	O
a	O
high	O
level	O
of	O
sequence	O
conservation	O
relative	O
to	O
rat	O
KHK	O
.	O

Direct	O
evidence	O
that	O
mutation	O
of	O
the	O
KHK	O
structural	O
gene	O
is	O
the	O
cause	O
of	O
essential	B
fructosuria	I
was	O
also	O
obtained	O
.	O

In	O
a	O
well	O
-	O
characterized	O
family	O
,	O
in	O
which	O
three	O
of	O
eight	O
siblings	O
have	O
fructosuria	B
,	O
all	O
affected	O
individuals	O
are	O
compound	O
heterozygotes	O
for	O
two	O
mutations	O
Gly40Arg	O
and	O
Ala43Thr	O
.	O

Both	O
mutations	O
result	O
from	O
G	O
-	O
-	O
>	O
A	O
transitions	O
,	O
and	O
each	O
alters	O
the	O
same	O
conserved	O
region	O
of	O
the	O
KHK	O
protein	O
.	O

Neither	O
mutation	O
was	O
seen	O
in	O
a	O
sample	O
of	O
52	O
unrelated	O
control	O
individuals	O
.	O

An	O
additional	O
conservative	O
amino	O
acid	O
change	O
(	O
Val49IIe	O
)	O
was	O
present	O
on	O
the	O
KHK	O
allele	O
bearing	O
Ala43Thr	O

Homozygous	O
presence	O
of	O
the	O
crossover	O
(	O
fusion	O
gene	O
)	O
mutation	O
identified	O
in	O
a	O
type	B
II	I
Gaucher	I
disease	I
fetus	O
:	O
is	O
this	O
analogous	O
to	O
the	O
Gaucher	O
knock	O
-	O
out	O
mouse	O
model	O
?	O

Gaucher	B
disease	I
(	O
GD	B
)	O
is	O
an	O
inherited	O
deficiency	B
of	I
beta	I
-	I
glucocerebrosidase	I
(	O
EC	O
3	O
.	O
1	O
.	O
2	O
.	O
45	O
,	O
gene	O
symbol	O
GBA	O
)	O
.	O

In	O
type	B
I	I
GD	I
,	O
the	O
CNS	O
is	O
not	O
involved	O
(	O
nonneuronopathic	O
)	O
,	O
whereas	O
in	O
type	B
II	I
GD	I
(	O
acute	O
neuronopathic	O
)	O
CNS	O
involvement	O
is	O
early	O
and	O
rapidly	O
progressive	O
,	O
while	O
in	O
type	B
III	I
GD	I
(	O
subacute	O
neuronopathic	O
)	O
CNS	O
involvement	O
occurs	O
later	O
and	O
is	O
slowly	O
progressive	O
.	O

The	O
T6433C	O
(	O
L444P	O
)	O
substitution	O
is	O
prevalent	O
in	O
type	B
GD	I
II	I
.	O

It	O
may	O
occur	O
alone	O
as	O
a	O
single	O
base	O
-	O
pair	O
mutation	O
but	O
often	O
is	O
found	O
as	O
part	O
of	O
a	O
complex	O
allele	O
containing	O
additional	O
GBA	O
nucleotide	O
substitutions	O
,	O
G6468C	O
(	O
A456P	O
)	O
and	O
G6482C	O
(	O
V460V	O
)	O
,	O
without	O
(	O
recNciI	O
)	O
or	O
with	O
(	O
recTL	O
)	O
G5957C	O
(	O
D409H	O
)	O
.	O

This	O
complex	O
allele	O
is	O
presumed	O
to	O
have	O
formed	O
by	O
recombination	O
(	O
crossover	O
,	O
fusion	O
)	O
of	O
the	O
structural	O
gene	O
with	O
the	O
pseudogene	O
,	O
which	O
contains	O
the	O
mutated	O
sequences	O
.	O

Two	O
complex	O
alleles	O
have	O
never	O
been	O
demonstrated	O
to	O
coexist	O
in	O
any	O
individual	O
.	O

We	O
devised	O
a	O
selective	O
PCR	O
method	O
for	O
the	O
specific	O
amplification	O
of	O
the	O
normal	O
and	O
/	O
or	O
fusion	O
gene	O
.	O

Using	O
this	O
procedure	O
we	O
demonstrated	O
the	O
fusion	O
gene	O
in	O
homozygous	O
form	O
for	O
the	O
first	O
time	O
,	O
in	O
a	O
Macedonian	O
/	O
Ashkenazi	O
Jewish	O
GD	B
type	I
II	I
fetus	O
.	O

Both	O
parents	O
were	O
carriers	O
of	O
the	O
recombination	O
.	O

This	O
was	O
confirmed	O
by	O
direct	O
sequence	O
analysis	O
.	O

A	O
previous	O
conceptus	O
in	O
this	O
family	O
was	O
stillborn	B
at	O
36	O
weeks	O
,	O
with	O
features	O
of	O
severe	O
type	B
II	I
GD	I
.	O

Neonates	O
showing	O
a	O
severe	O
clinical	O
phenotype	O
,	O
analogous	O
to	O
the	O
early	O
neonatal	O
lethal	O
disease	O
occurring	O
in	O
mice	O
homozygous	O
for	O
a	O
null	O
allele	O
produced	O
by	O
targeted	O
disruption	O
of	O
GBA	O
,	O
have	O
been	O
described	O
elsewhere	O
,	O
but	O
the	O
specific	O
mutations	O
in	O
these	O
cases	O
have	O
not	O
yet	O
been	O
characterized	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Late	O
infantile	O
metachromatic	B
leukodystrophy	I
in	O
Israel	O
.	O

Metachromatic	B
Leukodystrophy	I
(	O
MLD	B
)	O
is	O
a	O
neurodegenerative	B
disease	I
in	O
which	O
the	O
lysosomal	O
enzyme	O
,	O
Aryl	O
sulfatase	O
A	O
(	O
ARSA	O
)	O
is	O
deficient	O
.	O

The	O
disease	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
its	O
frequency	O
is	O
estimated	O
to	O
be	O
1	O
/	O
40	O
,	O
000	O
live	O
births	O
.	O

The	O
gene	O
of	O
ARSA	O
has	O
been	O
cloned	O
and	O
up	O
to	O
now	O
eight	O
mutations	O
causing	O
MLD	B
have	O
been	O
reported	O
.	O

Another	O
mutation	O
,	O
PD	O
,	O
leads	O
to	O
the	O
deficiency	O
of	O
the	O
enzyme	O
in	O
vitro	O
(	O
pseudodeficiency	O
)	O
without	O
any	O
known	O
clinical	O
effect	O
.	O

The	O
PD	O
mutation	O
is	O
frequent	O
in	O
all	O
populations	O
.	O

In	O
Israel	O
,	O
late	O
infantile	O
MLD	B
was	O
found	O
to	O
be	O
very	O
frequent	O
in	O
a	O
small	O
Jewish	O
isolate	O
,	O
the	O
Habbanite	O
Jews	O
(	O
1	O
/	O
75	O
live	O
births	O
)	O
.	O

The	O
molecular	O
analysis	O
demonstrated	O
that	O
in	O
the	O
Habbanite	O
population	O
,	O
the	O
mutation	O
occurred	O
on	O
an	O
allele	O
with	O
the	O
PD	O
mutation	O
.	O

The	O
loss	O
of	O
ARSA	O
activity	O
is	O
due	O
to	O
a	O
point	O
mutation	O
C	O
>	O
T	O
leading	O
to	O
a	O
change	O
of	O
proline	O
to	O
leucine	O
.	O

MLD	B
is	O
also	O
frequent	O
among	O
Moslem	O
Arabs	O
in	O
Jerusalem	O
.	O

The	O
mutation	O
is	O
a	O
transition	O
G	O
>	O
A	O
destroying	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
2	O
.	O

This	O
mutation	O
has	O
been	O
reported	O
in	O
patients	O
with	O
the	O
late	O
infantile	O
MLD	B
from	O
different	O
ethnic	O
groups	O
.	O

The	O
Christian	O
Arabs	O
in	O
Israel	O
also	O
have	O
a	O
high	O
incidence	O
of	O
the	O
disease	O
(	O
1	O
/	O
10	O
,	O
000	O
live	O
births	O
)	O
;	O
the	O
mutation	O
in	O
this	O
population	O
is	O
still	O
unknown	O
.	O

Knowledge	O
of	O
the	O
different	O
mutations	O
causing	O
MLD	B
in	O
these	O
defined	O
populations	O
will	O
allow	O
a	O
carrier	O
screening	O
program	O
to	O
be	O
carried	O
out	O
and	O
prevent	O
the	O
birth	O
of	O
additional	O
affected	O
children	O
.	O
.	O

A	O
single	O
amino	O
acid	O
substitution	O
(	O
G103D	O
)	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produces	O
Kniest	B
dysplasia	I
.	O

Kniest	B
dysplasia	I
is	O
a	O
moderately	O
severe	O
chondrodysplasia	B
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
II	O
collagen	O
,	O
COL2A1	O
.	O

Characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	B
trunk	I
and	I
extremities	I
,	O
mid	B
-	I
face	I
hypoplasia	I
,	O
cleft	B
palate	I
,	O
myopia	B
,	O
retinal	B
detachment	I
,	O
and	O
hearing	B
loss	I
.	O

Recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
Kniest	B
dysplasia	I
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
Kniest	B
dysplasia	I
phenotype	O
.	O

We	O
used	O
SSCP	O
to	O
analyze	O
an	O
amplified	O
genomic	O
DNA	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
Kniest	B
dysplasia	I
.	O

An	O
abnormality	O
was	O
identified	O
in	O
one	O
patient	O
.	O

DNA	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
patient	O
was	O
heterozygous	O
for	O
a	O
G	O
to	O
A	O
transition	O
that	O
implied	O
substitution	O
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	O
by	O
aspartate	O
.	O

The	O
mutation	O
was	O
not	O
observed	O
in	O
DNA	O
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband	O
.	O

Protein	O
microsequencing	O
demonstrated	O
expression	O
of	O
the	O
abnormal	O
allele	O
in	O
cartilage	O
.	O

These	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
Kniest	B
dysplasia	I
and	O
further	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
domain	O
,	O
which	O
includes	O
the	O
region	O
encoded	O
by	O
exon	O
12	O
,	O
in	O
the	O
type	O
II	O
collagen	O
protein	O
leads	O
to	O
this	O
disorder	O
.	O
.	O

CAG	O
expansions	O
in	O
a	O
novel	O
gene	O
for	O
Machado	B
-	I
Joseph	I
disease	I
at	O
chromosome	O
14q32	O
.	O
1	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
containing	O
CAG	O
repeats	O
and	O
mapped	O
it	O
to	O
chromosome	O
14q32	O
.	O

1	O
,	O
the	O
genetic	O
locus	O
for	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
.	O

In	O
normal	O
individuals	O
the	O
gene	O
contains	O
between	O
13	O
and	O
36	O
CAG	O
repeats	O
,	O
whereas	O
most	O
of	O
the	O
clinically	O
diagnosed	O
patients	O
and	O
all	O
of	O
the	O
affected	O
members	O
of	O
a	O
family	O
with	O
the	O
clinical	O
and	O
pathological	O
diagnosis	O
of	O
MJD	B
show	O
expansion	O
of	O
the	O
repeat	O
-	O
number	O
(	O
from	O
68	O
-	O
79	O
)	O
.	O

Southern	O
blot	O
analyses	O
and	O
genomic	O
cloning	O
demonstrates	O
the	O
existence	O
of	O
related	O
genes	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
similar	O
abnormalities	O
in	O
related	O
genes	O
may	O
give	O
rise	O
to	O
diseases	O
similar	O
to	O
MJD	B
.	O

Mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
families	O
with	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
.	O

We	O
analysed	O
50	O
probands	O
with	O
a	O
family	O
history	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
for	O
germline	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
BRCA1	O
candidate	O
gene	O
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
on	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O

A	O
total	O
of	O
eight	O
putative	O
disease	O
-	O
causing	O
alterations	O
were	O
identified	O
four	O
of	O
these	O
are	O
frameshifts	O
and	O
two	O
are	O
nonsense	O
mutations	O
.	O

In	O
addition	O
,	O
we	O
found	O
two	O
missense	O
mutations	O
,	O
one	O
of	O
which	O
changes	O
the	O
final	O
cysteine	O
of	O
the	O
BRCA1	O
zinc	O
finger	O
motif	O
to	O
glycine	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
tumour	B
suppressor	O
model	O
,	O
and	O
support	O
the	O
notion	O
that	O
this	O
candidate	O
gene	O
is	O
in	O
fact	O
BRCA1	O
.	O

The	O
heterogeneity	O
of	O
mutations	O
,	O
coupled	O
with	O
the	O
large	O
size	O
of	O
the	O
gene	O
,	O
indicates	O
that	O
clinical	O
application	O
of	O
BRCA1	O
mutation	O
testing	O
will	O
be	O
technically	O
challenging	O
.	O
.	O

Confirmation	O
of	O
BRCA1	O
by	O
analysis	O
of	O
germline	O
mutations	O
linked	O
to	O
breast	B
and	I
ovarian	I
cancer	I
in	O
ten	O
families	O
.	O

We	O
provide	O
genetic	O
evidence	O
supporting	O
the	O
identity	O
of	O
the	O
candidate	O
gene	O
for	O
BRCA1	O
through	O
the	O
characterization	O
of	O
germline	O
mutations	O
in	O
63	O
breast	B
cancer	I
patients	O
and	O
10	O
ovarian	B
cancer	I
patients	O
in	O
ten	O
families	O
with	O
cancer	B
linked	O
to	O
chromosome	O
17q21	O
.	O

Nine	O
different	O
mutations	O
were	O
detected	O
by	O
screening	O
BRCA1	O
DNA	O
and	O
RNA	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Seven	O
mutations	O
lead	O
to	O
protein	O
truncations	O
at	O
sites	O
throughout	O
the	O
gene	O
.	O

One	O
missense	O
mutation	O
(	O
which	O
occurred	O
independently	O
in	O
two	O
families	O
)	O
leads	O
to	O
loss	O
of	O
a	O
cysteine	O
in	O
the	O
zinc	O
binding	O
domain	O
.	O

An	O
intronic	O
single	O
basepair	O
substitution	O
destroys	O
an	O
acceptor	O
site	O
and	O
activates	O
a	O
cryptic	O
splice	O
site	O
,	O
leading	O
to	O
a	O
59	O
basepair	O
insertion	O
and	O
chain	O
termination	O
.	O

The	O
four	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
had	O
chain	O
termination	O
mutations	O
in	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
.	O
.	O

High	O
resolution	O
genetic	O
analysis	O
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	O
for	O
the	O
origin	O
of	O
the	O
myotonic	B
dystrophy	I
mutation	O
.	O

The	O
mutation	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
has	O
been	O
identified	O
as	O
an	O
amplification	O
of	O
an	O
unstable	O
trinucleotide	O
(	O
CTG	O
)	O
n	O
repeat	O
in	O
over	O
99	O
%	O
of	O
the	O
global	O
DM	B
population	O
.	O

It	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
an	O
Alu	O
element	O
polymorphism	O
within	O
the	O
DM	B
kinase	O
gene	O
,	O
suggesting	O
that	O
DM	B
is	O
a	O
consequence	O
of	O
one	O
or	O
few	O
ancestral	O
mutations	O
.	O

A	O
recent	O
analysis	O
utilizing	O
this	O
polymorphism	O
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	O
marker	O
,	O
suggested	O
that	O
similar	O
to	O
Fragile	B
X	I
syndrome	I
,	O
DM	B
exhibited	O
a	O
founder	O
effect	O
(	O
Imbert	O
et	O
al	O
.	O
,	O
1993	O
Nature	O
Genet	O
.	O
4	O
,	O
72	O
-	O
76	O
)	O
.	O

In	O
contrast	O
,	O
the	O
low	O
reproductive	O
fitness	O
of	O
individuals	O
with	O
congenital	O
DM	B
(	O
the	O
endpoint	O
of	O
genetic	O
anticipation	O
in	O
myotonic	B
dystrophy	I
)	O
suggests	O
a	O
higher	O
rate	O
of	O
new	O
mutations	O
.	O

We	O
present	O
a	O
high	O
resolution	O
genetic	O
analysis	O
of	O
the	O
DM	B
locus	O
using	O
PCR	O
based	O
assays	O
of	O
nine	O
polymorphisms	O
,	O
spanning	O
a	O
physical	O
distance	O
of	O
30	O
kb	O
,	O
within	O
and	O
immediately	O
flanking	O
the	O
DM	B
kinase	O
gene	O
.	O

The	O
persistent	O
complete	O
allelic	O
association	O
of	O
the	O
DM	B
mutation	O
with	O
all	O
these	O
polymorphisms	O
provides	O
further	O
support	O
to	O
previous	O
observations	O
and	O
suggests	O
more	O
strongly	O
that	O
the	O
DM	B
mutation	O
occurred	O
on	O
the	O
background	O
of	O
a	O
particular	O
haplotype	O
in	O
which	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
became	O
inherently	O
unstable	O
and	O
therefore	O
predisposed	O
to	O
amplification	O
.	O

Genetic	O
instability	O
in	O
human	O
ovarian	B
cancer	I
cell	O
lines	O
.	O

We	O
have	O
analyzed	O
the	O
stability	O
of	O
microsatellites	O
in	O
cell	O
lines	O
derived	O
from	O
human	O
ovarian	B
cancers	I
and	O
found	O
that	O
5	O
out	O
of	O
10	O
of	O
the	O
ovarian	B
tumor	I
cell	O
lines	O
are	O
genetically	O
unstable	O
at	O
the	O
majority	O
of	O
the	O
loci	O
analyzed	O
.	O

In	O
clones	O
and	O
subclones	O
derived	O
serially	O
from	O
one	O
of	O
these	O
cell	O
lines	O
(	O
2774	O
;	O
serous	B
cystadenocarcinoma	I
)	O
,	O
a	O
very	O
high	O
proportion	O
of	O
microsatellites	O
distributed	O
in	O
many	O
different	O
regions	O
of	O
the	O
genome	O
change	O
their	O
size	O
in	O
a	O
mercurial	O
fashion	O
.	O

We	O
conclude	O
that	O
genomic	O
instability	O
in	O
ovarian	B
tumors	I
is	O
a	O
dynamic	O
and	O
ongoing	O
process	O
whose	O
high	O
frequency	O
may	O
have	O
been	O
previously	O
underestimated	O
by	O
PCR	O
-	O
based	O
allelotyping	O
of	O
bulk	O
tumor	B
tissue	O
.	O

We	O
have	O
identified	O
the	O
source	O
of	O
the	O
genetic	O
instability	O
in	O
one	O
ovarian	B
tumor	I
as	O
a	O
point	O
mutation	O
(	O
R524P	O
)	O
in	O
the	O
human	O
mismatch	O
-	O
repair	O
gene	O
MSH2	O
(	O
Salmonella	O
MutS	O
homologue	O
)	O
,	O
which	O
has	O
recently	O
been	O
shown	O
to	O
be	O
involved	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

Patient	O
2774	O
was	O
a	O
38	O
-	O
year	O
-	O
old	O
heterozygote	O
,	O
and	O
her	O
normal	O
tissue	O
carried	O
both	O
mutant	O
and	O
wild	O
-	O
type	O
alleles	O
of	O
the	O
human	O
MSH2	O
gene	O
.	O

However	O
the	O
wild	O
-	O
type	O
allele	O
was	O
lost	O
at	O
some	O
point	O
early	O
during	O
tumorigenesis	O
so	O
that	O
DNA	O
isolated	O
either	O
from	O
the	O
patients	O
ovarian	B
tumor	I
or	O
from	O
the	O
2774	O
cell	O
line	O
carries	O
only	O
the	O
mutant	O
allele	O
of	O
the	O
human	O
MSH2	O
gene	O
.	O

The	O
genetic	O
instability	O
observed	O
in	O
the	O
tumor	B
and	O
cell	O
line	O
DNA	O
,	O
together	O
with	O
the	O
germ	O
-	O
line	O
mutation	O
in	O
a	O
mismatch	O
-	O
repair	O
gene	O
,	O
suggest	O
that	O
the	O
MSH2	O
gene	O
is	O
involved	O
in	O
the	O
onset	O
and	O
/	O
or	O
progression	O
in	O
a	O
subset	O
of	O
ovarian	B
cancer	I
.	O
.	O

BRCA1	O
mutations	O
in	O
primary	O
breast	B
and	I
ovarian	I
carcinomas	I
.	O

Loss	O
of	O
heterozygosity	O
data	O
from	O
familial	B
tumors	I
suggest	O
that	O
BRCA1	O
,	O
a	O
gene	O
that	O
confers	O
susceptibility	O
to	O
ovarian	B
and	I
early	I
-	I
onset	I
breast	B
cancer	I
,	O
encodes	O
a	O
tumor	B
suppressor	O
.	O

The	O
BRCA1	O
region	O
is	O
also	O
subject	O
to	O
allelic	O
loss	O
in	O
sporadic	B
breast	I
and	I
ovarian	I
cancers	I
,	O
an	O
indication	O
that	O
BRCA1	O
mutations	O
may	O
occur	O
somatically	O
in	O
these	O
tumors	B
.	O

The	O
BRCA1	O
coding	O
region	O
was	O
examined	O
for	O
mutations	O
in	O
primary	O
breast	B
and	I
ovarian	I
tumors	I
that	O
show	O
allele	O
loss	O
at	O
the	O
BRCA1	O
locus	O
.	O

Mutations	O
were	O
detected	O
in	O
3	O
of	O
32	O
breast	O
and	O
1	O
of	O
12	O
ovarian	B
carcinomas	I
;	O
all	O
four	O
mutations	O
were	O
germline	O
alterations	O
and	O
occurred	O
in	O
early	O
-	O
onset	O
cancers	B
.	O

These	O
results	O
suggest	O
that	O
mutation	O
of	O
BRCA1	O
may	O
not	O
be	O
critical	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
breast	B
and	I
ovarian	I
cancers	I
that	O
arise	O
in	O
the	O
absence	O
of	O
a	O
mutant	O
germline	O
allele	O
.	O
.	O

PAX6	O
gene	O
dosage	O
effect	O
in	O
a	O
family	O
with	O
congenital	B
cataracts	I
,	O
aniridia	B
,	O
anophthalmia	B
and	O
central	B
nervous	I
system	I
defects	I
.	O

The	O
human	O
eye	O
malformation	O
aniridia	B
results	O
from	O
haploinsufficiency	B
of	I
PAX6	I
,	O
a	O
paired	O
box	O
DNA	O
-	O
binding	O
protein	O
.	O

To	O
study	O
this	O
dosage	O
effect	O
,	O
we	O
characterized	O
two	O
PAX6	O
mutations	O
in	O
a	O
family	O
segregating	O
aniridia	B
and	O
a	O
milder	O
syndrome	O
consisting	O
of	O
congenital	B
cataracts	I
and	O
late	O
onset	O
corneal	B
dystrophy	I
.	O

The	O
nonsense	O
mutations	O
,	O
at	O
codons	O
103	O
and	O
353	O
,	O
truncate	O
PAX6	O
within	O
the	O
N	O
-	O
terminal	O
paired	O
and	O
C	O
-	O
terminal	O
PST	O
domains	O
,	O
respectively	O
.	O

The	O
wild	O
-	O
type	O
PST	O
domain	O
activates	O
transcription	O
autonomously	O
and	O
the	O
mutant	O
form	O
has	O
partial	O
activity	O
.	O

A	O
compound	O
heterozygote	O
had	O
severe	O
craniofacial	B
and	I
central	I
nervous	I
system	I
defects	I
and	O
no	B
eyes	I
.	O

The	O
pattern	O
of	O
malformations	O
is	O
similar	O
to	O
that	O
in	O
homozygous	O
Sey	O
mice	O
and	O
suggests	O
a	O
critical	O
role	O
for	O
PAX6	O
in	O
controlling	O
the	O
migration	O
and	O
differentiation	O
of	O
specific	O
neuronal	O
progenitor	O
cells	O
in	O
the	O
brain	O
.	O
.	O

A	O
physical	O
map	O
and	O
candidate	O
genes	O
in	O
the	O
BRCA1	O
region	O
on	O
chromosome	O
17q12	O
-	O
21	O
.	O

We	O
have	O
constructed	O
a	O
physical	O
map	O
of	O
a	O
4	O
cM	O
region	O
on	O
chromosome	O
17q12	O
-	O
21	O
that	O
contains	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
.	O

The	O
map	O
comprises	O
a	O
contig	O
of	O
137	O
overlapping	O
yeast	O
artificial	O
chromosomes	O
and	O
P1	O
clones	O
,	O
onto	O
which	O
we	O
have	O
placed	O
112	O
PCR	O
markers	O
.	O

We	O
have	O
localized	O
more	O
than	O
20	O
genes	O
on	O
this	O
map	O
,	O
ten	O
of	O
which	O
had	O
not	O
been	O
mapped	O
to	O
the	O
region	O
previously	O
,	O
and	O
have	O
isolated	O
30	O
cDNA	O
clones	O
representing	O
partial	O
sequences	O
of	O
as	O
yet	O
unidentified	O
genes	O
.	O

Two	O
genes	O
that	O
lie	O
within	O
a	O
narrow	O
region	O
defined	O
by	O
meiotic	O
breakpoints	O
in	O
BRCA1	O
patients	O
have	O
been	O
sequenced	O
in	O
breast	B
cancer	I
patients	O
without	O
revealing	O
any	O
deleterious	O
mutations	O
.	O

These	O
new	O
reagents	O
should	O
facilitate	O
the	O
identification	O
of	O
BRCA1	O
.	O
.	O

The	O
LEC	O
rat	O
has	O
a	O
deletion	O
in	O
the	O
copper	O
transporting	O
ATPase	O
gene	O
homologous	O
to	O
the	O
Wilson	B
disease	I
gene	O
.	O

The	O
Long	O
-	O
Evans	O
Cinnamon	O
(	O
LEC	O
)	O
rat	O
shows	O
similarity	O
to	O
Wilson	B
disease	I
in	O
many	O
clinical	O
and	O
biochemical	O
features	O
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
the	O
rat	O
gene	O
(	O
Atp7b	O
)	O
homologous	O
to	O
the	O
human	O
Wilson	B
disease	I
gene	O
(	O
ATP7B	O
)	O
and	O
have	O
used	O
them	O
to	O
identify	O
a	O
partial	O
deletion	O
in	O
the	O
Atp7b	O
gene	O
in	O
the	O
LEC	O
rat	O
.	O

The	O
deletion	O
removes	O
at	O
least	O
900	O
bp	O
of	O
the	O
coding	O
region	O
at	O
the	O
3	O
end	O
,	O
includes	O
the	O
crucial	O
ATP	O
binding	O
domain	O
and	O
extends	O
downstream	O
of	O
the	O
gene	O
.	O

Our	O
results	O
provide	O
convincing	O
evidence	O
for	O
defining	O
the	O
LEC	O
rat	O
as	O
an	O
animal	O
model	O
for	O
Wilson	B
disease	I
.	O

This	O
model	O
will	O
be	O
important	O
for	O
studying	O
liver	O
pathophysiology	O
,	O
for	O
developing	O
therapy	O
for	O
Wilson	B
disease	I
and	O
for	O
studying	O
the	O
pathway	O
of	O
copper	O
transport	O
and	O
its	O
possible	O
interaction	O
with	O
other	O
heavy	O
metals	O
.	O
.	O

Genomic	O
organization	O
of	O
the	O
adrenoleukodystrophy	B
gene	O
.	O

Adrenoleukodystrophy	B
(	O
ALD	B
)	O
,	O
the	O
most	O
frequent	O
peroxisomal	B
disorder	I
,	O
is	O
a	O
severe	O
neurodegenerative	B
disease	I
associated	O
with	O
an	O
impairment	B
of	I
very	I
long	I
chain	I
fatty	I
acids	I
beta	I
-	I
oxidation	I
.	O

We	O
have	O
recently	O
identified	O
by	O
positional	O
cloning	O
the	O
gene	O
responsible	O
for	O
ALD	B
,	O
located	O
in	O
Xq28	O
.	O

It	O
encodes	O
a	O
new	O
member	O
of	O
the	O
"	O
ABC	O
"	O
superfamily	O
of	O
membrane	O
-	O
associated	O
transporters	O
that	O
shows	O
,	O
in	O
particular	O
,	O
significant	O
homology	O
to	O
the	O
70	O
-	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
.	O

We	O
report	O
here	O
a	O
detailed	O
characterization	O
of	O
the	O
ALD	B
gene	O
structure	O
.	O

It	O
extends	O
over	O
21	O
kb	O
and	O
consists	O
of	O
10	O
exons	O
.	O

To	O
facilitate	O
the	O
detection	O
of	O
mutations	O
in	O
ALD	B
patients	O
,	O
we	O
have	O
determined	O
the	O
intronic	O
sequences	O
flanking	O
the	O
exons	O
as	O
well	O
as	O
the	O
sequence	O
of	O
the	O
3	O
untranslated	O
region	O
and	O
of	O
the	O
immediate	O
5	O
promoter	O
region	O
.	O

Sequences	O
present	O
in	O
distal	O
exons	O
cross	O
-	O
hybridize	O
strongly	O
to	O
additional	O
sequences	O
in	O
the	O
human	O
genome	O
.	O

The	O
ALD	B
gene	O
has	O
been	O
positioned	O
on	O
a	O
pulsed	O
-	O
field	O
map	O
between	O
DXS15	O
and	O
the	O
L1CAM	O
gene	O
,	O
about	O
650	O
kb	O
upstream	O
from	O
the	O
color	O
pigment	O
genes	O
.	O

The	O
frequent	O
occurrence	O
of	O
color	O
vision	O
anomalies	O
observed	O
in	O
patients	O
with	O
adrenomyeloneuropathy	B
(	O
the	O
adult	O
onset	O
form	O
of	O
ALD	B
)	O
thus	O
does	O
not	O
represent	O
a	O
contiguous	B
gene	I
syndrome	I
but	O
a	O
secondary	O
manifestation	O
of	O
ALD	B
.	O
.	O

The	O
murine	O
homologues	O
of	O
the	O
Huntington	B
disease	I
gene	O
(	O
Hdh	O
)	O
and	O
the	O
alpha	O
-	O
adducin	O
gene	O
(	O
Add1	O
)	O
map	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O
3	O
.	O

Huntington	B
disease	I
(	O
HD	B
)	O
is	O
a	O
severe	O
autosomal	B
dominant	I
neurodegenerative	I
disorder	I
associated	O
with	O
a	O
novel	O
gene	O
(	O
IT15	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
the	O
cloning	O
of	O
Hdh	O
,	O
the	O
murine	O
homologue	O
of	O
IT15	O
.	O

Here	O
,	O
using	O
an	O
interspecific	O
backcross	O
,	O
we	O
have	O
mapped	O
both	O
Hdh	O
and	O
the	O
mouse	O
homologue	O
of	O
human	O
alpha	O
-	O
adducin	O
(	O
Add1	O
)	O
,	O
a	O
membrane	O
-	O
associated	O
cytoskeletal	O
protein	O
gene	O
.	O

Both	O
of	O
these	O
genes	O
map	O
in	O
the	O
same	O
position	O
on	O
mouse	O
chromosome	O
5	O
in	O
a	O
region	O
associated	O
with	O
ancestral	O
chromosomal	O
rearrangements	O
and	O
show	O
no	O
recombination	O
with	O
D5H4S43	O
,	O
D5H4S115	O
,	O
and	O
D5H4S62	O
,	O
the	O
murine	O
homologues	O
of	O
D4S43	O
,	O
D4S115	O
,	O
and	O
D4S62	O
,	O
respectively	O
.	O

Further	O
mapping	O
studies	O
of	O
humans	O
,	O
mice	O
,	O
and	O
other	O
mammalian	O
species	O
should	O
reveal	O
the	O
nature	O
of	O
the	O
rearrangements	O
affecting	O
this	O
chromosomal	O
segment	O
during	O
mammalian	O
evolution	O
.	O
.	O

Genetic	O
cholesteryl	B
ester	I
transfer	I
protein	I
deficiency	I
caused	O
by	O
two	O
prevalent	O
mutations	O
as	O
a	O
major	O
determinant	O
of	O
increased	O
levels	O
of	O
high	O
density	O
lipoprotein	O
cholesterol	O
.	O

Genetic	O
determinants	O
of	O
HDL	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
levels	O
in	O
the	O
general	O
population	O
are	O
poorly	O
understood	O
.	O

We	O
previously	O
described	O
plasma	O
cholesteryl	B
ester	I
transfer	I
protein	I
(	I
CETP	I
)	I
deficiency	I
due	O
to	O
an	O
intron	O
14	O
G	O
(	O
+	O
1	O
)	O
-	O
to	O
-	O
A	O
mutation	O
(	O
Int14	O
A	O
)	O
in	O
several	O
families	O
with	O
very	O
high	O
HDL	O
-	O
C	O
levels	O
in	O
Japan	O
.	O

Subjects	O
with	O
HDL	O
-	O
C	O
>	O
or	O
=	O
100	O
mg	O
/	O
dl	O
(	O
n	O
=	O
130	O
)	O
were	O
screened	O
by	O
PCR	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
the	O
CETP	O
gene	O
.	O

Two	O
other	O
mutations	O
were	O
identified	O
by	O
DNA	O
sequencing	O
or	O
primer	O
-	O
mediated	O
restriction	O
map	O
modification	O
of	O
PCR	O
products	O
a	O
novel	O
intron	O
14	O
splice	O
donor	O
site	O
mutation	O
caused	O
by	O
a	O
T	O
insertion	O
at	O
position	O
+	O
3	O
from	O
the	O
exon14	O
/	O
intron14	O
boundary	O
(	O
Int14	O
T	O
)	O
and	O
a	O
missense	O
mutation	O
(	O
Asp442	O
to	O
Gly	O
)	O
within	O
exon	O
15	O
(	O
D442G	O
)	O
.	O

The	O
Int14	O
T	O
mutation	O
was	O
only	O
found	O
in	O
one	O
family	O
.	O

However	O
,	O
the	O
D442G	O
and	O
Int14	O
A	O
mutations	O
were	O
highly	O
prevalent	O
in	O
subjects	O
with	O
HDL	O
-	O
C	O
>	O
or	O
=	O
60	O
mg	O
/	O
dl	O
,	O
with	O
combined	O
allele	O
frequencies	O
of	O
9	O
%	O
,	O
12	O
%	O
,	O
21	O
%	O
and	O
43	O
%	O
for	O
HDL	O
-	O
C	O
60	O
-	O
79	O
,	O
80	O
-	O
99	O
,	O
100	O
-	O
119	O
,	O
and	O
>	O
or	O
=	O
120	O
mg	O
/	O
dl	O
,	O
respectively	O
.	O

Furthermore	O
,	O
prevalences	O
of	O
the	O
D442G	O
and	O
Int14	O
A	O
mutations	O
were	O
extremely	O
high	O
in	O
a	O
general	O
sample	O
of	O
Japanese	O
men	O
(	O
n	O
=	O
236	O
)	O
,	O
with	O
heterozygote	O
frequencies	O
of	O
7	O
%	O
and	O
2	O
%	O
,	O
respectively	O
.	O

These	O
two	O
mutations	O
accounted	O
for	O
about	O
10	O
%	O
of	O
the	O
total	O
variance	O
of	O
HDL	O
-	O
C	O
in	O
this	O
population	O
.	O

The	O
phenotype	O
in	O
a	O
genetic	O
compound	O
heterozygote	O
(	O
Int14	O
T	O
and	O
Int14	O
A	O
)	O
was	O
similar	O
to	O
that	O
of	O
Int14	O
A	O
homozygotes	O
(	O
no	O
detectable	O
CETP	O
and	O
markedly	O
increased	O
HDL	O
-	O
C	O
)	O
,	O
indicating	O
that	O
the	O
Int14	O
T	O
produces	O
a	O
null	O
allele	O
.	O

In	O
four	O
D442G	O
homozygotes	O
,	O
mean	O
HDL	O
-	O
C	O
levels	O
(	O
86	O
+	O
/	O
-	O
26	O
mg	O
/	O
dl	O
)	O
were	O
lower	O
than	O
in	O
Int14	O
A	O
homozygotes	O
(	O
158	O
+	O
/	O
-	O
35	O
mg	O
/	O
dl	O
)	O
,	O
reflecting	O
residual	O
CETP	O
activity	O
in	O
plasma	O
.	O

In	O
47	O
D442G	O
heterozygotes	O
,	O
mean	O
HDL	O
-	O
C	O
levels	O
were	O
91	O
+	O
/	O
-	O
23	O
mg	O
/	O
dl	O
,	O
similar	O
to	O
the	O
level	O
in	O
D442G	O
homozygotes	O
,	O
and	O
significantly	O
greater	O
than	O
mean	O
HDL	O
-	O
C	O
levels	O
in	O
Int14	O
A	O
heterozygotes	O
(	O
69	O
+	O
/	O
-	O
15	O
mg	O
/	O
dl	O
)	O
.	O

Thus	O
,	O
the	O
D442G	O
mutation	O
acts	O
differently	O
to	O
the	O
null	O
mutations	O
with	O
weaker	O
effects	O
on	O
HDL	O
in	O
the	O
homozygous	O
state	O
and	O
stronger	O
effects	O
in	O
the	O
heterozygotes	O
,	O
suggesting	O
dominant	O
expression	O
of	O
a	O
partially	O
defective	O
allele	O
.	O

CETP	B
deficiency	I
,	O
reflecting	O
two	O
prevalent	O
mutations	O
(	O
D442G	O
and	O
Int14	O
A	O
)	O
,	O
is	O
the	O
first	O
example	O
of	O
a	O
genetic	B
deficiency	I
state	O
which	O
is	O
sufficiently	O
common	O
to	O
explain	O
a	O
significant	O
fraction	O
of	O
the	O
variation	O
in	O
HDL	O
-	O
C	O
in	O
the	O
general	O
population	O
.	O
.	O

Treatment	O
of	O
cerebrotendinous	B
xanthomatosis	I
:	O
effects	O
of	O
chenodeoxycholic	O
acid	O
,	O
pravastatin	O
,	O
and	O
combined	O
use	O
.	O

Treatments	O
by	O
oral	O
administration	O
of	O
chenodeoxycholic	O
acid	O
(	O
CDCA	O
)	O
alone	O
,	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
(	O
HMG	O
)	O
CoA	O
reductase	O
inhibitor	O
(	O
pravastatin	O
)	O
alone	O
,	O
and	O
combination	O
of	O
the	O
two	O
drugs	O
were	O
attempted	O
for	O
7	O
patients	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

CDCA	O
treatment	O
at	O
a	O
dose	O
of	O
300	O
mg	O
/	O
day	O
reduced	O
serum	O
cholestanol	O
(	O
67	O
.	O
3	O
%	O
reduction	O
)	O
,	O
lathosterol	O
(	O
50	O
.	O
8	O
%	O
)	O
,	O
campesterol	O
(	O
61	O
.	O
7	O
%	O
)	O
and	O
sitosterol	O
(	O
12	O
.	O
7	O
%	O
)	O
.	O

However	O
,	O
the	O
sera	O
of	O
the	O
patients	O
changed	O
to	O
be	O
"	O
atherogenic	O
"	O
;	O
total	O
cholesterol	O
,	O
triglyceride	O
and	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-	O
cholesterol	O
were	O
increased	O
,	O
while	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
cholesterol	O
was	O
decreased	O
.	O

Contrarily	O
,	O
pravastatin	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
day	O
improved	O
the	O
sera	O
of	O
the	O
patients	O
to	O
be	O
markedly	O
"	O
anti	O
-	O
atherogenic	O
"	O
,	O
but	O
the	O
reductions	O
of	O
cholestanol	O
(	O
30	O
.	O
4	O
%	O
)	O
,	O
lathosterol	O
(	O
44	O
.	O
0	O
%	O
)	O
,	O
campesterol	O
(	O
22	O
.	O
9	O
%	O
)	O
and	O
sitosterol	O
(	O
9	O
.	O
6	O
%	O
)	O
were	O
inadequate	O
.	O

Combined	O
treatment	O
with	O
CDCA	O
and	O
pravastatin	O
showed	O
good	O
overlapping	O
of	O
the	O
effects	O
of	O
each	O
drug	O
alone	O
.	O

The	O
sera	O
of	O
the	O
patients	O
were	O
apparently	O
more	O
"	O
anti	O
-	O
atherogenic	O
"	O
than	O
those	O
after	O
CDCA	O
treatment	O
.	O

Serum	O
cholestanol	O
concentration	O
was	O
still	O
2	O
.	O

7	O
times	O
higher	O
than	O
in	O
controls	O
,	O
but	O
the	O
serum	O
lathosterol	O
level	O
was	O
within	O
the	O
normal	O
range	O
,	O
indicating	O
that	O
the	O
enhancement	O
of	O
overall	O
cholesterol	O
synthesis	O
in	O
the	O
patients	O
was	O
sufficiently	O
suppressed	O
.	O

Plant	O
sterol	O
levels	O
were	O
also	O
within	O
the	O
normal	O
range	O
.	O

The	O
combination	O
of	O
CDCA	O
and	O
pravastatin	O
was	O
a	O
good	O
treatment	O
for	O
CTX	B
,	O
based	O
on	O
the	O
improvement	O
of	O
serum	O
lipoprotein	O
metabolism	O
,	O
the	O
suppression	O
of	O
cholesterol	O
synthesis	O
,	O
and	O
reductions	O
of	O
cholestanol	O
and	O
plant	O
sterol	O
levels	O
.	O

In	O
all	O
of	O
7	O
patients	O
,	O
the	O
progression	O
of	O
disease	O
was	O
arrested	O
,	O
but	O
dramatic	O
effects	O
on	O
clinical	O
manifestations	O
,	O
xanthoma	B
,	O
and	O
electrophysiological	O
findings	O
could	O
not	O
be	O
found	O
after	O
the	O
treatment	O
of	O
these	O
drugs	O

Mutation	O
spectrum	O
in	O
the	O
CHM	B
gene	O
of	O
Danish	O
and	O
Swedish	O
choroideremia	B
patients	O
.	O

The	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	B
(	O
CHM	B
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	B
.	O

We	O
have	O
performed	O
mutation	O
screening	O
in	O
patients	O
from	O
15	O
Danish	O
and	O
Swedish	O
families	O
by	O
using	O
Southern	O
blot	O
hybridization	O
and	O
the	O
polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
technique	O
.	O

Causative	O
mutations	O
in	O
the	O
CHM	B
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families	O
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach	O
.	O

In	O
four	O
of	O
these	O
families	O
deletions	O
of	O
different	O
sizes	O
were	O
found	O
.	O

Thus	O
,	O
in	O
one	O
patient	O
,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon	O
,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
CHM	B
gene	O
.	O

Mapping	O
of	O
the	O
deletion	O
endpoints	O
in	O
these	O
four	O
patients	O
and	O
in	O
another	O
11	O
male	O
patients	O
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	O
map	O
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21	O
.	O

In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	O
at	O
least	O
8	O
causative	O
mutations	O
were	O
found	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Interestingly	O
,	O
all	O
CHM	B
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	B
patients	O
give	O
rise	O
to	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
codon	O
.	O
.	O

Predominance	O
of	O
the	O
adrenomyeloneuropathy	B
phenotype	O
of	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
in	O
The	O
Netherlands	O
:	O
a	O
survey	O
of	O
30	O
kindreds	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
X	B
-	I
ALD	I
)	O
is	O
an	O
inherited	B
disorder	I
of	O
peroxisomal	O
beta	O
-	O
oxidation	O
associated	O
with	O
accumulation	O
of	O
saturated	O
very	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
results	O
in	O
central	O
and	O
peripheral	O
demyelination	B
and	O
in	O
impaired	B
function	I
of	I
adrenal	I
cortex	I
and	I
testes	I
.	O

The	O
phenotypic	O
expression	O
is	O
highly	O
variable	O
,	O
childhood	B
cerebral	I
ALD	I
(	O
CCALD	B
)	O
and	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
being	O
the	O
main	O
variants	O
.	O

We	O
explored	O
the	O
30	O
Dutch	O
kindreds	O
well	O
known	O
to	O
the	O
Dutch	O
X	B
-	I
ALD	I
/	O
AMN	B
Study	O
Group	O
and	O
phenotyped	O
77	O
male	O
patients	O
35	O
(	O
46	O
%	O
)	O
had	O
AMN	B
and	O
24	O
(	O
31	O
%	O
)	O
CCALD	B
or	O
adolescent	B
cerebral	I
ALD	I
(	O
AdolCALD	B
)	O
.	O

These	O
percentages	O
differ	O
significantly	O
from	O
previous	O
reports	O
,	O
in	O
which	O
25	O
to	O
28	O
%	O
of	O
the	O
patients	O
developed	O
AMN	B
and	O
53	O
to	O
57	O
%	O
CCALD	B
or	O
AdolCALD	B
.	O

Our	O
findings	O
indicate	O
that	O
-	O
-	O
at	O
least	O
in	O
the	O
Netherlands	O
-	O
-	O
AMN	B
may	O
be	O
the	O
most	O
frequent	O
phenotype	O
of	O
X	B
-	I
ALD	I
.	O
.	O

Adrenoleukodystrophy	B
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O

An	O
antibody	O
against	O
the	O
synthetic	O
C	O
-	O
terminal	O
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	O
responsible	O
for	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ALD	B
gene	O
.	O

The	O
antibody	O
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	O
in	O
control	O
fibroblasts	O
,	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	O
with	O
ALD	B
(	O
#	O
163	O
)	O
,	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	B
gene	O
was	O
undetectable	O
based	O
on	O
Northern	O
blot	O
analysis	O
.	O

The	O
293T	O
cells	O
transfected	O
with	O
the	O
full	O
-	O
coding	O
cDNA	O
inserted	O
in	O
the	O
expression	O
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein	O
,	O
as	O
detected	O
by	O
Western	O
blot	O
.	O

In	O
an	O
immunocytological	O
study	O
,	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern	O
,	O
in	O
the	O
normal	O
fibroblasts	O
.	O

However	O
,	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells	O
.	O

These	O
data	O
thus	O
indicate	O
that	O
the	O
ALD	B
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O
.	O

Isolation	O
of	O
the	O
gene	O
for	O
McLeod	B
syndrome	I
that	O
encodes	O
a	O
novel	O
membrane	O
transport	O
protein	O
.	O

McLeod	B
syndrome	I
is	O
an	O
X	B
-	I
linked	I
multisystem	I
disorder	I
characterized	O
by	O
abnormalities	O
in	O
the	O
neuromuscular	O
and	O
hematopoietic	O
systems	O
.	O

We	O
have	O
assembled	O
a	O
cosmid	O
contig	O
of	O
360	O
kb	O
that	O
encompasses	O
the	O
McLeod	B
gene	O
locus	O
.	O

A	O
50	O
kb	O
deletion	O
was	O
detected	O
by	O
screening	O
DNA	O
from	O
patients	O
with	O
radiolabeled	O
whole	O
cosmids	O
,	O
and	O
two	O
transcription	O
units	O
were	O
identified	O
within	O
this	O
deletion	O
.	O

The	O
mRNA	O
expression	O
pattern	O
of	O
one	O
of	O
them	O
,	O
designated	O
as	O
XK	O
,	O
correlates	O
closely	O
to	O
the	O
McLeod	B
phenotype	O
.	O

XK	O
encodes	O
a	O
novel	O
protein	O
with	O
structural	O
characteristics	O
of	O
prokaryotic	O
and	O
eukaryotic	O
membrane	O
transport	O
proteins	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
XK	O
from	O
two	O
unrelated	O
McLeod	B
patients	O
has	O
identified	O
point	O
mutations	O
at	O
conserved	O
splice	O
donor	O
and	O
acceptor	O
sites	O
.	O

These	O
findings	O
provide	O
direct	O
evidence	O
that	O
XK	O
is	O
responsible	O
for	O
McLeod	B
syndrome	I
.	O
.	O

X	B
-	I
linked	I
spastic	I
paraplegia	I
and	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
are	O
allelic	B
disorders	I
at	O
the	O
proteolipid	O
protein	O
locus	O
.	O

Three	O
forms	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
have	O
been	O
defined	O
.	O

One	O
locus	O
(	O
SPG	O
1	O
)	O
maps	O
to	O
Xq28	O
while	O
two	O
clinically	O
distinct	O
forms	O
map	O
to	O
Xq22	O
(	O
SPG2	O
)	O
.	O

A	O
rare	O
X	B
-	I
linked	I
dysmyelinating	I
disorder	I
of	O
the	O
central	O
nervous	O
system	O
,	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
,	O
has	O
also	O
been	O
mapped	O
to	O
Xq21	O
-	O
q22	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
which	O
encodes	O
two	O
myelin	O
proteins	O
,	O
PLP	O
and	O
DM20	O
.	O

While	O
narrowing	O
the	O
genetic	O
interval	O
containing	O
SPG2	O
in	O
a	O
large	O
pedigree	O
,	O
we	O
found	O
that	O
PLP	O
was	O
the	O
closest	O
marker	O
to	O
the	O
disease	O
locus	O
,	O
implicating	O
PLP	O
as	O
a	O
possible	O
candidate	O
gene	O
.	O

We	O
have	O
found	O
that	O
a	O
point	O
mutation	O
(	O
His139Tyr	O
)	O
in	O
exon	O
3B	O
of	O
an	O
affected	O
male	O
produces	O
a	O
mutant	O
PLP	O
but	O
a	O
normal	O
DM20	O
,	O
and	O
segregates	O
with	O
the	O
disease	O
(	O
Zmax	O
=	O
6	O
.	O
63	O
,	O
theta	O
=	O
0	O
.	O
00	O
)	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
SPG2	O
and	O
PMD	B
are	O
allelic	B
disorders	I

Canavan	B
disease	I
:	O
mutations	O
among	O
Jewish	O
and	O
non	O
-	O
Jewish	O
patients	O
.	O

Canavan	B
disease	I
is	O
an	O
autosomal	B
recessive	I
leukodystrophy	I
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

Sixty	O
-	O
four	O
probands	O
were	O
analyzed	O
for	O
mutations	O
in	O
the	O
ASPA	O
gene	O
.	O

Three	O
point	O
mutations	O
-	O
-	O
693C	O
-	O
-	O
>	O
A	O
,	O
854A	O
-	O
-	O
>	O
C	O
,	O
and	O
914C	O
-	O
-	O
>	O
A	O
-	O
-	O
were	O
identified	O
in	O
the	O
coding	O
sequence	O
.	O

The	O
693C	O
-	O
-	O
>	O
A	O
and	O
914C	O
-	O
-	O
>	O
A	O
base	O
changes	O
,	O
resulting	O
in	O
nonsense	O
tyr231	O
-	O
-	O
>	O
ter	O
and	O
missense	O
ala305	O
-	O
-	O
>	O
glu	O
mutations	O
,	O
respectively	O
,	O
lead	O
to	O
complete	O
loss	O
of	O
ASPA	O
activity	O
in	O
in	O
vitro	O
expression	O
studies	O
.	O

The	O
854A	O
-	O
-	O
>	O
C	O
transversion	O
converted	O
glu	O
to	O
ala	O
in	O
codon	O
285	O
.	O

The	O
glu285	O
-	O
-	O
>	O
ala	O
mutant	O
ASPA	O
has	O
2	O
.	O

5	O
%	O
of	O
the	O
activity	O
expressed	O
by	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

A	O
fourth	O
mutation	O
,	O
433	O
-	O
-	O
2	O
(	O
A	O
-	O
-	O
>	O
G	O
)	O
transition	O
,	O
was	O
identified	O
at	O
the	O
splice	O
-	O
acceptor	O
site	O
in	O
intron	O
2	O
.	O

The	O
splice	O
-	O
site	O
mutation	O
would	O
lead	O
to	O
skipping	O
of	O
exon	O
3	O
,	O
accompanied	O
by	O
a	O
frameshift	O
,	O
and	O
thus	O
would	O
produce	O
aberrant	O
ASPA	O
.	O

Of	O
the	O
128	O
unrelated	O
Canavan	B
chromosomes	O
analyzed	O
,	O
88	O
were	O
from	O
probands	O
of	O
Ashkenazi	O
Jewish	O
descent	O
.	O

The	O
glu285	O
-	O
-	O
>	O
ala	O
mutation	O
was	O
predominant	O
(	O
82	O
.	O
9	O
%	O
)	O
in	O
this	O
population	O
,	O
followed	O
by	O
the	O
tyr231	O
-	O
-	O
>	O
ter	O
(	O
14	O
.	O
8	O
%	O
)	O
and	O
433	O
-	O
-	O
2	O
(	O
A	O
-	O
-	O
>	O
G	O
)	O
(	O
1	O
.	O
1	O
%	O
)	O
mutations	O
.	O

The	O
three	O
mutations	O
account	O
for	O
98	O
.	O

8	O
%	O
of	O
the	O
Canavan	B
chromosomes	O
of	O
Ashkenazi	O
Jewish	O
origin	O
.	O

The	O
ala305	O
-	O
-	O
>	O
glu	O
mutation	O
was	O
found	O
exclusively	O
in	O
non	O
-	O
Jewish	O
probands	O
of	O
European	O
descent	O
and	O
constituted	O
60	O
%	O
of	O
the	O
40	O
mutant	O
chromosomes	O
.	O

Predominant	O
occurrence	O
of	O
certain	O
mutations	O
among	O
Ashkenazi	O
Jewish	O
and	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
would	O
suggest	O
a	O
founding	O
-	O
father	O
effect	O
in	O
propagation	O
of	O
these	O
mutant	O
chromosomes	O

Intelligence	O
quotient	O
profile	O
in	O
myotonic	B
dystrophy	I
,	O
intergenerational	O
deficit	O
,	O
and	O
correlation	O
with	O
CTG	O
amplification	O
.	O

An	O
abbreviated	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
Revised	O
(	O
WAIS	O
-	O
R	O
)	O
was	O
used	O
to	O
assess	O
verbal	O
and	O
arithmetical	O
cognitive	O
performance	O
in	O
55	O
subjects	O
with	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
covering	O
all	O
grades	O
of	O
disease	O
severity	O
,	O
and	O
31	O
controls	O
at	O
50	O
%	O
risk	O
of	O
inheriting	O
DM	B
.	O

Scaled	O
scores	O
from	O
the	O
assessment	O
were	O
converted	O
into	O
an	O
intelligence	O
quotient	O
(	O
IQ	O
)	O
estimation	O
on	O
each	O
person	O
.	O

Significant	O
IQ	O
differences	O
were	O
found	O
between	O
(	O
1	O
)	O
all	O
55	O
DM	B
subjects	O
(	O
mean	O
90	O
.	O
2	O
,	O
SD	O
16	O
.	O
1	O
)	O
and	O
31	O
controls	O
(	O
102	O
.	O
6	O
,	O
SD	O
9	O
.	O
4	O
)	O
,	O
with	O
no	O
sex	O
differences	O
in	O
either	O
group	O
;	O
(	O
2	O
)	O
15	O
affected	O
parents	O
(	O
99	O
.	O
3	O
,	O
SD	O
12	O
.	O
2	O
)	O
and	O
their	O
affected	O
children	O
(	O
88	O
.	O
1	O
,	O
SD	O
17	O
.	O
2	O
)	O
,	O
where	O
significance	O
was	O
dependent	O
on	O
parental	O
sex	O
being	O
female	O
;	O
and	O
(	O
3	O
)	O
15	O
pairs	O
of	O
affected	O
sibs	O
(	O
89	O
.	O
6	O
,	O
SD	O
13	O
.	O
2	O
)	O
and	O
their	O
normal	O
sibs	O
(	O
100	O
.	O
2	O
,	O
SD	O
7	O
.	O
6	O
)	O
.	O

IQ	O
steadily	O
declined	O
as	O
(	O
1	O
)	O
the	O
age	O
of	O
onset	O
of	O
signs	O
and	O
symptoms	O
decreased	O
,	O
and	O
(	O
2	O
)	O
the	O
CTG	O
expansion	O
size	O
increased	O
.	O

The	O
correlation	O
appeared	O
to	O
be	O
more	O
linear	O
with	O
age	O
of	O
onset	O
.	O

The	O
correlation	O
of	O
IQ	O
difference	O
and	O
CTG	O
expansion	O
difference	O
in	O
both	O
the	O
DM	B
parent	O
-	O
child	O
pairs	O
and	O
normal	O
sib	O
-	O
affected	O
sib	O
pairs	O
was	O
poor	O
,	O
indicating	O
that	O
CTG	O
expansion	O
is	O
not	O
a	O
reliable	O
predictor	O
of	O
IQ	O
either	O
in	O
individual	O
persons	O
or	O
families	O
.	O

Further	O
analysis	O
of	O
cognitive	O
function	O
in	O
DM	B
is	O
required	O
to	O
clarify	O
specific	O
deficits	O
characteristic	O
of	O
this	O
patient	O
group	O

Adenomatous	B
polyposis	I
coli	I
and	O
a	O
cytogenetic	O
deletion	O
of	O
chromosome	O
5	O
resulting	O
from	O
a	O
maternal	O
intrachromosomal	O
insertion	O
.	O

We	O
present	O
the	O
clinical	O
and	O
laboratory	O
findings	O
in	O
an	O
institutionalised	O
adult	O
patient	O
originally	O
referred	O
for	O
autism	B
.	O

A	O
high	O
risk	O
of	O
colorectal	B
cancer	I
was	O
predicted	O
when	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
,	O
del	O
(	O
5	O
)	O
(	O
q15q22	O
.	O
3	O
)	O
,	O
was	O
detected	O
in	O
her	O
lymphocytes	O
and	O
deletion	O
of	O
the	O
MCC	O
and	O
APC	B
genes	O
confirmed	O
by	O
molecular	O
analysis	O
.	O

Adenomatous	B
polyposis	I
coli	I
and	O
carcinoma	B
of	I
the	I
rectum	I
were	O
subsequently	O
diagnosed	O
in	O
the	O
patient	O
.	O

She	O
was	O
profoundly	O
mentally	B
retarded	I
,	O
autistic	B
,	O
and	O
had	O
minor	O
dysmorphic	B
features	I
consistent	O
with	O
those	O
of	O
previous	O
patients	O
with	O
similar	O
deletions	O
.	O

The	O
deletion	O
arose	O
as	O
a	O
result	O
of	O
recombination	O
within	O
the	O
small	O
insertion	O
loop	O
formed	O
at	O
meiosis	O
by	O
the	O
direct	O
insertion	O
(	O
dir	O
ins	O
(	O
5	O
)	O
(	O
q22	O
.	O
3q14	O
.	O
2q15	O
)	O
)	O
found	O
in	O
the	O
patients	O
mother	O
.	O

This	O
family	O
further	O
confirms	O
the	O
cytogenetic	O
mapping	O
of	O
both	O
MCC	O
and	O
APC	B
genes	O
to	O
5q22	O
and	O
comparison	O
with	O
other	O
recent	O
cases	O
suggests	O
that	O
both	O
genes	O
and	O
their	O
closely	O
linked	O
markers	O
lie	O
within	O
the	O
5q22	O
.	O

1	O
subband	O

Familial	B
male	I
breast	I
cancer	I
is	O
not	O
linked	O
to	O
the	O
BRCA1	O
locus	O
on	O
chromosome	O
17q	O
.	O

Breast	B
cancer	I
in	O
men	O
is	O
about	O
a	O
hundredfold	O
less	O
common	O
than	O
in	O
women	O
and	O
this	O
has	O
hindered	O
research	O
into	O
its	O
genetic	O
basis	O
.	O

We	O
have	O
examined	O
22	O
families	O
with	O
at	O
least	O
one	O
case	O
of	O
male	B
breast	I
cancer	I
for	O
linkage	O
to	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
locus	O
,	O
BRCA1	O
,	O
on	O
chromosome	O
17q	O
.	O

We	O
found	O
strong	O
evidence	O
against	O
linkage	O
to	O
BRCA1	O
(	O
lod	O
score	O
-	O
16	O
.	O
63	O
)	O
and	O
the	O
best	O
estimate	O
of	O
the	O
proportion	O
of	O
linked	O
families	O
was	O
0	O
%	O
(	O
95	O
%	O
CI	O
0	O
-	O
18	O
%	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
there	O
is	O
a	O
gene	O
(	O
s	O
)	O
other	O
than	O
BRCA1	O
which	O
predisposes	O
to	O
early	O
-	O
onset	O
breast	B
cancer	I
in	O
women	O
and	O
which	O
confers	O
a	O
higher	O
risk	O
of	O
male	B
breast	I
cancer	I
.	O

Identification	O
of	O
additional	O
pedigrees	O
that	O
include	O
cases	O
of	O
male	B
breast	I
cancer	I
may	O
therefore	O
facilitate	O
the	O
mapping	O
and	O
isolation	O
of	O
this	O
gene	O
.	O

The	O
EWS	O
gene	O
,	O
involved	O
in	O
Ewing	B
family	I
of	I
tumors	I
,	O
malignant	B
melanoma	I
of	I
soft	I
parts	I
and	O
desmoplastic	B
small	I
round	I
cell	I
tumors	I
,	O
codes	O
for	O
an	O
RNA	O
binding	O
protein	O
with	O
novel	O
regulatory	O
domains	O
.	O

The	O
EWS	O
gene	O
,	O
which	O
maps	O
to	O
band	O
q12	O
of	O
human	O
chromosome	O
22	O
,	O
is	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
human	O
solid	B
tumors	I
including	O
Ewing	B
sarcoma	I
,	O
related	O
primitive	O
neuroectodermal	B
tumors	I
,	O
malignant	B
melanoma	I
of	I
soft	I
parts	I
and	O
desmoplastic	B
small	I
round	I
cell	I
tumors	I
.	O

In	O
these	O
tumors	B
,	O
the	O
EWS	O
is	O
fused	O
to	O
genes	O
encoding	O
transcriptional	O
activators	O
/	O
repressors	O
,	O
like	O
Fli	O
-	O
1	O
or	O
erg	O
or	O
ATF	O
1	O
or	O
wt1	O
.	O

To	O
better	O
understand	O
the	O
function	O
of	O
the	O
EWS	O
protein	O
,	O
we	O
cloned	O
the	O
EWS	O
cDNA	O
.	O

Sequence	O
analysis	O
of	O
this	O
cDNA	O
revealed	O
differential	O
splicing	O
involving	O
two	O
exons	O
encoding	O
72	O
amino	O
acids	O
.	O

Both	O
alternatively	O
spliced	O
transcripts	O
,	O
EWS	O
and	O
EWS	O
-	O
b	O
,	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cells	O
.	O

Because	O
EWS	O
proteins	O
contain	O
putative	O
conserved	O
RNA	O
binding	O
motifs	O
,	O
we	O
studied	O
the	O
RNA	O
binding	O
properties	O
of	O
the	O
EWS	O
protein	O
.	O

The	O
EWS	O
-	O
b	O
protein	O
binds	O
to	O
RNA	O
in	O
vitro	O
and	O
,	O
specifically	O
,	O
to	O
poly	O
G	O
and	O
poly	O
U	O
.	O

The	O
RNA	O
binding	O
activity	O
was	O
localized	O
to	O
the	O
carboxy	O
terminal	O
86	O
amino	O
acids	O
,	O
which	O
constitute	O
RGG	O
box	O
.	O

Thus	O
the	O
amino	O
terminal	O
domain	O
of	O
EWS	O
(	O
NTD	O
-	O
EWS	O
)	O
,	O
which	O
is	O
involved	O
in	O
chromosome	O
translocation	O
may	O
regulate	O
the	O
specificity	O
of	O
RNA	O
binding	O
activity	O
of	O
EWS	O
.	O

An	O
EWS	O
-	O
erg	O
chimeric	O
protein	O
,	O
which	O
is	O
found	O
in	O
Ewings	B
sarcoma	I
cells	O
,	O
functions	O
as	O
a	O
transcriptional	O
activator	O
.	O

Mutational	O
analysis	O
of	O
EWS	O
-	O
erg	O
chimeric	O
protein	O
revealed	O
that	O
NTD	O
-	O
EWS	O
functions	O
as	O
a	O
regulatory	O
domain	O
for	O
the	O
transcriptional	O
activation	O
properties	O
of	O
EWS	O
-	O
erg	O
chimeric	O
protein	O
.	O
.	O

Canavan	B
disease	I
:	O
genomic	O
organization	O
and	O
localization	O
of	O
human	O
ASPA	O
to	O
17p13	O
-	O
ter	O
and	O
conservation	O
of	O
the	O
ASPA	O
gene	O
during	O
evolution	O
.	O

Canavan	B
disease	I
,	O
or	O
spongy	B
degeneration	I
of	I
the	I
brain	I
,	O
is	O
a	O
severe	O
leukodystrophy	B
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
was	O
identified	O
in	O
human	O
ASPA	O
coding	O
sequence	O
from	O
patients	O
with	O
Canavan	B
disease	I
.	O

The	O
human	O
ASPA	O
gene	O
has	O
been	O
cloned	O
and	O
found	O
to	O
span	O
29	O
kb	O
of	O
the	O
genome	O
.	O

Human	O
aspartoacylase	O
is	O
coded	O
by	O
six	O
exons	O
intervened	O
by	O
five	O
introns	O
.	O

The	O
exons	O
vary	O
from	O
94	O
(	O
exon	O
III	O
)	O
to	O
514	O
(	O
exon	O
VI	O
)	O
bases	O
.	O

The	O
exon	O
/	O
intron	O
splice	O
junction	O
sites	O
follow	O
the	O
gt	O
/	O
ag	O
consensus	O
sequence	O
rule	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
human	O
/	O
mouse	O
somatic	O
cell	O
hybrid	O
cell	O
lines	O
localized	O
ASPA	O
to	O
human	O
chromosome	O
17	O
.	O

The	O
human	O
ASPA	O
locus	O
was	O
further	O
mapped	O
in	O
the	O
17p13	O
-	O
ter	O
region	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
bovine	O
aspa	O
gene	O
has	O
also	O
been	O
cloned	O
,	O
and	O
its	O
exon	O
/	O
intron	O
organization	O
is	O
identical	O
to	O
that	O
of	O
the	O
human	O
gene	O
.	O

The	O
500	O
-	O
base	O
sequence	O
upstream	O
of	O
the	O
initiator	O
ATG	O
codon	O
in	O
the	O
human	O
gene	O
and	O
that	O
in	O
the	O
bovine	O
gene	O
are	O
77	O
%	O
identical	O
.	O

Human	O
ASPA	O
coding	O
sequences	O
cross	O
-	O
hybridize	O
with	O
genomic	O
DNA	O
from	O
yeast	O
,	O
chicken	O
,	O
rabbit	O
,	O
cow	O
,	O
dog	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
monkey	O
.	O

The	O
specificity	O
of	O
cross	O
-	O
species	O
hybridization	O
of	O
coding	O
sequences	O
suggests	O
that	O
aspartoacylase	O
has	O
been	O
conserved	O
during	O
evolution	O
.	O

It	O
should	O
now	O
be	O
possible	O
to	O
identify	O
mutations	O
in	O
the	O
noncoding	O
genomic	O
sequences	O
that	O
lead	O
to	O
Canavan	B
disease	I
and	O
to	O
study	O
the	O
regulation	O
of	O
ASPA	O
.	O
.	O

Myotonic	B
dystrophy	I
:	O
size	O
-	O
and	O
sex	O
-	O
dependent	O
dynamics	O
of	O
CTG	O
meiotic	O
instability	O
,	O
and	O
somatic	O
mosaicism	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
a	O
progressive	O
neuromuscular	B
disorder	I
which	O
results	O
from	O
elongations	O
of	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B
gene	O
.	O

A	O
correlation	O
has	O
been	O
demonstrated	O
between	O
the	O
increase	O
in	O
the	O
repeat	O
number	O
of	O
this	O
sequence	O
and	O
the	O
severity	O
of	O
the	O
disease	O
.	O

However	O
,	O
the	O
clinical	O
status	O
of	O
patients	O
cannot	O
be	O
unambiguously	O
ascertained	O
solely	O
on	O
the	O
basis	O
of	O
the	O
number	O
of	O
CTG	O
repeats	O
.	O

Moreover	O
,	O
the	O
exclusive	O
maternal	O
inheritance	O
of	O
the	O
congenital	O
form	O
remains	O
unexplained	O
.	O

Our	O
observation	O
of	O
differently	O
sized	O
repeats	O
in	O
various	O
DM	B
tissues	O
from	O
the	O
same	O
individual	O
may	O
explain	O
why	O
the	O
size	O
of	O
the	O
mutation	O
observed	O
in	O
lymphocytes	O
does	O
not	O
necessarily	O
correlate	O
with	O
the	O
severity	O
and	O
nature	O
of	O
symptoms	O
.	O

Through	O
a	O
molecular	O
and	O
genetic	O
study	O
of	O
142	O
families	O
including	O
418	O
DM	B
patients	O
,	O
we	O
have	O
investigated	O
the	O
dynamics	O
of	O
the	O
CTG	O
repeat	O
meiotic	O
instability	O
.	O

A	O
positive	O
correlation	O
between	O
the	O
size	O
of	O
the	O
repeat	O
and	O
the	O
intergenerational	O
enlargement	O
was	O
observed	O
similarly	O
through	O
male	O
and	O
female	O
meioses	O
for	O
<	O
or	O
=	O
0	O
.	O

5	O
-	O
kb	O
CTG	O
sequences	O
.	O

Beyond	O
0	O
.	O

5	O
kb	O
,	O
the	O
intergenerational	O
variation	O
was	O
more	O
important	O
through	O
female	O
meioses	O
,	O
whereas	O
a	O
tendency	O
to	O
compression	O
was	O
observed	O
almost	O
exclusively	O
in	O
male	O
meioses	O
,	O
for	O
>	O
or	O
=	O
1	O
.	O

5	O
-	O
kb	O
fragments	O
.	O

This	O
implies	O
a	O
size	O
-	O
and	O
sex	O
-	O
dependent	O
meiotic	O
instability	O
.	O

Moreover	O
,	O
segregation	O
analysis	O
supports	O
the	O
hypothesis	O
of	O
a	O
maternal	O
as	O
well	O
as	O
a	O
familial	O
predisposition	O
for	O
the	O
occurrence	O
of	O
the	O
congenital	O
form	O
.	O

Finally	O
,	O
this	O
analysis	O
reveals	O
a	O
significant	O
excess	O
of	O
transmitting	O
grandfathers	O
partially	O
accounted	O
for	O
by	O
increased	O
fertility	O
in	O
affected	O
males	O

Illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
lymphocytes	O
for	O
identification	O
of	O
mutations	O
in	O
phenylketonuria	B
.	O

Taking	O
advantage	O
of	O
the	O
illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
,	O
we	O
have	O
been	O
able	O
to	O
analyse	O
the	O
PAH	O
cDNA	O
sequence	O
of	O
hyperphenylalaninemic	B
children	O
in	O
circulating	O
lymphocytes	O
.	O

Using	O
this	O
approach	O
,	O
we	O
have	O
also	O
identified	O
3	O
novel	O
mutations	O
in	O
cDNA	O
from	O
liver	O
and	O
lymphocytes	O
of	O
two	O
patients	O
.	O

One	O
mutation	O
,	O
detected	O
by	O
the	O
abnormal	O
pattern	O
of	O
migration	O
of	O
an	O
amplified	O
fragment	O
,	O
is	O
a	O
C	O
to	O
T	O
transition	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
10	O
,	O
which	O
resulted	O
in	O
the	O
skipping	O
of	O
exon	O
11	O
with	O
the	O
premature	O
termination	O
of	O
RNA	O
translation	O
downstream	O
from	O
exon	O
12	O
(	O
-	O
3	O
IVS10	O
)	O
.	O

The	O
other	O
two	O
mutations	O
are	O
missense	O
mutations	O
in	O
exons	O
10	O
and	O
11	O
(	O
respectively	O
,	O
L333F	O
and	O
E390G	O
)	O
.	O

The	O
present	O
study	O
supports	O
the	O
view	O
that	O
circulating	O
lymphocytes	O
give	O
easy	O
access	O
to	O
PAH	O
gene	O
transcripts	O
whose	O
nucleotide	O
sequence	O
is	O
identical	O
to	O
that	O
reported	O
in	O
liver	O
and	O
therefore	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	O
genetic	O
studies	O
in	O
phenylketonuria	B
.	O
.	O

High	O
residual	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
in	O
a	O
patient	O
with	O
late	B
-	I
infantile	I
metachromatic	I
leukodystrophy	I
.	O

We	O
identified	O
a	O
patient	O
suffering	O
from	O
late	B
-	I
infantile	I
metachromatic	I
leukodystrophy	I
(	O
MLD	B
)	O
who	O
has	O
a	O
residual	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
of	O
about	O
10	O
%	O
.	O

Fibroblasts	O
of	O
the	O
patient	O
show	O
significant	O
sulfatide	O
degradation	O
activity	O
exceeding	O
that	O
of	O
adult	B
MLD	I
patients	O
.	O

Analysis	O
of	O
the	O
ARSA	O
gene	O
in	O
this	O
patient	O
revealed	O
heterozygosity	O
for	O
two	O
new	O
mutant	O
alleles	O
in	O
one	O
allele	O
,	O
deletion	O
of	O
C	O
447	O
in	O
exon	O
2	O
leads	O
to	O
a	O
frameshift	O
and	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
position	O
105	O
;	O
in	O
the	O
second	O
allele	O
,	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
in	O
exon	O
5	O
causes	O
a	O
Gly309	O
-	O
-	O
>	O
Ser	O
substitution	O
.	O

Transient	O
expression	O
of	O
the	O
mutant	O
Ser309	O
-	O
ARSA	O
resulted	O
in	O
only	O
13	O
%	O
enzyme	O
activity	O
of	O
that	O
observed	O
in	O
cells	O
expressing	O
normal	O
ARSA	O
.	O

The	O
mutant	O
ARSA	O
is	O
correctly	O
targeted	O
to	O
the	O
lysosomes	O
but	O
is	O
unstable	O
.	O

These	O
findings	O
are	O
in	O
contrast	O
to	O
previous	O
results	O
showing	O
that	O
the	O
late	B
-	I
infantile	I
type	I
of	I
MLD	I
is	O
always	O
associated	O
with	O
the	O
complete	O
absence	O
of	O
ARSA	O
activity	O
.	O

The	O
expression	O
of	O
the	O
mutant	O
ARSA	O
protein	O
may	O
be	O
influenced	O
by	O
particular	O
features	O
of	O
oligodendrocytes	O
,	O
such	O
that	O
the	O
level	O
of	O
mutant	O
enzyme	O
is	O
lower	O
in	O
these	O
cells	O
than	O
in	O
others	O
.	O
.	O

An	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
missense	O
mutation	O
(	O
T274M	O
)	O
causing	O
late	B
-	I
infantile	I
metachromatic	I
leukodystrophy	I
.	O

Metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
;	O
EC	O
3	O
.	O
1	O
.	O
6	O
.	O
8	O
)	O
.	O

The	O
8	O
ARSA	O
exons	O
and	O
adjacent	O
intron	O
boundaries	O
from	O
a	O
patient	O
with	O
late	B
-	I
infantile	I
metachromatic	I
leukodystrophy	I
were	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
in	O
seven	O
discrete	O
reactions	O
.	O

Amplified	O
ARSA	O
exons	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
sequence	O
alterations	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
followed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
products	O
.	O

The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
C	O
-	O
-	O
>	O
T	O
transition	O
in	O
exon	O
IV	O
that	O
results	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
threonine	O
residue	O
at	O
amino	O
acid	O
274	O
with	O
a	O
methionine	O
(	O
T274M	O
)	O
.	O

Analysis	O
of	O
a	O
further	O
29	O
MLD	B
patients	O
revealed	O
the	O
presence	O
of	O
five	O
additional	O
homozygotes	O
for	O
T274M	O
.	O

All	O
6	O
T274M	O
homozygotes	O
(	O
representing	O
four	O
families	O
)	O
were	O
of	O
Lebanese	O
descent	O
,	O
and	O
all	O
were	O
known	O
to	O
be	O
the	O
result	O
of	O
consanguineous	O
marriages	O
.	O

The	O
altered	O
amino	O
acid	O
is	O
rigidly	O
conserved	O
among	O
10	O
sulfatases	O
from	O
Escherichia	O
coli	O
to	O
humans	O
;	O
therefore	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
resultant	O
mutant	O
protein	O
will	O
have	O
little	O
or	O
no	O
enzyme	O
activity	O
.	O

This	O
is	O
consistent	O
with	O
the	O
very	O
low	O
ARSA	O
activity	O
measured	O
in	O
these	O
patients	O
and	O
their	O
uniformly	O
severe	O
clinical	O
presentation	O

Mutations	O
in	O
the	O
PAX6	O
gene	O
in	O
patients	O
with	O
hereditary	O
aniridia	B
.	O

The	O
14	O
exons	O
of	O
the	O
PAX6	O
gene	O
have	O
been	O
analysed	O
exon	O
-	O
by	O
-	O
exon	O
using	O
SSCP	O
in	O
6	O
aniridia	B
families	O
.	O

In	O
each	O
family	O
band	O
shifts	O
were	O
observed	O
on	O
the	O
SSCP	O
gels	O
for	O
only	O
one	O
exon	O
and	O
direct	O
PCR	O
-	O
sequencing	O
revealed	O
mutations	O
in	O
each	O
case	O
.	O

Two	O
mutations	O
involved	O
C	O
-	O
-	O
>	O
T	O
transitions	O
in	O
CGAarg	O
codons	O
in	O
exons	O
9	O
and	O
11	O
.	O

Another	O
C	O
-	O
-	O
>	O
T	O
transition	O
converted	O
a	O
CAG	O
-	O
glutamine	O
to	O
a	O
TAG	O
-	O
stop	O
in	O
exon	O
7	O
.	O

Small	O
insertions	O
created	O
frameshifts	O
which	O
produced	O
downstream	O
stop	O
codons	O
in	O
another	O
two	O
patients	O
and	O
an	O
A	O
-	O
-	O
>	O
T	O
mutation	O
disrupted	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
5	O
in	O
the	O
remaining	O
family	O
.	O

Thus	O
,	O
complete	O
inactivation	O
of	O
the	O
PAX6	O
gene	O
is	O
predicted	O
in	O
all	O
cases	O
.	O

Analysis	O
of	O
other	O
affected	O
members	O
of	O
the	O
families	O
showed	O
that	O
,	O
in	O
each	O
case	O
,	O
all	O
affected	O
individuals	O
carried	O
the	O
same	O
family	O
-	O
specific	O
mutation	O
.	O

One	O
polymorphism	O
was	O
found	O
in	O
exon	O
7	O
.	O

This	O
data	O
strongly	O
supports	O
the	O
candidature	O
of	O
PAX6	O
as	O
the	O
gene	O
responsible	O
for	O
hereditary	O
aniridia	B
.	O
.	O

Three	O
novel	O
mutations	O
in	O
five	O
unrelated	O
subjects	O
with	O
hereditary	O
protein	B
S	I
deficiency	I
type	I
I	I
.	O

A	O
panel	O
of	O
eight	O
unrelated	O
subjects	O
with	O
inherited	O
type	B
I	I
protein	I
S	I
deficiency	I
was	O
screened	O
for	O
mutations	O
in	O
the	O
PROS1	O
gene	O
.	O

In	O
five	O
subjects	O
an	O
abnormality	O
was	O
found	O
but	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
remaining	O
three	O
subjects	O
.	O

Two	O
subjects	O
shared	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
position	O
+	O
5	O
of	O
the	O
donor	O
splice	O
site	O
consensus	O
sequence	O
of	O
intron	O
10	O
.	O

Also	O
in	O
two	O
subjects	O
an	O
A	O
-	O
-	O
>	O
T	O
transversion	O
was	O
detected	O
in	O
the	O
stopcodon	O
of	O
the	O
PROS1	O
gene	O
;	O
this	O
transversion	O
predicts	O
a	O
protein	O
S	O
molecule	O
that	O
is	O
extended	O
by	O
14	O
amino	O
acids	O
.	O

The	O
fifth	O
subject	O
was	O
found	O
to	O
possess	O
two	O
sequence	O
abnormalities	O
.	O

One	O
allele	O
carried	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
near	O
the	O
donor	O
splice	O
junction	O
of	O
intron	O
2	O
,	O
but	O
this	O
abnormality	O
is	O
probably	O
neutral	O
,	O
since	O
it	O
was	O
inherited	O
from	O
the	O
parent	O
with	O
normal	O
protein	O
S	O
antigen	O
levels	O
.	O

In	O
the	O
other	O
allele	O
a	O
single	O
T	O
insertion	O
in	O
codon	O
-	O
25	O
was	O
found	O
.	O

Analysis	O
of	O
platelet	O
RNA	O
showed	O
that	O
only	O
the	O
mRNA	O
with	O
the	O
A	O
-	O
-	O
>	O
T	O
mutation	O
in	O
the	O
stopcodon	O
is	O
present	O
in	O
amounts	O
comparable	O
to	O
wildtype	O
RNA	O
.	O

mRNA	O
from	O
the	O
alleles	O
with	O
the	O
other	O
two	O
mutations	O
was	O
either	O
undetectable	O
or	O
present	O
in	O
greatly	O
reduced	O
amounts	O
.	O

The	O
latter	O
indicates	O
that	O
a	O
mRNA	O
based	O
approach	O
is	O
not	O
feasible	O
for	O
the	O
genetic	O
analysis	O
of	O
protein	B
S	I
deficiency	I
type	I
I	I
.	O
.	O

Characteristics	O
of	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
myotonic	B
dystrophy	I
.	O

In	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
size	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
DM	B
kinase	O
gene	O
generally	O
increases	O
in	O
successive	O
generations	O
with	O
clinical	O
evidence	O
of	O
anticipation	O
.	O

However	O
,	O
there	O
have	O
also	O
been	O
cases	O
with	O
an	O
intergenerational	O
contraction	O
of	O
the	O
repeat	O
.	O

We	O
examined	O
1	O
,	O
489	O
DM	B
parent	O
-	O
offspring	O
pairs	O
,	O
of	O
which	O
95	O
(	O
6	O
.	O
4	O
%	O
)	O
showed	O
such	O
contractions	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
PBL	O
)	O
.	O

In	O
56	O
of	O
the	O
95	O
pairs	O
,	O
clinical	O
data	O
allowed	O
an	O
analysis	O
of	O
their	O
anticipation	O
status	O
.	O

It	O
is	O
surprising	O
that	O
anticipation	O
occurred	O
in	O
27	O
(	O
48	O
%	O
)	O
of	O
these	O
56	O
pairs	O
,	O
while	O
none	O
clearly	O
showed	O
a	O
later	O
onset	O
of	O
DM	B
in	O
the	O
symptomatic	O
offspring	O
.	O

The	O
contraction	O
occurred	O
in	O
76	O
(	O
10	O
%	O
)	O
of	O
753	O
paternal	O
transmissions	O
and	O
in	O
19	O
(	O
3	O
%	O
)	O
of	O
736	O
maternal	O
transmissions	O
.	O

Anticipation	O
was	O
observed	O
more	O
frequently	O
in	O
maternal	O
(	O
85	O
%	O
)	O
than	O
in	O
paternal	O
(	O
37	O
%	O
)	O
transmissions	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
parental	O
repeat	O
size	O
correlated	O
with	O
the	O
size	O
of	O
intergenerational	O
contraction	O
(	O
r2	O
=	O
.	O
50	O
,	O
P	O
<	O
<	O
.	O
001	O
)	O
,	O
and	O
the	O
slope	O
of	O
linear	O
regression	O
was	O
steeper	O
in	O
paternal	O
(	O
-	O
.	O
62	O
)	O
than	O
in	O
maternal	O
(	O
-	O
.	O
30	O
)	O
transmissions	O
(	O
P	O
<	O
<	O
.	O
001	O
)	O
.	O

Sixteen	O
DM	B
parents	O
had	O
multiple	O
DM	B
offspring	O
with	O
the	O
CTG	O
repeat	O
contractions	O
.	O

This	O
frequency	O
was	O
higher	O
than	O
the	O
frequency	O
expected	O
from	O
the	O
probability	O
of	O
the	O
repeat	O
contractions	O
(	O
6	O
.	O
4	O
%	O
)	O
and	O
the	O
size	O
of	O
DM	B
sib	O
population	O
(	O
1	O
.	O
54	O
DM	B
offspring	O
per	O
DM	B
parent	O
,	O
in	O
968	O
DM	B
parents	O
)	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
leukocyte	O
DNA	O
frequently	O
accompanies	O
apparent	O
anticipation	O
,	O
especially	O
when	O
DM	B
is	O
maternally	O
transmitted	O
,	O
and	O
(	O
2	O
)	O
the	O
paternal	O
origin	O
of	O
the	O
repeat	O
and	O
the	O
presence	O
of	O
the	O
repeat	O
contraction	O
in	O
a	O
sibling	O
increase	O
the	O
probability	O
of	O
the	O
CTG	O
repeat	O
contraction	O

Gonosomal	O
mosaicism	O
in	O
myotonic	B
dystrophy	I
patients	O
:	O
involvement	O
of	O
mitotic	O
events	O
in	O
(	O
CTG	O
)	O
n	O
repeat	O
variation	O
and	O
selection	O
against	O
extreme	O
expansion	O
in	O
sperm	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
abnormal	O
expansion	O
of	O
a	O
polymorphic	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
DM	B
protein	O
kinase	O
gene	O
.	O

We	O
determined	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
lengths	O
in	O
a	O
broad	O
range	O
of	O
tissue	O
DNAs	O
from	O
patients	O
with	O
mild	O
,	O
classical	O
,	O
or	O
congenital	O
manifestation	O
of	O
DM	B
.	O

Differences	O
in	O
the	O
repeat	O
length	O
were	O
seen	O
in	O
somatic	O
tissues	O
from	O
single	O
DM	B
individuals	O
and	O
twins	O
.	O

Repeats	O
appeared	O
to	O
expand	O
to	O
a	O
similar	O
extent	O
in	O
tissues	O
originating	O
from	O
the	O
same	O
embryonal	O
origin	O
.	O

In	O
most	O
male	O
patients	O
carrying	O
intermediate	O
-	O
or	O
small	O
-	O
sized	O
expansions	O
in	O
blood	O
,	O
the	O
repeat	O
lengths	O
covered	O
a	O
markedly	O
wider	O
range	O
in	O
sperm	O
.	O

In	O
contrast	O
,	O
male	O
patients	O
with	O
large	O
allele	O
expansions	O
in	O
blood	O
(	O
>	O
700	O
CTGs	O
)	O
had	O
similar	O
or	O
smaller	O
repeats	O
in	O
sperm	O
,	O
when	O
detectable	O
.	O

Sperm	O
alleles	O
with	O
>	O
1	O
,	O
000	O
CTGs	O
were	O
not	O
seen	O
.	O

We	O
conclude	O
that	O
DM	B
patients	O
can	O
be	O
considered	O
gonosomal	O
mosaics	O
,	O
i	O
.	O

e	O
e	O
.	O
,	O
combined	O
somatic	O
and	O
germ	O
-	O
line	O
tissue	O
mosaics	O
.	O

Most	O
remarkably	O
,	O
we	O
observed	O
multiple	O
cases	O
where	O
the	O
length	O
distributions	O
of	O
intermediate	O
-	O
or	O
small	O
-	O
sized	O
alleles	O
in	O
fathers	O
sperm	O
were	O
significantly	O
different	O
from	O
that	O
in	O
their	O
offsprings	O
blood	O
.	O

Our	O
combined	O
findings	O
indicate	O
that	O
intergenerational	O
length	O
changes	O
in	O
the	O
unstable	O
CTG	O
repeat	O
are	O
most	O
likely	O
to	O
occur	O
during	O
early	O
embryonic	O
mitotic	O
divisions	O
in	O
both	O
somatic	O
and	O
germ	O
-	O
line	O
tissue	O
formation	O
.	O

Both	O
the	O
initial	O
CTG	O
length	O
,	O
the	O
overall	O
number	O
of	O
cell	O
divisions	O
involved	O
in	O
tissue	O
formation	O
,	O
and	O
perhaps	O
a	O
specific	O
selection	O
process	O
in	O
spermatogenesis	O
may	O
influence	O
the	O
dynamics	O
of	O
this	O
process	O
.	O

A	O
model	O
explaining	O
mitotic	O
instability	O
and	O
sex	O
-	O
dependent	O
segregation	O
phenomena	O
in	O
DM	B
manifestation	O
is	O
discussed	O

Regionally	O
clustered	O
APC	B
mutations	O
are	O
associated	O
with	O
a	O
severe	O
phenotype	O
and	O
occur	O
at	O
a	O
high	O
frequency	O
in	O
new	O
mutation	O
cases	O
of	O
adenomatous	B
polyposis	I
coli	I
.	O

Germline	O
mutation	O
in	O
APC	O
at	O
5q21	O
-	O
22	O
results	O
in	O
the	O
dominantly	O
inherited	O
syndrome	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
.	O

Somatic	O
mutation	O
in	O
this	O
gene	O
is	O
an	O
early	O
event	O
in	O
colorectal	O
tumourigenesis	O
.	O

Both	O
types	O
of	O
mutation	O
are	O
concentrated	O
in	O
the	O
5	O
half	O
of	O
exon	O
15	O
.	O

We	O
have	O
used	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
heteroduplex	O
analysis	O
to	O
screen	O
for	O
variants	O
in	O
this	O
region	O
of	O
the	O
gene	O
in	O
a	O
total	O
of	O
45	O
affected	O
but	O
unrelated	O
individuals	O
.	O

Eighteen	O
patients	O
had	O
no	O
family	O
history	O
of	O
the	O
disease	O
;	O
of	O
these	O
11	O
were	O
classified	O
as	O
having	O
a	O
severe	O
phenotype	O
,	O
based	O
on	O
an	O
early	O
age	O
at	O
presentation	O
or	O
cancer	B
development	O
.	O

This	O
compared	O
with	O
6	O
of	O
27	O
familial	O
cases	O
.	O

A	O
5	O
bp	O
deletion	O
at	O
codon	O
1309	O
reported	O
to	O
occur	O
in	O
10	O
-	O
15	O
%	O
of	O
unselected	O
APC	B
patients	O
worldwide	O
,	O
was	O
found	O
in	O
5	O
of	O
the	O
18	O
new	O
mutation	O
cases	O
and	O
4	O
of	O
the	O
27	O
familial	O
cases	O
all	O
nine	O
were	O
classed	O
as	O
severe	O
.	O

A	O
further	O
3	O
new	O
mutations	O
and	O
1	O
familial	O
mutation	O
were	O
located	O
downstream	O
from	O
codon	O
1309	O
,	O
these	O
individuals	O
similarly	O
being	O
classed	O
as	O
phenotypically	O
severe	O
.	O

In	O
contrast	O
all	O
of	O
the	O
APC	B
mutations	O
detected	O
in	O
affected	O
individuals	O
with	O
an	O
average	O
phenotype	O
were	O
located	O
prior	O
to	O
codon	O
1309	O
.	O

The	O
frequent	O
association	O
of	O
a	O
severe	O
phenotype	O
with	O
fresh	O
mutation	O
may	O
explain	O
the	O
apparent	O
conflict	O
of	O
a	O
high	O
mutation	O
rate	O
(	O
20	O
-	O
30	O
%	O
)	O
in	O
a	O
condition	O
,	O
which	O
on	O
average	O
,	O
is	O
lethal	O
at	O
a	O
post	O
-	O
reproductive	O
age	O
.	O
.	O

Mutations	O
at	O
the	O
PAX6	O
locus	O
are	O
found	O
in	O
heterogeneous	O
anterior	B
segment	I
malformations	I
including	O
Peters	B
'	I
anomaly	I
.	O

Mutation	O
or	O
deletion	O
of	O
the	O
PAX6	O
gene	O
underlies	O
many	O
cases	O
of	O
aniridia	B
.	O

Three	O
lines	O
of	O
evidence	O
now	O
converge	O
to	O
implicate	O
PAX6	O
more	O
widely	O
in	O
anterior	B
segment	I
malformations	I
including	O
Peters	B
anomaly	I
.	O

First	O
,	O
a	O
child	O
with	O
Peters	B
anomaly	I
is	O
deleted	O
for	O
one	O
copy	O
of	O
PAX6	O
.	O

Second	O
,	O
affected	O
members	O
of	O
a	O
family	O
with	O
dominantly	O
inherited	O
anterior	B
segment	I
malformations	I
,	O
including	O
Peters	B
anomaly	I
are	O
heterozygous	O
for	O
an	O
R26G	O
mutation	O
in	O
the	O
PAX6	O
paired	O
box	O
.	O

Third	O
,	O
a	O
proportion	O
of	O
Sey	O
/	O
+	O
Smalleye	O
mice	O
,	O
heterozygous	O
for	O
a	O
nonsense	O
mutation	O
in	O
murine	O
Pax	O
-	O
6	O
,	O
have	O
an	O
ocular	O
phenotype	O
resembling	O
Peters	B
anomaly	I
.	O

We	O
therefore	O
propose	O
that	O
a	O
variety	O
of	O
anterior	B
segment	I
anomalies	I
may	O
be	O
associated	O
with	O
PAX6	O
mutations	O
.	O
.	O

Huntington	B
disease	I
without	O
CAG	O
expansion	O
:	O
phenocopies	O
or	O
errors	O
in	O
assignment	O
?	O

Huntington	B
disease	I
(	O
HD	B
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
expanded	O
CAG	O
repeat	O
within	O
a	O
novel	O
gene	O
on	O
4p16	O
.	O

3	O
(	O
IT15	O
)	O
.	O

A	O
total	O
of	O
30	O
of	O
1	O
,	O
022	O
affected	O
persons	O
(	O
2	O
.	O
9	O
%	O
of	O
our	O
cohort	O
)	O
did	O
not	O
have	O
an	O
expanded	O
CAG	O
in	O
the	O
disease	O
range	O
.	O

The	O
reasons	O
for	O
not	O
observing	O
expansion	O
in	O
affected	O
individuals	O
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	O
length	O
both	O
for	O
diagnosis	O
of	O
affected	O
patients	O
and	O
for	O
predictive	O
testing	O
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
HD	B
.	O

Here	O
we	O
show	O
that	O
the	O
majority	O
(	O
18	O
)	O
of	O
the	O
individuals	O
with	O
normal	O
sized	O
alleles	O
represent	O
misdiagnosis	O
,	O
sample	O
mix	O
-	O
up	O
,	O
or	O
clerical	O
error	O
.	O

The	O
remaining	O
12	O
patients	O
represent	O
possible	O
phenocopies	O
for	O
HD	B
.	O

In	O
at	O
least	O
four	O
cases	O
,	O
family	O
studies	O
of	O
these	O
phenocopies	O
excluded	O
4p16	O
.	O

3	O
as	O
the	O
region	O
responsible	O
for	O
the	O
phenotype	O
.	O

Mutations	O
in	O
the	O
HD	B
gene	O
that	O
are	O
other	O
than	O
CAG	O
expansion	O
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases	O
;	O
however	O
,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons	O
,	O
retrospective	O
review	O
of	O
these	O
patients	O
clinical	O
features	O
identified	O
characteristics	O
not	O
typical	O
for	O
HD	B
.	O

This	O
study	O
shows	O
that	O
on	O
rare	O
occasions	O
mutations	O
in	O
other	O
,	O
as	O
-	O
yet	O
-	O
undefined	O
genes	O
can	O
present	O
with	O
a	O
clinical	O
phenotype	O
very	O
similar	O
to	O
that	O
of	O
HD	B

Frequent	O
detection	O
of	O
codon	O
877	O
mutation	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
advanced	B
prostate	I
cancers	I
.	O

Prostatic	O
tissue	O
specimens	O
derived	O
from	O
transurethral	O
resections	O
of	O
patients	O
with	O
metastatic	B
prostate	I
cancer	I
were	O
analyzed	O
for	O
genetic	O
alterations	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
.	O

Direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
-	O
derived	O
DNAs	O
of	O
6	O
of	O
24	O
specimens	O
revealed	O
a	O
codon	O
877	O
mutation	O
(	O
ACT	O
-	O
-	O
>	O
GCT	O
,	O
Thr	O
-	O
-	O
>	O
Ala	O
)	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
AR	O
gene	O
.	O

This	O
same	O
AR	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
a	O
metastatic	B
prostate	I
cancer	I
cell	O
line	O
,	O
LNCaP	O
,	O
where	O
this	O
mutation	O
confers	O
upon	O
the	O
AR	O
an	O
altered	O
ligand	O
-	O
binding	O
specificity	O
which	O
is	O
stimulated	O
by	O
estrogens	O
,	O
progestagens	O
,	O
and	O
antiandrogens	O
.	O

It	O
is	O
possible	O
that	O
analogous	O
to	O
an	O
activated	O
/	O
altered	O
growth	O
factor	O
receptor	O
oncogene	O
,	O
codon	O
877	O
mutant	O
AR	O
with	O
altered	O
ligand	O
binding	O
may	O
provide	O
a	O
selective	O
growth	O
advantage	O
in	O
the	O
genesis	O
of	O
a	O
subset	O
of	O
advanced	B
prostate	I
cancer	I
.	O

Although	O
estrogens	O
are	O
used	O
infrequently	O
,	O
antiandrogens	O
are	O
used	O
increasingly	O
in	O
hormonal	O
therapy	O
for	O
patients	O
with	O
advanced	B
prostate	I
cancer	I
.	O

The	O
stimulatory	O
effect	O
of	O
these	O
therapeutic	O
agents	O
on	O
the	O
codon	O
877	O
mutant	O
AR	O
further	O
suggests	O
that	O
this	O
frequently	O
observed	O
AR	O
mutation	O
may	O
contribute	O
to	O
the	O
treatment	O
refractory	O
disease	O
.	O
.	O

The	O
human	O
gene	O
for	O
alkaptonuria	B
(	O
AKU	B
)	O
maps	O
to	O
chromosome	O
3q	O
.	O

Alkaptonuria	B
(	O
AKU	B
;	O
McKusick	O
no	O
.	O
203500	O
)	O
is	O
a	O
rare	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
the	O
lack	O
of	O
homogentisic	O
acid	O
oxidase	O
activity	O
.	O

Patients	O
excrete	O
large	O
amounts	O
of	O
homogentisic	O
acid	O
in	O
their	O
urine	O
and	O
a	O
black	O
ochronotic	O
pigment	O
is	O
deposited	O
in	O
their	O
cartilage	O
and	O
collagenous	O
tissues	O
.	O

Ochronosis	B
is	O
the	O
predominant	O
clinical	O
complication	O
of	O
the	O
disease	O
leading	O
to	O
ochronotic	B
arthropathy	I
,	O
dark	O
urine	O
,	O
pigment	O
changes	O
of	O
the	O
skin	O
,	O
and	O
other	O
clinical	O
features	O
.	O

A	O
mutation	O
causing	O
alkaptonuria	B
in	O
the	O
mouse	O
has	O
mapped	O
to	O
chromosome	O
16	O
.	O

Considering	O
conserved	O
synteny	O
,	O
we	O
were	O
able	O
to	O
map	O
the	O
human	O
gene	O
to	O
chromosome	O
3q	O
in	O
six	O
alkaptonuria	B
pedigrees	O
of	O
Slovak	O
origin	O
.	O
.	O

Structure	O
of	O
the	O
human	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
.	O

Intestinal	O
uptake	O
of	O
dietary	O
glucose	O
and	O
galactose	O
is	O
mediated	O
by	O
the	O
SGLT1	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
of	O
the	O
brush	O
border	O
.	O

An	O
SGLT1	O
missense	O
mutation	O
underlies	O
hereditary	B
glucose	I
/	I
galactose	I
malabsorption	I
,	O
characterized	O
by	O
potentially	O
fatal	O
diarrhea	B
;	O
conversely	O
,	O
oral	O
rehydration	O
therapy	O
exploits	O
normal	O
transport	O
to	O
alleviate	O
life	O
-	O
threatening	O
diarrhea	B
of	O
infectious	O
origin	O
.	O

We	O
have	O
mapped	O
the	O
entire	O
human	O
SGLT1	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
from	O
cosmid	O
and	O
lambda	O
phage	O
clones	O
representing	O
a	O
genomic	O
region	O
of	O
112	O
kilobases	O
.	O

Transcription	O
initiation	O
occurred	O
from	O
a	O
site	O
27	O
base	O
pairs	O
3	O
of	O
a	O
TATAA	O
sequence	O
.	O

All	O
exon	O
-	O
flanking	O
regions	O
were	O
sequenced	O
,	O
and	O
the	O
entire	O
112	O
-	O
kilobase	O
region	O
mapped	O
with	O
four	O
restriction	O
enzymes	O
.	O

SGLT1	O
is	O
comprised	O
of	O
15	O
exons	O
(	O
spanning	O
72	O
kilobases	O
)	O
;	O
a	O
possible	O
evolutionary	O
origin	O
from	O
a	O
six	O
-	O
membrane	O
-	O
span	O
ancestral	O
precursor	O
via	O
a	O
gene	O
duplication	O
event	O
is	O
suggested	O
from	O
comparison	O
of	O
exons	O
against	O
protein	O
secondary	O
structure	O
and	O
from	O
sequence	O
considerations	O
.	O

A	O
new	O
missense	O
mutation	O
in	O
exon	O
1	O
causing	O
glucose	B
/	I
galactose	I
malabsorption	I
is	O
also	O
described	O
.	O

This	O
is	O
the	O
first	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
cotransporter	O
gene	O
structure	O
reported	O
.	O

These	O
data	O
facilitate	O
the	O
search	O
for	O
new	O
glucose	B
/	I
galactose	I
malabsorption	I
-	O
related	O
mutations	O
in	O
this	O
important	O
gene	O
and	O
provide	O
a	O
basis	O
for	O
future	O
evolutionary	O
comparisons	O
with	O
other	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
cotransporters	O
.	O
.	O

Four	O
novel	O
PEPD	O
alleles	O
causing	O
prolidase	B
deficiency	I
.	O

Mutations	O
at	O
the	O
PEPD	O
locus	O
cause	O
prolidase	B
deficiency	I
(	O
McKusick	O
170100	O
)	O
,	O
a	O
rare	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
iminodipeptiduria	B
,	O
skin	B
ulcers	I
,	O
mental	B
retardation	I
,	O
and	O
recurrent	O
infections	O
.	O

Four	O
PEPD	O
mutations	O
from	O
five	O
severely	O
affected	O
individuals	O
were	O
characterized	O
by	O
analysis	O
of	O
reverse	O
-	O
transcribed	O
,	O
PCR	O
-	O
amplified	O
(	O
RT	O
-	O
PCR	O
)	O
cDNA	O
.	O

We	O
used	O
SSCP	O
analysis	O
on	O
four	O
overlapping	O
cDNA	O
fragments	O
covering	O
the	O
entire	O
coding	O
region	O
of	O
the	O
PEPD	O
gene	O
and	O
detected	O
abnormal	O
SSCP	O
bands	O
for	O
the	O
fragment	O
spanning	O
all	O
or	O
part	O
of	O
exons	O
13	O
-	O
15	O
in	O
three	O
of	O
the	O
probands	O
.	O

Direct	O
sequencing	O
of	O
the	O
mutant	O
cDNAs	O
showed	O
a	O
G	O
-	O
-	O
>	O
A	O
,	O
1342	O
substitution	O
(	O
G448R	O
)	O
in	O
two	O
patients	O
and	O
a	O
3	O
-	O
bp	O
deletion	O
(	O
delta	O
E452	O
or	O
delta	O
E453	O
)	O
in	O
another	O
.	O

In	O
the	O
other	O
two	O
probands	O
the	O
amplified	O
products	O
were	O
of	O
reduced	O
size	O
.	O

Direct	O
sequencing	O
of	O
these	O
mutant	O
cDNAs	O
revealed	O
a	O
deletion	O
of	O
exon	O
5	O
in	O
one	O
patient	O
and	O
of	O
exon	O
7	O
in	O
the	O
other	O
.	O

Intronic	O
sequences	O
flanking	O
exons	O
5	O
and	O
7	O
were	O
identified	O
using	O
inverse	O
PCR	O
followed	O
by	O
direct	O
sequencing	O
.	O

Conventional	O
PCR	O
and	O
direct	O
sequencing	O
then	O
established	O
the	O
intron	O
-	O
exon	O
borders	O
of	O
the	O
mutant	O
genomic	O
DNA	O
revealing	O
two	O
splice	O
acceptor	O
mutations	O
a	O
G	O
-	O
-	O
>	O
C	O
substitution	O
at	O
position	O
-	O
1	O
of	O
intron	O
4	O
and	O
an	O
A	O
-	O
-	O
>	O
G	O
substitution	O
at	O
position	O
-	O
2	O
of	O
intron	O
6	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
severe	O
form	O
of	O
prolidase	B
deficiency	I
is	O
caused	O
by	O
multiple	O
PEPD	O
alleles	O
.	O

In	O
this	O
report	O
we	O
attempt	O
to	O
begin	O
the	O
process	O
of	O
describing	O
these	O
alleles	O
and	O
cataloging	O
their	O
phenotypic	O
expression	O
.	O
.	O

Recombinations	O
in	O
individuals	O
homozygous	O
by	O
descent	O
localize	O
the	O
Friedreich	B
ataxia	I
locus	O
in	O
a	O
cloned	O
450	O
-	O
kb	O
interval	O
.	O

The	O
locus	O
for	O
Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
,	O
a	O
severe	O
neurodegenerative	B
disease	I
,	O
is	O
tightly	O
linked	O
to	O
markers	O
D9S5	O
and	O
D9S15	O
,	O
and	O
analysis	O
of	O
rare	O
recombination	O
events	O
has	O
suggested	O
the	O
order	O
cen	O
-	O
FRDA	O
-	O
D9S5	O
-	O
D9S15	O
-	O
qter	O
.	O

We	O
report	O
here	O
the	O
construction	O
of	O
a	O
YAC	O
contig	O
extending	O
800	O
kb	O
centromeric	O
to	O
D9S5	O
and	O
the	O
isolation	O
of	O
five	O
new	O
microsatellite	O
markers	O
from	O
this	O
region	O
.	O

In	O
order	O
to	O
map	O
these	O
markers	O
with	O
respect	O
to	O
the	O
FRDA	B
locus	O
,	O
all	O
within	O
a	O
1	O
-	O
cM	O
confidence	O
interval	O
,	O
we	O
sought	O
to	O
increase	O
the	O
genetic	O
information	O
of	O
available	O
FRDA	B
families	O
by	O
considering	O
homozygosity	O
by	O
descent	O
and	O
association	O
with	O
founder	O
haplotypes	O
in	O
isolated	O
populations	O
.	O

This	O
approach	O
allowed	O
us	O
to	O
identify	O
one	O
phase	O
-	O
known	O
recombination	O
and	O
one	O
probable	O
historic	O
recombination	O
on	O
haplotypes	O
from	O
Reunion	O
Island	O
patients	O
,	O
both	O
of	O
which	O
place	O
three	O
of	O
the	O
five	O
markers	O
proximal	O
to	O
FRDA	B
.	O

This	O
represents	O
the	O
first	O
identification	O
of	O
close	O
FRDA	B
flanking	O
markers	O
on	O
the	O
centromeric	O
side	O
.	O

The	O
two	O
other	O
markers	O
allowed	O
us	O
to	O
narrow	O
the	O
breakpoint	O
of	O
a	O
previously	O
identified	O
distal	O
recombination	O
that	O
is	O
>	O
180	O
kb	O
from	O
D9S5	O
(	O
26P	O
)	O
.	O

Taken	O
together	O
,	O
the	O
results	O
place	O
the	O
FRDA	B
locus	O
in	O
a	O
450	O
-	O
kb	O
interval	O
,	O
which	O
is	O
small	O
enough	O
for	O
direct	O
search	O
of	O
candidate	O
genes	O
.	O

A	O
detailed	O
rare	O
cutter	O
restriction	O
map	O
and	O
a	O
cosmid	O
contig	O
covering	O
this	O
interval	O
were	O
constructed	O
and	O
should	O
facilitate	O
the	O
search	O
of	O
genes	O
in	O
this	O
region	O
.	O
.	O

Investigation	O
of	O
thermoregulatory	O
characteristics	O
in	O
patients	O
with	O
Prader	B
-	I
Willi	I
syndrome	I
.	O

A	O
survey	O
instrument	O
is	O
used	O
to	O
assess	O
temperature	O
regulation	O
characteristics	O
in	O
children	O
with	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
compared	O
to	O
3	O
control	O
groups	O
sibs	O
of	O
PWS	B
patients	O
(	O
SIB	O
)	O
,	O
neurodevelopmentally	B
handicapped	I
children	O
(	O
ND	O
)	O
,	O
and	O
age	O
and	O
gender	O
matched	O
well	O
children	O
(	O
WC	O
)	O
.	O

Significant	O
differences	O
were	O
found	O
between	O
PWS	B
patients	O
,	O
SIB	O
controls	O
,	O
and	O
WC	O
controls	O
in	O
the	O
prevalence	O
of	O
febrile	O
convulsions	O
,	O
fever	O
-	O
associated	O
symptoms	O
,	O
and	O
temperature	O
less	O
than	O
94	O
degrees	O
F	O
.	O

No	O
differences	O
were	O
noted	O
in	O
any	O
variable	O
between	O
the	O
PWS	B
patients	O
and	O
the	O
ND	O
controls	O
,	O
suggesting	O
that	O
these	O
abnormalities	O
are	O
not	O
unique	O
to	O
PWS	B
,	O
but	O
can	O
occur	O
in	O
any	O
neurodevelopmentally	B
handicapped	I
individual	O
,	O
further	O
suggesting	O
these	O
do	O
not	O
necessarily	O
reflect	O
syndrome	O
-	O
specific	O
hypothalamic	B
abnormalities	I
.	O
.	O

Phenotypic	O
variation	O
including	O
retinitis	B
pigmentosa	I
,	O
pattern	B
dystrophy	I
,	O
and	O
fundus	B
flavimaculatus	I
in	O
a	O
single	O
family	O
with	O
a	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Mutations	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
have	O
been	O
reported	O
in	O
autosomal	B
dominant	I
retinitis	I
pigmentosa	I
,	O
pattern	O
macular	B
dystrophy	I
,	O
and	O
retinitis	B
punctata	I
albescens	I
.	O

We	O
report	O
herein	O
the	O
occurrence	O
of	O
three	O
separate	O
phenotypes	O
within	O
a	O
single	O
family	O
with	O
a	O
novel	O
3	O
-	O
base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
.	O

DESIGN	O
Case	O
reports	O
with	O
clinical	O
features	O
,	O
fluorescein	O
angiography	O
,	O
kinetic	O
perimetry	O
,	O
electrophysiological	O
studies	O
,	O
and	O
molecular	O
genetics	O
.	O

SETTING	O
University	O
medical	O
centers	O
.	O

PATIENTS	O
A	O
75	O
-	O
year	O
-	O
old	O
woman	O
,	O
her	O
two	O
daughters	O
(	O
aged	O
44	O
and	O
50	O
years	O
)	O
,	O
and	O
her	O
49	O
-	O
year	O
-	O
old	O
son	O
were	O
screened	O
for	O
peripherin	O
/	O
RDS	O
mutations	O
because	O
of	O
the	O
presence	O
of	O
multiple	O
phenotypes	O
within	O
the	O
same	O
family	O
.	O

RESULTS	O
The	O
mother	O
presented	O
at	O
age	O
63	O
years	O
with	O
a	O
profoundly	O
abnormal	O
electroretinogram	O
(	O
ERG	O
)	O
and	O
adult	O
-	O
onset	O
retinitis	B
pigmentosa	I
that	O
progressed	O
dramatically	O
over	O
12	O
years	O
,	O
with	O
marked	O
loss	O
of	O
peripheral	O
visual	O
field	O
.	O

One	O
daughter	O
developed	O
pattern	B
macular	I
dystrophy	I
at	O
age	O
31	O
years	O
.	O

At	O
age	O
44	O
years	O
,	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
but	O
her	O
clinical	O
disease	O
was	O
limited	O
to	O
the	O
macula	O
.	O

Another	O
daughter	O
presented	O
at	O
age	O
42	O
years	O
with	O
macular	B
degeneration	I
and	O
over	O
10	O
years	O
developed	O
the	O
clinical	O
picture	O
of	O
fundus	B
flavimaculatus	I
.	O

Her	O
peripheral	O
visual	O
field	O
was	O
preserved	O
but	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
.	O

The	O
son	O
had	O
onset	O
of	O
macular	B
degeneration	I
at	O
age	O
44	O
years	O
.	O

Pericentral	B
scotomas	I
were	O
present	O
and	O
the	O
ERG	O
was	O
markedly	O
abnormal	O
.	O

Fluorescein	O
angiography	O
revealed	O
punctate	O
pigment	O
epithelial	O
transmission	O
defects	O
.	O

CONCLUSIONS	O
A	O
3	O
-	O
base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
can	O
produce	O
clinically	O
disparate	O
phenotypes	O
even	O
within	O
the	O
same	O
family	O
.	O
.	O

Assignment	O
of	O
the	O
human	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
to	O
chromosome	O
22q13	O
.	O
1	O
.	O

The	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
encodes	O
the	O
primary	O
carrier	O
protein	O
responsible	O
for	O
the	O
uptake	O
of	O
the	O
dietary	O
sugars	O
glucose	O
and	O
galactose	O
from	O
the	O
intestinal	O
lumen	O
.	O

SGLT1	O
transport	O
activity	O
is	O
currently	O
exploited	O
in	O
oral	O
rehydration	O
therapy	O
.	O

The	O
75	O
-	O
kDa	O
glycoprotein	O
is	O
localized	O
in	O
the	O
brush	O
border	O
of	O
the	O
intestinal	O
epithelium	O
and	O
is	O
predicted	O
to	O
comprise	O
12	O
membrane	O
spans	O
.	O

In	O
two	O
patients	O
with	O
the	O
autosomal	B
recessive	I
disease	I
glucose	I
/	I
galactose	I
malabsorption	I
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	O
mutation	O
in	O
SGLT1	O
,	O
and	O
the	O
Asp28	O
-	O
-	O
>	O
Asn	O
change	O
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
SGLT1	O
transport	O
activity	O
.	O

The	O
SGLT1	O
gene	O
was	O
previously	O
shown	O
to	O
reside	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
(	O
11	O
.	O
2	O
-	O
-	O
>	O
qter	O
)	O
.	O

We	O
have	O
used	O
a	O
cosmid	O
probe	O
for	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
which	O
refines	O
the	O
localization	O
to	O
22q13	O
.	O

1	O
,	O
and	O
provide	O
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
SGLT1	O
probe	O
as	O
a	O
diagnostic	O
for	O
genetic	B
diseases	I
associated	O
with	O
translocations	O
of	O
chromosome	O
22	O
.	O

Restriction	O
of	O
ocular	O
fundus	O
lesions	O
to	O
a	O
specific	O
subgroup	O
of	O
APC	B
mutations	O
in	O
adenomatous	B
polyposis	I
coli	I
patients	O
.	O

In	O
humans	O
,	O
alteration	O
of	O
the	O
tumor	B
suppressor	O
gene	O
,	O
APC	B
,	O
causes	O
adenomatous	B
polyposis	I
coli	I
,	O
a	O
condition	O
causing	O
predisposition	O
to	O
colorectal	B
cancer	I
.	O

The	O
syndrome	O
inconsistently	O
associates	O
characteristic	O
patches	O
of	O
congenital	B
hypertrophy	I
of	I
the	I
retinal	I
pigment	I
epithelium	I
(	O
CHRPE	B
)	O
.	O

Ocular	O
examination	O
revealed	O
that	O
patients	O
expressing	O
CHRPE	B
tend	O
to	O
cluster	O
within	O
specific	O
families	O
.	O

The	O
exact	O
APC	B
mutation	O
was	O
identified	O
in	O
42	O
unrelated	O
patients	O
.	O

In	O
all	O
cases	O
these	O
mutations	O
were	O
predicted	O
to	O
lead	O
to	O
the	O
synthesis	O
of	O
a	O
truncated	O
protein	O
.	O

The	O
extent	O
of	O
CHRPE	B
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
position	O
of	O
the	O
mutation	O
along	O
the	O
coding	O
sequence	O
.	O

CHRPE	B
lesions	O
are	O
almost	O
always	O
absent	O
if	O
the	O
mutation	O
occurs	O
before	O
exon	O
9	O
,	O
but	O
are	O
systematically	O
present	O
if	O
it	O
occurs	O
after	O
this	O
exon	O
.	O

Thus	O
,	O
the	O
range	O
of	O
phenotypic	O
expression	O
observed	O
among	O
affected	O
patients	O
may	O
result	O
in	O
part	O
from	O
different	O
allelic	O
manifestations	O
of	O
APC	B
mutations	O
.	O
.	O

The	O
effects	O
of	O
dystrophin	O
gene	O
mutations	O
on	O
the	O
ERG	O
in	O
mice	O
and	O
humans	O
.	O

PURPOSE	O
.	O

The	O
authors	O
earlier	O
findings	O
of	O
a	O
negative	O
electroretinogram	O
(	O
ERG	O
)	O
in	O
a	O
boy	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
led	O
them	O
to	O
investigate	O
dystrophin	O
gene	O
deletions	O
and	O
ERGs	O
in	O
five	O
boys	O
with	O
DMD	B
.	O

The	O
authors	O
wanted	O
to	O
determined	O
whether	O
there	O
were	O
similar	O
ERG	O
findings	O
in	O
an	O
animal	O
model	O
for	O
DMD	B
,	O
the	O
mdx	O
mouse	O
.	O

METHODS	O
.	O

Ganzfeld	O
ERGs	O
were	O
recorded	O
in	O
five	O
boys	O
with	O
DMD	B
after	O
a	O
complete	O
ophthalmic	O
examination	O
.	O

The	O
dystrophin	O
gene	O
was	O
analyzed	O
by	O
Southern	O
blot	O
hybridization	O
.	O

ERGs	O
were	O
recorded	O
in	O
anesthetized	O
mdx	O
and	O
control	O
mice	O
with	O
a	O
modified	O
Grass	O
photostimulator	O
(	O
Grass	O
Instrument	O
Company	O
,	O
Quincy	O
,	O
MA	O
)	O
.	O

RESULTS	O
.	O

Ophthalmic	O
examinations	O
in	O
all	O
five	O
boys	O
had	O
normal	O
findings	O
,	O
yet	O
an	O
abnormal	O
negative	O
ERG	O
was	O
recorded	O
for	O
each	O
subject	O
.	O

The	O
subjects	O
gene	O
deletions	O
were	O
variable	O
,	O
ranging	O
from	O
large	O
deletions	O
to	O
no	O
detectable	O
deletions	O
.	O

The	O
ERGs	O
of	O
the	O
mdx	O
mice	O
were	O
normal	O
and	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
the	O
control	O
mice	O
.	O

CONCLUSIONS	O
.	O

The	O
authors	O
believe	O
the	O
unique	O
ERG	O
recorded	O
for	O
the	O
human	O
subjects	O
is	O
a	O
manifestation	O
of	O
DMD	B
associated	O
with	O
defects	O
at	O
the	O
dystrophin	O
gene	O
locus	O
and	O
represents	O
a	O
new	O
clinical	O
entity	O
.	O

The	O
ERG	O
of	O
the	O
mdx	O
mouse	O
may	O
be	O
spared	O
for	O
several	O
reasons	O
,	O
including	O
milder	O
effects	O
of	O
the	O
mouse	O
gene	O
defect	O
,	O
differences	O
in	O
muscle	O
and	O
retinal	O
gene	O
product	O
,	O
or	O
species	O
differences	O
in	O
the	O
biochemical	O
role	O
of	O
dystrophin	O
.	O

The	O
ERG	O
shows	O
promise	O
of	O
becoming	O
a	O
noninvasive	O
diagnostic	O
tool	O
for	O
DMD	B
and	O
its	O
milder	O
allelic	O
forms	O
.	O
.	O

Association	O
of	O
the	O
APC	B
tumor	I
suppressor	O
protein	O
with	O
catenins	O
.	O

Mutations	O
of	O
APC	O
appear	O
to	O
initiate	O
sporadic	O
and	O
inherited	O
forms	O
of	O
human	O
colorectal	B
cancer	I
.	O

Although	O
these	O
mutations	O
have	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
APC	B
gene	O
product	O
.	O

Two	O
cellular	O
proteins	O
that	O
associate	O
with	O
APC	B
were	O
identified	O
by	O
nucleotide	O
sequence	O
analysis	O
and	O
peptide	O
mapping	O
as	O
the	O
E	O
-	O
cadherin	O
-	O
associated	O
proteins	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
.	O

A	O
27	O
-	O
residue	O
fragment	O
of	O
APC	O
containing	O
a	O
15	O
-	O
amino	O
acid	O
repeat	O
was	O
sufficient	O
for	O
the	O
interaction	O
with	O
the	O
catenins	O
.	O

These	O
results	O
suggest	O
an	O
important	O
link	O
between	O
tumor	B
initiation	O
and	O
cell	O
adhesion	O
.	O
.	O

Difference	O
in	O
methylation	O
patterns	O
within	O
the	O
D15S9	O
region	O
of	O
chromosome	O
15q11	O
-	O
13	O
in	O
first	O
cousins	O
with	O
Angelman	B
syndrome	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
.	O

Abnormalities	O
of	O
chromosome	O
region	O
15q11	O
-	O
13	O
are	O
associated	O
with	O
Angelman	B
syndrome	I
(	O
AS	B
)	O
and	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Differences	O
between	O
the	O
methylation	O
patterns	O
of	O
the	O
region	O
of	O
chromosome	O
15q11	O
-	O
13	O
which	O
hybridizes	O
to	O
the	O
highly	O
conserved	O
DNA	O
,	O
DN34	O
,	O
in	O
normal	O
individuals	O
and	O
in	O
patients	O
with	O
AS	B
and	O
PWS	B
have	O
been	O
described	O
.	O

We	O
report	O
on	O
a	O
family	O
in	O
which	O
first	O
cousins	O
are	O
affected	O
by	O
AS	B
and	O
PWS	B
as	O
a	O
result	O
of	O
a	O
familial	O
paracentric	O
inversion	O
of	O
15q11	O
-	O
q13	O
.	O

The	O
results	O
of	O
the	O
studies	O
on	O
this	O
family	O
demonstrate	O
the	O
differences	O
in	O
the	O
methylation	O
patterns	O
in	O
the	O
2	O
conditions	O
and	O
the	O
phenomenon	O
of	O
genomic	O
imprinting	O
,	O
whereby	O
genetic	O
information	O
is	O
expressed	O
differently	O
dependent	O
on	O
the	O
parent	O
of	O
origin	O
.	O
.	O

Haplotype	O
studies	O
in	O
Wilson	B
disease	I
.	O

In	O
51	O
families	O
with	O
Wilson	B
disease	I
,	O
we	O
have	O
studied	O
DNA	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(	O
CA	O
repeats	O
)	O
in	O
the	O
13q14	O
.	O

3	O
region	O
,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
Wilson	B
disease	I
gene	O
(	O
WND	B
)	O
.	O

In	O
addition	O
to	O
a	O
marker	O
(	O
D13S133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(	O
D13S314	O
,	O
D13S315	O
,	O
and	O
D13S316	O
)	O
close	O
to	O
the	O
WND	B
locus	O
.	O

We	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314	O
,	O
D13S133	O
,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
WND	B
mutation	O
.	O

We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
WND	B
and	O
normal	O
haplotypes	O
in	O
northern	O
European	O
families	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
Wilson	B
disease	I
.	O

Genetic	O
analysis	O
of	O
the	O
BRCA1	O
region	O
in	O
a	O
large	O
breast	O
/	O
ovarian	O
family	O
:	O
refinement	O
of	O
the	O
minimal	O
region	O
containing	O
BRCA1	O
.	O

We	O
have	O
analyzed	O
a	O
single	O
multi	O
-	O
affected	O
breast	B
/	I
ovarian	I
cancer	I
pedigree	O
(	O
BOV3	O
)	O
and	O
have	O
shown	O
consistent	O
inheritance	O
of	O
markers	O
on	O
chromosome	O
17q	O
with	O
the	O
disease	O
confirming	O
that	O
this	O
family	O
is	O
due	O
to	O
the	O
BRCA1	O
gene	O
.	O

Analysis	O
of	O
17q	O
haplotypes	O
shows	O
a	O
recombination	O
event	O
in	O
a	O
bilateral	O
breast	B
cancer	I
case	O
which	O
suggests	O
that	O
the	O
BRCA1	O
gene	O
lies	O
distal	O
to	O
D17S857	O
;	O
D17S857	O
is	O
thus	O
the	O
new	O
proximal	O
boundary	O
for	O
the	O
region	O
containing	O
BRCA1	O
.	O

Combining	O
this	O
information	O
with	O
previously	O
published	O
mapping	O
information	O
suggests	O
that	O
BRCA1	O
is	O
contained	O
in	O
a	O
region	O
estimated	O
at	O
1	O
-	O
1	O
.	O

5	O
Mb	O
in	O
length	O
.	O

All	O
seven	O
breast	B
tumour	I
/	O
blood	O
pairs	O
examined	O
from	O
this	O
family	O
show	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tumours	B
.	O

The	O
allel	O
retained	O
in	O
each	O
tumour	B
was	O
from	O
the	O
disease	O
-	O
bearing	O
chromosome	O
implicating	O
BRCA1	O
as	O
a	O
tumour	B
suppressor	O
gene	O
.	O

We	O
have	O
sequenced	O
the	O
17	O
beta	O
-	O
oestradiol	O
dehydrogenase	O
genes	O
(	O
EDH17B1	O
and	O
EDH17B2	O
)	O
which	O
have	O
been	O
suggested	O
as	O
candidate	O
genes	O
for	O
BRCA1	O
in	O
four	O
members	O
of	O
this	O
family	O
.	O

No	O
germline	O
mutations	O
were	O
detected	O
.	O

Myotonic	B
dystrophy	I
kinase	O
is	O
a	O
component	O
of	O
neuromuscular	O
junctions	O
.	O

The	O
clinical	O
manifestation	O
of	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
correlated	O
to	O
the	O
extent	O
of	O
expansion	O
of	O
an	O
unstable	O
[	O
CTG	O
]	O
n	O
DNA	O
motif	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
this	O
trinucleotide	O
motif	O
forms	O
part	O
of	O
the	O
last	O
,	O
3	O
untranslated	O
exon	O
of	O
a	O
gene	O
which	O
potentially	O
encodes	O
multiple	O
protein	O
isoforms	O
of	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
(	O
myotonic	B
dystrophy	I
protein	O
kinase	O
,	O
DM	O
-	O
PK	O
)	O
.	O

We	O
report	O
here	O
on	O
the	O
development	O
of	O
antisera	O
against	O
synthetic	O
DM	O
-	O
PK	O
peptide	O
antigens	O
and	O
their	O
use	O
in	O
biochemical	O
and	O
histochemical	O
studies	O
.	O

Immunoreactive	O
DM	O
-	O
kinase	O
protein	O
of	O
53	O
kD	O
is	O
present	O
at	O
low	O
levels	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
extracts	O
of	O
DM	B
patients	O
and	O
normal	O
controls	O
.	O

Immunohistochemical	O
staining	O
revealed	O
that	O
DM	O
-	O
PK	O
is	O
localised	O
prominently	O
at	O
sites	O
of	O
neuromuscular	O
and	O
myotendinous	O
junctions	O
(	O
NMJs	O
and	O
MTJs	O
)	O
of	O
human	O
and	O
rodent	O
skeletal	O
muscles	O
.	O

Furthermore	O
,	O
very	O
low	O
levels	O
of	O
immunoreactive	O
DM	O
-	O
PK	O
protein	O
are	O
present	O
in	O
the	O
sarcoplasm	O
of	O
predominantly	O
type	O
I	O
fibres	O
in	O
various	O
muscles	O
.	O

Strikingly	O
,	O
presence	O
of	O
the	O
protein	O
can	O
also	O
be	O
demonstrated	O
for	O
NMJs	O
of	O
muscular	O
tissues	O
of	O
adult	O
and	O
congenital	O
cases	O
of	O
DM	B
,	O
with	O
no	O
gross	O
changes	O
in	O
structural	O
organisation	O
.	O

Our	O
findings	O
provide	O
a	O
basis	O
for	O
further	O
characterisation	O
of	O
the	O
role	O
of	O
the	O
kinase	O
in	O
protein	O
assembly	O
processes	O
or	O
signal	O
mediation	O
at	O
synaptic	O
sites	O
and	O
ultimately	O
for	O
the	O
understanding	O
of	O
the	O
complex	O
pathophysiology	O
of	O
DM	B
.	O
.	O

Markedly	O
accelerated	O
catabolism	O
of	O
apolipoprotein	O
A	O
-	O
II	O
(	O
ApoA	O
-	O
II	O
)	O
and	O
high	O
density	O
lipoproteins	O
containing	O
ApoA	O
-	O
II	O
in	O
classic	O
lecithin	O
:	O
cholesterol	B
acyltransferase	I
deficiency	I
and	O
fish	B
-	I
eye	I
disease	I
.	O

Classic	B
(	I
complete	I
)	I
lecithin	I
cholesterol	I
acyltransferase	I
(	I
LCAT	I
)	I
deficiency	I
and	O
Fish	B
-	I
eye	I
disease	I
(	O
partial	B
LCAT	I
deficiency	I
)	O
are	O
genetic	O
syndromes	O
associated	O
with	O
markedly	O
decreased	O
plasma	O
levels	O
of	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
but	O
not	O
with	O
an	O
increased	O
risk	O
of	O
atherosclerotic	B
cardiovascular	I
disease	I
.	O

We	O
investigated	O
the	O
metabolism	O
of	O
the	O
HDL	O
apolipoproteins	O
(	O
apo	O
)	O
apoA	O
-	O
I	O
and	O
apoA	O
-	O
II	O
in	O
a	O
total	O
of	O
five	O
patients	O
with	O
LCAT	B
deficiency	I
,	O
one	O
with	O
classic	B
LCAT	I
deficiency	I
and	O
four	O
with	O
Fish	B
-	I
eye	I
disease	I
.	O

Plasma	O
levels	O
of	O
apoA	O
-	O
II	O
were	O
decreased	O
to	O
a	O
proportionately	O
greater	O
extent	O
(	O
23	O
%	O
of	O
normal	O
)	O
than	O
apoA	O
-	O
I	O
(	O
30	O
%	O
of	O
normal	O
)	O
.	O

In	O
addition	O
,	O
plasma	O
concentrations	O
of	O
HDL	O
particles	O
containing	O
both	O
apoA	O
-	O
I	O
and	O
apoA	O
-	O
II	O
(	O
LpA	O
-	O
I	O
A	O
-	O
II	O
)	O
were	O
much	O
lower	O
(	O
18	O
%	O
of	O
normal	O
)	O
than	O
those	O
of	O
particles	O
containing	O
only	O
apoA	O
-	O
I	O
(	O
LpA	O
-	O
I	O
)	O
(	O
51	O
%	O
of	O
normal	O
)	O
.	O

The	O
metabolic	O
basis	O
for	O
the	O
low	O
levels	O
of	O
apoA	O
-	O
II	O
and	O
LpA	O
-	O
I	O
A	O
-	O
II	O
was	O
investigated	O
in	O
all	O
five	O
patients	O
using	O
both	O
exogenous	O
radiotracer	O
and	O
endogenous	O
stable	O
isotope	O
labeling	O
techniques	O
.	O

The	O
mean	O
plasma	O
residence	O
time	O
of	O
apoA	O
-	O
I	O
was	O
decreased	O
at	O
2	O
.	O

08	O
+	O
/	O
-	O
0	O
.	O

27	O
d	O
(	O
controls	O
4	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
65	O
days	O
)	O
;	O
however	O
,	O
the	O
residence	O
time	O
of	O
apoA	O
-	O
II	O
was	O
even	O
shorter	O
at	O
1	O
.	O

66	O
+	O
/	O
-	O
0	O
.	O

24	O
d	O
(	O
controls	O
5	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
61	O
d	O
)	O
.	O

In	O
addition	O
,	O
the	O
catabolism	O
of	O
apoA	O
-	O
I	O
in	O
LpA	O
-	O
I	O
A	O
-	O
II	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
apoA	O
-	O
I	O
in	O
LpA	O
-	O
I	O
.	O

In	O
summary	O
,	O
genetic	O
syndromes	O
of	O
either	O
complete	B
or	I
partial	I
LCAT	I
deficiency	I
result	O
in	O
low	O
levels	O
of	O
HDL	O
through	O
preferential	O
hypercatabolism	O
of	O
apoA	O
-	O
II	O
and	O
HDL	O
particles	O
containing	O
apoA	O
-	O
II	O
.	O

Because	O
LpA	O
-	O
I	O
has	O
been	O
proposed	O
to	O
be	O
more	O
protective	O
than	O
LpA	O
-	O
I	O
A	O
-	O
II	O
against	O
atherosclerosis	B
,	O
this	O
selective	O
effect	O
on	O
the	O
metabolism	O
of	O
LpA	O
-	O
I	O
A	O
-	O
II	O
may	O
provide	O
a	O
potential	O
explanation	O
why	O
patients	O
with	O
classic	B
LCAT	I
deficiency	I
and	O
Fish	B
-	I
eye	I
disease	I
are	O
not	O
at	O
increased	O
risk	O
for	O
premature	O
atherosclerosis	B
despite	O
markedly	O
decreased	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
apoA	O
-	O
I	O

X	B
linked	I
recessive	I
thrombocytopenia	I
.	O

A	O
Saudi	O
Arab	O
boy	O
presented	O
in	O
early	O
childhood	O
with	O
thrombocytopenia	B
,	O
morphologically	O
large	O
and	O
normal	O
sized	O
platelets	O
,	O
increased	O
mean	O
platelet	O
volume	O
,	O
and	O
a	O
hypermegakaryocytic	O
bone	O
marrow	O
.	O

There	O
was	O
no	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
any	O
significant	O
immunological	B
abnormalities	I
.	O

Similar	O
findings	O
in	O
two	O
other	O
brothers	O
suggested	O
strongly	O
that	O
they	O
were	O
all	O
suffering	O
from	O
an	O
X	B
linked	I
recessive	I
thrombocytopenic	I
disorder	I
.	O

Results	O
of	O
DNA	O
analysis	O
with	O
the	O
probe	O
M27	O
beta	O
are	O
consistent	O
with	O
X	O
linkage	O
and	O
indicate	O
also	O
that	O
the	O
locus	O
of	O
the	O
relevant	O
gene	O
lies	O
close	O
to	O
or	O
is	O
identical	O
to	O
the	O
locus	O
of	O
the	O
gene	O
for	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
.	O

Because	O
of	O
various	O
features	O
which	O
include	O
the	O
presence	O
of	O
large	O
and	O
normal	O
sized	O
platelets	O
(	O
rather	O
than	O
small	O
platelets	O
)	O
and	O
freedom	O
from	O
significant	O
immune	B
deficiencies	I
,	O
it	O
is	O
likely	O
that	O
the	O
X	B
linked	I
recessive	I
thrombocytopenia	I
in	O
this	O
family	O
is	O
an	O
isolated	O
entity	O
quite	O
distinct	O
from	O
the	O
classical	O
WAS	B
phenotype	O
.	O

However	O
,	O
a	O
modified	O
expression	O
of	O
the	O
WAS	B
gene	O
producing	O
a	O
mild	O
phenotypic	O
variant	O
cannot	O
be	O
excluded	O
entirely	O
.	O
.	O

Macular	B
dystrophy	I
associated	O
with	O
mutations	O
at	O
codon	O
172	O
in	O
the	O
human	O
retinal	B
degeneration	I
slow	O
gene	O
.	O

BACKGROUND	O
Recently	O
,	O
mutations	O
in	O
the	O
retinal	B
degeneration	I
slow	O
(	O
rds	O
)	O
gene	O
which	O
codes	O
for	O
peripherin	O
-	O
rds	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
autosomal	B
dominant	I
retinitis	I
pigmentosa	I
.	O

Because	O
this	O
gene	O
is	O
expressed	O
in	O
both	O
rods	O
and	O
cones	O
,	O
mutations	O
in	O
the	O
rds	O
gene	O
might	O
be	O
expected	O
to	O
cause	O
degeneration	O
affecting	O
either	O
the	O
scotopic	O
or	O
photopic	O
systems	O
.	O

Mutations	O
at	O
codon	O
172	O
of	O
the	O
rds	O
gene	O
have	O
been	O
identified	O
in	O
three	O
families	O
with	O
autosomal	O
dominantly	O
inherited	O
,	O
progressive	O
macular	B
dystrophy	I
.	O

METHODS	O
Affected	O
individuals	O
underwent	O
ophthalmic	O
examination	O
,	O
scotopic	O
perimetry	O
,	O
dark	O
adaptometry	O
,	O
measurement	O
of	O
color	O
-	O
contrast	O
sensitivity	O
,	O
and	O
electroretinography	O
to	O
characterize	O
the	O
photoreceptor	O
dysfunction	O
.	O

RESULTS	O
In	O
all	O
but	O
one	O
affected	O
member	O
,	O
symptoms	O
of	O
progressive	O
central	O
visual	B
loss	I
developed	O
in	O
the	O
third	O
or	O
fourth	O
decade	O
of	O
life	O
accompanied	O
by	O
central	B
scotoma	I
and	O
well	O
-	O
demarcated	O
atrophy	B
of	I
the	I
retinal	I
pigment	I
epithelium	I
and	O
choriocapillaris	B
of	I
the	I
macula	I
.	O

In	O
general	O
,	O
cone	O
and	O
rod	O
thresholds	O
were	O
elevated	O
,	O
and	O
color	O
-	O
contrast	O
sensitivity	O
was	O
absent	O
in	O
the	O
central	O
visual	O
field	O
.	O

Peripherally	O
,	O
the	O
scotopic	O
sensitivities	O
were	O
normal	O
,	O
as	O
was	O
the	O
recovery	O
from	O
bleach	O
.	O

Cone	O
electroretinograms	O
were	O
diminished	O
in	O
amplitude	O
,	O
and	O
delayed	O
in	O
all	O
affected	O
adults	O
except	O
one	O
.	O

Rod	O
electroretinograms	O
were	O
normal	O
or	O
near	O
normal	O
in	O
amplitude	O
,	O
and	O
had	O
normal	O
implicit	O
times	O
.	O

Affected	O
asymptomatic	O
children	O
had	O
macular	O
changes	O
,	O
abnormal	O
color	O
-	O
contrast	O
sensitivity	O
,	O
and	O
reduced	O
pattern	O
and	O
cone	O
electroretinograms	O
.	O

CONCLUSION	O
These	O
results	O
indicate	O
that	O
mutations	O
in	O
the	O
rds	O
gene	O
can	O
be	O
expressed	O
as	O
a	O
macular	B
dystrophy	I
,	O
with	O
evidence	O
of	O
primary	O
cone	B
dysfunction	I
and	O
preservation	O
of	O
peripheral	O
rod	O
function	O
.	O
.	O

Anonymous	O
marker	O
loci	O
within	O
400	O
kb	O
of	O
HLA	O
-	O
A	O
generate	O
haplotypes	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
hemochromatosis	B
gene	O
(	O
HFE	O
)	O

The	O
hemochromatosis	B
gene	O
(	O
HFE	O
)	O
maps	O
to	O
6p21	O
.	O

3	O
and	O
is	O
less	O
than	O
1	O
cM	O
from	O
the	O
HLA	O
class	O
I	O
genes	O
;	O
however	O
,	O
the	O
precise	O
physical	O
location	O
of	O
the	O
gene	O
has	O
remained	O
elusive	O
and	O
controversial	O
.	O

The	O
unambiguous	O
identification	O
of	O
a	O
crossover	O
event	O
within	O
hemochromatosis	B
families	O
is	O
very	O
difficult	O
;	O
it	O
is	O
particularly	O
hampered	O
by	O
the	O
variability	O
of	O
the	O
phenotypic	O
expression	O
as	O
well	O
as	O
by	O
the	O
sex	O
-	O
and	O
age	O
-	O
related	O
penetrance	O
of	O
the	O
disease	O
.	O

For	O
these	O
practical	O
considerations	O
,	O
traditional	O
linkage	O
analysis	O
could	O
prove	O
of	O
limited	O
value	O
in	O
further	O
refining	O
the	O
extrapolated	O
physical	O
position	O
of	O
HFE	O
.	O

We	O
therefore	O
embarked	O
upon	O
a	O
linkage	O
-	O
disequilibrium	O
analysis	O
of	O
HFE	O
and	O
normal	O
chromosomes	O
from	O
the	O
Brittany	O
population	O
.	O

In	O
the	O
present	O
report	O
,	O
66	O
hemochromatosis	B
families	O
yielding	O
151	O
hemochromatosis	B
chromosomes	O
and	O
182	O
normal	O
chromosomes	O
were	O
RFLP	O
-	O
typed	O
with	O
a	O
battery	O
of	O
probes	O
,	O
including	O
two	O
newly	O
derived	O
polymorphic	O
markers	O
from	O
the	O
6	O
.	O

7	O
and	O
HLA	O
-	O
F	O
loci	O
located	O
150	O
and	O
250	O
kb	O
telomeric	O
to	O
HLA	O
-	O
A	O
,	O
respectively	O
.	O

The	O
results	O
suggest	O
a	O
strong	O
peak	O
of	O
existing	O
linkage	O
disequilibrium	O
focused	O
within	O
the	O
i82	O
-	O
to	O
-	O
6	O
.	O

7	O
interval	O
(	O
approximately	O
250	O
kb	O
)	O
.	O

The	O
zone	O
of	O
linkage	O
disequilibrium	O
is	O
flanked	O
by	O
the	O
i97	O
locus	O
,	O
positioned	O
30	O
kb	O
proximal	O
to	O
i82	O
,	O
and	O
the	O
HLA	O
-	O
F	O
gene	O
,	O
found	O
250	O
kb	O
distal	O
to	O
HLA	O
-	O
A	O
,	O
markers	O
of	O
which	O
display	O
no	O
significant	O
association	O
with	O
HFE	O
.	O

These	O
data	O
support	O
the	O
possibility	O
that	O
HFE	O
resides	O
within	O
the	O
400	O
-	O
kb	O
expanse	O
of	O
DNA	O
between	O
i97	O
and	O
HLA	O
-	O
F	O
.	O

Alternatively	O
,	O
the	O
very	O
tight	O
association	O
of	O
HLA	O
-	O
A3	O
and	O
allele	O
1	O
of	O
the	O
6	O
.	O

7	O
locus	O
,	O
both	O
of	O
which	O
are	O
comprised	O
by	O
the	O
major	O
ancestral	O
or	O
founder	O
HFE	O
haplotype	O
in	O
Brittany	O
,	O
supports	O
the	O
possibility	O
that	O
the	O
disease	O
gene	O
may	O
reside	O
immediately	O
telomeric	O
to	O
the	O
6	O
.	O

7	O
locus	O
within	O
the	O
linkage	O
-	O
disequilibrium	O
zone	O
.	O

Additionally	O
,	O
hemochromatosis	B
haplotypes	O
possessing	O
HLA	O
-	O
A11	O
and	O
the	O
low	O
-	O
frequency	O
HLA	O
-	O
F	O
polymorphism	O
(	O
allele	O
2	O
)	O
are	O
supportive	O
of	O
a	O
separate	O
founder	O
chromosome	O
containing	O
a	O
second	O
,	O
independently	O
arising	O
mutant	O
allele	O
.	O

Overall	O
,	O
the	O
establishment	O
of	O
a	O
likely	O
"	O
hemochromatosis	B
critical	O
region	O
"	O
centromeric	O
boundary	O
and	O
the	O
identification	O
of	O
a	O
linkage	O
-	O
disequilibrium	O
zone	O
both	O
significantly	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
DNA	O
required	O
to	O
be	O
searched	O
for	O
novel	O
coding	O
sequences	O
constituting	O
the	O
HFE	B
defect	I

Genomic	O
structure	O
of	O
the	O
EWS	O
gene	O
and	O
its	O
relationship	O
to	O
EWSR1	O
,	O
a	O
site	O
of	O
tumor	B
-	O
associated	O
chromosome	O
translocation	O
.	O

The	O
EWS	O
gene	O
has	O
been	O
identified	O
based	O
on	O
its	O
location	O
at	O
the	O
chromosome	O
22	O
breakpoint	O
of	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
(	O
q24	O
;	O
q12	O
)	O
translocation	O
that	O
characterizes	O
Ewing	B
sarcoma	I
and	O
related	O
neuroectodermal	B
tumors	I
.	O

The	O
EWS	O
gene	O
spans	O
about	O
40	O
kb	O
of	O
DNA	O
and	O
is	O
encoded	O
by	O
17	O
exons	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
exons	O
is	O
identical	O
to	O
that	O
of	O
the	O
previously	O
described	O
cDNA	O
.	O

The	O
first	O
7	O
exons	O
encode	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
EWS	O
,	O
which	O
consists	O
of	O
a	O
repeated	O
degenerated	O
polypeptide	O
of	O
7	O
to	O
12	O
residues	O
rich	O
in	O
tyrosine	O
,	O
serine	O
,	O
threonine	O
,	O
glycine	O
,	O
and	O
glutamine	O
.	O

Exons	O
11	O
,	O
12	O
,	O
and	O
13	O
encode	O
the	O
putative	O
RNA	O
binding	O
domain	O
.	O

The	O
three	O
glycine	O
-	O
and	O
arginine	O
-	O
rich	O
motifs	O
of	O
the	O
gene	O
are	O
mainly	O
encoded	O
by	O
exons	O
8	O
-	O
9	O
,	O
14	O
,	O
and	O
16	O
.	O

The	O
DNA	O
sequence	O
in	O
the	O
5	O
region	O
of	O
the	O
gene	O
has	O
features	O
of	O
a	O
CpG	O
-	O
rich	O
island	O
and	O
lacks	O
canonical	O
promoter	O
elements	O
,	O
such	O
as	O
TATA	O
and	O
CCAAT	O
consensus	O
sequences	O
.	O

Positions	O
of	O
the	O
chromosome	O
22	O
breakpoints	O
were	O
determined	O
for	O
19	O
Ewing	B
tumors	I
.	O

They	O
were	O
localized	O
in	O
introns	O
7	O
or	O
8	O
in	O
18	O
cases	O
and	O
in	O
intron	O
10	O
in	O
1	O
case	O
.	O
.	O

Norrie	B
disease	I
gene	O
:	O
characterization	O
of	O
deletions	O
and	O
possible	O
function	O
.	O

Positional	O
cloning	O
experiments	O
have	O
resulted	O
recently	O
in	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Norrie	B
disease	I
(	O
pseudoglioma	B
;	O
NDP	B
)	O
,	O
a	O
severe	O
X	B
-	I
linked	I
neurodevelopmental	I
disorder	I
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
analysis	O
of	O
human	O
genomic	O
DNA	O
clones	O
encompassing	O
the	O
NDP	B
gene	O
.	O

The	O
gene	O
spans	O
28	O
kb	O
and	O
consists	O
of	O
3	O
exons	O
,	O
the	O
first	O
of	O
which	O
is	O
entirely	O
contained	O
within	O
the	O
5	O
untranslated	O
region	O
.	O

Detailed	O
analysis	O
of	O
genomic	O
deletions	O
in	O
Norrie	B
patients	O
shows	O
that	O
they	O
are	O
heterogeneous	O
,	O
both	O
in	O
size	O
and	O
in	O
position	O
.	O

By	O
PCR	O
analysis	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
NDP	B
gene	O
was	O
not	O
confined	O
to	O
the	O
eye	O
or	O
to	O
the	O
brain	O
.	O

An	O
extensive	O
DNA	O
and	O
protein	O
sequence	O
comparison	O
between	O
the	O
human	O
NDP	B
gene	O
and	O
related	O
genes	O
from	O
the	O
database	O
revealed	O
homology	O
with	O
cysteine	O
-	O
rich	O
protein	O
-	O
binding	O
domains	O
of	O
immediate	O
-	O
-	O
early	O
genes	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
.	O

We	O
propose	O
that	O
NDP	O
is	O
a	O
molecule	O
related	O
in	O
function	O
to	O
these	O
genes	O
and	O
may	O
be	O
involved	O
in	O
a	O
pathway	O
that	O
regulates	O
neural	O
cell	O
differentiation	O
and	O
proliferation	O
.	O
.	O

The	O
normal	O
Huntington	B
disease	I
(	O
HD	B
)	O
allele	O
,	O
or	O
a	O
closely	O
linked	O
gene	O
,	O
influences	O
age	O
at	O
onset	O
of	O
HD	B
.	O

We	O
evaluated	O
the	O
hypothesis	O
that	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
influenced	O
by	O
the	O
normal	O
HD	B
allele	O
by	O
comparing	O
transmission	O
patterns	O
of	O
genetically	O
linked	O
markers	O
at	O
the	O
D4S10	O
locus	O
in	O
the	O
normal	O
parent	O
against	O
age	O
at	O
onset	O
in	O
the	O
affected	O
offspring	O
.	O

Analysis	O
of	O
information	O
from	O
21	O
sibships	O
in	O
14	O
kindreds	O
showed	O
a	O
significant	O
tendency	O
for	O
sibs	O
who	O
have	O
similar	O
onset	O
ages	O
to	O
share	O
the	O
same	O
D4S10	O
allele	O
from	O
the	O
normal	O
parent	O
.	O

Affected	O
sibs	O
who	O
inherited	O
different	O
D4S10	O
alleles	O
from	O
the	O
normal	O
parent	O
tended	O
to	O
have	O
more	O
variable	O
ages	O
at	O
onset	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
expression	O
of	O
HD	B
is	O
modulated	O
by	O
the	O
normal	O
HD	B
allele	O
or	O
by	O
a	O
closely	O
linked	O
locus	O
.	O
.	O

Further	O
investigation	O
of	O
the	O
HEXA	O
gene	O
intron	O
9	O
donor	O
splice	O
site	O
mutation	O
frequently	O
found	O
in	O
non	O
-	O
Jewish	O
Tay	B
-	I
Sachs	I
disease	I
patients	O
from	O
the	O
British	O
Isles	O
.	O

In	O
a	O
previous	O
study	O
we	O
found	O
that	O
a	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
causing	O
mutation	O
in	O
the	O
intron	O
9	O
donor	O
splice	O
site	O
of	O
the	O
HEXA	O
gene	O
occurs	O
at	O
high	O
frequency	O
in	O
non	O
-	O
Jewish	O
patients	O
and	O
carriers	O
from	O
the	O
British	O
Isles	O
.	O

It	O
was	O
found	O
more	O
frequently	O
in	O
subjects	O
of	O
Irish	O
,	O
Scottish	O
,	O
and	O
Welsh	O
origin	O
compared	O
with	O
English	O
origin	O
(	O
63	O
%	O
and	O
31	O
%	O
respectively	O
)	O
.	O

We	O
have	O
now	O
tested	O
,	O
in	O
a	O
blind	O
study	O
,	O
26	O
American	O
TSD	B
carriers	O
and	O
28	O
non	O
-	O
carriers	O
who	O
have	O
British	O
ancestry	O
for	O
the	O
intron	O
9	O
splice	O
site	O
mutation	O
.	O

Six	O
of	O
the	O
carriers	O
and	O
none	O
of	O
the	O
controls	O
were	O
positive	O
for	O
the	O
mutation	O
.	O

All	O
six	O
had	O
Irish	O
ancestry	O
,	O
compared	O
with	O
nine	O
of	O
the	O
20	O
other	O
(	O
intron	O
9	O
mutation	O
negative	O
)	O
TSD	B
carriers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
confirm	O
the	O
previously	O
found	O
high	O
frequency	O
of	O
the	O
intron	O
9	O
mutation	O
in	O
non	O
-	O
Jewish	O
TSD	B
families	O
of	O
British	O
Isles	O
,	O
particularly	O
Irish	O
,	O
origin	O
,	O
and	O
reinforce	O
the	O
need	O
to	O
screen	O
such	O
families	O
for	O
this	O
mutation	O
.	O

Molecular	O
mechanisms	O
of	O
oncogenic	O
mutations	O
in	O
tumors	B
from	O
patients	O
with	O
bilateral	B
and	I
unilateral	I
retinoblastoma	I
.	O

The	O
RB1	O
gene	O
from	O
12	O
human	O
retinoblastoma	B
tumors	I
has	O
been	O
analyzed	O
exon	O
-	O
by	O
-	O
exon	O
with	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O

Mutations	O
were	O
found	O
in	O
all	O
tumors	B
,	O
and	O
one	O
-	O
third	O
of	O
the	O
tumors	B
had	O
independent	O
mutations	O
in	O
both	O
alleles	O
neither	O
of	O
which	O
were	O
found	O
in	O
the	O
germ	O
line	O
,	O
confirming	O
their	O
true	O
sporadic	O
nature	O
.	O

In	O
the	O
remaining	O
two	O
-	O
thirds	O
of	O
the	O
tumors	B
only	O
one	O
mutation	O
was	O
found	O
,	O
consistent	O
with	O
the	O
loss	O
-	O
of	O
-	O
heterozygosity	O
theory	O
of	O
tumorigenesis	O
.	O

Point	O
mutations	O
,	O
the	O
majority	O
of	O
which	O
were	O
C	O
-	O
-	O
>	O
T	O
transitions	O
,	O
were	O
the	O
most	O
common	O
abnormality	O
and	O
usually	O
resulted	O
in	O
the	O
conversion	O
of	O
an	O
arginine	O
codon	O
to	O
a	O
stop	O
codon	O
.	O

Small	O
deletions	O
were	O
the	O
second	O
most	O
common	O
abnormality	O
and	O
most	O
often	O
created	O
a	O
downstream	O
stop	O
codon	O
as	O
the	O
result	O
of	O
a	O
reading	O
frameshift	O
.	O

Deletions	O
and	O
point	O
mutations	O
also	O
affected	O
splice	O
junctions	O
.	O

Direct	O
repeats	O
were	O
present	O
at	O
the	O
breakpoint	O
junctions	O
in	O
the	O
majority	O
of	O
deletions	O
,	O
supporting	O
a	O
slipped	O
-	O
mispairing	O
mechanism	O
.	O

Point	O
mutations	O
generally	O
produced	O
DNA	O
sequences	O
which	O
resulted	O
in	O
perfect	O
homology	O
with	O
endogenous	O
sequences	O
which	O
lay	O
within	O
14	O
bp	O
.	O
.	O

PAX6	O
mutations	O
in	O
aniridia	B
.	O

Aniridia	B
is	O
a	O
congenital	B
malformation	I
of	I
the	I
eye	I
,	O
chiefly	O
characterised	O
by	O
iris	B
hypoplasia	I
,	O
which	O
can	O
cause	O
blindness	B
.	O

The	O
PAX6	O
gene	O
was	O
isolated	O
as	O
a	O
candidate	O
aniridia	B
gene	O
by	O
positional	O
cloning	O
from	O
the	O
smallest	O
region	O
of	O
overlap	O
of	O
aniridia	B
-	O
associated	O
deletions	O
.	O

Subsequently	O
PAX6	O
intragenic	O
mutations	O
were	O
demonstrated	O
in	O
Smalleye	O
,	O
a	O
mouse	O
mutant	O
which	O
is	O
an	O
animal	O
model	O
for	O
aniridia	B
,	O
and	O
six	O
human	O
aniridia	B
patients	O
.	O

In	O
this	O
paper	O
we	O
describe	O
four	O
additional	O
PAX6	O
point	O
mutations	O
in	O
aniridia	B
patients	O
,	O
both	O
sporadic	O
and	O
familial	O
.	O

These	O
mutations	O
highlight	O
regions	O
of	O
the	O
gene	O
which	O
are	O
essential	O
for	O
normal	O
PAX6	O
function	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
at	O
which	O
we	O
have	O
found	O
PAX6	O
mutations	O
suggests	O
that	O
lesions	O
in	O
PAX6	O
will	O
account	O
for	O
most	O
cases	O
of	O
aniridia	B
.	O
.	O

Detection	O
of	O
a	O
novel	O
arginine	O
vasopressin	O
defect	O
by	O
dideoxy	O
fingerprinting	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
is	O
a	O
familial	O
form	O
of	O
diabetes	B
insipidus	I
.	O

This	O
disorder	O
is	O
associated	O
with	O
variable	O
levels	O
of	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
and	O
diabetes	B
insipidus	I
of	O
varying	O
severity	O
,	O
which	O
responds	O
to	O
exogenous	O
AVP	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
,	O
the	O
AVP	O
genes	O
of	O
members	O
of	O
a	O
large	O
kindred	O
were	O
analyzed	O
.	O

A	O
new	O
method	O
,	O
called	O
dideoxy	O
fingerprinting	O
,	O
was	O
used	O
to	O
detect	O
an	O
AVP	O
mutation	O
that	O
was	O
characterized	O
by	O
DNA	O
sequencing	O
.	O

The	O
novel	O
defect	O
found	O
changes	O
the	O
last	O
codon	O
of	O
the	O
AVP	O
signal	O
peptide	O
from	O
alanine	O
to	O
threonine	O
,	O
which	O
should	O
perturb	O
cleavage	O
of	O
mature	O
AVP	O
from	O
its	O
precursor	O
protein	O
and	O
inhibit	O
its	O
secretion	O
or	O
action	O
.	O
.	O

Germinal	O
mosaicism	O
in	O
a	O
Duchenne	B
muscular	I
dystrophy	I
family	O
:	O
implications	O
for	O
genetic	O
counselling	O
.	O

In	O
this	O
study	O
we	O
describe	O
a	O
three	O
-	O
generation	O
family	O
in	O
which	O
two	O
siblings	O
were	O
affected	O
by	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

Immunohistochemical	O
analysis	O
of	O
muscle	O
dystrophin	O
and	O
haplotype	O
analysis	O
of	O
the	O
DMD	B
locus	O
revealed	O
that	O
the	O
X	O
chromosome	O
carrying	O
the	O
DMD	B
gene	O
was	O
transmitted	O
from	O
the	O
healthy	O
maternal	O
grandfather	O
to	O
his	O
three	O
daughters	O
,	O
including	O
the	O
probands	O
mother	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
grandfather	O
was	O
a	O
germinal	O
mosaic	O
for	O
the	O
DMD	B
gene	O
.	O

The	O
definition	O
of	O
the	O
carrier	O
status	O
in	O
two	O
possible	O
carriers	O
led	O
us	O
to	O
give	O
accurate	O
genetic	O
counselling	O
and	O
to	O
prevent	O
the	O
birth	O
of	O
an	O
affected	O
boy	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
the	O
usefulness	O
of	O
haplotype	O
analysis	O
and	O
immunohistochemical	O
muscle	O
dystrophin	O
studies	O
to	O
detect	O
hidden	O
germinal	O
mosaicism	O
and	O
to	O
improve	O
genetic	O
counselling	O
.	O
.	O

Genetic	O
mapping	O
of	O
the	O
breast	B
-	I
ovarian	I
cancer	I
syndrome	I
to	O
a	O
small	O
interval	O
on	O
chromosome	O
17q12	O
-	O
21	O
:	O
exclusion	O
of	O
candidate	O
genes	O
EDH17B2	O
and	O
RARA	O
.	O

A	O
susceptibility	O
gene	O
for	O
hereditary	B
breast	I
-	I
ovarian	I
cancer	I
,	O
BRCA1	O
,	O
has	O
been	O
assigned	O
by	O
linkage	O
analysis	O
to	O
chromosome	O
17q21	O
.	O

Candidate	O
genes	O
in	O
this	O
region	O
include	O
EDH17B2	O
,	O
which	O
encodes	O
estradiol	O
17	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
II	O
(	O
17	O
beta	O
-	O
HSD	O
II	O
)	O
,	O
and	O
RARA	O
,	O
the	O
gene	O
for	O
retinoic	O
acid	O
receptor	O
alpha	O
.	O

We	O
have	O
typed	O
22	O
breast	B
and	I
breast	I
-	I
ovarian	I
cancer	I
families	O
with	O
eight	O
polymorphisms	O
from	O
the	O
chromosome	O
17q12	O
-	O
21	O
region	O
,	O
including	O
two	O
in	O
the	O
EDH17B2	O
gene	O
.	O

Genetic	O
recombination	O
with	O
the	O
breast	B
cancer	I
trait	O
excludes	O
RARA	O
from	O
further	O
consideration	O
as	O
a	O
candidate	O
gene	O
for	O
BRCA1	O
.	O

Both	O
BRCA1	O
and	O
EDH17B2	O
map	O
to	O
a	O
6	O
cM	O
interval	O
(	O
between	O
THRA1	O
and	O
D17S579	O
)	O
and	O
no	O
recombination	O
was	O
observed	O
between	O
the	O
two	O
genes	O
.	O

However	O
,	O
direct	O
sequencing	O
of	O
overlapping	O
PCR	O
products	O
containing	O
the	O
entire	O
EDH17B2	O
gene	O
in	O
four	O
unrelated	O
affected	O
women	O
did	O
not	O
uncover	O
any	O
sequence	O
variation	O
,	O
other	O
than	O
previously	O
described	O
polymorphisms	O
.	O

Mutations	O
in	O
the	O
EDH17B2	O
gene	O
,	O
therefore	O
do	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
hereditary	B
breast	I
-	I
ovarian	I
cancer	I
syndrome	I
.	O

Single	O
meiotic	O
crossovers	O
in	O
affected	O
women	O
suggest	O
that	O
BRCA1	O
is	O
flanked	O
by	O
the	O
loci	O
RARA	O
and	O
D17S78	O
.	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
with	O
possible	O
dominant	O
effects	O
on	O
plasma	O
high	O
density	O
lipoproteins	O
.	O

Plasma	O
HDL	O
are	O
a	O
negative	O
risk	O
factor	O
for	O
atherosclerosis	B
.	O

Cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
;	O
476	O
amino	O
acids	O
)	O
transfers	O
cholesteryl	O
ester	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
.	O

Subjects	O
with	O
homozygous	O
CETP	B
deficiency	I
caused	O
by	O
a	O
gene	O
splicing	O
defect	O
have	O
markedly	O
elevated	O
HDL	O
;	O
however	O
,	O
heterozygotes	O
have	O
only	O
mild	O
increases	O
in	O
HDL	O
.	O

We	O
describe	O
two	O
probands	O
with	O
a	O
CETP	O
missense	O
mutation	O
(	O
442	O
D	O
G	O
)	O
.	O

Although	O
heterozygous	O
,	O
they	O
have	O
threefold	O
increases	O
in	O
HDL	O
concentration	O
and	O
markedly	O
decreased	O
plasma	O
CETP	O
mass	O
and	O
activity	O
,	O
suggesting	O
that	O
the	O
mutation	O
has	O
dominant	O
effects	O
on	O
CETP	O
and	O
HDL	O
in	O
vivo	O
.	O

Cellular	O
expression	O
of	O
mutant	O
cDNA	O
results	O
in	O
secretion	O
of	O
only	O
30	O
%	O
of	O
wild	O
type	O
CETP	O
activity	O
.	O

Moreover	O
,	O
coexpression	O
of	O
wild	O
type	O
and	O
mutant	O
cDNAs	O
leads	O
to	O
inhibition	O
of	O
wild	O
type	O
secretion	O
and	O
activity	O
.	O

The	O
dominant	O
effects	O
of	O
the	O
CETP	O
missense	O
mutation	O
during	O
cellular	O
expression	O
probably	O
explains	O
why	O
the	O
probands	O
have	O
markedly	O
increased	O
HDL	O
in	O
the	O
heterozygous	O
state	O
,	O
and	O
suggests	O
that	O
the	O
active	O
molecular	O
species	O
of	O
CETP	O
may	O
be	O
multimeric	O
.	O
.	O

Familial	B
Mediterranean	I
fever	I
in	O
the	O
colchicine	O
era	O
:	O
the	O
fate	O
of	O
one	O
family	O
.	O

In	O
order	O
to	O
demonstrate	O
the	O
effect	O
of	O
prophylactic	O
colchicine	O
treatment	O
on	O
the	O
natural	O
history	O
of	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
,	O
a	O
family	O
is	O
presented	O
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	O
by	O
FMF	B
.	O

Each	O
patient	O
represents	O
a	O
different	O
stage	O
of	O
the	O
amyloidotic	B
kidney	I
disease	I
of	O
FMF	B
and	O
the	O
effect	O
of	O
continuous	O
colchicine	O
treatment	O
on	O
its	O
course	O
.	O

Considered	O
together	O
,	O
the	O
members	O
of	O
this	O
family	O
present	O
an	O
almost	O
complete	O
clinical	O
,	O
genetic	O
,	O
and	O
behavioral	O
picture	O
of	O
the	O
disease	O
.	O
.	O

Detection	O
of	O
a	O
new	O
submicroscopic	O
Norrie	B
disease	I
deletion	O
interval	O
with	O
a	O
novel	O
DNA	O
probe	O
isolated	O
by	O
differential	O
Alu	O
PCR	O
fingerprint	O
cloning	O
.	O

Differential	O
Alu	O
PCR	O
fingerprint	O
cloning	O
was	O
used	O
to	O
isolate	O
a	O
DNA	O
probe	O
from	O
the	O
Xp11	O
.	O

4	O
-	O
-	O
>	O
p11	O
.	O

21	O
region	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

This	O
novel	O
sequence	O
,	O
cpXr318	O
(	O
DXS742	O
)	O
,	O
detects	O
a	O
new	O
submicroscopic	O
deletion	O
interval	O
at	O
the	O
Norrie	B
disease	I
locus	O
(	O
NDP	O
)	O
.	O

Combining	O
our	O
data	O
with	O
the	O
consensus	O
genetic	O
map	O
of	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
we	O
propose	O
the	O
physical	O
order	O
Xcen	O
-	O
DXS14	O
-	O
DXS255	O
-	O
(	O
DXS426	O
,	O
TIMP	O
)	O
-	O
(	O
DXS742	O
-	O
(	O
[	O
MAOB	O
-	O
MAOA	O
-	O
DXS7	O
]	O
,	O
NDP	O
)	O
-	O
DXS77	O
-	O
DXS228	O
)	O
-	O
DXS209	O
-	O
DXS148	O
-	O
DXS196	O
-	O
+	O
+	O
+	O
Xpter	O
.	O

The	O
cpXr318	O
probe	O
and	O
a	O
subclone	O
from	O
a	O
cosmid	O
corresponding	O
to	O
the	O
DXS7	O
locus	O
were	O
converted	O
into	O
sequence	O
-	O
tagged	O
sites	O
.	O

Finally	O
,	O
DXS742	O
,	O
DSX7	O
,	O
DXS77	O
,	O
and	O
MAOA	O
were	O
integrated	O
into	O
a	O
physical	O
map	O
spanning	O
the	O
Norrie	B
disease	I
locus	O

Putative	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
gene	O
shares	O
unexpected	O
homology	O
with	O
ABC	O
transporters	O
.	O

Adrenoleukodystrophy	B
(	O
ALD	B
)	O
is	O
an	O
X	B
-	I
linked	I
disease	I
affecting	O
1	O
/	O
20	O
,	O
000	O
males	O
either	O
as	O
cerebral	B
ALD	I
in	O
childhood	O
or	O
as	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
in	O
adults	O
.	O

Childhood	O
ALD	B
is	O
the	O
more	O
severe	O
form	O
,	O
with	O
onset	O
of	O
neurological	O
symptoms	O
between	O
5	O
-	O
12	O
years	O
of	O
age	O
.	O

Central	B
nervous	I
system	I
demyelination	I
progresses	O
rapidly	O
and	O
death	O
occurs	O
within	O
a	O
few	O
years	O
.	O

AMN	B
is	O
a	O
milder	O
form	O
of	O
the	O
disease	O
with	O
onset	O
at	O
15	O
-	O
30	O
years	O
of	O
age	O
and	O
a	O
more	O
progressive	O
course	O
.	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
disease	I
)	O
may	O
remain	O
the	O
only	O
clinical	O
manifestation	O
of	O
ALD	B
.	O

The	O
principal	O
biochemical	O
abnormality	O
of	O
ALD	B
is	O
the	O
accumulation	O
of	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
because	O
of	O
impaired	O
beta	O
-	O
oxidation	O
in	O
peroxisomes	O
.	O

The	O
normal	O
oxidation	O
of	O
VLCFA	O
-	O
CoA	O
in	O
patients	O
fibroblasts	O
suggested	O
that	O
the	O
gene	O
coding	O
for	O
the	O
VLCFA	O
-	O
CoA	O
synthetase	O
could	O
be	O
a	O
candidate	O
gene	O
for	O
ALD	B
.	O

Here	O
we	O
use	O
positional	O
cloning	O
to	O
identify	O
a	O
gene	O
partially	O
deleted	O
in	O
6	O
of	O
85	O
independent	O
patients	O
with	O
ALD	B
.	O

In	O
familial	O
cases	O
,	O
the	O
deletions	O
segregated	O
with	O
the	O
disease	O
.	O

An	O
identical	O
deletion	O
was	O
detected	O
in	O
two	O
brothers	O
presenting	O
with	O
different	O
clinical	O
ALD	B
phenotypes	O
.	O

Candidate	O
exons	O
were	O
identified	O
by	O
computer	O
analysis	O
of	O
genomic	O
sequences	O
and	O
used	O
to	O
isolate	O
complementary	O
DNAs	O
by	O
exon	O
connection	O
and	O
screening	O
of	O
cDNA	O
libraries	O
.	O

The	O
deduced	O
protein	O
sequence	O
shows	O
significant	O
sequence	O
identity	O
to	O
a	O
peroxisomal	O
membrane	O
protein	O
of	O
M	O
(	O
r	O
)	O
70K	O
that	O
is	O
involved	O
in	O
peroxisome	O
biogenesis	O
and	O
belongs	O
to	O
the	O
ATP	O
-	O
binding	O
cassette	O
superfamily	O
of	O
transporters	O
.	O
.	O

Targeted	O
modification	O
of	O
the	O
apolipoprotein	O
B	O
gene	O
results	O
in	O
hypobetalipoproteinemia	B
and	O
developmental	B
abnormalities	I
in	O
mice	O
.	O

Familial	B
hypobetalipoproteinemia	I
is	O
an	O
autosomal	B
codominant	I
disorder	I
resulting	O
in	O
a	O
dramatic	O
reduction	O
in	O
plasma	O
concentrations	O
of	O
apolipoprotein	O
(	O
apo	O
)	O
B	O
,	O
cholesterol	O
,	O
and	O
beta	O
-	O
migrating	O
lipoproteins	O
.	O

A	O
benefit	O
of	O
hypobetalipoproteinemia	B
is	O
that	O
mildly	O
affected	O
individuals	O
may	O
be	O
protected	O
from	O
coronary	B
vascular	I
disease	I
.	O

We	O
have	O
used	O
gene	O
targeting	O
to	O
generate	O
mice	O
with	O
a	O
modified	O
Apob	O
allele	O
.	O

Mice	O
containing	O
this	O
allele	O
display	O
all	O
of	O
the	O
hallmarks	O
of	O
human	O
hypobetalipoproteinemia	B
they	O
produce	O
a	O
truncated	O
apoB	O
protein	O
,	O
apoB70	O
,	O
and	O
have	O
markedly	O
decreased	O
plasma	O
concentrations	O
of	O
apoB	O
,	O
beta	O
-	O
lipoproteins	O
,	O
and	O
total	O
cholesterol	O
.	O

In	O
addition	O
,	O
the	O
mice	O
manifest	O
several	O
characteristics	O
that	O
are	O
occasionally	O
observed	O
in	O
human	O
hypobetalipoproteinemia	B
,	O
including	O
reduced	O
plasma	O
triglyceride	O
concentrations	O
,	O
fasting	O
chylomicronemia	B
,	O
and	O
reduced	O
high	O
density	O
lipoprotein	O
cholesterol	O
.	O

An	O
unexpected	O
finding	O
is	O
that	O
the	O
modified	O
Apob	O
allele	O
is	O
strongly	O
associated	O
with	O
exencephalus	B
and	O
hydrocephalus	B
.	O

These	O
mice	O
should	O
help	O
increase	O
our	O
understanding	O
of	O
hypobetalipoproteinemia	B
,	O
atherogenesis	B
,	O
and	O
the	O
etiology	O
of	O
exencephalus	B
and	O
hydrocephalus	B
.	O
.	O

A	O
novel	O
disease	O
with	O
deficiency	B
of	I
mitochondrial	I
very	I
-	I
long	I
-	I
chain	I
acyl	I
-	I
CoA	I
dehydrogenase	I
.	O

Palmitoyl	O
-	O
CoA	O
dehydrogenase	O
activity	O
in	O
skin	O
fibroblasts	O
from	O
seven	O
patients	O
with	O
unidentified	O
defects	O
of	O
fatty	O
acid	O
oxidation	O
was	O
measured	O
in	O
the	O
presence	O
and	O
absence	O
of	O
antibodies	O
against	O
medium	O
-	O
chain	O
,	O
long	O
-	O
chain	O
,	O
and	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenases	O
(	O
VLCAD	O
)	O
.	O

Two	O
of	O
the	O
patients	O
,	O
4	O
-	O
5	O
month	O
old	O
boys	O
,	O
were	O
found	O
to	O
have	O
a	O
novel	O
disease	O
,	O
VLCAD	B
deficiency	I
,	O
as	O
judged	O
from	O
the	O
results	O
of	O
very	O
low	O
palmitoyl	O
-	O
CoA	O
dehydrogenase	O
activity	O
and	O
the	O
lack	O
of	O
immunoreactivity	O
toward	O
antibody	O
raised	O
to	O
purified	O
VLCAD	O
.	O
.	O

Molecular	O
characterization	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
patients	O
of	O
Chinese	O
descent	O
and	O
identification	O
of	O
new	O
base	O
substitutions	O
in	O
the	O
human	O
G6PD	O
gene	O
.	O

The	O
underlying	O
DNA	O
changes	O
associated	O
with	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
-	I
deficient	I
Asians	O
have	O
not	O
been	O
extensively	O
investigated	O
.	O

To	O
fill	O
this	O
gap	O
,	O
we	O
sequenced	O
the	O
G6PD	O
gene	O
of	O
43	O
G6PD	B
-	I
deficient	I
Chinese	O
whose	O
G6PD	O
was	O
well	O
characterized	O
biochemically	O
.	O

DNA	O
samples	O
were	O
obtained	O
from	O
peripheral	O
blood	O
of	O
these	O
individuals	O
for	O
sequencing	O
using	O
a	O
direct	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
sequencing	O
procedure	O
.	O

From	O
these	O
43	O
samples	O
,	O
we	O
have	O
identified	O
five	O
different	O
types	O
of	O
nucleotide	O
substitutions	O
in	O
the	O
G6PD	O
gene	O
at	O
cDNA	O
1388	O
from	O
G	O
to	O
A	O
(	O
Arg	O
to	O
His	O
)	O
;	O
at	O
cDNA	O
1376	O
from	O
G	O
to	O
T	O
(	O
Arg	O
to	O
Leu	O
)	O
;	O
at	O
cDNA	O
1024	O
from	O
C	O
to	O
T	O
(	O
Leu	O
to	O
Phe	O
)	O
;	O
at	O
cDNA	O
392	O
from	O
G	O
to	O
T	O
(	O
Gly	O
to	O
Val	O
)	O
;	O
at	O
cDNA	O
95	O
from	O
A	O
to	O
G	O
(	O
His	O
to	O
Arg	O
)	O
.	O

These	O
five	O
nucleotide	O
substitutions	O
account	O
for	O
over	O
83	O
%	O
of	O
our	O
43	O
G6PD	B
-	I
deficient	I
samples	O
and	O
these	O
substitutions	O
have	O
not	O
been	O
reported	O
in	O
non	O
-	O
Asians	O
.	O

The	O
substitutions	O
found	O
at	O
cDNA	O
392	O
and	O
cDNA	O
1024	O
are	O
new	O
findings	O
.	O

The	O
substitutions	O
at	O
cDNA	O
1376	O
and	O
1388	O
account	O
for	O
over	O
50	O
%	O
of	O
the	O
43	O
samples	O
examined	O
indicating	O
a	O
high	O
prevalence	O
of	O
these	O
two	O
alleles	O
among	O
G6PD	B
-	I
deficient	I
Chinese	O
.	O

Our	O
findings	O
add	O
support	O
to	O
the	O
notion	O
that	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
much	O
of	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
.	O
.	O

Identification	O
of	O
mutations	O
in	O
Danish	O
choroideremia	B
families	O
.	O

We	O
have	O
searched	O
for	O
mutations	O
in	O
the	O
choroideremia	B
gene	O
(	O
CHM	B
)	O
in	O
patients	O
from	O
12	O
Danish	O
families	O
in	O
which	O
CHM	B
is	O
segregating	O
.	O

Employing	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
,	O
and	O
direct	O
DNA	O
sequencing	O
,	O
different	O
mutations	O
have	O
been	O
identified	O
in	O
6	O
patients	O
.	O

All	O
the	O
mutations	O
will	O
interfere	O
with	O
the	O
correct	O
translation	O
of	O
the	O
mRNA	O
predicting	O
a	O
truncated	O
protein	O
or	O
no	O
gene	O
product	O
at	O
all	O
.	O
.	O

Structure	O
and	O
genomic	O
sequence	O
of	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
kinase	O
)	O
gene	O
.	O

The	O
mutation	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
CTG	O
trinucleotide	O
repeat	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
gene	O
encoding	O
for	O
a	O
protein	O
with	O
putative	O
serine	O
-	O
threonine	O
protein	O
kinase	O
activity	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
genomic	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
DM	B
kinase	O
gene	O
.	O

A	O
comparison	O
of	O
these	O
sequences	O
with	O
each	O
other	O
and	O
with	O
known	O
cDNA	O
sequences	O
from	O
both	O
species	O
,	O
led	O
us	O
to	O
predict	O
a	O
translation	O
initiation	O
codon	O
,	O
as	O
well	O
as	O
determine	O
the	O
organization	O
of	O
the	O
DM	B
kinase	O
gene	O
.	O

Several	O
polymorphisms	O
within	O
the	O
human	O
DM	B
kinase	O
gene	O
have	O
been	O
identified	O
,	O
and	O
PCR	O
assays	O
to	O
detect	O
two	O
of	O
these	O
are	O
described	O
.	O

The	O
complete	O
sequence	O
and	O
characterization	O
of	O
the	O
structure	O
of	O
the	O
DM	B
kinase	O
gene	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
novel	O
polymorphisms	O
within	O
the	O
gene	O
,	O
represent	O
an	O
important	O
step	O
in	O
a	O
further	O
understanding	O
of	O
the	O
genetics	O
of	O
myotonic	B
dystrophy	I
and	O
the	O
molecular	O
biology	O
of	O
the	O
gene	O
.	O
.	O

Autosomal	O
recessive	O
transmission	O
of	O
hemophilia	B
A	I
due	O
to	O
a	O
von	B
Willebrand	I
factor	O
mutation	O
.	O

The	O
differential	O
diagnosis	O
of	O
the	O
genetic	B
bleeding	I
disorders	I
,	O
hemophilia	B
A	I
and	O
von	B
Willebrand	I
disease	I
,	O
is	O
occasionally	O
confounded	O
by	O
the	O
close	O
molecular	O
relationship	O
of	O
coagulation	O
factor	O
VIII	O
and	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
.	O

This	O
report	O
describes	O
the	O
autosomal	O
inheritance	O
of	O
a	O
hemophilia	B
A	I
phenotype	O
due	O
to	O
a	O
mutation	O
of	O
vWF	O
that	O
results	O
in	O
defective	O
factor	O
VIII	O
binding	O
.	O

The	O
proband	O
was	O
a	O
female	O
patient	O
with	O
low	O
levels	O
of	O
factor	O
VIII	O
activity	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
DNA	O
sequencing	O
were	O
employed	O
to	O
examine	O
exons	O
encoding	O
the	O
putative	O
factor	O
VIII	O
binding	O
domain	O
of	O
vWF	O
.	O

The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
point	O
mutation	O
causing	O
a	O
Thr	O
-	O
-	O
>	O
Met	O
substitution	O
at	O
amino	O
acid	O
position	O
28	O
in	O
the	O
mature	O
vWF	O
subunit	O
.	O

The	O
phenotypic	O
expression	O
of	O
the	O
mutation	O
was	O
determined	O
to	O
be	O
recessive	O
because	O
heterozygous	O
family	O
members	O
were	O
clinically	O
unaffected	O
.	O

Recombinant	O
vWF	O
containing	O
the	O
observed	O
amino	O
acid	O
substitution	O
was	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
.	O

The	O
mutant	O
vWF	O
was	O
processed	O
and	O
secreted	O
normally	O
,	O
and	O
was	O
functionally	O
equivalent	O
to	O
wild	O
-	O
type	O
vWF	O
in	O
its	O
ability	O
to	O
bind	O
to	O
platelets	O
.	O

However	O
,	O
the	O
mutant	O
failed	O
to	O
bind	O
factor	O
VIII	O
,	O
demonstrating	O
that	O
the	O
mutation	O
was	O
functionally	O
related	O
to	O
the	O
observed	O
hemophilia	B
phenotype	O
.	O

The	O
family	O
we	O
describe	O
demonstrates	O
the	O
recessive	O
inheritance	O
of	O
a	O
recently	O
recognized	O
class	O
of	O
genetic	O
bleeding	O
disorders	O
,	O
we	O
call	O
"	O
autosomal	O
hemophilia	B
.	O

"	O
We	O
conclude	O
that	O
vWF	O
mutation	O
may	O
be	O
an	O
under	O
recognized	O
cause	O
of	O
hemophilia	B
,	O
especially	O
in	O
cases	O
where	O
the	O
inheritance	O
pattern	O
is	O
not	O
consistent	O
with	O
X	O
-	O
linked	O
transmission	O
.	O

Somatic	O
von	B
Hippel	I
-	I
Lindau	I
mutation	O
in	O
clear	O
cell	O
papillary	B
cystadenoma	I
of	I
the	I
epididymis	I
.	O

Papillary	B
cystadenoma	I
of	I
the	I
epididymis	I
is	O
an	O
uncommon	O
benign	O
lesion	O
that	O
may	O
occur	O
sporadically	O
or	O
as	O
a	O
manifestation	O
of	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
.	O

Neither	O
immunohistochemical	O
studies	O
nor	O
molecular	O
genetic	O
analyses	O
of	O
the	O
VHL	B
gene	O
have	O
been	O
reported	O
previously	O
for	O
this	O
lesion	O
.	O

The	O
authors	O
describe	O
two	O
cases	O
of	O
clear	O
cell	O
papillary	B
cystadenoma	I
of	I
the	I
epididymis	I
,	O
both	O
of	O
which	O
were	O
initially	O
confused	O
with	O
metastatic	B
renal	I
cell	I
carcinoma	I
.	O

Both	O
lesions	O
showed	O
positive	O
immunohistochemical	O
staining	O
for	O
low	O
and	O
intermediate	O
molecular	O
weight	O
keratins	O
(	O
Cam	O
5	O
.	O
2	O
and	O
AE1	O
/	O
AE3	O
)	O
,	O
EMA	O
,	O
vimentin	O
,	O
alpha	O
1	O
-	O
antitrypsin	O
,	O
and	O
alpha	O
1	O
-	O
antichymotrypsin	O
.	O

Each	O
was	O
negative	O
for	O
CEA	O
.	O

Because	O
clear	O
cell	O
papillary	B
cystadenoma	I
is	O
similar	O
to	O
renal	B
cell	I
carcinoma	I
histologically	O
,	O
and	O
because	O
both	O
occur	O
as	O
components	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
complex	O
,	O
the	O
authors	O
analyzed	O
both	O
cases	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
VHL	B
gene	O
.	O

A	O
somatic	O
VHL	B
gene	O
mutation	O
was	O
detected	O
in	O
one	O
of	O
the	O
two	O
tumors	B
by	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

Direct	O
sequencing	O
revealed	O
a	O
cytosine	O
to	O
thymine	O
transition	O
at	O
nucleotide	O
694	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
an	O
arginine	O
with	O
a	O
stop	O
codon	O
after	O
the	O
sixth	O
amino	O
acid	O
of	O
exon	O
3	O
.	O

As	O
the	O
VHL	B
gene	O
is	O
believed	O
to	O
function	O
as	O
a	O
tumor	B
suppressor	O
gene	O
,	O
VHL	B
gene	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
tumorigenesis	O
in	O
sporadic	O
cystadenomas	B
of	I
the	I
epididymis	I
.	O

Identification	O
of	O
WASP	O
mutations	O
in	O
patients	O
with	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
and	O
isolated	B
thrombocytopenia	I
reveals	O
allelic	O
heterogeneity	O
at	O
the	O
WAS	B
locus	O
.	O

Mutation	O
in	O
the	O
gene	O
encoding	O
the	O
recently	O
isolated	O
WASP	O
protein	O
has	O
now	O
been	O
identified	O
as	O
the	O
genetic	B
defect	I
responsible	O
for	O
the	O
X	B
-	I
linked	I
Wiskott	I
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
a	O
primary	O
immunodeficiency	B
disease	I
associated	O
with	O
extensive	O
phenotypic	O
variability	O
.	O

To	O
elucidate	O
the	O
range	O
of	O
WASP	O
mutations	O
responsible	O
for	O
WAS	B
,	O
we	O
used	O
PCR	O
-	O
SSCP	O
analysis	O
to	O
screen	O
for	O
WASP	O
gene	O
mutation	O
in	O
19	O
unrelated	O
boys	O
with	O
the	O
diagnosis	O
of	O
classical	O
or	O
attenuated	O
WAS	B
or	O
isolated	B
thrombocytopenia	I
.	O

All	O
19	O
patients	O
had	O
WASP	O
mutations	O
,	O
each	O
of	O
which	O
localized	O
to	O
the	O
initial	O
three	O
or	O
terminal	O
three	O
exons	O
of	O
the	O
gene	O
,	O
and	O
the	O
majority	O
of	O
which	O
were	O
unique	O
in	O
each	O
case	O
.	O

However	O
,	O
a	O
missense	O
mutation	O
which	O
results	O
in	O
substitution	O
of	O
the	O
arginine	O
at	O
WAS	B
codon	O
86	O
was	O
identified	O
in	O
three	O
boys	O
with	O
severe	O
WAS	B
as	O
well	O
as	O
in	O
one	O
boy	O
presenting	O
with	O
thrombocytopenia	B
alone	O
.	O

While	O
the	O
three	O
mutations	O
found	O
in	O
the	O
isolated	B
thrombocytopenia	I
patients	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
about	O
one	O
-	O
half	O
of	O
the	O
gene	O
alterations	O
detected	O
in	O
both	O
severe	O
and	O
attenuated	O
WAS	B
patients	O
result	O
in	O
frameshifted	O
transcript	O
and	O
premature	O
translation	O
termination	O
.	O

These	O
findings	O
therefore	O
confirm	O
the	O
association	O
of	O
WAS	B
with	O
WASP	O
mutation	O
and	O
identify	O
WASP	O
mutation	O
as	O
a	O
cause	O
for	O
isolated	O
congenital	B
thrombocytopenia	I
in	O
males	O
.	O

While	O
the	O
WASP	O
gene	O
defects	O
responsible	O
for	O
isolated	B
thrombocytopenia	I
and	O
other	O
mild	O
presentations	O
of	O
WAS	B
do	O
not	O
appear	O
distinct	O
from	O
those	O
resulting	O
in	O
severe	O
WAS	B
,	O
these	O
data	O
indicate	O
that	O
analysis	O
of	O
WASP	O
gene	O
mutation	O
provides	O
a	O
valuable	O
tool	O
for	O
distinguishing	O
the	O
spectrum	O
of	O
WAS	B
patients	O
and	O
the	O
subset	O
of	O
males	O
with	O
isolated	B
thrombocytopenia	I
who	O
represent	O
mild	O
cases	O
of	O
WAS	B
.	O
.	O

WASP	O
gene	O
mutations	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
and	O
X	B
-	I
linked	I
thrombocytopenia	I
.	O

The	O
WASP	O
gene	O
has	O
been	O
recently	O
cloned	O
from	O
Xp11	O
.	O

23	O
and	O
shown	O
to	O
be	O
mutated	O
in	O
three	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
.	O

We	O
have	O
developed	O
a	O
screening	O
protocol	O
for	O
identifying	O
WASP	O
gene	O
alterations	O
in	O
genomic	O
DNA	O
and	O
have	O
identified	O
a	O
spectrum	O
of	O
novel	O
mutations	O
in	O
12	O
additional	O
unrelated	O
families	O
.	O

These	O
missense	O
,	O
nonsense	O
and	O
frameshift	O
mutations	O
involve	O
eight	O
of	O
the	O
12	O
exons	O
of	O
the	O
gene	O
.	O

Two	O
mutations	O
creating	O
premature	O
termination	O
codons	O
were	O
associated	O
with	O
lack	O
of	O
detectable	O
mRNA	O
on	O
Northern	O
blots	O
.	O

Four	O
amino	O
acid	O
substitutions	O
,	O
Leu27Phe	O
,	O
Thr48Ile	O
,	O
Val75Met	O
and	O
Arg477Lys	O
,	O
were	O
found	O
in	O
patients	O
with	O
congenital	B
thrombocytopenia	I
and	O
no	O
clinically	O
evident	O
immune	O
defect	O
indicating	O
that	O
the	O
WASP	O
gene	O
is	O
the	O
site	O
for	O
mutations	O
in	O
X	B
-	I
linked	I
thrombocytopenia	I
as	O
well	O
as	O
in	O
WAS	B
.	O

A	O
T	O
-	O
cell	O
line	O
from	O
a	O
WAS	B
patient	O
contained	O
two	O
independent	O
DNA	O
alterations	O
,	O
a	O
constitutional	O
frameshift	O
mutation	O
,	O
also	O
present	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
patient	O
,	O
and	O
compensatory	O
splice	O
site	O
mutation	O
unique	O
to	O
the	O
cell	O
line	O
.	O

The	O
distribution	O
of	O
eight	O
missense	O
mutations	O
provides	O
valuable	O
information	O
on	O
amino	O
acids	O
which	O
are	O
essential	O
for	O
normal	O
protein	O
function	O
,	O
and	O
suggests	O
that	O
sites	O
in	O
the	O
first	O
two	O
exons	O
are	O
hot	O
-	O
spots	O
for	O
mutation	O
.	O

Evidence	O
for	O
inter	O
-	O
generational	O
instability	O
in	O
the	O
CAG	O
repeat	O
in	O
the	O
MJD1	O
gene	O
and	O
for	O
conserved	O
haplotypes	O
at	O
flanking	O
markers	O
amongst	O
Japanese	O
and	O
Caucasian	O
subjects	O
with	O
Machado	B
-	I
Joseph	I
disease	I
.	O

The	O
size	O
of	O
the	O
(	O
CAG	O
)	O
n	O
repeat	O
array	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
MJD1	O
gene	O
and	O
the	O
haplotype	O
at	O
a	O
series	O
of	O
microsatellite	O
markers	O
surrounding	O
the	O
MJD1	O
gene	O
were	O
examined	O
in	O
a	O
large	O
cohort	O
of	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
.	O

Our	O
data	O
provide	O
five	O
novel	O
observations	O
.	O

First	O
,	O
MJD	B
is	O
associated	O
with	O
expansion	O
fo	O
the	O
array	O
from	O
the	O
normal	O
range	O
of	O
14	O
-	O
37	O
repeats	O
to	O
68	O
-	O
84	O
repeats	O
in	O
most	O
Japanese	O
and	O
Caucasian	O
subjects	O
,	O
but	O
no	O
subjects	O
were	O
observed	O
with	O
expansions	O
intermediate	O
in	O
size	O
between	O
those	O
of	O
the	O
normal	O
and	O
MJD	B
affected	O
groups	O
.	O

Second	O
,	O
the	O
expanded	O
allele	O
associated	O
with	O
MJD	B
displays	O
inter	O
-	O
generational	O
instability	O
,	O
particularly	O
in	O
male	O
meioses	O
,	O
and	O
this	O
instability	O
was	O
associated	O
with	O
the	O
clinical	O
phenomenon	O
of	O
anticipation	O
.	O

Third	O
,	O
the	O
size	O
of	O
the	O
expanded	O
allele	O
is	O
not	O
only	O
inversely	O
correlated	O
with	O
the	O
age	O
-	O
of	O
-	O
onset	O
of	O
MJD	B
(	O
r	O
=	O
-	O
0	O
.	O
738	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
is	O
also	O
correlated	O
with	O
the	O
frequency	O
of	O
other	O
clinical	O
features	O
[	O
e	O
.	O
g	O
.	O
pseudoexophthalmos	O
and	O
pyramidal	O
signs	O
were	O
more	O
frequent	O
in	O
subjects	O
with	O
large	O
repeats	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
05	O
respectively	O
)	O
]	O
.	O

Fourth	O
,	O
the	O
disease	O
phenotype	O
is	O
significantly	O
more	O
severe	O
and	O
had	O
an	O
early	O
age	O
of	O
onset	O
(	O
16	O
years	O
)	O
in	O
a	O
subject	O
homozygous	O
for	O
the	O
expanded	O
allele	O
,	O
which	O
contrasts	O
with	O
Huntington	B
disease	I
and	O
suggests	O
that	O
the	O
expanded	O
allele	O
in	O
the	O
MJD1	O
gene	O
could	O
exert	O
its	O
effect	O
either	O
by	O
a	O
dominant	O
negative	O
effect	O
(	O
putatively	O
excluded	O
in	O
HD	B
)	O
or	O
by	O
a	O
gain	O
of	O
function	O
effect	O
as	O
proposed	O
for	O
HD	B
.	O

Finally	O
,	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
MJD	B
share	O
haplotypes	O
at	O
several	O
markers	O
surrounding	O
the	O
MJD1	O
gene	O
,	O
which	O
are	O
uncommon	O
in	O
the	O
normal	O
Japanese	O
and	O
Caucasian	O
population	O
,	O
and	O
which	O
suggests	O
the	O
existence	O
either	O
of	O
common	O
founders	O
in	O
these	O
populations	O
or	O
of	O
chromosomes	O
susceptible	O
to	O
pathologic	O
expansion	O
of	O
the	O
CAG	O
repeat	O
in	O
the	O
MJD1	O
gene	O
.	O

A	O
4	O
-	O
megabase	O
YAC	O
contig	O
that	O
spans	O
the	O
Langer	B
-	I
Giedion	I
syndrome	I
region	O
on	O
human	O
chromosome	O
8q24	O
.	O
1	O
:	O
use	O
in	O
refining	O
the	O
location	O
of	O
the	O
trichorhinophalangeal	B
syndrome	I
and	O
multiple	O
exostoses	O
genes	O
(	O
TRPS1	O
and	O
EXT1	O
)	O
.	O

We	O
have	O
constructed	O
a	O
physical	O
map	O
covering	O
over	O
4	O
Mb	O
of	O
human	O
chromosome	O
8q24	O
.	O

1	O
and	O
used	O
this	O
map	O
to	O
refine	O
the	O
locations	O
of	O
the	O
genes	O
responsible	O
for	O
Langer	B
-	I
Giedion	I
syndrome	I
.	O

The	O
map	O
is	O
composed	O
of	O
overlapping	O
YAC	O
clones	O
that	O
were	O
identified	O
and	O
ordered	O
in	O
relation	O
to	O
sequence	O
tagged	O
sites	O
mapped	O
to	O
the	O
Langer	O
-	O
Giedion	O
chromosomal	O
region	O
on	O
somatic	O
cell	O
hybrids	O
.	O

The	O
minimal	O
region	O
of	O
overlap	O
of	O
Langer	B
-	I
Giedion	I
syndrome	I
deletions	O
,	O
previously	O
identified	O
by	O
analysis	O
of	O
15	O
patients	O
,	O
was	O
placed	O
on	O
the	O
map	O
by	O
analysis	O
of	O
2	O
patients	O
whose	O
deletions	O
define	O
the	O
endpoints	O
.	O

The	O
chromosome	O
8	O
breakpoint	O
of	O
a	O
balanced	O
t	O
(	O
8	O
;	O
9	O
)	O
(	O
q24	O
.	O
11	O
;	O
q33	O
.	O
3	O
)	O
translocation	O
from	O
a	O
patient	O
with	O
trichorhinophalangeal	B
syndrome	I
(	O
TRPS	B
I	O
)	O
was	O
found	O
to	O
be	O
located	O
just	O
within	O
the	O
proximal	O
end	O
of	O
the	O
minimal	O
deletion	O
region	O
.	O

A	O
deletion	O
of	O
8q24	O
.	O

11	O
-	O
q24	O
.	O

3	O
in	O
a	O
patient	O
with	O
multiple	O
exostoses	O
was	O
found	O
to	O
overlap	O
the	O
distal	O
end	O
of	O
the	O
LGS	B
deletion	O
region	O
,	O
indicating	O
that	O
the	O
EXT1	O
gene	O
is	O
distal	O
to	O
the	O
TRPS1	O
gene	O
and	O
supporting	O
the	O
hypothesis	O
that	O
Langer	B
-	I
Giedion	I
syndrome	I
is	O
due	O
to	O
loss	O
of	O
functional	O
copies	O
of	O
both	O
the	O
TRPS1	O
and	O
the	O
EXT1	O
genes	O

BRCA1	O
mutations	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
young	O
women	O
with	O
breast	B
cancer	I
.	O

BACKGROUND	O
.	O

Inherited	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
are	O
associated	O
with	O
a	O
high	O
risk	O
of	O
breast	B
and	I
ovarian	I
cancer	I
in	O
some	O
families	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
BRCA1	O
mutations	O
to	O
breast	B
cancer	I
in	O
the	O
general	O
population	O
.	O

We	O
analyzed	O
DNA	O
samples	O
from	O
women	O
enrolled	O
in	O
a	O
population	O
-	O
based	O
study	O
of	O
early	O
-	O
onset	O
breast	B
cancer	I
to	O
assess	O
the	O
spectrum	O
and	O
frequency	O
of	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
in	O
young	O
women	O
with	O
breast	B
cancer	I
.	O

METHODS	O
.	O

We	O
studied	O
80	O
women	O
in	O
whom	O
breast	B
cancer	I
was	O
diagnosed	O
before	O
the	O
age	O
of	O
35	O
,	O
and	O
who	O
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
family	O
history	O
.	O

Genomic	O
DNA	O
was	O
studied	O
for	O
BRCA1	O
mutations	O
by	O
analysis	O
involving	O
single	O
-	O
strand	O
conformation	O
polymorphisms	O
and	O
with	O
allele	O
-	O
specific	O
assays	O
.	O

Alterations	O
were	O
defined	O
by	O
DNA	O
sequencing	O
.	O

RESULTS	O
.	O

Germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
the	O
80	O
women	O
.	O

Four	O
additional	O
rare	O
sequence	O
variants	O
of	O
unknown	O
functional	O
importance	O
were	O
also	O
identified	O
.	O

Two	O
of	O
the	O
mutations	O
and	O
three	O
of	O
the	O
rare	O
sequence	O
variants	O
were	O
found	O
among	O
the	O
39	O
women	O
who	O
reported	O
no	O
family	O
history	O
of	O
breast	B
or	I
ovarian	I
cancer	I
.	O

None	O
of	O
the	O
mutations	O
and	O
only	O
one	O
of	O
the	O
rare	O
variants	O
was	O
identified	O
in	O
a	O
reference	O
population	O
of	O
73	O
unrelated	O
subjects	O
.	O

CONCLUSIONS	O
.	O

Alterations	O
in	O
BRCA1	O
were	O
identified	O
in	O
approximately	O
10	O
percent	O
of	O
this	O
cohort	O
of	O
young	O
women	O
with	O
breast	B
cancer	I
.	O

The	O
risk	O
of	O
harboring	O
a	O
mutation	O
was	O
not	O
limited	O
to	O
women	O
with	O
family	O
histories	O
of	O
breast	B
or	I
ovarian	I
cancer	I
.	O

These	O
results	O
represent	O
a	O
minimal	O
estimate	O
of	O
the	O
frequency	O
of	O
BRCA1	O
mutations	O
in	O
this	O
population	O
.	O

Comprehensive	O
methods	O
of	O
identifying	O
BRCA1	O
mutations	O
and	O
understanding	O
their	O
importance	O
will	O
be	O
needed	O
before	O
testing	O
of	O
women	O
in	O
the	O
general	O
population	O
can	O
be	O
undertaken	O
.	O
.	O

Novel	O
inherited	O
mutations	O
and	O
variable	O
expressivity	O
of	O
BRCA1	O
alleles	O
,	O
including	O
the	O
founder	O
mutation	O
185delAG	O
in	O
Ashkenazi	O
Jewish	O
families	O
.	O

Thirty	O
-	O
seven	O
families	O
with	O
four	O
or	O
more	O
cases	O
of	O
breast	B
cancer	I
or	O
breast	B
and	I
ovarian	I
cancer	I
were	O
analyzed	O
for	O
mutations	O
in	O
BRCA1	O
.	O

Twelve	O
different	O
germ	O
-	O
line	O
mutations	O
,	O
four	O
novel	O
and	O
eight	O
previously	O
observed	O
,	O
were	O
detected	O
in	O
16	O
families	O
.	O

Five	O
families	O
of	O
Ashkenazi	O
Jewish	O
descent	O
carried	O
the	O
185delAG	O
mutation	O
and	O
shared	O
the	O
same	O
haplotype	O
at	O
eight	O
polymorphic	O
markers	O
spanning	O
approximately	O
850	O
kb	O
at	O
BRCA1	O
.	O

Expressivity	O
of	O
185delAG	O
in	O
these	O
families	O
varied	O
,	O
from	O
early	O
-	O
onset	O
breast	B
cancer	I
without	O
ovarian	B
cancer	I
.	O

Mutation	O
4184delTCAA	O
occurred	O
independently	O
in	O
two	O
families	O
.	O

In	O
one	O
family	O
,	O
penetrance	O
was	O
complete	O
,	O
with	O
females	O
developing	O
early	O
-	O
onset	O
breast	B
cancer	I
or	O
ovarian	B
cancer	I
and	O
the	O
male	O
carrier	O
developing	O
prostatic	B
cancer	I
,	O
whereas	O
,	O
in	O
the	O
other	O
family	O
,	O
penetrance	O
was	O
incomplete	O
and	O
only	O
breast	B
cancer	I
occurred	O
,	O
diagnosed	O
at	O
ages	O
38	O
-	O
81	O
years	O
.	O

Two	O
novel	O
nonsense	O
mutations	O
led	O
to	O
the	O
loss	O
of	O
mutant	O
BRCA1	O
transcript	O
in	O
families	O
with	O
10	O
and	O
6	O
cases	O
of	O
early	O
-	O
onset	O
breast	B
cancer	I
and	O
ovarian	B
cancer	I
.	O

A	O
665	O
-	O
nt	O
segment	O
of	O
the	O
BRCA1	O
3	O
-	O
UTR	O
and	O
1	O
.	O

3	O
kb	O
of	O
genomic	O
sequence	O
including	O
the	O
putative	O
promoter	O
region	O
were	O
invariant	O
by	O
single	O
-	O
strand	O
conformation	O
analysis	O
in	O
13	O
families	O
without	O
coding	O
-	O
sequence	O
mutations	O
.	O

Overall	O
in	O
our	O
series	O
,	O
BRCA1	O
mutations	O
have	O
been	O
detected	O
in	O
26	O
families	O
16	O
with	O
positive	O
BRCA1	O
lod	O
scores	O
,	O
7	O
with	O
negative	O
lod	O
scores	O
(	O
reflecting	O
multiple	O
sporadic	O
breast	B
cancers	I
)	O
,	O
and	O
3	O
not	O
tested	O
for	O
linkage	O
.	O

Three	O
other	O
families	O
have	O
positive	O
lod	O
scores	O
for	O
linkage	O
to	O
BRCA2	O
,	O
but	O
13	O
families	O
without	O
detected	O
BRCA1	O
mutations	O
have	O
negative	O
lod	O
scores	O
for	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variant	O
,	O
G6PD	O
Orissa	O
(	O
44	O
Ala	O
-	O
-	O
>	O
Gly	O
)	O
,	O
is	O
the	O
major	O
polymorphic	O
variant	O
in	O
tribal	O
populations	O
in	O
India	O
.	O

Deficiency	B
of	I
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	O
G6PD	O
)	O
is	O
usually	O
found	O
at	O
high	O
frequencies	O
in	O
areas	O
of	O
the	O
world	O
where	O
malaria	B
has	O
been	O
endemic	O
.	O

The	O
frequency	O
and	O
genetic	O
basis	O
of	O
G6PD	B
deficiency	I
have	O
been	O
studied	O
in	O
Africa	O
,	O
around	O
the	O
Mediterranean	O
,	O
and	O
in	O
the	O
Far	O
East	O
,	O
but	O
little	O
such	O
information	O
is	O
available	O
about	O
the	O
situation	O
in	O
India	O
.	O

To	O
determine	O
the	O
extent	O
of	O
heterogeneity	O
of	O
G6PD	O
,	O
we	O
have	O
studied	O
several	O
different	O
Indian	O
populations	O
by	O
screening	O
for	O
G6PD	B
deficiency	I
,	O
followed	O
by	O
molecular	O
analysis	O
of	O
deficient	O
alleles	O
.	O

The	O
frequency	O
of	O
G6PD	B
deficiency	I
varies	O
between	O
3	O
%	O
and	O
15	O
%	O
in	O
different	O
tribal	O
and	O
urban	O
groups	O
.	O

Remarkably	O
,	O
a	O
previously	O
unreported	O
deficient	O
variant	O
,	O
G6PD	O
Orissa	O
(	O
44	O
Ala	O
-	O
-	O
>	O
Gly	O
)	O
,	O
is	O
responsible	O
for	O
most	O
of	O
the	O
G6PD	B
deficiency	I
in	O
tribal	O
Indian	O
populations	O
but	O
is	O
not	O
found	O
in	O
urban	O
populations	O
,	O
where	O
most	O
of	O
the	O
G6PD	B
deficiency	I
is	O
due	O
to	O
the	O
G6PD	O
Mediterranean	O
(	O
188	O
Ser	O
-	O
-	O
>	O
Phe	O
)	O
variant	O
.	O

The	O
KmNADP	O
of	O
G6PD	O
Orissa	O
is	O
fivefold	O
higher	O
than	O
that	O
of	O
the	O
normal	O
enzyme	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
alanine	O
residue	O
that	O
is	O
replaced	O
by	O
glycine	O
is	O
part	O
of	O
a	O
putative	O
coenzyme	O
-	O
binding	O
site	O
.	O
.	O

Evidence	O
for	O
linkage	O
of	O
bipolar	B
disorder	I
to	O
chromosome	O
18	O
with	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
.	O

A	O
susceptibility	O
gene	O
on	O
chromosome	O
18	O
and	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
have	O
been	O
suggested	O
for	O
bipolar	B
affective	I
disorder	I
(	O
BPAD	B
)	O
.	O

We	O
have	O
studied	O
28	O
nuclear	O
families	O
selected	O
for	O
apparent	O
unilineal	O
transmission	O
of	O
the	O
BPAD	B
phenotype	O
,	O
by	O
using	O
31	O
polymorphic	O
markers	O
spanning	O
chromosome	O
18	O
.	O

Evidence	O
for	O
linkage	O
was	O
tested	O
with	O
affected	O
-	O
sib	O
-	O
pair	O
and	O
LOD	O
score	O
methods	O
under	O
two	O
definitions	O
of	O
the	O
affected	O
phenotype	O
.	O

The	O
affected	O
-	O
sibpair	O
analyses	O
indicated	O
excess	O
allele	O
sharing	O
for	O
markers	O
on	O
18p	O
within	O
the	O
region	O
reported	O
previously	O
.	O

The	O
greatest	O
sharing	O
was	O
at	O
D18S37	O
64	O
%	O
in	O
bipolar	O
and	O
recurrent	O
unipolar	O
(	O
RUP	O
)	O
sib	O
pairs	O
(	O
P	O
=	O
.	O
0006	O
)	O
.	O

In	O
addition	O
,	O
excess	O
sharing	O
of	O
the	O
paternally	O
,	O
but	O
not	O
maternally	O
,	O
transmitted	O
alleles	O
was	O
observed	O
at	O
three	O
markers	O
on	O
18q	O
at	O
D18S41	O
,	O
51	O
bipolar	O
and	O
RUP	O
sib	O
pairs	O
were	O
concordant	O
for	O
paternally	O
transmitted	O
alleles	O
,	O
and	O
21	O
pairs	O
were	O
discordant	O
(	O
P	O
=	O
0004	O
)	O
.	O

The	O
evidence	O
for	O
linkage	O
to	O
loci	O
on	O
both	O
18p	O
and	O
18q	O
was	O
strongest	O
in	O
the	O
11	O
paternal	O
pedigrees	O
,	O
i	O
.	O

e	O
e	O
.	O
,	O
those	O
in	O
which	O
the	O
father	O
or	O
one	O
of	O
the	O
fathers	O
sibs	O
is	O
affected	O
.	O

In	O
these	O
pedigrees	O
,	O
the	O
greatest	O
allele	O
sharing	O
(	O
81	O
%	O
;	O
P	O
=	O
.	O
00002	O
)	O
and	O
the	O
highest	O
LOD	O
score	O
(	O
3	O
.	O
51	O
;	O
phi	O
=	O
0	O
.	O
0	O
)	O
were	O
observed	O
at	O
D18S41	O
.	O

Our	O
results	O
provide	O
further	O
support	O
for	O
linkage	O
of	O
BPAD	B
to	O
chromosome	O
18	O
and	O
the	O
first	O
molecular	O
evidence	O
for	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
operating	O
in	O
this	O
disorder	O
.	O

The	O
number	O
of	O
loci	O
involved	O
,	O
and	O
their	O
precise	O
location	O
,	O
require	O
further	O
study	O

A	O
prevalent	O
mutation	O
for	O
galactosemia	B
among	O
black	O
Americans	O
.	O

OBJECTIVE	O
To	O
define	O
the	O
mutation	O
causing	O
galactosemia	B
in	O
patients	O
of	O
black	O
American	O
origin	O
who	O
have	O
no	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
activity	O
in	O
erythrocytes	O
but	O
good	O
clinical	O
outcome	O
.	O

METHODS	O
We	O
discovered	O
a	O
mutation	O
caused	O
by	O
a	O
C	O
-	O
-	O
>	O
T	O
transition	O
at	O
base	O
-	O
pair	O
1158	O
of	O
the	O
GALT	O
gene	O
that	O
results	O
in	O
a	O
serine	O
-	O
to	O
-	O
leucine	O
substitution	O
at	O
codon	O
135	O
(	O
S135L	O
)	O
.	O

We	O
developed	O
a	O
method	O
with	O
which	O
to	O
screen	O
populations	O
for	O
its	O
prevalence	O
.	O

We	O
compared	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
among	O
erythrocytes	O
,	O
leukocytes	O
,	O
and	O
transformed	O
lymphoblasts	O
,	O
as	O
well	O
as	O
total	O
body	O
oxidation	O
of	O
D	O
-	O
(	O
13C	O
)	O
-	O
galactose	O
to	O
13CO2	O
among	O
three	O
genotypes	O
for	O
GALT	O
(	O
S135L	O
/	O
S135L	O
,	O
Q188R	O
/	O
Q188R	O
,	O
and	O
Normal	O
/	O
Normal	O
)	O
.	O

RESULTS	O
We	O
found	O
a	O
48	O
%	O
prevalence	O
of	O
the	O
S135L	O
mutation	O
among	O
17	O
black	O
American	O
patients	O
with	O
classic	B
galactosemia	I
and	O
a	O
1	O
%	O
prevalence	O
in	O
a	O
population	O
of	O
50	O
black	O
Americans	O
without	O
galactosemia	B
.	O

The	O
S135L	O
mutation	O
was	O
not	O
found	O
in	O
84	O
white	O
patients	O
with	O
G	O
/	O
G	O
galactosemia	B
nor	O
in	O
87	O
white	O
control	O
subjects	O
without	O
galactosemia	B
.	O

We	O
found	O
normal	O
whole	O
body	O
oxidation	O
of	O
D	O
-	O
(	O
13C	O
)	O
-	O
galactose	O
by	O
the	O
patient	O
homozygous	O
for	O
S135L	O
and	O
various	O
degrees	O
of	O
enzyme	O
impairment	O
among	O
different	O
tissues	O
.	O

CONCLUSIONS	O
The	O
S135L	O
mutation	O
in	O
the	O
GALT	O
gene	O
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	B
among	O
black	O
patients	O
.	O

Because	O
GALT	O
activity	O
varies	O
in	O
different	O
tissues	O
of	O
patients	O
homozygous	O
for	O
S135L	O
,	O
they	O
may	O
have	O
a	O
better	O
clinical	O
outcome	O
than	O
patients	O
who	O
are	O
homozygous	O
for	O
Q188R	O
when	O
both	O
are	O
treated	O
from	O
infancy	O
.	O
.	O

A	O
high	O
incidence	O
of	O
BRCA1	O
mutations	O
in	O
20	O
breast	B
-	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
analyzed	O
20	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
the	O
majority	O
of	O
which	O
show	O
positive	O
evidence	O
of	O
linkage	O
to	O
chromosome	O
17q12	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

BRCA1	O
mutations	O
cosegregating	O
with	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
were	O
identified	O
in	O
16	O
families	O
,	O
including	O
1	O
family	O
with	O
a	O
case	O
of	O
male	B
breast	I
cancer	I
.	O

Nine	O
of	O
these	O
mutations	O
have	O
not	O
been	O
reported	O
previously	O
.	O

The	O
majority	O
of	O
mutations	O
were	O
found	O
to	O
generate	O
a	O
premature	O
stop	O
codon	O
leading	O
to	O
the	O
formation	O
of	O
a	O
truncated	O
BRCA1	O
protein	O
of	O
2	O
%	O
-	O
88	O
%	O
of	O
the	O
expected	O
normal	O
length	O
.	O

Two	O
mutations	O
altered	O
the	O
RING	O
finger	O
domain	O
.	O

Sequencing	O
of	O
genomic	O
DNA	O
led	O
to	O
the	O
identification	O
of	O
a	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
BRCA1	O
in	O
12	O
families	O
,	O
and	O
cDNA	O
analysis	O
revealed	O
an	O
abnormal	O
or	O
missing	O
BRCA1	O
transcript	O
in	O
4	O
of	O
the	O
8	O
remaining	O
families	O
.	O

A	O
total	O
of	O
eight	O
mutations	O
were	O
associated	O
with	O
a	O
reduced	O
quantity	O
of	O
BRCA1	O
transcript	O
.	O

We	O
were	O
unable	O
to	O
detect	O
BRCA1	O
mutations	O
in	O
4	O
of	O
the	O
20	O
families	O
,	O
but	O
only	O
1	O
of	O
these	O
was	O
clearly	O
linked	O
to	O
BRCA1	O
.	O

It	O
is	O
expected	O
that	O
the	O
majority	O
of	O
clear	O
examples	O
of	O
the	O
breast	B
-	I
ovarian	I
syndrome	I
will	O
be	O
associated	O
with	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
BRCA1	O
.	O
.	O

Brca1	B
deficiency	I
results	O
in	O
early	O
embryonic	B
lethality	I
characterized	O
by	O
neuroepithelial	B
abnormalities	I
.	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc	O
-	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
at	O
least	O
80	O
%	O
of	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
,	O
as	O
well	O
as	O
some	O
non	O
-	O
familial	O
sporadic	O
ovarian	B
cancers	I
.	O

The	O
loss	O
of	O
wild	O
-	O
type	O
BRCA1	O
in	O
tumours	B
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
BRCA1	O
allele	O
suggests	O
that	O
BRCA1	O
encodes	O
a	O
tumour	B
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
BRCA1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation	O
,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	B
susceptibility	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function	O
,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
Brca1	O
allele	O
.	O

Analysis	O
of	O
mice	O
homozygous	O
for	O
the	O
mutant	O
allele	O
indicate	O
that	O
Brca1	O
is	O
critical	O
for	O
normal	O
development	O
,	O
as	O
these	O
mice	O
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(	O
E10	O
-	O
E13	O
)	O
.	O

Abnormalities	O
in	O
Brca1	B
-	I
deficient	I
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	B
bifida	I
and	O
anencephaly	B
.	O

In	O
addition	O
,	O
the	O
neuroepithelium	O
in	O
Brca1	B
-	I
deficient	I
embryos	O
appeared	O
disorganized	O
,	O
with	O
signs	O
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	O
death	O
.	O
.	O

Identification	O
of	O
mutations	O
in	O
the	O
ALD	O
-	O
gene	O
of	O
20	O
families	O
with	O
adrenoleukodystrophy	B
/	O
adrenomyeloneuropathy	B
.	O

Adrenoleukodystrophy	B
(	O
ALD	B
)	O
,	O
an	O
X	B
-	I
linked	I
inherited	I
metabolic	I
disorder	I
,	O
is	O
the	O
most	O
frequent	O
inborn	B
peroxisomal	I
disease	I
.	O

It	O
leads	O
to	O
demyelination	B
in	I
the	I
central	I
and	I
peripheral	I
nervous	I
system	I
.	O

Defective	O
beta	O
-	O
oxidation	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFAs	O
;	O
C22	O
0	O
-	O
C26	O
0	O
)	O
in	O
peroxisomes	O
has	O
been	O
shown	O
to	O
lead	O
to	O
an	O
accumulation	O
of	O
VLCFAs	O
in	O
leukoid	O
areas	O
of	O
the	O
central	O
nervous	O
system	O
,	O
peripheral	O
nerves	O
,	O
adrenal	O
gland	O
,	O
and	O
blood	O
.	O

The	O
ALD	B
gene	O
has	O
been	O
recently	O
identified	O
and	O
encodes	O
a	O
745	O
-	O
amino	O
-	O
acid	O
protein	O
.	O

We	O
screened	O
patients	O
with	O
adrenoleukodystrophy	B
/	O
adrenomyeloneuropathy	B
(	O
ALD	B
/	O
AMN	B
)	O
from	O
20	O
kindreds	O
for	O
mutations	O
in	O
the	O
ALD	B
gene	O
.	O

Eleven	O
missense	O
and	O
two	O
nonsense	O
mutations	O
,	O
five	O
deletions	O
,	O
and	O
one	O
insertion	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
eight	O
reverse	O
transcribed	O
fragments	O
of	O
the	O
ALD	B
-	O
gene	O
mRNA	O
.	O

Four	O
mutations	O
could	O
be	O
shown	O
to	O
be	O
de	O
novo	O
.	O

All	O
mutations	O
could	O
be	O
confirmed	O
in	O
carriers	O
by	O
sequencing	O
genomic	O
DNA	O
.	O

No	O
correlation	O
between	O
the	O
type	O
of	O
mutation	O
and	O
the	O
severity	O
of	O
the	O
phenotype	O
could	O
be	O
observed	O
.	O

The	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
ALD	B
gene	O
of	O
30	O
healthy	O
persons	O
.	O
.	O

The	O
murine	O
homolog	O
of	O
the	O
human	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
Brca1	O
maps	O
to	O
mouse	O
chromosome	O
11D	O
.	O

The	O
recently	O
cloned	O
human	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
17q21	O
.	O

We	O
have	O
isolated	O
murine	O
genomic	O
clones	O
containing	O
Brca1	O
as	O
a	O
first	O
step	O
in	O
generating	O
a	O
mouse	O
model	O
for	O
the	O
loss	O
of	O
BRCA1	O
function	O
.	O

A	O
mouse	O
genomic	O
library	O
was	O
screened	O
using	O
probes	O
corresponding	O
to	O
exon	O
11	O
of	O
the	O
human	O
BRCA1	O
gene	O
.	O

Two	O
overlapping	O
mouse	O
clones	O
were	O
identified	O
that	O
hybridized	O
to	O
human	O
BRCA1	O
exons	O
9	O
-	O
12	O
.	O

Sequence	O
analysis	O
of	O
1	O
.	O

4	O
kb	O
of	O
the	O
region	O
of	O
these	O
clones	O
corresponding	O
to	O
part	O
of	O
human	O
exon	O
11	O
revealed	O
72	O
%	O
nucleic	O
acid	O
identity	O
but	O
only	O
50	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
human	O
gene	O
.	O

The	O
longest	O
of	O
the	O
mouse	O
Brca1	O
genomic	O
clones	O
maps	O
to	O
chromosome	O
11D	O
,	O
as	O
determined	O
by	O
two	O
-	O
color	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
synteny	O
to	O
human	O
chromosome	O
17	O
was	O
confirmed	O
by	O
cohybridization	O
with	O
the	O
mouse	O
probe	O
for	O
the	O
NF1	O
-	O
gene	O
.	O

This	O
comparative	O
study	O
confirms	O
that	O
the	O
relative	O
location	O
of	O
the	O
BRCA1	O
gene	O
has	O
been	O
conserved	O
between	O
mice	O
and	O
humans	O
.	O

Atelosteogenesis	B
type	I
II	I
is	O
caused	O
by	O
mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
-	O
transporter	O
gene	O
(	O
DTDST	O
)	O
:	O
evidence	O
for	O
a	O
phenotypic	O
series	O
involving	O
three	O
chondrodysplasias	B
.	O

Atelosteogenesis	B
type	I
II	I
(	O
AO	B
II	I
)	O
is	O
a	O
neonatally	O
lethal	O
chondrodysplasia	B
whose	O
clinical	O
and	O
histological	O
characteristics	O
resemble	O
those	O
of	O
another	O
chondrodysplasia	B
,	O
the	O
much	O
less	O
severe	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
.	O

The	O
similarity	O
suggests	O
a	O
shared	O
pathogenesis	O
involving	O
lesions	O
in	O
the	O
same	O
biochemical	O
pathway	O
and	O
perhaps	O
the	O
same	O
gene	O
.	O

DTD	B
is	O
caused	O
by	O
mutations	O
in	O
the	O
recently	O
identified	O
diastrophic	B
dysplasia	I
sulfate	O
-	O
transporter	O
gene	O
(	O
DTDST	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
AOII	B
patients	O
also	O
have	O
DTDST	O
mutations	O
,	O
which	O
lead	O
to	O
defective	O
uptake	O
of	O
inorganic	O
sulfate	O
and	O
insufficient	O
sulfation	O
of	O
macromolecules	O
by	O
patient	O
mesenchymal	O
cells	O
in	O
vitro	O
.	O

Together	O
with	O
our	O
recent	O
observation	O
that	O
a	O
third	O
even	O
more	O
severe	O
chondrodysplasia	B
,	O
achondrogenesis	O
type	O
IB	O
,	O
is	O
also	O
caused	O
by	O
mutations	O
in	O
DTDST	O
,	O
these	O
results	O
demonstrate	O
a	O
phenotypic	O
series	O
of	O
three	O
chondrodysplasias	B
of	O
increasing	O
severity	O
caused	O
by	O
lesions	O
in	O
a	O
single	O
sulfate	O
-	O
transporter	O
gene	O
.	O

The	O
severity	O
of	O
the	O
phenotype	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
predicted	O
effect	O
of	O
the	O
mutations	O
on	O
the	O
residual	O
activity	O
of	O
the	O
DTDST	O
protein	O
.	O
.	O

Haplotype	O
and	O
phenotype	O
analysis	O
of	O
six	O
recurrent	O
BRCA1	O
mutations	O
in	O
61	O
families	O
:	O
results	O
of	O
an	O
international	O
study	O
.	O

Several	O
BRCA1	O
mutations	O
have	O
now	O
been	O
found	O
to	O
occur	O
in	O
geographically	O
diverse	O
breast	B
and	I
ovarian	I
cancer	I
families	O
.	O

To	O
investigate	O
mutation	O
origin	O
and	O
mutation	O
-	O
specific	O
phenotypes	O
due	O
to	O
BRCA1	O
,	O
we	O
constructed	O
a	O
haplotype	O
of	O
nine	O
polymorphic	O
markers	O
within	O
or	O
immediately	O
flanking	O
the	O
BRCA1	O
locus	O
in	O
a	O
set	O
of	O
61	O
breast	B
/	I
ovarian	I
cancer	I
families	O
selected	O
for	O
having	O
one	O
of	O
six	O
recurrent	O
BRCA1	O
mutations	O
.	O

Tests	O
of	O
both	O
mutations	O
and	O
family	O
-	O
specific	O
differences	O
in	O
age	O
at	O
diagnosis	O
were	O
not	O
significant	O
.	O

A	O
comparison	O
of	O
the	O
six	O
mutations	O
in	O
the	O
relative	O
proportions	O
of	O
cases	O
of	O
breast	B
and	I
ovarian	I
cancer	I
was	O
suggestive	O
of	O
an	O
effect	O
(	O
P	O
=	O
.	O
069	O
)	O
,	O
with	O
57	O
%	O
of	O
women	O
presumed	O
affected	O
because	O
of	O
the	O
1294	O
del	O
40	O
BRCA1	O
mutation	O
having	O
ovarian	B
cancer	I
,	O
compared	O
with	O
14	O
%	O
of	O
affected	O
women	O
with	O
the	O
splice	O
-	O
site	O
mutation	O
in	O
intron	O
5	O
of	O
BRCA1	O
.	O

For	O
the	O
BRCA1	O
mutations	O
studied	O
here	O
,	O
the	O
individual	O
mutations	O
are	O
estimated	O
to	O
have	O
arisen	O
9	O
-	O
170	O
generations	O
ago	O
.	O

In	O
general	O
,	O
a	O
high	O
degree	O
of	O
haplotype	O
conservation	O
across	O
the	O
region	O
was	O
observed	O
,	O
with	O
haplotype	O
differences	O
most	O
often	O
due	O
to	O
mutations	O
in	O
the	O
short	O
-	O
tandem	O
-	O
repeat	O
markers	O
,	O
although	O
some	O
likely	O
instances	O
of	O
recombination	O
also	O
were	O
observed	O
.	O

For	O
several	O
of	O
the	O
instances	O
,	O
there	O
was	O
evidence	O
for	O
multiple	O
,	O
independent	O
,	O
BRCA1	O
mutational	O
events	O
.	O

Isolation	O
of	O
the	O
mouse	O
homologue	O
of	O
BRCA1	O
and	O
genetic	O
mapping	O
to	O
mouse	O
chromosome	O
11	O
.	O

The	O
BRCA1	O
gene	O
is	O
in	O
large	O
part	O
responsible	O
for	O
hereditary	B
human	I
breast	I
and	I
ovarian	I
cancer	I
.	O

Here	O
we	O
report	O
the	O
isolation	O
of	O
the	O
murine	O
Brca1	O
homologue	O
cDNA	O
clones	O
.	O

In	O
addition	O
,	O
we	O
identified	O
genomic	O
P1	O
clones	O
that	O
contain	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
mouse	O
Brca1	O
locus	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
the	O
mouse	O
and	O
human	O
coding	O
regions	O
are	O
75	O
%	O
identical	O
at	O
the	O
nucleotide	O
level	O
while	O
the	O
predicted	O
amino	O
acid	O
identity	O
is	O
only	O
58	O
%	O
.	O

A	O
DNA	O
sequence	O
variant	O
in	O
the	O
Brca1	O
locus	O
was	O
identified	O
and	O
used	O
to	O
map	O
this	O
gene	O
on	O
a	O
(	O
Mus	O
m	O
.	O
musculus	O
Czech	O
II	O
x	O
C57BL	O
/	O
KsJ	O
)	O
F1	O
x	O
C57BL	O
/	O
KsJ	O
intersubspecific	O
backcross	O
to	O
distal	O
mouse	O
chromosome	O
11	O
.	O

The	O
mapping	O
of	O
this	O
gene	O
to	O
a	O
region	O
highly	O
syntenic	O
with	O
human	O
chromosome	O
17	O
,	O
coupled	O
with	O
Southern	O
and	O
Northern	O
analyses	O
,	O
confirms	O
that	O
we	O
isolated	O
the	O
murine	O
Brca1	O
homologue	O
rather	O
than	O
a	O
related	O
RING	O
finger	O
gene	O
.	O

The	O
isolation	O
of	O
the	O
mouse	O
Brca1	O
homologue	O
will	O
facilitate	O
the	O
creation	O
of	O
mouse	O
models	O
for	O
germline	O
BRCA1	B
defects	I
.	O
.	O

Emerin	B
deficiency	I
at	O
the	O
nuclear	O
membrane	O
in	O
patients	O
with	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Mutations	O
in	O
the	O
STA	O
gene	O
at	O
the	O
Xq28	O
locus	O
have	O
been	O
found	O
in	O
patients	O
with	O
X	B
-	I
linked	I
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

This	O
gene	O
encodes	O
a	O
hitherto	O
unknown	O
protein	O
named	O
emerin	O
.	O

To	O
elucidate	O
the	O
subcellular	O
localization	O
of	O
emerin	O
,	O
we	O
raised	O
two	O
antisera	O
against	O
synthetic	O
peptide	O
fragments	O
predicted	O
from	O
emerin	O
cDNA	O
.	O

Using	O
both	O
antisera	O
,	O
we	O
found	O
positive	O
nuclear	O
membrane	O
staining	O
in	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
in	O
the	O
normal	O
controls	O
and	O
in	O
patients	O
with	O
neuromuscular	B
diseases	I
other	O
than	O
EDMD	B
.	O

In	O
contrast	O
,	O
a	O
deficiency	O
in	O
immunofluorescent	O
staining	O
of	O
skeletal	O
and	O
cardiac	O
muscle	O
from	O
EDMD	B
patients	O
was	O
observed	O
.	O

A	O
34	O
kD	O
protein	O
is	O
immunoreactive	O
with	O
the	O
antisera	O
-	O
-	O
the	O
protein	O
is	O
equivalent	O
to	O
that	O
predicted	O
for	O
emerin	O
.	O

Together	O
,	O
our	O
findings	O
suggest	O
the	O
specific	O
deficiency	B
of	I
emerin	I
in	O
the	O
nuclear	O
membrane	O
of	O
muscle	O
cells	O
in	O
patients	O
with	O
EDMD	B
.	O
.	O

Growth	B
retardation	I
and	O
tumour	B
inhibition	O
by	O
BRCA1	O
.	O

Inherited	O
mutations	O
in	O
BRCA1	O
predispose	O
to	O
breast	B
and	I
ovarian	I
cancer	I
,	O
but	O
the	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
breast	B
and	I
ovarian	I
cancer	I
has	O
previously	O
been	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
retroviral	O
transfer	O
of	O
the	O
wild	O
-	O
type	O
BRCA1	O
gene	O
inhibits	O
growth	O
in	O
vitro	O
of	O
all	O
breast	B
and	I
ovarian	I
cancer	I
cell	O
lines	O
tested	O
,	O
but	O
not	O
colon	B
or	I
lung	I
cancer	I
cells	O
or	O
fibroblasts	O
.	O

Mutant	O
BRCA1	O
has	O
no	O
effect	O
on	O
growth	O
of	O
breast	B
cancer	I
cells	O
;	O
ovarian	B
cancer	I
cell	O
growth	O
is	O
not	O
affected	O
by	O
BRCA1	O
mutations	O
in	O
the	O
5	O
portion	O
of	O
the	O
gene	O
,	O
but	O
is	O
inhibited	O
by	O
3	O
BRCA1	O
mutations	O
.	O

Development	O
of	O
MCF	B
-	I
7	I
tumours	I
in	O
nude	O
mice	O
is	O
inhibited	O
when	O
MCF	O
-	O
7	O
cells	O
are	O
transfected	O
with	O
wild	O
-	O
type	O
,	O
but	O
not	O
mutant	O
,	O
BRCA1	O
.	O

Most	O
importantly	O
,	O
among	O
mice	O
with	O
established	O
MCF	B
-	I
7	I
tumours	I
,	O
peritoneal	O
treatment	O
with	O
a	O
retroviral	O
vector	O
expressing	O
wild	O
-	O
type	O
BRCA1	O
significantly	O
inhibits	O
tumour	B
growth	O
and	O
increased	O
survival	O
.	O
.	O

